PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hanzawa, H; de Ruwe, MJ; Albert, TK; van der Vliet, PC; Timmers, HTM; Boelens, R				Hanzawa, H; de Ruwe, MJ; Albert, TK; van der Vliet, PC; Timmers, HTM; Boelens, R			The structure of the C4C4 RING finger of human NOT4 reveals features distinct from those of C3HC4 RING fingers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATORY COMPLEX; MAGNETIC-RESONANCE SPECTROSCOPY; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; BINDING DOMAIN; DIFFERENTIALLY AFFECTS; NEGATIVE REGULATOR; CCR4-NOT COMPLEX; PROTEIN-KINASE; ZINC-FINGER	The NOT4 protein is a component of the CCR4.NOT complex, a global regulator of RNA polymerase II transcription. Human NOT4 (hNOT4) contains a RING finger motif of the C4C4 type. We expressed and purified the N-terminal region of hNOT4 (residues 1-78) encompassing the RING finger motif and determined the solution structure by heteronuclear NMR. MMR experiments using a Cd-113-substituted hNOT4 RING finger showed that two metal ions are bound through cysteine residues in a cross-brace manner. The three-dimensional structure of the hNOT4 RING finger was refined with root mean square deviation values of 0.58 +/- 0.13 Angstrom for the backbone atoms and 1.08 +/- 0.12 Angstrom for heavy atoms. The hNOT4 RING finger consists of an cw-helix and three long loops that are stabilized by zinc coordination. The overall folding of the hNOT4 RING finger is similar to that of the C3HC4 RING fingers. The relative orientation of the two zinc-chelating loops and the alpha -helix is well conserved. However, for the other regions, the secondary structural elements are distinct.	Univ Utrecht, Bijvoet Ctr Biomol Res, NL-3584 CH Utrecht, Netherlands; Sankyo Co Ltd, Biomed Res Labs, Shinagawa Ku, Tokyo 140, Japan; Univ Utrecht, Med Ctr, Physiol Chem Lab, NL-3508 AB Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Biomed Genet, NL-3508 AB Utrecht, Netherlands	Utrecht University; Daiichi Sankyo Company Limited; Utrecht University; Utrecht University	Boelens, R (corresponding author), Univ Utrecht, Bijvoet Ctr Biomol Res, Padualaan 8, NL-3584 CH Utrecht, Netherlands.		Boelens, Rolf/B-4702-2009	Boelens, Rolf/0000-0002-6939-8913; Albert, Thomas Karl/0000-0002-2488-0706				Albert TK, 2000, NUCLEIC ACIDS RES, V28, P809, DOI 10.1093/nar/28.3.809; Ayhan M, 1996, INORG CHEM, V35, P5902, DOI 10.1021/ic951653x; Bai YL, 1999, MOL CELL BIOL, V19, P6642; BARLOW PN, 1994, J MOL BIOL, V237, P201, DOI 10.1006/jmbi.1994.1222; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; BODDY MN, 1994, TRENDS BIOCHEM SCI, V19, P198, DOI 10.1016/0968-0004(94)90020-5; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Bottomley MJ, 1999, J BIOMOL NMR, V13, P381, DOI 10.1023/A:1008393903034; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; COLLART MA, 1993, EMBO J, V12, P177, DOI 10.1002/j.1460-2075.1993.tb05643.x; COLLART MA, 1994, GENE DEV, V8, P525, DOI 10.1101/gad.8.5.525; Crowley P, 2000, J AM CHEM SOC, V122, P2968, DOI 10.1021/ja9942787; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DENIS CL, 1984, GENETICS, V108, P833; DENIS CL, 1990, GENETICS, V124, P283; DRAPER MP, 1994, MOL CELL BIOL, V14, P4522, DOI 10.1128/MCB.14.7.4522; DRAPER MP, 1995, MOL CELL BIOL, V15, P3487; Dux P, 1997, J BIOMOL NMR, V10, P301, DOI 10.1023/A:1018393225804; Fletcher CM, 1996, J BIOMOL NMR, V8, P292, DOI 10.1007/BF00410328; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Goodfellow BJ, 1998, PROTEIN SCI, V7, P928; IYER V, 1995, MOL CELL BIOL, V15, P7059; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KLEYWEGT GJ, 1993, J MAGN RESON SER B, V102, P166, DOI 10.1006/jmrb.1993.1079; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Liu HY, 1997, EMBO J, V16, P5289, DOI 10.1093/emboj/16.17.5289; Liu HY, 1998, EMBO J, V17, P1096, DOI 10.1093/emboj/17.4.1096; MAHADEVAN S, 1990, MOL CELL BIOL, V10, P4447, DOI 10.1128/MCB.10.9.4447; NAGAI K, 1995, TRENDS BIOCHEM SCI, V20, P235, DOI 10.1016/S0968-0004(00)89024-6; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NEUHAUS D, 1992, J MOL BIOL, V228, P637, DOI 10.1016/0022-2836(92)90846-C; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; Oberholzer U, 1998, GENE, V207, P61, DOI 10.1016/S0378-1119(97)00605-7; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; SAKAI A, 1992, NUCLEIC ACIDS RES, V20, P6227, DOI 10.1093/nar/20.23.6227; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; SKOWYRA D, 1999, SCIENCE, V662, P284; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOYN JH, 1991, GENE, V104, P63, DOI 10.1016/0378-1119(91)90465-N; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	48	75	79	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10185	10190		10.1074/jbc.M009298200	http://dx.doi.org/10.1074/jbc.M009298200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11087754	hybrid			2022-12-25	WOS:000167996400080
J	Henderson, JP; Byun, J; Williams, MV; Mueller, DM; McCormick, ML; Heinecke, JW				Henderson, JP; Byun, J; Williams, MV; Mueller, DM; McCormick, ML; Heinecke, JW			Production of brominating intermediates by myeloperoxidase - A transhalogenation pathway for generating mutagenic nucleobases during inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-CHLORIDE SYSTEM; LUNG-CANCER RISK; HUMAN NEUTROPHILS EMPLOY; HYDROGEN-PEROXIDE; HYPOCHLOROUS ACID; HUMAN PHAGOCYTES; EOSINOPHIL PEROXIDASE; ESCHERICHIA-COLI; MAMMALIAN-CELLS; MUTT PROTEIN	The existence of interhalogen compounds was proposed more than a century ago, but no biological roles have been attributed to these highly oxidizing intermediates. In this study, we determined whether the peroxidases of white blood cells can generate the interhalogen gas bromine chloride (BrCl), Myeloperoxidase, the heme enzyme secreted by activated neutrophils and monocytes, uses H2O2 and Cl- to produce HOCl, a chlorinating intermediate. In contrast, eosinophil peroxidase preferentially converts Br- to HOBr, Remarkably, both myeloperoxidase and eosinophil peroxidase were able to brominate deoxycytidine, a nucleoside, and uracil, a nucleo,ase, at plasma concentrations of Br- (100 muM) and Cl- (100 mM). The two enzymes used different reaction pathways, however. When HOCl brominated deoxycytidine, the reaction required Br- and was inhibited by taurine. In contrast, bromination by HOBr was independent of Br- and unaffected by taurine, Moreover, taurine inhibited 5-bromodeoxycytidine production by the myeloperoxidase-H2O2-Cl-- Br- system but not by the eosinophil peroxidase-H2O2-Cl--Br- system, indicating that bromination by myeloperoxidase involves the initial production of HOCl. Both HOCl-Br- and the myeloperoxidase-H2O2-Cl--Br- system generated a gas that converted cyclohexene into 1-bromo-2-chlorocyclohexane, implicating BrCl in the reaction. Moreover, human neutrophils used myeloperoxidase, H2O2, and Br- to brominate deoxycytidine by a taurine-sensitive pathway, suggesting that transhalogenation reactions may be physiologically relevant. 5-Bromouracil incorporated into nuclear DNA is a well known mutagen. Our observations therefore raise the possibility that transhalogenation reactions initiated by phagocytes provide one pathway for mutagenesis and cytotoxicity at sites of inflammation.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52241 USA; Univ Iowa, Vet Affairs Med Ctr, Res Serv, Iowa City, IA 52241 USA	Washington University (WUSTL); Washington University (WUSTL); University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Heinecke, JW (corresponding author), Div Atherosclerosis Nutr & Lipid Res, Box 8046,660 S Euclid Ave, St Louis, MO 63110 USA.		Henderson, Jeffrey P/D-3337-2015		NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012293, R01AG019309] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00954] Funding Source: Medline; NIA NIH HHS [AG12293, AG19309] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; BEERS RF, 1952, J BIOL CHEM, V195, P133; BRYANT RE, 1980, J INFECT DIS, V142, P594, DOI 10.1093/infdis/142.4.594; Byun J, 1999, BIOCHEMISTRY-US, V38, P2590, DOI 10.1021/bi9822980; Carr AC, 1997, BIOCHEM J, V327, P275, DOI 10.1042/bj3270275; Cascorbi I, 2000, CANCER RES, V60, P644; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DAVIDSON RL, 1988, P NATL ACAD SCI USA, V85, P4406, DOI 10.1073/pnas.85.12.4406; De La Mare P.B., 1976, ELECTROPHILIC HALOGE; DERBYSHIRE DH, 1950, J CHEM SOC, P564, DOI 10.1039/jr9500000564; DETOGNI P, 1988, BLOOD, V71, P463; DOMIGAN NM, 1995, J BIOL CHEM, V270, P16542, DOI 10.1074/jbc.270.28.16542; Dunford H. B., 1999, HEME PEROXIDASES; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Henderson JP, 1999, J BIOL CHEM, V274, P33440, DOI 10.1074/jbc.274.47.33440; HOLZBECHER J, 1980, CLIN BIOCHEM, V13, P277, DOI 10.1016/S0009-9120(80)80009-9; HURST JK, 1989, CRIT REV BIOCHEM MOL, V24, P271, DOI 10.3109/10409238909082555; ISHII A, 1994, MUTAT RES, V305, P273, DOI 10.1016/0027-5107(94)90247-X; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KETTLE AJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P58, DOI 10.1016/0167-4838(88)90297-X; Klebanoff S.J., 1978, NEUTROPHIL FUNCTION; KUMAR K, 1987, INORG CHEM, V26, P2706, DOI 10.1021/ic00263a030; Le Marchand L, 2000, CANCER EPIDEM BIOMAR, V9, P181; London SJ, 1997, CANCER RES, V57, P5001; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; MARQUEZ LA, 1994, J BIOL CHEM, V269, P7950; Maurer H.R., 1971, DISC ELECTROPHORESIS; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; MORITA Y, 1986, J BIOCHEM-TOKYO, V99, P761, DOI 10.1093/oxfordjournals.jbchem.a135535; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; MORRIS SM, 1991, MUTAT RES, V258, P161, DOI 10.1016/0165-1110(91)90007-I; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; ONEILL JP, 1983, MUTAT RES, V109, P259, DOI 10.1016/0027-5107(83)90051-9; PATTON W, 1972, BIOCHEM BIOPH RES CO, V48, P880, DOI 10.1016/0006-291X(72)90690-0; PENMAN BW, 1976, LIFE SCI, V19, P563, DOI 10.1016/0024-3205(76)90237-X; Piedrafita FJ, 1996, J BIOL CHEM, V271, P14412, DOI 10.1074/jbc.271.24.14412; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; RAMACHANDRAN S, 1976, T ROY SOC TROP MED H, V70, P159, DOI 10.1016/0035-9203(76)90180-2; RAMSEY PG, 1982, J IMMUNOL, V128, P415; Reynolds WF, 1997, BLOOD, V90, P2730, DOI 10.1182/blood.V90.7.2730.2730_2730_2737; ROSIN MP, 1994, CANCER RES, V54, pS1929; ROSIN MP, 1994, MUTAT RES, V305, P283, DOI 10.1016/0027-5107(94)90248-8; Schabath MB, 2000, CARCINOGENESIS, V21, P1163, DOI 10.1093/carcin/21.6.1163; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; SOWERS LC, 1989, J MOL BIOL, V205, P437, DOI 10.1016/0022-2836(89)90353-7; STETMASZYNSKA T, 1978, EUR J BIOCHEM, V92, P301; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; TEST ST, 1984, J CLIN INVEST, V74, P1341, DOI 10.1172/JCI111544; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1995, J BIOL CHEM, V270, P2906, DOI 10.1074/jbc.270.7.2906; Tobler A., 1991, BLOOD CELL BIOCH VOL, P255; vanDalen CJ, 1997, BIOCHEM J, V327, P487; WANG TX, 1994, INORG CHEM, V33, P5872, DOI 10.1021/ic00103a040; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEITZMAN SA, 1985, SCIENCE, V227, P1231, DOI 10.1126/science.3975611; WEITZMAN SA, 1990, BLOOD, V76, P655; WILBUR DS, 1982, J ORG CHEM, V47, P359, DOI 10.1021/jo00341a037; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	69	108	112	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7867	7875		10.1074/jbc.M005379200	http://dx.doi.org/10.1074/jbc.M005379200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11096071	hybrid			2022-12-25	WOS:000167474900028
J	Kierzek, AM; Zaim, J; Zielenkiewicz, P				Kierzek, AM; Zaim, J; Zielenkiewicz, P			The effect of transcription and translation initiation frequencies on the stochastic fluctuations in prokaryotic gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; CELLS; DEGRADATION	The kinetics of prokaryotic gene expression has been modelled by the Monte Carlo computer simulation algorithm of Gillespie, which allowed the study of random fluctuations in the number of protein molecules during gene expression. The model, when applied to the simulation of LacZ gene expression, is in good agreement with experimental data. The influence of the frequencies of transcription and translation initiation on random fluctuations in gene expression has been studied in a number of simulations in which promoter and ribosome binding site effectiveness has been changed in the range of values reported for various prokaryotic genes. We show that the genes expressed from strong promoters produce the protein evenly, with a rate that does not vary significantly among cells. The genes with very weak promoters express the protein in "bursts" occurring at random time intervals. Therefore, if the low level of gene expression results from the low frequency of transcription initiation, huge fluctuations arise. In contrast, the protein can be produced with a low and uniform rate if the gene has a strong promoter and a slow rate of ribosome binding (a weak ribosome binding site). The implications of these findings for the expression of regulatory proteins are discussed.	Polish Acad Sci, Inst Biochem & Biophys, PL-02106 Warsaw, Poland; Warsaw Univ, Inst Expt Plant Biol, PL-02106 Warsaw, Poland	Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences; University of Warsaw	Kierzek, AM (corresponding author), Polish Acad Sci, Inst Biochem & Biophys, Pawinskiego 5A, PL-02106 Warsaw, Poland.			Kierzek, Andrzej/0000-0002-2605-9057; Zielenkiewicz, Piotr/0000-0001-8151-6874				Alberts B., 1994, MOL BIOL CELL; Arkin A, 1998, GENETICS, V149, P1633; BERQUIST PL, 1978, MOL GEN GENET, V164, P105; Bremer H, 1996, ESCHERICHIA COLI SAL; Carrier TA, 1999, J THEOR BIOL, V201, P25, DOI 10.1006/jtbi.1999.1010; Carrier TA, 1997, J THEOR BIOL, V189, P195, DOI 10.1006/jtbi.1997.0509; DRAPER DE, 1996, ESCHERICHIA COLI SAL, P902; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; GILLESPIE DT, 1977, J PHYS CHEM-US, V81, P2340, DOI 10.1021/j100540a008; GILLESPIE DT, 1992, PHYSICA A, V188, P404, DOI 10.1016/0378-4371(92)90283-V; GOLDBERG AL, 1974, ANNU REV BIOCHEM, V43, P835, DOI 10.1146/annurev.bi.43.070174.004155; KENNELL D, 1977, J MOL BIOL, V114, P1, DOI 10.1016/0022-2836(77)90279-0; Levin MD, 1998, BIOPHYS J, V74, P175, DOI 10.1016/S0006-3495(98)77777-X; LIN SY, 1975, CELL, V4, P107, DOI 10.1016/0092-8674(75)90116-6; MALONEY PC, 1973, J MOL BIOL, V73, P77, DOI 10.1016/0022-2836(73)90160-5; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; Neidhardt FC, 1999, J BACTERIOL, V181, P7405, DOI 10.1128/JB.181.24.7405-7408.1999; Newlands S, 1998, GENE DEV, V12, P2748, DOI 10.1101/gad.12.17.2748; RECORD TM, 1996, ESCHERICHIA COLI SAL, P792; Siegele DA, 1997, P NATL ACAD SCI USA, V94, P8168, DOI 10.1073/pnas.94.15.8168; TYSON JJ, 1985, J THEOR BIOL, V113, P29, DOI 10.1016/S0022-5193(85)80074-6; YARCHUK O, 1992, J MOL BIOL, V226, P581, DOI 10.1016/0022-2836(92)90617-S	23	128	131	2	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8165	8172		10.1074/jbc.M006264200	http://dx.doi.org/10.1074/jbc.M006264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11062240	hybrid			2022-12-25	WOS:000167474900069
J	Vergis, JM; Bulock, KG; Fleming, KG; Beardsley, GP				Vergis, JM; Bulock, KG; Fleming, KG; Beardsley, GP			Human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase/inosine 5 '-monophosphate cyclohydrolase - A bifunctional protein requiring dimerization for transformylase activity but not for cyclohydrolase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOTIDE TRANSFORMYLASE; IMP CYCLOHYDROLASE; METHOTREXATE; INHIBITION; 5,10-DIDEAZA-5,6,7,8-TETRAHYDROFOLATE; FORMYLTRANSFERASE; POLYGLUTAMATES; PURIFICATION; MECHANISM; SYNTHASE	The bifunctional enzyme aminoimidazole carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) is responsible for catalysis of the last two steps in the de novo purine pathway. Gel filtration studies performed on human enzyme suggested that this enzyme is monomeric in solution. However, cross-linking studies performed on both yeast and avian ATIC indicated that this enzyme might be dimeric. To determine the oligomeric state of this protein in solution, we carried out sedimentation equilibrium analysis of ATIC over a broad concentration range. We find that ATIC participates in a monomer/dimer equilibrium with a dissociation constant of 240 +/- 50 nM at 4 degreesC. To determine whether the presence of substrates affects the monomer/dimer equilibrium, further ultracentrifugation studies were performed. These showed that the equilibrium is only significantly shifted in the presence of both AICAR and a folate analog, resulting in a 10-fold reduction in the dissociation constant. The enzyme concentration dependence on each of the catalytic activities was studied in steady state kinetic experiments. These indicated that the transformylase activity requires dimerization whereas the cyclohydrolase activity only slightly prefers the dimeric form over the monomeric form.	Yale Univ, Sch Med, Dept Pediat, New Haven, CT 06510 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Johns Hopkins Univ, Dept Biophys, Baltimore, MD 21218 USA	Yale University; Yale University; Yale University; Johns Hopkins University	Beardsley, GP (corresponding author), Yale Univ, Sch Med, Dept Pediat, LMP 3096,333 Cedar St, New Haven, CT 06510 USA.		Fleming, Karen/E-7892-2011		NATIONAL CANCER INSTITUTE [R01CA050721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016769, R01GM057534] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA50721] Funding Source: Medline; NIGMS NIH HHS [GM51245, R01 GM057534-02, GM16769] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEGRA CJ, 1985, P NATL ACAD SCI USA, V82, P4881, DOI 10.1073/pnas.82.15.4881; BAGGOTT JE, 1986, BIOCHEM J, V236, P193, DOI 10.1042/bj2360193; BALDWIN SW, 1991, BIOCHEMISTRY-US, V30, P1997, DOI 10.1021/bi00221a037; BEARDSLEY G P, 1986, P953; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BEARDSLEY GP, 1990, CHEMISTRY AND BIOLOGY OF PTERIDINES 1989, P1001; BLACK SL, 1978, ANAL BIOCHEM, V90, P397, DOI 10.1016/0003-2697(78)90042-8; CRONSTEIN BN, 1993, J CLIN INVEST, V92, P2675, DOI 10.1172/JCI116884; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; KURGANOV B. L, 1967, MOL BIOL, V1, P17; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MUELLER WT, 1981, BIOCHEMISTRY-US, V20, P337, DOI 10.1021/bi00505a017; RABINOWITZ JC, 1963, METHOD ENZYMOL, V6, P814, DOI 10.1016/0076-6879(63)06256-X; Rayl EA, 1996, J BIOL CHEM, V271, P2225, DOI 10.1074/jbc.271.4.2225; Rowe P.B, 1971, METHODS ENZYMOL B, V18, P733; Sambrook J., 2002, MOL CLONING LAB MANU; SHAW G, 1962, J CHEM SOC, P2937, DOI 10.1039/jr9620002937; Sugita T, 1997, J BIOCHEM-TOKYO, V122, P309; Szabados E, 1998, INT J BIOCHEM CELL B, V30, P933, DOI 10.1016/S1357-2725(98)00026-0; Szabados E, 1998, ADV EXP MED BIOL, V431, P241; SZABADOS E, 1994, ANAL BIOCHEM, V221, P401, DOI 10.1006/abio.1994.1433; TAYLOR EC, 1985, J MED CHEM, V28, P914, DOI 10.1021/jm00145a012; Tibbetts AS, 2000, J BIOL CHEM, V275, P20920, DOI 10.1074/jbc.M909851199; Wall M, 2000, BIOCHEMISTRY-US, V39, P11303, DOI 10.1021/bi0007268	25	29	31	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7727	7733		10.1074/jbc.M009940200	http://dx.doi.org/10.1074/jbc.M009940200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11096114	hybrid			2022-12-25	WOS:000167474900010
J	Luo, S; Wang, ZY; Kobayashi, M; Nozawa, T				Luo, S; Wang, ZY; Kobayashi, M; Nozawa, T			The dimerization of folded monomers of ribulose 1,5-bisphosphate carboxylase/oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOSPIRILLUM-RUBRUM; BISPHOSPHATE CARBOXYLASE; ESCHERICHIA-COLI; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; RIBULOSEBISPHOSPHATE CARBOXYLASE; 1,5-DIPHOSPHATE CARBOXYLASE; LIQUID-CHROMATOGRAPHY; PROTEINS; DISSOCIATION; ATP	Spontaneous refolding and reconstitution processes of dimeric ribulose 1,5-bisphosphate carboxylase/oxygenase (Rubisco) from Rhodospirillum rubrum have been investigated using size-exclusion high performance liquid chromatography (HPLC), spectroscopic, and activity measurements. When the unfolded Rubisco in guanidine hydrochloride is diluted at 4 degreesC, a folding intermediate (Rubisco-I) is rapidly formed, which remains in an unstable monomeric state and gradually develops into folded monomer (Rubiseo-M) at 4 degreesC but undergoes irreversible aggregation at 25 degreesC, Refolding of Rubisco-I to Rubisco-M is a very slow process, taking about 20 h for 70% conversion at 4 degreesC, Rubisco-M is stable at 4 degreesC and is capable of forming an active dimer spontaneously when incubated at a temperature higher than 10 degreesC, The dynamic dimerization process has been measured in a temperature range of 4-35 degreesC by HPLC, and the results demonstrate that the dimerization is strongly facilitated by the temperature. It is found that dithiothreitol is essential for the spontaneous reconstitution of Rubisco.	Tohoku Univ, Fac Engn, Interdisciplinary Res Ctr, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan	Tohoku University	Nozawa, T (corresponding author), Tohoku Univ, Fac Engn, Interdisciplinary Res Ctr, Dept Biomol Engn, Sendai, Miyagi 9808579, Japan.			Luo, Shen/0000-0002-1912-6741				BENEDEK K, 1993, J CHROMATOGR, V646, P91, DOI 10.1016/S0021-9673(99)87010-1; BHATTACHARYYA D, 1993, BIOCHEMISTRY-US, V32, P9726, DOI 10.1021/bi00088a027; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; Chang BS, 1996, BIOPHYS J, V71, P3399, DOI 10.1016/S0006-3495(96)79534-6; ELLIS RJ, 1990, SCIENCE, V250, P954, DOI 10.1126/science.250.4983.954; ERIJMAN L, 1993, BIOCHEMISTRY-US, V32, P5187, DOI 10.1021/bi00070a030; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOLOUBINOFF P, 1989, NATURE, V337, P44, DOI 10.1038/337044a0; HARTMAN FC, 1994, ANNU REV BIOCHEM, V63, P197, DOI 10.1146/annurev.biochem.63.1.197; HARTMAN FC, 1984, ARCH BIOCHEM BIOPHYS, V232, P280, DOI 10.1016/0003-9861(84)90544-7; Jones MD, 1996, J BIOL CHEM, V271, P11301, DOI 10.1074/jbc.271.19.11301; LEBRAS G, 1989, BIOCHEMISTRY-US, V28, P6836, DOI 10.1021/bi00443a009; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; MUSEI G, 1985, BIOCHEMISTRY-US, V24, P2034; ORMEROD JG, 1961, ARCH BIOCHEM BIOPHYS, V94, P449, DOI 10.1016/0003-9861(61)90073-X; REGNIER FE, 1983, METHOD ENZYMOL, V91, P137; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; ROY H, 1988, BIOCHIM BIOPHYS ACTA, V957, P323, DOI 10.1016/0167-4838(88)90221-X; SCHNEIDER G, 1990, J MOL BIOL, V211, P989, DOI 10.1016/0022-2836(90)90088-4; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; TABITA FR, 1974, J BIOL CHEM, V249, P3459; TABITA FR, 1974, J BIOL CHEM, V249, P3453; Tabita FR, 1999, PHOTOSYNTH RES, V60, P1, DOI 10.1023/A:1006211417981; VANDERVIES SM, 1992, BIOCHEMISTRY-US, V31, P3635, DOI 10.1021/bi00129a012; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; Wang ZY, 1998, PHOTOSYNTH RES, V58, P103, DOI 10.1023/A:1006094721113; Wang ZY, 1998, ANAL BIOCHEM, V257, P26, DOI 10.1006/abio.1997.2521	28	6	6	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7023	7026		10.1074/jbc.M006838200	http://dx.doi.org/10.1074/jbc.M006838200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11092881	hybrid			2022-12-25	WOS:000167442900024
J	Zang, Q; Springer, TA				Zang, Q; Springer, TA			Amino acid residues in the PSI domain and cysteine-rich repeats of the integrin beta(2) subunit that restrain activation of the integrin alpha(x)beta(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING REGION; I-DOMAIN; MONOCLONAL-ANTIBODY; A-DOMAIN; PROPELLER DOMAIN; LEUKOCYTE DIFFERENTIATION; CONFORMATIONAL-CHANGES; REGULATED EXPRESSION; P150,95 CD11C/CD18; RECOGNITION SITE	The leukocyte integrin alpha (X)beta (2) (p150,95) recognizes the iC3b complement fragment and functions as the complement receptor type 4. alpha (X)beta (2) is more resistant to activation than other beta (2) integrins and is inactive in transfected cells. However, when human alpha (X) is paired with chicken or mouse beta (2), alpha (X)beta (2) is activated for binding to iC3b. Activating substitutions were mapped to individual residues or groups of residues in the N-terminal plexin/semaphorin/integrin (PSI) domain and C-terminal cysteine-rich repeats 2 and 3. These regions are linked,by a long range disulfide bond. Substitutions in the PSI domain synergized with substitutions in the cysteine-rich repeats. Substitutions T4P, T22A, Q5255, and V526L gave full activation. Activation of binding to iC3b: correlated with exposure of the CBR LFA-1/2 epitope in cysteine-rich repeat 3. The data suggest that the activating substitutions are present in an interface that restrains the human alpha (X)/human beta (2) integrin in the inactive state. The opening of this interface is linked to structural rearrangements in other domains that activate ligand binding.	Harvard Univ, Sch Med, Dept Pathol, Ctr Blood Res, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Springer, TA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.			Zang, Qun (Sophia)/0000-0002-6397-8896	NCI NIH HHS [CA 31799] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031799, R37CA031799] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREW D, 1993, EUR J IMMUNOL, V23, P2217, DOI 10.1002/eji.1830230925; BAZZONI G, 1995, J BIOL CHEM, V270, P25570, DOI 10.1074/jbc.270.43.25570; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; Bork P, 1999, TRENDS BIOCHEM SCI, V24, P261, DOI 10.1016/S0968-0004(99)01416-4; CALVETE JJ, 1991, BIOCHEM J, V274, P63, DOI 10.1042/bj2740063; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; Douglass WA, 1998, FEBS LETT, V440, P414, DOI 10.1016/S0014-5793(98)01498-7; DU XP, 1993, J BIOL CHEM, V268, P23087; DUBRIDGE RB, 1987, MOL CELL BIOL, V7, P379, DOI 10.1128/MCB.7.1.379; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Faull RJ, 1996, J BIOL CHEM, V271, P25099, DOI 10.1074/jbc.271.41.25099; HEINZEL SS, 1988, J VIROL, V62, P3738, DOI 10.1128/JVI.62.10.3738-3746.1988; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOGG N, 1986, EUR J IMMUNOL, V16, P240, DOI 10.1002/eji.1830160306; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; HUANG CC, 1995, J BIOL CHEM, V270, P19008, DOI 10.1074/jbc.270.32.19008; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3156, DOI 10.1073/pnas.94.7.3156; Kashiwagi H, 1999, BLOOD, V93, P2559, DOI 10.1182/blood.V93.8.2559.408k12_2559_2568; KEIZER GD, 1987, EUR J IMMUNOL, V17, P1317, DOI 10.1002/eji.1830170915; KEIZER GD, 1987, J IMMUNOL, V138, P3130; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; LIU CY, 1997, BLOOD, V90, P573; LOIKE JD, 1991, P NATL ACAD SCI USA, V88, P1044, DOI 10.1073/pnas.88.3.1044; Lu CF, 1998, J BIOL CHEM, V273, P15138, DOI 10.1074/jbc.273.24.15138; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MYONES BL, 1988, J CLIN INVEST, V82, P640, DOI 10.1172/JCI113643; Ni HY, 1998, J BIOL CHEM, V273, P7981, DOI 10.1074/jbc.273.14.7981; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; PETRUZZELLI L, 1995, J IMMUNOL, V155, P854; POSTIGO AA, 1991, J EXP MED, V174, P1313, DOI 10.1084/jem.174.6.1313; Puzon-McLaughlin W, 2000, J BIOL CHEM, V275, P7795, DOI 10.1074/jbc.275.11.7795; ROSS GD, 1992, J LEUKOCYTE BIOL, V51, P109, DOI 10.1002/jlb.51.2.109; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SHIH DT, 1993, J CELL BIOL, V122, P1361, DOI 10.1083/jcb.122.6.1361; Shimaoka M, 2000, NAT STRUCT BIOL, V7, P674, DOI 10.1038/77978; Springer TA, 1997, P NATL ACAD SCI USA, V94, P65, DOI 10.1073/pnas.94.1.65; SPRINGER TA, 1990, CLIN ASPECTS IMMUNOL, P199; STACKER SA, 1991, J IMMUNOL, V146, P648; Stephens P, 1995, CELL ADHES COMMUN, V3, P375, DOI 10.3109/15419069509081292; Takagi J, 1997, J BIOCHEM, V121, P914; TEVELDE AA, 1987, IMMUNOLOGY, V61, P261; Tozer EC, 1996, J BIOL CHEM, V271, P21978, DOI 10.1074/jbc.271.36.21978; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; VanderVieren M, 1995, IMMUNITY, V3, P683, DOI 10.1016/1074-7613(95)90058-6; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Zang Q, 2000, J BIOL CHEM, V275, P22202, DOI 10.1074/jbc.M002883200; ZUCKER MB, 1984, THROMB HAEMOSTASIS, V51, P119	50	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6922	6929		10.1074/jbc.M005868200	http://dx.doi.org/10.1074/jbc.M005868200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11096074	hybrid			2022-12-25	WOS:000167442900010
J	Deng, K; Shenoy, SK; Tso, SC; Yu, L; Yu, CA				Deng, K; Shenoy, SK; Tso, SC; Yu, L; Yu, CA			Reconstitution of mitochondrial processing peptidase from the core proteins (subunits I and II) of bovine heart mitochondrial cytochrome bc(1) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; SUCCINATE-UBIQUINONE REDUCTASE; SPINACH LEAF MITOCHONDRIA; C REDUCTASE; RAT-LIVER; BETA-SUBUNIT; YEAST MITOCHONDRIA; ESCHERICHIA-COLI; IMPORT; BINDING	Mature core I and core II proteins of the bovine heart mitochondrial cytochrome bc(1) complex were individually overexpressed in Escherichia coli as soluble proteins using the expression vector pET-I and pET-II, respectively. Purified recombinant core I and core II alone show no mitochondrial processing peptidase (MPP) activity. When these two proteins are mixed together, MPP activity is observed. Maximum activity is obtained when the molar ratio of these two core proteins reaches 1. This indicates that only the two core subunits of thebc(1) complex are needed for MPP activity. The properties of reconstituted MPP are similar to those of Triton X-100- activated MPP in the bovine be, complex. When Rieske iron-sulfur protein precursor is used as substrate for reconstituted MPP, the processing activity stops when the amount of product formation (subunit IX) equals the amount of reconstituted MPP used in the system. Addition of Triton X-100 to the product-inhibited reaction mixture restores MPP activity, indicating that Triton X-100 dissociates bound subunit IX from the active site of reconstituted MPP, The aromatic group, rather than the hydroxyl group, at Tyr(57) of core I is essential for reconstitutive activity.	Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Yu, CA (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Stillwater, OK 74078 USA.		Shenoy, Sudha/AAN-4075-2021	Shenoy, Sudha/0000-0002-2565-4663	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030721, R37GM030721] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 30721] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARRETZ M, 1994, J BIOL CHEM, V269, P4959; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; Boteva R, 1996, ARCH BIOCHEM BIOPHYS, V332, P323, DOI 10.1006/abbi.1996.0348; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT U, 1993, J BIOL CHEM, V268, P8387; Braun HP, 1999, PLANTA, V209, P267, DOI 10.1007/s004250050632; BRAUN HP, 1995, TRENDS BIOCHEM SCI, V20, P171, DOI 10.1016/S0968-0004(00)88999-9; BRAUN HP, 1992, EMBO J, V11, P3219, DOI 10.1002/j.1460-2075.1992.tb05399.x; Chen YR, 1996, J BIOL CHEM, V271, P2057, DOI 10.1074/jbc.271.4.2057; Deng KP, 1998, J BIOL CHEM, V273, P20752, DOI 10.1074/jbc.273.33.20752; EMMERMANN M, 1993, J BIOL CHEM, V268, P18936; ERIKSSON AC, 1994, BBA-BIOENERGETICS, V1186, P221, DOI 10.1016/0005-2728(94)90181-3; ERIKSSON AC, 1992, BIOCHIM BIOPHYS ACTA, V1140, P208, DOI 10.1016/0005-2728(92)90010-Y; ERIKSSON AC, 1996, J BIOENERG BIOMEMBR, V28, P283; GELI V, 1993, P NATL ACAD SCI USA, V90, P6247, DOI 10.1073/pnas.90.13.6247; GENCIC S, 1991, EUR J BIOCHEM, V199, P123, DOI 10.1111/j.1432-1033.1991.tb16099.x; Glaser E, 1999, J BIOENERG BIOMEMBR, V31, P259, DOI 10.1023/A:1005475930477; GORNALL AG, 1949, J BIOL CHEM, V177, P751; HAMMEN PK, 1994, BIOCHEMISTRY-US, V33, P8610, DOI 10.1021/bi00194a028; HARTL FU, 1986, CELL, V47, P939, DOI 10.1016/0092-8674(86)90809-3; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; ISAYA G, 1995, METHOD ENZYMOL, V248, P556; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; JAPA S, 1989, ARCH BIOCHEM BIOPHYS, V268, P716, DOI 10.1016/0003-9861(89)90340-8; KITADA S, 1995, J BIOCHEM-TOKYO, V117, P1148, DOI 10.1093/oxfordjournals.jbchem.a124836; Kitada S, 1998, J BIOL CHEM, V273, P32547, DOI 10.1074/jbc.273.49.32547; KLEIBER J, 1990, P NATL ACAD SCI USA, V87, P7978, DOI 10.1073/pnas.87.20.7978; Kojima K, 1998, J BIOL CHEM, V273, P32542, DOI 10.1074/jbc.273.49.32542; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee GY, 1998, BBA-BIOENERGETICS, V1363, P35, DOI 10.1016/S0005-2728(97)00089-3; Luciano P, 1996, EXPERIENTIA, V52, P1077, DOI 10.1007/BF01952105; Luciano P, 1998, J MOL BIOL, V280, P193, DOI 10.1006/jmbi.1998.1858; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NIIDOME T, 1994, J BIOL CHEM, V269, P24719; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; OU WJ, 1989, EMBO J, V8, P2505; PACES V, 1993, P NATL ACAD SCI USA, V90, P5355, DOI 10.1073/pnas.90.11.5355; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; SAAVEDRAALANIS VM, 1994, J BIOL CHEM, V269, P9284; Sambrook J, 1998, MOL CLONING LAB MANU, V2nd; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SCHNEIDER H, 1990, J BIOL CHEM, V265, P9881; Shenoy SK, 1999, J BIOL CHEM, V274, P8717, DOI 10.1074/jbc.274.13.8717; SJOLING S, 1994, J BIOL CHEM, V269, P32059; THORNTON K, 1993, J BIOL CHEM, V268, P19906; USUI S, 1990, BIOCHEM BIOPH RES CO, V167, P575, DOI 10.1016/0006-291X(90)92063-6; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; Yu CA, 1996, BBA-BIOENERGETICS, V1275, P47, DOI 10.1016/0005-2728(96)00049-7; YU L, 1995, J BIOL CHEM, V270, P25634, DOI 10.1074/jbc.270.43.25634	52	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6499	6505		10.1074/jbc.M007128200	http://dx.doi.org/10.1074/jbc.M007128200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11073949	hybrid			2022-12-25	WOS:000167261000058
J	Lerga, A; Hallier, M; Delva, L; Orvain, C; Gallais, I; Marie, J; Moreau-Gachelin, F				Lerga, A; Hallier, M; Delva, L; Orvain, C; Gallais, I; Marie, J; Moreau-Gachelin, F			Identification of an RNA binding specificity for the potential splicing factor TLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; HUMAN MYELOID-LEUKEMIA; POLYMERASE-II; DNA-BINDING; CHROMOSOMAL TRANSLOCATION; ONCOPROTEIN TLS/FUS; RECOGNITION MOTIFS; EWING FAMILY; PROTEIN; FUSION	The TLS/FUS gene is involved in a recurrent chromosomal translocation in human myxoid liposarcomas. We previously reported that TLS is a potential splicing regulator able to modulate the 5'-splice site selection in an E1A pre-mRNA. Using an in vitro selection procedure, we investigated whether TLS exhibits a specificity with regard to RNA recognition. The RNAs selected by TLS share a common GGUG motif. Mutation of a G or U residue within this motif abolishes the interaction of TLS with the selected RNAs, We showed that TLS can bind GCUG-containing RNAs with a 250 nM affinity. By UV cross-linking/competition and immunoprecipitation experiments, we demonstrated that TLS recognizes a GGUG-containing RNA in nuclear extracts. Each one of the RNA binding domains (the three RGG boxes and the RNA recognition motif) contributes to the specificity of the TLS RNA interaction, whereas only RRM and RGG2-3 participate to the E1A alternative splicing in vivo. The specificity of the TLS RNA interaction was also observed using as natural pre-mRNA, the G-rich IVSB7 intron of the beta -tropomyosin pre-mRNA, Moreover, we determined that RNA binding specificities of TLS and high nuclear ribonucleoprotein A1 were different. Hence, our results help define the role of the specific interaction of TLS with RNA during the splicing process of a pre-mRNA.	Inst Curie Rech, INSERM, U528, F-75248 Paris 05, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Moreau-Gachelin, F (corresponding author), Inst Curie Rech, INSERM, U528, 26 Rue Ulm, F-75248 Paris 05, France.		Hallier, Marc/L-2031-2015	DELVA, Laurent/0000-0002-1086-3964				Baechtold H, 1999, J BIOL CHEM, V274, P34337, DOI 10.1074/jbc.274.48.34337; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1998, MOL CELL BIOL, V18, P1489, DOI 10.1128/MCB.18.3.1489; Bertrand P, 1999, ONCOGENE, V18, P4515, DOI 10.1038/sj.onc.1203048; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CALVIO C, 1995, RNA, V1, P724; Chandler SD, 1997, P NATL ACAD SCI USA, V94, P3596, DOI 10.1073/pnas.94.8.3596; CROZAT A, 1993, NATURE, V363, P640, DOI 10.1038/363640a0; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DIRKSEN WP, 1994, J BIOL CHEM, V269, P6431; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; GhisolfiNieto L, 1996, J MOL BIOL, V260, P34, DOI 10.1006/jmbi.1996.0380; Hackl W, 1996, J MOL BIOL, V264, P843, DOI 10.1006/jmbi.1996.0681; HACKL W, 1994, J CELL BIOL, V124, P261, DOI 10.1083/jcb.124.3.261; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; Hicks GG, 2000, NAT GENET, V24, P175, DOI 10.1038/72842; ICHIKAWA H, 1994, CANCER RES, V54, P2865; Ichikawa H, 1999, MOL CELL BIOL, V19, P7639; IMMANUEL D, 1995, MOL CELL BIOL, V15, P4562; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KRAINER AR, 1984, CELL, V36, P993, DOI 10.1016/0092-8674(84)90049-7; Kuroda M, 2000, EMBO J, V19, P453, DOI 10.1093/emboj/19.3.453; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; McCullough AJ, 1997, MOL CELL BIOL, V17, P4562, DOI 10.1128/MCB.17.8.4562; OHNO T, 1994, ONCOGENE, V9, P3087; PANAGOPOULOS I, 1994, GENE CHROMOSOME CANC, V11, P256, DOI 10.1002/gcc.2870110408; Perrotti D, 1998, EMBO J, V17, P4442, DOI 10.1093/emboj/17.15.4442; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; PRASAD DDK, 1994, ONCOGENE, V9, P3717; RABBITTS TH, 1993, NAT GENET, V4, P175, DOI 10.1038/ng0693-175; SIRANDPUGNET P, 1995, NUCLEIC ACIDS RES, V23, P3501, DOI 10.1093/nar/23.17.3501; STOLOW DT, 1995, NUCLEIC ACIDS RES, V23, P835, DOI 10.1093/nar/23.5.835; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; TAMBOURIN P, 1983, P NATL ACAD SCI-BIOL, V80, P6269, DOI 10.1073/pnas.80.20.6269; Wu SP, 1999, NATURE, V402, P832, DOI 10.1038/45590; Wu SP, 1997, EMBO J, V16, P4421, DOI 10.1093/emboj/16.14.4421; Xu RM, 1997, STRUCTURE, V5, P559, DOI 10.1016/S0969-2126(97)00211-6; Yang L, 2000, MOL CELL BIOL, V20, P3345, DOI 10.1128/MCB.20.10.3345-3354.2000; Yang L, 1998, J BIOL CHEM, V273, P27761, DOI 10.1074/jbc.273.43.27761; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1997, J CELL SCI, V110, P1741; ZUCMAN J, 1993, EMBO J, V12, P4481, DOI 10.1002/j.1460-2075.1993.tb06137.x	48	136	138	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6807	6816		10.1074/jbc.M008304200	http://dx.doi.org/10.1074/jbc.M008304200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11098054	hybrid			2022-12-25	WOS:000167261000094
J	Vaughan-Thomas, A; Young, RD; Phillips, AC; Duance, VC				Vaughan-Thomas, A; Young, RD; Phillips, AC; Duance, VC			Characterization of type XI collagen-glycosaminoglycan interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; CARTILAGE COLLAGENS; V COLLAGEN; PRO-ALPHA-1(XI) COLLAGEN; BINDING SITE; CHAINS; GENE; SURFACE; IX; IMMUNOLOCALIZATION	Using competitive binding experiments, it was found that native type XI collagen binds heparin, heparan sulfate, and dermatan sulfate. However, interactions were not evident with hyaluronic acid, keratan sulfate, or chondroitin sulfate chains over the concentration range studied. Chondrocyte-matrix interactions were investigated using cell attachment to solid phase type XI collagen. Pretreatment of chondrocytes with either heparin or heparinase significantly reduced attachment to type XI collagen, Incubation of denatured and cyanogen bromide-cleaved type XI collagen with radiolabeled heparin identified sites of interaction on the alpha1(XI) and alpha2(XI) chains. NH2-terminal sequence data confirmed that the predominant heparin-binding peptide contained the sequence GKPGPRGQRGPTGPRGSRGAR from the alpha1(XI) chain. Using rotary shadowing electron microscopy of native type XI collagen molecules and heparin-bovine serum albumin conjugate, an additional binding site was identified at one end of the triple helical region of the collagen molecule. This coincides with consensus heparin binding motifs present at the aminoterminal ends of both the alpha1(XI) and the alpha2(XI) chains. The contribution of glycosaminoglycan-type XI collagen interactions to cartilage matrix stabilization is discussed.	Cardiff Univ, Connect Tissue Biol Labs, Sch Biosci, Cardiff CF10 3US, S Glam, Wales; Univ Bristol, Sch Vet Sci, Collagen Res Grp, Bristol BS18 7DY, Avon, England	Cardiff University; University of Bristol	Vaughan-Thomas, A (corresponding author), Cardiff Univ, Connect Tissue Biol Labs, Sch Biosci, Museum Ave, Cardiff CF10 3US, S Glam, Wales.							BERNARD M, 1988, J BIOL CHEM, V263, P17159; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BURGESON RE, 1979, BIOCHEM BIOPH RES CO, V87, P1124, DOI 10.1016/S0006-291X(79)80024-8; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Delacoux F, 1998, J BIOL CHEM, V273, P15069, DOI 10.1074/jbc.273.24.15069; DEPREZ PN, 1995, J BIOL CHEM, V270, P11043, DOI 10.1074/jbc.270.19.11043; DUANCE VC, 1991, BIOCHEM SOC T, V19, P376; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; FICHARD A, 1994, MATRIX BIOL, V14, P515; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; KODA JE, 1985, J BIOL CHEM, V260, P8157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; MACIEWICZ RA, 1990, FEBS LETT, V269, P189, DOI 10.1016/0014-5793(90)81151-D; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; NAH HD, 1992, J BIOL CHEM, V267, P22581; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; RICARDBLUM S, 1982, FEBS LETT, V146, P343, DOI 10.1016/0014-5793(82)80949-6; RUOSLAHTI E, 1980, BIOCHIM BIOPHYS ACTA, V631, P350, DOI 10.1016/0304-4165(80)90308-6; SMITH GN, 1985, J BIOL CHEM, V260, P761; SMITH GN, 1987, COLLAGEN REL RES, V7, P315; SMITH GN, 1989, MATRIX, V9, P186; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VAUGHANTHOMAS A, 1994, INT J EXP PATHOL, V75, P41; WARDALE RJ, 1993, J CELL SCI, V105, P975; WU JJ, 1995, J BIOL CHEM, V270, P18865, DOI 10.1074/jbc.270.32.18865; WU JJ, 1991, J BIOL CHEM, V266, P5625; YAOI Y, 1990, BIOCHIM BIOPHYS ACTA, V1035, P139, DOI 10.1016/0304-4165(90)90108-9; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	34	38	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5303	5309		10.1074/jbc.M008764200	http://dx.doi.org/10.1074/jbc.M008764200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11084037	hybrid			2022-12-25	WOS:000168484300103
J	Gerber, BO; Meng, EC; Dotsch, V; Baranski, TJ; Bourne, HR				Gerber, BO; Meng, EC; Dotsch, V; Baranski, TJ; Bourne, HR			An activation switch in the ligand binding pocket of the C5a receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; TRANSMEMBRANE HELICES; RHODOPSIN ACTIVATION; MUTANT CYCLES; C-TERMINUS; ANTAGONISTS; SITE; IDENTIFICATION; ANALOGS; ANAPHYLATOXIN	Although agonists are thought to occupy binding pockets within the seven-helix core of serpentine receptors, the topography of these binding pockets and the conformational changes responsible for receptor activation are poorly understood. To identify the ligand binding pocket in the receptor for complement factor 5a (C5aR), we assessed binding affinities of hexapeptide ligands, each mutated at a single position, for seven mutant C5aRs, each mutated at a single position in the putative ligand binding site. In ChaW tan antagonist) and W5Cha tan agonist), the side chains at position 5 are tryptophan and cyclohexylalanine, respectively. Comparisons of binding affinities indicated that the hexapeptide residue at this position interacts with two C5aR residues, IIe-116 (helix III) and Val-286 (helix VII); in a C5aR model these two side chains point toward one another. Both the I116A and the V286A mutations markedly increased binding affinity of W5Cha but not that of ChaW, Moreover, ChaW, the antagonist hexapeptide, acted as a full agonist on the I116A mutant. These results argue that C5aR residues Ile-116 and Val-286 interact with the side chain at position 5 of the hexapeptide ligand to form an activation switch. Based on this and previous work, we present a docking model for the hexapeptide within the C5aR binding pocket. We propose that agonists induce a small change in the relative orientations of helices III and VII and that these helices work together to allow movement of helix VI away from the receptor core, thereby triggering G protein activation,	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bourne, HR (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, Box 0450,513 Parnassus Ave, San Francisco, CA 94143 USA.		Doetsch, Volker/D-5697-2011	Dotsch, Volker/0000-0001-5720-212X	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027800, R37GM027800] Funding Source: NIH RePORTER; NCRR NIH HHS [P41-RR-01081] Funding Source: Medline; NIGMS NIH HHS [GM-27800] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Baldwin JM, 1997, J MOL BIOL, V272, P144, DOI 10.1006/jmbi.1997.1240; Baranski TJ, 1999, J BIOL CHEM, V274, P15757, DOI 10.1074/jbc.274.22.15757; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; DEMARTINO JA, 1995, J BIOL CHEM, V270, P15966, DOI 10.1074/jbc.270.27.15966; DEMARTINO JA, 1994, J BIOL CHEM, V269, P14446; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; Finch AM, 1999, J MED CHEM, V42, P1965, DOI 10.1021/jm9806594; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; GARCIA PD, 1995, EMBO J, V14, P4460, DOI 10.1002/j.1460-2075.1995.tb00125.x; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Herzyk P, 1998, J MOL BIOL, V281, P741, DOI 10.1006/jmbi.1998.1981; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; KAWAI M, 1992, J MED CHEM, V35, P220, DOI 10.1021/jm00080a004; KONTEATIS ZD, 1994, J IMMUNOL, V153, P4200; MOLLISON KW, 1989, P NATL ACAD SCI USA, V86, P292, DOI 10.1073/pnas.86.1.292; OR YS, 1992, J MED CHEM, V35, P402, DOI 10.1021/jm00080a030; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PEASE JE, 1994, EUR J IMMUNOL, V24, P211, DOI 10.1002/eji.1830240133; Pellas TC, 1998, J IMMUNOL, V160, P5616; Pogozheva ID, 1997, BIOPHYS J, V72, P1963, DOI 10.1016/S0006-3495(97)78842-8; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; SCHREIBER G, 1995, J MOL BIOL, V248, P478, DOI 10.1006/jmbi.1995.0235; Sheikh SP, 1999, J BIOL CHEM, V274, P17033, DOI 10.1074/jbc.274.24.17033; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; Shieh T, 1997, J MOL BIOL, V269, P373, DOI 10.1006/jmbi.1997.1035; SICILIANO SJ, 1994, P NATL ACAD SCI USA, V91, P1214, DOI 10.1073/pnas.91.4.1214; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SZYPERSKI T, 1992, J BIOMOL NMR, V2, P323, DOI 10.1007/BF01874811; TOTH MJ, 1994, PROTEIN SCI, V3, P1159, DOI 10.1002/pro.5560030802; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; Wong AK, 1998, J MED CHEM, V41, P3417, DOI 10.1021/jm9800651; Zhang XL, 1997, PROTEINS, V28, P261, DOI 10.1002/(SICI)1097-0134(199706)28:2<261::AID-PROT13>3.0.CO;2-G	45	68	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3394	3400		10.1074/jbc.M007748200	http://dx.doi.org/10.1074/jbc.M007748200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11062244	hybrid			2022-12-25	WOS:000166784900054
J	Liu, QS; Schonbrunn, A				Liu, QS; Schonbrunn, A			Agonist-induced phosphorylation sf somatostatin receptor subtype 1 (Sst1) - Relationship to desensitization and internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULINOMA CELLS; PITUITARY-CELLS; PROTEIN-KINASE; UP-REGULATION; RAT; SITES; LOCALIZATION; MECHANISMS; ACTIVATION; INHIBITION	The sst1 somatostatin (SRIF) receptor subtype is widely expressed in the endocrine, gastrointestinal, and neuronal systems as well as in hormone-sensitive tumors, yet little is known about its regulation. Here we investigated the desensitization, internalization, and phosphorylation of sst1 expressed in CHO-K1 cells. Treatment of cells with 100 nM SRIF for 30 min reduced maximal SRIF inhibition of adenylyl cyclase from 40 to 10%. This desensitization was rapid (t(1/2) < 2 min) and dependent on agonist concentration (EC50 = 2 nM). However, internalization of receptor-bound ligand occurred slowly (t(1/2) > 180 min). Incubation of cells with SRIF also caused a rapid (tw < 2 min) increase in sst1 receptor phosphorylation in a dose-dependent manner (EC,, = 1.3 nan), as determined in a mobility shift phosphorylation assay. Receptor phosphorylation was not affected by pertussis toxin, indicating a requirement for receptor occupancy rather than signaling. The protein kinase C activator, phorbol 12-myristate 13-acetate also stimulated sst1 receptor phosphorylation whereas forskolin did not. Both agonist- and phorbol 12-myristate 18-acetate-stimulated receptor phosphorylation occurred mainly on serine. These studies are the first to demonstrate phosphorylation of the sst1 receptor and suggest that phosphorylation mediated uncoupling, rather than sequestration, leads to its desensitization.	Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, Houston, TX 77225 USA	University of Texas System; University of Texas Health Science Center Houston	Schonbrunn, A (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Integrat Biol & Pharmacol, POB 20708, Houston, TX 77225 USA.	Agnes.Schonbrunn@uth.tmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032234] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32234] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Backstrom JR, 2000, J BIOL CHEM, V275, P23620, DOI 10.1074/jbc.M000922200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNO JF, 1993, ENDOCRINOLOGY, V133, P2561, DOI 10.1210/en.133.6.2561; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Chen LC, 1997, J BIOL CHEM, V272, P18666, DOI 10.1074/jbc.272.30.18666; Ferguson SSG, 1998, SEMIN CELL DEV BIOL, V9, P119, DOI 10.1006/scdb.1997.0216; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; Gu YZ, 1995, MOL PHARMACOL, V48, P1004; HADCOCK JR, 1994, MOL PHARMACOL, V45, P410; HERELD D, 1994, J BIOL CHEM, V269, P7036; HERSHBERGER RE, 1994, ENDOCRINOLOGY, V134, P1277, DOI 10.1210/en.134.3.1277; Hipkin RW, 2000, J BIOL CHEM, V275, P5591, DOI 10.1074/jbc.275.8.5591; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Hofland LJ, 1999, J CLIN ENDOCR METAB, V84, P775, DOI 10.1210/jc.84.2.775; HOU CF, 1994, J BIOL CHEM, V269, P10357; Hukovic N, 1999, J BIOL CHEM, V274, P24550, DOI 10.1074/jbc.274.35.24550; Hukovic N, 1996, ENDOCRINOLOGY, V137, P4046, DOI 10.1210/en.137.9.4046; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kreienkamp H J, 1999, Results Probl Cell Differ, V26, P215; Krempels K, 1997, GASTROENTEROLOGY, V112, P1948, DOI 10.1053/gast.1997.v112.pm9178687; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lanneau C, 2000, ENDOCRINOLOGY, V141, P967, DOI 10.1210/en.141.3.967; Lanneau C, 1998, EUR J NEUROSCI, V10, P204, DOI 10.1046/j.1460-9568.1998.00041.x; Meyerhof W, 1998, Rev Physiol Biochem Pharmacol, V133, P55; Nouel D, 1997, ENDOCRINOLOGY, V138, P296, DOI 10.1210/en.138.1.296; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; PRESKY DH, 1986, J CELL BIOL, V102, P878, DOI 10.1083/jcb.102.3.878; Reubi J C, 1997, Q J Nucl Med, V41, P63; REUBI JC, 1995, J CLIN ENDOCR METAB, V80, P2806, DOI 10.1210/jc.80.9.2806; Roosterman D, 1998, FEBS LETT, V425, P137, DOI 10.1016/S0014-5793(98)00221-X; Roosterman D, 1997, J NEUROENDOCRINOL, V9, P741, DOI 10.1046/j.1365-2826.1997.00632.x; Roth A, 1997, J BIOL CHEM, V272, P23769, DOI 10.1074/jbc.272.38.23769; Schaer JC, 1997, INT J CANCER, V70, P530, DOI 10.1002/(SICI)1097-0215(19970304)70:5<530::AID-IJC7>3.0.CO;2-Z; Schafer J, 1999, NEUROPEPTIDES, V33, P457, DOI 10.1054/npep.1999.0762; SCHONBRUNN A, 2000, ENDOCRINOLOGY, P427; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; Selmer IS, 2000, REGUL PEPTIDES, V90, P1, DOI 10.1016/S0167-0115(00)00108-7; Smith RD, 1998, MOL ENDOCRINOL, V12, P634, DOI 10.1210/me.12.5.634; SULLIVAN SJ, 1986, J BIOL CHEM, V261, P3571; TARENTINO AL, 1989, METHOD CELL BIOL, V32, P111; TOMURA H, 1994, BIOCHEM BIOPH RES CO, V200, P986, DOI 10.1006/bbrc.1994.1547; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; Williams BY, 1996, MOL PHARMACOL, V50, P716; Zhu LJ, 1998, ENDOCRINOLOGY, V139, P350, DOI 10.1210/en.139.1.350	44	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3709	3717		10.1074/jbc.M008873200	http://dx.doi.org/10.1074/jbc.M008873200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11073961	hybrid			2022-12-25	WOS:000166784900095
J	Willars, GB; Royall, JE; Nahorski, SR; El-Gehani, F; Everest, H; McArdle, CA				Willars, GB; Royall, JE; Nahorski, SR; El-Gehani, F; Everest, H; McArdle, CA			Rapid down-regulation of the type I inositol 1,4,5-trisphosphate receptor and desensitization of gonadotropin-releasing hormone-mediated Ca2+ responses in alpha T3-1 gonadotropes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROBLASTOMA-CELLS; PITUITARY-CELLS; GENERATION; ACTIVATION; EXPRESSION; CALCIUM; CONSEQUENCES; MOBILIZATION; STIMULATION; DEGRADATION	Despite no evidence for desensitization of phospholipase C-coupled gonadotropin-releasing hormone (GnRH) receptors, we previously reported marked suppression of GnRH-mediated Ca2+ responses in alpha T3-1 cells by pre-exposure to GnRH. This suppression could not be accounted for solely by reduced inositol 1,4,5-trisphosphate (Ins(1,4,5)P-3) responses, thereby implicating uncoupling of Ins(1,4,5)P-3 production and Ca2+ mobilization (McArdle, C. A., Willars, G. B., Fowkes, R, C., Nahorski, S. R., Davidson, J. S., and Forrest-Owen, W. (1996) J. Biol. Chem. 271, 23711-23117). In the current study we demonstrate that GnRH causes a homologous and heterologous desensitization of Ca2+ signaling in alpha T3-1 cells that is coincident with a rapid (t(1/2) < 20 min), marked, and functionally relevant loss of type I Ins(1,4,5)P-3 receptor immunoreactivity and binding. Furthermore, using an <alpha>T3-1 cell line expressing recombinant muscarinic M, receptors we show that the unique resistance of the GnRH receptor to rapid desensitization contributes to a fast, profound, and sustained loss of Ins(1,4,5)P-3 receptor immunoreactivity. These data highlight a potential role for rapid Ins(1,4,5)P-3 receptor down-regulation in homologous and heterologous desensitization and in particular suggest that this mechanism may contribute to the suppression of the reproductive system that is exploited in the major clinical applications of GnRH analogues.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; Univ Bristol, Neuroendocrine Unit, Dept Med, Bristol BS2 8HW, Avon, England	University of Leicester; University of Bristol	Willars, GB (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Med Sci Bldg,POB 138,Univ Rd, Leicester LE1 9HN, Leics, England.	gbw2@leicester.ac.uk	McArdle, Craig/AAQ-5660-2021	McArdle, Craig/0000-0003-4836-5351				BARBIERI RL, 1992, TRENDS ENDOCRIN MET, V3, P30, DOI 10.1016/1043-2760(92)90089-J; BELCHETZ PE, 1978, SCIENCE, V202, P631, DOI 10.1126/science.100883; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bootman MD, 1997, CELL, V91, P367, DOI 10.1016/S0092-8674(00)80420-1; DAVIDSON JS, 1994, BIOCHEM J, V300, P299, DOI 10.1042/bj3000299; Garrel G, 1997, ENDOCRINOLOGY, V138, P2259, DOI 10.1210/en.138.6.2259; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HANSEN JR, 1987, MOL ENDOCRINOL, V1, P808, DOI 10.1210/mend-1-11-808; Harris D, 1997, J BIOL CHEM, V272, P13534, DOI 10.1074/jbc.272.21.13534; Heding A, 1998, J BIOL CHEM, V273, P11472, DOI 10.1074/jbc.273.19.11472; JENKINSON S, 1994, MOL PHARMACOL, V46, P1138; Mackrill JJ, 1996, BIOCHEM J, V318, P871, DOI 10.1042/bj3180871; McArdle CA, 1996, J BIOL CHEM, V271, P23711, DOI 10.1074/jbc.271.39.23711; MCARDLE CA, 1995, ENDOCRINOLOGY, V136, P4864, DOI 10.1210/en.136.11.4864; MCARDLE CA, 1992, ENDOCRINOLOGY, V130, P3567, DOI 10.1210/en.130.6.3567; McArdle CA, 1999, MOL CELL ENDOCRINOL, V151, P129, DOI 10.1016/S0303-7207(99)00024-6; MOENTER SM, 1992, ENDOCRINOLOGY, V130, P503, DOI 10.1210/en.130.1.503; MOENTER SM, 1991, ENDOCRINOLOGY, V129, P1175, DOI 10.1210/endo-129-3-1175; Oberdorf J, 1997, J NEUROCHEM, V69, P1897; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; SHAH BH, 1994, MOL PHARMACOL, V46, P1; SIMPSON PB, 1994, J NEUROCHEM, V63, P2369; Sipma H, 1998, CELL CALCIUM, V23, P11, DOI 10.1016/S0143-4160(98)90070-7; STOJILKOVIC SS, 1994, ENDOCR REV, V15, P462, DOI 10.1210/er.15.4.462; Thrower EC, 1996, BIOCHEM J, V318, P61, DOI 10.1042/bj3180061; Tse FW, 1997, NEURON, V18, P121, DOI 10.1016/S0896-6273(01)80051-9; Wilcox RA, 1997, FEBS LETT, V402, P241, DOI 10.1016/S0014-5793(96)01540-2; Willars GB, 1999, J BIOL CHEM, V274, P30146, DOI 10.1074/jbc.274.42.30146; Willars GB, 1998, J BIOL CHEM, V273, P5037, DOI 10.1074/jbc.273.9.5037; Willars GB, 1998, BIOCHEM J, V333, P301, DOI 10.1042/bj3330301; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 1996, J BIOL CHEM, V271, P16652, DOI 10.1074/jbc.271.28.16652; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234	34	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3123	3129		10.1074/jbc.M008916200	http://dx.doi.org/10.1074/jbc.M008916200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11069921	hybrid			2022-12-25	WOS:000166784900021
J	Van Rompaey, L; Potter, M; Adams, C; Grosveld, G				Van Rompaey, L; Potter, M; Adams, C; Grosveld, G			Tel induces a G1 arrest and suppresses Ras-induced transformation	ONCOGENE			English	Article						Tel; transformation; tumor suppressor	ACUTE LYMPHOBLASTIC-LEUKEMIA; MEDIATED CELLULAR-TRANSFORMATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; ACUTE MYELOID-LEUKEMIA; ABL TYROSINE KINASE; HEMATOLOGIC MALIGNANCIES; MYELOPROLIFERATIVE DISORDERS; TRANSCRIPTIONAL REPRESSOR; CONGENITAL FIBROSARCOMA; TUMOR-SUPPRESSOR	The Tel gene is a major target of translocations in leukemia and loss of heterozygosity is regularly observed for the non-translocated allele, thus supporting the notion that Tel is a tumor suppressor. Most tumor suppressors influence cellular proliferation, differentiation and cell death and thereby prevent oncogenic transformation and genetic instability. We found that overexpression of Tel retards proliferation of many cell types, primary cells and immortalized cells, by inducing a G1 arrest. Tel's block of cellular proliferation is rescued by high seeding densities. Furthermore, Tel suppressed Ras-mediated colony growth in soft agar and tumor formation in nude mice. The Pointed and DNA binding (DB) domains of Tel were required for all Tel-induced phenotype.	St Jude Childrens Res Hosp, Dept Genet, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Grosveld, G (corresponding author), St Jude Childrens Res Hosp, Dept Genet, 332 N Lauderdale St, Memphis, TN 38105 USA.				NCI NIH HHS [CA21765, CA72999-03] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baens M, 1999, GENOMICS, V56, P40, DOI 10.1006/geno.1998.5685; BUIJS A, 1995, ONCOGENE, V10, P1511; Carroll M, 1996, P NATL ACAD SCI USA, V93, P14845, DOI 10.1073/pnas.93.25.14845; Cazzaniga G, 1999, BLOOD, V94, P4370, DOI 10.1182/blood.V94.12.4370.424k34_4370_4373; Chakrabarti SR, 1999, BIOCHEM BIOPH RES CO, V264, P871, DOI 10.1006/bbrc.1999.1605; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Chase A, 1999, BLOOD, V93, P1025, DOI 10.1182/blood.V93.3.1025.403a20_1025_1031; Cools J, 1999, BLOOD, V94, P1820, DOI 10.1182/blood.V94.5.1820.417k09_1820_1824; Du W, 1999, CANCER RES, V59, P2059; Eguchi M, 1999, BLOOD, V93, P1355, DOI 10.1182/blood.V93.4.1355; Fenrick R, 1999, MOL CELL BIOL, V19, P6566; Foos G, 1998, J BIOL CHEM, V273, P18871, DOI 10.1074/jbc.273.30.18871; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GOLUB T, 1996, BIOCHIM BIOPHYS ACTA, V1288, P7; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; Golub TR, 1996, MOL CELL BIOL, V16, P4107; GOLUB TR, 1995, P NATL ACAD SCI USA, V92, P4917, DOI 10.1073/pnas.92.11.4917; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; Hoglund M, 1996, BLOOD, V87, P324, DOI 10.1182/blood.V87.1.324.bloodjournal871324; Iijima Y, 2000, BLOOD, V95, P2126; Jousset C, 1997, EMBO J, V16, P69, DOI 10.1093/emboj/16.1.69; Knezevich SR, 1998, NAT GENET, V18, P184, DOI 10.1038/ng0298-184; Knezevich SR, 1998, CANCER RES, V58, P5046; KWIATKOWSKI B, 1999, AM SOC HEMATOLOGY, V94, pA1155; Kwiatkowski BA, 1998, J BIOL CHEM, V273, P17525, DOI 10.1074/jbc.273.28.17525; La Starza R, 1999, BRIT J HAEMATOL, V107, P340, DOI 10.1046/j.1365-2141.1999.01724.x; Lacronique V, 1997, SCIENCE, V278, P1309, DOI 10.1126/science.278.5341.1309; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; Liu Q, 2000, EMBO J, V19, P1827, DOI 10.1093/emboj/19.8.1827; Lopez R, 1999, J BIOL CHEM, V274, P30132, DOI 10.1074/jbc.274.42.30132; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; PAPADOPOULOS P, 1995, CANCER RES, V55, P34; Peeters P, 1997, CANCER RES, V57, P564; Peeters P, 1997, BLOOD, V90, P2535, DOI 10.1182/blood.V90.7.2535.2535_2535_2540; Poirel H, 1997, ONCOGENE, V14, P349, DOI 10.1038/sj.onc.1200829; Potter MD, 2000, BLOOD, V95, P3341, DOI 10.1182/blood.V95.11.3341.011k44_3341_3348; Ritchie KA, 1999, LEUKEMIA, V13, P1790, DOI 10.1038/sj.leu.2401494; ROMANA SP, 1995, BLOOD, V85, P3662, DOI 10.1182/blood.V85.12.3662.bloodjournal85123662; Rowley JD, 1999, SEMIN HEMATOL, V36, P59; Sato Y, 1997, BLOOD, V90, P4886; SATO Y, 1995, BLOOD, V86, P1525, DOI 10.1182/blood.V86.4.1525.bloodjournal8641525; Schwaller J, 1998, EMBO J, V17, P5321, DOI 10.1093/emboj/17.18.5321; SGOURAS DN, 1995, EMBO J, V14, P4781, DOI 10.1002/j.1460-2075.1995.tb00160.x; SHUMAKER DK, 1994, EXP CELL RES, V214, P440, DOI 10.1006/excr.1994.1280; Shurtleff SA, 1995, LEUKEMIA, V9, P1985; STEGMAIER K, 1995, BLOOD, V86, P38, DOI 10.1182/blood.V86.1.38.bloodjournal86138; Stegmaier K, 1996, CANCER RES, V56, P1413; Suto Y, 1997, GENE CHROMOSOME CANC, V18, P254, DOI 10.1002/(SICI)1098-2264(199704)18:4<254::AID-GCC3>3.0.CO;2-#; Takeuchi S, 1997, LEUKEMIA, V11, P1220, DOI 10.1038/sj.leu.2400743; Tomasson MH, 1999, BLOOD, V93, P1707, DOI 10.1182/blood.V93.5.1707.405k24_1707_1714; Tomasson MH, 2000, J CLIN INVEST, V105, P423, DOI 10.1172/JCI8902; Van Rompaey L., 1999, Neoplasia (New York), V1, P526; Wai DH, 2000, ONCOGENE, V19, P906, DOI 10.1038/sj.onc.1203396; Wang LC, 1997, EMBO J, V16, P4374, DOI 10.1093/emboj/16.14.4374; Wang LC, 1998, GENE DEV, V12, P2392, DOI 10.1101/gad.12.15.2392; Wasylyk B, 1998, TRENDS BIOCHEM SCI, V23, P213, DOI 10.1016/S0968-0004(98)01211-0; WASYLYK C, 1994, ONCOGENE, V9, P3665; Wlodarska I, 1996, CYTOGENET CELL GENET, V72, P229, DOI 10.1159/000134197; Xing XM, 2000, NAT MED, V6, P189, DOI 10.1038/72294; Yagasaki F, 1999, GENE CHROMOSOME CANC, V26, P192, DOI 10.1002/(SICI)1098-2264(199911)26:3<192::AID-GCC2>3.0.CO;2-E; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	62	46	46	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5244	5250		10.1038/sj.onc.1203899	http://dx.doi.org/10.1038/sj.onc.1203899			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077441				2022-12-25	WOS:000165059700005
J	Iyer, S; Leonidas, DD; Swaminathan, GJ; Maglione, D; Battisti, M; Tucci, M; Persico, MG; Acharya, KR				Iyer, S; Leonidas, DD; Swaminathan, GJ; Maglione, D; Battisti, M; Tucci, M; Persico, MG; Acharya, KR			The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL MITOGEN; KINASE DOMAIN RECEPTOR; HIGH-AFFINITY BINDING; FACTOR VEGF; FACTOR B; ANGSTROM RESOLUTION; TYROSINE KINASE; LIGAND-BINDING; FLT-1; IDENTIFICATION	The angiogenic molecule placenta growth factor (PlGF) is a member of the cysteine-knot family of growth factors. In this study, a mature isoform of the human PlGF protein, PlGF-1, was crystallized as a homodimer in the crystallographic asymmetric unit, and its crystal structure was elucidated at 2.0 Angstrom resolution. The overall structure of PlGF-1 is similar to that of vascular endothelial growth factor (VEGF) with which it shares 42% amino acid sequence identity. Based on structural and biochemical data, we have mapped several important residues on the PlGF-1 molecule that are involved in recognition of the fms-like tyrosine kinase receptor (Flt-1, also known as VEGFR-1). We propose a model for the association of PlGF-1 and Flt-1 domain 2 with precise shape complementarity, consider the relevance of this assembly for PlGF-1 signal transduction, and provide a structural basis for altered specificity of this molecule.	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Geymonat SpA, I-03012 Anagni, FR, Italy; CNR, Int Inst Genet & Biophys, I-80125 Naples, Italy	University of Bath; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR)	Acharya, KR (corresponding author), Univ Bath, Dept Biol & Biochem, Claverton Down, Bath BA2 7AY, Avon, England.	K.R.Acharya@bath.ac.uk	Leonidas, Demetres/F-7228-2013; Leonidas, Demetres/AAE-9296-2021	Leonidas, Demetres/0000-0002-3874-2523; Leonidas, Demetres/0000-0002-3874-2523; Acharya, K. Ravi/0000-0002-3009-4058; Swaminathan, Jawahar/0000-0002-0215-4084				Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Barleon B, 1997, J BIOL CHEM, V272, P10382; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger A.T., 1992, X PLOR VERSION 3 1 M; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bussolino F, 1997, TRENDS BIOCHEM SCI, V22, P251, DOI 10.1016/S0968-0004(97)01074-8; Cao YH, 1997, BIOCHEM BIOPH RES CO, V235, P493, DOI 10.1006/bbrc.1997.6813; Cao YH, 1996, J BIOL CHEM, V271, P3154, DOI 10.1074/jbc.271.6.3154; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; Cunningham SA, 1997, BIOCHEM BIOPH RES CO, V231, P596, DOI 10.1006/bbrc.1997.6156; DavisSmyth T, 1996, EMBO J, V15, P4919, DOI 10.1002/j.1460-2075.1996.tb00872.x; DISALVO J, 1995, J BIOL CHEM, V270, P7717, DOI 10.1074/jbc.270.13.7717; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fuh G, 1998, J BIOL CHEM, V273, P11197, DOI 10.1074/jbc.273.18.11197; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; HOLLAND DR, 1994, J MOL BIOL, V239, P385, DOI 10.1006/jmbi.1994.1380; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Joukov V, 1996, EMBO J, V15, P290; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Levy AP, 1989, GROWTH FACTORS, V2, P9, DOI 10.3109/08977198909069077; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; MAGLIONE D, 1993, ONCOGENE, V8, P925; MAGLIONE D, 1992, GROWTH FACTORS OF THE VASCULAR AND NERVOUS SYSTEMS, P28; Maglione D, 2000, FARMACO, V55, P165, DOI 10.1016/S0014-827X(00)00012-4; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; MIDGAL M, 1998, J BIOL CHEM, V273, P22272; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OEFNER C, 1992, EMBO J, V11, P3921, DOI 10.1002/j.1460-2075.1992.tb05485.x; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; Orlandini M, 1996, P NATL ACAD SCI USA, V93, P11675, DOI 10.1073/pnas.93.21.11675; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK JE, 1994, J BIOL CHEM, V269, P25646; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Ribatti D, 1996, INT J DEV BIOL, V40, P1189; RISAU W, 1990, Progress in Growth Factor Research, V2, P71, DOI 10.1016/0955-2235(90)90010-H; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SCHLUNEGGER MP, 1992, NATURE, V358, P430, DOI 10.1038/358430a0; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; TERMAN BI, 1994, GROWTH FACTORS, V11, P187, DOI 10.3109/08977199409046916; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Yonekura H, 1999, J BIOL CHEM, V274, P35172, DOI 10.1074/jbc.274.49.35172; Ziche M, 1997, LAB INVEST, V76, P517	61	87	101	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12153	12161		10.1074/jbc.M008055200	http://dx.doi.org/10.1074/jbc.M008055200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11069911	hybrid			2022-12-25	WOS:000168081800097
J	Roubert, C; Cox, PJ; Bruss, M; Hamon, M; Bonisch, H; Giros, B				Roubert, C; Cox, PJ; Bruss, M; Hamon, M; Bonisch, H; Giros, B			Determination of residues in the norepinephrine transporter that are critical for tricyclic antidepressant affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE DOPAMINE TRANSPORTER; HUMAN SEROTONIN TRANSPORTER; SUBSTRATE TRANSPORT; MOLECULAR-CLONING; RADIATION INACTIVATION; STRUCTURAL DOMAINS; CYSTEINE RESIDUES; EXPRESSION; COCAINE; RECOGNITION	The norepinephrine (NET) and dopamine (DAT) transporters are highly homologous proteins, displaying many pharmacological similarities. Both transport dopamine with higher affinity than norepinephrine and are targets for the psychostimulants cocaine and amphetamine, However, they strikingly contrast in their affinities for tricyclic antidepressants (TCA). Previous studies, based on chimeric proteins between DAT and NET suggest that domains ranging from putative transmembrane domain (TMD) 5 to 8 are involved in the high affinity binding of TCA to NET. We substituted 24 amino acids within this region in the human NET with their counterparts in the human DAT, resulting in 22 different mutants. Mutations of residues located in extra- or intracytoplasmic loops have no effect on binding affinity of neither TCA nor cocaine. Three point mutations in TMD6 (F316C), -7 (V356S), and -8 (G400L) induced a loss of TCA binding affinity of 8-, 5-, and 4-fold, respectively, without affecting the affinity of cocaine. The triple mutation F316C/V356S/G400L produced a 40-fold shift in desipramine affinity. These three residues are strongly conserved in all TCA-sensitive transporters cloned in mammalian and nonmammalian species. A strong shift in TCA affinity (IC,,) was also observed for double mutants F316C/D336T (35-fold) and S399P/G400L (80-fold for nortriptyline and 1000-fold for desipramine), Reverse mutations P401S/L402G in hDAT did not elicit any gain in TCA affinities, whereas C318F and S358V resulted in a 3- and 10-fold increase in affinity, respectively. Our results clearly indicate that two residues located in TMD6 and -7 of hNET may play an important role in TCA interaction and that a critical region in TMD8 is likely to be involved in the tertiary structure allowing the high affinity binding of TCA.	Fac Med Creteil, INSERM, U513, F-94000 Creteil, France; Fac Med Pitie Salpetriere, INSERM, U288, F-75013 Paris, France; Univ Bonn, Inst Pharmacol & Toxicol, D-53113 Bonn, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; University of Bonn	Giros, B (corresponding author), Fac Med Creteil, INSERM, U513, 8 Rue Gen Sarrail, F-94000 Creteil, France.		GIROS, Bruno/ABD-5790-2021	GIROS, Bruno/0000-0001-5876-9822				AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; Apparsundaram S, 1997, J NEUROSCI, V17, P2691; AXELROD JULIUS, 1965, RECENT PROG HORMONE RES, V21, P597; Barker EL, 1996, MOL PHARMACOL, V50, P957; BARKER EL, 1994, MOL PHARMACOL, V46, P799; BERGER SP, 1994, MOL PHARMACOL, V46, P726; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Bruss M, 1997, MOL BRAIN RES, V52, P257, DOI 10.1016/S0169-328X(97)00267-2; BRUSS M, 1995, J BIOL CHEM, V270, P9197; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; BUCK KJ, 1994, P NATL ACAD SCI USA, V91, P12584, DOI 10.1073/pnas.91.26.12584; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; COREY JL, 1994, P NATL ACAD SCI USA, V91, P1188, DOI 10.1073/pnas.91.3.1188; COYLE JT, 1969, J PHARMACOL EXP THER, V170, P221; DEMCHYSHYN LL, 1994, P NATL ACAD SCI USA, V91, P5158, DOI 10.1073/pnas.91.11.5158; Galli A, 1998, P NATL ACAD SCI USA, V95, P13260, DOI 10.1073/pnas.95.22.13260; GIROS B, 1991, FEBS LETT, V295, P149, DOI 10.1016/0014-5793(91)81406-X; GIROS B, 1994, J BIOL CHEM, V269, P15985; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; GIROS B, 1992, MOL PHARMACOL, V42, P383; GLOWINSKI J, 1964, NATURE, V204, P1318, DOI 10.1038/2041318a0; GU H, 1994, J BIOL CHEM, V269, P7124; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; IVERSEN LL, 1974, BIOCHEM PHARMACOL, V23, P1927, DOI 10.1016/0006-2952(74)90250-0; Jayanthi LD, 1998, MOL PHARMACOL, V54, P601; KILTY JE, 1991, SCIENCE, V254, P578, DOI 10.1126/science.1948035; KITAYAMA S, 1993, SYNAPSE, V15, P58, DOI 10.1002/syn.890150107; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; Lin F, 1996, BIOPHYS J, V71, P3126, DOI 10.1016/S0006-3495(96)79506-1; LINGEN B, 1994, FEBS LETT, V342, P235, DOI 10.1016/0014-5793(94)80508-3; Melikian HE, 1996, MOL PHARMACOL, V50, P266; MILNER HE, 1994, BBA-BIOMEMBRANES, V1190, P185, DOI 10.1016/0005-2736(94)90051-5; Nguyen TT, 1996, J NEUROCHEM, V67, P645; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; PIFL C, 1993, J NEUROSCI, V13, P4246, DOI 10.1523/jneurosci.13-10-04246.1993; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; RICHELSON E, 1984, EUR J PHARMACOL, V104, P27; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; Sonders MS, 1996, CURR OPIN NEUROBIOL, V6, P294, DOI 10.1016/S0959-4388(96)80111-5; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; Sur C, 1997, P NATL ACAD SCI USA, V94, P7639, DOI 10.1073/pnas.94.14.7639; Sur C, 1997, BIOCHEM BIOPH RES CO, V241, P68, DOI 10.1006/bbrc.1997.7771; UHL GR, 1992, TRENDS PHARMACOL SCI, V13, P421, DOI 10.1016/0165-6147(92)90133-Q; USDIN TB, 1991, P NATL ACAD SCI USA, V88, P11168, DOI 10.1073/pnas.88.24.11168; WANG JB, 1995, J NEUROCHEM, V64, P1416	45	43	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8254	8260		10.1074/jbc.M009798200	http://dx.doi.org/10.1074/jbc.M009798200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11092898	hybrid			2022-12-25	WOS:000167474900081
J	Shannon, TR; Chu, GX; Kraniass, EG; Bers, DM				Shannon, TR; Chu, GX; Kraniass, EG; Bers, DM			Phospholamban decreases the energetic efficiency of the Sarcoplasmic reticulum Ca pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; MYOCARDIAL-CONTRACTILITY; CALCIUM-BINDING; RELEASE; PHOSPHORYLATION; HEART; TRANSPORT; VESICLES; LOAD; THAPSIGARGIN	We tested the hypothesis that increased Sarcoplasmic reticulum (SR) Ca content ([Ca](SRT)) in phospholamban knockout mice (PLB-KO) is because of increased SR Ca pump efficiency defined by the steady-state SR [Ca] gradient. The time course of thapsigargin-sensitive ATP-dependent Ca-45 influx into and efflux out of cardiac SR vesicles from PLB-KO and wild-type (WT) mice was measured at 100 nM free [Ca]. We found that PLB decreased the initial SR Ca uptake rate (0.13 versus 0.31 nmol/mg/s) and decreased steady-state 45Ca content (0.9 versus 4.1 nmol/mg protein). Furthermore, at similar total SR [Ca], the pump-mediated Ca efflux rate was higher in WT (0.065 versus 0.037 nmol/mg/s). The pump-independent leak rate constant (k(leak)) was also measured at 100 nM free [Ca]. The results indicate that k(leak) was < 1% of pump-mediated backflux and was not different among nonpentameric mutant PLB (PLB-C41F), WT pentameric PLB (same expression level), and PLB-KO, Therefore differences in passive SR Ca leak cannot be the cause of the higher thapsigargin-sensitive Ca efflux from the WT membranes. We conclude that the decreased total SR [Ca] in WT mice is caused by decreased SR Ca influx rate, an increased Ca-pump backflux, and unaltered leak. Based upon both thermodynamic and kinetic analysis, we conclude that PLB decreases the energetic efficiency of the SR Ca pump.	Loyola Univ, Med Ctr, Dept Physiol, Maywood, IL 60153 USA; Univ Cincinnati, Dept Pharmacol & Cell Biophys, Cincinnati, OH 45267 USA	Loyola University Chicago; University System of Ohio; University of Cincinnati	Bers, DM (corresponding author), Loyola Univ, Med Ctr, Dept Physiol, 2160 S 1st Ave, Maywood, IL 60153 USA.		Bers, Donald M/C-4507-2012	Bers, Donald/0000-0002-2237-9483	NHLBI NIH HHS [HL30077, HL09412] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030077, R37HL030077] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN DG, 1985, J PHYSIOL-LONDON, V361, P185, DOI 10.1113/jphysiol.1985.sp015640; BASSANI JWM, 1995, AM J PHYSIOL-CELL PH, V268, pC1313, DOI 10.1152/ajpcell.1995.268.5.C1313; BASSANI RA, 1995, BIOPHYS J, V68, P2015, DOI 10.1016/S0006-3495(95)80378-4; BERS DM, 1986, AM J PHYSIOL, V251, pC861, DOI 10.1152/ajpcell.1986.251.6.C861; BERS DM, 1994, METHOD CELL BIOL, V40, P3; CHENG H, 1993, SCIENCE, V262, P740, DOI 10.1126/science.8235594; Chu GX, 1998, J BIOL CHEM, V273, P33674, DOI 10.1074/jbc.273.50.33674; Dettbarn C, 1997, MOL PHARMACOL, V52, P1124, DOI 10.1124/mol.52.6.1124; FEHER JJ, 1984, BIOPHYS J, V45, P1135, DOI 10.1016/S0006-3495(84)84261-7; FEHER JJ, 1982, J BIOL CHEM, V257, P191; Frank K, 2000, BIOCHEMISTRY-US, V39, P14176, DOI 10.1021/bi001049k; Ginsburg KS, 1998, J GEN PHYSIOL, V111, P491, DOI 10.1085/jgp.111.4.491; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HOVEMADSEN L, 1993, AM J PHYSIOL, V264, pC677, DOI 10.1152/ajpcell.1993.264.3.C677; Huser J, 1998, AM J PHYSIOL-HEART C, V274, pH1800, DOI 10.1152/ajpheart.1998.274.5.H1800; ISENBERG G, 1994, J PHYSIOL-LONDON, V480, P423, DOI 10.1113/jphysiol.1994.sp020372; JACKSON AP, 1987, FEBS LETT, V216, P35, DOI 10.1016/0014-5793(87)80752-4; Koss KL, 1997, BASIC RES CARDIOL, V92, P17, DOI 10.1007/BF00794064; Koss KL, 1996, CIRC RES, V79, P1059, DOI 10.1161/01.RES.79.6.1059; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; Kranias E.G., 1998, AM J PHYSIOL, V274, P1335; KRANIAS EG, 1985, BIOCHIM BIOPHYS ACTA, V844, P193, DOI 10.1016/0167-4889(85)90090-4; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MAKINOSE M, 1971, FEBS LETT, V12, P269, DOI 10.1016/0014-5793(71)80195-3; MARTELL AE, 1974, CRITICAL STABILITY C, P269; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Overend CL, 1997, J PHYSIOL-LONDON, V502, P471, DOI 10.1111/j.1469-7793.1997.471bj.x; PAGE E, 1978, AM J PHYSIOL, V235, pC147, DOI 10.1152/ajpcell.1978.235.5.C147; PAGE E, 1971, P NATL ACAD SCI USA, V68, P1465, DOI 10.1073/pnas.68.7.1465; POST JA, 1992, J MEMBRANE BIOL, V129, P49; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; Santana LF, 1997, J PHYSIOL-LONDON, V503, P21, DOI 10.1111/j.1469-7793.1997.021bi.x; Satoh H, 1997, AM J PHYSIOL-HEART C, V272, pH657, DOI 10.1152/ajpheart.1997.272.2.H657; Shannon TR, 1997, BIOPHYS J, V73, P1524, DOI 10.1016/S0006-3495(97)78184-0; Shannon TR, 2000, BIOPHYS J, V78, P322, DOI 10.1016/S0006-3495(00)76595-7; Shannon TR, 2000, BIOPHYS J, V78, P334, DOI 10.1016/S0006-3495(00)76596-9; SHANNON TR, 1997, ANN NY ACAD SCI, V853, P350; SPENCER CI, 1995, J PHYSIOL-LONDON, V488, P267, DOI 10.1113/jphysiol.1995.sp020965; Spencer CI, 1997, J PHYSIOL-LONDON, V504, P565, DOI 10.1111/j.1469-7793.1997.565bd.x; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TAKENAKA H, 1982, J BIOL CHEM, V257, P2649; WEBER A, 1966, BIOCHEM Z, V345, P329; WEGENER AD, 1984, J BIOL CHEM, V259, P1834	43	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7195	7201		10.1074/jbc.M007085200	http://dx.doi.org/10.1074/jbc.M007085200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11087739	hybrid			2022-12-25	WOS:000167442900048
J	Boot, RG; Blommaart, EFC; Swart, E; Ghauharali-van der Vlugt, K; Bijl, N; Moe, C; Place, A; Aerts, JMFG				Boot, RG; Blommaart, EFC; Swart, E; Ghauharali-van der Vlugt, K; Bijl, N; Moe, C; Place, A; Aerts, JMFG			Identification of a novel acidic mammalian chitinase distinct from chitotriosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; SMOOTH-MUSCLE CELLS; CHITINOLYTIC ENZYMES; CANDIDA-ALBICANS; PROTEIN FAMILY; BRUGIA-MALAYI; GENE; MEMBER; GLYCOPROTEIN; ALLOSAMIDIN	Chitinases are ubiquitous chitin-fragmenting hydro lases. Recently we discovered the first human chitinase, named chitotriosidase, that is specifically expressed by phagocytes. We here report the identification, purification, and subsequent cloning of a second mammalian chitinase. This enzyme is characterized by an acidic isoelectric point and therefore named acidic mammalian chitinase (AMCase). In rodents and man the enzyme is relatively abundant in the gastrointestinal tract and is found to a lesser extent in the lung. Like chitotriosidase, AMCase is synthesized as a 50-kDa protein containing a 39-kDa N-terminal catalytic domain, a hinge region, and a C-terminal chitin-binding domain. In contrast to chitotriosidase, the enzyme is extremely acid stable and shows a distinct second pH optimum around pH 2. AMCase is capable of cleaving artificial chitin-like substrates as well as crab shell chitin and chitin as present in the fungal cell wall. Our study has revealed the existence of a chitinolytic enzyme in the gastrointestinal tract and lung that may play a role in digestion and/or defense.	Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1100 DE Amsterdam, Netherlands; Univ Maryland, Ctr Marine Biotechnol, Inst Biotechnol, Baltimore, MD 21202 USA	University of Amsterdam; Academic Medical Center Amsterdam; University System of Maryland; University of Maryland Baltimore	Boot, RG (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Biochem, POB 22700, NL-1100 DE Amsterdam, Netherlands.	r.g.boot@amc.uva.nl	Aerts, Johannes/A-1028-2009; Place, Allen R/F-9267-2013	Aerts, Johannes/0000-0001-8168-2565; Boot, Rolf/0000-0002-7031-3390				ARAUJO ACG, 1993, J HISTOCHEM CYTOCHEM, V41, P571, DOI 10.1177/41.4.8450196; Boatman Dorothy E., 1997, Human Reproduction (Oxford), V12, P133; BOOT RG, 1995, J BIOL CHEM, V270, P26252, DOI 10.1074/jbc.270.44.26252; Boot RG, 1998, J BIOL CHEM, V273, P25680, DOI 10.1074/jbc.273.40.25680; Boussac M, 2000, ELECTROPHORESIS, V21, P665, DOI 10.1002/(SICI)1522-2683(20000201)21:3<665::AID-ELPS665>3.0.CO;2-U; Cai GP, 1997, J CELL BIOCHEM, V67, P257, DOI 10.1002/(SICI)1097-4644(19971101)67:2<257::AID-JCB11>3.0.CO;2-C; COULSON AFW, 1994, FEBS LETT, V354, P41, DOI 10.1016/0014-5793(94)01084-6; DEBONO M, 1994, ANNU REV MICROBIOL, V48, P471, DOI 10.1146/annurev.mi.48.100194.002351; DICKINSON K, 1989, J GEN MICROBIOL, V135, P1417; ESCOTT GM, 1995, INFECT IMMUN, V63, P4770, DOI 10.1128/IAI.63.12.4770-4773.1995; FLACH J, 1992, EXPERIENTIA, V48, P701, DOI 10.1007/BF02124285; FUHRMAN JA, 1985, MOL BIOCHEM PARASIT, V17, P93, DOI 10.1016/0166-6851(85)90130-6; Girard C, 1999, INSECT BIOCHEM MOLEC, V29, P549, DOI 10.1016/S0965-1748(99)00029-6; GOODAY GW, 1996, CHITIN ENZYMOLOGY, P125; Guo YF, 1995, J INHERIT METAB DIS, V18, P717, DOI 10.1007/BF02436762; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; HECTOR RF, 1986, J CLIN MICROBIOL, V24, P620, DOI 10.1128/JCM.24.4.620-624.1986; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; HOLLAK CEM, 1994, J CLIN INVEST, V93, P1288, DOI 10.1172/JCI117084; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; JACKSON P, 1990, BIOCHEM J, V270, P705, DOI 10.1042/bj2700705; JEUNIAUX C, 1961, NATURE, V192, P135, DOI 10.1038/192135a0; Jin HM, 1998, GENOMICS, V54, P316, DOI 10.1006/geno.1998.5593; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; KRAMER KJ, 1993, INSECT BIOCHEM MOLEC, V23, P691, DOI 10.1016/0965-1748(93)90043-R; LINDSAY GJH, 1984, J FISH BIOL, V24, P529, DOI 10.1111/j.1095-8649.1984.tb04823.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALETTE B, 1995, MOL REPROD DEV, V41, P384, DOI 10.1002/mrd.1080410315; Malinda KM, 1999, EXP CELL RES, V250, P168, DOI 10.1006/excr.1999.4511; MANSON FDC, 1992, J FISH BIOL, V40, P919, DOI 10.1111/j.1095-8649.1992.tb02637.x; MCNAB R, 1991, FEMS MICROBIOL LETT, V82, P79, DOI 10.1111/j.1574-6968.1991.tb04843.x; MILEWSKI S, 1992, J GEN MICROBIOL, V138, P2545, DOI 10.1099/00221287-138-12-2545; MORRISON BW, 1994, ONCOGENE, V9, P3417; NEVILLE AC, 1976, J CELL SCI, V21, P73; Owhashi M, 2000, J BIOL CHEM, V275, P1279, DOI 10.1074/jbc.275.2.1279; PLACE AR, 1996, CHITIN ENZYMOLOGY, V2, P39; Prager E.M., 1996, Experientia Supplementum (Basel), V75, P9; PRAGER EM, 1996, LYSOZYMES MODEL ENZY, P323; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Renkema GH, 1997, EUR J BIOCHEM, V244, P279, DOI 10.1111/j.1432-1033.1997.00279.x; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; Saito A, 1999, GENE, V239, P325, DOI 10.1016/S0378-1119(99)00394-7; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; SHAHABUDDIN M, 1994, EXP PARASITOL, V79, P85, DOI 10.1006/expr.1994.1066; Shen ZC, 1997, J BIOL CHEM, V272, P28895, DOI 10.1074/jbc.272.46.28895; SHIMAHARA K, 1988, METHOD ENZYMOL, V161, P417; Tellam R. L., 1996, P86; Tjoelker LW, 2000, J BIOL CHEM, V275, P514, DOI 10.1074/jbc.275.1.514; TRUDEL J, 1989, ANAL BIOCHEM, V178, P362, DOI 10.1016/0003-2697(89)90653-2; Van Steijn GJ, 1999, EUR J ORAL SCI, V107, P328, DOI 10.1046/j.0909-8836.1999.eos107503.x; Verhage HG, 1997, HUM REPROD UPDATE, V3, P541, DOI 10.1093/humupd/3.6.541	51	396	424	0	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6770	6778		10.1074/jbc.M009886200	http://dx.doi.org/10.1074/jbc.M009886200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11085997	hybrid, Green Published			2022-12-25	WOS:000167261000090
J	Gaemers, IC; Vos, HL; Volders, HH; van der Valk, SW; Hilkens, J				Gaemers, IC; Vos, HL; Volders, HH; van der Valk, SW; Hilkens, J			A STAT-responsive element in the promoter of the episialin/MUC1 gene is involved in its overexpression in carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUC1 MUCIN EXPRESSION; BREAST-CARCINOMA; INTERFERON-GAMMA; EPITHELIAL-CELLS; MAMMARY-GLAND; MONOCLONAL-ANTIBODIES; TRANSCRIPTION FACTORS; MOLECULAR-CLONING; O-GLYCOSYLATION; MESSENGER-RNA	The mucin-like glycoprotein episialin (MUC1) is highly overproduced by a number of human carcinomas. We have shown previously in a variety of mammalian cell lines that overexpression of this very large transmembrane molecule diminishes cellular adhesion, suggesting that episialin/MUC1 overexpression may play an important role in tumor invasion and metastasis. By using in situ hybridization, we show here that episialin/MUC1 mRNA expression can be increased more than 10-fold in breast carcinoma cells relative to the expression in adjacent normal breast epithelium. In search of the molecular mechanism of this overexpression, we observed that the episialin/MUC1 promoter contains a candidate binding site for transcription factors of the STAT family similar to 500 base pairs upstream of the transcription start site. Cytokines and/or growth factors such as interleukin-6 or interferon-gamma can activate STATs. In the human breast carcinoma cell line T47D, both compounds are able to stimulate transcription of a luciferase reporter gene under the control of a 750-base pair MUC1 promoter fragment proximal to the transcription start site. The observed increase is entirely mediated by the single STAT-binding site, since mutation of this site abolishes stimulation of the reporter by interleukin-6 and interferon-gamma. In addition, mutation of the STAT site also decreased the promoter activity in nonstimulated T47D cells, suggesting that the STAT-binding site is among the elements that are involved in the overexpression of MUC1 in tumor cells.	Netherlands Canc Inst, Div Tumor Biol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Hilkens, J (corresponding author), Netherlands Canc Inst, Div Tumor Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	jhi@nki.nl		Hilkens, John/0000-0002-0932-7793	NCI NIH HHS [1R01 CA79580-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079580] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABE M, 1993, P NATL ACAD SCI USA, V90, P282, DOI 10.1073/pnas.90.1.282; ABE M, 1990, J CELL PHYSIOL, V143, P226, DOI 10.1002/jcp.1041430205; Agrawal B, 1998, NAT MED, V4, P43, DOI 10.1038/nm0198-043; Agrawal B, 1998, CANCER RES, V58, P4079; Akira S, 1992, Semin Cancer Biol, V3, P17; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2449; BEHRENS J, 1994, INVAS METAST, V14, P61; Bieche I, 1997, CANCER GENET CYTOGEN, V98, P75, DOI 10.1016/S0165-4608(96)00410-4; BILLES F, 2000, BLOOD, V95, P2930; Bracke ME, 1996, CURR TOP MICROBIOL, V213, P123; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BURCHELL J, 1993, EPITHELIAL CELL BIOL, V2, P155; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK S, 1994, DIS MARKERS, V12, P43, DOI 10.1155/1994/480236; CLEVENGER CV, 1995, AM J PATHOL, V146, P695; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dyomin VG, 2000, BLOOD, V95, P2666; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; GINSBURG E, 1995, CANCER RES, V55, P2591; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; GouilleuxGruart V, 1996, BLOOD, V87, P1692; Guddo F, 1998, J CLIN PATHOL, V51, P667, DOI 10.1136/jcp.51.9.667; Hanisch FG, 1996, EUR J BIOCHEM, V236, P318, DOI 10.1111/j.1432-1033.1996.00318.x; Hawley RG, 1998, LEUKEMIA LYMPHOMA, V29, P465, DOI 10.3109/10428199809050906; Hilkens J, 1996, BREAST CANCER - ADVANCES IN BIOLOGY AND THERAPEUTICS, P281; Hilkens J, 1998, TUMOR BIOL, V19, P67, DOI 10.1159/000056506; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; HILKENS J, 1989, CANCER RES, V49, P786; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; KLEIN B, 1994, CYTOKINES HUMAN MULT; Kovarik A, 1996, J BIOL CHEM, V271, P18140, DOI 10.1074/jbc.271.30.18140; KOVARIK A, 1993, J BIOL CHEM, V268, P9917; KRUEGER J, 1991, J CELL BIOCHEM, V45, P327, DOI 10.1002/jcb.240450404; LIGTENBERG MJL, 1990, J BIOL CHEM, V265, P5573; LIGTENBERG MJL, 1992, CANCER RES, V52, P2318; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lloyd KO, 1996, J BIOL CHEM, V271, P33325, DOI 10.1074/jbc.271.52.33325; LOOK DC, 1994, J BIOL CHEM, V269, P8952; NAKAMORI S, 1994, GASTROENTEROLOGY, V106, P353, DOI 10.1016/0016-5085(94)90592-4; PARRY G, 1992, J CELL SCI, V101, P191; PERUSSIA B, 1983, J EXP MED, V158, P1092, DOI 10.1084/jem.158.4.1092; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; SPICER AP, 1995, J BIOL CHEM, V270, P30093; SPICER AP, 1991, J BIOL CHEM, V266, P15099; Sun SC, 1999, ONCOGENE, V18, P1401, DOI 10.1038/sj.onc.1202430; Takao S, 1999, CANCER-AM CANCER SOC, V86, P1966, DOI 10.1002/(SICI)1097-0142(19991115)86:10<1966::AID-CNCR13>3.0.CO;2-M; TAMM I, 1991, P NATL ACAD SCI USA, V88, P4414, DOI 10.1073/pnas.88.10.4414; TAMM I, 1994, P NATL ACAD SCI USA, V91, P3329, DOI 10.1073/pnas.91.8.3329; VANDEWIELVANKEMENADE E, 1993, J IMMUNOL, V151, P767; VANDUINEN SG, 1984, CANCER-AM CANCER SOC, V53, P1566, DOI 10.1002/1097-0142(19840401)53:7<1566::AID-CNCR2820530724>3.0.CO;2-9; VOS HL, 1991, BIOCHEM BIOPH RES CO, V181, P121, DOI 10.1016/S0006-291X(05)81390-7; WATSON CJ, 1995, BRIT J CANCER, V71, P840, DOI 10.1038/bjc.1995.162; WESSELING J, 1995, J CELL BIOL, V129, P255, DOI 10.1083/jcb.129.1.255; Wesseling J, 1996, MOL BIOL CELL, V7, P565, DOI 10.1091/mbc.7.4.565; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; YUNIS JJ, 1989, BLOOD, V73, P931; ZARETSKY JZ, 1990, FEBS LETT, V265, P46, DOI 10.1016/0014-5793(90)80880-R; Zhang K, 1996, J CELL BIOCHEM, V60, P538, DOI 10.1002/(SICI)1097-4644(19960315)60:4<538::AID-JCB10>3.3.CO;2-A; ZOTTER S, 1987, LAB INVEST, V57, P193	62	109	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6191	6199		10.1074/jbc.M009449200	http://dx.doi.org/10.1074/jbc.M009449200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11084045	hybrid			2022-12-25	WOS:000167261000020
J	Liu, QL; Krzewska, J; Liberek, K; Craig, EA				Liu, QL; Krzewska, J; Liberek, K; Craig, EA			Mitochondrial Hsp70 Ssc1: Role in protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE DNAK; NUCLEOTIDE EXCHANGE; SUBSTRATE-BINDING; ESCHERICHIA-COLI; SEQUENTIAL ACTION; IMPORT; TRANSLOCATION; MECHANISM; PREPROTEINS; MUTATIONS	Ssc1, the major Hsp70 of the mitochondrial matrix, is involved in the translocation of proteins from the cytosol into the matrix and their subsequent folding. To better understand the physiological mechanism of action of this Hsp70, we have undertaken a biochemical analysis of Ssc1 and two mutant proteins, Ssc1-2 and Ssc1-201. ssc1-2 is a temperature-sensitive mutant defective in both translocation and folding; ssc1-201 contains a second mutation in this ssc1 gene that suppresses the temperature-sensitive growth defect of ssc1-2, correcting the translocation but not the folding defect. We found that although Ssc1 was competent to facilitate the refolding of denatured luciferase in vitro, both Ssc1-2 and Ssc1-201 showed significant defects, consistent with the data obtained with isolated mitochondria. Purified Ssc1-2 had a lowered affinity for a peptide substrate compared with wild-type Ssc1 but only in the ADP-bound state. This peptide binding defect was reversed in the suppressor protein Ssc1-201. However, a defect in the ability of Hsp40 to stimulate the ATPase activity of Ssc1-2 was not corrected in Ssc1-201. Thus, the inability of these two mutant proteins to efficiently facilitate luciferase refolding correlates with their defect in stimulation of ATPase activity by Hsp40s, indicating that this interaction is critical for protein folding in mitochondria.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	University of Wisconsin System; University of Wisconsin Madison; Fahrenheit Universities; University of Gdansk	Craig, EA (corresponding author), Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA.		Liberek, Krzysztof/F-5812-2011	Liberek, Krzysztof/0000-0002-7532-9279	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027870] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM27870] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azem A, 1997, J BIOL CHEM, V272, P20901, DOI 10.1074/jbc.272.33.20901; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CRAIG EA, 1993, SCIENCE, V260, P1902, DOI 10.1126/science.8100364; Davis JE, 1999, P NATL ACAD SCI USA, V96, P9269, DOI 10.1073/pnas.96.16.9269; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAMBILL BD, 1993, J CELL BIOL, V123, P109, DOI 10.1083/jcb.123.1.109; Gassler CS, 1998, P NATL ACAD SCI USA, V95, P15229, DOI 10.1073/pnas.95.26.15229; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GREENE LE, 1995, J BIOL CHEM, V270, P2967, DOI 10.1074/jbc.270.7.2967; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; HA JH, 1999, MOL CHAPERONES FOLDI, P573; Hajek P, 1997, MOL CELL BIOL, V17, P7169, DOI 10.1128/MCB.17.12.7169; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Horst M, 1997, EMBO J, V16, P1842, DOI 10.1093/emboj/16.8.1842; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; KANG PJ, 1990, NATURE, V348, P137, DOI 10.1038/348137a0; Karzai AW, 1996, J BIOL CHEM, V271, P11236, DOI 10.1074/jbc.271.19.11236; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; LALORAYA S, 1994, P NATL ACAD SCI USA, V91, P6481, DOI 10.1073/pnas.91.14.6481; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; MANNINGKRIEG UC, 1991, EMBO J, V10, P3273, DOI 10.1002/j.1460-2075.1991.tb04891.x; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Mayer MP, 1999, J MOL BIOL, V289, P1131, DOI 10.1006/jmbi.1999.2844; Miao BJ, 1997, J MOL BIOL, V265, P541, DOI 10.1006/jmbi.1996.0762; Montgomery DL, 1999, J MOL BIOL, V286, P915, DOI 10.1006/jmbi.1998.2514; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; ROWLEY N, 1994, CELL, V77, P249, DOI 10.1016/0092-8674(94)90317-4; Sakuragi S, 1999, J BIOL CHEM, V274, P11275, DOI 10.1074/jbc.274.16.11275; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; Schneider HC, 1996, EMBO J, V15, P5796, DOI 10.1002/j.1460-2075.1996.tb00966.x; Suh WC, 1998, P NATL ACAD SCI USA, V95, P15223, DOI 10.1073/pnas.95.26.15223; VESTWEBER D, 1988, EMBO J, V7, P1147, DOI 10.1002/j.1460-2075.1988.tb02924.x; Voisine C, 1999, CELL, V97, P565, DOI 10.1016/S0092-8674(00)80768-0; Voos W, 1996, EMBO J, V15, P2668, DOI 10.1002/j.1460-2075.1996.tb00627.x; WESTERMANN B., 1995, EMBO J, V13, P1998; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	39	89	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6112	6118		10.1074/jbc.M009519200	http://dx.doi.org/10.1074/jbc.M009519200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096111	hybrid			2022-12-25	WOS:000167261000010
J	Marintcheva, B; Weller, SK				Marintcheva, B; Weller, SK			Residues within the conserved helicase motifs of UL9, the origin-binding protein of herpes simplex virus-1, are essential for helicase activity but not for dimerization or origin binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; ESCHERICHIA-COLI REP; SINGLE-STRANDED-DNA; NUCLEOTIDE EXCISION-REPAIR; TYPE-1 ORIGIN; CRYSTAL-STRUCTURE; RNA HELICASE; CONFORMATIONAL-CHANGES; MUTATIONAL ANALYSIS; REPLICATION COMPARTMENTS	UL9, an essential gene for herpes simplex virus type 1 (HSV-1) DNA replication, exhibits helicase and origin DNA binding activities. It has been hypothesized that UL9 binds and unwinds the HSV-1 origin of replication, creating a replication bubble and promoting the assembly of the viral replication machinery; however, direct confirmation of this hypothesis has not been possible. Based on the presence of conserved helicase motifs, UL9 has been classified as a superfamily II helicase. Mutations in conserved residues of the helicase motifs I-VI of UL9 have been isolated, and most of them fail to complement a UL9 null virus in vivo (Martinez R., Shao L., and Weller S. (1992) J. Virol. 66, 6735-6746). In addition, mutants in motifs I, II, and VI were found to be transdominant (Malik, A. K., and Weller, S. K. (1996) J. Virol. 70, 7859-7866). Here we present the characterization of the biochemical properties of the UL9 helicase motif mutants. We report that mutations in motifs I-PV and VI affect the ATPase activity, and all but the motif LII mutation completely abolish the helicase activity. In addition, mutations in these motifs do not interfere with UL9 dimerization or the ability of UL9 to bind the HSV-1 origin of replication. Based on the similarity of the helicase motif sequences between UL9 and UvrB, another superfamily II member with helicase like activity, we were able to map the UL9 mutations on the structure of the UvrB protein and provide an explanation for the observed phenotypes. Our results indicate that the helicase function of UL9 is indispensable for viral replication, supporting the hypothesis that UL9 is essential for unwinding the HSV-1 origin of replication in vivo. Furthermore, the data presented provide insights into the mechanism of transdominance of the UL9 helicase motif mutants.	Univ Connecticut, Ctr Hlth, Dept Microbiol, Farmington, CT 06030 USA	University of Connecticut	Weller, SK (corresponding author), Univ Connecticut, Ctr Hlth, Dept Microbiol, 263 Farmington Ave, Farmington, CT 06030 USA.	Weller@NSO2.uchc.edu	Weller, Sandra/N-3979-2013	Weller, Sandra/0000-0002-4519-6276	NIAID NIH HHS [AI21747] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021747, R37AI021747] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABBOTTS AP, 1995, J GEN VIROL, V76, P3125, DOI 10.1099/0022-1317-76-12-3125; ARBUCKLE MI, 1993, J GEN VIROL, V74, P1349, DOI 10.1099/0022-1317-74-7-1349; Ausubel FA, 1990, CURRENT PROTOCOLS MO; Benz J, 1999, STRUCTURE, V7, P671, DOI 10.1016/S0969-2126(99)80088-4; BEYNON RJ, 1989, PROTEOLYTIC ENZYMES, P189; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; BLUMEL J, 1995, J GEN VIROL, V76, P3119, DOI 10.1099/0022-1317-76-12-3119; BOEHMER PE, 1993, J BIOL CHEM, V268, P1220; BOEHMER PE, 1993, P NATL ACAD SCI USA, V90, P8444, DOI 10.1073/pnas.90.18.8444; BROSH RM, 1995, J BACTERIOL, V177, P5612, DOI 10.1128/jb.177.19.5612-5621.1995; Brosh RM, 1996, J BIOL CHEM, V271, P25360, DOI 10.1074/jbc.271.41.25360; BRUCKNER RC, 1991, J BIOL CHEM, V266, P2669; Burkham J, 1998, J VIROL, V72, P10100, DOI 10.1128/JVI.72.12.10100-10107.1998; CARMICHAEL EP, 1988, J VIROL, V62, P91, DOI 10.1128/JVI.62.1.91-99.1988; CHALBERG M, 1997, DNA REPLICATION EUCA, P721; CHAO KL, 1990, J BIOL CHEM, V265, P1067; Chao L, 1999, J VIROL, V73, P8798, DOI 10.1128/JVI.73.10.8798-8807.1999; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; Dillingham MS, 1999, NUCLEIC ACIDS RES, V27, P3310, DOI 10.1093/nar/27.16.3310; EARNSHAW DL, 1994, BIOCHEM BIOPH RES CO, V199, P1333, DOI 10.1006/bbrc.1994.1377; ELIAS P, 1992, J BIOL CHEM, V267, P17424; FIERER DS, 1992, J VIROL, V66, P3986, DOI 10.1128/JVI.66.7.3986-3995.1992; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GravesWoodward KL, 1997, J BIOL CHEM, V272, P4623, DOI 10.1074/jbc.272.7.4623; GUARINO LA, 1990, VIROLOGY, V179, P1, DOI 10.1016/0042-6822(90)90266-T; Hall MC, 1997, J BIOL CHEM, V272, P18614, DOI 10.1074/jbc.272.30.18614; Hall MC, 1998, J MOL BIOL, V277, P257, DOI 10.1006/jmbi.1997.1614; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; He XD, 2000, J VIROL, V74, P5726, DOI 10.1128/JVI.74.12.5726-5728.2000; Kim DW, 1997, J VIROL, V71, P9400, DOI 10.1128/JVI.71.12.9400-9409.1997; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Korolev S, 1998, PROTEIN SCI, V7, P605, DOI 10.1002/pro.5560070309; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEE SSK, 1995, P NATL ACAD SCI USA, V92, P7882, DOI 10.1073/pnas.92.17.7882; Lee SSK, 1997, P NATL ACAD SCI USA, V94, P2838, DOI 10.1073/pnas.94.7.2838; Lehman IR, 1999, J BIOL CHEM, V274, P28059, DOI 10.1074/jbc.274.40.28059; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; Liptak LM, 1996, J VIROL, V70, P1759, DOI 10.1128/JVI.70.3.1759-1767.1996; Lukonis CJ, 1997, J VIROL, V71, P2390, DOI 10.1128/JVI.71.3.2390-2399.1997; Machius M, 1999, P NATL ACAD SCI USA, V96, P11717, DOI 10.1073/pnas.96.21.11717; Makhov AM, 1996, EMBO J, V15, P1742, DOI 10.1002/j.1460-2075.1996.tb00520.x; Malik AK, 1996, J VIROL, V70, P7859, DOI 10.1128/JVI.70.11.7859-7866.1996; Malik AK, 1996, VIROLOGY, V224, P380, DOI 10.1006/viro.1996.0545; MALIK AK, 1992, VIROLOGY, V190, P702, DOI 10.1016/0042-6822(92)90908-8; Marians KJ, 1997, STRUCTURE, V5, P1129, DOI 10.1016/S0969-2126(97)00263-3; MARTINEZ R, 1992, J VIROL, V66, P6735, DOI 10.1128/JVI.66.11.6735-6746.1992; MCLEAN GW, 1994, J GEN VIROL, V75, P2699, DOI 10.1099/0022-1317-75-10-2699; Monahan SJ, 1998, VIROLOGY, V241, P122, DOI 10.1006/viro.1997.8953; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14565, DOI 10.1021/bi00252a024; MOORE KJM, 1994, BIOCHEMISTRY-US, V33, P14550, DOI 10.1021/bi00252a023; Murata LB, 1999, J BIOL CHEM, V274, P37079, DOI 10.1074/jbc.274.52.37079; PERRY HC, 1993, VIROLOGY, V193, P73, DOI 10.1006/viro.1993.1104; Porter DJT, 1998, J BIOL CHEM, V273, P18906, DOI 10.1074/jbc.273.30.18906; Porter DJT, 1998, J BIOL CHEM, V273, P14247, DOI 10.1074/jbc.273.23.14247; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHULZ GE, 1992, CURR OPIN STRUC BIOL, V2, P61; SKALITER R, 1994, P NATL ACAD SCI USA, V91, P10665, DOI 10.1073/pnas.91.22.10665; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; Soultanas P, 1999, J MOL BIOL, V290, P137, DOI 10.1006/jmbi.1999.2873; STORY RM, 1992, NATURE, V355, P374, DOI 10.1038/355374a0; STOW ND, 1992, J GEN VIROL, V73, P313, DOI 10.1099/0022-1317-73-2-313; STOW ND, 1993, VIROLOGY, V196, P413, DOI 10.1006/viro.1993.1496; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; Theis K, 1999, EMBO J, V18, P6899, DOI 10.1093/emboj/18.24.6899; Theis K, 2000, MUTAT RES-DNA REPAIR, V460, P277, DOI 10.1016/S0921-8777(00)00032-X; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Wardell AD, 1999, J GEN VIROL, V80, P701, DOI 10.1099/0022-1317-80-3-701; WEIR HM, 1989, NUCLEIC ACIDS RES, V17, P1409, DOI 10.1093/nar/17.4.1409; WELLER SK, 1995, DNA PROVIRUS, P189; WONG I, 1993, P NATL ACAD SCI USA, V90, P5428, DOI 10.1073/pnas.90.12.5428; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463	74	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6605	6615		10.1074/jbc.M007743200	http://dx.doi.org/10.1074/jbc.M007743200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11062243	hybrid			2022-12-25	WOS:000167261000071
J	Liu, ZT; Chang, GQ; Leibowitz, SF				Liu, ZT; Chang, GQ; Leibowitz, SF			Diacylglycerol kinase zeta in hypothalamus interacts with long form leptin receptor - Relation to dietary fat and body weight regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; MESSENGER-RNA; RAT-BRAIN; DIABETIC MICE; OBESITY; GENE; ACTIVATION; MUTATION; SYSTEM; HUMANS	Leptin and its long form receptor, Ob-Rb, in hypothalamic nuclei play a key role in regulating energy balance. The mutation of Ob-Rb into one of its natural variants, Ob-Ra, results in severe obesity in rodents. We demonstrate here that diacylglycerol kinase zeta (DGK zeta) interacts, via its ankyrin repeats, with the cytoplasmic portion of Ob-Rb in yeast two-hybrid systems, in protein precipitation experiments in vitro and in vivo, It does not interact, however, with the short form, Ob-Ra, which mediates the entry of leptin into the brain. Furthermore, we show by in situ hybridization that DGK zeta is expressed in neurons of hypothalamic nuclei known to synthesize Ob-Rb and to participate in energy homeostasis, The mutant ob-/ab- and db-/db- mice exhibit increased hypothalamic DGK zeta mRNA level compared with their wild-type controls, suggesting a role for the leptin/ OB-Rb system in regulating DGK zeta expression. Further experiments show that hypothalamic DGK zeta mRNA level is stimulated by the consumption of a high-fat diet. In addition, DGK zeta mRNA is statistically significantly lower in rats and inbred mice that become obese on a high-fat diet compared with their lean counterparts. In fact, it is strongly, negatively correlated with both body fat and circulating levels of leptin. Taken together, our evidence suggests that DGK zeta constitutes a downstream component of the leptin signaling pathway and that reduced hypothalamic DGK zeta' mRNA, and possibly activity, is associated with obesity.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Leibowitz, SF (corresponding author), Rockefeller Univ, 1230 York Ave,Box 278, New York, NY 10021 USA.	leibow@rockvax.rockefeller.edu			NIMH NIH HHS [MH43422] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH043422] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Avignon A, 1996, DIABETES, V45, P1396, DOI 10.2337/diabetes.45.10.1396; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P9378, DOI 10.1073/pnas.83.24.9378; Bjorbaek C, 1998, ENDOCRINOLOGY, V139, P3485, DOI 10.1210/en.139.8.3485; Bray GA, 1998, AM J CLIN NUTR, V68, P1157, DOI 10.1093/ajcn/68.6.1157; Bunting M, 1996, J BIOL CHEM, V271, P10230, DOI 10.1074/jbc.271.17.10230; Chavez M, 1998, J CLIN INVEST, V102, P340, DOI 10.1172/JCI603; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Considine RV, 1996, NEW ENGL J MED, V334, P292, DOI 10.1056/NEJM199602013340503; CONSIDINE RV, 1995, J CLIN INVEST, V95, P2938, DOI 10.1172/JCI118001; Ding L, 1997, P NATL ACAD SCI USA, V94, P5519, DOI 10.1073/pnas.94.11.5519; Ding L, 1998, FEBS LETT, V429, P109, DOI 10.1016/S0014-5793(98)00490-6; Elmquist JK, 1998, J COMP NEUROL, V395, P535; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Flores I, 1996, J BIOL CHEM, V271, P10334, DOI 10.1074/jbc.271.17.10334; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; GIRAUDO SQ, 1994, AM J PHYSIOL, V266, pR1578, DOI 10.1152/ajpregu.1994.266.5.R1578; Goto K, 1996, P NATL ACAD SCI USA, V93, P11196, DOI 10.1073/pnas.93.20.11196; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hubank M, 1999, METHOD ENZYMOL, V303, P325; Hwa JJ, 1996, HORM METAB RES, V28, P659, DOI 10.1055/s-2007-979873; Iritani N, 2000, J NUTR, V130, P1183, DOI 10.1093/jn/130.5.1183; KELLEHER JA, 1989, J NEUROSCI RES, V23, P87, DOI 10.1002/jnr.490230112; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Leibowitz SF, 1998, J NEUROSCI, V18, P2709; MARONEY AC, 1989, J CELL BIOCHEM, V40, P165, DOI 10.1002/jcb.240400205; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; Mercer JG, 1996, FEBS LETT, V387, P113, DOI 10.1016/0014-5793(96)00473-5; Ming MC, 1998, J LIPID RES, V39, P1655; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; OHANIAN J, 1994, BIOCHEM J, V300, P51, DOI 10.1042/bj3000051; Pettitt TR, 1999, J BIOL CHEM, V274, P36181, DOI 10.1074/jbc.274.51.36181; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; RAO KVR, 1994, J NEUROCHEM, V63, P1454; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Satoh N, 1998, NEUROSCI LETT, V249, P107, DOI 10.1016/S0304-3940(98)00401-7; SCHAAP D, 1993, BIOCHEM J, V289, P875, DOI 10.1042/bj2890875; SOLING HD, 1989, J BIOL CHEM, V264, P10643; Spanswick D, 1997, NATURE, V390, P521, DOI 10.1038/37379; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; Wang J, 1998, AM J PHYSIOL-ENDOC M, V274, pE1057, DOI 10.1152/ajpendo.1998.274.6.E1057; Welch CC, 1996, BRAIN RES, V721, P126, DOI 10.1016/0006-8993(96)00151-5; WEST DB, 1992, AM J PHYSIOL, V262, pR1025, DOI 10.1152/ajpregu.1992.262.6.R1025; West DB, 1998, AM J CLIN NUTR, V67, p505S, DOI 10.1093/ajcn/67.3.505S; [No title captured]	50	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5900	5907		10.1074/jbc.M007311200	http://dx.doi.org/10.1074/jbc.M007311200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11078732	hybrid			2022-12-25	WOS:000167115100067
J	De Candia, E; Hall, SW; Rutella, S; Landolfi, R; Andrews, RK; De Cristofaro, R				De Candia, E; Hall, SW; Rutella, S; Landolfi, R; Andrews, RK; De Cristofaro, R			Binding of thrombin to glycoprotein Ib accelerates the hydrolysis of Par-1 on intact platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASE-ACTIVATED RECEPTOR-1; VON-WILLEBRAND-FACTOR; ALPHA-THROMBIN; DOMAIN; HEPARIN; INHIBITION; INTERACTS; COMPLEX; GPIB; SITE	The activation of human platelets by alpha -thrombin is mediated at least in part by cleavage of protease-activated G-protein-coupled receptors, PAR-1 and PAR-4. Platelet glycoprotein Iba also has a high affinity binding site for alpha -thrombin, and this interaction contributes to platelet activation through a still unknown mechanism. In the present study the hypothesis that GpIb alpha may contribute to platelet activation by modulating the hydrolysis of PAR-1 on the platelet membrane was investigated. Gel-filtered platelets from normal individuals were stimulated by alpha -thrombin, and the kinetics of PAR-1 hydrolysis by enzyme was followed with flow cytometry using an anti-PAR-1 monoclonal antibody (SPAN 12) that recognizes only intact PAR-1 molecules. This strategy allowed measurement of the apparent h(cat)/K-m value for thrombin hydrolysis of PAR-1 on intact platelets, which was equal to 1.5 +/- 0.1 x 10(7) M-1 sec(-1) The hydrolysis rate of PAR-1 by thrombin was measured under conditions in which thrombin binding to GpIb was inhibited by different strategies, with the following results, 1) Elimination of GpIb alpha on platelet membranes by mocarhagin treatment reduced the k(cat)/K-m value by about 6-fold, 2) A monoclonal anti-GpIb antibody reduced the apparent k(cat)/K-m value by about 5-fold. 3) An oligonucleotide DNA aptamer, HD22, which binds to the thrombin heparin-binding site (HBS) and inhibits thrombin interaction with GpIb alpha, reduced the apparent k(cat)/K-m value by about 5-fold, 4) Displacement of Lu-thrombin from the binding site on GpIb using PPACK-thrombin reduced the apparent k(cat)/K-m value by about 5-fold, and 5) mutation at the HBS of thrombin (R98A) caused a 5-fold reduction of the apparent h(cat)/K-m value of PAR-1 hydrolysis, Altogether these results show that thrombin interaction with GpIb enhances the specificity of thrombin cleavage of PAR-1 on intact platelets, suggesting that GpIb may function as a "cofactor" for PAR-1 activation by thrombin.	Univ Cattolica Sacro Cuore, Sch Med, Inst Med Semeiot, Haemostasis Res Ctr, I-00168 Rome, Italy; Univ Cattolica Sacro Cuore, Sch Med, Dept Hematol, I-00168 Rome, Italy; Stanford Univ Hosp, Div Hematol, Stanford, CA 94305 USA; Baker Med Res Inst, Hazel & Pip Appel Vasc Biol Lab, Melbourne, Vic 8008, Australia	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Stanford University; Baker Heart and Diabetes Institute	De Cristofaro, R (corresponding author), Univ Cattolica Sacro Cuore, Ist Semeiot Med, Ctr Ric Fisiopatol Emostasi, Largo F Vito 1, I-00168 Rome, Italy.	rdecristofaro@rm.unicatt.it	De Cristofaro, Raimondo/K-3942-2018; Landolfi, Raffaele/AAL-4496-2020; Rutella, Sergio/AAF-9210-2020; Rutella, Sergio/AAF-9187-2020; De Candia, Erica/K-9632-2016	De Cristofaro, Raimondo/0000-0002-8066-8849; Landolfi, Raffaele/0000-0002-7913-8576; Rutella, Sergio/0000-0003-1970-7375; De Candia, Erica/0000-0003-0942-2819; Andrews, Robert Keith/0000-0001-9577-8082	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057530] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL57530-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BOUTON MC, 1995, BIOCHEM J, V305, P635, DOI 10.1042/bj3050635; BRASS LF, 1994, J BIOL CHEM, V269, P2943; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; Coughlin SR, 1999, THROMB HAEMOSTASIS, V82, P353; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; De Candia E, 1999, CIRCULATION, V99, P3308, DOI 10.1161/01.CIR.99.25.3308; de Cristofaro R, 1998, BIOCHEM J, V332, P643, DOI 10.1042/bj3320643; De Cristofaro R, 2000, J BIOL CHEM, V275, P3887, DOI 10.1074/jbc.275.6.3887; DeCandia E, 1997, THROMB HAEMOSTASIS, V77, P735; DECRISTOFARO R, 1993, BIOCHEM J, V289, P475, DOI 10.1042/bj2890475; DELUCA M, 1995, J BIOL CHEM, V270, P26734, DOI 10.1074/jbc.270.45.26734; Dormann D, 2000, BLOOD, V96, P2469, DOI 10.1182/blood.V96.7.2469.h8002469_2469_2478; Esmon CT, 2000, THROMB HAEMOSTASIS, V83, P639; Fersht A, 1985, ENZYME STRUCTURE MEC, P105; FOX JEB, 1988, J BIOL CHEM, V263, P4882; Greco NJ, 1996, BIOCHEMISTRY-US, V35, P906, DOI 10.1021/bi951503y; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; HANDA M, 1986, J BIOL CHEM, V261, P2579; ISHII K, 1994, J BIOL CHEM, V269, P1125; KETNER C, 1979, THROMB RES, V14, P969; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; Mazzucato M, 1998, J BIOL CHEM, V273, P1880, DOI 10.1074/jbc.273.4.1880; Molino M, 1997, J BIOL CHEM, V272, P6011, DOI 10.1074/jbc.272.9.6011; Nakanishi-Matsui M, 2000, NATURE, V404, P609, DOI 10.1038/35007085; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NURDEN AT, 1983, BLOOD CELLS, V9, P333; Ravanat C, 2000, THROMB HAEMOSTASIS, V83, P327; Shapiro MJ, 2000, J BIOL CHEM, V275, P25216, DOI 10.1074/jbc.M004589200; Shen Y, 2000, BLOOD, V95, P903, DOI 10.1182/blood.V95.3.903.003k37_903_910; Tasset DM, 1997, J MOL BIOL, V272, P688, DOI 10.1006/jmbi.1997.1275; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Ward CM, 1996, BIOCHEMISTRY-US, V35, P4929, DOI 10.1021/bi952456c; Wu YP, 2000, ARTERIOSCL THROM VAS, V20, P1661, DOI 10.1161/01.ATV.20.6.1661; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	34	178	183	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4692	4698		10.1074/jbc.M008160200	http://dx.doi.org/10.1074/jbc.M008160200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11084032	hybrid, Green Accepted			2022-12-25	WOS:000168484300024
J	Hardy, CD; Schultz, CS; Collins, K				Hardy, CD; Schultz, CS; Collins, K			Requirements for the dGTP-dependent repeat addition processivity of recombinant Tetrahymena telomerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE-TRANSCRIPTASE; RNA; ELONGATION; COMPLEXES	Telomerase is a reverse transcriptase responsible for adding simple sequence repeats to chromosome 3'-ends. The template for telomeric repeat synthesis is carried within the RNA component of the telomerase ribonucleoprotein complex. Telomerases can copy their internal templates with repeat addition processivity, reusing the same template multiple times in the extension of a single primer. For some telomerases, optimal repeat addition processivity requires high micromolar dGTP concentrations, a much higher dGTP concentration than required for processive nucleotide addition within a repeat. We have investigated the requirements for dGTP-dependent repeat addition processivity using recombinant Tetrahymena telomerase. By altering the template sequence, we show that repeat addition processivity retains the same dGTP-dependence even if dGTP is not the first nucleotide incorporated in the second repeat. Furthermore, no dNTP other than dGTP can stimulate repeat addition processivity, even if it is the first nucleotide incorporated in the second repeat. Using structural variants of dGTP, we demonstrate that the stimulation of repeat addition processivity is specific for dGTP base and sugar constituents but requires only a single phosphate group, However, all nucleotides that stimulate repeat addition processivity also inhibit or compete with dGTP incorporation into product DNA, By assaying telomerase complexes reconstituted with a variety of altered templates, we find that repeat addition processivity has an unanticipated template or product sequence specificity. Finally, we show that a novel, nascent product DNA binding site establishes dGTP-dependent repeat addition processivity.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Collins, K (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, 401 Barker Hall, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054198] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 54198] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUTEXIER C, 1994, GENE DEV, V8, P563, DOI 10.1101/gad.8.5.563; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; Benjamin S, 2000, MOL CELL BIOL, V20, P4224, DOI 10.1128/MCB.20.12.4224-4237.2000; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Collins K, 1999, ANNU REV BIOCHEM, V68, P187, DOI 10.1146/annurev.biochem.68.1.187; COLLINS K, 1995, EMBO J, V14, P5422, DOI 10.1002/j.1460-2075.1995.tb00226.x; COLLINS K, 1993, GENE DEV, V7, P1364, DOI 10.1101/gad.7.7b.1364; Collins K, 1998, P NATL ACAD SCI USA, V95, P8485, DOI 10.1073/pnas.95.15.8485; Coyne RS, 1996, ANNU REV GENET, V30, P557, DOI 10.1146/annurev.genet.30.1.557; Gandhi L, 1998, GENE DEV, V12, P721, DOI 10.1101/gad.12.5.721; GILLEY D, 1995, GENE DEV, V9, P2214, DOI 10.1101/gad.9.18.2214; Greene EC, 1998, GENE DEV, V12, P2921, DOI 10.1101/gad.12.18.2921; GREIDER CW, 1996, DNA REPLICATION EUKA, P619; Hammond PW, 1997, NUCLEIC ACIDS RES, V25, P3698, DOI 10.1093/nar/25.18.3698; LEE MS, 1993, MOL CELL BIOL, V13, P6586, DOI 10.1128/MCB.13.10.6586; Licht JD, 1999, GENE DEV, V13, P1116, DOI 10.1101/gad.13.9.1116; Maine IP, 1999, BIOCHEMISTRY-US, V38, P15325, DOI 10.1021/bi991596+; Miller MC, 2000, EMBO J, V19, P4412, DOI 10.1093/emboj/19.16.4412; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; Prescott J, 1997, GENE DEV, V11, P2790, DOI 10.1101/gad.11.21.2790; Price CM, 1999, CURR OPIN GENET DEV, V9, P218, DOI 10.1016/S0959-437X(99)80032-X; Ricchetti M, 1996, BIOCHEMISTRY-US, V35, P14970, DOI 10.1021/bi961274v; Sun D, 1999, BIOCHEMISTRY-US, V38, P4037, DOI 10.1021/bi982249n; ZAKIAN VA, 1995, SCIENCE, V270, P1601, DOI 10.1126/science.270.5242.1601	24	50	51	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4863	4871		10.1074/jbc.M005158200	http://dx.doi.org/10.1074/jbc.M005158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11096070	hybrid			2022-12-25	WOS:000168484300046
J	Hirose, J; Kawashima, H; Yoshie, O; Tashiro, K; Miyasaka, M				Hirose, J; Kawashima, H; Yoshie, O; Tashiro, K; Miyasaka, M			Versican interacts with chemokines and modulates cellular responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; LYMPHOID-TISSUE CHEMOKINE; HIGH ENDOTHELIAL VENULES; SIGNAL SEQUENCE TRAP; L-SELECTIN; MOLECULAR-CLONING; HEPARAN-SULFATE; GROWTH-FACTOR; ADHESION MOLECULE-1; T-LYMPHOCYTES	We previously reported that versican, a large, chondroitin sulfate proteoglycan, isolated from a renal adenocarcinoma cell line, ACHN, binds L-selectin. Here we report that versican also binds certain chemokines and regulates chemokine function. This binding was strongly inhibited by the chondroitinase digestion of versican or by the addition of soluble chondroitin sulfate (CS) B, CS E, or heparan sulfate. Furthermore, these glycosaminoglycans (GAGs) could bind directly to the chemokines that bind versican, Thus, versican appears to interact with chemokines via its GAGs. We next examined if versican or GAGs affect secondary lymphoid tissue chemokine (SLC)-induced integrin activation and Ca2+ mobilization in lymphoid cells expressing a receptor for SLC, CC chemokine receptor 7. Interestingly, whereas heparan sulfate supported both alpha (4)beta (7) integrin-dependent binding to mucosal addressin cell adhesion molecule-1 (MAdCAM-1)-IgG and Ca2+ mobilization induced by SLC, versican or CS B inhibited these cellular responses, and the extent of inhibition was dependent on the dose of versican or CS B added. These findings suggest that different proteoglycans have different functions in the regulation of chemokine activities and that versican may negatively regulate the function of SLC via its GAG chains.	Osaka Univ, Grad Sch Med, Ctr Biomed Res, Dept Bioregulat, Suita, Osaka 5650871, Japan; Kinki Univ, Sch Med, Dept Microbiol, Osaka Sayama 5898511, Japan; Kyoto Univ, Ctr Mol Biol & Genet, Sakyo Ku, Kyoto 6068507, Japan	Osaka University; Kindai University (Kinki University); Kyoto University	Miyasaka, M (corresponding author), Osaka Univ, Grad Sch Med, Ctr Biomed Res, Dept Bioregulat, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.		Miyasaka, Masayuki/AAM-6343-2020	Yoshie, Osamu/0000-0003-4353-5809				Ali S, 2000, J BIOL CHEM, V275, P11721, DOI 10.1074/jbc.275.16.11721; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; AVNUR Z, 1984, CELL, V38, P811, DOI 10.1016/0092-8674(84)90276-9; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; Burns JM, 1999, P NATL ACAD SCI USA, V96, P14499, DOI 10.1073/pnas.96.25.14499; Derry CJ, 1999, EUR J IMMUNOL, V29, P419, DOI 10.1002/(SICI)1521-4141(199902)29:02<419::AID-IMMU419>3.0.CO;2-A; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Hesselgesser J, 1998, J IMMUNOL, V160, P877; Hieshima K, 1997, J IMMUNOL, V159, P1140; Hieshima K, 1997, J BIOL CHEM, V272, P5846, DOI 10.1074/jbc.272.9.5846; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Iizuka T, 2000, J IMMUNOL, V164, P2463, DOI 10.4049/jimmunol.164.5.2463; Imai T, 1996, J BIOL CHEM, V271, P21514, DOI 10.1074/jbc.271.35.21514; Iozzo RV, 1996, FASEB J, V10, P598, DOI 10.1096/fasebj.10.5.8621059; Isogai Z, 1996, CANCER RES, V56, P3902; Kawashima H, 1999, INT IMMUNOL, V11, P393, DOI 10.1093/intimm/11.3.393; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Koopmann W, 1997, J BIOL CHEM, V272, P10103; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Nagira M, 1997, J BIOL CHEM, V272, P19518, DOI 10.1074/jbc.272.31.19518; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; Pachynski RK, 1998, J IMMUNOL, V161, P952; Petersen F, 1998, J IMMUNOL, V161, P4347; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAKSELA O, 1988, J CELL BIOL, V107, P743, DOI 10.1083/jcb.107.2.743; Sassetti C, 2000, J BIOL CHEM, V275, P9001, DOI 10.1074/jbc.275.12.9001; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TANAKA Y, 1993, IMMUNOL TODAY, V14, P111, DOI 10.1016/0167-5699(93)90209-4; Tanaka Y, 1996, J EXP MED, V184, P1987, DOI 10.1084/jem.184.5.1987; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; Wolff EA, 1999, J BIOL CHEM, V274, P2518, DOI 10.1074/jbc.274.4.2518; Yoshida R, 1998, J BIOL CHEM, V273, P7118, DOI 10.1074/jbc.273.12.7118; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	39	172	174	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5228	5234		10.1074/jbc.M007542200	http://dx.doi.org/10.1074/jbc.M007542200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11083865	hybrid			2022-12-25	WOS:000168484300093
J	Ilg, T; Demar, M; Harbecke, D				Ilg, T; Demar, M; Harbecke, D			Phosphoglycan repeat-deficient Leishmania mexicana parasites remain infectious to macrophages and mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETED ACID-PHOSPHATASE; LIPOPHOSPHOGLYCAN BIOSYNTHESIS; MONOCLONAL-ANTIBODIES; MOLECULAR-CLONING; PROTEOPHOSPHOGLYCAN; PROMASTIGOTES; AMASTIGOTES; VIRULENCE; DONOVANI; DISTINCT	The human pathogen Leishmania synthesizes phosphoglycans (PGs) formed by variably modified phosphodisaccharide [6-Gal beta1-4Man alpha1-PO4] repeats and mannooligosaccharide phosphate [(Man alpha1-2)(0-5)Man alpha1-PO4] caps that occur lipid-bound on lipophosphoglycan, protein-bound on proteophosphoglycans, and as an unlinked form. PG repeat synthesis has been described as essential for survival and development of Leishmania throughout their life cycle, including for virulence to the mammalian host. In this study, this proposal was investigated in Leishmania mexicana using a spontaneous mutant that was fortuitously isolated from an infected mouse, and by generating a lmexlpg2 gene deletion mutant (Delta lmexlpg2), that lacks a Gels GDP-Man transporter. The spontaneous mutant lacks PG repeats but synthesizes normal levels of manno oligosaccharide phosphate caps, whereas the Delta lmexlpg2 mutant is deficient in PG repeat synthesis and down-regulates cap expression. In contrast to expectations, both L, mexicana mutants not only retain their ability to bind to macrophages, but are also indistinguishable from wild type parasites with respect to colonization of and multiplication within host cells. Moreover, in mouse infection studies, the spontaneous L. mexicana repeat-deficient mutant and the Delta lmexlpg2 mutant showed no significant difference to a wild type strain with respect to the severity of disease caused by these parasites. Therefore, at least in Leishmania mexicana, PG repeat synthesis is not an absolute requirement for virulence.	Max Planck Inst Biol, D-72076 Tubingen, Germany	Max Planck Society	Ilg, T (corresponding author), Max Planck Inst Biol, Corrensstr 38, D-72076 Tubingen, Germany.	thomas.ilg@tuebingen.mpg.de						ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6; Beverley SM, 1998, TRENDS MICROBIOL, V6, P35, DOI 10.1016/S0966-842X(97)01180-3; Butcher BA, 1996, J BIOL CHEM, V271, P20573, DOI 10.1074/jbc.271.34.20573; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; Descoteaux A, 1999, BBA-MOL BASIS DIS, V1455, P341, DOI 10.1016/S0925-4439(99)00065-4; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; ELHAY M, 1990, MOL BIOCHEM PARASIT, V40, P255, DOI 10.1016/0166-6851(90)90047-P; Gopfert U, 1999, BIOCHEM J, V344, P787, DOI 10.1042/0264-6021:3440787; GREIS KD, 1992, J BIOL CHEM, V267, P5876; HUANG CC, 1993, J BIOL CHEM, V268, P24060; Ilg T, 2000, PARASITOL TODAY, V16, P489, DOI 10.1016/S0169-4758(00)01791-9; Ilg T, 1999, BIOCHEM SOC T, V27, P518; Ilg T, 1999, J BIOL CHEM, V274, P31410, DOI 10.1074/jbc.274.44.31410; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1991, J CELL SCI, V99, P175; ILG T, 1995, EUR J CELL BIOL, V66, P205; Ilg T, 1998, J BIOL CHEM, V273, P13509, DOI 10.1074/jbc.273.22.13509; ILG T, 1991, P NATL ACAD SCI USA, V88, P8774, DOI 10.1073/pnas.88.19.8774; Ilg T, 2000, EMBO J, V19, P1953, DOI 10.1093/emboj/19.9.1953; Ilgoutz SC, 1999, EMBO J, V18, P2746, DOI 10.1093/emboj/18.10.2746; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; MCCONVILLE MJ, 1992, J BIOL CHEM, V267, P5855; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1993, J BIOL CHEM, V268, P15595; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; Mengeling BJ, 1997, GLYCOBIOLOGY, V7, P873, DOI 10.1093/glycob/7.7.873-c; Peters C, 1997, EUR J IMMUNOL, V27, P2666, DOI 10.1002/eji.1830271028; Peters C, 1997, INFECT IMMUN, V65, P783, DOI 10.1128/IAI.65.2.783-786.1997; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; PIMENTA PFP, 1994, P NATL ACAD SCI USA, V91, P9155, DOI 10.1073/pnas.91.19.9155; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; SACKS DL, 1995, J EXP MED, V181, P685, DOI 10.1084/jem.181.2.685; Sacks DL, 2000, P NATL ACAD SCI USA, V97, P406, DOI 10.1073/pnas.97.1.406; SACKS DL, 1989, EXP PARASITOL, V69, P100, DOI 10.1016/0014-4894(89)90176-8; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Stierhof YD, 1998, J MOL BIOL, V282, P137, DOI 10.1006/jmbi.1998.2012; Stierhof YD, 1999, EUR J CELL BIOL, V78, P675, DOI 10.1016/S0171-9335(99)80036-3; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x	43	72	78	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4988	4997		10.1074/jbc.M008030200	http://dx.doi.org/10.1074/jbc.M008030200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11071892	hybrid			2022-12-25	WOS:000168484300063
J	Masuda, Y; Sasaki, A; Shibuya, H; Ueno, N; Ikeda, K; Watanabe, K				Masuda, Y; Sasaki, A; Shibuya, H; Ueno, N; Ikeda, K; Watanabe, K			Dlxin-1, a novel protein that binds D1x5 and regulates its transcriptional function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOBLAST DIFFERENTIATION; GROWTH SUPPRESSOR; BRANCHIAL ARCHES; HOMEOBOX GENES; WD-REPEAT; EXPRESSION; DLX5; MSX2; IDENTIFICATION; FAMILY	Dlx5, a member of the Dir family of homeodomain proteins, plays a critical role in bone development and fracture healing, To understand the molecular mechanism underlying the transcriptional regulation by Dlx5, we performed yeast two-hybrid screening and isolated a novel protein, Dlxin-1, that binds Dlx5 and regulates its transcriptional function. Dlxin-1 cDNA encodes a 775-amino acid protein that has a partial homology with necdin at the C terminus and 25 repeats of hexapeptides (WQXPXX) in the middle region. Dlxin-1 mRNA is expressed in various adult tissues, but not the spleen, and also in osteoblastic and chondrogenic cell lines. During embryogenesis, a strong signal for Dlxin-1 mRNA was found in cell layers surrounding cartilaginous elements in bone rudiment during dig-it formation. Dlxin-1 binds not only Dlx5 but also Dlx7 and Msx2 and forms homo-multimers in vivo. Transfection and reporter gene assays indicate that Dlxin-1 activates the transcriptional function of Dlx5. Therefore, Dlxin-1 may act as a regulator of the function of Dir family members in bone formation.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; Natl Inst Basic Biol, Div Morphogenesis, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)	Watanabe, K (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, 36-3 Gengo, Aichi 4748522, Japan.		Watanabe, Ken/I-3960-2013	Watanabe, Ken/0000-0003-0664-3915; Ueno, Naoto/0000-0002-8375-2317				Acampora D, 1999, DEVELOPMENT, V126, P3795; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Benson MD, 2000, J BIOL CHEM, V275, P13907, DOI 10.1074/jbc.275.18.13907; Catron KM, 1996, MECH DEVELOP, V55, P185, DOI 10.1016/0925-4773(96)00503-5; Chen XW, 1996, ANN NY ACAD SCI, V785, P38, DOI 10.1111/j.1749-6632.1996.tb56242.x; Crackower MA, 1996, HUM MOL GENET, V5, P571, DOI 10.1093/hmg/5.5.571; Depew MJ, 1999, DEVELOPMENT, V126, P3831; DEPLAEN E, 1994, IMMUNOGENETICS, V40, P360, DOI 10.1007/BF01246677; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; Liu YH, 1999, DEV BIOL, V205, P260, DOI 10.1006/dbio.1998.9114; Maas R, 1996, ANN NY ACAD SCI, V785, P171, DOI 10.1111/j.1749-6632.1996.tb56256.x; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; Miyama K, 1999, DEV BIOL, V208, P123, DOI 10.1006/dbio.1998.9197; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Newberry EP, 1997, BIOCHEMISTRY-US, V36, P10451, DOI 10.1021/bi971008x; Newberry EP, 1999, BIOCHEMISTRY-US, V38, P10678, DOI 10.1021/bi990967j; Newberry EP, 1998, BIOCHEMISTRY-US, V37, P16360, DOI 10.1021/bi981878u; Pold M, 1999, GENOMICS, V59, P161, DOI 10.1006/geno.1999.5870; Qiu MS, 1997, DEV BIOL, V185, P165, DOI 10.1006/dbio.1997.8556; Ryoo HM, 1997, MOL ENDOCRINOL, V11, P1681, DOI 10.1210/me.11.11.1681; Satokata I, 2000, NAT GENET, V24, P391, DOI 10.1038/74231; SIMEONE A, 1994, P NATL ACAD SCI USA, V91, P2250, DOI 10.1073/pnas.91.6.2250; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; SUDOL M, 1995, FEBS LETT, V369, P67, DOI 10.1016/0014-5793(95)00550-S; Taniura H, 1999, J BIOL CHEM, V274, P16242, DOI 10.1074/jbc.274.23.16242; Taniura H, 1998, J BIOL CHEM, V273, P720, DOI 10.1074/jbc.273.2.720; UMEZAWA A, 1992, J CELL PHYSIOL, V151, P197, DOI 10.1002/jcp.1041510125; VAINIO S, 1993, CELL, V75, P45, DOI 10.1016/S0092-8674(05)80083-2; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Yang L, 1998, J NEUROSCI, V18, P8322; Yaoita H, 2000, J BONE MINER METAB, V18, P63, DOI 10.1007/s007740050013; Zhang HL, 1997, MOL CELL BIOL, V17, P2920, DOI 10.1128/MCB.17.5.2920	34	85	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5331	5338		10.1074/jbc.M008590200	http://dx.doi.org/10.1074/jbc.M008590200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11084035	hybrid			2022-12-25	WOS:000168484300107
J	Hannah, VC; Ou, JF; Luong, A; Goldstein, JL; Brown, MS				Hannah, VC; Ou, JF; Luong, A; Goldstein, JL; Brown, MS			Unsaturated fatty acids down-regulate SREBP isoforms 1a and 1c by two mechanisms in HEK-293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEINS; CLEAVAGE-ACTIVATING PROTEIN; BOUND TRANSCRIPTION FACTOR; GENE-EXPRESSION; RECEPTOR-ALPHA; CULTURED-CELLS; MESSENGER-RNAS; CHOLESTEROL; PATHWAY; BIOSYNTHESIS	Sterol regulatory element-binding proteins (SREBPs) are membrane-bound transcription factors that increase the synthesis of fatty acids as well as cholesterol in animal cells. All three SREBP isoforms (SREBP-1a, -1c, and -2) are subject to feedback regulation by cholesterol, which blocks their proteolytic release from membranes. Previous data indicate that the SREBPs are also negatively regulated by unsaturated fatty acids, but the mechanism is uncertain. In the current experiments, unsaturated fatty acids decreased the nuclear content of SREBP-1, but not SREBP-2, in cultured human embryonic kidney (HEK)-293 cells. The potency of unsaturated fatty acids increased with increasing chain length and degree of unsaturation, Oleate, linoleate, and arachidonate were all effective, but the saturated fatty acids palmitate and stearate were not effective, Downregulation occurred at two levels, The mRNAs encoding SREBP-1a and SREBP-1c were markedly reduced, and the proteolytic processing of these SREBPs was inhibited, When SREBP-1a was produced by a cDNA expressed from an independent promoter, unsaturated fatty acids reduced nuclear SREBP-1a without affecting the mRNA level. There was no effect when the cDNA encoded a truncated version that was not membrane-bound, When administered together, sterols and unsaturated fatty acids potentiated each other in reducing nuclear SREBP-1, In the absence of fatty acids, sterols did not cause a sustained reduction of nuclear SREBP-1, but they did reduce nuclear SREBP-2, We conclude that unsaturated fatty acids, as well as sterols, can downregulate nuclear SREBPs and that unsaturated fatty acids have their greatest inhibitory effects on SREBP-1a and SREBP-1c, whereas sterols have their greatest inhibitory effects on SREBP-2.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Goldstein, JL (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd,Rm L5238, Dallas, TX 75390 USA.				NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08203, GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BUCOLO G, 1973, CLIN CHEM, V19, P476; CHAM BE, 1976, J LIPID RES, V17, P176; DeBose-Boyd RA, 1999, CELL, V99, P703, DOI 10.1016/S0092-8674(00)81668-2; Duncan EA, 1997, J BIOL CHEM, V272, P12778, DOI 10.1074/jbc.272.19.12778; Edwards PA, 1999, ANNU REV BIOCHEM, V68, P157, DOI 10.1146/annurev.biochem.68.1.157; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; Jump DB, 1999, PROSTAG LEUKOTR ESS, V60, P345, DOI 10.1016/S0952-3278(99)80010-6; Kim HJ, 1999, J BIOL CHEM, V274, P25892, DOI 10.1074/jbc.274.36.25892; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; Magana MM, 1997, J LIPID RES, V38, P1630; Nohturfft A, 2000, CELL, V102, P315, DOI 10.1016/S0092-8674(00)00037-4; Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Price PT, 2000, CURR OPIN LIPIDOL, V11, P3, DOI 10.1097/00041433-200002000-00002; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Sessler AM, 1998, J NUTR, V128, P923, DOI 10.1093/jn/128.6.923; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Sul HS, 1998, ANNU REV NUTR, V18, P331, DOI 10.1146/annurev.nutr.18.1.331; Thewke DP, 1998, J BIOL CHEM, V273, P21402, DOI 10.1074/jbc.273.33.21402; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210	32	338	350	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4365	4372		10.1074/jbc.M007273200	http://dx.doi.org/10.1074/jbc.M007273200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11085986	hybrid			2022-12-25	WOS:000166921200085
J	Pompeo, F; Bourne, Y; van Heijenoort, J; Fassy, F; Mengin-Lecreulx, D				Pompeo, F; Bourne, Y; van Heijenoort, J; Fassy, F; Mengin-Lecreulx, D			Dissection of the bifunctional Escherichia coli N-acetylglucosamine-1-phosphate uridyltransferase enzyme into autonomously functional domains and evidence that trimerization is absolutely required for glucosamine-1-phosphate acetyltransferase activity and cell growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; 1-PHOSPHATE URIDYLTRANSFERASE; CYTOPLASMIC STEPS; CRYSTAL-STRUCTURE; GLMU PROTEIN; BETA-HELIX; GENE; CLONING; MUTANT; K-12	The bifunctional N-acetylglucosamine-1-phosphate uridyltransferase (GlmU) enzyme catalyzes both the acetylation of glucosamine 1-phosphate and the uridylation of N-acetylglucosamine 1-phosphate, two subsequent steps in the pathway for UDP-N-acetylglucosamine synthesis in bacteria. In our previous work describing its initial characterization in Escherichia coli, we proposed that the 456-amino acid (50.1 kDa) protein might possess separate uridyltransferase (N-terminal) and acetyltransferase (C-terminal) domains, In the present study, we confirm this hypothesis by expression of the two independently folding and functional domains. A fragment containing the N-terminal 331 amino acids (Tr331, 37,1 kDa) has uridyltransferase activity only, with steady-state kinetic parameters similar to the full-length protein. Further deletion of 80 amino acid residues at the C terminus results in a 250-amino acid fragment (28.6 kDa) still exhibiting significant uridyltransferase activity. Conversely, a fragment containing the 233 C-terminal amino acids (24.7 kDa) exhibits acetyltransferase activity exclusively. None of these individual domains could complement a chromosomal glmU mutation, indicating that each of the two activities is essential for cell viability. Analysis of truncated GlmU proteins by gel filtration further localizes regions of the protein involved in its trimeric organization. Interestingly, overproduction of the truncated Tr331 protein in a wild-type strain results in a rapid depletion of endogenous acetyltransferase activity, an arrest of peptidoglycan synthesis and cell lysis, It is shown that the acetyltransferase activity of the full-length protein is abolished once trapped within heterotrimers formed in presence of the truncated protein, suggesting that this enzyme activity absolutely requires a trimeric organization and that the catalytic site involves regions of contact between adjacent monomers, Data are discussed in connection with the recently obtained crystal structure of the truncated Tr831 protein.	Univ Paris 11, CNRS, Lab Enveloppes Bacteriennes & Antibiot, UMR 8619, F-91405 Orsay, France; CNRS, F-13402 Marseille 20, France; Aventis Pharma Hoechst Marion Roussel, F-93230 Romainville, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Sanofi-Aventis; Sanofi France	Mengin-Lecreulx, D (corresponding author), Univ Paris 11, CNRS, Lab Enveloppes Bacteriennes & Antibiot, UMR 8619, Bat 430, F-91405 Orsay, France.	dominique.mengin-lecreulx@ebp.u-psud.fr	Pompeo, Frederique/Q-5772-2017; Bourne, Yves/AAC-4635-2022	Bourne, Yves/0000-0003-3850-0548; Fassy, Florence/0000-0001-8337-9674; MENGIN-LECREULX, Dominique/0000-0003-3205-0275				Beaman TW, 1998, BIOCHEMISTRY-US, V37, P6689, DOI 10.1021/bi980106v; Beaman TW, 1997, BIOCHEMISTRY-US, V36, P489, DOI 10.1021/bi962522q; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown K, 1999, EMBO J, V18, P4096, DOI 10.1093/emboj/18.15.4096; CABIB E, 1982, ANNU REV BIOCHEM, V51, P763, DOI 10.1146/annurev.bi.51.070182.003555; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; DOBROGOS.WJ, 1968, J BACTERIOL, V95, P578, DOI 10.1128/JB.95.2.578-584.1968; DUTKAMALEN S, 1988, BIOCHIMIE, V70, P287, DOI 10.1016/0300-9084(88)90073-9; FISHER W, 1990, GLYCOLIPIDS PHOSPHOG, P123; Gehring AM, 1996, BIOCHEMISTRY-US, V35, P579, DOI 10.1021/bi952275a; HOFMANN M, 1994, EUR J BIOCHEM, V221, P741, DOI 10.1111/j.1432-1033.1994.tb18787.x; HOVEJENSEN B, 1992, J BACTERIOL, V174, P6852, DOI 10.1128/JB.174.21.6852-6856.1992; Kisker C, 1996, EMBO J, V15, P2323, DOI 10.1002/j.1460-2075.1996.tb00588.x; KUHN HM, 1988, FEMS MICROBIOL LETT, V54, P195, DOI 10.1111/j.1574-6968.1988.tb02743.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; MENGINLECREULX D, 1982, J BACTERIOL, V151, P1109, DOI 10.1128/JB.151.3.1109-1117.1982; MENGINLECREULX D, 1994, J BACTERIOL, V176, P5788, DOI 10.1128/JB.176.18.5788-5795.1994; MenginLecreulx D, 1996, J BIOL CHEM, V271, P32, DOI 10.1074/jbc.271.1.32; MENGINLECREULX D, 1993, J BACTERIOL, V175, P6150, DOI 10.1128/JB.175.19.6150-6157.1993; MENGINLECREULX D, 1985, J BACTERIOL, V163, P208, DOI 10.1128/JB.163.1.208-212.1985; Mio T, 1999, J BIOL CHEM, V274, P424, DOI 10.1074/jbc.274.1.424; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; PLUMBRIDGE JA, 1993, J BACTERIOL, V175, P4951, DOI 10.1128/JB.175.16.4951-4956.1993; Pompeo F, 1998, J BACTERIOL, V180, P4799, DOI 10.1128/JB.180.18.4799-4803.1998; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARVAS M, 1971, J BACTERIOL, V105, P467, DOI 10.1128/JB.105.2.467-471.1971; STEVENSON G, 1994, J BACTERIOL, V176, P4144, DOI 10.1128/JB.176.13.4144-4156.1994; ULLRICH J, 1995, J BACTERIOL, V177, P6902, DOI 10.1128/jb.177.23.6902-6909.1995; VAARA M, 1992, FEMS MICROBIOL LETT, V97, P249, DOI 10.1016/0378-1097(92)90344-N; VANHEIJENOORT J, 1996, ESCHERICHIA COLI SAL, P1025; WALKER JE, 1984, BIOCHEM J, V224, P799, DOI 10.1042/bj2240799; Wang-Gillam A, 1998, J BIOL CHEM, V273, P27055, DOI 10.1074/jbc.273.42.27055; WHITE RJ, 1968, BIOCHEM J, V106, P847, DOI 10.1042/bj1060847; WU HC, 1971, J BACTERIOL, V105, P455, DOI 10.1128/JB.105.2.455-466.1971; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	38	24	26	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3833	3839		10.1074/jbc.M004788200	http://dx.doi.org/10.1074/jbc.M004788200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11084021	hybrid			2022-12-25	WOS:000166921200017
J	Zhang, D; Pasternack, MS; Beresford, PJ; Wagner, L; Greenberg, AH; Lieberman, J				Zhang, D; Pasternack, MS; Beresford, PJ; Wagner, L; Greenberg, AH; Lieberman, J			Induction of rapid histone degradation by the cytotoxic T lymphocyte protease granzyme A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA FRAGMENTATION; PROTEOLYTIC DIGESTION; MEDIATED CYTOTOXICITY; CHROMATIN CONDENSATION; MYELOID LEUKEMOGENESIS; PUTATIVE ONCOGENE; LIMIT PEPTIDES; PHOSPHATASE 2A; TARGET-CELLS; A BINDS	The cytotoxic T lymphocyte protease granzyme A induces caspase-independent cell death in which DNA single-strand nicking is observed instead of oligonucleosomal fragmentation. Granzyme A is a specific tryptase that concentrates in the nucleus of targeted cells and synergistically enhances DNA fragmentation induced by the caspase activator granzyme B. Here we show that granzyme A treatment of isolated nuclei enhances DNA accessibility to exogenous endonucleases. In vitro and after cell loading with perforin, GrnA completely degrades histone H1 and cleaves core histones into similar to 16kDa fragments. Histone digestion provides a mechanism for unfolding compacted chromatin and facilitating endogenous DNase access to DNA during T cell and natural killer cell granule-mediated apoptosis.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Manitoba	Lieberman, J (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.	lieberman@cbr.med.harvard.edu	Lieberman, Judy/A-2717-2015	ZHANG, DONG/0000-0002-1068-8334	NIAID NIH HHS [AI45587] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045587, R56AI045587] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADACHI Y, 1994, J BIOL CHEM, V269, P2258; ALLAN J, 1982, J CELL BIOL, V93, P285, DOI 10.1083/jcb.93.2.285; ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; Beresford PJ, 1999, IMMUNITY, V10, P585, DOI 10.1016/S1074-7613(00)80058-8; Beresford PJ, 1997, P NATL ACAD SCI USA, V94, P9285, DOI 10.1073/pnas.94.17.9285; BOHM L, 1981, EUR J BIOCHEM, V119, P67, DOI 10.1111/j.1432-1033.1981.tb05577.x; BOHM L, 1980, EUR J BIOCHEM, V106, P525, DOI 10.1111/j.1432-1033.1980.tb04599.x; BOHM L, 1984, BIOSCIENCE REP, V4, P365, DOI 10.1007/BF01122502; BOHM L, 1982, EUR J BIOCHEM, V123, P299, DOI 10.1111/j.1432-1033.1982.tb19767.x; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; CHIU VK, 1995, J IMMUNOL, V154, P2023; Cote J, 1995, METH MOL G, P108, DOI [10.1016/S1067-2389(06)80009-9, DOI 10.1016/S1067-2389(06)80009-9]; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; Davie JR, 1998, J CELL BIOCHEM, P203; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; FORNEROD M, 1995, ONCOGENE, V10, P1739; Froelich CJ, 1996, J BIOL CHEM, V271, P29073, DOI 10.1074/jbc.271.46.29073; Galvin JP, 1999, J IMMUNOL, V162, P5345; GIOUD M, 1983, J IMMUNOL, V131, P269; Hendzel MJ, 1998, J BIOL CHEM, V273, P24470, DOI 10.1074/jbc.273.38.24470; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; Jans DA, 1998, J CELL SCI, V111, P2645; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; Kawase H, 1996, GENES CELLS, V1, P1045, DOI 10.1046/j.1365-2443.1996.d01-223.x; Li M, 1996, BIOCHEMISTRY-US, V35, P6998, DOI 10.1021/bi960581y; Li M, 1996, J BIOL CHEM, V271, P11059, DOI 10.1074/jbc.271.19.11059; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Nagata K, 1998, EXP CELL RES, V240, P274, DOI 10.1006/excr.1997.3930; NAGATA K, 1995, P NATL ACAD SCI USA, V92, P4279, DOI 10.1073/pnas.92.10.4279; NAKAJIMA H, 1995, J EXP MED, V181, P1037, DOI 10.1084/jem.181.3.1037; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; PASTERNACK MS, 1991, J BIOL CHEM, V266, P14703; Pinkoski MJ, 1996, J BIOL CHEM, V271, P10225, DOI 10.1074/jbc.271.17.10225; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; RUSSELL JH, 1983, IMMUNOL REV, V72, P97, DOI 10.1111/j.1600-065X.1983.tb01074.x; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Sarin A, 1998, J IMMUNOL, V161, P2810; Sarin A, 1997, IMMUNITY, V6, P209, DOI 10.1016/S1074-7613(00)80427-6; Schroter M, 1995, EUR J IMMUNOL, V25, P3509, DOI 10.1002/eji.1830251245; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; SIMON MM, 1993, CYTOTOXIC CELLS RECO, P278; Sower LE, 1996, J IMMUNOL, V156, P2585; Sutton VR, 1997, J IMMUNOL, V158, P5783; THOMAS JO, 1984, FEBS LETT, V169, P90, DOI 10.1016/0014-5793(84)80295-1; Trapani JA, 1996, J BIOL CHEM, V271, P4127; VAESEN M, 1994, BIOL CHEM H-S, V375, P113, DOI 10.1515/bchm3.1994.375.2.113; VANGURI P, 1993, J IMMUNOL, V150, P2431; VONLINDERN M, 1992, MOL CELL BIOL, V12, P3346, DOI 10.1128/MCB.12.8.3346; WEINTRAUB H, 1974, P NATL ACAD SCI USA, V71, P4249, DOI 10.1073/pnas.71.10.4249; WILLIAMS MS, 1994, J IMMUNOL, V153, P4247; Wolffe AP, 1997, INT J BIOCHEM CELL B, V29, P1463, DOI 10.1016/S1357-2725(97)00026-5; Xia ZN, 1998, BIOCHEM BIOPH RES CO, V243, P384, DOI 10.1006/bbrc.1998.8102; Yoon YS, 1996, J BIOL CHEM, V271, P9129, DOI 10.1074/jbc.271.15.9129	58	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3683	3690		10.1074/jbc.M005390200	http://dx.doi.org/10.1074/jbc.M005390200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11060286	Green Published, hybrid			2022-12-25	WOS:000166784900091
J	Di Lisa, F; Menabo, R; Canton, M; Barile, M; Bernardi, P				Di Lisa, F; Menabo, R; Canton, M; Barile, M; Bernardi, P			Opening of the mitochondrial permeability transition pore causes depletion of mitochondrial and cytosolic NAD(+) and is a causative event in the death of myocytes in postischemic reperfusion of the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; PYRIDINE-NUCLEOTIDE HYDROLYSIS; CYCLOSPORINE-A; ADENINE-DINUCLEOTIDE; ISCHEMIC MYOCARDIUM; INNER MEMBRANE; ADP-RIBOSE; INJURY; CALCIUM; RELEASE	The opening of the mitochondrial permeability transition pore (PTP) has been suggested to play a key role in various forms of cell death, but direct evidence in intact tissues is still lacking. We found that in the rat heart, 92% of NAD(+) glycohydrolase activity is associated with mitochondria. This activity was not modified by the addition of Triton X-100, although it was abolished by mild treatment with the protease Nagarse, a condition that did not affect the energy-linked properties of mitochondria. The addition of Ca2+ to isolated rat heart mitochondria resulted in a profound decrease in their NAD(+) content, which followed mitochondrial swelling. Cyclosporin A(CsA), a PTP inhibitor, completely prevented NAD(+) depletion but had no effect on the glycohydrolase activity. Thus, in isolated mitochondria PTP opening makes NAD(+) available for its enzymatic hydrolysis, Perfused rat hearts subjected to global ischemia for 30 min displayed a 30% decrease in tissue NAD(+) content, which was not modified by extending the duration of ischemia, Reperfusion resulted in a more severe reduction of both total and mitochondrial contents of NAD(+), which could be measured in the coronary effluent together with lactate dehydrogenase. The addition of 0.2 muM CsA or of its analogue MeVal-4-Cs (which does not inhibit calcineurin) maintained higher NAD(+) contents, especially in mitochondria, and significantly protected the heart from reperfusion damage, as shown by the reduction in lactate dehydrogenase release. Thus, upon reperfusion after prolonged ischemia, PTP opening in the heart can be documented as a CsA-sensitive release of NAD(+), which is then partly degraded by glycohydrolase and partly released when sarcolemmal integrity is compromised. These results demonstrate that PTP opening is a causative event in reperfusion damage of the heart.	Univ Padua, CNR, Unit Study Biomembranes, I-35121 Padua, Italy; Univ Padua, Dept Biol Chem, I-35121 Padua, Italy; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Bari, Dept Biochem & Mol Biol, I-70125 Bari, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Padua; University of Padua; University of Padua; Universita degli Studi di Bari Aldo Moro	Di Lisa, F (corresponding author), Univ Padua, Dipartimento Chim Biol, Viale Giuseppe Colombo 3, I-35121 Padua, Italy.		Bernardi, Paolo/C-3656-2008; Barile, Maria/R-6171-2016	Bernardi, Paolo/0000-0001-9187-3736; canton, marcella/0000-0002-8967-4049; Barile, Maria/0000-0001-5025-551X; Di Lisa, Fabio/0000-0001-9757-8818				Barile M, 1997, EUR J BIOCHEM, V249, P777, DOI 10.1111/j.1432-1033.1997.00777.x; Barile M, 1996, BIOCHEM MOL BIOL INT, V38, P297; BARRIO JR, 1972, P NATL ACAD SCI USA, V69, P2039, DOI 10.1073/pnas.69.8.2039; BERGMEYER HU, 1974, METHODEN ENZYMATISCH, P607; BERNARDI P, 1994, J BIOENERG BIOMEMBR, V26, P509, DOI 10.1007/BF00762735; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; BOYER CS, 1993, J BIOL CHEM, V268, P4016; Di Lisa F, 1998, BBA-BIOENERGETICS, V1366, P69, DOI 10.1016/S0005-2728(98)00121-2; DILISA F, 1993, AM J PHYSIOL, V264, pH2188, DOI 10.1152/ajpheart.1993.264.6.H2188; DILISA F, 1995, J PHYSIOL-LONDON, V486, P1; DILISA F, 1994, AM J PHYSIOL, V267, pH455, DOI 10.1152/ajpheart.1994.267.2.H455; DUCHEN MR, 1993, CARDIOVASC RES, V27, P1790, DOI 10.1093/cvr/27.10.1790; FREI B, 1985, EUR J BIOCHEM, V149, P633, DOI 10.1111/j.1432-1033.1985.tb08971.x; GANOTE C, 1993, CARDIOVASC RES, V27, P1387, DOI 10.1093/cvr/27.8.1387; GANOTE CE, 1980, J MOL CELL CARDIOL, V12, P387, DOI 10.1016/0022-2828(80)90049-8; GANOTE CE, 1976, AM J PATHOL, V84, P327; GRIFFITHS EJ, 1993, J MOL CELL CARDIOL, V25, P1461, DOI 10.1006/jmcc.1993.1162; GRIFFITHS EJ, 1995, BIOCHEM J, V307, P93, DOI 10.1042/bj3070093; IDELLWENGER JA, 1978, J BIOL CHEM, V253, P4310; JENNINGS RB, 1991, ANNU REV MED, V42, P225, DOI 10.1146/annurev.med.42.1.225; JENNINGS RB, 1990, CIRCULATION, V82, P2; KLINGENBERG M, 1985, METHOD ENZYMAT AN, V7, P251; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LINDENMAYER GE, 1968, CIRC RES, V23, P439, DOI 10.1161/01.RES.23.3.439; LOTSCHER HR, 1980, J BIOL CHEM, V255, P9325; MINEZAKI KK, 1994, J PHYSIOL-LONDON, V476, P459, DOI 10.1113/jphysiol.1994.sp020147; MIYATA H, 1992, CIRC RES, V71, P605, DOI 10.1161/01.RES.71.3.605; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; NAZARETH W, 1991, J MOL CELL CARDIOL, V23, P1351, DOI 10.1016/0022-2828(91)90181-K; Nicolli A, 1996, J BIOL CHEM, V271, P2185, DOI 10.1074/jbc.271.4.2185; NISHINAKA Y, 1993, J CARDIOVASC PHARM, V21, P448, DOI 10.1097/00005344-199303000-00015; NUNEZ R, 1976, AM J PHYSIOL, V231, P1173, DOI 10.1152/ajplegacy.1976.231.4.1173; PALMER JW, 1977, J BIOL CHEM, V252, P8731; Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; RICHTER C, 1990, BIOCHEM PHARMACOL, V40, P779, DOI 10.1016/0006-2952(90)90315-C; RICHTER C, 1983, P NATL ACAD SCI-BIOL, V80, P3188, DOI 10.1073/pnas.80.11.3188; Ruiz F, 2000, EUR J PHARMACOL, V404, P29, DOI 10.1016/S0014-2999(00)00584-7; Rustin P, 1996, J BIOL CHEM, V271, P14785, DOI 10.1074/jbc.271.25.14785; SCHAPER J, 1983, J AM COLL CARDIOL, V1, P1037, DOI 10.1016/S0735-1097(83)80106-5; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; SHEN AC, 1972, AM J PATHOL, V67, P417; SILVERMAN HS, 1994, CARDIOVASC RES, V28, P581, DOI 10.1093/cvr/28.5.581; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; VELOSO D, 1974, ANAL BIOCHEM, V62, P449, DOI 10.1016/0003-2697(74)90177-8; VINOGRADOV A, 1972, ARCH BIOCHEM BIOPHYS, V152, P646, DOI 10.1016/0003-9861(72)90261-5; ZENKE G, 1993, ANN NY ACAD SCI, V685, P330, DOI 10.1111/j.1749-6632.1993.tb35882.x; ZIMMERMAN AN, 1966, NATURE, V211, P646, DOI 10.1038/211646a0	48	550	567	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2571	2575		10.1074/jbc.M006825200	http://dx.doi.org/10.1074/jbc.M006825200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11073947	hybrid			2022-12-25	WOS:000166784800040
J	Maiti, NR; Surewicz, WK				Maiti, NR; Surewicz, WK			The role of disulfide bridge in the folding and stability of the recombinant human prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES; THERMODYNAMIC STABILITY; MOLECULAR-BIOLOGY; MOLTEN GLOBULE; PRP 27-30; SCRAPIE; CONVERSION; DISEASES; DOMAIN; STATE	It is believed that the critical step in the pathogenesis of transmissible spongiform encephalopathies is a transition of prion protein (PrP) from an alpha -helical conformation, PrPC, to a beta -sheet-rich form, PrPSc. Native prion protein contains a single disulfide bond linking Cys residues at positions 179 and 214. To elucidate the role of this bridge in the stability and folding of the protein, we studied the reduced form of the recombinant human PrP as well as the variant of PrP in which cysteines were replaced with alanine residues. At neutral pH, the reduced prion protein and the Cys-free mutant were insoluble and formed amorphous aggregates. However, the proteins could be refolded in a monomeric form under the conditions of mildly acidic pH, Spectroscopic experiments indicate that the monomeric Cys-free and reduced PrP have molten globule-like properties, i.e. they are characterized by compromised tertiary interactions, an increased exposure of hydrophobic surfaces, lack of cooperative unfolding transition in urea, and partial loss of native (alpha -helical) secondary structure. In the presence of sodium chloride, these partially unfolded proteins undergo a transition to a beta -sheet-rich structure. However, this transition is invariably associated with protein oligomerization, The present data argue against the notion that reduced prion protein can exist in a stable monomeric form that is rich in beta -sheet structure.	Case Western Reserve Univ, Dept Pathol, Cleveland, OH 44106 USA	Case Western Reserve University	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Pathol, 2085 Adelbert Rd, Cleveland, OH 44106 USA.	wks3@pop.cwru.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038604] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38604] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baskakov IV, 2000, BIOCHEMISTRY-US, V39, P2792, DOI 10.1021/bi9923353; Bonander N, 2000, EUR J BIOCHEM, V267, P4511, DOI 10.1046/j.1432-1327.2000.01501.x; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 1997, TRENDS CELL BIOL, V7, P56, DOI 10.1016/S0962-8924(96)10054-4; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; Chesebro B, 1997, NAT MED, V3, P491, DOI 10.1038/nm0597-491; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; EDWIN F, 2000, BIOCHIM BIOPHYS ACTA, V1479, P68; EWBANK JJ, 1993, BIOCHEMISTRY-US, V32, P3694, DOI 10.1021/bi00065a023; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; GRIFFITH JS, 1967, NATURE, V215, P1043, DOI 10.1038/2151043a0; Herrmann LM, 1998, NEUROREPORT, V9, P2457, DOI 10.1097/00001756-199808030-00006; Horiuchi M, 1999, STRUCTURE, V7, pR231, DOI 10.1016/S0969-2126(00)80049-0; Hosszu LLP, 1999, NAT STRUCT BIOL, V6, P740, DOI 10.1038/11507; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Liu H, 1999, BIOCHEMISTRY-US, V38, P5362, DOI 10.1021/bi982878x; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ptitsyn OB, 1995, ADV PROTEIN CHEM, V47, P83, DOI 10.1016/S0065-3233(08)60546-X; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Riek R, 1996, NATURE, V382, P180, DOI 10.1038/382180a0; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STAHL N, 1991, FASEB J, V5, P2799, DOI 10.1096/fasebj.5.13.1916104; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; TURK E, 1988, EUR J BIOCHEM, V176, P21, DOI 10.1111/j.1432-1033.1988.tb14246.x; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; WOODY RW, 1995, METHOD ENZYMOL, V246, P34; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zhang H, 1997, BIOCHEMISTRY-US, V36, P3543, DOI 10.1021/bi961965r	44	99	104	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2427	2431		10.1074/jbc.M007862200	http://dx.doi.org/10.1074/jbc.M007862200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11069909	hybrid			2022-12-25	WOS:000166784800019
J	Iwata, N; Yamamoto, H; Sasaki, S; Itoh, F; Suzuki, H; Kikuchi, T; Kaneto, H; Iku, S; Ozeki, I; Karino, Y; Satoh, T; Toyota, J; Satoh, M; Endo, T; Imai, K				Iwata, N; Yamamoto, H; Sasaki, S; Itoh, F; Suzuki, H; Kikuchi, T; Kaneto, H; Iku, S; Ozeki, I; Karino, Y; Satoh, T; Toyota, J; Satoh, M; Endo, T; Imai, K			Frequent hypermethylation of CpG islands and loss of expression of the 14-3-3 sigma gene in human hepatocellular carcinoma	ONCOGENE			English	Article						cell cycle; G2 arrest; 14-3-3 sigma; hypermethylation; hepatocarcinogenesis	STRAND CONFORMATION POLYMORPHISM; DNA METHYLATION; CELL-CYCLE; CANCER; P16(INK4A); PROGRESSION; PROMOTER; PROTEIN; CLONING; LINES	The 14-3-3 sigma gene has been implicated in G2/M cell cycle arrest by p53, Frequent inactivation of the 14-3-3 sigma gene by hypermethylation of CpG islands has recently been reported in human breast carcinoma. The aim of this study was to examine the methylation status of CpG islands of the 14-3-3 sigma gene in hepatocellular carcinoma (HCC), The methylation status of the 14-3-3 sigma gene was evaluated in four normal liver tissues and 19 paired specimens of carcinoma and adjacent non-tumorous liver tissues using bisulfite-single strand conformation polymorphism (bisulfite-SSCP), a combination of sodium bisulfite modification and fluorescence-based polymerase chain reaction (PCR)-SSCP, The 14-3-3 sigma protein expression was examined by immunohistochemical staining. Hypermethylation of CpG islands of the 14-3-3 sigma gene was detected in 89% (17/19) of the HCC tissues but not in any of the four normal liver tissues. All of the 14 methylation-positive HCC samples analysed by immunohistochemistry showed loss of 14-3-3 sigma expression, while both of the methylation-negative HCC samples retained the expression, and a significant correlation was found between methylation and loss of expression. Lower levels of methylation were detected in adjacent non-tumorous liver tissues (6/16 in cirrhotic tissues and 1/3 in chronic hepatitis tissues), but the 14-3-3 sigma expression was retained in all of these tissues. In a methylation-positive HCC cell line, HLE, 5-aza-2'-deoxycytidine (5-aza-dC)-induced demethylation of CpG islands led to reactivation of gene expression, indicating that hypermethylation plays a causal role in inactivation of the 14-3-3 sigma gene in HCC, Hypermethylation and the resulting loss of expression of the 14-3-3 sigma gene corresponds to one of the most common abnormalities reported to date in HCC, suggesting their crucial role in the development and/or progression of HCC.	Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan; Sapporo Kosei Gen Hosp, Dept Gastroenterol 3, Sapporo, Hokkaido 0600033, Japan; Sapporo Kosei Gen Hosp, Dept Clin Pathol, Sapporo, Hokkaido 0600033, Japan; Sapporo Med Univ, Dept Clin Pathol, Sapporo, Hokkaido 0608543, Japan	Sapporo Medical University; Sapporo Kosei General Hospital; Sapporo Kosei General Hospital; Sapporo Medical University	Sasaki, S (corresponding author), Sapporo Med Univ, Dept Internal Med 1, Sapporo, Hokkaido 0608543, Japan.							Ahuja N, 1998, CANCER RES, V58, P5489; Baylin SB, 1998, ADV CANCER RES, V72, P141; Belinsky SA, 1998, P NATL ACAD SCI USA, V95, P11891, DOI 10.1073/pnas.95.20.11891; Burri N, 1999, BIOTECHNIQUES, V26, P232, DOI 10.2144/99262bm10; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chaubert P, 1997, HEPATOLOGY, V25, P1376, DOI 10.1002/hep.510250613; DELLAMBRA E, 1995, J CELL SCI, V108, P3569; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Ferguson AT, 2000, P NATL ACAD SCI USA, V97, P6049, DOI 10.1073/pnas.100566997; Gonzalgo ML, 1998, CANCER RES, V58, P1245; Herman JG, 1999, GASTROENTEROLOGY, V116, P483, DOI 10.1016/S0016-5085(99)70146-0; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hsieh CJ, 1998, CANCER RES, V58, P3942; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; JONES PA, 1999, NAT GENET, V11, P136; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; Kanai Y, 2000, CANCER LETT, V148, P73, DOI 10.1016/S0304-3835(99)00316-X; Klump B, 1998, GASTROENTEROLOGY, V115, P1381, DOI 10.1016/S0016-5085(98)70016-2; Laronga C, 2000, J BIOL CHEM, V275, P23106, DOI 10.1074/jbc.M905616199; Liew CT, 1999, ONCOGENE, V18, P789, DOI 10.1038/sj.onc.1202359; Maekawa M, 1999, BIOCHEM BIOPH RES CO, V262, P671, DOI 10.1006/bbrc.1999.1230; Matsuda Y, 1999, GASTROENTEROLOGY, V116, P394, DOI 10.1016/S0016-5085(99)70137-X; Melis R, 1999, ELECTROPHORESIS, V20, P1055, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<1055::AID-ELPS1055>3.0.CO;2-O; Nagai H, 1997, ONCOGENE, V14, P2927, DOI 10.1038/sj.onc.1201136; Nishida N, 1997, HISTOL HISTOPATHOL, V12, P1019; OKUDA K, 1992, HEPATOLOGY, V15, P948, DOI 10.1002/hep.1840150532; Ostergaard M, 1997, CANCER RES, V57, P4111; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Piwnica-Worms H, 1999, NATURE, V401, P535, DOI 10.1038/44029; PRASAD GL, 1992, CELL GROWTH DIFFER, V3, P507; Suzuki H, 2000, ELECTROPHORESIS, V21, P904, DOI 10.1002/(SICI)1522-2683(20000301)21:5<904::AID-ELPS904>3.3.CO;2-W; Tajima M, 1998, JPN J CANCER RES, V89, P262, DOI 10.1111/j.1349-7006.1998.tb00557.x; Vellucci VF, 1995, GENE, V166, P213, DOI 10.1016/0378-1119(95)00543-9; Wilentz RE, 1998, CANCER RES, V58, P4740; Wong IHN, 1999, CANCER RES, V59, P71; Yamamoto H, 1999, CANCER RES, V59, P3313	37	213	227	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5298	5302		10.1038/sj.onc.1203898	http://dx.doi.org/10.1038/sj.onc.1203898			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077447				2022-12-25	WOS:000165059700011
J	Yun, CW; Lee, JH; Park, H; Jin, YM; Park, S; Park, K; Cho, H				Yun, CW; Lee, JH; Park, H; Jin, YM; Park, S; Park, K; Cho, H			Chemotherapeutic drug, adriamycin, restores the function of p53 protein in hepatitis B virus X (HBx) protein-expressing liver cells	ONCOGENE			English	Article						HBx; p53; liver cancer; chemotherapeutic drug; subcellular localization; cytoplasmic sequestration	WILD-TYPE P53; P53-DEPENDENT APOPTOSIS; GENE-PRODUCT; TRANSCRIPTIONAL ACTIVITY; ADENOVIRUS TYPE-5; GENOTOXIC STRESS; GROWTH ARREST; CANCER; DNA; TRANSACTIVATION	Hepatitis B virus X (HBx) protein implicated in the development of liver cancer may inhibit the function of p53 tumor suppressor protein through cytoplasmic retention of p53 protein. Here, we attempt to investigate whether the functional inhibition of p53 protein by HBx protein is reversible. First, we provide the evidence for the association of endogenous p53 protein with HBx by co-immunoprecipitation in stable Chang cells that express HBx protein in an inducible manner (ChangX-34), By immunofluorescence microscopy, the major location of p53 protein of ChangX-34 cells was confirmed at the nuclear periphery as well as in the cytoplasm where HBx protein is mainly expressed. Surprisingly, anticancer drug, adriamycin induces the nuclear translocation of p53 protein sequestered in the cytoplasm, This change is accompanied by the restoration of p53 activity, which results in increased transcriptional activity at the p53-responsive DNA elements as well as increase of p21(WAF1) mRNA expression. Further, we observed the induction of cell death and G1 arrest in these cells upon adriamycin treatment regardless of HBx expression. Together, we demonstrate that functional inhibition of p53 protein through its cytoplasmic retention by HBx protein is reversible. These results may be extended into other tumors of which p53 activity is modulated by viral oncoproteins.	Ajou Univ, Sch Med, Dept Biochem, Suwon 442749, South Korea; Ajou Univ Hosp, Dept Pathol, Suwon 442749, South Korea; Ajou Univ, Sch Med, Dept Microbiol, Suwon 442749, South Korea; Samsung Biomed Res Inst, Ctr Mol Med, Seoul, South Korea	Ajou University; Ajou University; Ajou University Hospital; Ajou University; Samsung; Sungkyunkwan University (SKKU); Samsung Medical Center	Cho, H (corresponding author), Ajou Univ, Sch Med, Dept Biochem, Wonchon Dong 5, Suwon 442749, South Korea.			Cho, Hyeseong/0000-0002-4672-8887; Yun, Chawon/0000-0002-0046-4732				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; Chresta CM, 1996, CANCER RES, V56, P1834; Doitsh G, 1999, ONCOGENE, V18, P7506, DOI 10.1038/sj.onc.1203209; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; GIACCIA AJ, 1998, GENE DEV, V12, P3158; Gonin S, 1999, ONCOGENE, V18, P8011, DOI 10.1038/sj.onc.1203319; Greenblatt MS, 1997, CANCER RES, V57, P426; Harris MP, 1996, CANCER GENE THER, V3, P121; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; HENKLER F, 1995, CANCER RES, V55, P6084; HOHNE M, 1990, EMBO J, V9, P1137, DOI 10.1002/j.1460-2075.1990.tb08220.x; Houghton Janet A., 1999, Current Opinion in Oncology, V11, P475, DOI 10.1097/00001622-199911000-00008; JIANG D, 1993, ONCOGENE, V8, P2805; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim JR, 1998, EXP MOL MED, V30, P145, DOI 10.1038/emm.1998.21; Klein NP, 1999, EMBO J, V18, P5019, DOI 10.1093/emboj/18.18.5019; Lee H, 1995, J BIOL CHEM, V270, P31405, DOI 10.1074/jbc.270.52.31405; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lin Y, 1997, CANCER RES, V57, P5137; MACGUIRE HF, 1991, SCIENCE, V252, P842; McCormick F, 1999, CANCER J SCI AM, V5, P139; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; NATOLI G, 1995, J HEPATOL, V22, P14; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PRICE BD, 1994, CANCER RES, V54, P896; QIN S, 1998, HEPATOLOGY, V27, P1109; QUADRI I, 1995, P NATL ACAD SCI USA, V92, P1003; Rubenwolf S, 1997, J VIROL, V71, P1115, DOI 10.1128/JVI.71.2.1115-1123.1997; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Takada S, 1997, ONCOGENE, V15, P1895, DOI 10.1038/sj.onc.1201369; Teodoro JG, 1997, J VIROL, V71, P3620, DOI 10.1128/JVI.71.5.3620-3627.1997; Thomas M, 1996, ONCOGENE, V13, P265; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TRUANT R, 1995, J VIROL, V69, P1851, DOI 10.1128/JVI.69.3.1851-1859.1995; UEDA H, 1995, NAT GENET, V9, P41, DOI 10.1038/ng0195-41; ULLRICH SJ, 1993, P NATL ACAD SCI USA, V90, P5954, DOI 10.1073/pnas.90.13.5954; Urban S, 1997, HEPATOLOGY, V26, P1045, DOI 10.1002/hep.510260437; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wu GS, 1999, ONCOGENE, V18, P6411, DOI 10.1038/sj.onc.1203025; Yoo YD, 1996, J CLIN INVEST, V97, P388, DOI 10.1172/JCI118427; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163	53	39	41	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5163	5172		10.1038/sj.onc.1203896	http://dx.doi.org/10.1038/sj.onc.1203896			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064453				2022-12-25	WOS:000090124100005
J	Nielsen, PK; Yamada, Y				Nielsen, PK; Yamada, Y			Identification of cell-binding sites on the laminin alpha(5) N-terminal domain by site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-BETA-1 INTEGRINS; SULFATE PROTEOGLYCANS; SHORT ARM; CHAIN; ADHESION; HEPARIN; ALPHA-1-BETA-1; DYSTROGLYCAN; ALPHA-3-BETA-1; SPECIFICITY	The newly discovered laminin alpha (5) chain is a multidomain, extracellular matrix protein implicated in various biological functions such as the development of blood vessels and nerves. The N-terminal globular domain of the laminin a chains has an important role for biological activities through interactions with cell surface receptors. In this study, we identified residues that are critical for cell binding within the laminin alpha (5) N-terminal globular domain VI (similar to 270 residues) using site-directed mutagenesis and synthetic peptides. A recombinant protein of domain VI and the first four epidermal growth factor-like repeats of domain V, generated in a mammalian expression system, was highly active for HT-1080 cell binding, while a recombinant protein consisting of only the epidermal growth factor-like repeats showed no cell binding. By competition analysis with synthetic peptides for cell binding, we identified two sequences: S2, (123)GQVFHVAYVLIKF(135) and S6, (225)RDFTKATNIRLRFLR(239), within domain VI that inhibited cell binding to domain VI. Alanine substitution mutagenesis indicated that four residues (Tyr(130), Arg(225), Lys(229), and Arg(239)) within these two sequences are crucial for cell binding. Real-time heparin-binding kinetics of the domain VI mutants analyzed by surface plasmon resonance indicated that Arg(239) of S6 was critical for both heparin and cell binding. In addition, cell binding to domain VI was inhibited by heparin/heparan sulfate, which suggests an overlap of cell and heparin-binding sites. Furthermore, inhibition studies using integrin subunit monoclonal antibodies showed that integrin alpha (3)beta (1) was a major receptor for domain VI binding. Our results provide evidence that two sites spaced about 90 residues apart within the laminin alpha (5) chain N-terminal globular domain VI are critical for cell surface receptor binding.	NIDCR, Mol Biol Sect, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Yamada, Y (corresponding author), NIDCR, Mol Biol Sect, Craniofacial Dev Biol & Regenerat Branch, NIH, Bldg 30,Rm 405,30 Convent Dr,MSC 4370, Bethesda, MD 20892 USA.							Andac Z, 1999, J MOL BIOL, V287, P253, DOI 10.1006/jmbi.1999.2606; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Colognato H, 1997, J BIOL CHEM, V272, P29330, DOI 10.1074/jbc.272.46.29330; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; Ettner N, 1998, FEBS LETT, V430, P217, DOI 10.1016/S0014-5793(98)00601-2; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; Miner JH, 1999, INT J BIOCHEM CELL B, V31, P811, DOI 10.1016/S1357-2725(99)00030-8; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 2000, DEV BIOL, V217, P278, DOI 10.1006/dbio.1999.9546; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Moyano JV, 1999, J BIOL CHEM, V274, P135, DOI 10.1074/jbc.274.1.135; Newham P, 1997, J BIOL CHEM, V272, P19429, DOI 10.1074/jbc.272.31.19429; Nielsen PK, 2000, J BIOL CHEM, V275, P14517, DOI 10.1074/jbc.275.19.14517; Nomizu M, 1998, J BIOL CHEM, V273, P32491, DOI 10.1074/jbc.273.49.32491; Patton BL, 1998, NATURE, V393, P698, DOI 10.1038/31502; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; Shimizu H, 1999, J BIOL CHEM, V274, P11995, DOI 10.1074/jbc.274.17.11995; Son YJ, 2000, J BIOL CHEM, V275, P451, DOI 10.1074/jbc.275.1.451; Talts JF, 1999, EMBO J, V18, P863, DOI 10.1093/emboj/18.4.863; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286	26	49	49	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					10906	10912		10.1074/jbc.M008743200	http://dx.doi.org/10.1074/jbc.M008743200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11098055	hybrid			2022-12-25	WOS:000167980900047
J	Romijn, RAP; Bouma, B; Wuyster, W; Gros, P; Kroon, J; Sixma, JJ; Huizinga, EG				Romijn, RAP; Bouma, B; Wuyster, W; Gros, P; Kroon, J; Sixma, JJ; Huizinga, EG			Identification of the collagen-binding site of the von Willebrand factor A3-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA-2-BETA-1 VLA-2; PLATELET GLYCOPROTEIN-IB; VONWILLEBRAND-FACTOR; A3 DOMAIN; CRYSTAL-STRUCTURE; MOLECULAR REPLACEMENT; LIGAND-BINDING; ANTIBODY; COMPLEX; REFINEMENT	Von Willebrand factor (vWF) is a multimeric glycoprotein that mediates platelet adhesion and thrombus formation at sites of vascular injury. vWF functions as a molecular bridge between collagen and platelet receptor glycoprotein Ib. The major collagen-binding site of VWF is contained within the A3 domain, but its precise location is unknown. To localize the collagen-binding site, we determined the crystal structure of A3 in complex with an Fab fragment of antibody RU5 that inhibits collagen binding. The structure shows that RU5 recognizes a nonlinear epitope consisting of residues 962-966, 981-997, and 1022-1026, Alanine mutants were constructed of residues Arg(963), Glu(987), His(990), Arg(1016) and His(1023), located in or close to the epitope, Mutants were expressed as fully processed multimeric vWF, Mutation of His(1023) abolished collagen binding, whereas mutation of Arg(963) and Arg(1016) reduced collagen binding by 25-35%. These residues are part of loops alpha3 beta4 and alpha1 beta2 and alpha -helix 3, respectively, and lie near the bottom face of the domain. His(1023) and flanking residues display multiple conformations in available A3-crystal structures, suggesting that binding of A3 to collagen involves an induced-fit mechanism, The collagen-binding site of A3 is located distant from the top face of the domain where collagen-binding sites are found in homologous integrin I domains.	Univ Utrecht, Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, NL-3508 GA Utrecht, Netherlands; Inst Biomembranes, NL-3508 GA Utrecht, Netherlands; Univ Utrecht, Bijvoet Ctr Biomol Res, Dept Crystal & Struct Chem, NL-3584 CH Utrecht, Netherlands	Utrecht University; Utrecht University	Huizinga, EG (corresponding author), Univ Utrecht, Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, HP G03-647,POB 85500, NL-3508 GA Utrecht, Netherlands.		Gros, Piet/I-5569-2016; Gros, Piet/AAD-6452-2019	Gros, Piet/0000-0002-7782-2585; Gros, Piet/0000-0002-7782-2585				[Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bienkowska J, 1997, J BIOL CHEM, V272, P25162, DOI 10.1074/jbc.272.40.25162; BOCKENSTEDT P, 1986, J CLIN INVEST, V78, P551, DOI 10.1172/JCI112608; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P46, DOI 10.1107/S0108767389009633; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CARROLL WL, 1988, MOL IMMUNOL, V25, P991, DOI 10.1016/0161-5890(88)90005-3; COLOMBATTI A, 1991, BLOOD, V77, P2305; CRUZ MA, 1995, J BIOL CHEM, V270, P10822, DOI 10.1074/jbc.270.18.10822; CRUZ MA, 1997, BLOOD S 1, V90, P23; DUBEL S, 1994, J IMMUNOL METHODS, V175, P89, DOI 10.1016/0022-1759(94)90334-4; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Fischer BE, 1996, THROMB RES, V84, P55, DOI 10.1016/0049-3848(96)00161-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALE JE, 1995, ANAL BIOCHEM, V231, P46, DOI 10.1006/abio.1995.1501; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; Huizinga EG, 1997, STRUCTURE, V5, P1147, DOI 10.1016/S0969-2126(97)00266-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KRAULIS P, 1991, J APPL CRYSTALLOGR, V25, P649; Lankhof H, 1996, THROMB HAEMOSTASIS, V75, P950; LAWRIE AS, 1990, THROMB RES, V59, P369, DOI 10.1016/0049-3848(90)90139-4; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOHRI H, 1989, J BIOL CHEM, V264, P17361; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Obert B, 1999, BLOOD, V93, P1959, DOI 10.1182/blood.V93.6.1959.406k01_1959_1968; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pannu NS, 1996, ACTA CRYSTALLOGR A, V52, P659, DOI 10.1107/S0108767396004370; PERKINS SJ, 1994, J MOL BIOL, V238, P104, DOI 10.1006/jmbi.1994.1271; PIETU G, 1987, J LAB CLIN MED, V109, P637; Rich RL, 1999, J BIOL CHEM, V274, P24906, DOI 10.1074/jbc.274.35.24906; Ruggeri ZM, 1999, THROMB HAEMOSTASIS, V82, P576; RUGGERI ZM, 1993, FASEB J, V7, P308, DOI 10.1096/fasebj.7.2.8440408; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Smith C, 2000, J BIOL CHEM, V275, P4205, DOI 10.1074/jbc.275.6.4205; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; van der Plas RM, 2000, THROMB HAEMOSTASIS, V84, P1005; vandenElsen JMH, 1997, PROTEINS, V29, P113; Vischer UM, 1999, CRIT REV ONCOL HEMAT, V30, P93, DOI 10.1016/S1040-8428(98)00045-6; [No title captured]	44	72	77	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					9985	9991		10.1074/jbc.M006548200	http://dx.doi.org/10.1074/jbc.M006548200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11098050	hybrid			2022-12-25	WOS:000167996400056
J	Volonte, D; Galbiati, F; Pestell, RG; Lisanti, MP				Volonte, D; Galbiati, F; Pestell, RG; Lisanti, MP			Cellular stress induces the tyrosine phosphorylation of caveolin-1 (Tyr(14)) via activation of p38 mitogen-activated protein kinase and c-Src kinase - Evidence for caveolae, the actin cytoskeleton, and focal adhesions as mechanical sensors of osmotic stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; SIGNAL TRANSDUCER; INDUCED APOPTOSIS; MEMBRANE DOMAINS; OXIDATIVE STRESS; EXPRESSION; COMPONENT; CHOLESTEROL; PATHWAY; GROWTH	Environmental stressors have been recently shown to activate intracellular mitogen-activated protein (MAP) kinases, such as p38 MAP kinase, leading to changes in cellular functioning. However, little is known about the downstream elements in these signaling cascades. In this study, we show that caveolin-1 is phosphorylated on tyrosine 14 in NIH 3T3 cells after stimulation with a variety of cellular stressors (ie. high osmolarity, H2O2, and UV light). To detect this phosphorylation event, we employed a phosphospecific monoclonal antibody probe that recognizes only tyrosine 14-phosphorylated caveolin-1. Since p38 MAP kinase and c-Src have been previously implicated in the stress response, we next assessed their role in the tyrosine phosphorylation of caveolin-1. Interestingly, we show that the p38 inhibitor (SB203580) and a dominant-negative mutant of c-Src (SRC-RF) both block the stress-induced tyrosine phosphorylation of caveolin-1 (Tyr(P)(14)), In contrast, inhibition of the p42/44 MAP kinase cascade did not affect the tyrosine phosphorylation of caveolin-1. These results indicate that extracellular stressors can induce caveolin-1 tyrosine phosphorylation through the activation of well established upstream elements, such as p38 MAP kinase and c-Src kinase, However, heat shock did not promote the tyrosine phosphorylation of caveolin-1 and did not activate p38 MAP kinase, Finally, we show that after hyperosmotic shock, tyrosine-phosphorylated caveolin-1 is localized near focal adhesions, the major sites of tyrosine kinase signaling. In accordance with this localization, disruption of the actin cytoskeleton dramatically potentiates the tyrosine phosphorylation of caveolin-1. Taken together, our results clearly define a novel signaling pathway involving p38 MAP kinase activation and caveolin-1 (Tyr(P)(14)). Thus, tyrosine phosphorylation of caveolin-1 may represent an important downstream element in the signal transduction cascades activated by cellular stress.	Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Albert Einstein Canc Ctr, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept dev & Mol Biol, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Galbiati, Ferruccio/AAF-3527-2020; Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; 	NATIONAL CANCER INSTITUTE [R01CA070897, R01CA075503] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056399] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA70897, R01-CA75503] Funding Source: Medline; NHLBI NIH HHS [P50-HL56399] Funding Source: Medline; Telethon [470/BI] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon)		BELLOMO G, 1992, ANN NY ACAD SCI, V663, P97, DOI 10.1111/j.1749-6632.1992.tb38653.x; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Edwards YS, 1998, AM J PHYSIOL-LUNG C, V275, pL670, DOI 10.1152/ajplung.1998.275.4.L670; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GALCHEVAGARGOVA Z, 1994, SCIENCE, V265, P806, DOI 10.1126/science.8047888; Gao J, 1997, EMBO J, V16, P6414, DOI 10.1093/emboj/16.21.6414; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GARCIAPEREZ A, 1991, PHYSIOL REV, V71, P1081, DOI 10.1152/physrev.1991.71.4.1081; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huot J, 1996, CANCER RES, V56, P273; Huot J, 1997, CIRC RES, V80, P383, DOI 10.1161/01.RES.80.3.383; Ivanov VN, 2000, ONCOGENE, V19, P3003, DOI 10.1038/sj.onc.1203602; Keller D, 1999, BIOCHEM BIOPH RES CO, V261, P464, DOI 10.1006/bbrc.1999.1023; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Krump E, 1997, J BIOL CHEM, V272, P17303, DOI 10.1074/jbc.272.28.17303; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; Liu PS, 2000, J BIOL CHEM, V275, P31648, DOI 10.1074/jbc.M004599200; Mathews CC, 1996, J CELL PHYSIOL, V166, P323; Morales MP, 2000, BIOCHEM BIOPH RES CO, V270, P1029, DOI 10.1006/bbrc.2000.2550; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; PALMER A, 1998, J CELL BIOL, V141, P905; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; Qin SF, 1997, J BIOL CHEM, V272, P17994, DOI 10.1074/jbc.272.29.17994; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHWARTZ LM, 1993, IMMUNOL TODAY, V14, P582, DOI 10.1016/0167-5699(93)90197-S; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; Zundel W, 2000, MOL CELL BIOL, V20, P1507, DOI 10.1128/MCB.20.5.1507-1514.2000	49	203	207	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8094	8103		10.1074/jbc.M009245200	http://dx.doi.org/10.1074/jbc.M009245200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11094059	hybrid			2022-12-25	WOS:000167474900060
J	Lucarelli, M; Fuso, A; Strom, R; Scarpa, S				Lucarelli, M; Fuso, A; Strom, R; Scarpa, S			The dynamics of myogenin site-specific demethylation is strongly correlated with its expression and with muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-CHROMOSOME INACTIVATION; DNA CYTOSINE-5 METHYLTRANSFERASE; CPG-BINDING-PROTEIN; DE-NOVO METHYLATION; GENE-EXPRESSION; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; MAMMALIAN PROTEIN; CELL-LINES; GERM-LINE	The molecular mechanisms underlying the activation of tissue-specific genes have not yet been fully clarified. We analyzed the methylation status of specific CCGG sites in the 5'-flanking region and exon 1 of myogenin gene, a very important myogenic differentiation factor. We demonstrated a loss of methylation, at the onset of C2C12 muscle cell Line differentiation, limited to the CCGG site of myogenin 5'-flanking region, which was strongly correlated with the transcriptional activation of this gene and with myogenic differentiation. The same CCGG site was also found to be hypomethylated, in vive, in embryonic mouse muscle (a myogenin-expressing tissue), as opposed to nonmuscle (nonexpressing) tissues that had a fully methylated site. In a C2C12-derived clone with enhanced myogenic ability, demethylation occurred within 2 h of induction of differentiation, :suggesting the involvement of some active demethylation mechanism(s) that occur in the absence of DNA replication. Exposure to drugs that inhibit DNA methylation by acting on the S-adenosylmethionine metabolism produced a further reduction, to a few minutes, in the duration of the demethylation dynamics, These effects suggest that the final site-specific DNA methylation pattern of tissue-specific:genes is defined through a continuous, relatively fast interplay between active DNA demethylation and re-methylation mechanisms.	Univ Rome La Sapienza, Dept Biotecnol Cellulari & Ematol, Lab Clin Chrirurg 1, I-00161 Rome, Italy; Univ Rome La Sapienza, Dept Surg 1, I-00161 Rome, Italy	Sapienza University Rome; Sapienza University Rome	Scarpa, S (corresponding author), Univ Rome La Sapienza, Dept Biotecnol Cellulari & Ematol, Lab Clin Chrirurg 1, Via A Scarpa 14, I-00161 Rome, Italy.		Lucarelli, Marco/AAC-1667-2019; Fuso, Andrea/G-7390-2012	Lucarelli, Marco/0000-0002-5538-2494; Fuso, Andrea/0000-0001-9467-5671				ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; ARNHEIM N, 1979, J MOL BIOL, V134, P743, DOI 10.1016/0022-2836(79)90483-2; Arnold HH, 1998, CURR OPIN GENET DEV, V8, P539, DOI 10.1016/S0959-437X(98)80008-7; Baylin SB, 1998, ADV CANCER RES, V72, P141; Bergman Y, 1998, BIOL CHEM, V379, P401; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Bird A, 1999, SCIENCE, V286, P2287, DOI 10.1126/science.286.5448.2287; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Bowles JT, 1998, MED HYPOTHESES, V51, P179, DOI 10.1016/S0306-9877(98)90079-2; BOYES J, 1992, EMBO J, V11, P327, DOI 10.1002/j.1460-2075.1992.tb05055.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunk BP, 1996, DEV BIOL, V177, P490, DOI 10.1006/dbio.1996.0180; CANTONI GL, 1985, BIOCH BIOL DNA METHY, P47; Cervoni N, 1999, J BIOL CHEM, V274, P8363, DOI 10.1074/jbc.274.13.8363; CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; CHIANG PK, 1985, METHOD PHARMACOL, V6, P127; Eden S, 1998, NATURE, V394, P842, DOI 10.1038/29680; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; Falk KI, 1998, J VIROL, V72, P2969, DOI 10.1128/JVI.72.4.2969-2974.1998; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Ginder GD, 1998, ANN NY ACAD SCI, V850, P70, DOI 10.1111/j.1749-6632.1998.tb10464.x; GOLDHAMER DJ, 1995, DEVELOPMENT, V121, P637; Goto T, 1998, MICROBIOL MOL BIOL R, V62, P362, DOI 10.1128/MMBR.62.2.362-378.1998; Heard E, 1997, ANNU REV GENET, V31, P571, DOI 10.1146/annurev.genet.31.1.571; Heby O, 1995, INT J DEV BIOL, V39, P737; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hsu DW, 1999, P NATL ACAD SCI USA, V96, P9751, DOI 10.1073/pnas.96.17.9751; Hug M, 1996, FEBS LETT, V379, P251, DOI 10.1016/0014-5793(95)01521-3; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; JONES PA, 1990, P NATL ACAD SCI USA, V87, P6117, DOI 10.1073/pnas.87.16.6117; Jones PA, 1984, DNA METHYLATION BIOC, P165; Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Jost JP, 1997, NUCLEIC ACIDS RES, V25, P4545, DOI 10.1093/nar/25.22.4545; JOST JP, 1994, J BIOL CHEM, V269, P1040; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KESHET I, 1985, P NATL ACAD SCI USA, V82, P2560, DOI 10.1073/pnas.82.9.2560; Kuriyama S, 1998, GENE THER, V5, P1299, DOI 10.1038/sj.gt.3300738; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LI L, 1992, ADV CANCER RES, V58, P95, DOI 10.1016/S0065-230X(08)60292-4; Lu S, 1997, P NATL ACAD SCI USA, V94, P4692, DOI 10.1073/pnas.94.9.4692; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Ng HH, 2000, MOL CELL BIOL, V20, P1394, DOI 10.1128/MCB.20.4.1394-1406.2000; Ohlsson R, 1998, TRENDS GENET, V14, P435, DOI 10.1016/S0168-9525(98)01583-2; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; PAROUSH Z, 1990, CELL, V63, P1229, DOI 10.1016/0092-8674(90)90418-E; Pradhan S, 1999, J BIOL CHEM, V274, P33002, DOI 10.1074/jbc.274.46.33002; Ramchandani S, 1999, P NATL ACAD SCI USA, V96, P6107, DOI 10.1073/pnas.96.11.6107; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Reik W, 1999, NAT GENET, V23, P380, DOI 10.1038/70476; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; Sambrook J, 1989, MOL CLONING LAB MANU, VII; Sambrook J, 1989, MOL CLONING LAB MANU, V1-3; SCARPA S, 1985, CELL DIFFER DEV, V17, P105, DOI 10.1016/0045-6039(85)90476-2; SCARPA S, 1984, P NATL ACAD SCI-BIOL, V81, P3064, DOI 10.1073/pnas.81.10.3064; Scarpa S, 1996, CELL GROWTH DIFFER, V7, P1051; Schaefer BC, 1997, MOL CELL BIOL, V17, P364, DOI 10.1128/MCB.17.1.364; Shiraishi M, 1999, BIOL CHEM, V380, P1127, DOI 10.1515/BC.1999.141; SIEGFRIED Z, 1997, CURR BIOL, V7, P305; SINGERSAM J, 1990, NUCLEIC ACIDS RES, V18, P687, DOI 10.1093/nar/18.3.687; SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987; STALLCUP MR, 1983, J BIOL CHEM, V258, P2802; SZYF M, 1992, J BIOL CHEM, V267, P12831; Szyf M, 1996, PHARMACOL THERAPEUT, V70, P1, DOI 10.1016/0163-7258(96)00002-2; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Warnecke PM, 1999, MOL CELL BIOL, V19, P164; Weiss A, 1996, CELL, V86, P709, DOI 10.1016/S0092-8674(00)80146-4; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; ZINGG JM, 1994, NUCLEIC ACIDS RES, V22, P2234, DOI 10.1093/nar/22.12.2234	77	105	111	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7500	7506		10.1074/jbc.M008234200	http://dx.doi.org/10.1074/jbc.M008234200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11096088	Green Published, hybrid			2022-12-25	WOS:000167442900088
J	Saridakis, V; Christendat, D; Kimber, MS; Dharamsi, A; Edwards, AM; Pai, EF				Saridakis, V; Christendat, D; Kimber, MS; Dharamsi, A; Edwards, AM; Pai, EF			Insights into ligand binding and catalysis of a central step in NAD(+) synthesis - Structures of Methanobacterium thermoautotrophicum NMN adenylyltransferase complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE MONONUCLEOTIDE ADENYLYLTRANSFERASE; COMPLETE GENOME SEQUENCE; PROTEIN; ENZYME; CYTIDYLYLTRANSFERASE; IDENTIFICATION; RESIDUES; PROGRAM; SUITE; SITE	Nicotinamide mononucleotide adenylyltransferase (NMNATase) catalyzes the linking of NMN+ or NaMN+ with ATP, which in all organisms is one of the common step in the synthesis of the ubiquitous coenzyme NAD(+) via both de novo and salvage biosynthetic pathways. The structure of Methanobacterium thermoautotrophicum NMNATase determined using multiwavelength anomalous dispersion phasing revealed a nucleotide-binding fold common to nucleotidyltransferase proteins. An NAD+ molecule and a sulfate ion were bound in the active site allowing the identification of residues involved in product binding. In addition, the role of the conserved (16)HXGH(19) active site motif in catalysis was probed by mutagenic, enzymatic and crystallographic techniques, including the characterization of an NMN+/SO42- complex of mutant H19A NMNATase.	Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, CH Best Inst, Banting & Best Dept Med Res, Toronto, ON M5S 1A8, Canada; Integrat Proteom, Toronto, ON M5G 1L6, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Pai, EF (corresponding author), Ontario Canc Inst, Div Mol & Struct Biol, 610 Univ Ave, Toronto, ON M5G 2M9, Canada.	pai@hera.med.utoronto.ca	Kimber, Matthew/Q-8144-2019; Pai, Emil/R-8908-2019; Pai, Emil F/D-2526-2013	Pai, Emil/0000-0002-1162-7242; Edwards, Aled/0000-0002-4782-6016; Kimber, Matthew/0000-0001-9454-5586	NCRR NIH HHS [RR07707] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BRICK P, 1989, J MOL BIOL, V208, P83, DOI 10.1016/0022-2836(89)90090-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Christendat D, 2000, NAT STRUCT BIOL, V7, P903; D'Angelo I, 2000, STRUCTURE, V8, P993, DOI 10.1016/S0969-2126(00)00190-8; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Emanuelli M, 1999, FEBS LETT, V455, P13, DOI 10.1016/S0014-5793(99)00852-2; Hatzfeld Y, 2000, GENE, V248, P51, DOI 10.1016/S0378-1119(00)00132-3; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Izard T, 1999, EMBO J, V18, P2021, DOI 10.1093/emboj/18.8.2021; JAYARAM HN, 1986, BIOCHEM PHARMACOL, V35, P587, DOI 10.1016/0006-2952(86)90352-7; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; LOWE G, 1983, EUR J BIOCHEM, V132, P117, DOI 10.1111/j.1432-1033.1983.tb07334.x; Magni G, 1999, ADV ENZYMOL RAMB, V73, P135, DOI 10.1002/9780470123195.ch5; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Park YS, 1997, J BIOL CHEM, V272, P15161, DOI 10.1074/jbc.272.24.15161; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; Raffaelli N, 1997, J BACTERIOL, V179, P7718, DOI 10.1128/jb.179.24.7718-7723.1997; Raffaelli N, 1999, FEBS LETT, V444, P222, DOI 10.1016/S0014-5793(99)00068-X; Raffaelli N, 1999, MOL CELL BIOCHEM, V193, P99, DOI 10.1023/A:1006968328186; Raffaelli N, 1999, J BACTERIOL, V181, P5509, DOI 10.1128/JB.181.17.5509-5511.1999; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Smith DR, 1997, J BACTERIOL, V179, P7135, DOI 10.1128/jb.179.22.7135-7155.1997; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Veitch DP, 1998, EUR J BIOCHEM, V255, P227, DOI 10.1046/j.1432-1327.1998.2550227.x; Venkatachalam KV, 1999, J BIOL CHEM, V274, P2601, DOI 10.1074/jbc.274.5.2601; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Weber CH, 1999, STRUCTURE, V7, P1113, DOI 10.1016/S0969-2126(99)80178-6; Zarembinski TI, 1998, P NATL ACAD SCI USA, V95, P15189, DOI 10.1073/pnas.95.26.15189; [No title captured]	36	48	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7225	7232		10.1074/jbc.M008810200	http://dx.doi.org/10.1074/jbc.M008810200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11063748	hybrid			2022-12-25	WOS:000167442900052
J	Slepak, TI; Webster, KA; Zang, J; Prentice, H; O'Dowd, A; Hicks, MN; Bishopric, NH				Slepak, TI; Webster, KA; Zang, J; Prentice, H; O'Dowd, A; Hicks, MN; Bishopric, NH			Control of cardiac-specific transcription by p300 through myocyte enhancer factor-2D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN GENE; HEAVY-CHAIN GENE; SERUM RESPONSE FACTOR; CREB-BINDING-PROTEIN; HELIX-LOOP-HELIX; MUSCLE-SPECIFIC ENHANCER; VENTRICULAR MYOCYTES; MADS-BOX; DILATED CARDIOMYOPATHY; PRESSURE-OVERLOAD	The transcriptional integrator p300 regulates gene expression by interaction with sequence-specific DNA-binding proteins and local remodeling of chromatin, p300 is required for cardiac-specific gene transcription, but the molecular basis of this requirement is unknown. Here we report that the MADS (MCM-1, agamous, deficiens, serum response factor) box transcription factor myocyte enhancer factor-2D (MEF-2D) acts as the principal conduit for cardiac transcriptional activation by p300, p300 activation of the native 2130-base pair human skeletal alpha -actin promoter required a single hybrid MEF-2/GATA-4 DNA motif centered at -1256 base pairs. Maximal expression of the promoter in cultured myocytes and in vivo correlated with binding of both MEF-2 and p300, but not GATA-4, to this AT-rich motif, p300 and MEF-2 were coprecipitated from cardiac nuclear extracts by an oligomer containing this element. p300 was found exclusively in a complex with MEF-2D at this and related sites in other cardiac-restricted promoters. MEF-2D, but not other MEFs, significantly potentiated cardiac specific transcription by p300, No physical or functional interaction was observed between p300 and other factors implicated in skeletal actin transcription, including GATA-4, TEF-1, or SRF. These results show that, in the intact cell, p300 interactions with its protein targets are highly selective and that MEF-2D is the preferred channel for p300-mediated transcriptional control in the heart.	Univ Miami, Dept Mol & Cellular Pharmacol, Miami, FL 33101 USA; Univ Glasgow, Glasgow Royal Infirm, Dept Mol Genet, Glasgow G11 6NU, Lanark, Scotland; Univ Glasgow, Glasgow Royal Infirm, Dept Med Cardiol, Glasgow G11 6NU, Lanark, Scotland	University of Miami; University of Glasgow; University of Glasgow	Bishopric, NH (corresponding author), Univ Miami, Dept Mol & Cellular Pharmacol, POB 106189,R-189, Miami, FL 33101 USA.			Webster, Keith A/0000-0002-6431-3642	NHLBI NIH HHS [HL49891, HL44578] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049891, R29HL044578, R01HL044578] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAM SE, 1993, ONCOGENE, V8, P1639; Adachi S, 1998, LIFE SCI, V63, P1779, DOI 10.1016/S0024-3205(98)00452-4; ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BISHOPRIC NH, 1991, P NATL ACAD SCI USA, V88, P2132, DOI 10.1073/pnas.88.6.2132; Bishopric NH, 1997, J BIOL CHEM, V272, P20584, DOI 10.1074/jbc.272.33.20584; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Blobel GA, 1998, P NATL ACAD SCI USA, V95, P2061, DOI 10.1073/pnas.95.5.2061; BOHELER KR, 1991, J CLIN INVEST, V88, P323, DOI 10.1172/JCI115295; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; Giles RH, 1998, AM J HUM GENET, V63, P1240, DOI 10.1086/302044; Giordano A, 1999, J CELL PHYSIOL, V181, P218, DOI 10.1002/(SICI)1097-4652(199911)181:2<218::AID-JCP4>3.0.CO;2-5; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREPIN C, 1994, MOL CELL BIOL, V14, P3115, DOI 10.1128/MCB.14.5.3115; Hasegawa K, 1997, J BIOL CHEM, V272, P20049, DOI 10.1074/jbc.272.32.20049; Hasegawa K, 1997, CIRCULATION, V96, P3943; Herzig TC, 1997, P NATL ACAD SCI USA, V94, P7543, DOI 10.1073/pnas.94.14.7543; IZUMO S, 1988, P NATL ACAD SCI USA, V85, P339, DOI 10.1073/pnas.85.2.339; Kakita T, 1999, J BIOL CHEM, V274, P34096, DOI 10.1074/jbc.274.48.34096; KARNS LR, 1995, J BIOL CHEM, V270, P410, DOI 10.1074/jbc.270.1.410; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KIRSHENBAUM LA, 1995, J BIOL CHEM, V270, P7791, DOI 10.1074/jbc.270.14.7791; LEE JE, 1995, SCIENCE, V268, P836, DOI 10.1126/science.7754368; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; MACLELLAN WR, 1994, J BIOL CHEM, V269, P16754; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; MOLKENTIN JD, 1993, J BIOL CHEM, V268, P19512; Molkentin JD, 1996, J BIOL CHEM, V271, P17199, DOI 10.1074/jbc.271.29.17199; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P4947, DOI 10.1128/MCB.14.7.4947; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MOLKENTIN JD, 1994, MOL CELL BIOL, V14, P5056, DOI 10.1128/MCB.14.8.5056; Muscat George E. O., 1992, Gene Expression, V2, P111; Naya FJ, 1999, DEVELOPMENT, V126, P2045; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; PARKER TG, 1990, P NATL ACAD SCI USA, V87, P7066, DOI 10.1073/pnas.87.18.7066; PRENTICE H, 1994, J MOL CELL CARDIOL, V26, P1393, DOI 10.1006/jmcc.1994.1157; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Sambrook J., 2002, MOL CLONING LAB MANU; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Snowden AW, 1998, BIOCHEM PHARMACOL, V55, P1947, DOI 10.1016/S0006-2952(98)00020-3; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sugden PH, 1998, J MOL MED, V76, P725, DOI 10.1007/s001090050275; TANAKA M, 1995, J AM COLL CARDIOL, V26, P85, DOI 10.1016/0735-1097(95)00145-P; Tanaka Y, 1997, P NATL ACAD SCI USA, V94, P10215, DOI 10.1073/pnas.94.19.10215; TAYLOR A, 1988, GENOMICS, V3, P323, DOI 10.1016/0888-7543(88)90123-1; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	60	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7575	7585		10.1074/jbc.M004625200	http://dx.doi.org/10.1074/jbc.M004625200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11096067	hybrid			2022-12-25	WOS:000167442900097
J	Arimura, T; Suematsu, N; Zhou, YB; Nishimura, J; Satoh, S; Takeshita, A; Kanaide, H; Kimura, A				Arimura, T; Suematsu, N; Zhou, YB; Nishimura, J; Satoh, S; Takeshita, A; Kanaide, H; Kimura, A			Identification, characterization, and functional analysis of heart-specific myosin light chain phosphatase small subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE MYOSIN; KINASE-RELATED PROTEIN; PORCINE RENAL-ARTERY; REGULATORY SUBUNIT; MOLECULAR-CLONING; CA2+ SENSITIVITY; CALCIUM SENSITIVITY; TARGET SUBUNIT-1; BINDING PROTEIN; CARDIAC-CELLS	Myosin light chain phosphatase consists of three subunits, a 38-kDa catalytic subunit, a large 110-130-kDa myosin binding subunit, and a small subunit of 20-21 kDa. The catalytic subunit and the large subunit have been well characterized. The small subunit has been cloned and studied from smooth muscle, but little is known about its function and specificity in the other muscles such as cardiac muscle. In this study, cDNAs for heart-specific small subunit isoforms, hHS-M-21, were isolated and characterized. Evidence was obtained from an analysis of genome to suggest that the small subunit was the product of the same gene as the large subunit. Using permeabilized renal artery preparation and permeabilized cardiac myocytes, it was shown that the small subunit increased sensitivity to Ca2+ in muscle contraction. It was also shown using an overlay assay that hHS-M-21 bound the large subunit. Mapping experiments demonstrated that the binding domain and the domain involved in the increasing Ca2+ sensitivity mapped to the same N-terminal region of hHS-M-21. These observations suggest that the heart-specific small subunit hHS-M-21 plays a regulatory role in cardiac muscle contraction by its binding to the large subunit.	Tokyo Med & Dent Univ, Med Res Inst, Div Adult Dis, Div Mol Pathogenesis,Chiyoda Ku, Tokyo 1010062, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Fukuoka 8128582, Japan; Kyushu Univ, Fac Med, Angiocardiol Res Inst, Div Mol Cardiol, Fukuoka 8128582, Japan; Tokyo Med & Dent Univ, Med Res Inst, Etiol & Pathogenesis Res Unit, Tokyo 1010062, Japan	Tokyo Medical & Dental University (TMDU); Kyushu University; Kyushu University; Tokyo Medical & Dental University (TMDU)	Kimura, A (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Div Adult Dis, Div Mol Pathogenesis,Chiyoda Ku, 2-3-10 Kandasurugadai, Tokyo 1010062, Japan.		Arimura, Takuro/AAA-2745-2022; Kimura, Akinori/I-5989-2018	Arimura, Takuro/0000-0002-0929-3140; Kimura, Akinori/0000-0002-4933-2132				ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; Aoki H, 2000, NAT MED, V6, P183, DOI 10.1038/72287; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YH, 1994, FEBS LETT, V356, P51, DOI 10.1016/0014-5793(94)01231-8; CHISHOLM AAK, 1988, BIOCHIM BIOPHYS ACTA, V971, P163, DOI 10.1016/0167-4889(88)90188-7; CLEMENT O, 1992, BIOCHEM J, V285, P311, DOI 10.1042/bj2850311; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; EBASHI S, 1984, J MOL CELL CARDIOL, V16, P129, DOI 10.1016/S0022-2828(84)80701-4; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fujioka M, 1998, GENOMICS, V49, P59, DOI 10.1006/geno.1998.5222; Gailly P, 1996, EUR J BIOCHEM, V239, P326, DOI 10.1111/j.1432-1033.1996.0326u.x; GALLAGHER PJ, 1991, J BIOL CHEM, V266, P23945; Gallagher PJ, 1997, J MUSCLE RES CELL M, V18, P1, DOI 10.1023/A:1018616814417; Hartshorne D J, 1989, Adv Exp Med Biol, V255, P269; Hartshorne DJ, 1999, MOL CELL BIOCHEM, V190, P79, DOI 10.1023/A:1006917032557; Hartshorne DJ, 1998, J MUSCLE RES CELL M, V19, P325, DOI 10.1023/A:1005385302064; Haystead CMM, 1995, FEBS LETT, V377, P123, DOI 10.1016/0014-5793(95)01318-0; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; Ichikawa K, 1996, BIOCHEMISTRY-US, V35, P6313, DOI 10.1021/bi960208q; IINO M, 1988, BIOCHEM BIOPH RES CO, V152, P417, DOI 10.1016/S0006-291X(88)80730-7; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; Ishibashi Y, 1996, AM J PHYSIOL-HEART C, V271, pH1978, DOI 10.1152/ajpheart.1996.271.5.H1978; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; ITO M, 1989, J BIOL CHEM, V264, P13971; Johnson D, 1997, EUR J BIOCHEM, V244, P931, DOI 10.1111/j.1432-1033.1997.00931.x; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Moorhead G, 1998, FEBS LETT, V438, P141, DOI 10.1016/S0014-5793(98)01276-9; Morano I, 1999, J MOL MED-JMM, V77, P544, DOI 10.1007/s001099900031; MORANO I, 1988, BASIC RES CARDIOL, V83, P350, DOI 10.1007/BF02005820; MORANO I, 1985, FEBS LETT, V189, P221, DOI 10.1016/0014-5793(85)81027-9; MUMBY MC, 1987, J BIOL CHEM, V262, P6257; NISHIMURA J, 1988, BIOCHEM BIOPH RES CO, V157, P677, DOI 10.1016/S0006-291X(88)80303-6; Nishio H, 1997, BIOCHEM BIOPH RES CO, V236, P570, DOI 10.1006/bbrc.1997.7005; OKUBO S, 1994, BIOCHEM BIOPH RES CO, V200, P429, DOI 10.1006/bbrc.1994.1467; SAIDA K, 1978, J GEN PHYSIOL, V72, P1, DOI 10.1085/jgp.72.1.1; Satoh S, 1999, PFLUG ARCH EUR J PHY, V437, P702, DOI 10.1007/s004240050835; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SHIRAZI A, 1994, J BIOL CHEM, V269, P31598; Silver DL, 1997, J BIOL CHEM, V272, P25353, DOI 10.1074/jbc.272.40.25353; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; STRANG KT, 1994, CIRC RES, V74, P542, DOI 10.1161/01.RES.74.3.542; Takahashi N, 1997, GENOMICS, V44, P150, DOI 10.1006/geno.1997.4859; Tanaka J, 1998, BIOCHEMISTRY-US, V37, P16697, DOI 10.1021/bi980782x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vorotnikov AV, 1997, INT J BIOCHEM CELL B, V29, P727, DOI 10.1016/S1357-2725(96)00156-2; Wu XQ, 1998, J BIOL CHEM, V273, P11362, DOI 10.1074/jbc.273.18.11362; YOSHIKAI S, 1992, ARCH BIOCHEM BIOPHYS, V299, P242, DOI 10.1016/0003-9861(92)90270-7; Zhou YB, 1999, J PHYSIOL-LONDON, V516, P55, DOI 10.1111/j.1469-7793.1999.055aa.x; Zhou YB, 1999, BIOCHEM BIOPH RES CO, V254, P158, DOI 10.1006/bbrc.1998.9915; [No title captured]	53	32	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6073	6082		10.1074/jbc.M008566200	http://dx.doi.org/10.1074/jbc.M008566200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11067852	hybrid			2022-12-25	WOS:000167261000005
J	Gotte, M; Kameoka, M; McLellan, N; Cellai, L; Wainberg, MA				Gotte, M; Kameoka, M; McLellan, N; Cellai, L; Wainberg, MA			Analysis of efficiency and fidelity of HIV-1 (+)-strand DNA synthesis reveals a novel rate-limiting step during retroviral reverse transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSFER-RNAS; MINOR-GROOVE; TYPE-1; INITIATION; PRIMER; POLYMERASE; MUTATIONS; BINDING; PROCESSIVITY	We have analyzed the efficiency and accuracy of polymerization at several different stages during the initiation of human immunodeficiency virus type 1 (HIV-1) (+)-strand DNA synthesis. This reaction is of particular interest, as it involves the recruitment by reverse transcriptase of an RNA primer that serves as substrate for both the polymerase and RNase H activities of the enzyme. We found that the correct incorporation of the first two nucleotides was severely compromised and that formation of mismatches was completely absent at this stage of initiation. Although the fidelity of incorporations decreased concomitantly with ensuing polymerization, the elongation of mispaired primers was literally blocked. Instead, mispaired primer strands initiated a switch from active synthesis of DNA to premature RNase H-mediated primer removal These findings suggest the existence of a fragile equilibrium between these two enzymatic activities that is shifted toward RNase H cleavage once the polymerization process is aggravated. Our data show that the initiation of HIV-1 (+)-strand DNA synthesis differs significantly from reactions involving other primer/template combinations, including tRNA-primed (-)-strand DNA synthesis.	McGill Univ, Jewish Gen Hosp, AIDS Ctr, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Expt Med, Montreal, PQ, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ, Canada; CNR, Ist Strutturist Chim, I-00016 Rome, Italy	Lady Davis Institute; McGill University; McGill University; McGill University; Consiglio Nazionale delle Ricerche (CNR)	Gotte, M (corresponding author), McGill Univ, Jewish Gen Hosp, AIDS Ctr, Lady Davis Inst, 3755 Chemin Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.	mgoette@ldi.jgh.mcgill.ca		Kameoka, Masanori/0000-0001-5525-9915				Back NKT, 1996, EMBO J, V15, P4040, DOI 10.1002/j.1460-2075.1996.tb00777.x; Bebenek K, 1997, NAT STRUCT BIOL, V4, P194, DOI 10.1038/nsb0397-194; Bebenek K, 1993, REVERSE TRANSCRIPTAS, P85; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; Boyer PL, 2000, P NATL ACAD SCI USA, V97, P3056, DOI 10.1073/pnas.97.7.3056; BOYER PL, 1995, ANTIMICROB AGENTS CH, V39, P1624, DOI 10.1128/AAC.39.7.1624; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; CHARNEAU P, 1994, J MOL BIOL, V241, P651, DOI 10.1006/jmbi.1994.1542; Essink BBO, 1999, J BIOMED SCI, V6, P121; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; Gotte M, 1998, J BIOL CHEM, V273, P10139, DOI 10.1074/jbc.273.17.10139; GOTTE M, 1995, EMBO J, V14, P833, DOI 10.1002/j.1460-2075.1995.tb07061.x; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; Gotte M, 1999, ARCH BIOCHEM BIOPHYS, V365, P199, DOI 10.1006/abbi.1999.1209; Huang HF, 1998, SCIENCE, V282, P1669, DOI 10.1126/science.282.5394.1669; HUBER HE, 1990, J BIOL CHEM, V265, P10565; Isel C, 1996, EMBO J, V15, P917, DOI 10.1002/j.1460-2075.1996.tb00426.x; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+; Klarmann GJ, 1997, J VIROL, V71, P9259, DOI 10.1128/JVI.71.12.9259-9269.1997; Kootstra NA, 2000, J VIROL, V74, P1712, DOI 10.1128/JVI.74.4.1712-1717.2000; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; Lanchy JM, 1998, J BIOL CHEM, V273, P24425, DOI 10.1074/jbc.273.38.24425; Lanchy JM, 1996, EMBO J, V15, P7178, DOI 10.1002/j.1460-2075.1996.tb01109.x; Lavigne M, 1999, J MOL BIOL, V285, P977, DOI 10.1006/jmbi.1998.2367; LEGRICE SFJ, 1990, EUR J BIOCHEM, V187, P307, DOI 10.1111/j.1432-1033.1990.tb15306.x; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; MARQUET R, 1995, BIOCHIMIE, V77, P113, DOI 10.1016/0300-9084(96)88114-4; MartinHernandez AM, 1996, EMBO J, V15, P4434, DOI 10.1002/j.1460-2075.1996.tb00816.x; MEYERHANS A, 1994, J VIROL, V68, P535, DOI 10.1128/JVI.68.1.535-540.1994; OBRIEN WA, 1994, J VIROL, V68, P1258, DOI 10.1128/JVI.68.2.1258-1263.1994; Palaniappan C, 1998, J BIOL CHEM, V273, P3808, DOI 10.1074/jbc.273.7.3808; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Powell MD, 1999, J BIOL CHEM, V274, P19885, DOI 10.1074/jbc.274.28.19885; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Quan YD, 1998, J BIOL CHEM, V273, P21918, DOI 10.1074/jbc.273.34.21918; ROBERTS JD, 1988, SCIENCE, V242, P1171, DOI 10.1126/science.2460925; Sarafianos SG, 1999, CHEM BIOL, V6, pR137, DOI 10.1016/S1074-5521(99)80071-4; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; SCHATZ O, 1989, FEBS LETT, V257, P311, DOI 10.1016/0014-5793(89)81559-5; SCHINZAI RF, 2000, INT ANTIVIRAL NEWS, P65; Sharma PL, 1999, J VIROL, V73, P8448, DOI 10.1128/JVI.73.10.8448-8456.1999; Szyperski T, 1999, J BIOMOL NMR, V13, P343, DOI 10.1023/A:1008350604637; TELESNITSKY A, 1909, RETROVIRUSES, P121; Thrall SH, 1998, BIOCHEMISTRY-US, V37, P13349; Vartanian JP, 1997, J MOL BIOL, V270, P139, DOI 10.1006/jmbi.1997.1104; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992; Zhang H, 1996, J VIROL, V70, P2809, DOI 10.1128/JVI.70.5.2809-2824.1996	56	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6711	6719		10.1074/jbc.M009097200	http://dx.doi.org/10.1074/jbc.M009097200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096104	hybrid			2022-12-25	WOS:000167261000083
J	Patel, PH; Kawate, H; Adman, E; Ashbach, M; Loeb, LK				Patel, PH; Kawate, H; Adman, E; Ashbach, M; Loeb, LK			A single highly mutable catalytic site amino acid is critical for DNA polymerase fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I KLENOW FRAGMENT; TYPE-1 REVERSE-TRANSCRIPTASE; NONPOLYPOSIS COLON-CANCER; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MISMATCH REPAIR; ACTIVE-SITE; POL-V; MUTATION; PURIFICATION	DNA polymerases contain active sites that are structurally superimposable and conserved in amino acid sequence. To probe the biochemical and structure-function relationship of DNA polymerases, a large library (200,000 members) of mutant Thermus aquaticus DNA polymerase I (Taq pol I) was created containing random substitutions within a portion of the dNTP binding site (Motif A; amino acids 605-617), and a fraction of all selected active Tag pol I (291 out of 8000) was tested for base pairing fidelity; seven unique mutants that efficiently misincorporate bases and/or extend mismatched bases were identified and sequenced. These mutants all contain substitutions of one specific amino acid, Ile-614, which forms part of the hydrophobic pocket that binds the base and ribose portions of the incoming nucleotide, Mutant Tag pol Is containing hydrophilic substitution I614K exhibit 10-fold lower base misincorporation fidelity, as well as a high propensity to extend mispairs, In addition, these low fidelity mutants containing hydrophilic substitution for lle-614 can bypass damaged templates that include an abasic site and vinyl chloride adduct ethenoA, During polymerase chain reaction, Tag pol I mutant I614K exhibits an error rate that is >20-fold higher relative to the wild-type enzyme and efficiently catalyzes both transition and transversion errors. These studies have generated polymerase chain reaction-proficient mutant polymerases containing substitutions within the active site that confers low base pairing fidelity and a high error rate, Considering the structural and sequence conservation of Motif A, it is likely that a similar substitution will yield active low fidelity DNA polymerases that are mutagenic.	Univ Washington, Sch Med, Dept Pathol, Joseph Gottstein Mem Canc Lab, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Loeb, LK (corresponding author), Univ Washington, Sch Med, Dept Pathol, Joseph Gottstein Mem Canc Lab, Seattle, WA 98195 USA.				NCI NIH HHS [CA78885, R35 CA39903, CA09437] Funding Source: Medline; NIGMS NIH HHS [5T32 GM3207266] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039903, R01CA078885, T32CA009437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032072] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BOOSALIS MS, 1987, J BIOL CHEM, V262, P14689; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; DELARUE M, 1990, PROTEIN ENG, V3, P461, DOI 10.1093/protein/3.6.461; DESAI SD, 1994, BIOCHEMISTRY-US, P11868; DONG Q, 1993, J BIOL CHEM, V268, P24163; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; DRAKE JW, 1991, P NATL ACAD SCI USA, V88, P7160, DOI 10.1073/pnas.88.16.7160; ECHOLS H, 1983, P NATL ACAD SCI-BIOL, V80, P2189, DOI 10.1073/pnas.80.8.2189; ECHOLS H, 1982, BIOCHIMIE, V64, P571, DOI 10.1016/S0300-9084(82)80089-8; ENGELKE DR, 1990, ANAL BIOCHEM, V191, P396, DOI 10.1016/0003-2697(90)90238-5; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Goodman MF, 2000, TRENDS BIOCHEM SCI, V25, P189, DOI 10.1016/S0968-0004(00)01564-4; Goodman MF, 1998, GENETICS, V148, P1475; GRIMM E, 1995, NUCLEIC ACIDS RES, V23, P4518, DOI 10.1093/nar/23.21.4518; JOHNSON KA, 1993, ANNU REV BIOCHEM, V62, P685, DOI 10.1146/annurev.bi.62.070193.003345; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; JOYCE CM, 1992, J BIOL CHEM, V267, P24485; Kim B, 1998, BIOCHEMISTRY-US, V37, P5831, DOI 10.1021/bi972672g; Kornberg A., 1992, DNA REPLICATION; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1981, SCIENCE, V213, P765, DOI 10.1126/science.6454965; LeClerc JE, 1996, SCIENCE, V274, P1208, DOI 10.1126/science.274.5290.1208; Li Y, 1998, EMBO J, V17, P7514, DOI 10.1093/emboj/17.24.7514; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; Loeb LA, 1996, CANCER SURV, V28, P329; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; Mao EF, 1997, J BACTERIOL, V179, P417, DOI 10.1128/jb.179.2.417-422.1997; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller JH, 1998, MUTAT RES-DNA REPAIR, V409, P99, DOI 10.1016/S0921-8777(98)00049-4; MODRICH P, 1989, J BIOL CHEM, V264, P6597; Oliver A, 2000, SCIENCE, V288, P1251, DOI 10.1126/science.288.5469.1251; Patel PH, 2000, P NATL ACAD SCI USA, V97, P5095, DOI 10.1073/pnas.97.10.5095; PATEL PH, 1995, BIOCHEMISTRY-US, V34, P5351, DOI 10.1021/bi00016a006; PATEL PH, 1994, P NATL ACAD SCI USA, V91, P549, DOI 10.1073/pnas.91.2.549; Patel PH, 2000, J BIOL CHEM, V275, P40266, DOI 10.1074/jbc.M005757200; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; Radman M, 1999, ANN NY ACAD SCI, V870, P146, DOI 10.1111/j.1749-6632.1999.tb08874.x; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; SCHAAPER RM, 1989, GENETICS, V121, P205; Suzuki M, 1997, J BIOL CHEM, V272, P11228; TABOR S, 1995, P NATL ACAD SCI USA, V92, P6339, DOI 10.1073/pnas.92.14.6339; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; Wang J, 1997, CELL, V89, P1087, DOI 10.1016/S0092-8674(00)80296-2; Welch DM, 2000, SCIENCE, V288, P1211, DOI 10.1126/science.288.5469.1211	49	80	87	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5044	5051		10.1074/jbc.M008701200	http://dx.doi.org/10.1074/jbc.M008701200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11069916	hybrid			2022-12-25	WOS:000168484300070
J	Zhen, XC; Wei, L; Wu, QQ; Zhang, Y; Chen, Q				Zhen, XC; Wei, L; Wu, QQ; Zhang, Y; Chen, Q			Mitogen-activated protein kinase p38 mediates regulation of chondrocyte differentiation by parathyroid hormone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE MATRIX PROTEIN; ENDOCHONDRAL BONE-FORMATION; OSTEOBLAST-LIKE CELLS; X COLLAGEN-SYNTHESIS; TERMINAL KINASE; RECEPTOR; PEPTIDE; EXPRESSION; MATURATION; CALCIUM	Parathyroid hormone (PTH) and its related peptide regulate endochondral ossification by inhibiting chondrocyte differentiation toward hypertrophy. However, the intracellular pathway for transducing PTH/PTH-related peptide signals in chondrocytes remains unclear. Here, we show that this pathway is mediated by mitogen-activated protein kinase (MAPK) p38. Incubation of hypertrophic chondrocytes with PTH (1-34) induces an inhibition of p38 kinase activity in a time- and dose-dependent manner. Inhibition of protein kinase C prevents PTH-induced p38 MAPK inhibition, whereas inhibition of protein kinase A has no effect. Thus, protein kinase C, but not protein kinase A, is required for the inhibition of p38 MAPK by PTH. Treatment of hypertrophic chondrocytes by PTH or by p38 MAPK inhibitor SB203580 up-regulates Bcl-2, suggesting that Bcl-2 lies downstream of p38 MAPK in the PTH signaling pathway. Inhibition of p38 MAPK in hypertrophic chondrocytes by either PTH, SB303580, or both together leads to a decrease of hypertrophic marker type X collagen mRNA and an increase of the expression of prehypertrophic marker cartilage matrix protein. Therefore, inhibition of p38 converts a hypertrophic cell phenotype to a prehypertrophic one, thereby preventing precocious chondrocyte hypertrophy, Taken together, these data suggest a major role for p38 MAPK in transmitting PTH signals to regulate chondrocyte differentiation.	Penn State Univ, Dept Orthopaed & Rehabil, Coll Med, Musculoskeletal Res Lab, Hershey, PA 17033 USA; Penn State Univ, Dept Cellular & Mol Physiol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Chen, Q (corresponding author), Penn State Univ, Dept Orthopaed & Rehabil, Coll Med, Musculoskeletal Res Lab, Hershey, PA 17033 USA.		Chen, Qian/C-4354-2011	Chen, Qian/0000-0003-4406-5618; zhen, xuechu/0000-0001-7458-2566	NIA NIH HHS [AG00811, AG17021, AG14399] Funding Source: Medline; NIGMS NIH HHS [P20 GM104937] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM104937] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG014399, R01AG014399, R01AG017021] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; ABOUSAMRA AB, 1989, ENDOCRINOLOGY, V124, P1107, DOI 10.1210/endo-124-3-1107; AMIZUKA N, 1994, J CELL BIOL, V126, P1611, DOI 10.1083/jcb.126.6.1611; Amling M, 1997, J CELL BIOL, V136, P205, DOI 10.1083/jcb.136.1.205; BALLOCK RT, 1994, J CELL BIOL, V126, P1311, DOI 10.1083/jcb.126.5.1311; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; BLIND E, 1995, ENDOCRINOLOGY, V136, P4271, DOI 10.1210/en.136.10.4271; BONEN DK, 1991, J CELL BIOL, V115, P1171, DOI 10.1083/jcb.115.4.1171; CHEN Q, 1995, DEV BIOL, V172, P293, DOI 10.1006/dbio.1995.0024; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; Chung UI, 1998, P NATL ACAD SCI USA, V95, P13030, DOI 10.1073/pnas.95.22.13030; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; Geng Y, 1996, J CLIN INVEST, V98, P2425, DOI 10.1172/JCI119056; Gibson G, 1997, EXP CELL RES, V233, P372, DOI 10.1006/excr.1997.3576; GIBSON GJ, 1985, J CELL BIOL, V101, P277, DOI 10.1083/jcb.101.1.277; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; He HL, 1997, J CELL BIOL, V138, P1219, DOI 10.1083/jcb.138.6.1219; IWAMOTO M, 1994, J BIOL CHEM, V269, P17245; KARAPLIS AC, 1994, GENE DEV, V8, P277, DOI 10.1101/gad.8.3.277; KISS I, 1989, J BIOL CHEM, V264, P8126; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; MITCHELL J, 1990, ENDOCRINOLOGY, V126, P2650, DOI 10.1210/endo-126-5-2650; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Rajpurohit R, 1999, J CELL PHYSIOL, V179, P287, DOI 10.1002/(SICI)1097-4652(199906)179:3<287::AID-JCP6>3.0.CO;2-T; Schipani E, 1997, P NATL ACAD SCI USA, V94, P13689, DOI 10.1073/pnas.94.25.13689; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; Wu QQ, 2000, EXP CELL RES, V256, P383, DOI 10.1006/excr.2000.4847; Yang MS, 1998, MOL CELLS, V8, P266; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; Zerega B, 1999, J BONE MINER RES, V14, P1281, DOI 10.1359/jbmr.1999.14.8.1281; Zhen XC, 1998, MOL PHARMACOL, V54, P453, DOI 10.1124/mol.54.3.453	35	82	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4879	4885		10.1074/jbc.M004990200	http://dx.doi.org/10.1074/jbc.M004990200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11098049	hybrid			2022-12-25	WOS:000168484300048
J	Kumari, D; Usdin, K				Kumari, D; Usdin, K			Interaction of the transcription factors USF1, USF2, and alpha-Pal/Nrf-1 with the FMR1 promoter - Implications for Fragile X mental retardation syndrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSGENIC MICE; BINDING-PROTEIN; GENE; CELLS; REACTIVATION; METHYLATION; INSTABILITY; INITIATION; REGION	Hypermethylation of the FMR1 promoter reduces its transcriptional activity, resulting in the mental retardation and macroorchidism characteristic of Fragile X syndrome. How exactly methylation causes transcriptional silencing is not known but is relevant if current attempts to reactivate the gene are to be successful. Understanding the effect of methylation requires a better understanding of the factors responsible for FMR1 gene expression, To this end we have identified five evolutionarily conserved transcription factor binding sites in this promoter and shown that four of them are important for transcriptional activity in neuronally derived cells. We have also shown that USF1, USF2, and alpha -Pal/Nrf-1 are the major transcription factors that bind the promoter in brain and testis extracts and suggest that elevated levels of these factors account in part for elevated FMR1 expression in these organs. We also show that methylation abolishes alpha -Pal/Nrf-1 binding to the promoter and affects binding of USF1 and USF2 to a lesser degree. Methylation may therefore inhibit FMR1 transcription not only by recruiting histone deacetylases but also by blocking transcription factor binding. This suggests that for efficient reactivation of the FMR1 promoter, significant demethylation must occur and that current approaches to gene reactivation using histone deacetylase inhibitors alone may therefore have limited effect.	NIDDK, Sect Genomic Struct & Funct, Mol & Cellular Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Usdin, K (corresponding author), NIDDK, Sect Genomic Struct & Funct, Mol & Cellular Biol Lab, NIH, Bldg 8,Rm 202,8 Ctr Dr,MSC 0830, Bethesda, MD 20892 USA.		Kumari, Daman/AAN-6704-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK057602, ZIADK057602] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BACHNER D, 1993, HUM MOL GENET, V2, P2043, DOI 10.1093/hmg/2.12.2043; BAKKER CE, 1994, CELL, V78, P23; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Carrillo C, 1999, NEUROSCI LETT, V276, P149, DOI 10.1016/S0304-3940(99)00798-3; Chiurazzi P, 1999, HUM MOL GENET, V8, P2317, DOI 10.1093/hmg/8.12.2317; Chiurazzi P, 1998, HUM MOL GENET, V7, P109, DOI 10.1093/hmg/7.1.109; Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drouin R, 1997, HUM MOL GENET, V6, P2051, DOI 10.1093/hmg/6.12.2051; EFIOK BJS, 1994, J BIOL CHEM, V269, P18921; Escriva H, 1999, BIOCHIMIE, V81, P965, DOI 10.1016/S0300-9084(99)00223-0; FENG Y, 1995, SCIENCE, V268, P731, DOI 10.1126/science.7732383; HERGERSBERG M, 1995, HUM MOL GENET, V4, P359, DOI 10.1093/hmg/4.3.359; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; HWU WL, 1993, BIOCHEM BIOPH RES CO, V193, P324, DOI 10.1006/bbrc.1993.1627; Hwu WL, 1997, DNA CELL BIOL, V16, P449, DOI 10.1089/dna.1997.16.449; Johnson AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1420, DOI 10.1152/ajpcell.1999.276.6.C1420; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; Lavedan C, 1998, GENOMICS, V50, P229, DOI 10.1006/geno.1998.5299; Muller-Hartmann H, 2000, J BIOL CHEM, V275, P6447, DOI 10.1074/jbc.275.9.6447; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; Schwemmle S, 1997, AM J HUM GENET, V60, P1354, DOI 10.1086/515456; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; Xiao QX, 1998, J MOL CELL CARDIOL, V30, P87, DOI 10.1006/jmcc.1997.0574	28	75	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4357	4364		10.1074/jbc.M009629200	http://dx.doi.org/10.1074/jbc.M009629200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11058604	hybrid			2022-12-25	WOS:000166921200084
J	Tallant, TC; Paul, L; Krzycki, JA				Tallant, TC; Paul, L; Krzycki, JA			The MtsA subunit of the methylthiol : coenzyme M methyltransferase of Methanosarcina barkeri catalyses both half-reactions of corrinoid-dependent dimethylsulfide: Coenzyme M methyl transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE SYNTHASE; ESTUARINE METHANOGEN; INTERTIDAL SEDIMENTS; SULFUR-COMPOUNDS; SP-NOV; PROTEIN; DIMETHYLSULFONIOPROPIONATE; ISOZYMES; MONOMETHYLAMINE; METABOLISM	Methanogenesis from dimethylsulfide requires the intermediate methylation of coenzyme M. This reaction is catalyzed by a methylthio:coenzyme M methyltransferase composed of two polypeptides, MtsA (a methylcobalamin: coenzyme M methyltransferase) and MtsB (homologous to a class of corrinoid proteins involved in methanogenesis), Recombinant MtsA was purified and found to be a homodimer that bound one zinc atom per polypeptide, but no corrinoid cofactor. MtsA is an active methylcobalamin: coenzyme M methyltransferase, but also methylates cob(I)alamin with dimethylsulfide, yielding equimolar methylcobalamin and methanethiol in an endergonic reaction with a K-eq of 5 x 10(-4). MtsA and cob(I)alamin mediate dimethylsulfide:coenzyme M methyl transfer in the complete absence of MtsB. Dimethylsulfide inhibited methylcobalamin:coenzyme methyl transfer by MtsA. Inhibition by dimethylsulfide was mixed with respect to methylcobalamin, but competitive with coenzyme M. MtbA, a MtsA homolog participating in coenzyme M methylation with methylamines, was not inhibited by dimethylsulfide and did not catalyze detectable dimethylsulfide:cob(I)alamin methyl transfer. These results are most consistent with a model for the native methylthiol:coenzyme M methyltransferase in which MtsA mediates the methylation of corrinoid bound to MtsB with dimethylsulfide and subsequently demethylates MtsB-bound corrinoid with coenzyme M, possibly employing elements of the same methyltransferase active site for both reactions.	Ohio State Univ, Dept Microbiol, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Krzycki, JA (corresponding author), Ohio State Univ, Dept Microbiol, 484 W 12Th Ave, Columbus, OH 43210 USA.							BAK F, 1992, ARCH MICROBIOL, V157, P529; Boone David R., 1993, P35; Burke SA, 1997, J BIOL CHEM, V272, P16570, DOI 10.1074/jbc.272.26.16570; Burke SA, 1998, J BACTERIOL, V180, P3432, DOI 10.1128/JB.180.13.3432-3440.1998; BURKE SA, 1995, J BACTERIOL, V177, P4410, DOI 10.1128/jb.177.15.4410-4416.1995; CHARLSON RJ, 1987, NATURE, V326, P655, DOI 10.1038/326655a0; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; FAHEY RC, 1981, ANAL BIOCHEM, V111, P357, DOI 10.1016/0003-2697(81)90573-X; Ferguson DJ, 1997, J BACTERIOL, V179, P846, DOI 10.1128/jb.179.3.846-852.1997; Ferguson DJ, 1996, J BIOL CHEM, V271, P5189; Ferguson DJ, 2000, J BIOL CHEM, V275, P29053, DOI 10.1074/jbc.M910218199; Ferry JG, 1999, FEMS MICROBIOL REV, V23, P13, DOI 10.1016/S0168-6445(98)00029-1; GRAHAME DA, 1989, J BIOL CHEM, V264, P12890; Jonkers HM, 1996, FEMS MICROBIOL LETT, V136, P283; KIENE RP, 1987, APPL ENVIRON MICROB, V53, P2426, DOI 10.1128/AEM.53.10.2426-2434.1987; KIENE RP, 1986, APPL ENVIRON MICROB, V52, P1037, DOI 10.1128/AEM.52.5.1037-1045.1986; KREFT JU, 1994, EUR J BIOCHEM, V226, P945, DOI 10.1111/j.1432-1033.1994.00945.x; KREMER J, 1994, J BACTERIOL, V176, P253, DOI 10.1128/JB.176.1.253-255.1994; KREMER JD, 1993, J BACTERIOL, V175, P4824, DOI 10.1128/JB.175.15.4824-4833.1993; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LeClerc GM, 1996, J BIOL CHEM, V271, P18725, DOI 10.1074/jbc.271.31.18725; Ludwig ML, 1997, ANNU REV BIOCHEM, V66, P269, DOI 10.1146/annurev.biochem.66.1.269; MCCARTY S, 1993, FEMS MICROBIOL LETT, V112, P93, DOI 10.1111/j.1574-6968.1993.tb06429.x; NEWTON GL, 1981, ANAL BIOCHEM, V114, P383, DOI 10.1016/0003-2697(81)90498-X; NI SS, 1994, INT J SYST BACTERIOL, V44, P357, DOI 10.1099/00207713-44-2-357; OREMLAND RS, 1994, INT J SYST BACTERIOL, V44, P573, DOI 10.1099/00207713-44-3-573; Paul L, 1996, J BACTERIOL, V178, P6599, DOI 10.1128/jb.178.22.6599-6607.1996; Paul L, 2000, J BACTERIOL, V182, P2520, DOI 10.1128/JB.182.9.2520-2529.2000; POL A, 1984, BIOCHIM BIOPHYS ACTA, V797, P83, DOI 10.1016/0304-4165(84)90385-4; Sambrook J., 2002, MOL CLONING LAB MANU; Sauer K, 1997, EUR J BIOCHEM, V243, P670, DOI 10.1111/j.1432-1033.1997.t01-1-00670.x; Sauer K, 2000, EUR J BIOCHEM, V267, P2498, DOI 10.1046/j.1432-1327.2000.01245.x; SEEFELDT LC, 1994, ANAL BIOCHEM, V221, P379, DOI 10.1006/abio.1994.1429; SOWERS KR, 1984, APPL ENVIRON MICROB, V47, P971, DOI 10.1128/AEM.47.5.971-978.1984; Tallant TC, 1997, J BACTERIOL, V179, P6902, DOI 10.1128/jb.179.22.6902-6911.1997; TAYLOR BF, 1991, APPL ENVIRON MICROB, V57, P3581, DOI 10.1128/AEM.57.12.3581-3584.1991; Thauer RK, 1998, MICROBIOL-UK, V144, P2377, DOI 10.1099/00221287-144-9-2377; VANDERMAAREL MJEC, 1995, APPL ENVIRON MICROB, V61, P48, DOI 10.1128/AEM.61.1.48-51.1995; vanderMaarel MJEC, 1997, MAR GEOL, V137, P5, DOI 10.1016/S0025-3227(96)00074-6; VANDERMEIJDEN P, 1984, J BACTERIOL, V160, P629, DOI 10.1128/JB.160.2.629-635.1984; VANDERMEIJDEN P, 1983, ARCH MICROBIOL, V134, P238, DOI 10.1007/BF00407765; Vannelli T, 1999, P NATL ACAD SCI USA, V96, P4615, DOI 10.1073/pnas.96.8.4615; VISSCHER PT, 1994, FEMS MICROBIOL ECOL, V14, P179, DOI 10.1016/0168-6496(94)90095-7; WACKETT LP, 1987, BIOCHEMISTRY-US, V26, P6012, DOI 10.1021/bi00393a010; WEISS DS, 1994, EUR J BIOCHEM, V226, P799, DOI 10.1111/j.1432-1033.1994.00799.x; Zhou ZHS, 1999, BIOCHEMISTRY-US, V38, P15915, DOI 10.1021/bi992062b; ZINDER SH, 1978, J GEN MICROBIOL, V105, P335, DOI 10.1099/00221287-105-2-335	47	48	83	2	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4485	4493		10.1074/jbc.M007514200	http://dx.doi.org/10.1074/jbc.M007514200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11073950	hybrid			2022-12-25	WOS:000166921200100
J	Wynn, RM; Ho, R; Chuang, JL; Chuang, DT				Wynn, RM; Ho, R; Chuang, JL; Chuang, DT			Roles of active site and novel K+ ion-binding site residues in human mitochondrial branched-chain alpha-ketoacid decarboxylase/dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIPHOSPHATE-DEPENDENT ENZYME; SYRUP-URINE-DISEASE; PYRUVATE DECARBOXYLASE; THIAMIN DIPHOSPHATE; CRYSTAL-STRUCTURE; DEHYDROGENASE COMPLEX; ZYMOMONAS-MOBILIS; SACCHAROMYCES-CEREVISIAE; ALPHA-2-BETA-2; TRANSKETOLASE	The human mitochondrial branched-chain alpha -ketoacid decarboxylase/dehydrogenase (BCKD) is a heterotetrameric (alpha (2)beta (2)) thiamine diphosphate (TDP)-dependent enzyme. The recently solved human BCKD structure at 2.7 Angstrom showed that the two TDP-binding pockets are located at the interfaces between alpha and beta' subunits and between alpha' and beta subunits. In the present study, we show that the E76A-beta' mutation results in complete inactivation of BCKD. The result supports the catalytic role of the invariant Glu-76-beta' residue in increasing basicity of the N-4' amino group during the proton abstraction from the C-2 atom on the thiazolium ring. A substitution of His-146-beta' with Ala also renders the enzyme completely inactive. The data are consistent with binding of the alpha -ketoacid substrate by this residue based on the Pseudomonas BCKD structure. Alterations in Asn-222-alpha, Tyr-224-alpha; or Glu-193-alpha, which coordinates to the Mg2+ ion, result in an inactive enzyme (E193A-alpha) or a mutant BCKD with markedly higher K-m for TDP and a reduced level of the bound cofactor (Y224A-alpha and N222S-alpha). Arg-114-alpha Arg-220-alpha, and His-291-alpha interact with TDP by directly binding to phosphate oxygens of the cofactor. We show that natural mutations of these residues in maple syrup urine disease (MSUD) patients (R114W-alpha and R220W-alpha) or site-directed mutagenesis (H291A-alpha) also result in an inactive or partially active enzyme, respectively Another MSUD mutation (T166M-alpha), which affects one of the residues that coordinate to the K+ ion on the alpha subunit, also causes inactivation of the enzyme and an attenuated ability to bind TDP. In addition, fluorescence measurements establish that Trp-136-beta in human BCKD is the residue quenched by TDP binding. Thus, our results define the functional roles of key amino acid residues in human BCKD and provide a structural basis for MSUD.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chuang, DT (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5823 Harry Hines Blvd, Dallas, TX 75390 USA.	David.Chuang@UTSouthwestern.edu		Wynn, Richard/0000-0002-1879-2136	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026758] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-26758] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; ALI MS, 1995, J BIOL CHEM, V270, P4570, DOI 10.1074/jbc.270.9.4570; Arjunan P, 1996, J MOL BIOL, V256, P590, DOI 10.1006/jmbi.1996.0111; CANDY JM, 1994, BIOCHEM J, V300, P7, DOI 10.1042/bj3000007; Chabriere E, 1999, NAT STRUCT BIOL, V6, P182; CHUANG DT, 2000, METABOLIC MOL BASES, P1971; CHUANG JL, 1995, J CLIN INVEST, V95, P954, DOI 10.1172/JCI117804; Chuang JL, 2000, METHOD ENZYMOL, V324, P413; Chuang JL, 1999, J BIOL CHEM, V274, P10395, DOI 10.1074/jbc.274.15.10395; DAVIE JR, 1995, J BIOL CHEM, V270, P19861, DOI 10.1074/jbc.270.34.19861; DAVIE JR, 1992, J BIOL CHEM, V267, P16601; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; DIEFENBACH RJ, 1992, FEBS LETT, V296, P95, DOI 10.1016/0014-5793(92)80411-9; DIEFENBACH RJ, 1991, BIOCHEM J, V276, P439, DOI 10.1042/bj2760439; Dobritzsch D, 1998, J BIOL CHEM, V273, P20196, DOI 10.1074/jbc.273.32.20196; DYDA F, 1993, BIOCHEMISTRY-US, V32, P6165, DOI 10.1021/bi00075a008; HARRIS RA, 1995, ADV ENZYME REGUL, V35, P147, DOI 10.1016/0065-2571(94)00020-4; Hasson MS, 1998, BIOCHEMISTRY-US, V37, P9918, DOI 10.1021/bi973047e; Hawes JW, 1995, J BIOL CHEM, V270, P31071, DOI 10.1074/jbc.270.52.31071; HAWKINS CF, 1989, FEBS LETT, V255, P77, DOI 10.1016/0014-5793(89)81064-6; HENNIG J, 1966, BIOCH PHYSL THIAMIN, P243; Jordan F, 1998, BBA-PROTEIN STRUCT M, V1385, P287, DOI 10.1016/S0167-4838(98)00075-2; Kern D, 1997, SCIENCE, V275, P67, DOI 10.1126/science.275.5296.67; LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x; Malashkevich VN, 1999, J MOL BIOL, V294, P193, DOI 10.1006/jmbi.1999.3254; MULLER YA, 1993, SCIENCE, V259, P965, DOI 10.1126/science.8438155; NIKKOLA M, 1994, J MOL BIOL, V238, P387, DOI 10.1006/jmbi.1994.1299; PETTIT FH, 1978, P NATL ACAD SCI USA, V75, P4881, DOI 10.1073/pnas.75.10.4881; SHIMOMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P210, DOI 10.1016/0003-9861(88)90252-4; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; WYNN RM, 1992, J BIOL CHEM, V267, P12400; Wynn RM, 1998, J BIOL CHEM, V273, P13110, DOI 10.1074/jbc.273.21.13110; Wynn RM, 2000, J BIOL CHEM, V275, P30512, DOI 10.1074/jbc.M005075200; YEAMAN SJ, 1989, BIOCHEM J, V257, P625, DOI 10.1042/bj2570625; ZHAO Y, 1994, J BIOL CHEM, V269, P18583	36	16	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4168	4174		10.1074/jbc.M008038200	http://dx.doi.org/10.1074/jbc.M008038200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11069910	hybrid			2022-12-25	WOS:000166921200059
J	Li, JF; Huang, FL; Huang, KP				Li, JF; Huang, FL; Huang, KP			Glutathiolation of proteins by glutathione disulfide S-oxide derived from S-nitrosoglutathione - Modifications of rat brain neurogranin/RC3 and neuromodulin/GAP-43	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING-PROTEIN; CARBONIC-ANHYDRASE-III; KINASE-C SUBSTRATE; NITRIC-OXIDE; IN-VIVO; PHOSPHATASE-ACTIVITY; NITROSO-GLUTATHIONE; FATTY ACYLATION; CYSTEINE; THIOLS	S-Nitrosoglutathione (GSNO) undergoes spontaneous degradation that generates several nitrogen-containing compounds and oxidized glutathione derivatives. We identified glutathione sulfonic acid, glutathione disulfide S-oxide (GS(O)SG), glutathione disulfide S-dioxide, and GSSG as the major decomposition products of GSNO. Each of these compounds and GSNO were tested for their efficacies to modify rat brain neurogranin/RC3 (Ng) and neuromodulin/GAP-43 (Nm), Among them, GS(O)SG was found to be the most potent in causing glutathiolation of both proteins; four glutathiones were incorporated into the four Cys residues of Ng, and two were incorporated into the two Cys residues of Nm. Ng and Nm are two in vivo substrates of protein kinase C; their phosphorylations by protein kinase C attenuate the binding affinities of both proteins for calmodulin. When compared with their respective unmodified forms, the glutathiolated Ng was a poorer substrate and glutathiolated Nm a better substrate for protein kinase C. Glutathiolation of these two proteins caused no change in their binding affinities for calmodulin. Treatment of [S-35]cysteine-labeled rat brain slices with xanthine/xanthine oxidase or a combination of xanthine/xanthine oxidase with sodium nitroprusside resulted in an increase in cellular level of GS(O)SG. These treatments, as well as those by other oxidants, all resulted in an increase in thiolation of proteins; among them, thiolation of Ng was positively identified by immunoprecipitation. These results show that GS(O)SG is one of the most potent glutathiolating agents generated upon oxidative stress.	NICHD, Metab Regulat Sect, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Huang, KP (corresponding author), NICHD, Metab Regulat Sect, Endocrinol & Reprod Res Branch, NIH, Bldg 49,Rm 6A36,49 Convent Dr,MSC 4510, Bethesda, MD 20892 USA.	kphuang@helix.nih.gov	Li, Junfa/H-8707-2013	Li, Junfa/0000-0002-1930-9724	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000187] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000187] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALEXANDER KA, 1987, J BIOL CHEM, V262, P6108; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Cabiscol E, 1996, P NATL ACAD SCI USA, V93, P4170, DOI 10.1073/pnas.93.9.4170; CABISCOL E, 1995, J BIOL CHEM, V270, P14742, DOI 10.1074/jbc.270.24.14742; Cappiello M, 1996, J BIOL CHEM, V271, P33539, DOI 10.1074/jbc.271.52.33539; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; Davis DA, 1996, BIOCHEMISTRY-US, V35, P2482, DOI 10.1021/bi951525k; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; FINLEY JW, 1981, J AGR FOOD CHEM, V29, P404, DOI 10.1021/jf00104a045; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; HESS DT, 1993, NATURE, V366, P562, DOI 10.1038/366562a0; HOUBRE D, 1991, J BIOL CHEM, V266, P7121; HUANG KP, 1993, ARCH BIOCHEM BIOPHYS, V305, P570, DOI 10.1006/abbi.1993.1463; Huang KP, 1999, J NEUROCHEM, V72, P1294, DOI 10.1046/j.1471-4159.1999.0721294.x; Huang KP, 2000, BIOCHEMISTRY-US, V39, P7291, DOI 10.1021/bi000336l; Ji YB, 1999, ARCH BIOCHEM BIOPHYS, V362, P67, DOI 10.1006/abbi.1998.1013; JOSEPHY PD, 1984, TETRAHEDRON LETT, V25, P1685, DOI 10.1016/S0040-4039(01)81144-8; KashibaIwatsuki M, 1996, FEBS LETT, V389, P149, DOI 10.1016/0014-5793(96)00560-1; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; Li JF, 1999, J BIOL CHEM, V274, P1294, DOI 10.1074/jbc.274.3.1294; Mahoney CW, 1996, J BIOL CHEM, V271, P28798, DOI 10.1074/jbc.271.46.28798; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; MEYER DJ, 1994, FEBS LETT, V345, P177, DOI 10.1016/0014-5793(94)00429-3; Mohr S, 1999, J BIOL CHEM, V274, P9427, DOI 10.1074/jbc.274.14.9427; Padgett CM, 1998, ARCH BIOCHEM BIOPHYS, V358, P232, DOI 10.1006/abbi.1998.0859; PARK EM, 1988, BIOCHIM BIOPHYS ACTA, V964, P151, DOI 10.1016/0304-4165(88)90161-4; PARK JW, 1988, BIOCHEM BIOPH RES CO, V152, P916, DOI 10.1016/S0006-291X(88)80127-X; Percival MD, 1999, BIOCHEMISTRY-US, V38, P13574, DOI 10.1021/bi991028u; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; Sheu FS, 2000, BIOPHYS J, V78, P1216, DOI 10.1016/S0006-3495(00)76679-3; Sheu FS, 1996, J BIOL CHEM, V271, P22407, DOI 10.1074/jbc.271.37.22407; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; Singh SP, 1996, P NATL ACAD SCI USA, V93, P14428, DOI 10.1073/pnas.93.25.14428; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Ward NE, 1998, J BIOL CHEM, V273, P12558, DOI 10.1074/jbc.273.20.12558; Wong PSY, 1998, BIOCHEMISTRY-US, V37, P5362, DOI 10.1021/bi973153g	40	77	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3098	3105		10.1074/jbc.M008260200	http://dx.doi.org/10.1074/jbc.M008260200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11060308	hybrid			2022-12-25	WOS:000166784900018
J	Ramesh, V; RajBhandary, UL				Ramesh, V; RajBhandary, UL			Importance of the anticodon sequence in the aminoacylation of tRNAs by methionyl-tRNA synthetase and by Valyl-tRNA synthetase in an archaebacterium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATOR TRANSFER-RNAS; PROTEIN-SYNTHESIS; HALOBACTERIUM-VOLCANII; CRYSTAL-STRUCTURE; SHUTTLE VECTORS; AMINO-ACIDS; RECOGNITION; CODONS; STEM	The mode of recognition of tRNAs by aminoacyl-tRNA synthetases and translation factors is largely unknown in archaebacteria. To study this process, we have cloned the wild type initiator tRNA gene from the moderate halophilic archaebacterium Haloferax volcanii and mutants derived from it into a plasmid capable of expressing the tRNA in these cells. Analysis of tRNAs in vivo show that the initiator tRNA is aminoacylated but is not formylated in H. volcanii, This result provides direct support for the notion that protein synthesis in archaebacteria is initiated with methionine and not with formylmethionine. We have analyzed the effect of two different mutations (CAU-->CUA and CAU-->GAC) in the anticodon sequence of the initiator tRNA on its recognition by the aminoacyl-tRNA synthetases in vivo. The CAU-->CUA mutant was not aminoacylated to any significant extent in vivo, suggesting the importance of the anticodon in aminoacylation of tRNA by methionyl-tRNA synthetase. This mutant initiator tRNA can, however, be aminoacylated in vitro by the Escherichia coli glutaminyl-tRNA synthetase, suggesting that the lack of aminoacylation is due to the absence in H. volcanii of a synthetase, which recognizes the mutant tRNA Archaebacteria lack glutaminyl-tRNA synthetase and utilize a two-step pathway involving glutamyl-tRNA synthetase and glutamine amidotransferase to generate glutaminyl-tRNA The lack of aminoacylation of the mutant tRNA indicates that this mutant tRNA is not a substrate for the H, volcanii glutamyl-tRNA synthetase. The CAU-->GAC anticodon mutant is most likely aminoacylated with valine in vivo. Thus, the anticodon plays an important role in the recognition of tRNA by at least two of the halobacterial aminoacyl-tRNA synthetases.	MIT, Dept Biol, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	RajBhandary, UL (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	bhandary@mit.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM017151] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37GM17151] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnez JG, 1997, TRENDS BIOCHEM SCI, V22, P211, DOI 10.1016/S0968-0004(97)01052-9; BAYLEY ST, 1978, CRC CR REV MICROBIOL, V6, P151, DOI 10.3109/10408417809090622; BIOU V, 1994, SCIENCE, V263, P1404, DOI 10.1126/science.8128220; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; Cusack S, 1998, STRUCTURE, V6, P101, DOI 10.1016/S0969-2126(98)00011-2; DANIELS CJ, 1984, EMBO J, V3, P745, DOI 10.1002/j.1460-2075.1984.tb01878.x; Drabkin HJ, 1998, MOL CELL BIOL, V18, P5140, DOI 10.1128/MCB.18.9.5140; GUILLON JM, 1992, J MOL BIOL, V224, P359, DOI 10.1016/0022-2836(92)91000-F; GUPTA R, 1984, J BIOL CHEM, V259, P9461; HECKMAN JE, 1978, CELL, V1, P183; HOLMES ML, 1991, J BACTERIOL, V173, P3807, DOI 10.1128/JB.173.12.3807-3813.1991; HOUSMAN D, 1970, NATURE, V227, P913, DOI 10.1038/227913a0; Ibba M, 1999, P NATL ACAD SCI USA, V96, P418, DOI 10.1073/pnas.96.2.418; Ibba M, 1997, SCIENCE, V278, P1119, DOI 10.1126/science.278.5340.1119; KITA T, 1980, J CLIN INVEST, V66, P1094, DOI 10.1172/JCI109938; KUCHINO Y, 1982, NATURE, V298, P684, DOI 10.1038/298684a0; LAM WL, 1989, P NATL ACAD SCI USA, V86, P5478, DOI 10.1073/pnas.86.14.5478; LEE CP, 1991, J BIOL CHEM, V266, P18012; Li Y, 2000, J BACTERIOL, V182, P2886, DOI 10.1128/JB.182.10.2886-2892.2000; Lipman RSA, 2000, BIOCHEMISTRY-US, V39, P7792, DOI 10.1021/bi0004955; MATTHAEI JH, 1966, COLD SPRING HARB SYM, V31, P25, DOI 10.1101/SQB.1966.031.01.009; NIEUWLANDT DT, 1990, J BACTERIOL, V172, P7104, DOI 10.1128/jb.172.12.7104-7110.1990; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; RAJBHANDARY UL, 1969, J BIOL CHEM, V244, P1104; Rajbhandary Uttam L., 1995, P511; Ramesh V, 1997, RNA, V3, P1220; ROULD MA, 1989, SCIENCE, V246, P1089; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHULMAN LH, 1985, BIOCHEMISTRY-US, V24, P7309, DOI 10.1021/bi00346a043; SCHULMAN LH, 1988, SCIENCE, V242, P765, DOI 10.1126/science.3055296; SMITH AE, 1970, NATURE, V226, P607, DOI 10.1038/226607a0; Stathopoulos C, 2000, SCIENCE, V287, P479, DOI 10.1126/science.287.5452.479; Steer BA, 1999, J BIOL CHEM, V274, P35601, DOI 10.1074/jbc.274.50.35601; Steer BA, 1999, P NATL ACAD SCI USA, V96, P13644, DOI 10.1073/pnas.96.24.13644; STEINBERG S, 1993, NUCLEIC ACIDS RES, V21, P3011, DOI 10.1093/nar/21.13.3011; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; VARSHNEY U, 1990, P NATL ACAD SCI USA, V87, P1586, DOI 10.1073/pnas.87.4.1586; WHITE BN, 1972, BIOCHIM BIOPHYS ACTA, V272, P583, DOI 10.1016/0005-2787(72)90513-8; WHITE BN, 1972, CAN J BIOCHEM CELL B, V50, P600, DOI 10.1139/o72-082; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229	40	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3660	3665		10.1074/jbc.M008206200	http://dx.doi.org/10.1074/jbc.M008206200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11058596	hybrid			2022-12-25	WOS:000166784900088
J	Burczynski, ME; Sridhar, GR; Palackal, NT; Penning, TM				Burczynski, ME; Sridhar, GR; Palackal, NT; Penning, TM			The reactive oxygen species- and Michael acceptor-inducible human aldo-keto reductase AKR1C1 reduces the alpha,beta-unsaturated aldehyde 4-hydroacy-2-nonenal to 1,4-dihydroxy-2-nonene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION PRODUCT; GLUTATHIONE-S-TRANSFERASE; HUMAN DIHYDRODIOL DEHYDROGENASE; POLYCYCLIC AROMATIC-HYDROCARBONS; OXIDATIVE STRESS; ALCOHOL-DEHYDROGENASE; GENE-EXPRESSION; RAT-LIVER; 3-ALPHA-HYDROXYSTEROID DEHYDROGENASE; HEPATOCELLULAR METABOLISM	The human aldo-keto reductase AKR1C1 (20 alpha (3 alpha)-hydroxysteroid dehydrogenase) is induced by electrophilic Michael accepters and reactive oxygen species (ROS) via a presumptive antioxidant response element (Burczynski, M. E., Lin, H. K., and Penning, T. M. (1999) Cancer Res. 59, 607-614). Physiologically, AKR1C1 regulates progesterone action by converting the hormone into its inactive metabolite 20 alpha -hydroxyprogesterone, and toxicologically this enzyme activates polycyclic aromatic hydrocarbon trans-dihydrodiols to redox-cycling o-quinones, However, the significance of its potent induction by Michael accepters and oxidative stress is unknown. 4-Hydroxy-8-nonenal (HNE) and other alpha,beta -unsaturated aldehydes produced during lipid peroxidation were reduced by AKR1C1 with high catalytic efficiency. Kinetic studies revealed that AKR1C1 reduced HNE (K-m = 34 muM, k(cat) = 8.8 min(-1)) with a k(cat)/K-m similar to that for 20 alpha -hydroxysteroids. Six other homogeneous recombinant AKRs were examined for their ability to reduce HNE. Of these, AKR1C1 possessed one of the highest specific activities and was the only isoform induced by oxidative stress and by agents that deplete glutathione (ethacrynic acid). Several hydroxysteroid dehydrogenases of the AKR1C subfamily catalyzed the reduction of HNE with higher activity than aldehyde reductase (AKR1A1). NMR spectroscopy identified the product of the NADPH-dependent reduction of HNE as 1,4-dihydroxy-2-nonene. The K-m of recombinant AKR1C1 for nicotinamide cofactors (K-m NADPH similar to6 muM, K-m(app) NADH >6 mM) suggested that it is primed for reductive metabolism of HNE. Isoformspecific reverse transcription-polymerase chain reaction showed that exposure of HeppG2 cells to HNE resulted in elevated levels of AKR1C1 mRNA. Thus, HNE induces its own metabolism via AKR1C1, and this enzyme may play a hitherto unrecognized role in a response mounted to counter oxidative stress. AKRs represent alternative GSH-independent/NADPH-dependent routes for the reductive elimination of HNE. Of these, AKR1C1 provides an inducible cytosolic barrier to HNE following ROS exposure.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Penning, TM (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 3620 Hamilton Walk, Philadelphia, PA 19104 USA.	penning@pharm.med.upenn.edu		Penning, Trevor/0000-0002-3937-1066	NATIONAL CANCER INSTITUTE [R01CA039504, R01CA055711] Funding Source: NIH RePORTER; NCI NIH HHS [CA39504, CA55711] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; AWASTHI YC, 1995, BIOCHEM ARCH, V11, P47; BATES RW, 1990, TETRAHEDRON, V46, P4063, DOI 10.1016/S0040-4020(01)90541-1; Burczynski JM, 1999, FREE RADICAL BIO MED, V26, P987, DOI 10.1016/S0891-5849(98)00289-5; Burczynski ME, 1999, POLYCYCL AROMAT COMP, V16, P205, DOI 10.1080/10406639908020587; Burczynski ME, 1998, BIOCHEMISTRY-US, V37, P6781, DOI 10.1021/bi972725u; Burczynski ME, 1999, CANCER RES, V59, P607; CIACCIO PJ, 1994, J BIOL CHEM, V269, P15558; CIACCIO PJ, 1995, MOL PHARMACOL, V48, P639; DALTON T, 1994, NUCLEIC ACIDS RES, V22, P5016, DOI 10.1093/nar/22.23.5016; DELBELLO B, 1994, BIOCHEM J, V304, P385, DOI 10.1042/bj3040385; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; ESTERBAUER H, 1985, BIOCHEM J, V228, P363, DOI 10.1042/bj2280363; Facchinetti F, 1998, CELL MOL NEUROBIOL, V18, P667, DOI 10.1023/A:1020221919154; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; Fukuda A, 1997, BIOCHEM BIOPH RES CO, V236, P505, DOI 10.1006/bbrc.1997.6585; Grune T, 1997, J LIPID RES, V38, P1660; GRUNE T, 1991, BIOCHEM INT, V25, P963; HARTLEY DP, 1995, ARCH BIOCHEM BIOPHYS, V316, P197, DOI 10.1006/abbi.1995.1028; Hubatsch I, 1998, BIOCHEM J, V330, P175, DOI 10.1042/bj3300175; JAGT DLV, 1995, BBA-PROTEIN STRUCT M, V1249, P117; Jez JM, 1998, BIOCHEMISTRY-US, V37, P9695, DOI 10.1021/bi980294p; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; Jez JM, 1997, BIOCHEM PHARMACOL, V54, P639, DOI 10.1016/S0006-2952(97)84253-0; Klaassen CD, 1998, ENVIRON HEALTH PERSP, V106, P297, DOI 10.2307/3433930; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; Lee SH, 2000, CHEM RES TOXICOL, V13, P565, DOI 10.1021/tx000057z; LEONARDUZZI G, 1995, BIOCHEM BIOPH RES CO, V214, P669, DOI 10.1006/bbrc.1995.2338; LI Y, 1993, J BIOL CHEM, V268, P21454; Lin HK, 1997, MOL ENDOCRINOL, V11, P1971, DOI 10.1210/me.11.13.1971; Markesbery WR, 1999, BRAIN PATHOL, V9, P133; Matsuura K, 1997, BIOCHEM J, V323, P61, DOI 10.1042/bj3230061; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nair J, 1999, MUTAT RES-FUND MOL M, V424, P59, DOI 10.1016/S0027-5107(99)00008-1; NGUYEN T, 1992, J BIOL CHEM, V267, P13535; O'Connor T, 1999, BIOCHEM J, V343, P487, DOI 10.1042/0264-6021:3430487; PALACKAL NT, 1999, P AM ASSOC CANC RES, V40, P4883; Parola M, 1996, FREE RADICAL BIO MED, V20, P351, DOI 10.1016/0891-5849(96)02055-2; PAWLOWSKI JE, 1994, J BIOL CHEM, V269, P13502; Penning TM, 1997, ENDOCR REV, V18, P281, DOI 10.1210/er.18.3.281; Penning TM, 2000, BIOCHEM J, V351, P67, DOI 10.1042/0264-6021:3510067; PETERSON G, 1995, J NUTR, V125, pS784, DOI 10.1093/jn/125.suppl_3.784S; PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010; Poulsen HE, 1998, EUR J CANCER PREV, V7, P9; Rindgen D, 1999, CHEM RES TOXICOL, V12, P1195, DOI 10.1021/tx990034o; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SELLIN S, 1991, BIOCHEMISTRY-US, V30, P2514, DOI 10.1021/bi00223a031; SHI MM, 1994, J BIOL CHEM, V269, P26512; Siems WG, 1997, J LIPID RES, V38, P612; SMITHGALL TE, 1986, J BIOL CHEM, V261, P6184; SMITHGALL TE, 1988, J BIOL CHEM, V263, P1814; SPITZ DR, 1995, J CELL PHYSIOL, V165, P600, DOI 10.1002/jcp.1041650318; Spycher SE, 1997, FASEB J, V11, P181, DOI 10.1096/fasebj.11.2.9039961; Srivastava S, 1998, BIOCHEMISTRY-US, V37, P12909, DOI 10.1021/bi9804333; Srivastava S, 1995, BIOCHEM BIOPH RES CO, V217, P741, DOI 10.1006/bbrc.1995.2835; Srivastava S, 1998, J BIOL CHEM, V273, P10893, DOI 10.1074/jbc.273.18.10893; STOLZ A, 1993, J BIOL CHEM, V268, P10448; Suc I, 1998, FASEB J, V12, P665, DOI 10.1096/fasebj.12.9.665; Sun AY, 1998, J BIOMED SCI, V5, P401; Suzuki-Yamamoto T, 1999, FEBS LETT, V462, P335, DOI 10.1016/S0014-5793(99)01551-3; TRUSH MA, 1991, FREE RADICAL BIO MED, V10, P201, DOI 10.1016/0891-5849(91)90077-G; UCHIDA K, 1994, BIOCHEMISTRY-US, V33, P12487, DOI 10.1021/bi00207a016; WELLS WW, 1994, J BIOENERG BIOMEMBR, V26, P369, DOI 10.1007/BF00762777; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1; Yi P, 1997, CHEM RES TOXICOL, V10, P1259, DOI 10.1021/tx970100r; Yoritaka A, 1996, P NATL ACAD SCI USA, V93, P2696, DOI 10.1073/pnas.93.7.2696	66	142	146	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2890	2897		10.1074/jbc.M006655200	http://dx.doi.org/10.1074/jbc.M006655200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11060293	hybrid			2022-12-25	WOS:000166784800081
J	Giasson, BI; Murray, IVJ; Trojanowski, JQ; Lee, VMY				Giasson, BI; Murray, IVJ; Trojanowski, JQ; Lee, VMY			A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; LEWY BODY DISEASE; A-BETA COMPONENT; PARKINSONS-DISEASE; ALZHEIMERS-DISEASE; NACP/ALPHA-SYNUCLEIN; PRESYNAPTIC PROTEIN; CYTOPLASMIC INCLUSIONS; NERVOUS-SYSTEM; IN-VITRO	Neuronal and oligodendrocytic aggregates of fibrillar alpha -synuclein define several diseases of the nervous system. It is likely that these inclusions impair vital metabolic processes and compromise vialibity of affected cells. Here, we report that a 12-amino acid stretch ((71)VTGVTAVAQKTV(82)) in the middle of the hydrophobic domain of human alpha -synuclein is necessary and sufficient for its fibrillization based on the following observations: 1) human beta -synuclein is highly homologous to alpha -synuclein but lacks these 12 residues, and it does not assemble into filaments in vitro; 2) the rate of alpha -synuclein polymerization in vitro decreases after the introduction of a single charged amino acid within these 12 residues, and a deletion within this region abrogates assembly; 3) this stretch of 12 amino acids appears to form the core of alpha -synuclein filaments, because it is resistant to proteolytic digestion in alpha -synuclein filaments; and 4) synthetic peptides corresponding to this 12-amino acid stretch self-polymerize to form filaments, and these peptides promote fibrillization of full-length human alpha -synuclein in vitro. Thus, we have identified key sequence elements necessary for the assembly of human alpha -synuclein into filaments, and these elements may be exploited as targets for the design of drugs that inhibit alpha -synuclein fibrillization and might arrest disease progression.	Univ Penn, Sch Med, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Lee, VMY (corresponding author), Hosp Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, Maloney 3, Philadelphia, PA 19104 USA.		Murray, Ian/O-5983-2015	Murray, Ian/0000-0003-1196-1360				Arima K, 1998, ACTA NEUROPATHOL, V96, P439, DOI 10.1007/s004010050917; Arima K, 1998, BRAIN RES, V808, P93, DOI 10.1016/S0006-8993(98)00734-3; Baba M, 1998, AM J PATHOL, V152, P879; Bayer TA, 1999, NEUROSCI LETT, V266, P213, DOI 10.1016/S0304-3940(99)00311-0; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; Buchman VL, 1998, J NEUROSCI, V18, P9335; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Culvenor JG, 1999, AM J PATHOL, V155, P1173, DOI 10.1016/S0002-9440(10)65220-0; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jakes R, 1999, NEUROSCI LETT, V269, P13, DOI 10.1016/S0304-3940(99)00411-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; Masliah E, 1996, AM J PATHOL, V148, P201; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; SHIBAYAMAIMAZU T, 1993, BRAIN RES, V622, P17, DOI 10.1016/0006-8993(93)90796-P; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Surguchov A, 1999, MOL CELL NEUROSCI, V13, P95, DOI 10.1006/mcne.1999.0735; Takeda A, 1998, AM J PATHOL, V152, P367; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Wakabayashi K, 1999, NEUROPATH APPL NEURO, V25, P363	36	721	734	1	64	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2380	2386		10.1074/jbc.M008919200	http://dx.doi.org/10.1074/jbc.M008919200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11060312	hybrid			2022-12-25	WOS:000166784800013
J	Minko, IG; Washington, MT; Prakash, L; Prakash, S; Lloyd, RS				Minko, IG; Washington, MT; Prakash, L; Prakash, S; Lloyd, RS			Translesion DNA synthesis by yeast DNA polymerase eta on templates containing N-2-guanine adducts of 1,3-butadiene metabolites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XERODERMA-PIGMENTOSUM; SACCHAROMYCES-CEREVISIAE; BUTADIENE MONOXIDE; THYMINE DIMER; BYPASS; PURINE; DAMAGE; CELLS; GENE	Yeast DNA polymerase eta can replicate through cis-syn cyclobutane pyrimidine dimers and 8-oxoguanine lesions with the same efficiency and accuracy as replication of an undamaged template. Previously, it has been shown that Escherichia coli DNA polymerases I, II, and III are incapable of bypassing DNA substrates containing N-2-guanine adducts of stereoisomeric 1,3-butadiene metabolites. Here we showed that yeast polymerase eta replicates DNA containing the monoadducts (S)-butadiene monoepoxide and (S,S)-butadiene diolepoxide N-2-guanines albeit at an similar to 200-300-fold lower efficiency relative to the control guanine, Interestingly, nucleotide incorporation opposite the (R)-butadiene monoepoxide and the (R,R)-butadiene diolepoxide N-2-guanines was similar to 10-fold less efficient than incorporation opposite their S stereoisomers, Polymerase eta preferentially incorporates the correct nucleotide opposite and downstream of all four adducts, except that it shows high misincorporation frequencies for elongation of C paired with (R)butadiene monoepoxide N-2-guanine. Additionally, polymerase eta does not bypass the (R,R)- and (S,S)butadiene diolepoxide N-2-guanine-N-2-guanine intrastrand cross-links, and replication is completely blocked just prior to the lesion. Collectively, these data suggest that polymerase eta can tolerate the geometric distortions in DNA conferred by the N-2-guanine butadiene monoadducts but not the intrastrand cross-links.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Lloyd, RS (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, 5-144 MRB,301 Univ Blvd, Galveston, TX 77555 USA.		Prakash, Satya/C-6420-2013	Washington, Todd/0000-0001-8680-2992; Prakash, Louise/0000-0001-9143-6261; Prakash, Satya/0000-0001-7228-1444; Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [ES06676, S11-ES10018, ES05355] Funding Source: Medline; NIGMS NIH HHS [GM19261] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, S11ES010018] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Carmical JR, 2000, J BIOL CHEM, V275, P19482, DOI 10.1074/jbc.M002037200; Carmical JR, 2000, CHEM RES TOXICOL, V13, P18, DOI 10.1021/tx9901332; COCHRANE JE, 1994, CARCINOGENESIS, V15, P713, DOI 10.1093/carcin/15.4.713; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; Creighton S, 1995, METHOD ENZYMOL, V262, P232; Haracska L, 2000, NAT GENET, V25, P458, DOI 10.1038/78169; HARRIS CM, 1991, J AM CHEM SOC, V113, P4328, DOI 10.1021/ja00011a044; Himmelstein MW, 1997, CRIT REV TOXICOL, V27, P1, DOI 10.3109/10408449709037482; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; LUKER MA, 1982, MUTAT RES, V92, P63, DOI 10.1016/0027-5107(82)90210-X; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McDonald JP, 1997, GENETICS, V147, P1557; Meng QX, 2000, MUTAT RES-GEN TOX EN, V464, P169, DOI 10.1016/S1383-5718(99)00157-6; Selzer RR, 1996, CHEM RES TOXICOL, V9, P126, DOI 10.1021/tx950101o; Selzer RR, 1999, CARCINOGENESIS, V20, P285, DOI 10.1093/carcin/20.2.285; VANGALA RR, 1993, ARCH TOXICOL, V67, P34, DOI 10.1007/BF02072032; Washington MT, 2000, P NATL ACAD SCI USA, V97, P3094, DOI 10.1073/pnas.050491997; Washington MT, 1999, J BIOL CHEM, V274, P36835, DOI 10.1074/jbc.274.52.36835; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Yuan FH, 2000, J BIOL CHEM, V275, P8233, DOI 10.1074/jbc.275.11.8233; ZABOROWSKA D, 1983, MUTAT RES, V120, P21, DOI 10.1016/0165-7992(83)90069-6	27	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2517	2522		10.1074/jbc.M007867200	http://dx.doi.org/10.1074/jbc.M007867200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11062246	hybrid			2022-12-25	WOS:000166784800031
J	Jishage, K; Arita, M; Igarashi, K; Iwata, T; Watanabe, M; Ogawa, M; Ueda, O; Kamada, N; Inoue, K; Arai, H; Suzuki, H				Jishage, K; Arita, M; Igarashi, K; Iwata, T; Watanabe, M; Ogawa, M; Ueda, O; Kamada, N; Inoue, K; Arai, H; Suzuki, H			alpha-tocopherol transfer protein is important for the normal development of placental labyrinthine trophoblasts in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; RAT-LIVER; EMBRYOPATHY; MEMBRANES	alpha -Tocopherol transfer protein (alpha -TTP), a cytosolic protein that specifically binds alpha -tocopherol, is known as a product of the causative gene in patients with ataxia that is associated with vitamin E deficiency. Targeted disruption of the alpha -TTP gene revealed that alpha -tocopherol concentration in the circulation was regulated by alpha -TTP expression levels. Male alpha -TTP-/- mice were fertile; however, placentas of pregnant alpha -TTP-/- females were severely impaired with marked reduction of labyrinthine trophoblasts, and the embryos died at mid-gestation even when fertilized eggs of alpha -TTP+/+ mice were transferred into alpha -TTP-/- recipients. The use of excess alpha -tocopherol or a synthetic antioxidant (BO-653) dietary supplement by alpha -TTP-/- females prevented placental failure and allowed full-term pregnancies. In alpha -TTP+/+ animals, alpha -TTP gene expression was observed in the uterus, and its level transiently increased after implantation (4.5 days postcoitum). Our results suggest that oxidative stress in the labyrinth region of the placenta is protected by vitamin E during development and that in addition to the hepatic alpha -TTP, which governs plasma alpha -tocopherol level, the uterine alpha -TTP may also play an important role in supplying this vitamin.	Chugai Pharmaceut Co Ltd, Pharmaceut Technol Lab, Shizuoka 4128513, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Bunkyo Ku, Tokyo 1130033, Japan	Chugai Pharmaceutical Co., Ltd.; Roche Holding; University of Tokyo	Suzuki, H (corresponding author), Chugai Pharmaceut Co Ltd, Pharmaceut Technol Lab, 1-135 Komakado, Shizuoka 4128513, Japan.			Arita, Makoto/0000-0001-9902-0463				Acuff RV, 1998, AM J CLIN NUTR, V67, P459, DOI 10.1093/ajcn/67.3.459; AZUMA S, 1991, Japanese Journal of Animal Reproduction, V37, P37; Cross JC, 1998, ANN NY ACAD SCI, V857, P23, DOI 10.1111/j.1749-6632.1998.tb10104.x; Evans HM, 1922, SCIENCE, V56, P650, DOI 10.1126/science.56.1458.650; HAGAY ZJ, 1995, AM J OBSTET GYNECOL, V173, P1036, DOI 10.1016/0002-9378(95)91323-8; KAUFMAN MH, 1922, ATLAS MOUSE DEV, P476; Kim HS, 1998, FREE RADICAL RES, V28, P87, DOI 10.3109/10715769809097879; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; OUAHCHI K, 1995, NAT GENET, V9, P141, DOI 10.1038/ng0295-141; Poranen AK, 1996, PLACENTA, V17, P401, DOI 10.1016/S0143-4004(96)90021-1; Qanungo S, 1999, CLIN CHIM ACTA, V285, P1, DOI 10.1016/S0009-8981(99)00051-0; SATO Y, 1991, FEBS LETT, V288, P41, DOI 10.1016/0014-5793(91)80999-J; Sen A, 1998, INDIAN J BIOCHEM BIO, V35, P216; Siman CM, 1997, DIABETES, V46, P1054, DOI 10.2337/diabetes.46.6.1054; Sivan E, 1996, AM J OBSTET GYNECOL, V175, P793, DOI 10.1016/S0002-9378(96)80001-9; SUZUKI H, 1994, J MAMM OVA RES, V11, P49; WILLIAMS FM, 1989, AGE AGEING, V18, P39, DOI 10.1093/ageing/18.1.39; Znamenskaya T. K., 1994, Ukrainskii Biokhimicheskii Zhurnal, V66, P93	18	148	155	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1669	1672		10.1074/jbc.C000676200	http://dx.doi.org/10.1074/jbc.C000676200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11076932	hybrid			2022-12-25	WOS:000166528000002
J	Lagarkova, MA; Boitchenko, VE; Mescheryakov, AA; Kashkarova, UA; Nedospasov, SA				Lagarkova, MA; Boitchenko, VE; Mescheryakov, AA; Kashkarova, UA; Nedospasov, SA			Human cortactin as putative cancer antigen	ONCOGENE			English	Article						breast cancer; cortactin; cancer antigen; tumor marker	CHROMOSOME 11Q13 AMPLIFICATION; CYCLIN D1; EMS1 GENE; TUMOR-ANTIGENS; POOR-PROGNOSIS; BREAST-CANCER; CONTACT SITES; PHOSPHORYLATION; EMS1/CORTACTIN; OVEREXPRESSION	Humoral immune response against overexpressed oncogenic or tumor supressor proteins has been demonstrated for many types of cancer, In this study we report on the detection of the autologous antibody response to putative oncogene, human cortactin using serological analysis of breast carcinoma expression library. Cortactin maps to chromosome 11q13, the region amplified in about 15% of primary breast carcinomas and 30% of head and neck squamous cell carcinomas, Cortactin overexpression due to such amplification might affect adhesive properties of human cancer cells and is associated with poor disease prognosis, Accordingly, we detected overexpression of cortactin transcript in autologous tumor and amplification/overexpression of cortactin in tumors of breast cancer patients serologically positive for this marker, We demonstrate that 15% of breast cancer patients elicit humoral immune response against human cortactin.	Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Ctr Mol Med, Lab Mol Immunol, Moscow 119899, Russia; Russian Acad Med Sci, Oncol Sci Ctr, Moscow, Russia; Russian Acad Sci, VA Engelhardt Mol Biol Inst, Lab Mol Immunol, Moscow 117984, Russia	Lomonosov Moscow State University; Russian Academy of Medical Sciences; Russian Academy of Sciences; Engelhardt Institute of Molecular Biology, RAS	Lagarkova, MA (corresponding author), Moscow MV Lomonosov State Univ, Belozersky Inst Physicochem Biol, Ctr Mol Med, Lab Mol Immunol, Moscow 119899, Russia.		Nedospasov, Sergei/Q-7319-2016; Nedospasov, Sergei/J-5936-2013; Nedospasov, Sergei/L-1990-2015; Nedospasov, Sergei/C-3043-2018; Lagarkova, Maria/A-3296-2014	Meshcheryakov, Andrey/0000-0002-6009-653X; Lagarkova, Maria/0000-0001-9594-1134				BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Brass N, 1999, BLOOD, V93, P2158, DOI 10.1182/blood.V93.7.2158.407a34_2158_2166; Bringuier PP, 1996, ONCOGENE, V12, P1747; Campbell DH, 1999, CANCER RES, V59, P5376; DARPA P, 1988, P NATL ACAD SCI USA, V85, P2543, DOI 10.1073/pnas.85.8.2543; Disis ML, 1996, CURR OPIN IMMUNOL, V8, P637, DOI 10.1016/S0952-7915(96)80079-3; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Hui R, 1998, ONCOGENE, V17, P1053, DOI 10.1038/sj.onc.1202023; MEREDITH SD, 1995, ARCH OTOLARYNGOL, V121, P790; Old LJ, 1998, J EXP MED, V187, P1163, DOI 10.1084/jem.187.8.1163; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Schuuring E, 1998, CELL ADHES COMMUN, V6, P185, DOI 10.3109/15419069809004475; SCHUURING E, 1993, MOL CELL BIOL, V13, P2891, DOI 10.1128/MCB.13.5.2891; SCHUURING E, 1995, GENE, V159, P83, DOI 10.1016/0378-1119(94)00562-7; SCHUURING E, 1992, CANCER RES, V52, P5229; vanDamme H, 1997, J BIOL CHEM, V272, P7374, DOI 10.1074/jbc.272.11.7374; VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	22	9	9	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5204	5207		10.1038/sj.onc.1203826	http://dx.doi.org/10.1038/sj.onc.1203826			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064458				2022-12-25	WOS:000090124100010
J	Wellmann, H; Kaltschmidt, B; Kaltschmidt, C				Wellmann, H; Kaltschmidt, B; Kaltschmidt, C			Retrograde transport of transcription factor NF-kappa B in living neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOCAL PROTEIN-SYNTHESIS; NERVE GROWTH-FACTOR; GENE-EXPRESSION; HIPPOCAMPAL-NEURONS; AXONAL-TRANSPORT; OXIDATIVE STRESS; ACTIVATION; INDUCTION; SYNAPSES; LOCALIZATION	The mechanism by which signals such as those produced by glutamate are transferred to the nucleus may involve direct transport of an activated transcription factor to trigger long-term transcriptional changes. Ionotropic glutamate receptor activation or depolarization activates transcription factor NF-kappaB and leads to translocation of NF-kappaB from the cytoplasm to the nucleus. We investigated the dynamics of NF-kappaB translocation in living neurons by tracing the NF-kappaB subunit RelA (p65) with jellyfish green fluorescent protein. We found that green fluorescent protein-RelA was located in either the nucleus or cytoplasm and neurites, depending on the coexpression of the cognate inhibitor of NF-kappaB, I kappaB-alpha. Stimulation with glutamate, kainate, or potassium chloride resulted in a redistribution of NF-kappaB from neurites to the nucleus. This transport depended on an intact nuclear localization signal on RelA. Thus, in addition to its role as a transcription factor, NF-kappaB may be a signal transducer, transmitting transient glutamatergic signals from distant sites to the nucleus.	Univ Witten Herdecke, Inst Neurobiochem, D-58448 Witten, Germany	Witten Herdecke University	Kaltschmidt, C (corresponding author), Univ Witten Herdecke, Inst Neurobiochem, Stockumer Str 10, D-58448 Witten, Germany.	c.kaltschmidt@uni-wh.de						AMBRON RT, 1992, J NEUROSCI, V12, P2813; AMBRON RT, 1995, J NEUROSCI, V15, P3440; AMBRON RT, 1985, J NEUROSCI, V5, P2866; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; Bethea JR, 1998, J NEUROSCI, V18, P3251; Cantera R, 1999, MOL CELL NEUROSCI, V13, P131, DOI 10.1006/mcne.1999.0739; Carter BD, 1996, SCIENCE, V272, P542, DOI 10.1126/science.272.5261.542; Corriveau RA, 1998, NEURON, V21, P505, DOI 10.1016/S0896-6273(00)80562-0; Crino P, 1998, P NATL ACAD SCI USA, V95, P2313, DOI 10.1073/pnas.95.5.2313; de Hoop MJ, 1998, CELL BIOLOGY - A LABORATORY HANDBOOK, 2ND EDITION, VOL 1, P154; Delcroix JD, 1999, J NEUROSCI, V19, part. no.; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Kaltschmidt B, 2000, NEUROREPORT, V11, P839, DOI 10.1097/00001756-200003200-00036; Kaltschmidt B, 2000, EXP BRAIN RES, V130, P100, DOI 10.1007/s002210050011; Kaltschmidt B, 1997, P NATL ACAD SCI USA, V94, P2642, DOI 10.1073/pnas.94.6.2642; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129; Kaltschmidt C, 1998, TRENDS NEUROSCI, V21, P106, DOI 10.1016/S0166-2236(97)89560-4; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; KALTSCHMIDT C, 1995, BIOL CHEM H-S, V376, P9; Kang HJ, 1996, SCIENCE, V273, P1402, DOI 10.1126/science.273.5280.1402; Lezoualc'h F, 1998, J NEUROSCI, V18, P3224; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Meberg PJ, 1996, MOL BRAIN RES, V38, P179, DOI 10.1016/0169-328X(95)00229-L; Neumann H, 1997, J EXP MED, V185, P305, DOI 10.1084/jem.185.2.305; NEUMANN H, 1995, SCIENCE, V269, P549, DOI 10.1126/science.7624779; NGUYEN PV, 1994, SCIENCE, V265, P1104, DOI 10.1126/science.8066450; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Post A, 1998, J NEUROSCI, V18, P8236; Povelones M, 1997, J NEUROSCI, V17, P4915; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; SCHMIED R, 1993, J NEUROSCI, V13, P4064; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; Suzuki T, 1997, NEUROREPORT, V8, P2931, DOI 10.1097/00001756-199709080-00025; WELLMANN H, 1999, J NEUROSCI METH, P9255; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	54	97	100	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11821	11829		10.1074/jbc.M009253200	http://dx.doi.org/10.1074/jbc.M009253200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11096106	hybrid			2022-12-25	WOS:000168081800054
J	Ola, A; Waga, S; Ellison, V; Stillman, B; McGurk, M; Leigh, IM; Waseem, NH; Waseem, A				Ola, A; Waga, S; Ellison, V; Stillman, B; McGurk, M; Leigh, IM; Waseem, NH; Waseem, A			Human-Saccharomyces cerevisiae proliferating cell nuclear antigen hybrids - Oligomeric structure and functional characterization using in vitro DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; LAGGING STRAND SYNTHESIS; DELTA-AUXILIARY PROTEIN; C-TERMINAL REGION; POLYMERASE-DELTA; HUMAN PCNA; ACCESSORY PROTEINS; TRIMERIC STRUCTURE; MISMATCH REPAIR; MULTIPLE STAGES	The proliferating cell nuclear antigen (PCNA) is a highly conserved protein required for the assembly of the DNA polymerase delta (pol delta) holoenzyme, Because PCNAs from Saccharomyces cerevisiae and human do not complement each other using in vitro or in vivo assays, hybrids of the two proteins would help identify region(s) involved in the assembly of the pol S holoenzyme, Two mutants of human PCNA, HU1 (D21E) and HU3 (D120E), and six hybrids of human and S, cerevisiae PCNA, HC1, HC5, CH2, CH3, CH4, and CH5, were prepared by swapping corresponding regions between the two proteins, In solution, all PCNA assembled into trimers, albeit to different extents, These PCNA variants were tested for stimulation of pol delta and in vitro replication of M13 and SV40 DNA as well as to stimulate the ATPase activity of replication factor C (RF-C), Our data suggest that in addition to the interdomain connecting loop and C terminus, an additional site in the N terminus is required for pol delta interaction. PCNA mutants and hybrids that stimulated pol delta and RF-C were deficient in M13 and SV40 DNA replication assays, indicating that PCNA-induced pol delta stimulation and RF-C-mediated loading are not sufficient for coordinated DNA synthesis at a replication fork.	Kings Coll London, Guys Kings & St Thomas Dent Inst, Head & Neck Canc Res Program, London SE1 9RT, England; Kings Coll London, Pediat Res Unit, Div Med & Mol Genet, London SE1 9RT, England; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Royal London Hosp, Imperial Canc Res Fund, Skin Tumor Lab, London E1 2AT, England	University of London; King's College London; University of London; King's College London; Cold Spring Harbor Laboratory; Barts Health NHS Trust; Royal London Hospital; Cancer Research UK	Waseem, A (corresponding author), Kings Coll London, Guys Hosp, GKT Dent Inst, Dept Craniofacial Dev, Floor 28, London SE1 9RT, England.	ahmed.waseem@kcl.ac.nk	Waseem, Naushin/C-9573-2013	Stillman, Bruce/0000-0002-9453-4091				Arroyo MP, 1996, J BIOL CHEM, V271, P15971, DOI 10.1074/jbc.271.27.15971; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BRAND SR, 1994, J IMMUNOL, V153, P3070; BRILL SJ, 1991, GENE DEV, V5, P1589, DOI 10.1101/gad.5.9.1589; BURGERS PMJ, 1993, J BIOL CHEM, V268, P19923; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; Cox LS, 1997, TRENDS CELL BIOL, V7, P493, DOI 10.1016/S0962-8924(97)01170-7; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; EKI T, 1991, J VIROL, V65, P4874, DOI 10.1128/JVI.65.9.4874-4881.1991; Ellison V, 1998, J BIOL CHEM, V273, P5979, DOI 10.1074/jbc.273.10.5979; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIEN K, 1992, MOL CELL BIOL, V12, P155, DOI 10.1128/MCB.12.1.155; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; HENDERSON DS, 1994, EMBO J, V13, P1450, DOI 10.1002/j.1460-2075.1994.tb06399.x; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; JONSSON ZO, 1995, EMBO J, V14, P5745, DOI 10.1002/j.1460-2075.1995.tb00261.x; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P9515, DOI 10.1073/pnas.96.17.9515; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KRISHNA TSR, 1994, J MOL BIOL, V241, P265, DOI 10.1006/jmbi.1994.1495; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SH, 1991, J BIOL CHEM, V266, P594; LI JJ, 1985, MOL CELL BIOL, V5, P1238, DOI 10.1128/MCB.5.6.1238; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MATSUMOTO Y, 1994, MOL CELL BIOL, V14, P6187, DOI 10.1128/MCB.14.9.6187; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; MELENDY T, 1991, J BIOL CHEM, V266, P1942; Mossi R, 1997, J BIOL CHEM, V272, P1769, DOI 10.1074/jbc.272.3.1769; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; NG L, 1990, J BIOL CHEM, V265, P11948; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; NOMURA A, 1994, J CELL SCI, V107, P3291; Oku T, 1998, GENES CELLS, V3, P357, DOI 10.1046/j.1365-2443.1998.00199.x; OREILLY DR, 1989, NATURE, V337, P606, DOI 10.1038/337606a0; Piard K, 1998, NUCLEIC ACIDS RES, V26, P2598, DOI 10.1093/nar/26.11.2598; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Reynolds N, 2000, EMBO J, V19, P1108, DOI 10.1093/emboj/19.5.1108; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shibahara K, 1999, CELL, V96, P575, DOI 10.1016/S0092-8674(00)80661-3; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; SUZUKA I, 1989, P NATL ACAD SCI USA, V86, P3189, DOI 10.1073/pnas.86.9.3189; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P609, DOI 10.1128/MCB.9.2.609; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; TSURIMOTO T, 1989, MOL CELL BIOL, V9, P3839, DOI 10.1128/MCB.9.9.3839; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; WAGA S, 1994, J BIOL CHEM, V269, P10923; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; WASEEM NH, 1990, J CELL SCI, V96, P121; WASEEM NH, 1991, THESIS U LONDON, P86; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMAGUCHI M, 1991, J CELL SCI, V100, P729; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189; ZHANG P, 1995, BIOCHEMISTRY-US, V34, P10703, DOI 10.1021/bi00034a002; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713	75	1	2	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10168	10177		10.1074/jbc.M008929200	http://dx.doi.org/10.1074/jbc.M008929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11094057	hybrid			2022-12-25	WOS:000167996400078
J	Vandromme, M; Rochat, A; Meier, R; Carnac, G; Besser, D; Hemmings, BA; Fernandez, A; Lamb, NJC				Vandromme, M; Rochat, A; Meier, R; Carnac, G; Besser, D; Hemmings, BA; Fernandez, A; Lamb, NJC			Protein kinase B beta/Akt2 plays a specific role in muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; MYOGENIC CELL-LINE; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; AKT; EXPRESSION; MYOD; ACTIVATION; INHIBITION; TRANSLOCATION	Insulin-like growth factors positively regulate muscle differentiation through activation of the phosphatidylinositol 3-kinase/protein kinase B (PKB/Akt) signaling pathway, Here, we compare the role of the two closely related alpha (Akt1) and beta (Akt2) isoforms of PKB in muscle differentiation. During differentiation of C2.7 or L6D2 myoblasts, PKB beta was up-regulated whereas expression of PKB alpha was unaltered. Although the two isoforms were found active in both myoblasts and myotubes, cell fractionation experiments indicated that they displayed distinct subcellular localizations in differentiated cells with only PKB beta localized in the nuclei. In a transactivation assay, PKB beta (either wild-type or constitutively active) was more efficient than PKB alpha in activating muscle-specific gene expression. Moreover, microinjection of specific antibodies to PKB beta inhibited differentiation of muscle cells, whereas control or anti-PKB alpha antibodies did not. On the other hand, microinjection of the anti-PKB alpha antibodies caused a block in cell cycle progression in both non muscle and muscle cells, whereas anti-PKB beta antibodies had no effect. Taken together, these results show that PKB beta plays a crucial role in the commitment of myoblasts to differentiation that cannot be substituted by PKB alpha.	CNRS, Inst Genet Humaine, UPR 1142, F-34396 Montpellier 4, France; Friedrich Miescher Inst, CH-4056 Basel, Switzerland; Rockefeller Univ, Mol Cell Biol Lab, New York, NY 10021 USA	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Friedrich Miescher Institute for Biomedical Research; Rockefeller University	Lamb, NJC (corresponding author), CNRS, Inst Genet Humaine, UPR 1142, 141 Rue Cardonille, F-34396 Montpellier 4, France.	ned.lamb@igh.cnrs.fr	Vandromme, Marie/ABC-3003-2021; Besser, Daniel/A-8304-2012; Rochat, Anne/M-7167-2016; Vandromme, Marie M/N-6615-2018	Besser, Daniel/0000-0002-4958-9624; 				Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Altomare DA, 1998, ONCOGENE, V16, P2407, DOI 10.1038/sj.onc.1201750; ALTOMARE DA, 1995, ONCOGENE, V11, P1055; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Asano T, 2000, J BIOL CHEM, V275, P17671, DOI 10.1074/jbc.M910391199; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Calera MR, 1998, BIOCHEM BIOPH RES CO, V251, P835, DOI 10.1006/bbrc.1998.9566; Calera MR, 1998, J BIOL CHEM, V273, P7201, DOI 10.1074/jbc.273.13.7201; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Coffer PJ, 1998, BIOCHEM J, V335, P1; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; FLORINI JR, 1991, J BIOL CHEM, V266, P15917; FLORINI JR, 1994, CURRENT DIRECTIONS I, P319; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; GauthierRouviere C, 1996, MOL BIOL CELL, V7, P719, DOI 10.1091/mbc.7.5.719; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Hill K, 2000, J BIOL CHEM, V275, P3741, DOI 10.1074/jbc.275.6.3741; Hill MM, 1999, MOL CELL BIOL, V19, P7771; Hooshmand-Rad R, 2000, J CELL SCI, V113, P207; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Kaliman P, 1996, J BIOL CHEM, V271, P19146, DOI 10.1074/jbc.271.32.19146; Kitzmann M, 1998, J CELL BIOL, V142, P1447, DOI 10.1083/jcb.142.6.1447; Laine J, 2000, MOL CELL, V6, P395, DOI 10.1016/S1097-2765(00)00039-3; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; Lawlor MA, 2000, MOL CELL BIOL, V20, P3256, DOI 10.1128/MCB.20.9.3256-3265.2000; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Montarras D, 1996, J CELL SCI, V109, P551; Moon RT, 1997, TRENDS GENET, V13, P157, DOI 10.1016/S0168-9525(97)01093-7; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Pekarsky Y, 2000, P NATL ACAD SCI USA, V97, P3028, DOI 10.1073/pnas.040557697; Peterson RT, 1999, CURR BIOL, V9, pR521, DOI 10.1016/S0960-9822(99)80326-1; Pinset C, 1997, CR ACAD SCI III-VIE, V320, P367, DOI 10.1016/S0764-4469(97)85024-X; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Shield MA, 1996, MOL CELL BIOL, V16, P5058; Summers SA, 1999, J BIOL CHEM, V274, P23858, DOI 10.1074/jbc.274.34.23858; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; Toker A, 2000, J BIOL CHEM, V275, P8271, DOI 10.1074/jbc.275.12.8271; VANDROMME M, 1992, J CELL BIOL, V118, P1489, DOI 10.1083/jcb.118.6.1489; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477	50	94	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8173	8179		10.1074/jbc.M005587200	http://dx.doi.org/10.1074/jbc.M005587200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11087731	hybrid			2022-12-25	WOS:000167474900070
J	Gimelbrant, AA; Haley, SL; McClintock, TS				Gimelbrant, AA; Haley, SL; McClintock, TS			Olfactory receptor trafficking involves conserved regulatory steps	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE PHEROMONE RECEPTORS; ODORANT RECEPTORS; FUNCTIONAL EXPRESSION; MULTIGENE FAMILY; TASTE RECEPTORS; ENDOPLASMIC-RETICULUM; PROTEIN; DROSOPHILA; CELLS; IDENTIFICATION	Olfactory receptors are difficult to functionally express in heterologous cells. They are typically retained in the endoplasmic reticulum of cells commonly used for functional expression studies and are only released to the plasma membrane in mature cells of the olfactory receptor neuron lineage. A recently developed olfactory cell line, odora, traffics olfactory receptors to the plasma membrane when differentiated. We found that undifferentiated odora cells do not traffic olfactory receptors to their surface, even though they release the receptors to the Golgi apparatus and endosomes. This behavior differs from other cell lines tested thus far. Differentiated odora cells also properly traffic vomeronasal receptors of the VN1 type, which lack sequence similarity to olfactory receptors. ODR-4, a protein that is necessary for plasma membrane trafficking of a chemosensory receptor in nematodes, facilitates trafficking of rat olfactory receptor U131 in odora and Chinese hamster ovary cells. Olfactory receptor trafficking from the endoplasmic reticulum to the plasma membrane involves at least two steps whose regulation depends on the maturation state of cells in the olfactory receptor neuron lineage. These results also indicate that some components of the regulatory mechanism are conserved.	Univ Kentucky, Med Ctr, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky	McClintock, TS (corresponding author), Univ Kentucky, Med Ctr, Dept Physiol, 800 Rose St, Lexington, KY 40536 USA.			Gimelbrant, Alexander/0000-0001-6986-0285	NIDCD NIH HHS [DC02736, R01 DC002736] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002736] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Clyne PJ, 2000, SCIENCE, V287, P1830, DOI 10.1126/science.287.5459.1830; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Ferreira PA, 1996, NATURE, V383, P637, DOI 10.1038/383637a0; Ferreira PA, 1997, P NATL ACAD SCI USA, V94, P1556, DOI 10.1073/pnas.94.4.1556; Gimelbrant AA, 1999, J NEUROCHEM, V72, P2301, DOI 10.1046/j.1471-4159.1999.0722301.x; GREEN WN, 1995, TRENDS NEUROSCI, V18, P280, DOI 10.1016/0166-2236(95)93915-K; Hoon MA, 1999, CELL, V96, P541, DOI 10.1016/S0092-8674(00)80658-3; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; LODISH HF, 1988, J BIOL CHEM, V263, P2107; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; McClintock TS, 1997, MOL BRAIN RES, V48, P270, DOI 10.1016/S0169-328X(97)00099-5; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Menco BPM, 1997, J NEUROCYTOL, V26, P297, DOI 10.1023/A:1018552601444; Mombaerts P, 1999, ANNU REV NEUROSCI, V22, P487, DOI 10.1146/annurev.neuro.22.1.487; Monastyrskaia K, 1999, J RECEPT SIGNAL TR R, V19, P687, DOI 10.3109/10799899909036680; Murrell JR, 1999, J NEUROSCI, V19, P8260; Roche KW, 1999, J NEUROSCI, V19, P3926; Ryba NJP, 1997, NEURON, V19, P371, DOI 10.1016/S0896-6273(00)80946-0; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; Speca DJ, 1999, NEURON, V23, P487, DOI 10.1016/S0896-6273(00)80802-8; STAMNES MA, 1991, CELL, V65, P219, DOI 10.1016/0092-8674(91)90156-S; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; Wellerdieck C, 1997, CHEM SENSES, V22, P467, DOI 10.1093/chemse/22.4.467; Xu ZJ, 1999, J BIOL CHEM, V274, P21149, DOI 10.1074/jbc.274.30.21149; Zhang Y, 1997, P NATL ACAD SCI USA, V94, P12162, DOI 10.1073/pnas.94.22.12162; Zhao HQ, 1998, SCIENCE, V279, P237, DOI 10.1126/science.279.5348.237	36	70	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7285	7290		10.1074/jbc.M005433200	http://dx.doi.org/10.1074/jbc.M005433200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11060288	hybrid			2022-12-25	WOS:000167442900060
J	Bernhardt, TG; Struck, DK; Young, R				Bernhardt, TG; Struck, DK; Young, R			The lysis protein E of phi X174 is a specific inhibitor of the MraY-catalyzed step in peptidoglycan synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLMURAMYL-PENTAPEPTIDE-TRANSLOCASE; BACTERIOPHAGE-Q-BETA; ESCHERICHIA-COLI; MOLECULAR-CLONING; MUREIDOMYCIN-A; CELL-LYSIS; GENE-E; ANTIBIOTICS; TUNICAMYCIN; MECHANISM	Coliphage phi X174 encodes a single lysis protein, E, a 91-amino acid membrane protein. Dominant mutations have been isolated in the host gene mraY that confer E resistance. mraY encodes translocase I, which catalyzes the formation of the first lipid intermediate in bacterial cell wall synthesis, suggesting a model in which E inhibits MraY and promotes cell lysis in a manner analogous to cell wall synthesis inhibitors like penicillin. To test this model biochemically, we monitored the effect of E on cell wall synthesis in vivo and in vitro. We find that expression of Emyc, encoding an epitope-tagged E protein, from a multicopy plasmid inhibits the incorporation of [H-3]diaminopimelic acid into cell wall and leads to a profile of labeled precursors consistent with MraY inhibition. Moreover, we find that membranes isolated after Emyc expression are drastically reduced in MraY activity, whereas the activity of Rfe, an enzyme in the same superfamily, was unaffected. We therefore conclude that E is indeed a cell wall synthesis inhibitor and that this inhibition results from a specific block at the MraY-catalyzed step in the pathway.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Young, R (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, 2128 TAMU, College Stn, TX 77843 USA.			Young, Ry/0000-0001-8001-2914	NIGMS NIH HHS [GM27099, R01 GM027099] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027099, R37GM027099] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS JF, 1979, CELL, V18, P247, DOI 10.1016/0092-8674(79)90044-8; BANERJEE DK, 1989, J BIOL CHEM, V264, P2024; Bayles KW, 2000, TRENDS MICROBIOL, V8, P274, DOI 10.1016/S0966-842X(00)01762-5; BEREMAND MN, 1979, CELL, V18, P257, DOI 10.1016/0092-8674(79)90045-X; Bernhardt TG, 2000, P NATL ACAD SCI USA, V97, P4297, DOI 10.1073/pnas.97.8.4297; Bouhss A, 1999, MOL MICROBIOL, V34, P576, DOI 10.1046/j.1365-2958.1999.01623.x; Boyle DS, 1998, J BACTERIOL, V180, P6429; Brandish PE, 1996, J BIOL CHEM, V271, P7609, DOI 10.1074/jbc.271.13.7609; Brandish PE, 1996, ANTIMICROB AGENTS CH, V40, P1640, DOI 10.1128/AAC.40.7.1640; BUCKLEY KJ, 1986, MOL GEN GENET, V204, P120, DOI 10.1007/BF00330198; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; HARKNESS RE, 1989, J BIOL CHEM, V264, P6177; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; IKEDA M, 1991, J BACTERIOL, V173, P1021, DOI 10.1128/jb.173.3.1021-1026.1991; INUKAI M, 1993, ANTIMICROB AGENTS CH, V37, P980, DOI 10.1128/AAC.37.5.980; ISONO F, 1989, J ANTIBIOT, V42, P674, DOI 10.7164/antibiotics.42.674; KARNIK S, 1983, EMBO J, V2, P1521, DOI 10.1002/j.1460-2075.1983.tb01617.x; LEHRMAN MA, 1994, GLYCOBIOLOGY, V4, P768, DOI 10.1093/glycob/4.6.768; LUGTENBERG EJ, 1971, J BACTERIOL, V108, P20, DOI 10.1128/JB.108.1.20-29.1971; LUGTENBERG EJJ, 1971, J MICROBIOL SEROL, V37, P537; MARATEA D, 1985, GENE, V40, P39, DOI 10.1016/0378-1119(85)90022-8; MEIERDIETER U, 1992, J BIOL CHEM, V267, P746; Miller J. H., 1992, LAB MANUAL HDB ESCHE; Nanninga N, 1998, MICROBIOL MOL BIOL R, V62, P110, DOI 10.1128/MMBR.62.1.110-129.1998; NOMURA S, 1978, J BACTERIOL, V136, P818, DOI 10.1128/JB.136.2.818-821.1978; RAAB R, 1986, J BACTERIOL, V167, P1035, DOI 10.1128/jb.167.3.1035-1042.1986; RESSIG JL, 1955, J BIOL CHEM, V217, P959; Sambrook J., 2002, MOL CLONING LAB MANU; STONE KJ, 1971, P NATL ACAD SCI USA, V68, P3223, DOI 10.1073/pnas.68.12.3223; STORCH GA, 1981, J CLIN INVEST, V68, P639, DOI 10.1172/JCI110298; STRUCK DK, 1977, J BIOL CHEM, V252, P1007; STRUCK DK, 1980, BIOCH GLYCOPROTEINS, P35; STRUVE WG, 1966, BIOCHEMISTRY-US, V5, P82, DOI 10.1021/bi00865a012; TANAKA H, 1979, BIOCHEM BIOPH RES CO, V86, P902, DOI 10.1016/0006-291X(79)91797-2; TOMASZ A, 1979, ANNU REV MICROBIOL, V33, P113, DOI 10.1146/annurev.mi.33.100179.000553; WIENTJES FB, 1985, J BACTERIOL, V164, P331, DOI 10.1128/JB.164.1.331-337.1985; WINTER RB, 1983, CELL, V33, P877, DOI 10.1016/0092-8674(83)90030-2; YOUNG KD, 1982, J VIROL, V44, P993, DOI 10.1128/JVI.44.3.993-1002.1982; Young R, 2000, TRENDS MICROBIOL, V8, P120, DOI 10.1016/S0966-842X(00)01705-4	39	89	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6093	6097		10.1074/jbc.M007638200	http://dx.doi.org/10.1074/jbc.M007638200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11078734	hybrid			2022-12-25	WOS:000167261000007
J	Heery, DM; Hoare, S; Hussain, S; Parker, MG; Sheppard, H				Heery, DM; Hoare, S; Hussain, S; Parker, MG; Sheppard, H			Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGEN-RECEPTOR; NUCLEAR RECEPTORS; LIGAND-BINDING; TRANSCRIPTIONAL COACTIVATORS; HISTONE ACETYLTRANSFERASE; MOLECULAR DETERMINANTS; ACTIVATION FUNCTIONS; HORMONE-RECEPTORS; P300; DOMAIN	An alpha -helical motif containing the sequence LXXLL is required for the ligand-dependent binding of transcriptional co-activators to nuclear receptors. By using a peptide inhibition assay, we have defined the minimal "core" LXXLL motif as an 8-amino acid sequence spanning positions -2 to +6 relative to the primary conserved leucine residue. In yeast two-hybrid assays, core LXXLL motif sequences derived from steroid receptor co-activator (SRC1), the 140-kDa receptor interacting protein (RIP140), and CREB-binding protein (CBP) displayed differences in selectivity and affinity for nuclear receptor ligand binding domains. Although core LXXLL motifs from SRC1 and RIP140 mediated strong interactions with steroid and retinoid receptors, three LXXLL motifs present in the global co-activator CBP were found to have very weak affinity for these proteins. Core motifs with high affinity for steroid and retinoid receptors were generally found to contain a hydrophobic residue at position -1 relative to the first conserved leucine and a nonhydrophobic residue at position +2. Our results indicate that variant residues in LXXLL core motifs influence the affinity and selectivity of co-activators for nuclear receptors.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Imperial Canc Res Fund, London WC2A 3PX, England	University of Leicester; Cancer Research UK	Heery, DM (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.	dh37@le.ac.uk		Sheppard, Hilary/0000-0003-1147-4618; Heery, David/0000-0002-5035-2392				Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Dowell P, 1997, J BIOL CHEM, V272, P33435, DOI 10.1074/jbc.272.52.33435; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang NW, 1998, EMBO J, V17, P3398, DOI 10.1093/emboj/17.12.3398; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Leers J, 1998, MOL CELL BIOL, V18, P6001, DOI 10.1128/MCB.18.10.6001; LHorset F, 1996, MOL CELL BIOL, V16, P6029; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; Mak HY, 1999, MOL CELL BIOL, V19, P3895; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; METZGER D, 1992, NUCLEIC ACIDS RES, V20, P2813, DOI 10.1093/nar/20.11.2813; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Needham M, 2000, J STEROID BIOCHEM, V72, P35, DOI 10.1016/S0960-0760(00)00027-3; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; ONATE SA, 1995, SCIENCE, V270, P1354; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; Perissi V, 1999, P NATL ACAD SCI USA, V96, P3652, DOI 10.1073/pnas.96.7.3652; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 2000, MOL CELL BIOL, V20, P2718, DOI 10.1128/MCB.20.8.2718-2726.2000; Ren YS, 2000, MOL CELL BIOL, V20, P5433, DOI 10.1128/MCB.20.15.5433-5446.2000; Shao G, 2000, MOL ENDOCRINOL, V14, P1198, DOI 10.1210/me.14.8.1198; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Swope DL, 1996, J BIOL CHEM, V271, P28138, DOI 10.1074/jbc.271.45.28138; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YAO TP, 1996, P NATL ACAD SCI USA, V95, P5527; Yoshida E, 1998, GENE, V208, P307, DOI 10.1016/S0378-1119(98)00008-0; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	51	125	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6695	6702		10.1074/jbc.M009404200	http://dx.doi.org/10.1074/jbc.M009404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11078741	hybrid			2022-12-25	WOS:000167261000081
J	Linseman, DA; Heidenreich, KA; Fisher, SK				Linseman, DA; Heidenreich, KA; Fisher, SK			Stimulation of M-3 muscarinic receptors induces phosphorylation of the Cdc42 effecter activated Cdc42Hs-associated kinase-1 via a Fyn tyrosine kinase signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; HUMAN NEUROBLASTOMA-CELLS; SUBCELLULAR-LOCALIZATION; LYSOPHOSPHATIDIC ACID; ALZHEIMERS-DISEASE; NEURITE RETRACTION; NERVOUS-SYSTEM; GROWTH-FACTOR; RHO; GTPASES	The tyrosine kinase, activated Cdc42Hs-associated kinase-1 (ACR-1), is a specific effector of the Rho family GTPase Cdc42. GTP-bound Cdc42 has been shown to facilitate neurite outgrowth elicited by activation of muscarinic cholinergic receptors (mAChRs). Because tyrosine kinase activity is a requirement for neuritogenesis in several cell systems, we investigated whether endogenous mAChRs (principally of the M-3 subtype) expressed in human SN-SY5Y neuroblastoma cells would signal to ACK-1. Incubation of cells with the cholinergic agonist oxotremorine-M (Oxo-M) induced an approximately 6-fold increase in the tyrosine phosphorylation of ACK-1 which was inhibited by atropine. ACK-1 phosphorylation was blocked by Clostridium difficile toxin B, an inhibitor of Rho family GTPases. In contrast, disruption of the actin cytoskeleton with cytochalasin D stimulated ACK-1 phosphorylation, and moreover, addition of Oxo-M 60 cells preincubated with this agent elicited a further increase in phosphorylation, indicating that an intact cytoskeleton is not required for mAChR signaling to ACH-1. Although stimulation of M-3 mAChRs induces bath an increase in intracellular Ca2+ and activation of protein kinase C (PKC), neither of these second messenger pathways was required for receptor-stimulated ACK-1 phosphorylation. Instead, inhibition of PKC resulted in a 2-fold increase in Oxo-M-stimulated ACK-1 phosphorylation, whereas acute activation of PRC with phorbol ester decreased ACK-1 phosphorylation. The agonist-induced tyrosine phosphorylation of ACK-1 was blocked by inhibitors of Src family kinases, and ACK-1 was coprecipitated with Fyn (but not Src) in an agonist-dependent manner. Finally, scrape loading cells with glutathione S-transferase fusion proteins of either the Fyn-SH2 or Fyn-SH3 domain significantly attenuated mAChR-stimulated ACK-1 tyrosine phosphorylation, The data are the first to shaw phosphorylation of ACK-1 after stimulation of a receptor coupled to neurite outgrowth and indicate that a Rho family GTPase (i.e, Cdc42) and Fyn are essential upstream elements of this signaling pathway.	Denver Vet Affairs Med Ctr, Denver, CO 80220 USA; Univ Michigan, Mental Hlth Res Inst, Dept Pharmacol, Ann Arbor, MI 48104 USA; Univ Michigan, Mental Hlth Res Inst, Neurosci Lab, Ann Arbor, MI 48104 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Veterans Affairs Medical Center - Denver; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Linseman, DA (corresponding author), Denver Vet Affairs Med Ctr, 111H,Rm 9C120,1055 Clermont St, Denver, CO 80220 USA.		Linseman, Daniel/L-3846-2019		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [F31MH012193] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS023831] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM07767] Funding Source: Medline; NIMH NIH HHS [MH12193] Funding Source: Medline; NINDS NIH HHS [NS23831] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Avery EE, 1997, DRUG AGING, V11, P450, DOI 10.2165/00002512-199711060-00004; BARRY ELR, 1988, J BIOL CHEM, V263, P10464; Bi EF, 1999, CURR BIOL, V9, pR160, DOI 10.1016/S0960-9822(99)80102-X; BIEDLER JL, 1973, CANCER RES, V33, P2643; Bourdoulous S, 1998, J CELL BIOL, V143, P267, DOI 10.1083/jcb.143.1.267; Boxall AR, 1996, NEURON, V16, P805, DOI 10.1016/S0896-6273(00)80100-2; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; BURGAYA F, 1995, EUR J NEUROSCI, V7, P1810, DOI 10.1111/j.1460-9568.1995.tb00700.x; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eisenmann KM, 1999, NAT CELL BIOL, V1, P507, DOI 10.1038/70302; FISHER SK, 1994, NEUROCHEM RES, V19, P549, DOI 10.1007/BF00971329; Flinn HM, 1996, J CELL SCI, V109, P1133; Girault JA, 1999, TRENDS NEUROSCI, V22, P257, DOI 10.1016/S0166-2236(98)01358-7; GRANT SGN, 1995, GENE DEV, V9, P1909, DOI 10.1101/gad.9.15.1909; Growdon JH, 1997, LIFE SCI, V60, P993, DOI 10.1016/S0024-3205(97)00039-8; Hunter T, 1998, PHILOS T R SOC B, V353, P583, DOI 10.1098/rstb.1998.0228; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Klesse LJ, 1999, MICROSC RES TECHNIQ, V45, P210, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<210::AID-JEMT4>3.3.CO;2-6; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; Kranenburg O, 1999, MOL BIOL CELL, V10, P1851, DOI 10.1091/mbc.10.6.1851; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; LAMBERT DG, 1990, BIOCHEM J, V265, P555, DOI 10.1042/bj2650555; LAMBERT DG, 1989, EUR J PHARMACOL, V165, P71, DOI 10.1016/0014-2999(89)90771-1; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Levey AI, 1996, P NATL ACAD SCI USA, V93, P13541, DOI 10.1073/pnas.93.24.13541; Linseman DA, 1999, J NEUROCHEM, V73, P1933; Linseman DA, 2000, J NEUROCHEM, V74, P2010, DOI 10.1046/j.1471-4159.2000.0742010.x; Linseman DA, 1998, J NEUROCHEM, V70, P940; Luo LQ, 1996, PERSPECT DEV NEUROBI, V4, P199; MALENKA RC, 1994, CELL, V78, P535, DOI 10.1016/0092-8674(94)90517-7; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; Neet K, 1996, GENES CELLS, V1, P147, DOI 10.1046/j.1365-2443.1996.d01-234.x; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; ROSNER H, 1995, EUR J CELL BIOL, V66, P324; Rosner H, 1996, NEUROSCI LETT, V219, P175, DOI 10.1016/S0304-3940(96)13201-8; ROSS RA, 1985, CANCER RES, V45, P1628; Satoh T, 1996, FEBS LETT, V386, P230, DOI 10.1016/0014-5793(96)00449-8; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SLOWIEJKO DM, 1994, J NEUROCHEM, V62, P1795; Snapper SB, 1999, ANNU REV IMMUNOL, V17, P905, DOI 10.1146/annurev.immunol.17.1.905; Threadgill R, 1997, NEURON, V19, P625, DOI 10.1016/S0896-6273(00)80376-1; WALL SJ, 1991, MOL PHARMACOL, V40, P783; WILLIAMS EJ, 1994, J CELL BIOL, V124, P1029, DOI 10.1083/jcb.124.6.1029; WINKLER J, 1995, NATURE, V375, P484, DOI 10.1038/375484a0; Worley T, 1996, J NEUROSCI, V16, P2294; Yang WN, 1997, J BIOL CHEM, V272, P24819, DOI 10.1074/jbc.272.40.24819; Yang WN, 1999, J BIOL CHEM, V274, P8524, DOI 10.1074/jbc.274.13.8524	55	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5622	5628		10.1074/jbc.M006812200	http://dx.doi.org/10.1074/jbc.M006812200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11087735	hybrid			2022-12-25	WOS:000167115100031
J	Reuven, NB; Arad, G; Stasiak, AZ; Stasiak, A; Livneh, Z				Reuven, NB; Arad, G; Stasiak, AZ; Stasiak, A; Livneh, Z			Lesion bypass by the Escherichia coli DNA polymerase V requires assembly of a RecA nucleoprotein filament	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SOS-REGULATED PROTEINS; BINDING-PROTEIN; DUPLEX DNA; TRANSLESION REPLICATION; MUTAGENESIS PROTEINS; III HOLOENZYME; COMPLEX; UMUC; SSB	Translesion replication is carried out in Escherichia coli by the SOS-inducible DNA polymerase V (UmuC), an error-prone polymerase, which is specialized for replicating through lesions in DNA, leading to the formation of mutations. Lesion bypass by pol V requires the SOS-regulated proteins UmuD' and RecA and the single-strand DNA-binding protein (SSB). Using an in vitro assay system for translesion replication based on a gapped plasmid carrying a site-specific synthetic abasic site, we show that the assembly of a RecA nucleoprotein filament is required for lesion bypass by pol V. This is based on the reaction requirements for stoichiometric amounts of RecA and for single-stranded gaps longer than 100 nucleotides and on direct visualization of RecA-DNA filaments by electron microscopy. SSB is likely to facilitate the assembly of the RecA nucleoprotein filament; however, it has at least one additional role in lesion bypass. ATP gammaS, which is known to strongly increase binding of RecA to DNA, caused a drastic inhibition of pol V activity. Lesion bypass does not require stoichiometric binding of UmuD' along RecA filaments. In summary, the RecA nucleoprotein filament, previously known to be required for SOS induction and ho mologous recombination, is also a critical intermediate in translesion replication.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Univ Lausanne, Lab Analyse Ultrastruct, CH-1015 Lausanne, Switzerland	Weizmann Institute of Science; University of Lausanne	Livneh, Z (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	zvi.livneh@weizmann.ac.il	Stasiak, Andrzej/E-5551-2010; Reuven, Nina/AAM-8711-2020	Stasiak, Andrzej/0000-0002-0398-1989; Reuven, Nina/0000-0003-1569-3818				Boudsocq F, 1997, J MOL BIOL, V270, P201, DOI 10.1006/jmbi.1997.1098; COX MM, 1983, J BIOL CHEM, V258, P2577; Cox MM, 1998, GENES CELLS, V3, P65, DOI 10.1046/j.1365-2443.1998.00175.x; COX MM, 1981, J BIOL CHEM, V256, P4676; Eggleston AK, 1996, TRENDS GENET, V12, P20, DOI 10.1016/0168-9525(96)81384-9; FLORY J, 1982, CELL, V28, P747, DOI 10.1016/0092-8674(82)90054-X; FRANK EG, 1993, P NATL ACAD SCI USA, V90, P8169, DOI 10.1073/pnas.90.17.8169; FREITAG N, 1989, P NATL ACAD SCI USA, V86, P8363, DOI 10.1073/pnas.86.21.8363; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Goldsmith M, 2000, P NATL ACAD SCI USA, V97, P11227, DOI 10.1073/pnas.200361997; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; Johnson RE, 1999, SCIENCE, V283, P1001, DOI 10.1126/science.283.5404.1001; Johnson RE, 1999, P NATL ACAD SCI USA, V96, P12224, DOI 10.1073/pnas.96.22.12224; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LITTLE JW, 1982, CELL, V29, P11, DOI 10.1016/0092-8674(82)90085-X; LIVNEH Z, 1993, CRIT REV BIOCHEM MOL, V28, P465, DOI 10.3109/10409239309085136; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; Maor-Shoshani A, 2000, P NATL ACAD SCI USA, V97, P565, DOI 10.1073/pnas.97.2.565; MUNIYAPPA K, 1990, NUCLEIC ACIDS RES, V18, P3967, DOI 10.1093/nar/18.13.3967; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Peat TS, 1996, STRUCTURE, V4, P1401, DOI 10.1016/S0969-2126(96)00148-7; Peat TS, 1996, NATURE, V380, P727, DOI 10.1038/380727a0; RAJAGOPALAN M, 1992, P NATL ACAD SCI USA, V89, P10777, DOI 10.1073/pnas.89.22.10777; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; Rehrauer WM, 1998, J BIOL CHEM, V273, P32384, DOI 10.1074/jbc.273.49.32384; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; Reuven NB, 1998, MOL CELL, V2, P191, DOI 10.1016/S1097-2765(00)80129-X; ROCA AI, 1990, CRIT REV BIOCHEM MOL, V25, P415, DOI 10.3109/10409239009090617; Roca AI, 1997, PROG NUCLEIC ACID RE, V56, P129, DOI 10.1016/S0079-6603(08)61005-3; SHANER SL, 1987, J BIOL CHEM, V262, P9211; SHANER SL, 1987, J BIOL CHEM, V262, P9220; SOMMER S, 1993, MOL MICROBIOL, V10, P963, DOI 10.1111/j.1365-2958.1993.tb00968.x; SPENGLER SJ, 1984, COLD SPRING HARB SYM, V49, P745, DOI 10.1101/SQB.1984.049.01.084; Stasiak AZ, 2000, CURR BIOL, V10, P337, DOI 10.1016/S0960-9822(00)00385-7; Tang MJ, 2000, NATURE, V404, P1014, DOI 10.1038/35010020; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tang MJ, 1998, P NATL ACAD SCI USA, V95, P9755, DOI 10.1073/pnas.95.17.9755; Tomer G, 1999, BIOCHEMISTRY-US, V38, P5948, DOI 10.1021/bi982599+; Tomer G, 1998, P NATL ACAD SCI USA, V95, P14106, DOI 10.1073/pnas.95.24.14106; TSANG SS, 1985, J MOL BIOL, V185, P295, DOI 10.1016/0022-2836(85)90405-X; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WILLIAMS JGK, 1981, J BIOL CHEM, V256, P7573; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191	47	36	42	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5511	5517		10.1074/jbc.M006828200	http://dx.doi.org/10.1074/jbc.M006828200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11084028	hybrid			2022-12-25	WOS:000167115100016
J	Blaydes, JP; Luciani, MG; Pospisilova, S; Ball, HML; Vojtesek, B; Hupp, TR				Blaydes, JP; Luciani, MG; Pospisilova, S; Ball, HML; Vojtesek, B; Hupp, TR			Stoichiometric phosphorylation of human p53 at Ser(315) stimulates p53-dependent transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING FUNCTION; CELL-CYCLE ARREST; WILD-TYPE P53; IONIZING-RADIATION; ACTIVATION FUNCTION; NEGATIVE REGULATION; IN-VITRO; RAT P53; PROTEIN; KINASE	p53 protein activity as a transcription factor can be activated in vivo by antibodies that target its C-terminal negative regulatory domain suggesting that cellular enzymes that target this domain may play a role in stimulating p53 dependent gene expression. A phospho-specific monoclonal antibody to the C-terminal Ser(315) phospho-epitope was used to determine whether phosphorylation of endogenous p53 at Ser(315) can be detected in vivo, whether steady-state Ser(315) phosphorylation increases or decreases in an irradiated cell, and whether this phosphorylation event activates or inhibits p53 in vivo. A native phospho-specific IgG binding assay was developed for quantitating the extent of p53 phosphorylation at Ser(315) where one, two, three, or four phosphates/ tetramer could be defined after in vitro phosphorylation by cyclin-dependent protein kinases, Using this assay, near-stoichiometric Ser(315) phosphorylation of endogenous p53 protein was detected in vivo after UV irradiation of MCF7 and A375 cells, coinciding with elevated p53-dependent transcription. Transfection of the p53 gene with an alanine mutation at the Ser(315) site into Saos-2 cells gave rise to a form of p53 protein with a substantially reduced specific activity as a transcription factor, The treatment of cells with the cyclin-dependent protein kinase inhibitor Roscovitine promoted a reduction in the specific activity of endogenous p53 or ectopically expressed p53, These results indicate that the majority of p53 protein has been phosphorylated at Ser(315) after irradiation damage and identify a cyclin-dependent kinase pathway that plays a role in stimulating p53 function.	Univ Dundee, Dundee Canc Res Ctr, Canc Res Campaign Labs, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Masaryk Mem Canc Inst, Dept Cellular & Mol Oncol, Brno 65653, Czech Republic	University of Dundee; Masaryk Memorial Cancer Institute	Hupp, TR (corresponding author), Univ Dundee, Dundee Canc Res Ctr, Canc Res Campaign Labs, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.	T.R.Hupp@dundee.ac.uk	Pospisilova, Sarka/D-7200-2012; Blaydes, Jeremy/AAC-6939-2019	Pospisilova, Sarka/0000-0001-7136-2680; Blaydes, Jeremy/0000-0001-8525-0209				ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; Abraham J, 2000, J MOL BIOL, V295, P853, DOI 10.1006/jmbi.1999.3415; Anderson JA, 1997, MOL BIOL CELL, V8, P1195, DOI 10.1091/mbc.8.7.1195; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; Blaydes JP, 2000, ONCOGENE, V19, P3829, DOI 10.1038/sj.onc.1203773; Blaydes JP, 1997, ONCOGENE, V14, P1859, DOI 10.1038/sj.onc.1201018; Blaydes JP, 1998, ONCOGENE, V16, P3317, DOI 10.1038/sj.onc.1201880; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Chehab NH, 2000, GENE DEV, V14, P278; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1995, NAT STRUCT BIOL, V2, P321, DOI 10.1038/nsb0495-321; Craig AL, 1999, ONCOGENE, V18, P6305, DOI 10.1038/sj.onc.1203085; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Cuddihy AR, 1999, MOL CELL BIOL, V19, P2475; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; de Fromentel CC, 1999, ONCOGENE, V18, P551, DOI 10.1038/sj.onc.1202338; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FISCELLA M, 1993, ONCOGENE, V8, P1519; FUCHS B, 1995, EUR J BIOCHEM, V228, P625, DOI 10.1111/j.1432-1033.1995.0625m.x; Gil-Gomez G, 1998, EMBO J, V17, P7209, DOI 10.1093/emboj/17.24.7209; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Hansen S, 1996, J BIOL CHEM, V271, P30922, DOI 10.1074/jbc.271.48.30922; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Harlow E., 1988, ANTIBODIES LAB MANUA; Hayashi S, 1999, GENES CELLS, V4, P111, DOI 10.1046/j.1365-2443.1999.00243.x; Hecker D, 1996, ONCOGENE, V12, P953; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hupp TR, 2000, BIOCHEM J, V352, P1, DOI 10.1042/0264-6021:3520001; Jaspersen SL, 1999, CURR BIOL, V9, P227, DOI 10.1016/S0960-9822(99)80111-0; KASTAN MB, 1991, CANCER RES, V51, P6304; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Lane DP, 1999, BRIT J CANCER, V80, P1; Lee CW, 1998, ONCOGENE, V16, P2695, DOI 10.1038/sj.onc.1201818; Li LW, 2000, J BIOL CHEM, V275, P2410, DOI 10.1074/jbc.275.4.2410; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lohrum M, 1996, ONCOGENE, V13, P2527; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; Luciani MG, 2000, J MOL BIOL, V300, P503, DOI 10.1006/jmbi.2000.3830; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Nitta M, 1997, ONCOGENE, V15, P561, DOI 10.1038/sj.onc.1201210; Okano-Uchida T, 1998, DEV BIOL, V197, P39, DOI 10.1006/dbio.1998.8881; PIETENPOL JA, 1994, P NATL ACAD SCI USA, V91, P1998, DOI 10.1073/pnas.91.6.1998; Pospisilova S, 2000, J IMMUNOL METHODS, V237, P51, DOI 10.1016/S0022-1759(99)00246-X; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Romanowski P, 2000, J BIOL CHEM, V275, P4239, DOI 10.1074/jbc.275.6.4239; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Shieh SY, 2000, GENE DEV, V14, P289; Tang H, 1998, J BIOL CHEM, V273, P29156, DOI 10.1074/jbc.273.44.29156; TARUNINA M, 1993, ONCOGENE, V8, P3165; THIAGALINGAM S, 1995, P NATL ACAD SCI USA, V92, P6062, DOI 10.1073/pnas.92.13.6062; THOMPSON RJ, 1984, TRENDS BIOCHEM SCI, V9, P1, DOI 10.1016/0968-0004(84)90033-1; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tyner SD, 1999, MOL CARCINOGEN, V24, P197, DOI 10.1002/(SICI)1098-2744(199903)24:3<197::AID-MC6>3.0.CO;2-V; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; WELLERSON R, 1986, HYBRIDOMA, V5, P199, DOI 10.1089/hyb.1986.5.199; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660	80	72	74	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4699	4708		10.1074/jbc.M003485200	http://dx.doi.org/10.1074/jbc.M003485200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11078726	hybrid			2022-12-25	WOS:000168484300025
J	Jornvall, H; Blokzijl, A; ten Dijke, P; Ibanez, CF				Jornvall, H; Blokzijl, A; ten Dijke, P; Ibanez, CF			The orphan receptor serine/threonine kinase ALK7 signals arrest of proliferation and morphological differentiation in a neuronal cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; TGF-BETA; I RECEPTOR; ACTIVATION; PROMOTER; SMAD; EXPRESSION; COMPLEX; CLONING; IDENTIFICATION	The signaling capabilities and biological functions of activin receptor-like kinase 7 (ALK7), a type I receptor serine/threonine kinase predominantly expressed in the nervous system, are unknown. We have constructed a cell line derived from the rat pheochromocytoma PC12 in which expression of a constitutively active mutant of ALK7 (T194D) is under the control of a tetracycline-inducible promoter. For comparison, another cell line was engineered with tetracycline-regulated expression of a constitutively active variant of the transforming growth factor-p type I receptor ALK5. Expression of activated ALK7 in PC12 cells resulted in activation of Smad2 and Smad3, but not Smad1, as well as the mitogen-activated protein kinases extracellular signal-regulated kinase and c-Jun N-terminal kinase, Reporter assays demonstrated that ALK7 activation stimulates transcription from the Smad-binding element of the Jun-B gene, the plasminogen activator inhibitor-1 gene, and AP-1 elements. In addition, ALK7 activation induced expression of endogenous gene products, including Smad7, c-fos mRNA, and plasminogen activator inhibitor-1. Thymidine incorporation assays revealed an anti-proliferative effect of ALK7 activation in PC12 cells, which correlated with increased transcription from the promoters of cycline-dependent kinase inhibitors p15(INK4B) and p21. Unexpectedly, ALK7 signaling produced a remarkable change in cell morphology characterized by cell flattening and elaboration of blunt, short cell processes. Interestingly, no such changes were observed upon induction of activated ALK5. The alterations in cell morphology upon ALK7 activation were more pronounced in cultures grown in full serum, were accompanied by rearrangements of actin filaments, and were maintained for several days after withdrawal of treatment. PC12 cultures that had been "primed" in this way showed an accelerated and augmented differentiation response to nerve growth factor. These results indicate that ALK7 may participate in the control of proliferation of neuronal precursors and morphological differentiation of postmitotic neurons.	Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	Karolinska Institutet; Netherlands Cancer Institute	Blokzijl, A (corresponding author), Karolinska Inst, Dept Neurosci, Div Mol Neurobiol, S-17177 Stockholm, Sweden.		Dijke, Peter ten/AAG-4660-2021	Dijke, Peter ten/0000-0002-7234-342X				Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Brodin G, 1999, CANCER RES, V59, P2731; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; Frey RS, 1997, CANCER RES, V57, P628; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HEUMANN R, 1983, EXP CELL RES, V145, P179, DOI 10.1016/S0014-4827(83)80019-6; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kang Y, 1996, BIOCHEM MOL BIOL INT, V40, P993; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAIHO M, 1991, MOL CELL BIOL, V11, P972, DOI 10.1128/MCB.11.2.972; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Lorentzon M, 1996, EXP NEUROL, V142, P351, DOI 10.1006/exnr.1996.0204; Massague J, 2000, GENE DEV, V14, P627; Moustakas A, 1999, J CELL SCI, V112, P1169; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Ryden M, 1996, J BIOL CHEM, V271, P30603, DOI 10.1074/jbc.271.48.30603; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Trupp M, 1999, J BIOL CHEM, V274, P20885, DOI 10.1074/jbc.274.30.20885; Tsuchida K, 1996, MOL CELL NEUROSCI, V7, P467, DOI 10.1006/mcne.1996.0034; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Watanabe R, 1999, BIOCHEM BIOPH RES CO, V254, P707, DOI 10.1006/bbrc.1998.0118; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA J, 2000, SCI SIGNAL TRANSDUCT	30	46	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5140	5146		10.1074/jbc.M005200200	http://dx.doi.org/10.1074/jbc.M005200200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11084022	hybrid			2022-12-25	WOS:000168484300083
J	Rasmussen, SGF; Carroll, FI; Maresch, MJ; Jensen, AD; Tate, CG; Gether, U				Rasmussen, SGF; Carroll, FI; Maresch, MJ; Jensen, AD; Tate, CG; Gether, U			Biophysical characterization of the cocaine binding pocket in the serotonin transporter using a fluorescent cocaine analogue as a molecular reporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOGENIC-AMINE TRANSPORTERS; HUMAN DOPAMINE TRANSPORTER; TRANSMEMBRANE DOMAIN; HIGH-AFFINITY; ADRENERGIC-RECEPTOR; I-125 RTI-55; MICE LACKING; SITE; SUBSTRATE; RECOGNITION	To explore the biophysical properties of the binding site for cocaine and related compounds in the serotonin transporter SERT, a high affinity cocaine analogue (3 beta-(4-methylphenyl)tropane-2 beta -carboxylic acid N-(N-methyl-N- (4-nitrobenzo-2-oxa-1,3-diazol-7-yl) ethanol amine ester hydrochloride (RTI-233); K-I = 14 nM) that contained the environmentally sensitive fluorescent moiety 7-nitrobenzo-2-oxa-1,3-diazole (NBD) was synthesized. Specific binding of RTI-233 to the rat serotonin transporter, purified from Sf-9 insect cells, was demonstrated by the competitive inhibition of fluorescence using excess serotonin, citalopram, or RTI-55 (B beta -carbomethoxy-3 beta-(4-iodophenyl)tropane). Moreover, specific binding was evidenced by measurement of steady-state fluorescence anisotropy, showing constrained mobility of bound RTI-233 relative to RTI-233 free in solution. The fluorescence of bound RTI-233 displayed an emission maximum (lambda (max)) of 532 nm, corresponding to a 4-nm blue shift as compared with the lambda (max) of RTI-233 in aqueous solution and corresponding to the lambda (max) of RTI-233 in 80% dioxane, Collisional quenching experiments revealed that the aqueous quencher potassium iodide was able to quench the fluorescence of RTI-233 in the binding pocket (K-SV = 1.7 M-1), although not to the same extent as free RTI-233 (K-SV = 7.2 M-1). Conversely, the hydrophobic quencher 2,2,6,6-tetramethylpiperidine-N-oxyl (TEMPO) quenched the fluorescence of bound RTI-233 more efficiently than free RTI-233. These data are consistent with a highly hydrophobic microenvironment in the binding pocket for cocaine-like uptake inhibitors. However, in contrast to what has been observed for small-molecule binding sites in, for example, G protein-coupled receptors, the bound cocaine analogue was still accessible for aqueous quenching and, thus, partially exposed to solvent.	Univ Copenhagen, Panum Inst, Dept Med Physiol 12 5 22, Div Cellular & Mol Physiol, DK-2200 Copenhagen N, Denmark; Res Triangle Inst, Res Triangle Pk, NC 27709 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	University of Copenhagen; Research Triangle Institute; MRC Laboratory Molecular Biology	Gether, U (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Physiol 12 5 22, Div Cellular & Mol Physiol, DK-2200 Copenhagen N, Denmark.			Rasmussen, Soren/0000-0002-1853-1841; Gether, Ulrik/0000-0002-0020-3807; Tate, Christopher/0000-0002-2008-9183	NATIONAL INSTITUTE ON DRUG ABUSE [P01DA012408, R37DA005477] Funding Source: NIH RePORTER; NIDA NIH HHS [P01 DA 12408, R37 DA 05477] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; Barker EL, 1998, METHOD ENZYMOL, V296, P475; BOJA JW, 1992, SYNAPSE, V12, P27, DOI 10.1002/syn.890120104; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; Caine SB, 1998, NAT NEUROSCI, V1, P90, DOI 10.1038/335; CARROLL FI, 1995, J MED CHEM, V38, P379, DOI 10.1021/jm00002a020; Carroll FI, 1997, NEUROTRANSMITTER TRA, P263; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Eshleman AJ, 1999, J PHARMACOL EXP THER, V289, P877; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; GETHER U, 1995, J BIOL CHEM, V270, P28268; Giros B, 1996, NATURE, V379, P606, DOI 10.1038/379606a0; GIROS B, 1994, J BIOL CHEM, V269, P15985; GIROS B, 1993, TRENDS PHARMACOL SCI, V14, P43, DOI 10.1016/0165-6147(93)90029-J; HORN AS, 1990, PROG NEUROBIOL, V34, P387, DOI 10.1016/0301-0082(90)90033-D; Itokawa M, 2000, MOL PHARMACOL, V57, P1093; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, DOI [10.1007/978-1-4757-3061-6, 10.1007/978-1-4757-3061-6_6, DOI 10.1007/978-1-4757-3061-6_6]; Lin ZC, 2000, FASEB J, V14, P715, DOI 10.1096/fasebj.14.5.715; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; LONDON E, 1986, ANAL BIOCHEM, V154, P57, DOI 10.1016/0003-2697(86)90495-1; Nelson N, 1998, J NEUROCHEM, V71, P1785; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; POVLOCK SL, 1997, NEUROTRANSMITTER TRA, P1; RITZ MC, 1987, SCIENCE, V237, P1219, DOI 10.1126/science.2820058; Rocha BA, 1998, NAT NEUROSCI, V1, P132, DOI 10.1038/381; ROTHMAN RB, 1994, J PHARMACOL EXP THER, V270, P296; Tate CG, 1999, J BIOL CHEM, V274, P17551, DOI 10.1074/jbc.274.25.17551; TATE CG, 1994, J BIOL CHEM, V269, P26303; TOTA MR, 1990, J BIOL CHEM, V265, P16891; Turcatti G, 1997, J BIOL CHEM, V272, P21167, DOI 10.1074/jbc.272.34.21167; VAUGHAN RA, 1995, MOL PHARMACOL, V47, P956; Wise RA, 1996, ANNU REV NEUROSCI, V19, P319, DOI 10.1146/annurev.ne.19.030196.001535; Xu F, 2000, NAT NEUROSCI, V3, P465, DOI 10.1038/74839	35	26	29	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4717	4723		10.1074/jbc.M008067200	http://dx.doi.org/10.1074/jbc.M008067200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11062247	hybrid			2022-12-25	WOS:000168484300027
J	Rudolph, AE; Porche-Sorbet, R; Miletich, JP				Rudolph, AE; Porche-Sorbet, R; Miletich, JP			Definition of a factor Va binding site in factor Xa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RUSSELLS VIPER VENOM; TISSUE FACTOR; PROTHROMBINASE COMPLEX; ACTIVE-SITE; COAGULATION INHIBITOR; ANTITHROMBIN-III; PROTEASE DOMAIN; FACTOR VIIIA; FACTOR IXA; HEPARIN	We reported previously that residue 347 in activated fX (fXa) contributes to binding of the cofactor, factor Va (fVa) (Rudolph, A. E., Porche-Sorbet, R. and Miletich, J. P. (2000) Biochemistry 39, 2861-2867). Four additional residues that participate in Na binding have now been identified by mutagenesis. All five resulting fX species, fX(R306A), fX(E310N), fX(R347N), fX(K351A), and fX(K414A), are activated and inhibited normally. However, the rate of inhibition by antithrombin III in the presence of submaximal concentrations of heparin is reduced for all the enzymes. In the absence of fVa, all of the enzymes bind and activate prothrombin similarly except fXa(E310N), which has a reduced apparent affinity (similar to3-fold) for prothrombin compared with wild type fXa (fXa(WT)). In the absence of phospholipid, fVa enhances the catalytic activity of fXa(WT) significantly, but the response of the variant enzymes was greatly diminished. On addition of 100 nm PC:PS (3:1) vesicles, fVa enhanced fXa(WT), fXa(R306A), and fXa(E310N) similarly, whereas fXa(R347N), fXa(K351A), and fXa(K414A) demonstrated near-normal catalytic activity but reduced apparent affinity for fVa under these conditions. All enzymes function similarly to fXa(WT) on activated platelets, which provide saturating fVa on an ideal surface. Loss of binding affinity for fVa as a result of the substitutions in residues Arg-347, Lys-351, and Lys-414 was verified by a competition binding assay. Thus, Arg-347, Lys-351, and Lys-414 are likely part of a core fVa binding site, whereas Arg-306 and Glu-310 serve a less critical role.	Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, Div Lab Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Rudolph, AE (corresponding author), Pharmacia Corp, 800 N Lindbergh Blvd, St Louis, MO 63167 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL14147] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bajaj SP, 1999, THROMB HAEMOSTASIS, V82, P218; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; BROZE GJ, 1984, J CLIN INVEST, V73, P933, DOI 10.1172/JCI111317; BROZE GJ, 1988, BLOOD, V71, P335; CHATTOPADHYAY A, 1992, J BIOL CHEM, V267, P12323; CRAIG PA, 1989, J BIOL CHEM, V264, P5452; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; GIRARD TJ, 1989, NATURE, V338, P518, DOI 10.1038/338518a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HUANG ZF, 1993, J BIOL CHEM, V268, P26950; HUSTEN EJ, 1987, J BIOL CHEM, V262, P12953; JESTY J, 1974, J BIOL CHEM, V249, P5614; KISIEL W, 1976, BIOCHEMISTRY-US, V15, P4901, DOI 10.1021/bi00667a023; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Mathus A, 1999, J BIOL CHEM, V274, P18477, DOI 10.1074/jbc.274.26.18477; NEMERSON Y, 1982, PROG HEMOST THROMB, V6, P237; NEMERSON Y, 1986, BLOOD, V71, P1; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OWEN BA, 1990, BIOCHEMISTRY-US, V29, P9412, DOI 10.1021/bi00492a015; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PFEIFFER RA, 1982, HUM GENET, V62, P358, DOI 10.1007/BF00304557; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; Rudolph AE, 1996, J BIOL CHEM, V271, P28601, DOI 10.1074/jbc.271.45.28601; Rudolph AE, 2000, BIOCHEMISTRY-US, V39, P2861, DOI 10.1021/bi992379b; Rudolph AE, 1997, PROTEIN EXPRES PURIF, V10, P373, DOI 10.1006/prep.1997.0752; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; WALKER RK, 1993, J BIOL CHEM, V268, P13920	32	37	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5123	5128		10.1074/jbc.M006961200	http://dx.doi.org/10.1074/jbc.M006961200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087737	hybrid			2022-12-25	WOS:000168484300080
J	Massillon, D				Massillon, D			Regulation of the glucose-6-phosphatase gene by glucose occurs by transcriptional and post-transcriptional mechanisms - Differential effect of glucose and xylitol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; PENTOSE-PHOSPHATE PATHWAY; 3' UNTRANSLATED REGION; WHITE ADIPOSE-TISSUE; FATTY-ACID-SYNTHASE; CELLS IN-VITRO; MESSENGER-RNA; RAT HEPATOCYTES; CONSCIOUS RATS; LIVER GLUCOSE-6-PHOSPHATASE	To understand how glucose regulates the expression of the glucose-6-phosphatase gene, the effect of glucose was studied in primary cultures of rat hepatocytes. Glucose-8-phosphatase mRNA levels increased about 10-fold when hepatocytes were incubated with 20 mM glucose. The rate of transcription of the glucose-6-phosphatase gene increased about 3-fold in hepatocytes incubated with glucose. The half-life of glucose-6-phosphatase mRNA was estimated to be 90 min in the absence of glucose and 3 h in its presence. Inhibition of the oxidative and the nonoxidative branches of the pentose phosphate pathway blocked the stimulation of glucose-6-phosphatase expression by glucose but not by xylitol or carbohydrates that enter the glycolytic/gluconeogenic pathways at the level of the triose phosphates. These results indicate that (i) the glucose induction of the mRNA for the catalytic unit of glucose-6-phosphatase occurs by transcriptional and post-transcriptional mechanisms and that (ii) xylitol and glucose increase the expression of this gene through different signaling pathways.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA	Case Western Reserve University	Massillon, D (corresponding author), Case Western Reserve Univ, Sch Med, Dept Nutr, 10900 Euclid Ave, Cleveland, OH 44106 USA.	dxm71@po.cwru.edu						ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ARION WJ, 1980, J BIOL CHEM, V255, P396; BARZILAI N, 1995, BIOCHEM J, V310, P819, DOI 10.1042/bj3100819; BERGMEYER HU, METHODS ENZYMATIC AN, P266; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BOHJANEN PR, 1992, J BIOL CHEM, V267, P6302; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; Boros LG, 1997, CANCER RES, V57, P4242; Braun L, 1996, FEBS LETT, V390, P183, DOI 10.1016/0014-5793(96)00654-0; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BURCELIN R, 1992, BIOCHEM J, V288, P675, DOI 10.1042/bj2880675; BURCHELL A, 1990, FASEB J, V4, P2978, DOI 10.1096/fasebj.4.12.2168325; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CARMONA A, 1990, INT J BIOCHEM, V22, P595, DOI 10.1016/0020-711X(90)90034-Z; CLEVELAND D W, 1989, New Biologist, V1, P121; COPER H, 1964, BIOCHIM BIOPHYS ACTA, V89, P23, DOI 10.1016/0926-6569(64)90097-5; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; Doiron B, 1996, J BIOL CHEM, V271, P5321, DOI 10.1074/jbc.271.10.5321; Downs SM, 1998, BIOL REPROD, V58, P1084, DOI 10.1095/biolreprod58.4.1084; Dupriez VJ, 1997, DNA CELL BIOL, V16, P1075, DOI 10.1089/dna.1997.16.1075; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; FOUFELLE F, 1994, EUR J BIOCHEM, V223, P893, DOI 10.1111/j.1432-1033.1994.tb19066.x; FOUFELLE F, 1992, ADV ENZYME REGUL, V36, P199; GARDNER LB, 1993, DIABETES, V42, P1614, DOI 10.2337/diabetes.42.11.1614; HASHIZUME K, 1975, ENDOCRINOLOGY, V97, P962, DOI 10.1210/endo-97-4-962; JAKOB A, 1971, J BIOL CHEM, V246, P7623; Kahn A, 1997, BIOCHIMIE, V79, P113, DOI 10.1016/S0300-9084(97)81501-5; KAHN CR, 1989, MOL ENDOCRINOL, V3, P840, DOI 10.1210/mend-3-5-840; Kang RJ, 1996, J BIOCHEM-TOKYO, V119, P162; KOHLER E, 1970, FEBS LETT, V6, P225, DOI 10.1016/0014-5793(70)80063-1; LANGE AJ, 1994, BIOCHEM BIOPH RES CO, V201, P302, DOI 10.1006/bbrc.1994.1702; Leffert H L, 1979, Methods Enzymol, V58, P536; LEFRANCOISMARTINEZ AM, 1995, J BIOL CHEM, V270, P2640, DOI 10.1074/jbc.270.6.2640; Liu YQ, 1996, J BIOL CHEM, V271, P8824, DOI 10.1074/jbc.271.15.8824; LIU ZQ, 1994, BIOCHEM BIOPH RES CO, V205, P680, DOI 10.1006/bbrc.1994.2719; Massillon D, 1998, J BIOL CHEM, V273, P228, DOI 10.1074/jbc.273.1.228; Massillon D, 1996, J BIOL CHEM, V271, P9871, DOI 10.1074/jbc.271.17.9871; Mitanchez D, 1997, ENDOCR REV, V18, P520, DOI 10.1210/er.18.4.520; Mourrieras F, 1997, BIOCHEM J, V326, P345, DOI 10.1042/bj3260345; MUNNICH A, 1984, J BIOL CHEM, V259, P228; NISHIMURA M, 1995, J BIOL CHEM, V270, P26341, DOI 10.1074/jbc.270.44.26341; NORDLIE RC, 1993, P SOC EXP BIOL MED, V203, P274; NORDLIE RC, 1976, GLUCONEOGENESIS ITS, P93; PRIPBUUS C, 1995, EUR J BIOCHEM, V230, P309, DOI 10.1111/j.1432-1033.1995.tb20564.x; Rencurel F, 1996, BIOCHEM J, V314, P903, DOI 10.1042/bj3140903; ROSSETTI L, 1993, J CLIN INVEST, V92, P1126, DOI 10.1172/JCI116681; Street JC, 1996, J BIOL CHEM, V271, P4113; Street JC, 1997, CANCER RES, V57, P3956; SUDO J, 1984, JPN J PHARMACOL, V36, P491, DOI 10.1254/jjp.36.491; SUKALSKI KA, 1989, ADV ENZYMOL RAMB, V62, P93; VANDEWERVE G, 1989, J BIOL CHEM, V264, P6033; VAULONT S, 1986, J BIOL CHEM, V261, P7621; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; VINCENT MF, 1989, FASEB J, V3, P1855, DOI 10.1096/fasebj.3.7.2523832; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931	55	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4055	4062		10.1074/jbc.M007939200	http://dx.doi.org/10.1074/jbc.M007939200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11087741	hybrid			2022-12-25	WOS:000166921200045
J	Moukil, MA; Van Schaftingen, E				Moukil, MA; Van Schaftingen, E			Analysis of the cooperativity of human beta-cell glucokinase through the stimulatory effect of glucose on fructose phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER GLUCOKINASE; HEXOKINASE-D GLUCOKINASE; MECHANISTIC ORIGIN; CO-OPERATIVITY; PHOSPHATE; ENZYMES; EXPRESSION; BEHAVIOR; KINETICS; BINDING	Using overexpressed Escherichia coli sorbitol-6-phosphate dehydrogenase to monitor fructose 6-phosphate formation, we found that the stimulation of fructose phosphorylation by glucose was reduced in two human beta -cell glucokinase mutants with a low Hill coefficient or when the activity of wild type glucokinase was decreased by replacing ATP with poorer nucleotide substrates. Mutation of two other residues, neighboring glucose-binding residues in the catalytic site, also reduced the affinity for glucose as a stimulator of fructose phosphorylation. Among a series of glucose analogs, only 3, all substrates of glucokinase, stimulated fructose phosphorylation; other analogs were either inactive or inhibited glucokinase. Glucose increased the apparent affinity for inhibitors that are glucose analogs but not for the glucokinase regulatory protein or palmitoyl-CoA. These data indicate that the stimulatory effect of glucose on fructose phosphorylation reflects the positive cooperativity for glucose and is mediated by binding of glucose to the catalytic site. They support models involving the existence of two slowly interconverting conformations of glucokinase that differ through their affinity for glucose and for glucose analogs. me show by computer simulation that such a model can account for the kinetic properties of glucokinase, including the differential ability of mannoheptulose and N-acetylglucosamine to suppress cooperativity.	Catholic Univ Louvain, B-1200 Brussels, Belgium; Christian de Duve Inst Cellular Pathol, Chim Physiol Lab, B-1200 Brussels, Belgium	Universite Catholique Louvain	Van Schaftingen, E (corresponding author), Catholic Univ Louvain, 7539 Ave Hippocrate 75, B-1200 Brussels, Belgium.	vanschaftingen@bchm.ucl.ac.be	Van+Schaftingen, Emile/AAF-5532-2020	Van Schaftingen, Emile/0000-0002-6199-7647				Agius L, 2000, BIOCHEM J, V346, P413, DOI 10.1042/0264-6021:3460413; Aleshin AE, 1998, J MOL BIOL, V282, P345, DOI 10.1006/jmbi.1998.2017; ANDERSON CM, 1978, J MOL BIOL, V123, P207, DOI 10.1016/0022-2836(78)90321-2; BERGMEYER HU, 1988, METHOD ENZYMAT AN, V6, P169; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARDENAS ML, 1978, ARCH BIOCHEM BIOPHYS, V190, P142, DOI 10.1016/0003-9861(78)90261-8; CARDENAS ML, 1984, BIOCHEM J, V222, P363, DOI 10.1042/bj2220363; CHARLES RS, 1994, DIABETES, V43, P784, DOI 10.2337/diab.43.6.784; CONNOLLY BA, 1979, EUR J BIOCHEM, V99, P299, DOI 10.1111/j.1432-1033.1979.tb13257.x; CORNISHBOWDEN A, 1987, J THEOR BIOL, V124, P1, DOI 10.1016/S0022-5193(87)80248-5; CORNISHBOWDEN A, 1986, BIOCHEM J, V240, P293, DOI 10.1042/bj2400293; DAWSON CM, 1969, BIOCHIM BIOPHYS ACTA, V176, P657, DOI 10.1016/0005-2760(69)90238-0; FERDINAND W, 1966, BIOCHEM J, V98, P278, DOI 10.1042/bj0980278; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; LIN SX, 1990, J BIOL CHEM, V265, P9670; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Moukil MA, 2000, DIABETES, V49, P195, DOI 10.2337/diabetes.49.2.195; NEET KE, 1990, BIOCHEMISTRY-US, V29, P770, DOI 10.1021/bi00455a026; NIEMEYER H, 1975, ENZYME, V20, P321, DOI 10.1159/000458957; PARRY MJ, 1966, BIOCHEM J, V99, P266, DOI 10.1042/bj0990266; PETTERSSON G, 1986, EUR J BIOCHEM, V154, P167, DOI 10.1111/j.1432-1033.1986.tb09374.x; POLLARDKNIGHT D, 1987, BIOCHEM J, V245, P625, DOI 10.1042/bj2450625; RANDLE PJ, 1993, DIABETOLOGIA, V36, P269, DOI 10.1007/BF00400227; Scruel O, 1997, MOL CELL BIOCHEM, V175, P263, DOI 10.1023/A:1006834010660; STORER AC, 1977, BIOCHEM J, V165, P61, DOI 10.1042/bj1650061; STORER AC, 1976, BIOCHEM J, V159, P7, DOI 10.1042/bj1590007; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tiedge M, 2000, ARCH BIOCHEM BIOPHYS, V375, P251, DOI 10.1006/abbi.1999.1666; TIPPETT PS, 1982, J BIOL CHEM, V257, P2839; VEIGADACUNHA M, 1994, EUR J BIOCHEM, V225, P43, DOI 10.1111/j.1432-1033.1994.00043.x; VeigadaCunha M, 1996, DIABETOLOGIA, V39, P1173, DOI 10.1007/BF02658503; XU LZ, 1994, J BIOL CHEM, V269, P27458; YAMADA M, 1987, J BIOL CHEM, V262, P5455	34	25	26	2	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3872	3878		10.1074/jbc.M008722200	http://dx.doi.org/10.1074/jbc.M008722200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11076949	hybrid			2022-12-25	WOS:000166921200022
J	Xu, WP; Mimnaugh, E; Rosser, MFN; Nicchitta, C; Marcu, M; Yarden, Y; Neckers, L				Xu, WP; Mimnaugh, E; Rosser, MFN; Nicchitta, C; Marcu, M; Yarden, Y; Neckers, L			Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by the chaperone protein Hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; HETEROPROTEIN COMPLEX; STRESS PROTEINS; NEU ONCOGENE; ANSAMYCINS; FAMILY; TRANSFORMATION; IDENTIFICATION; EXPRESSION	ErbB receptors are a family of ligand-activated tyrosine kinases that play a central role in proliferation, differentiation, and oncogenesis, ErbB2 is overexpressed in >25% of breast and ovarian cancers and is correlated with poor prognosis. Although ErbB2 and ErbB1 are highly homologous, they respond quite differently to geldanamycin (GA), an antibiotic that is a specific inhibitor of the chaperone protein Hsp90. Thus, although both mature and nascent ErbB2 proteins are down-regulated by GA, only nascent ErbB1 is sensitive to the drug. To reveal the underlying mechanism behind these divergent responses, we made a chimeric receptor (ErbB1/2) composed of the extracellular and transmembrane domains of ErbB1 and the intracellular domain of ErbB2. The ErbB1/2 protein is functional since its kinase activity was stimulated by epidermal growth factor. The sensitivity of ErbB1/2 to GA was similar to that of ErbB2 and unlike that of ErbB1, indicating that the intracellular domain of the chimera confers GA sensitivity. This finding also suggests that the GA sensitivity of mature ErbB2 depends on cytosolic Hsp90, rather than Grp94,a homolog of Hsp90 that is restricted to the lumen of the endoplasmic reticulum, although both chaperones bind to and are inhibited by GA Lack of Grp94 involvement in mediating ErbB2 sensitivity to GA is further suggested by the fact that a GA derivative with low affinity for Grp94 efficiently depleted ErbB2 protein in treated cells. To localize the specific region of ErbB2 that confers GA sensitivity, we made truncated receptors with progressive deletions of the cytoplasmic domain and tested the GA sensitivity of these molecules. We found that ErbB2 constructs containing an intact kinase domain retained GA sensitivity, whereas those lacking the kinase domain (ErbB2/DK) lost responsiveness to GA completely. Hsp90 co-immunoprecipitated with all ErbB2 constructs that were sensitive to GA, but not with ErbB2/DK or ErbB1, Both tyrosine-phosphorylated and non-phosphorylated ErbB2 proteins were similarly sensitive to GA, as was a kinase-dead ErbB2 mutant. These data suggest that Hsp90 uniquely stabilizes ErbB2 via interaction with its kinase domain and that GA stimulates ErbB2 degradation secondary to disruption of ErbB2/Hsp90 association.	NCI, Dept Cell & Canc Biol, Med Branch, NIH, Rockville, MD 20850 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Duke University; Weizmann Institute of Science	Neckers, L (corresponding author), NCI, Dept Cell & Canc Biol, Med Branch, NIH, 9610 Med Ctr Dr,Suite 300, Rockville, MD 20850 USA.		YARDEN, YOSEF/K-1467-2012					BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; Chavany C, 1996, J BIOL CHEM, V271, P4974; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Klapper LN, 1999, P NATL ACAD SCI USA, V96, P4995, DOI 10.1073/pnas.96.9.4995; Klapper LN, 2000, ADV CANCER RES, V77, P25; Klapper LN, 2000, CANCER RES, V60, P3384; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; MIMNAUGH EG, 1995, J BIOL CHEM, V270, P28654, DOI 10.1074/jbc.270.48.28654; Mimnaugh EG, 1996, J BIOL CHEM, V271, P22796, DOI 10.1074/jbc.271.37.22796; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Neckers L, 1999, INVEST NEW DRUG, V17, P361, DOI 10.1023/A:1006382320697; ORourke DM, 1997, P ASSOC AM PHYSICIAN, V109, P209; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Prodromou C, 1997, CELL, V90, P65, DOI 10.1016/S0092-8674(00)80314-1; Rosser MFN, 2000, J BIOL CHEM, V275, P22798, DOI 10.1074/jbc.M001477200; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Sakagami M, 1999, CELL STRESS CHAPERON, V4, P19, DOI 10.1054/csac.1998.0115; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Stein RA, 2000, J MOL EVOL, V50, P397, DOI 10.1007/s002390010043; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WOLTJER RL, 1992, P NATL ACAD SCI USA, V89, P7801, DOI 10.1073/pnas.89.16.7801; Zheng FF, 2000, CANCER RES, V60, P2090	32	308	319	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3702	3708		10.1074/jbc.M006864200	http://dx.doi.org/10.1074/jbc.M006864200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11071886	hybrid			2022-12-25	WOS:000166784900094
J	Pal, S; Datta, K; Khosravi-Far, R; Mukhopadhyay, D				Pal, S; Datta, K; Khosravi-Far, R; Mukhopadhyay, D			Role of protein kinase C zeta in Ras-mediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIH 3T3 CELLS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; TUMOR ANGIOGENESIS; BLOOD-VESSELS; ONCOGENIC RAS; FACTOR GENE; IN-VITRO; MITOGEN; TRANSFORMATION	Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF), a multifunctional cytokine, is regulated by different factors including degree of cell differentiation, hypoxia, and certain oncogenes namely, ras and src, The up-regulation of VPF/VEGF expression by Ras has been found to be through both transcription and mRNA stability. The present study investigates a novel pathway whereby Ras promotes the transcription of VPF/VEGF by activating protein kinase C zeta (PKC zeta), The Res-mediated overexpression of VPF/VEGF was also found to be inhibited by using the antisense or the dominant-negative mutant of PKC zeta In co-transfection assays, by overexpressing oncogenic Ha-Ras (12 V) and PKC zeta, there was an additive effect up to 4-fold in activation of Spl-mediated VPF/VEGF transcription. It has been shown through electrophoretic mobility shift assay that Ras promoted the PKC zeta -induced binding of Spl to the VPF/VEGF promoter. In the presence of PDK-1, a major activating kinase for PKC, the Ras-mediated activation of VPF/VEGF promoter through PKC zeta was further increased, suggesting that PKC zeta can serve as an effector for both Ras and PDK-1, In other experiments, with the use of a dominant-negative mutant of phosphatidylinositol 3-kinase, the activation of VPF/VEGF promoter through Ras, PDK-1, and PKC zeta was completely repressed, indicating phosphatidylinositol 3-kinase as an important component of this pathway. Taken together, these data elucidate the signaling mechanism of Res-mediated VPF/VEGF transcriptional activation through PKC zeta and also provide insight into PKC zeta and Spl-dependent transcriptional regulation of VPF/VEGF.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Pal, S (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave,RN 270H, Boston, MA 02215 USA.		Khosravi-Far, Roya/C-3789-2008		NCI NIH HHS [CA78383, CA 78396] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078383, K01CA078396, R29CA078383] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1994, J BIOL CHEM, V269, P31706; DOMINGUEZ I, 1992, MOL CELL BIOL, V12, P3776, DOI 10.1128/MCB.12.9.3776; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Dvorak H.F., 1984, DEV ONCOL, V22, P96; DVORAK HF, 1990, PROG CLIN BIOL RES, V354, P317; DVORAK HF, 1991, J EXP MED, V174, P1275, DOI 10.1084/jem.174.5.1275; DVORAK HF, 1988, AM J PATHOL, V133, P95; EGAN SE, 1993, NATURE, V365, P781, DOI 10.1038/365781a0; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FINKENZELLER G, 1992, CANCER RES, V52, P4821; FISCHER S, 1995, MOL BRAIN RES, V28, P141, DOI 10.1016/0169-328X(94)00193-I; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Folkman J, 1996, SCI AM, V275, P150, DOI 10.1038/scientificamerican0996-150; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARADA S, 1994, J CLIN INVEST, V93, P2490, DOI 10.1172/JCI117258; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HILL CS, 1993, CELL, V73, P385; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; KHOSRAVIFAR R, 1994, MOL CELL BIOL, V14, P6848, DOI 10.1128/MCB.14.10.6848; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; LEVY AP, 1995, CIRC RES, V76, P758, DOI 10.1161/01.RES.76.5.758; Liao DF, 1997, J BIOL CHEM, V272, P6146, DOI 10.1074/jbc.272.10.6146; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MUKHOPADHYAY D, 1995, CANCER RES, V55, P6161; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; RAK J, 1995, CANCER RES, V55, P4575; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; SCHAAP D, 1993, J BIOL CHEM, V268, P20232; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P273, DOI 10.1016/0968-0004(93)90031-H; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shih SC, 1999, J BIOL CHEM, V274, P15407, DOI 10.1074/jbc.274.22.15407; White FC, 1997, GROWTH FACTORS, V14, P199, DOI 10.3109/08977199709021520; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3	69	67	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2395	2403		10.1074/jbc.M007818200	http://dx.doi.org/10.1074/jbc.M007818200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11060301	hybrid			2022-12-25	WOS:000166784800015
J	Liong, EC; Dou, Y; Scott, EE; Olson, JS; Phillips, GN				Liong, EC; Dou, Y; Scott, EE; Olson, JS; Phillips, GN			Waterproofing the heme pocket - Role of proximal amino acid side chains in preventing hemin loss from myoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPERM WHALE MYOGLOBIN; LIGAND-BINDING; CRYSTAL-STRUCTURE; PROTEIN-STRUCTURE; MUTANT; INTERMEDIATE; APOMYOGLOBIN; DISSOCIATION; METMYOGLOBIN; CAVITIES	The ability of myoglobin to bind oxygen reversibly depends critically on retention of the heme prosthetic group. Globin side chains at the Leu(89)(F4), His(97)(FG3), Ile(99)(FG5), and Leu(104)(G5) positions on the proximal side of the heme pocket strongly influence heme affinity. The roles of these amino acids in preventing heme loss have been examined by determining high resolution structures of 14 different mutants at these positions using x-ray crystallography. Leu(89) and His(97) are important surface amino acids that interact either sterically or electrostatically with the edges of the porphyrin ring, Ile(99) and Leu(104) are located in the interior region of the proximal pocket beneath ring C of the heme prosthetic group. The apolar amino acids Leu(89), Ile(99), and Leu(104) "waterproof" the heme pocket by forming a barrier to solvent penetration, minimizing the size of the proximal cavity, and maintaining a hydrophobic environment. Substitutions with smaller or polar side chains at these positions result in exposure of the heme to solvent, the appearance of crystallographically defined water molecules in or near the proximal pocket, and large increases in the rate of hemin loss. Thus, the naturally occurring amino acid side chains at these positions serve to prevent hydration of the His(93)-Fe(III) bond and are highly conserved in all known myoglobins and hemoglobins.	Rice Univ, Dept Biochem & Cell Biol, Houston, TX 77005 USA; Rice Univ, WM Keck Ctr Computat Biol, Houston, TX 77005 USA	Rice University; Rice University	Phillips, GN (corresponding author), Univ Wisconsin, Dept Biochem, 483 Babcock Dr, Madison, WI 53706 USA.			Olson, John/0000-0002-0760-5403	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047020] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040252] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47020] Funding Source: Medline; NIAMS NIH HHS [AR40252] Funding Source: Medline; NIGMS NIH HHS [GM35649] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonini E., 1971, HEMOGLOBIN MYOGLOBIN; BARRICK D, 1994, BIOCHEMISTRY-US, V33, P6546, DOI 10.1021/bi00187a023; BENSON ES, 1973, BIOCHEMISTRY-US, V12, P2699, DOI 10.1021/bi00738a024; BRAULT D, 1974, BIOCHEMISTRY-US, V13, P4591, DOI 10.1021/bi00719a019; BRUNGER AT, 1992, XPLOR VERSION 3 1; Brunori M, 2000, P NATL ACAD SCI USA, V97, P2058, DOI 10.1073/pnas.040459697; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CARVER TE, 1992, J BIOL CHEM, V267, P14443; Chu K, 2000, NATURE, V403, P921, DOI 10.1038/35002641; COLE SJ, 1970, J AM CHEM SOC, V92, P2991, DOI 10.1021/ja00713a011; COLE SJ, 1971, J AM CHEM SOC, V93, P2153, DOI 10.1021/ja00738a011; DICKERSON RE, 1983, BENJAMIN CUMMINGS SE; DOU Y, 1997, THESIS CASE W RESERV; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; GRIKO YV, 1988, J MOL BIOL, V202, P127, DOI 10.1016/0022-2836(88)90525-6; HARGROVE MS, 1994, J BIOL CHEM, V269, P4207; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11293, DOI 10.1021/bi960371l; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11310, DOI 10.1021/bi9603736; Hargrove MS, 1996, BIOCHEMISTRY-US, V35, P11300, DOI 10.1021/bi960372d; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; LIONG CE, 1999, THESIS RICE U HOUSTO; Ostermann A, 2000, NATURE, V404, P205, DOI 10.1038/35004622; PHILLIPS GN, 1990, PROTEINS, V7, P358, DOI 10.1002/prot.340070407; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; Sack J. S., 1988, J MOL GRAPHICS, V6, P244; Scott EE, 1997, BIOCHEMISTRY-US, V36, P11909, DOI 10.1021/bi970719s; Scott EE, 2001, J BIOL CHEM, V276, P5177, DOI 10.1074/jbc.M008282200; Scott EE, 1998, THESIS RICE U HOUSTO; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; Yang F, 1996, J MOL BIOL, V256, P762, DOI 10.1006/jmbi.1996.0123	34	79	81	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9093	9100		10.1074/jbc.M008593200	http://dx.doi.org/10.1074/jbc.M008593200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11084036	hybrid			2022-12-25	WOS:000167607700065
J	Krykbaev, RA; Liu, WR; Jeffrey, PD; Margolies, MN				Krykbaev, RA; Liu, WR; Jeffrey, PD; Margolies, MN			Phage display-selected sequences of the heavy-chain CDR3 loop of the anti-digoxin antibody 26-10 define a high affinity binding site for position 16-substituted analogs of digoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-GENE LIBRARIES; FINE SPECIFICITY; VARIABLE REGION; FAB FRAGMENT; MUTAGENESIS; MUTATIONS; COMPLEMENTARITY; HUMANIZATION; IMMUNIZATION; REPERTOIRES	The heavy-chain CDR3 region of the high affinity (K-alpha = 1.3 x 10(10) M-1) anti-digoxin monoclonal antibody 26-10 was modified previously to shift its specificity, by substitution of tryptophan 100 by arginine, toward binding analogs of digoxin containing substitutions at position 16. To further change specificity, two 5 mer libraries of the randomly mutagenized phage displayed 26-10 HCDR3 region (positions 94-98) were penned against digoxin-bovine serum albumin (BSA) as well as against 16-acetylgitoxin-BSA. When a mutant Fab that binds 16-substituted analogs preferentially was used as a parent sequence, clones were obtained with affinities for digoxin increased 2-4-fold, by panning on digoxin-BSA yet retaining the specificity shift. Selection on 16-acetylgitoxin-BSA, however, resulted in nine clones that bound gitoxin (16-OH) up to 150-fold higher than the wild-type 26-10, due to a consensus mutation of Ser(H95) to Gly(H95). The residues at both position H95 (serine) and position H100 (tryptophan) contact hapten in the crystal structure of the Fab 26-10-digoxin complex. Thus, by mutating hapten contact residues, it is possible to reorder the combining site of a high affinity antibody, resulting in altered specificity, yet retain or substantially increase the relative affinity for the cross-reactive ligand.	Massachusetts Gen Hosp, Dept Surg, Boston, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA 02129 USA; Mem Sloan Kettering Canc Ctr, Dept Cellular Biochem & Biophys, Crystallog Facil, New York, NY 10021 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Memorial Sloan Kettering Cancer Center	Margolies, MN (corresponding author), Massachusetts Gen Hosp E, Antibody Engn Lab, 149 13th St,Box 31, Charlestown, MA 02129 USA.	mmargolies@partners.org		Jeffrey, Philip/0000-0002-4351-5341	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047415] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL47415] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barbas CF, 1996, TRENDS BIOTECHNOL, V14, P230, DOI 10.1016/0167-7799(96)10029-9; BARBAS CF, 1992, P NATL ACAD SCI USA, V89, P4457, DOI 10.1073/pnas.89.10.4457; BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BARBAS CF, 1991, METHODS COMPANION ME, V2, P119; Chames P, 1998, J IMMUNOL, V161, P5421; CLACKSON T, 1991, NATURE, V352, P624, DOI 10.1038/352624a0; COLLET TA, 1992, P NATL ACAD SCI USA, V89, P10026, DOI 10.1073/pnas.89.21.10026; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; GUSSOW D, 1991, METHOD ENZYMOL, V203, P99; HAWKINS RE, 1992, J MOL BIOL, V226, P889, DOI 10.1016/0022-2836(92)90639-2; Hemminki A, 1998, IMMUNOTECHNOLOGY, V4, P59, DOI 10.1016/S1380-2933(98)00002-5; Hemminki A, 1998, PROTEIN ENG, V11, P311, DOI 10.1093/protein/11.4.311; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; Iba Y, 1998, PROTEIN ENG, V11, P361, DOI 10.1093/protein/11.5.361; JEFFREY PD, 1993, P NATL ACAD SCI USA, V90, P10310, DOI 10.1073/pnas.90.21.10310; Kabat EA, 1991, SEQUENCES PROTEINS I; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSSIE PH, 1994, J IMMUNOL, V152, P146; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MARKS JD, 1992, BIO-TECHNOL, V10, P779, DOI 10.1038/nbt0792-779; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MUDGETTHUNTER M, 1985, MOL IMMUNOL, V22, P477, DOI 10.1016/0161-5890(85)90132-4; MUDGETTHUNTER M, 1982, J IMMUNOL, V129, P1165; NEAR RI, 1991, J IMMUNOL, V146, P627; NOVOTNY J, 1983, BIOCHEMISTRY-US, V22, P1153, DOI 10.1021/bi00274a025; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; Rader C, 1998, P NATL ACAD SCI USA, V95, P8910, DOI 10.1073/pnas.95.15.8910; ROSE DR, 1983, J MOL BIOL, V165, P203, DOI 10.1016/S0022-2836(83)80252-6; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHILDBACH JF, 1994, PROTEIN SCI, V3, P737; SCHILDBACH JF, 1993, PROTEIN SCI, V2, P206; SCHILDBACH JF, 1993, J BIOL CHEM, V268, P21739; SCHILDBACH JF, 1991, J BIOL CHEM, V266, P4640; Sheets MD, 1999, P NATL ACAD SCI USA, V96, P795; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; SHORT MK, 1995, J BIOL CHEM, V270, P28541, DOI 10.1074/jbc.270.48.28541; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; VERHOEYEN M, 1988, SCIENCE, V239, P1534, DOI 10.1126/science.2451287; WATERHOUSE P, 1993, NUCLEIC ACIDS RES, V21, P2265, DOI 10.1093/nar/21.9.2265	40	9	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8149	8158		10.1074/jbc.M008108200	http://dx.doi.org/10.1074/jbc.M008108200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11060305	hybrid			2022-12-25	WOS:000167474900067
J	Sturbois-Balcerzak, B; Stone, SJ; Sreenivas, A; Vance, JE				Sturbois-Balcerzak, B; Stone, SJ; Sreenivas, A; Vance, JE			Structure and expression of the murine phosphatidylserine synthase-1 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; RAT-LIVER; TRANSBILAYER MOVEMENT; INSITU HYBRIDIZATION; BIOSYNTHETIC-ENZYMES; APOPTOTIC CELLS; PLASMA-MEMBRANE; PHOSPHATIDYLETHANOLAMINE; MITOCHONDRIA; PHOSPHOLIPIDS	In mammalian cells, phosphatidylserine is synthesized by two different enzymes, phosphatidylserine synthase (PSS)-1 and -2, via a base exchange reaction in which the head group of a phospholipid (phosphatidylcholine or phosphatidylethanolamine) is replaced by L-serine. Since the amino acid sequences of PSS1 and PSS2 are only similar to 30% identical, it is likely that they are encoded by different genes. We have screened a murine liver genomic DNA library, included in bacterial artificial chromosomes, with full-length murine PSS1 cDNA and isolated a clone containing the majority of the PSS1 gene. This gene spans similar to 35 kilobases and contains 13 exons and 12 introns. The sizes of the exons range from 44 to 1035 base pairs. The gene was localized to chromosome 13 in region B-C1. According to reverse transcriptase-mediated polymerase chain reaction, PSS1 and PSS2 mRNAs were expressed in all murine tissues examined. The mRNA encoding PSS1 was most abundant in kidney, brain, and liver, whereas PSS2 mRNA was most highly expressed in testis. In general agreement with the levels of mRNA expression, the choline exchange activity (contributed by PSS1, but not PSS2) was highest in brain, whereas serine and ethanolamine exchange activities were highest in testis and kidney. The transcriptional initiation site for PSS1 was identified 111 base pairs upstream of the ATG specifying the start of translation. The putative 5'-proximal promoter region of the gene contained no TATA or CAAT box, but did have a high GC content. Isolation of the murine PSS1 gene is a step toward generation of genetically modified mouse models that will help to understand the functions of PSS1 and PSS2 in animal biology.	Univ Alberta, Heritage Med Res Ctr 332, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada	University of Alberta; University of Alberta	Vance, JE (corresponding author), Univ Alberta, Heritage Med Res Ctr 332, Dept Med, Edmonton, AB T6G 2S2, Canada.							Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; BEVERS EM, 1982, EUR J BIOCHEM, V122, P429, DOI 10.1111/j.1432-1033.1982.tb05898.x; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Daleke DL, 2000, BBA-MOL CELL BIOL L, V1486, P108, DOI 10.1016/S1388-1981(00)00052-4; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HUBSCHER G, 1959, BIOCHIM BIOPHYS ACTA, V36, P518, DOI 10.1016/0006-3002(59)90194-5; JELSEMA CL, 1978, J BIOL CHEM, V253, P7960; KADANOGA JT, 1978, TRENDS BIOCHEM SCI, V11, P20; KIM SH, 1986, NUCLEIC ACIDS RES, V14, P3103, DOI 10.1093/nar/14.7.3103; KUGE O, 1986, J BIOL CHEM, V261, P5795; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; MARTIN OC, 1987, J BIOL CHEM, V262, P5890; MOORE TS, 1982, ANNU REV PLANT PHYS, V33, P235, DOI 10.1146/annurev.pp.33.060182.001315; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NIKAWA J, 1987, EUR J BIOCHEM, V167, P7, DOI 10.1111/j.1432-1033.1987.tb13297.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OKADA M, 1994, J BACTERIOL, V176, P7456, DOI 10.1128/JB.176.24.7456-7461.1994; Saito K, 1996, FEBS LETT, V395, P262, DOI 10.1016/0014-5793(96)01049-6; Saito K, 1998, J BIOL CHEM, V273, P17199, DOI 10.1074/jbc.273.27.17199; SCHROIT AJ, 1991, BIOCHIM BIOPHYS ACTA, V1071, P313, DOI 10.1016/0304-4157(91)90019-S; SHIAO YJ, 1995, J BIOL CHEM, V270, P11190, DOI 10.1074/jbc.270.19.11190; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; Stone SJ, 1999, BIOCHEM J, V342, P57, DOI 10.1042/0264-6021:3420057; Stone SJ, 1998, J BIOL CHEM, V273, P7293, DOI 10.1074/jbc.273.13.7293; Stout JG, 1997, J CLIN INVEST, V99, P2232, DOI 10.1172/JCI119397; SUZUKI TT, 1985, J BIOL CHEM, V260, P1394; van de Rijke FM, 2000, J HISTOCHEM CYTOCHEM, V48, P743, DOI 10.1177/002215540004800602; Vance JE, 1998, TRENDS BIOCHEM SCI, V23, P423, DOI 10.1016/S0968-0004(98)01297-3; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1991, J BIOL CHEM, V266, P89; VANCE JE, 1990, J BIOL CHEM, V265, P7248; Vincent P, 1999, FEBS LETT, V464, P80, DOI 10.1016/S0014-5793(99)01682-8; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; VOELKER DR, 1993, J BIOL CHEM, V268, P7069; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4	41	31	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8205	8212		10.1074/jbc.M009776200	http://dx.doi.org/10.1074/jbc.M009776200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11084049	hybrid			2022-12-25	WOS:000167474900074
J	Zhang, YM; Rao, MS; Heath, RJ; Price, AC; Olson, AJ; Rock, CO; White, SW				Zhang, YM; Rao, MS; Heath, RJ; Price, AC; Olson, AJ; Rock, CO; White, SW			Identification and analysis of the acyl carrier protein (ACP) docking site on beta-ketoacyl-ACP synthase III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; ENZYMATIC-SYNTHESIS; MOLECULAR-SURFACES; ACTIVE-SITE; GENE; REDUCTASE; BINDING; FABH	The molecular details that govern the specific interactions between acyl carrier protein (ACP) and the enzymes of fatty acid biosynthesis are unknown. We investigated the mechanism of ACP protein interactions using a computational analysis to dock the NMR structure of ACP with the crystal structure of beta -ketoacyl-ACP synthase III (FabH) and experimentally tested the model by the biochemical analysis of FabH mutants. The activities of the mutants were assessed using both an ACP-dependent and an ACP-independent assay. The ACP interaction surface was defined by mutations that compromised FabH activity in the ACP-dependent assay but had no effect in the ACP-independent assay. ACP docked to a positively charged/hydrophobic patch adjacent to the active site tunnel on FabH, which included a conserved arginine (Arg-249) that was required for ACP docking. Kinetic analysis and direct binding studies between FabH and ACP confirmed the identification of Arg-249 as critical for FabH ACP interaction. Our experiments reveal the significance of the positively charged/hydrophobic patch located adjacent to the active site cavities of the fatty acid biosynthesis enzymes and the high degree of sequence conservation in helix II of ACP across species.	St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; Scripps Research Institute; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Dept Biochem, 332 N Lauderdale St, Memphis, TN 38105 USA.		White, Stephen W/N-8164-2018	Heath, Richard/0000-0002-1795-1254	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034496, R37GM034496] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIGMS NIH HHS [GM34496] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baldock C, 1998, J MOL BIOL, V284, P1529, DOI 10.1006/jmbi.1998.2271; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; CHOTHIA C, 1977, P NATL ACAD SCI USA, V74, P4130, DOI 10.1073/pnas.74.10.4130; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; CRONAN JE, 1982, J BIOL CHEM, V257, P5013; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; Davies C, 2000, STRUCTURE, V8, P185, DOI 10.1016/S0969-2126(00)00094-0; DUNCAN BS, 1993, BIOPOLYMERS, V33, P219, DOI 10.1002/bip.360330204; DUNCAN BS, 1996, 5 ANN C EV PROGR, P411; GALLY HU, 1978, BIOCHEMISTRY-US, V17, P5377, DOI 10.1021/bi00618a009; HEATH RJ, 1995, J BIOL CHEM, V270, P26538, DOI 10.1074/jbc.270.44.26538; Heath RJ, 1996, J BIOL CHEM, V271, P10996, DOI 10.1074/jbc.271.18.10996; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; HILL RB, 1995, THESIS YALE U NEW HA; HOLACK TA, 1988, EUR J BIOCHEM, V179, P9; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P6135, DOI 10.1021/bi00416a046; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; Huang WJ, 1998, EMBO J, V17, P1183, DOI 10.1093/emboj/17.5.1183; JACKOWSKI S, 1987, J BIOL CHEM, V262, P7927; JACKOWSKI S, 1989, J BIOL CHEM, V264, P7324; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIM Y, 1989, BIOCHEMISTRY-US, V28, P8792, DOI 10.1021/bi00448a017; KIM YM, 1991, PROTEIN-STRUCT FUNCT, V8, P377; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; Leesong M, 1996, STRUCTURE, V4, P253, DOI 10.1016/S0969-2126(96)00030-5; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Lipmann F, 1980, Adv Microb Physiol, V21, P227; MAPLE JR, 1994, J COMPUT CHEM, V15, P162, DOI 10.1002/jcc.540150207; MEHLER EL, 1991, PROTEIN ENG, V4, P903, DOI 10.1093/protein/4.8.903; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; More MI, 1996, SCIENCE, V272, P1655, DOI 10.1126/science.272.5268.1655; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Olsen JG, 1999, FEBS LETT, V460, P46, DOI 10.1016/S0014-5793(99)01303-4; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Qiu XY, 1999, J BIOL CHEM, V274, P36465, DOI 10.1074/jbc.274.51.36465; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; Rehm BHA, 1998, J BIOL CHEM, V273, P24044, DOI 10.1074/jbc.273.37.24044; ROCK CO, 1979, J BIOL CHEM, V254, P9778; ROCK CO, 1979, J BIOL CHEM, V254, P7123; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; ROCK CO, 1981, J BIOL CHEM, V256, P2669; Ruf W, 1999, BIOCHEMISTRY-US, V38, P1957, DOI 10.1021/bi982254r; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; SACKMANN U, 1991, EUR J BIOCHEM, V200, P463, DOI 10.1111/j.1432-1033.1991.tb16205.x; Sanner MF, 1996, BIOPOLYMERS, V38, P305, DOI 10.1002/(SICI)1097-0282(199603)38:3<305::AID-BIP4>3.3.CO;2-8; Schaefer AL, 1996, P NATL ACAD SCI USA, V93, P9505, DOI 10.1073/pnas.93.18.9505; SERRE L, 1995, J BIOL CHEM, V270, P12961, DOI 10.1074/jbc.270.22.12961; STERN JR, 1955, METHOD ENZYMOL, V1, P573, DOI 10.1016/0076-6879(55)01100-2; Strynadka NCJ, 1996, NAT STRUCT BIOL, V3, P233, DOI 10.1038/nsb0396-233; TSAY JT, 1992, J BIOL CHEM, V267, P6807; VANAMAN TC, 1968, J BIOL CHEM, V243, P6420; Zhang Y, 1998, J BACTERIOL, V180, P3295, DOI 10.1128/JB.180.13.3295-3303.1998	58	147	149	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8231	8238		10.1074/jbc.M008042200	http://dx.doi.org/10.1074/jbc.M008042200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11078736	hybrid			2022-12-25	WOS:000167474900078
J	Dambly, S; Boutry, M				Dambly, S; Boutry, M			The two major plant plasma membrane H+-ATPases display different regulatory properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-POINT MUTATIONS; C-TERMINAL REGION; SACCHAROMYCES-CEREVISIAE; YEAST GROWTH; PHOSPHORYLATION; BINDING; PROTEINS; ENZYME; 14-3-3-PROTEINS; EXPRESSION	The major plant plasma membrane H+-ATPases fall into two gene categories, subfamilies I and II, However, in many plant tissues, expression of the two subfamilies overlaps, thus precluding individual characterization. Yeast expression of PMA2 and PMA4, representatives of the two plasma membrane H+-ATPase subfamilies in Nicotiana plumbaginifolia, has previously shown that (i) the isoforms have distinct enzymatic properties and that (ii) PMA2 is regulated by phosphorylation of its penultimate residue (Thr) and binds regulatory 14-3-3 proteins, resulting in the displacement of the autoinhibitory C-terminal domain. To obtain insights into regulatory differences between the two subfamilies, we have constructed various chimeric proteins in which the 110 residue C-terminal-encoding region of PMA2 was progressively substituted by the corresponding sequence from PMA4, The PMA2 autoinhibitory domain was localized to a region between residues 851 and 915 and could not be substituted by the corresponding region of PMA4. In contrast to PMA2, PMA4 was poorly phosphorylated at its penultimate residue (Thr) and bound 14-3-3 proteins weakly. The only sequence difference around the phosphorylation site is located two residues upstream of the phosphorylated Thr, It is Ser in PMA2 (as in most members of subfamily I) and His in PMA4 (as in most members of subfamily II). Substitution of His by Ser in PMA4 resulted in an enzyme showing increased phosphorylation status, 14-13-3 binding, and ATPase activity, as well as improved yeast growth. The reverse substitution of Ser by His in PMA2 resulted in the failure of this enzyme to complement the absence of yeast H+-ATPases. These results show that the two plant H+-ATPase subfamilies differ functionally in their regulatory properties.	Univ Catholique Louvain, Unite Biochim Physiol, B-1348 Louvain, Belgium	Universite Catholique Louvain	Boutry, M (corresponding author), Univ Catholique Louvain, Unite Biochim Physiol, Croix Sud 2-20, B-1348 Louvain, Belgium.			Boutry, Marc/0000-0002-2315-6900				Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Camoni L, 2000, J BIOL CHEM, V275, P9919, DOI 10.1074/jbc.275.14.9919; DEXAERDE AD, 1995, J BIOL CHEM, V270, P23828, DOI 10.1074/jbc.270.40.23828; EWING NN, 1994, PLANT PHYSIOL, V106, P547, DOI 10.1104/pp.106.2.547; Finnie C, 1999, PLANT MOL BIOL, V40, P545, DOI 10.1023/A:1006211014713; Fuglsang AT, 1999, J BIOL CHEM, V274, P36774, DOI 10.1074/jbc.274.51.36774; Holtman WL, 2000, FEBS LETT, V474, P48, DOI 10.1016/S0014-5793(00)01575-1; Kinoshita T, 1999, EMBO J, V18, P5548, DOI 10.1093/emboj/18.20.5548; Luo H, 1999, PLANT PHYSIOL, V119, P627, DOI 10.1104/pp.119.2.627; Maudoux O, 2000, J BIOL CHEM, V275, P17762, DOI 10.1074/jbc.M909690199; Moriau L, 1999, PLANT J, V19, P31, DOI 10.1046/j.1365-313X.1999.00495.x; Morsomme P, 1996, EMBO J, V15, P5513, DOI 10.1002/j.1460-2075.1996.tb00936.x; Morsomme P, 2000, BBA-BIOMEMBRANES, V1465, P1, DOI 10.1016/S0005-2736(00)00128-0; Morsomme P, 1998, J BIOL CHEM, V273, P34837, DOI 10.1074/jbc.273.52.34837; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Olsson A, 1998, PLANT PHYSIOL, V118, P551, DOI 10.1104/pp.118.2.551; OUFSTTOLE M, 2000, PLANTA, V210, P715; PALMGREN MG, 1994, J BIOL CHEM, V269, P3027; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; SIKORSKI RS, 1989, GENETICS, V122, P19; SUSSMAN MR, 1994, ANNU REV PLANT PHYS, V45, P211, DOI 10.1146/annurev.pp.45.060194.001235; Svennelid F, 1999, PLANT CELL, V11, P2379, DOI 10.1105/tpc.11.12.2379; TRECO D, 1994, CURRENT PROTOCOLS MO, V2; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhao RM, 2000, PLANT CELL, V12, P535, DOI 10.1105/tpc.12.4.535	26	18	18	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7017	7022		10.1074/jbc.M007740200	http://dx.doi.org/10.1074/jbc.M007740200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11080498	hybrid			2022-12-25	WOS:000167442900023
J	Katagiri, M; Hakeda, Y; Chikazu, D; Ogasawara, T; Takato, T; Kumegawa, M; Nakamura, K; Kawaguchi, H				Katagiri, M; Hakeda, Y; Chikazu, D; Ogasawara, T; Takato, T; Kumegawa, M; Nakamura, K; Kawaguchi, H			Mechanism of stimulation of osteoclastic bone resorption through Gas6/Tyro 3, a receptor tyrosine kinase signaling, in mouse osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; ARREST-SPECIFIC GENE; NF-KAPPA-B; DIFFERENTIATION FACTOR; PROTEIN-S; EXPRESSION; SURVIVAL; LIGAND; GAS6; ACTIVATION	The signaling through receptor tyrosine kinases expressed on mature osteoclasts has recently been suggested to be involved in osteoclastic bone resorption. This study investigated the mechanism and the possible physiological relevance of Gas6/Tyro 3, a receptor tyrosine kinase signaling pathway in osteoclasts in stimulating osteoclastic bone resorption using several mouse culture Systems. Gas6, expressed ubiquitously in bone cells, did not affect the differentiation or the survival of osteoclasts, but stimulated osteoclast function to form resorbed pits on a dentine slice. The expression of its receptor, Tyro 3, was seen only in mature osteoclasts among bone cells. Gas6 up-regulated the phosphorylation of cellular proteins including p42/p44 mitogen-activated protein kinase (MAPK), but not p38 or c-Jun N-terminal kinase MAPK, and increased the kinase activity:of immunoprecipitated Tyro 3 in isolated osteoclasts. The ability of Gas6 to stimulate pit formation resorbed by osteoclasts was abrogated by PD98059, a specific inhibitor of p42/p44 MAPK. In addition, the Gas6 mRNA level in bone marrow was up-regulated by ovariectomy and was reduced by estrogen replacement. These results strongly suggest that Gas6 acts directly on mature osteoclasts through activation of Tyro 3 and p42/p44 MAPK, possibly contributing to the bone loss by estrogen deficiency.	Meikai Univ, Sch Dent, Dept Oral Anat, Sakado, Saitama 3500248, Japan; Univ Tokyo, Grad Sch Med, Dept Orthopaed Surg, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Oral & Maxillofacial Surg, Bunkyo Ku, Tokyo 1138655, Japan	Meikai University; University of Tokyo; University of Tokyo	Kawaguchi, H (corresponding author), Meikai Univ, Sch Dent, Dept Oral Anat, Sakado, Saitama 3500248, Japan.	kawaguchi-ort@h.u-tokyo.ac.jp	Ogasawara, Toru/I-1629-2014	Ogasawara, Toru/0000-0002-2996-081X				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BOYCE BF, 1992, J CLIN INVEST, V90, P1622, DOI 10.1172/JCI116032; Cenci S, 2000, J CLIN INVEST, V105, P1279, DOI 10.1172/JCI8672; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; Chikazu D, 2000, J BIOL CHEM, V275, P31444, DOI 10.1074/jbc.M910132199; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DAI W, 1994, ONCOGENE, V9, P975; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FUJIMOTO J, 1994, ONCOGENE, V9, P693; FULLER K, 1993, J EXP MED, V178, P1733, DOI 10.1084/jem.178.5.1733; Galibert L, 1998, J BIOL CHEM, V273, P34120, DOI 10.1074/jbc.273.51.34120; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Goruppi S, 1996, ONCOGENE, V12, P471; Insogna KL, 1997, J CLIN INVEST, V100, P2476, DOI 10.1172/JCI119790; Iotsova V, 1997, NAT MED, V3, P1285, DOI 10.1038/nm1197-1285; Jimi E, 1998, J BIOL CHEM, V273, P8799, DOI 10.1074/jbc.273.15.8799; Jimi E, 1999, J IMMUNOL, V163, P434; Kawaguchi H, 2000, J BONE MINER RES, V15, P466, DOI 10.1359/jbmr.2000.15.3.466; Kimble RB, 1996, J BIOL CHEM, V271, P28890, DOI 10.1074/jbc.271.46.28890; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAI C, 1994, ONCOGENE, V9, P2567; Lan ZD, 2000, BLOOD, V95, P633, DOI 10.1182/blood.V95.2.633; Lea CK, 1999, ENDOCRINOLOGY, V140, P273, DOI 10.1210/en.140.1.273; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Manabe N, 1999, RHEUMATOLOGY, V38, P714, DOI 10.1093/rheumatology/38.8.714; MANFIOLETTI G, 1993, MOL CELL BIOL, V13, P4976, DOI 10.1128/MCB.13.8.4976; MARK MR, 1994, J BIOL CHEM, V269, P10720; Miyazaki T, 2000, J CELL BIOL, V148, P333, DOI 10.1083/jcb.148.2.333; Nakagawa M, 2000, FEBS LETT, V473, P161, DOI 10.1016/S0014-5793(00)01520-9; Nakamura YS, 1998, STEM CELLS, V16, P229, DOI 10.1002/stem.160229; NAKANO T, 1995, J BIOL CHEM, V270, P5702, DOI 10.1074/jbc.270.11.5702; Nakano T, 1996, FEBS LETT, V387, P78, DOI 10.1016/0014-5793(96)00395-X; Niida S, 1999, J EXP MED, V190, P293, DOI 10.1084/jem.190.2.293; O'Donnell K, 1999, AM J PATHOL, V154, P1171, DOI 10.1016/S0002-9440(10)65369-2; OHASHI K, 1994, ONCOGENE, V9, P699; SCHULZ NT, 1995, MOL BRAIN RES, V28, P273, DOI 10.1016/0169-328X(94)00216-2; Srivastava S, 1998, J CLIN INVEST, V102, P1850, DOI 10.1172/JCI4561; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; TOSHIMA J, 1995, BIOCHEM BIOPH RES CO, V209, P656, DOI 10.1006/bbrc.1995.1549; VARNUM BC, 1995, NATURE, V373, P623, DOI 10.1038/373623a0; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; ZIMMERMANN M, 1983, PAIN, V16, P109, DOI 10.1016/0304-3959(83)90201-4	44	59	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7376	7382		10.1074/jbc.M007393200	http://dx.doi.org/10.1074/jbc.M007393200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11084030	hybrid			2022-12-25	WOS:000167442900071
J	Ramarao, MK; Bianchetta, MJ; Lanken, J; Cohen, JB				Ramarao, MK; Bianchetta, MJ; Lanken, J; Cohen, JB			Role of rapsyn tetratricopeptide repeat and coiled-coil domains in self-association and nicotinic acetylcholine receptor clustering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTSYNAPTIC PROTEIN; ALPHA-SUBUNIT; MEMBRANES; FINGER; TPR	Rapsyn, a 43-kDa peripheral membrane protein of skeletal muscle, is essential for clustering nicotinic acetylcholine receptors (nAChR) in the postsynaptic membrane, Previous studies with rapsyn NH2-terminal fragments fused to green fluorescent protein, expressed in 293T cells along with nAChRs, establish the following: Rapsyn-(1-90), containing the myristoylated amino terminus and two tetratricopeptide repeats (TPRs), was sufficient for self-association at the plasma membrane; rapsyn-(1-287), containing seven TPRs, did not cluster nAChRs; whereas rapsyn-(1-360), containing a coiled-coil domain (rapsyn-(298-331)), clustered nAChRs, To further analyze the role of rapsyn structural domains in self-association and nAChR clustering, we have characterized the clustering properties of additional rapsyn mutants containing deletions and substitutions within the TPR and coiled-coil domains. A mutant lacking the coiled-coil domain alone (rapsyn-(Delta 288-348)), failed to cluster nAChRs, Within the coiled-coil domain neutralization of the charged side chains was tolerated, while alanine substitutions of large hydrophobic residues resulted in the loss of nAChR clustering. Rapsyn self-association requires at least two TPRs, as a single TPR (TPR1 or TPR2 alone) was not sufficient. While TPRs 1 and 2 are sufficient for self-association, they are not necessary, as TPRs 3-7 also formed clusters similar to wild-type rapsyn, Fragments containing TPRs co-localized with full-length rapsyn, while the expressed coiled-coil or RING-MB domain did not, These results are discussed in terms of a homology model of rapsyn, based on the three-dimensional structure of the TPR domain of protein phosphatase 5.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Cohen, JB (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	jonathan_cohen@hms.harvard.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS018458, R01NS019522] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 19522, NS 18458] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		APEL ED, 1995, NEURON, V15, P115, DOI 10.1016/0896-6273(95)90069-1; Apel ED, 1997, NEURON, V18, P623, DOI 10.1016/S0896-6273(00)80303-7; Bezakova G, 1998, MOL CELL NEUROSCI, V11, P274, DOI 10.1006/mcne.1998.0688; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; BRIDGMAN PC, 1987, J CELL BIOL, V105, P1829, DOI 10.1083/jcb.105.4.1829; Buckel A, 1998, ANN NY ACAD SCI, V841, P14, DOI 10.1111/j.1749-6632.1998.tb10906.x; BURDEN SJ, 1983, CELL, V35, P687, DOI 10.1016/0092-8674(83)90101-0; CARR C, 1989, J CELL BIOL, V109, P1753, DOI 10.1083/jcb.109.4.1753; CARR C, 1989, FEBS LETT, V243, P65, DOI 10.1016/0014-5793(89)81219-0; Cartaud A, 1998, J BIOL CHEM, V273, P11321, DOI 10.1074/jbc.273.18.11321; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; FRAIL DE, 1988, J BIOL CHEM, V263, P15602; FREEMONT PS, 1993, ANN NY ACAD SCI, V684, P174, DOI 10.1111/j.1749-6632.1993.tb32280.x; FROEHNER SC, 1991, J CELL BIOL, V114, P1, DOI 10.1083/jcb.114.1.1; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; GAUTAM M, 1995, NATURE, V377, P232, DOI 10.1038/377232a0; Gillespie SKH, 1996, NEURON, V16, P953, DOI 10.1016/S0896-6273(00)80118-X; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; Jabet C, 2000, J BIOL CHEM, V275, P9011, DOI 10.1074/jbc.275.12.9011; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lupas A, 1996, METHOD ENZYMOL, V266, P513; MAIMONE MM, 1993, NEURON, V11, P53, DOI 10.1016/0896-6273(93)90270-2; Maimone MM, 1999, MOL CELL NEUROSCI, V14, P340, DOI 10.1006/mcne.1999.0779; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; Murray D, 1997, STRUCTURE, V5, P985, DOI 10.1016/S0969-2126(97)00251-7; Nautiyal S, 1999, PROTEIN SCI, V8, P84; Ollendorf V, 1997, J BIOL CHEM, V272, P32011, DOI 10.1074/jbc.272.51.32011; OSHEA EK, 2000, CELL, P699; PHILLIPS WD, 1991, J CELL BIOL, V115, P1713, DOI 10.1083/jcb.115.6.1713; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; Ponting CCP, 1996, BIOCHEM J, V314, P1053, DOI 10.1042/bj3141053; Ramarao MK, 1998, P NATL ACAD SCI USA, V95, P4007, DOI 10.1073/pnas.95.7.4007; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SCOTLAND PB, 1993, J CELL BIOL, V123, P719, DOI 10.1083/jcb.123.3.719; Smith RL, 2000, P NATL ACAD SCI USA, V97, P3901, DOI 10.1073/pnas.070506797; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; YU XM, 1994, J NEUROSCI, V14, P785; Zhang H, 1999, PROTEIN SCI, V8, P1658, DOI 10.1110/ps.8.8.1658; Zhou H, 1999, J CELL BIOL, V146, P1133, DOI 10.1083/jcb.146.5.1133	42	97	101	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7475	7483		10.1074/jbc.M009888200	http://dx.doi.org/10.1074/jbc.M009888200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11087759	hybrid			2022-12-25	WOS:000167442900085
J	Slee, EA; Adrain, C; Martin, SJ				Slee, EA; Adrain, C; Martin, SJ			Executioner caspase-3,-6, and-7 perform distinct, non-redundant roles during the demolition phase of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TNF-INDUCED APOPTOSIS; DNA FRAGMENTATION; CYTOCHROME-C; CELL-DEATH; RETINOBLASTOMA PROTEIN; ACTIVATED DNASE; FODRIN CLEAVAGE; BCL-2 ACTION; GRANZYME-B; LAMIN-A	Apoptosis is orchestrated by a family of cysteine proteases known: as the caspases. Fourteen mammalian caspases have been identified, three of which (caspase-3, -6, and -7) are thought to coordinate the execution phase of apoptosis by cleaving multiple structural and repair proteins. However, the relative contributions that the "executioner" caspases make to the demolition of the cell: remains speculative. Here we have used cell-free extracts immune-depleted of either caspase-3, -6, or -7 to examine the caspase requirements for apoptosis-associated proteolysis of 14 caspase substrates as well as nuclear condensation, chromatin margination, and DNA fragmentation. We show that caspase-3 is the primary executioner caspase in this system, necessary for cytochrome c/dATP-inducible cleavage of fodrin, gelsolin, U1 small nuclear ribonucleopretein, DNA fragmentation factor 45 (DFF45)/inhibitor of caspase-activated DNase (ICAD), receptor-interacting protein (RIP), X-linked inhibitor of apoptosis protein (X-IAP), signal transducer and activator of transcription-1 (STAT1), topoisomerase I, vimentin, Rb, and lamin B but not for cleavage of poly(ADP-ribose) polymerase (PARP) or lamin A. In addition, caspase-3 was also essential for apoptosis-associated: chromatin margination, DNA fragmentation, and nuclear collapse in this system. Surprisingly, although caspase-6 and -7 are considered to be important downstream-effector caspases, depletion of either caspase had minimal impact on any of the parameters investigated, calling into question their precise role during the execution phase of apoptosis.	Univ Dublin Trinity Coll, Smurfit Inst, Dept Genet, Mol Cell Biol Lab, Dublin 2, Ireland	Trinity College Dublin			Adrain, Colin/I-6259-2013	Adrain, Colin/0000-0001-7597-4393; Martin, Seamus/0000-0002-8539-3143				Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; CASCIOLAROSEN LA, 1994, J BIOL CHEM, V269, P30757; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Garcia-Calvo M, 1999, CELL DEATH DIFFER, V6, P362, DOI 10.1038/sj.cdd.4400497; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; King P, 1998, J BIOL CHEM, V273, P8699, DOI 10.1074/jbc.273.15.8699; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Martin SJ, 1996, EMBO J, V15, P2407, DOI 10.1002/j.1460-2075.1996.tb00598.x; MARTIN SJ, 1995, EMBO J, V14, P5191, DOI 10.1002/j.1460-2075.1995.tb00203.x; MARTIN SJ, 1995, J BIOL CHEM, V270, P6425, DOI 10.1074/jbc.270.12.6425; Martin SJ, 1996, J BIOL CHEM, V271, P28753, DOI 10.1074/jbc.271.46.28753; McGinnis KM, 1998, J BIOL CHEM, V273, P19993, DOI 10.1074/jbc.273.32.19993; Morishima N, 1999, GENES CELLS, V4, P401, DOI 10.1046/j.1365-2443.1999.00270.x; Nath R, 1996, BIOCHEM J, V319, P683, DOI 10.1042/bj3190683; NEAMATI N, 1995, J IMMUNOL, V154, P3788; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Samejima K, 1999, J BIOL CHEM, V274, P4335, DOI 10.1074/jbc.274.7.4335; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Vanags DM, 1996, J BIOL CHEM, V271, P31075, DOI 10.1074/jbc.271.49.31075; VOELKELJOHNSON C, 1995, J IMMUNOL, V154, P1707; Waterhouse NJ, 1998, CELL DEATH DIFFER, V5, P1051, DOI 10.1038/sj.cdd.4400425; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Zheng TS, 1999, CELL DEATH DIFFER, V6, P1043, DOI 10.1038/sj.cdd.4400593; Zheng TS, 1998, P NATL ACAD SCI USA, V95, P13618, DOI 10.1073/pnas.95.23.13618; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	58	781	804	1	36	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7320	7326		10.1074/jbc.M008363200	http://dx.doi.org/10.1074/jbc.M008363200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11058599	Green Published, hybrid			2022-12-25	WOS:000167442900064
J	Dorfman, R; Walsh, PN				Dorfman, R; Walsh, PN			Noncovalent interactions of the apple 4 domain that mediate coagulation factor XI homodimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA THROMBOPLASTIN ANTECEDENT; MOLECULAR-WEIGHT KININOGEN; BINDING-SITE; ELECTROSTATIC INTERACTIONS; MOLTEN GLOBULE; FACTOR-IX; ACTIVATION; IDENTIFICATION; REDUCTASE; PROTEINS	The Apple 4 (A4) domain of human plasma factor XI (FXI) was used to investigate the process of FXI noncovalent dimer formation. Recombinant 6-histidine-tagged A4 domain proteins were prepared utilizing a bacterial expression system. Purification was accomplished under denaturing conditions, followed by a refolding protocol to facilitate correct disulfide bond formation. Analysis of the A4 domain (C321S mutant) by size exclusion chromatography indicated the presence of a slowly equilibrating reversible monomer-dimer equilibrium. The elution profiles reveal highly symmetrical peaks for both dimeric and monomeric species with elution times that were highly reproducible for varying amounts of both the dimeric and monomeric species. The monomer-dimer equilibrium was found to be dependent upon changes in both pH and salt concentration. Under conditions approximating physiologic salt concentration and pH (20 mM HEPES, 100 mM NaCl, and 1 mM EDTA, pH 7.4), it was determined that the monomer-dimer equilibrium was characterized by a dissociation constant (K-D) value of 229 +/- 26 nM with a calculated DeltaG value of 9.1 kcal/mol. This report identifies electrostatic contributions and the presence of a hydrophobic component that mediate interactions at the A4 domain interface. The rate of dissociation for the recombinant A4 domain C321S mutant was examined by monitoring the increase in 4,4'-dianilino-1,1'-binaphthyl 5,5'-disulfonic acid dipotassium salt fluorescence under dissociating conditions, giving a value for a dissociation rate constant (k(off)) of 4.3 x 10(-3) s(-1).	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Med, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Walsh, PN (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, 3400 N Broad St, Philadelphia, PA 19140 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL064943, R01HL046213, P01HL056914] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56914, HL46213, HL64943] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aoki K, 1997, J BIOL CHEM, V272, P32158, DOI 10.1074/jbc.272.51.32158; ARAKAWA T, 1985, METHOD ENZYMOL, V114, P49; ASAKAI R, 1987, BIOCHEMISTRY-US, V26, P7221, DOI 10.1021/bi00397a004; BAGLIA FA, 1991, J BIOL CHEM, V266, P24190; BAGLIA FA, 1995, J BIOL CHEM, V270, P6734, DOI 10.1074/jbc.270.12.6734; BAGLIA FA, 1992, J BIOL CHEM, V267, P4247; Baglia FA, 1996, J BIOL CHEM, V271, P3652; BAGLIA FA, 1993, J BIOL CHEM, V268, P3838; Baglia FA, 1998, BIOCHEMISTRY-US, V37, P2271, DOI 10.1021/bi972113+; BERNHARDT R, 1988, BIOMED BIOCHIM ACTA, V47, P581; CARREY EA, 1989, PROTEIN STRUCTURE PR, P117; Creighton T. E., 1993, PROTEINS STRUCTURES, P6; CREIGHTON TE, 1992, PROTEIN FOLDING; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; FERSHT A, 1999, STRUCTURE MECH PROTE, P147; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P4508, DOI 10.1021/bi00719a006; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; Gailani D, 1999, BLOOD, V94, p621A; Gallagher CN, 1997, BIOCHEMISTRY-US, V36, P1281, DOI 10.1021/bi961347a; Ho DH, 1998, J BIOL CHEM, V273, P16382, DOI 10.1074/jbc.273.26.16382; Ho DH, 2000, BIOCHEMISTRY-US, V39, P316, DOI 10.1021/bi991851q; JAHICKE R, 1989, PROTEIN STRUCTURE PR, P191; JANIN J, 1988, J MOL BIOL, V204, P155, DOI 10.1016/0022-2836(88)90606-7; KURACHI K, 1977, BIOCHEMISTRY-US, V16, P5831, DOI 10.1021/bi00645a030; Larsen TA, 1998, STRUCT FOLD DES, V6, P421, DOI 10.1016/S0969-2126(98)00044-6; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; Maleki SJ, 1997, BIOCHEMISTRY-US, V36, P6762, DOI 10.1021/bi970262m; Manning LR, 1996, PROTEIN SCI, V5, P775; McCoy AJ, 1997, J MOL BIOL, V268, P570, DOI 10.1006/jmbi.1997.0987; MCMULLEN BA, 1991, BIOCHEMISTRY-US, V30, P2056, DOI 10.1021/bi00222a008; MEIJERS JCM, 1992, BIOCHEMISTRY-US, V31, P4680, DOI 10.1021/bi00134a021; Moulis JM, 1995, BIOCHEMISTRY-US, V34, P16781, DOI 10.1021/bi00051a028; NADLER SG, 1988, ARCH BIOCHEM BIOPHYS, V261, P418, DOI 10.1016/0003-9861(88)90358-X; NAITO K, 1991, J BIOL CHEM, V266, P7353; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; PTITSYN OB, 1994, PROTEIN ENG, V7, P593, DOI 10.1093/protein/7.5.593; SAITO H, 1977, BLOOD, V50, P377; SAXENA VP, 1970, BIOCHEMISTRY-US, V9, P5015; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SHI L, 1994, BIOCHEMISTRY-US, V33, P7536, DOI 10.1021/bi00190a006; SHIMIZU T, 1991, J BIOL CHEM, V266, P3372; STRYER L, 1988, BIOCHEMISTRY-US, P16; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Sudhakar K, 1996, J BIOL CHEM, V271, P23015, DOI 10.1074/jbc.271.38.23015; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; THOMPSON RE, 1977, J CLIN INVEST, V60, P1376, DOI 10.1172/JCI108898; UVERSKY VN, 1993, BIOCHEMISTRY-US, V32, P13288, DOI 10.1021/bi00211a042; VOZNESENSKY AI, 1994, J BIOL CHEM, V269, P15724; WALSH PN, 1981, FED PROC, V40, P2086; Wolberg AS, 1997, BIOCHEMISTRY-US, V36, P4074, DOI 10.1021/bi962274y; Wu J, 1997, PROTEIN SCI, V6, P391; ZIMMERMAN JK, 1971, J BIOL CHEM, V246, P7289	53	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6429	6438		10.1074/jbc.M010340200	http://dx.doi.org/10.1074/jbc.M010340200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11092900	hybrid			2022-12-25	WOS:000167261000049
J	Grimshaw, JPA; Jelesarov, I; Schonfeld, HJ; Christen, P				Grimshaw, JPA; Jelesarov, I; Schonfeld, HJ; Christen, P			Reversible thermal transition in GrpE, the nucleotide exchange factor of the DnaK heat-shock system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE DNAK; ESCHERICHIA-COLI; STRUCTURAL-ANALYSIS; SUBSTRATE PROTEIN; ATP HYDROLYSIS; HSP70; MACHINERY; BINDING; COMPLEX; CYCLE	DnaK, a Hsp70 acting in concert with its co chaperones DnaJ and GrpE, is essential for Escherichia coli to survive environmental stress, including exposure to elevated temperatures. Here we explored the influence of temperature on the structure of the individual components and the functional properties of the chaperone system. GrpE undergoes extensive but fully reversible conformational changes in the physiologically relevant temperature range (transition midpoint at similar to 48 degreesC), as observed with both circular dichroism measurements and differential scanning calorimetry, whereas no thermal transitions occur in DnaK and DnaJ between 15 degreesC and 48 degreesC. The conformational changes in GrpE appear to be important in controlling the interconversion of T-state DnaK (ATP-liganded, low affinity for polypeptide substrates) and R-state DnaK (ADP-liganded, high affinity for polypeptide substrates). The rate of the T --> R conversion of DnaK due to DnaJ triggered ATP hydrolysis follows an Arrhenius temperature dependence. In contrast, the rate of the R --> T conversion due to GrpE catalyzed ADP/ATP exchange increases progressively less with increasing temperature and even decreases at temperatures above similar to 40 degreesC, indicating a temperature-dependent reversible inactivation of GrpE. At heat-shock temperatures, the reversible structural changes of GrpE thus shift DnaK toward its high-affinity R state.	Univ Zurich, Inst Biochem, CH-8057 Zurich, Switzerland; F Hoffmann La Roche & Co Ltd, Pharmaceut Res Metab Dis, CH-4070 Basel, Switzerland	University of Zurich; Roche Holding	Christen, P (corresponding author), Univ Zurich, Inst Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.							ANG D, 1989, J BACTERIOL, V171, P2748, DOI 10.1128/jb.171.5.2748-2755.1989; Banecki B, 1996, J BIOL CHEM, V271, P14840, DOI 10.1074/jbc.271.25.14840; BUCHBERGER A, 1994, NAT STRUCT BIOL, V1, P95, DOI 10.1038/nsb0294-95; Buchberger A, 1999, J BIOL CHEM, V274, P38017, DOI 10.1074/jbc.274.53.38017; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; Diamant S, 1998, BIOCHEMISTRY-US, V37, P9688, DOI 10.1021/bi980338u; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Feifel B, 1996, EUR J BIOCHEM, V237, P318, DOI 10.1111/j.1432-1033.1996.0318n.x; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; HELLEBUST H, 1990, J BACTERIOL, V172, P5030, DOI 10.1128/jb.172.9.5030-5034.1990; HERENDEEN SL, 1979, J BACTERIOL, V139, P185, DOI 10.1128/JB.139.1.185-194.1979; LANDRY SJ, 1992, NATURE, V355, P455, DOI 10.1038/355455a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Manukhov IV, 1999, FEBS LETT, V448, P265, DOI 10.1016/S0014-5793(99)00384-1; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; MONTGOMERY D, 1993, J MOL BIOL, V232, P680, DOI 10.1006/jmbi.1993.1418; Packschies L, 1997, BIOCHEMISTRY-US, V36, P3417, DOI 10.1021/bi962835l; PALLEROS DR, 1994, J BIOL CHEM, V269, P13107; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; Pierpaoli EV, 1998, BIOCHEMISTRY-US, V37, P16741, DOI 10.1021/bi981762y; Pierpaoli EV, 1997, J MOL BIOL, V269, P757, DOI 10.1006/jmbi.1997.1072; Plotnikov VV, 1997, ANAL BIOCHEM, V250, P237, DOI 10.1006/abio.1997.2236; Reid KL, 1996, CELL STRESS CHAPERON, V1, P127, DOI 10.1379/1466-1268(1996)001<0127:PIBMOT>2.3.CO;2; Russell R, 1998, BIOCHEMISTRY-US, V37, P596, DOI 10.1021/bi972025p; SCHMID D, 1992, EUR J BIOCHEM, V208, P699, DOI 10.1111/j.1432-1033.1992.tb17237.x; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schonfeld HJ, 1995, PROG COLL POL SCI S, V99, P7; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Theyssen H, 1996, J MOL BIOL, V263, P657, DOI 10.1006/jmbi.1996.0606; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	36	76	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6098	6104		10.1074/jbc.M009290200	http://dx.doi.org/10.1074/jbc.M009290200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11084044	hybrid			2022-12-25	WOS:000167261000008
J	Dieci, G; Corradini, R; Sforza, S; Marchelli, R; Ottonello, S				Dieci, G; Corradini, R; Sforza, S; Marchelli, R; Ottonello, S			Inhibition of RNA polymerase III elongation by a T-10 peptide nucleic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO TRANSCRIPTION; LAC REPRESSOR; DNA-BINDING; STRAND DISPLACEMENT; GENE-EXPRESSION; SEQUENCE; PNA; RECOGNITION; ELEMENT; CELLS	The terminator elements of eukaryotic class III genes strongly contribute to overall transcription efficiency by allowing fast RNA polymerase III (pol III) recycling. Being constituted by a run of thymidine residues on the coding strand (a poly(dA) tract on the transcribed strand), pol III terminators are expected to form highly stable triple-helix complexes with oligothymine peptide nucleic acids (PNAs). We analyzed the effect of a T-10 PNA on in vitro transcription of three yeast class III genes (coding for two different tRNAs and the U6 small nuclear RNA) having termination signals of at least ten T residues, At nanomolar concentrations, the PNA almost completely inhibited transcription of supercoiled, but not linearized, templates in a sequence-specific manner. The total RNA output of the first transcription cycle was not affected by PNA concentrations strongly inhibiting multiple round transcription. Thus, an impairment of pol III recycling fully accounts for the observed inhibition. As revealed by the size and the state (free or transcription complex-associated) of the RNAs produced in PNA-inhibited reactions, pol III is "roadblocked" by the DNA-PNA adduct before reaching the terminator region. On different templates, the distance between the active site and the leading edge of the arrested polymerase ranged from 10 to 20 base pairs. Given their ability to efficiently block pol III elongation, oligothymine PNAs lend themselves as potential cell growth inhibitors interfering with eukaryotic class III gene transcription.	Univ Parma, Ist Sci Biochim, I-43100 Parma, Italy; Univ Parma, Dipartimento Chim Organ & Ind, I-43100 Parma, Italy	University of Parma; University of Parma	Dieci, G (corresponding author), Univ Parma, Ist Sci Biochim, I-43100 Parma, Italy.	gdieci@unipr.it; s.ottonello@unipr.it	Dieci, Giorgio/B-3434-2012; Corradini, Roberto/K-4791-2015; Sforza, Stefano/AAE-9579-2019	Dieci, Giorgio/0000-0002-8792-3961; Corradini, Roberto/0000-0002-8026-0923; Sforza, Stefano/0000-0001-5559-3411				ALLISON DS, 1985, EMBO J, V4, P2657, DOI 10.1002/j.1460-2075.1985.tb03984.x; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; Bentin T, 1996, BIOCHEMISTRY-US, V35, P8863, DOI 10.1021/bi960436k; Bobkova EV, 1997, J BIOL CHEM, V272, P22832, DOI 10.1074/jbc.272.36.22832; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; CHRISTENSEN L, 1995, J PEPT SCI, V1, P175, DOI DOI 10.1002/PSC.310010304; Cutrona G, 2000, NAT BIOTECHNOL, V18, P300, DOI 10.1038/73745; DEUSCHLE U, 1990, SCIENCE, V248, P480, DOI 10.1126/science.2158670; DEUSCHLE U, 1986, P NATL ACAD SCI USA, V83, P4134, DOI 10.1073/pnas.83.12.4134; Dickinson LA, 1998, P NATL ACAD SCI USA, V95, P12890, DOI 10.1073/pnas.95.22.12890; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; Dieci G, 2000, J MOL BIOL, V299, P601, DOI 10.1006/jmbi.2000.3783; Dieci G, 1996, CELL, V84, P245, DOI 10.1016/S0092-8674(00)80979-4; Faria M, 2000, P NATL ACAD SCI USA, V97, P3862, DOI 10.1073/pnas.97.8.3862; GABRIELSEN OS, 1987, NUCLEIC ACIDS RES, V15, P5699, DOI 10.1093/nar/15.14.5699; GambacortiPasserini C, 1996, BLOOD, V88, P1411, DOI 10.1182/blood.V88.4.1411.bloodjournal8841411; GERLACH VL, 1995, MOL CELL BIOL, V15, P1455; Gottesfeld JM, 1997, NATURE, V387, P202, DOI 10.1038/387202a0; Haaima G, 1996, ANGEW CHEM INT EDIT, V35, P1939; HANVEY JC, 1992, SCIENCE, V258, P1481, DOI 10.1126/science.1279811; JEONG SW, 1995, MOL CELL BIOL, V15, P5929; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; Kassavetis GA, 1998, P NATL ACAD SCI USA, V95, P9196, DOI 10.1073/pnas.95.16.9196; Lagriffoule P, 1997, CHEM-EUR J, V3, P912, DOI 10.1002/chem.19970030613; Larsen HJ, 1996, NUCLEIC ACIDS RES, V24, P458, DOI 10.1093/nar/24.3.458; MATSUZAKI H, 1994, J MOL BIOL, V235, P1173, DOI 10.1006/jmbi.1994.1072; Mologni L, 1999, BIOCHEM BIOPH RES CO, V264, P537, DOI 10.1006/bbrc.1999.1548; NIELSEN PE, 1991, SCIENCE, V254, P1497, DOI 10.1126/science.1962210; Nielsen PE, 1999, CURR OPIN BIOTECH, V10, P71, DOI 10.1016/S0958-1669(99)80013-5; NIELSEN PE, 1993, ANTI-CANCER DRUG DES, V8, P53; NIELSEN PE, 1994, GENE, V149, P139, DOI 10.1016/0378-1119(94)90422-7; Nielsen Peter E., 1994, Journal of Molecular Recognition, V7, P165, DOI 10.1002/jmr.300070303; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; PAVCO PA, 1990, J BIOL CHEM, V265, P9960; Praseuth D, 1999, BBA-GENE STRUCT EXPR, V1489, P181, DOI 10.1016/S0167-4781(99)00149-9; Puschl A, 1998, TETRAHEDRON LETT, V39, P4707, DOI 10.1016/S0040-4039(98)00862-4; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; SELLITTI MA, 1987, P NATL ACAD SCI USA, V84, P3199, DOI 10.1073/pnas.84.10.3199; Sforza S, 1999, EUR J ORG CHEM, V1999, P197; Sforza S, 2000, EUR J ORG CHEM, V2000, P2905; SHI YB, 1988, J MOL BIOL, V199, P277, DOI 10.1016/0022-2836(88)90314-2; VICKERS TA, 1995, NUCLEIC ACIDS RES, V23, P3003; White RJ, 1997, TRENDS BIOCHEM SCI, V22, P77, DOI 10.1016/S0968-0004(96)10067-0; WHITEHALL SK, 1994, J BIOL CHEM, V269, P2299	44	10	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5720	5725		10.1074/jbc.M009367200	http://dx.doi.org/10.1074/jbc.M009367200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11073963	hybrid			2022-12-25	WOS:000167115100044
J	Hirose, K; Kawashima, T; Iwamoto, I; Nosaka, T; Kitamura, T				Hirose, K; Kawashima, T; Iwamoto, I; Nosaka, T; Kitamura, T			MgcRacGAP is involved in cytokinesis through associating with mitotic spindle and midbody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; GAMMA-TUBULIN; HEMATOPOIETIC-CELLS; ACTIN-CYTOSKELETON; EXCHANGE FACTOR; ALPHA-TUBULIN; RHO-GTPASE; RECEPTOR; KINASE; BINDING	We have recently cloned a cDNA for a full-length form of MgcRacGAP. Here we show using anti-MgcRacGAP antibodies that, unlike other known GAPs for Rho family, MgcRacGAP localized to the nucleus in interphase, accumulated to the mitotic spindle in metaphase, and was condensed in the midbody during cytokinesis. Overexpression of an N-terminal deletion mutant resulted in the production of multinucleated cells in HeLa cells. This mutant lost the ability to localize in the mitotic spindle and midbody. MgcRacGAP was also found to bind alpha-, beta, and gamma -tubulins through its N-terminal myosin-like domain. These results indicate that MgcRacGAP dynamically moves during cell cycle progression probably through binding to tubulins and plays critical roles in cytokinesis, Furthermore, using a GAP-inactive mutant, we have shown that the GAP activity of MgcRacGAP is required for cytokinesis, suggesting that inactivation of the Rho family of GTPases may be required for normal progression of cytokinesis.	Univ Tokyo, Inst Med Sci, Div Hematopoiet Factors, Minato Ku, Tokyo 1088639, Japan; Chiba Univ, Sch Med, Dept Internal Med 2, Chiba 2600856, Japan	University of Tokyo; Chiba University	Kitamura, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Hematopoiet Factors, Minato Ku, Tokyo 1088639, Japan.		Kitamura, Toshio/AAA-2071-2021; Hirose, Koichi/I-1506-2017	Hirose, Koichi/0000-0001-7498-9630				ALBRITTON LM, 1989, CELL, V57, P659, DOI 10.1016/0092-8674(89)90134-7; ALEXANDROVA N, 1995, MOL CELL BIOL, V15, P5188; AMIZUKA N, 1992, ARCH HISTOL CYTOL, V55, P77, DOI 10.1679/aohc.55.77; Arar C, 1999, BIOCHEM J, V343, P225, DOI 10.1042/0264-6021:3430225; BAKER BW, 1992, NUCLEIC ACIDS RES, V20, P5234, DOI 10.1093/nar/20.19.5234; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; Chen GC, 1997, GENE DEV, V11, P2958, DOI 10.1101/gad.11.22.2958; Drechsel DN, 1997, CURR BIOL, V7, P12, DOI 10.1016/S0960-9822(06)00023-6; Dutartre H, 1996, J CELL SCI, V109, P367; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Feng Y, 1999, BIOCHEM J, V339, P435, DOI 10.1042/0264-6021:3390435; Glotzer M, 1997, CURR OPIN CELL BIOL, V9, P815, DOI 10.1016/S0955-0674(97)80082-8; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; Guillen N, 1998, J CELL SCI, V111, P1729; Jantsch-Plunger V, 2000, J CELL BIOL, V149, P1391, DOI 10.1083/jcb.149.7.1391; JULIAN M, 1993, J CELL SCI, V105, P145; Kawashima T, 2000, BLOOD, V96, P2116; Kimura K, 2000, J BIOL CHEM, V275, P17233, DOI 10.1074/jbc.C000212200; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larochelle DA, 1996, J CELL BIOL, V133, P1321, DOI 10.1083/jcb.133.6.1321; LEE KS, 1995, MOL CELL BIOL, V15, P7143; MABUCHI I, 1986, INT REV CYTOL, V101, P175, DOI 10.1016/S0074-7696(08)60249-1; Madaule P, 1998, NATURE, V394, P491, DOI 10.1038/28873; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nishimura Y, 1998, FEBS LETT, V441, P121, DOI 10.1016/S0014-5793(98)01531-2; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; PRATT WB, 1989, CANCER RES, V49, pS2222; Prokopenko SN, 1999, GENE DEV, V13, P2301, DOI 10.1101/gad.13.17.2301; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schiebel E, 2000, CURR OPIN CELL BIOL, V12, P113, DOI 10.1016/S0955-0674(99)00064-2; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; SHU HB, 1995, J CELL SCI, V108, P2955; TAKAISHI K, 1995, ONCOGENE, V11, P39; Tatsumoto T, 1999, J CELL BIOL, V147, P921, DOI 10.1083/jcb.147.5.921; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Toure A, 1998, J BIOL CHEM, V273, P6019, DOI 10.1074/jbc.273.11.6019; VAN AL, 1997, GENE DEV, V11, P2295; Wooltorton EJ, 1999, DNA CELL BIOL, V18, P265, DOI 10.1089/104454999315321	46	144	149	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5821	5828		10.1074/jbc.M007252200	http://dx.doi.org/10.1074/jbc.M007252200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11085985	hybrid			2022-12-25	WOS:000167115100057
J	Engstova, H; Zackova, M; Ruzicka, M; Meinhardt, A; Hanus, J; Kramer, R; Jezek, P				Engstova, H; Zackova, M; Ruzicka, M; Meinhardt, A; Hanus, J; Kramer, R; Jezek, P			Natural and azido fatty acids inhibit phosphate transport and activate fatty acid anion uniport mediated by the mitochondrial phosphate carrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BROWN ADIPOSE-TISSUE; UNCOUPLING PROTEIN; HEART-MITOCHONDRIA; ADP/ATP CARRIER; 4-AZIDO-2-NITROPHENYL PHOSPHATE; INORGANIC-PHOSPHATE; NUCLEOTIDE-BINDING; YEAST MITOCHONDRIA; CYCLING MECHANISM; MOLECULAR ASPECTS	The electroneutral P-i uptake via the phosphate carrier (PIC) in rat liver and heart mitochondria is inhibited by fatty acids (FAs), by 12-(4-azido-2-nitrophenylamino)dodecanoic acid (AzDA) and heptylbenzoic acid (similar to1 muM doses) and by lauric, palmitic, or 12-azidododecanoic acids (similar to0.1 mM doses). In turn, reconstituted E. coli-expressed yeast PIC mediated anionic FA uniport with a similar pattern leading to FA cycling and Hf uniport. The kinetics of P-i/P-i exchange on recombinant PIC in the presence of AzDA better corresponded to a competitive inhibition mechanism. Methanephosphonate was identified as a new PIC substrate. Decanephosphonate, butanephosphonate, 4-nitrophenylphosphate, and other P-i analogs were not translocated and did not inhibit P-i transport. However, methylenediphosphonate and iminodi(methylenephosphonate) inhibited both electroneutral P-i uptake and FA cycling via PIG. AzDA analog 16-(4-azido-2-nitrophenylamino)-[H-3(4)]-hexadecanoic acid (H-3-AzHA) bound upon photoactivation to several mitochondrial proteins, including the 30- and 34-kDa bands. The latter was ascribed to PIC due to its specific elution pattern on Blue Sepharose and Affi-Gel. H-3-AzHA photolabeling of recombinant PIC was prevented by methanephosphonate and diphosphonates and after premodification with 4-azido-2-nitrophenylphosphate. Hence, the demonstrated PIC interaction with monovalent long-chain FA anions, but with divalent phosphonates of short chain only, indicates a pattern distinct from that valid for the mitochondrial uncoupling protein-1.	Acad Sci Czech Republ, Inst Physiol, Dept 375, Dept Membrane Transport Biophys, CZ-14220 Prague, Czech Republic; Univ Cologne, Inst Biochem, D-50674 Cologne, Germany; Acad Sci Czech Republ, Isotope Lab, Inst Expt Bot, CZ-14220 Prague, Czech Republic	Czech Academy of Sciences; Institute of Physiology of the Czech Academy of Sciences; University of Cologne; Czech Academy of Sciences; Institute of Experimental Botany of the Czech Academy of Sciences	Jezek, P (corresponding author), Acad Sci Czech Republ, Inst Physiol, Dept 375, Dept Membrane Transport Biophys, Videnska 1083, CZ-14220 Prague, Czech Republic.	jezek@biomed.cas.cz	Ruzicka, Michal/B-8270-2012; Meinhardt, Andrea/P-6161-2014; Engstova, Hana/C-1015-2012; Engstova, Hana/AAF-6522-2020; Jezek, Petr/B-9264-2012	Meinhardt, Andrea/0000-0003-3833-8210; Engstova, Hana/0000-0001-6341-8242; Jezek, Petr/0000-0002-2720-9395; Zackova, Marketa/0000-0002-5504-9851				BEAVIS AD, 1985, J BIOL CHEM, V260, P3424; BISACCIA F, 1984, BIOCHIM BIOPHYS ACTA, V766, P386, DOI 10.1016/0005-2728(84)90254-8; BRUSTOVETSKY N, 1994, J BIOL CHEM, V269, P27329; ElMoualij B, 1997, YEAST, V13, P573, DOI 10.1002/(SICI)1097-0061(199705)13:6<573::AID-YEA107>3.0.CO;2-I; FERREIRA GC, 1993, J BIOENERG BIOMEMBR, V25, P483, DOI 10.1007/BF01108405; FREITAG H, 1978, EUR J BIOCHEM, V83, P53, DOI 10.1111/j.1432-1033.1978.tb12067.x; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Halestrap AP, 2000, BIOCHEM SOC T, V28, P170, DOI 10.1042/bst0280170; Herick K, 1995, PROG CELL R, V5, P83; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jezek P, 1996, J BIOL CHEM, V271, P6199, DOI 10.1074/jbc.271.11.6199; Jezek P, 2000, IUBMB LIFE, V49, P63; JEZEK P, 1990, J BIOL CHEM, V265, P19303; Jezek P, 1997, FEBS LETT, V408, P166, DOI 10.1016/S0014-5793(97)00335-9; Jezek P, 1997, FEBS LETT, V408, P161, DOI 10.1016/S0014-5793(97)00334-7; Jezek P, 1997, J BIOL CHEM, V272, P24272, DOI 10.1074/jbc.272.39.24272; Jezek P, 1998, AM J PHYSIOL-CELL PH, V275, pC496, DOI 10.1152/ajpcell.1998.275.2.C496; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; KAPLAN RS, 1989, METHOD ENZYMOL, V173, P732; King EJ, 1939, BIOCHEM J, V33, P1182, DOI 10.1042/bj0331182; Kramer R, 1996, KIDNEY INT, V49, P947, DOI 10.1038/ki.1996.133; KRAMER R, 1989, BIOCHIM BIOPHYS ACTA, V974, P1, DOI 10.1016/S0005-2728(89)80160-4; KRAMER R, 1994, BBA-BIOENERGETICS, V1185, P1, DOI 10.1016/0005-2728(94)90189-9; LAUQUIN G, 1980, BIOCHEMISTRY-US, V19, P4620, DOI 10.1021/bi00561a013; Modriansky M, 1997, J BIOL CHEM, V272, P24759, DOI 10.1074/jbc.272.40.24759; PALMIERI F, 1993, J BIOENERG BIOMEMBR, V25, P493, DOI 10.1007/BF01108406; Phelps A, 1996, BIOCHEMISTRY-US, V35, P10757, DOI 10.1021/bi961052x; ROJO M, 1994, BBA-BIOENERGETICS, V1187, P360, DOI 10.1016/0005-2728(94)90010-8; Ruzicka M, 1996, FEBS LETT, V382, P239, DOI 10.1016/0014-5793(96)00161-5; SCHALLER H, 1978, ACTA BIOL MED GER, V37, P31; Schonfeld P, 1997, FEBS LETT, V420, P167, DOI 10.1016/S0014-5793(97)01511-1; Schonfeld P, 1996, EUR J BIOCHEM, V240, P387, DOI 10.1111/j.1432-1033.1996.0387h.x; Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269; Schroers A, 1997, J BIOL CHEM, V272, P10558; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; STAPPEN R, 1993, BIOCHIM BIOPHYS ACTA, V1149, P40, DOI 10.1016/0005-2736(93)90022-R; STAPPEN R, 1994, J BIOL CHEM, V269, P11240; TOMMASINO M, 1987, BIOCHIM BIOPHYS ACTA, V890, P39, DOI 10.1016/0005-2728(87)90066-1; WALKER JE, 1993, J BIOENERG BIOMEMBR, V25, P435, DOI 10.1007/BF01108401; Wieckowski MR, 1997, BIOCHEM BIOPH RES CO, V232, P414; Winkler E, 1997, BIOCHEMISTRY-US, V36, P148, DOI 10.1021/bi962178x; WOHLRAB H, 1986, BIOCHIM BIOPHYS ACTA, V853, P115, DOI 10.1016/0304-4173(86)90007-8; WOJTCZAK L, 1979, FUNCTION MOL ASPECTS, P327; Zackova M, 2000, INT J BIOCHEM CELL B, V32, P499, DOI 10.1016/S1357-2725(00)00006-6	45	20	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4683	4691		10.1074/jbc.M009409200	http://dx.doi.org/10.1074/jbc.M009409200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11085992	hybrid			2022-12-25	WOS:000168484300023
J	Frantz, S; Kelly, RA; Bourcier, T				Frantz, S; Kelly, RA; Bourcier, T			Role of TLR-8 in the activation of nuclear factor kappa B by oxidative stress in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; CUTTING EDGE; SIGNALING PATHWAY; CELL ACTIVATION; DROSOPHILA TOLL; INNATE IMMUNITY; MUSCLE-CELLS; APOPTOSIS; LIPOPOLYSACCHARIDE; LIPOPROTEINS	Growing evidence from patients with heart failure and from experimental animal models implicates effecters of innate immunity in the pathogenesis of this syndrome. The expression of the innate immunity signaling protein, Toll-like receptor 4 (TLR4), is increased in cardiac myocytes in situ and in failing myocardium, but the mechanism by which TLRs may be activated in the failing heart remains unclear. We report that TLR2, which is expressed in cardiac myocytes, participates in the response of these cells to oxidative stress, a major contributor to the pathogenesis of cardiac dysfunction. Hydrogen peroxide increased nuclear factor kappaB (NF-kappaB) activation in Chinese hamster ovary fibroblasts that overexpress TLR2 but not in normal or TLR4-overexpressing Chinese hamster ovary cells, an effect that was abrogated by an alpha -TLR2 antibody. In neonatal rat ventricular myocytes, the alpha -TLR2 antibody inhibited hydrogen peroxide-induced nuclear translocation of NF-kappaB and activator protein-1 (AP-1), Inhibition of TLR2 had no effect on tumor necrosis factor alpha -induced NF-kappaB or AP-1 activation, on the DNA binding of the basal transcription factor Oct-1, or on hydrogen peroxide-induced phosphorylation of p38 MAP kinase. Importantly, oxidative stress-induced cytotoxicity was enhanced by blocking TLR2. Given the importance of cytotoxicity and apoptosis to the pathology of the ischemic heart, an anti-apoptotic effect of TLR2 in cardiac myocytes exposed to elevated levels of ROS may limit further cardiac dysfunction.	Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Bourcier, T (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.		Frantz, Stefan/G-1723-2012		NHLBI NIH HHS [HL52320, HL36141] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036141, R37HL036141, P50HL052320] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aliprantis AO, 2000, EMBO J, V19, P3325, DOI 10.1093/emboj/19.13.3325; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Anversa P, 1998, LAB INVEST, V78, P767; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; BOURCIER T, 1999, METHODS MOL MED VASC, P159; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Frantz S, 1999, J CLIN INVEST, V104, P271, DOI 10.1172/JCI6709; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Heine H, 1999, J IMMUNOL, V162, P6971; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Hoshino K, 1999, J IMMUNOL, V162, P3749; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Kapadia Samir, 1998, Cardiology Clinics, V16, P645, DOI 10.1016/S0733-8651(05)70041-2; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Matzinger P, 1998, SEMIN IMMUNOL, V10, P399, DOI 10.1006/smim.1998.0143; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Mustapha S, 2000, AM J PHYSIOL-HEART C, V279, pH939, DOI 10.1152/ajpheart.2000.279.3.H939; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; PENG M, 1995, CELL MOL BIOL RES, V41, P189; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Schuster JM, 2000, J LEUKOCYTE BIOL, V67, P767, DOI 10.1002/jlb.67.6.767; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Turner NA, 1998, J MOL CELL CARDIOL, V30, P1789, DOI 10.1006/jmcc.1998.0743; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; von Harsdorf R, 1999, CIRCULATION, V99, P2934, DOI 10.1161/01.CIR.99.22.2934; Yang RB, 1999, J IMMUNOL, V163, P639; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	42	229	251	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5197	5203		10.1074/jbc.M009160200	http://dx.doi.org/10.1074/jbc.M009160200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11083876	hybrid			2022-12-25	WOS:000168484300089
J	Kelso, GF; Porteous, CM; Coulter, CV; Hughes, G; Porteous, WK; Ledgerwood, EC; Smith, RAJ; Murphy, MP				Kelso, GF; Porteous, CM; Coulter, CV; Hughes, G; Porteous, WK; Ledgerwood, EC; Smith, RAJ; Murphy, MP			Selective targeting of a redox-active ubiquinone to mitochondria within cells - Antioxidant and antiapoptotic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC ION INTERACTIONS; ALPHA-TOCOPHEROL; VITAMIN-E; MEMBRANE; PEROXYNITRITE; ACTIVATION; APOPTOSIS; OXIDATION; PROTEINS; DISEASES	With the recognition of the central role of mitochondria in apoptosis, there is a need to develop specific tools to manipulate mitochondrial function within cells. Here we report on the development of a novel antioxidant that selectively blocks mitochondrial oxidative damage, enabling the roles of mitochondrial oxidative stress in different types of cell death to be inferred. This antioxidant, named mitoQ, is a ubiquinone derivative targeted to mitochondria by covalent attachment to a lipophilic triphenylphosphonium cation through an aliphatic carbon chain. Due to the large mitochondrial membrane potential, the cation was accumulated within mitochondria inside cells, where the ubiquinone moiety inserted into the lipid bilayer and was reduced by the respiratory chain. The ubiquinol derivative thus formed was an effective antioxidant that prevented lipid peroxidation and protected mitochondria from oxidative damage. After detoxifying a reactive oxygen species, the ubiquinol moiety was regenerated by the respiratory chain enabling its antioxidant activity to be recycled. In cell culture studies, the mitochondrially localized antioxidant protected mammalian cells from hydrogen peroxide-induced apoptosis but not from apoptosis induced by staurosporine or tumor necrosis factor-alpha. This was compared with untargeted ubiquinone analogs, which were ineffective in preventing apoptosis, These results suggest that mitochondrial oxidative stress may be a critical step in apoptosis induced by hydrogen peroxide but not for apoptosis induced by staurosporine or tumor necrosis factor-a, We have shown that selectively manipulating mitochondrial antioxidant status with targeted and recyclable antioxidants is a feasible approach to investigate the role of mitochondrial oxidative damage in apoptotic cell death. This approach will have further applications in investigating mitochondrial dysfunction in a range of experimental models.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Otago, Dept Chem, Dunedin, New Zealand; Univ Otago, Dept Biochem, Dunedin, New Zealand	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Otago; University of Otago	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	michael.murphy@stonebow.otago.ac.nz	Murphy, Michael P/C-2120-2009; Ledgerwood, Elizabeth/M-3939-2018	Murphy, Michael P/0000-0003-1115-9618; Ledgerwood, Elizabeth/0000-0002-4956-6043				AMES BN, 1995, BBA-MOL BASIS DIS, V1271, P165, DOI 10.1016/0925-4439(95)00024-X; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BROWN GC, 1985, BIOCHEM J, V225, P399, DOI 10.1042/bj2250399; BURNS RJ, 1995, ARCH BIOCHEM BIOPHYS, V322, P60, DOI 10.1006/abbi.1995.1436; Burns RJ, 1997, ARCH BIOCHEM BIOPHYS, V339, P33, DOI 10.1006/abbi.1996.9861; CABRINI L, 1981, ARCH BIOCHEM BIOPHYS, V208, P11, DOI 10.1016/0003-9861(81)90117-X; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; CRANE F. L., 1971, Methods in Enzymology, V18C, P137, DOI 10.1016/S0076-6879(71)18022-6; CRANE FL, 1977, ANNU REV BIOCHEM, V46, P439, DOI 10.1146/annurev.bi.46.070177.002255; ERNSTER L, 1992, BIOFACTORS, V3, P241; Faraco PR, 1999, BIOCHEM BIOPH RES CO, V261, P385, DOI 10.1006/bbrc.1999.1042; FLEWELLING RF, 1986, BIOPHYS J, V49, P541, DOI 10.1016/S0006-3495(86)83664-5; FLEWELLING RF, 1986, BIOPHYS J, V49, P531, DOI 10.1016/S0006-3495(86)83663-3; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Grant CM, 1997, FEBS LETT, V410, P219, DOI 10.1016/S0014-5793(97)00592-9; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; INGOLD KU, 1993, P NATL ACAD SCI USA, V90, P45, DOI 10.1073/pnas.90.1.45; KAGAN VE, 1994, METHOD ENZYMOL, V234, P343; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LAND EJ, 1970, J BIOL CHEM, V245, P1890; Lass A, 1998, ARCH BIOCHEM BIOPHYS, V352, P229, DOI 10.1006/abbi.1997.0606; Lass A, 1999, FREE RADICAL BIO MED, V26, P1375, DOI 10.1016/S0891-5849(98)00330-X; LIBERMAN EA, 1969, NATURE, V222, P1076, DOI 10.1038/2221076a0; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; MAGUIRE JJ, 1989, J BIOL CHEM, V264, P21462; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; MUKAI K, 1990, BIOCHIM BIOPHYS ACTA, V1035, P77, DOI 10.1016/0304-4165(90)90176-W; Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; Murphy MP, 1998, GEN PHARMACOL, V31, P179, DOI 10.1016/S0306-3623(97)00418-7; ONO A, 1994, BIOCHEMISTRY-US, V33, P4312, DOI 10.1021/bi00180a027; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1; Schopfer F, 2000, BIOCHEM J, V349, P35, DOI 10.1042/0264-6021:3490035; SCHWERZMANN K, 1986, J CELL BIOL, V102, P97, DOI 10.1083/jcb.102.1.97; SCOTT ID, 1980, BIOCHEM J, V186, P21, DOI 10.1042/bj1860021; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V323, P343, DOI 10.1006/abbi.1995.9955; TAKADA M, 1984, METHOD ENZYMOL, V105, P147; TRIBBLE DL, 1994, P NATL ACAD SCI USA, V91, P1183, DOI 10.1073/pnas.91.3.1183; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; YU CA, 1982, BIOCHEMISTRY-US, V21, P4096, DOI 10.1021/bi00260a028	49	824	884	1	76	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4588	4596		10.1074/jbc.M009093200	http://dx.doi.org/10.1074/jbc.M009093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11092892	hybrid			2022-12-25	WOS:000168484300011
J	Montagna, LG; Ivanov, MI; Bliska, JB				Montagna, LG; Ivanov, MI; Bliska, JB			Identification of residues in the N-terminal domain of the Yersinia tyrosine phosphatase that are critical for substrate recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-AERUGINOSA EXOS; VIRULENCE DETERMINANT; EUKARYOTIC CELLS; FOCAL ADHESIONS; BINDING PROTEIN; YOPH; MECHANISM; CHAPERONES; REGION; PHOSPHORYLATION	YopH is a 468-amino acid protein-tyrosine phosphatase that is produced by pathogenic Yersinia species. YopH is translocated into host mammalian cells via a type III protein secretion system. Translocation of YopH into human epithelial cells results in dephosphorylation of p130(Cas) and paxillin, disruption of focal adhesions, and inhibition of integrin-mediated bacterial phagocytosis, Previous studies have shown that the N-terminal 129 amino acids of YopH comprise a bifunctional domain. This domain binds to the SycH chaperone in Yersinia to orchestrate translocation and to tyrosine-phosphorylated target proteins in host cells to mediate substrate recognition. We used random mutagenesis in combination with the yeast two-hybrid system to identify residues in the YopH N-terminal domain that are involved in substrate-binding activity. Four single codon changes (Q11R, V31G, A33D, and N34D) were identified that interfered with binding of the YopH N-terminal domain to tyrosine-phosphorylated p130(Cas) but not to SycH. These mutations did not impair YopH translocation into HeLa cells infected with Yersinia pseudotuberculosis, Introduction of the V31G substitution into catalytically inactive (substrate-trapping) forms of YopH interfered with the ability of these proteins to bind to p130(Cas) and to localize to focal adhesions in HeLa cells. In addition, the V31G substitution reduced the ability of catalytically active YopH to dephosphorylate target proteins in HeLa cells. These data indicate that the substrate- and SycH-binding activities of the YopH N-terminal domain can be separated and that the former activity is important for recognition and dephosphorylation of substrates by YopH in vivo.	SUNY Stony Brook, Sch Med, Ctr Infect Dis, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Bliska, JB (corresponding author), SUNY Stony Brook, Sch Med, Ctr Infect Dis, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NIAID NIH HHS [AI3389, AI35175] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI035175] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aepfelbacher M, 1999, BIOL CHEM, V380, P795, DOI 10.1515/BC.1999.099; BARTEL PL, 1995, METHOD ENZYMOL, V254, P241; Black DS, 2000, CELL MICROBIOL, V2, P401, DOI 10.1046/j.1462-5822.2000.00061.x; Black DS, 2000, MOL MICROBIOL, V37, P515, DOI 10.1046/j.1365-2958.2000.02021.x; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Black DS, 1998, MOL MICROBIOL, V29, P1263, DOI 10.1046/j.1365-2958.1998.01014.x; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1993, INFECT IMMUN, V61, P3914, DOI 10.1128/IAI.61.9.3914-3921.1993; BLISKA JB, 1995, INFECT IMMUN, V63, P681, DOI 10.1128/IAI.63.2.681-685.1995; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; Bliska JB, 2000, TRENDS MICROBIOL, V8, P205, DOI 10.1016/S0966-842X(00)01738-8; Cambronne ED, 2000, MOL MICROBIOL, V37, P263, DOI 10.1046/j.1365-2958.2000.01974.x; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Fallman M, 1997, J CLIN INVEST, V99, P1153, DOI 10.1172/JCI119270; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; Hamid N, 1999, MICROB PATHOGENESIS, V27, P231, DOI 10.1006/mpat.1999.0301; Harlow E., 1988, ANTIBODIES LABORATOR, P310; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; Keegan K, 1996, ONCOGENE, V12, P1537; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Palmer LE, 1999, INFECT IMMUN, V67, P708, DOI 10.1128/IAI.67.2.708-716.1999; Pederson KJ, 1999, MOL MICROBIOL, V32, P393, DOI 10.1046/j.1365-2958.1999.01359.x; Pederson KJ, 2000, MOL MICROBIOL, V37, P287, DOI 10.1046/j.1365-2958.2000.01990.x; Persson C, 1999, MOL MICROBIOL, V33, P828, DOI 10.1046/j.1365-2958.1999.01529.x; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; PERSSON C, 1995, MOL MICROBIOL, V18, P135, DOI 10.1111/j.1365-2958.1995.mmi_18010135.x; SPEE JH, 1993, NUCLEIC ACIDS RES, V21, P777, DOI 10.1093/nar/21.3.777; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; von Pawel-Rammingen U, 2000, MOL MICROBIOL, V36, P737, DOI 10.1046/j.1365-2958.2000.01898.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WATTIAU P, 1994, P NATL ACAD SCI USA, V91, P10493, DOI 10.1073/pnas.91.22.10493; Wattiau P, 1996, MOL MICROBIOL, V20, P255, DOI 10.1111/j.1365-2958.1996.tb02614.x; Woestyn S, 1996, MOL MICROBIOL, V20, P1261, DOI 10.1111/j.1365-2958.1996.tb02645.x; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P15266, DOI 10.1021/bi00255a007; Zumbihl R, 1999, J BIOL CHEM, V274, P29289, DOI 10.1074/jbc.274.41.29289	37	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5005	5011		10.1074/jbc.M009045200	http://dx.doi.org/10.1074/jbc.M009045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11069923	hybrid			2022-12-25	WOS:000168484300065
J	Scheele, JS; Bruner, E; Zemojtel, T; Martasek, P; Roman, LJ; Masters, BSS; Sharma, VS; Magde, D				Scheele, JS; Bruner, E; Zemojtel, T; Martasek, P; Roman, LJ; Masters, BSS; Sharma, VS; Magde, D			Kinetics of CO and NO ligation with the Cys(331) -> Ala mutant of neuronal nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STOPPED-FLOW SPECTROPHOTOMETRY; SPECTRAL CHARACTERIZATION; FLASH-PHOTOLYSIS; CARBON-MONOXIDE; L-ARGININE; TETRAHYDROBIOPTERIN; HEME; SUBSTRATE; BINDING; HEMOPROTEIN	Nitric-oxide syntheses (NOS) catalyze the conversion of L-arginine to NO, which then stimulates many physiological processes. In the active form, each NOS is a dimer; each strand has both a heme-binding oxygenase domain and a reductase domain. In neuronal NOS (nNOS), there is a conserved cysteine motif (CX4C) that participates in a ZnS4 center, which stabilizes the dimer interface and/or the flavoprotein-heme domain interface. Previously, the Cys(331) --> Ala mutant was produced, and it proved to be inactive in catalysis and to have structural defects that disrupt the binding of L-Arg and tetrahydrobiopterin (BH4). Because binding L-Arg and BH4 to wild type nNOS profoundly affects CO binding with little effect on NO binding, ligand binding to the mutant was characterized as follows. 1) The mutant initially has behavior different from native protein but reminiscent of isolated heme domain subchains. 2) Adding L-Arg and BH4 has little effect immediately but substantial effect after extended incubation. 3) Incubation for 12 h restores behavior similar but not quite identical to that of wild type nNOS. Such incubation was shown previously to restore most but not all catalytic activity. These kinetic studies substantiate the hypothesis that zinc content is related to a structural rather than a catalytic role in maintaining active nNOS.	Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Freiburg, Dept Med, D-79106 Freiburg, Germany; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78284 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of Freiburg; University of Texas System; University of Texas Health San Antonio	Magde, D (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA.		Martásek, Pavel/G-6622-2017; Zemojtel, Tomasz/C-8947-2009	Martásek, Pavel/0000-0001-6165-4444; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030050, R37HL030050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052419] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30050] Funding Source: Medline; NIGMS NIH HHS [GM52419] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Huang LX, 1999, BIOCHEMISTRY-US, V38, P1912, DOI 10.1021/bi981954t; HURSHMAN AR, 1995, BIOCHEMISTRY-US, V34, P5627, DOI 10.1021/bi00016a038; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KWON NS, 1989, J BIOL CHEM, V264, P20496; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; MAYER B, 1990, FEBS LETT, V277, P215, DOI 10.1016/0014-5793(90)80848-D; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; Miller RT, 1999, J BIOL CHEM, V274, P14537, DOI 10.1074/jbc.274.21.14537; Olson J S, 1981, Methods Enzymol, V76, P631; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Renodon A, 1998, BIOCHEMISTRY-US, V37, P6367, DOI 10.1021/bi972297s; Sato H, 1998, FEBS LETT, V430, P377, DOI 10.1016/S0014-5793(98)00699-1; Scheele JS, 1997, J BIOL CHEM, V272, P12523, DOI 10.1074/jbc.272.19.12523; Scheele JS, 1999, J BIOL CHEM, V274, P13105, DOI 10.1074/jbc.274.19.13105; SHARMA VS, 1983, BIOCHEMISTRY-US, V22, P3897, DOI 10.1021/bi00285a026; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; TAYEH MA, 1989, J BIOL CHEM, V264, P19654; Tetreau C, 1999, BIOCHEMISTRY-US, V38, P7210, DOI 10.1021/bi9901026; WANG JL, 1994, P NATL ACAD SCI USA, V91, P10512, DOI 10.1073/pnas.91.22.10512; WANG JL, 1995, BIOCHEMISTRY-US, V34, P7080, DOI 10.1021/bi00021a020; Wang JL, 1997, BIOCHEMISTRY-US, V36, P4595, DOI 10.1021/bi962309u; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001	24	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4733	4736		10.1074/jbc.M007461200	http://dx.doi.org/10.1074/jbc.M007461200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11067850	hybrid			2022-12-25	WOS:000168484300029
J	Steinhusen, U; Weiske, J; Badock, V; Tauber, R; Bommert, K; Huber, O				Steinhusen, U; Weiske, J; Badock, V; Tauber, R; Bommert, K; Huber, O			Cleavage and shedding of E-cadherin after induction of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; TRANSCRIPTION FACTOR LEF-1; CASPASE-MEDIATED CLEAVAGE; PROGRAMMED CELL-DEATH; SOLUBLE E-CADHERIN; BETA-CATENIN; IN-VITRO; PROTEOLYTIC CLEAVAGE; NUCLEAR-LOCALIZATION; ADHERENS JUNCTIONS	Apoptotic cell death induces dramatic molecular changes in cells, becoming apparent on the structural level as membrane blebbing, condensation of the cytoplasm and nucleus, and loss of cell-cell contacts. The activation of caspases is one of the fundamental steps during programmed cell death. Here we report a detailed analysis of the fate of the Ca2+-dependent cell adhesion molecule E-cadherin in apoptotic epithelial cells and show that during apoptosis fragments of E-cadherin with apparent molecular masses of 24, 29, and 84 kDa are generated by two distinct proteolytic activities. In addition to a caspase-3-mediated cleavage releasing the cytoplasmic domain of E-cadherin, a metalloproteinase sheds the extracellular domain from the cell surface during apoptosis, Immunofluorescence analysis confirmed that concomitant with the disappearance of E-cadherin staining at the cell surface, the E-cadherin cytoplasmic domain accumulates in the cytosol, In the presence of inhibitors of caspase-3 and/or metalloproteinases, cleavage of E-cadherin was almost completely blocked. The simultaneous cleavage of the intracellular and extracellular domains of E-cadherin may provide a highly efficient mechanism to disrupt cadherin-mediated cell-cell contacts in apoptotic cells, a prerequisite for cell rounding and exit from the epithelium.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Chem & Pathobiochem, D-12200 Berlin, Germany; Max Delbruck Ctr Mol Med, Dept Med Oncol & Tumorimmunol, D-13092 Berlin, Germany; Max Delbruck Ctr Mol Med, Dept Prot Chem, D-13092 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Huber, O (corresponding author), Free Univ Berlin, Klinikum Benjamin Franklin, Inst Klin Chem & Pathobiochem, Hindenburgdamm 30, D-12200 Berlin, Germany.	Huber@ukbf.fu-berlin.de	Bommert, Kurt/G-9247-2011; Huber, Otmar/AAA-4548-2021	Huber, Otmar/0000-0003-4359-1747				Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; ABERLE H, 1994, J CELL SCI, V107, P3655; BANKS RE, 1995, J CLIN PATHOL, V48, P179, DOI 10.1136/jcp.48.2.179; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brancolini C, 1998, CELL DEATH DIFFER, V5, P1042, DOI 10.1038/sj.cdd.4400443; BRANCOLINI C, 1995, EMBO J, V14, P5179, DOI 10.1002/j.1460-2075.1995.tb00202.x; Brancolini C, 1997, J CELL BIOL, V139, P759, DOI 10.1083/jcb.139.3.759; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Buendia B, 1999, J CELL SCI, V112, P1743; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Crouch DH, 1996, ONCOGENE, V12, P2689; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; EHARDT P, 1997, J BIOL CHEM, V272, P15049; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huber O, 1999, J CELL SCI, V112, P4415; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Kahn J, 1998, CELL, V92, P809, DOI 10.1016/S0092-8674(00)81408-7; Kantak SS, 1998, J BIOL CHEM, V273, P16953, DOI 10.1074/jbc.273.27.16953; KATAYAMA M, 1994, BRIT J CANCER, V69, P580, DOI 10.1038/bjc.1994.106; Kothakota S, 1997, SCIENCE, V278, P294, DOI 10.1126/science.278.5336.294; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; MATSUYOSHI N, 1995, BRIT J DERMATOL, V132, P745; Mittl PRE, 1997, J BIOL CHEM, V272, P6539, DOI 10.1074/jbc.272.10.6539; MOHLER KM, 1994, NATURE, V370, P218, DOI 10.1038/370218a0; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nollet F, 1999, Mol Cell Biol Res Commun, V2, P77, DOI 10.1006/mcbr.1999.0155; Orsulic S, 1999, J CELL SCI, V112, P1237; Orth K, 1996, J BIOL CHEM, V271, P16443, DOI 10.1074/jbc.271.28.16443; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PARADIES NE, 1993, J NEUROSCI RES, V36, P33, DOI 10.1002/jnr.490360105; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sadot E, 1998, P NATL ACAD SCI USA, V95, P15339, DOI 10.1073/pnas.95.26.15339; Schmeiser K, 1998, FEBS LETT, V433, P51, DOI 10.1016/S0014-5793(98)00850-3; Schmeiser K, 1999, CELL DEATH DIFFER, V6, P377, DOI 10.1038/sj.cdd.4400504; Song ZW, 1999, TRENDS CELL BIOL, V9, pM49, DOI 10.1016/S0968-0004(99)01485-1; Steinhusen U, 2000, J BIOL CHEM, V275, P16345, DOI 10.1074/jbc.M001458200; Takahashi A, 1996, J BIOL CHEM, V271, P32487, DOI 10.1074/jbc.271.51.32487; Vallorosi CJ, 2000, J BIOL CHEM, V275, P3328, DOI 10.1074/jbc.275.5.3328; Van de Craen M, 1999, FEBS LETT, V458, P167, DOI 10.1016/S0014-5793(99)01153-9; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; Webb SJ, 1999, FASEB J, V13, P339, DOI 10.1096/fasebj.13.2.339; Wen CH, 1997, DEVELOPMENT, V124, P4759; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; Xue D, 1997, NATURE, V390, P305, DOI 10.1038/36889; Yap AS, 1997, ANNU REV CELL DEV BI, V13, P119, DOI 10.1146/annurev.cellbio.13.1.119	71	211	219	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4972	4980		10.1074/jbc.M006102200	http://dx.doi.org/10.1074/jbc.M006102200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11076937	hybrid			2022-12-25	WOS:000168484300061
J	Wu, Z; Simister, NE				Wu, Z; Simister, NE			Tryptophan- and dileucine-based endocytosis signals in the neonatal Fc receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 INTERNALIZATION SIGNALS; DI-LEUCINE MOTIF; CYTOPLASMIC DOMAIN; IMMUNOGLOBULIN-G; TRANSFERRIN RECEPTOR; INTESTINAL TRANSPORT; BIDIRECTIONAL TRANSCYTOSIS; INTRACELLULAR MOVEMENT; RAPID INTERNALIZATION; CRYSTAL-STRUCTURE	The neonatal Fc receptor, FcRn, transports immunoglobulin G across intestinal cells in suckling rats. FcRn enters these cells by endocytosis and is present on the apical and basolateral surfaces. We investigated the roles of aromatic amino acids and a dileucine motif in the cytoplasmic domain of rat FcRn. We expressed mutant FcRn in which alanine replaced Trp-311, Leu-322, and Leu-323, or Phe-340 in the inner medullary collecting duct cell line IMCD. Individual replacement of the aromatic amino acids or the dileucine motif only partially blocked endocytosis of I-125-Fc, whereas uptake by FcRn containing alanine residues in place of both Trp-311 and the dileucine motif was reduced to the level obtained with the tailless receptor. Leu-314 was required for the function of the tryptophan-based endocytosis signal, and Asp-317 and Asp-318 were required for the dileucine-based signal. Nonvectorial delivery of newly synthesized FcRn to the two cell surfaces was unaffected by loss of the endocytosis signals. However, the steady-state distribution of endocytosis mutants was predominantly apical, unlike wild-type FcRn, which was predominantly basolateral. This shift appeared to arise because the loss of endocytosis signals inhibited apical to basolateral transcytosis of FcRn more than basolateral to apical transcytosis.	Brandeis Univ, WM Keck Inst Cellular Visualizat, Rosenstiel Ctr Basic Biomed Sci, Waltham, MA 02254 USA; Brandeis Univ, Dept Biol, Waltham, MA 02254 USA	Brandeis University; Brandeis University	Simister, NE (corresponding author), Brandeis Univ, WM Keck Inst Cellular Visualizat, Rosenstiel Ctr Basic Biomed Sci, Waltham, MA 02254 USA.	simister@brandeis.edu			NICHD NIH HHS [HD01146, HD27691] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K02HD001146, R01HD027691] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AHOUSE JJ, 1993, J IMMUNOL, V151, P6076; BENLOUNES N, 1995, BIOL NEONATE, V67, P254, DOI 10.1159/000244173; BERRYMAN M, 1995, J CELL SCI, V108, P2347; Borvak J, 1998, INT IMMUNOL, V10, P1289, DOI 10.1093/intimm/10.9.1289; BOS CR, 1995, J BIOL CHEM, V270, P665, DOI 10.1074/jbc.270.2.665; BREITFELD PP, 1990, J BIOL CHEM, V265, P13750; Bresnahan PA, 1998, CURR BIOL, V8, P1235, DOI 10.1016/S0960-9822(07)00517-9; Broadwell RD, 1996, EXP NEUROL, V142, P47, DOI 10.1006/exnr.1996.0178; BURMEISTER WP, 1994, NATURE, V372, P336, DOI 10.1038/372336a0; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; BUTOR C, 1992, EXP CELL RES, V203, P115, DOI 10.1016/0014-4827(92)90046-B; CANFIELD WM, 1991, J BIOL CHEM, V266, P5682; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; DAVIS CG, 1986, CELL, V45, P15, DOI 10.1016/0092-8674(86)90533-7; DAVIS CG, 1987, J BIOL CHEM, V262, P4075; Dietrich J, 1997, J CELL BIOL, V138, P271, DOI 10.1083/jcb.138.2.271; DUNCAN JR, 1988, J CELL BIOL, V106, P617, DOI 10.1083/jcb.106.3.617; Ghetie V, 1996, EUR J IMMUNOL, V26, P690, DOI 10.1002/eji.1830260327; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; Greenberg M, 1998, CURR BIOL, V8, P1239, DOI 10.1016/S0960-9822(07)00518-0; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; HUNZIKER W, 1994, EMBO J, V13, P2963, DOI 10.1002/j.1460-2075.1994.tb06594.x; ISRAEL EJ, 1995, J IMMUNOL, V154, P6246; Israel EJ, 1996, IMMUNOLOGY, V89, P573, DOI 10.1046/j.1365-2567.1996.d01-775.x; JADOT M, 1992, J BIOL CHEM, V267, P11069; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JONES EA, 1972, J CLIN INVEST, V51, P2916, DOI 10.1172/JCI107116; Junghans RP, 1996, P NATL ACAD SCI USA, V93, P5512, DOI 10.1073/pnas.93.11.5512; Kristoffersen EK, 1996, EUR J IMMUNOL, V26, P1668, DOI 10.1002/eji.1830260741; Leach JL, 1996, J IMMUNOL, V157, P3317; LEACH L, 1991, HISTOCHEM J, V23, P444, DOI 10.1007/BF01041374; LETOURNEUR F, 1992, CELL, V69, P1143, DOI 10.1016/0092-8674(92)90636-Q; McCarthy KM, 2000, J CELL SCI, V113, P1277; MCGRAW TE, 1990, CELL REGUL, V1, P369, DOI 10.1091/mbc.1.4.369; MEADS TJ, 1994, PLACENTA, V15, P525, DOI 10.1016/S0143-4004(05)80421-7; MOSTOV KE, 1995, BIOESSAYS, V17, P129, DOI 10.1002/bies.950170208; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; Pitcher C, 1999, MOL BIOL CELL, V10, P677, DOI 10.1091/mbc.10.3.677; Praetor A, 1999, J CELL SCI, V112, P2291; RAGHAVAN M, 1995, P NATL ACAD SCI USA, V92, P11200, DOI 10.1073/pnas.92.24.11200; RAGHAVAN M, 1994, IMMUNITY, V1, P303, DOI 10.1016/1074-7613(94)90082-5; ROBERTS DM, 1990, J CELL BIOL, V111, P1867, DOI 10.1083/jcb.111.5.1867; RODEWALD R, 1984, J CELL BIOL, V99, pS159, DOI 10.1083/jcb.99.1.159s; RODEWALD R, 1976, J CELL BIOL, V71, P666, DOI 10.1083/jcb.71.2.666; RODEWALD R, 1973, J CELL BIOL, V58, P189, DOI 10.1083/jcb.58.1.189; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SIMISTER NE, 1989, COLD SPRING HARB SYM, V54, P571, DOI 10.1101/SQB.1989.054.01.068; Simister NE, 1998, IMMUNOL MED, V26, P63; Simister NE, 1996, EUR J IMMUNOL, V26, P1527, DOI 10.1002/eji.1830260718; SIMISTER NE, 1989, NATURE, V337, P184, DOI 10.1038/337184a0; SNIDER MD, 1985, J CELL BIOL, V100, P826, DOI 10.1083/jcb.100.3.826; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; Stefaner I, 1999, J BIOL CHEM, V274, P8998, DOI 10.1074/jbc.274.13.8998; STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; Vaughn DE, 1998, STRUCTURE, V6, P63, DOI 10.1016/S0969-2126(98)00008-2; WALLACE KH, 1980, BIOCHEM J, V188, P9, DOI 10.1042/bj1880009; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	60	60	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5240	5247		10.1074/jbc.M006684200	http://dx.doi.org/10.1074/jbc.M006684200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11096078	hybrid			2022-12-25	WOS:000168484300095
J	Ye, RQ; Bodero, A; Zhou, BB; Khanna, KK; Lavin, MF; Lees-Miller, SP				Ye, RQ; Bodero, A; Zhou, BB; Khanna, KK; Lavin, MF; Lees-Miller, SP			The plant isoflavenoid genistein activates p53 and Chk2 in an ATM-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATAXIA-TELANGIECTASIA GENE; DNA-DAMAGE CHECKPOINT; BREAST-CANCER CELLS; PROTEIN-KINASE; TYROSINE KINASE; IONIZING-RADIATION; CATALYTIC SUBUNIT; TOPOISOMERASE-II; IN-VITRO; C-ABL	Genistein is an isoflavenoid that is abundant in soy beans. Genistein has been reported to have a wide range of biological activities and to play a role in the diminished incidence of breast cancer in populations that consume a soy-rich diet. Genistein was originally identified as an inhibitor of tyrosine kinases; however, it also inhibits topoisomerase II by stabilizing the covalent DNA cleavage complex, an event predicted to cause DNA damage. The topoisomerase II inhibitor etoposide acts in a similar manner. Here we show that genistein induces the up-regulation of p53 protein, phosphorylation of p53 at serine 15, activation of the sequence-specific DNA binding properties of p53, and phosphorylation of the hCds1/Chk2 protein kinase at threonine 68. Phosphorylation and activation of p53 and phosphorylation of Chk2 were not observed in ATM-deficient cells. In contrast, the topoisomerase II inhibitor etoposide induced phosphorylation of p53 and Chk2 in ATM-positive and ATM-deficient cells. In addition, genistein-treated ATM-deficient cells were significantly more susceptible to genistein-induced killing than were ATM-positive cells. Together our data suggest that ATM is required for activation of a DNA damage-induced pathway that activates p53 and Chk2 in response to genistein.	Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada; SmithKline Beecham Pharmaceut, Dept Oncol Res, King Of Prussia, PA 19406 USA; Royal Brisbane Hosp, Queensland Inst Med Res, Brisbane, Qld 4029, Australia	University of Calgary; GlaxoSmithKline; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital	Lees-Miller, SP (corresponding author), Univ Calgary, Dept Biol Sci, 2500 Univ Dr 1 NW, Calgary, AB T2N 1N4, Canada.		Khanna, Kum Kum/I-1747-2013; Lavin, Martin F/F-5961-2014	Lavin, Martin F/0000-0002-5940-4769; Lees-Miller, Susan/0000-0001-5809-2516; Khanna, Kum Kum/0000-0001-8650-5381				ADLERCREUTZ H, 1992, J STEROID BIOCHEM, V41, P331, DOI 10.1016/0960-0760(92)90359-Q; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; Balabhadrapathruni S, 2000, ONCOL REP, V7, P3; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Becker BN, 1999, J RECEPT SIGNAL TR R, V19, P975, DOI 10.3109/10799899909038435; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Canman CE, 1998, ONCOGENE, V17, P3301, DOI 10.1038/sj.onc.1202577; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CasciolaRosen L, 1996, J EXP MED, V183, P1957, DOI 10.1084/jem.183.5.1957; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Chan DW, 2000, J BIOL CHEM, V275, P7803, DOI 10.1074/jbc.275.11.7803; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; CONSTANTINOU A, 1995, J NAT PRODUCTS, V58, P217, DOI 10.1021/np50116a009; Darbon JM, 2000, J BIOL CHEM, V275, P15363, DOI 10.1074/jbc.275.20.15363; Gescher A, 1998, BRIT J CLIN PHARMACO, V45, P1, DOI 10.1046/j.1365-2125.1998.00640.x; GORCZYCA W, 1993, CANCER RES, V53, P3186; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HOUNDSWORTH J, 1980, NUCLEIC ACIDS RES, V8, P3709; Hsieh CY, 1998, CANCER RES, V58, P3833; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KHARBANDA S, 1994, ONCOGENE, V9, P3005; Lakin ND, 1999, ONCOGENE, V18, P3989, DOI 10.1038/sj.onc.1202973; LAMARTINIERE CA, 1995, P SOC EXP BIOL MED, V208, P120; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEE HP, 1991, LANCET, V337, P1197, DOI 10.1016/0140-6736(91)92867-2; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; Li YW, 1999, ONCOGENE, V18, P3166, DOI 10.1038/sj.onc.1202650; MARKOVITS J, 1989, CANCER RES, V49, P5111; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MCCABE MJ, 1993, BIOCHEM BIOPH RES CO, V194, P944, DOI 10.1006/bbrc.1993.1912; MESSINA MJ, 1994, NUTR CANCER, V21, P113, DOI 10.1080/01635589409514310; MIKSICEK RJ, 1993, MOL PHARMACOL, V44, P37; Nakamura Y, 1998, NAT MED, V4, P1231, DOI 10.1038/3207; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PAINTER RB, 1980, P NATL ACAD SCI-BIOL, V77, P7315, DOI 10.1073/pnas.77.12.7315; Sarkaria JN, 1999, CANCER RES, V59, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	55	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4828	4833		10.1074/jbc.M004894200	http://dx.doi.org/10.1074/jbc.M004894200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11096068	hybrid			2022-12-25	WOS:000168484300041
J	Bayer, N; Schober, D; Huttinger, M; Blaas, D; Fuchs, R				Bayer, N; Schober, D; Huttinger, M; Blaas, D; Fuchs, R			Inhibition of clathrin-dependent endocytosis has multiple effects on human rhinovirus serotype 2 cell entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; COATED PIT FORMATION; HELA-CELLS; POTASSIUM-DEPLETION; MEDIATED ENDOCYTOSIS; DIPHTHERIA-TOXIN; DIFFERENT MECHANISMS; HYPERTONIC MEDIUM; EPITHELIAL-CELLS; CYTO-TOXICITY	Minor group human rhinoviruses (exemplified by human rhinovirus serotype 2 (HRV2)) use members of the low density lipoprotein receptor family for cell entry; all these receptors possess clathrin-coated pit localization signals. Viral infection should thus be inhibited under conditions of impaired clathrin-mediated endocytosis. However, Madshus et at reported an increase in the cytopathic effect of HRV2 infection in HEp-2 cells upon suppression of clathrin-dependent endocytosis by hypotonic shock and potassium depletion (Madshus, I. H., Sandvig, K., Olsnes, S., and van Deurs, B. (1987) J. Cell, Physiol. 131, 14-22.) To resolve this apparent contradiction, we investigated the binding, internalization, conformational changes, and productive uncoating of HRV2 in HeLa cells subjected to hypotonic shock and potassium depletion. This treatment led to an increase in HRV2 binding, with internalization being barely affected. The generation of C-antigenic particles requiring pH less than or equal to5.6 was strongly reduced due to an elevation of the pH in endosomal compartments. However, K+ depletion only slightly affected de novo viral protein synthesis, suggesting that productivity of viral RNA in the cytoplasm is enhanced and thus compensates for the reduction in C-antigenic particles. The distinct steps in the entry pathway of HRV2 are thus differently influenced by potassium depletion. Viral internalization under conditions of inhibited clathrin-dependent endocytosis without the need to disturb the ionic milieu was confirmed in HeLa cells overexpressing the nonfunctional dynamin-1 mutant K44A. Unexpectedly, overexpression of dynamin-1 K44A resulted in elevated endosomal pH compared with overexpression of wild-type dynamin.	Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Dept Med Chem, A-1090 Vienna, Austria; Univ Vienna, Vienna Bioctr, Inst Med Biochem, Div Biochem, A-1030 Vienna, Austria	University of Vienna; University of Vienna; University of Vienna; Vienna Biocenter (VBC)	Fuchs, R (corresponding author), Univ Vienna, Dept Pathophysiol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	renate.fuchs@akh-wien.ac.at						ABRAHAM G, 1984, J VIROL, V51, P340, DOI 10.1128/JVI.51.2.340-345.1984; Bayer N, 1999, FEBS LETT, V463, P175, DOI 10.1016/S0014-5793(99)01610-5; Bayer N, 1998, J VIROL, V72, P9645, DOI 10.1128/JVI.72.12.9645-9655.1998; Boleti H, 1999, J CELL SCI, V112, P1487; CARPENTIER JL, 1989, J CELL PHYSIOL, V138, P519, DOI 10.1002/jcp.1041380311; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; Chow CW, 1999, J BIOL CHEM, V274, P37551, DOI 10.1074/jbc.274.53.37551; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; CUPERS P, 1994, J CELL BIOL, V127, P725, DOI 10.1083/jcb.127.3.725; DAMKE H, 1995, METHOD ENZYMOL, V257, P209; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; De Tulleo L, 1998, EMBO J, V17, P4585, DOI 10.1093/emboj/17.16.4585; GHOSH PC, 1985, J CELL BIOL, V101, P350, DOI 10.1083/jcb.101.2.350; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; GRUENBERGER M, 1991, J GEN VIROL, V72, P431, DOI 10.1099/0022-1317-72-2-431; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HANSEN SH, 1991, J CELL BIOL, V113, P731, DOI 10.1083/jcb.113.4.731; HERZ J, 1991, J BIOL CHEM, V266, P21232; Hewat EA, 1996, EMBO J, V15, P1515, DOI 10.1002/j.1460-2075.1996.tb00495.x; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; KRAMERGUTH A, 1997, AM J PHYSIOL, V42, pC1409; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LI Y, 2000, J BIOL CHEM, V275, P17185; Liou ML, 1998, CELL TISSUE RES, V293, P389, DOI 10.1007/s004410051130; Llorente A, 1998, J CELL BIOL, V140, P553, DOI 10.1083/jcb.140.3.553; LONBERGHOLM K, 1972, J VIROL, V9, P29, DOI 10.1128/JVI.9.1.29-40.1972; LONBERGHOLM K, 1973, J VIROL, V12, P114, DOI 10.1128/JVI.12.1.114-123.1973; LONBERGHOLM K, 1976, J VIROL, V19, P857, DOI 10.1128/JVI.19.3.857-870.1976; MADSHUS IH, 1987, J CELL PHYSIOL, V131, P14, DOI 10.1002/jcp.1041310104; MADSHUS IH, 1987, J CELL PHYSIOL, V131, P6, DOI 10.1002/jcp.1041310103; Marlovits TC, 1998, J BIOL CHEM, V273, P33835, DOI 10.1074/jbc.273.50.33835; Marlovits TC, 1998, FASEB J, V12, P695, DOI 10.1096/fasebj.12.9.695; Marlovits TC, 1998, J VIROL, V72, P10246, DOI 10.1128/JVI.72.12.10246-10250.1998; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; MURPHY RF, 1984, J CELL BIOL, V98, P1757, DOI 10.1083/jcb.98.5.1757; NEUBAUER C, 1987, VIROLOGY, V158, P255, DOI 10.1016/0042-6822(87)90264-9; Nicoziani P, 2000, MOL BIOL CELL, V11, P481, DOI 10.1091/mbc.11.2.481; Parker JSL, 2000, J VIROL, V74, P1919, DOI 10.1128/JVI.74.4.1919-1930.2000; Parton RG, 1999, IMMUNOL REV, V168, P23, DOI 10.1111/j.1600-065X.1999.tb01280.x; PRCHLA E, 1995, J CELL BIOL, V131, P111, DOI 10.1083/jcb.131.1.111; PREHLA E, 1994, J VIROL, V68, P3713; Rybak SL, 1998, J CELL PHYSIOL, V176, P216, DOI 10.1002/(SICI)1097-4652(199807)176:1<216::AID-JCP23>3.3.CO;2-M; SANDVIG K, 1985, J CELL PHYSIOL, V124, P54, DOI 10.1002/jcp.1041240110; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; Schober D, 1998, J VIROL, V72, P1354, DOI 10.1128/JVI.72.2.1354-1364.1998; SKERN T, 1984, VIROLOGY, V136, P125, DOI 10.1016/0042-6822(84)90253-8; Skretting G, 1999, J CELL SCI, V112, P3899; STAUNTON DE, 1992, J IMMUNOL, V148, P3271; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; TANASUGARN L, 1984, J CELL BIOL, V98, P717, DOI 10.1083/jcb.98.2.717; TOMASSINI JE, 1989, P NATL ACAD SCI USA, V86, P4907, DOI 10.1073/pnas.86.13.4907; Trowbridge IS, 1991, CURR OPIN CELL BIOL, V3, P1062, DOI 10.1016/0955-0674(91)90130-Q; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V; VANRENSWOUDE J, 1982, P NATL ACAD SCI-BIOL, V79, P6186; Vilhardt F, 1999, MOL BIOL CELL, V10, P179, DOI 10.1091/mbc.10.1.179; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; Werling D, 1999, J LEUKOCYTE BIOL, V66, P50, DOI 10.1002/jlb.66.1.50	60	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3952	3962		10.1074/jbc.M004722200	http://dx.doi.org/10.1074/jbc.M004722200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11073943	hybrid			2022-12-25	WOS:000166921200033
J	Ellis, CE; Schwartzberg, PL; Grider, TL; Fink, DW; Nussbaum, RL				Ellis, CE; Schwartzberg, PL; Grider, TL; Fink, DW; Nussbaum, RL			alpha-Synuclein is phosphorylated by members of the Src family of protein-tyrosine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; T-CELL ACTIVATION; A-BETA COMPONENT; ALZHEIMERS-DISEASE; C-SRC; PARKINSONS-DISEASE; SYNAPTIC VESICLES; MUTATION; IDENTIFICATION; ASSOCIATION	alpha -Synuclein (alpha -Syn) is implicated in the pathogenesis of Parkinson's Disease, genetically through missense mutations linked to early onset disease and pathologically through its presence in Lewy bodies. alpha -Syn is phosphorylated on serine residues; however, tyrosine phosphorylation of alpha -Syn has not been established (1, 2). A comparison of the protein sequence between Synuclein family members revealed that all four tyrosine residues of alpha -Syn are conserved in all orthologs and beta -Syn paralogs described to date, suggesting that these residues may be of functional importance (3). For this reason, experiments were performed to determine whether alpha -Syn could be phosphorylated on tyrosine residue(s) in human cells. Indeed, alpha -Syn is phosphorylated within 2 min of pervanadate treatment in alpha -Syn-transfected cells. Tyrosine phosphorylation occurs primarily on tyrosine 125 and was inhibited by PP2, a selective inhibitor of Src protein-tyrosine kinase (PTK) family members at concentrations consistent with inhibition of Src function (4). Finally, we demonstrate that alpha -Syn can be phosphorylated directly both in cotransfection experiments using c-Src and Fyn expression vectors and in in vitro kinase assays with purified kinases. These data suggest that alpha -Syn can be a target for phosphorylation by the Src family of PTKs.	NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA; US FDA, Ctr Biol Evaluat & Res, Lab Stem Cell Biol Neurotroph Factors, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); US Food & Drug Administration (FDA)	Nussbaum, RL (corresponding author), NHGRI, Genet Dis Res Branch, NIH, 49 Convent Dr,MSC 4472, Bethesda, MD 20892 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000117] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Cantley LC, 1997, ADV SEC MESS PHOSPH, V31, P41; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Debnath J, 1999, MOL CELL BIOL, V19, P1498; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; Gurd JW, 1997, NEUROCHEM INT, V31, P635, DOI 10.1016/S0197-0186(97)00022-3; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HARLOW E, 1988, ANTIBODIES LAB MANUA, P522; Hosaka M, 1999, NEURON, V24, P377, DOI 10.1016/S0896-6273(00)80851-X; HU Q, 1995, J BIOL CHEM, V270, P1928, DOI 10.1074/jbc.270.4.1928; Huyer G, 1997, J BIOL CHEM, V272, P843, DOI 10.1074/jbc.272.2.843; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Lee G, 1998, J CELL SCI, V111, P3167; Llinas R, 1997, P NATL ACAD SCI USA, V94, P1990, DOI 10.1073/pnas.94.5.1990; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; ODELL TJ, 1991, NATURE, V353, P558, DOI 10.1038/353558a0; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Onofri F, 1997, P NATL ACAD SCI USA, V94, P12168, DOI 10.1073/pnas.94.22.12168; PANG DT, 1988, P NATL ACAD SCI USA, V85, P762, DOI 10.1073/pnas.85.3.762; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Salter MW, 1998, BIOCHEM PHARMACOL, V56, P789, DOI 10.1016/S0006-2952(98)00124-5; SNYDER MA, 1985, MOL CELL BIOL, V5, P1772, DOI 10.1128/MCB.5.7.1772; SOMMERS CL, 1995, ONCOGENE, V11, P245; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Zhao WQ, 2000, P NATL ACAD SCI USA, V97, P8098, DOI 10.1073/pnas.97.14.8098	42	118	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3879	3884		10.1074/jbc.M010316200	http://dx.doi.org/10.1074/jbc.M010316200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11078745	hybrid			2022-12-25	WOS:000166921200023
J	Hattan, SJ; Laue, TM; Chasteen, ND				Hattan, SJ; Laue, TM; Chasteen, ND			Purification and characterization of a novel calcium-binding protein from the extrapallial fluid of the mollusc, Mytilus edulis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC MATRIX; SHELL FORMATION; PHOSPHOPROTEIN PARTICLES; MINERALIZED TISSUES; CARBONATE; BIOMINERALIZATION; CRYSTALLIZATION; MACROMOLECULES; ORGANIZATION; INVITRO	In the bivalve molluse Mytilus edulis shell thickening occurs from the extrapallial (EP) fluid wherein secreted shell matrix macromolecules are thought to self-assemble into a framework that regulates the growth of CaCO3 crystals, which eventually constitute similar to 95% of the mature shell Herein is the initial report on the purification and characterization of a novel EP fluid glycoprotein, which is likely a building block of the shell-soluble organic matrix. This primary EP fluid protein comprises 56% of the total protein in the fluid and is shown to be a dimer of 28,340 Ha monomers estimated to be 14.3% by weight carbohydrate. The protein is acidic (pI = 4.43) and rich in histidine content (11.14%) as well as in Asx and Glx residues (25.15% total). The N terminus exhibits an unusual repeat sequence of histidine and aspartate residues that occur in pairs: NPVDDHHDDHH-DAPIVEHHD similar to. Ultracentrifugation and polyacrylamide gel electrophoresis demonstrate that the protein binds calcium and in so doing assembles into a series of higher order protomers, which appear to have extended structures. Circular dichroism shows that the protein-calcium binding/protomer formation is coupled to a significant rearrange ment in the protein's secondary structure in which there is a major reduction in beta -sheet with an associated increase in alpha -helical content of the protein A model for shell organic matrix self-assembly is proposed.	Univ New Hampshire, Dept Chem, Durham, NH 03824 USA; Univ New Hampshire, Dept Biochem & Mol Biol, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire; University System Of New Hampshire; University of New Hampshire	Chasteen, ND (corresponding author), Univ New Hampshire, Dept Chem, Parsons Hall, Durham, NH 03824 USA.	ndc@cisunix.unh.edu	Laue, Tom/AAI-5136-2020	Laue, Tom/0000-0003-3571-9368	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020194] Funding Source: NIH RePORTER; NIGMS NIH HHS [R37-GM20194] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDADI L, 1992, ANGEW CHEM INT EDIT, V31, P153, DOI 10.1002/anie.199201531; ADDADI L, 1985, P NATL ACAD SCI USA, V82, P4110, DOI 10.1073/pnas.82.12.4110; BEELEY JG, 1985, LAB TECHNIQUES BIOCH, V16, P24; Belcher AM, 1996, NATURE, V381, P56, DOI 10.1038/381056a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRENSHAW MA, 1972, BIOL BULL, V143, P506, DOI 10.2307/1540180; CRENSHAW MA, 1969, AM ZOOL, V9, P881; CRENSHAW MA, 1987, MECH MINERALIZATION, P355; DUBOIS M, 1956, ANAL CHEM, V28, P356; EYSTER LS, 1984, AM ZOOL, V24, P871; GERARD C, 1990, METHOD ENZYMOL, V182, P536; GREENFIELD EM, 1984, AM ZOOL, V24, P925; GUNTHORPE ME, 1990, BIOL BULL, V179, P191, DOI 10.2307/1541769; HALLORAN BA, 1995, COMP BIOCHEM PHYS B, V111, P221, DOI 10.1016/0305-0491(94)00245-P; HARE PE, 1963, SCIENCE, V139, P216, DOI 10.1126/science.139.3551.216; HATTAN SJ, 1996, GLYCOBIOLOGY, V6, P755; KRAMPITZ G, 1983, BIOMINERALIZATION BI, P231; KRAMPITZ GP, 1982, BIOL MINERALIZATION, P219; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Laue T. M., 1992, ANAL ULTRACENTRIFUGA, P63; Lowenstam H.A., 1989, BIOMINERALISATION, P7; MANN S, 1988, NATURE, V334, P692, DOI 10.1038/334692a0; MANN S, 1988, NATURE, V332, P119, DOI 10.1038/332119a0; MARSH ME, 1985, J EXP ZOOL, V234, P237, DOI 10.1002/jez.1402340209; MARSH ME, 1983, J EXP ZOOL, V226, P193, DOI 10.1002/jez.1402260204; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; MISOGIANES MJ, 1979, ANAL BIOCHEM, V100, P324, DOI 10.1016/0003-2697(79)90236-7; Naggar E, 2000, GLYCOBIOLOGY, V10, P1119; Nair PS, 1999, ARCH BIOCHEM BIOPHYS, V366, P8, DOI 10.1006/abbi.1999.1196; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; PEITRZAK JE, 1976, HYDROBIOLOGIA, V50, P89; ROWE AJ, 1977, BIOPOLYMERS, V16, P2595, DOI 10.1002/bip.1977.360161202; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; STAFFORD WF, 1992, ANAL ULTRACENTRIFUGA, V3, P359; WADA K, 1980, MECH MINERALIZATION, P175; WATABE N, 1960, NATURE, V188, P334, DOI 10.1038/188334a0; WEINER S, 1986, CRC CR REV BIOCH MOL, V20, P365, DOI 10.3109/10409238609081998; WEINER S, 1984, PHILOS T ROY SOC B, V304, P425, DOI 10.1098/rstb.1984.0036; WEINER S, 1983, BIOCHEMISTRY-US, V22, P4139, DOI 10.1021/bi00286a023; WEINER S, 1975, SCIENCE, V190, P987, DOI 10.1126/science.1188379; WEINER S, 1977, J EXP MAR BIOL ECOL, V30, P45, DOI 10.1016/0022-0981(77)90026-0; WEINER S, 1984, AM ZOOL, V24, P945; Wheeler A.P., 1989, P95; WHEELER AP, 1984, AM ZOOL, V24, P933; WIERZBICKI A, 1994, CALCIFIED TISSUE INT, V54, P133, DOI 10.1007/BF00296064; WILBUR KM, 1984, BIOL BULL, V166, P251, DOI 10.2307/1541446; WILBUR KM, 1984, AM ZOOL, V24, P839; YOUNG SD, 1977, MAR BIOL, V41, P253, DOI 10.1007/BF00394911	48	100	103	2	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4461	4468		10.1074/jbc.M006803200	http://dx.doi.org/10.1074/jbc.M006803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11084027	hybrid			2022-12-25	WOS:000166921200097
J	Hughes, TE; Zhang, HL; Logothetis, DE; Berlot, CH				Hughes, TE; Zhang, HL; Logothetis, DE; Berlot, CH			Visualization of a functional G alpha(q)-green fluorescent protein fusion in living cells - Association with the plasma membrane is disrupted by mutational activation and by elimination of palmitoylation sites, but not by activation mediated by receptors or Alf(4)(-)*S	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ADENYLYL-CYCLASE; ALPHA-SUBUNITS; K+ CHANNEL; SIGNAL-TRANSDUCTION; PHOSPHOLIPASE-C; AMINO-TERMINUS; GTP-BINDING; G(S-ALPHA); GENE	To investigate how G protein alpha subunit localization is regulated under basal and activated conditions, we inserted green fluorescent protein (GFP) into an internal loop of G alpha (q), ,alpha (q)-GFP stimulates phospholipase C in response to activated receptors and inhibits py dependent activation of basal G protein-gated inwardly rectifying K+ currents as effectively as alpha (q) does. Association of alpha (q)-GFP with the plasma membrane is reduced by mutational activation and eliminated by mutation of the alpha (q) pahnitoylation sites, suggesting that a, must be in the inactive, palmitoylated state to be targeted to this location. We tested the effects of activation by receptors and by Alf(4)(-) on the localization of alpha (q)-GFP in cells expressing both alpha (q)-GFP and a protein kinase C gamma -red fluorescent protein fusion that translocates to the plasma membrane in response to activation of G(q). In cells that clearly exhibit protein kinase C gamma -red fluorescent protein translocation responses, relocalization of (alpha (q)-GFP is not observed. Thus, under conditions associated with palmitate turnover and By dissociation, alpha (q)-GFP remains associated with the plasma membrane, These results suggest that upon reaching the plasma membrane alpha (q) receives an anchoring signal in addition to palmitoylation and association with By, or that during activation, one or both of these factors continues to retain alpha (q) in this location.	Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Ophthalmol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Visual Sci, New Haven, CT 06520 USA; NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, New York, NY 10029 USA	Yale University; Yale University; Yale University; Icahn School of Medicine at Mount Sinai; New York University	Berlot, CH (corresponding author), Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06520 USA.			Hughes, Thomas/0000-0001-5880-9951; Hughes, Thomas/0000-0002-8430-070X	NATIONAL EYE INSTITUTE [R01EY008362] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050369, R01GM050369] Funding Source: NIH RePORTER; NEI NIH HHS [EY08362] Funding Source: Medline; NHLBI NIH HHS [HL54185] Funding Source: Medline; NIGMS NIH HHS [GM50369] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM, 1987, CURRENT PROTOCOLS MO, V1-5; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; Bhamre S, 1998, J PHARMACOL EXP THER, V286, P1482; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; Cote M, 1997, ENDOCRINOLOGY, V138, P3299, DOI 10.1210/en.138.8.3299; DEGTYAREV MY, 1993, J BIOL CHEM, V268, P23769; DEGTYAREV MY, 1993, BIOCHEMISTRY-US, V32, P8057, DOI 10.1021/bi00083a001; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; Drmota T, 1998, J BIOL CHEM, V273, P21699, DOI 10.1074/jbc.273.34.21699; Dunphy JT, 1996, J BIOL CHEM, V271, P7154, DOI 10.1074/jbc.271.12.7154; EDGERTON MD, 1994, FEBS LETT, V354, P195, DOI 10.1016/0014-5793(94)01101-X; Evanko DS, 2000, J BIOL CHEM, V275, P1327, DOI 10.1074/jbc.275.2.1327; Feng X, 1998, J BIOL CHEM, V273, P10755, DOI 10.1074/jbc.273.17.10755; Grishina G, 1997, J BIOL CHEM, V272, P20619, DOI 10.1074/jbc.272.33.20619; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; GUYER CA, 1990, J BIOL CHEM, V265, P17307; He C, 1999, J BIOL CHEM, V274, P12517, DOI 10.1074/jbc.274.18.12517; Hepler JR, 1996, J BIOL CHEM, V271, P496, DOI 10.1074/jbc.271.1.496; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huang CF, 1999, P NATL ACAD SCI USA, V96, P412, DOI 10.1073/pnas.96.2.412; Huang CF, 1997, MOL BIOL CELL, V8, P2365, DOI 10.1091/mbc.8.12.2365; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Jones TLZ, 1997, BIOCHEMISTRY-US, V36, P7185, DOI 10.1021/bi9628376; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Kleuss C, 1997, P NATL ACAD SCI USA, V94, P6116, DOI 10.1073/pnas.94.12.6116; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marsh SR, 1998, MOL PHARMACOL, V53, P981; MCCALLUM JF, 1995, BIOCHEM J, V310, P1021, DOI 10.1042/bj3101021; Medina R, 1996, J BIOL CHEM, V271, P24720, DOI 10.1074/jbc.271.40.24720; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; MUMBY SM, 1994, P NATL ACAD SCI USA, V91, P2800, DOI 10.1073/pnas.91.7.2800; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NOEL JP, 1993, NATURE, V366, P654, DOI 10.1038/366654a0; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Stanislaus D, 1997, MOL ENDOCRINOL, V11, P738, DOI 10.1210/me.11.6.738; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; UHLEN S, 1995, PHARM COMMUN, V6, P155; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; WEDEGAERTNER PB, 1993, J BIOL CHEM, V268, P25001; Wedegaertner PB, 1996, MOL BIOL CELL, V7, P1225, DOI 10.1091/mbc.7.8.1225; WEDEGAERTNER PB, 1994, CELL, V77, P1063, DOI 10.1016/0092-8674(94)90445-6; WILSON BS, 1994, ENDOCRINOLOGY, V134, P233, DOI 10.1210/en.134.1.233; WILSON PT, 1995, J BIOL CHEM, V270, P9667, DOI 10.1074/jbc.270.16.9667; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	55	112	115	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4227	4235		10.1074/jbc.M007608200	http://dx.doi.org/10.1074/jbc.M007608200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11076942	hybrid			2022-12-25	WOS:000166921200067
J	Steinhilb, ML; Turner, RS; Gaut, JR				Steinhilb, ML; Turner, RS; Gaut, JR			The protease inhibitor, MG132, blocks maturation of the amyloid precursor protein Swedish mutant preventing cleavage by beta-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; ENDOPLASMIC-RETICULUM; GAMMA-SECRETASE; BETA-PROTEIN-42 SECRETION; CELLS; DEGRADATION; MUTATION; PATHWAY; SUBSTRATE; NEURONS	Amyloid (AP) peptides found aggregated into plaques in Alzheimer's disease are derived from the sequential cleavage of the amyloid precursor protein (APP) first by beta- and then by gamma -secretases. Peptide aldehydes, which inhibit cysteine proteases and proteasomes, reportedly block AP peptide secretion by interfering with gamma -secretase cleavage. Using a novel, specific, and sensitive enzyme-linked immunosorbent assay for the beta -secretase-cleaved fragment of the Swedish mutant of APP (APPSw), we determined that the peptide aldehyde, MG132, prevented beta -secretase cleavage. This block in beta -secretase cleavage was not observed with clasto-lactacystin beta -lactone and thus, cannot be attributed to proteasomal inhibition. MG132 inhibition of beta -secretase cleavage was compared with the serine protease inhibitor, 4-(2-aminoethyl)benzenesulfonyl fluoride hydrochloride (AEBSF). AEBSF inhibition of beta -secretase cleavage was immediate and did not affect alpha -secretase cleavage. With MG132, inhibition was delayed and it decreased secretion of alpha -cleaved APPSw as well. Furthermore, MG132 treatment impaired maturation of full-length APPSw. Both inhibited intracellular formation of the beta -cleaved product. These results suggest that peptide aldehydes such as MG132 have multiple effects on the maturation and processing of APP. We conclude that the MG132-induced decrease in beta -secretase cleavage of APPSw is due to a block in maturation. This is sufficient to explain the previously reported peptide aldehyde-induced decrease in AP peptide secretion.	Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Dept Neurol, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Ctr Geriatr Res Educ & Clin, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Steinhilb, ML (corresponding author), Univ Michigan, Inst Gerontol, 300 N Ingalls,Rm 973, Ann Arbor, MI 48109 USA.		Turner, Raymond Scott/G-2263-2011	Turner, Raymond Scott/0000-0001-7534-2935	NATIONAL INSTITUTE ON AGING [T32AG000114, P50AG008671] Funding Source: NIH RePORTER; NIA NIH HHS [P50 AG008671, T32AG00114] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Acquati F, 2000, FEBS LETT, V468, P59, DOI 10.1016/S0014-5793(00)01192-3; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Bennett BD, 2000, J BIOL CHEM, V275, P20647, DOI 10.1074/jbc.M002688200; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Citron M, 1996, NEURON, V17, P171, DOI 10.1016/S0896-6273(00)80290-1; Citron M, 1996, P NATL ACAD SCI USA, V93, P13170, DOI 10.1073/pnas.93.23.13170; Forman MS, 1997, J BIOL CHEM, V272, P32247, DOI 10.1074/jbc.272.51.32247; Gregori L, 1997, J BIOL CHEM, V272, P58; HAASS C, 1995, NAT MED, V1, P1291, DOI 10.1038/nm1295-1291; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; HIGAKI J, 1995, NEURON, V14, P651, DOI 10.1016/0896-6273(95)90322-4; Klafki HW, 1996, J BIOL CHEM, V271, P28655, DOI 10.1074/jbc.271.45.28655; Klafki HW, 1995, NEUROSCI LETT, V201, P29, DOI 10.1016/0304-3940(95)12122-K; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Marambaud P, 1997, J NEUROCHEM, V69, P2500, DOI 10.1046/j.1471-4159.1997.69062500.x; Marambaud P, 1997, J NEUROCHEM, V68, P698; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Naslund J, 2000, JAMA-J AM MED ASSOC, V283, P1571, DOI 10.1001/jama.283.12.1571; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Skovronsky DM, 2000, BIOCHEMISTRY-US, V39, P810, DOI 10.1021/bi991728z; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Walter J, 1997, P NATL ACAD SCI USA, V94, P5349, DOI 10.1073/pnas.94.10.5349; Walter J, 1997, J BIOL CHEM, V272, P1896, DOI 10.1074/jbc.272.3.1896; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y; Yamazaki T, 1998, NEUROBIOL AGING, V19, pS77, DOI 10.1016/S0197-4580(98)00031-1; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Yang YN, 1998, J BIOL CHEM, V273, P25552, DOI 10.1074/jbc.273.40.25552; Zhang LL, 1999, J BIOL CHEM, V274, P8966, DOI 10.1074/jbc.274.13.8966	32	60	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4476	4484		10.1074/jbc.M008793200	http://dx.doi.org/10.1074/jbc.M008793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11084038	hybrid			2022-12-25	WOS:000166921200099
J	Frippiat, C; Chen, QM; Zdanov, S; Magalhaes, JP; Remacle, J; Toussaint, O				Frippiat, C; Chen, QM; Zdanov, S; Magalhaes, JP; Remacle, J; Toussaint, O			Subcytotoxic H2O2 stress triggers a release of transforming growth factor-beta 1, which induces biomarkers of cellular senescence of human diploid fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOBLASTOMA PROTEIN; HYDROGEN-PEROXIDE; GENE-PRODUCT; I COLLAGEN; CELLS; ARREST; PHOSPHORYLATION; FIBRONECTIN; INHIBITION; EXPRESSION	Stress-induced premature senescence (SIPS) is induced 3 days after exposure of human diploid fibroblasts to subcytotoxic oxidative stress with H2O2, with appearance of several biomarkers of replicative senescence. In this work, we show that transforming growth factor-beta1 (TGF-beta1) regulates the induction of several of these biomarkers in SIPS: cellular morphology, senescence-associated beta -galactosidase activity, increase in the steady-state level of fibronectin, apolipoprotein J, osteonectin, and SM22 mRNk Indeed, the neutralization of TGF-beta1 or its receptor (TGF-beta RII) using specific antibodies decreases sharply the percentage of cells positive for the senescent-associated beta -galactosidase activity and displaying a senescent morphology, In the presence of each of these antibodies, the steady-state level of fibronectin, osteonectin, apolipoprotein J, and SM22 mRNA is no more increased at 72 h after stress. Results obtained on fibroblasts retrovirally transfected with the human papillomavirus E7 cDNA suggest that retinoblastoma protein (Rb) regulates the expression of TGF-beta1 in stressful conditions, leading to SIPS and overexpression of these four genes.	Univ Namur, Fac Univ Notre Dame Paix, Dept Biol, Unit Cellular Biochem & Biol, B-5000 Namur, Belgium; Univ Arizona, Dept Pharmacol, Tucson, AZ 85721 USA	University of Namur; University of Arizona	Toussaint, O (corresponding author), Univ Namur, Fac Univ Notre Dame Paix, Dept Biol, Unit Cellular Biochem & Biol, 61 Rue Bruxelles, B-5000 Namur, Belgium.		Zdanov, Stephanie/G-2524-2012; de Magalhaes, Joao Pedro/B-4741-2010	de Magalhaes, Joao Pedro/0000-0002-6363-2465				BAYREUTHER K, 1988, P NATL ACAD SCI USA, V85, P5112, DOI 10.1073/pnas.85.14.5112; Brack Christine, 2000, EMBO (European Molecular Biology Organization) Journal, V19, P1929, DOI 10.1093/emboj/19.9.1929; Bumann J., 1995, Strahlentherapie und Onkologie, V171, P35; CHEN Q, 1994, P NATL ACAD SCI USA, V91, P4130, DOI 10.1073/pnas.91.10.4130; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dumont P, 2000, FREE RADICAL BIO MED, V28, P361, DOI 10.1016/S0891-5849(99)00249-X; FURUKAWA Y, 1992, J BIOL CHEM, V267, P17121; Herrera RE, 1996, MOL BIOL CELL, V7, P1335, DOI 10.1091/mbc.7.9.1335; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Katakura Y, 1999, BIOCHEM BIOPH RES CO, V255, P110, DOI 10.1006/bbrc.1999.0129; KIM SJ, 1992, NATURE, V358, P331, DOI 10.1038/358331a0; MOCALI A, 1995, EXP CELL RES, V216, P388, DOI 10.1006/excr.1995.1049; Owens GK, 1998, ACTA PHYSIOL SCAND, V164, P623, DOI 10.1111/j.1365-201X.1998.tb10706.x; REED MJ, 1994, J CELL PHYSIOL, V158, P169, DOI 10.1002/jcp.1041580121; Rodemann HP, 1996, KIDNEY INT, V49, pS32; Schoecklmann HO, 1997, KIDNEY INT, V51, P1228, DOI 10.1038/ki.1997.168; Shiba H, 1998, J CELL PHYSIOL, V174, P194; Toussaint O, 2000, EXP GERONTOL, V35, P927, DOI 10.1016/S0531-5565(00)00180-7; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; Wegrowski Y, 1999, EXP CELL RES, V247, P475, DOI 10.1006/excr.1998.4378	22	260	270	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2531	2537		10.1074/jbc.M006809200	http://dx.doi.org/10.1074/jbc.M006809200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11060295	hybrid			2022-12-25	WOS:000166784800033
J	Xu, AG; Chen, KY				Xu, AG; Chen, KY			Hypusine is required for a sequence-specific interaction of eukaryotic initiation factor 5A with postsystematic evolution of ligands by exponential enrichment RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYHYPUSINE SYNTHASE; PROTEIN-SYNTHESIS; CELL VIABILITY; NUCLEOCYTOPLASMIC TRANSPORT; FACTOR EIF-5A; FACTOR 4D; GROWTH; IDENTIFICATION; PURIFICATION; INHIBITORS	Hypusine is formed through a spermidine-dependent posttranslational modification of eukaryotic initiation factor 5A (eIF-5A) at a specific lysine residue. The reaction is catalyzed by deoxyhypusine synthase and deoxyhypusine hydroxylase. eIF-5A is the only protein in eukaryotes and archaebacteria known to contain hypusine, Although both eIF-5A and deoxyhypusine synthase are essential genes for cell survival and proliferation, the precise biological function of eIF-5A is unclear. We have previously proposed that eIF-5A may function as a bimodular protein, capable of interacting with protein and nucleic acid (Liu, Y. P., Nemeroff, M., van, Y, P., and Chen, K, Y, (1997) Biol, Signals 6, 166-174), Here we used the method of systematic evolution of ligands by exponential enrichment (SELEX) to identify the sequence specificity of the potential eIF-5A RNA targets. The post-SELEX RNA obtained after 16 rounds of selection exhibited a significant increase in binding affinity for eIF-5A with an apparent dissociation constant of 1 x 10(-7) M, The hypusine residue was found to be critical for this sequence-specific binding. The post-SELEX RNAs shared a high sequence homology characterized by two conserved motifs, UAACCA and AAUGUCACAC. The consensus sequence was determined as AAAUGUCACAC by sequence alignment and binding studies. BLAST analysis indicated that this sequence was present in >400 human expressed sequence tag sequences. The C terminus of eIF-5A contains a cold shock domain-like structure, similar to that present in cold shock protein A (CspA), However, unlike CspA, the binding of eIF-5A to either the post-SELEX RNA or the 5'-untranslated region of CspA mRNA did not affect the sensitivity of these RNAs to ribonucleases. These data suggest that the physiological significance of eIF-5A-RNA interaction depends on hypusine and the core motif of the target RNA.	Rutgers State Univ, Dept Chem, Piscataway, NJ 08854 USA; Canc Inst New Jersey, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Chen, KY (corresponding author), Rutgers State Univ, Dept Chem, POB 939, Piscataway, NJ 08855 USA.	KYCHEN@rutchem.rutgers.edu		Chen, Kuang Yu/0000-0002-5629-7785	NATIONAL CANCER INSTITUTE [R01CA049695] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA49695] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNE R, 1978, J BIOL CHEM, V253, P3070; Berglund JA, 1997, NUCLEIC ACIDS RES, V25, P1042, DOI 10.1093/nar/25.5.1042; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Chen KY, 1997, BIOL SIGNAL, V6, P105; Chen ZP, 1996, CANCER LETT, V105, P233, DOI 10.1016/0304-3835(96)04287-5; Chen ZP, 1997, CANCER LETT, V115, P235, DOI 10.1016/S0304-3835(97)04741-1; Chen ZP, 1997, J CELL PHYSIOL, V170, P248, DOI 10.1002/(SICI)1097-4652(199703)170:3<248::AID-JCP5>3.0.CO;2-O; Cusack Stephen, 1999, Current Opinion in Structural Biology, V9, P66; DUNCAN RF, 1986, J BIOL CHEM, V261, P2903; Elfgang C, 1999, P NATL ACAD SCI USA, V96, P6229, DOI 10.1073/pnas.96.11.6229; GORDON ED, 1987, J BIOL CHEM, V262, P16590; HEAPHY S, 1990, CELL, V60, P685, DOI 10.1016/0092-8674(90)90671-Z; Jiang WN, 1997, J BIOL CHEM, V272, P196; KANG HA, 1994, J BIOL CHEM, V269, P3934; KATAHIRA J, 1995, J VIROL, V69, P3125, DOI 10.1128/JVI.69.5.3125-3133.1995; Kim KK, 1998, P NATL ACAD SCI USA, V95, P10419, DOI 10.1073/pnas.95.18.10419; Lee YB, 1999, BIOCHEM J, V340, P273, DOI 10.1042/0264-6021:3400273; Lipowsky G, 2000, EMBO J, V19, P4362, DOI 10.1093/emboj/19.16.4362; Liu YP, 1997, BIOL SIGNAL, V6, P166; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Park MH, 1998, J BIOL CHEM, V273, P1677, DOI 10.1074/jbc.273.3.1677; PARK MH, 1994, J BIOL CHEM, V269, P27827; PARK MH, 1989, J BIOL CHEM, V264, P18531; PARK MH, 1993, BIOFACTORS, V4, P95; Park MH, 1997, BIOL SIGNAL, V6, P115; Peat TS, 1998, STRUCT FOLD DES, V6, P1207, DOI 10.1016/S0969-2126(98)00120-8; RUHL M, 1993, J CELL BIOL, V123, P1309, DOI 10.1083/jcb.123.6.1309; Sasaki K, 1996, FEBS LETT, V384, P151, DOI 10.1016/0014-5793(96)00310-9; Schatz O, 1998, P NATL ACAD SCI USA, V95, P1607, DOI 10.1073/pnas.95.4.1607; SCHNIER J, 1991, MOL CELL BIOL, V11, P3105, DOI 10.1128/MCB.11.6.3105; Shi XP, 1996, BBA-MOL CELL RES, V1310, P119, DOI 10.1016/0167-4889(95)00165-4; Singh US, 1998, J BIOL CHEM, V273, P1946, DOI 10.1074/jbc.273.4.1946; SMITMCBRIDE Z, 1989, J BIOL CHEM, V264, P18527; TAO Y, 1994, BIOCHEM J, V302, P517, DOI 10.1042/bj3020517; Tome ME, 1997, BIOL SIGNAL, V6, P150; Trifillis P, 1999, RNA, V5, P1071, DOI 10.1017/S1355838299981803; TUREK C, 1990, SCIENCE, V1249, P505; ZU D, 1998, EMBO J, V17, P2914	39	77	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2555	2561		10.1074/jbc.M008982200	http://dx.doi.org/10.1074/jbc.M008982200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11060315	hybrid			2022-12-25	WOS:000166784800037
J	Pereno, R; Giron-Michel, J; Gaggero, A; Gazes, E; Meazza, R; Monetti, M; Monaco, E; Mishal, Z; Jasmin, C; Indiveri, F; Ferrini, S; Azzarone, B				Pereno, R; Giron-Michel, J; Gaggero, A; Gazes, E; Meazza, R; Monetti, M; Monaco, E; Mishal, Z; Jasmin, C; Indiveri, F; Ferrini, S; Azzarone, B			IL-15/IL-15R alpha intracellular trafficking in human melanoma cells and signal transduction through the IL-15R alpha	ONCOGENE			English	Article						IL-15; IL-15R alpha; secretion pattern; NF-kappa B; melanoma progression	NF-KAPPA-B; IL-15; RECEPTOR; EXPRESSION; CYTOKINE; PROTEINS; ISOFORMS; PEPTIDES; ALPHA; CHAIN	There are two IL-15 isoforms and eight isoforms for the IL-15R alpha chain whose biological role is poorly understood. Here, we have analysed the intracellular trafficking of IL-15 and IL-15R alpha and tried to shed some light on their function(s), In IL-15/GFP CHO transfectants both IL-15 isoforms show nuclear localization. Two melanoma cell lines (MELP and MELREO) spontaneously expressing the IL-15 isoforms, display different intracellular trafficking of the IL-15/IL-15R alpha complex, In MELP cells only IL-15R alpha is detected inside the nucleus, whereas IL-15 and IL-15R alpha assemble at the cell surface and are internalized, Moreover, the transducing molecule TRAF2 co-immunoprecipitates with IL-15R alpha and may be deflected to TNFRI using anti-IL-15 blocking mAbs and TNF-alpha, By contrast, MELREO cells display IL-15R alpha and IL-15 nuclear localization but only a partial co-localization of these molecules on the cell surface. In these cells, TRAF2 is strongly associated with IL-15R alpha and cannot be deflected by any treatment, Since TRAF2 activates the transcription factor NF-kappaB, IL-15 through IL-15R alpha, could have a role in the control of this pathway. Indeed, anti-IL-15 MaB inhibit the constitutive nuclear localization of NF kappaB and the phosphorylation of its inhibitor I kappa -B alpha, Thus, IL-15R alpha controls NF-KB activation, however differences in the intracellular trafficking of the IL-15 and/or IL-15R alpha suggest a different biological role for this complex in MELP versus MELREO cells.	Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France; Ist Nazl Ric Canc, I-16132 Genoa, Italy; DIMI, Fac Med, I-16132 Genoa, Italy; DOCS, Fac Med, F-94800 Villejuif, France; Lab Cytometrie, CNRS, UPS 47, F-94800 Villejuif, France; Hop Paul Brousse, INSERM, U268, F-94807 Villejuif, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Genoa; IRCCS AOU San Martino IST; Centre National de la Recherche Scientifique (CNRS); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Azzarone, B (corresponding author), Hop Paul Brousse, INSERM, U506, F-94807 Villejuif, France.		Indiveri, Francesco/AAE-9086-2020; Giron-Michel, Julien/Q-4503-2018; Azzarone, Bruno/AAH-9251-2019; Meazza, Raffaella/AAC-2425-2019	Giron-Michel, Julien/0000-0001-6613-6099; Azzarone, Bruno/0000-0002-5962-3849; Meazza, Raffaella/0000-0003-0242-3157; Ferrini, Silvano/0000-0001-7254-2616; Induveri, Francesco/0000-0002-9280-2232				Alleva DG, 1997, J IMMUNOL, V159, P2941; ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; Baker SJ, 1996, ONCOGENE, V12, P1; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bamford RN, 1996, P NATL ACAD SCI USA, V93, P2897, DOI 10.1073/pnas.93.7.2897; Barzegar C, 1998, ONCOGENE, V16, P2503, DOI 10.1038/sj.onc.1201775; Bulfone-Paus S, 1999, FASEB J, V13, P1575, DOI 10.1096/fasebj.13.12.1575; Dubois S, 1999, J BIOL CHEM, V274, P26978, DOI 10.1074/jbc.274.38.26978; Duffey DC, 1999, CANCER RES, V59, P3468; Gaggero A, 1999, EUR J IMMUNOL, V29, P1265, DOI 10.1002/(SICI)1521-4141(199904)29:04<1265::AID-IMMU1265>3.0.CO;2-V; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; Hallahan DE, 1998, CANCER RES, V58, P5484; Meazza R, 1997, EUR J IMMUNOL, V27, P1049, DOI 10.1002/eji.1830270502; Meazza R, 1996, ONCOGENE, V12, P2187; Musso T, 1999, BLOOD, V93, P3531; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Shah MH, 1998, NAT MED, V4, P643, DOI 10.1038/nm0698-643a; Tagaya Y, 1997, P NATL ACAD SCI USA, V94, P14444, DOI 10.1073/pnas.94.26.14444; Waldmann TA, 1999, ANNU REV IMMUNOL, V17, P19, DOI 10.1146/annurev.immunol.17.1.19; Washizu J, 1998, IMMUNOGENETICS, V48, P1, DOI 10.1007/s002510050393	21	61	72	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5153	5162		10.1038/sj.onc.1203873	http://dx.doi.org/10.1038/sj.onc.1203873			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064452				2022-12-25	WOS:000090124100004
J	Larsen, RA; Postle, K				Larsen, RA; Postle, K			Conserved residues Ser(16) and His(20) and their relative positioning are essential for TonB activity, cross-linking of TonB with ExbB, and the ability of TonB to respond to proton motive force	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI TONB; CYTOPLASMIC MEMBRANE-PROTEIN; ENERGY TRANSDUCTION COMPLEX; CELL-ENVELOPE INTEGRITY; OUTER-MEMBRANE; IRON TRANSPORT; NUCLEOTIDE-SEQUENCES; SIGNAL-TRANSDUCTION; MUTATIONAL ANALYSIS; COUPLED TRANSPORT	The cytoplasmic membrane protein TonB couples the proton electrochemical potential of the cytoplasmic membrane to transport events at the outer membrane of Gram-negative bacteria. The amino-terminal signal anchor of TonB and its interaction with the cytoplasmic membrane protein ExbB are essential to this process, The TonB signal anchor is predicted to form an alpha -helix, with a conserved face comprised of residues Ser(16), His(20), Leu(27), and Ser(31). Deletion of either Ser(16) or His(20) or of individual intervening but not flanking residues rendered TonB inactive and unable to assume a proton motive force-dependent conformation. In vivo formaldehyde cross-linking experiments revealed that the ability of this subset of mutants to form a characteristic heterodimer with ExbB was greatly diminished. Replacement of residues 17-19 by three consecutive alanines produced a wild type TonB allele, indicating that the intervening residues (Val, Cys, and Ile) contributed only to spacing. These data indicated that the spatial relationship of Ser(16) to His(20) was essential to function and suggested that the motif HXXYS defines the minimal requirement for the coupling of TonB to the cytoplasmic membrane electrochemical gradient, Deletion of Trp(11) resulted in a TonB that remained active yet was unable to cross-link with ExbB, Because Trp(11) was demonstrably not involved in the actual cross-linking, these results suggest that the TonB/ExbB interaction detected by cross-linking occurred at a step in the energy transduction cycle distinct from the coupling of TonB to the electrochemical gradient.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Postle, K (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.		Larsen, Ray/AHE-8563-2022	Postle, Kathleen/0000-0001-9451-777X	NIGMS NIH HHS [GM42146, R01 GM042146] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042146] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMER BMM, 1995, J BACTERIOL, V177, P4742, DOI 10.1128/jb.177.16.4742-4747.1995; BASSFORD PJ, 1976, J BACTERIOL, V128, P242, DOI 10.1128/JB.128.1.242-247.1976; BRADBEER C, 1991, BIOFACTORS, V3, P11; BRADBEER C, 1993, J BACTERIOL, V175, P3146, DOI 10.1128/JB.175.10.3146-3150.1993; BRAUN V, 1989, J BACTERIOL, V171, P6387, DOI 10.1128/jb.171.11.6387-6390.1989; Braun V, 1996, J BACTERIOL, V178, P2836, DOI 10.1128/jb.178.10.2836-2845.1996; BRAUN V, 1995, FEMS MICROBIOL REV, V16, P295, DOI 10.1111/j.1574-6976.1995.tb00177.x; BRAUN V, 1993, MOL MICROBIOL, V8, P261, DOI 10.1111/j.1365-2958.1993.tb01570.x; DAVIES JK, 1975, J BACTERIOL, V123, P96, DOI 10.1128/JB.123.1.96-101.1975; EICKHELMERICH K, 1989, J BACTERIOL, V171, P5117, DOI 10.1128/jb.171.9.5117-5126.1989; FROST GE, 1975, J BACTERIOL, V124, P704, DOI 10.1128/JB.124.2.704-712.1975; Germon P, 1998, J BACTERIOL, V180, P6433, DOI 10.1128/JB.180.24.6433-6439.1998; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; HANCOCK REW, 1976, J BACTERIOL, V125, P409, DOI 10.1128/JB.125.2.409-415.1976; HANNAVY K, 1990, J MOL BIOL, V216, P897, DOI 10.1016/S0022-2836(99)80009-6; HANTKE K, 1981, FEMS MICROBIOL LETT, V12, P31; HANTKE K, 1975, FEBS LETT, V49, P301, DOI 10.1016/0014-5793(75)80771-X; Higgs PI, 1998, J BACTERIOL, V180, P6031, DOI 10.1128/JB.180.22.6031-6038.1998; HILL CW, 1981, P NATL ACAD SCI-BIOL, V78, P7069, DOI 10.1073/pnas.78.11.7069; Holroyd C, 1984, MICROBIOLOGY 1984, P21; JASKULA JC, 1994, J BACTERIOL, V176, P2326, DOI 10.1128/JB.176.8.2326-2338.1994; KADNER RJ, 1990, MOL MICROBIOL, V4, P2027, DOI 10.1111/j.1365-2958.1990.tb00562.x; KAMPFENKEL K, 1992, J BACTERIOL, V174, P5485, DOI 10.1128/JB.174.16.5485-5487.1992; KAMPFENKEL K, 1993, J BIOL CHEM, V268, P6050; KARLSSON M, 1993, MOL MICROBIOL, V8, P379, DOI 10.1111/j.1365-2958.1993.tb01581.x; KOEBNIK R, 1993, MOL MICROBIOL, V9, P219, DOI 10.1111/j.1365-2958.1993.tb01683.x; KOSTER W, 1990, MOL GEN GENET, V223, P379; KYTE J, 1982, J MOL BIOL, V157, P5; LARSEN RA, 1994, MOL MICROBIOL, V13, P627, DOI 10.1111/j.1365-2958.1994.tb00457.x; LARSEN RA, 1993, MOL MICROBIOL, V10, P943, DOI 10.1111/j.1365-2958.1993.tb00966.x; Larsen RA, 1997, J BACTERIOL, V179, P3213, DOI 10.1128/jb.179.10.3213-3221.1997; Larsen RA, 1996, J BACTERIOL, V178, P1363, DOI 10.1128/jb.178.5.1363-1373.1996; Larsen RA, 1999, MOL MICROBIOL, V31, P1809, DOI 10.1046/j.1365-2958.1999.01317.x; Letain TE, 1997, MOL MICROBIOL, V24, P271, DOI 10.1046/j.1365-2958.1997.3331703.x; LEVENGOOD SK, 1991, P NATL ACAD SCI USA, V88, P5939, DOI 10.1073/pnas.88.14.5939; LEVENGOOD SK, 1989, J BACTERIOL, V171, P6600, DOI 10.1128/jb.171.12.6600-6609.1989; MATSUSHIRO A, 1963, VIROLOGY, V19, P475, DOI 10.1016/0042-6822(63)90041-2; MICHAEL SF, 1994, BIOTECHNIQUES, V16, P410; Miller JH, 1972, EXPT MOL GENETICS, P201; Moeck GS, 1997, J BIOL CHEM, V272, P28391, DOI 10.1074/jbc.272.45.28391; Moeck GS, 1998, MOL MICROBIOL, V28, P675, DOI 10.1046/j.1365-2958.1998.00817.x; MULLER MM, 1993, J BACTERIOL, V175, P6059, DOI 10.1128/JB.175.18.6059-6061.1993; POSTLE K, 1988, J BIOL CHEM, V263, P11000; POSTLE K, 1993, J BIOENERG BIOMEMBR, V25, P591; POSTLE K, 1983, P NATL ACAD SCI-BIOL, V80, P5235, DOI 10.1073/pnas.80.17.5235; REYNOLDS PR, 1980, J BIOL CHEM, V255, P4313; ROOF SK, 1991, J BACTERIOL, V173, P5554, DOI 10.1128/jb.173.17.5554-5557.1991; SKARE JT, 1991, MOL MICROBIOL, V5, P2883, DOI 10.1111/j.1365-2958.1991.tb01848.x; SKARE JT, 1993, J BIOL CHEM, V268, P16302; SUN TP, 1987, J BACTERIOL, V169, P2667, DOI 10.1128/jb.169.6.2667-2674.1987; TRAUB I, 1993, MOL MICROBIOL, V8, P409, DOI 10.1111/j.1365-2958.1993.tb01584.x; VIANNEY A, 1994, J BACTERIOL, V176, P822, DOI 10.1128/jb.176.3.822-829.1994	52	48	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8111	8117		10.1074/jbc.M007479200	http://dx.doi.org/10.1074/jbc.M007479200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11087740	hybrid			2022-12-25	WOS:000167474900062
J	Basran, J; Patel, S; Sutcliffe, MJ; Scrutton, NS				Basran, J; Patel, S; Sutcliffe, MJ; Scrutton, NS			Importance of barrier shape in enzyme-catalyzed reactions - Vibrationally assisted hydrogen tunneling in tryptophan tryptophylquinone-dependent amine dehydrogenases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOPROTEIN METHYLAMINE DEHYDROGENASE; ELECTRON-TRANSFER COMPLEX; PROTON-TRANSFER; COUPLED MOTION; OXIDASE; MECHANISM; AMICYANIN; DYNAMICS; INTERMEDIATE; ENZYMOLOGY	C-H bond breakage by tryptophan tryptophylquinone (TTQ) dependent methylamine dehydrogenase (MADH) occurs by vibrationally assisted tunneling (Basran, J., Sutcliffe, M. J., and Scrutton, N. S. (1999) Biochemistry 38, 3218-3222). We show here a similar mechanism in TTQ-dependent aromatic amine dehydrogenase (AADH). The rate of TTQ reduction by dopamine in AADH has a large, temperature independent kinetic isotope effect (KIE = 12.9 +/- 0.2), which is highly suggestive of vibrationally assisted tunneling. H-transfer is compromised with benzylamine as substrate and the KIE is deflated (4.8 +/- 0.2). The KIE is temperature independent, but reaction rates are strongly dependent on temperature. With tryptamine as substrate reaction rates can be determined only at low temperature as C-H bond cleavage is rapid, and an exceptionally large KIE (54.7 +/- 1.0) is observed. Studies with deuterated tryptamine suggest vibrationally assisted tunneling is the mechanism of deuterium and, by inference, hydrogen transfer. Bond cleavage by MADH using a slow substrate (ethanolamine) occurs with an inflated KIE (14.7 +/- 0.2 at 25 degreesC). The KIE is temperature-dependent, consistent with differential tunneling of protium and deuterium. Our observations illustrate the different modes of H-transfer in MADH and AADH with fast and slow substrates and highlight the importance of barrier shape in determining reaction rate.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; Univ Leicester, Dept Chem, Leicester LE1 7RH, Leics, England	University of Leicester; University of Leicester	Scrutton, NS (corresponding author), Univ Leicester, Dept Biochem, Univ Rd, Leicester LE1 7RH, Leics, England.			Sutcliffe, Mike/0000-0003-0414-1700				Alston WC, 1996, BIOCHEMISTRY-US, V35, P12873, DOI 10.1021/bi960831a; Antoniou D, 1997, P NATL ACAD SCI USA, V94, P12360, DOI 10.1073/pnas.94.23.12360; Basran J, 1999, BIOCHEMISTRY-US, V38, P3218, DOI 10.1021/bi982719d; Bell R. P., 1980, TUNNEL EFFECT CHEM, P51; BORGIS D, 1991, J CHEM PHYS, V94, P3619, DOI 10.1063/1.459733; BROOKS HB, 1994, BIOCHEMISTRY-US, V33, P5696, DOI 10.1021/bi00185a005; BROOKS HB, 1993, BIOCHEMISTRY-US, V32, P2725, DOI 10.1021/bi00061a034; Bruice TC, 2000, BIOCHEMISTRY-US, V39, P6267, DOI 10.1021/bi0003689; BRUNO WJ, 1992, BIOPHYS J, V63, P689, DOI 10.1016/S0006-3495(92)81654-5; BRUNTON G, 1976, J AM CHEM SOC, V98, P6803, DOI 10.1021/ja00438a005; Cannon WR, 1996, NAT STRUCT BIOL, V3, P821, DOI 10.1038/nsb1096-821; CHA Y, 1989, SCIENCE, V243, P1325, DOI 10.1126/science.2646716; CHANDRASEKAR R, 1986, J BIOL CHEM, V261, P3616; CHEN LY, 1992, BIOCHEMISTRY-US, V31, P4959, DOI 10.1021/bi00136a006; CHEN LY, 1994, SCIENCE, V264, P86, DOI 10.1126/science.8140419; CHEN LY, 1992, PROTEINS, V14, P288, DOI 10.1002/prot.340140214; DAVIDSON VL, 1990, METHOD ENZYMOL, V188, P241; DAVIDSON VL, 1992, BIOCHEMISTRY-US, V31, P3385, DOI 10.1021/bi00128a012; GOVINDARAJ S, 1994, J BACTERIOL, V176, P2922, DOI 10.1128/JB.176.10.2922-2929.1994; GRANT KL, 1989, BIOCHEMISTRY-US, V28, P6597, DOI 10.1021/bi00442a010; Harris RJ, 2000, BIOCHEMISTRY-US, V39, P1189, DOI 10.1021/bi991941v; Hiromi K., 1979, KINETICS FAST ENZYME; HYUN YL, 1995, BBA-PROTEIN STRUCT M, V1251, P198, DOI 10.1016/0167-4838(95)00117-D; HYUN YL, 1995, BIOCHEMISTRY-US, V34, P12249, DOI 10.1021/bi00038a020; Jonsson T, 1996, J AM CHEM SOC, V118, P10319, DOI 10.1021/ja961827p; JONSSON T, 1994, BIOCHEMISTRY-US, V33, P14871, DOI 10.1021/bi00253a026; Karsten WE, 1999, BIOCHEMISTRY-US, V38, P4398, DOI 10.1021/bi982439y; Klinman J P, 1978, Adv Enzymol Relat Areas Mol Biol, V46, P415; Kohen A, 1999, CHEM BIOL, V6, pR191, DOI 10.1016/S1074-5521(99)80058-1; Kohen A, 1999, NATURE, V399, P496, DOI 10.1038/20981; Kohen A, 1997, BIOCHEMISTRY-US, V36, P2603, DOI 10.1021/bi962492r; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; Kuznetsov AM, 1999, CAN J CHEM, V77, P1085, DOI 10.1139/cjc-77-5-6-1085; MCWHIRTER RB, 1989, PQQ AND QUINOPROTEINS, P259; MILLER WH, 1986, SCIENCE, V233, P171, DOI 10.1126/science.233.4760.171; Nesheim JC, 1996, BIOCHEMISTRY-US, V35, P10240, DOI 10.1021/bi960596w; Scrutton NS, 1999, EUR J BIOCHEM, V264, P666, DOI 10.1046/j.1432-1327.1999.00645.x; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; Sutcliffe MJ, 2000, TRENDS BIOCHEM SCI, V25, P405, DOI 10.1016/S0968-0004(00)01642-X; Sutcliffe MJ, 2000, PHILOS T ROY SOC A, V358, P367, DOI 10.1098/rsta.2000.0536; Van Hook W, 1971, ISOTOPE EFFECTS CHEM, P1; Whittaker MM, 1998, BIOCHEMISTRY-US, V37, P8426, DOI 10.1021/bi980328t; Zhu ZY, 1998, BIOCHEM J, V329, P175, DOI 10.1042/bj3290175	43	95	97	0	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6234	6242		10.1074/jbc.M008141200	http://dx.doi.org/10.1074/jbc.M008141200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11087744	hybrid			2022-12-25	WOS:000167261000025
J	Giardina, PC; Gioannini, T; Buscher, BA; Zaleski, A; Zheng, DS; Stoll, L; Teghanemt, A; Apicella, MA; Weiss, J				Giardina, PC; Gioannini, T; Buscher, BA; Zaleski, A; Zheng, DS; Stoll, L; Teghanemt, A; Apicella, MA; Weiss, J			Construction of acetate auxotrophs of Neisseria meningitidis to study host-meningococcal endotoxin interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOPOLYSACCHARIDE-BINDING-PROTEIN; MONOCYTE DIFFERENTIATION ANTIGEN; PERMEABILITY-INCREASING PROTEIN; PERITONEAL INFLAMMATORY EXUDATE; POLYSIALIC ACID CAPSULE; GRAM-NEGATIVE BACTERIA; TOLL-LIKE RECEPTOR-4; SOLUBLE CD14; EPITHELIAL-CELLS; INTERLEUKIN-8 EXPRESSION	To facilitate studies of the molecular determinants of host-meningococcal lipooligosaccharide (endotoxin) interactions at patho-physiologically relevant endotoxin concentrations (i.e. less than or equal to 10 ng/ml), we have generated acetate auxotrophs NMBACE1 from encapsulated Neisseria meningitidis (serogroup B, strain NMB) and NMBACE2 from an isogenic bacterial mutant lacking the polysialic acid capsule. Growth of the auxotrophs in medium containing [C-14]acetate yielded C-14-lipooligosaccharides containing similar to 600 cpm/ng. Gel sieving resolved C-14-lipooligosaccharide-containing aggregates with an estimated molecular mass of greater than or equal to 20 x 10(6) Da (peak A) and similar to1 x 106 Da (peak B) from both strains. Lipooligosaccharides in peaks A and B had the same fatty acid composition and SDS polyacrylamide gel electrophoresis profile. C-14-Labeled capsule copurified with 14C-lipooligosaccharides in peak B from NMBACE1, whereas the other aggregates contained only C-14-lipooligosaccharide. For all aggregates, lipopolysaccharide-binding protein and soluble CD14-induced delivery of lipooligosaccharides to endothelial cells and cell activation correlated with disaggregation of lipooligosaccharides. These processes were inhibited by the presence of capsule but unaffected by the size of the aggregates. In contrast, endotoxin activation of cells containing membrane CD14 was unaffected by capsule but diminished when endotoxin was presented in larger aggregates. These findings demonstrate that the physical presentation of lipooligosaccharide, including possible interactions with capsule, affect the ability of meningococcal endotoxin to interact with and activate specific host targets.	Univ Iowa, Dept Med, Div Infect Dis, Inflammat Program, Iowa City, IA 52242 USA; Univ Iowa, Dept Microbiol, Div Infect Dis, Inflammat Program, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Div Infect Dis, Inflammat Program, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Weiss, J (corresponding author), Univ Iowa, Dept Med, Div Infect Dis, Inflammat Program, 200 Hawkins Dr, Iowa City, IA 52242 USA.			Weiss, Jerrold/0000-0003-1476-4485	NIAID NIH HHS [R01AI145728, P01AI44642, AI07343] Funding Source: Medline; NIDDK NIH HHS [DK05472] Funding Source: Medline; PHS HHS [P014462] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK005472, R37DK005472] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXEYEV MF, 1995, BIOTECHNIQUES, V18, P52; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Becher B, 1996, J NEUROSCI RES, V45, P375; Boudjellab N, 1998, AM J VET RES, V59, P1563; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRANDTZAEG P, 1992, J CLIN INVEST, V89, P816, DOI 10.1172/JCI115660; BRANDTZAEG P, 1989, J INFECT DIS, V160, P58, DOI 10.1093/infdis/160.1.58; BRANDTZAEG P, 1989, THROMB RES, V55, P459, DOI 10.1016/0049-3848(89)90054-6; BRANDTZAEG P, 1989, REGUL PEPTIDES, V24, P37, DOI 10.1016/0167-0115(89)90209-7; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; CAMUSSI G, 1995, J IMMUNOL, V155, P316; Denning GM, 1998, INFECT IMMUN, V66, P5777, DOI 10.1128/IAI.66.12.5777-5784.1998; DEVOE IW, 1973, J EXP MED, V138, P1156, DOI 10.1084/jem.138.5.1156; Diamond G, 1996, P NATL ACAD SCI USA, V93, P5156, DOI 10.1073/pnas.93.10.5156; Ding SZ, 1997, BIOCHEM BIOPH RES CO, V240, P561, DOI 10.1006/bbrc.1997.7699; ELSBACH P, 1993, CURR OPIN IMMUNOL, V5, P103, DOI 10.1016/0952-7915(93)90088-A; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; HARRIS HW, 1993, J CLIN INVEST, V91, P1028, DOI 10.1172/JCI116259; HAZIOT A, 1988, J IMMUNOL, V141, P547; HAZIOT A, 1993, J IMMUNOL, V150, P5556; Iovine NM, 1997, P NATL ACAD SCI USA, V94, P10973, DOI 10.1073/pnas.94.20.10973; Kahler CM, 1998, INFECT IMMUN, V66, P5939, DOI 10.1128/IAI.66.12.5939-5947.1998; Kahler CM, 1998, CRIT REV MICROBIOL, V24, P281, DOI 10.1080/10408419891294216; Katz SS, 1999, J BIOL CHEM, V274, P36579, DOI 10.1074/jbc.274.51.36579; Kitchens RL, 1998, J IMMUNOL, V160, P1920; Klein R, 1996, CLIN EXP PHARMACOL P, V23, P754, DOI 10.1111/j.1440-1681.1996.tb01773.x; KULSHIN VA, 1992, J BACTERIOL, V174, P1793, DOI 10.1128/jb.174.6.1793-1800.1992; McNeil G, 1997, MICROB PATHOGENESIS, V22, P295, DOI 10.1006/mpat.1996.0126; MORSE SA, 1977, GONOCOCCUS, P213; MUNFORD RS, 1992, J IMMUNOL METHODS, V148, P115, DOI 10.1016/0022-1759(92)90164-O; Neveling U, 1998, BBA-PROTEIN STRUCT M, V1385, P367, DOI 10.1016/S0167-4838(98)00080-6; PETTIT FH, 1982, METHOD ENZYMOL, V89, P376; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRINCE A, 1992, MICROB PATHOGENESIS, V13, P251, DOI 10.1016/0882-4010(92)90035-M; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Read RC, 1996, INFECT IMMUN, V64, P3210, DOI 10.1128/IAI.64.8.3210-3217.1996; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; STEPHENS DS, 1994, INFECT IMMUN, V62, P2947, DOI 10.1128/IAI.62.7.2947-2952.1994; Tanikawa K, 1998, PROG CLIN BIOL RES, V397, P191; Tapping RI, 1997, J BIOL CHEM, V272, P23157, DOI 10.1074/jbc.272.37.23157; Thieblemont N, 1999, J EXP MED, V190, P523, DOI 10.1084/jem.190.4.523; Tobias PS, 1999, CLIN INFECT DIS, V28, P476, DOI 10.1086/515163; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; Tobias PS, 1997, J PERIODONTAL RES, V32, P99, DOI 10.1111/j.1600-0765.1997.tb01388.x; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; Vasselon T, 1999, J EXP MED, V190, P509, DOI 10.1084/jem.190.4.509; Vogel SN, 1998, PROG CLIN BIOL RES, V397, P137; Weinrauch Y, 1999, INFECT IMMUN, V67, P3376, DOI 10.1128/IAI.67.7.3376-3382.1999; WESTPHAL O., 1965, METHOD CARBOHYD CHEM, V5, P83; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel M M, 1995, Prog Clin Biol Res, V392, P287; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; Yoshimura A, 1997, J PERIODONTAL RES, V32, P279, DOI 10.1111/j.1600-0765.1997.tb00535.x; Yu B, 1996, J BIOL CHEM, V271, P4100	63	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5883	5891		10.1074/jbc.M009273200	http://dx.doi.org/10.1074/jbc.M009273200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11084043	hybrid			2022-12-25	WOS:000167115100065
J	Lombardi, R; Riezman, H				Lombardi, R; Riezman, H			Rvs161p and Rvs167p, the two yeast amphiphysin homologs, function together in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ACTIN CYTOSKELETON; INTERNALIZATION STEP; PROTEIN INTERACTIONS; IN-VIVO; ENDOCYTOSIS; GENE; VIABILITY; COMPLEXES; DOMAINS	Mutations in RVS161 and RVS167, the two yeast amphiphysin homologs, cause very similar growth phenotypes, a depolarized actin cytoskeleton, and a defect in the internalization step of endocytosis. Rvs161p and Rvs167p have been shown to interact in the two-hybrid system, but their localization in the cell may be different thus raising the question whether the interaction is physiologically relevant. Here we demonstrate that the two proteins function together in vivo. We find that the steady state level of Rvs167p is strongly reduced in an rvs161 Delta strain. Similarly the level of Rvs161p is strongly reduced in an rvs167 Delta strain, We demonstrate that these reduced protein levels at steady state are due to a decreased stability of either Rvs protein in the absence of the other protein. Furthermore, we find that the amount and ratio of Rvs161p and Rvs167p are critical parameters for receptor-mediated endocytosis. In addition, by using the two-hybrid system we show that the interaction of Rvs167p with actin is not abolished in an abp1 Delta strain suggesting that Abp1p is not essential for this interaction.	Univ Basel, Bioctr, CH-4056 Basel, Switzerland	University of Basel	Riezman, H (corresponding author), Univ Basel, Bioctr, Klingelbergstr 70, CH-4056 Basel, Switzerland.	Howard.Riezman@unibas.ch		Riezman, Howard/0000-0003-4680-9422				AMBERG DC, 1995, NAT STRUCT BIOL, V2, P28, DOI 10.1038/nsb0195-28; Balguerie A, 1999, J CELL SCI, V112, P2529; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Bauerfeind R, 1997, J BIOL CHEM, V272, P30984, DOI 10.1074/jbc.272.49.30984; BENEDETTI H, 1994, MOL BIOL CELL, V5, P1023, DOI 10.1091/mbc.5.9.1023; Brizzio V, 1998, J CELL BIOL, V141, P567, DOI 10.1083/jcb.141.3.567; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; Colwill K, 1999, GENETICS, V152, P881; CROUZET M, 1991, YEAST, V7, P727, DOI 10.1002/yea.320070708; DAVID C, 1994, FEBS LETT, V351, P73, DOI 10.1016/0014-5793(94)00826-4; DULIC V, 1991, METHOD ENZYMOL, V194, P697; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; GELI MJ, 2000, EMBO J, V19; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee J, 1998, CURR BIOL, V8, P1310, DOI 10.1016/S0960-9822(07)00561-1; LICHTE B, 1992, EMBO J, V11, P2521, DOI 10.1002/j.1460-2075.1992.tb05317.x; Lila T, 1997, MOL BIOL CELL, V8, P367, DOI 10.1091/mbc.8.2.367; Madania A, 1999, MOL BIOL CELL, V10, P3521, DOI 10.1091/mbc.10.10.3521; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Navarro P, 1997, BBA-PROTEIN STRUCT M, V1343, P187, DOI 10.1016/S0167-4838(97)00108-8; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIVADON P, 1995, MOL GEN GENET, V246, P485, DOI 10.1007/BF00290452; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Wigge P, 1997, MOL BIOL CELL, V8, P2003, DOI 10.1091/mbc.8.10.2003; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8	30	47	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					6016	6022		10.1074/jbc.M008735200	http://dx.doi.org/10.1074/jbc.M008735200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11096097	hybrid			2022-12-25	WOS:000167115100081
J	Alonso, A; Saxena, M; Williams, S; Mustelin, T				Alonso, A; Saxena, M; Williams, S; Mustelin, T			Inhibitory role for dual specificity phosphatase VHR in T cell antigen receptor and CD28-induced Erk and Jnk activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; KINASE-ACTIVITY; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; CRYSTAL-STRUCTURE; CATALYTIC ROLE; GENE; EXPRESSION; TRANSCRIPTION; STIMULATION	The 21-kDa dual specific protein phosphatase VH1-related (VHR) is one of the smallest known phosphatases, and its function has remained obscure. We report that this enzyme is expressed in lymphoid cells and is not induced by T cell antigen receptor like other dual specificity phosphatases. Introduction of exogenous VHR into Jurkat T cells caused a marked decrease in the transcriptional activation of a nuclear factor of activated T cells and an activator protein-1-driven reporter gene in response to ligation of T cell antigen receptors. The inhibition was dose-dependent and was similar at different doses of anti-receptor antibody. Catalytically inactive VHR mutants caused an increase in gene activation, suggesting a role for endogenous VHR in this response. In contrast, the activation of a nuclear factor KB-driven reporter was not affected. The inhibitory effects of VHR were also seen at the level of the mitogen-activated kinases Erk1, Erk2, Jnk1, Jnk2, and on reporter genes that directly depend on these kinases, namely Elk, c-Jun, and activator protein-1. In contrast, p38 kinase activation was not affected by VHR, and p38-assisted gene activation was less sensitive. Our results suggest that VHR is a negative regulator of the Erk and Jnk pathways in T cells and, therefore, may play a role in aspects of T lymphocyte physiology that depend on these kinases.	La Jolla Canc Res Ctr, Burnham Inst, Lab Signal Transduct, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Mustelin, T (corresponding author), La Jolla Canc Res Ctr, Burnham Inst, Lab Signal Transduct, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	tmustelin@burnhman-inst.org	Alonso, Andrés/L-7523-2014	Alonso, Andrés/0000-0001-8674-9378; Mustelin, Tomas/0000-0001-5912-8840	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041481, R01AI040552, R21AI040552, R01AI035603, R01AI048032] Funding Source: NIH RePORTER; NIAID NIH HHS [AI40552, AI48032, AI35603, AI41481] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARFORD D, 1994, SCIENCE, V263, P1397, DOI 10.1126/science.8128219; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; DENU JM, 1995, P NATL ACAD SCI USA, V92, P5910, DOI 10.1073/pnas.92.13.5910; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; DENU JM, 1995, BIOCHEMISTRY-US, V34, P3396, DOI 10.1021/bi00010a031; Dorfman K, 1996, ONCOGENE, V13, P925; Gjorloff-Wingren A, 1999, EUR J IMMUNOL, V29, P3845, DOI 10.1002/(SICI)1521-4141(199912)29:12<3845::AID-IMMU3845>3.0.CO;2-U; GUAN KL, 1991, NATURE, V350, P359, DOI 10.1038/350359a0; Hata D, 1998, J BIOL CHEM, V273, P10979, DOI 10.1074/jbc.273.18.10979; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Jascur T, 1997, J BIOL CHEM, V272, P14483, DOI 10.1074/jbc.272.22.14483; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; King AG, 1995, ONCOGENE, V11, P2553; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; NEL AE, 1990, J IMMUNOL, V144, P2683; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Sabapathy K, 1999, CURR BIOL, V9, P116, DOI 10.1016/S0960-9822(99)80065-7; Salmon RA, 1997, J IMMUNOL, V159, P5309; Saxena M, 1999, J BIOL CHEM, V274, P11693, DOI 10.1074/jbc.274.17.11693; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Saxena M, 2000, SEMIN IMMUNOL, V12, P387, DOI 10.1006/smim.2000.0219; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUN H, 1994, SCIENCE, V266, P285, DOI 10.1126/science.7939666; Todd JL, 1999, J BIOL CHEM, V274, P13271, DOI 10.1074/jbc.274.19.13271; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; Yuvaniyama J, 1996, SCIENCE, V272, P1328, DOI 10.1126/science.272.5266.1328; ZHOU GC, 1994, J BIOL CHEM, V269, P28084	37	99	103	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4766	4771		10.1074/jbc.M006497200	http://dx.doi.org/10.1074/jbc.M006497200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11085983	hybrid			2022-12-25	WOS:000168484300033
J	Hu, XL; Bi, J; Loh, HH; Wei, LN				Hu, XL; Bi, J; Loh, HH; Wei, LN			An intronic Ikaros-binding element mediates retinoic acid suppression of the kappa opioid receptor gene, accompanied by histone deacetylation on the promoters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORPHINE-INDUCED ANALGESIA; TRANSCRIPTION FACTOR; VISCERAL PAIN; MESSENGER-RNA; MOUSE; EXPRESSION; MICE; REPRESSION; LIGAND; WITHDRAWAL	The mouse kappa opioid receptor (KOR) gene is constitutively expressed in mouse embryonal carcinoma P19 stem cells and suppressed by retinoic acid (RA) in cells undergoing neuronal differentiation. A negative regulatory element is located within intron 1 of the KOR gene, which contains an Ikaros (Ik)-binding site (GG-GAAgGGGAT). This sequence is an Ik-1 respondive, functionally negative element as demonstrated in the context of both natural KOR and heterologous promoters. The two underlined G residues of the second half-site are critical for Ik-1 binding and Ik-mediated repression of the KOR gene. RA induces Ik-1 expression within 1 day of treatment and suppresses KOR expression between 2 and 3 days. Overexpression of Ik-1 in P19 suppresses endogenous KOR gene expression, accompanied by increased binding of Ik-1 to the Ik-binding site and chromatin histone deacetylation on KOR promoters. It is proposed that in an RA-induced P19 differentiation model, RA elevates Ik-1 expression, which recruits histone deacetylase to intron 1 of the KOR gene and silences KOR gene promoters.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Wei, LN (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson,321 Church St SE, Minneapolis, MN 55455 USA.	weixx009@tc.umn.edu		, Jing/0000-0001-8959-0999	NIDA NIH HHS [DA00564, DA70554, DA11806, DA11190] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA011806, R01DA000564, R01DA011190, R56DA000564] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Black D, 1998, GUT, V43, P312, DOI 10.1136/gut.43.3.312; Chen HC, 1999, NEUROSCIENCE, V92, P1143, DOI 10.1016/S0306-4522(99)00030-5; Chinpaisal C, 1998, J BIOL CHEM, V273, P18077, DOI 10.1074/jbc.273.29.18077; ELDE R, 1995, ANN NY ACAD SCI, V757, P390, DOI 10.1111/j.1749-6632.1995.tb17497.x; GEORGOPOULOS K, 1992, SCIENCE, V258, P808, DOI 10.1126/science.1439790; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; HAHM KM, 1994, MOL CELL BIOL, V14, P7111, DOI 10.1128/MCB.14.11.7111; Hu XL, 1999, MOL BRAIN RES, V69, P35, DOI 10.1016/S0169-328X(99)00077-7; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; KITCHEN I, 1990, EUR J PHARMACOL, V175, P93, DOI 10.1016/0014-2999(90)90157-2; KNAPP RJ, 1995, FASEB J, V9, P516, DOI 10.1096/fasebj.9.7.7737460; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Lee CH, 1998, MOL CELL BIOL, V18, P6745, DOI 10.1128/MCB.18.11.6745; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; LOH HH, 1990, ANNU REV PHARMACOL, V30, P123; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; Lu SL, 1997, MOL PHARMACOL, V52, P415, DOI 10.1124/mol.52.3.415; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Naruse Y, 1999, P NATL ACAD SCI USA, V96, P13691, DOI 10.1073/pnas.96.24.13691; Rius R A, 1991, Brain Res Dev Brain Res, V58, P237; Simonin F, 1998, EMBO J, V17, P886, DOI 10.1093/emboj/17.4.886; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Tian MT, 1997, J EXP MED, V185, P1517, DOI 10.1084/jem.185.8.1517; Wei LN, 2000, MOL PHARMACOL, V57, P401; WEI LN, 1996, HDB PSYCHIAT GENETIC, P77; Zhu YX, 1998, J NEUROSCI, V18, P2538	29	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4597	4603		10.1074/jbc.M005477200	http://dx.doi.org/10.1074/jbc.M005477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11092879	hybrid			2022-12-25	WOS:000168484300012
J	Bai, JX; Cederbaum, AI				Bai, JX; Cederbaum, AI			Adenovirus-mediated overexpression of catalase in the cytosolic or mitochondrial compartment protects against cytochrome P450 2E1-dependent toxicity in HepG2 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; HYDROGEN-PEROXIDE; LIPID-PEROXIDATION; INDUCED APOPTOSIS; PERMEABILITY TRANSITION; GLUTATHIONE-PEROXIDASE; LIVER-INJURY; G2 CELLS; FISH-OIL; 2E1	Cytochrome P450 2E1 (CYPSE1) is an effective producer of reactive oxygen species such as superoxide radical and hydrogen peroxide, which may contribute to the development of alcohol liver disease or cytotoxicity, To investigate the protective role of catalase against CYP2E1-dependent cytotoxicity, E47 cells, a transfected HepG2 cell line overexpressing CYPSE1, were infected with adenoviral vectors containing human catalase cDNA (AdCat) and catalase cDNA with a mitochondrial leader sequence (AdmCat), Forty-eight hours after infection with AdCat or AdmCat at a multiplicity of infection of 100, intracellular catalase protein was increased >2-fold compared with uninfected E47 cells and E47 cells infected with empty adenoviral vector (AdNull) as determined by Western blotting and catalase activity measurements. Overexpression of catalase in the cytosol (AdCat) and in mitochondria (AdmCat) was confirmed by confocal microscopy. Cell death caused by arachidonic acid plus iron was considerably suppressed in both AdCat- and AdmCat-infected E47 cells as determined by assays of 3-(4,5-dimethylthiazol-2-yl)-2,5-di-phenyltetrazolium bromide absorbance, lactate dehydrogenase release, and morphology changes. AdCat- and AdmCat-infected cells were also more resistant to the loss of mitochondrial membrane potential and to the increase in lipid peroxidation induced by arachidonic acid and iron. This study indicates that catalase in the cytosol and catalase in mitochondria are capable of protecting HepG2 cells expressing CYP2E1 against cytotoxicity induced by oxidants that promote lipid peroxidation and suggests the possibility that such agents may be useful in protecting against the development of alcohol liver injury.	CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Cederbaum, AI (corresponding author), CUNY Mt Sinai Sch Med, Dept Biochem & Mol Biol, POB 1020,1 Gustave L Levy Pl, New York, NY 10029 USA.	Arthur.cederbaum@mssm.edu			NCRR NIH HHS [1-S10-RR0-9145-01] Funding Source: Medline; NIAAA NIH HHS [AA06610, AA03312] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA006610, R01AA006610, R01AA003312, R56AA003312] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Bai JX, 1999, J BIOL CHEM, V274, P26217, DOI 10.1074/jbc.274.37.26217; BETT AJ, 1994, P NATL ACAD SCI USA, V91, P8802, DOI 10.1073/pnas.91.19.8802; BONDY SC, 1992, TOXICOL LETT, V63, P231, DOI 10.1016/0378-4274(92)90086-Y; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CASTILLO T, 1992, HEPATOLOGY, V16, P992, DOI 10.1002/hep.1840160423; Chen Q, 1997, J BIOL CHEM, V272, P14532, DOI 10.1074/jbc.272.23.14532; Chen Q, 1998, MOL PHARMACOL, V53, P638, DOI 10.1124/mol.53.4.638; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; DAI Y, 1993, BIOCHEMISTRY-US, V32, P6928, DOI 10.1021/bi00078a017; DAI Y, 1995, J PHARMACOL EXP THER, V273, P1497; DIANZANI MU, 1985, ALCOHOL ALCOHOLISM, V20, P161; Dringen R, 1997, BRAIN RES, V759, P67, DOI 10.1016/S0006-8993(97)00233-3; Gores GJ, 1998, BBA-BIOENERGETICS, V1366, P167, DOI 10.1016/S0005-2728(98)00111-X; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P168, DOI 10.1021/tx00020a008; Henle ES, 1997, J BIOL CHEM, V272, P19095, DOI 10.1074/jbc.272.31.19095; Hirokawa M, 1998, ALCOHOL CLIN EXP RES, V22, p111S, DOI 10.1111/acer.1998.22.s3_part1.111s; KOOP DR, 1992, FASEB J, V6, P724, DOI 10.1096/fasebj.6.2.1537462; Kowaltowski AJ, 1998, J BIOL CHEM, V273, P12766, DOI 10.1074/jbc.273.21.12766; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; LAETHEM RM, 1993, J BIOL CHEM, V268, P12912; Lemasters JJ, 1998, BIOFACTORS, V8, P283, DOI 10.1002/biof.5520080316; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Markesbery WR, 1997, FREE RADICAL BIO MED, V23, P134, DOI 10.1016/S0891-5849(96)00629-6; Matsui A, 2000, CANCER LETT, V151, P87, DOI 10.1016/S0304-3835(99)00424-3; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; Melendez JA, 1996, J BIOL CHEM, V271, P18898, DOI 10.1074/jbc.271.31.18898; MICHIELS C, 1994, FREE RADICAL BIO MED, V17, P235, DOI 10.1016/0891-5849(94)90079-5; MORIMOTO M, 1994, P SOC EXP BIOL MED, V207, P197, DOI 10.3181/00379727-207-43807; NANJI AA, 1994, ALCOHOL CLIN EXP RES, V18, P1280, DOI 10.1111/j.1530-0277.1994.tb00119.x; NIEHAUS WG, 1968, EUR J BIOCHEM, V6, P126, DOI 10.1111/j.1432-1033.1968.tb00428.x; Ornoy A, 1999, TERATOLOGY, V60, P376, DOI 10.1002/(SICI)1096-9926(199912)60:6<376::AID-TERA10>3.0.CO;2-Q; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; RADI R, 1991, J BIOL CHEM, V266, P22028; Sakurai K, 1998, MOL PHARMACOL, V54, P1024, DOI 10.1124/mol.54.6.1024; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Singh K, 1997, Indian J Med Sci, V51, P226; Tada-Oikawa S, 1999, FEBS LETT, V442, P65, DOI 10.1016/S0014-5793(98)01618-4; TRITSCHLER HJ, 1994, BIOCHEM MOL BIOL INT, V34, P169; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Wu DF, 1996, J BIOL CHEM, V271, P23914, DOI 10.1074/jbc.271.39.23914; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	42	51	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4315	4321		10.1074/jbc.M008895200	http://dx.doi.org/10.1074/jbc.M008895200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11071897	hybrid			2022-12-25	WOS:000166921200078
J	Miller, T; Szczesna, D; Housmans, PR; Zhao, JJ; de Freitas, F; Gomes, AV; Culbreath, L; McCue, J; Wang, Y; Xu, YY; Glenn, W; Kerrick, L; Potter, JD				Miller, T; Szczesna, D; Housmans, PR; Zhao, JJ; de Freitas, F; Gomes, AV; Culbreath, L; McCue, J; Wang, Y; Xu, YY; Glenn, W; Kerrick, L; Potter, JD			Abnormal contractile function in transgenic mice expressing a familial hypeptrophic cardiomyopathy-linked troponin T (I79N) mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN GENE; HYPERTROPHIC CARDIOMYOPATHY; SARCOPLASMIC-RETICULUM; ALPHA-TROPOMYOSIN; CALCIUM-BINDING; CA2+ REGULATION; ATPASE ACTIVITY; PH SENSITIVITY; MOUSE MODEL; MUSCLE	This study characterizes a transgenic animal model for the troponin T (TnT) mutation (I79N) associated with familial hypertrophic cardiomyopathy. To study the functional consequences of this mutation, we examined a wild type and two I79N-transgenic mouse lines of human cardiac TnT driven by a murine alpha -myosin heavy chain promoter. Extensive characterization of the transgenic I79N lines compared with wild type and/or nontransgenic mice demonstrated: 1) normal survival and no cardiac hypertrophy even with chronic exercise; 2) large increases in Ca2+ sensitivity of ATPase activity and force in skinned fibers; 3) a substantial increase in the rate of force activation and an increase in the rate of force relaxation; 4) lower maximal force/cross-sectional area and ATPase activity; 5) loss of sensitivity to pH-induced shifts in the Ca2+ dependence of force; and 6) computer simulations that reproduced experimental observations and suggested that the I79N mutation decreases the apparent off rate of Ca2+ from troponin C and increases cross-bridge detachment rate g. Simulations for intact living fibers predict a higher basal contractility, a faster rate of force development, slower relaxation, and increased resting tension in transgenic I79N myocardium compared with transgenic wild type. These mechanisms may contribute to mortality in humans, especially in stimulated contractile states.	Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA; Univ Miami, Sch Med, Dept Physiol & Biophys, Miami, FL 33136 USA; Mayo Clin & Mayo Fdn, Dept Anesthesiol, Rochester, MN 55905 USA	University of Miami; University of Miami; Mayo Clinic	Potter, JD (corresponding author), Univ Miami, Sch Med, Dept Mol & Cellular Pharmacol, 1600 NW 10th Ave, Miami, FL 33136 USA.	jdpotter@miami.edu	Gomes, Aldrin V/I-6529-2018	Gomes, Aldrin V/0000-0002-9819-3036	NHLBI NIH HHS [HL-42325] Funding Source: Medline; NIAMS NIH HHS [AR-40906, AR-45391] Funding Source: Medline; NIGMS NIH HHS [GM-36365] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042325, R37HL042325] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045391, R01AR040906] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036365] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen K, 2000, J APPL PHYSIOL, V88, P180, DOI 10.1152/jappl.2000.88.1.180; AUSUBEL FM, 1995, CURRENT PROTOCOLS MO, pCH8; BALL KL, 1994, BIOCHEMISTRY-US, V33, P8464, DOI 10.1021/bi00194a010; BAYLOR SM, 1983, J PHYSIOL-LONDON, V344, P625, DOI 10.1113/jphysiol.1983.sp014959; BLINKS JR, 1986, CIRCULATION, V73, P85; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DONALDSON SKB, 1975, J GEN PHYSIOL, V66, P427, DOI 10.1085/jgp.66.4.427; EPSTEIN ND, 1992, CIRCULATION, V86, P345, DOI 10.1161/01.CIR.86.2.345; Epstein ND, 1998, ADV EXP MED BIOL, V453, P105; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FABIATO A, 1983, AM J PHYSIOL, V245, pC1; Flavigny J, 1998, J MOL MED-JMM, V76, P208, DOI 10.1007/s001090050210; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Gergely J, 1998, ADV EXP MED BIOL, V453, P169; GREASER ML, 1971, J BIOL CHEM, V246, P4226; GRIFFITHS PJ, 1980, PFLUG ARCH EUR J PHY, V387, P167, DOI 10.1007/BF00584268; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; HOFMANN PA, 1987, AM J PHYSIOL, V253, pC541, DOI 10.1152/ajpcell.1987.253.4.C541; Homsher E, 2000, J PHYSIOL-LONDON, V524, P233, DOI 10.1111/j.1469-7793.2000.00233.x; Housmans PR, 2000, ANESTHESIOLOGY, V93, P189, DOI 10.1097/00000542-200007000-00030; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; Kimura A, 1997, NAT GENET, V16, P379, DOI 10.1038/ng0897-379; LANDESBERG A, 1994, AM J PHYSIOL, V266, pH1260, DOI 10.1152/ajpheart.1994.266.3.H1260; Lim DS, 2000, J MOL CELL CARDIOL, V32, P365, DOI 10.1006/jmcc.1999.1081; Lin D, 1996, J CLIN INVEST, V97, P2842, DOI 10.1172/JCI118740; LORKOVIC H, 1966, CIRC RES, V19, P711, DOI 10.1161/01.RES.19.4.711; Malnic B, 1998, J BIOL CHEM, V273, P10594, DOI 10.1074/jbc.273.17.10594; Mikane T, 1997, AM J PHYSIOL-HEART C, V273, pH2891, DOI 10.1152/ajpheart.1997.273.6.H2891; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; Morimoto S, 1998, AM J PHYSIOL-CELL PH, V275, pC200, DOI 10.1152/ajpcell.1998.275.1.C200; Morimoto S, 2000, BIOCHEM BIOPH RES CO, V267, P912, DOI 10.1006/bbrc.1999.2068; Oberst L, 1998, J CLIN INVEST, V102, P1498, DOI 10.1172/JCI4088; PANNIER JL, 1968, ARCH INT PHYS BIOCH, V76, P624, DOI 10.3109/13813456809058730; Parsons B, 1997, J MUSCLE RES CELL M, V18, P599, DOI 10.1023/A:1018623604365; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; Poetter K, 1996, NAT GENET, V13, P63, DOI 10.1038/ng0596-63; POTTER JD, 1995, J BIOL CHEM, V270, P2557, DOI 10.1074/jbc.270.6.2557; Prabhakar R, 1999, J BIOL CHEM, V274, P29558, DOI 10.1074/jbc.274.41.29558; Prakash YS, 2000, ANESTHESIOLOGY, V92, P1114, DOI 10.1097/00000542-200004000-00030; Reinach FC, 1997, CELL STRUCT FUNCT, V22, P219, DOI 10.1247/csf.22.219; ROBERTSON SP, 1981, BIOPHYS J, V34, P559, DOI 10.1016/S0006-3495(81)84868-0; Rust EM, 1999, J CLIN INVEST, V103, P1459, DOI 10.1172/JCI6377; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Satoh M, 1999, BIOCHEM BIOPH RES CO, V262, P411, DOI 10.1006/bbrc.1999.1221; SOLARO RJ, 1989, MOL CELL BIOCHEM, V89, P163; Solaro RJ, 1999, CIRC RES, V84, P122; SUBRAMANIAM A, 1993, J BIOL CHEM, V268, P4331; Sweeney HL, 1998, P NATL ACAD SCI USA, V95, P14406, DOI 10.1073/pnas.95.24.14406; Szczesna D, 2000, J BIOL CHEM, V275, P624, DOI 10.1074/jbc.275.1.624; SZCZESNA D, 2001, IN PRESS ROLE INTERA, V2; TAKASHI R, 1979, ANAL BIOCHEM, V92, P375, DOI 10.1016/0003-2697(79)90674-2; Tardiff JC, 1999, J CLIN INVEST, V104, P469, DOI 10.1172/JCI6067; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; THIERFELDER L, 1994, CELL, V77, P701, DOI 10.1016/0092-8674(94)90054-X; TOWNSEND PJ, 1994, GENOMICS, V21, P311, DOI 10.1006/geno.1994.1271; TREISMAN R, 1982, CELL, V29, P903, DOI 10.1016/0092-8674(82)90452-4; Wang Y, 1999, J MUSCLE RES CELL M, V20, P645, DOI 10.1023/A:1005559613516; WATKINS H, 1995, HUM MOL GENET, V4, P1721, DOI 10.1093/hmg/4.suppl_1.1721; WATKINS H, 1993, NAT GENET, V3, P333, DOI 10.1038/ng0493-333; Watkins H, 1996, J CLIN INVEST, V98, P2456, DOI 10.1172/JCI119063; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WILLIAMSON JR, 1976, CIRCULATION, V53, P3; Yanaga F, 1999, J BIOL CHEM, V274, P8806, DOI 10.1074/jbc.274.13.8806; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; ZOT AS, 1989, BIOCHEMISTRY-US, V28, P6751, DOI 10.1021/bi00442a031	69	101	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3743	3755		10.1074/jbc.M006746200	http://dx.doi.org/10.1074/jbc.M006746200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11060294	hybrid			2022-12-25	WOS:000166921200005
J	Maeda, T; Abe, M; Kurisu, K; Jikko, A; Furukawa, S				Maeda, T; Abe, M; Kurisu, K; Jikko, A; Furukawa, S			Molecular cloning and characterization of a novel gene, CORS26, encoding a putative secretory protein and its possible involvement in skeletal development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; TUMOR-NECROSIS-FACTOR; CELL-LINE; C3H10T1/2 CELLS; MOUSE C1Q; B-CHAIN; EXPRESSION; DIFFERENTIATION; CDNA; LOCALIZATION	We cloned a novel mouse cDNA, CORS26 (collagenous repeat-containing sequence of 26-kDa protein), encoding a secretory protein by suppression subtractive hybridization between transforming growth factor-beta1-treated and untreated C3H10T1/2 cells. The deduced amino acid sequence of CORS26 consists of 246 amino acids with a secretory signal peptide and contains a collagenous region (Gly-X-Y repeats) at the NH2 terminus and a complement factor C1q globular domain at the COOH terminus. CORS26 is structurally similar to C1q and to adipocyte-specific protein Acrp30. Transfection analysis suggested that CORS26 is a secretory protein. Northern blot analysis revealed that CORS26 mRNA was present at high levels in rib growth plate cartilage and at moderate levels in kidney of adult mice. CORS26 mRNA was not detected in NIH3T3 cells, BALB/3T3 cells, C3H10T1/2 cells, or osteoblastic MC3T3-E1 cells by reverse transcription-polymerase chain reaction analysis. In situ hybridization of mouse embryos between 13 and 15 days postcoitus revealed relatively high levels of CORS26 mRNA in condensed prechondrocytic cells of cartilage primordia and developing cartilages. However, CORS26 mRNA were undetectable in mature chondrocytes. Furthermore, overexpression of CORS26 enhanced the growth of C3H10T1/2 cells in vitro. The present findings suggest that the CORS26 gene may play an important role in skeletal development.	Osaka Univ, Grad Sch Dent, Dept Radiol & Radiat Oncol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Dent, Dept Anat & Dev Biol, Suita, Osaka 5650871, Japan	Osaka University; Osaka University	Maeda, T (corresponding author), Osaka Univ, Grad Sch Dent, Dept Radiol & Radiat Oncol, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.							AHRENS M, 1993, DNA CELL BIOL, V12, P871, DOI 10.1089/dna.1993.12.871; AHRENS PB, 1977, DEV BIOL, V60, P69, DOI 10.1016/0012-1606(77)90110-5; Aikawa T, 1996, J BONE MINER RES, V11, P544; Atkinson BL, 1997, J CELL BIOCHEM, V65, P325, DOI 10.1002/(SICI)1097-4644(19970601)65:3<325::AID-JCB3>3.0.CO;2-U; Berube NG, 1999, MOL BRAIN RES, V63, P233, DOI 10.1016/S0169-328X(98)00278-2; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; DENKER AE, 1995, DIFFERENTIATION, V59, P25, DOI 10.1046/j.1432-0436.1995.5910025.x; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; GRIGORIADIS AE, 1990, DEV BIOL, V142, P313, DOI 10.1016/0012-1606(90)90352-J; Haas AR, 1999, DIFFERENTIATION, V64, P77, DOI 10.1046/j.1432-0436.1999.6420077.x; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; IZUMI T, 1992, J BONE MINER RES, V7, P115; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; MALHOTRA R, 1993, BIOCHEM J, V293, P15, DOI 10.1042/bj2930015; Martin H, 1990, EUR J IMMUNOL, V20, P1641, DOI 10.1002/eji.1830200804; Naismith James H., 1995, Journal of Inflammation, V47, P1; NEDWIN GE, 1985, NUCLEIC ACIDS RES, V13, P6361, DOI 10.1093/nar/13.17.6361; PETRY F, 1991, J IMMUNOL, V147, P3988; PETRY F, 1992, EUR J BIOCHEM, V209, P129, DOI 10.1111/j.1432-1033.1992.tb17269.x; PETRY F, 1989, FEBS LETT, V258, P89, DOI 10.1016/0014-5793(89)81622-9; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; TAKAMATSU N, 1993, MOL CELL BIOL, V13, P1516, DOI 10.1128/MCB.13.3.1516; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WADA C, 1991, MOL BRAIN RES, V9, P71, DOI 10.1016/0169-328X(91)90131-G; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; WILKINSON DG, 1989, DEVELOPMENT, V105, P131	30	88	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3628	3634		10.1074/jbc.M007898200	http://dx.doi.org/10.1074/jbc.M007898200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11071891	hybrid			2022-12-25	WOS:000166784900084
J	Watson, JM; Harding, TW; Golubovskaya, V; Morris, JS; Hunter, D; Li, X; Haskill, JS; Earp, HS				Watson, JM; Harding, TW; Golubovskaya, V; Morris, JS; Hunter, D; Li, X; Haskill, JS; Earp, HS			Inhibition of the calcium-dependent tyrosine kinase (CADTK) blocks monocyte spreading and motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ACTIVATED PROTEIN-KINASE; LIVER EPITHELIAL-CELLS; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; EXTRACELLULAR-MATRIX; T-LYMPHOCYTES; PYK2; PHOSPHORYLATION; INDUCTION	Freshly isolated peripheral blood monocytes lack focal adhesion kinase (p125(FAK)) but activate a second member of this kinase family, calcium-dependent tyrosine kinase (CADTK; also known as Pyk2/CAK beta /RAFTK/FAK2), upon adhesion or stimulation with chemokines, To study the role of CADTK in monocyte adherence and motility, we performed immunocytochemical localization that showed CADTK at the leading edge and fling lamellipodial structures in freshly isolated, adhered human monocytes, We next introduced CADTK/CAK beta -related non-kinase (CRNK), the C-terminal noncatalytic domain of CADTK, into monocytes by electroporation and showed that it inhibited CADTK autophosphorylation. Introduction of the fusion protein glutathione S-transferase (GST)-CRNK also reduced (i) cell spreading, as reflected in a reduced cell area 30 min after adhesion, (ii) adhesion-induced phosphotyrosine increases and redistribution into lamellipodia, and (iii) adhesion-induced extracellular signal-regulated protein kinase (ERK) activation. In control experiments, introduction of GST or GST-C3 transferase tan inhibitor of RhoA GTPase activity) by electroporation did not affect these parameters. Monocytes adhered in the presence of autologous serum were highly motile even after introduction of GST (83% motile cells). However, only 26% of monocytes with introduced GST-CRNK were motile. In contrast, GST-CRNK-treated monocytes were fully capable of phagocytosis and adhesion-induced cytokine gene induction, suggesting that CADTK is not involved in these cellular activities and that GST-CRNK introduction does not inhibit global monocyte functions. These results suggest that CADTK is crucial for the in vitro monocyte cytoskeletal reorganization necessary for cell motility and is likely to be required in vivo for recruitment to sites of inflammation.	Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; Univ N Carolina, Comprehens Ctr Inflammatory Disorders, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Earp, HS (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA081503] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P60DE013079] Funding Source: NIH RePORTER; NCI NIH HHS [CA81503] Funding Source: Medline; NIAID NIH HHS [AI26774] Funding Source: Medline; NIDCR NIH HHS [1-P60-DE13079] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Aepfelbacher M, 1996, J IMMUNOL, V157, P5070; Astier A, 1997, J BIOL CHEM, V272, P228; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; Brown MC, 1998, NAT STRUCT BIOL, V5, P677, DOI 10.1038/1370; CIANCIOLO G, 1981, J CLIN INVEST, V68, P831, DOI 10.1172/JCI110338; DELPOZO MA, 1995, J CELL BIOL, V131, P495, DOI 10.1083/jcb.131.2.495; Dikic I, 1998, J BIOL CHEM, V273, P14301, DOI 10.1074/jbc.273.23.14301; Dutt P, 1998, J IMMUNOL, V161, P3652; Fuortes M, 1999, J CLIN INVEST, V104, P327, DOI 10.1172/JCI6018; Ganju RK, 1997, J EXP MED, V185, P1055, DOI 10.1084/jem.185.6.1055; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Gismondi A, 2000, J IMMUNOL, V164, P2272, DOI 10.4049/jimmunol.164.5.2272; Gismondi A, 1997, J IMMUNOL, V159, P4729; Harkin DG, 1996, CELL MOTIL CYTOSKEL, V35, P345, DOI 10.1002/(SICI)1097-0169(1996)35:4<345::AID-CM6>3.0.CO;2-5; HASKILL S, 1988, J IMMUNOL, V140, P1690; Hatch WC, 1998, BLOOD, V91, P3967, DOI 10.1182/blood.V91.10.3967.3967_3967_3973; Herzog H, 1996, GENOMICS, V32, P484, DOI 10.1006/geno.1996.0149; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li X, 1997, J BIOL CHEM, V272, P14341, DOI 10.1074/jbc.272.22.14341; Li X, 1999, J BIOL CHEM, V274, P8917, DOI 10.1074/jbc.274.13.8917; Li X, 1998, J BIOL CHEM, V273, P9361, DOI 10.1074/jbc.273.16.9361; Li XO, 1997, J BIOL CHEM, V272, P14996, DOI 10.1074/jbc.272.23.14996; LIN TH, 1995, J BIOL CHEM, V270, P16189, DOI 10.1074/jbc.270.27.16189; Lipsky BP, 1998, J BIOL CHEM, V273, P11709, DOI 10.1074/jbc.273.19.11709; LOFQUIST AK, 1995, MOL CELL BIOL, V15, P1737; Matsuya M, 1998, J BIOL CHEM, V273, P1003, DOI 10.1074/jbc.273.2.1003; McDonald JT, 2000, IMMUNOL INVEST, V29, P71; Mondal K, 2000, J LEUKOCYTE BIOL, V67, P216, DOI 10.1002/jlb.67.2.216; Nieto M, 1999, BLOOD, V94, P2767, DOI 10.1182/blood.V94.8.2767.420k26_2767_2777; Ohmori T, 2000, BIOCHEM J, V347, P561, DOI 10.1042/0264-6021:3470561; Okazaki H, 1997, J BIOL CHEM, V272, P32443, DOI 10.1074/jbc.272.51.32443; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Rodriguez-Fernandez JL, 1999, MOL BIOL CELL, V10, P1891, DOI 10.1091/mbc.10.6.1891; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; Sayed MR, 2000, J CELL PHYSIOL, V183, P314, DOI 10.1002/(SICI)1097-4652(200006)183:3<314::AID-JCP3>3.0.CO;2-J; Schaller MD, 1997, J BIOL CHEM, V272, P25319, DOI 10.1074/jbc.272.40.25319; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sieg DJ, 1999, J CELL SCI, V112, P2677; SPORN SA, 1990, J IMMUNOL, V144, P4434; Suen PW, 1999, J CELL SCI, V112, P4067; Timms JF, 1999, CURR BIOL, V9, P927, DOI 10.1016/S0960-9822(99)80401-1; Wang JF, 2000, BLOOD, V95, P2505, DOI 10.1182/blood.V95.8.2505.008k24_2505_2513; Williams LM, 2000, J IMMUNOL, V164, P2028, DOI 10.4049/jimmunol.164.4.2028; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yu H, 1996, J BIOL CHEM, V271, P29993, DOI 10.1074/jbc.271.47.29993; YUROCHKO AD, 1992, P NATL ACAD SCI USA, V89, P9034, DOI 10.1073/pnas.89.19.9034	57	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3536	3542		10.1074/jbc.M006916200	http://dx.doi.org/10.1074/jbc.M006916200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11062241	Green Published, hybrid			2022-12-25	WOS:000166784900072
J	Rymer, DL; Good, TA				Rymer, DL; Good, TA			The role of G protein activation in the toxicity of amyloidogenic A beta-(1-40), A beta-(25-35), and bovine calcitonin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							GTP-BINDING PROTEIN; RAT HIPPOCAMPAL-NEURONS; HUMAN ENDOTHELIAL-CELLS; BETA-PROTEIN; ALZHEIMERS-DISEASE; SIGNAL-TRANSDUCTION; ADENYLATE-CYCLASE; MEDULLARY CARCINOMA; CORTICAL-NEURONS; FIBRIL FORMATION	More than 16 different proteins have been identified as amyloid in clinical diseases; among these, beta -amyloid (AP) of Alzheimer's disease is the best characterized. In the present study, we performed experiments with A beta and calcitonin, another amyloid-forming peptide, to examine the role of G protein activation in amyloid toxicity. We demonstrated that the peptides, when prepared under conditions that promoted beta -sheet and amyloid fibril (or protofibril) formation, increased high affinity GTPase activity, but the nonamyloidogenic peptides had no discernible effects on GTP hydrolysis. These increases in GTPase activity were correlated to toxicity. In addition, G protein inhibitors significantly reduced the toxic effects of the amyloidogenic A beta and calcitonin peptides, Our results further indicated that the amyloidogenic peptides significantly increased GTPase activity of purified G alpha (o), and G alpha (i) subunits and that the effect was not receptor-mediated. Collectively, these results imply that the amyloidogenic structure, regardless of the actual peptide or protein sequence, may be sufficient to cause toxicity and that toxicity is mediated, at least partially, through G protein activation. Our abilities to manipulate G protein activity may lead to novel treatments for Alzheimer's disease and the other amyloidoses.	Texas A&M Univ, Dept Chem Engn, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station	Good, TA (corresponding author), Texas A&M Univ, Dept Chem Engn, 337 Zachry, College Stn, TX 77843 USA.							AKTORIES K, 1983, N-S ARCH PHARMACOL, V324, P196, DOI 10.1007/BF00503894; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P10573, DOI 10.1073/pnas.90.22.10573; ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BERGER G, 1988, VIRCHOWS ARCH A, V412, P543, DOI 10.1007/BF00844290; BERTHIAUME F, 1994, BBA-BIOMEMBRANES, V1191, P209, DOI 10.1016/0005-2736(94)90251-8; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BIRNBAUMER L, 1990, SOC GEN PHY, V45, P169; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BRORSON JR, 1995, J NEUROBIOL, V26, P325, DOI 10.1002/neu.480260305; Brouillet E, 1999, J NEUROSCI, V19, P1717; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BROWN AM, 1990, PROG CLIN BIOL RES, V334, P303; BURCH RM, 1987, P NATL ACAD SCI USA, V84, P6374, DOI 10.1073/pnas.84.18.6374; BURGEVIN MC, 1994, NEUROREPORT, V5, P2429, DOI 10.1097/00001756-199412000-00006; BUSCIGLIO J, 1993, J NEUROCHEM, V61, P1565, DOI 10.1111/j.1471-4159.1993.tb13658.x; BUTLER M, 1986, ARCH PATHOL LAB MED, V110, P647; BUTLER SJ, 1988, BIOCHEM J, V251, P201, DOI 10.1042/bj2510201; Butterfield DA, 1997, CHEM RES TOXICOL, V10, P495, DOI 10.1021/tx960130e; BUTTERFIELD DA, 1994, BIOCHEM BIOPH RES CO, V200, P710, DOI 10.1006/bbrc.1994.1508; BYARD R W, 1990, Pediatric Pathology, V10, P581; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; CASTANO EM, 1995, CURR OPIN NEUROL, V8, P279, DOI 10.1097/00019052-199508000-00006; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; ChooSmith LP, 1997, FEBS LETT, V402, P95, DOI 10.1016/S0014-5793(96)01504-9; ChooSmith LP, 1997, J BIOL CHEM, V272, P22987, DOI 10.1074/jbc.272.37.22987; Cribbs DH, 1997, J BIOL CHEM, V272, P7431, DOI 10.1074/jbc.272.11.7431; DAMMRICH J, 1984, HISTOCHEMISTRY, V81, P369, DOI 10.1007/BF00514331; DAVIDSON RM, 1994, BRAIN RES, V643, P324, DOI 10.1016/0006-8993(94)90041-8; DELELLIS RA, 1979, LAB INVEST, V40, P140; DORLAND RB, 1979, J BIOL CHEM, V254, P1337; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; Freissmuth M, 1996, MOL PHARMACOL, V49, P602; Freissmuth M, 1999, TRENDS PHARMACOL SCI, V20, P237, DOI 10.1016/S0165-6147(99)01337-1; Ghanta J, 1996, J BIOL CHEM, V271, P29525, DOI 10.1074/jbc.271.47.29525; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLENNER GG, 1980, NEW ENGL J MED, V302, P1283, DOI 10.1056/NEJM198006053022305; GLENNER GG, 1980, NEW ENGL J MED, V302, P1333, DOI 10.1056/NEJM198006123022403; GLENNER GG, 1974, ANNU REV MED, V25, P131, DOI 10.1146/annurev.me.25.020174.001023; Good TA, 1996, BIOPHYS J, V70, P296, DOI 10.1016/S0006-3495(96)79570-X; GOREVIC PD, 1987, BIOCHEM BIOPH RES CO, V147, P854, DOI 10.1016/0006-291X(87)91008-4; Gudi SRP, 1996, CIRC RES, V79, P834, DOI 10.1161/01.RES.79.4.834; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HOWLETT DR, 1995, NEURODEGENERATION, V4, P23, DOI 10.1006/neur.1995.0003; HUANG RRC, 1990, MOL PHARMACOL, V37, P304; JONES DT, 1990, J BIOL CHEM, V265, P2671; JONES DT, 1987, J BIOL CHEM, V262, P14241; Kelly JW, 1998, CURR OPIN STRUC BIOL, V8, P101, DOI 10.1016/S0959-440X(98)80016-X; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; Kelly JW, 1998, P NATL ACAD SCI USA, V95, P930, DOI 10.1073/pnas.95.3.930; Klinker JF, 1996, NEUROSCI LETT, V213, P25, DOI 10.1016/0304-3940(96)12816-0; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1293, DOI 10.1177/37.8.2666512; KOH JY, 1990, BRAIN RES, V533, P315, DOI 10.1016/0006-8993(90)91355-K; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; Lazari MDM, 1997, BIOCHEM PHARMACOL, V54, P399; LI WY, 1995, BRAIN RES, V682, P207, DOI 10.1016/0006-8993(95)00264-Q; Liu YB, 1997, J NEUROCHEM, V69, P2285; LORENZO A, 1994, P NATL ACAD SCI USA, V91, P12243, DOI 10.1073/pnas.91.25.12243; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mattson MP, 1997, CHEM RES TOXICOL, V10, P507, DOI 10.1021/tx9601317; McLaurin J, 1998, J BIOL CHEM, V273, P4506, DOI 10.1074/jbc.273.8.4506; McLaurin J, 1996, J BIOL CHEM, V271, P26482, DOI 10.1074/jbc.271.43.26482; OFFERMANNS S, 1989, EUR J BIOCHEM, V180, P283, DOI 10.1111/j.1432-1033.1989.tb14645.x; Pallitto MM, 1999, BIOCHEMISTRY-US, V38, P3570, DOI 10.1021/bi982119e; PEDERSEN SE, 1982, P NATL ACAD SCI-BIOL, V79, P7228, DOI 10.1073/pnas.79.23.7228; Pike CJ, 1996, J NEUROCHEM, V67, P1774; POLLACK SJ, 1995, NEUROSCI LETT, V184, P113, DOI 10.1016/0304-3940(94)11182-I; Sadler IIJ, 1995, NEUROREPORT, V7, P49; SCHNECKO A, 1994, BRAIN RES, V644, P291, DOI 10.1016/0006-8993(94)91692-6; SCHUBERT D, 1995, P NATL ACAD SCI USA, V92, P1989, DOI 10.1073/pnas.92.6.1989; SCHULTZ G, 1990, ANNU REV PHYSIOL, V52, P275, DOI 10.1146/annurev.ph.52.030190.001423; SEIFERT R, 1987, BIOCHEM BIOPH RES CO, V146, P1296, DOI 10.1016/0006-291X(87)90790-X; Seilheimer B, 1997, J STRUCT BIOL, V119, P59, DOI 10.1006/jsbi.1997.3859; SHEN CL, 1994, BIOPHYS J, V67, P1238, DOI 10.1016/S0006-3495(94)80593-4; SHEN CL, 1995, BIOPHYS J, V69, P640, DOI 10.1016/S0006-3495(95)79940-4; SILK ST, 1989, J BIOL CHEM, V264, P21466; SILVER MM, 1988, J HISTOCHEM CYTOCHEM, V36, P1031, DOI 10.1177/36.8.3392392; SIMMONS MA, 1993, NEUROSCI LETT, V150, P133, DOI 10.1016/0304-3940(93)90519-Q; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Singh IN, 1998, BRAIN RES, V800, P275, DOI 10.1016/S0006-8993(98)00532-0; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; SIPE JD, 1992, ANNU REV BIOCHEM, V61, P947, DOI 10.1146/annurev.bi.61.070192.004503; SLETTEN K, 1976, J EXP MED, V143, P993, DOI 10.1084/jem.143.4.993; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Soomets U, 1999, BRAIN RES, V850, P179, DOI 10.1016/S0006-8993(99)02142-3; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; Taubes G, 1996, SCIENCE, V271, P1493, DOI 10.1126/science.271.5255.1493; TOMIYAMA T, 1994, BIOCHEM BIOPH RES CO, V204, P76, DOI 10.1006/bbrc.1994.2428; TROP M, 1970, J BIOCH, V116, P19; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Ward RV, 2000, BIOCHEM J, V348, P137, DOI 10.1042/0264-6021:3480137; WHITSON JS, 1994, BIOCHEM BIOPH RES CO, V199, P163, DOI 10.1006/bbrc.1994.1209; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	101	48	50	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2523	2530		10.1074/jbc.M005800200	http://dx.doi.org/10.1074/jbc.M005800200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11060290	hybrid			2022-12-25	WOS:000166784800032
J	Wu, M; Schleif, R				Wu, M; Schleif, R			Strengthened arm-dimerization domain interactions in AraC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACE ELECTROSTATIC INTERACTIONS; L-ARABINOSE OPERON; PROTEIN STABILITY; BINDING	Constitutive mutations were sought and found in the N-terminal arm of the Escherichia coli regulatory protein of the arabinose operon, AraC protein. A new mutation, N16D, was of particular interest. Asn-16 is not seen in the crystal structure of the AraC dimerization domain determined in the absence of arabinose, because the N-terminal arm 18 residues are disordered, but in the presence of arabinose, residues 7-18 fold over the arabinose and make many interactions with it. In this state Asn-le lies near two positively charged amino acids, Lys-43 and Arg-99. We propose that the introduction of the negatively charged aspartic residue at position 16 creates a charge-charge interaction network among Asp-16, Lys-43, and Arg-99 that holds the arm to the dimerization domain even in the absence of arabinose. This frees the DNA-binding domains and allows them to bind cia to I-1-I-2 half-sites and activate transcription. Mutating the two positively charged residues to alanines individually and collectively decreased or eliminated the constitutivity created by the N16D mutation.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University	Schleif, R (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	bob@gene.bio.jhu.edu		Wu, Martin/0000-0003-3093-4077; Schleif, Robert/0000-0002-4430-7085	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM018277, R01GM018277] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM18277] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEVERIN S, 1971, J BACTERIOL, V107, P79, DOI 10.1128/JB.107.1.79-86.1971; DAOPIN S, 1991, BIOCHEMISTRY-US, V30, P7142, DOI 10.1021/bi00243a015; ENGLESBE.E, 1965, J BACTERIOL, V90, P946, DOI 10.1128/JB.90.4.946-957.1965; EUSTANCE RJ, 1994, J MOL BIOL, V242, P330; HAHN S, 1984, J MOL BIOL, V180, P61, DOI 10.1016/0022-2836(84)90430-3; HENDRICKSON W, 1984, J MOL BIOL, V178, P611, DOI 10.1016/0022-2836(84)90241-9; HENDRICKSON W, 1985, P NATL ACAD SCI USA, V82, P3129, DOI 10.1073/pnas.82.10.3129; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; IRR J, 1970, GENETICS, V65, P27; LEE N, 1987, P NATL ACAD SCI USA, V84, P8814, DOI 10.1073/pnas.84.24.8814; LOBELL RB, 1990, SCIENCE, V250, P528, DOI 10.1126/science.2237403; Reed WL, 1999, J MOL BIOL, V294, P417, DOI 10.1006/jmbi.1999.3224; SALI D, 1991, J MOL BIOL, V220, P779, DOI 10.1016/0022-2836(91)90117-O; Saviola B, 1998, J MOL BIOL, V278, P539, DOI 10.1006/jmbi.1998.1712; Schleif R. F., 1981, PRACTICAL METHODS MO; Seabold RR, 1998, J MOL BIOL, V278, P529, DOI 10.1006/jmbi.1998.1713; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; Soisson SM, 1997, SCIENCE, V276, P421, DOI 10.1126/science.276.5311.421; WALLACE R, 1982, THESIS U CALIFORNIA; Xiao L, 1999, J MOL BIOL, V289, P1435, DOI 10.1006/jmbi.1999.2810; Zhang X, 1996, J MOL BIOL, V258, P14, DOI 10.1006/jmbi.1996.0230	21	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2562	2564		10.1074/jbc.M008705200	http://dx.doi.org/10.1074/jbc.M008705200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11069917	hybrid			2022-12-25	WOS:000166784800038
J	Tinkelenberg, AH; Liu, Y; Alcantara, F; Khan, S; Guo, ZM; Bard, M; Sturley, SL				Tinkelenberg, AH; Liu, Y; Alcantara, F; Khan, S; Guo, ZM; Bard, M; Sturley, SL			Mutations in yeast ARV1 alter intracellular sterol distribution and are complemented by human ARV1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-CHOLESTEROL ACYLTRANSFERASE; BUDDING YEAST; CLONING; MACROPHAGES; INHIBITION; ERGOSTEROL; MEMBRANES; REDUCTASE; CAVEOLIN; DATABASE	Intracellular cholesterol redistribution between membranes and its subsequent esterification are critical aspects of lipid homeostasis that prevent free sterol toxicity. To identify genes that mediate sterol trafficking, we screened for yeast mutants that were inviable in the absence of sterol esterification. Mutations in the novel gene, ARV1, render cells dependent on sterol esterification for growth, nystatin-sensitive, temperature-sensitive, and anaerobically inviable. Cells lacking Arv1p display altered intracellular sterol distribution and are defective in sterol uptake, consistent with a role for Arv1p in trafficking sterol into the plasma membrane. Human ARV1, a predicted sequence ortholog of yeast ARV1, complements the defects associated with deletion of the yeast gene. The genes are predicted to encode transmembrane proteins with potential zinc-binding motifs. We propose that ARV1 is a novel mediator of eukaryotic sterol homeostasis.	Columbia Univ Coll Phys & Surg, Inst Human Nutr, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Physiol, New York, NY 10032 USA; Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46205 USA	Columbia University; Columbia University; Columbia University; Indiana University System; Indiana University-Purdue University Indianapolis	Sturley, SL (corresponding author), Columbia Univ Coll Phys & Surg, Inst Human Nutr, 630 W 168th St, New York, NY 10032 USA.	sls37@columbia.edu			NIDDK NIH HHS [DK54320, DK07715] Funding Source: Medline; NIGMS NIH HHS [GM62104] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054320] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062104] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ArthingtonSkaggs BA, 1996, FEBS LETT, V392, P161, DOI 10.1016/0014-5793(96)00807-1; Ausubel FM, 1998, CURRENT PROTOCOLS MO; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BITMAN J, 1982, J LIQ CHROMATOGR, V5, P1155, DOI 10.1080/01483918208067575; BLOCH KE, 1983, CRC CR REV BIOCH MOL, V14, P47, DOI 10.3109/10409238309102790; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; CHANG TY, 1983, ENZYMES, V16, P523; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; Corpet F, 1998, NUCLEIC ACIDS RES, V26, P323, DOI 10.1093/nar/26.1.323; Cross FR, 1997, YEAST, V13, P647, DOI 10.1002/(SICI)1097-0061(19970615)13:7<647::AID-YEA115>3.0.CO;2-#; Crowley JH, 1998, J BACTERIOL, V180, P4177, DOI 10.1128/JB.180.16.4177-4183.1998; Cruz JC, 2000, J BIOL CHEM, V275, P41309, DOI 10.1074/jbc.M008272200; DIMSTERDENK D, 1994, MOL BIOL CELL, V5, P655, DOI 10.1091/mbc.5.6.655; EPSTEIN CB, 1992, GENE DEV, V6, P1695, DOI 10.1101/gad.6.9.1695; Erdeniz N, 1997, GENOME RES, V7, P1174, DOI 10.1101/gr.7.12.1174; FREEMAN CP, 1966, J LIPID RES, V7, P324; GOLLUB EG, 1974, BIOCHEM BIOPH RES CO, V56, P471, DOI 10.1016/0006-291X(74)90866-3; Hahn S, 2000, GENE DEV, V14, P719; HOSTAGER BS, 2000, J BIOL CHEM; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKSON RL, 1976, ATHEROSCLER REV, V1, P1; Kellner-Weibel G, 1999, ATHEROSCLEROSIS, V146, P309, DOI 10.1016/S0021-9150(99)00155-0; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; KRANZ JE, 1990, P NATL ACAD SCI USA, V87, P6629, DOI 10.1073/pnas.87.17.6629; Kutateladze TG, 1999, MOL CELL, V3, P805, DOI 10.1016/S1097-2765(01)80013-7; LEWIS TL, 1988, YEAST, V4, P93, DOI 10.1002/yea.320040203; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; PARKS LW, 1995, LIPIDS, V30, P227, DOI 10.1007/BF02537825; Rost B, 1996, METHOD ENZYMOL, V266, P525; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SHERMAN F, 1991, METHOD ENZYMOL, V194, P21; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; TABAS I, 1986, J BIOL CHEM, V261, P3147; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Wang MM, 1998, BIOCHEMISTRY-US, V37, P11797, DOI 10.1021/bi980290k; WARNER GJ, 1995, J BIOL CHEM, V270, P5772, DOI 10.1074/jbc.270.11.5772; XU XX, 1991, J BIOL CHEM, V266, P17040; Yang HY, 1996, SCIENCE, V272, P1353, DOI 10.1126/science.272.5266.1353; Yang HY, 1997, J BIOL CHEM, V272, P3980, DOI 10.1074/jbc.272.7.3980; Yu CJ, 1996, J BIOL CHEM, V271, P24157, DOI 10.1074/jbc.271.39.24157	44	80	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40667	40670		10.1074/jbc.C000710200	http://dx.doi.org/10.1074/jbc.C000710200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11063737	hybrid			2022-12-25	WOS:000166114600003
J	Domowicz, MS; Pirok, EW; Novak, TE; Schwartz, NB				Domowicz, MS; Pirok, EW; Novak, TE; Schwartz, NB			Role of the C-terminal G3 domain in sorting and secretion of aggrecan core protein and ubiquitin-mediated degradation of accumulated mutant precursors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-DEPENDENT ANIMAL LECTINS; SITE-DIRECTED MUTAGENESIS; ENDOPLASMIC-RETICULUM; QUALITY-CONTROL; SUGAR LIGANDS; PROTEOGLYCAN; CHONDRODYSTROPHY; XYLOSYLATION; NANOMELIA; BINDING	Aggrecan is a complex multidomain macromolecule that undergoes extensive processing and post-translational modification. A thorough understanding of the events and signals that promote translocation of aggrecan through the secretory pathway is lacking. To investigate which features of the C-terminal G3 region are necessary for:successful translocation of the core protein, a number of deletion constructs based on the chick aggrecan cDNA sequence were prepared and transiently expressed in COS-l cells and the natural host, embryonic chick chondrocytes; stable cell lines were established as well. The present results clearly establish a precise requirement for that portion of the G3 C-lectin domain encoded by exon 15 for: (i) translocation from the endoplasmic reticulum (ER) to the Golgi, (ii) secretion from the cell, (iii) galactosylation of chondroitin sulfate (CS):chains, (iv) generation of Ca+2-dependent galactose binding ability, Furthermore, in the absence of this subdomain there is excess accumulation in the ER of expression products leading to a stress-related response involving the chaperones Grp78 and protein disulfide isomerase, followed by degradation via a ubiquitin-proteosome pathway. All of these events in the model system faithfully mimic the naturally occurring nanomelic mutant, which also elicits a ubiquitin-mediated degradation response due to the accumulation of the truncated core protein precursor. This study represents the first report of the mode of degradation of overexpressed or misfolded proteoglycans and suggests that, although proteoglycans follow different glycosylation pathways from other glycoproteins, they are monitored by an ER surveillance system similar to that which detects other misfolded proteins.	Univ Chicago, Dept Pediat, Comm Dev Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Comm Dev Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Schwartz, NB (corresponding author), Univ Chicago, Dept Pediat, Comm Dev Biol, 5841 S Maryland Ave,MC 5058, Chicago, IL 60637 USA.		Domowicz, Miriam/AAG-7886-2022; Domowicz, Miriam/AFL-7930-2022	Domowicz, Miriam/0000-0001-7860-4427; Domowicz, Miriam/0000-0001-7860-4427	NHLBI NIH HHS [HL-07237] Funding Source: Medline; NIAMS NIH HHS [AR-19622] Funding Source: Medline; NICHD NIH HHS [HD-09402] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD009402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR019622, R01AR019622] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aridor M, 2000, SCIENCE, V287, P816, DOI 10.1126/science.287.5454.816; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; Brissett NC, 1998, BIOCHEM J, V329, P415; CAMPBELL SC, 1988, J CELL BIOL, V106, P2191, DOI 10.1083/jcb.106.6.2191; Day JM, 1999, J BIOL CHEM, V274, P38107, DOI 10.1074/jbc.274.53.38107; de Virgilio M, 1998, J BIOL CHEM, V273, P9734, DOI 10.1074/jbc.273.16.9734; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Geoghegan KF, 1999, ANAL BIOCHEM, V267, P169, DOI 10.1006/abio.1998.2990; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; IOBST ST, 1994, J BIOL CHEM, V269, P15512; IOBST ST, 1994, J BIOL CHEM, V269, P15505; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; Kolatkar AR, 1996, J BIOL CHEM, V271, P6679, DOI 10.1074/jbc.271.12.6679; KRUEGER RC, 1992, J BIOL CHEM, V267, P12149; Ledent P, 1997, FEBS LETT, V413, P194, DOI 10.1016/S0014-5793(97)00908-3; Li H, 1995, J MOL EVOL, V41, P878; LI H, 1993, J BIOL CHEM, V268, P23504; Luo W, 1996, J BIOL CHEM, V271, P16447, DOI 10.1074/jbc.271.28.16447; Pirok EW, 1997, J BIOL CHEM, V272, P11566, DOI 10.1074/jbc.272.17.11566; Rivera VM, 2000, SCIENCE, V287, P826, DOI 10.1126/science.287.5454.826; Sambrook J., 2002, MOL CLONING LAB MANU; SCHWARTZ NB, 1995, TRENDS GLYCOSCI GLYC, V7, P429, DOI 10.4052/tigg.7.429; VERTEL BM, 1994, BIOCHEM J, V301, P211, DOI 10.1042/bj3010211; VERTEL BM, 1993, J CELL SCI, V104, P939; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Zheng J, 1998, J BIOL CHEM, V273, P12999, DOI 10.1074/jbc.273.21.12999; Zhivotovsky B, 1997, BIOCHEM BIOPH RES CO, V230, P481, DOI 10.1006/bbrc.1996.6016	29	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 10	2000	275	45					35098	35105		10.1074/jbc.275.45.35098	http://dx.doi.org/10.1074/jbc.275.45.35098			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	375VW	11063750	hybrid			2022-12-25	WOS:000165422800038
J	Yeh, CT; Shen, CH; Tai, DI; Chu, CM; Liaw, YF				Yeh, CT; Shen, CH; Tai, DI; Chu, CM; Liaw, YF			Identification and characterization of a prevalent hepatitis B virus X protein mutant in Taiwanese patients with hepatocellular carcinoma	ONCOGENE			English	Article						hepatitis B virus; hepatocellular carcinoma; mutant; X protein	TRANSGENIC MICE; HBX PROTEIN; DELETION MUTANTS; GENE PRODUCT; ANTIGEN; DNA; KINASE; PATHOGENESIS; INFECTIONS; APOPTOSIS	The aim of this study was to investigate whether there was a particular hepatitis B virus (HBV) X protein (HBx) mutant associated with Taiwanese patients with hepatocellular carcinoma (HCC). Initially, the entire coding region of HBx gene from the serum samples of 14 Taiwanese patients were sequenced. A novel mutant, HBx-A31, was preferentially found in patients with HCC. Sera from 67 patients with HCC and 100 patients with chronic hepatitis B were thus subjected for codon 31 analysis using a dual amplification created restriction site method. HBx-A31 was detected more frequently in patients with HCC (52% versus 12%; P<0.001) and in patients with liver cirrhosis (44% versus 6%; P<0.001). Site directed mutagenesis experiment revealed that HBx-A31 was less effective in transactivating HBV enhancer I-X promoter complex, less efficient in supporting HBV replication, and less potent in enhancing TNF-alpha induced increment of CPP32/caspase 3 activities in HepG2 cells. In conclusion, a prevalent HBx mutant was identified in Taiwanese patients with hepatocellular carcinoma. Development of this mutant might represent a strategy of the virus to escape immune surveillance and thus contribute to the process of multiple-step hepatocarcinogenesis.	Chang Gung Mem Hosp, Liver Res Unit, Taipei 105, Taiwan; Chang Gung Univ, Sch Med, Taipei 105, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Yeh, CT (corresponding author), Chang Gung Mem Hosp, Liver Res Unit, 199 Tung Hwa N Rd, Taipei 105, Taiwan.		Liaw, Yun-Fan/B-4305-2009					BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; CHISARI FV, 1989, CELL, V59, P1145, DOI 10.1016/0092-8674(89)90770-8; Chu CM, 1996, J CLIN MICROBIOL, V34, P1815, DOI 10.1128/JCM.34.7.1815-1818.1996; Dopheide TAA, 1996, J GEN VIROL, V77, P173, DOI 10.1099/0022-1317-77-2-173; DUNSFORD HA, 1990, CANCER RES, V50, P3400; FEITELSON M, 1992, CLIN MICROBIOL REV, V5, P275, DOI 10.1128/CMR.5.3.275-301.1992; FEITELSON MA, 1995, GASTROENTEROLOGY, V108, P1810, DOI 10.1016/0016-5085(95)90144-2; FEITELSON MA, 1993, ONCOGENE, V8, P1109; GANEM D, 1987, ANNU REV BIOCHEM, V56, P651, DOI 10.1146/annurev.biochem.56.1.651; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Greenblatt MS, 1997, CANCER RES, V57, P426; Hsia CC, 1997, BIOCHEM BIOPH RES CO, V241, P726, DOI 10.1006/bbrc.1997.7882; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Klein NP, 1997, MOL CELL BIOL, V17, P6427, DOI 10.1128/MCB.17.11.6427; LEE TH, 1990, J VIROL, V64, P5939, DOI 10.1128/JVI.64.12.5939-5947.1990; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; LIAW YF, 1988, HEPATOLOGY, V8, P493, DOI 10.1002/hep.1840080310; LIAW YF, 1994, VIRAL HEPATITIS LIVE, P419; LUCITO R, 1992, J VIROL, V66, P983, DOI 10.1128/JVI.66.2.983-991.1992; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; OHAKI Y, 1983, CANCER, V51, P822, DOI 10.1002/1097-0142(19830301)51:5<822::AID-CNCR2820510513>3.0.CO;2-C; Qadri I, 1996, J BIOL CHEM, V271, P15443, DOI 10.1074/jbc.271.26.15443; ROBINSON WS, 1994, ANNU REV MED, V45, P297; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; Szmuness W, 1978, Prog Med Virol, V24, P40; Tai DI, 2000, HEPATOLOGY, V31, P656, DOI 10.1002/hep.510310316; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; WANG XW, 1995, CANCER RES, V55, P6012; WU JY, 1990, CELL, V63, P687, DOI 10.1016/0092-8674(90)90135-2; Yeh CT, 1998, J MED VIROL, V55, P42, DOI 10.1002/(SICI)1096-9071(199805)55:1<42::AID-JMV8>3.0.CO;2-O; Yeh CT, 2000, HEPATOLOGY, V31, P1318, DOI 10.1053/jhep.2000.7296; Yeh CT, 1997, J VIROL METHODS, V65, P219, DOI 10.1016/S0166-0934(97)02187-3; Yeh CT, 2000, J HEPATOL, V32, P829, DOI 10.1016/S0168-8278(00)80253-6; Yen T. S. Benedict, 1996, Journal of Biomedical Science, V3, P20	39	63	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5213	5220		10.1038/sj.onc.1203903	http://dx.doi.org/10.1038/sj.onc.1203903			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077437				2022-12-25	WOS:000165059700001
J	Santoro, MM; Penengo, L; Orecchia, S; Cilli, M; Gaudino, G				Santoro, MM; Penengo, L; Orecchia, S; Cilli, M; Gaudino, G			The Ron oncogenic activity induced by the MEN2B-like substitution overcomes the requirement for the multifunctional docking site	ONCOGENE			English	Article						Ron; substrate specificity; tumorigenesis; tyrosine phosphorylation	MACROPHAGE-STIMULATING PROTEIN; KINASE CATALYTIC DOMAIN; INVASIVE GROWTH; RECEPTOR FAMILY; MUTATIONS; ACTIVATION; TRANSFORMATION; GENE; IDENTIFICATION; PROTOONCOGENE	Oncogenic activation of the Ron tyrosine kinase (Macrophage Stimulating Protein receptor) relies on substitutions of two highly conserved residues in the catalytic domain (D1232V and M1254T), which result in ligand-independent activation of the receptor, in vivo tumorigenesis and metastasis. We show here that the Y/F conversion of the Y-1317 residue in the kinase domain impairs tumorigenic and metastatic properties of Ron activated by the MEN2B-like mutation (Ron(M1254T)), but not by other two oncogenic substitutions, Furthermore, Ron(M1254T) lacking the multifunctional docking site retains transforming and metastatic activity, These data reveal that the transforming activity of Ron(M1254T) mutant is dependent on Y-1317 phosphorylation, suggesting a shift in intramolecular substrate specificity. Consistently, a shift of Ron(M1254T) kinase substrate specificity was observed by in vitro peptide phosphorylation assays and in vitro receptor autophosphorylation, The Y-1317 phosphorylation elicits by itself activation of PI-3K/Akt and MAPK signalling pathways, Our data indicate that the accomplishment of the full oncogenic phenotype of Ron(M1254T) requires the phosphorylation both of the canonical C-terminal docking site and of the unique Y-1317 residue in the tyrosine kinase domain.	Dibit HSR, I-20138 Milan, Italy; Univ Piemonte Orientale Amedeo Avogadro, Dept Med Sci, I-28100 Novara, Italy; Ist Nazl Ric Canc, I-16132 Genoa, Italy	University of Eastern Piedmont Amedeo Avogadro; University of Genoa; IRCCS AOU San Martino IST	Gaudino, G (corresponding author), Dibit HSR, Via Olgettina 58, I-20138 Milan, Italy.		Cilli, Michele/AAB-8529-2019	PENENGO, Lorenza/0000-0001-7888-4473; Cilli, Michele/0000-0003-4083-8986; SANTORO, Massimo Mattia/0000-0003-4605-5085				Bardelli A, 1998, P NATL ACAD SCI USA, V95, P14379, DOI 10.1073/pnas.95.24.14379; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; GAUDINO G, 1994, EMBO J, V13, P3524, DOI 10.1002/j.1460-2075.1994.tb06659.x; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jeffers M, 1999, ONCOGENE, V18, P5120, DOI 10.1038/sj.onc.1202902; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; LI BQ, 1995, BIOCHEM BIOPH RES CO, V216, P110, DOI 10.1006/bbrc.1995.2598; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Petti LM, 1998, ONCOGENE, V16, P843, DOI 10.1038/sj.onc.1201590; Piao XH, 1996, P NATL ACAD SCI USA, V93, P14665, DOI 10.1073/pnas.93.25.14665; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; Santoro MM, 1996, MOL CELL BIOL, V16, P7072; Santoro MM, 1998, ONCOGENE, V17, P741, DOI 10.1038/sj.onc.1201994; Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Songyang Zhou, 1995, Trends in Biochemical Sciences, V20, P470, DOI 10.1016/S0968-0004(00)89103-3; STENBERG MJE, 1989, NATURE, V339, P587; Wang MH, 1996, ONCOGENE, V13, P2167; WANG MH, 1994, SCIENCE, V266, P117, DOI 10.1126/science.7939629; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; Williams TA, 1999, J CELL PHYSIOL, V181, P507, DOI 10.1002/(SICI)1097-4652(199912)181:3<507::AID-JCP15>3.0.CO;2-Q; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	25	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5208	5211		10.1038/sj.onc.1203819	http://dx.doi.org/10.1038/sj.onc.1203819			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064459	Green Published			2022-12-25	WOS:000090124100011
J	Pecqueur, C; Alves-Guerra, MC; Gelly, C; Levi-Meyrueis, C; Couplan, E; Collins, S; Ricquier, D; Bouillaud, F; Miroux, B				Pecqueur, C; Alves-Guerra, MC; Gelly, C; Levi-Meyrueis, C; Couplan, E; Collins, S; Ricquier, D; Bouillaud, F; Miroux, B			Uncoupling protein 2, in vivo distribution, induction upon oxidative stress, and evidence for translational regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; BROWN ADIPOSE-TISSUE; MITOCHONDRIAL CARRIER FAMILY; SKELETAL-MUSCLE; MESSENGER-RNA; MEMBRANE-PROTEINS; HIGH EXPRESSION; GENE; RAT; UCP3	Uncoupling protein 2 (UCP2) belongs to the mitochondrial anion carrier family and partially uncouples respiration from ATP synthesis when expressed in recombinant yeast mitochondria. We generated a highly sensitive polyclonal antibody against human UCP2. Its reactivity toward mitochondrial proteins was compared between wild type and ucp2(-/-) mice, leading to non-ambiguous identification of UCP2. We detected UCP2 in spleen, lung, stomach, and white adipose tissue. No UCP2 was detected in heart, skeletal muscle, liver, and brown adipose tissue. The level of UCP2 in spleen mitochondria is less than 1% of the level of UCP1 in brown adipose tissue mitochondria. Starvation and LPS treatments increase UCP2 level up to 12 times in lung and stomach, which supports the hypothesis that UCP2 responds to oxidative stress situations. Stimulation of the UCP2 expression occurs without any change in UCP2 mRNA levels. This is explained by translational regulation of the UCP2 mRNA, We have shown that an upstream open reading frame located in exon two of the ucp2 gene strongly inhibits the expression of the protein. This further level of regulation of the ucp2 gene provides a mechanism by which expression can be strongly and rapidly induced under stress conditions.	CEREMOD, CNRS, UPR 9078, F-92190 Meudon, France; Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol, Durham, NC 27710 USA	Centre National de la Recherche Scientifique (CNRS); Duke University; Duke University	Miroux, B (corresponding author), CEREMOD, CNRS, UPR 9078, 9 Rue Jules Hetzel, F-92190 Meudon, France.	bmiroux@infobiogen.fr	Alves-Guerra, Marie-Clotilde/P-4356-2017; Bouillaud, Frédéric R/L-3238-2017; Miroux, Bruno/E-9267-2017; Pecqueur, Claire/L-3073-2015	Alves-Guerra, Marie-Clotilde/0000-0002-7918-1216; Bouillaud, Frédéric R/0000-0002-7518-9237; Pecqueur, Claire/0000-0002-7612-1672; Miroux, Bruno/0000-0002-3066-4700				Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Boss O, 2000, DIABETES, V49, P143, DOI 10.2337/diabetes.49.2.143; Boss O, 1997, FEBS LETT, V412, P111, DOI 10.1016/S0014-5793(97)00755-2; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bouchard C, 1997, HUM MOL GENET, V6, P1887, DOI 10.1093/hmg/6.11.1887; Busquets S, 1998, FEBS LETT, V440, P348, DOI 10.1016/S0014-5793(98)01485-9; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CASSARD AM, 1990, J CELL BIOCHEM, V43, P255, DOI 10.1002/jcb.240430306; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; Cortez-Pinto H, 1999, GASTROENTEROLOGY, V116, P1184, DOI 10.1016/S0016-5085(99)70022-3; Cortez-Pinto H, 1998, BIOCHEM BIOPH RES CO, V251, P313, DOI 10.1006/bbrc.1998.9473; Echtay KS, 1999, FEBS LETT, V450, P8, DOI 10.1016/S0014-5793(99)00460-3; ElMoualij B, 1997, YEAST, V13, P573, DOI 10.1002/(SICI)1097-0061(199705)13:6<573::AID-YEA107>3.0.CO;2-I; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Faggioni R, 1998, BIOCHEM BIOPH RES CO, V244, P75, DOI 10.1006/bbrc.1998.8219; Fleury C, 1999, INT J BIOCHEM CELL B, V31, P1261, DOI 10.1016/S1357-2725(99)00049-7; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Harlow E., 1988, ANTIBODIES LAB MANUA, P298; Hodny Z, 1998, FEBS LETT, V425, P185, DOI 10.1016/S0014-5793(98)00230-0; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jezek P, 1999, FEBS LETT, V455, P79, DOI 10.1016/S0014-5793(99)00853-4; KAPLAN RS, 1993, J BIOL CHEM, V268, P13682; Kochetov AV, 1998, FEBS LETT, V440, P351, DOI 10.1016/S0014-5793(98)01482-3; KRAMER R, 1989, BIOCHIM BIOPHYS ACTA, V974, P1, DOI 10.1016/S0005-2728(89)80160-4; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; Larrouy D, 1997, BIOCHEM BIOPH RES CO, V235, P760, DOI 10.1006/bbrc.1997.6852; Lee FYJ, 1999, HEPATOLOGY, V29, P677, DOI 10.1002/hep.510290320; Liu QY, 1998, GENE, V207, P1, DOI 10.1016/S0378-1119(97)00596-9; Lowe J, 1998, NATURE, V391, P203, DOI 10.1038/34472; Matthias A, 1999, J BIOL CHEM, V274, P28150, DOI 10.1074/jbc.274.40.28150; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; MIROUX B, 1992, J BIOL CHEM, V267, P13603; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Pecqueur C, 1999, BIOCHEM BIOPH RES CO, V255, P40, DOI 10.1006/bbrc.1998.0146; Qian H, 1998, BIOCHEM BIOPH RES CO, V246, P660, DOI 10.1006/bbrc.1998.8680; Rashid A, 1999, HEPATOLOGY, V29, P1131, DOI 10.1002/hep.510290428; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Richard D, 1998, J COMP NEUROL, V397, P549; RICQUIER D, 1984, FEBS LETT, V178, P240, DOI 10.1016/0014-5793(84)80608-0; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RICQUIER D, 1986, J BIOL CHEM, V261, P13905; RICQUIER D, 1983, BIOCHEM J, V210, P859, DOI 10.1042/bj2100859; Ryan LK, 1997, IN VITRO CELL DEV-AN, V33, P647, DOI 10.1007/s11626-997-0116-0; Sanchis D, 1998, J BIOL CHEM, V273, P34611, DOI 10.1074/jbc.273.51.34611; Simoneau JA, 1998, FASEB J, V12, P1739, DOI 10.1096/fasebj.12.15.1739; Sivitz WI, 1999, ENDOCRINOLOGY, V140, P1511, DOI 10.1210/en.140.4.1511; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; SMITH LJ, 1992, AM REV RESPIR DIS, V146, P1452, DOI 10.1164/ajrccm/146.6.1452; Solanes G, 1997, J BIOL CHEM, V272, P25433, DOI 10.1074/jbc.272.41.25433; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829; YEGEN B, 1990, PHARMACOL RES, V22, P45, DOI 10.1016/1043-6618(90)90742-V; Yoshitomi H, 1998, GENE, V215, P77, DOI 10.1016/S0378-1119(98)00279-0; ZARRILLI R, 1989, MOL ENDOCRINOL, V3, P1498, DOI 10.1210/mend-3-9-1498	60	391	416	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8705	8712		10.1074/jbc.M006938200	http://dx.doi.org/10.1074/jbc.M006938200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11098051	hybrid			2022-12-25	WOS:000167607700013
J	Abdul-Ghani, M; Gougeon, PY; Prosser, DC; Da-Silva, LF; Ngsee, JK				Abdul-Ghani, M; Gougeon, PY; Prosser, DC; Da-Silva, LF; Ngsee, JK			PRA isoforms are targeted to distinct membrane compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; POST-GOLGI VESICLES; ENDOPLASMIC-RETICULUM; TRANSMEMBRANE PROTEINS; BINDING PROTEINS; SNARE PROTEINS; RAB3 SUBFAMILY; COMPLEX; DOCKING; TRANSPORT	The prenylated Rab acceptor (PRA) 1 is a protein that binds prenylated Rab GTPases and inhibits their removal from the membrane by GDI. We describe here the isolation of a second isoform that can also bind Rab GTPases in a guanine nucleotide-independent manner. The two PRA isoforms showed distinct intracellular localization with PRA1 localized primarily to the Golgi complex and PRA2 to the endoplasmic reticulum (ER) compartment. The localization signal was mapped to the COOH-terminal domain of the two proteins. A DXEE motif served to target PRA1 to the Golgi. Mutation of any one of the acidic residues within this motif resulted in significant retention of PRA1 in the ER compartment. Moreover, the introduction of a di-acidic motif to the COOH-terminal domain of PRA2 resulted in partial localization to the Golgi complex. The domain responsible for ER localization of PRA2 was also confined to the carboxyl terminus. Our results showed that these sorting signals were primarily responsible for the differential localization of the two PRA isoforms.	Univ Ottawa, Loeb Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute	Ngsee, JK (corresponding author), Univ Ottawa, Loeb Hlth Res Inst, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.			Prosser, Derek/0000-0002-6738-2758				Advani RJ, 1999, J CELL BIOL, V146, P765, DOI 10.1083/jcb.146.4.765; Advani RJ, 1998, J BIOL CHEM, V273, P10317, DOI 10.1074/jbc.273.17.10317; Albert S, 1999, J BIOL CHEM, V274, P33186, DOI 10.1074/jbc.274.47.33186; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; Brigance WT, 2000, MOL BIOL CELL, V11, P171, DOI 10.1091/mbc.11.1.171; Cao XC, 2000, J CELL BIOL, V149, P55, DOI 10.1083/jcb.149.1.55; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; ELFERINK LA, 1992, J BIOL CHEM, V267, P5768; Elkind NB, 2000, J CELL BIOL, V149, P95, DOI 10.1083/jcb.149.1.95; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; FISCHER V, 1990, P NATL ACAD SCI USA, V87, P1988; Fukui K, 1997, J BIOL CHEM, V272, P4655, DOI 10.1074/jbc.272.8.4655; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Guo W, 1999, EMBO J, V18, P1071, DOI 10.1093/emboj/18.4.1071; Hutt DM, 2000, J BIOL CHEM, V275, P18511, DOI 10.1074/jbc.M909309199; JACKSON MR, 1993, J CELL BIOL, V121, P317, DOI 10.1083/jcb.121.2.317; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JOHNSTON PA, 1991, NEURON, V7, P101, DOI 10.1016/0896-6273(91)90078-E; KHOSRAVIFAR R, 1991, P NATL ACAD SCI USA, V88, P6264, DOI 10.1073/pnas.88.14.6264; KHOSRAVIFAR R, 1992, J BIOL CHEM, V267, P24363; KINSELLA BT, 1992, J BIOL CHEM, V267, P3940; Martincic I, 1997, J BIOL CHEM, V272, P26991, DOI 10.1074/jbc.272.43.26991; MATTEOLI M, 1991, J CELL BIOL, V115, P625, DOI 10.1083/jcb.115.3.625; MIYAZAKI A, 1994, FEBS LETT, V350, P3033; Munro S, 1999, CURR BIOL, V9, P377, DOI 10.1016/S0960-9822(99)80166-3; Murthy VN, 1999, NAT NEUROSCI, V2, P503, DOI 10.1038/9149; NGSEE JK, 1991, J BIOL CHEM, V266, P2675; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Nuoffer C, 1997, MOL BIOL CELL, V8, P1305, DOI 10.1091/mbc.8.7.1305; Sacher M, 1998, EMBO J, V17, P2494, DOI 10.1093/emboj/17.9.2494; SCHUTZE MP, 1994, EMBO J, V13, P1696, DOI 10.1002/j.1460-2075.1994.tb06434.x; Sevier CS, 2000, MOL BIOL CELL, V11, P13, DOI 10.1091/mbc.11.1.13; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; Szczesna-Skorupa E, 2000, J BIOL CHEM, V275, P19409, DOI 10.1074/jbc.M002394200; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VanRheenen SM, 1999, J CELL BIOL, V147, P729, DOI 10.1083/jcb.147.4.729; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; WalchSolimena C, 1997, J CELL BIOL, V137, P1495, DOI 10.1083/jcb.137.7.1495; WEI C, 1992, ONCOGENE, V7, P467; ZAHRAOUI A, 1988, NUCLEIC ACIDS RES, V16, P1204, DOI 10.1093/nar/16.3.1204; Zeng Q, 1998, MOL BIOL CELL, V9, P2423, DOI 10.1091/mbc.9.9.2423	46	68	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6225	6233		10.1074/jbc.M009073200	http://dx.doi.org/10.1074/jbc.M009073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096102	hybrid			2022-12-25	WOS:000167261000024
J	Florin, L; Tsokoglou, A; Happe, T				Florin, L; Tsokoglou, A; Happe, T			A novel type of iron hydrogenase in the green alga Scenedesmus obliquus is linked to the photosynthetic electron transport chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; MOLECULAR-HYDROGEN; CRYSTAL-STRUCTURE; CLOSTRIDIUM-PASTEURIANUM; CHLAMYDOMONAS-REINHARDI; CARBON-DIOXIDE; GENE; PURIFICATION; FERREDOXIN; MECHANISM	Hydrogen evolution is observed in the green alga Scenedesmus obliquus after a phase of anaerobic adaptation. In this study we report the biochemical and genetical characterization of a new type of iron hydrogenase (HydA) in this photosynthetic organism. The monomeric enzyme has a molecular mass of 44.5 kDa. The complete hydA cDNA of 2609 base pairs comprises an open reading frame encoding a polypeptide of 448 amino acids. The protein contains a short transit peptide that routes the nucleus encoded hydrogenase to the chloroplast. Antibodies raised against the iron hydrogenase from Chlamydomonas reinhardtii react with both the isolated and in Escherichia coli overexpressed protein of S. obliquus as shown by Western blotting. By analyzing 5 kilobases of the genomic DNA, the transcription initiation site and five introns within hydA were revealed. Northern experiments suggest that hydA transcription is induced during anaerobic incubation. Alignments of S. obliquus HydA with known iron hydrogenases and sequencing of the N terminus of the purified protein confirm that HydA belongs to the class of iron hydrogenases. The C terminus of the enzyme including the catalytic site (H cluster) reveals a high degree of identity to iron hydrogenases. However, the lack of additional Fe S clusters in the N-terminal domain indicates a novel pathway of electron transfer. Inhibitor experiments show that the ferredoxin PetF functions as natural electron donor linking the enzyme to the photosynthetic electron transport chain. PetF probably binds to the hydrogenase through electrostatic interactions.	Univ Bonn, Inst Bot, D-53115 Bonn, Germany	University of Bonn	Happe, T (corresponding author), Univ Bonn, Inst Bot, Karlrobert Kreiten Str 13, D-53115 Bonn, Germany.	t.happe@uni-bonn.de		Happe, Thomas/0000-0003-1206-5234				Adams MWW, 2000, CURR OPIN CHEM BIOL, V4, P214, DOI 10.1016/S1367-5931(99)00077-0; ADAMS MWW, 1980, BIOCHIM BIOPHYS ACTA, V594, P105, DOI 10.1016/0304-4173(80)90007-5; ADAMS MWW, 1990, BIOCHIM BIOPHYS ACTA, V1020, P115, DOI 10.1016/0005-2728(90)90044-5; Akhmanova A, 1998, NATURE, V396, P527, DOI 10.1038/25023; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Atta M, 2000, BBA-PROTEIN STRUCT M, V1476, P368, DOI 10.1016/S0167-4838(99)00245-9; BAMBERGER ES, 1982, PLANT PHYSIOL, V69, P1268, DOI 10.1104/pp.69.6.1268; BENAMOTZ A, 1975, BIOCHEM BIOPH RES CO, V64, P355, DOI 10.1016/0006-291X(75)90261-2; Bes MT, 1999, STRUCT FOLD DES, V7, P1201, DOI 10.1016/S0969-2126(00)80054-4; BISHOP NI, 1966, ANN REV PLANT PHYSIO, V17, P185, DOI 10.1146/annurev.pp.17.060166.001153; BOICHENKO VA, 1994, PHOTOSYNTHETICA, V30, P527; Bui ETN, 1996, MOL BIOCHEM PARASIT, V76, P305, DOI 10.1016/0166-6851(96)02567-4; Cammack R, 1999, NATURE, V397, P214, DOI 10.1038/16601; Chenchik Alex, 1996, P273; FRANCIS K, 1989, PHOTOSYNTHETICA, V23, P43; FRANZEN LG, 1990, FEBS LETT, V260, P165, DOI 10.1016/0014-5793(90)80094-Y; Gaffron H, 1939, NATURE, V143, P204, DOI 10.1038/143204a0; Gaffron H, 1940, AM J BOT, V27, P273, DOI 10.2307/2436697; Gaffron Hans, 1942, JOUR GEN PHYSIOL, V26, P219, DOI 10.1085/jgp.26.2.219; Gong BW, 2000, BIOTECHNIQUES, V28, P846, DOI 10.2144/00285bm04; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; Gorwa MF, 1996, J BACTERIOL, V178, P2668, DOI 10.1128/jb.178.9.2668-2675.1996; Greenbaum E, 1998, BIOHYDROGEN, P235; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HAPPE T, 1993, EUR J BIOCHEM, V214, P475, DOI 10.1111/j.1432-1033.1993.tb17944.x; HAPPE T, 1994, EUR J BIOCHEM, V222, P769, DOI 10.1111/j.1432-1033.1994.tb18923.x; JOHANNINGMEIER U, 1984, J BIOL CHEM, V259, P3541; Kaji M, 1999, FEMS MICROBIOL LETT, V181, P329, DOI 10.1016/S0378-1097(99)00556-X; KEEGSTRA K, 1989, CELL, V56, P247, DOI 10.1016/0092-8674(89)90898-2; MEYER J, 1991, BIOCHEMISTRY-US, V30, P9697, DOI 10.1021/bi00104a018; Moulis JM, 1995, BIOCHEMISTRY-US, V34, P16781, DOI 10.1021/bi00051a028; Nicolet Y, 2000, TRENDS BIOCHEM SCI, V25, P138, DOI 10.1016/S0968-0004(99)01536-4; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; Peters JW, 1999, CURR OPIN STRUC BIOL, V9, P670, DOI 10.1016/S0959-440X(99)00028-7; Peters JW, 1998, SCIENCE, V282, P1853, DOI 10.1126/science.282.5395.1853; PRZYBYLA AE, 1992, FEMS MICROBIOL LETT, V88, P109, DOI 10.1016/0378-1097(92)90687-J; Quinn JM, 1998, METHOD ENZYMOL, V297, P263; RANDT C, 1985, PHOTOCHEM PHOTOBIOL, V42, P553, DOI 10.1111/j.1751-1097.1985.tb01609.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITTER JM, 1988, EUR J BIOCHEM, V172, P405, DOI 10.1111/j.1432-1033.1988.tb13901.x; SCHNACKENBERG J, 1993, FEBS LETT, V327, P21, DOI 10.1016/0014-5793(93)81030-4; SENGER H, 1979, PLANTA, V145, P53, DOI 10.1007/BF00379927; SIEBERT PD, 1995, NUCLEIC ACIDS RES, V23, P1087, DOI 10.1093/nar/23.6.1087; Silflow Carolyn D., 1998, Advances in Photosynthesis, V7, P25; SILFLOW CD, 1985, MOL CELL BIOL, V5, P2389, DOI 10.1128/MCB.5.9.2389; STOKKERMANS J, 1989, FEMS MICROBIOL LETT, V58, P217; Thauer RK, 1996, CHEM REV, V96, P3031, DOI 10.1021/cr9500601; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trebst A., 1980, METH ENZYMOL, V69, P675, DOI DOI 10.1016/S0076-6879(80)69067-3; Verhagen MFJM, 1999, BBA-BIOENERGETICS, V1412, P212, DOI 10.1016/S0005-2728(99)00062-6; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; VOORDOUW G, 1987, EUR J BIOCHEM, V162, P31, DOI 10.1111/j.1432-1033.1987.tb10537.x; WU LF, 1993, FEMS MICROBIOL LETT, V104, P243; ZINN T, 1994, Z NATURFORSCH C, V49, P33; ZIRNGIBL C, 1992, EUR J BIOCHEM, V208, P511, DOI 10.1111/j.1432-1033.1992.tb17215.x	57	190	205	0	30	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6125	6132		10.1074/jbc.M008470200	http://dx.doi.org/10.1074/jbc.M008470200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096090	hybrid			2022-12-25	WOS:000167261000012
J	Thur, J; Rosenberg, K; Nitsche, DP; Pihlajamaa, T; Ala-Kokko, L; Heinegard, D; Paulsson, M; Maurer, P				Thur, J; Rosenberg, K; Nitsche, DP; Pihlajamaa, T; Ala-Kokko, L; Heinegard, D; Paulsson, M; Maurer, P			Mutations in cartilage oligomeric matrix protein causing pseudoachondroplasia and multiple epiphyseal dysplasia affect binding of calcium and collagen I, II, and IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNOVIAL-FLUID; ELECTRON-MICROSCOPY; COMP GENE; IDENTIFICATION; SERUM; CHAIN; ZINC; REVEALS; MARKER; CELLS	Mutations in type 3 repeats of cartilage oligomeric matrix protein (COMP) cause two skeletal dysplasias, pseudoachondroplasia (PSACH) and multiple epiphyseal dysplasia (MED). We expressed recombinant wildtype COMP that showed structural and functional properties identical to COMP isolated from cartilage. A fragment encompassing the eight type 3 repeats binds 14 calcium ions with moderate affinity and high cooperativity and presumably forms one large disulfide bonded folding unit. A recombinant PSACH mutant COMP in which Asp-469 was deleted (D469 Delta) and a MED mutant COMP in which Asp-361 was substituted by Tyr (D361Y) were both secreted into the cell culture medium of human cells. Circular dichroism spectroscopy revealed only small changes in the secondary structures of D469 Delta and D361Y, demonstrating that the mutations do not dramatically affect the folding and stability of COMP. However, the local conformations of the type 3 repeats were disturbed, and the number of bound calcium ions was reduced to 10 and 8, respectively. In addition to collagen I and II, collagen IX also binds to COMP with high affinity. The PSACH and MED mutations reduce the binding to collagens I, II, and IX and result in an altered zinc dependence. These interactions may contribute to the development of the patient phenotypes and may explain why MED can also be caused by mutations in collagen IX genes.	Univ Cologne, Fac Med, Inst Biochem, D-50931 Cologne, Germany; Lund Univ, Dept Cell & Mol Biol, Sect Connect Tissue Biol, S-22100 Lund, Sweden; Univ Oulu, Bioctr, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem, FIN-90014 Oulu, Finland	University of Cologne; Lund University; University of Oulu; University of Oulu	Maurer, P (corresponding author), Univ Cologne, Inst Biochem 2, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.	patrik.maurer@uni-koeln.de						Ballo R, 1997, AM J MED GENET, V68, P396, DOI 10.1002/(SICI)1096-8628(19970211)68:4<396::AID-AJMG4>3.3.CO;2-R; Bonnemann CG, 2000, P NATL ACAD SCI USA, V97, P1212, DOI 10.1073/pnas.97.3.1212; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; BRUCKNER P, 1988, J BIOL CHEM, V263, P16911; BUNEAUX F, 1978, REV RHUM, V45, P699; Cohn DH, 1996, ANN NY ACAD SCI, V785, P188, DOI 10.1111/j.1749-6632.1996.tb56258.x; Deere M, 1999, AM J MED GENET, V85, P486, DOI 10.1002/(SICI)1096-8628(19990827)85:5<486::AID-AJMG10>3.0.CO;2-O; Deere M, 1998, AM J MED GENET, V80, P510, DOI 10.1002/(SICI)1096-8628(19981228)80:5<510::AID-AJMG14>3.0.CO;2-F; Delot E, 1999, HUM MOL GENET, V8, P123, DOI 10.1093/hmg/8.1.123; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DiCesare PE, 1996, J ORTHOPAED RES, V14, P946, DOI 10.1002/jor.1100140615; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; DiCesare PE, 1997, FEBS LETT, V412, P249, DOI 10.1016/S0014-5793(97)00789-8; ENGEL J, 1987, METHOD ENZYMOL, V145, P3; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; Ferguson HL, 1997, AM J MED GENET, V70, P287; FORSLIND K, 1992, BRIT J RHEUMATOL, V31, P593; Fukuta S, 1998, MATRIX BIOL, V17, P65, DOI 10.1016/S0945-053X(98)90074-9; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Hagg R, 1997, J BIOL CHEM, V272, P20650, DOI 10.1074/jbc.272.33.20650; Hecht JT, 1998, MATRIX BIOL, V17, P269, DOI 10.1016/S0945-053X(98)90080-4; Hecht JT, 1998, MATRIX BIOL, V17, P625, DOI 10.1016/S0945-053X(98)90113-5; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Holden P, 1999, AM J HUM GENET, V65, P31, DOI 10.1086/302440; Hummel KM, 1998, BRIT J RHEUMATOL, V37, P721; Ikegawa S, 1998, HUM GENET, V103, P633, DOI 10.1007/s004390050883; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; Kuhne SAM, 1998, RHEUMATOL INT, V18, P21, DOI 10.1007/s002960050049; LANGER M, 1993, EURO ENVIRONM MANAG, V1, P47; Lohiniva J, 2000, AM J MED GENET, V90, P216, DOI 10.1002/(SICI)1096-8628(20000131)90:3<216::AID-AJMG6>3.0.CO;2-1; LOHMANDER LS, 1994, ANN RHEUM DIS, V53, P8, DOI 10.1136/ard.53.1.8; Loughlin J, 1998, HUM MUTAT, pS10; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; Malashkevich VN, 1996, SCIENCE, V274, P761, DOI 10.1126/science.274.5288.761; MAYNARD JA, 1972, LAB INVEST, V26, P40; MISENHEIMER TM, 1995, J BIOL CHEM, V270, P1729, DOI 10.1074/jbc.270.4.1729; MORGELIN M, 1992, J BIOL CHEM, V267, P6137; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; NAKATA K, 1993, P NATL ACAD SCI USA, V90, P2870, DOI 10.1073/pnas.90.7.2870; Neidhart M, 1997, BRIT J RHEUMATOL, V36, P1151; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Olsen BR, 1997, INT J BIOCHEM CELL B, V29, P555, DOI 10.1016/S1357-2725(96)00100-8; Paassilta P, 1999, AM J HUM GENET, V64, P1036, DOI 10.1086/302328; Pihlajamaa T, 1999, J BIOL CHEM, V274, P22464, DOI 10.1074/jbc.274.32.22464; Recklies AD, 1998, ARTHRITIS RHEUM, V41, P997, DOI 10.1002/1529-0131(199806)41:6<997::AID-ART6>3.0.CO;2-G; Rimoin DL, 1998, AM J MED GENET, V79, P376; RIZZO R, 1995, J EXP ZOOL, V273, P82, DOI 10.1002/jez.1402730111; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; SAXNE T, 1992, BRIT J RHEUMATOL, V31, P583; SCHOR RA, 1973, CLIN ORTHOP RELAT R, P346; Smith RKW, 1997, MATRIX BIOL, V16, P255, DOI 10.1016/S0945-053X(97)90014-7; SPRANGER J, 1976, CLIN ORTHOP RELAT R, P46; SREERAMA N, 1994, J MOL BIOL, V242, P497, DOI 10.1006/jmbi.1994.1597; STANESCU R, 1993, AM J MED GENET, V45, P501, DOI 10.1002/ajmg.1320450420; STANESCU V, 1982, EUR J PEDIATR, V138, P221, DOI 10.1007/BF00441206; Susic S, 1997, CLIN GENET, V51, P219; Susic S, 1998, HUM MUTAT, pS125; Van der Rest M, 1987, STRUCTURE FUNCTION C, P195; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; Visconti CS, 1996, ARCH BIOCHEM BIOPHYS, V328, P135, DOI 10.1006/abbi.1996.0153; Zhou XL, 2000, J BIOL CHEM, V275, P21241, DOI 10.1074/jbc.M904498199	66	172	185	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6083	6092		10.1074/jbc.M009512200	http://dx.doi.org/10.1074/jbc.M009512200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11084047	hybrid			2022-12-25	WOS:000167261000006
J	Futaki, S; Suzuki, T; Ohashi, W; Yagami, T; Tanaka, S; Ueda, K; Sugiura, Y				Futaki, S; Suzuki, T; Ohashi, W; Yagami, T; Tanaka, S; Ueda, K; Sugiura, Y			Arginine-rich peptides - An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTENNAPEDIA HOMEODOMAIN; 3RD HELIX; CELLS; TRANSDUCTION; RECEPTOR; SEQUENCE	A basic peptide derived from human immunodeficiency virus (HIV)-1 Tat protein (positions 48-60) has been reported to have the ability to translocate through the cell membranes and accumulate in the nucleus, the characteristics of which are utilized for the delivery of exogenous proteins into cells. Based on the fluorescence microscopic observations of mouse macrophage RAW264.7 cells, we found that various arginine-rich peptides have a translocation activity very similar to Tat-(48-60). These included such peptides as the (D)-amino acid- and arginine-substituted Tat-(48-60), the RNA-binding peptides derived from virus proteins, such as HIV-1 Rev, and flock house virus coat proteins, and the DNA binding segments of leucine zipper proteins, such as cancer-related proteins c-Fos and c-Jun, and the yeast transcription factor GCN4, These segments have no specific primary and secondary structures in common except that they have several arginine residues in the sequences. Moreover, these peptides were able to be internalized even at 4 degreesC, These results strongly suggested the possible existence of a common internalization mechanism ubiquitous to arginine-rich peptides, which is not explained by a typical endocytosis, Using (Arg)(n) (n = 4-16) peptides, we also demonstrated that there would be an optimal number of arginine residues (n similar to 8) for the efficient translocation.	Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan; Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan	Kyoto University; National Institute of Health Sciences - Japan	Futaki, S (corresponding author), Kyoto Univ, Inst Chem Res, Uji, Kyoto 6110011, Japan.							CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; Chang HC, 1997, AIDS, V11, P1421, DOI 10.1097/00002030-199712000-00006; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; FAWELL S, 1994, P NATL ACAD SCI USA, V91, P664, DOI 10.1073/pnas.91.2.664; Futaki S, 1997, BIOORGAN MED CHEM, V5, P1883, DOI 10.1016/S0968-0896(97)00119-3; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Huq I, 1999, BIOCHEMISTRY-US, V38, P5172, DOI 10.1021/bi982638h; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Rojas M, 1998, NAT BIOTECHNOL, V16, P370, DOI 10.1038/nbt0498-370; Rojas M, 1996, J BIOL CHEM, V271, P27456, DOI 10.1074/jbc.271.44.27456; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Tachibana R, 1998, BIOCHEM BIOPH RES CO, V251, P538, DOI 10.1006/bbrc.1998.9460; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010	19	1366	1536	9	233	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5836	5840		10.1074/jbc.M007540200	http://dx.doi.org/10.1074/jbc.M007540200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11084031	hybrid			2022-12-25	WOS:000167115100059
J	Hill, JJ; Peralta, EG				Hill, JJ; Peralta, EG			Inhibition of a G(i)-activated potassium channel (GIRK1/4) by the G(q)-coupled m1 muscarinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; PROTEIN-KINASE-C; RECTIFYING K+-CHANNEL; GTP-BINDING PROTEINS; XENOPUS-OOCYTES; INWARD RECTIFICATION; BRAIN NEURONS; I-KACH; ACTIVATION; G(BETA-GAMMA)	The G protein-coupled inwardly rectifying K+ channel, GIRK1/GIRK4, can be activated by receptors coupled to the G alpha (i) subunit. An opposing role for G alpha (q) receptor signaling in GIRK regulation has only recently begun to be established. We have studied the effects of mi muscarinic acetylcholine receptor (mAChR) stimulation, which is known to mobilize calcium and activate protein kinase C (PKC) by a G alpha (q)-dependent mechanism, on whole cell GIRK1/4 currents in Xenopus oocytes. We found that stimulation of the mi mAChR suppresses both basal and dopamine 2 receptor-activated GIRK 1/4 currents. Overexpression of G beta gamma subunits attenuates this effect, suggesting that increased binding of G beta gamma to the GIRK channel can effectively compete with the G(q) mediated inhibitory signal. This G(q) signal requires the use of second messenger molecules; pharmacology implicates a role for PKC and Ca2+ responses as mi mAChR-mediated inhibition of GIRK channels is mimicked by PMA and Ca2+ ionophore A23187. We have analyzed a series of mutant and chimeric channels suggesting that the GIRK4 subunit is capable of responding to G(q) signals and that the resulting current inhibition does not occur via phosphorylation of a canonical PKC site on the channel itself.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA	Harvard University	Hill, JJ (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.							ASHKENAZI A, 1989, TRENDS PHARM SCI S, V10, P16; Chan KW, 1996, J GEN PHYSIOL, V107, P381, DOI 10.1085/jgp.107.3.381; Chan KW, 1996, P NATL ACAD SCI USA, V93, P14193, DOI 10.1073/pnas.93.24.14193; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; DASCAL N, 1984, J PHYSIOL-LONDON, V352, P551, DOI 10.1113/jphysiol.1984.sp015310; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; HUANG CL, 1995, NEURON, V15, P1133, DOI 10.1016/0896-6273(95)90101-9; HUANG XY, 1993, CELL, V75, P1145, DOI 10.1016/0092-8674(93)90324-J; INOUE M, 1988, J PHYSIOL-LONDON, V407, P177, DOI 10.1113/jphysiol.1988.sp017409; KOFUJI P, 1995, P NATL ACAD SCI USA, V92, P6542, DOI 10.1073/pnas.92.14.6542; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P29059, DOI 10.1074/jbc.270.49.29059; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; KUNKEL MT, 1995, CELL, V83, P443, DOI 10.1016/0092-8674(95)90122-1; LISMAA TP, 1992, CURR OPIN CELL BIOL, V4, P195; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MIHARA S, 1987, J PHYSIOL-LONDON, V390, P335, DOI 10.1113/jphysiol.1987.sp016704; NAIR LA, 1995, CIRC RES, V76, P832, DOI 10.1161/01.RES.76.5.832; NAKAJIMA Y, 1988, P NATL ACAD SCI USA, V85, P3643, DOI 10.1073/pnas.85.10.3643; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; Rogalski SL, 1999, J NEUROCHEM, V72, P1409, DOI 10.1046/j.1471-4159.1999.721409.x; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Silverman SK, 1996, J BIOL CHEM, V271, P30524, DOI 10.1074/jbc.271.48.30524; SOEJIMA M, 1984, PFLUG ARCH EUR J PHY, V400, P424, DOI 10.1007/BF00587544; STANFIELD PR, 1985, NATURE, V315, P498, DOI 10.1038/315498a0; Stevens EB, 1999, MOL PHARMACOL, V55, P1020, DOI 10.1124/mol.55.6.1020; VELIMIROVIC BM, 1995, P NATL ACAD SCI USA, V92, P1590, DOI 10.1073/pnas.92.5.1590; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; YAMADA M, 1994, BIOCHEM BIOPH RES CO, V200, P1484, DOI 10.1006/bbrc.1994.1618; Zhu GY, 1999, J BIOL CHEM, V274, P11643, DOI 10.1074/jbc.274.17.11643	39	47	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5505	5510		10.1074/jbc.M008213200	http://dx.doi.org/10.1074/jbc.M008213200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11060307	hybrid			2022-12-25	WOS:000167115100015
J	Minami, T; Rosenberg, RD; Aird, WC				Minami, T; Rosenberg, RD; Aird, WC			Transforming growth factor-beta(1)-mediated inhibition of the flk-1/KDR gene is mediated by a 5 '-untranslated region palindromic GATA site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR ENDOTHELIAL-CELLS; FACTOR RECEPTOR-2; FACTOR VEGF; EXPRESSION; TRANSCRIPTION; PROMOTER; BINDING; KDR/FLK-1; GROWTH-FACTOR-BETA-1; PHOSPHORYLATION	The angiogenic effects of vascular endothelial growth factor are mediated predominantly by the FLK-1/KDR receptor. An understanding of the transcriptional control mechanisms underlying flk-1/KDR expression should provide insight into the molecular basis of angiogenesis. In this study, we show that transforming growth factor-beta (1) (TGF-beta (1)) down-regulates expression of the endogenous flk-1/KDR gene in endothelial cells. In transient transfection assays, this effect was mapped to a palindromic GATA site in the 5'-untranslated region. In electrophoretic mobility shift assays, the palindromic GATA site was shown to bind to two molecules of GATA protein. Moreover, DNA-GATA interactions were inhibited by TGF-beta (1). Finally, in cotransfection assays, transactivation of the flk-1/KDR promoter by GATA-1 or GATA-2 was attenuated in TGF-beta (1)-treated cells. Taken together, these results suggest that the TGF-beta -1-mediated inhibition of the flk-1/KDR gene is mediated by a 5'-untranslated region palindromic GATA site.	MIT, Dept Biol, Cambridge, MA 02139 USA; Beth Israel Deaconess Med Ctr, Dept Mol Biol, Boston, MA 02215 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center	Rosenberg, RD (corresponding author), MIT, Dept Biol, 68-480,31 Ames St, Cambridge, MA 02139 USA.				NHLBI NIH HHS [P50 HL63609-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL063609] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; GAJDUSEK CM, 1993, J CELL PHYSIOL, V157, P133, DOI 10.1002/jcp.1041570118; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Hammes HP, 1998, DIABETES, V47, P401, DOI 10.2337/diabetes.47.3.401; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; Illi B, 2000, CIRC RES, V86, pE110; JONES KA, 1985, CELL, V42, P559, DOI 10.1016/0092-8674(85)90113-8; Kappel A, 1999, BLOOD, V93, P4284, DOI 10.1182/blood.V93.12.4284.412k25_4284_4292; Li J, 1996, AM J PHYSIOL-HEART C, V270, pH1803, DOI 10.1152/ajpheart.1996.270.5.H1803; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; Mandriota SJ, 1996, J BIOL CHEM, V271, P11500, DOI 10.1074/jbc.271.19.11500; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Morimoto T, 2000, J BIOL CHEM, V275, P13721, DOI 10.1074/jbc.275.18.13721; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Partington GA, 1999, NUCLEIC ACIDS RES, V27, P1168, DOI 10.1093/nar/27.4.1168; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Patterson C, 1997, J BIOL CHEM, V272, P8410, DOI 10.1074/jbc.272.13.8410; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; Pierelli L, 2000, BLOOD, V95, P3001; Ronicke V, 1996, CIRC RES, V79, P277, DOI 10.1161/01.RES.79.2.277; Saadeh PB, 1999, AM J PHYSIOL-CELL PH, V277, pC628, DOI 10.1152/ajpcell.1999.277.4.C628; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Suzuma K, 1998, MICROVASC RES, V56, P183, DOI 10.1006/mvre.1998.2111; TOWATARI M, 1995, J BIOL CHEM, V270, P4101, DOI 10.1074/jbc.270.8.4101; Trainor CD, 1996, MOL CELL BIOL, V16, P2238; White LA, 2000, BBA-GENE STRUCT EXPR, V1490, P259, DOI 10.1016/S0167-4781(00)00002-6; Wu YX, 1999, J BIOL CHEM, V274, P3207, DOI 10.1074/jbc.274.5.3207; YOSHIZUMI M, 1997, J BIOL CHEM, V272; Yu SJ, 1999, BIOCHEM BIOPH RES CO, V259, P544, DOI 10.1006/bbrc.1999.0808	30	59	63	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5395	5402		10.1074/jbc.M008798200	http://dx.doi.org/10.1074/jbc.M008798200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11098056	hybrid			2022-12-25	WOS:000168484300115
J	Phillips, SA; Barr, VA; Haft, DH; Taylor, SI; Haft, CR				Phillips, SA; Barr, VA; Haft, DH; Taylor, SI; Haft, CR			Identification and characterization of SNX15, a novel sorting nexin involved in protein trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; SACCHAROMYCES-CEREVISIAE; INSULIN-RECEPTOR; SEQUENCE ALIGNMENT; MEMBRANE-PROTEINS; PDGF RECEPTORS; GENE; TRANSPORT; ACTIVATION; KINASE	Sorting nexins are a family of phox homology domain containing proteins that are homologous to yeast proteins involved in protein trafficking. We have identified a novel 342-amino acid residue sorting nexin, SNX15, and a 252-amino acid splice variant, SNX15A. Unlike many sorting nexins, a SNX15 ortholog has not been identified in yeast or Caenorhabditis elegans, By Northern blot analysis, SNX15 mRNA is widely expressed. Although predicted to be a soluble protein, both endogenous and overexpressed SNX15 are found on membranes and in the cytosol. The phox homology domain of SNX15 is required for its membrane association and for association with the platelet-derived growth factor receptor. We did not detect association of SNX15 with receptors for epidermal growth factor or insulin. However, overexpression of SNX15 led to a decrease in the processing of insulin and hepatocyte growth factor receptors to their mature subunits. Immunofluorescence studies showed that SNX15 overexpression resulted in mislocalization of furin, the endoprotease responsible for cleavage of insulin and hepatocyte growth factor receptors. Based on our data and the existing findings with yeast orthologs of other sorting nexins, we propose that overexpression of SNX15 disrupts the normal trafficking of proteins from the plasma membrane to recycling endosomes or the trans-Golgi network.	NIDDK, Diabet Branch, NIH, Bethesda, MD 20892 USA; Inst Genome Res, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); J. Craig Venter Institute	Haft, CR (corresponding author), NIDDK, Diabet Branch, NIH, Bldg 10,Rm 8N244, Bethesda, MD 20892 USA.	carol_haft@nih.gov						Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Babst M, 1997, EMBO J, V16, P1820, DOI 10.1093/emboj/16.8.1820; Barr VA, 2000, TRAFFIC, V1, P904, DOI 10.1034/j.1600-0854.2000.011109.x; Bass J, 1998, J CELL BIOL, V141, P637, DOI 10.1083/jcb.141.3.637; Bhattacharya D, 1996, MOL PHYLOGENET EVOL, V6, P339, DOI 10.1006/mpev.1996.0084; BOSSHART H, 1994, J CELL BIOL, V126, P1157, DOI 10.1083/jcb.126.5.1157; BOWENPOPE DF, 1982, J BIOL CHEM, V257, P5161; Bryant NJ, 1998, MICROBIOL MOL BIOL R, V62, P230, DOI 10.1128/MMBR.62.1.230-247.1998; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DENISON SH, 1995, J BIOL CHEM, V270, P28519, DOI 10.1074/jbc.270.48.28519; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; EKENA K, 1995, MOL CELL BIOL, V15, P1671; FinkenEigen M, 1997, CURR GENET, V31, P469, DOI 10.1007/s002940050232; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Galtier N, 1996, COMPUT APPL BIOSCI, V12, P543; Guru SC, 1997, GENOME RES, V7, P725, DOI 10.1101/gr.7.7.725; HAFT CR, 1994, J BIOL CHEM, V269, P26286; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; HEDO JA, 1983, J BIOL CHEM, V258, P20; Horazdovsky BF, 1997, MOL BIOL CELL, V8, P1529, DOI 10.1091/mbc.8.8.1529; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Li WS, 1997, GENETICS, V145, P63; MERLINO GT, 1991, GENE DEV, V5, P1395, DOI 10.1101/gad.5.8.1395; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Nothwehr SF, 1997, J CELL SCI, V110, P1063; Novick P, 1997, CURR OPIN CELL BIOL, V9, P496, DOI 10.1016/S0955-0674(97)80025-7; OLSON TS, 1988, J BIOL CHEM, V263, P7342; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Patel S, 1998, TRENDS CELL BIOL, V8, P65, DOI 10.1016/S0962-8924(97)01212-9; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; Quon MJ, 1996, BIOCHEM BIOPH RES CO, V226, P587, DOI 10.1006/bbrc.1996.1400; Retief J D, 2000, Methods Mol Biol, V132, P243; ROBERTSON BJ, 1993, J BIOL CHEM, V268, P24274; Scheuring S, 1999, GENE, V234, P149, DOI 10.1016/S0378-1119(99)00163-8; Seaman MNJ, 1998, J CELL BIOL, V142, P665, DOI 10.1083/jcb.142.3.665; SU SSY, 1993, NUCLEIC ACIDS RES, V21, P3789, DOI 10.1093/nar/21.16.3789; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Vaillancourt RR, 1996, ONCOGENE, V13, P151; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; Voos W, 1998, J CELL BIOL, V140, P577, DOI 10.1083/jcb.140.3.577; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8	45	68	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5074	5084		10.1074/jbc.M004671200	http://dx.doi.org/10.1074/jbc.M004671200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11085978	hybrid			2022-12-25	WOS:000168484300074
J	Knouff, C; Malloy, S; Wilder, J; Altenburg, MK; Maeda, N				Knouff, C; Malloy, S; Wilder, J; Altenburg, MK; Maeda, N			Doubling expression of the low density lipoprotein receptor by truncation of the 3 '-untranslated region sequence ameliorates type III hyperlipoproteinemia in mice expressing the human ApoE2 isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIET-INDUCED HYPERCHOLESTEROLEMIA; MESSENGER-RNA STABILITY; MOUSE APOLIPOPROTEIN-E; LDL RECEPTOR; TRANSGENIC MICE; GENE; METABOLISM; ATHEROSCLEROSIS; STABILIZATION; GEMFIBROZIL	The primary receptor mediating clearance of apolipoprotein (apo)E- and apoB100-containing lipoproteins from the circulation is the low density lipoprotein (LDL) receptor, Reduced expression of the LDLR is believed to be a precipitating factor in the pathogenesis of type III hyperlipoproteinemia (HLP) in some humans homozygous for the apoE2 allele (APOE*2). To test the effect of genetic changes in LDL receptor expression on the pathogenesis of type Ill HLP, we have generated a variant allele at the endogenous mouse Ldlr locus that ex presses the human LDL receptor transcript. Transcription of the human LDLR minigene is regulated by the endogenous mouse promoter sequence, but a truncation of S'-untranslated region results in increased mRNA stability. Consequently, in liver of heterozygotes, steady state levels of mouse and human LDLR transcripts are 50 and 180% the levels of total transcript in wild type mice, respectively. Overall, the 2.3-fold normal level of LDLR message in heterozygotes completely ameliorates type II HLP caused by the homozygosity for the human APOE*2 allele, normalizing their plasma lipoprotein profile. We conclude that a modest increase in expression of the LDLR through message stabilization is sufficient to prevent precipitation of type III HLP in mice.	Univ N Carolina, Dept Pathol & Lab Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Maeda, N (corresponding author), Univ N Carolina, Dept Pathol & Lab Med, Rm 701,Brinkhous Bullitt Bldg, Chapel Hill, NC 27599 USA.	nobuyo@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042630, R37HL042630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM020069, R01GM020069] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42630] Funding Source: Medline; NIGMS NIH HHS [GM20069] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BREWER HB, 1983, ANN INTERN MED, V98, P623, DOI 10.7326/0003-4819-98-5-623; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Civeira F, 1999, AM HEART J, V138, P156, DOI 10.1016/S0002-8703(99)70262-0; CORSINI A, 1992, ATHEROSCLEROSIS, V93, P95, DOI 10.1016/0021-9150(92)90203-S; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Goto D, 1997, ARTERIOSCL THROM VAS, V17, P2707, DOI 10.1161/01.ATV.17.11.2707; Huang YD, 1998, J BIOL CHEM, V273, P17483, DOI 10.1074/jbc.273.28.17483; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; Knouff C, 1999, J CLIN INVEST, V103, P1579, DOI 10.1172/JCI6172; KOLLER BH, 1991, P NATL ACAD SCI USA, V88, P10730, DOI 10.1073/pnas.88.23.10730; Lopez D, 1997, ARCH BIOCHEM BIOPHYS, V344, P215, DOI 10.1006/abbi.1997.0193; MA PTS, 1986, P NATL ACAD SCI USA, V83, P792, DOI 10.1073/pnas.83.3.792; Mahley RW, 1999, J LIPID RES, V40, P1933; Mahley RW, 1999, J LIPID RES, V40, P1; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MORGANROTH J, 1975, ANN INTERN MED, V82, P158, DOI 10.7326/0003-4819-82-2-158; POLVINO WJ, 1992, SOMAT CELL MOLEC GEN, V18, P443, DOI 10.1007/BF01233084; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; Sullivan PM, 1997, J BIOL CHEM, V272, P17972, DOI 10.1074/jbc.272.29.17972; Sullivan PM, 1998, J CLIN INVEST, V102, P130, DOI 10.1172/JCI2673; TENG BB, 1990, J BIOL CHEM, V265, P20616; TREMBLEY JH, 1994, CELL GROWTH DIFFER, V5, P99; Twisk J, 2000, J CLIN INVEST, V105, P521, DOI 10.1172/JCI8623; van Dijk KW, 1999, J LIPID RES, V40, P336; van Dijk KW, 1998, ARTERIOSCL THROM VAS, V18, P7, DOI 10.1161/01.ATV.18.1.7; vanVlijmen BJM, 1996, J BIOL CHEM, V271, P30595, DOI 10.1074/jbc.271.48.30595; Wilson GM, 1998, J LIPID RES, V39, P1025; Wilson GM, 1997, J LIPID RES, V38, P437; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0; YOKODE M, 1990, SCIENCE, V250, P1273, DOI 10.1126/science.2244210; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	36	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3856	3862		10.1074/jbc.M009423200	http://dx.doi.org/10.1074/jbc.M009423200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11076954	hybrid, Green Published			2022-12-25	WOS:000166921200020
J	Stefan, M; Koch, A; Mancini, A; Mohr, A; Weidner, KM; Niemann, H; Tamura, T				Stefan, M; Koch, A; Mancini, A; Mohr, A; Weidner, KM; Niemann, H; Tamura, T			Src homology 2-containing inositol 5-phosphatase 1 binds to the multifunctional docking site of c-Met and potentiates hepatocyte growth factor-induced branching tubulogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; SCATTER FACTOR; EPITHELIAL MORPHOGENESIS; FACTOR/SCATTER FACTOR; SH2 DOMAIN; SIGNAL-TRANSDUCTION; CELL MOTILITY; PROTEIN; IDENTIFICATION; PHOSPHORYLATION	Hepatocyte growth factor (HGF)/scatter factor is a multifunctional cytokine that induces mitogenesis, motility, and morphogenesis in epithelial, endothelial, and neuronal cells. The receptor for HGF/scatter factor was identified as c-Met tyrosine kinase, and activation of the receptor induces multiple signaling cascades,To gain further insight into c-Met-mediated multiple events at a molecular level, we isolated several signaling molecules including a novel binding partner of c-Met, SH2 domain-containing inositol 5-phosphatase 1 (SHIP-1), Western blot analysis revealed that SHIP-1 is expressed in the epithelial cell line, Madin-Darby canine kidney (MDCK) cells. SHIP-1 binds at phosphotyrosine 1356 at the multifunctional docking site. Because a number of signaling molecules such as Grb2, phosphatidylinositol 3-kinase, and Gab1 bind to the multifunctional docking site, we further performed an in vitro competition study using glutathione S-transferase- or His-tagged signaling molecules with c-Met tyrosine kinase, Our binding study revealed that SHIP-1, (Grb2, and Gab1 bound preferentially over phosphatidylinositol 3-kinase. Surprisingly, MDCK cells that overexpress SHIP-1 demonstrated branching tubulogenesis within 2 days after HGF treatment, whereas wild-type MDCK cells showed tubulogenesis only after 6 days following treatment without altering cell scattering or cell growth potency. Furthermore, overexpression of a mutant SHIP-1 lacking catalytic activity impaired HGF-mediated branching tubulogenesis.	Hannover Med Sch, Inst Biochem, D-30623 Hannover, Germany; Roche Diagnost GmbH, Pharma Res Penzberg, D-82372 Penzberg, Germany	Hannover Medical School; Roche Holding	Tamura, T (corresponding author), Hannover Med Sch, Inst Biochem, OE 4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	Tamura.Teruko@MH-Hannover.de		Mohr, Andrea/0000-0002-4295-0341				BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; GLINIAK BC, 1990, CELL, V63, P1073, DOI 10.1016/0092-8674(90)90510-L; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; HERBST R, 1995, BIOCHEMISTRY-US, V34, P5971, DOI 10.1021/bi00017a026; Jeffers M, 1996, MOL CELL BIOL, V16, P1115; Joos H, 1996, J BIOL CHEM, V271, P24476, DOI 10.1074/jbc.271.40.24476; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; LEVYTOLEDANO R, 1994, J BIOL CHEM, V269, P31178; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Matsumoto K, 1993, EXS, V65, P225; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NUSRAT A, 1994, J CLIN INVEST, V93, P2056, DOI 10.1172/JCI117200; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; PELICCI G, 1995, ONCOGENE, V10, P1631; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; Rohrschneider LR, 2000, GENE DEV, V14, P505; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Royal I, 1997, J CELL PHYSIOL, V173, P196, DOI 10.1002/(SICI)1097-4652(199711)173:2<196::AID-JCP20>3.0.CO;2-D; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; Sachs M, 1996, J CELL BIOL, V133, P1095, DOI 10.1083/jcb.133.5.1095; SALCINI AE, 1994, ONCOGENE, V9, P2827; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Tamura T, 1999, ONCOGENE, V18, P6488, DOI 10.1038/sj.onc.1203062; Thommes K, 1999, BIOCHEM J, V341, P211, DOI 10.1042/0264-6021:3410211; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Unkeless JC, 1997, CURR OPIN IMMUNOL, V9, P338, DOI 10.1016/S0952-7915(97)80079-9; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Wada T, 1999, ENDOCRINOLOGY, V140, P4585, DOI 10.1210/en.140.10.4585; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	59	36	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3017	3023		10.1074/jbc.M009333200	http://dx.doi.org/10.1074/jbc.M009333200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11069926	hybrid			2022-12-25	WOS:000166784900008
J	Wang, DZ; Richmond, A				Wang, DZ; Richmond, A			Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; CARCINOMA-CELL-LINES; TRANSCRIPTIONAL ACTIVITY; CONSTITUTIVE ACTIVATION; COUPLED RECEPTORS; GENE-EXPRESSION; ONCOGENIC RAS; TNF-ALPHA; P38; IDENTIFICATION	Melanoma growth stimulatory activity/growth-regulated protein (MGSA/GRO), a CXC chemokine, plays an important role in inflammation, wound healing, growth regulation, angiogenesis, and tumorigenesis, Constitutive expression of MGSA/GRO alpha in melanoma tumors is associated with constitutive nuclear factor (NF)-kappaB activity. We show here that either exogenous addition or continuous expression of MGSA/GRO alpha in immortalized melanocytes enhances NF-kappaB activation, as well as mitogen-activated protein (MAP) kinase kinase kinase (MEKK) 1, MAP kinase kinase (MEK) 3/6, and p38 MAP kinase activation. Expression of dominant negative MRas (S27N), dominant negative MEKK1 (K432M), or specific chemical inhibitors for p38 MAP kinase (SB202190 and SB203580) block MGSA/GRO alpha -induced NF-kappaB transactivation, demonstrating that Pas, MEKK1, and p38 are involved in the signal pathways of MGSA/GRO alpha activation of NF-kappaB, Expression of dominant active Res or dominant active MEKK1 alone can also stimulate NF-kappaB activation. The expression of dominant negative MEKK1 inhibits the Pas-induced NF-kappaB activation, suggesting that MEKK1 is a downstream target of Pas, Moreover, MGSA/GRO alpha induction of NF-kappaB is independent of the MEK1/ERK cascade, because MGSA/GRO alpha failed to increase ERK and ELK activation, and specific chemical inhibitors for MEK1 (PD98059) had no effect on MGSA/GRO alpha -enhanced NF-kappaB activation. These data demonstrate that NF-kappaB activation is required for MGSA/GRO alpha -induced melanocyte transformation through a Ras/MEKK1/p38 cascade in melanocytes.	Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Vet Affairs, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Richmond, A (corresponding author), Vanderbilt Univ, Sch Med, Dept Cell Biol, 221 Kirkland Hall, Nashville, TN 37232 USA.	ann.richmond@mcmail.vanderbilt.edu	Richmond, Ann/A-3048-2014	RICHMOND, ANN/0000-0002-9580-900X	NATIONAL CANCER INSTITUTE [P30CA068485, R01CA056704, R23CA034590, R01CA034590] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007751] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA056704-07, R01 CA056704-08, R01 CA056704-09, CA34590, R01 CA034590, P30 CA068485, CA56704] Funding Source: Medline; NHLBI NIH HHS [2T32HL07751-06, T32 HL007751] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALENTIEN E, 1991, ONCOGENE, V6, P1115; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; Carlotti F, 1999, J BIOL CHEM, V274, P37941, DOI 10.1074/jbc.274.53.37941; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dong G, 1999, CANCER RES, V59, P3495; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; GEISER T, 1993, J BIOL CHEM, V268, P15419; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; Gilmore TD, 1996, ONCOGENE, V13, P1367; Giri DK, 1998, J BIOL CHEM, V273, P14008, DOI 10.1074/jbc.273.22.14008; Haghnegahdar H, 2000, J LEUKOCYTE BIOL, V67, P53, DOI 10.1002/jlb.67.1.53; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HASKILL S, 1990, P NATL ACAD SCI USA, V87, P7732, DOI 10.1073/pnas.87.19.7732; HIGGINS KA, 1993, P NATL ACAD SCI USA, V90, P9901, DOI 10.1073/pnas.90.21.9901; IIDA N, 1990, MOL CELL BIOL, V10, P5596, DOI 10.1128/MCB.10.10.5596; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Jansen B, 1999, P NATL ACAD SCI USA, V96, P14019, DOI 10.1073/pnas.96.24.14019; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luan J, 1997, J LEUKOCYTE BIOL, V62, P588, DOI 10.1002/jlb.62.5.588; MATTEI S, 1994, INT J CANCER, V56, P853, DOI 10.1002/ijc.2910560617; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Norgauer J, 1996, J IMMUNOL, V156, P1132; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Owen JD, 1997, INT J CANCER, V73, P94, DOI 10.1002/(SICI)1097-0215(19970926)73:1<94::AID-IJC15>3.0.CO;2-5; Powell MB, 1999, CARCINOGENESIS, V20, P1747, DOI 10.1093/carcin/20.9.1747; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rausch O, 1999, J BIOL CHEM, V274, P4096, DOI 10.1074/jbc.274.7.4096; RICHMOND A, 1986, J CELL PHYSIOL, V129, P375, DOI 10.1002/jcp.1041290316; RICHMOND A, 1996, CHEMOATTRACTANT LIGA, P87; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RUSSELL M, 1995, J BIOL CHEM, V270, P11757, DOI 10.1074/jbc.270.20.11757; Shattuck-Brandt RL, 1997, DNA SEQUENCE, V7, P379, DOI 10.3109/10425179709034060; ShattuckBrandt RL, 1997, CANCER RES, V57, P3032; Shyamala V, 1998, BIOCHEMISTRY-US, V37, P15918, DOI 10.1021/bi9811415; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; TEKAMPOLSON P, 1990, J EXP MED, V172, P911, DOI 10.1084/jem.172.3.911; Toyoshima F, 1997, J CELL BIOL, V139, P1005, DOI 10.1083/jcb.139.4.1005; Tuyt LML, 1999, J IMMUNOL, V162, P4893; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Visconti R, 1997, ONCOGENE, V15, P1987, DOI 10.1038/sj.onc.1201373; Wang DZ, 2000, ONCOGENE, V19, P4647, DOI 10.1038/sj.onc.1203820; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Welch DR, 2000, CANCER RES, V60, P1552; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; Yang XY, 1999, J BIOL CHEM, V274, P27981, DOI 10.1074/jbc.274.39.27981; Ye RD, 1996, ADV EXP MED BIOL, V416, P143; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	70	81	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3650	3659		10.1074/jbc.M006115200	http://dx.doi.org/10.1074/jbc.M006115200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11062239	hybrid, Green Accepted			2022-12-25	WOS:000166784900087
J	Wang, GQ; Gastman, BR; Wieckowski, E; Goldstein, LA; Rabinovitz, A; Yin, XM; Rabinowich, H				Wang, GQ; Gastman, BR; Wieckowski, E; Goldstein, LA; Rabinovitz, A; Yin, XM; Rabinowich, H			Apoptosis-resistant mitochondria in T cells selected for resistance to Fas signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C RELEASE; PERMEABILITY TRANSITION PORE; CASPASE ACTIVATION; LYMPHOCYTE APOPTOSIS; MEDIATED APOPTOSIS; DEATH RECEPTORS; BAX; PROTEIN; PATHWAYS; MODULATION	Jurkat leukemic T cells are highly sensitive to the extrinsic pathways of apoptosis induced via the death receptor Fas or tumor necrosis factor-related apoptosis-inducing ligand as well as to the intrinsic/mitochondrial pathways of death induced by VP-16 or staurosporin, We report here that clonal Jurkat cell lines selected for resistance to Fas-induced apoptosis were cross-resistant to VP-16 or staurosporin. Each of the apoptotic pathways was blocked at an apical phase, where common regulators of apoptosis have not yet been defined The Fas pathway was blocked at the level of caspase-8, whereas the intrinsic pathway was blocked at the mitochondria No processing or activity of caspases was detected in resistant cells in response to either Fas-cross-linking or VP-16 treatment. Also, no apoptosis-associated alterations in the mitochondrial inner membrane, outer membrane, or matrix were detected in resistant Jurkat cells treated with VP-16, Thus, no changes in permeability transition, loss in inner membrane cardiolipin, generation of reactive oxygen species, or release of cytochrome c were observed in resistant cells treated with VP-16. Further, unlike purified mitochondria from wild type cells, those obtained from resistant cells did not release cytochrome c or apoptosis-inducing factor in response to recombinant Bax or truncated Bid. These results identify a defect in mitochondria ability to release intermembrane proteins in response to Bid or Bax as a mechanism of resistance to chemotherapeuetic drugs. Further, the selection of VP-16-resistant mitochondria via elimination of Fas-susceptible cells may suggest the existence of a shared regulatory component between the extrinsic and intrinsic pathways of apoptosis.	Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rabinowich, H (corresponding author), Univ Pittsburgh, Inst Canc, W952 Biomed Sci Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.				NCI NIH HHS [R01 CA 84134-01] Funding Source: Medline; NIDCR NIH HHS [P01DE 12321-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P01DE012321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boesen-de Cock JGR, 1999, J BIOL CHEM, V274, P14255, DOI 10.1074/jbc.274.20.14255; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Cecconi F, 1998, CELL, V94, P727, DOI 10.1016/S0092-8674(00)81732-8; Cheng EHY, 1997, SCIENCE, V278, P1966, DOI 10.1126/science.278.5345.1966; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dou QP, 1997, J CELL BIOCHEM, V64, P586; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Gastman BR, 2000, BLOOD, V95, P2015, DOI 10.1182/blood.V95.6.2015; Gastman BR, 1999, CANCER RES, V59, P1422; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Johnson DE, 2000, CANCER RES, V60, P1818; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Kluck RM, 1999, J CELL BIOL, V147, P809, DOI 10.1083/jcb.147.4.809; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Landowski TH, 1999, BLOOD, V94, P265, DOI 10.1182/blood.V94.1.265.413k37_265_274; Landowski TH, 1997, BLOOD, V89, P1854, DOI 10.1182/blood.V89.6.1854; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; NI R, 1994, EXP CELL RES, V215, P332, DOI 10.1006/excr.1994.1349; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; PETIT JM, 1992, EUR J BIOCHEM, V209, P267, DOI 10.1111/j.1432-1033.1992.tb17285.x; PETIT PX, 1990, EUR J BIOCHEM, V194, P389, DOI 10.1111/j.1432-1033.1990.tb15632.x; Rabinowich H, 1998, J CLIN INVEST, V101, P2579, DOI 10.1172/JCI1518; Rochat-Steiner V, 2000, J EXP MED, V192, P1165, DOI 10.1084/jem.192.8.1165; ROTHE G, 1990, J LEUKOCYTE BIOL, V47, P440, DOI 10.1002/jlb.47.5.440; Roy Sophie, 2000, Molecular Medicine Today, V6, P264, DOI 10.1016/S1357-4310(00)01729-9; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tamm I, 2000, CLIN CANCER RES, V6, P1796; Tang DM, 2000, J BIOL CHEM, V275, P9303, DOI 10.1074/jbc.275.13.9303; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wagenknecht B, 1999, CELL DEATH DIFFER, V6, P370, DOI 10.1038/sj.cdd.4400503; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zhang CH, 1996, J IMMUNOL, V157, P3980; Zhang H, 2000, P NATL ACAD SCI USA, V97, P2597, DOI 10.1073/pnas.97.6.2597; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	56	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3610	3619		10.1074/jbc.M006222200	http://dx.doi.org/10.1074/jbc.M006222200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11063743	hybrid			2022-12-25	WOS:000166784900082
J	Bruckheimer, EM; Brisbay, S; Johnson, DJ; Gingrich, JR; Greenberg, N; McDonnell, TJ				Bruckheimer, EM; Brisbay, S; Johnson, DJ; Gingrich, JR; Greenberg, N; McDonnell, TJ			Bcl-2 accelerates multistep prostate carcinogenesis in vivo	ONCOGENE			English	Article						bcl-2; prostate cancer; apoptosis; TRAMP; transgenic; androgen	TRANSGENIC MICE; TUMOR-ANTIGEN; T-ANTIGEN; CANCER PROGRESSION; TRAMP MODEL; CELL-DEATH; IN-VIVO; EXPRESSION; GENE; CARCINOMA	The impact of bcl-2 proto-oncogene expression on the pathogenesis and progression of prostate cancer was examined in a transgenic mouse model. Probasin-bcl-2 transgenic mice were crossed with TRAMP (TRansgenic Adenocarcinoma Mouse Prostate) mice that express the SV40 early genes (T/t antigens) under probasin control, Prostate size, cell proliferation, apoptosis, and the incidence and latency of tumor formation were evaluated. The double transgenic, probasin-bcl-2 X TRAMP F-1 (BxT) mice exhibited an increase in the wet weight of the prostate, This was associated with an increase in proliferation, attributable to Tit antigens, and a decrease in apoptosis attributable to bcl-2, The latency to tumor formation was also decreased in the BxT mice compared to the TRAMP mice. The incidence of metastases was identical in both the TRAMP and BxT mice, Lastly, the incidence of hormone-independent prostate cancer was reduced in the BxT mice compared to the TRAMP mice. Together, these results demonstrate that bcl-2 can facilitate multistep prostate carcinogenesis in vivo.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biomath, Houston, TX 77030 USA; Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Baylor College of Medicine	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA.			Gingrich, Jeffrey/0000-0002-4516-2893	NCI NIH HHS [T32CA67759-01, CA58204] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA067759, P50CA058204] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bauer JJ, 1995, CLIN CANCER RES, V1, P1295; Beham AW, 1998, INT J MOL MED, V1, P953; BERNER A, 1993, BRIT J CANCER, V68, P380, DOI 10.1038/bjc.1993.344; BOOKSTEIN R, 1990, P NATL ACAD SCI USA, V87, P7762, DOI 10.1073/pnas.87.19.7762; Bruckheimer EM, 2000, ONCOGENE, V19, P2404, DOI 10.1038/sj.onc.1203571; COLOMBEL M, 1993, AM J PATHOL, V143, P390; Damania B, 1996, GENE DEV, V10, P1369, DOI 10.1101/gad.10.11.1369; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Eng MH, 1999, UROLOGY, V54, P1112, DOI 10.1016/S0090-4295(99)00297-6; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gingrich JR, 1999, PROSTATE CANCER P D, V2, P70, DOI 10.1038/sj/pcan/4500296; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; Heidenberg HB, 1996, UROLOGY, V48, P971, DOI 10.1016/S0090-4295(96)00365-2; Hsu CX, 1998, J UROLOGY, V160, P1500, DOI 10.1016/S0022-5347(01)62603-X; Johnson MI, 1998, ONCOL REP, V5, P553; Keshgegian AA, 1998, AM J CLIN PATHOL, V110, P443; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LINZER DIH, 1979, VIROLOGY, V98, P308, DOI 10.1016/0042-6822(79)90554-3; Mateer SC, 1998, J BIOL CHEM, V273, P35339, DOI 10.1074/jbc.273.52.35339; MAY E, 1991, VIROLOGY, V180, P285, DOI 10.1016/0042-6822(91)90033-8; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MCDONNELL TJ, 1993, MOL CARCINOGEN, V8, P209, DOI 10.1002/mc.2940080402; Pettaway C A, 1998, Tech Urol, V4, P35; RAFFO AJ, 1995, CANCER RES, V55, P4438; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Sullivan GF, 1998, CLIN CANCER RES, V4, P1393; THOMAS DJ, 1993, BRIT J UROL, V72, P778, DOI 10.1111/j.1464-410X.1993.tb16267.x; Westin P, 1997, INT J ONCOL, V10, P113	32	36	36	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5251	5258		10.1038/sj.onc.1203881	http://dx.doi.org/10.1038/sj.onc.1203881			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077442				2022-12-25	WOS:000165059700006
J	Weisman, R; Choder, M				Weisman, R; Choder, M			The fission yeast TOR homolog, tor1(+), is required for the response to starvation and other stresses via a conserved serine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE HOMOLOG; ATF1 TRANSCRIPTION FACTOR; SCHIZOSACCHAROMYCES-POMBE; SIGNALING PATHWAY; SACCHAROMYCES-CEREVISIAE; STATIONARY-PHASE; CELL-CYCLE; RAPAMYCIN; PROTEINS; TARGET	Targets of rapamycin (TORs) are conserved phosphatidylinositol kinase-related kinases that are involved in the coordination between nutritional or mitogenic signals and cell growth, Here we report the initial characterization of two Schizosaccharomyces pombe TOR homologs, tor1(+) and tor2(+). tor2(+) is an essential gene, whereas tor1(+) is required only under starvation and other stress conditions. Specifically, Delta tor1 cells fail to enter stationary phase or undergo sexual development and are sensitive to cold, osmotic stress, and oxidative stress, In complex with the prolyl isomerase FKBP12, the drug rapamycin binds a conserved domain in TORs, FRB, thus inhibiting some of the functions of TORs, Mutations at a conserved serine within the FRB domain of Saccharomyces cerevisiae TOR proteins led to rapamycin resistance but did not otherwise affect the functions of the proteins. The S. pombe tor1(+) exhibits different features; substitution of the conserved serine residue, Ser(1834), With arginine compromises its functions and has no effect on the inhibition that rapamycin exerts on sexual development in S, pombe.	Tel Aviv Univ, Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel	Tel Aviv University	Weisman, R (corresponding author), Tel Aviv Univ, Fac Life Sci, Dept Mol Microbiol & Biotechnol, IL-69978 Tel Aviv, Israel.	ronitt@post.tau.ac.il	weisman, ronit/D-3741-2016; weisman, ronit/R-6969-2016					Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; CAFFERKEY R, 1993, MOL CELL BIOL, V13, P6012, DOI 10.1128/MCB.13.10.6012; Cardenas ME, 1999, CLIN MICROBIOL REV, V12, P583, DOI 10.1128/CMR.12.4.583; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; Cruz MC, 1999, MOL CELL BIOL, V19, P4101; Cutler NS, 1999, MOL CELL ENDOCRINOL, V155, P135, DOI 10.1016/S0303-7207(99)00121-5; Davey J, 1998, YEAST, V14, P1529, DOI 10.1002/(SICI)1097-0061(199812)14:16<1529::AID-YEA357>3.0.CO;2-0; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Forsburg SL, 1999, TRENDS GENET, V15, P340, DOI 10.1016/S0168-9525(99)01798-9; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Hall MN, 1996, BIOCHEM SOC T, V24, P234, DOI 10.1042/bst0240234; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; MORENO S, 1991, METHOD ENZYMOL, V194, P795; MORENO S, 1994, NATURE, V367, P236, DOI 10.1038/367236a0; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; SCHRAIDT A, 1998, EMBO J, V17, P6924; SCHRAIDT A, 1996, P NATL ACAD SCI USA, V93, P13780; SCHRAIDT A, 1997, CELL, V88, P531; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Snaith HA, 1999, GENETICS, V152, P839; STAN R, 1994, J BIOL CHEM, V269, P32027; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; Weisman R, 1997, J BACTERIOL, V179, P6325, DOI 10.1128/jb.179.20.6325-6334.1997; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289; Zaragoza D, 1998, MOL CELL BIOL, V18, P4463, DOI 10.1128/MCB.18.8.4463; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6; Zheng XF, 1997, P NATL ACAD SCI USA, V94, P3070, DOI 10.1073/pnas.94.7.3070	42	150	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7027	7032		10.1074/jbc.M010446200	http://dx.doi.org/10.1074/jbc.M010446200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11096119	hybrid			2022-12-25	WOS:000167442900025
J	Desautels, M; Den Haese, JP; Slupsky, CM; McIntosh, LP; Hemmingsen, SM				Desautels, M; Den Haese, JP; Slupsky, CM; McIntosh, LP; Hemmingsen, SM			Cdc4p, a contractile ring protein essential for cytokinesis in Schizosaccharomyces pombe, interacts with a phosphatidylinositol 4-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DIVISION CYCLE; MYOSIN HEAVY-CHAIN; FISSION YEAST; LIGHT-CHAIN; ACTOMYOSIN RING; F-ACTIN; IDENTIFICATION; BINDING; GENE; LOCALIZATION	The proposed function of Cdc4p, an essential contractile ring protein in Schizosaccharomyces pombe, is that of a myosin essential light chain. However, five conditionally lethal cdc4 alleles exhibit complementation in diploids. Such interallelic complementation is not readily explained if the sole function of Cde4p is that of a myosin essential light chain. Complementation of cdc4 alleles could occur only if different mutant forms can assemble into an active oligomeric complex or if Cdc4p has more than one essential function. To search for other proteins that may interact with Cdc4p, we performed a two-hybrid screen and identified two such candidates: one similar to Saccharomyces cerevisiae Vps27p and the other a putative phosphatidylinositol (PI) 4-kinase. finding of Cdc4p to the latter and to myosin heavy chain (Myo2p) was confirmed by immunosorbent assays. Deletion studies demonstrated interaction between the Cdc4p C-terminal domain and the PI 4-kinase C-terminal domain. Furthermore, interaction was abolished by the Cdc4p C-terminal domain point mutation, Gly(107) to Ser. This allele also causes failure of cytokinesis. Ectopic expression of the PI 4-kinase C-terminal domain caused cytokinesis defects that were most extreme in cells carrying the G107S allele. We suggest that Cdc4p plays multiple roles in cytokinesis and that interaction with a PI I-kinase may be important for contractile ring assembly and/or function.	Univ Saskatchewan, Coll Med, Dept Physiol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Coll Med, Dept Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada; Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada; Univ British Columbia, Dept Chem, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada	University of Saskatchewan; University of Saskatchewan; National Research Council Canada; University of British Columbia; University of British Columbia	Desautels, M (corresponding author), Univ Saskatchewan, Coll Med, Dept Physiol, Saskatoon, SK S7N 5E5, Canada.							BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; Balasubramanian MK, 1998, GENETICS, V149, P1265; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chang F, 1996, CELL, V84, P191, DOI 10.1016/S0092-8674(00)80973-3; Chang F, 1996, J CELL SCI, V109, P131; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Eng K, 1998, CURR BIOL, V8, P611, DOI 10.1016/S0960-9822(98)70248-9; Field C, 1999, CURR OPIN CELL BIOL, V11, P68, DOI 10.1016/S0955-0674(99)80009-X; GARCIABUSTOS JF, 1994, EMBO J, V13, P2352, DOI 10.1002/j.1460-2075.1994.tb06519.x; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; Gould KL, 1997, GENE DEV, V11, P2939, DOI 10.1101/gad.11.22.2939; Ishiguro J, 1996, FEBS LETT, V392, P237, DOI 10.1016/0014-5793(96)00819-8; Jang YJ, 1996, GENE, V172, P125, DOI 10.1016/0378-1119(96)00058-3; JANMEY PA, 1994, ANNU REV PHYSIOL, V56, P169, DOI 10.1146/annurev.ph.56.030194.001125; Kitayama C, 1997, J CELL BIOL, V137, P1309, DOI 10.1083/jcb.137.6.1309; KOHALMI SE, 1998, PLANT MOL BIOL MANUA; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI MH, 1998, NATURE, V393, P487; MARKS J, 1985, EUR J CELL BIOL, V39, P27; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; McCollum D, 1999, J BIOL CHEM, V274, P17691, DOI 10.1074/jbc.274.25.17691; MCCOLLUM D, 1995, J CELL BIOL, V130, P651, DOI 10.1083/jcb.130.3.651; McCollum D, 1999, FEBS LETT, V451, P321, DOI 10.1016/S0014-5793(99)00619-5; Motegi F, 1997, FEBS LETT, V420, P161, DOI 10.1016/S0014-5793(97)01510-X; Naqvi NI, 1999, EMBO J, V18, P854, DOI 10.1093/emboj/18.4.854; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; RAPPAPORT R, 1996, CYTOKINESIS ANIMALS; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shannon KB, 2000, CURR BIOL, V10, P727, DOI 10.1016/S0960-9822(00)00539-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weissbach L, 1998, BIOCHEM BIOPH RES CO, V251, P269, DOI 10.1006/bbrc.1998.9371; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0	35	34	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5932	5942		10.1074/jbc.M008715200	http://dx.doi.org/10.1074/jbc.M008715200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11087749	hybrid			2022-12-25	WOS:000167115100071
J	Ribardo, DA; Crowe, SE; Kuhl, KR; Peterson, JW; Chopra, AK				Ribardo, DA; Crowe, SE; Kuhl, KR; Peterson, JW; Chopra, AK			Prostaglandin levels in stimulated macrophages are controlled by phospholipase A(2)-activating protein and by activation of phospholipase C and D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY-BOWEL-DISEASE; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; ARACHIDONIC-ACID METABOLISM; ARTHRITIS SYNOVIAL-FLUID; MESSENGER-RNA EXPRESSION; CROHNS-DISEASE; PHOSPHOLIPASE-A2-ACTIVATING PROTEIN; P388D(1) MACROPHAGES; SIGNAL-TRANSDUCTION	Prostaglandins (PG), which are responsible for a large array of biological functions in eukaryotic cells, are produced from arachidonic acid by phospholipases and cyclooxygenase enzymes COX-1 and COX-2. We demonstrated that PG levels in cells were partly controlled by a regulatory protein, phospholipase A(2) (PLA(2))-activating protein (PLAA). Treatment of murine macrophages with lipopolysaccharide, interleukin-1 beta, and tumor necrosis factor-alpha increased PLAA levels at early time points (2-30 min), which correlated with an up-regulation in cytosolic PLA(2) and PGE(2) levels. Both COX-2 and secretory PLA(2) were also increased in lipopolysaccharide-stimulated macrophages, however, at later time points of 4-24 h. The role of PLAA in eicosanoid formation in macrophages was confirmed by the use of an antisense plaa oligonucleotide. Within amino acid residues 503-538, PLAA exhibited homology with melittin, and increased PGE(2) production was noted in macrophages stimulated with melittin. In addition to PLA(2), we demonstrated that activation of phospholipase C and D significantly controlled PGE(2) production. Finally, increased antigen levels of PLAA, COX-2, and phospholipases were demonstrated in biopsy specimens from patients with varying amounts of intestinal mucosal inflammation, which corresponded to increased levels of phospholipase activity. These results could provide a basis for the development of new therapeutic tools to control inflammation.	Univ Texas, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Chopra, AK (corresponding author), Univ Texas, Med Branch, Dept Microbiol & Immunol, 301 Univ Blvd, Galveston, TX 77555 USA.	achopra@utmb.edu						Abate A, 1998, PROSTAG OTH LIPID M, V56, P277, DOI 10.1016/S0090-6980(98)00061-6; Abate A, 1998, LIFE SCI, V62, P1081, DOI 10.1016/S0024-3205(98)00031-9; Akiba S, 1999, J BIOL CHEM, V274, P19906, DOI 10.1074/jbc.274.28.19906; Arbibe L, 1997, J IMMUNOL, V159, P391; Arslan A, 1996, PROSTAGLANDINS, V52, P463, DOI 10.1016/S0090-6980(96)00125-6; AUSUBEL FM, 1992, CURRENT PROTOCOLS MO, P4; Balsinde J, 1997, J BIOL CHEM, V272, P29317, DOI 10.1074/jbc.272.46.29317; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BARBOUR SE, 1993, J BIOL CHEM, V268, P21875; Bastian BC, 1996, ARCH DERMATOL RES, V288, P147; Beasley D, 1999, AM J PHYSIOL-HEART C, V276, pH1369, DOI 10.1152/ajpheart.1999.276.4.H1369; BLONDELLE SE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P331, DOI 10.1016/0167-4838(93)90024-L; BOMALASKI JS, 1995, J IMMUNOL, V154, P4027; BOMALASKI JS, 1990, J LAB CLIN MED, V116, P814; BOMALASKI JS, 1990, ADV EXP MED BIOL, V279, P231; BOMALASKI JS, 1989, AGENTS ACTIONS, V27, P425, DOI 10.1007/BF01972841; BOMALASKI JS, 1992, J IMMUNOL, V148, P155; Bowton DL, 1997, AM J RESP CRIT CARE, V155, P421, DOI 10.1164/ajrccm.155.2.9032172; Brandtzaeg P, 1997, SPRINGER SEMIN IMMUN, V18, P555, DOI 10.1007/BF00824058; Chopra AK, 1999, BBA-GENE STRUCT EXPR, V1444, P125, DOI 10.1016/S0167-4781(98)00249-8; Chopra AK, 2000, INFECT IMMUN, V68, P2808, DOI 10.1128/IAI.68.5.2808-2818.2000; Clark M A, 1990, Adv Exp Med Biol, V275, P125; CLARK MA, 1991, P NATL ACAD SCI USA, V88, P5418, DOI 10.1073/pnas.88.12.5418; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; DAVID SA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P269, DOI 10.1016/0005-2760(92)90006-H; De Marino V, 1999, INT ARCH ALLERGY IMM, V118, P200, DOI 10.1159/000024066; DUBOURDIEU DJ, 1990, BIOCHIM BIOPHYS ACTA, V1054, P326, DOI 10.1016/0167-4889(90)90104-L; El-Zaatari FAK, 1999, CURR MICROBIOL, V39, P115, DOI 10.1007/s002849900430; Elinder LS, 1997, ARTERIOSCL THROM VAS, V17, P2257, DOI 10.1161/01.ATV.17.10.2257; Fujishima H, 1999, P NATL ACAD SCI USA, V96, P4803, DOI 10.1073/pnas.96.9.4803; Gijon MA, 1999, J LEUKOCYTE BIOL, V65, P330, DOI 10.1002/jlb.65.3.330; Haapamaki MM, 1999, AM J GASTROENTEROL, V94, P713, DOI 10.1111/j.1572-0241.1999.00941.x; Homaidan FR, 1997, AM J PHYSIOL-GASTR L, V272, pG1338, DOI 10.1152/ajpgi.1997.272.6.G1338; Huber CM, 1997, J CELL SCI, V110, P2955; KIM DK, 1995, AM J PHYSIOL-LUNG C, V269, pL109, DOI 10.1152/ajplung.1995.269.1.L109; Kim JH, 1999, J IMMUNOL, V163, P5462; Kuwata H, 1998, J BIOL CHEM, V273, P1733, DOI 10.1074/jbc.273.3.1733; Lennartz MR, 1999, INT J BIOCHEM CELL B, V31, P415, DOI 10.1016/S1357-2725(98)00108-3; Lin WW, 1999, BRIT J PHARMACOL, V126, P1419, DOI 10.1038/sj.bjp.0702436; Lio YC, 1996, BBA-LIPID LIPID MET, V1302, P55, DOI 10.1016/0005-2760(96)00002-1; Liu SJ, 1998, AM J PHYSIOL-HEART C, V275, pH1462, DOI 10.1152/ajpheart.1998.275.4.H1462; Lo CJ, 1998, J TRAUMA, V45, P19, DOI 10.1097/00005373-199807000-00004; Lo CJ, 1997, J SURG RES, V69, P408, DOI 10.1006/jsre.1997.5103; Longo WE, 1999, J SURG RES, V84, P51, DOI 10.1006/jsre.1999.5603; MAULET Y, 1982, ANAL BIOCHEM, V127, P61, DOI 10.1016/0003-2697(82)90144-0; MINAMI T, 1994, GUT, V35, P1593, DOI 10.1136/gut.35.11.1593; MOLLAY C, 1976, BIOCHIM BIOPHYS ACTA, V426, P317, DOI 10.1016/0005-2736(76)90340-0; MOLLAY C, 1974, FEBS LETT, V46, P141, DOI 10.1016/0014-5793(74)80354-6; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1997, J BIOL CHEM, V272, P19891, DOI 10.1074/jbc.272.32.19891; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; PEITSCH MC, 1993, TRENDS BIOCHEM SCI, V18, P292, DOI 10.1016/0968-0004(93)90038-O; Petersen JW, 1996, GUT, V39, P698, DOI 10.1136/gut.39.5.698; Polizotto RS, 1999, J CELL BIOCHEM, V74, P670, DOI 10.1002/(SICI)1097-4644(19990915)74:4<670::AID-JCB16>3.3.CO;2-R; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; ROSHAK A, 1994, J BIOL CHEM, V269, P25999; Roshak A, 1996, J RHEUMATOL, V23, P420; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; Saini SS, 1997, BIOCHEM BIOPH RES CO, V238, P436, DOI 10.1006/bbrc.1997.7295; Schultsz C, 1999, GASTROENTEROLOGY, V117, P1089, DOI 10.1016/S0016-5085(99)70393-8; SHIER WT, 1979, P NATL ACAD SCI USA, V76, P195, DOI 10.1073/pnas.76.1.195; Shinohara H, 1999, J BIOL CHEM, V274, P12263, DOI 10.1074/jbc.274.18.12263; STEINER MR, 1993, BIOCHIM BIOPHYS ACTA, V1166, P124, DOI 10.1016/0005-2760(93)90292-H; Sutton CL, 2000, GUT, V46, P58, DOI 10.1136/gut.46.1.58; Tanaka Y, 1997, BIOL PHARM BULL, V20, P322; TONG W, 1995, MOL CHEM NEUROPATHOL, V25, P1, DOI 10.1007/BF02815083; TSUNODA Y, 1994, BIOCHEM BIOPH RES CO, V203, P1716, DOI 10.1006/bbrc.1994.2384; Ueno N, 2000, FEBS LETT, V475, P242, DOI 10.1016/S0014-5793(00)01691-4; Van Dullemen HM, 1998, SCAND J GASTROENTERO, V33, P1094; VanDullemen H, 1997, SCAND J GASTROENTERO, V32, P92; WERKMEISTER JA, 1993, BIOCHIM BIOPHYS ACTA, V1157, P50, DOI 10.1016/0304-4165(93)90077-L; Williams JA, 1997, J BIOL CHEM, V272, P25693, DOI 10.1074/jbc.272.41.25693; Wu T, 1996, BBA-MOL CELL RES, V1310, P175, DOI 10.1016/0167-4889(95)00143-3; Yang VW, 1996, GASTROENTEROL CLIN N, V25, P317, DOI 10.1016/S0889-8553(05)70249-1; Zeitz M, 1997, DIGESTION, V58, P59, DOI 10.1159/000201529	76	40	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5467	5475		10.1074/jbc.M006690200	http://dx.doi.org/10.1074/jbc.M006690200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11094054	hybrid			2022-12-25	WOS:000167115100010
J	Fares, FA; Levi, F; Reznick, AZ; Kraiem, Z				Fares, FA; Levi, F; Reznick, AZ; Kraiem, Z			Engineering a potential antagonist of human thyrotropin and thyroid-stimulating antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CHORIONIC-GONADOTROPIN; COMMON ALPHA-SUBUNIT; ASPARAGINE-LINKED OLIGOSACCHARIDES; BETA-SUBUNIT; CG-BETA; GLYCOSYLATION; SECRETION; EXPRESSION; SEQUENCE; DESIGN	Thyrotropin (TSH) and the gonadotropins (FSH, LH, hCG) are a family of heterodimeric glycoprotein hormones composed of two noncovalently linked subunits, alpha and beta. We have recently converted the hTSH heterodimer to a biologically active single chain (hTSH beta .CTP alpha) by fusing the common a-subunit to the C-terminal end of the hTSH beta -subunit in the presence of a similar to 30-amino acid peptide from hCG beta (CTP) as a linker. The hTSH beta .CTP alpha single chain was used to investigate the role of the N-linked oligosaccharides of alpha- and beta -subunits in the secretion and function of hTSH. Using overlapping PCR mutagenesis, two deglycosylated variants were prepared: one lacking both oligosaccharide chains on the alpha -subunit (hTSH beta .CTP beta (1+2)) and the other lacking the oligosaccharide chain on the beta -subunit (hTSH beta .CTP alpha deg)). The single chain variants were expressed in CHO cells and were secreted into the medium. hTSH variants lacking the oligosaccharide chains were less potent than hTSH beta .CTP alpha wild-type with respect to cAMP formation and thyroid hormone secretion in cultured human thyroid follicles, Both deglycosylated variants competed with hTSH in a dose-dependent manner. The hTSH beta .CTP alpha (1+2) variant blocked cAMP formation and thyroid hormone secretion stimulated by hTSH as web as by the antibody, thyroid-stimulating immunoglobulins, responsible for the most common cause of hyperthyroidism, Graves disease. Thus, this variant behaves as a potential antagonist, offering a novel therapeutic strategy in the treatment of thyrotoxicosis caused by Graves' disease and TSH-secreting pituitary adenoma.	Carmel Hosp, Dept Biochem & Mol Genet, IL-34362 Haifa, Israel; Carmel Hosp, Dept Anat & Cell Biol, IL-34362 Haifa, Israel; Carmel Hosp, Endocrine Res Unit, IL-34362 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel	Clalit Health Services; Carmel Medical Center; Clalit Health Services; Carmel Medical Center; Clalit Health Services; Carmel Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Fares, FA (corresponding author), Carmel Hosp, Dept Biochem & Mol Genet, 7 Michal St 7, IL-34362 Haifa, Israel.	fares@actcom.co.il						BenMenahem D, 1996, TRENDS ENDOCRIN MET, V7, P100, DOI 10.1016/1043-2760(96)88667-X; BIELINSKA M, 1989, J BIOL CHEM, V264, P17113; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; FARES FA, 1992, P NATL ACAD SCI USA, V89, P4304, DOI 10.1073/pnas.89.10.4304; Fares FA, 1996, ENDOCRINOLOGY, V137, P555, DOI 10.1210/en.137.2.555; Fares FA, 1998, ENDOCRINOLOGY, V139, P2459, DOI 10.1210/en.139.5.2459; FURUHASHI M, 1995, MOL ENDOCRINOL, V9, P54, DOI 10.1210/me.9.1.54; Grossmann M, 1997, J BIOL CHEM, V272, P21312, DOI 10.1074/jbc.272.34.21312; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JOSHI L, 1995, ENDOCRINOLOGY, V136, P3839, DOI 10.1210/en.136.9.3839; JOSHI L, 1995, P NATL ACAD SCI USA, V92, P9062; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KRAIEM Z, 1991, J ENDOCRINOL, V131, P499, DOI 10.1677/joe.0.1310499; LAPOLT PS, 1992, ENDOCRINOLOGY, V131, P2514, DOI 10.1210/en.131.6.2514; LASH RW, 1992, J ENDOCRINOL INVEST, V15, P255, DOI 10.1007/BF03348723; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; MATZUK MM, 1988, J CELL BIOL, V106, P1049, DOI 10.1083/jcb.106.4.1049; MATZUK MM, 1987, P NATL ACAD SCI USA, V84, P6354, DOI 10.1073/pnas.84.18.6354; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; SAIRAM MR, 1983, HORMONAL PROTEINS PE, P1; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; Sugahara T, 1996, J BIOL CHEM, V271, P10445, DOI 10.1074/jbc.271.18.10445; SUGAHARA T, 1995, P NATL ACAD SCI USA, V92, P2041, DOI 10.1073/pnas.92.6.2041; Sugahara T, 1996, MOL CELL ENDOCRINOL, V125, P71, DOI 10.1016/S0303-7207(96)03944-5; SUGANUMA N, 1989, J BIOL CHEM, V264, P19302; Szkudlinski MW, 1996, TRENDS ENDOCRIN MET, V7, P277, DOI 10.1016/S1043-2760(96)00129-4; Wallis M., 1985, BIOCH POLYPEPTIDE HO, P147	27	11	11	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4543	4548		10.1074/jbc.M008093200	http://dx.doi.org/10.1074/jbc.M008093200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11083869	hybrid			2022-12-25	WOS:000168484300005
J	Lipscomb, EA; Sarmiere, PD; Freemann, RS				Lipscomb, EA; Sarmiere, PD; Freemann, RS			SM-20 is a novel mitochondrial protein that causes caspase-dependent cell death in nerve growth factor-dependent neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPRIVED SYMPATHETIC NEURONS; FACTOR-RESPONSIVE GENE; CYTOCHROME-C; CAENORHABDITIS-ELEGANS; POSTMITOTIC NEURONS; FACTOR DEPRIVATION; SMOOTH-MUSCLE; CYCLIN D1; EXPRESSION; APOPTOSIS	Sympathetic neurons undergo protein synthesis-dependent apoptosis when deprived of nerve growth factor (NGF). Expression of SM-20 is up-regulated in NGF-deprived sympathetic neurons, and ectopic SM-20 is sufficient to promote neuronal death in the presence of NGF. We now report that SM-20 is a mitochondrial protein that promotes cell death through a caspase-dependent mechanism. SM-20 immunofluorescenee was present in the cytoplasm in a punctate pattern that colocalized with cytochrome oxidase I and with mitochondria-selective dyes. Analysis of SM-20/dihydrofolate reductase fusion proteins revealed that the first 25 amino acids of SM-20 contain a functional mitochondrial targeting sequence. An amino-terminal truncated form of SM-20 was not restricted to mitochondria but instead localized throughout the cytosol and nucleus. Nevertheless, the truncated SM-20 retained the ability to induce neuronal death, similar to the wild type protein, SM-20-induced death was accompanied by caspase-3 activation and was blocked by a general caspase inhibitor. Additionally, overexpression of SM-20, under conditions where cell death is blocked by a general caspase inhibitor, did not result in widespread release of cytochrome c from mitochondria, These results indicate that SM-20 is a novel mitochondrial protein that may be an important mediator of neurotrophin-withdrawal-mediated cell death.	Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA	University of Rochester; University of Rochester	Freemann, RS (corresponding author), Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, 601 Elmwood Ave, Rochester, NY 14642 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R56NS034400, R01NS034400] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES07026] Funding Source: Medline; NINDS NIH HHS [NS34400, R01 NS034400] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Crowder RJ, 1998, J NEUROSCI, V18, P2933; Darby C, 1999, P NATL ACAD SCI USA, V96, P15202, DOI 10.1073/pnas.96.26.15202; Deshmukh M, 1998, NEURON, V21, P695, DOI 10.1016/S0896-6273(00)80587-5; Deshmukh M, 1996, J CELL BIOL, V135, P1341, DOI 10.1083/jcb.135.5.1341; Dupuy D, 2000, GENOMICS, V69, P348, DOI 10.1006/geno.2000.6343; EDWARDS SN, 1991, J NEUROCHEM, V57, P2140, DOI 10.1111/j.1471-4159.1991.tb06434.x; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HURT EC, 1986, TRENDS BIOCHEM SCI, V11, P204, DOI 10.1016/0968-0004(86)90007-1; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Madden SL, 1996, CANCER RES, V56, P5384; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MARTIN DP, 1990, J NEUROSCI, V10, P184; MODICANAPOLITANO JS, 1989, CANCER RES, V49, P3369; Moschella MC, 1999, GENE EXPRESSION, V8, P59; Neame SJ, 1998, J CELL BIOL, V142, P1583, DOI 10.1083/jcb.142.6.1583; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 1997, J NEUROSCI, V17, P8975; Putcha GV, 1999, J NEUROSCI, V19, P7476, DOI 10.1523/JNEUROSCI.19-17-07476.1999; REED JC, 1991, CANCER RES, V51, P6529; TRENT C, 1983, GENETICS, V104, P619; Watson A, 1998, J NEUROSCI, V18, P751; Wax SD, 1996, LAB INVEST, V74, P797; WAX SD, 1994, J BIOL CHEM, V269, P13041	31	76	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5085	5092		10.1074/jbc.M008407200	http://dx.doi.org/10.1074/jbc.M008407200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11060309	hybrid			2022-12-25	WOS:000168484300075
J	Rajarathnam, K; Li, YL; Rohrer, T; Gentz, R				Rajarathnam, K; Li, YL; Rohrer, T; Gentz, R			Solution structure and dynamics of myeloid progenitor inhibitory factor-1 (MPIF-1), a novel monomeric CC chemokine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; MODEL-FREE APPROACH; GLYCOSAMINOGLYCAN-BINDING-SITE; MAGNETIC-RESONANCE RELAXATION; BACKBONE DYNAMICS; RECEPTOR-BINDING; NEUTROPHIL ACTIVATION; NMR ASSIGNMENTS; BETA-CHEMOKINE; IDENTIFICATION	MPIF-1, a CC chemokine, is a specific inhibitor of myeloid progenitor cells and is the most potent activator of monocytes. The solution structure of myeloid progenitor inhibitor factor-1 (MPIF-1) has been determined by NMR spectroscopy. The structure reveals that MPIF-1 is a monomer with a well defined core except for termini residues and adopts the chemokine fold of three beta -strands and an overlying alpha -helix. In addition to the four cysteines that characterize most chemokines, MPIF-1 has two additional cysteines that form a disulfide bond. The backbone dynamics indicate that the disulfide bonds and the adjacent residues that include the functionally important N-terminal and N-terminal loop residues show significant dynamics. MPIF-1 is a highly basic protein (pI >9), and the structure reveals distinct positively charged pockets that could be correlated to proteoglycan binding. MPIF-1 is processed from a longer proprotein at the N terminus and the latter is also functional though with reduced potency, and both proteins exist as monomers under a variety of solution conditions. MPIF-1 is therefore unique because longer pro-proteins of all other chemokines oligomerize in solution. The MPIF-1 structure should serve as a template for future functional studies that could lead to therapeutics for preventing chemotherapy-associated myelotoxicity.	Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; Human Genome Sci Inc, Dept Prot Express, Rockville, MD 20850 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; GlaxoSmithKline; Human Genome Sciences Inc	Rajarathnam, K (corresponding author), Univ Texas, Med Branch, Dept Human Biol Chem & Genet, Galveston, TX 77555 USA.				NCRR NIH HHS [RR08961] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR008961] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Ali S, 2000, J BIOL CHEM, V275, P11721, DOI 10.1074/jbc.275.16.11721; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Berkhout TA, 2000, BIOCHEM PHARMACOL, V59, P591, DOI 10.1016/S0006-2952(99)00354-8; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; Chakravarty L, 1998, J BIOL CHEM, V273, P29641, DOI 10.1074/jbc.273.45.29641; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; CLORE GM, 1990, J AM CHEM SOC, V112, P4989, DOI 10.1021/ja00168a070; Crump MP, 1999, PROTEIN SCI, V8, P2041, DOI 10.1110/ps.8.10.2041; Crump MP, 1998, J BIOL CHEM, V273, P22471, DOI 10.1074/jbc.273.35.22471; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; GRZESIEK S, 1995, J AM CHEM SOC, V117, P5312, DOI 10.1021/ja00124a014; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; Jarnagin K, 1999, BIOCHEMISTRY-US, V38, P16167, DOI 10.1021/bi9912239; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; Kim KS, 1996, FEBS LETT, V395, P277, DOI 10.1016/0014-5793(96)01024-1; Koopmann W, 1997, J BIOL CHEM, V272, P10103; Koopmann W, 1999, J IMMUNOL, V163, P2120; Koradi R, 1996, J MOL GRAPHICS, V14, P29; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; LiWang AC, 1999, BIOCHEMISTRY-US, V38, P442, DOI 10.1021/bi9812726; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MOSER B, 1993, J BIOL CHEM, V268, P7125; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; Nardelli B, 1999, J IMMUNOL, V162, P435; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; PASCAL SM, 1994, J MAGN RESON SER B, V103, P197, DOI 10.1006/jmrb.1994.1031; Patel VP, 1997, J EXP MED, V185, P1163, DOI 10.1084/jem.185.7.1163; Rajarathnam K, 1997, J BIOL CHEM, V272, P1725, DOI 10.1074/jbc.272.3.1725; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; Rajarathnam K, 1999, BIOCHEMISTRY-US, V38, P7653, DOI 10.1021/bi990033v; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Sharma D, 2000, J BIOMOL NMR, V18, P165, DOI 10.1023/A:1008398416292; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Sticht H, 1999, BIOCHEMISTRY-US, V38, P5995, DOI 10.1021/bi990065i; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Ye JQ, 1999, J BIOMOL NMR, V15, P115, DOI 10.1023/A:1008376728947; Youn BS, 1998, BLOOD, V91, P3118, DOI 10.1182/blood.V91.9.3118.3118_3118_3126; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413	53	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4909	4916		10.1074/jbc.M005085200	http://dx.doi.org/10.1074/jbc.M005085200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11060285	hybrid			2022-12-25	WOS:000168484300053
J	Alsayed, Y; Uddin, S; Mahmud, N; Lekmine, F; Kalvakolanu, DV; Minucci, S; Bokoch, G; Platanias, LC				Alsayed, Y; Uddin, S; Mahmud, N; Lekmine, F; Kalvakolanu, DV; Minucci, S; Bokoch, G; Platanias, LC			Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; BREAST-CANCER CELLS; INDUCED ERYTHROID-DIFFERENTIATION; N-TERMINAL KINASE; MAP KINASE; SIGNALING PATHWAY; GENE-EXPRESSION; UP-REGULATION; SERINE PHOSPHORYLATION; GROWTH-INHIBITION	Several signaling pathways are activated by all-transretinoic acid (RA) to mediate induction of differentiation and apoptosis of malignant cells. In the present study we provide evidence that the p38 MAP kinase pathway is activated in a RA-dependent manner in the NB-4, acute promyelocytic leukemia, and the MCF-7, breast carcinoma, cell lines. RA treatment of cells induces a time- and dose-dependent phosphorylation of p38, and such phosphorylation results in activation of its catalytic domain. p38 activation is not inducible by RA in a variant NB-4 cell line, NB-4.007/6, which is resistant to the effects of RA, suggesting a role for this pathway in the induction of RA responses. Our data also demonstrate that the small G-protein Rad is activated by RA and functions as an upstream regulator of p38 activation, whereas the MAPKAPH-2 serine kinase is a downstream effector for the RA-activated p38. To obtain information on the functional role of the Rac1/p38/MAPKAPK-2 pathway in RA signaling, the effects of pharmacological inhibition of p38 on RA-induced gene transcription and cell differentiation were determined Our results indicate that treatment of cells with the SE203580 inhibitor does not inhibit RA-dependent gene transcription via retinoic acid response elements or induction of Stat1 protein expression. However, treatment with SB203580 or SB202190 strongly enhances RA-dependent induction of cell differentiation and RA-regulated growth inhibitory responses. Altogether, our findings demonstrate that the Rac1/p38 MAP kinase pathway is activated in a RA-dependent manner and exhibits negative regulatory effects on the induction of differentiation.	Univ Illinois, Sect Hematol Oncol, Dept Med, Chicago, IL 60607 USA; Univ Illinois, Chicago, IL 60607 USA; Vet Adm W Side Med Ctr, Chicago, IL 60607 USA; Univ Maryland, Dept Microbiol & Immunol, Baltimore, MD 21201 USA; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University System of Maryland; University of Maryland Baltimore; IRCCS European Institute of Oncology (IEO); Scripps Research Institute; Scripps Research Institute	Platanias, LC (corresponding author), Univ Illinois, Sect Hematol Oncol, Dept Med, MBRB,MC-734,Rm 3150,900 S Ashland Ave, Chicago, IL 60607 USA.		Minucci, Saverio/J-9669-2012	Uddin, Shahab/0000-0003-1886-6710	NATIONAL CANCER INSTITUTE [R01CA071401, R01CA078282, R29CA073381, R01CA077816] Funding Source: NIH RePORTER; NCI NIH HHS [CA73381, CA77816, CA71401, CA78282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agadir A, 1999, J BIOL CHEM, V274, P29779, DOI 10.1074/jbc.274.42.29779; Ahmad S, 1997, J BIOL CHEM, V272, P29991, DOI 10.1074/jbc.272.48.29991; Battle TE, 2000, EXP CELL RES, V254, P287, DOI 10.1006/excr.1999.4766; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Berra E, 1998, J BIOL CHEM, V273, P10792, DOI 10.1074/jbc.273.17.10792; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; Brodowicz T, 1999, BRIT J CANCER, V80, P1350, DOI 10.1038/sj.bjc.6690528; CASTAIGNE S, 1990, BLOOD, V76, P1704; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; CHEN JY, 1995, EMBO J, V14, P1187, DOI 10.1002/j.1460-2075.1995.tb07102.x; Chen YH, 1999, BLOOD, V94, P251, DOI 10.1182/blood.V94.1.251.413k42_251_259; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fanelli M, 1999, BLOOD, V93, P1477, DOI 10.1182/blood.V93.5.1477.405a33_1477_1481; Foltz IN, 1997, J BIOL CHEM, V272, P3296, DOI 10.1074/jbc.272.6.3296; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Gaboli M, 1998, LEUKEMIA LYMPHOMA, V30, P11, DOI 10.3109/10428199809050925; Gianni M, 1997, BLOOD, V89, P1001, DOI 10.1182/blood.V89.3.1001; GOEBERT M, 1997, EMBO J, V16, P3563; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Gollob JA, 1999, J IMMUNOL, V162, P4472; GRIGNANI F, 1994, BLOOD, V83, P10; Han GR, 1997, J BIOL CHEM, V272, P13711, DOI 10.1074/jbc.272.21.13711; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hsu SL, 1999, EXP CELL RES, V248, P87, DOI 10.1006/excr.1999.4397; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jiang Y, 1996, J BIOL CHEM, V271, P17920, DOI 10.1074/jbc.271.30.17920; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; KAMIE Y, 1996, CELL, V85, P403; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kolla V, 1996, J BIOL CHEM, V271, P10508, DOI 10.1074/jbc.271.18.10508; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; KRAMER RM, 1995, J BIOL CHEM, V270, P27395, DOI 10.1074/jbc.270.46.27395; KRUMER JL, 1997, J BIOL CHEM, V272, P20490; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Lechner C, 1996, P NATL ACAD SCI USA, V93, P4355, DOI 10.1073/pnas.93.9.4355; Lee HY, 1998, J BIOL CHEM, V273, P7066, DOI 10.1074/jbc.273.12.7066; Lee HY, 1999, MOL CELL BIOL, V19, P1973; LEE JC, 1994, NATURE, V372, P730; Li ZJ, 1996, BIOCHEM BIOPH RES CO, V228, P334, DOI 10.1006/bbrc.1996.1662; Mangiarotti R, 1998, BRIT J CANCER, V77, P186, DOI 10.1038/bjc.1998.32; Matikainen S, 1997, CELL GROWTH DIFFER, V8, P687; Mertens S, 1996, FEBS LETT, V383, P273, DOI 10.1016/0014-5793(96)00255-4; MINNUCCI S, 1994, MOL CELL BIOL, V14, P360; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Nagy L, 1998, CELL DEATH DIFFER, V5, P11, DOI 10.1038/sj.cdd.4400337; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Nicke B, 1999, BIOCHEM BIOPH RES CO, V261, P572, DOI 10.1006/bbrc.1999.1086; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Salojin KV, 1999, J IMMUNOL, V163, P844; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Stein B, 1997, J BIOL CHEM, V272, P19509, DOI 10.1074/jbc.272.31.19509; Szondy Z, 1998, CELL DEATH DIFFER, V5, P4, DOI 10.1038/sj.cdd.4400313; Uddin S, 2000, J BIOL CHEM, V275, P27634; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; Van heusden J, 1998, BRIT J CANCER, V77, P26, DOI 10.1038/bjc.1998.5; vanderLeede BM, 1997, J BIOL CHEM, V272, P17921, DOI 10.1074/jbc.272.29.17921; Weihua Xiao, 1997, Journal of Biological Chemistry, V272, P9742; Wesselborg S, 1997, J BIOL CHEM, V272, P12422, DOI 10.1074/jbc.272.19.12422; Wickrema A, 1999, J BIOL CHEM, V274, P24469, DOI 10.1074/jbc.274.35.24469; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xu XC, 1999, CANCER RES, V59, P2477; Yen A, 1998, CANCER RES, V58, P3163; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	73	130	137	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4012	4019		10.1074/jbc.M007431200	http://dx.doi.org/10.1074/jbc.M007431200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11060298	hybrid			2022-12-25	WOS:000166921200040
J	Takeda, DY; Wohlschlegel, JA; Dutta, A				Takeda, DY; Wohlschlegel, JA; Dutta, A			A bipartite substrate recognition motif for cyclin-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; CDK; PHOSPHORYLATION; INHIBITION; CELLS	Cy or RXL motifs have been previously shown to be cyclin binding motifs found in a wide range of cyclin-Cdk interacting proteins. We report the first kinetic analysis of the contribution of a Cy motif on a substrate to phosphorylation by cyclin dependent kinases, For both cyclin A-Cdk2 and cyclin E-Cdk2 enzymes, the presence of a Cy motif decreased the K-m(peptide) 75-120-fold while the k(cat) remained unchanged, The large effect of the Cy motif on the K-m(peptide) suggests that the Cy motif and (S/T)PX(K/R) together constitute a bipartite substrate recognition sequence for cyclin-dependent kinases, Systematic changes in the length of the linker between the Cy motif and the phosphoacceptor serine suggest that both sites are engaged simultaneously to the cyclin and the Cdk, respectively, and eliminate a "bind and release" mechanism to increase the local concentration of the substrate. PS100, a peptide containing a Cy motif, acts as a competitive inhibitor of cyclin-Cdk complexes with a 15-fold lower K-i for cyclin E-Cdk2 than for cyclin A-Cdk2. These results provide kinetic proof that a Cy motif located a minimal distance from the SPXK is essential for optimal phosphorylation by Cdks and suggest that small chemicals that mimic the Cy motif would be specific inhibitors of substrate recognition by cyclin-dependent kinases.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Dutta, A (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.		Dutta, Anindya/P-3203-2016	Takeda, David/0000-0002-5986-1169; Dutta, Anindya/0000-0002-4319-0073				Adams PD, 1999, MOL CELL BIOL, V19, P1068; Adams PD, 1996, MOL CELL BIOL, V16, P6623; Blacklow SC, 1996, NAT STRUCT BIOL, V3, P758, DOI 10.1038/nsb0996-758; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; Chen YNP, 1999, P NATL ACAD SCI USA, V96, P4325, DOI 10.1073/pnas.96.8.4325; Dutta A, 1997, ANNU REV CELL DEV BI, V13, P293, DOI 10.1146/annurev.cellbio.13.1.293; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Holmes JK, 1996, J BIOL CHEM, V271, P25240, DOI 10.1074/jbc.271.41.25240; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Saha P, 1997, MOL CELL BIOL, V17, P4338, DOI 10.1128/MCB.17.8.4338; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; ZHU L, 1995, GENE DEV, V9, P1740, DOI 10.1101/gad.9.14.1740	19	103	105	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1993	1997		10.1074/jbc.M005719200	http://dx.doi.org/10.1074/jbc.M005719200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11067844	hybrid			2022-12-25	WOS:000166528000048
J	Tanida, I; Tanida-Miyake, E; Ueno, T; Kominami, E				Tanida, I; Tanida-Miyake, E; Ueno, T; Kominami, E			The human homolog of Saccharomyces cerevisiae Apg7p is a protein-activating enzyme for multiple substrates including human Apg12p, GATE-16, GABARAP, and MAP-LC3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONJUGATION SYSTEM; AUTOPHAGY; YEAST; UBIQUITIN; DEGRADATION; CYTOPLASM; PATHWAY; VACUOLE; MECHANISMS; SUBUNIT	Autophagy is a process that involves the bulk degradation of cytoplasmic components by the lysosomal/vacuolar system. In the yeast, Saccharomyces cerevisiae, an autophagosome is formed in the cytosol. The outer membrane of the autophagosome is fused with the vacuole, releasing the inner membrane structure, an autophagic body, into the vacuole. The autophagic body is subsequently degraded by vacuolar hydrolases. Taking advantage of yeast genetics, apg (autophagy-defective) mutants were isolated that are defective in terms of formation of autophagic bodies under nutrient starvation conditions. One of the APG gene products, Apg12p, is covalently attached to Apg5p via the C-terminal Gly of Apg12p as in the case of ubiquitylation, and this conjugation is essential for autophagy. Apg7p is a novel E1 enzyme essential for the Apg12p-conjugation system. In mammalian cells, the human Apg12p homolog (hApg12p) also conjugates with the human Apg5p homolog. In this study, the unique characteristics of hApg7p are shown. A two-hybrid experiment indicated that hApg12p interacts with hA33g12p. Site-directed mutagenesis revealed that Cys(572) Of hApg7p is an authentic active site cysteine residue essential for the formation of the hApg7p.hApg12p intermediate. Overexpression of hApg7p enhances the formation of the hApg5p.hApg12p conjugate, indicating that hApg7p is an E1-like enzyme essential for the hApg12p conjugation system. Crosslinking experiments and glycerol-gradient centrifugation analysis showed that the mammalian Apg7p homolog forms a homodimer as in yeast Apg7p. Each of three human Apg8p counterparts, i.e. the Golgi-associated ATPase enhancer of 16 kDa, GABA(A) receptor-associated protein, and microtubule-associated protein light chain 3, coimmunoprecipitates with hApg7p and conjugates with mutant hApg7p(C572S) to form a stable intermediate via an ester bond. These results indicate that hApg7p is an authentic protein-activating enzyme for hApg12p and the three Apg8p homologs.	Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan	Juntendo University	Kominami, E (corresponding author), Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.		Tanida, Isei/C-8277-2009; Kominami, Eiki/D-3802-2009	Tanida, Isei/0000-0001-8999-3990				Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Baba M, 1995, CELL STRUCT FUNCT, V20, P465, DOI 10.1247/csf.20.465; BABA M, 1994, J CELL BIOL, V124, P903, DOI 10.1083/jcb.124.6.903; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; Hammond EM, 1998, FEBS LETT, V425, P391, DOI 10.1016/S0014-5793(98)00266-X; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; James P, 1996, GENETICS, V144, P1425; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kaiser C., 1994, METHODS YEAST GENETI; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Legesse-Miller A, 2000, J BIOL CHEM, V275, P32966, DOI 10.1074/jbc.M000917200; Mann SS, 1996, J NEUROSCI RES, V43, P535, DOI 10.1002/(SICI)1097-4547(19960301)43:5<535::AID-JNR3>3.0.CO;2-J; MANN SS, 1994, J BIOL CHEM, V269, P11492; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Nishino I, 2000, NATURE, V406, P906, DOI 10.1038/35022604; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Peltonen L, 2000, CURR OPIN GENET DEV, V10, P299, DOI 10.1016/S0959-437X(00)00086-1; Sagiv Y, 2000, EMBO J, V19, P1494, DOI 10.1093/emboj/19.7.1494; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Tanaka Y, 2000, NATURE, V406, P902, DOI 10.1038/35022595; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; Xue LZ, 1999, MOL CELL NEUROSCI, V14, P180, DOI 10.1006/mcne.1999.0780; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	44	264	277	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1701	1706		10.1074/jbc.C000752200	http://dx.doi.org/10.1074/jbc.C000752200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11096062	hybrid			2022-12-25	WOS:000166528000008
J	Mixon, M; Kittrell, F; Medina, D				Mixon, M; Kittrell, F; Medina, D			Expression of Brca1 and splice variant Brca1 Delta 11 RNA levels in mouse mammary gland during normal development and tumorigenesis	ONCOGENE			English	Article						genes; Brca1; breast neoplasms; gene expression	HEREDITARY BREAST-CANCER; DNA-DAMAGE; CELL-CYCLE; MEIOTIC CELLS; IN-VIVO; DIFFERENTIATION; REPAIR; MUTATIONS; TISSUES; GENE	Expression of Brca1 in mouse mammary cancer has yet to be analysed. We use a progressive model of neoplasia based on several mouse epithelial cell lines that represent distinct steps toward the fully tumorigenic state. Using RNase protection analysis because acceptable anti-Brca1 antibodies are not available we investigated the expression of Brca1 and a splice variant, Brca1 Delta 11, in several mammary hyperplasias and tumors that arose from them, and in normal mammary gland through pregnancy and involution, Expression of Brca1 was highest in rapidly proliferating cells. Expression of the full-length Brca1 was detectable in the virgin gland, was slightly elevated in the midpregnant gland, and decreased to levels similar to the age-matched virgin gland in the completely involuted gland, Expression of both forms of Brca1 was detectable in 9/9 paired hyperplasias and tumors, with levels of total Brca1, but not the splice variant Brca1 Delta 11, in tumors higher than those in the hyperplasias. While in disagreement with the observation that Brca1 levels decrease in human breast cancer progression, these patterns support the notion that Brca1 expression is associated with proliferating cells, and suggests that the link with differentiation seen in normal cells can be removed when cells become tumorigenic.	Baylor Coll Med, Dept Cell Biol, Houston, TX 77030 USA	Baylor College of Medicine	Medina, D (corresponding author), Baylor Coll Med, Dept Cell Biol, 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA64255] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA064255] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Blackshear PE, 1998, ONCOGENE, V16, P61, DOI 10.1038/sj.onc.1201506; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chen YM, 1996, CANCER RES, V56, P3168; EASTON D, 1993, CANCER SURV, V18, P95; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Husain A, 1998, CANCER RES, V58, P1120; Jiang C, 1997, CARCINOGENESIS, V18, P2085, DOI 10.1093/carcin/18.11.2085; Kainu T, 1996, CANCER RES, V56, P2912; KITTRELL FS, 1992, CANCER RES, V52, P1924; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Liu CY, 1996, GENE DEV, V10, P1835, DOI 10.1101/gad.10.14.1835; Lu ML, 1996, CANCER RES, V56, P4578; LYNCH HT, 1994, WORLD J SURG, V18, P21, DOI 10.1007/BF00348188; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; Marks JR, 1997, ONCOGENE, V14, P115, DOI 10.1038/sj.onc.1200808; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Medina D, 1996, Cancer Treat Res, V83, P37; Medina D, 1998, MOL CARCINOGEN, V22, P199, DOI 10.1002/(SICI)1098-2744(199807)22:3<199::AID-MC8>3.0.CO;2-G; MEDINA D, 1993, CANCER RES, V53, P663; Merajver SD, 1995, CLIN CANCER RES, V1, P539; Rajan JV, 1997, DEV BIOL, V184, P385, DOI 10.1006/dbio.1997.8526; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Shao NS, 1996, ONCOGENE, V13, P1; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thomas JE, 1997, CELL GROWTH DIFFER, V8, P801; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; Wilson CA, 1997, ONCOGENE, V14, P1, DOI 10.1038/sj.onc.1200924; Xu CF, 1997, GENE CHROMOSOME CANC, V18, P102, DOI 10.1002/(SICI)1098-2264(199702)18:2<102::AID-GCC4>3.3.CO;2-A	34	21	21	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5237	5243		10.1038/sj.onc.1203905	http://dx.doi.org/10.1038/sj.onc.1203905			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077440				2022-12-25	WOS:000165059700004
J	Blandl, T; Zajicek, J; Prorok, M; Castellino, FJ				Blandl, T; Zajicek, J; Prorok, M; Castellino, FJ			Sequence requirements for the N-methyl-D-aspartate receptor antagonist activity of conantokin-R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; K-DEPENDENT CARBOXYLASE; BINDING PROPERTIES; CONUS-GEOGRAPHUS; INDUCED CURRENTS; IN-VITRO; PEPTIDE; IDENTIFICATION; CONOTOXIN; CALCIUM	Conantokin-R (con-R), a gamma -carboxyglutamate-containing 27-residue peptide, is a natural peptide inhibitor of the N-methyl-D-aspartate (NMDA) subtype glutamate receptor. Synthetic analogs of con-R were generated to evaluate the importance of the individual structural elements of this peptide in its NMDA receptor antagonist activity, measured by inhibition of the spermine-enhanced binding of the NMDA receptor-specific channel blocker, [H-3]MK-801, to rat brain membranes. Progressive C-terminal truncations of the 27-residue peptide revealed stages of severe activity loss, These occurred at con-R[1-11] and con-R[1-7], corresponding to the deletions of Leu(12)-Pro(27)and Met(8)-pro(27) respectively. A second set of analogs featured single Ala substitutions in the fully active Con-R[1-17] fragment. The replacement of Met(8) and Leu(12) by Ala resulted in approximate 20- and 55-fold decreases of inhibitor potency, respectively. In addition to these two residues, the only other positions where a single Ale substitution led to substantial losses (from 11-fold to > 1000-fold) of activity were those of the first five N-terminal amino acids. Based on the above findings, the binding epitope of con-R was localized to the N-terminal turn of the helix and other residues on one face along two subsequent turns. This contribution pattern of the side chains in activity closely resembles the results obtained with another member of this peptide family, conantokin-T. The secondary structure and metal ion binding properties of the con-R variants were also evaluated using circular dichroism spectroscopy. Bivalent cation dependent increases of a-helix content were observed in most analogs. However, analogs with replacement of Gla(11) and Gla(15), as well as truncation fragments shorter than 15 residues, lost the ability to be stabilized by metal ions. These results confirmed the location of the primary divalent cation binding locus at Gla(11) and Gla's. Additional interactions were indicated by the reduced a-helix stability in the Ala analogs of Gla(4), Lys(7), and Arg(14).	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame	Castellino, FJ (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.	castellino.1@nd.edu			NHLBI NIH HHS [HL-19982] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019982] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bandyopadhyay PK, 1998, J BIOL CHEM, V273, P5447, DOI 10.1074/jbc.273.10.5447; Blandl T, 1999, J PEPT RES, V53, P453, DOI 10.1034/j.1399-3011.1999.00042.x; Blandl T, 1997, BIOCHEM J, V328, P777, DOI 10.1042/bj3280777; Blandl T, 1998, FEBS LETT, V435, P257, DOI 10.1016/S0014-5793(98)01077-1; Blandl T, 2000, FEBS LETT, V470, P139, DOI 10.1016/S0014-5793(00)01309-0; BODENHAUSEN G, 1984, J MAGN RESON, V58, P370, DOI 10.1016/0022-2364(84)90142-2; CHANDLER P, 1993, J BIOL CHEM, V268, P17173; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Chen ZG, 1998, J BIOL CHEM, V273, P16248, DOI 10.1074/jbc.273.26.16248; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; Craig AG, 1997, J BIOL CHEM, V272, P4689, DOI 10.1074/jbc.272.8.4689; ESMON CT, 1975, J BIOL CHEM, V250, P4744; Fainzilber M, 1998, BIOCHEMISTRY-US, V37, P1470, DOI 10.1021/bi971571f; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; HAACK JA, 1990, J BIOL CHEM, V265, P6025; HAMMERLAND LG, 1992, EUR J PHARM-MOLEC PH, V226, P239, DOI 10.1016/0922-4106(92)90067-6; Klein RC, 1999, NEUROPHARMACOLOGY, V38, P1819, DOI 10.1016/S0028-3908(99)00065-9; Lirazan MB, 2000, BIOCHEMISTRY-US, V39, P1583, DOI 10.1021/bi9923712; MCINTOSH JM, 1984, J BIOL CHEM, V259, P4343; MENA EE, 1990, NEUROSCI LETT, V118, P241, DOI 10.1016/0304-3940(90)90637-O; Nakamura T, 1996, PROTEIN SCI, V5, P524; Nielsen KJ, 1999, J MED CHEM, V42, P415, DOI 10.1021/jm981052q; PRICE PA, 1976, P NATL ACAD SCI USA, V73, P1447, DOI 10.1073/pnas.73.5.1447; Prorok M, 1996, BIOCHEMISTRY-US, V35, P16528, DOI 10.1021/bi9621122; Prorok M, 1998, J BIOL CHEM, V273, P19573, DOI 10.1074/jbc.273.31.19573; REHEMTULLA A, 1993, P NATL ACAD SCI USA, V90, P4611, DOI 10.1073/pnas.90.10.4611; Rigby AC, 1999, P NATL ACAD SCI USA, V96, P5758, DOI 10.1073/pnas.96.10.5758; Rigby AC, 1997, BIOCHEMISTRY-US, V36, P6906, DOI 10.1021/bi970321w; ROTH DA, 1993, P NATL ACAD SCI USA, V90, P8372, DOI 10.1073/pnas.90.18.8372; Skjaerbaek N, 1997, J BIOL CHEM, V272, P2291; SKOLNICK P, 1992, J NEUROCHEM, V59, P1516, DOI 10.1111/j.1471-4159.1992.tb08468.x; Stanley TB, 1997, FEBS LETT, V407, P85, DOI 10.1016/S0014-5793(97)00299-8; STATES DJ, 1982, J MAGN RESON, V48, P286, DOI 10.1016/0022-2364(82)90279-7; STENFLO J, 1974, P NATL ACAD SCI USA, V71, P2730, DOI 10.1073/pnas.71.7.2730; Warder SE, 1998, J BIOL CHEM, V273, P7512, DOI 10.1074/jbc.273.13.7512; Warder SE, 1997, FEBS LETT, V411, P19, DOI 10.1016/S0014-5793(97)00573-5; White HS, 2000, J PHARMACOL EXP THER, V292, P425; WU SM, 1991, SCIENCE, V254, P1634, DOI 10.1126/science.1749935; WU SM, 1991, P NATL ACAD SCI USA, V88, P2236, DOI 10.1073/pnas.88.6.2236; YANAGAWA Y, 1988, BIOCHEMISTRY-US, V27, P6256, DOI 10.1021/bi00417a009; Zhou LM, 1996, J NEUROCHEM, V66, P620	41	28	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7391	7396		10.1074/jbc.M006648200	http://dx.doi.org/10.1074/jbc.M006648200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11096077	hybrid			2022-12-25	WOS:000167442900073
J	Fukushima, K; Yamashita, K				Fukushima, K; Yamashita, K			Interleukin-2 carbohydrate recognition modulates CTLL-2 cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-N-ACETYLGLUCOSAMINIDASE; JAK-3 JANUS KINASE; IL-2 RECEPTOR; GROWTH-FACTOR; AMINO-TERMINUS; ALPHA-CHAIN; P-SELECTIN; BINDING; SPECIFICITY; LECTIN	Interleukin-2 (IL-2) specifically recognizes high-mannose type glycans with five or six mannosyl residues. To determine whether the carbohydrate recognition activity of IL-2 contributes to its physiological activity, the inhibitory effects of high-mannose type glycans on IL 2 dependent CTLL-2 cell proliferation were investigated. Man(5)GlcNAc(2)Asn added to CTLL-2 cell cultures inhibited not only phosphorylation of tyrosine kinases but also IL-2-dependent cell proliferation. We found that a complex of IL-2, IL-2 receptor alpha, beta, gamma subunits, and tyrosine kinases was formed in rhIL-2-stimulated CTLL-2 cells. Among the components of this complex, only the IL-2 receptor a subunit was stained with Galanthus nivalis agglutinin which specifically recognizes high-mannose type glycans. This staining was diminished after digestion of the glycans with endo-beta -N-acetylglucosaminidase H or D, suggesting that at least a N-glycan containing Man(5)GlcNAc(2) is linked to the extracellular portion of the IL-2 receptor a subunit. Our findings indicate that IL-2 binds the IL-2 receptor a subunit through Man(5)GlcNAc(2) and a specific peptide sequence on the surface of CTLL-2 cells. When IL-2 binds to the IL-2R alpha subunit, this may trigger formation of the high affinity complex of IL-2-IL-2R alpha, -beta, and -gamma subunits, leading to cellular signaling.	Sasaki Inst, Dept Biochem, Chiyoda Ku, Tokyo 1010062, Japan; Japan Sci & Technol Corp, CREST, Chiyoda Ku, Tokyo 1010062, Japan	Japan Science & Technology Agency (JST)	Yamashita, K (corresponding author), Sasaki Inst, Dept Biochem, Chiyoda Ku, 2-2 Kenda Surugadai, Tokyo 1010062, Japan.							ANDERSON DM, 1995, J BIOL CHEM, V270, P29862; ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; BARANSKI TJ, 1992, J BIOL CHEM, V267, P23342; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; CAO XQ, 1993, P NATL ACAD SCI USA, V90, P8464, DOI 10.1073/pnas.90.18.8464; DHARMESH SM, 1993, J BIOL CHEM, V268, P17096; FAN JQ, 1995, J BIOL CHEM, V270, P17723, DOI 10.1074/jbc.270.30.17723; FOXALL C, 1992, J CELL BIOL, V117, P895, DOI 10.1083/jcb.117.4.895; Fukushima K, 1997, J BIOL CHEM, V272, P10579; GILLIS S, 1978, J IMMUNOL, V120, P2027; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KONO T, 1990, P NATL ACAD SCI USA, V87, P1806, DOI 10.1073/pnas.87.5.1806; Mizuno M, 1999, SYNTHESIS-STUTTGART, P162; Najjam S, 1998, GLYCOBIOLOGY, V8, P509, DOI 10.1093/glycob/8.5.509; Nelson BH, 1998, ADV IMMUNOL, V70, P1, DOI 10.1016/S0065-2776(08)60386-7; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAUVE K, 1991, P NATL ACAD SCI USA, V88, P4636, DOI 10.1073/pnas.88.11.4636; SHERBLOM AP, 1989, J IMMUNOL, V143, P939; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SHIMUZU A, 1985, NUCLEIC ACIDS RES, V13, P1505, DOI 10.1093/nar/13.5.1505; TAI T, 1977, J BIOL CHEM, V252, P6687; TAI T, 1975, J BIOL CHEM, V250, P8569; TAI T, 1975, BIOCHEM BIOPH RES CO, V65, P968, DOI 10.1016/S0006-291X(75)80480-3; TAI T, 1977, BIOCHEM BIOPH RES CO, V78, P434, DOI 10.1016/0006-291X(77)91273-6; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; TANAKA N, 1994, P NATL ACAD SCI USA, V91, P7271, DOI 10.1073/pnas.91.15.7271; TANIGUCHI T, 1986, IMMUNOL REV, V92, P121, DOI 10.1111/j.1600-065X.1986.tb01497.x; TORIGOE T, 1992, P NATL ACAD SCI USA, V89, P2674, DOI 10.1073/pnas.89.7.2674; TSUJI T, 1987, BIOCHEMISTRY-US, V26, P3129, DOI 10.1021/bi00385a028; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; YAMASHITA K, 1983, J BIOL CHEM, V258, P1098; Zanetta JP, 1996, BIOCHEM J, V318, P49, DOI 10.1042/bj3180049	36	19	21	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7351	7356		10.1074/jbc.M008781200	http://dx.doi.org/10.1074/jbc.M008781200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11076950	hybrid			2022-12-25	WOS:000167442900068
J	Kanaya, E; Watanabe, K; Nakajima, N; Okada, K; Shimura, Y				Kanaya, E; Watanabe, K; Nakajima, N; Okada, K; Shimura, Y			Zinc release from the CH2C6 zinc finger domain of FILAMENTOUS FLOWER protein from Arabidopsis thaliana induces self-assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIM DOMAIN; TRANSCRIPTION FACTOR; ASSOCIATION; ENCODES; MOTIF; GENE; DEFINES; FAMILY; CLAW; BOX	The FILAIMENTOUS FLOWER gene from Arabidopsis thaliana is a member of a gene family whose role is to specify abaxial cell fate in lateral organs. Analysis of the amino terminal region of the FILAMENTOUS FLOWER protein suggests that seven cysteine residues at positions 14, 26, 30, 33, 54, 56, and 57, and two histidine residues at positions 18 and 24 contribute to a putative zinc finger motif, Cys-X-3-His-X-5-His-X-Cys-X-3-Cys-X(2)Cys-X-20-Cys-X-Cys-Cys. Zinc determination experiments revealed that the FILAMENTOUS FLOWER protein binds two zinc ions per molecule. Chemical modification was required to release one zinc ion, whereas the other was released spontaneously or more rapidly in the presence of metallochromic indicator. The loss of a zinc ion and the subsequent structural change of the zinc finger domain were correlated with the multimerization of the FILAMENTOUS FLOWER protein. A cysteine residue at position 56 in the FILAMENTOUS FLOWER protein potentially interferes with zinc ligation within the zinc finger and causes this zinc release, In support of this, substitution of the Cys(56) by alanine suppressed both the zinc release and the multimerization of the FILAMENTOUS FLOWER protein. Deletion analysis showed that the region between positions 45 and 107 functions in the intermolecular contacts between FILAMENTOUS FLOWER proteins. This region corresponds to the carboxyl-terminal half of the zinc finger domain and the following hydrophobic region containing two putative ol helices. Our results suggest that the FILAMENTOUS FLOWER protein forms a range of different conformers. This attribute may lead to a greater degree of functional flexibility that is central to its role as an abaxial cell fate regulator.	Biomol Engn Res Inst, Suita, Osaka 5650874, Japan; Kyoto Univ, Grad Sch Sci, Dept Bot, Kyoto 6068502, Japan	Kyoto University	Kanaya, E (corresponding author), Biomol Engn Res Inst, 6-2-3 Furuedai, Suita, Osaka 5650874, Japan.							ARCHER VEV, 1994, P NATL ACAD SCI USA, V91, P316, DOI 10.1073/pnas.91.1.316; Armstrong N, 1999, PROTEIN SCI, V8, P1475, DOI 10.1110/ps.8.7.1475; Bach I, 2000, MECH DEVELOP, V91, P5, DOI 10.1016/S0925-4773(99)00314-7; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; Bellon SF, 1997, NAT STRUCT BIOL, V4, P586, DOI 10.1038/nsb0797-586; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Bowman JL, 1999, DEVELOPMENT, V126, P2387; Brown KE, 1997, CELL, V91, P845, DOI 10.1016/S0092-8674(00)80472-9; Elefanty AG, 1996, EMBO J, V15, P319, DOI 10.1002/j.1460-2075.1996.tb00362.x; Golz JF, 1999, CURR BIOL, V9, pR861, DOI 10.1016/S0960-9822(00)80047-0; Goodwin T. W., 1946, BIOCHEM JOUR, V40, P628; HOCHMAN J, 1977, P NATL ACAD SCI USA, V74, P1167, DOI 10.1073/pnas.74.3.1167; HUNT JB, 1984, J BIOL CHEM, V259, P4793; Kanaya E, 1999, J BIOL CHEM, V274, P16068, DOI 10.1074/jbc.274.23.16068; KOMAKI MK, 1988, DEVELOPMENT, V104, P195; KOSA JL, 1994, BIOCHEMISTRY-US, V33, P468, DOI 10.1021/bi00168a011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mackay JP, 1998, J BIOL CHEM, V273, P30560, DOI 10.1074/jbc.273.46.30560; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MICHELSEN JW, 1993, P NATL ACAD SCI USA, V90, P4404, DOI 10.1073/pnas.90.10.4404; MICHELSEN JW, 1994, J BIOL CHEM, V269, P11108; Miller J. H., 1972, EXPT MOL GENETICS, P433; OKADA K, 1994, PLANT MOL BIOL, V26, P1357, DOI 10.1007/BF00016480; Pizzi S, 1999, J BIOL CHEM, V274, P2539, DOI 10.1074/jbc.274.4.2539; Potuschak T, 1998, P NATL ACAD SCI USA, V95, P7904, DOI 10.1073/pnas.95.14.7904; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Sawa S, 1999, GENE DEV, V13, P1079, DOI 10.1101/gad.13.9.1079; Sawa S, 1999, PLANT CELL, V11, P69, DOI 10.1105/tpc.11.1.69; Siegfried KR, 1999, DEVELOPMENT, V126, P4117; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Torii KU, 1999, J BIOL CHEM, V274, P27674, DOI 10.1074/jbc.274.39.27674; Villanneva JM, 1999, GENE DEV, V13, P3160, DOI 10.1101/gad.13.23.3160; Williams AJ, 1999, MOL CELL BIOL, V19, P8526; WU CSC, 1981, BIOCHEMISTRY-US, V20, P566, DOI 10.1021/bi00506a019; Zhang Z, 1998, NUCLEIC ACIDS RES, V26, P3986, DOI 10.1093/nar/26.17.3986	38	9	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7383	7390		10.1074/jbc.M009491200	http://dx.doi.org/10.1074/jbc.M009491200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11092895	hybrid			2022-12-25	WOS:000167442900072
J	Rossi, R; Milzani, A; Dalle-Donne, I; Giannerini, F; Giustarini, D; Lusini, L; Colombo, R; Di Simplicio, P				Rossi, R; Milzani, A; Dalle-Donne, I; Giannerini, F; Giustarini, D; Lusini, L; Colombo, R; Di Simplicio, P			Different metabolizing ability of thiol reactants in human and rat blood - Biochemical and pharmacological implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN MIXED DISULFIDES; TERT-BUTYL HYDROPEROXIDE; GLUTATHIONE-CONJUGATE; REVERSIBLE OXIDATION; BIOLOGICAL-SYSTEMS; NITRIC-OXIDE; HEMOGLOBIN; MENADIONE; ERYTHROCYTE; BINDING	The effect of oxidants, electrophiles, and NO donors in rat or human erythrocytes was analyzed to investigate the influence of protein sulfhydryl groups on the metabolism of these thiol reactants, Oxidant-evoked alterations in thiolic homeostasis were significantly different in the two models; large amounts of glutathione protein mixed disulfides were produced in rat but not in human erythrocytes by treatment with hydroperoxides or diamide, The disappearance of all forms of glutathione (reduced, disulfide, protein mixed disulfide) was induced by menadione only in human erythrocytes. The treatment of rat red blood cells with electrophiles produced glutathione S-conjugates to a much lower extent than inhuman red blood cells; GSH was only minimally depleted in rat red blood cells. The NO donor S-nitroso-cysteine induced a rapid transnitrosation reaction with hemoglobin in rat erythrocytes producing high levels of S-nitrosohemoglobin; this reaction in human red blood cells was negligible. All drugs were cleared more rapidly in rat than in human erythrocytes. Unlike human Hb, rat hemoglobin contains three families of protein SH groups; one of these located at position beta 125 is directly implicated in the metabolism of thiol reactants. This is thought to influence significantly the biochemical, pharmacological, and toxicological effects of some drugs.	Univ Siena, Dept Neurosci, Pharmacol Sect, I-53100 Siena, Italy; Univ Milan, Dept Biol, Lab Biochem & Biophys Cytoskeleton, I-20133 Milan, Italy	University of Siena; University of Milan	Di Simplicio, P (corresponding author), Univ Siena, Dept Neurosci, Pharmacol Sect, Via A Moro 4, I-53100 Siena, Italy.	DISIMPLICIO@UNISI.IT	Dalle-Donne, Isabella/AHE-8993-2022; Giustarini, Daniela/AAV-6629-2021; Milzani, Aldo/AHE-3364-2022; Rossi, Ranieri/C-8743-2011; Dalle-Donne, Isabella/K-1436-2018	Milzani, Aldo/0000-0002-1496-6872; Rossi, Ranieri/0000-0002-0187-4530; Dalle-Donne, Isabella/0000-0001-7098-6213; Giustarini, Daniela/0000-0003-4929-5316				Awasthi S, 1998, BIOCHEMISTRY-US, V37, P5231, DOI 10.1021/bi972130z; BECKER K, 1995, METHOD ENZYMOL, V251, P173, DOI 10.1016/0076-6879(95)51120-2; BEUTLER E, 1969, J CLIN INVEST, V48, P1957, DOI 10.1172/JCI106162; BRODIE AE, 1987, BIOCHEM BIOPH RES CO, V148, P120, DOI 10.1016/0006-291X(87)91084-9; CONDO SG, 1981, EUR J BIOCHEM, V116, P243, DOI 10.1111/j.1432-1033.1981.tb05325.x; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; DAVIS DC, 1974, LIFE SCI, V14, P2099, DOI 10.1016/0024-3205(74)90092-7; Di Simplicio P, 1998, ARCH BIOCHEM BIOPHYS, V355, P145, DOI 10.1006/abbi.1998.0694; Di Simplicio P, 1998, NITRIC OXIDE AND THE CELL, P47; DISIMPLICIO P, 1994, BBA-GEN SUBJECTS, V1199, P245; DiSimplicio P, 1996, BBA-GEN SUBJECTS, V1289, P252, DOI 10.1016/0304-4165(95)00160-3; DRODGE W, 1994, OXIDATIVE STRESS CEL, P285; FERRANTI P, 1993, INT J BIOCHEM, V25, P1943, DOI 10.1016/0020-711X(88)90329-1; FRISCHER H, 1977, J LAB CLIN MED, V89, P1080; GAREL MC, 1982, EUR J BIOCHEM, V123, P513; Giardina B, 1981, Methods Enzymol, V76, P417; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HALASZ P, 1976, EUR J BIOCHEM, V71, P571, DOI 10.1111/j.1432-1033.1976.tb11147.x; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; JOCELYN PC, 1972, BIOCH SH GROUP; KELM M, 1990, CIRC RES, V66, P1561, DOI 10.1161/01.RES.66.6.1561; KLOTZSCH H, 1965, METHOD ENZYMAT AN, P363; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MANNERVIK B, 1986, THIOREDOXIN GLUTARED, P349; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; MEISTER A, 1983, BIOCHEM SOC T, V11, P793, DOI 10.1042/bst0110793; Meister A., 1989, GLUTATHIONE CHEM BIO, P1; Riggs A., 1981, Methods in Enzymology, V76, P5; ROSS D, 1985, CHEM-BIOL INTERACT, V55, P177, DOI 10.1016/S0009-2797(85)80126-5; Rossi R, 1998, J BIOL CHEM, V273, P19198, DOI 10.1074/jbc.273.30.19198; ROSSI R, 1995, BBA-GEN SUBJECTS, V1243, P230, DOI 10.1016/0304-4165(94)00133-I; Rossi R, 1997, ANAL BIOCHEM, V254, P215, DOI 10.1006/abio.1997.2424; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; Sies H, 1988, GLUTATHIONE CONJUGAT; SMITH CV, 1989, GLUTATHIONE CHEM BIO, P1; Stamler JS, 1997, SCIENCE, V276, P2034, DOI 10.1126/science.276.5321.2034; Stern A., 1985, OXIDATIVE STRESS, P331; TORCHINSKY YM, 1981, SULPHUR PROTEINS; VAGE C, 1994, TOXICOL APPL PHARM, V129, P309, DOI 10.1006/taap.1994.1255; WEFERS H, 1983, ARCH BIOCHEM BIOPHYS, V224, P568, DOI 10.1016/0003-9861(83)90244-8; WHEELER GP, 1977, BIOCHEM PHARMACOL, V26, P2331, DOI 10.1016/0006-2952(77)90436-1; WINTERBOURN CC, 1979, BIOCHEM J, V179, P665, DOI 10.1042/bj1790665; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513; ZINS GR, 1968, J PHARMACOL EXP THER, V163, P210	44	76	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7004	7010		10.1074/jbc.M005156200	http://dx.doi.org/10.1074/jbc.M005156200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11096069	hybrid			2022-12-25	WOS:000167442900021
J	Garami, A; Ilg, T				Garami, A; Ilg, T			The role of phosphomannose isomerase in Leishmania mexicana glycoconjugate synthesis and virulence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETED ACID-PHOSPHATASE; HETEROLOGOUS EXPRESSION; CANDIDA-ALBICANS; N-GLYCOSYLATION; GENE; MANNOSE; LIPOPHOSPHOGLYCAN; BIOSYNTHESIS; CLONING; PROTEOPHOSPHOGLYCAN	Phosphomannose isomerase (PMI) catalyzes the reversible interconversion of fructose 6-phosphate and mannose 6-phosphate, which is the first step in the bio synthesis of activated mannose donors required for the biosynthesis of various glycoconjugates. Leishmania species synthesize copious amounts of mannose-containing glycolipids and glycoproteins, which are involved in virulence of these parasitic protozoa. To investigate the role of PMI for parasite glycoconjugate synthesis, we have cloned the PMI gene (Imexpmi) from Leishmania mexicana, generated gene deletion mutants (Delta lmexpmi), and analyzed their phenotype, Delta lmexpmi mutants lack completely the high PMI activity found in wild type parasites, but are, in contrast to fungi, able to grow in media deficient for free mannose. The mutants are unable to synthesize phosphoglycan repeats [-6-Gal beta1-4Man alpha1-PO4-] and mannose-containing glycoinositolphospholipids, and the surface expression of the glycosylphosphatidylinositol-anchored dominant surface glycoprotein leishmanolysin is strongly decreased, unless the parasite growth medium is supplemented with mannose. The Delta lmexpmi mutant is attenuated in infections of macrophages in vitro and of mice, suggesting that PMI may be a target for anti-leishmania drug development. L. mexicana Delta lmexpmi provides the first conditional mannose-controlled system for parasite glycoconjugate assembly with potential applications for the investigation of their biosynthesis, intracellular sorting, and function.	Max Planck Inst Biol, D-72076 Tubingen, Germany	Max Planck Society	Ilg, T (corresponding author), Max Planck Inst Biol, Corrensstr 38, D-72076 Tubingen, Germany.	thomas.ilg@tuebingen.mpg.de		Garami, Attila R/0000-0001-5920-8760				ALEXANDER J, 1992, ADV PARASIT, V31, P175, DOI 10.1016/S0065-308X(08)60022-6; Benzel I, 2000, MOL BIOCHEM PARASIT, V111, P77, DOI 10.1016/S0166-6851(00)00306-6; Beverley SM, 1998, TRENDS MICROBIOL, V6, P35, DOI 10.1016/S0966-842X(97)01180-3; CARVER MA, 1991, J BIOL CHEM, V266, P10974; Cleasby A, 1996, NAT STRUCT BIOL, V3, P470, DOI 10.1038/nsb0596-470; CRUZ A, 1991, P NATL ACAD SCI USA, V88, P7170, DOI 10.1073/pnas.88.16.7170; de Koning TJ, 1998, BIOCHEM BIOPH RES CO, V245, P38, DOI 10.1006/bbrc.1998.8385; Descoteaux A, 1999, BBA-MOL BASIS DIS, V1455, P341, DOI 10.1016/S0925-4439(99)00065-4; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Freeze HH, 1999, BBA-MOL BASIS DIS, V1455, P167, DOI 10.1016/S0925-4439(99)00072-1; GOULD GW, 1993, BIOCHEM J, V295, P329, DOI 10.1042/bj2950329; GRACY RW, 1968, J BIOL CHEM, V243, P3161; Ilg T, 2000, PARASITOL TODAY, V16, P489, DOI 10.1016/S0169-4758(00)01791-9; Ilg T, 1999, J BIOL CHEM, V274, P31410, DOI 10.1074/jbc.274.44.31410; ILG T, 1993, EUR J BIOCHEM, V217, P603, DOI 10.1111/j.1432-1033.1993.tb18283.x; ILG T, 1991, P NATL ACAD SCI USA, V88, P8774, DOI 10.1073/pnas.88.19.8774; Ilg T, 2001, J BIOL CHEM, V276, P4988, DOI 10.1074/jbc.M008030200; ILG T, 1993, FEBS LETT, V327, P103, DOI 10.1016/0014-5793(93)81049-6; Ilg T, 2000, EMBO J, V19, P1953, DOI 10.1093/emboj/19.9.1953; Ilgoutz SC, 1999, EMBO J, V18, P2746, DOI 10.1093/emboj/18.10.2746; Jaeken J, 1998, AM J HUM GENET, V62, P1535, DOI 10.1086/301873; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; Mahoney AB, 1999, ARCH BIOCHEM BIOPHYS, V372, P367, DOI 10.1006/abbi.1999.1531; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MCCONVILLE MJ, 1993, J BIOL CHEM, V268, P15595; Misslitz A, 2000, MOL BIOCHEM PARASIT, V107, P251, DOI 10.1016/S0166-6851(00)00195-X; Moss JM, 1999, J BIOL CHEM, V274, P6678, DOI 10.1074/jbc.274.10.6678; Niehues R, 1998, J CLIN INVEST, V101, P1414, DOI 10.1172/JCI2350; Panneerselvam K, 1996, J BIOL CHEM, V271, P9417, DOI 10.1074/jbc.271.16.9417; Panneerselvam K, 1997, J BIOL CHEM, V272, P23123, DOI 10.1074/jbc.272.37.23123; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Piani A, 1999, MICROBES INFECT, V1, P589, DOI 10.1016/S1286-4579(99)80058-6; PROUDFOOT AEI, 1994, EUR J BIOCHEM, V219, P415, DOI 10.1111/j.1432-1033.1994.tb19954.x; PROUDFOOT AEI, 1994, J PROTEIN CHEM, V13, P619, DOI 10.1007/BF01890460; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; RUSSELL DG, 1987, EUR J BIOCHEM, V164, P213, DOI 10.1111/j.1432-1033.1987.tb11013.x; SCHNEIDER P, 1994, J BIOL CHEM, V269, P18332; SMITH DJ, 1995, YEAST, V11, P301, DOI 10.1002/yea.320110402; SMITH DJ, 1992, MOL CELL BIOL, V12, P2924, DOI 10.1128/MCB.12.7.2924; SMITH DJ, 1994, MOL CELL BIOL, V14, P6030, DOI 10.1128/MCB.14.9.6030; SOLS A, 1960, SCIENCE, V131, P297, DOI 10.1126/science.131.3396.297; Stierhof YD, 1998, J MOL BIOL, V282, P137, DOI 10.1006/jmbi.1998.2012; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x	43	65	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6566	6575		10.1074/jbc.M009226200	http://dx.doi.org/10.1074/jbc.M009226200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11084042	hybrid			2022-12-25	WOS:000167261000067
J	Gonzalez, MI; Robins, DM				Gonzalez, MI; Robins, DM			Oct-1 preferentially interacts with androgen receptor in a DNA-dependent manner that facilitates recruitment of SRC-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OCTAMER TRANSCRIPTION FACTORS; LIGAND-BINDING DOMAIN; GLUCOCORTICOID RESPONSE ELEMENT; STEROID-HORMONE RECEPTORS; CARBOXYL-TERMINAL REGIONS; RETINOIC ACID RECEPTOR; NUCLEAR RECEPTOR; GENE ACTIVATION; AF2 DOMAINS; COACTIVATOR	Gene regulation by steroid hormone receptors depends on the particular character of the DNA response element, the array of neighboring transcription factors, and recruitment of coactivators that interface with the transcriptional machinery. We are studying these complex interactions for the androgen dependent enhancer of the mouse sex-limited protein (Slp) gene. This enhancer has, in addition to multiple androgen receptor (AR)-binding sites, a central region (FPIV) with a binding site for the ubiquitous transcription factor Oct-1 that appears crucial for hormonal regulation in vivo. To examine the role of Oct-1 in androgen-specific gene activation, we tested the interaction of Oct-1 with AR versus glucocorticoid receptor (GR) in vivo and in vitro. Oct-1 coimmunoprecipitated from cell lysates with both AR and GR, but significant association with AR required both proteins to be DNA-bound. This was confirmed by sensitivity of the protein association to treatment with ethidium bromide or micrococcal nuclease. Addition of DNA to micrococcal nuclease-treated samples restored interaction, even when binding sites were on separate DNA molecules, suggesting association was due to direct protein protein interaction and not indirect tethering via the DNA, AR/GR chimeras revealed that interaction of the N and C termini of AR was required to communicate the DNA bound state that enhances interaction with Oct-1. Protease digestion assays of hormone-bound receptors revealed further conformational changes in the ligand binding domain of AR, but not GR, upon DNA binding. Furthermore, these conformational changes led to increased interaction with the coactivator SRC-1, via the NID 4 domain, suggesting DNA binding facilitates recruitment of SRC-1 by the AR-Oct-1 complex. Altogether, these results suggest that the precise arrangement of binding sites in the Slp enhancer ensures proper hormonal response by imposing differential interactions between receptors and Oct-1, which in turn contributes to SRC-1 recruitment to the promoter.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Cell & Mol Biol Program, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Robins, DM (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA.			Robins, Diane M./0000-0001-6727-6309	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056356] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-56356, R01 DK056356] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADLER AJ, 1993, MOL CELL BIOL, V13, P6326, DOI 10.1128/MCB.13.10.6326; ADLER AJ, 1991, MOL ENDOCRINOL, V5, P1587, DOI 10.1210/mend-5-11-1587; ADLER AJ, 1992, P NATL ACAD SCI USA, V89, P11660, DOI 10.1073/pnas.89.24.11660; Alen P, 1999, MOL CELL BIOL, V19, P6085; ALLAN GF, 1992, J BIOL CHEM, V267, P19513; Ambrosetti DC, 1997, MOL CELL BIOL, V17, P6321, DOI 10.1128/MCB.17.11.6321; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Burgos-Trinidad M, 1999, MOL CELL ENDOCRINOL, V149, P107, DOI 10.1016/S0303-7207(98)00253-6; Chandran UR, 1999, J BIOL CHEM, V274, P2372, DOI 10.1074/jbc.274.4.2372; Chandran UR, 1999, BEHAV BRAIN RES, V105, P29, DOI 10.1016/S0166-4328(99)00080-7; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SY, 1997, J BIOL CHEM, V272, P14087, DOI 10.1074/jbc.272.22.14087; Dai JL, 1996, MOL ENDOCRINOL, V10, P1582, DOI 10.1210/me.10.12.1582; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; Eraly SA, 1998, MOL ENDOCRINOL, V12, P469, DOI 10.1210/me.12.4.469; Folkers GE, 1998, J BIOL CHEM, V273, P32200, DOI 10.1074/jbc.273.48.32200; FRITSCH M, 1992, J BIOL CHEM, V267, P1823; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Ikeda M, 1996, J BIOL CHEM, V271, P23096, DOI 10.1074/jbc.271.38.23096; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Inamoto S, 1997, J BIOL CHEM, V272, P29852, DOI 10.1074/jbc.272.47.29852; Klein ES, 2000, J BIOL CHEM, V275, P19401, DOI 10.1074/jbc.M002472200; Kraus WL, 1995, P NATL ACAD SCI USA, V92, P12314, DOI 10.1073/pnas.92.26.12314; KUIL CW, 1995, J BIOL CHEM, V270, P27569, DOI 10.1074/jbc.270.46.27569; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; KUPFER SR, 1993, J BIOL CHEM, V268, P17519; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LAI JS, 1992, P NATL ACAD SCI USA, V89, P6958, DOI 10.1073/pnas.89.15.6958; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; Lee SK, 1998, J BIOL CHEM, V273, P16651, DOI 10.1074/jbc.273.27.16651; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Ma H, 1999, MOL CELL BIOL, V19, P6164; Malik KF, 1997, MOL BRAIN RES, V45, P99, DOI 10.1016/S0169-328X(96)00238-0; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, J STEROID BIOCHEM, V69, P3, DOI 10.1016/S0960-0760(98)00144-7; Na SY, 1998, J BIOL CHEM, V273, P10831, DOI 10.1074/jbc.273.18.10831; Ning YM, 1999, J BIOL CHEM, V274, P30624, DOI 10.1074/jbc.274.43.30624; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; Prefontaine GG, 1999, J BIOL CHEM, V274, P26713, DOI 10.1074/jbc.274.38.26713; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; REICHMAN ME, 1984, BIOCHEMISTRY-US, V23, P5376, DOI 10.1021/bi00317a042; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; ROBINS DM, 1994, J STEROID BIOCHEM, V49, P251, DOI 10.1016/0960-0760(94)90265-8; SCARLETT CO, 1995, MOL ENDOCRINOL, V9, P413, DOI 10.1210/me.9.4.413; Scarlett CO, 1997, DNA CELL BIOL, V16, P45, DOI 10.1089/dna.1997.16.45; Scheller A, 1998, J BIOL CHEM, V273, P24216, DOI 10.1074/jbc.273.37.24216; Scheller A, 1996, MOL CELL ENDOCRINOL, V121, P75, DOI 10.1016/0303-7207(96)03854-3; Schoenmakers E, 2000, J BIOL CHEM, V275, P12290, DOI 10.1074/jbc.275.16.12290; Schreiber J, 1997, J BIOL CHEM, V272, P32286, DOI 10.1074/jbc.272.51.32286; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; WONG CI, 1993, J BIOL CHEM, V268, P19004; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270	61	38	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6420	6428		10.1074/jbc.M008689200	http://dx.doi.org/10.1074/jbc.M008689200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096094	hybrid			2022-12-25	WOS:000167261000048
J	Cunningham, ML; Waldo, GL; Hollinger, S; Hepler, JR; Harden, TK				Cunningham, ML; Waldo, GL; Hollinger, S; Hepler, JR; Harden, TK			Protein kinase C phosphorylates RGS2 and modulates its capacity for negative regulation of G alpha(11) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; STIMULATED PHOSPHOINOSITIDE HYDROLYSIS; TURKEY ERYTHROCYTE-MEMBRANES; HETEROTRIMERIC G-PROTEINS; PHOSPHOLIPASE-C; PHORBOL-ESTER; ALPHA-SUBUNITS; FREE-CALCIUM; INOSITOL TRISPHOSPHATE; GUANINE-NUCLEOTIDES	RGS proteins (regulators of G protein signaling) attenuate heterotrimeric G protein signaling by functioning as both GTPase-activating proteins (GAPs) and inhibitors of G protein/effector interaction. RGS2 has been shown to regulate G alpha (q)-mediated inositol lipid signaling. Although purified RGS2 blocks PLC-P activation by the nonhydrolyzable GTP analog guanosine 5'-O-thiophosphate (GTP gammaS), its capacity to regulate inositol lipid signaling under conditions where GTPase-promoted hydrolysis of GTP is operative has not been fully explored. Utilizing the turkey erythrocyte membrane model of inositol lipid signaling, me investigated regulation by RGS2 of both GTP and GTP gammaS-stimulated G alpha (11) signaling. Different inhibitory potencies of RGS2 were observed under conditions assessing its activity as a GAP versus as an effector antagonist; i.e. RGS2 was a 10-20-fold more potent inhibitor of aluminum fluoride and GTP-stimulated PLC-betat activity than of GTP gammaS-promoted PLC-betat activity. We also examined whether RGS2 was regulated by downstream components of the inositol lipid signaling pathway. RGS2 was phosphorylated by PKC in vitro to a stoichiometry of approximately unity by both a mixture of PRC isozymes and individual calcium and phospholipid-dependent PKC isoforms. Moreover, RGS2 was phosphorylated in intact COS7 cells in response to PKC activation by 4 beta -phorbol 12 beta -myristate 13 alpha -acetate and, to a lesser extent, by the P2Y(2) receptor agonist UTP. In vitro phosphorylation of RGS2 by PKC decreased its capacity to attenuate both GTP and GTP gammaS-stimulated PLC-betat activation, with the ex tent of attenuation correlating with the level of RGS2 phosphorylation. A phosphorylation-dependant: inhibition of RGS2 GAP activity was also observed in proteoliposomes reconstituted with purified P2Y(1) receptor and G alpha (q)beta gamma. These results identify for the first time a phosphorylation-induced change in the activity of an RGS protein and suggest a mechanism for potentiation of inositol lipid signaling by PKC.	Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Emory University	Harden, TK (corresponding author), Univ N Carolina, Sch Med, Dept Pharmacol, CB 7365,Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029536, R01GM038213, R01GM029536] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM29536, GM38213] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benzing T, 2000, J BIOL CHEM, V275, P28167; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1996, J BIOL CHEM, V271, P27209, DOI 10.1074/jbc.271.44.27209; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BERRIE CP, 1995, CELL CALCIUM, V18, P232, DOI 10.1016/0143-4160(95)90068-3; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; BOYER JL, 1989, J BIOL CHEM, V264, P884; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; Cobbold P H, 1990, Semin Cell Biol, V1, P311; COBBOLD PH, 1991, CELL CALCIUM, V12, P87, DOI 10.1016/0143-4160(91)90011-3; Cunningham ML, 1999, MOL PHARMACOL, V56, P265, DOI 10.1124/mol.56.2.265; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Filtz TM, 1999, BIOCHEM J, V338, P257, DOI 10.1042/0264-6021:3380257; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; FISHER SK, 1995, EUR J PHARM-MOLEC PH, V288, P231, DOI 10.1016/0922-4106(95)90035-7; FISHER SK, 1994, NEUROCHEM RES, V19, P549, DOI 10.1007/BF00971329; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; HARDEN TK, 1987, J BIOL CHEM, V262, P9057; HEPLER JR, 1988, J BIOL CHEM, V263, P7610; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Heximer SP, 1999, J BIOL CHEM, V274, P34253, DOI 10.1074/jbc.274.48.34253; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Ingi T, 1998, J NEUROSCI, V18, P7178; JAMES SR, 1994, BIOCHEM J, V304, P359, DOI 10.1042/bj3040359; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MENNITI FS, 1991, MOL PHARMACOL, V40, P727; MORRIS AJ, 1990, J BIOL CHEM, V265, P13501; MORRIS AJ, 1990, J BIOL CHEM, V265, P13508; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; ORELLANA SA, 1985, J BIOL CHEM, V260, P5236; Pedram A, 2000, J BIOL CHEM, V275, P7365, DOI 10.1074/jbc.275.10.7365; RITTENHOUSE SE, 1985, J BIOL CHEM, V260, P8657; ROONEY TA, 1991, J BIOL CHEM, V266, P15068; SANCHEZBUENO A, 1990, BIOCHEM J, V268, P627, DOI 10.1042/bj2680627; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; VAZIRI C, 1992, BIOCHEM J, V284, P917, DOI 10.1042/bj2840917; Waldo GL, 1996, BIOCHEM J, V316, P559, DOI 10.1042/bj3160559; WALDO GL, 1991, J BIOL CHEM, V266, P14217; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1987, BIOCHEM J, V246, P619, DOI 10.1042/bj2460619; Xu X, 1999, J BIOL CHEM, V274, P3549, DOI 10.1074/jbc.274.6.3549; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687	49	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5438	5444		10.1074/jbc.M007699200	http://dx.doi.org/10.1074/jbc.M007699200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11063746	Green Published, hybrid			2022-12-25	WOS:000167115100006
J	Lee, Y; Wang, MY; Kakuma, T; Wang, ZW; Babcock, E; McCorkle, K; Higa, M; Zhou, YT; Unger, RH				Lee, Y; Wang, MY; Kakuma, T; Wang, ZW; Babcock, E; McCorkle, K; Higa, M; Zhou, YT; Unger, RH			Liporegulation in diet-induced obesity - The antisteatotic role of hyperleptinemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETES-MELLITUS; LEPTIN; RATS; PATHOGENESIS; RESISTANCE; INDUCTION; MUTATION; DISEASE; ISLETS; CELLS	To test the hypothesis that the physiologic liporegulatory role of hyperleptinemia is to prevent steatosis during caloric excess, we induced obesity by feeding normal Harlan Sprague-Dawley rats a 60% fat diet. Hyperleptinemia began within 24 h and increased progressively to 26 ng/ml after 10 weeks, correlating with an similar to 150-fold increase in body fat (r = 0.91, p < 0.0001). During this time, the triacylglycerol (TG) content of nonadipose tissues rose only 1-2.7-fold implying anti-steatotic activity. In rodents without leptin action (fa/fa rats and ob/ob and db/db mice) receiving a 6% fat diet, nonadipose tissue TG was 4-100 times normal. In normal rats on a 60% fat diet, peroxisome proliferator-activated receptor cu protein and liver-carnitine palmitoyl-transferase-1 (L-CPT-1) mRNA increased in liver. In their pancreatic islets, fatty-acid oxidation increased 30% without detectable increase in the expression of peroxisome proliferator-activated receptor-cy or oxidative enzymes, whereas lipogenesis from [C-14]glucose was slightly below that of the 4% fat-fed rats (p < 0.05). Tissue-specific overexpression of wild-type leptin receptors in the livers of fa/fa rats, in which marked steatosis is uniformly present, reduced TG accumulation in liver but nowhere else. We conclude that a physiologic role of the hyperleptinemia of caloric excess is to protect nonadipocytes from steatosis and lipotoxicity by preventing the up-regulation of lipogenesis and increasing fatty-acid oxidation.	Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Gifford Labs,Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Radiol, Dallas, TX 75390 USA; Vet Affairs Med Ctr, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Unger, RH (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Gifford Labs,Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	runger@mednet.swmed.edu			NIDDK NIH HHS [DK02700-37] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK002700, R01DK002700] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; CHEN SY, 1994, DIABETES, V43, P878, DOI 10.2337/diabetes.43.7.878; Cook WS, 2000, BIOCHEM BIOPH RES CO, V278, P250, DOI 10.1006/bbrc.2000.3739; DANNO H, 1992, J NUTR SCI VITAMINOL, V38, P517, DOI 10.3177/jnsv.38.517; FOLCH J, 1957, J BIOL CHEM, V226, P497; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Gavrilova O, 2000, J CLIN INVEST, V105, P271, DOI 10.1172/JCI7901; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hirose H, 1996, J BIOL CHEM, V271, P5633, DOI 10.1074/jbc.271.10.5633; Iida M, 1996, BIOCHEM BIOPH RES CO, V224, P597, DOI 10.1006/bbrc.1996.1070; Jensen J, 1996, J BIOL CHEM, V271, P18749, DOI 10.1074/jbc.271.31.18749; Kakuma T, 2000, P NATL ACAD SCI USA, V97, P8536, DOI 10.1073/pnas.97.15.8536; Lee Y, 1997, DIABETES, V46, P408, DOI 10.2337/diabetes.46.3.408; LEE Y, 1994, P NATL ACAD SCI USA, V91, P10878, DOI 10.1073/pnas.91.23.10878; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; MCGARRY JD, 1992, SCIENCE, V258, P766, DOI 10.1126/science.1439783; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; Neel JV, 1999, NUTR REV, V57, pS2, DOI 10.1111/j.1753-4887.1999.tb01782.x; O'Doherty RM, 2000, J CLIN INVEST, V105, P479, DOI 10.1172/JCI8673; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Phillips MS, 1996, NAT GENET, V13, P18, DOI 10.1038/ng0596-18; Qian H, 1998, P SOC EXP BIOL MED, V219, P160, DOI 10.3181/00379727-219-44330; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Shimabukuro M, 1997, P NATL ACAD SCI USA, V94, P4637, DOI 10.1073/pnas.94.9.4637; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; STEIN DT, 1995, INT J OBESITY, V19, P804; Surwit RS, 2000, DIABETES, V49, P1203, DOI 10.2337/diabetes.49.7.1203; Unger RH, 1997, TRENDS ENDOCRIN MET, V8, P276, DOI 10.1016/S1043-2760(97)00094-5; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; Vincent HK, 1999, INT J OBESITY, V23, P67, DOI 10.1038/sj.ijo.0800761; Wang MY, 1998, P NATL ACAD SCI USA, V95, P714, DOI 10.1073/pnas.95.2.714; Wang ZW, 2001, FASEB J, V15, P108, DOI 10.1096/fj.00-0310com; Wang ZW, 1999, P NATL ACAD SCI USA, V96, P10373, DOI 10.1073/pnas.96.18.10373; Zhou YT, 1998, DIABETES, V47, P1904, DOI 10.2337/diabetes.47.12.1904; Zhou YT, 2000, P NATL ACAD SCI USA, V97, P1784, DOI 10.1073/pnas.97.4.1784; Zhou YT, 1998, P NATL ACAD SCI USA, V95, P8898, DOI 10.1073/pnas.95.15.8898; Zhou YT, 1999, P NATL ACAD SCI USA, V96, P2391, DOI 10.1073/pnas.96.5.2391	38	209	221	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5629	5635		10.1074/jbc.M008553200	http://dx.doi.org/10.1074/jbc.M008553200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11096093	hybrid			2022-12-25	WOS:000167115100032
J	Petit, JM; van Wuytswinkel, O; Briat, JF; Lobreaux, S				Petit, JM; van Wuytswinkel, O; Briat, JF; Lobreaux, S			Characterization of an iron-dependent regulatory sequence involved in the transcriptional control of AtFer1 and ZmFer1 plant ferritin genes by iron	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL TRANSPORTER; MESSENGER-RNA; EXPRESSION; ELEMENT; ARABIDOPSIS; FAMILY; STORAGE	In eukaryotic cells, ferritin synthesis is controlled by the intracellular iron status. In mammalian cells, iron derepresses ferritin mRNA translation, whereas it induces ferritin gene transcription in plants. Promoter deletion and site-directed mutagenesis analysis, combined with gel shift assays, has allowed identification of a new cis-regulatory element in the promoter region of the ZmFer1 maize ferritin gene. This Iron-Dependent Regulatory Sequence (IDRS) is responsible for transcriptional repression of ZmFer1 under low iron supply conditions. The IDRS is specific to the ZmFer1 iron-dependent regulation and does not mediate the antioxidant response that we have previously reported (Savino et al. (1997) J. Biol. Chem. 272, 33319-33326), In addition, we have cloned AtFer1, the Arabidopsis thaliana ZmFerl orthologue. The IDRS element is conserved in the AtFer1 promoter region and is functional as shown by transient assay in A thaliana cells and stable transformation in A. thaliana transgenic plants, demonstrating its ubiquity in the plant kingdom.	Agro M INRA, CNRS, UMR 5004, Lab Biochim & Physiol Mol Plantes, F-34060 Montpellier 1, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); INRAE; Institut Agro; Montpellier SupAgro; Universite de Montpellier	Lobreaux, S (corresponding author), Agro M INRA, CNRS, UMR 5004, Lab Biochim & Physiol Mol Plantes, F-34060 Montpellier 1, France.	lobreaux@ensam.inra.fr						Altschul Stephen F., J MOL BIOL, V215, P403, DOI [10.1016/S0022-2836(05)80360-2, DOI 10.1016/S0022-2836(05)80360-2]; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brazzolotto X, 1999, J BIOL CHEM, V274, P21625, DOI 10.1074/jbc.274.31.21625; Briat JF, 1999, CELL MOL LIFE SCI, V56, P155, DOI 10.1007/s000180050014; Chinery R, 1997, J BIOL CHEM, V272, P30356, DOI 10.1074/jbc.272.48.30356; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; Curie C, 2000, BIOCHEM J, V347, P749, DOI 10.1042/0264-6021:3470749; Eide D, 1996, P NATL ACAD SCI USA, V93, P5624, DOI 10.1073/pnas.93.11.5624; EYAL Y, 1995, PLANT CELL, V7, P373, DOI 10.1105/tpc.7.3.373; Faniello MC, 1999, J BIOL CHEM, V274, P7623, DOI 10.1074/jbc.274.12.7623; FOBISLOISY I, 1995, EUR J BIOCHEM, V231, P609, DOI 10.1111/j.1432-1033.1995.0609d.x; Gaymard F, 1996, BIOCHEM J, V318, P67, DOI 10.1042/bj3180067; GUERINOT ML, 1994, PLANT PHYSIOL, V104, P815, DOI 10.1104/pp.104.3.815; HALLIWELL B, 1988, ATLAS SCI BIOCH, P48; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; HOFGEN R, 1988, NUCLEIC ACIDS RES, V16, P9877, DOI 10.1093/nar/16.20.9877; Lagarde D, 1996, PLANT J, V9, P195, DOI 10.1046/j.1365-313X.1996.09020195.x; LESCURE AM, 1991, P NATL ACAD SCI USA, V88, P8222, DOI 10.1073/pnas.88.18.8222; LOBREAUX S, 1995, PLANT J, V8, P443, DOI 10.1046/j.1365-313X.1995.08030443.x; LOBREAUX S, 1992, PLANT MOL BIOL, V19, P563, DOI 10.1007/BF00026783; MCELROY D, 1991, MOL GEN GENET, V231, P150, DOI 10.1007/BF00293832; MENKENS AE, 1995, TRENDS BIOCHEM SCI, V20, P506, DOI 10.1016/S0968-0004(00)89118-5; Mori S, 1999, CURR OPIN PLANT BIOL, V2, P250, DOI 10.1016/S1369-5266(99)80043-0; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Proudhon D, 1996, J MOL EVOL, V42, P325, DOI 10.1007/BF02337543; Robinson NJ, 1999, NATURE, V397, P694, DOI 10.1038/17800; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Savino G, 1997, J BIOL CHEM, V272, P33319, DOI 10.1074/jbc.272.52.33319; Thomine S, 2000, P NATL ACAD SCI USA, V97, P4991, DOI 10.1073/pnas.97.9.4991; VANWUYTSWINKEL O, 1995, BIOCHEM J, V305, P253, DOI 10.1042/bj3050253; VASIL V, 1989, PLANT PHYSIOL, V91, P1575, DOI 10.1104/pp.91.4.1575; Villain P, 1996, J BIOL CHEM, V271, P32593, DOI 10.1074/jbc.271.51.32593; VOYTAS DF, 1990, GENETICS, V126, P713; Wei JZ, 2000, J BIOL CHEM, V275, P17488, DOI 10.1074/jbc.M910334199; Winge DR, 1998, CURR OPIN CHEM BIOL, V2, P216, DOI 10.1016/S1367-5931(98)80063-X; ZHOU DX, 1992, J BIOL CHEM, V267, P23515	39	110	122	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5584	5590		10.1074/jbc.M005903200	http://dx.doi.org/10.1074/jbc.M005903200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11092880	hybrid			2022-12-25	WOS:000167115100026
J	Chellan, P; Nagaraj, RH				Chellan, P; Nagaraj, RH			Early glycation products produce pentosidine cross-links on native proteins - Novel mechanism of pentosidine formation and propagation of glycation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN LENS PROTEINS; ADVANCED MAILLARD REACTION; METHYLGLYOXAL-DERIVED MODIFICATIONS; GLYCOSYLATION END-PRODUCTS; IN-VITRO; DIABETIC-RETINOPATHY; OXIDATIVE STRESS; SUPEROXIDE ANION; CATARACT; ENDPRODUCTS	Bovine lens alpha -crystallin was immobilized on EAH-Sepharose gel and glycated using D-ribose. Incubation with 500 and 100 mM D-ribose for 2 and 15 days produced short-term glycated (STGP gel) and long-term glycated proteins (LTGP gel). Both STGP and LTGP gels produced oxygen free radicals. Hydroxyl radical production was twice that in STGP gel compared with the LTGP gel. Incubation with the glycated gels produced pentosidine in a mixture of N-alpha -acetylarginine + N-alpha -acetyllysine, bovine lens proteins (BLP), and lysozyme; the amounts measured with STGP gel were higher than those with LTGP gel. Reactive oxygen species scavengers decreased the formation of pentosidine. Pentosidine was also formed in BLP when incubated with water-insoluble proteins extracted from aged or brunescent human lenses. Early glycated proteins from aged or diabetic lenses were bound to a boronate affinity column, the protein-containing gel was incubated with BLP, and pentosidine was measured in the incubation mixtures. With this method we found that diabetic lens proteins produced more pentosidine on BLP than did aged lens proteins. Further investigation indicates that two and three carbon carbohydrates possibly formed from oxidative cleavage of early glycation products are involved in pentosidine formation. Based on our findings, we propose a novel pathway for pentosidine formation on native proteins from glycated proteins.	Case Western Reserve Univ, Dept Ophthalmol, Ctr Vis Res, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44106 USA	Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University	Nagaraj, RH (corresponding author), Case Western Reserve Univ, Dept Ophthalmol, Ctr Vis Res, Wearn Bldg 643, Cleveland, OH 44106 USA.	nhr@po.cwru.edu			NEI NIH HHS [R01EY-09912, P30EY-11373] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY011373, R01EY009912] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; ARAKI N, 1995, EUR J BIOCHEM, V230, P408, DOI 10.1111/j.1432-1033.1995.0408h.x; ARAKI N, 1992, J BIOL CHEM, V267, P10211; BHUYAN DK, 1994, METHOD ENZYMOL, V233, P630; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; BROWNLEE M, 1994, DIABETES, V43, P836, DOI 10.2337/diab.43.6.836; CARUBELLI R, 1995, FREE RADICAL BIO MED, V18, P265, DOI 10.1016/0891-5849(94)E0134-5; Elgawish A, 1996, J BIOL CHEM, V271, P12964, DOI 10.1074/jbc.271.22.12964; ENGERMAN RL, 1987, DIABETES, V36, P808, DOI 10.2337/diabetes.36.7.808; Farboud B, 1999, MOL VIS, V5, pU1; GARLICK RL, 1984, J CLIN INVEST, V74, P1742, DOI 10.1172/JCI111592; Garner B, 2000, EXP EYE RES, V70, P81, DOI 10.1006/exer.1999.0754; Giardino I, 1996, J CLIN INVEST, V97, P1422, DOI 10.1172/JCI118563; GIBLIN FJ, 1995, EXP EYE RES, V60, P219, DOI 10.1016/S0014-4835(05)80105-8; GILLERY P, 1988, DIABETES METAB, V14, P25; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; Goldstein LE, 2000, BIOCHEMISTRY-US, V39, P7266, DOI 10.1021/bi992997s; HALLIWELL B, 1999, FREE RADICAL BIO MED, P361; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HARDING JJ, 1991, CATARACT BIOCH EPIDE, P180; KATO H, 1994, MAILLARD REACTIONS C, P309; Khalifah RG, 1999, BIOCHEM BIOPH RES CO, V257, P251, DOI 10.1006/bbrc.1999.0371; KUME S, 1995, AM J PATHOL, V147, P654; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lederer MO, 1999, BIOORGAN MED CHEM, V7, P2499, DOI 10.1016/S0968-0896(99)00212-6; LI LK, 1978, EXP EYE RES, V27, P553, DOI 10.1016/0014-4835(78)90140-9; Liggins J, 1996, BIOCHEM BIOPH RES CO, V219, P186, DOI 10.1006/bbrc.1996.0203; Linetsky M, 1999, EXP EYE RES, V69, P239, DOI 10.1006/exer.1999.0710; Linetsky M, 1996, EXP EYE RES, V63, P67, DOI 10.1006/exer.1996.0092; LYONS TJ, 1991, DIABETES, V40, P1010, DOI 10.2337/diabetes.40.8.1010; MCDERMOTT MJ, 1989, CURR EYE RES, V8, P771, DOI 10.3109/02713688909000867; Miyata T, 1996, J CLIN INVEST, V98, P1088, DOI 10.1172/JCI118889; MONBOISSE JC, 1990, ADV EXP MED BIOL, V264, P551; Monnier VM, 1996, NEPHROL DIAL TRANSPL, V11, P20; MULLARKEY CJ, 1990, BIOCHEM BIOPH RES CO, V173, P932, DOI 10.1016/S0006-291X(05)80875-7; Nagai R, 2000, DIABETES, V49, P1714, DOI 10.2337/diabetes.49.10.1714; NAGARAJ RH, 1992, BIOCHIM BIOPHYS ACTA, V1116, P34, DOI 10.1016/0304-4165(92)90125-E; Nagaraj RH, 1996, DIABETES, V45, P587, DOI 10.2337/diabetes.45.5.587; NAGARAJ RH, 1991, P NATL ACAD SCI USA, V88, P10257, DOI 10.1073/pnas.88.22.10257; Ortwerth BJ, 1997, PHOTOCHEM PHOTOBIOL, V65, P666, DOI 10.1111/j.1751-1097.1997.tb01909.x; ORTWERTH BJ, 1995, PHOTOCHEM PHOTOBIOL, V62, P454, DOI 10.1111/j.1751-1097.1995.tb02368.x; RESMINI P, 1990, Italian Journal of Food Science, V2, P173; Saxena P, 2000, INVEST OPHTH VIS SCI, V41, P1473; SCHMIDT AM, 1994, ARTERIOSCLER THROMB, V14, P1521, DOI 10.1161/01.ATV.14.10.1521; Schmidt AM, 1996, DIABETES, V45, pS77, DOI 10.2337/diab.45.3.S77; SELL DR, 1989, J BIOL CHEM, V264, P21597; Shamsi FA, 1998, INVEST OPHTH VIS SCI, V39, P2355; Shamsi FA, 1998, J BIOL CHEM, V273, P6928, DOI 10.1074/jbc.273.12.6928; Shipanova IN, 1997, ARCH BIOCHEM BIOPHYS, V344, P29, DOI 10.1006/abbi.1997.0195; SMITH MA, 1994, P NATL ACAD SCI USA, V91, P5710, DOI 10.1073/pnas.91.12.5710; SMITH PR, 1992, EUR J BIOCHEM, V210, P729, DOI 10.1111/j.1432-1033.1992.tb17474.x; Soulis T, 1999, DIABETOLOGIA, V42, P472, DOI 10.1007/s001250051181; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; SPECTOR A, 1979, SCIENCE, V204, P1323, DOI 10.1126/science.377484; SRIVASTAVA SK, 1988, DIABETES, V37, P1505, DOI 10.2337/diabetes.37.11.1505; Stitt AW, 1997, AM J PATHOL, V150, P523; Tessier F, 1999, J BIOL CHEM, V274, P20796, DOI 10.1074/jbc.274.30.20796; VLASSARA H, 1992, DIABETES, V41, P52, DOI 10.2337/diab.41.2.S52; VLASSARA H, 1992, P NATL ACAD SCI USA, V89, P12043, DOI 10.1073/pnas.89.24.12043; VLASSARA H, 1988, SCIENCE, V240, P1546, DOI 10.1126/science.3259727; VLASSARA H, 1994, LAB INVEST, V70, P138; Westwood ME, 1996, IMMUNOL LETT, V50, P17, DOI 10.1016/0165-2478(96)02496-0	62	50	54	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3895	3903		10.1074/jbc.M008626200	http://dx.doi.org/10.1074/jbc.M008626200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11076948	hybrid			2022-12-25	WOS:000166921200025
J	McRory, JE; Santi, CM; Hamming, KSC; Mezeyova, J; Sutton, KG; Baillie, DL; Stea, A; Snutch, TP				McRory, JE; Santi, CM; Hamming, KSC; Mezeyova, J; Sutton, KG; Baillie, DL; Stea, A; Snutch, TP			Molecular and functional characterization of a family of rat brain T-type calcium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHARMACOLOGICAL PROPERTIES; CA2+ CURRENTS; CELLS; CHICK; NEURONS; ELECTROPHYSIOLOGY; INACTIVATION; SELECTIVITY; EXPRESSION; MEMBRANE	Voltage-gated calcium channels represent a heterogenous family of calcium-selective channels that can be distinguished by their molecular, electrophysiological, and pharmacological characteristics. We report here the molecular cloning and functional expression of three members of the low voltage-activated calcium channel family from rat brain (alpha (1G), alpha (1H) and alpha (1I)). Northern blot and reverse transcriptase-polymerase chain reaction analyses show alpha (1G), and alpha (1H), and alpha (1I) to be expressed throughout the newborn and juvenile rat brain. In contrast, while alpha (1G) and alpha (1H) mRNA are expressed in all regions in adult rat brain, alpha (1I) mRNA expression is restricted to the striatum. Expression of alpha (1G), alpha (1H), and alpha (1I) subunits in HEK293 cells resulted in calcium currents with typical T-type channel characteristics: low voltage activation, negative steady-state inactivation, strongly voltage-dependent activation and inactivation, and slow deactivation, In addition, the direct electrophysiological comparison of alpha (1G), alpha (1H), and alpha (1I) under identical recording conditions also identified unique characteristics including activation and inactivation kinetics and permeability to divalent cations. Simulation of alpha (IG),alpha (1H), and alpha (1I) T-type channels in a thalamic neuron model cell produced unique firing patterns (burst versus tonic) typical of different brain nuclei and suggests that the three channel types make distinct contributions to neuronal physiology.	Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; NeuroMed Technol Inc, Vancouver, BC V6T 1Z4, Canada; Simon Fraser Univ, Dept Mol Biol & Biochem, Burnaby, BC V5A 1S6, Canada; Univ Coll Fraser Valley, Abbotsford, BC V2S 7M8, Canada	University of British Columbia; Simon Fraser University; University of Fraser Valley	Snutch, TP (corresponding author), Univ British Columbia, Biotechnol Lab, Rm 237-6174 Univ Blvd, Vancouver, BC V6T 1Z3, Canada.	snutch@zoology.ubc.ca	Snutch, Terrance P/L-3464-2019	Snutch, Terrance P/0000-0001-5182-1296				AKAIKE N, 1989, J PHYSIOL-LONDON, V412, P181, DOI 10.1113/jphysiol.1989.sp017610; BABITCH J, 1990, NATURE, V346, P321, DOI 10.1038/346321b0; BARGAS J, 1994, J NEUROSCI, V14, P6667; BEAN BP, 1985, J GEN PHYSIOL, V86, P1, DOI 10.1085/jgp.86.1.1; Bkaily G, 1997, MOL CELL BIOCHEM, V176, P199, DOI 10.1023/A:1006832608377; BOSSU JL, 1985, PFLUG ARCH EUR J PHY, V403, P360, DOI 10.1007/BF00589247; CARBONE E, 1984, BIOPHYS J, V46, P413, DOI 10.1016/S0006-3495(84)84037-0; CARBONE E, 1984, NATURE, V310, P501, DOI 10.1038/310501a0; CARBONE E, 1987, J PHYSIOL-LONDON, V386, P571, DOI 10.1113/jphysiol.1987.sp016552; CARBONE E, 1987, J PHYSIOL-LONDON, V386, P547, DOI 10.1113/jphysiol.1987.sp016551; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CHEN CF, 1990, J GEN PHYSIOL, V96, P603, DOI 10.1085/jgp.96.3.603; COHEN CJ, 1988, P NATL ACAD SCI USA, V85, P2412, DOI 10.1073/pnas.85.7.2412; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; ENYEART JJ, 1993, MOL ENDOCRINOL, V7, P1031, DOI 10.1210/me.7.8.1031; FEDULOVA SA, 1985, J PHYSIOL-LONDON, V359, P431, DOI 10.1113/jphysiol.1985.sp015594; FOX AP, 1987, J PHYSIOL-LONDON, V394, P149, DOI 10.1113/jphysiol.1987.sp016864; HAGIWARA N, 1988, J PHYSIOL-LONDON, V395, P233, DOI 10.1113/jphysiol.1988.sp016916; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HOEHN K, 1993, J NEUROSCI, V13, P1244; HUGUENARD JR, 1992, J NEUROSCI, V12, P3804, DOI 10.1523/jneurosci.12-10-03804.1992; HUGUENARD JR, 1992, J NEUROPHYSIOL, V68, P1373, DOI 10.1152/jn.1992.68.4.1373; Huguenard JR, 1996, ANNU REV PHYSIOL, V58, P329, DOI 10.1146/annurev.physiol.58.1.329; Klockner U, 1999, EUR J NEUROSCI, V11, P4171, DOI 10.1046/j.1460-9568.1999.00849.x; Lee A, 1999, NATURE, V399, P155, DOI 10.1038/20194; Lee JH, 1999, J NEUROSCI, V19, P1912; LLINAS R, 1981, J PHYSIOL-LONDON, V315, P549, DOI 10.1113/jphysiol.1981.sp013763; MASON WT, 1989, J PHYSIOL-LONDON, V415, P367, DOI 10.1113/jphysiol.1989.sp017726; MATTESON DR, 1986, J GEN PHYSIOL, V87, P161, DOI 10.1085/jgp.87.1.161; MCCLESKEY EW, 1991, CURR TOP MEMBR, V39, P295; MCCOBB DP, 1991, NEURON, V7, P119, DOI 10.1016/0896-6273(91)90080-J; MCCORMICK DA, 1992, J NEUROPHYSIOL, V68, P1384, DOI 10.1152/jn.1992.68.4.1384; Mittman S, 1999, NEUROSCI LETT, V269, P121, DOI 10.1016/S0304-3940(99)00319-5; MLINAR B, 1993, J GEN PHYSIOL, V102, P217, DOI 10.1085/jgp.102.2.217; Monteil A, 2000, J BIOL CHEM, V275, P16530, DOI 10.1074/jbc.C000090200; Monteil A, 2000, J BIOL CHEM, V275, P6090, DOI 10.1074/jbc.275.9.6090; NAMBU A, 1994, J NEUROPHYSIOL, V72, P1127, DOI 10.1152/jn.1994.72.3.1127; NILIUS B, 1985, NATURE, V316, P443, DOI 10.1038/316443a0; NOWYCKY MC, 1985, NATURE, V316, P440, DOI 10.1038/316440a0; NUSS HB, 1993, CIRC RES, V73, P777, DOI 10.1161/01.RES.73.4.777; Perez-Reyes E, 1998, NATURE, V391, P896, DOI 10.1038/36110; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Randall AD, 1997, NEUROPHARMACOLOGY, V36, P879, DOI 10.1016/S0028-3908(97)00086-5; Santi CM, 1996, AM J PHYSIOL-CELL PH, V271, pC1583, DOI 10.1152/ajpcell.1996.271.5.C1583; Sculptoreanu A, 2000, MOL CELL BIOCHEM, V203, P23, DOI 10.1023/A:1007010020228; Serrano JR, 2000, BIOPHYS J, V78, p455A; Serrano JR, 1999, J GEN PHYSIOL, V114, P185, DOI 10.1085/jgp.114.2.185; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; STEA A, 1995, HDB RECEPTORS CHANNE, P113; Sutton KG, 1999, NATURE, V401, P800, DOI 10.1038/44586; SWANDULLA D, 1988, J GEN PHYSIOL, V92, P197, DOI 10.1085/jgp.92.2.197; Talley EM, 1999, J NEUROSCI, V19, P1895; Wang L, 1999, ENDOCRINOLOGY, V140, P1200, DOI 10.1210/en.140.3.1200; WILLIAMS ME, 1994, J BIOL CHEM, V269, P22347; Williams ME, 1999, J NEUROCHEM, V72, P791, DOI 10.1046/j.1471-4159.1999.0720791.x; XU XP, 1990, P NATL ACAD SCI USA, V87, P4655, DOI 10.1073/pnas.87.12.4655; ZHOU ZF, 1994, J MOL CELL CARDIOL, V26, P1211, DOI 10.1006/jmcc.1994.1139	58	202	218	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3999	4011		10.1074/jbc.M008215200	http://dx.doi.org/10.1074/jbc.M008215200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11073957	hybrid			2022-12-25	WOS:000166921200039
J	Tschantz, WR; Digits, JA; Pyun, HJ; Coates, RM; Casey, PJ				Tschantz, WR; Digits, JA; Pyun, HJ; Coates, RM; Casey, PJ			Lysosomal prenylcysteine lyase is a FAD-dependent thioether oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; PALMITOYL-PROTEIN THIOESTERASE; BOVINE BRAIN; EXPRESSION	Prenylated proteins contain either a 15-carbon farnesyl or a 20-carbon geranylgeranyl isoprenoid covalently attached via a thioether bond to a cysteine residue at or near their C terminus. As prenylated proteins comprise up to 2% of the total protein in eukaryotic cells, and the thioether bond is a stable modification, their degradation raises a metabolic challenge to cells. A lysosomal enzyme termed prenylcysteine lyase has been identified that cleaves prenylcysteines to cysteine and an unidentified isoprenoid product. Here we show that the isoprenoid product of prenylcysteine lyase is the C-l aldehyde of the isoprenoid moiety (farnesal in the case of C-15). The enzyme requires molecular oxygen as a cosubstrate and utilizes a noncovalently bound flavin cofactor in an NAD(P)H-independent manner. Additionally, a stoichiometric amount of hydrogen peroxide is produced during the reaction. These surprising findings indicate that prenylcysteine lyase utilizes a novel oxidative mechanism to cleave thioether bonds and provide insight into the unique role this enzyme plays in the cellular metabolism of prenylcysteines.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Illinois, Dept Chem, Urbana, IL 61801 USA	Duke University; Duke University; University of Illinois System; University of Illinois Urbana-Champaign	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.			Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [GM46372, GM13956] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashby MN, 1998, CURR OPIN LIPIDOL, V9, P99, DOI 10.1097/00041433-199804000-00004; BESSEY OA, 1949, J BIOL CHEM, V180, P755; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Coves J, 1999, BIOCHEM J, V342, P465, DOI 10.1042/0264-6021:3420465; EPSTEIN WW, 1991, P NATL ACAD SCI USA, V88, P9668, DOI 10.1073/pnas.88.21.9668; Fu HW, 1999, RECENT PROG HORM RES, V54, P315; Hoober KL, 1996, J BIOL CHEM, V271, P30510, DOI 10.1074/jbc.271.48.30510; LEOPOLD EJ, 1990, ORG SYNTH, V7, P258; Lu JY, 1996, P NATL ACAD SCI USA, V93, P10046, DOI 10.1073/pnas.93.19.10046; MARCH J, 1985, ADV ORG CHEM, P884; MOOMAW JF, 1995, METHOD ENZYMOL, V250, P12; Rando RR, 1996, BBA-LIPID LIPID MET, V1300, P5, DOI 10.1016/0005-2760(95)00233-2; Tschantz WR, 1999, J BIOL CHEM, V274, P35802, DOI 10.1074/jbc.274.50.35802; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0; Walsh C, 1979, ENZYMATIC REACTION M, P358; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; Zhang LL, 1997, J BIOL CHEM, V272, P23354, DOI 10.1074/jbc.272.37.23354; Zhou MJ, 1997, ANAL BIOCHEM, V253, P162, DOI 10.1006/abio.1997.2391	19	33	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2321	2324		10.1074/jbc.C000616200	http://dx.doi.org/10.1074/jbc.C000616200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11078725	hybrid			2022-12-25	WOS:000166784800004
J	Hu, YF; Miyake, T; Ye, QN; Li, R				Hu, YF; Miyake, T; Ye, QN; Li, R			Characterization of a novel trans-activation domain of BRCA1 that functions in concert with the BRCA1 C-terminal (BRCT) domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL DNA-REPLICATION; PREDICTING COILED COILS; TRANSCRIPTIONAL ACTIVATION; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; BREAST; COMPLEX; GENE; PHOSPHORYLATION; ASSOCIATION	Mutations in the breast cancer susceptibility gene, BRCA1, account for a significant proportion of hereditary breast and ovarian cancers. The BRCA1 C-terminal (BRCT) domain, which can activate transcription when fused to a heterologous DNA binding domain, is required for BRCA1 function in suppression of tumorigenesis, Here, we provide evidence for a new activation domain in BRCA1 that lies adjacent to the BRCT domain. We name the two domains ADI and AD2, respectively. Like AD2, the newly discovered AD1 can act independently as an activation domain in both yeast and human cells. However, unlike AD2, ADI activity in mammalian cells is cell type context-dependent. Furthermore, combination of these two domains in mammalian cells can result in a robust synergy in transcriptional activation. A highly conserved coiled-coil motif in AD1 is required for the cooperative transcription activation. Interestingly, the functional cooperativity between AD1 and AD2 is absent in certain breast and ovarian cancer cell lines, although each domain can still activate transcription. Therefore, the differential and cooperative actions of the two activation modules may contribute to the heterogeneous risk of BRCA1, mutations in different tissues.	Univ Virginia, Dept Biochem & Mol Genet, Ctr Hlth Sci, Charlottesville, VA 22908 USA	University of Virginia	Li, R (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Ctr Hlth Sci, Charlottesville, VA 22908 USA.	rl2t@virginia.edu						BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; GAYTHER SA, 1995, NAT GENET, V11, P428, DOI 10.1038/ng1295-428; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Humphrey JS, 1997, P NATL ACAD SCI USA, V94, P5820, DOI 10.1073/pnas.94.11.5820; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Larson JS, 1997, CANCER RES, V57, P3351; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li R, 1998, MOL CELL BIOL, V18, P1296, DOI 10.1128/MCB.18.3.1296; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Miyake T, 2000, J BIOL CHEM, V275, P40169, DOI 10.1074/jbc.M007138200; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; Moynahan ME, 1999, MOL CELL, V4, P511, DOI 10.1016/S1097-2765(00)80202-6; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Neish AS, 1998, NUCLEIC ACIDS RES, V26, P847, DOI 10.1093/nar/26.3.847; Ouchi T, 1998, P NATL ACAD SCI USA, V95, P2302, DOI 10.1073/pnas.95.5.2302; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Rahman N, 1998, ANNU REV GENET, V32, P95, DOI 10.1146/annurev.genet.32.1.95; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tomlinson GE, 1998, CANCER RES, V58, P3237; Wang Y, 2000, GENE DEV, V14, P927; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	35	36	42	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40910	40915		10.1074/jbc.C000607200	http://dx.doi.org/10.1074/jbc.C000607200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11067843	hybrid			2022-12-25	WOS:000166114600034
J	Miyake, M; Inufusa, H; Adachi, M; Ishida, H; Hashida, H; Tokuhara, T; Kakehi, Y				Miyake, M; Inufusa, H; Adachi, M; Ishida, H; Hashida, H; Tokuhara, T; Kakehi, Y			Suppression of pulmonary metastasis using adenovirally motility related protein-1 (MRP-1/CD9) gene delivery	ONCOGENE			English	Article						MRP-1/CD9; adenovirus; gene therapy; metastasis	CELL MOTILITY; BREAST-CANCER; TRANSMEMBRANE-4 SUPERFAMILY; TM4SF PROTEINS; POOR-PROGNOSIS; BRAIN-TUMORS; LUNG-CANCER; IN-VIVO; EXPRESSION; THERAPY	Previously we showed that MRP-1/CD9 might prevent tumor metastasis by suppression of cell motility and invasion of tissue barriers. The present study explored the possibility of preventing metastasis of mouse melanoma BL6 by expression of MRP-1/CD9 through gene transfer. A replication-deficient adenovirus vector was used for the in vivo transfer of MRP-1/CD9 cDNA, Intratumor injection of an adenovirus vector (rAd-MRP-1/CD9) expressing MRP-1/CD9 resulted in a 73.7% reduction in the number of pulmonary metastases of mice and the median survival time of mice treated with rAd-MRP-1/CD9 was significantly longer than those treated with the rAd-beta -gal vector (103.2+/-8.5 days vs 71.2+/-5.2 days, P<0.001 respectively). These results support the expression of MRP-1/CD9 through gene transfer as a therapeutic strategy for preventing metastases and prolonging survival, and support the feasibility of gene transfer in a clinically relevant setting.	Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Kita Ku, Osaka 5308480, Japan; Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Oncol 5, Kita Ku, Osaka 5308480, Japan; Kinki Univ, Sch Med, Dept Surg 1, Osaka 5898511, Japan; Kyoto Univ, Dept Urol & Pathol, Kyoto 6068501, Japan	Kitano Hospital; Kitano Hospital; Kindai University (Kinki University); Kyoto University	Miyake, M (corresponding author), Kitano Hosp, Tazuke Kofukai Med Res Inst, Dept Thorac Surg, Kita Ku, 13-3 Kamiyama Cho, Osaka 5308480, Japan.							Adachi M, 1998, J CLIN ONCOL, V16, P1397, DOI 10.1200/JCO.1998.16.4.1397; BARNES R, 1991, AM J PATHOL, V139, P245; Bonnekoh B, 1998, J INVEST DERMATOL, V110, P867, DOI 10.1046/j.1523-1747.1998.00221.x; BOUCHEIX C, 1991, J BIOL CHEM, V266, P117; Cajot JF, 1997, CANCER RES, V57, P2593; CHEN SH, 1995, P NATL ACAD SCI USA, V92, P2577, DOI 10.1073/pnas.92.7.2577; CULVER KW, 1992, SCIENCE, V256, P1550, DOI 10.1126/science.1317968; Curiel DT, 1996, AM J RESP CELL MOL, V14, P1; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Harris MP, 1996, CANCER GENE THER, V3, P121; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HIGASHIYAMA M, 1995, CANCER RES, V55, P6040; IKEYAMA S, 1993, J EXP MED, V177, P1231, DOI 10.1084/jem.177.5.1231; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kondo K, 1998, CANCER RES, V58, P2014; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MASELLISSMITH A, 1994, J IMMUNOL, V152, P2768; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; MIYAKE M, 1991, BIOCHEMISTRY-US, V30, P3328, DOI 10.1021/bi00227a023; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Miyake M, 1996, CANCER RES, V56, P1244; Mori M, 1998, CLIN CANCER RES, V4, P1507; OLDFIELD EH, 1993, HUM GENE THER, V4, P39, DOI 10.1089/hum.1993.4.1-39; RADFORD KJ, 1995, INT J CANCER, V62, P631, DOI 10.1002/ijc.2910620523; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Sheng S, 1996, P NATL ACAD SCI USA, V93, P11669, DOI 10.1073/pnas.93.21.11669; Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; Tachibana I, 1999, J CELL BIOL, V146, P893, DOI 10.1083/jcb.146.4.893; TOH Y, 1994, J BIOL CHEM, V269, P22958; Uchida S, 1999, BRIT J CANCER, V79, P1168, DOI 10.1038/sj.bjc.6690186	33	47	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5221	5226		10.1038/sj.onc.1203919	http://dx.doi.org/10.1038/sj.onc.1203919			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077438				2022-12-25	WOS:000165059700002
J	Sanchez-Perez, I; Martinez-Gomariz, M; Williams, D; Keyse, SM; Perona, R				Sanchez-Perez, I; Martinez-Gomariz, M; Williams, D; Keyse, SM; Perona, R			CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin	ONCOGENE			English	Article						cisplatin; JNK1; CL100-MKP-1; hVH-5; apoptosis	PROTEIN-TYROSINE-PHOSPHATASE; DUAL-SPECIFICITY PHOSPHATASE; SIGNAL-TRANSDUCTION PATHWAYS; KINASE KINASE KINASE; DNA-DAMAGING AGENTS; C-JUN; MAP KINASE; IN-VIVO; CELL-DEATH; CONDITIONAL EXPRESSION	Treatment of cells with cisplatin induces a sustained activation of the stress activated protein kinase SAPK/JNK and the mitogen-activated protein kinase p38, Activation of JNK by cisplatin is necessary for the induction of apoptosis, Expression of the MAPK phosphatases CL100/MKP-1 and hVH-5 selectively prevents JNK/SAPK activation by cisplatin in a dose dependent fashion and results in protection against cisplatin-induced apoptosis, In contrast, expression of the ERK-specific phosphatase Pyst1 inhibits JNK/SAPK activity only when expressed at very high levels and does not confer protection against cisplatin. Furthermore, expression of a catalytically inactive mutant of CL100 in 293 cells decreases the IC50 for cisplatin and increases the toxicity of transplatin, This effect seems to be mediated by an increase in JNK activity since p38 activity is unaffected. These results suggest that dual-specificity MAPK phosphatases may be candidate drug targets in order to optimize cisplatin based therapeutic protocols.	CSIC, Inst Invest Biomed, UAM, E-28029 Madrid, Spain; Ninewells Hosp, Biomed Res Ctr, Mol Pharmacol Unit, Imperial Canc Res Fund, Dundee DD1 9SY, Scotland	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Dundee	Perona, R (corresponding author), CSIC, Inst Invest Biomed, UAM, Arturo Duperier 4, E-28029 Madrid, Spain.		Keyse, Stephen M./B-9575-2009; Sánchez-Pérez, Isabel/R-4107-2016	Keyse, Stephen M./0000-0002-5150-8221; Sánchez-Pérez, Isabel/0000-0002-4829-201X				ALESSI DR, 1993, ONCOGENE, V8, P2015; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Camps M, 1998, SCIENCE, V280, P1262, DOI 10.1126/science.280.5367.1262; CHARLES CH, 1993, P NATL ACAD SCI USA, V90, P5292, DOI 10.1073/pnas.90.11.5292; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; Chu YF, 1996, J BIOL CHEM, V271, P6497, DOI 10.1074/jbc.271.11.6497; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Dowd S, 1998, J CELL SCI, V111, P3389; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Franklin CC, 1995, ONCOGENE, V11, P2365; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Franklin CC, 1997, J BIOL CHEM, V272, P16917, DOI 10.1074/jbc.272.27.16917; Groom LA, 1996, EMBO J, V15, P3621, DOI 10.1002/j.1460-2075.1996.tb00731.x; GUAN KL, 1995, J BIOL CHEM, V270, P7197, DOI 10.1074/jbc.270.13.7197; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ISHIBASHI T, 1994, J BIOL CHEM, V269, P29897; ISHIBASHI T, 1992, P NATL ACAD SCI USA, V89, P12170, DOI 10.1073/pnas.89.24.12170; Johnson NL, 1996, J BIOL CHEM, V271, P3229, DOI 10.1074/jbc.271.6.3229; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; King AG, 1995, ONCOGENE, V11, P2553; KWAK SP, 1994, J BIOL CHEM, V269, P3596; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Laderoute KR, 1999, J BIOL CHEM, V274, P12890, DOI 10.1074/jbc.274.18.12890; Leav I, 1996, LAB INVEST, V75, P361; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Loda M, 1996, AM J PATHOL, V149, P1553; Magi-Galluzzi C, 1998, VIRCHOWS ARCH, V432, P407, DOI 10.1007/s004280050184; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MARTELL KJ, 1995, J NEUROCHEM, V65, P1823; MELLO JA, 1995, BIOCHEMISTRY-US, V34, P14783, DOI 10.1021/bi00045a020; MISRAPRESS A, 1995, J BIOL CHEM, V270, P14587, DOI 10.1074/jbc.270.24.14587; Muda M, 1996, J BIOL CHEM, V271, P27205, DOI 10.1074/jbc.271.44.27205; Muda M, 1997, J BIOL CHEM, V272, P5141, DOI 10.1074/jbc.272.8.5141; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; NOGUCHI T, 1993, MOL CELL BIOL, V13, P5195, DOI 10.1128/MCB.13.9.5195; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PINTO AL, 1985, P NATL ACAD SCI USA, V82, P4616, DOI 10.1073/pnas.82.14.4616; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROHAN PJ, 1993, SCIENCE, V259, P1763, DOI 10.1126/science.7681221; Sanchez-Perez I, 1999, FEBS LETT, V453, P151, DOI 10.1016/S0014-5793(99)00690-0; Sanchez-Perez I, 1998, ONCOGENE, V16, P533, DOI 10.1038/sj.onc.1201578; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Srikanth S, 1999, MOL CELL BIOCHEM, V199, P169, DOI 10.1023/A:1006980326855; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tanoue T, 1999, J BIOL CHEM, V274, P19949, DOI 10.1074/jbc.274.28.19949; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Theodosiou AM, 1996, HUM MOL GENET, V5, P675, DOI 10.1093/hmg/5.5.675; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	57	120	126	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5142	5152		10.1038/sj.onc.1203887	http://dx.doi.org/10.1038/sj.onc.1203887			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064451				2022-12-25	WOS:000090124100003
J	Bhatnagar, A; Willins, DL; Gray, JA; Woods, J; Benovic, JL; Roth, BL				Bhatnagar, A; Willins, DL; Gray, JA; Woods, J; Benovic, JL; Roth, BL			The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED DOWN-REGULATION; BETA(2)-ADRENERGIC RECEPTOR; BETA-ARRESTIN; IN-VITRO; MEDIATED ENDOCYTOSIS; ANTIPSYCHOTIC-DRUGS; PYRAMIDAL CELLS; COATED VESICLES; AGONIST; BINDING	5-Hydroxytryptamine 2A (5-HT2A) receptors, a major site of action of clozapine and other atypical antipsychotic medications, are, paradoxically, internalized in vitro and in vivo by antagonists and agonists, The mechanisms responsible for this paradoxical regulation of 5-HT2A receptors are unknown. In this study, the arrestin and dynamin dependences of agonist- and antagonist-mediated internalization were investigated in live cells using green fluorescent protein (GFP)-tagged 5-HT2A receptors (SR2-GFP). Preliminary experiments indicated that GFP tagging of 5-HT2A receptors had no effect on either the binding affinities of several ligands or agonist efficacy. Likewise, both the native receptor and SR2-GFP were Internalized via endosomes in vitro, Experiments with a dynamin dominant-negative mutant (dynamin K44A) demonstrated that both agonist- and antagonist-induced internalization were dynamin-dependent. By contrast, both the agonist- and antagonist-induced internalization of SR2-GFP were insensitive to three different arrestin (Arr) dominant-negative mutants (Arr-2 V53D, Arr-2-(319-418), and Arr-3-(284-409)), Interestingly, 5-HT2A receptor activation by agonists, but not antagonists, induced greater Arr-3 than Arr-2 translocation to the plasma membrane. Importantly, the agonist-induced internalization of 5-HT2A receptors was accompanied by differential sorting of Arr-2, Arr-3, and 5-HT2A receptors into distinct plasma membrane and intracellular compartments. The agonist-induced redistribution of Arr-2 and Arr-3 into intracellular vesicles and plasma membrane compartments distinct from those involved in 5-HT2A receptor internalization implies novel roles for Arr-2 and Arr-3 independent of 5-HT2A receptor internalization and desensitization.	Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Psychiat, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Neurosci, Cleveland, OH 44106 USA; Thomas Jefferson Univ, Sch Med, Kimmel Canc Ctr, Philadelphia, PA 19107 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Jefferson University	Roth, BL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Biochem, Rm W438,10900 Euclid Ave, Cleveland, OH 44106 USA.	roth@biocserver.cwru.edu	Roth, Bryan/ABE-7032-2020; Roth, Bryan L/F-3928-2010; Gray, John Alan/Y-5730-2019	Roth, Bryan/0000-0002-0561-6520; Gray, John/0000-0002-7287-0748	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH057635, K02MH001366, R01MH061887] Funding Source: NIH RePORTER; NIMH NIH HHS [KO2MH01366, R01MH57635, R01MH61887] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Aghajanian GK, 1997, NEUROPHARMACOLOGY, V36, P589, DOI 10.1016/S0028-3908(97)00051-8; Barak LS, 1999, J BIOL CHEM, V274, P7565, DOI 10.1074/jbc.274.11.7565; BENNETT DB, 1985, J NEUROSCI, V5, P3010; Berry SA, 1996, MOL PHARMACOL, V50, P306; Chu P, 1997, J BIOL CHEM, V272, P27124, DOI 10.1074/jbc.272.43.27124; CHUANG DM, 1986, J NEUROSCI, V6, P2578; Egan CT, 1998, J PHARMACOL EXP THER, V286, P85; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Gagnon AW, 1998, J BIOL CHEM, V273, P6976, DOI 10.1074/jbc.273.12.6976; Gelber EI, 1999, J NEUROCHEM, V72, P2206, DOI 10.1046/j.1471-4159.1999.0722206.x; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1997, J BIOL CHEM, V272, P15011, DOI 10.1074/jbc.272.23.15011; Laporte SA, 2000, J BIOL CHEM, V275, P23120, DOI 10.1074/jbc.M002581200; MELTZER HY, 1989, J PHARMACOL EXP THER, V251, P238; Newton RA, 1997, J NEUROCHEM, V69, P1031; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; PEROUTKA SJ, 1980, SCIENCE, V210, P88, DOI 10.1126/science.6251550; ROTH BL, 1991, EUR J PHARM-MOLEC PH, V207, P169, DOI 10.1016/0922-4106(91)90093-W; Roth BL, 1998, CRIT REV NEUROBIOL, V12, P319, DOI 10.1615/CritRevNeurobiol.v12.i4.30; ROTH BL, 1981, J BIOL CHEM, V256, P117; Roth BL, 1998, DRUG ALCOHOL DEPEN, V51, P73, DOI 10.1016/S0376-8716(98)00067-2; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; Willins DL, 1998, ANN NY ACAD SCI, V861, P121, DOI 10.1111/j.1749-6632.1998.tb10182.x; Willins DL, 1999, NEUROSCIENCE, V91, P599, DOI 10.1016/S0306-4522(98)00653-8; Willins DL, 1997, SYNAPSE, V27, P79, DOI 10.1002/(SICI)1098-2396(199709)27:1<79::AID-SYN8>3.0.CO;2-A; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	29	126	129	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8269	8277		10.1074/jbc.M006968200	http://dx.doi.org/10.1074/jbc.M006968200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11069907	Green Published, hybrid			2022-12-25	WOS:000167474900083
J	Velours, J; Vaillier, J; Paumard, P; Soubannier, V; Lai-Zhang, J; Mueller, DM				Velours, J; Vaillier, J; Paumard, P; Soubannier, V; Lai-Zhang, J; Mueller, DM			Bovine coupling factor 6, with just 14.5% shared identity, replaces subunit h in the yeast ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEART-MITOCHONDRIA; SACCHAROMYCES-CEREVISIAE; SUBMITOCHONDRIAL PARTICLES; OXIDATIVE-PHOSPHORYLATION; COMPLEX; F1-ATPASE; ROTATION; F-0; STALK; PURIFICATION	The mammalian mitochondrial ATP synthase is composed of at least 16 polypeptides. With the exception of coupling factor F-6, there are likely yeast homologs for each of these polypeptides. There are no obvious yeast homologs of F-6, as predicted from primary sequence comparison of the putative peptides encoded by the open reading frames in the yeast genome. In this manuscript, we demonstrate that expression of bovine F-6 complements a null mutant in ATP14 gene in yeast Saccharomyces cerevisiae. Subunit h of the yeast ATP synthase is encoded by ATP14 and is just 14.5% identical to bovine F-6. Expression of bovine F-6 in an atp14 null mutant strain recovers oxidative phosphorylation, and the ATP synthase is active, although functioning with a lower efficiency than the wild type enzyme. Like subunit h, bovine F-6 is shown to interact mainly with subunit 4 (subunit b), a component of the second stalk of the enzyme. These data indicated the subunit h is the yeast homolog of mammalian coupling factor F-6.	Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Finch Univ Hlth Sci Chicago Med Sch, Dept Biochem & Mol Biol, N Chicago, IL 60064 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Chicago Medical School	Velours, J (corresponding author), Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, 1 rue Camille St Saens, F-33077 Bordeaux, France.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044412] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44412] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; BELOGRUDOV GI, 1995, J BIOL CHEM, V270, P2053, DOI 10.1074/jbc.270.5.2053; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Collinson IR, 1996, BIOCHEMISTRY-US, V35, P12640, DOI 10.1021/bi960969t; COLLINSON IR, 1994, J MOL BIOL, V242, P408; COLLINSON IR, 1994, BIOCHEMISTRY-US, V33, P7971, DOI 10.1021/bi00191a026; DECHATEAUBODEAU GA, 1976, BIOCHIMIE PARIS, V58, P601; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; FESSENDENRADEN JM, 1972, J BIOL CHEM, V247, P2351; Guerin B, 1979, Methods Enzymol, V55, P149; JOSHI S, 1990, J BIOL CHEM, V265, P14518; JOSHI S, 1989, J BIOL CHEM, V264, P15548; Ko YH, 2000, J BIOL CHEM, V275, P32931, DOI 10.1074/jbc.M004453200; Lai-Zhang J, 2000, EUR J BIOCHEM, V267, P2409, DOI 10.1046/j.1432-1327.2000.01253.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PAUL MF, 1992, EUR J BIOCHEM, V205, P163, DOI 10.1111/j.1432-1033.1992.tb16764.x; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; PRESCOTT M, 1995, BIOCHEM BIOPH RES CO, V207, P943, DOI 10.1006/bbrc.1995.1276; RIGOULET M, 1979, FEBS LETT, V102, P18, DOI 10.1016/0014-5793(79)80919-9; RISLER JL, 1988, J MOL BIOL, V204, P1019, DOI 10.1016/0022-2836(88)90058-7; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SANDRI G, 1985, ARCH BIOCHEM BIOPHYS, V239, P595, DOI 10.1016/0003-9861(85)90729-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SIKORSKI RS, 1989, GENETICS, V122, P19; SOMLO M, 1968, EUR J BIOCHEM, V5, P276, DOI 10.1111/j.1432-1033.1968.tb00368.x; Soubannier V, 1999, BIOCHEMISTRY-US, V38, P15017, DOI 10.1021/bi9916067; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Velours J, 2000, BBA-BIOENERGETICS, V1458, P443, DOI 10.1016/S0005-2728(00)00093-1; WALKER JE, 1985, J MOL BIOL, V184, P677, DOI 10.1016/0022-2836(85)90313-4; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	36	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8602	8607		10.1074/jbc.M008123200	http://dx.doi.org/10.1074/jbc.M008123200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11083870	hybrid			2022-12-25	WOS:000167474900124
J	Koljak, R; Jarving, I; Kurg, R; Boeglin, WE; Varvas, K; Valmsen, K; Ustav, M; Brash, AR; Samel, N				Koljak, R; Jarving, I; Kurg, R; Boeglin, WE; Varvas, K; Valmsen, K; Ustav, M; Brash, AR; Samel, N			The basis of prostaglandin synthesis in coral - Molecular cloning and expression of a cyclooxygenase from the Arctic soft coral Gersemia fruticosa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE H SYNTHASES-1; CRYSTAL-STRUCTURE; ARACHIDONIC-ACID; STRUCTURAL BASIS; RNA ISOLATION; BIOSYNTHESIS; PATHWAY; IDENTIFICATION; INHIBITION; PROTEINS	In vertebrates, the synthesis of prostaglandin hormones is catalyzed by cyclooxygenase (COX)-1, a constitutively expressed enzyme with physiological functions, and COX-2, induced in inflammation and cancer. Prostaglandins have been detected in high concentrations in certain corals, and previous evidence suggested their biosynthesis through a lipoxygenase-allene oxide pathway. Here we describe the discovery of an ancestor of cyclooxygenases that is responsible for prostaglandin biosynthesis in coral. Using a homology-based polymerase chain reaction cloning strategy, the cDNA encoding a polypeptide with similar to 50% amino acid identity to both mammalian COX-1 and COX-2 was cloned and sequenced from the Arctic soft coral Gersemia fruticosa, Nearly all the amino acids essential for substrate binding and catalysis as determined in the mammalian enzymes are represented in coral COX: the arachidonate-binding Arg(120) and Tyr(355) are present, as are the heme-coordinating His(207), and His(338); the catalytic Tyr(385); and the target of aspirin attack, Ser(530). A key amino acid that determines the sensitivity to selective COX-2 inhibitors (Ile(523) in COX-1 and Val(523) in COX-2) is present in coral COX as isoleucine. The conserved Glu(524), implicated in the binding of certain COX inhibitors, is represented as alanine, Expression of the G. fruticosa cDNA afforded a functional cyclooxygenase that converted exogenous arachidonic acid to prostaglandins. The biosynthesis was inhibited by indomethacin, whereas the selective COX-2 inhibitor nimesulide was ineffective. We conclude that the cyclooxygenase occurs widely in the animal kingdom and that vertebrate COX-1 and COX-2 are evolutionary derivatives of the invertebrate precursor.	Tallinn Univ Technol, Inst Chem, Dept Bioorgan Chem, EE-12618 Tallinn, Estonia; Estonian Bioctr, EE-51010 Tartu, Estonia; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA	Tallinn University of Technology; Estonian Biocentre; Vanderbilt University	Samel, N (corresponding author), Tallinn Univ Technol, Inst Chem, Dept Bioorgan Chem, Akad Tee 15, EE-12618 Tallinn, Estonia.	samel@chemnet.ee	Ustav, Mart/G-6484-2017; Samel, Nigulas/A-1420-2019; Kurg, Reet/J-2829-2015	Kurg, Reet/0000-0001-7188-9693; Valmsen, Karin/0000-0001-5303-6654	FIC NIH HHS [TW00404] Funding Source: Medline; NIGMS NIH HHS [GM53638] Funding Source: Medline	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bhattacharyya DK, 1996, J BIOL CHEM, V271, P2179, DOI 10.1074/jbc.271.4.2179; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BUNDY GL, 1986, ADV PROSTAG THROMB L, V14, P229; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COREY EJ, 1987, J AM CHEM SOC, V109, P289, DOI 10.1021/ja00235a053; COREY EJ, 1975, J CHEM SOC CHEM COMM, P277, DOI 10.1039/c39750000277; COREY EJ, 1973, J AM CHEM SOC, V95, P2054, DOI 10.1021/ja00787a079; Gerday C, 2000, TRENDS BIOTECHNOL, V18, P103, DOI 10.1016/S0167-7799(99)01413-4; GERWICK WH, 1999, COMPREHENSIVE NATURA, P207; Gierse JK, 1996, J BIOL CHEM, V271, P15810, DOI 10.1074/jbc.271.26.15810; Guo QP, 1996, J BIOL CHEM, V271, P19134, DOI 10.1074/jbc.271.32.19134; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Kaldalu N, 2000, BIOTECHNIQUES, V28, P456, DOI 10.2144/00283st02; Kiefer JR, 2000, NATURE, V405, P97, DOI 10.1038/35011103; Kim SY, 1999, J BIOL CHEM, V274, P11761, DOI 10.1074/jbc.274.17.11761; Koljak R, 1997, SCIENCE, V277, P1994, DOI 10.1126/science.277.5334.1994; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Kulmacz RJ, 1998, FEBS LETT, V430, P154, DOI 10.1016/S0014-5793(98)00657-7; Kurg R, 1999, J VIROL, V73, P4670, DOI 10.1128/JVI.73.6.4670-4677.1999; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y, 1998, J BIOL CHEM, V273, P29830, DOI 10.1074/jbc.273.45.29830; Luong C, 1996, NAT STRUCT BIOL, V3, P927, DOI 10.1038/nsb1196-927; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; MORITA I, 1995, J BIOL CHEM, V270, P10902, DOI 10.1074/jbc.270.18.10902; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OTTO JC, 1993, J BIOL CHEM, V268, P18234; OTTO JC, 1995, J LIPID MEDIAT CELL, V12, P139, DOI 10.1016/0929-7855(95)00015-I; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; REN Y, 1995, ARCH BIOCHEM BIOPHYS, V316, P751, DOI 10.1006/abbi.1995.1100; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; Song I, 1996, ARCH BIOCHEM BIOPHYS, V334, P67, DOI 10.1006/abbi.1996.0430; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; SU X, 1988, ANAL BIOCHEM, V174, P650, DOI 10.1016/0003-2697(88)90068-1; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Trifan OC, 1999, J BIOL CHEM, V274, P34141, DOI 10.1074/jbc.274.48.34141; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; VARVAS K, 1994, TETRAHEDRON LETT, V35, P8267, DOI 10.1016/0040-4039(94)88299-1; VARVAS K, 1993, TETRAHEDRON LETT, V34, P3643, DOI 10.1016/S0040-4039(00)73658-6; Varvas K, 1999, J BIOL CHEM, V274, P9923, DOI 10.1074/jbc.274.15.9923; Zou J, 1999, BIOCHEM J, V340, P153, DOI 10.1042/bj3400153	44	49	49	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7033	7040		10.1074/jbc.M009803200	http://dx.doi.org/10.1074/jbc.M009803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11085996	hybrid			2022-12-25	WOS:000167442900026
J	Eyries, M; Michaud, A; Deinum, J; Agrapart, M; Chomilier, J; Kramers, C; Soubrier, F				Eyries, M; Michaud, A; Deinum, J; Agrapart, M; Chomilier, J; Kramers, C; Soubrier, F			Increased shedding of angiotensin-converting enzyme by a mutation identified in the stalk region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC CLUSTER-ANALYSIS; PLASMA ACE LEVELS; CLEAVAGE-SECRETION; CELL-SURFACE; PROTEOLYTIC RELEASE; LINKAGE ANALYSIS; MEMBRANE; PROTEIN; GENE; POLYMORPHISM	Angiotensin-converting enzyme (ACE), an enzyme that plays a major role in vasoactive peptide metabolism, is a type 1 ectoprotein, which is released from the plasma membrane by a proteolytic cleavage occurring in the stalk sequence adjacent to the membrane anchor. In this study, we have discovered the molecular mechanism underlying the marked increase of plasma ACE levels observed in three unrelated individuals. We have identified a Pro(1199) -> Leu mutation in the juxtamembrane stalk region. In vitro analysis revealed that the shedding of [Leu(1199)]ACE was enhanced compared with wild-type ACE. The solubilization process of [Leu(1199)]ACE was stimulated by phorbol esters and inhibited by compound 3, an inhibitor of ACE-secretase. The results of Western blot analysis were consistent with a cleavage at the major described site (Arg(1203) down arrow Ser(1204)). Two-dimensional structural analysis of ACE showed that the mutated residue was critical for the positioning of a specific loop containing the cleavage site. We therefore propose that a local conformational modification caused by the Pro(1199) -> Leu mutation leads to more accessibility at the stalk region for ACE secretase and is responsible for the enhancement of the cleavage-secretion process. Our results show that different molecular mechanisms are responsible for the common genetic variation of plasma ACE and for its more rare familial elevation.	Fac Med Pitie Salpetriere, INSERM, U525, F-75013 Paris, France; Coll France, Unit 36, F-75005 Paris, France; Univ Rotterdam, Dept Internal Med 1, NL-3015 GD Rotterdam, Netherlands; Univ Paris 06, CNRS, UMR 7590, F-75252 Paris 05, France; Univ Paris 07, CNRS, UMR 7590, F-75252 Paris 05, France; Univ Nijmegen, Med Ctr, Dept Pharmacol & Toxicol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; College de France; Erasmus University Rotterdam; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Radboud University Nijmegen; Radboud University Nijmegen	Soubrier, F (corresponding author), Fac Med Pitie Salpetriere, INSERM, U525, 91 Blvd Hop, F-75013 Paris, France.		Kramers, C./L-4458-2015; Deinum, J./L-4261-2015	Deinum, J./0000-0003-2465-1986; CHOMILIER, Jacques/0000-0002-4250-0762				ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Arribas J, 1997, J BIOL CHEM, V272, P17160, DOI 10.1074/jbc.272.27.17160; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; BELDENT V, 1995, J BIOL CHEM, V270, P28962, DOI 10.1074/jbc.270.48.28962; BELDENT V, 1993, J BIOL CHEM, V268, P26428; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; CORVOL P, 1995, METHOD ENZYMOL, V248, P283; COSTEROUSSE O, 1993, BIOCHEM J, V290, P33, DOI 10.1042/bj2900033; DANSER AHJ, 1995, CIRCULATION, V92, P1387, DOI 10.1161/01.CIR.92.6.1387; Ehlers MRW, 1996, BIOCHEMISTRY-US, V35, P9549, DOI 10.1021/bi9602425; ELDORRY HA, 1982, J BIOL CHEM, V257, P4128; ERDOS EG, 1987, LAB INVEST, V56, P345; HOOPER NM, 1987, BIOCHEM J, V247, P85, DOI 10.1042/bj2470085; HOOPER NM, 1991, INT J BIOCHEM, V23, P641, DOI 10.1016/0020-711X(91)90032-I; HUBERT C, 1991, J BIOL CHEM, V266, P15377; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; LUISETTI M, 1990, EUR RESPIR J, P441; OKABE T, 1985, Q J MED, V55, P55; RAMCHANDRAN R, 1995, BIOCHEMISTRY-US, V34, P12645, DOI 10.1021/bi00039a021; RAMCHANDRAN R, 1994, J BIOL CHEM, V269, P2125; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; Santhamma KR, 2000, J BIOL CHEM, V275, P23253, DOI 10.1074/jbc.M000593200; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TIRET L, 1992, AM J HUM GENET, V51, P197; Villard E, 1996, AM J HUM GENET, V58, P1268; WEI L, 1991, J BIOL CHEM, V266, P9002; WEI L, 1991, J BIOL CHEM, V266, P5540; WOODCOCK S, 1992, PROTEIN ENG, V5, P629, DOI 10.1093/protein/5.7.629; Woodman ZL, 2000, BIOCHEM J, V347, P711, DOI 10.1042/0264-6021:3470711	31	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5525	5532		10.1074/jbc.M007706200	http://dx.doi.org/10.1074/jbc.M007706200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11076943	Green Published, hybrid			2022-12-25	WOS:000167115100018
J	Holden, P; Meadows, RS; Chapman, KL; Grant, ME; Kadler, KE; Briggs, MD				Holden, P; Meadows, RS; Chapman, KL; Grant, ME; Kadler, KE; Briggs, MD			Cartilage oligomeric matrix protein interacts with type IX collagen, and disruptions to these interactions identify a pathogenetic mechanism in a bone dysplasia family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE EPIPHYSEAL DYSPLASIA; ARTICULAR-CARTILAGE; PSEUDOACHONDROPLASIA; COMP; MUTATIONS; GENE; IDENTIFICATION; CHAIN; EXTRACTION; FORMS	Cartilage oligomeric matrix protein (COMP) and type IX collagen are key structural components of the cartilage extracellular matrix and have important roles in tissue development and homeostasis. Mutations in the genes encoding these glycoproteins result in two related human bone dysplasias, pseudoachondroplasia and multiple epiphyseal. dysplasia, which together comprise a "bone dysplasia family." It has been proposed that these diseases have a similar pathophysiology, which is highlighted by the fact that mutations in either the COMP or the type IX collagen genes produce multiple epiphyseal dysplasia, suggesting that their gene products interact. To investigate the interactions between COMP and type IX collagen, we have used rotary shadowing electron microscopy and real time biomolecular (BIAcore) analysis. Analysis of COMP-type IX collagen complexes demonstrated that COMP interacts with type IX collagen through the noncollagenous domains of type IX collagen and the C-terminal domain of COMP. Furthermore, peptide mapping identified a putative collagen-binding site that is associated with known human mutations. These data provide evidence that disruptions to COMP-type IX collagen interactions define a pathogenetic mechanism in a bone dysplasia family.	Univ Manchester, Sch Biol Sci, Wellcome Trust, Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Briggs, MD (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust, Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		KADLER, KARL/ABI-2403-2020	KADLER, KARL/0000-0003-4977-4683				BEIGHTON P, 1993, MCKUSICHS HERITABLE, P557; BISHOP P, 1992, BIOCHEM BIOPH RES CO, V185, P392, DOI 10.1016/S0006-291X(05)80998-2; BISHOP PN, 1994, BIOCHEM J, V299, P497, DOI 10.1042/bj2990497; Bonnemann CG, 2000, P NATL ACAD SCI USA, V97, P1212, DOI 10.1073/pnas.97.3.1212; Briggs MD, 1998, AM J HUM GENET, V62, P311, DOI 10.1086/301713; BRIGGS MD, 1995, NAT GENET, V10, P330, DOI 10.1038/ng0795-330; BRUCKNER P, 1988, J BIOL CHEM, V263, P16911; Deere M, 1999, AM J MED GENET, V85, P486, DOI 10.1002/(SICI)1096-8628(19990827)85:5<486::AID-AJMG10>3.0.CO;2-O; Deere M, 1998, AM J MED GENET, V80, P510, DOI 10.1002/(SICI)1096-8628(19981228)80:5<510::AID-AJMG14>3.0.CO;2-F; Delot E, 1998, J BIOL CHEM, V273, P26692, DOI 10.1074/jbc.273.41.26692; DICESARE P, 1994, FEBS LETT, V354, P237, DOI 10.1016/0014-5793(94)01134-6; DICESARE PE, 1994, EUR J BIOCHEM, V223, P927, DOI 10.1111/j.1432-1033.1994.tb19070.x; Douglas SP, 1998, GLYCOBIOLOGY, V8, P1013, DOI 10.1093/glycob/8.10.1013; Douglas SP, 1998, MATRIX BIOL, V16, P497, DOI 10.1016/S0945-053X(98)90020-8; Dreyer SD, 1998, CLIN GENET, V54, P464; Hecht JT, 1998, MATRIX BIOL, V17, P269, DOI 10.1016/S0945-053X(98)90080-4; Hecht JT, 1998, MATRIX BIOL, V17, P625, DOI 10.1016/S0945-053X(98)90113-5; HECHT JT, 1995, NAT GENET, V10, P325, DOI 10.1038/ng0795-325; HEDBOM E, 1992, J BIOL CHEM, V267, P6132; Holden P, 1999, AM J HUM GENET, V65, P31, DOI 10.1086/302440; Maddox BK, 1997, J BIOL CHEM, V272, P30993, DOI 10.1074/jbc.272.49.30993; Maddox BK, 2000, J BIOL CHEM, V275, P11412, DOI 10.1074/jbc.275.15.11412; MAROTEAUX P, 1980, EUR J PEDIATR, V133, P227, DOI 10.1007/BF00496081; MOULD AP, 1985, J ULTRA MOL STRUCT R, V91, P66, DOI 10.1016/0889-1605(85)90077-1; Mundlos S, 1997, FASEB J, V11, P227, DOI 10.1096/fasebj.11.4.9068611; Muragaki Y, 1996, NAT GENET, V12, P103, DOI 10.1038/ng0196-103; NEWTON G, 1994, GENOMICS, V24, P435, DOI 10.1006/geno.1994.1649; OLDBERG A, 1992, J BIOL CHEM, V267, P22346; Olsen BR, 1997, INT J BIOCHEM CELL B, V29, P555, DOI 10.1016/S1357-2725(96)00100-8; Paassilta P, 1999, AM J HUM GENET, V64, P1036, DOI 10.1086/302328; REESE CA, 1982, BIOCHEMISTRY-US, V21, P826, DOI 10.1021/bi00534a002; Rimoin DL, 1998, AM J MED GENET, V79, P376; RIMOIN DL, 1994, HUM GENET, V93, P236, DOI 10.1007/BF00212015; RIMOIN DL, 1997, EMERY RIMOINS PRINCI, V2, P2779; Rosenberg K, 1998, J BIOL CHEM, V273, P20397, DOI 10.1074/jbc.273.32.20397; SMITH GN, 1992, J RHEUMATOL, V19, P14; SPRANGER J, 1988, PATHOL IMMUNOPATH R, V7, P76, DOI 10.1159/000157098; van Mourik JBA, 1998, ULTRASTRUCT PATHOL, V22, P249, DOI 10.3109/01913129809033476	38	160	170	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					6046	6055		10.1074/jbc.M009507200	http://dx.doi.org/10.1074/jbc.M009507200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11087755	hybrid			2022-12-25	WOS:000167115100085
J	Kneidinger, B; Graninger, M; Adam, G; Puchberger, M; Kosma, P; Zayni, S; Messner, P				Kneidinger, B; Graninger, M; Adam, G; Puchberger, M; Kosma, P; Zayni, S; Messner, P			Identification of two GDP-6-deoxy-D-lyxo-4-hexulose reductases synthesizing GDP-D-rhamnose in Aneurinibacillus thermoaerophilus L420-91(T)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE 4-EPIMERASE; ESCHERICHIA-COLI; MANNOSE 4,6-DEHYDRATASE; L-FUCOSE; NOVO SYNTHESIS; MUR1 GENE; LIPOPOLYSACCHARIDE; POLYSACCHARIDE; BIOSYNTHESIS; CONVERSION	The glycan repeats of the surface layer glycoprotein of Aneurinibacillus thermoaerophilus L420-91(T) contain D-rhamnose and 3-acetamido-3,6-dideoxy-D-galactose, both of which are also constituents of lipopolysaccharides of Gram-negative plant and human pathogenic bacteria. The two genes required for biosynthesis of the nucleotide-activated precursor GDP-D-rhamnose, gmd and rmd, were cloned, sequenced, and overexpressed in Escherichia coli. The corresponding enzymes Gmd and Rmd were purified to homogeneity, and functional studies were performed. GDP-D-mannose dehydratase (Gmd) converted GDP-D-mannose to GDP-6-deoxy-D-lyxo-4-hexulose, with NADP(+) as cofactor. The reductase Rmd catalyzed the second step in the pathway, namely the reduction of the keto-intermediate to the final product GDP-D-rhamnose using both NADH and NADPH as hydride donor. The elution behavior of the intermediate and end product was analyzed by high performance liquid chromatography. Nuclear magnetic resonance spectroscopy was used to identify the structure of the final product of the reaction sequence as GDP-cr-D-rhamnose. This is the first characterization of a GDP-6-deoxy-D-lyxo-4-hexulose reductase. In addition, Gmd has been shown to be a bifunctional enzyme with both dehydratase and reductase activities. So far, no enzyme catalyzing these two types of reactions has been identified. Both Gmd and Rmd are members of the SDR (short chain dehydrogenase/reductase) protein family.	Univ Bodenkultur Wien, Zentrum Ultrastrukturforsch, A-1180 Vienna, Austria; Univ Bodenkultur Wien, Ludwig Boltzmann Inst Mol Nanotechnol, A-1180 Vienna, Austria; Univ Bodenkultur Wien, Zentrum Angew Genet, A-1190 Vienna, Austria; Univ Bodenkultur Wien, Inst Chem, A-1190 Vienna, Austria	University of Natural Resources & Life Sciences, Vienna; Ludwig Boltzmann Institute; University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna; University of Natural Resources & Life Sciences, Vienna	Messner, P (corresponding author), Univ Bodenkultur Wien, Zentrum Ultrastrukturforsch, A-1180 Vienna, Austria.	pmessner@edv1.boku.ac.at	Kosma, Paul/Y-7443-2019; Messner, Paul/Q-5345-2017	Kosma, Paul/0000-0001-5342-7161; Adam, Gerhard/0000-0002-3008-3797; Messner, Paul/0000-0002-3246-5801				Albermann C, 2000, GLYCOBIOLOGY, V10, P875, DOI 10.1093/glycob/10.9.875; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BAKER ME, 1992, FEBS LETT, V301, P89, DOI 10.1016/0014-5793(92)80216-4; Bisso A, 1999, FEBS LETT, V456, P370, DOI 10.1016/S0014-5793(99)00982-5; Bonin CP, 2000, PLANT J, V21, P445, DOI 10.1046/j.1365-313x.2000.00698.x; Bonin CP, 1997, P NATL ACAD SCI USA, V94, P2085, DOI 10.1073/pnas.94.5.2085; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROSCHAT KO, 1985, EUR J BIOCHEM, V153, P1693; BULET P, 1984, EUR J BIOCHEM, V144, P255, DOI 10.1111/j.1432-1033.1984.tb08458.x; Cerantola S, 1997, EUR J BIOCHEM, V246, P360, DOI 10.1111/j.1432-1033.1997.00360.x; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Deacon AM, 2000, STRUCT FOLD DES, V8, P453, DOI 10.1016/S0969-2126(00)00128-3; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Graninger M, 1999, J BIOL CHEM, V274, P25069, DOI 10.1074/jbc.274.35.25069; Heyndrickx M, 1997, INT J SYST BACTERIOL, V47, P808, DOI 10.1099/00207713-47-3-808; HICKMAN J, 1966, J BIOL CHEM, V241, P1424; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; Jornvall H, 1999, FEBS LETT, V445, P261, DOI 10.1016/S0014-5793(99)00130-1; KNEIDINGER B, 2001, IN PRESS BIOTECHNIQU; Kocharova NA, 2000, BIOCHEMISTRY-US, V39, P4755, DOI 10.1021/bi992635k; KOSMA P, 1995, GLYCOCONJUGATE J, V12, P99, DOI 10.1007/BF00731875; LABESSE G, 1994, BIOCHEM J, V304, P95, DOI 10.1042/bj3040095; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MARKOVITZ A, 1964, J BIOL CHEM, V239, P2091; MeierStauffer K, 1996, INT J SYST BACTERIOL, V46, P532, DOI 10.1099/00207713-46-2-532; Menon S, 1999, J BIOL CHEM, V274, P26743, DOI 10.1074/jbc.274.38.26743; Messner P, 2000, GLYCOMICROBIOLOGY, P93; PALMIERI MJ, 1991, ANAL BIOCHEM, V194, P388, DOI 10.1016/0003-2697(91)90246-P; REEVES PR, 1994, COMPR BIOCHEM, V27, P271; Rizzi M, 1998, STRUCTURE, V6, P1453, DOI 10.1016/S0969-2126(98)00144-0; Rocchetta HL, 1998, MOL MICROBIOL, V29, P1419, DOI 10.1046/j.1365-2958.1998.01024.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sara M, 2000, J BACTERIOL, V182, P859, DOI 10.1128/JB.182.4.859-868.2000; Schaffer C, 1996, MICROB DRUG RESIST, V2, P17, DOI 10.1089/mdr.1996.2.17; Senchenkova SN, 1996, EUR J BIOCHEM, V239, P434, DOI 10.1111/j.1432-1033.1996.0434u.x; Sleytr UB, 1999, TRENDS MICROBIOL, V7, P253, DOI 10.1016/S0966-842X(99)01513-9; SMITH ARW, 1985, EUR J BIOCHEM, V149, P73, DOI 10.1111/j.1432-1033.1985.tb08895.x; Somers WS, 1998, STRUCTURE, V6, P1601, DOI 10.1016/S0969-2126(98)00157-9; Somoza JR, 2000, STRUCTURE, V8, P123, DOI 10.1016/S0969-2126(00)00088-5; Stern RJ, 1999, MICROBIOL-UK, V145, P663, DOI 10.1099/13500872-145-3-663; Sturla L, 1997, FEBS LETT, V412, P126, DOI 10.1016/S0014-5793(97)00762-X; Sullivan FX, 1998, J BIOL CHEM, V273, P8193, DOI 10.1074/jbc.273.14.8193; SUMPER M, 1995, GLYCOPROTEINS, P455; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P10685, DOI 10.1021/bi9704313; Thoden JB, 2000, BIOCHEMISTRY-US, V39, P5691, DOI 10.1021/bi000215l; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012; YAMAMOTO K, 1993, ARCH BIOCHEM BIOPHYS, V300, P694, DOI 10.1006/abbi.1993.1096; YOKOTA S, 1987, EUR J BIOCHEM, V167, P203, DOI 10.1111/j.1432-1033.1987.tb13324.x	51	58	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5577	5583		10.1074/jbc.M010027200	http://dx.doi.org/10.1074/jbc.M010027200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11096116	hybrid			2022-12-25	WOS:000167115100025
J	Coppolino, MG; Kong, C; Mohtashami, M; Schreiber, AD; Brumell, JH; Finlay, BB; Grinstein, S; Trimble, WS				Coppolino, MG; Kong, C; Mohtashami, M; Schreiber, AD; Brumell, JH; Finlay, BB; Grinstein, S; Trimble, WS			Requirement for N-ethylmaleimide-sensitive factor activity at different stages of bacterial invasion and phagocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED PHAGOCYTOSIS; FUSION PROTEIN; PHOSPHOINOSITIDE 3-KINASE; SALMONELLA-TYPHIMURIUM; EPITHELIAL-CELLS; MEMBRANE-FUSION; PLASMA-MEMBRANE; MACROPHAGES; VESICLES; COMPARTMENTS	Bacterial invasion, like the process of phagocytosis, involves extensive and localized protrusion of the host cell plasma membrane. To examine the molecular mechanisms of the membrane remodeling that accompanies bacterial invasion, soluble NSF attachment protein receptor (SNARE)-mediated membrane traffic was studied in cultured cells during infection by Salmonella typhimurium. A green fluorescent protein-tagged chimera of VAMP3, a SNARE characteristic of recycling endosomes, was found to accumulate at sites of Salmonella invasion. To analyze the possible role of SNARE-mediated membrane traffic in bacterial infection, invasion was measured in cells expressing a dominant-negative form of N-ethylmaleimide-sensitive factor (NSF), an essential regulator of membrane fusion. Inhibition of NSF activity did not affect cellular invasion by S. typhimurium nor the associated membrane remodeling. By contrast, Fc gamma receptor-mediated phagocytosis was greatly reduced in the presence of the mutant NSF. Most important, dominant-negative NSF significantly impaired the fusion of Salmonella-containing vacuoles with endomembranes. These observations indicate that the membrane protrusions elicited by Salmonella invasion, unlike those involved in phagocytosis, occur via an NSF-independent mechanism, whereas maturation of Salmonella-containing vacuoles is NSF-dependent.	Hosp Sick Children, Cell Biol Programme, Res Inst, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA; Biotechnol Lab, Philadelphia, PA 19104 USA; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Pennsylvania; University of British Columbia	Trimble, WS (corresponding author), Hosp Sick Children, Cell Biol Programme, Res Inst, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.							Allen LAH, 1996, CURR OPIN IMMUNOL, V8, P36, DOI 10.1016/S0952-7915(96)80102-6; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; BROWN EJ, 1995, BIOESSAYS, V17, P109, DOI 10.1002/bies.950170206; Brumell JH, 1999, CURR BIOL, V9, pR277, DOI 10.1016/S0960-9822(99)80178-X; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Collazo CM, 1997, GENE, V192, P51, DOI 10.1016/S0378-1119(96)00825-6; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; Downey GP, 1999, J BIOL CHEM, V274, P28436, DOI 10.1074/jbc.274.40.28436; FRANCIS CL, 1992, MOL MICROBIOL, V6, P3077, DOI 10.1111/j.1365-2958.1992.tb01765.x; FURUKAWA R, 1994, CELL MOTIL CYTOSKEL, V29, P46, DOI 10.1002/cm.970290105; GARCIADELPORTILLO F, 1995, J CELL BIOL, V129, P81, DOI 10.1083/jcb.129.1.81; GARCIADELPORTILLO F, 1995, TRENDS MICROBIOL, V3, P373, DOI 10.1016/S0966-842X(00)88982-9; GREENBERG S, 1990, J EXP MED, V172, P1853, DOI 10.1084/jem.172.6.1853; Greenberg S, 1996, P NATL ACAD SCI USA, V93, P1103, DOI 10.1073/pnas.93.3.1103; GRIFFIN FM, 1976, J EXP MED, V144, P788, DOI 10.1084/jem.144.3.788; Hackam DJ, 1998, P NATL ACAD SCI USA, V95, P11691, DOI 10.1073/pnas.95.20.11691; Holevinsky KO, 1998, BIOPHYS J, V75, P2577, DOI 10.1016/S0006-3495(98)77703-3; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jones BD, 1996, ANNU REV IMMUNOL, V14, P533, DOI 10.1146/annurev.immunol.14.1.533; Lennartz MR, 1997, J CELL SCI, V110, P2041; Lowry MB, 1998, J BIOL CHEM, V273, P24513, DOI 10.1074/jbc.273.38.24513; MANIAK M, 1995, CELL, V83, P915, DOI 10.1016/0092-8674(95)90207-4; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; Mecsas J, 1998, MOL MICROBIOL, V28, P1269, DOI 10.1046/j.1365-2958.1998.00891.x; Meresse S, 1999, NAT CELL BIOL, V1, pE183, DOI 10.1038/15620; Mignaco JA, 1997, BBA-BIOENERGETICS, V1321, P252, DOI 10.1016/S0005-2728(97)00049-2; Mukherjee K, 2000, J CELL BIOL, V148, P741, DOI 10.1083/jcb.148.4.741; Randhawa VK, 2000, MOL BIOL CELL, V11, P2403, DOI 10.1091/mbc.11.7.2403; Roy L, 2000, MOL BIOL CELL, V11, P2529, DOI 10.1091/mbc.11.8.2529; Sinai AP, 1997, ANNU REV MICROBIOL, V51, P415, DOI 10.1146/annurev.micro.51.1.415; Suzaki E, 1997, CELL MOTIL CYTOSKEL, V38, P215; Teruel MN, 1999, J NEUROSCI METH, V93, P37, DOI 10.1016/S0165-0270(99)00112-0; Van Ooij C, 1998, INFECT IMMUN, V66, P5364, DOI 10.1128/IAI.66.11.5364-5371.1998; Ward DM, 1997, J CELL BIOL, V139, P665, DOI 10.1083/jcb.139.3.665; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945	38	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4772	4780		10.1074/jbc.M007792200	http://dx.doi.org/10.1074/jbc.M007792200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11092884	hybrid			2022-12-25	WOS:000168484300034
J	Kirsch, KH; Georgescu, MM; Shishido, T; Langdon, WY; Birge, RB; Hanafusa, H				Kirsch, KH; Georgescu, MM; Shishido, T; Langdon, WY; Birge, RB; Hanafusa, H			The adapter type protein CMS/CD2AP binds to the proto-oncogenic protein c-Cbl through a tyrosine phosphorylation-regulated Src homology 3 domain interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED NEGATIVE REGULATION; GROWTH-FACTOR RECEPTOR; CELL ANTIGEN RECEPTOR; EGF RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; IN-VIVO; PROTOONCOGENE PRODUCT; SH3 DOMAINS; T-CELLS	CMS/CD2AP is a cytoplasmic protein critical for the integrity of the kidney glomerular filtration and the T cell function. CMS contains domains and motifs characteristic for protein-protein interactions, and it is involved in the regulation of the actin cytoskeleton, We report here that the individual SH3 domains of CMS bind to phosphotyrosine proteins of similar to 80, 90, and 180 kDa in cell lysates stimulated with epidermal growth factor. The second SH3 domain of CMS bound specifically to a tyrosine-phosphorylated protein of 120 kDa, which we identified as the proto-oncoprotein c-Cbl. The c-Cbl-binding site for CMS mapped to the carboxyl terminus of c-Cbl and is different from the proline-rich region known to bind SH3-containing proteins. CMS binding to c-Cbl was markedly attenuated in a tyrosine phosphorylation-defective c-Cbl mutant indicating that this interaction is dependent on the tyrosine phosphorylation of CMS. It also implies that CMS interacts with c-Cbl in an inducible fashion upon stimulation of a variety of cell-surface receptors. Immunofluorescence analysis revealed that both proteins colocalize at lamellipodia and leading edges of cells, and we propose that the interaction of CMS with c-Cbl offers a mechanism by which c-Cbl associates and regulates the actin cytoskeleton.	Rockefeller Univ, Mol Oncol Lab, New York, NY 10021 USA; Rockefeller Univ, Lab Mol Genet & Immunol, New York, NY 10021 USA; Univ Western Australia, Dept Pathol, Nedlands, WA 6907, Australia; Osaka Biosci Inst, Suita, Osaka 5650874, Japan	Rockefeller University; Rockefeller University; University of Western Australia	Kirsch, KH (corresponding author), Rockefeller Univ, Mol Oncol Lab, Box 220, New York, NY 10021 USA.		Georgescu, Maria-Magdalena/AAJ-6359-2020	Kirsch, Kathrin/0000-0003-1532-1715	NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA09673, CA44356] Funding Source: Medline; NIGMS NIH HHS [GM55760] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Birge RB, 1996, GENES CELLS, V1, P595, DOI 10.1046/j.1365-2443.1996.00258.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Eisenbraun MD, 2000, J IMMUNOL, V164, P6105, DOI 10.4049/jimmunol.164.12.6105; Fukazawa T, 1996, J BIOL CHEM, V271, P14554, DOI 10.1074/jbc.271.24.14554; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Hime GR, 1997, ONCOGENE, V14, P2709, DOI 10.1038/sj.onc.1201223; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; KIM TJ, 1995, J BIOL CHEM, V270, P27504, DOI 10.1074/jbc.270.46.27504; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; Kirsch KH, 1998, J BIOL CHEM, V273, P25673, DOI 10.1074/jbc.273.40.25673; Langdon WY, 1995, AUST NZ J MED, V25, P859, DOI 10.1111/j.1445-5994.1995.tb02892.x; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Manie SN, 1997, EXP HEMATOL, V25, P45; Marengere LEM, 1997, J IMMUNOL, V159, P70; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Myung PS, 2000, CURR OPIN IMMUNOL, V12, P256, DOI 10.1016/S0952-7915(00)00085-6; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; Pawson T, 2000, GENE DEV, V14, P1027; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ribon V, 1998, MOL CELL BIOL, V18, P872, DOI 10.1128/MCB.18.2.872; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; Scaife RM, 2000, J CELL SCI, V113, P215; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Shishido T, 2000, P NATL ACAD SCI USA, V97, P6439, DOI 10.1073/pnas.060030697; Sparks AB, 1996, P NATL ACAD SCI USA, V93, P1540, DOI 10.1073/pnas.93.4.1540; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Tanaka S, 1996, NATURE, V383, P528, DOI 10.1038/383528a0; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	44	77	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4957	4963		10.1074/jbc.M005784200	http://dx.doi.org/10.1074/jbc.M005784200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11067845	hybrid			2022-12-25	WOS:000168484300059
J	Kudo, T; Takaya, N; Park, SY; Shiro, Y; Shoun, H				Kudo, T; Takaya, N; Park, SY; Shiro, Y; Shoun, H			A positively charged cluster formed in the heme-distal pocket of cytochrome P450nor is essential for interaction with NADH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE REDUCTASE; CRYSTAL-STRUCTURE; CYLINDROCARPON-TONKINENSE; AMINO-ACID; PROTEIN; FUNGUS; SEQUENCE; CDNA	Arg and Lys residues are concentrated on the distal side of cytochrome P450nor (P450nor) to form a positively charged cluster facing from the outside to the inside of the distal heme pocket. We constructed mutant proteins in which the Arg and Lys residues were replaced with Glu, Gin, or Ala. The results showed that this cluster plays crucial roles in NADH interaction. We also showed that some anions such as bromide (Br-) perturbed the heme environment along with the reduction step in P450nor-catalyzed reactions, which was similar to the effects caused by the mutations. We determined by x-ray crystallography that a Br-, termed an anion hole, occupies a key region neighboring heme, which is the terminus of the positively charged cluster and the terminus of the hydrogen bond network that acts as a proton delivery system, A comparison of the predicted mechanisms between the perturbations caused by Br- and the mutations suggested that Arg(174) and Arg(64) play a crucial role in binding NADH to the protein, These results indicated that the positively charged cluster is the unique structure of P450nor that responds to direct interaction with NADH.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; RIKEN, Harima Inst SPring 8, Sayo, Hyogo 6795148, Japan	University of Tsukuba; RIKEN	Shoun, H (corresponding author), Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan.	p450nor@sakura.cc.tsukuba.ac.jp	Shiro, Yoshitsugu Y/J-3757-2014	Shiro, Yoshitsugu Y/0000-0003-0695-8327				ADACHI S, 2001, IN PRESS NUCL INST A; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, XPLOR SYSTEM XRAY CR; CUPPVICKERY JR, 1995, NAT STRUCT BIOL, V2, P144, DOI 10.1038/nsb0295-144; GOTOH O, 1992, J BIOL CHEM, V267, P83; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KIZAWA H, 1991, J BIOL CHEM, V266, P10632; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kudo T, 1996, BIOCHIMIE, V78, P792, DOI 10.1016/S0300-9084(97)82538-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; Nakahara K, 1996, J BIOCHEM-TOKYO, V120, P1082, DOI 10.1093/oxfordjournals.jbchem.a021525; Obayashi E, 1998, J AM CHEM SOC, V120, P12964, DOI 10.1021/ja9813764; Okamoto N, 1997, ARCH BIOCHEM BIOPHYS, V337, P338, DOI 10.1006/abbi.1996.9786; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Park SY, 1997, NAT STRUCT BIOL, V4, P827, DOI 10.1038/nsb1097-827; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; SCRUTTON NS, 1990, NATURE, V343, P38, DOI 10.1038/343038a0; SHIRO Y, 1995, J BIOL CHEM, V270, P1617, DOI 10.1074/jbc.270.4.1617; SHOUN H, 1983, J BIOCHEM, V94, P1219, DOI 10.1093/oxfordjournals.jbchem.a134467; USUDA K, 1995, APPL ENVIRON MICROB, V61, P883, DOI 10.1128/AEM.61.3.883-889.1995; WIERENGA RK, 1985, BIOCHEMISTRY-US, V24, P1346, DOI 10.1021/bi00327a012	24	41	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5020	5026		10.1074/jbc.M007244200	http://dx.doi.org/10.1074/jbc.M007244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11076941	hybrid			2022-12-25	WOS:000168484300067
J	Nollen, EAA; Kabakov, AE; Brunsting, JF; Kanon, B; Hohfeld, J; Kampinga, HH				Nollen, EAA; Kabakov, AE; Brunsting, JF; Kanon, B; Hohfeld, J; Kampinga, HH			Modulation of in vivo Hsp70 chaperone activity by Hip and Bag-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOTIC PROTEIN BAG-1; HEAT-SHOCK PROTEIN-70; MAMMALIAN-CELLS; REACTION CYCLE; IN-VIVO; HSP70/HSC70; AGGREGATION; CLONING; HSP40; THERMOTOLERANCE	The chaperone activity of Hsp70 is influenced by the activities of both positive and negative regulatory proteins. In this study, we provide first time evidence for the stimulating effect of the Hsp70-interacting protein Hip on the chaperone activity in the mammalian cytosol, Overexpressing Hip enhances the refolding of the heat-inactivated reporter enzyme luciferase expressed in hamster lung fibroblasts. Also, it protects luciferase from irreversible denaturation under conditions of ATP depletion. We demonstrate that these stimulating actions depend on both the presence of the central Hsp70-binding site and the amino-terminal homo-oligomerization domain of Hip. The carboxyl terminus (amino acids 257-368) comprising the 7 GGMP repeats (Hsc70-like domain) and the Sti1p-like domain are dispensable for the Hip-mediated stimulation of the cellular chaperone activity. Bag-1, which inhibits the Hsp70 chaperone activity both in vitro and in vivo, was found to compete with the stimulatory action of Hip. In cells overexpressing both Hip and Bag-1, the inhibitory effects of Bag-1 were found to be dominant. Our results reveal that in vivo a complex level of regulation of the cellular chaperone activity exists that not only depends on the concentration of Hsp70 but also on the concentration, affinity, and intracellular localization of positive and negative coregulators. As the Hsp70 chaperone machine is also protective in the absence of ATP, our data also demonstrate that cycling between an ATP/ADP-bound state is not absolutely required for the Hsp70 chaperone machine to be active in vivo.	Univ Groningen, Fac Med Sci, Dept Radiat & Stress Cell Biol, NL-9713 AV Groningen, Netherlands; Med Radiol Res Inst, Obninsk 249020, Russia; Univ Bonn, Inst Cell Biol, D-53121 Bonn, Germany	University of Groningen; University of Bonn	Kampinga, HH (corresponding author), Univ Groningen, Fac Med Sci, Dept Radiat & Stress Cell Biol, NL-9713 AV Groningen, Netherlands.			Kampinga, Harm/0000-0002-8966-8466				Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Beissinger M, 1998, BIOL CHEM, V379, P245; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; Bruce BD, 1997, EUR J BIOCHEM, V245, P738, DOI 10.1111/j.1432-1033.1997.00738.x; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Gebauer M, 1997, FEBS LETT, V417, P109, DOI 10.1016/S0014-5793(97)01267-2; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HATTORI H, 1993, J CELL SCI, V104, P629; HOHFELD J, 1995, CELL, V83, P589; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; HUNT C, 1985, P NATL ACAD SCI USA, V82, P6455, DOI 10.1073/pnas.82.19.6455; Irmer H, 1997, J BIOL CHEM, V272, P2230; KABAKOV AE, 1993, EXPERIENTIA, V49, P706, DOI 10.1007/BF01923956; KABAKOV AE, 1997, HEAT SHOCK PROTEINS, P49; KAMPINGA HH, 1993, J CELL SCI, V104, P11; Loktionova SA, 1998, AM J PHYSIOL-HEART C, V275, pH2147, DOI 10.1152/ajpheart.1998.275.6.H2147; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Michels AA, 1999, J BIOL CHEM, V274, P36757, DOI 10.1074/jbc.274.51.36757; Michels AA, 1997, J BIOL CHEM, V272, P33283, DOI 10.1074/jbc.272.52.33283; MICHELS AA, 1995, EUR J BIOCHEM, V234, P382, DOI 10.1111/j.1432-1033.1995.382_b.x; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; NGUYEN VT, 1994, EUR J BIOCHEM, V220, P239; Nollen EAA, 1999, MOL CELL BIOL, V19, P2069; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; OHTSUKA K, 1986, International Journal of Hyperthermia, V2, P267, DOI 10.3109/02656738609016485; PELHAM HRB, 1984, EMBO J, V3, P3095, DOI 10.1002/j.1460-2075.1984.tb02264.x; Prapapanich V, 1998, MOL CELL BIOL, V18, P944, DOI 10.1128/MCB.18.2.944; Prapapanich V, 1996, MOL ENDOCRINOL, V10, P420, DOI 10.1210/me.10.4.420; STEGE GJJ, 1994, EXP CELL RES, V214, P279, DOI 10.1006/excr.1994.1259; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; Takayama S, 1998, CANCER RES, V58, P3116; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; WELCH WJ, 1988, J CELL BIOL, V106, P1117, DOI 10.1083/jcb.106.4.1117; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483	38	92	95	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4677	4682		10.1074/jbc.M009745200	http://dx.doi.org/10.1074/jbc.M009745200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11076956	hybrid			2022-12-25	WOS:000168484300022
J	Xiang, B; Yu, GH; Guo, J; Chen, L; Hu, W; Pei, G; Ma, L				Xiang, B; Yu, GH; Guo, J; Chen, L; Hu, W; Pei, G; Ma, L			Heterologous activation of protein kinase C stimulates phosphorylation of delta-opioid receptor at Serine 344, resulting in beta-arrestin- and clathrin-mediated receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLYL-CYCLASE; OPIATE RECEPTOR; XENOPUS OOCYTES; PHORBOL ESTERS; AGONIST; DESENSITIZATION; MORPHINE; ANTINOCICEPTION; TOLERANCE; KAPPA	The purpose of the current study is to investigate the effect of opioid-independent, heterologous activation of protein kinase C (PKC) on the responsiveness of opioid receptor and the underlying molecular mechanisms. Our result showed that removing the C terminus of delta opioid receptor (DOR) containing six Ser/Thr residues abolished both DPDPE- and phorbol 12-myristate 13-acetate (PMA)-induced DOR phosphorylation. The phosphorylation levels of DOR mutants T352A, T353A, and T358A/T361A/S363S were comparable to that of the wildtype DOR, whereas S344G substitution blocked PMA-induced receptor phosphorylation, indicating that PKC-mediated phosphorylation occurs at Ser-344. PKC-mediated Ser-344 phosphorylation was also induced by activation of G(q)-coupled alpha (1A)-adrenergic receptor or increase in intracellular Ca2+ concentration. Activation of PKC by PMA, alpha (1A)-adrenergic receptor agonist, and ionomycin resulted in DOE internalization that required phosphorylation of Ser-344, Expression of dominant negative p-arrestin and hypertonic sucrose treatment blocked PMA-induced DOR internalization, suggesting that PKC mediates DOR internalization via a beta -arrestin- and clathrin-dependent mechanism. Further study demonstrated that agonist-dependent G protein-coupled receptor kinase (GRK) phosphorylation sites in DOR are not targets of PKC. Agonist-dependent, GRK-mediated receptor phosphorylation and agonist-independent, PKC-mediated DOR phosphorylation were additive, but agonist-induced receptor phosphorylation could inhibit PKC-catalyzed heterologous DOR phosphorylation and subsequent internalization. These data demonstrate that the responsiveness of opioid receptor is regulated by both PKC and GRK through agonist-dependent and agonist-independent mechanisms and PKC-mediated receptor phosphorylation is an important molecular mechanism of heterologous regulation of opioid receptor functions.	Fudan Univ, Med Ctr, Natl Lab Med Neurobiol, Shanghai 200032, Peoples R China; Chinese Acad Sci, Shanghai Inst Biol Sci, Shanghai Inst Biochem & Cell Biol, Shanghai 200031, Peoples R China	Fudan University; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS	Ma, L (corresponding author), Fudan Univ, Med Ctr, Natl Lab Med Neurobiol, 138 Yi Xue Yuan Rd, Shanghai 200032, Peoples R China.	lanma@shmu.edu.cn	Ma, Lan/B-9295-2009	Ma, Lan/0000-0001-9034-5472				Aley KO, 1997, J NEUROSCI, V17, P3907; Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Appleyard SM, 1997, J NEUROCHEM, V69, P2405; AvidorReiss T, 1997, J BIOL CHEM, V272, P5040, DOI 10.1074/jbc.272.8.5040; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Cai YC, 1997, MOL PHARMACOL, V51, P583, DOI 10.1124/mol.51.4.583; Cheng ZJ, 1998, J BIOL CHEM, V273, P24328, DOI 10.1074/jbc.273.38.24328; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Cvejic S, 1996, J BIOL CHEM, V271, P4073; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; Fan GH, 1998, MOL PHARMACOL, V53, P684, DOI 10.1124/mol.53.4.684; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Guo J, 2000, MOL PHARMACOL, V58, P1050, DOI 10.1124/mol.58.5.1050; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; Hipkin RW, 2000, J BIOL CHEM, V275, P5591, DOI 10.1074/jbc.275.8.5591; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KAVALIERS M, 1991, BRAIN RES, V554, P65, DOI 10.1016/0006-8993(91)90172-R; Kawabe J, 1996, FEBS LETT, V384, P273, DOI 10.1016/0014-5793(96)00331-6; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; LOUIE AK, 1990, J PHARMACOL EXP THER, V253, P401; MAO JR, 1995, BRAIN RES, V677, P257, DOI 10.1016/0006-8993(95)00161-I; MAYER DJ, 1995, PAIN, V61, P365, DOI 10.1016/0304-3959(95)00023-L; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; Narita M, 1997, NEUROSCIENCE, V76, P291; Narita M, 1996, BRIT J PHARMACOL, V118, P1829, DOI 10.1111/j.1476-5381.1996.tb15610.x; NARITA M, 1995, EUR J PHARMACOL, V280, pR1, DOI 10.1016/0014-2999(95)00322-C; Ohsawa M, 1999, EUR J PHARMACOL, V373, P181, DOI 10.1016/S0014-2999(99)00273-3; Ohsawa M, 1998, J PHARMACOL EXP THER, V286, P780; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PEI G, 1995, MOL PHARMACOL, V48, P173; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Taguchi K, 1998, N-S ARCH PHARMACOL, V357, P100, DOI 10.1007/PL00005143; TERWILLIGER RZ, 1994, J NEUROCHEM, V63, P1983; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; UEDA H, 1995, J NEUROSCI, V15, P7485; VazquezPrado J, 1997, J BIOL CHEM, V272, P27330, DOI 10.1074/jbc.272.43.27330; VOCCI FJ, 1980, J PHARMACOL EXP THER, V214, P463; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449; ZHANG LJ, 1990, LIFE SCI, V47, P1775, DOI 10.1016/0024-3205(90)90352-R; Zhao J, 1997, BIOCHEM BIOPH RES CO, V238, P71, DOI 10.1006/bbrc.1997.7242	45	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4709	4716		10.1074/jbc.M006187200	http://dx.doi.org/10.1074/jbc.M006187200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11085981	hybrid			2022-12-25	WOS:000168484300026
J	Arrecubieta, C; Hammarton, TC; Barrett, B; Chareonsudjai, S; Hodson, N; Rainey, D; Roberts, IS				Arrecubieta, C; Hammarton, TC; Barrett, B; Chareonsudjai, S; Hodson, N; Rainey, D; Roberts, IS			The transport of group 2 capsular polysaccharides across the peripiasmic space in Escherichia coli - Roles for the KpsE and KpsD proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-NEGATIVE BACTERIA; POLYSIALIC ACID; OUTER-MEMBRANE; GENE-CLUSTER; PERIPLASMIC PROTEIN; MOLECULAR ANALYSIS; K5 POLYSACCHARIDE; ENCODING PROTEINS; CELL-SURFACE; TOLB PROTEIN	The cell surface expression of group 2 capsular polysaccharides involves the translocation of the polysaccharide from its site of synthesis on the inner face of the cytoplasmic membrane onto the cell surface. The transport process is independent of the repeat structure of the polysaccharide, and translocation across the periplasm requires the cytoplasmic membrane-anchored protein KpsE and the periplasmic protein KpsD, In this paper we establish the topology of the KpsE protein and demonstrate that the C terminus interacts with the periplasmic face of the cytoplasmic membrane. By chemical cross-linking we show that KpsE is likely to exist as a dimer and that dimerization is independent of the other Kps proteins or the synthesis of capsular polysaccharide, No interaction between KpsD and KpsE could be demonstrated by chemical cross-linking, although in the presence of both KpsE and Lpp, KpsD could be cross-linked to a 7-kDa protein of unknown identity. In addition, we demonstrate that KpsD is present not only within the periplasm but is also in both the cytoplasmic and outer membrane fractions and that the correct membrane association of KpsD was dependent on KpsE, Lpp, and the secreted polysaccharide molecule. Both KpsD and KpsE showed increased proteinase K sensitivity in the different mutant backgrounds, reflecting conformational changes in the HpsD and KpsE proteins as a result of the disruption of the transport process. Collectively the data suggest that the trans-periplasmic export involves KpsD acting as the link between the cytoplasmic membrane transporter and the outer membrane with KpsE acting to facilitate this transport process.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Roberts, IS (corresponding author), Univ Manchester, Sch Biol Sci, 1-800 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Hammarton, Tansy/A-5632-2011; Chareonsudjai, Sorujsiri/AFM-5607-2022	Hammarton, Tansy/0000-0002-0799-6600; Chareonsudjai, Sorujsiri/0000-0001-7176-2924; Hodson, Nigel/0000-0002-7486-1976				BENEDETTI H, 1991, EMBO J, V10, P1989, DOI 10.1002/j.1460-2075.1991.tb07728.x; Bliss JM, 1996, MOL MICROBIOL, V21, P221, DOI 10.1046/j.1365-2958.1996.6461357.x; BOLIVAR F, 1977, GENE, V2, P95, DOI 10.1016/0378-1119(77)90000-2; BRONNER D, 1993, J BACTERIOL, V175, P5984, DOI 10.1128/JB.175.18.5984-5992.1993; CHOI DS, 1986, J BIOL CHEM, V261, P8953; Clavel T, 1998, MOL MICROBIOL, V29, P359, DOI 10.1046/j.1365-2958.1998.00945.x; DEMAAGD RA, 1986, J BACTERIOL, V167, P1083, DOI 10.1128/jb.167.3.1083-1085.1986; Dobrogosz W. J., 1981, MANUAL METHODS GENER, P365; Drummelsmith J, 2000, EMBO J, V19, P57, DOI 10.1093/emboj/19.1.57; ESUMEH F, 1996, THESIS U LEICESTER L; GITTINS JR, 1994, FEMS MICROBIOL REV, V13, P1; HAMMARTON TC, 1999, THESIS U MANCHESTER; HIGH NJ, 1988, INFECT IMMUN, V56, P513, DOI 10.1128/IAI.56.2.513-517.1988; Hsing WH, 1998, J BACTERIOL, V180, P4538, DOI 10.1128/JB.180.17.4538-4546.1998; ISNARD M, 1994, J BACTERIOL, V176, P6392, DOI 10.1128/jb.176.20.6392-6396.1994; JACKSON ME, 1988, MOL MICROBIOL, V2, P563, DOI 10.1111/j.1365-2958.1988.tb00064.x; KARKHANIS YD, 1978, ANAL BIOCHEM, V85, P595, DOI 10.1016/0003-2697(78)90260-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lazdunski CJ, 1998, J BACTERIOL, V180, P4993, DOI 10.1128/JB.180.19.4993-5002.1998; LAZZARONI JC, 1995, J MOL BIOL, V246, P1, DOI 10.1006/jmbi.1994.0058; Letoffe S, 1996, EMBO J, V15, P5804, DOI 10.1002/j.1460-2075.1996.tb00967.x; MAIER C, 1988, J BIOL CHEM, V263, P2493; Paulsen IT, 1997, MICROBIOL-SGM, V143, P2685, DOI 10.1099/00221287-143-8-2685; PAVELKA MS, 1991, J BACTERIOL, V173, P4603, DOI 10.1128/jb.173.15.4603-4610.1991; PAVELKA MS, 1994, J BIOL CHEM, V269, P20149; PAZZANI C, 1993, J BACTERIOL, V175, P5978, DOI 10.1128/JB.175.18.5978-5983.1993; PETIT C, 1995, MOL MICROBIOL, V17, P611, DOI 10.1111/j.1365-2958.1995.mmi_17040611.x; PHOENIX DA, 1994, MICROBIOL-UK, V140, P73, DOI 10.1099/13500872-140-1-73; PIGEON RP, 1994, MOL MICROBIOL, V14, P871, DOI 10.1111/j.1365-2958.1994.tb01323.x; Prilipov A, 1998, FEMS MICROBIOL LETT, V163, P65, DOI 10.1111/j.1574-6968.1998.tb13027.x; Rigg GP, 1998, MICROBIOL-SGM, V144, P2905, DOI 10.1099/00221287-144-10-2905; Robbins J B, 1974, NEW ENGL J MED, V90, P267; Roberts IS, 1996, ANNU REV MICROBIOL, V50, P285, DOI 10.1146/annurev.micro.50.1.285; ROBERTS IS, 1988, J BACTERIOL, V170, P1305, DOI 10.1128/jb.170.3.1305-1310.1988; ROSENOW C, 1995, J BACTERIOL, V177, P1137, DOI 10.1128/jb.177.5.1137-1143.1995; Sambrook J., 2002, MOL CLONING LAB MANU; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; SILVER RP, 1987, J BACTERIOL, V169, P5489, DOI 10.1128/jb.169.12.5489-5495.1987; SMITH AN, 1990, MOL MICROBIOL, V4, P1863, DOI 10.1111/j.1365-2958.1990.tb02035.x; STEVENS MP, 1994, FEMS MICROBIOL LETT, V124, P93, DOI 10.1111/j.1574-6968.1994.tb07267.x; Thanabalu T, 1998, EMBO J, V17, P6487, DOI 10.1093/emboj/17.22.6487; White B.A., 1997, PCR CLONING PROTOCOL, P141, DOI [10.1385/0-89603-483-6:141, DOI 10.1385/0-89603-483-6:141]; Whitfield C, 1999, MOL MICROBIOL, V31, P1307, DOI 10.1046/j.1365-2958.1999.01276.x; WUNDER DE, 1994, J BACTERIOL, V176, P4025, DOI 10.1128/JB.176.13.4025-4033.1994; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	45	32	34	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4245	4250		10.1074/jbc.M008183200	http://dx.doi.org/10.1074/jbc.M008183200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11078739	hybrid			2022-12-25	WOS:000166921200069
J	Arata, Y; Hirabayashi, J; Kasai, K				Arata, Y; Hirabayashi, J; Kasai, K			Sugar binding properties of the two lectin domains of the tandem repeat-type galectin LEC-1 (N32) of Caenorhabditis elegans - Detailed analysis by an improved frontal affinity chromatography method	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; 32-KDA GALECTIN; CARBOHYDRATE RECOGNITION; PROTEIN; FAMILY; LACTOSE; LIBRARIES; COMPOUND; COMPLEX; TRYPSIN	The 32-kDa galectin (LEC-1 or N32) of the nematode Caenorhabditis elegans is the first example of a tandem repeat-type galectin and is composed of two domains, each of which is homologous to typical vertebrate 14kDa-type galectins, To elucidate the biological meaning of this unique structure containing two probable sugar binding sites in one molecule, we analyzed in detail the sugar binding properties of the two domains by using a newly improved frontal affinity chromatography system. The whole molecule (LEC-1), the N-terminal lectin domain (Nh), and the C-terminal lectin domain (Ch) were expressed in Escherichia coli, purified, and immobilized on HiTrap gel agarose columns, and the extent of retardation of various sugars by the columns was measured. To raise the sensitivity of the system, we used 35 different fluorescence-labeled oligosaccharides (pyridylaminated (PA) sugars). All immobilized proteins showed affinity for N-acetyllactosamine-containing N-linked complex-type sugar chains, and the binding was stronger for more branched sugars. Ch showed 2-5-fold stronger binding toward all complex-type sugars compared with Nh. Both Nh and Oh preferred Gal beta1-3GlcNAc to Gal beta1-4GlcNAc. Because the Fuc alphal-2Gal beta1-3GlcNAc (H antigen) structure was found to interact with all immobilized protein columns significantly, the K-d value of pentasaccharide Fuc alpha1-2Gal beta1-3GlcNAc beta1-3Gal beta1-4Glc-PA for each column was determined by analyzing the concentration dependence. Obtained values for immobilized LEC-1, Nh, and Ch were 6.0 x 10(-5), 1.3 x 10(-4), and 6.5 x 10(-5) M, respectively. The most significant difference between Nh and Oh was in their affinity for GalNAc alpha1-3 (Fuc alpha1-2) Gal beta1-3GlcNAc beta1-3Gal beta1-4Glc-PA, which contains the blood group A antigen; the K-d value for immobilized Nh was 4.8 x 10(-5) M, and that for Ch was 8.1 x 10(-4) M, The present results clearly indicate that the two sugar binding sites of LEC-1 have different sugar binding properties.	Teikyo Univ, Fac Pharmaceut Sci, Dept Biol Chem, Sagamiko, Kanagawa 1990195, Japan	Teikyo University	Arata, Y (corresponding author), Teikyo Univ, Fac Pharmaceut Sci, Dept Biol Chem, Sagamiko, Kanagawa 1990195, Japan.							Arata Y, 1997, J BIOCHEM-TOKYO, V121, P1002, DOI 10.1093/oxfordjournals.jbchem.a021686; Arata Y, 1996, HISTOCHEM J, V28, P201, DOI 10.1007/BF02331444; Arata Y, 1997, J BIOL CHEM, V272, P26669, DOI 10.1074/jbc.272.42.26669; Arata Y, 2001, J CHROMATOGR A, V905, P337, DOI 10.1016/S0021-9673(00)00967-5; BARONDES SH, 1994, CELL, V76, P597, DOI 10.1016/0092-8674(94)90498-7; BOURNE Y, 1994, NAT STRUCT BIOL, V1, P863, DOI 10.1038/nsb1294-863; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIU ML, 1994, J BIOL CHEM, V269, P31770; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; GITT MA, 1995, GLYCOCONJUGATE J, V4, P548; HADARI YR, 1995, J BIOL CHEM, V270, P3447, DOI 10.1074/jbc.270.7.3447; HASE S, 1978, BIOCHEM BIOPH RES CO, V85, P257, DOI 10.1016/S0006-291X(78)80037-0; Heegaard NHH, 1999, ELECTROPHORESIS, V20, P3122, DOI 10.1002/(SICI)1522-2683(19991001)20:15/16<3122::AID-ELPS3122>3.3.CO;2-D; Heegaard NHH, 1998, J CHROMATOGR B, V715, P29, DOI 10.1016/S0378-4347(98)00258-8; HIRABAYASHI J, 1992, J BIOL CHEM, V267, P15485; HIRABAYASHI J, 1991, J BIOL CHEM, V266, P23648; HIRABAYASHI J, 1993, GLYCOBIOLOGY, V3, P297, DOI 10.1093/glycob/3.4.297; Hirabayashi J, 2000, J CHROMATOGR A, V890, P261, DOI 10.1016/S0021-9673(00)00545-8; HIRABAYASHI J, 1994, GLYCOCONJUGATE J, V11, P437, DOI 10.1007/BF00731280; HIRABAYASHI J, 1992, J BIOCHEM-TOKYO, V111, P553, DOI 10.1093/oxfordjournals.jbchem.a123794; HIRABAYASHI J, 2001, IN PRESS PROTEOMICS; KASAI K, 1986, J CHROMATOGR, V376, P33, DOI 10.1016/S0378-4347(00)80822-1; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; KASAI KI, 1978, J BIOCHEM, V84, P1061, DOI 10.1093/oxfordjournals.jbchem.a132220; KASAI KI, 1978, J BIOCHEM-TOKYO, V84, P1051, DOI 10.1093/oxfordjournals.jbchem.a132219; LIAO DI, 1994, P NATL ACAD SCI USA, V91, P1428, DOI 10.1073/pnas.91.4.1428; LOBSANOV YD, 1993, J BIOL CHEM, V268, P27034; Malmqvist M, 1999, BIOCHEM SOC T, V27, P335, DOI 10.1042/bst0270335; NONAKA T, 1999, GLYCOCONJ J, V16, pS119; ODA Y, 1993, J BIOL CHEM, V268, P5929; OHYAMA Y, 1985, J BIOL CHEM, V260, P6882; PFEIFER K, 1993, GLYCOBIOLOGY, V3, P179, DOI 10.1093/glycob/3.2.179; Schriemer DC, 1998, ANGEW CHEM INT EDIT, V37, P3383, DOI 10.1002/(SICI)1521-3773(19981231)37:24<3383::AID-ANIE3383>3.0.CO;2-C; Woodbury CP, 1999, J CHROMATOGR B, V725, P113, DOI 10.1016/S0378-4347(99)00006-7	34	80	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3068	3077		10.1074/jbc.M008602200	http://dx.doi.org/10.1074/jbc.M008602200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11058602	hybrid			2022-12-25	WOS:000166784900015
J	Gu, J; Milligan, J; Huang, LE				Gu, J; Milligan, J; Huang, LE			Molecular mechanism of hypoxia-inducible factor 1 alpha-p300 interaction - A leucine-rich interface regulated by a single cysteine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; TRANSCRIPTION FACTOR; ALPHA-SUBUNIT; SOLID TUMORS; FACTOR-I; ACTIVATION; PROTEIN; ANGIOGENESIS; CBP; STABILIZATION	Hypoxia-inducible factor Icu (HIF1 alpha) plays a pivotal role in embryogenesis, angiogenesis, and tumorigenesis. HIF1 alpha -mediated transcription requires the coactivator p300, at least in part, through interaction with the cysteine- and histidine-rich 1 domain of p300. To understand the molecular basis of this interaction, we have developed a random mutagenesis screen in yeast approach for efficient identification of residues that are functionally critical for protein interactions. As a result, four residues (Leu-795, Cys-800, Leu-818, and Leu-822) in the C-terminal activation domain of HIF1 alpha have been identified as crucial for HIF1 transactivation in mammalian systems. Moreover, data from residue substitution experiments indicate the stringent necessity of leucine and hydrophobic cysteine for C-terminal activation domain function. Likewise, Leu-344, Leu-345, Cys388, and Cys-393 in the cysteine- and histidine-rich 1 domain of p300 have also been shown to be essential for the functional interaction, We propose that hypoxia-induced HIF1 alpha -p300 interaction relies upon a leucine-rich hydrophobic interface that is regulated by the hydrophilic and hydrophobic sulfhydryls of HIF1 alpha Cys-800.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School	Huang, LE (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA.			Huang, Eric/0000-0002-6444-1708	NIDDK NIH HHS [F32 DK09856, R01 DK41234] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041234, F32DK009856] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Gothie E, 2000, J BIOL CHEM, V275, P6922, DOI 10.1074/jbc.275.10.6922; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang BH, 1997, J BIOL CHEM, V272, P19253, DOI 10.1074/jbc.272.31.19253; Johnson PR, 1998, CELL, V94, P217, DOI 10.1016/S0092-8674(00)81421-X; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Newton AL, 2000, J BIOL CHEM, V275, P15128, DOI 10.1074/jbc.M910396199; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10321, DOI 10.1073/pnas.93.19.10321; Wenger RH, 2000, J EXP BIOL, V203, P1253	41	105	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3550	3554		10.1074/jbc.M009522200	http://dx.doi.org/10.1074/jbc.M009522200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11063749	hybrid			2022-12-25	WOS:000166784900074
J	Neal, JW; Clipstone, NA				Neal, JW; Clipstone, NA			Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED T-CELLS; TRANSCRIPTION FACTOR NFAT1; NF-ATC; NUCLEAR FACTOR; GENE-EXPRESSION; INTACT-CELLS; IMMUNOSUPPRESSIVE DRUGS; C-JUN; PROTEIN; PHOSPHORYLATION	The NFAT family of transcription factors is required for the expression of numerous immunologically important genes and plays a pivotal role in both the initiation and coordination of the immune response. NFAT family members appear to be regulated primarily at the level of their subcellular localization. Here we show that NFATc is additionally regulated at the level of its DNA binding activity. Using gel mobility shift assays, we demonstrate that the intrinsic DNA binding activity of NFATc is negatively regulated by phosphorylation. We found that activation of calcineurin activity in cells and dephosphorylation of NFATc in vitro enhanced NFATc DNA binding activity, whereas phosphorylation of NFATc in vitro inhibited its ability to bind DNA. Through the analysis of NFATc mutants, we identified the conserved SerPro repeat motifs as critical quantitative determinants of NFATc DNA binding activity. In addition, we provide several lines of evidence to suggest that the phosphorylation of the Ser-Pro repeats by glycogen synthase kinase-3 inhibits the ability of NFATc to bind DNA. Taken together, these studies afford new insights into the regulation of NFATc and underscore the potential role of glycogen synthase kinase-3 in the regulation of NFAT-dependent gene expression.	Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University	Clipstone, NA (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA.	n-clipstone@northwestern.edu			NIGMS NIH HHS [GM55292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BOISE LH, 1993, MOL CELL BIOL, V13, P1911, DOI 10.1128/MCB.13.3.1911; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; CAELLES C, 1995, MOL CELL BIOL, V15, P6694; CASTIGLI E, 1993, J IMMUNOL, V150, P3284; Chen L, 1998, NATURE, V392, P42, DOI 10.1038/32100; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Coqueret O, 1998, J BIOL CHEM, V273, P2561, DOI 10.1074/jbc.273.5.2561; Cowley DO, 2000, GENE DEV, V14, P366; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; EldarFinkelman H, 1996, P NATL ACAD SCI USA, V93, P10228, DOI 10.1073/pnas.93.19.10228; ELDARFINKELMAN H, 1995, J BIOL CHEM, V270, P987, DOI 10.1074/jbc.270.3.987; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JAIN J, 1992, NATURE, V356, P801, DOI 10.1038/356801a0; JAIN JN, 1995, J BIOL CHEM, V270, P4138, DOI 10.1074/jbc.270.8.4138; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Kitaura J, 2000, J EXP MED, V192, P729, DOI 10.1084/jem.192.5.729; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MCCAFFREY PG, 1993, J BIOL CHEM, V268, P3747; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; Ohteki T, 2000, J EXP MED, V192, P99, DOI 10.1084/jem.192.1.99; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; Ranger AM, 2000, J EXP MED, V191, P9, DOI 10.1084/jem.191.1.9; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROONEY JW, 1994, EMBO J, V13, P625, DOI 10.1002/j.1460-2075.1994.tb06300.x; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; SHAW KTY, 1995, P NATL ACAD SCI USA, V92, P11205, DOI 10.1073/pnas.92.24.11205; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Wolfe SA, 1997, NATURE, V385, P172, DOI 10.1038/385172a0; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; Zhou P, 1998, CELL, V92, P687, DOI 10.1016/S0092-8674(00)81136-8; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	60	129	132	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3666	3673		10.1074/jbc.M004888200	http://dx.doi.org/10.1074/jbc.M004888200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11063740	hybrid			2022-12-25	WOS:000166784900089
J	Sun, QA; Zappacosta, F; Factor, VM; Wirth, PJ; Hatfield, DL; Gladyshev, VN				Sun, QA; Zappacosta, F; Factor, VM; Wirth, PJ; Hatfield, DL; Gladyshev, VN			Heterogeneity within animal thioredoxin reductases - Evidence for alternative first exon splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELENOCYSTEINE INSERTION-SEQUENCE; LUNG ADENOCARCINOMA CELLS; HELA-CELLS; FUNCTIONAL EXPRESSION; GENOMIC ORGANIZATION; CDNA CLONING; GENE; IDENTIFICATION; HEPARIN; PURIFICATION	Animal thioredoxin reductases (TRs) are selenocysteine-containing flavoenzymes that utilize NADPH for reduction of thioredoxins and other protein and nonprotein substrates. Three types of mammalian TRs are known, with TR1 being a cytosolic enzyme, and TR3, a mitochondrial enzyme. Previously characterized TR1 and TR3 occurred as homodimers of 55-57-kDa subunits, We report here that TR1 isolated from mouse liver, mouse liver tumor, and a human T-cell line exhibited extensive heterogeneity as detected by electrophoretic, immunoblot, and mass spectrometry analyses. In particular, a 67-kDa band of TR1 was detected. Furthermore, a novel form of mouse TR1 cDNA encoding a 67-kDa selenoprotein subunit with an additional N-terminal sequence was identified. Subsequent homology analyses revealed three distinct isoforms of mouse and rat TR1 mRNA These forms differed in 5' sequences that resulted from the alternative use of the first three exons but had common downstream sequences. Similarly, expression of multiple mRNA forms was observed for human TR3 and Drosophila TR, In these genes, alternative first exon splicing resulted in the formation of predicted mitochondrial and cytosolic proteins. In addition, a human TR3 gene overlapped with the gene for catechol-O-methyltransferase (COMT) on a complementary DNA strand, such that mitochondrial TR3 and membrane-bound COMT mRNAs had common first exon sequences; however, transcription start sites for predicted cytosolic TR3 and soluble COMT forms were separated by similar to 30 kilobases, Thus, this study demonstrates a remarkable heterogeneity within TRs, which, at least in part, results from evolutionary conserved genetic mechanisms employing alternative first exon splicing. Multiple transcription start sites within TR genes may be relevant to complex regulation of expression and/or organelle- and cell type-specific location of animal thioredoxin reductases.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; SmithKline Beecham Pharmaceut, King Of Prussia, PA 19406 USA; NCI, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA; NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA	University of Nebraska System; University of Nebraska Lincoln; GlaxoSmithKline; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gladyshev, VN (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.		Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013	Gladyshev, Vadim/0000-0002-0372-7016				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Appella E, 2000, EXS, V88, P1; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Fujiwara N, 1999, BIOCHEM J, V340, P439, DOI 10.1042/0264-6021:3400439; Gasdaska JR, 1999, J BIOL CHEM, V274, P25379, DOI 10.1074/jbc.274.36.25379; Gasdaska PY, 1999, FEBS LETT, V442, P105, DOI 10.1016/S0014-5793(98)01638-X; GASDASKA PY, 1995, FEBS LETT, V373, P5, DOI 10.1016/0014-5793(95)01003-W; Gladyshev VN, 1998, BIOCHEM BIOPH RES CO, V251, P488, DOI 10.1006/bbrc.1998.9495; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gogos JA, 1998, P NATL ACAD SCI USA, V95, P9991, DOI 10.1073/pnas.95.17.9991; Gorlatov SN, 1998, P NATL ACAD SCI USA, V95, P8520, DOI 10.1073/pnas.95.15.8520; Gorlatov SN, 1999, ARCH BIOCHEM BIOPHYS, V369, P133, DOI 10.1006/abbi.1999.1356; Halliwell B, 1999, FREE RADICAL RES, V31, P261, DOI 10.1080/10715769900300841; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Kawai H, 2000, GENE, V242, P321, DOI 10.1016/S0378-1119(99)00498-9; Kelner MJ, 2000, J BIOL CHEM, V275, P13000, DOI 10.1074/jbc.275.17.13000; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Lescure A, 1999, J BIOL CHEM, V274, P38147, DOI 10.1074/jbc.274.53.38147; Liu SY, 1997, P NATL ACAD SCI USA, V94, P6138, DOI 10.1073/pnas.94.12.6138; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Miranda-Vizuete A, 1999, BBA-GENE STRUCT EXPR, V1447, P113, DOI 10.1016/S0167-4781(99)00129-3; OKAMOTO T, 1994, BIOCHEMISTRY-US, V33, P11536, DOI 10.1021/bi00204a016; Rundlof AK, 2000, BIOCHEM J, V347, P661, DOI 10.1042/0264-6021:3470661; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Simpson ER, 1997, FASEB J, V11, P29, DOI 10.1096/fasebj.11.1.9034163; St George-Hyslop PH, 1999, SEMIN NEUROL, V19, P371, DOI 10.1055/s-2008-1040852; Strassburg CP, 1997, MOL PHARMACOL, V52, P212, DOI 10.1124/mol.52.2.212; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; SUTTON CW, 1995, ELECTROPHORESIS, V16, P308, DOI 10.1002/elps.1150160151; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; TENHUNEN J, 1994, EUR J BIOCHEM, V223, P1049, DOI 10.1111/j.1432-1033.1994.tb19083.x; Watabe S, 1999, EUR J BIOCHEM, V264, P74, DOI 10.1046/j.1432-1327.1999.00578.x; Zappacosta F, 1997, P NATL ACAD SCI USA, V94, P6313, DOI 10.1073/pnas.94.12.6313; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581	36	76	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3106	3114		10.1074/jbc.M004750200	http://dx.doi.org/10.1074/jbc.M004750200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11060283	Green Submitted, hybrid			2022-12-25	WOS:000166784900019
J	Segal, Y; Zhuang, LY; Rondeau, E; Sraer, JD; Zhou, J				Segal, Y; Zhuang, LY; Rondeau, E; Sraer, JD; Zhou, J			Regulation of the paired type IV collagen genes COL4A5 and COL4A6 Role of the proximal promoter region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE COLLAGEN; RECESSIVE ALPORT SYNDROME; HEAD-TO-HEAD; BIDIRECTIONAL PROMOTER; DIVERGENT TRANSCRIPTION; DIFFUSE LEIOMYOMATOSIS; COORDINATE REGULATION; BASAL LAMINAE; CHAINS; IDENTIFICATION	Tissue-specific expression patterns of the paired type IV collagen genes COL4A5 and COL4A6 form the basis for organ involvement in X-linked Alport syndrome, a disorder in which these genes are mutated. We investigated the proximal promoter region of COL4A5 and COL4A6 using glomerular visceral epithelial cells, in which COL4A5 alone is transcribed; keratinocytes, in which the genes are co-transcribed; and additional model cell Lines. By RNase protection assays, the intergenic region is 292 base pairs, Transcription start sites for two 5' splice variants of COL4A6 are 1 kilobase apart. Transient transfections with reporter gene constructs revealed that the minimal promoters for COL4A5 and COL4A6 are within 100 base pairs of their respective transcription start sites and are functionally distinct. In further transfection, gel shift and footprinting assays, we defined a bidirectional positive regulatory element, which functions in several cell types, but not in glomerular visceral epithelial cells selectively transcribing COL4A5. The existence of separate promoters for COL4A5 and COL4A6 permits fine control over their expression. Activation through the bidirectional element can bring about co-expression of the genes, exploiting their paired arrangement. Features of the proximal promoter region frame its roles in a hierarchy regulating type IV collagen gene expression.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Renal Div,HIM 522, Boston, MA 02115 USA; Hop Tenon, INSERM, U489, F-75970 Paris, France	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Zhou, J (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Renal Div,HIM 522, 77 Ave Louis Pasteur, Boston, MA 02115 USA.		Segal, Yoav/E-2326-2019		NIDDK NIH HHS [DK02419, DK48317] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048317, K08DK002419] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashraf SI, 1998, CURR BIOL, V8, pR683, DOI 10.1016/S0960-9822(98)70435-X; BARKER DF, 1990, SCIENCE, V248, P1224, DOI 10.1126/science.2349482; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; BRUGGEMAN LA, 1992, ONCOGENE, V7, P1497; BURBELO PD, 1991, J BIOL CHEM, V266, P22297; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; BUTKOWSKI RJ, 1989, KIDNEY INT, V35, P1195, DOI 10.1038/ki.1989.110; DELARUE F, 1991, KIDNEY INT, V40, P906, DOI 10.1038/ki.1991.292; DESJARDINS M, 1991, J CELL BIOL, V113, P689, DOI 10.1083/jcb.113.3.689; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Elferink CJ, 1996, BIOTECHNIQUES, V20, P470; ENDERS GC, 1995, BIOL REPROD, V53, P1489, DOI 10.1095/biolreprod53.6.1489; FISCHER G, 1993, BIOCHEM J, V292, P687, DOI 10.1042/bj2920687; Gabbitas B, 1996, J BIOL CHEM, V271, P9033, DOI 10.1074/jbc.271.15.9033; GAVALAS A, 1995, J BIOL CHEM, V270, P2403, DOI 10.1074/jbc.270.5.2403; GUBLER MC, 1995, KIDNEY INT, V47, P1142, DOI 10.1038/ki.1995.163; HANIEL A, 1995, J BIOL CHEM, V270, P11209, DOI 10.1074/jbc.270.19.11209; Heidet L, 2000, AM J PATHOL, V156, P1901, DOI 10.1016/S0002-9440(10)65063-8; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; HUH NE, 1991, NUCLEIC ACIDS RES, V19, P93, DOI 10.1093/nar/19.1.93; Kawai S., 1996, Journal of the American Society of Nephrology, V7, P1615; KLEPPEL MM, 1992, J BIOL CHEM, V267, P4137; KLEPPEL MM, 1989, AM J PATHOL, V134, P813; KOLLMAR R, 1993, P SOC EXP BIOL MED, V203, P127; Kuncio GS, 1996, AM J PHYSIOL-RENAL, V271, pF120, DOI 10.1152/ajprenal.1996.271.1.F120; LAURIE GW, 1989, J CELL BIOL, V109, P1351, DOI 10.1083/jcb.109.3.1351; LEE LK, 1993, J CELL PHYSIOL, V157, P169, DOI 10.1002/jcp.1041570122; Lemmink HH, 1996, J CLIN INVEST, V98, P1114, DOI 10.1172/JCI118893; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; Miner JH, 1996, J CELL BIOL, V135, P1403, DOI 10.1083/jcb.135.5.1403; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; NINOMIYA Y, 1995, J CELL BIOL, V130, P1219, DOI 10.1083/jcb.130.5.1219; Papavassiliou A G, 1994, Methods Mol Biol, V30, P43; PEISSEL B, 1995, J CLIN INVEST, V96, P1948, DOI 10.1172/JCI118241; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; RENIERI A, 1994, HUM MUTAT, V4, P195, DOI 10.1002/humu.1380040304; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SCHMIDT C, 1993, BIOCHIM BIOPHYS ACTA, V1174, P1, DOI 10.1016/0167-4781(93)90085-R; Segal Y, 1999, AM J HUM GENET, V64, P62, DOI 10.1086/302213; Simoneau A, 1998, DEV DYNAM, V212, P437; STURM RA, 1988, NUCLEIC ACIDS RES, V16, P8571, DOI 10.1093/nar/16.17.8571; SUGIMOTO M, 1994, P NATL ACAD SCI USA, V91, P11679, DOI 10.1073/pnas.91.24.11679; Takeoka H, 1998, BIOCHEM BIOPH RES CO, V252, P290, DOI 10.1006/bbrc.1998.9530; TANAKA S, 1993, J BIOL CHEM, V268, P8862; Thorner PS, 1996, J BIOL CHEM, V271, P13821, DOI 10.1074/jbc.271.23.13821; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; VEAL JM, 1988, BIOCHEMISTRY-US, V27, P1822, DOI 10.1021/bi00406a004; Wingender E, 1997, NUCLEIC ACIDS RES, V25, P265, DOI 10.1093/nar/25.1.265; WRIGHT KL, 1995, J EXP MED, V181, P1459, DOI 10.1084/jem.181.4.1459; YOSHIOKA K, 1994, AM J PATHOL, V144, P986; Yu W, 1999, SCIENCE, V285, P1080, DOI 10.1126/science.285.5430.1080; ZHOU J, 1994, J BIOL CHEM, V269, P13193; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449	54	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11791	11797		10.1074/jbc.M007477200	http://dx.doi.org/10.1074/jbc.M007477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11096082	Green Submitted, hybrid			2022-12-25	WOS:000168081800050
J	Hlaing, T; Guo, RF; Dilley, KA; Loussia, JM; Morrish, TA; Shi, MM; Vincenz, C; Ward, PA				Hlaing, T; Guo, RF; Dilley, KA; Loussia, JM; Morrish, TA; Shi, MM; Vincenz, C; Ward, PA			Molecular cloning and characterization of DEFCAP-L and -S, two isoforms of a novel member of the mammalian Ced-4 family of apoptosis proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEGANS CELL-DEATH; CYTOCHROME-C; PROTEASE; HOMOLOG; ACTIVATION; CASPASE-2; COMPLEX; CLEAVES; APAF-1; CD95	We report the deduced amino acid sequences of two alternately spliced isoforms, designated DEFCAP-L and -S, that differ in 44 amino acids and encode a novel member of the mammalian Ced-4 family of apoptosis proteins. Similar to the other mammalian Ced-4 proteins (Apaf-1 and Nod1), DEFCAP contains a caspase recruitment domain (CARD) and a putative nucleotide binding domain, signified by a consensus Walker's A box (P-loop) and B box (Mg2+-binding site). Like Nod1, but different from Apaf-1, DEFCAP contains a putative regulatory domain containing multiple leucine-rich repeats (I;RR). However, a distinguishing feature of the primary sequence of DEFCAP is that DEFCAP contains at its NH,terminus a pyrin-like motif and a proline-rich sequence, possibly involved in protein-protein interactions with Src homology domain 3-containing proteins. By using in vitro coimmunoprecipitation experiments, both long and short isoforms were capable of strongly interacting with caspase-2 and exhibited a weaker interaction with caspase-9, Transient overexpression of full-length DEFCAP-L, but not DEFCAP-S, in breast adenocarcinoma cells MCF7 resulted in significant levels of apoptosis, lie. vitro death assays with transient overexpression of deletion constructs of both isoforms using P-galactosidase as a reporter gene in MCF7 cells suggest the following: 1) the nucleotide binding domain may act as a negative regulator of the killing activity of DEFCAP; 2) the LRR/CARD represents a putative constitutively active inducer of apoptosis; 3) the killing activity of LRR/CARD is inhibitable by benzyloxycarbonyl-Val-Ala-Asp (OMe)-fluoromethyl ketone and to a lesser extent by Asp-Glu-Val-Asp (OMe)-fluoromethyl ketone; and 4) the CARD is critical for killing activity of DEFCAP; These results suggest that DEFCAP is a novel member of the mammalian Ced-4 family of proteins capable of inducing apoptosis, and understanding its regulation may elucidate the complex nature of the mammalian apoptosis-promoting machinery.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Pfizer Global Res & Dev, Drug Safety Evaluat, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Pfizer	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu		Morrish, Tammy/0000-0002-6725-0253				Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Cain K, 2000, J BIOL CHEM, V275, P6067, DOI 10.1074/jbc.275.9.6067; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; Duan HJ, 1996, J BIOL CHEM, V271, P16720, DOI 10.1074/jbc.271.28.16720; HENGARTNER MO, 1994, PHILOS T R SOC B, V345, P243, DOI 10.1098/rstb.1994.0100; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Kanuka H, 1999, MOL CELL, V4, P757, DOI 10.1016/S1097-2765(00)80386-X; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Li HL, 1997, J BIOL CHEM, V272, P21010, DOI 10.1074/jbc.272.34.21010; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Mancini M, 2000, J CELL BIOL, V149, P603, DOI 10.1083/jcb.149.3.603; Masumoto J, 1999, J BIOL CHEM, V274, P33835, DOI 10.1074/jbc.274.48.33835; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Rodriguez A, 1999, NAT CELL BIOL, V1, P272, DOI 10.1038/12984; Shearwin-Whyatt LM, 2000, CELL DEATH DIFFER, V7, P155, DOI 10.1038/sj.cdd.4400632; Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243; Susin SA, 1999, J EXP MED, V189, P381, DOI 10.1084/jem.189.2.381; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Vincenz C, 1997, J BIOL CHEM, V272, P6578, DOI 10.1074/jbc.272.10.6578; YUAN JY, 1992, DEVELOPMENT, V116, P309; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	29	122	131	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9230	9238		10.1074/jbc.M009853200	http://dx.doi.org/10.1074/jbc.M009853200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11076957	hybrid			2022-12-25	WOS:000167607700082
J	Hiatt, KK; Ingram, DA; Zhang, YY; Bollag, G; Clapp, DW				Hiatt, KK; Ingram, DA; Zhang, YY; Bollag, G; Clapp, DW			Neurofibromin GTPase-activating protein-related domains restore normal growth in Nf1-/- cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAP-RELATED DOMAIN; MAST-CELLS; HEMATOPOIETIC-CELLS; IN-VIVO; GENE; TYPE-1; MICE; FIBROBLASTS; LEUKEMIA; LEADS	Members of the Ras superfamily of signaling proteins modulate fundamental cellular processes by cycling between ari:active GTP-bound conformation and an inactive GDP-bound form. Neurofibromin, the protein product of the NF1 turner suppressor gene, and p120GAP are GTPase-activating proteins (GAPs) for p21(Ras) (Ras) and negatively regulate output by accelerating GTP hydrolysis On Ras. Neurofibromin and p120GAP differ markedly outside of their conserved GAP-related domains (GRDs), and it is therefore unknown if the respective GRDs contribute functional specificity. To address this question, we expressed the GRDs of neurofibromin and p120GAP in primary cells from Nf1 mutant mice in vitro and in vivo, Here we show that expression of neurofibromin GRD, but not the p120GAP GRD, restores normal growth and cytokine signaling in three lineages of primary Nf1-deficient cells that have been implicated in the pathogenesis of neurofibromatosis type 1 (NF1). Furthermore, utilizing a GAP-inactive mutant NF1 GRD identified in a family with NF1, we demonstrate that growth restoration is a function of NF1 GRD GAP activity on p21(Ras), Thus, the GRDs of neurofibromin and p120GAP specify nonoverlapping functions in multiple primary cell types.	Indiana Univ, Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Microbiol Immunol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Dept Pediat, Indianapolis, IN 46202 USA; Omyx Pharmaceut, Richmond, CA 94806 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis	Clapp, DW (corresponding author), Indiana Univ, Sch Med, Inst Canc Res, 1044 W Walnut,Rm 421, Indianapolis, IN 46202 USA.				NCI NIH HHS [R29 CA74177-01] Funding Source: Medline; NICHD NIH HHS [K12-HD0050] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA074177] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmadian MR, 1996, J BIOL CHEM, V271, P16409, DOI 10.1074/jbc.271.27.16409; Atit RP, 1999, J INVEST DERMATOL, V112, P835, DOI 10.1046/j.1523-1747.1999.00609.x; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; Birnbaum RA, 2000, MOL CELL, V5, P189, DOI 10.1016/S1097-2765(00)80415-3; BOLLAG G, 1992, NATURE, V356, P663, DOI 10.1038/356663a0; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; BRODEUR GM, 1994, NEW ENGL J MED, V330, P637, DOI 10.1056/NEJM199403033300912; CLAPP DW, 1995, EXP HEMATOL, V23, P630; EMANUEL PD, 1991, EXP HEMATOL, V19, P1017; Fahsold R, 2000, AM J HUM GENET, V66, P790, DOI 10.1086/302809; GALLI SJ, 1993, AM J PATHOL, V142, P965; HAWLEY RG, 1994, GENE THER, V1, P136; Ingram DA, 2000, J EXP MED, V191, P181, DOI 10.1084/jem.191.1.181; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Klose A, 1998, HUM MOL GENET, V7, P1261, DOI 10.1093/hmg/7.8.1261; Largaespada DA, 1996, NAT GENET, V12, P137, DOI 10.1038/ng0296-137; Li Y, 1996, CANCER RES, V56, P2872; MARKOWITZ D, 1988, VIROLOGY, V167, P400, DOI 10.1016/S0042-6822(88)90101-8; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; Rodewald HR, 1996, SCIENCE, V271, P818, DOI 10.1126/science.271.5250.818; ROSENBAUM T, 1995, DEVELOPMENT, V121, P3583; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1998, EMBO J, V17, P4313, DOI 10.1093/emboj/17.15.4313; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Side L, 1997, NEW ENGL J MED, V336, P1713, DOI 10.1056/NEJM199706123362404; The I, 1997, SCIENCE, V276, P791, DOI 10.1126/science.276.5313.791; Tsai M, 2000, P NATL ACAD SCI USA, V97, P9186, DOI 10.1073/pnas.160254997; Zhang YY, 1998, J EXP MED, V187, P1893, DOI 10.1084/jem.187.11.1893	33	86	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7240	7245		10.1074/jbc.M009202200	http://dx.doi.org/10.1074/jbc.M009202200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11080503	hybrid			2022-12-25	WOS:000167442900054
J	Banbula, A; Yen, J; Oleksy, A; Mak, P; Bugno, M; Travis, J; Potempa, J				Banbula, A; Yen, J; Oleksy, A; Mak, P; Bugno, M; Travis, J; Potempa, J			Porphyromonas gingivalis DPP-7 represents a novel type of dipeptidylpeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; BIOCHEMICAL-CHARACTERIZATION; BACTEROIDES-GINGIVALIS; GEL-ELECTROPHORESIS; PROTEASE GENE; PEPTIDASE-IV; PURIFICATION; PROTEINS; COLLAGENASE; EXPRESSION	A novel dipeptidylpeptidase (DPP-7) was purified from the membrane fraction of Porphyromonas gingivalis. This enzyme, with an apparent molecular mass of 76 kDa, has the specificity for both aliphatic and aromatic residues in the P1 position. Although it belongs to the serine class of peptidases, it does not resemble other known dipeptidylpeptidases. Interestingly, the amino acid sequence around the putative active site serine residue shows significant similarity to the C-terminal region of the Staphylococcus aureus V-8 endopeptidase. The genes encoding homologues of DPP-7 were found in genomes of Xylella fastidiosa, Shewanella putrefaciens, and P. gingivalis. It is likely that at least in P. gingivalis, DPP-7 and its homologue, in concert with other di- and tripeptidases, serve nutritional functions by providing dipeptides to this asaccharolytic bacterium.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Jagiellonian Univ, Inst Mol Biol, PL-34120 Krakow, Poland	University System of Georgia; University of Georgia; Jagiellonian University	Potempa, J (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.			Mak, Pawel/0000-0002-5222-3922	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE009761] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 09761] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Awano S, 1999, FEBS LETT, V460, P139, DOI 10.1016/S0014-5793(99)01326-5; Banbula A, 1999, J BIOL CHEM, V274, P9246, DOI 10.1074/jbc.274.14.9246; Banbula A, 2000, INFECT IMMUN, V68, P1176, DOI 10.1128/IAI.68.3.1176-1182.2000; Barrett A. J., 1998, HDB PROTEOLYTIC ENZY; Beauvais A, 1997, J BIOL CHEM, V272, P6238, DOI 10.1074/jbc.272.10.6238; BIRKEDALHANSEN H, 1988, J PERIODONTAL RES, V23, P258, DOI 10.1111/j.1600-0765.1988.tb01369.x; BOURGEAU G, 1992, INFECT IMMUN, V60, P3186, DOI 10.1128/IAI.60.8.3186-3192.1992; CARMONA C, 1987, NUCLEIC ACIDS RES, V15, P6757, DOI 10.1093/nar/15.16.6757; CHEN ZX, 1992, J BIOL CHEM, V267, P18896; Curtis MA, 1999, J PERIODONTAL RES, V34, P464, DOI 10.1111/j.1600-0765.1999.tb02282.x; ELLIS S, 1967, J BIOL CHEM, V242, P4623; KATO T, 1992, J BACTERIOL, V174, P3889, DOI 10.1128/jb.174.12.3889-3895.1992; Kiyama M, 1998, BBA-GENE STRUCT EXPR, V1396, P39, DOI 10.1016/S0167-4781(97)00225-X; Kumagai Y, 2000, INFECT IMMUN, V68, P716, DOI 10.1128/IAI.68.2.716-724.2000; LAWSON DA, 1992, INFECT IMMUN, V60, P1524, DOI 10.1128/IAI.60.4.1524-1529.1992; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCGUIRE MJ, 1992, ARCH BIOCHEM BIOPHYS, V295, P280, DOI 10.1016/0003-9861(92)90519-3; Nelson D, 1999, J BIOL CHEM, V274, P12245, DOI 10.1074/jbc.274.18.12245; Ogasawara W, 1996, J BACTERIOL, V178, P6288, DOI 10.1128/jb.178.21.6288-6295.1996; OTOGOTO JI, 1993, INFECT IMMUN, V61, P117, DOI 10.1128/IAI.61.1.117-123.1993; Pohl Jan, 1995, Letters in Peptide Science, V1, P291, DOI 10.1007/BF00119770; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Travis J, 2000, ADV EXP MED BIOL, V477, P455; VACHERON MJ, 1979, EUR J BIOCHEM, V100, P189, DOI 10.1111/j.1432-1033.1979.tb02048.x	26	44	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6299	6305		10.1074/jbc.M008789200	http://dx.doi.org/10.1074/jbc.M008789200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096098	hybrid			2022-12-25	WOS:000167261000033
J	Mzhavia, N; Berman, Y; Che, FY; Fricker, LD; Devi, LA				Mzhavia, N; Berman, Y; Che, FY; Fricker, LD; Devi, LA			ProSAAS processing in mouse brain and pituitary	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OBESE FAT/FAT MICE; CARBOXYPEPTIDASE-E; PROPROTEIN CONVERTASES; HORMONE BIOSYNTHESIS; BASIC RESIDUES; PRO-PROTEIN; PROHORMONE; PRECURSOR; PC2; SPECIFICITY	ProSAAS is a newly discovered protein with a neuroendocrine distribution generally similar to that of prohormone convertase 1 (PC1), a peptide-processing endopeptidase. Several proSAAS-derived peptides were previously identified in the brain and pituitary of the Cpe(fa)t/Cpe(fat) mouse based on the accumulation of C-terminally extended peptides due to the absence of enzymatically active carboxypeptidase E, a peptide-processing exopeptidase. In the present study, antisera against different regions of proSAAS were used to develop radioimmunoassays and examine the processing profile of proSAAS in wild type and Cpe(fat)/Cpe(fat) mouse tissues following gel filtration and reverse phase high performance liquid chromatography. In wild type mouse brain and pituitary, the majority of proSAAS is processed into smaller peptides. These proSAAS derived peptides elute from the reverse-phase column in the same positions as synthetic peptides that correspond to little SAAS, PEN, and big LEN. Mass spectrometry revealed the presence of peptides with the expected molecular masses of little SAAS and big LEN in the fractions containing immunoreactive peptides. The processing of proSAAS is slightly impaired in Cpe(fat)/Cpe(fat) mice, relative to wild-type mice, leading to the accumulation of partially processed peptides. One of these peptides, the C-terminally extended farm of PEN, is known to inhibit PC1 activity and this could account for the reduction in enzymatically active PC1 seen in Cpe(fat)/Cpe(fat) mice. The observation that little SAAS and big LEN are the major forms of these peptides produced in mouse brain and pituitary raises the possibility that these peptides function as neurotransmitters or hormones.	NYU Med Ctr, Dept Pharmacol, Sch Med, New York, NY 10016 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	New York University; Yeshiva University; Albert Einstein College of Medicine	Devi, LA (corresponding author), NYU Med Ctr, Dept Pharmacol, Sch Med, MSB 411,550 1st Ave, New York, NY 10016 USA.		Devi P, Lakshmi/GXM-5982-2022	Devi P, Lakshmi/0000-0001-9274-4776; Mzhavia, Nino/0000-0001-8602-9987	NIDA NIH HHS [R01-DA04494, K02-DA00194, K02-DA00458, K01-DA00342] Funding Source: Medline; NINDS NIH HHS [R01-NS26880] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [K02DA000194, K01DA000342, R01DA004494, K02DA000458] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; Bergeron F, 2000, J MOL ENDOCRINOL, V24, P1, DOI 10.1677/jme.0.0240001; Berman Y, 2000, J NEUROCHEM, V75, P1763, DOI 10.1046/j.1471-4159.2000.0751763.x; Berman Y, 2001, J BIOL CHEM, V276, P1466, DOI 10.1074/jbc.M008499200; Cameron A, 2000, FEBS LETT, V473, P135, DOI 10.1016/S0014-5793(00)01511-8; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; DAY R, 1992, MOL ENDOCRINOL, V6, P485, DOI 10.1210/me.6.3.485; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; Fricker LD, 2000, J NEUROSCI, V20, P639, DOI 10.1523/JNEUROSCI.20-02-00639.2000; Fricker LD, 1999, TRENDS BIOCHEM SCI, V24, P390, DOI 10.1016/S0968-0004(99)01448-6; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; Furuta M, 1998, J BIOL CHEM, V273, P3431, DOI 10.1074/jbc.273.6.3431; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; Li JY, 1999, EUR J NEUROSCI, V11, P528, DOI 10.1046/j.1460-9568.1999.00456.x; MAINS RE, 1990, FRONT NEUROENDOCRIN, V11, P52; Muller L, 2000, PROG NUCLEIC ACID RE, V63, P69, DOI 10.1016/S0079-6603(08)60720-5; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NATORI S, 2000, BIOCHIMIE PARIS, V76, P277; Qian YM, 2000, J BIOL CHEM, V275, P23596, DOI 10.1074/jbc.M001583200; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SEIDAH NG, 1991, ENZYME, V45, P271, DOI 10.1159/000468901; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; STEINER DF, 1992, J BIOL CHEM, V267, P23435; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P297; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	29	45	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6207	6213		10.1074/jbc.M009067200	http://dx.doi.org/10.1074/jbc.M009067200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11094058	hybrid			2022-12-25	WOS:000167261000022
J	Fujii, R; Okamoto, M; Aratani, S; Oishi, T; Ohshima, T; Taira, K; Baba, M; Fukamizu, A; Nakajima, T				Fujii, R; Okamoto, M; Aratani, S; Oishi, T; Ohshima, T; Taira, K; Baba, M; Fukamizu, A; Nakajima, T			A role of RNA helicase A in cis-acting transactivation response element-mediated transcriptional regulation of human immunodeficiency virus type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DSRNA-BINDING DOMAINS; CYCLIN T1; HIV-1 TAT; PROTEIN; DNA; EXPRESSION; KINASE; GENE; TRBP; REV	RNA helicase A (RHA) has two double-stranded (ds) RNA-binding domains (dsRBD1 and dsRBD2). These domains are conserved with the cis-acting transactivation response element (TAR)-binding protein (TRBP) and dsRNA-activated protein kinase (PKR). TRBP and PKR are involved in the regulation of HIV-1 gene expression through their binding to TAR RNA. This study shows that RHA also plays an important role in TAR-mediated HIV-1 gene expression. Wild-type RHA preferably bound to TAR RNA in vitro and in vivo. Overexpression of wild type RHA strongly enhanced viral mRNA synthesis and virion production as well as HIV-1 long terminal repeat-directed reporter (luciferase) gene expression. Substitution of lysine for glutamate at residue 236 in dsRBD2 (RHA(K236E)) reduced its affinity for TAR RNA and impaired HIV-1 transcriptional activity. These results indicate that TAR RNA is a preferred target of RHA dsRBDs and that RHA enhances HIV-1 transcription in vivo in part through the TAR-binding of RHA.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Kagoshima Univ, Fac Med, Ctr Chron Viral Dis, Div Human Retroviruses, Kagoshima 8908520, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan	University of Tsukuba; University of Tsukuba; Kagoshima University; Japan Science & Technology Agency (JST)	Nakajima, T (corresponding author), St Marianna Univ, Inst Med Sci, Dept Genome Sci, Miyamae Ku, 2-16-1 Sugao, Kawasaki, Kanagawa 2168512, Japan.	nakashit@marianna-u.ac.jp	fukamizu, akiyoshi/J-5350-2012; Baba, Masanori/G-3867-2011	fukamizu, akiyoshi/0000-0002-8786-6020; OHSHIMA, Takayuki/0000-0002-1501-6430				ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; Benkirane M, 1998, J BIOL CHEM, V273, P24898, DOI 10.1074/jbc.273.38.24898; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; BUTERA ST, 1994, J VIROL, V68, P2726, DOI 10.1128/JVI.68.4.2726-2730.1994; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Daviet L, 2000, EUR J BIOCHEM, V267, P2419, DOI 10.1046/j.1432-1327.2000.01256.x; Erard M, 1998, J MOL BIOL, V279, P1085, DOI 10.1006/jmbi.1998.1831; FELBER BK, 1989, P NATL ACAD SCI USA, V86, P1495, DOI 10.1073/pnas.86.5.1495; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; GATIGNOL A, 1993, MOL CELL BIOL, V13, P2193, DOI 10.1128/MCB.13.4.2193; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P2552, DOI 10.1093/nar/22.13.2552; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; KIM SY, 1989, J VIROL, V63, P3708, DOI 10.1128/JVI.63.9.3708-3713.1989; Koseki S, 1998, J CONTROL RELEASE, V53, P159, DOI 10.1016/S0168-3659(97)00250-2; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; MCCORMACK SJ, 1992, VIROLOGY, V188, P47, DOI 10.1016/0042-6822(92)90733-6; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; NABEL G, 1987, NATURE, V326, P711, DOI 10.1038/326711a0; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; NATARAJAN V, 1993, VIROLOGY, V196, P122, DOI 10.1006/viro.1993.1460; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; Tang HL, 1997, SCIENCE, V276, P1412, DOI 10.1126/science.276.5317.1412; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Ulich C, 1999, J VIROL, V73, P2499, DOI 10.1128/JVI.73.3.2499-2508.1999; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; ZHANG SS, 1994, BIOCHEMISTRY-US, V33, P3906, DOI 10.1021/bi00179a016; Zhang SS, 1997, J BIOL CHEM, V272, P11487; ZHANG SS, 1991, J BIOL CHEM, V266, P20483	42	94	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5445	5451		10.1074/jbc.M006892200	http://dx.doi.org/10.1074/jbc.M006892200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11096080	hybrid			2022-12-25	WOS:000167115100007
J	Manni, I; Mazzaro, G; Gurtner, A; Mantovani, R; Haugwitz, U; Krause, K; Engeland, K; Sacchi, A; Soddu, S; Piaggio, G				Manni, I; Mazzaro, G; Gurtner, A; Mantovani, R; Haugwitz, U; Krause, K; Engeland, K; Sacchi, A; Soddu, S; Piaggio, G			NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G(2) arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; CELL-CYCLE; DEPENDENT REGULATION; TUMOR SUPPRESSORS; BINDING; PROTEIN; ACTIVATION; CHECKPOINT; COMPLEX; GENE	During normal cell cycles, the function of mitotic cyclin-cdk1 complexes, as web as of cdc25C phosphatase, is required for G(2) phase progression. Accordingly, the G(2) arrest induced by DNA damage is associated with a down-regulation of mitotic cyclins, cdk1, and cdc25C phosphatase expression. We found that the promoter activity of these genes is repressed in the G(2) arrest induced by DNA damage. We asked whether the CCAAT-binding NF-Y modulates mitotic cyclins, cdk1, and cdc25C gene transcription during this type of G(2) arrest. In our experimental conditions, the integrity of the CCAAT boxes of cyclin B1, cyclin B2, and cdc25C promoters, as well as the presence of a functional NF-Y complex, is strictly required for the transcriptional inhibition of these promoters. Furthermore, a dominant-negative p53 protein, impairing doxorubicin-induced G(2) arrest, prevents transcriptional down-regulation of the mitotic cyclins, cdkl, and cdc25C genes. We conclude that, as already demonstrated for cdk1, NF-Y mediates the transcriptional inhibition of the mitotic cyclins and the cdc25C genes during p53-dependent G(2) arrest induced by DNA damage. These data suggest a transcriptional regulatory role of NF-Y in the G(2) checkpoint after DNA damage.	CNR, Ist Regina Elena, Lab Oncogenesi Mol, I-00158 Rome, Italy; Univ Modena & Reggio Emilia, Dipartimento Biol Anim, I-41100 Modena, Italy; Univ Leipzig, Max Burger Forschungszentrum, Med Klin 2, D-04103 Leipzig, Germany	Consiglio Nazionale delle Ricerche (CNR); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Universita di Modena e Reggio Emilia; Leipzig University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Piaggio, G (corresponding author), CNR, Ist Regina Elena, Lab Oncogenesi Mol, Via Messi DOro 156, I-00158 Rome, Italy.	piaggio@ifo.it	Soddu, Silvia/K-2467-2018; Gurtner, Aymone/J-7217-2018; Manni, Isabella/ABH-6460-2020; Soddu, Silvia/ABH-6774-2020; gurtner, aymone/AAB-8843-2020; Piaggio, Giulia/AAD-7336-2022; Engeland, Kurt/AAW-9965-2020; Piaggio, Giulia/J-7214-2018	Soddu, Silvia/0000-0001-8526-0044; Gurtner, Aymone/0000-0002-7661-9059; Manni, Isabella/0000-0003-4823-0596; Soddu, Silvia/0000-0001-8526-0044; gurtner, aymone/0000-0002-7661-9059; Engeland, Kurt/0000-0003-3525-0440; Piaggio, Giulia/0000-0003-2114-1892; Rother, Karen/0000-0002-0074-7329	Telethon [1035] Funding Source: Medline	Telethon(Fondazione Telethon)		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bellorini M, 1997, GENE, V193, P119, DOI 10.1016/S0378-1119(97)00109-1; Bellorini M, 1997, NUCLEIC ACIDS RES, V25, P2174, DOI 10.1093/nar/25.11.2174; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; Bregman DB, 2000, FRONT BIOSCI, V5, pD244, DOI 10.2741/Bregman; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Caretti G, 1999, MOL CELL BIOL, V19, P8591; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; de Toledo SM, 1998, CELL GROWTH DIFFER, V9, P887; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; Farmer G, 1996, NUCLEIC ACIDS RES, V24, P4281, DOI 10.1093/nar/24.21.4281; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Flatt PM, 2000, MOL CELL BIOL, V20, P4210, DOI 10.1128/MCB.20.12.4210-4223.2000; Gopalkrishnan RV, 1998, J BIOL CHEM, V273, P10972, DOI 10.1074/jbc.273.18.10972; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HWANG A, 1995, J BIOL CHEM, V270, P28419; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; KASTAN MB, 1991, CANCER RES, V51, P6304; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Krause K, 2000, NUCLEIC ACIDS RES, V28, P4410, DOI 10.1093/nar/28.22.4410; Lee Hu-Hui, 1995, Gene Expression, V4, P95; Li Q, 1998, EMBO J, V17, P6300, DOI 10.1093/emboj/17.21.6300; LI XY, 1992, J BIOL CHEM, V267, P8984; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MAITY A, 1994, RADIOTHER ONCOL, V31, P1, DOI 10.1016/0167-8140(94)90408-1; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Park M, 2000, CANCER RES, V60, P542; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Passalaris TM, 1999, MOL CELL BIOL, V19, P5872, DOI 10.1128/mcb.19.9.5872; PIAGGIO G, 1995, EXP CELL RES, V216, P396, DOI 10.1006/excr.1995.1050; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Scardigli R, 1997, GENE THER, V4, P1371, DOI 10.1038/sj.gt.3300530; SCHULZE A, 1995, P NATL ACAD SCI USA, V92, P11264, DOI 10.1073/pnas.92.24.11264; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; Sugrue MM, 1997, P NATL ACAD SCI USA, V94, P9648, DOI 10.1073/pnas.94.18.9648; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822	60	154	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5570	5576		10.1074/jbc.M006052200	http://dx.doi.org/10.1074/jbc.M006052200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11096075	hybrid			2022-12-25	WOS:000167115100024
J	Gliksman, NR; Santoyo, G; Novak, KD; Titus, MA				Gliksman, NR; Santoyo, G; Novak, KD; Titus, MA			Myosin I phosphorylation is increased by chemotactic stimulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN KINASE; CHEMOATTRACTANT-ELICITED INCREASES; ACANTHAMOEBA-CASTELLANII; DICTYOSTELIUM-DISCOIDEUM; PHOSPHOAMINO ACIDS; ACTIN ACTIVATION; TEDS RULE; PROTEIN; MUTANTS; CELLS	Directed cell migration occurs in response to extracellular cues. Following stimulation of a cell with chemoattractant, a significant rearrangement of the actin cytoskeleton is mediated by intracellular signaling pathways and results in polarization of the cell and movement via pseudopod extension. Amoeboid myosin Is play a critical role in regulating pseudopod formation in Dictyostelium, and their activity is activated by heavy chain phosphorylation. The effect of chemotactic stimulation on the in vivo phosphorylation level of a Dictyostelium myosin I, myoB, was tested. The myoB heavy chain is phosphorylated in vivo on serine 322 (the myosin TEDS rule phosphorylation site) in chemotactically competent cells. The level of myoB phosphorylation increases following stimulation of starving cells with the chemoattractant cAMP, A 3-fold peak increase in the level of phosphorylation is observed at 60 s following stimulation, a time at which the Dictyostelium cell actively extends pseudopodia. These findings suggest that chemotactic stimulation results in increased myoB activity via heavy chain phosphorylation and contributes to the global extension of pseudopodia that occurs prior to polarization and directed motility.	Univ Minnesota, Dept Genet Cell Biol & Dev, Minneapolis, MN 55455 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	University of Minnesota System; University of Minnesota Twin Cities; Duke University	Titus, MA (corresponding author), Univ Minnesota, Dept Genet Cell Biol & Dev, 6-160 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	titus@lenti.med.umn.edu		Novak, Kristine/0000-0001-9314-1803	NIGMS NIH HHS [GM46486, F32-GM16090] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM016090, R01GM046486] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAINES IC, 1995, J CELL BIOL, V130, P591, DOI 10.1083/jcb.130.3.591; BEMENT WM, 1995, CELL MOTIL CYTOSKEL, V31, P87, DOI 10.1002/cm.970310202; BERLOT CH, 1985, CELL, V43, P307, DOI 10.1016/0092-8674(85)90036-4; BERLOT CH, 1987, J BIOL CHEM, V262, P3918; BRZESKA H, 1990, J BIOL CHEM, V265, P3591; Brzeska H, 1999, P NATL ACAD SCI USA, V96, P394, DOI 10.1073/pnas.96.2.394; Brzeska H, 1996, J BIOL CHEM, V271, P27056, DOI 10.1074/jbc.271.43.27056; Chen MY, 1996, TRENDS GENET, V12, P52, DOI 10.1016/0168-9525(96)81400-4; Coluccio LM, 1997, AM J PHYSIOL-CELL PH, V273, pC347, DOI 10.1152/ajpcell.1997.273.2.C347; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; DHARMAWARDHANE S, 1989, CELL MOTIL CYTOSKEL, V13, P57, DOI 10.1002/cm.970130107; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; FUTRELLE RP, 1982, J CELL BIOL, V92, P807, DOI 10.1083/jcb.92.3.807; HALL AL, 1988, J CELL BIOCHEM, V37, P285, DOI 10.1002/jcb.240370304; HAMMER JA, 1983, J BIOL CHEM, V258, P168; HOWE CL, 1983, J CELL BIOL, V97, P974, DOI 10.1083/jcb.97.4.974; JUNG G, 1993, J BIOL CHEM, V268, P14981; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KUCZMARSKI ER, 1980, P NATL ACAD SCI-BIOL, V77, P7292, DOI 10.1073/pnas.77.12.7292; Lee SF, 1998, J BIOL CHEM, V273, P27911, DOI 10.1074/jbc.273.43.27911; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; Lee WL, 1999, J BIOL CHEM, V274, P35159, DOI 10.1074/jbc.274.49.35159; LIU G, 1988, J CELL SCI, V90, P123; Liu X, 2000, J BIOL CHEM, V275, P24886, DOI 10.1074/jbc.M004287200; LYNCH TJ, 1991, METHOD ENZYMOL, V196, P12; MARUTA H, 1977, J BIOL CHEM, V252, P8329; Novak KD, 1997, J CELL BIOL, V136, P633, DOI 10.1083/jcb.136.3.633; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; Novak KD, 1998, MOL BIOL CELL, V9, P75, DOI 10.1091/mbc.9.1.75; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; RAHMSDORF HJ, 1978, FEBS LETT, V88, P322, DOI 10.1016/0014-5793(78)80203-8; Schwarz EC, 2000, J CELL SCI, V113, P621; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SWANLJUNGCOLLINS H, 1992, J BIOL CHEM, V267, P3445; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERNER K, 1985, J CELL BIOL, V100, P1455, DOI 10.1083/jcb.100.5.1455; Wessels D, 1996, CELL MOTIL CYTOSKEL, V33, P64, DOI 10.1002/(SICI)1097-0169(1996)33:1<64::AID-CM7>3.0.CO;2-I; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; Wu C, 1997, J BIOL CHEM, V272, P30623, DOI 10.1074/jbc.272.49.30623; Yamashita RA, 1998, J BIOL CHEM, V273, P14644, DOI 10.1074/jbc.273.23.14644	45	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5235	5239		10.1074/jbc.M008319200	http://dx.doi.org/10.1074/jbc.M008319200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11084033	hybrid			2022-12-25	WOS:000168484300094
J	Witt, CC; Gerull, B; Davies, MJ; Centner, T; Linke, WA; Thierfelder, L				Witt, CC; Gerull, B; Davies, MJ; Centner, T; Linke, WA; Thierfelder, L			Hypercontractile properties of cardiac muscle fibers in a knock-in mouse model of cardiac myosin-binding protein-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; SKELETAL-MUSCLE; TROPONIN-I; REGULATORY DOMAIN; MYBP-C; PHOSPHORYLATION; MUTATIONS; GENE; ISOFORM; IDENTIFICATION	Myosin-binding protein-c (MyBP-C) is a component of all striated-muscle sarcomeres, with a well established structural role and a possible function for force regulation. Multiple mutations within the gene for cardiac MyBP-C, one of three known isoforms, have been linked to familial hypertrophic cardiomyopathy, Here we generated a knock-in mouse model that carries N-terminal-shortened cardiac MyBP-C, The mutant protein was designed to have a similar size as the skeletal MyBP-C isoforms, whereas known myosin and titin binding sites as well as the phosphorylatable MyBP-C motif were not altered. We have shown that mutant cardiac MyBP-C is readily incorporated into the sarcomeres of both heterozygous and homozygous animals and can still be phosphorylated by cAMP-dependent protein kinase. Although histological characterization of wild-type and mutant hearts did not reveal obvious differences in phenotype, left ventricular fibers from homozygous mutant mice exhibited an increased Ca2+ sensitivity of force development, particularly at lower Ca2+ concentrations, whereas maximal active force levels remained unchanged. The results allow us to propose a model of how cMyBP-C may affect myosin-head mobility and to rationalize why N-terminal mutations of the protein in some cases of familial hypertrophic cardiomyopathy could lead to a hypercontractile state.	Univ Heidelberg, Inst Physiol & Pathophysiol, D-69120 Heidelberg, Germany; Max Delbruck Ctr Mol Med, D-13122 Berlin, Germany; Univ Heidelberg, Klinikum Mannheim, Inst Anasthesiol & Operat Intens Med, D-68167 Mannheim, Germany; Univ London St Georges Hosp, Sch Med, British Heart Fdn, Cardiovasc Pathol Unit, London SW17 0RE, England; European Mol Biol Lab, D-69012 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Ruprecht Karls University Heidelberg; St Georges University London; University of London; University College London; UCL Medical School; European Molecular Biology Laboratory (EMBL)	Linke, WA (corresponding author), Univ Heidelberg, Inst Physiol & Pathophysiol, Neuenheimer Feld 326, D-69120 Heidelberg, Germany.		Linke, Wolfgang A/E-8662-2012	Linke, Wolfgang/0000-0003-0801-3773				Alyonycheva TN, 1997, J BIOL CHEM, V272, P20866, DOI 10.1074/jbc.272.33.20866; BENNETT P, 1986, J MUSCLE RES CELL M, V7, P550, DOI 10.1007/BF01753571; Bing W, 1997, BIOCHEM BIOPH RES CO, V236, P760, DOI 10.1006/bbrc.1997.7045; Bonne G, 1998, CIRC RES, V83, P580, DOI 10.1161/01.RES.83.6.580; Bottinelli R, 1998, CIRC RES, V82, P106; Carrier L, 1997, CIRC RES, V80, P427, DOI 10.1161/01.res.0000435859.24609.b3; Charron P, 1998, CIRCULATION, V97, P2230, DOI 10.1161/01.CIR.97.22.2230; DENNIS JE, 1984, J CELL BIOL, V98, P1514, DOI 10.1083/jcb.98.4.1514; Dohet C, 1995, FEBS LETT, V377, P131, DOI 10.1016/0014-5793(95)01319-9; Flavigny J, 1999, J MOL BIOL, V294, P443, DOI 10.1006/jmbi.1999.3276; Freiburg A, 1996, EUR J BIOCHEM, V235, P317, DOI 10.1111/j.1432-1033.1996.00317.x; GAUTEL M, 1995, EMBO J, V14, P1952, DOI 10.1002/j.1460-2075.1995.tb07187.x; Gilbert R, 1999, J CELL SCI, V112, P69; Gruen M, 1999, FEBS LETT, V453, P254, DOI 10.1016/S0014-5793(99)00727-9; Gruen M, 1999, J MOL BIOL, V286, P933, DOI 10.1006/jmbi.1998.2522; HARTZELL HC, 1984, J BIOL CHEM, V259, P5587; HERZIG JW, 1981, PFLUG ARCH EUR J PHY, V391, P208, DOI 10.1007/BF00596172; HOFMANN PA, 1991, J GEN PHYSIOL, V97, P1141, DOI 10.1085/jgp.97.6.1141; HOFMANN PA, 1994, CIRC RES, V74, P718, DOI 10.1161/01.RES.74.4.718; Kramer J, 1999, J MOL MED-JMM, V77, P294, DOI 10.1007/s001090050352; Kunst G, 2000, CIRC RES, V86, P51, DOI 10.1161/01.RES.86.1.51; Linke WA, 1999, J CELL BIOL, V146, P631, DOI 10.1083/jcb.146.3.631; McConnell BK, 1999, J CLIN INVEST, V104, P1235, DOI 10.1172/JCI7377; MCKENNA WJ, 1990, BRIT HEART J, V63, P287; Mogensen J, 1999, J CLIN INVEST, V103, pR39, DOI 10.1172/JCI6460; Niimura H, 1998, NEW ENGL J MED, V338, P1248, DOI 10.1056/NEJM199804303381802; OFFER G, 1973, J MOL BIOL, V74, P653, DOI 10.1016/0022-2836(73)90055-7; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; SCHLENDER KK, 1991, J BIOL CHEM, V266, P2811; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; VENEMA RC, 1993, J BIOL CHEM, V268, P2705; WATKINS H, 1995, NAT GENET, V11, P434, DOI 10.1038/ng1295-434; WEBER FE, 1993, EUR J BIOCHEM, V216, P661, DOI 10.1111/j.1432-1033.1993.tb18186.x; Weisberg A, 1996, P NATL ACAD SCI USA, V93, P8999, DOI 10.1073/pnas.93.17.8999; Winegrad S, 1999, CIRC RES, V84, P1117, DOI 10.1161/01.RES.84.10.1117; Winegrad S, 2000, CIRC RES, V86, P6, DOI 10.1161/01.RES.86.1.6; YAMAMOTO K, 1983, J BIOL CHEM, V258, P8395; Yang QL, 1999, CIRC RES, V85, P841, DOI 10.1161/01.RES.85.9.841; Yang QL, 1998, J CLIN INVEST, V102, P1292, DOI 10.1172/JCI3880	39	52	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5353	5359		10.1074/jbc.M008691200	http://dx.doi.org/10.1074/jbc.M008691200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11096095	hybrid			2022-12-25	WOS:000168484300110
J	Schlegel, A; Arvan, P; Lisanti, MP				Schlegel, A; Arvan, P; Lisanti, MP			Caveolin-1 binding to endoplasmic reticulum membranes and entry into the regulated secretory pathway are regulated by serine phosphorylation - Protein sorting at the level of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; GIRDLE MUSCULAR-DYSTROPHY; TRANS-GOLGI-NETWORK; PLASMA-MEMBRANE; IN-VIVO; EPITHELIAL-CELLS; GENE FAMILY; MOLECULAR CHARACTERIZATION; SUBCELLULAR-DISTRIBUTION; MUTATIONAL ANALYSIS	Caveolin-1 serves as the main coat protein of caveolae membranes, as an intracellular cholesterol shuttle, and as a regulator of diverse signaling molecules. Of the 12 residues conserved across all caveolin isoforms from all species examined to date, only Ser(80) and Ser(168) could serve as phosphorylation sites. me show here that mimicking chronic phosphorylation of Ser(80) by mutation to Glu tie. Cav-1(S80E), blocks phosphate incorporation. However, Cav-1(S168E) is phosphorylated to the same extent as wild-type caveolin-1. Cav-1(S80E) targets to the endoplasmic reticulum membrane, remains oligomeric, and maintains normal membrane topology. In contrast, Cav-1(S80A), which cannot be phosphorylated, targets to caveolae membranes. Some exocrine cells secrete caveolin-1 in a regulated manner. Cav-1(S80A) is not secreted by AR42J pancreatic adenocarcinoma cells even in the presence of dexamethasone, an agent that induces the secretory phenotype. Conversely, Cav-1(S80E) is secreted to a greater extent than wildtype caveolin-1 following dexamethasone treatment. We conclude that caveolin-1 phosphorylation on invariant serine residue 80 is required for endoplasmic reticulum retention and entry into the regulated secretory pathway.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Div Endocrinol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Lisanti, MP (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	lisanti@aecom.yu.edu	Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013	Lisanti, Michael/0000-0003-2034-1382; Schlegel, Amnon/0000-0003-4060-2252	NIGMS NIH HHS [T32-GM07288] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007288] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; DIETZEN DJ, 1995, J BIOL CHEM, V270, P6838, DOI 10.1074/jbc.270.12.6838; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Engelman JA, 1998, AM J HUM GENET, V63, P1578, DOI 10.1086/302172; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fielding CJ, 1999, BIOCHEMISTRY-US, V38, P2506, DOI 10.1021/bi981012o; Fielding PE, 1996, BIOCHEMISTRY-US, V35, P14932, DOI 10.1021/bi9613382; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Galbiati F, 1999, J BIOL CHEM, V274, P25632, DOI 10.1074/jbc.274.36.25632; GLENNEY JR, 1989, J CELL BIOL, V108, P2401, DOI 10.1083/jcb.108.6.2401; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; Ikezu T, 1998, BRAIN RES, V804, P177, DOI 10.1016/S0006-8993(98)00498-3; Ko YG, 1998, J CELL BIOCHEM, V71, P524, DOI 10.1002/(SICI)1097-4644(19981215)71:4<524::AID-JCB7>3.3.CO;2-2; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; Li SW, 1998, FEBS LETT, V434, P127, DOI 10.1016/S0014-5793(98)00945-4; Li SW, 1996, J BIOL CHEM, V271, P28647, DOI 10.1074/jbc.271.45.28647; Li SW, 1996, J BIOL CHEM, V271, P3863; LISANTI MP, 1989, J CELL BIOL, V109, P2145, DOI 10.1083/jcb.109.5.2145; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; Luton F, 1999, MOL CELL, V4, P627, DOI 10.1016/S1097-2765(00)80213-0; Luton F, 1999, MOL BIOL CELL, V10, P1409, DOI 10.1091/mbc.10.5.1409; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; Nomura R, 1999, MOL BIOL CELL, V10, P975, DOI 10.1091/mbc.10.4.975; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; RAJASEKARAN AK, 1993, J CELL SCI, V105, P333; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SARGIACOMO M, 1994, ONCOGENE, V9, P2589; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Scherer PE, 1997, J BIOL CHEM, V272, P29337, DOI 10.1074/jbc.272.46.29337; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song KS, 1997, J BIOL CHEM, V272, P4398, DOI 10.1074/jbc.272.7.4398; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; Uittenbogaard A, 2000, J BIOL CHEM, V275, P25595, DOI 10.1074/jbc.M003401200; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; Volonte D, 1999, FEBS LETT, V445, P431, DOI 10.1016/S0014-5793(99)00164-7; Way M, 1996, FEBS LETT, V378, P101, DOI 10.1016/0014-5793(96)82884-5; Zelenski NG, 1999, J BIOL CHEM, V274, P21973, DOI 10.1074/jbc.274.31.21973	67	88	97	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4398	4408		10.1074/jbc.M005448200	http://dx.doi.org/10.1074/jbc.M005448200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11078729	hybrid			2022-12-25	WOS:000166921200089
J	Inohara, N; Ogura, Y; Chen, FF; Muto, A; Nunez, G				Inohara, N; Ogura, Y; Chen, FF; Muto, A; Nunez, G			Human Nod1 confers responsiveness to bacterial lipopolysaccharides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL ACTIVATION; PROTEIN-KINASE; CYTOCHROME-C; RECRUITMENT; COMPLEX; RIP	The immune response to microbial pathogens is initiated by recognition of specific pathogen components by host cells both at the cell surface and in the cytosol, While the response triggered by pathogen products at the surface of immune cells is well characterized, that initiated in the cytosol is poorly understood. Nod1 is a member of a growing family of intracellular proteins with structural homology to apoptosis regulators Apaf-1/Ced-4 and a class of plant disease-resistant gene products. Here we show that bacterial lipopolysaccharides, but not other pathogen components tested, induced TLR4- and MyD88-independent NF-kappaB activation in human embryonic kidney 293T cells expressing trace amounts of Nod1, Nod2, another Nod family member, also conferred responsiveness to bacterial components but with a response pattern different from that observed with Nod1. As it was reported for plant disease-resistant R proteins, the leucine-rich repeats of Nod1 and Nod2 were required for lipopolysaccharide-induced NF-kappaB activation. A lipopolysaccharide binding activity could be specifically coimmunopurified with Nod1 from cytosolic extracts. These observations suggest that Nod1 and Nod2 are mammalian counterparts of plant disease-resistant gene products that may function as cytosolic receptors for pathogen components derived from invading bacteria.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.	Gabriel.Nunez@umich.edu	Nuñez, Gabriel/A-7160-2014		NCI NIH HHS [R01 CA64556] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Dixon MS, 2000, P NATL ACAD SCI USA, V97, P8807, DOI 10.1073/pnas.97.16.8807; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; Leister RT, 2000, PLANT J, V22, P345, DOI 10.1046/j.1365-313x.2000.00744.x; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Philpott DJ, 2000, J IMMUNOL, V165, P903, DOI 10.4049/jimmunol.165.2.903; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rietschel ET, 1996, CURR TOP MICROBIOL, V216, P39; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shimada T, 1999, INT IMMUNOL, V11, P1357, DOI 10.1093/intimm/11.8.1357; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	24	427	444	3	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2551	2554		10.1074/jbc.M009728200	http://dx.doi.org/10.1074/jbc.M009728200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11058605	hybrid			2022-12-25	WOS:000166784800036
J	Watanabe, M; Nameki, N; Matsuo-Takasaki, M; Nishimura, S; Okada, N				Watanabe, M; Nameki, N; Matsuo-Takasaki, M; Nishimura, S; Okada, N			tRNA recognition of tRNA-guanine transglycosylase from a hyperthermophilic archaeon, Pyrococcus horikoshii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER RIBONUCLEIC-ACID; TRANSFER-RNA TRANSGLYCOSYLASE; MODIFIED NUCLEOSIDE-Q; ESCHERICHIA-COLI; POSTTRANSCRIPTIONAL MODIFICATION; SUBSTRATE RECOGNITION; ANTICODON LOOP; BASE QUEUINE; SEQUENCES; ENZYME	In the biosynthesis of archaeosine, archaeal tRNA-guanine transglycosylase (TGT) catalyzes the replacement of guanine at position 15 in the D loop of most tRNAs by a free precursor base. We examined the tRNA recognition of TGT from a hyperthermophilic archaeon, Pyrococcus horikoshii. Mutational studies using variant tRNA(Val) transcripts revealed that both guanine and its location (position 15) were strictly recognized by TGT without any other sequence-specific requirements. It appeared that neither the global L-shaped structure of a tRNA nor the local conformation of the D loop contributed to recognition by TGT, A minihelix composed of the acceptor stem and D arm of tRNA(Val), designed as a potential minimal substrate, failed to serve as a substrate for TGT, Only a minihelix with mismatched nucleotides at the junction between the two domains served as a good substrate, suggesting that mismatched nucleotides in the helix provide the specific information that allows TGT to recognize the guanine in the D loop. Our findings indicate that the tRNA recognition requirements of P. horikoshii TGT are sufficiently limited and specific to allow the enzyme to recognize efficiently any tRNA species whose structure is not fully stabilized in an extremely high temperature environment.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Banyu Tsukuba Res Inst Merck, Tsukuba, Ibaraki 3002611, Japan	Tokyo Institute of Technology; Merck & Company	Okada, N (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Dept Biol Sci, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268501, Japan.		WATANABE, Masakatsu/V-9082-2019; Nameki, Nobukazu/H-1764-2013	WATANABE, Masakatsu/0000-0002-5744-197X; 				Ando S, 1999, FEBS LETT, V447, P25, DOI 10.1016/S0014-5793(99)00257-4; Bai Y, 2000, J BIOL CHEM, V275, P28731, DOI 10.1074/jbc.M002174200; CARBON P, 1983, EMBO J, V2, P1093, DOI 10.1002/j.1460-2075.1983.tb01551.x; Constantinesco F, 1999, NUCLEIC ACIDS RES, V27, P1308, DOI 10.1093/nar/27.5.1308; CROTHERS DM, 1974, J MOL BIOL, V87, P63, DOI 10.1016/0022-2836(74)90560-9; CURNOW AW, 1995, J BIOL CHEM, V270, P17264, DOI 10.1074/jbc.270.29.17264; DIRHEIMER G, 1995, BIOCHIMIE, V77, P99, DOI 10.1016/0300-9084(96)88111-9; Dirheimer G., 1995, P93; EDMONDS CG, 1991, J BACTERIOL, V173, P3138, DOI 10.1128/JB.173.10.3138-3148.1991; FREY B, 1988, J BACTERIOL, V170, P2078, DOI 10.1128/jb.170.5.2078-2082.1988; Gonzalez JM, 1998, EXTREMOPHILES, V2, P123, DOI 10.1007/s007920050051; GREGSON JM, 1993, J BIOL CHEM, V268, P10076; Grosjean H, 1996, J MOL BIOL, V255, P67, DOI 10.1006/jmbi.1996.0007; GUPTA R, 1984, J BIOL CHEM, V259, P9461; GUPTA R, 1986, SYST APPL MICROBIOL, V7, P102, DOI 10.1016/S0723-2020(86)80131-X; HARADA F, 1972, BIOCHEMISTRY-US, V11, P301, DOI 10.1021/bi00752a024; HILBERS CW, 1976, BIOCHEMISTRY-US, V15, P1874, DOI 10.1021/bi00654a013; HIMENO H, 1989, NUCLEIC ACIDS RES, V17, P7855, DOI 10.1093/nar/17.19.7855; Hori H, 1998, J BIOL CHEM, V273, P25721, DOI 10.1074/jbc.273.40.25721; Ishikawa K, 1998, J BIOL CHEM, V273, P17726, DOI 10.1074/jbc.273.28.17726; KASAI H, 1975, NUCLEIC ACIDS RES, V2, P1931, DOI 10.1093/nar/2.10.1931; KASAI H, 1976, J AM CHEM SOC, V98, P5044, DOI 10.1021/ja00432a071; KASAI H, 1975, BIOCHEMISTRY-US, V14, P4198, DOI 10.1021/bi00690a008; KATZE JR, 1984, BIOCHEMISTRY-US, V23, P1171, DOI 10.1021/bi00301a022; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KIM SH, 1974, P NATL ACAD SCI USA, V71, P4970, DOI 10.1073/pnas.71.12.4970; KOWALAK JA, 1994, BIOCHEMISTRY-US, V33, P7869, DOI 10.1021/bi00191a014; Kung FL, 1998, FEBS LETT, V431, P427, DOI 10.1016/S0014-5793(98)00801-1; NAKANISHI S, 1994, J BIOL CHEM, V269, P32221; OKADA N, 1977, NUCLEIC ACIDS RES, V4, P2931, DOI 10.1093/nar/4.8.2931; OKADA N, 1979, J BIOL CHEM, V254, P3067; OKADA N, 1979, J BIOL CHEM, V254, P3061; Pan BC, 1998, J MOL BIOL, V283, P977, DOI 10.1006/jmbi.1998.2140; PERSSON BC, 1993, MOL MICROBIOL, V8, P1011, DOI 10.1111/j.1365-2958.1993.tb01645.x; Romier C, 1997, FEBS LETT, V416, P93, DOI 10.1016/S0014-5793(97)01175-7; Romier C, 1996, EMBO J, V15, P2850, DOI 10.1002/j.1460-2075.1996.tb00646.x; SHINDOOKADA N, 1980, BIOCHEMISTRY-US, V19, P395, DOI 10.1021/bi00543a023; SLANY RK, 1993, BIOCHEMISTRY-US, V32, P7811, DOI 10.1021/bi00081a028; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Steinberg S, 1996, RNA, V2, P84; WATANABE K, 1980, J BIOCHEM-TOKYO, V87, P1; Watanabe M, 1997, J BIOL CHEM, V272, P20146, DOI 10.1074/jbc.272.32.20146; YUAN Y, 1995, EMBO J, V14, P159, DOI 10.1002/j.1460-2075.1995.tb06986.x	43	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2387	2394		10.1074/jbc.M005043200	http://dx.doi.org/10.1074/jbc.M005043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11060284	hybrid			2022-12-25	WOS:000166784800014
J	Strop, P; Smith, KS; Iverson, TM; Ferry, JG; Rees, DC				Strop, P; Smith, KS; Iverson, TM; Ferry, JG; Rees, DC			Crystal structure of the "cab"-type beta class carbonic anhydrase from the archaeon Methanobacterium thermoautotrophicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHANOSARCINA-THERMOPHILA; CATALYTIC MECHANISM; ACTIVE-SITE; RESOLUTION; DOMAIN	The structure of the "cab"-type beta class carbonic anhydrase from the archaeon Methanobacterium thermoautotrophicum (Cab) has been determined to 2.1-Angstrom resolution using the multiwavelength anomalous diffraction phasing technique. Cab exists as a dimer with a subunit fold similar to that observed in "plant'-type beta class carbonic anhydrases. The active site zinc is coordinated by protein ligands Cys(32), His(87), and Cys(90), with the tetrahedral coordination completed by a water molecule. The major difference between plant- and cab-type beta class carbonic anhydrases is in the organization of the hydrophobic pocket. The structure reveals a Hepes buffer molecule bound 8 Angstrom away from the active site zinc, which suggests a possible proton transfer pathway from the active site to the solvent.	CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA; Penn State Univ, Dept Biochem & Mol Biol, University Pk, PA 16802 USA; CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Penn State Univ, Ctr Microbial Struct Biol, University Pk, PA 16802 USA	California Institute of Technology; Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; California Institute of Technology; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Rees, DC (corresponding author), CALTECH, Howard Hughes Med Inst, Mail Code 147-75CH, Pasadena, CA 91125 USA.				NIGMS NIH HHS [GM45162, GM44661] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044661, R37GM045162, R01GM045162] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alber BE, 1999, BIOCHEMISTRY-US, V38, P13119, DOI 10.1021/bi9828876; ALBER BE, 1994, P NATL ACAD SCI USA, V91, P6909, DOI 10.1073/pnas.91.15.6909; Alber BE, 1996, J BACTERIOL, V178, P3270, DOI 10.1128/jb.178.11.3270-3274.1996; BADGER MR, 1994, ANNU REV PLANT PHYS, V45, P369, DOI 10.1146/annurev.pp.45.060194.002101; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BENNETT MJ, 1994, P NATL ACAD SCI USA, V91, P3127, DOI 10.1073/pnas.91.8.3127; BENNETT MJ, 1995, PROTEIN SCI, V4, P2455, DOI 10.1002/pro.5560041202; BORIACKSJODIN PA, 1995, P NATL ACAD SCI USA, V92, P10949, DOI 10.1073/pnas.92.24.10949; BRACEY MH, 1994, BIOCHEMISTRY-US, V33, P13126, DOI 10.1021/bi00248a023; BRUNGER AT, 1992, XPLOR MANUAL VERSION; COLEMAN JE, 1967, J BIOL CHEM, V242, P5212; Coleman JE, 1998, CURR OPIN CHEM BIOL, V2, P222, DOI 10.1016/S1367-5931(98)80064-1; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; ERIKSSON AE, 1993, PROTEINS, V16, P29, DOI 10.1002/prot.340160104; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Ferry JG, 1997, BIOFACTORS, V6, P25, DOI 10.1002/biof.5520060104; GUILLOTON MB, 1992, J BIOL CHEM, V267, P3731; HAKANSSON K, 1992, J MOL BIOL, V227, P1192, DOI 10.1016/0022-2836(92)90531-N; HewettEmmett D, 1996, MOL PHYLOGENET EVOL, V5, P50, DOI 10.1006/mpev.1996.0006; Iverson TM, 2000, BIOCHEMISTRY-US, V39, P9222, DOI 10.1021/bi000204s; Janin J, 1997, NAT STRUCT BIOL, V4, P973, DOI 10.1038/nsb1297-973; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANNAN KK, 1984, ANN NY ACAD SCI, V429, P49, DOI 10.1111/j.1749-6632.1984.tb12314.x; KANNAN KK, 1975, P NATL ACAD SCI USA, V72, P51, DOI 10.1073/pnas.72.1.51; Kimber MS, 2000, EMBO J, V19, P1407, DOI 10.1093/emboj/19.7.1407; Kisker C, 1996, EMBO J, V15, P2323, DOI 10.1002/j.1460-2075.1996.tb00588.x; LINDSKOG S, 1973, P NATL ACAD SCI USA, V70, P2505, DOI 10.1073/pnas.70.9.2505; LINDSKOG S, 1993, CURR OPIN STRUC BIOL, V3, P915, DOI 10.1016/0959-440X(93)90156-F; Lindskog S, 1997, PHARMACOL THERAPEUT, V74, P1, DOI 10.1016/S0163-7258(96)00198-2; MELDRUM N. IT., 1933, JOUR PHYSIOL, V80, P113; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitsuhashi S, 2000, J BIOL CHEM, V275, P5521, DOI 10.1074/jbc.275.8.5521; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; ROWLETT RS, 1994, BIOCHEMISTRY-US, V33, P13967, DOI 10.1021/bi00251a003; SLY WS, 1995, ANNU REV BIOCHEM, V64, P375, DOI 10.1146/annurev.bi.64.070195.002111; Smith KS, 1999, J BACTERIOL, V181, P6247, DOI 10.1128/JB.181.20.6247-6253.1999; Smith KS, 1999, P NATL ACAD SCI USA, V96, P15184, DOI 10.1073/pnas.96.26.15184; Smith KS, 2000, J BACTERIOL, V182, P6605, DOI 10.1128/JB.182.23.6605-6613.2000; SoltesRak E, 1997, J BACTERIOL, V179, P769, DOI 10.1128/jb.179.3.769-774.1997; Stams T, 1996, P NATL ACAD SCI USA, V93, P13589, DOI 10.1073/pnas.93.24.13589; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thanos CD, 1999, SCIENCE, V283, P833, DOI 10.1126/science.283.5403.833; Tripp BC, 2000, BIOCHEMISTRY-US, V39, P9232, DOI 10.1021/bi0001877; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054	46	102	103	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10299	10305		10.1074/jbc.M009182200	http://dx.doi.org/10.1074/jbc.M009182200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11096105	hybrid			2022-12-25	WOS:000167996400095
J	Healy, JMS; Menges, M; Doonan, JH; Murray, JAH				Healy, JMS; Menges, M; Doonan, JH; Murray, JAH			The Arabidopsis D-type cyclins CycD2 and CycD3 both interact in vivo with the PSTAIRE cyclin-dependent kinase Cdc2a but are differentially controlled	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT-CELL CYCLE; RETINOBLASTOMA PROTEIN; NUCLEAR-PROTEIN; GENE; FAMILY; PHOSPHORYLATION; REGULATORS; THALIANA; G(1); PROGRESSION	D-type cyclins (CycD) play key roles in linking the Arabidopsis cell cycle to extracellular and developmental signals, but little is known of their regulation at the post-transcriptional level or of their cyclin-dependent kinase (CDK) partners. Using new antisera to CycD2 and CycD3, we demonstrate that the CDK partner of these Arabidopsis cyclins is the PSTAIRE-containing CDK Cdc2a, Previous analysis has shown that transcript levels of CycD2 and CycD3 are regulated in response to sucrose levels and that both their mRNA levels and kinase activity are induced with different kinetics during the G(1) phase of cells reentering the division cycle from quiescence (1). Here we analyze the protein levels and kinase activity of CycD2 and CycD3. We show that CycD3 protein and kinase activity parallel the abundance of its mRNA and that CycD3 protein is rapidly lost from cells in stationary phase or following sucrose removal. In contrast to both CycD3 and the regulation of its own mRNA levels, CycD2 protein is present at constant levels. CycD2 kinase activity is regulated by sequestration of CycD2 protein in a form inaccessible to immunoprecipitation and probably not complexed to Cdc2a.	Univ Cambridge, Inst Biotechnol, Cambridge CB2 1QT, England; John Innes Ctr Plant Sci Res, Dept Cell Biol, Norwich NR4 7UH, Norfolk, England	University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Murray, JAH (corresponding author), Univ Cambridge, Inst Biotechnol, Tennis Court Rd, Cambridge CB2 1QT, England.		Healy, Sandra J/D-5256-2013; Murray, James AH/D-3399-2009	Murray, James AH/0000-0002-2282-3839; doonan, john/0000-0001-6027-1919	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000129] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; Cockcroft CE, 2000, NATURE, V405, P575, DOI 10.1038/35014621; DAHL M, 1995, PLANT CELL, V7, P1847; De Veylder L, 1999, PLANTA, V208, P453, DOI 10.1007/s004250050582; Diehl JA, 1997, MOL CELL BIOL, V17, P7362, DOI 10.1128/MCB.17.12.7362; DIEHL JA, 1997, GENE DEV, V11, P967; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; Fuerst RAUA, 1996, PLANT PHYSIOL, V112, P1023, DOI 10.1104/pp.112.3.1023; Gaudin V, 2000, PLANT PHYSIOL, V122, P1137, DOI 10.1104/pp.122.4.1137; Grafi G, 1996, P NATL ACAD SCI USA, V93, P8962, DOI 10.1073/pnas.93.17.8962; Helleboid S, 2000, J EXP BOT, V51, P1189, DOI 10.1093/jexbot/51.348.1189; Huntley R, 1998, PLANT MOL BIOL, V37, P155, DOI 10.1023/A:1005902226256; Huntley RP, 1999, CURR OPIN PLANT BIOL, V2, P440, DOI 10.1016/S1369-5266(99)00027-8; KATO J, 1993, GENE DEV, V7, P331; Kong LJ, 2000, EMBO J, V19, P3485, DOI 10.1093/emboj/19.13.3485; Lew DJ, 1996, CURR OPIN CELL BIOL, V8, P795, DOI 10.1016/S0955-0674(96)80080-9; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MAY MJ, 1993, PLANT PHYSIOL, V103, P621, DOI 10.1104/pp.103.2.621; Mironov V, 1999, PLANT CELL, V11, P509; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nakagami H, 1999, PLANT J, V18, P243, DOI 10.1046/j.1365-313X.1999.00449.x; PINES J, 1995, ADV CANCER RES, V66, P181, DOI 10.1016/S0065-230X(08)60254-7; Ramirez-Parra E, 1999, NUCLEIC ACIDS RES, V27, P3527, DOI 10.1093/nar/27.17.3527; Renaudin JP, 1996, PLANT MOL BIOL, V32, P1003, DOI 10.1007/BF00041384; Riou-Khamlichi C, 2000, MOL CELL BIOL, V20, P4513, DOI 10.1128/MCB.20.13.4513-4521.2000; Riou-Khamlichi C, 1999, SCIENCE, V283, P1541, DOI 10.1126/science.283.5407.1541; Roudier F, 2000, PLANT J, V23, P73, DOI 10.1046/j.1365-313x.2000.00794.x; Sekine M, 1999, FEBS LETT, V460, P117, DOI 10.1016/S0014-5793(99)01296-X; SEWING A, 1993, J CELL SCI, V104, P545; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SONI R, 1995, PLANT CELL, V7, P85, DOI 10.1105/tpc.7.1.85; Xie Q, 1996, EMBO J, V15, P4900, DOI 10.1002/j.1460-2075.1996.tb00870.x; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	37	81	92	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7041	7047		10.1074/jbc.M009074200	http://dx.doi.org/10.1074/jbc.M009074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11096103	hybrid			2022-12-25	WOS:000167442900027
J	Petrovan, RJ; Ruf, W				Petrovan, RJ; Ruf, W			Residue Met(156) contributes to the labile enzyme conformation of coagulation factor VIIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE FACTOR-X; TISSUE FACTOR; ACTIVE-SITE; CRYSTAL-STRUCTURE; PLASMINOGEN-ACTIVATOR; ALLOSTERIC REGULATION; CATALYTIC FUNCTION; BLOOD-COAGULATION; ANTITHROMBIN-III; BINDING	Serine protease activation is typically controlled by proteolytic cleavage of the scissile bond, resulting in spontaneous formation of the activating Ile(16)-Asp(194) salt bridge. The initiating coagulation protease factor VIIa (VIIa) differs by remaining in a zymogen-like conformation that confers the control of catalytic activity to the obligatory cofactor and receptor tissue factor (TF). This study demonstrates that the unusual hydrophobic Met(156) residue contributes to the propensity of the VIIa protease domain to remain in a zymogen-like conformation. Mutation of Met(156) to Gln, which is found in the same position of the highly homologous factor IX, had no influence on the amidolytic and proteolytic activity of TF-bound VIIa. Furthermore, the mutation did not appreciably stabilize the labile Ile(16)-Asp(194) salt bridge in the absence of cofactor. VIIa(Gln156) had increased affinity for TF, consistent with a long range conformational effect that stabilized the cofactor binding site in the VIIa protease domain. Notably, in the absence of cofactor, amidolytic and proteolytic function of VIIa(Gln156) were enhanced 3 and 9-fold, respectively, compared with wild-type VIIa. The mutation thus selectively influenced the catalytic activity of free VIIa, identifying the Met(156) residue position as a determinant for the zymogen-like properties of free VIIa.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Vasc Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Ruf, W (corresponding author), Scripps Res Inst, Dept Immunol, C204,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NHLBI NIH HHS [HL48752] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048752] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Dickinson CD, 1997, J BIOL CHEM, V272, P19875, DOI 10.1074/jbc.272.32.19875; Dickinson CD, 1996, P NATL ACAD SCI USA, V93, P14379, DOI 10.1073/pnas.93.25.14379; Dickinson CD, 1998, J MOL BIOL, V277, P959, DOI 10.1006/jmbi.1998.1639; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; Huang QL, 1996, J BIOL CHEM, V271, P21752, DOI 10.1074/jbc.271.36.21752; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JESPERS LS, 1995, BIO-TECHNOL, V13, P378, DOI 10.1038/nbt0495-378; Kemball-Cook G, 1999, J STRUCT BIOL, V127, P213, DOI 10.1006/jsbi.1999.4158; LAWSON JH, 1993, J BIOL CHEM, V268, P767; Petersen LC, 1999, EUR J BIOCHEM, V261, P124, DOI 10.1046/j.1432-1327.1999.00258.x; Petrovan RJ, 2000, BIOCHEMISTRY-US, V39, P14457, DOI 10.1021/bi0009486; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; RAO LVM, 1993, BLOOD, V81, P2600; Renatus M, 1997, BIOCHEMISTRY-US, V36, P13483, DOI 10.1021/bi971129x; Renatus M, 1997, EMBO J, V16, P4797, DOI 10.1093/emboj/16.16.4797; RUF W, 1994, BIOCHEMISTRY-US, V33, P11631, DOI 10.1021/bi00204a026; RUF W, 1991, P NATL ACAD SCI USA, V88, P8430, DOI 10.1073/pnas.88.19.8430; RUF W, 1992, J BIOL CHEM, V267, P6375; Ruf W, 1998, TRENDS CARDIOVAS MED, V8, P350, DOI 10.1016/S1050-1738(98)00031-0; Ruf W, 1999, BIOCHEMISTRY-US, V38, P1957, DOI 10.1021/bi982254r; RUF W, 1991, J BIOL CHEM, V266, P2158; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SELIGSOHN U, 1979, BLOOD, V53, P828; Shobe J, 1999, BIOCHEMISTRY-US, V38, P2745, DOI 10.1021/bi981951g; STONE MJ, 1995, BIOCHEM J, V310, P605, DOI 10.1042/bj3100605; Tachias K, 1997, J BIOL CHEM, V272, P28; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452	32	34	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6616	6620		10.1074/jbc.M004726200	http://dx.doi.org/10.1074/jbc.M004726200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11078728	hybrid			2022-12-25	WOS:000167261000072
J	Bonnefoy, A; Hantgan, R; Legrand, C; Frojmovic, MM				Bonnefoy, A; Hantgan, R; Legrand, C; Frojmovic, MM			A model of platelet aggregation involving multiple interactions of thrombospondin-1, fibrinogen, and GPIIbIIIa receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; INTEGRIN-ASSOCIATED PROTEIN; THROMBIN-SENSITIVE PROTEIN; ARG-GLY-ASP; MONOCLONAL-ANTIBODY; STIMULATED PLATELETS; ACTIVATED PLATELETS; TERMINAL DOMAIN; BINDING; INHIBITION	Thrombospondin-l (TSP) may, after secretion from platelet Lu granules, participate in platelet aggregation, but its mode of action is poorly understood. We evaluated the capacity of TSP to form inter-platelet crossbridges through its interaction with fibrinogen (Fg), using either Fg-coated beads or Fg bound to the activated GPIIbIIIa integrin (GPIIbIIIa*) immobilized on beads or on activated fixed platelets (AFP), i.e. in a system free of platelet signaling and secretion mechanisms. Aggregation at physiological shear rates (100-2000 s(-1)) was studied in a microcouette device and monitored by flow cytometry. Soluble TSP bound to and induced aggregation of Fg-coated beads dose-dependently, which could be blocked by the amino-terminal heparin-binding domain of TSP, TSP18. Soluble TSP did not bind to GPIIbIIIa*- coated beads or AFP, unless they were preincubated with Fg. The interaction of soluble TSP with Fg-GPIIbIIIa'''-coated beads or Fg-AFP resulted in the formation of aggregates via Fg-TSP-Fg cross-bridges, as demonstrated in a system where direct cross-bridges mediated by GPIIbIIIa*'-Fg on one particle and free GPIIbIIIa* on a second particle were blocked by the RGD mimetic Ro 44-9885. Soluble TSP increased the efficiency of Fg-mediated aggregation of AFP by 30-110% over all shear rates and GPIIbIIIa* occupancies evaluated. Surprisingly, TSP binding to Fg already bound to its GPIIbIIIa* receptor appears to block the ability of this occupied Fg to recognize another GPIIbIIIa* receptor, but this TSP can indeed cross-bridge to another Fg molecule on a second platelet. Finally, TSP-coated beads could directly coaggregate at shear rates from 100 to 2000 s(-1). Our studies provide a model for the contribution of secreted TSP in reinforcing inter-platelet interactions in flowing blood, through direct Fg-TSP-Fg and TSP-TSP cross-bridges.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada; Univ Paris 07, INSERM, U353, Inst Hematol,Hop St Louis, Paris 10, France; Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA	McGill University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Wake Forest University; Wake Forest Baptist Medical Center	Frojmovic, MM (corresponding author), McGill Univ, Dept Physiol, 3655 Drummond Ave 1137, Montreal, PQ H3G 1Y6, Canada.							AGAM G, 1988, THROMB HAEMOSTASIS, V59, P504; AGBANYO FR, 1993, J CLIN INVEST, V92, P288, DOI 10.1172/JCI116563; AIKEN ML, 1986, J CLIN INVEST, V78, P1713, DOI 10.1172/JCI112767; ALIG L, 1992, J MED CHEM, V35, P4393, DOI 10.1021/jm00101a017; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; ASCH AS, 1985, BLOOD, V66, P926; BACONBAGULEY T, 1990, J BIOL CHEM, V265, P2317; BAENZIGER NL, 1972, J BIOL CHEM, V247, P2723; BEISO P, 1990, BIOCHIM BIOPHYS ACTA, V1033, P7, DOI 10.1016/0304-4165(90)90186-Z; Bonnefoy A, 2000, BIOPHYS J, V78, P2834, DOI 10.1016/S0006-3495(00)76826-3; BOUKERCHE H, 1988, EUR J BIOCHEM, V171, P383, DOI 10.1111/j.1432-1033.1988.tb13802.x; Chung J, 1997, J BIOL CHEM, V272, P14740, DOI 10.1074/jbc.272.23.14740; Chung J, 1999, BLOOD, V94, P642, DOI 10.1182/blood.V94.2.642.414k35_642_648; DIXIT VM, 1985, BIOCHEMISTRY-US, V24, P4270, DOI 10.1021/bi00337a003; DIXIT VM, 1985, P NATL ACAD SCI USA, V82, P3472, DOI 10.1073/pnas.82.10.3472; DOOLITTLE RF, 1994, HAEMOSTASIS THROMBOS, P491; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; DUBERNARD V, 1991, J LAB CLIN MED, V118, P446; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; GARTNER TK, 1984, BIOCHEM BIOPH RES CO, V124, P290, DOI 10.1016/0006-291X(84)90950-1; Gawaz M, 1996, ARTERIOSCL THROM VAS, V16, P621, DOI 10.1161/01.ATV.16.5.621; GOLDSMITH HL, 1994, THROMB HAEMOSTASIS, V71, P78; Goldsmith HL, 2000, BIOPHYS J, V78, P1195, DOI 10.1016/S0006-3495(00)76677-X; HOURDILLE P, 1985, BLOOD, V65, P912; KAO KJ, 1986, THROMB HAEMOSTASIS, V55, P136; KARCZEWSKI J, 1989, J BIOL CHEM, V264, P21322; KIEFFER N, 1992, AM J PATHOL, V140, P57; KIEFFER N, 1988, BIOCHIM BIOPHYS ACTA, V967, P408, DOI 10.1016/0304-4165(88)90104-3; KOWALSKA MA, 1993, BIOCHEM J, V295, P725, DOI 10.1042/bj2950725; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; LAHAV J, 1988, BLOOD, V71, P1096, DOI 10.1182/blood.V71.4.1096.bloodjournal7141096; LAWLER J, 1985, J BIOL CHEM, V260, P3762; LAWLER J, 1982, J BIOL CHEM, V257, P2257; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LEGRAND C, 1992, BLOOD, V79, P1995; LEGRAND C, 1994, ARTERIOSCLER THROMB, V14, P1784, DOI 10.1161/01.ATV.14.11.1784; LEUNG LLK, 1982, J CLIN INVEST, V70, P542, DOI 10.1172/JCI110646; LEUNG LLK, 1984, J CLIN INVEST, V74, P1764, DOI 10.1172/JCI111595; MCGREGOR JL, 1989, J BIOL CHEM, V264, P501; MCGREGOR L, 1989, THROMB HAEMOSTASIS, V62, P962; Panetti TS, 1999, J BIOL CHEM, V274, P430, DOI 10.1074/jbc.274.1.430; PHILLIPS DR, 1980, J BIOL CHEM, V255, P1629; PYTELA R, 1986, SCIENCE, V231, P1559, DOI 10.1126/science.2420006; RabhiSabile S, 1996, FEBS LETT, V386, P82, DOI 10.1016/0014-5793(96)00408-5; RAMSAMOOJ P, 1990, THROMB RES, V58, P577, DOI 10.1016/0049-3848(90)90304-U; ROBERTS DD, 1993, THROMBOSPONDIN, P73; RYBAK ME, 1986, THROMB HAEMOSTASIS, V55, P240; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; TUSZYNSKI GP, 1985, J BIOL CHEM, V260, P2240; Voland C, 2000, J BONE MINER RES, V15, P361, DOI 10.1359/jbmr.2000.15.2.361; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; WENCELDRAKE JD, 1984, AM J PATHOL, V115, P156; WONG T, 1989, THROMB HAEMOSTASIS, V62, P733; Xia Z, 1996, BRIT J HAEMATOL, V93, P204, DOI 10.1046/j.1365-2141.1996.445980.x; XIA ZM, 1994, BIOPHYS J, V66, P2190, DOI 10.1016/S0006-3495(94)81015-X	55	54	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5605	5612		10.1074/jbc.M010091200	http://dx.doi.org/10.1074/jbc.M010091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11094060	hybrid			2022-12-25	WOS:000167115100029
J	Zang, TM; Hollman, DA; Crawford, PA; Crowder, MW; Makaroff, CA				Zang, TM; Hollman, DA; Crawford, PA; Crowder, MW; Makaroff, CA			Arabidopsis glyoxalase II contains a zinc/iron binuclear metal center that is essential for substrate binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAMASE; CRYSTAL-STRUCTURE; MOLECULAR-CLONING; ESCHERICHIA-COLI; PURIFICATION; ZINC; SYSTEM; ALPHA; METHYLGLYOXAL; MITOCHONDRIA	Glyoxalase II participates in the cellular detoxification of cytotoxic and mutagenic 2-oxoaldehydes. Because of its role in chemical detoxification, glyoxalase II has been studied as a potential anti-cancer and/or antiprotozoal target; however, very little is known about the active site and reaction mechanism of this important enzyme. To characterize the active site and kinetic mechanism of the enzyme, a detailed mutational study of Arabidopsis glyoxalase II was conducted. Data presented here demonstrate for the first time that the cytoplasmic form of Arabidopsis glyoxalase II contains an iron-zinc binuclear metal center that is essential for activity. Both metals participate in substrate binding, transition state stabilization, and the hydrolysis reaction. Subtle alterations in the geometry and/or electrostatics of the binuclear center have profound effects on the activity of the enzyme. Additional residues important in substrate binding have also been identified. An overall reaction mechanism for glyoxalase II is proposed based on the mutational and kinetic data from this study and crystallographic data on human glyoxalase II. Information presented here provides new insights into the active site and reaction mechanism of glyoxalase II that can be used for the rational design of glyoxalase II inhibitors.	Miami Univ, Dept Chem & Biochem, Oxford, OH 45056 USA	University System of Ohio; Miami University	Makaroff, CA (corresponding author), Miami Univ, Dept Chem & Biochem, Oxford, OH 45056 USA.	makaroca@muohio.edu		Makaroff, Christopher/0000-0001-6237-1868				ALLEN RE, 1993, BIOCHEM SOC T, V21, P535, DOI 10.1042/bst0210535; ALLEN RE, 1993, EUR J BIOCHEM, V213, P1261, DOI 10.1111/j.1432-1033.1993.tb17877.x; BALL JC, 1981, BIOCHEMISTRY-US, V20, P899, DOI 10.1021/bi00507a038; Cameron AD, 1999, STRUCTURE, V7, P1067, DOI 10.1016/S0969-2126(99)80174-9; Christianson DW, 1999, ANNU REV BIOCHEM, V68, P33, DOI 10.1146/annurev.biochem.68.1.33; Concha NO, 1996, STRUCTURE, V4, P823, DOI 10.1016/S0969-2126(96)00089-5; CREIGHTON DJ, 1988, BIOCHEMISTRY-US, V27, P7376, DOI 10.1021/bi00419a031; Crowder MW, 1997, FEBS LETT, V418, P351, DOI 10.1016/S0014-5793(97)01416-6; Crowder MW, 1996, BIOCHEMISTRY-US, V35, P12126, DOI 10.1021/bi960976h; CROWDER MW, 1999, ANTIMICROBIAL AGEN 1, V3, P105; D'souza VM, 1999, BIOCHEMISTRY-US, V38, P11079, DOI 10.1021/bi990872h; Dragani B, 1999, J MOL BIOL, V291, P481, DOI 10.1006/jmbi.1999.2965; ELIA AC, 1995, BIOCHEM MOL BIOL INT, V35, P763; Geeganage S, 1999, BIOCHEMISTRY-US, V38, P13398, DOI 10.1021/bi9910631; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; LO TWC, 1994, J BIOL CHEM, V269, P32299; Maiti MK, 1997, PLANT MOL BIOL, V35, P471, DOI 10.1023/A:1005891123344; Melino S, 1998, TRENDS BIOCHEM SCI, V23, P381, DOI 10.1016/S0968-0004(98)01264-X; Mondragon A, 1997, BIOCHEMISTRY-US, V36, P4934, DOI 10.1021/bi9631935; MURATA K, 1986, AGR BIOL CHEM TOKYO, V50, P135, DOI 10.1080/00021369.1986.10867352; NORTON SJ, 1993, BIOCHEM SOC T, V21, P545, DOI 10.1042/bst0210545; PAPOULIS A, 1995, BIOCHEMISTRY-US, V34, P648, DOI 10.1021/bi00002a032; RAHMAN A, 1990, J BIOCHEM TOXICOL, V5, P161, DOI 10.1002/jbt.2570050305; Ridderstrom M, 1997, BIOCHEM J, V322, P449, DOI 10.1042/bj3220449; Ridderstrom M, 1996, J BIOL CHEM, V271, P319, DOI 10.1074/jbc.271.1.319; SCHOWEN KB, 1982, METHOD ENZYMOL, V87, P551; SEGEL IH, 1993, ENZYME KINETICS BEHA, P544; Strater N, 1999, P NATL ACAD SCI USA, V96, P11151, DOI 10.1073/pnas.96.20.11151; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TALESA V, 1990, BIOCHEM INT, V22, P1115; TALESA V, 1989, BIOCHIM BIOPHYS ACTA, V993, P7, DOI 10.1016/0304-4165(89)90135-9; THORNALLEY PJ, 1993, MOL ASPECTS MED, V14, P287, DOI 10.1016/0098-2997(93)90002-U; Thornalley PJ, 1996, GEN PHARMACOL-VASC S, V27, P565, DOI 10.1016/0306-3623(95)02054-3; THORNALLEY PJ, 1990, BIOCHEM J, V269, P1; Twitchett MB, 1999, EUR J INORG CHEM, P2105; Ullah JH, 1998, J MOL BIOL, V284, P125, DOI 10.1006/jmbi.1998.2148; UOTILA L, 1973, BIOCHEMISTRY-US, V12, P3944, DOI 10.1021/bi00744a025; VANDERJAGT DL, 1993, BIOCHEM SOC T, V21, P522, DOI 10.1042/bst0210522; Wang XD, 1996, BIOCHEMISTRY-US, V35, P13946, DOI 10.1021/bi961436n; Wang ZG, 1999, BIOCHEMISTRY-US, V38, P10013, DOI 10.1021/bi990356r; Yanchak MP, 2000, BIOCHEMISTRY-US, V39, P11330, DOI 10.1021/bi0010524	41	71	76	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4788	4795		10.1074/jbc.M005090200	http://dx.doi.org/10.1074/jbc.M005090200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11085979	hybrid			2022-12-25	WOS:000168484300036
J	Befort, K; Filliol, D; Decaillot, FM; Gaveriaux-Ruff, C; Hoehe, MR; Kieffer, BL				Befort, K; Filliol, D; Decaillot, FM; Gaveriaux-Ruff, C; Hoehe, MR; Kieffer, BL			A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MORPHINE-INDUCED ANALGESIA; PROTEIN-COUPLED RECEPTORS; OPIATE RECEPTOR; MICE LACKING; ALCOHOL DEPENDENCE; KNOCKOUT MICE; PHARMACOLOGICAL CHARACTERIZATION; TRANSMEMBRANE DOMAIN; BINDING; GENE	Large scale sequencing of the human mu -opioid receptor (hMOR) gene has revealed polymorphic mutations that occur within the coding region. We have investigated whether the mutations N40D in the extracellular N-terminal region, N152D in the third transmembrane domain, and R265H and S268P in the third intracellular loop alter functional properties of the receptor expressed in mammalian cells. The N152D receptor was produced at low densities. Binding affinities of structurally diverse opioids (morphine, diprenorphine, DAMGO and CTOP) and the main endogenous opioid peptides (beta -endorphin, [Met]enkephalin, and dynorphin A) were not markedly changed in mutant receptors (<3-fold). Receptor signaling was strongly impaired in the S268P mutant, with a reduction of efficacy and potency of several agonists (DAMGO, <beta>-endorphin, and morphine) in two distinct functional assays. Signaling at N40D and R265H mutants was highly similar to wild type, and none of the mutations induced detectable constitutive activity. DAMGO-induced down-regulation of receptor-binding sites, following 20 h of treatment, was identical in wild-type and mutant receptors. Our data show that natural sequence variations in hMOR gene have little influence on ligand binding or receptor down-regulation but could otherwise modify receptor density and signaling. Importantly, the S268P mutation represents a loss-of-function mutation for the human mu -opioid receptor, which may have an incidence on opioid-regulated behaviors or drug addiction in vivo.	ESBS, CNRS, UPR 9050, Lab Recepteurs & Prot Membranaires, F-67400 Illkirch Graffenstaden, France; Max Delbruck Ctr Mol Med, Genome Res Lab, D-13092 Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Kieffer, BL (corresponding author), ESBS, CNRS, UPR 9050, Lab Recepteurs & Prot Membranaires, Parc Innovat, F-67400 Illkirch Graffenstaden, France.	briki@esbs.u-strasbg.fr	GAVERIAUX-RUFF, Claire/A-9671-2017	GAVERIAUX-RUFF, Claire/0000-0002-3523-8102				AKIL H, 1984, ANNU REV NEUROSCI, V7, P223, DOI 10.1146/annurev.ne.07.030184.001255; Akil H, 1997, SEMIN NEUROSCI, V9, P70, DOI 10.1006/smns.1997.0108; Befort K, 1996, NEUROCHEM RES, V21, P1301, DOI 10.1007/BF02532371; Befort K, 1996, MOL PHARMACOL, V49, P216; Bergen AW, 1997, MOL PSYCHIATR, V2, P490, DOI 10.1038/sj.mp.4000331; Berrettini WH, 1997, ADDICT BIOL, V2, P303, DOI 10.1080/13556219772598; BERRETTINI WH, 1994, NAT GENET, V7, P54, DOI 10.1038/ng0594-54; Bond C, 1998, P NATL ACAD SCI USA, V95, P9608, DOI 10.1073/pnas.95.16.9608; CARTER BD, 1993, MOL PHARMACOL, V43, P465; Chaturvedi K, 2000, MOL BRAIN RES, V76, P64, DOI 10.1016/S0169-328X(99)00332-0; Corbett A.D., 1993, OPIOIDS, P645, DOI [10.1007/978-3-642-77460-7_26, DOI 10.1007/978-3-642-77460-7_26]; Franke P, 1999, AM J MED GENET, V88, P462, DOI 10.1002/(SICI)1096-8628(19991015)88:5<462::AID-AJMG4>3.0.CO;2-S; Gaveriaux-Ruff C, 1998, P NATL ACAD SCI USA, V95, P6326, DOI 10.1073/pnas.95.11.6326; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Herz A, 1997, PSYCHOPHARMACOLOGY, V129, P99, DOI 10.1007/s002130050169; Hoehe MR, 2000, HUM MOL GENET, V9, P2895, DOI 10.1093/hmg/9.19.2895; INTURRISI CE, 1983, LIFE SCI, V33, P773, DOI 10.1016/0024-3205(83)90616-1; Kato S, 1998, EUR J PHARMACOL, V345, P221, DOI 10.1016/S0014-2999(98)00023-5; Kieffer BL, 1995, CELL MOL NEUROBIOL, V15, P615, DOI 10.1007/BF02071128; Koch T, 2000, MOL PHARMACOL, V58, P328, DOI 10.1124/mol.58.2.328; Koch T, 1997, J NEUROCHEM, V69, P1767; Kotler M, 1997, MOL PSYCHIATR, V2, P251, DOI 10.1038/sj.mp.4000248; Kreek MJ, 1996, MOL PSYCHIATR, V1, P232; LAW PY, 1994, J PHARMACOL EXP THER, V271, P1686; LAW PY, 1984, J BIOL CHEM, V259, P4096; Lefkowitz RJ, 1998, J BIOL CHEM, V273, P18677, DOI 10.1074/jbc.273.30.18677; LILES WC, 1986, J NEUROCHEM, V46, P89, DOI 10.1111/j.1471-4159.1986.tb12929.x; Loh HH, 1998, MOL BRAIN RES, V54, P321, DOI 10.1016/S0169-328X(97)00353-7; Matthes HWD, 1998, J NEUROSCI, V18, P7285; Matthes HWD, 1996, NATURE, V383, P819, DOI 10.1038/383819a0; Mayer P, 1997, NEUROREPORT, V8, P2547, DOI 10.1097/00001756-199707280-00025; Merkouris M, 1996, MOL PHARMACOL, V50, P985; MESTEK A, 1995, J NEUROSCI, V15, P2396, DOI 10.1523/JNEUROSCI.15-03-02396.1995; NEGUS SS, 1993, J PHARMACOL EXP THER, V265, P1245; Olson GA, 1998, PEPTIDES, V19, P1791, DOI 10.1016/S0196-9781(98)00137-5; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; Reid L D, 1984, Alcohol, V1, P33, DOI 10.1016/0741-8329(84)90033-8; Roberts AJ, 2000, J PHARMACOL EXP THER, V293, P1002; Roy S, 1998, MOL BRAIN RES, V56, P281, DOI 10.1016/S0169-328X(98)00051-5; Roy S, 1998, MOL BRAIN RES, V61, P190, DOI 10.1016/S0169-328X(98)00212-5; Sander T, 1998, ALCOHOL CLIN EXP RES, V22, P2108, DOI 10.1097/00000374-199812000-00030; Sander T, 2000, EPILEPSY RES, V39, P57, DOI 10.1016/S0920-1211(99)00109-6; Schuller AGP, 1999, NAT NEUROSCI, V2, P151, DOI 10.1038/5706; Shahrestanifar M, 1996, J BIOL CHEM, V271, P5505, DOI 10.1074/jbc.271.10.5505; Smolka M, 1999, PSYCHONEUROENDOCRINO, V24, P629, DOI 10.1016/S0306-4530(99)00017-7; Sora I, 1997, P NATL ACAD SCI USA, V94, P1544, DOI 10.1073/pnas.94.4.1544; Spiegel AM, 1996, ANNU REV PHYSIOL, V58, P143, DOI 10.1146/annurev.ph.58.030196.001043; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; Tian MT, 1997, J EXP MED, V185, P1517, DOI 10.1084/jem.185.8.1517; Town T, 1999, AM J MED GENET, V88, P458, DOI 10.1002/(SICI)1096-8628(19991015)88:5<458::AID-AJMG3>3.3.CO;2-J; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; WANG JB, 1993, P NATL ACAD SCI USA, V90, P10230, DOI 10.1073/pnas.90.21.10230; WANG JB, 1994, FEBS LETT, V338, P217, DOI 10.1016/0014-5793(94)80368-4; Wang WW, 1995, P NATL ACAD SCI USA, V92, P12436, DOI 10.1073/pnas.92.26.12436; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; [No title captured]	58	188	196	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3130	3137		10.1074/jbc.M006352200	http://dx.doi.org/10.1074/jbc.M006352200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11067846	Green Published, hybrid			2022-12-25	WOS:000166784900022
J	Hessel, E; Muller, P; Herrmann, A; Hofmann, KP				Hessel, E; Muller, P; Herrmann, A; Hofmann, KP			Light-induced reorganization of phospholipids in rod disc membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METARHODOPSIN-II; OUTER SEGMENTS; AMINOPHOSPHOLIPID TRANSLOCASE; ALPHA(1B)-ADRENERGIC RECEPTOR; PHOTORECEPTOR-MEMBRANES; ANIONIC PHOSPHOLIPIDS; ERYTHROCYTE-MEMBRANE; PLASMA-MEMBRANE; LIPID ASYMMETRY; CELL-MEMBRANES	The transbilayer redistribution of spin-labeled phospholipid analogues (SL-PL) with choline, serine, and ethanolamine head groups (PC, PS, and PE, respectively) was studied on intact disc vesicles of bovine rod outer segment membranes in the dark and after illumination. Redistribution was measured by the extraction of spin-labeled lipid analogues from the outer leaflet of membrane using the bovine serum albumin back-exchange assay. In the dark, PS was distributed asymmetrically, favoring the outer leaflet, whereas PC and PE showed small if any asymmetry. Green illumination for 1 min caused lipid head group-specific reorganization of SL-PL. Extraction of SL-PS by bovine serum albumin showed a fast transient (<10 min) enhancement, which was further augmented by a peptide stabilizing the active metarhodopsin II conformation. The data suggest a direct release of 1 molecule of bound PS per rhodopsin into the outer leaflet and subsequent redistribution between the two leaflets. SL-PE and SL-PC showed more complex kinetics, in both cases consistent with a prolonged period of reduced extraction (2 phospholipids per rhodopsin in each case). The different phases of SL-PL reorganization after illumination may be related to the formation and decay of the active rhodopsin species and to their subsequent regeneration process.	Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, D-10098 Berlin, Germany; Humboldt Univ, Math Nat Wissenschaftliche Fak 1, Inst Biol Biophys, D-10115 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Humboldt University of Berlin	Hessel, E (corresponding author), Humboldt Univ, Klinikum Charite, Inst Med Phys & Biophys, Ziegelstr 5-9, D-10098 Berlin, Germany.	elke.hessel@charite.de; kph@charite.de						Anderson RE, 1997, EXP EYE RES, V64, P181, DOI 10.1006/exer.1996.0195; ARNIS S, 1993, P NATL ACAD SCI USA, V90, P7849, DOI 10.1073/pnas.90.16.7849; Beck M, 1998, FEBS LETT, V436, P304, DOI 10.1016/S0014-5793(98)01156-9; Beleznay Z, 1997, EUR J BIOCHEM, V243, P58, DOI 10.1111/j.1432-1033.1997.58_1a.x; BOESZEBATTAGLIA K, 1992, EXP EYE RES, V54, P821, DOI 10.1016/0014-4835(92)90040-Y; BUSH RA, 1994, INVEST OPHTH VIS SCI, V35, P91; CONVERSE CA, 1979, EXP EYE RES, V29, P409, DOI 10.1016/0014-4835(79)90057-5; DAEMEN FJM, 1969, NATURE, V222, P879, DOI 10.1038/222879a0; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; DEGRIP WJ, 1975, EXP EYE RES, V21, P549, DOI 10.1016/0014-4835(75)90037-8; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; Dolis D, 1997, BIOPHYS CHEM, V68, P221, DOI 10.1016/S0301-4622(97)00048-3; Fellmann P, 1994, Methods Mol Biol, V27, P161; FLIESLER SJ, 1983, PROG LIPID RES, V22, P79; GIBSON NJ, 1993, BIOCHEMISTRY-US, V32, P2438, DOI 10.1021/bi00060a040; HAEST CWM, 1981, BIOCHIM BIOPHYS ACTA, V649, P701, DOI 10.1016/0005-2736(81)90174-7; Haest GWM, 1997, BIOCHEMISTRY-US, V36, P10885, DOI 10.1021/bi970555f; Hessel E, 2000, EUR J BIOCHEM, V267, P1473, DOI 10.1046/j.1432-1327.2000.01147.x; Hofmann K. P., 2000, HDB BIOL PHYSICS, P91, DOI 10.1016/s1383-8121(00)80006-8; HOFMANN KP, 1983, BIOCHIM BIOPHYS ACTA, V725, P60, DOI 10.1016/0005-2728(83)90224-4; Illing M, 1997, J BIOL CHEM, V272, P10303, DOI 10.1074/jbc.272.15.10303; KAMPS KMP, 1982, BIOCHIM BIOPHYS ACTA, V687, P296, DOI 10.1016/0005-2736(82)90558-2; KIBELBEK J, 1991, BIOCHEMISTRY-US, V30, P6761, DOI 10.1021/bi00241a019; Kisselev OG, 1999, P NATL ACAD SCI USA, V96, P4898, DOI 10.1073/pnas.96.9.4898; KUHN H, 1982, METHOD ENZYMOL, V81, P556; Kuypers F A, 1998, Curr Opin Hematol, V5, P122; Liu LP, 1997, BIOCHEMISTRY-US, V36, P5476, DOI 10.1021/bi970030n; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; Mitchell DC, 1996, J BIOL CHEM, V271, P19033, DOI 10.1074/jbc.271.32.19033; MITCHELL DC, 1992, BIOCHEMISTRY-US, V31, P8107, DOI 10.1021/bi00150a001; Molday RS, 1998, INVEST OPHTH VIS SCI, V39, P2493; MORROT G, 1989, BIOCHEMISTRY-US, V28, P3456, DOI 10.1021/bi00434a046; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Sachs K, 2000, J BIOL CHEM, V275, P6189, DOI 10.1074/jbc.275.9.6189; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; Scheer A, 1997, P NATL ACAD SCI USA, V94, P808, DOI 10.1073/pnas.94.3.808; Scheer A, 1999, EUR UROL, V36, P11, DOI 10.1159/000052312; SEIGNEURET M, 1984, P NATL ACAD SCI-BIOL, V81, P3751, DOI 10.1073/pnas.81.12.3751; SMITH HG, 1975, EXP EYE RES, V20, P211, DOI 10.1016/0014-4835(75)90134-7; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; Sullivan JM, 1999, BIOPHYS J, V77, P1333, DOI 10.1016/S0006-3495(99)76983-3; Sun H, 1999, J BIOL CHEM, V274, P8269, DOI 10.1074/jbc.274.12.8269; TSUI FC, 1990, BIOPHYS J, V57, P85, DOI 10.1016/S0006-3495(90)82509-1; van Klompenburg W, 1998, J MEMBRANE BIOL, V162, P1, DOI 10.1007/s002329900336; VANDERSTEEN ATM, 1983, BIOCHIM BIOPHYS ACTA, V733, P51, DOI 10.1016/0005-2736(83)90090-1; VANHOOGEVEST P, 1984, BIOCHIM BIOPHYS ACTA, V777, P241, DOI 10.1016/0005-2736(84)90426-7; WU G, 1993, BIOCHEMISTRY-US, V32, P879, DOI 10.1021/bi00054a020; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1	48	47	48	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2538	2543		10.1074/jbc.M009061200	http://dx.doi.org/10.1074/jbc.M009061200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11062249	hybrid			2022-12-25	WOS:000166784800034
J	Swinnen, JV; Heemers, H; Deboel, L; Foufelle, F; Heyns, W; Verhoeven, G				Swinnen, JV; Heemers, H; Deboel, L; Foufelle, F; Heyns, W; Verhoeven, G			Stimulation of tumor-associated fatty acid synthase expression by growth factor activation of the sterol regulatory element-binding protein pathway	ONCOGENE			English	Article						epidermal growth factor; prostate cancer; LNCaP; lipogenesis	ONCOGENIC ANTIGEN-519 OA-519; LIPOGENIC GENE-EXPRESSION; PROSTATE-CANCER CELLS; ANDROGEN RECEPTOR; BREAST-CANCER; TRANSGENIC MICE; KINASE PATHWAY; CULTURED-CELLS; MAP KINASE; LINE LNCAP	Increased expression of fatty acid synthase (FAS) is observed in a clinically aggressive subset of various common cancers and interference with FAS offers promising opportunities for selective chemotherapeutic intervention, The mechanisms by which FAS expression is (up)-regulated in these tumors remain, however, largely unknown. Recently we demonstrated that in LNCaP prostate cancer cells FAS expression is markedly elevated by androgens via an indirect pathway involving sterol regulatory element-binding proteins (SREBPs), Here, we also show that growth factors such as EGF are able to stimulate FAS mRNA, protein and activity. Several observations also indicate that the effects of EGF on FAS expression are ultimately mediated by SREBPs, EGF stimulates SREBP-1c mRNA expression and induces an increase in mature nuclear SREBP-1. Moreover, in transient transfection studies EGF stimulates the transcriptional activity of a 178 bp FAS promoter fragment harboring a complex SREBP-binding site. Deletion or mutation of this binding site abolishes these effects and ectopic expression of dominant negative SREBP-1 inhibits FAS expression and induction in intact LNCaP cells, Given the frequent dysregulation of growth factor signaling in cancer and the key role of SREBP-1 in lipid homeostasis, growth factor-induced activation of the SREBP pathway is proposed as one of the mechanisms responsible for upregulation of lipogenic gene expression in a subset of cancer cells.	Katholieke Univ Leuven, Fac Med Onderwijs & Navorsing, Lab Expt Med & Endocrinol, B-3000 Louvain, Belgium; Univ Paris 06, INSERM, U465, Ctr Rech Biomed Cordeliers, Paris, France	KU Leuven; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Swinnen, JV (corresponding author), Katholieke Univ Leuven, Fac Med Onderwijs & Navorsing, Lab Expt Med & Endocrinol, Herestr 49, B-3000 Louvain, Belgium.		Swinnen, Johannes V/AAA-2214-2022	Swinnen, Johannes V/0000-0002-7720-5077; FOUFELLE, Fabienne/0000-0002-0752-622X; DEBOEL, LUDO/0000-0002-2303-513X				Alo PL, 1999, TUMORI, V85, P35, DOI 10.1177/030089169908500108; Alo PL, 1996, CANCER, V77, P474, DOI 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CHAMBON M, 1989, J STEROID BIOCHEM, V33, P915, DOI 10.1016/0022-4731(89)90240-9; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; CULIG Z, 1995, EUR UROL, V27, P45; CULIG Z, 1995, WORLD J UROL, V13, P285; CULIG Z, 1996, PROSTATE, V28, P329; Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H; EPSTEIN JI, 1995, UROLOGY, V45, P81, DOI 10.1016/S0090-4295(95)96904-7; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fleischmann M, 2000, BIOCHEM J, V349, P13, DOI 10.1042/bj3490013; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; Fukazawa H, 2000, CANCER RES, V60, P2104; FURUYA Y, 1997, ANTICANCER RES, V17, P4583; Gansler TS, 1997, HUM PATHOL, V28, P686, DOI 10.1016/S0046-8177(97)90177-5; Hardman W., 1995, Modern Pathology, V8, p90A; Hobisch A, 1998, CANCER RES, V58, P4640; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; JENSEN V, 1995, J PATHOL, V176, P343, DOI 10.1002/path.1711760405; Kotzka J, 2000, J LIPID RES, V41, P99; Kotzka J, 1998, BIOCHEM BIOPH RES CO, V249, P375, DOI 10.1006/bbrc.1998.9161; Krontiras H, 1999, HEAD NECK-J SCI SPEC, V21, P325, DOI 10.1002/(SICI)1097-0347(199907)21:4<325::AID-HED6>3.3.CO;2-G; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Magana MM, 1996, J BIOL CHEM, V271, P32689, DOI 10.1074/jbc.271.51.32689; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Pizer ES, 1996, CANCER RES, V56, P745; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1998, CANCER-AM CANCER SOC, V83, P528, DOI 10.1002/(SICI)1097-0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X; Pizer ES, 2000, CANCER RES, V60, P213; Pizer ES, 1996, CANCER RES, V56, P2745; Pizer ES, 1998, CANCER RES, V58, P4611; Putz T, 1999, CANCER RES, V59, P227; Rashid A, 1997, AM J PATHOL, V150, P201; SCHUURMANS ALG, 1988, PROSTATE, V12, P55, DOI 10.1002/pros.2990120108; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; SHURBAJI MS, 1992, AM J CLIN PATHOL, V97, P686, DOI 10.1093/ajcp/97.5.686; Swinnen JV, 2000, INT J CANCER, V88, P176, DOI 10.1002/1097-0215(20001015)88:2<176::AID-IJC5>3.0.CO;2-3; Swinnen JV, 1997, P NATL ACAD SCI USA, V94, P12975, DOI 10.1073/pnas.94.24.12975; Swinnen JV, 1998, J STEROID BIOCHEM, V65, P191, DOI 10.1016/S0960-0760(97)00187-8; Swinnen JV, 1996, ENDOCRINOLOGY, V137, P4468, DOI 10.1210/en.137.10.4468; Swinnen JV, 1997, CANCER RES, V57, P1086; VERHOEVEN G, 1995, INT J ANDROL, V18, P23, DOI 10.1111/j.1365-2605.1995.tb00931.x; Visca P, 1999, CLIN CANCER RES, V5, P4111; Vlad L. D., 1999, Modern Pathology, V12, p70A; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	52	146	158	0	3	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5173	5181		10.1038/sj.onc.1203889	http://dx.doi.org/10.1038/sj.onc.1203889			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064454				2022-12-25	WOS:000090124100006
J	Vig, E; Green, M; Liu, YW; Yu, KY; Kwon, HJ; Tian, J; Goebl, MG; Harrington, MA				Vig, E; Green, M; Liu, YW; Yu, KY; Kwon, HJ; Tian, J; Goebl, MG; Harrington, MA			SIMPL is a tumor necrosis factor-specific regulator of nuclear factor-kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-ASSOCIATED KINASE; MICE LACKING; PROTEIN-KINASE; INDUCED PHOSPHORYLATION; LISTERIA-MONOCYTOGENES; EMBRYONIC LETHALITY; IKK-ALPHA; COMPLEX; ACTIVATION; EXPRESSION	The IL-1 receptor-associated kinase (IRAK/mPLK) is linked to the regulation of nuclear factor-kappaB (NF-kappaB)-dependent gene expression. Here we describe a novel binding partner of IRAK/mPLK that we term SIMPL (Signaling molecule that associates with the mouse pelle-like kinase). Overexpression of SIMPL leads to the activation of NF-kappaB dependent promoters, and inactivation of SIMPL inhibits IRAK/mPLK as well as tumor necrosis factor receptor type I-induced NF-kappaB activity. Dominant inhibitory alleles of I kappaB kinase (IKK alpha or IKK beta) block the activation of NF-kappaB by IRAK/mPLK and SIMPL. Furthermore, SIMPL binds IRAK/mPLK and the IKKs in vitro and in vivo. In the presence of antisense mRNA to SIMPL, the physical association between IRAK/mPLK and IKK beta but not IRAK/mPLK and IKK alpha is greatly diminished. Moreover, dominant-negative SIMPL blocks IKK alpha- or IKK beta -induced NF-kappaB activity. These results lead us to propose a model in which SIMPL functions to regulate NF-kappaB activity by linking IRAK/mPLK to IKK beta/alpha -containing complexes.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute	Harrington, MA (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.				NIAID NIH HHS [AI42798] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042798] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Cohen L, 1998, NATURE, V395, P292, DOI 10.1038/26254; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doi TS, 1999, P NATL ACAD SCI USA, V96, P2994, DOI 10.1073/pnas.96.6.2994; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; James P, 1996, GENETICS, V144, P1425; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Knop J, 1999, FEBS LETT, V448, P81, DOI 10.1016/S0014-5793(99)00322-1; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Maschera B, 1999, BIOCHEM J, V339, P227, DOI 10.1042/0264-6021:3390227; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Pfeuffer T, 2000, CELL MICROBIOL, V2, P101, DOI 10.1046/j.1462-5822.2000.00034.x; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; TEWRI M, 1995, J BIOL CHEM, V270, P22705; Thomas JA, 1999, J IMMUNOL, V163, P978; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Trofimova M, 1996, J BIOL CHEM, V271, P17609, DOI 10.1074/jbc.271.30.17609; Vig E, 1999, J BIOL CHEM, V274, P13077, DOI 10.1074/jbc.274.19.13077; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	39	26	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7859	7866		10.1074/jbc.M010399200	http://dx.doi.org/10.1074/jbc.M010399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11096118	hybrid			2022-12-25	WOS:000167474900027
J	Spector, D; Labarre, J; Toledano, MB				Spector, D; Labarre, J; Toledano, MB			A genetic investigation of the essential role of glutathione - Mutations in the proline biosynthesis pathway are the only suppressors of glutathione auxotrophy in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS-RESPONSE; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; YAP-1 TRANSCRIPTIONAL REGULATION; ESCHERICHIA-COLI CYTOPLASM; SACCHAROMYCES-CEREVISIAE; RIBONUCLEOTIDE REDUCTASE; DEFICIENT MUTANTS; HYDROGEN DONOR; TARGET GENE; THIOREDOXIN	In an attempt to elucidate the essential function of glutathione in Saccharomyces cerevisiae, we searched for suppressors of the GSH auxotrophy of Delta gsh1, a strain lacking the rate-limiting enzyme of glutathione biosynthesis. We found that specific mutations of PRO2, the second enzyme in proline biosynthesis, permitted the growth of Delta gsh1 in the absence of exogenous GSH, The suppression mechanism by alleles of PRO2 involved the biosynthesis of a trace amount of glutathione, Deletion of PRO1, the first enzyme of the proline biosynthesis pathway, or PRO2 eliminated the suppression, suggesting that gamma -glutamyl phosphate, the product of Pro1 and the physiological substrate of Pro2, is required as an obligate substrate of suppressor alleles of PRO2 for glutathione synthesis, A mutagenesis of a Delta gsh1 strain also lacking the proline pathway failed to generate any suppressor mutants under either aerobic or anaerobic conditions, confirming that glutathione is essential in yeast, This essential function is not related to DNA synthesis based on the terminal phenotype of glutathione-depleted cells or to toxic accumulation of non-native protein disulfides, Analysis of the suppressor strain demonstrates that normal glutathione levels are required for the tolerance to oxidants under acute, but not chronic stress conditions.	CEA, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France; Rutgers State Univ, Coll Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ 08855 USA; Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Grad Program Mol Genet & Microbiol, Piscataway, NJ 08854 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center	Toledano, MB (corresponding author), CEA, Serv Biochim & Genet Mol, Bat 142, F-91191 Gif Sur Yvette, France.							APONTOWEIL P, 1975, BIOCHIM BIOPHYS ACTA, V399, P10, DOI 10.1016/0304-4165(75)90206-8; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; COBLENZ A, 1994, FEMS MICROBIOL REV, V14, P303, DOI 10.1016/0168-6445(94)90047-7; DUNCAN WSS, 1996, FEMS MICROBIOL LETT, V141, P207; Grant CM, 1997, MOL BIOL CELL, V8, P1699, DOI 10.1091/mbc.8.9.1699; Grant CM, 1999, MOL CELL BIOL, V19, P2650; Grant CM, 1996, REDOX REP, V2, P223, DOI 10.1080/13510002.1996.11747054; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1997, FEBS LETT, V410, P219, DOI 10.1016/S0014-5793(97)00592-9; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; GREENBERG JT, 1986, J BACTERIOL, V168, P1026, DOI 10.1128/jb.168.2.1026-1029.1986; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; IZAWA S, 1995, FEBS LETT, V368, P73, DOI 10.1016/0014-5793(95)00603-7; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; Jeong JS, 1999, BIOCHEMISTRY-US, V38, P776, DOI 10.1021/bi9817818; KISTLER M, 1990, MUTAGENESIS, V5, P39, DOI 10.1093/mutage/5.1.39; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; MULLIEZ E, 1995, P NATL ACAD SCI USA, V92, P8759, DOI 10.1073/pnas.92.19.8759; OHTAKE Y, 1991, YEAST, V7, P953, DOI 10.1002/yea.320070907; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; Shi ZZ, 2000, P NATL ACAD SCI USA, V97, P5101, DOI 10.1073/pnas.97.10.5101; SIKORSKI RS, 1989, GENETICS, V122, P19; STEPHEN DWS, 1995, MOL MICROBIOL, V16, P415, DOI 10.1111/j.1365-2958.1995.tb02407.x; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; THOMAS D, 1990, J BIOL CHEM, V265, P15518; TOMENCHOK DM, 1987, J BACTERIOL, V169, P5364, DOI 10.1128/jb.169.12.5364-5372.1987; Wang PJ, 1997, MOL CELL BIOL, V17, P6114, DOI 10.1128/MCB.17.10.6114; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	38	65	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7011	7016		10.1074/jbc.M009814200	http://dx.doi.org/10.1074/jbc.M009814200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11084050	hybrid			2022-12-25	WOS:000167442900022
J	Steiner, H; Revesz, T; Neumann, M; Romig, H; Grim, MG; Pesold, B; Kretzschmar, HA; Hardy, J; Holton, JL; Baumeister, R; Houlden, H; Haass, C				Steiner, H; Revesz, T; Neumann, M; Romig, H; Grim, MG; Pesold, B; Kretzschmar, HA; Hardy, J; Holton, JL; Baumeister, R; Houlden, H; Haass, C			A pathogenic presenilin-1 deletion causes abberrant A beta 42 production in the absence of congophilic amyloid plaques	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; GAMMA-SECRETASE ACTIVITY; BETA-PEPTIDE PRODUCTION; PRECURSOR PROTEIN; CAENORHABDITIS-ELEGANS; SPASTIC PARAPARESIS; TRANSMEMBRANE ASPARTATES; INTRACELLULAR DOMAIN; PROTEOLYTIC RELEASE; MUTANT PRESENILIN	Familial Alzheimer's disease (FAD) is frequently associated with mutations in the preseniln-1 (PS1) gene. Almost all PS1-associated FAD mutations reported so far are exchanges of single conserved amino acids and cause the increased production of the highly amyloidogenic 42-residue amyloid beta -peptide A beta 42, Here we report the identification and pathological function of an unusual FAD-associated PS1 deletion (PS1 Delta I83/Delta M84). This FAD mutation is associated with spastic paraparesis clinically and causes accumulation of noncongophilic A beta -positive "cotton wool" plaques in brain parenchyma, Cerebral amyloid angiopathy due to A beta deposition was widespread as were neurofibrillary tangles and neuropil threads, although tau-positive neurites were sparse. Although significant deposition of A beta 42 was observed, no neuritic pathology was associated with these unusual lesions. Overexpressing PS1 Delta I83/Delta M84 in cultured cells results in a significantly elevated level of the highly amyloidogenic 42-amino acid amyloid beta -peptide A beta 42, Moreover, functional analysis in Caenorhabditis elegans reveals reduced activity of PS1 Delta I83/Delta M84 in Notch signaling. Our data therefore demonstrate that a small deletion of PS proteins can pathologically affect PS function in endoproteolysis of beta -amyloid precursor protein and in Notch signaling. Therefore, the PS1 Delta I83/Delta M84 deletion shows a very similar biochemical/functional phenotype like all other FAD-associated PS1 or PS2 point mutations, Since increased A beta 42 production is not associated with classical senile plaque formation, these data demonstrate that amyloid plaque formation is not a prerequisite for dementia and neurodegeneration.	Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers Dis Res, D-80336 Munich, Germany; UCL, Inst Neurol, Dept Neuropathol, London WC1N 3BG, England; Univ Munich, Inst Neuropathol, D-81377 Munich, Germany; Boehringer Ingelheim KG, CNS Res, D-55216 Ingelheim, Germany; Univ Munich, Gene Ctr, D-81377 Munich, Germany; Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; Inst Neurol, London WC1N 3BG, England	University of Munich; University of London; University College London; University of Munich; Boehringer Ingelheim; University of Munich; Mayo Clinic; University of London; University College London	Haass, C (corresponding author), Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers Dis Res, Schillerstr 44, D-80336 Munich, Germany.	chaass@pbm.med.uni-muenchen.de	Neumann, Manuela/F-6558-2011; Holton, Janice L/F-6831-2011; Hardy, John/C-2451-2009; Houlden, Henry J/C-1532-2008; Revesz, Tamas/A-8732-2010	Neumann, Manuela/0000-0002-6232-4057; Holton, Janice L/0000-0002-3882-5249; Hardy, John/0000-0002-3122-0423; Houlden, Henry J/0000-0002-2866-7777; Revesz, Tamas/0000-0003-2501-0259				Baumeister R, 1997, Genes Funct, V1, P149; Blacker D, 1998, NAT GENET, V19, P357, DOI 10.1038/1243; CAMPION D, 1995, HUM MOL GENET, V4, P2373, DOI 10.1093/hmg/4.12.2373; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Citron M, 1998, NEUROBIOL DIS, V5, P107, DOI 10.1006/nbdi.1998.0183; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Crook R, 1998, NAT MED, V4, P452, DOI 10.1038/nm0498-452; Cruts M, 1996, HUM MOL GENET, V5, P1449, DOI 10.1093/hmg/5.Supplement_1.1449; Cruts M, 1998, HUM MUTAT, V11, P183, DOI 10.1002/(SICI)1098-1004(1998)11:3<183::AID-HUMU1>3.3.CO;2-M; De Jonghe C, 1999, HUM MOL GENET, V8, P1529, DOI 10.1093/hmg/8.8.1529; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; HOLTON JL, 2001, IN PRESS AM J PATHOL; Houlden H, 2000, ANN NEUROL, V48, P806, DOI 10.1002/1531-8249(200011)48:5<806::AID-ANA18>3.0.CO;2-F; Hutton M, 1997, HUM MOL GENET, V6, P1639, DOI 10.1093/hmg/6.10.1639; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; Kamino K, 1996, NEUROSCI LETT, V208, P195, DOI 10.1016/0304-3940(96)12587-8; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; Leimer U, 1999, BIOCHEMISTRY-US, V38, P13602, DOI 10.1021/bi991453n; Lemere CA, 1996, NAT MED, V2, P1146, DOI 10.1038/nm1096-1146; Levitan D, 1996, P NATL ACAD SCI USA, V93, P14940, DOI 10.1073/pnas.93.25.14940; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Mann DMA, 1996, AM J PATHOL, V148, P1257; Mann DMA, 1996, ANN NEUROL, V40, P149, DOI 10.1002/ana.410400205; Murayama O, 1999, NEUROSCI LETT, V265, P61, DOI 10.1016/S0304-3940(99)00187-1; PerezTur J, 1995, NEUROREPORT, V7, P297; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Prihar G, 1999, NAT MED, V5, P1090, DOI 10.1038/13383; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; Ray WJ, 1999, J BIOL CHEM, V274, P36801, DOI 10.1074/jbc.274.51.36801; Revesz T, 1999, ACTA NEUROPATHOL, V97, P170, DOI 10.1007/s004010050970; Saura CA, 1999, J BIOL CHEM, V274, P13818, DOI 10.1074/jbc.274.20.13818; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Seeger M, 1997, P NATL ACAD SCI USA, V94, P5090, DOI 10.1073/pnas.94.10.5090; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Steiner H, 1999, BIOCHEMISTRY-US, V38, P14600, DOI 10.1021/bi9914210; Steiner H, 1999, J BIOL CHEM, V274, P7615, DOI 10.1074/jbc.274.12.7615; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; Thinakaran G, 1998, NEUROBIOL DIS, V4, P438, DOI 10.1006/nbdi.1998.0171; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 1999, J NEUROSCI, V19, P10627, DOI 10.1523/JNEUROSCI.19-24-10627.1999; Tomita T, 1998, J BIOL CHEM, V273, P21153, DOI 10.1074/jbc.273.33.21153; Vassar R, 2000, NEURON, V27, P419, DOI 10.1016/S0896-6273(00)00051-9; Verkkoniemi A, 2000, NEUROLOGY, V54, P1103, DOI 10.1212/WNL.54.5.1103; Vidal R, 2000, P NATL ACAD SCI USA, V97, P4920, DOI 10.1073/pnas.080076097; Vidal R, 1999, NATURE, V399, P776; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wisniewski T, 1998, NEUROREPORT, V9, P217, DOI 10.1097/00001756-199801260-00008; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P11223, DOI 10.1021/bi991080q; Wolfe MS, 1999, BIOCHEMISTRY-US, V38, P4720, DOI 10.1021/bi982562p; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	67	71	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7233	7239		10.1074/jbc.M007183200	http://dx.doi.org/10.1074/jbc.M007183200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11084029	hybrid			2022-12-25	WOS:000167442900053
J	Bulotta, S; Barsacchi, R; Rotiroti, D; Borgese, N; Clementi, E				Bulotta, S; Barsacchi, R; Rotiroti, D; Borgese, N; Clementi, E			Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-alpha - A novel feedback mechanism regulating cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INDUCED APOPTOSIS; FACTOR RECEPTOR; IN-VITRO; CERAMIDE; PROTEIN; INHIBITION; KINASE; AKT; PATHWAY	Cell death via apoptosis induced by tumor necrosis factor-alpha (TNF-alpha) plays an important role in many physiological and pathological conditions. The signal transduction pathway activated by this cytokine is known to be regulated by several intracellular messengers. In particular, in many systems nitric oxide (NO) has been shown to protect cells from TNF-alpha -induced apoptosis. However, whether NO can be generated by the cytokine to down-regulate its own apoptotic program has never been studied. We have addressed this question in HeLa Tet-off cell clones stably transfected with the endothelial NO synthase under a tetracycline-responsive promoter. Endothelial NO synthase, induced about 100-fold in these cells by removal of the antibiotic, retained the characteristics of the native enzyme of endothelial cells, both in terms of intracellular localization and functional activity. Expression of the endothelial NO synthase was sufficient to protect from TNF-alpha -induced apoptosis. This protection was mediated by the generation of NO. TNF-alpha itself stimulated endothelial NO synthase activity to generate NO through a pathway involving its lipid messenger, ceramide. Our results identify a novel mechanism of regulation of a signal transduction pathway activated by death receptors and suggest that NO may constitute a built-in mechanism by which TNF-alpha controls its own apoptotic program.	Univ Catanzaro Magna Graecia, Fac Pharm, Roccelletta Di Borgia 88021, Italy; CNR, Inst Biotechnol Appl Pharmacol, I-88021 Roccelletta Di Borgia, Italy; DIBIT H San Raffaele Inst, I-20132 Milan, Italy; CNR, Ctr Cellular & Mol Pharmacol, I-20129 Milan, Italy; Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, Italy	Magna Graecia University of Catanzaro; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR); University of Calabria	Clementi, E (corresponding author), DIBIT H San Rafaele Inst, Via Olgettina 58, I-20129 Milan, Italy.		Borgese, Nica/GWZ-8895-2022	Borgese, Nica/0000-0002-7537-3974				Aggarwal BB, 1996, EUR CYTOKINE NETW, V7, P93; Agnoletti L, 1999, CIRCULATION, V100, P1983, DOI 10.1161/01.CIR.100.19.1983; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Balconi G, 2000, ARTERIOSCL THROM VAS, V20, P1443, DOI 10.1161/01.ATV.20.6.1443; Bezombes C, 1998, FASEB J, V12, P101, DOI 10.1096/fasebj.12.1.101; Binder C, 1999, LAB INVEST, V79, P1703; Borner C, 1999, CELL DEATH DIFFER, V6, P497, DOI 10.1038/sj.cdd.4400525; Bradham CA, 1998, AM J PHYSIOL-GASTR L, V275, pG387, DOI 10.1152/ajpgi.1998.275.3.G387; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; Chung KC, 1999, J NEUROCHEM, V72, P1482, DOI 10.1046/j.1471-4159.1999.721482.x; CLEMENTI E, 1995, EUR J PHARM-MOLEC PH, V289, P113, DOI 10.1016/0922-4106(95)90176-0; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; Dbaibo GS, 1997, J EXP MED, V185, P481, DOI 10.1084/jem.185.3.481; De Nadai C, 2000, P NATL ACAD SCI USA, V97, P5480, DOI 10.1073/pnas.070062397; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; DESILVESTRIS M, 1995, FEBS LETT, V370, P69, DOI 10.1016/0014-5793(95)00797-D; Dimmeler S, 1999, ARTERIOSCL THROM VAS, V19, P656, DOI 10.1161/01.ATV.19.3.656; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dimmeler S, 1997, J EXP MED, V185, P601, DOI 10.1084/jem.185.4.601; Fiorucci S, 1999, GASTROENTEROLOGY, V116, P1089, DOI 10.1016/S0016-5085(99)70012-0; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; GarciaCardena G, 1996, P NATL ACAD SCI USA, V93, P6448, DOI 10.1073/pnas.93.13.6448; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; Higuchi M, 1996, J IMMUNOL, V157, P297; Igarashi J, 1999, P NATL ACAD SCI USA, V96, P12583, DOI 10.1073/pnas.96.22.12583; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Ko YG, 1999, J IMMUNOL, V162, P7217; Laouar A, 1999, J BIOL CHEM, V274, P23526, DOI 10.1074/jbc.274.33.23526; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Lievremont JP, 1999, J BIOL CHEM, V274, P15466, DOI 10.1074/jbc.274.22.15466; Liu B, 1998, J BIOL CHEM, V273, P11313, DOI 10.1074/jbc.273.18.11313; MACIEJEWSKI JP, 1995, J CLIN INVEST, V96, P1085, DOI 10.1172/JCI118094; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577, DOI 10.1152/ajpregu.1998.274.3.R577; Ozes ON, 1999, NATURE, V401, P82; Pan WH, 1997, NEUROSCI BIOBEHAV R, V21, P603, DOI 10.1016/S0149-7634(96)00047-4; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; Rodriguez A, 1999, ANAL BIOCHEM, V272, P171, DOI 10.1006/abio.1999.4156; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Schutze S, 1999, J BIOL CHEM, V274, P10203, DOI 10.1074/jbc.274.15.10203; Sciorati C, 1997, J BIOL CHEM, V272, P23211, DOI 10.1074/jbc.272.37.23211; SEELIG HP, 1994, J AUTOIMMUN, V7, P67, DOI 10.1006/jaut.1994.1006; SESSA WC, 1995, J BIOL CHEM, V270, P17641, DOI 10.1074/jbc.270.30.17641; Shaul PW, 1996, J BIOL CHEM, V271, P6518, DOI 10.1074/jbc.271.11.6518; Song W, 2000, CARDIOVASC RES, V45, P595, DOI 10.1016/S0008-6363(99)00395-8; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Tzeng E, 1998, SURGERY, V124, P278, DOI 10.1067/msy.1998.90569; Wright SC, 1996, FASEB J, V10, P325, DOI 10.1096/fasebj.10.2.8641566; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	60	79	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6529	6536		10.1074/jbc.M006535200	http://dx.doi.org/10.1074/jbc.M006535200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11085984	hybrid			2022-12-25	WOS:000167261000062
J	Das, S; Ghosh, R; Maitra, U				Das, S; Ghosh, R; Maitra, U			Eukaryotic translation initiation factor 5 functions as a GTPase-activating protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; BETA-SUBUNIT; IMMUNOCHEMICAL CHARACTERIZATION; GAMMA-SUBUNIT; IN-VITRO; EIF5; EXPRESSION; CLONING; COMPLEX; CDNA	Eukaryotic translation initiation factor 5 (eIFS) forms a complex with eIF2 by interacting with the beta subunit of eIF2. This interaction is essential for eIF5-promoted hydrolysis of GTP bound to the 40 S initiation complex. In this work, we show that, in addition to the eIF2 beta -binding region at the C terminus of eIF5, the N-terminal region of eIF5 is also required for eIF5-dependent GTP hydrolysis. Like other GTPase-activating proteins, eIF5 contains an invariant arginine residue (Arg-15) at its N terminus that is essential for its function. Mutation of this arginine residue to alanine or even to conservative lysine caused a severe defect in the ability of eIF5 to promote GTP hydrolysis from the 40 S initiation complex, although the ability of these mutant proteins to bind to eIF2 beta remained unchanged. These mutants were also defective in overall protein synthesis as well as in their ability to support cell growth of a Delta TIF5 yeast strain. Additionally, alanine substitution mutagenesis of eIFS defined Lys-33 and Lys-55 as also critical for eIF5 function in vitro and in vivo. The implications of these results in relation to other well characterized GAPs are discussed and provide additional evidence that eIF5 functions as a GTPase-activating protein.	Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Maitra, U (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Dev & Mol Biol, Jack Pearl Resnick Campus, Bronx, NY 10461 USA.				NATIONAL CANCER INSTITUTE [P30CA013330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015399] Funding Source: NIH RePORTER; NCI NIH HHS [P30CA13330] Funding Source: Medline; NIGMS NIH HHS [GM15399] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Asano K, 1999, EMBO J, V18, P1673, DOI 10.1093/emboj/18.6.1673; Bacher G, 1999, J CELL BIOL, V146, P723, DOI 10.1083/jcb.146.4.723; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; CHAKRABARTI A, 1991, J BIOL CHEM, V266, P14039; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P10524; CHAKRAVARTI D, 1993, J BIOL CHEM, V268, P5754; CHAUDHURI J, 1994, BIOCHEMISTRY-US, V33, P4794, DOI 10.1021/bi00182a007; CHEVESICH J, 1993, J BIOL CHEM, V268, P20659; DAS K, 1993, P NATL ACAD SCI USA, V90, P3058, DOI 10.1073/pnas.90.7.3058; Das S, 2000, MOL CELL BIOL, V20, P3942, DOI 10.1128/MCB.20.11.3942-3950.2000; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Gamblin SJ, 1998, CURR OPIN STRUC BIOL, V8, P195, DOI 10.1016/S0959-440X(98)80038-9; GASPAR NJ, 1994, J BIOL CHEM, V269, P3415; GHOSH S, 1989, J BIOL CHEM, V264, P5134; HANNIG EM, 1993, MOL CELL BIOL, V13, P506, DOI 10.1128/MCB.13.1.506; Huang HK, 1997, GENE DEV, V11, P2396, DOI 10.1101/gad.11.18.2396; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Maiti T, 1997, J BIOL CHEM, V272, P18333, DOI 10.1074/jbc.272.29.18333; MAITRA U, 1982, ANNU REV BIOCHEM, V51, P869, DOI 10.1146/annurev.bi.51.070182.004253; Merrick WC., 1996, TRANSLATION CONTROL, P31; RAYCHAUDHURI P, 1985, J BIOL CHEM, V260, P2132; Sambrook J., 2002, MOL CLONING LAB MANU; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Scheffzek K, 1996, NATURE, V384, P591, DOI 10.1038/384591a0; Scheffzek K, 1998, TRENDS BIOCHEM SCI, V23, P257, DOI 10.1016/S0968-0004(98)01224-9; Si KS, 1996, J BIOL CHEM, V271, P16934, DOI 10.1074/jbc.271.28.16934; Thompson GM, 2000, BIOCHEM J, V347, P703, DOI 10.1042/0264-6021:3470703; [No title captured]	29	70	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6720	6726		10.1074/jbc.M008863200	http://dx.doi.org/10.1074/jbc.M008863200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11092890	hybrid			2022-12-25	WOS:000167261000084
J	Aikawa, J; Grobe, K; Tsujimoto, M; Esko, JD				Aikawa, J; Grobe, K; Tsujimoto, M; Esko, JD			Multiple isozymes of heparan sulfate/heparin GlcNAc N-deacetylase/GlcN N-sulfotransferase - Structure and activity of the fourth member, NDST4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE PROTEOGLYCANS; MOLECULAR-CLONING; CDNA CLONING; EXPRESSION; BIOSYNTHESIS; DEACETYLATION; PROTEIN; MOUSE; GENE; IDENTIFICATION	We report the cloning and partial characterization of the fourth member of the vertebrate hepar-an sulfate/ heparin: GlcNAc N-deacetylase/GlcN N-sulfotransferase family, which we designate NDST4, Full-length cDNA clones containing the entire coding region of 872 amino acids were obtained from human and mouse cDNA libraries. The deduced amino acid sequence of NDST4 showed high sequence identity to NDST1, NDST2, and NDST3 in both species. NDST4 maps to human chromosome 4q25-26, Very close to NDST3, located at 4q26-27. These observations, taken together with phylogenetic data, suggest that the four NDSTs evolved from a common ancestral gene, which diverged to give rise to two subtypes, NDST3/4 and NDST1/2. Reverse transcription-polymerase chain reaction analysis of various mouse tissues revealed a restricted pattern of NDST4 mRNA expression when compared with NDST1 and NDST2, which are abundantly and ubiquitously expressed. Comparison of the enzymatic properties of the four murine NDSTs revealed striking differences in N-deacetylation and N-sulfation activities; NDST4 had weak deacetylase activity but high sulfotransferase, whereas NDST3 had the opposite properties. Molecular modeling of the sulfotransferase domains of the murine and human NDSTs showed varying surface charge distributions within the substrate binding cleft, suggesting that the differences in activity may reflect preferences for different substrates, An iterative model of heparan sulfate biosynthesis is suggested in which some NDST isozymes initiate the N-deacetylation and N-sulfation of the chains, whereas others bind to previously modified segments to fill in or extend the section of modified residues.	Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; RIKEN, Cellular Biochem Lab, Wako, Saitama 3510198, Japan	University of California System; University of California San Diego; RIKEN	Esko, JD (corresponding author), Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Med, La Jolla, CA 92093 USA.	jesko@ucsd.edu	Aikawa, Jun-ichi/D-3357-2017; Grobe, Kay/F-2399-2011	Aikawa, Jun-ichi/0000-0003-2250-8756; 	NHLBI NIH HHS [HL53745] Funding Source: Medline; NIGMS NIH HHS [R37GM33063] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053745] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aikawa J, 1999, J BIOL CHEM, V274, P2690, DOI 10.1074/jbc.274.5.2690; AIKAWA J, 1999, GLYCOCONJ, V16, P40; Bai XM, 1996, J BIOL CHEM, V271, P17711, DOI 10.1074/jbc.271.30.17711; BAME KJ, 1994, BIOCHEM J, V303, P81, DOI 10.1042/bj3030081; BAME KJ, 1991, J BIOL CHEM, V266, P10287; BAME KJ, 1989, J BIOL CHEM, V264, P8059; BAME KJ, 1991, J BIOL CHEM, V266, P12461; BRANDAN E, 1988, J BIOL CHEM, V263, P2417; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Conrad H. E., 1998, HEPARIN BINDING PROT; DIXON J, 1995, GENOMICS, V26, P239, DOI 10.1016/0888-7543(95)80206-2; ERIKSSON I, 1994, J BIOL CHEM, V269, P10438; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; HASHIMOTO Y, 1992, J BIOL CHEM, V267, P15744; Humphries DE, 1998, BIOCHEM J, V332, P303, DOI 10.1042/bj3320303; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kusche-Gullberg M, 1998, J BIOL CHEM, V273, P11902, DOI 10.1074/jbc.273.19.11902; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Liu JA, 1999, J BIOL CHEM, V274, P38155, DOI 10.1074/jbc.274.53.38155; MANDON E, 1994, J BIOL CHEM, V269, P11729; NISHIHARA S, 1993, BIOCHEM BIOPH RES CO, V190, P42, DOI 10.1006/bbrc.1993.1008; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; ORELLANA A, 1994, J BIOL CHEM, V269, P2270; PETTERSSON I, 1991, J BIOL CHEM, V266, P8044; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; RODEN L, 1980, BIOCH GLYCOPROTEINS, P264; SARRAS MP, 1991, DEV BIOL, V148, P495, DOI 10.1016/0012-1606(91)90267-7; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shworak NW, 1999, J BIOL CHEM, V274, P5170, DOI 10.1074/jbc.274.8.5170; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; Toyoda H, 2000, J BIOL CHEM, V275, P21856, DOI 10.1074/jbc.M003540200; vandenBorn J, 1995, J BIOL CHEM, V270, P31303, DOI 10.1074/jbc.270.52.31303; WEI Z, 1993, P NATL ACAD SCI USA, V90, P3885, DOI 10.1073/pnas.90.9.3885	37	178	186	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5876	5882		10.1074/jbc.M009606200	http://dx.doi.org/10.1074/jbc.M009606200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11087757	hybrid			2022-12-25	WOS:000167115100064
J	Bonev, BB; Gilbert, RJC; Andrew, PW; Byron, O; Watts, A				Bonev, BB; Gilbert, RJC; Andrew, PW; Byron, O; Watts, A			Structural analysis of the protein/lipid complexes associated with pore formation by the bacterial toxin pneumolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C INTERACTIONS; STREPTOCOCCUS-PNEUMONIAE; PHOSPHOLIPID-MEMBRANES; COMPLEMENT ACTIVATION; BIOLOGICAL-MEMBRANES; PERFRINGOLYSIN-O; STREPTOLYSIN-O; FORMING TOXIN; NMR; MECHANISM	\Pneumolysin, a major virulence factor of the human pathogen Streptococcus pneumoniae, is a soluble protein that disrupts cholesterol-containing membranes of cells by forming ring-shaped oligomers. Magic angle spinning and wideline static (31)p NMR have been used in combination with freeze-fracture electron microscopy to investigate the effect of pneumolysin on fully hydrated model membranes containing cholesterol and phosphatidylcholine and dicetyl phosphate (10:10:1 molar ratio), NMR spectra show that the interaction of pneumolysin with cholesterol-containing Liposomes results in the formation of a nonbilayer phospholipid phase and vesicle aggregation. The amount of the nonbilayer phase increases with increasing protein concentration. Freeze-fracture electron microscopy indicates the coexistence of aggregated vesicles and free ring-shaped structures in the presence of pneumolysin. On the basis of their size and analysis of the NMR spectra it is concluded that the rings are pneumolysin oligomers (containing 30-50 monomers) complexed with lipid (each with 840-1400 lipids). The lifetime of the phospholipid in either bilayer-associated complexes or free pneumolysin-lipid complexes is > 15 ms. It is further concluded that the effect of pneumolysin on lipid membranes is a complex combination of pore formation within the bilayer, extraction of lipid into free oligomeric complexes, aggregation and fusion of liposomes, and the destabilization of membranes leading to formation of small vesicles.	Univ Oxford, Dept Biochem, Biomembrane Struct Unit, Oxford OX1 3QU, England; Univ Leicester, Dept Microbiol & Immunol, Leicester LE1 9HN, Leics, England; Univ Glasgow, Inst Biomed & Life Sci, Div Infect & Immun, Glasgow G12 8QQ, Lanark, Scotland	University of Oxford; University of Leicester; University of Glasgow	Watts, A (corresponding author), Univ Oxford, Dept Biochem, Biomembrane Struct Unit, S Parks Rd, Oxford OX1 3QU, England.		Andrew, Peter W/G-7526-2012	Bonev, Boyan/0000-0001-7156-2412; Gilbert, Robert/0000-0001-9336-5604; Byron, Olwyn/0000-0001-7857-4520				Aguilar L, 1999, J BIOL CHEM, V274, P25193, DOI 10.1074/jbc.274.36.25193; Alexander JE, 1998, MICROB PATHOGENESIS, V24, P167, DOI 10.1006/mpat.1997.0185; BHAKDI S, 1985, INFECT IMMUN, V48, P713, DOI 10.1128/IAI.48.3.713-719.1985; BLOOM M, 1995, MOL MEMBR BIOL, V12, P9, DOI 10.3109/09687689509038489; BURNELL EE, 1980, BIOCHIM BIOPHYS ACTA, V603, P63, DOI 10.1016/0005-2736(80)90391-0; Carbone MA, 1996, BIOCHEMISTRY-US, V35, P3368, DOI 10.1021/bi952349i; CULLIS PR, 1979, BIOCHIM BIOPHYS ACTA, V559, P399, DOI 10.1016/0304-4157(79)90012-1; Gilbert RJC, 1998, J MOL BIOL, V284, P1223, DOI 10.1006/jmbi.1998.2258; Gilbert RJC, 1999, CELL, V97, P647, DOI 10.1016/S0092-8674(00)80775-8; Gilbert RJC, 1999, J MOL BIOL, V293, P1145, DOI 10.1006/jmbi.1999.3210; Korchev YE, 1998, BIOCHEM J, V329, P571; MITCHELL TJ, 1991, MOL MICROBIOL, V5, P1883, DOI 10.1111/j.1365-2958.1991.tb00812.x; Morgan P, 1996, REV MED MICROBIOL, V7, P221, DOI DOI 10.1097/00013542-199610000-00004; Nakamura M, 1998, J BIOCHEM, V123, P1145; PAKE GE, 1948, PHYS REV, V74, P1184, DOI 10.1103/PhysRev.74.1184; Palmer M, 1998, EMBO J, V17, P1598, DOI 10.1093/emboj/17.6.1598; PINHEIRO TJT, 1994, BIOCHEMISTRY-US, V33, P2459, DOI 10.1021/bi00175a014; Rossjohn J, 1997, CELL, V89, P685, DOI 10.1016/S0092-8674(00)80251-2; SEELIG J, 1980, Q REV BIOPHYS, V13, P19, DOI 10.1017/S0033583500000305; SEELIG J, 1977, Q REV BIOPHYS, V10, P353, DOI 10.1017/S0033583500002948; Shatursky O, 1999, CELL, V99, P293, DOI 10.1016/S0092-8674(00)81660-8; Shepard LA, 1998, BIOCHEMISTRY-US, V37, P14563, DOI 10.1021/bi981452f; Shotton D.M., 1995, RAPID FREEZING FREEZ, P31; SPOONER PJR, 1992, BIOCHEMISTRY-US, V31, P10129, DOI 10.1021/bi00156a037; Traikia M, 1997, J MAGN RESON, V125, P140, DOI 10.1006/jmre.1996.1068; Watts A, 1998, BBA-REV BIOMEMBRANES, V1376, P297, DOI 10.1016/S0304-4157(98)00012-4; WRIGHT JK, 1980, BIOCHEM J, V187, P775, DOI 10.1042/bj1870775; YEAGLE PL, 1990, BIOL MAGN RESON, V9, P1	28	48	49	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5714	5719		10.1074/jbc.M005126200	http://dx.doi.org/10.1074/jbc.M005126200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11076935	hybrid, Green Accepted			2022-12-25	WOS:000167115100043
J	Desrumaux, C; Labeur, C; Verhee, A; Tavernier, J; Vandekerckhove, J; Rosseneu, M; Peelman, F				Desrumaux, C; Labeur, C; Verhee, A; Tavernier, J; Vandekerckhove, J; Rosseneu, M; Peelman, F			A hydrophobic cluster at the surface of the human plasma phospholipid transfer protein is critical for activity on high density lipoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERICIDAL/PERMEABILITY-INCREASING PROTEIN; ESTER TRANSFER PROTEIN; APOLIPOPROTEIN-A-I; BINDING; SPECIFICITY; SEQUENCE; RESIDUES; LIPASE; PARTICLES; MECHANISM	The plasma phospholipid transfer protein (PLTP) belongs to the lipid transfer/lipopolysaccharide binding protein (LT/LBP) family, together with the cholesteryl ester transfer protein, the lipopolysaccharide binding protein (LBP) and the bactericidal permeability increasing protein (BPI). In the present study, we used the crystallographic data available for BPI to build a three-dimensional model for PLTP. Multiple sequence alignment suggested that, in PLTP, a cluster of hydrophobic residues substitutes for a cluster of positively charged residues found on the surface of LBP and BPI, which is critical for interaction with Lipopolysaccharides. According to the PLTP model, these hydrophobic residues are situated on an exposed hydrophobic patch at the N-terminal tip of the molecule. To assess the role of this hydrophobic cluster for the functional activity of PLTP, single point alanine mutants were engineered. Phospholipid transfer from liposomes to high density lipoprotein (HDL) by the W91A, F92A, and F93A PLTP mutants was drastically reduced, whereas their transfer activity toward very low density lipoprotein and low density lipoprotein did not change, The HDL size conversion activity of the mutants was reduced to the same extent as the PLTP transfer activity toward HDL. Based on these results, we propose that a functional solvent-exposed hydrophobic cluster in the PLTP molecule specifically contributes to the PLTP transfer activity on HDL substrates,	Univ Ghent, Fac Med, Lab Lipoprot Chem, B-9000 Ghent, Belgium; State Univ Ghent VIB, Fac Med, Dept Biochem, B-9000 Ghent, Belgium	Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University	Desrumaux, C (corresponding author), Univ Ghent, Vakgrp Biochem, Hosp Str 13, B-9000 Ghent, Belgium.	desrumauxcatherine@yahoo.com	Desrumaux, Catherine/O-1925-2018					Abrahamson SL, 1997, J BIOL CHEM, V272, P2149; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Beamer LJ, 1998, PROTEIN SCI, V7, P906; Beamer LJ, 1999, BIOCHEM PHARMACOL, V57, P225, DOI 10.1016/S0006-2952(98)00279-2; Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; BLANCHE PJ, 1981, BIOCHIM BIOPHYS ACTA, V665, P408, DOI 10.1016/0005-2760(81)90253-8; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; Bruce C, 1998, CURR OPIN STRUC BIOL, V8, P426, DOI 10.1016/S0959-440X(98)80118-8; Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297; DAY JR, 1994, J BIOL CHEM, V269, P9388; Desrumaux C, 1999, ARTERIOSCL THROM VAS, V19, P266, DOI 10.1161/01.ATV.19.2.266; Desrumaux C, 1998, J LIPID RES, V39, P131; Gelb MH, 1999, CURR OPIN STRUC BIOL, V9, P428, DOI 10.1016/S0959-440X(99)80059-1; GILSON MK, 1988, PROTEINS, V4, P7, DOI 10.1002/prot.340040104; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; Huuskonen J, 1996, BBA-LIPID LIPID MET, V1303, P207, DOI 10.1016/0005-2760(96)00103-8; Huuskonen J, 1998, J LIPID RES, V39, P2021; Huuskonen J, 1999, J LIPID RES, V40, P1123; Huuskonen J, 2000, CURR OPIN LIPIDOL, V11, P285, DOI 10.1097/00041433-200006000-00009; IBDAH JA, 1989, BIOCHEMISTRY-US, V28, P1126, DOI 10.1021/bi00429a029; IBDAH JA, 1988, BIOCHEMISTRY-US, V27, P7155, DOI 10.1021/bi00418a073; JACKSON RL, 1987, AM HEART J, V113, P551, DOI 10.1016/0002-8703(87)90631-4; Janssen MJW, 1999, EUR J BIOCHEM, V263, P782, DOI 10.1046/j.1432-1327.1999.00557.x; JAUHIAINEN M, 1993, J BIOL CHEM, V268, P4032; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; Karplus K, 1999, PROTEINS, P121; Lagrost L, 1998, CURR OPIN LIPIDOL, V9, P203, DOI 10.1097/00041433-199806000-00004; Lagrost L, 1997, TRENDS CARDIOVAS MED, V7, P218, DOI 10.1016/S1050-1738(97)00053-4; LAGROST L, 1994, BBA-LIPID LIPID MET, V1215, P209, DOI 10.1016/0005-2760(94)90047-7; Lamping N, 1996, J IMMUNOL, V157, P4648; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIVINGSTONE CD, 1993, COMPUT APPL BIOSCI, V9, P745; Lookene A, 1997, J BIOL CHEM, V272, P766, DOI 10.1074/jbc.272.2.766; Lusa S, 1996, BIOCHEM J, V313, P275, DOI 10.1042/bj3130275; MASSEY JB, 1985, BIOCHIM BIOPHYS ACTA, V835, P124, DOI 10.1016/0005-2760(85)90038-4; NISHIDA HI, 1993, J BIOL CHEM, V268, P16352; OOI CE, 1991, AGENTS ACTIONS, V34, P274, DOI 10.1007/BF01993301; Pussinen PJ, 1998, J LIPID RES, V39, P152; Rao R, 1997, BIOCHEMISTRY-US, V36, P3645, DOI 10.1021/bi962776b; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; Rosseneu M, 1988, Prog Clin Biol Res, V255, P143; Schumann RR, 2000, CHEM IMMUNOL, V74, P42; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Sumandea M, 1999, BIOCHEMISTRY-US, V38, P16290, DOI 10.1021/bi9921384; SWEENY SA, 1985, BIOCHIM BIOPHYS ACTA, V835, P279, DOI 10.1016/0005-2760(85)90283-8; Tansey JT, 1997, BIOCHEMISTRY-US, V36, P12227, DOI 10.1021/bi970356w; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TU AY, 1993, J BIOL CHEM, V268, P23098; WEISS J, 1984, J IMMUNOL, V132, P3109; WETTERAU JR, 1982, J BIOL CHEM, V257, P961; Wiese A, 1997, BIOCHEMISTRY-US, V36, P10311, DOI 10.1021/bi970177e; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842	52	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5908	5915		10.1074/jbc.M008420200	http://dx.doi.org/10.1074/jbc.M008420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11083872	hybrid			2022-12-25	WOS:000167115100068
J	Giraud, S; Greco, A; Brink, M; Diaz, JJ; Delafontaine, P				Giraud, S; Greco, A; Brink, M; Diaz, JJ; Delafontaine, P			Translation initiation of the insulin-like growth factor I receptor mRNA is mediated by an internal ribosome entry site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; TRACT-BINDING-PROTEIN; CELLULAR MESSENGER-RNA; C-MYC; ALTERNATIVE TRANSLATION; 5'-UNTRANSLATED REGION; SECONDARY STRUCTURE; PICORNAVIRUS RNA; GENE-EXPRESSION; POLIOVIRUS RNA	The insulin-like growth factor I receptor (IGF-IR) is a heterotetrameric receptor mediating the effects of insulin-like growth I and other growth factors. This receptor is encoded by an mRNA containing an unusually long, G-C-rich, and highly structured 5 ' untranslated region. Using bicistronic constructs, we demonstrated here that the 5 ' untranslated region of the IGF-IR allows translation initiation by internal ribosome entry and therefore constitutes an internal ribosome entry site. In vitro cross-linking revealed that this internal ribosome entry site binds a protein of 57 kDa. Immunoprecipitation of UV cross-linked proteins proved that this protein was the polypyrimidine tract-binding protein, a well known regulator of picornavirus mRNA translation. The efficiency of translation of the endogenous IGF-IR mRNA is not affected by rapamycin, which is a potent inhibitor of cap-dependent translation. This result provides evidence that the endogenous IGF-IR mRNA is translated, at least in part, through a cap-independent mechanism. This is the first report of a growth factor receptor containing sequence elements that allow translation initiation to occur by internal initiation. Because the IGF-IR has a pivotal function in the cell cycle, this mechanism of translation regulation could play a crucial role in the control of cell proliferation and differentiation.	Univ Hosp Geneva, Div Cardiol, CH-1211 Geneva 14, Switzerland; Fac Med Lyon RTH Laennec, INSERM, U369, F-69372 Lyon, France	University of Geneva; Institut National de la Sante et de la Recherche Medicale (Inserm)	Delafontaine, P (corresponding author), Univ Kansas, Med Ctr, Div Cardiovasc Dis, 1001 Eaton Bldg,3901 Rainbow Blvd, Kansas City, KS 66160 USA.		DIAZ, Jean-Jacques/AAT-3846-2021; DIAZ, Jean-Jacques/H-3018-2014	DIAZ, Jean-Jacques/0000-0002-7914-4319; DIAZ, Jean-Jacques/0000-0002-7914-4319; Brink, Marijke/0000-0002-1790-0190; Delafontaine, Patrice/0000-0003-3744-3617	NHLBI NIH HHS [HL 45317, HL 47035] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045317, R01HL047035, R29HL045317] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BASERGA R, 1995, CANCER RES, V55, P249; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; Bernstein J, 1997, J BIOL CHEM, V272, P9356; BOROVJAGIN AV, 1990, FEBS LETT, V261, P237, DOI 10.1016/0014-5793(90)80561-V; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Chetouani F, 1997, NUCLEIC ACIDS RES, V25, P3514, DOI 10.1093/nar/25.17.3514; COPPOLA D, 1994, MOL CELL BIOL, V14, P4588, DOI 10.1128/MCB.14.7.4588; DELAFONTAINE P, 1995, J BIOL CHEM, V270, P14383, DOI 10.1074/jbc.270.24.14383; DELAFONTAINE P, 1993, J BIOL CHEM, V268, P16866; Delafontaine P, 1996, TRENDS CARDIOVAS MED, V6, P187, DOI 10.1016/S1050-1738(96)00058-8; Delafontaine P, 1996, J CLIN INVEST, V97, P139, DOI 10.1172/JCI118381; Du J, 1999, ARTERIOSCL THROM VAS, V19, P2119, DOI 10.1161/01.ATV.19.9.2119; Du J, 1996, ENDOCRINOLOGY, V137, P1378, DOI 10.1210/en.137.4.1378; DU J, 1995, CIRC RES, V76, P963, DOI 10.1161/01.RES.76.6.963; GHETTI A, 1992, NUCLEIC ACIDS RES, V20, P3671, DOI 10.1093/nar/20.14.3671; Gosert R, 2000, MOL CELL BIOL, V20, P1583, DOI 10.1128/MCB.20.5.1583-1595.2000; GRECO A, 1994, J GEN VIROL, V75, P1693, DOI 10.1099/0022-1317-75-7-1693; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; HELLEN CUT, 1995, CAP INDEPENDENT TRAN, P31; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Izquierdo JM, 2000, BIOCHEM J, V346, P849, DOI 10.1042/0264-6021:3460849; JACKSON RJ, 1995, CAPINDEPENDENT TRANS; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Negulescu D, 1998, J BIOL CHEM, V273, P20109, DOI 10.1074/jbc.273.32.20109; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; Oumard A, 2000, MOL CELL BIOL, V20, P2755, DOI 10.1128/MCB.20.8.2755-2759.2000; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PESTOVA TV, 1991, J VIROL, V65, P6194, DOI 10.1128/JVI.65.11.6194-6204.1991; PFEIFLE B, 1987, ENDOCRINOLOGY, V120, P2251, DOI 10.1210/endo-120-6-2251; PIETRZKOWSKI Z, 1992, CELL GROWTH DIFFER, V3, P199; PILIPENKO EV, 1992, CELL, V68, P119, DOI 10.1016/0092-8674(92)90211-T; Pozner A, 2000, MOL CELL BIOL, V20, P2297, DOI 10.1128/MCB.20.7.2297-2307.2000; Scheidegger KJ, 2000, J BIOL CHEM, V275, P26864; Stein I, 1998, MOL CELL BIOL, V18, P3112, DOI 10.1128/MCB.18.6.3112; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Stoneley M, 1998, ONCOGENE, V16, P423, DOI 10.1038/sj.onc.1201763; Teerink H, 1995, BBA-GENE STRUCT EXPR, V1264, P403, DOI 10.1016/0167-4781(95)00185-9; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; WERNER H, 1994, VITAM HORM, V48, P1, DOI 10.1016/S0083-6729(08)60495-1; WERNER H, 1990, BIOCHEM BIOPH RES CO, V169, P1021, DOI 10.1016/0006-291X(90)91996-6; Werner H, 1996, P NATL ACAD SCI USA, V93, P8318, DOI 10.1073/pnas.93.16.8318; Weston CE, 1999, KIDNEY INT, V56, P1274, DOI 10.1046/j.1523-1755.1999.00692.x	51	51	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5668	5675		10.1074/jbc.M005928200	http://dx.doi.org/10.1074/jbc.M005928200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11063741	hybrid			2022-12-25	WOS:000167115100037
J	Guo, CH; Yu, SH; Davis, AT; Wang, HM; Green, JE; Ahmed, K				Guo, CH; Yu, SH; Davis, AT; Wang, HM; Green, JE; Ahmed, K			A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-2; TRANSCRIPTIONAL ACTIVITY; ANDROGENIC REGULATION; BETA-SUBUNIT; PROSTATE; PHOSPHORYLATION; INDUCTION; PROLIFERATION; STIMULATION; GROWTH	Protein kinase CK2 (CK2) has long been implicated in the regulation of cell growth and proliferation. Its activity is generally elevated in rapidly proliferating tissues, and nuclear matrix (NM) is an important subnuclear locale of its functional signaling. In the prostate, nuclear CK2 is rapidly lost commensurate with induction of receptor-mediated apoptosis after growth stimulus withdrawal. Ey contrast, chemical-induced apoptosis in prostate cancer and other cells (by etoposide and diethylstilbestrol) evokes an enhancement in CK2 associated with the NM that appears to be because of translocation of CK2 from the cytoplasmic to the nuclear compartment. This shuttling of CK2 to the NM may reflect a protective response to chemical-mediated apoptosis. Supporting evidence for this was obtained by employing cells that were transiently transfected with various expression plasmids of CK2 (thereby expressing additional CK2) prior to treatment with etoposide or diethylstilbestrol. Cells transfected with the CK2 alpha or CK2 alpha beta showed significant resistance to chemical-mediated apoptosis commensurate with the corresponding elevation in CK2 in the NM. Transfection with CK2 beta did not demonstrate this effect. These results suggest, for the first time, that besides the commonly appreciated function of CK2 in cell growth, it may also have a role in protecting cells against apoptosis.	Dept Vet Affairs Med Ctr, Minneapolis, MN 55417 USA; Univ Minnesota, Dept Lab Med & Pathol, Cellular & Mol Biochem Res Lab 151, Minneapolis, MN 55417 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55417 USA; NCI, Transgen Oncogenesis Grp, Lab Cell Regulat & Carcinogenesis, NIH, Bethesda, MD 20892 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ahmed, K (corresponding author), Vet Affairs Med Ctr, Cellular & Mol Biochem Res Lab 151, 1 Vet Dr, Minneapolis, MN 55417 USA.	ahmedk@tc.umn.edu			NCI NIH HHS [CA-15062] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA015062, R01CA015062, R37CA015062] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHMED K, 1993, P NATL ACAD SCI USA, V90, P4426, DOI 10.1073/pnas.90.10.4426; AHMED K, 1994, CELL MOL BIOL RES, V40, P1; Ahmed K, 1999, CRIT REV EUKAR GENE, V9, P329, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.170; AHMED K, 1986, ADV ENZYME REGUL, V25, P401, DOI 10.1016/0065-2571(86)90026-9; Ahmed RL, 1996, ANAL BIOCHEM, V237, P76, DOI 10.1006/abio.1996.0203; ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; ARENDS MJ, 1991, INT REV EXP PATHOL, V32, P223; BERGES RR, 1993, P NATL ACAD SCI USA, V90, P4426; Blanquet PR, 2000, PROG NEUROBIOL, V60, P211, DOI 10.1016/S0301-0082(99)00026-X; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Deptala A, 1999, INT J ONCOL, V15, P861; FURUYA Y, 1995, ENDOCRINOLOGY, V136, P1898, DOI 10.1210/en.136.5.1898; Furuya Y, 1995, JPN J CANCER RES, V86, P1159, DOI 10.1111/j.1349-7006.1995.tb03309.x; Gerner C, 1998, EXP CELL RES, V238, P472, DOI 10.1006/excr.1997.3866; Guerra B, 1999, ELECTROPHORESIS, V20, P391, DOI 10.1002/(SICI)1522-2683(19990201)20:2<391::AID-ELPS391>3.0.CO;2-N; Guo CH, 1999, CANCER RES, V59, P1146; Guo CH, 1998, J BIOL CHEM, V273, P13675, DOI 10.1074/jbc.273.22.13675; Guo CH, 1999, MOL CELL BIOCHEM, V191, P135, DOI 10.1023/A:1006881405383; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; Kumari SR, 1998, CANCER RES, V58, P5075; Leroy D, 1997, J BIOL CHEM, V272, P20820, DOI 10.1074/jbc.272.33.20820; LIN WJ, 1994, BIOCHEMISTRY-US, V33, P6998, DOI 10.1021/bi00188a032; LITCHFIELD DW, 1993, MOL CELL BIOCHEM, V128, P187, DOI 10.1007/BF01076770; MARIN O, 1994, BIOCHEM BIOPH RES CO, V198, P898, DOI 10.1006/bbrc.1994.1128; PALEN E, 1991, BIOCHEMISTRY-US, V30, P5586, DOI 10.1021/bi00236a035; Pinna L A, 1997, Prog Cell Cycle Res, V3, P77; RAFFRAY M, 1997, PHARMACOL THERAPEUT, V25, P153; Robertson CN, 1996, J NATL CANCER I, V88, P908, DOI 10.1093/jnci/88.13.908; SCHULZ P, 1990, CANCER RES, V50, P5008; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Takahashi A, 1996, CURR OPIN GENET DEV, V6, P50, DOI 10.1016/S0959-437X(96)90010-6; TAWFIC S, 1994, J BIOL CHEM, V269, P7489; TAWFIC S, 1995, J BIOL CHEM, V270, P21009, DOI 10.1074/jbc.270.36.21009; TAWFIC S, 1994, J BIOL CHEM, V269, P24615; Tawfic S, 1997, J CELL BIOCHEM, V64, P499; Tawfic S, 1999, J CELL BIOCHEM, V72, P242; Tawfic S, 1996, J CELL BIOCHEM, V62, P165, DOI 10.1002/(SICI)1097-4644(199608)62:2<165::AID-JCB4>3.0.CO;2-Q; TUAZON PT, 1991, ADV SEC MESS PHOSPH, V23, P123; Watabe M, 1997, CELL GROWTH DIFFER, V8, P871; Yu SH, 1999, J CELL BIOCHEM, V74, P127, DOI 10.1002/(SICI)1097-4644(19990701)74:1<127::AID-JCB14>3.3.CO;2-V	41	139	152	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5992	5999		10.1074/jbc.M004862200	http://dx.doi.org/10.1074/jbc.M004862200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11069898	hybrid			2022-12-25	WOS:000167115100078
J	Parker, A; Gu, YS; Mahoney, W; Lee, SH; Singh, KK; Lu, AL				Parker, A; Gu, YS; Mahoney, W; Lee, SH; Singh, KK; Lu, AL			Human homolog of the MutY repair protein (hMYH) physically interacts with proteins involved in long patch DNA base excision repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-BETA; LIGASE I; FUNCTIONAL EXPRESSION; MOLECULAR-CLONING; DEPENDENT REPAIR; TERMINAL REGION; BINDING PROTEIN; MISMATCH REPAIR; PCNA	The human MutY homolog (hMYH) is a DNA glycosylase involved in the removal of adenines or 2-hydroxyadenines misincorporated with template guanines or 7,8-dihydro-8-oxodeoxyguanines. hMYH is associated in vivo with apurinic/apyrimidinic endonuclease (APE1), proliferating cell nuclear antigen (PCNA), and replication protein A (RPA) in HeLa nuclear extracts as shown by immunoprecipitation and Western blotting. However, binding of hMYH to DNA polymerases beta and delta was not detected. By using constructs containing different portions of hMYH fused to glutathione S-transferase, we have demonstrated that the APE1-binding site is at a region around amino acid residue 300, that the PCNA binding activity is located at the C terminus, and that RPA binds to the N terminus of hMYH. A peptide consisting of residues 505-527 of hMYH that contains a conserved PCNA-binding motif binds PCNA, and subsequent amino acid substitution identified Phe-518 and Phe-519 as essential residues required for PCNA binding. RPA binds to a peptide that consists of residues 6-32 of hMYH and contains a conserved RPA-binding motif. The PCNA- and RPA-binding sites of hMYH are further confirmed by peptide and antibody titration. These results suggest that hMYH repair is a long patch base excision repair pathway.	Univ Maryland, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Univ Maryland, Combined PhD Program Biochem, Baltimore, MD 21201 USA; Indiana Univ, Ctr Canc, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Johns Hopkins Oncol Ctr, Radiat Res Program, Baltimore, MD 21231 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Johns Hopkins University; Johns Hopkins Medicine	Lu, AL (corresponding author), Univ Maryland, Dept Biochem & Mol Biol, 108 N Greene St, Baltimore, MD 21201 USA.	aluchang@umaryland.edu	Gu, Jason/AAG-8178-2021; Gu, Yesong/U-9802-2019	Gu, Jason/0000-0001-8278-6227; 	NATIONAL CANCER INSTITUTE [R56CA078391, R01CA078391] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009714] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052358, R01GM035132] Funding Source: NIH RePORTER; NCI NIH HHS [CA/ES78391] Funding Source: Medline; NIEHS NIH HHS [ES09714] Funding Source: Medline; NIGMS NIH HHS [GM52358, GM35132] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Bharati S, 1998, NUCLEIC ACIDS RES, V26, P4953, DOI 10.1093/nar/26.21.4953; Biswas EE, 1997, BIOCHEMISTRY-US, V36, P5955, DOI 10.1021/bi962890u; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; CHENG KC, 1992, J BIOL CHEM, V267, P166; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; Cunningham RP, 1997, CURR BIOL, V7, pR576, DOI 10.1016/S0960-9822(06)00286-7; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; DeMott MS, 1998, J BIOL CHEM, V273, P27492, DOI 10.1074/jbc.273.42.27492; Dianov GL, 2000, J BIOL CHEM, V275, P11809, DOI 10.1074/jbc.275.16.11809; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Dianov GL, 1999, BIOCHEMISTRY-US, V38, P11021, DOI 10.1021/bi9908890; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fortini P, 1999, J BIOL CHEM, V274, P15230, DOI 10.1074/jbc.274.21.15230; Frosina G, 1999, METH MOL B, V113, P301; FULLER SA, 1995, CURRENT PROTOCOLS MO; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gary R, 1999, MOL CELL BIOL, V19, P5373; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Kelman Z, 1999, P NATL ACAD SCI USA, V96, P9515, DOI 10.1073/pnas.96.17.9515; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Koundrioukoff S, 2000, J BIOL CHEM, V275, P22882, DOI 10.1074/jbc.M001850200; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Krokan HE, 1997, BIOCHEM J, V325, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Lu AL, 1998, J BIOL CHEM, V273, P25098, DOI 10.1074/jbc.273.39.25098; Lu AL, 2000, METH MOL B, V152, P3; Marintchev A, 2000, NUCLEIC ACIDS RES, V28, P2049, DOI 10.1093/nar/28.10.2049; Matsumoto Y, 1999, J BIOL CHEM, V274, P33703, DOI 10.1074/jbc.274.47.33703; Maxam A M, 1980, Methods Enzymol, V65, P499; McLennan AG, 1999, INT J MOL MED, V4, P79; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; Monteiro PMS, 1998, J SHELLFISH RES, V17, P3; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; Nagelhus TA, 1997, J BIOL CHEM, V272, P6561, DOI 10.1074/jbc.272.10.6561; Nicolaides NC, 1996, GENOMICS, V31, P395, DOI 10.1006/geno.1996.0067; Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; Parker A, 2000, NUCLEIC ACIDS RES, V28, P3206, DOI 10.1093/nar/28.17.3206; Pascucci B, 1999, J BIOL CHEM, V274, P33696, DOI 10.1074/jbc.274.47.33696; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Radicella JP, 1997, P NATL ACAD SCI USA, V94, P8010, DOI 10.1073/pnas.94.15.8010; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; Shinmura K, 1997, MUTAT RES-DNA REPAIR, V385, P75, DOI 10.1016/S0921-8777(97)00041-4; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; Takao M, 1999, NUCLEIC ACIDS RES, V27, P3638, DOI 10.1093/nar/27.18.3638; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsai-Wu JJ, 2000, J CELL BIOCHEM, V77, P666, DOI 10.1002/(SICI)1097-4644(20000615)77:4<666::AID-JCB14>3.0.CO;2-X; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; Tsurimoto Toshiki, 1999, Frontiers in Bioscience, V4, pd849, DOI 10.2741/Tsurimoto; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031; YEH YC, 1991, J BIOL CHEM, V266, P6480; Zhang P, 1998, J BIOL CHEM, V273, P713, DOI 10.1074/jbc.273.2.713; Zhang P, 1999, J BIOL CHEM, V274, P26647, DOI 10.1074/jbc.274.38.26647	73	292	306	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5547	5555		10.1074/jbc.M008463200	http://dx.doi.org/10.1074/jbc.M008463200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11092888	hybrid			2022-12-25	WOS:000167115100021
J	Bjorbaek, C; Buchholz, RM; Davis, SM; Bates, SH; Pierroz, DD; Gu, H; Neel, BG; Myers, MG; Flier, JS				Bjorbaek, C; Buchholz, RM; Davis, SM; Bates, SH; Pierroz, DD; Gu, H; Neel, BG; Myers, MG; Flier, JS			Divergent roles of SHP-2 in ERK activation by leptin receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-2; OBESE GENE; SIGNAL-TRANSDUCTION; NEUROPEPTIDE-Y; MESSENGER-RNA; IN-VIVO; PROTEIN; EXPRESSION; KINASE; IDENTIFICATION	The protein tyrosine phosphatase SHP-2 has been proposed to serve as a regulator of leptin signaling, but its specific roles are not fully examined. To directly investigate the role of SHP-2, we employed dominant negative strategies in transfected cells. We show that a catalytically inactive mutant of SHP-2 blocks leptin-stimulated ERK phosphorylation by the long leptin receptor, ObRb. SHP-2, lacking two C-terminal tyrosine residues, partially inhibits ERK phosphorylation. We find similar effects of the SHP-2 mutants after examining stimulation of an ERK-dependent egr-1 promoter-construct by leptin. We also demonstrate ERK phosphorylation and egr-1 mRNA expression in the hypothalamus by leptin. Analysis of signaling by ObRb lacking intracellular tyrosine residues or by the short leptin receptor, ObRa, enabled us to conclude that two pathways are critical for ERK activation. One pathway does not require the intracellular domain of ObRb, whereas the other pathway requires tyrosine residue 985 of ObRb. The phosphatase activity of SHP-2 is required for both pathways, whereas activation of ERK via Tyr-985 of ObRb also requires tyrosine phosphorylation of SHP-2. SHP-2 is thus a positive regulator of ERK by leptin receptors, and both the adaptor function and the phosphatase activity of SHP-2 are critical for this regulation.	Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Canc Biol Program, Boston, MA 02215 USA; Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School	Flier, JS (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol, 99 Brookline Ave, Boston, MA 02215 USA.	jflier@caregroup.harvard.edu	Gu, Haihua/G-6364-2011; Bjorbaek, Christian/S-4727-2019; Flier, jeffrey/AAG-6223-2019		NATIONAL CANCER INSTITUTE [R01CA049152, F32CA072144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028082, R01DK050693, R01DK056731] Funding Source: NIH RePORTER; NCI NIH HHS [CA72144, R01-CA-49152] Funding Source: Medline; NIDDK NIH HHS [DK-R37-28082, DK-50693, R01-DK-56731] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Ali S, 1996, EMBO J, V15, P135, DOI 10.1002/j.1460-2075.1996.tb00341.x; Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; Berti L, 1997, DIABETOLOGIA, V40, P606, DOI 10.1007/s001250050722; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bjorbaek C, 1998, ENDOCRINOLOGY, V139, P3485, DOI 10.1210/en.139.8.3485; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Carpenter LR, 1998, P NATL ACAD SCI USA, V95, P6061, DOI 10.1073/pnas.95.11.6061; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Cheung CC, 1997, ENDOCRINOLOGY, V138, P4489, DOI 10.1210/en.138.10.4489; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; Elias CF, 1999, NEURON, V23, P775, DOI 10.1016/S0896-6273(01)80035-0; Elmquist JK, 1997, ENDOCRINOLOGY, V138, P839, DOI 10.1210/en.138.2.839; Elmquist JK, 1998, J COMP NEUROL, V395, P535; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; Ghilardi N, 1997, MOL ENDOCRINOL, V11, P393, DOI 10.1210/me.11.4.393; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Gu HH, 1998, MOL CELL, V2, P729, DOI 10.1016/S1097-2765(00)80288-9; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hodge C, 1998, J BIOL CHEM, V273, P31327, DOI 10.1074/jbc.273.47.31327; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Kim H, 1999, MOL CELL BIOL, V19, P5326; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Li C, 1999, P NATL ACAD SCI USA, V96, P9677, DOI 10.1073/pnas.96.17.9677; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; Myers MG, 1998, J BIOL CHEM, V273, P26908, DOI 10.1074/jbc.273.41.26908; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Nicholson SE, 2000, P NATL ACAD SCI USA, V97, P6493, DOI 10.1073/pnas.100135197; Nillni EA, 2000, J BIOL CHEM, V275, P36124, DOI 10.1074/jbc.M003549200; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Park JA, 1999, J NEUROCHEM, V73, P450, DOI 10.1046/j.1471-4159.1999.0730450.x; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Schmitz J, 2000, J BIOL CHEM, V275, P12848, DOI 10.1074/jbc.275.17.12848; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; Takahashi Y, 1997, J BIOL CHEM, V272, P12897, DOI 10.1074/jbc.272.20.12897; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thornton JE, 1997, ENDOCRINOLOGY, V138, P5063, DOI 10.1210/en.138.11.5063; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; White DW, 1997, J BIOL CHEM, V272, P4065, DOI 10.1074/jbc.272.7.4065; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	63	281	296	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4747	4755		10.1074/jbc.M007439200	http://dx.doi.org/10.1074/jbc.M007439200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11085989	hybrid			2022-12-25	WOS:000168484300031
J	Gao, DX; McHenry, CS				Gao, DX; McHenry, CS			tau binds and organizes Escherichia coli replication proteins through distinct domains - Partial proteolysis of terminally tagged tau to determine candidate domains and to assign domain V as the alpha binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; COORDINATED LEADING-STRAND; LAGGING-STRAND; GAMMA-SUBUNIT; ACCESSORY PROTEINS; HOLOENZYME; COMPLEX; FORK; IDENTIFICATION; PURIFICATION	The tau subunit dimerizes Escherichia coli DNA polymerase III core through interactions with the a:subunit. In addition to playing critical roles in the structural organization of the holoenzyme, tau mediates intersubunit communications required for efficient replication fork function. We identified potential structural domains of this multifunctional subunit by limited proteolysis of C-terminal biotin-tagged I proteins, The cleavage sites of each of eight different proteases were found to be clustered within four regions of the tau subunit, The second susceptible region corresponds to the hinge between domain II and III of the highly homologous S' subunit, and the third region is near the C-terminal end of the tau-delta' alignment (Guenther, B., Onrust, R., Sali, A., O'Donnell, M., and Kuriyan, J. (1997) Cell 91, 335-345), We propose a five-domain structure for the tau protein, Domains I and II are based on the crystallographic structure of delta' by Guenther and colleagues. Domains III-V are based on our protease cleavage results, Using this information, we expressed biotin-tagged tau proteins lacking specific protease-resistant domains and analyzed their binding to the a subunit by surface plasmon resonance, Results from these studies indicated that the alpha binding site of tau lies within its C-terminal 147 residues (domain V).	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gao, DX (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.				NIGMS NIH HHS [GM35695] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; Cull MG, 1995, METHOD ENZYMOL, V262, P22; Dallmann HG, 2000, J BIOL CHEM, V275, P15512, DOI 10.1074/jbc.M909257199; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; FAY PJ, 1981, J BIOL CHEM, V256, P976; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KORNBERG A, 1988, J BIOL CHEM, V263, P1; LANZER M, 1988, P NATL ACAD SCI USA, V85, P8973, DOI 10.1073/pnas.85.23.8973; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; WU CA, 1992, J BIOL CHEM, V267, P4030; WU CA, 1992, J BIOL CHEM, V267, P4074; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	30	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4433	4440		10.1074/jbc.M009828200	http://dx.doi.org/10.1074/jbc.M009828200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11078743	hybrid			2022-12-25	WOS:000166921200093
J	Kirchhefer, U; Neumann, J; Baba, HK; Begrow, F; Kobayashi, YM; Reinke, U; Schmitz, W; Jones, LR				Kirchhefer, U; Neumann, J; Baba, HK; Begrow, F; Kobayashi, YM; Reinke, U; Schmitz, W; Jones, LR			Cardiac hypertrophy and impaired relaxation in transgenic mice overexpressing triadin 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL SARCOPLASMIC-RETICULUM; MUSCLE RYANODINE RECEPTOR; SKELETAL-MUSCLE; BIOCHEMICAL-CHARACTERIZATION; DILATED CARDIOMYOPATHY; GLYCOPROTEIN TRIADIN; HEART-CELLS; CALSEQUESTRIN; PROTEIN; MOUSE	Triadin 1 is a major transmembrane protein in cardiac junctional sarcoplasmic reticulum (SR), which forms a quaternary complex with the ryanodine receptor (Ca2+ release channel), junctin, and calsequestrin. To better understand the role of triadin 1 in excitation-contraction coupling in the heart, we generated transgenic mice with targeted overexpression of triadin 1 to mouse atrium and ventricle, employing the alpha -myosin heavy chain promoter to drive protein expression. The protein was overexpressed 5-fold in mouse ventricles, and overexpression was accompanied by cardiac hypertrophy. The levels of two other junctional SR proteins, the ryanodine receptor and junctin, were reduced by 55% and 73%, respectively in association with triadin 1 overexpression, whereas the levels of calsequestrin, the Ca2+ binding protein of junctional SR, and of phospholamban and SERCA2a, Ca2+-handling proteins of the free SR, were unchanged. Cardiac myocytes from triadin 1-over-expressing mice exhibited depressed contractility; Ca2+ transients decayed at a slower rate, and cell shortening and relengthening were diminished. The extent of depression of cell shortening of triadin 1-overexpressing cardiomyocytes was rate-dependent, being more depressed under low stimulation frequencies (0.5 Hz), but reaching comparable levels at higher frequencies of stimulation (5 Hz). Spontaneously beating, isolated work-performing heart preparations overexpressing triadin 1 also relaxed at a slower rate than control hearts, and failed to adapt to increased afterload appropriately. The fast time inactivation constant, tau (1), of the L-type Ca2+ channel was prolonged in transgenic cardiomyocytes. Our results provide evidence for the coordinated regulation of junctional SR protein expression in heart independent of free SR protein expression, and furthermore suggest an important role for triadin 1 in regulating the contractile properties of the heart during excitation-contraction coupling.	Univ Munster, Inst Pharmakol & Toxikol, D-48149 Munster, Germany; Univ Munster, Gerhard Domagk Inst Pathol, D-48149 Munster, Germany; Indiana Univ, Sch Med, Dept Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA	University of Munster; University of Munster; Indiana University System; Indiana University-Purdue University Indianapolis	Kirchhefer, U (corresponding author), Univ Munster, Inst Pharmakol & Toxikol, Domagkstr 12, D-48149 Munster, Germany.	kirchhef@uni-muenster.de			NHLBI NIH HHS [HL-28556] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028556] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Boknik P, 1997, J PHARMACOL EXP THER, V280, P277; BUSTAMANTE JO, 1991, J CARDIOVASC PHARM, V17, pS110, DOI 10.1097/00005344-199117002-00024; Carrion AM, 1999, NATURE, V398, P80, DOI 10.1038/18044; CASWELL AH, 1991, BIOCHEMISTRY-US, V30, P7507, DOI 10.1021/bi00244a020; Chen S, 1993, Methods Mol Biol, V15, P75, DOI 10.1385/0-89603-244-2:75; CHIEN KR, 1993, ANNU REV PHYSIOL, V55, P77, DOI 10.1146/annurev.ph.55.030193.000453; Cho MC, 1999, J BIOL CHEM, V274, P22251, DOI 10.1074/jbc.274.32.22251; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; Groh S, 1999, J BIOL CHEM, V274, P12278, DOI 10.1074/jbc.274.18.12278; GRUPP IL, 1993, AM J PHYSIOL, V265, pH1401, DOI 10.1152/ajpheart.1993.265.4.H1401; GULICK J, 1991, J BIOL CHEM, V266, P9180; Guo W, 1996, J BIOL CHEM, V271, P458, DOI 10.1074/jbc.271.1.458; GUO W, 1995, J BIOL CHEM, V270, P9027, DOI 10.1074/jbc.270.16.9027; HASENFUSS G, 1994, EUR HEART J, V15, P164, DOI 10.1093/oxfordjournals.eurheartj.a060471; HOGAN B, 1986, MANIPULATING MOUSE E; Hoit BD, 1997, AM J PHYSIOL-HEART C, V273, pH2528, DOI 10.1152/ajpheart.1997.273.5.H2528; Jones LR, 1998, J CLIN INVEST, V101, P1385, DOI 10.1172/JCI1362; Jones LR, 1995, J BIOL CHEM, V270, P30787, DOI 10.1074/jbc.270.51.30787; JONES LR, 1981, J BIOL CHEM, V256, P1809; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KNUDSON CM, 1993, J BIOL CHEM, V268, P12637; KNUDSON CM, 1993, J BIOL CHEM, V268, P12646; Kobayashi YM, 2000, J BIOL CHEM, V275, P17639, DOI 10.1074/jbc.M002091200; Kobayashi YM, 1999, J BIOL CHEM, V274, P28660, DOI 10.1074/jbc.274.40.28660; KOMURO I, 1993, ANNU REV PHYSIOL, V55, P55, DOI 10.1146/annurev.ph.55.030193.000415; Kuniyasu A, 1999, BIOCHEM J, V339, P343, DOI 10.1042/0264-6021:3390343; LEGUENNEC JY, 1991, EXP PHYSIOL, V76, P975, DOI 10.1113/expphysiol.1991.sp003560; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAHONY L, 1986, J BIOL CHEM, V261, P5257; MARTY I, 1995, BIOCHEM J, V307, P769, DOI 10.1042/bj3070769; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MITCHELL RD, 1988, J BIOL CHEM, V263, P1376; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; Muth JN, 1999, J BIOL CHEM, V274, P21503, DOI 10.1074/jbc.274.31.21503; NADALGINARD B, 1989, J CLIN INVEST, V84, P1693, DOI 10.1172/JCI114351; Ohkura M, 1998, BIOCHEMISTRY-US, V37, P12987, DOI 10.1021/bi972803d; PERREAULT CL, 1994, AM J PHYSIOL, V266, pH2436, DOI 10.1152/ajpheart.1994.266.6.H2436; PERUTZ M, 1994, PROTEIN SCI, V3, P1629, DOI 10.1002/pro.5560031002; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; REALINI C, 1994, FEBS LETT, V348, P109, DOI 10.1016/0014-5793(94)00569-9; REALINI C, 1995, J BIOL CHEM, V270, P29664; THIERFELDER S, 1994, PFLUG ARCH EUR J PHY, V427, P547, DOI 10.1007/BF00374273; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; ZHANG L, 2001, IN PRESS J MOL CELL	46	93	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4142	4149		10.1074/jbc.M006443200	http://dx.doi.org/10.1074/jbc.M006443200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11069905	hybrid			2022-12-25	WOS:000166921200056
J	Mendez, AJ; Lin, GR; Wade, DP; Lawn, RM; Oram, JF				Mendez, AJ; Lin, GR; Wade, DP; Lawn, RM; Oram, JF			Membrane lipid domains distinct from cholesterol/sphingomyelin-rich rafts are involved in the ABCA1-mediated lipid secretory pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN-MEDIATED REMOVAL; SIGNAL-TRANSDUCING MOLECULES; CASSETTE TRANSPORTER 1; GPI-ANCHORED PROTEINS; MESSENGER-RNA LEVELS; CELLULAR CHOLESTEROL; TANGIER-DISEASE; INTRACELLULAR CHOLESTEROL; ENDOPLASMIC-RETICULUM	Efflux of excess cellular cholesterol mediated by lipid-poor apolipoproteins occurs by an active mechanism distinct from passive diffusion and is controlled by the ATP-binding cassette transporter ABCA1, Here we examined whether ABCA1-mediated lipid efflux involves the selective removal of lipids associated with membrane rafts, plasma membrane domains enriched in cholesterol and sphingomyelin, ABCA1 was not associated with cholesterol and sphingolipid-rich membrane raft domains based on detergent solubility and lack of colocalization with marker proteins associated with raft domains. Lipid efflux to apoA-I was accounted for by decreases in cellular lipids not associated with cholesterol/sphingomyelin-rich membranes. Treating cells with filipin, to disrupt raft structure, or with sphingomyelinase, to digest plasma membrane sphingomyelin, did not impair apoA-I-mediated cholesterol or phosphatidylcholine efflux, In contrast, efflux of cholesterol to high density lipoproteins (HDL) or plasma was partially accounted for by depletion of cholesterol from membrane rafts. Additionally, HDL-mediated cholesterol efflux was partially inhibited by filipin and sphingomyelinase treatment. Ape-A-I-mediated cholesterol efflux was absent from fibroblasts with nonfunctional ABCA1 (Tangier disease cells), despite near normal amounts of cholesterol associated with raft domains and normal abilities of plasma and HDL to deplete cholesterol from these domains. Thus, the involvement of membrane rafts in cholesterol efflux applies to lipidated HDL particles but not to lipid-free apoA-I, We conclude that cholesterol and sphingomyelin-rich membrane rafts do not provide lipid for efflux promoted by apolipoproteins through the ABCA1-mediated lipid secretory pathway and that ABCA1 is not associated with these domains.	Univ Miami, Sch Med, Diabet Res Inst, Miami, FL 33101 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; CV Therapeut Inc, Palo Alto, CA 94304 USA	University of Miami; University of Washington; University of Washington Seattle; CV Therapeutics, Inc.	Mendez, AJ (corresponding author), Univ Miami, Sch Med, Diabet Res Inst R134, 1450 NW 10th Ave, Miami, FL 33138 USA.	amendez2@med.miami.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645, R01HL055362, R29HL053451] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645, HL55362, HL53451] Funding Source: Medline; NIDDK NIH HHS [DK02456] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asztalos B, 1997, ARTERIOSCL THROM VAS, V17, P1630, DOI 10.1161/01.ATV.17.9.1630; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; BARTLETT GR, 1959, J BIOL CHEM, V267, P1219; BIELICKI JK, 1992, J LIPID RES, V33, P1699; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; Chen WG, 2000, J BIOL CHEM, V275, P30794, DOI 10.1074/jbc.M004552200; Doyle DD, 1998, J BIOL CHEM, V273, P6937, DOI 10.1074/jbc.273.12.6937; FIELDING CJ, 1995, J LIPID RES, V36, P211; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; Fielding PE, 1996, BIOCHEMISTRY-US, V35, P14932, DOI 10.1021/bi9613382; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HARA H, 1991, J BIOL CHEM, V266, P3080; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; HARRISON SC, 1983, CELL, V33, P650, DOI 10.1016/0092-8674(83)90007-7; HEIDER JG, 1978, J LIPID RES, V19, P514; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jian B, 1998, J BIOL CHEM, V273, P5599, DOI 10.1074/jbc.273.10.5599; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KAWANO M, 1993, BIOCHEMISTRY-US, V32, P5025, DOI 10.1021/bi00070a008; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marcil M, 1999, LANCET, V354, P1341, DOI 10.1016/S0140-6736(99)07026-9; Mendez AJ, 1996, J LIPID RES, V37, P2510; MENDEZ AJ, 1995, J BIOL CHEM, V270, P5891, DOI 10.1074/jbc.270.11.5891; Mendez AJ, 1997, J LIPID RES, V38, P1807; MENDEZ AJ, 1991, J BIOL CHEM, V266, P10104; Oram J F, 1986, Methods Enzymol, V129, P645; Oram JF, 2000, CURR OPIN LIPIDOL, V11, P253, DOI 10.1097/00041433-200006000-00005; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 1999, J LIPID RES, V40, P1769; Oram JF, 1996, J LIPID RES, V37, P2473; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Philippova MP, 1998, FEBS LETT, V429, P207, DOI 10.1016/S0014-5793(98)00598-5; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PORN MI, 1990, BIOCHEM J, V271, P121, DOI 10.1042/bj2710121; Remaley AT, 1997, ARTERIOSCL THROM VAS, V17, P1813, DOI 10.1161/01.ATV.17.9.1813; Remaley AT, 1999, P NATL ACAD SCI USA, V96, P12685, DOI 10.1073/pnas.96.22.12685; Rietveld A, 1998, BBA-REV BIOMEMBRANES, V1376, P467, DOI 10.1016/S0304-4157(98)00019-7; ROBINSON JM, 1980, J HISTOCHEM CYTOCHEM, V28, P161, DOI 10.1177/28.2.6766487; ROGLER G, 1995, ARTERIOSCL THROM VAS, V15, P683, DOI 10.1161/01.ATV.15.5.683; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHNITZER JE, 1995, SCIENCE, V269, P1435, DOI 10.1126/science.7660128; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; WALKER J, 1993, BIOCHEMISTRY-US, V32, P14009, DOI 10.1021/bi00213a034; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308; Zhang WW, 1998, J LIPID RES, V39, P1601	68	166	171	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3158	3166		10.1074/jbc.M007717200	http://dx.doi.org/10.1074/jbc.M007717200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11073951	hybrid			2022-12-25	WOS:000166784900025
J	Trebak, M; Begg, GE; Chong, JM; Kanazireva, EV; Herlyn, D; Speicher, DW				Trebak, M; Begg, GE; Chong, JM; Kanazireva, EV; Herlyn, D; Speicher, DW			Oligomeric state of the colon carcinoma-associated glycoprotein GA733-2 (Ep-CAM/EGP40) and its role in GA733-mediated homotypic cell-cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; COLORECTAL-CARCINOMA; EP-CAM; MOLECULAR-CLONING; RANDOMIZED TRIAL; ANTIGEN; CANCER; TUMOR; EXPRESSION; DIMERIZATION	The GA733-2 antigen (GA733) is a homotypic calcium-independent cell adhesion molecule (CAM) present in most normal human epithelial cells and gastrointestinal carcinomas. Because oligomerization of some CAMs regulates cell adhesion and signal transduction, the correlation between GA733 oligomeric state and cell-cell adhesion was investigated. Sedimentation equilibrium studies showed that full-length ( FL) GA733 exists as dimers and tetramers in solution, whereas the GA733 extracellular domain (-EC) is a monomer, The K-d of GA733-FL is less than 10 nM for the monomer-dimer association, whereas the dimer-tetramer association is about 1000-fold weaker (K-d similar to 10 muM). Chemical crosslinking of purified GA733-FL in solution resulted in a major product corresponding to GA733 dimers, and minor amounts of trimers and tetramers. However, GA733-EC cross-linked under the same conditions was consistently a monomer. Chemical cross linking of dissociated colon carcinoma cells produced predominantly GA733 dimers, whereas cross-linking of cells in monolayers yielded some tetramers as well. GA733-FL retained its cell-cell adhesion function as shown by inhibition of cell aggregation, whereas monomeric GA733-EC was inactive. These data show that GA733 exists predominantly as high affinity noncovalent cis-dimers in solution and on dissociated colon carcinoma cells, The lower affinity association of dimers to form tetramers is most likely the head-to-head interaction between GA733 cis-dimers on opposing cells that represents its cell-cell adhesion activity.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Speicher, DW (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	speicher@wistar.upenn.edu	Trebak, Mohamed/E-7405-2014		NCI NIH HHS [CA74294, CA66671, CA10815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066671, P01CA074294, P30CA010815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balzar M, 1998, MOL CELL BIOL, V18, P4833, DOI 10.1128/MCB.18.8.4833; Balzar M, 1999, EXP CELL RES, V246, P108, DOI 10.1006/excr.1998.4263; Basak S, 1998, JNCI-J NATL CANCER I, V90, P691, DOI 10.1093/jnci/90.9.691; BASSON MD, 1994, J CELL PHYSIOL, V160, P491, DOI 10.1002/jcp.1041600312; BASU A, 1995, INT J CANCER, V62, P472, DOI 10.1002/ijc.2910620419; BIREBENT B, 2000, IN PRESS CLIN CANC R; BJORK P, 1993, J BIOL CHEM, V268, P24232; CASASSA EF, 1964, ADV PROTEIN CHEM, V19, P287, DOI 10.1016/S0065-3233(08)60191-6; Chothia C, 1997, ANNU REV BIOCHEM, V66, P823, DOI 10.1146/annurev.biochem.66.1.823; Fleming KG, 1997, J MOL BIOL, V272, P266, DOI 10.1006/jmbi.1997.1236; GOTTLINGER HG, 1986, INT J CANCER, V38, P47; Greimers R, 1996, CYTOMETRY, V23, P205, DOI 10.1002/(SICI)1097-0320(19960301)23:3<205::AID-CYTO4>3.0.CO;2-H; HERLYN D, 1987, P NATL ACAD SCI USA, V84, P8055, DOI 10.1073/pnas.84.22.8055; HERLYN D, 1991, In Vivo (Attiki), V5, P615; HERLYN D, 1984, J IMMUNOL METHODS, V73, P157, DOI 10.1016/0022-1759(84)90041-3; HERLYN M, 1979, P NATL ACAD SCI USA, V76, P1438, DOI 10.1073/pnas.76.3.1438; Hunter I, 1996, BIOCHEM J, V320, P847, DOI 10.1042/bj3200847; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; Li WP, 1997, J IMMUNOL, V159, P763; LINNENBACH AJ, 1989, P NATL ACAD SCI USA, V86, P27, DOI 10.1073/pnas.86.1.27; LISOWSKA E, 1983, BIOCHEM BIOPH RES CO, V115, P206, DOI 10.1016/0006-291X(83)90990-7; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; LITVINOV SV, 1995, TRENDS GLYCOSCI GLYC, V7, P375, DOI 10.4052/tigg.7.375; Litvinov SV, 1996, AM J PATHOL, V148, P865; LOIBNER H, 1990, LANCET, V335, P171, DOI 10.1016/0140-6736(90)90044-6; LUDWIG B, 1982, J BIOL CHEM, V257, P5576; MAZDZANOWSKI J, 1992, ELECTROPHORESIS, V13, P59, DOI 10.1002/elps.1150130112; Mbalaviele G, 1996, CANCER RES, V56, P4063; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; Newton JP, 1999, BIOCHEM BIOPH RES CO, V261, P283, DOI 10.1006/bbrc.1999.1018; NOSE A, 1988, CELL, V54, P993, DOI 10.1016/0092-8674(88)90114-6; OSBORN L, 1992, J EXP MED, V176, P99, DOI 10.1084/jem.176.1.99; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PETERSON MD, 1992, J CELL SCI, V102, P581; Piyathilake CJ, 2000, HUM PATHOL, V31, P482, DOI 10.1053/hp.2000.6711; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; POWE J, 1985, IMMUNOSCINTIGRAPHY, P139; REILLY PL, 1995, J IMMUNOL, V155, P529; REYNOLDS JA, 1976, P NATL ACAD SCI USA, V73, P4467, DOI 10.1073/pnas.73.12.4467; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1; Riethmuller G, 1998, J CLIN ONCOL, V16, P1788, DOI 10.1200/JCO.1998.16.5.1788; Ripani E, 1998, INT J CANCER, V76, P671; ROSS AH, 1986, BIOCHEM BIOPH RES CO, V135, P297, DOI 10.1016/0006-291X(86)90976-9; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHETYE J, 1988, CANCER IMMUNOL IMMUN, V27, P154; SHETYE J, 1989, ANTICANCER RES, V9, P395; Shih IM, 1997, CANCER RES, V57, P3835; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SOMASUNDARAM R, 1995, J IMMUNOL, V155, P3253; STAIB L, 2000, IN PRESS INT J CANC; Steele J C Jr, 1978, Methods Enzymol, V48, P11; STRASSBURG CP, 1992, CANCER RES, V52, P815; SZALA S, 1990, P NATL ACAD SCI USA, V87, P3542, DOI 10.1073/pnas.87.9.3542; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; Trebak M, 1999, J IMMUNOL METHODS, V230, P59, DOI 10.1016/S0022-1759(99)00122-2; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003; Zaloudik J, 1997, BRIT J CANCER, V76, P909, DOI 10.1038/bjc.1997.483	57	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2299	2309		10.1074/jbc.M004770200	http://dx.doi.org/10.1074/jbc.M004770200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11058587	hybrid			2022-12-25	WOS:000166528000087
J	Komatsu, K; Wharton, W; Hang, HY; Wu, C; Singh, S; Lieberman, HB; Pledger, WJ; Wang, HG				Komatsu, K; Wharton, W; Hang, HY; Wu, C; Singh, S; Lieberman, HB; Pledger, WJ; Wang, HG			PCNA interacts with hHus1/hRad9 in response to DNA damage and replication inhibition	ONCOGENE			English	Article						hRad9; hHus1; PCNA; DNA damage; cell-cycle checkpoints	CELL NUCLEAR ANTIGEN; CHECKPOINT CONTROL GENE; FISSION YEAST; SCHIZOSACCHAROMYCES-POMBE; POLYMERASE-DELTA; HUMAN HOMOLOG; PROTEIN-PCNA; CYCLE; REPAIR; RAD1	The hHus1 and several hRad proteins are involved in the control of DNA integrity checkpoints, although the mechanisms underlying these processes are unknown. Using a yeast two-hybrid system to detect protein-protein interactions, we found that human proliferating cell nuclear antigen (PCNA), a protein known to function in both DNA replication and repair, interacts with the human checkpoint-related protein Hus1 (hHus1). In human skin fibroblast cells, exposure to ionizing radiation of hydroxyurea triggers translocation of hHus1 from the cytosol to the nucleus, where it associates with PCNA as well as another checkpoint protein, hRad9. This nuclear translocation and the complex formation or hHus1 with PCNA and hRad9 correlate closely with changes in cell cycle distribution in response to radiation exposure. These results suggest that this multi-protein complex may be important for coordinating cell-cycle progression, DNA replication and repair of damaged DNA.	H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, Tampa, FL 33612 USA; H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA; Columbia Univ, Ctr Radiol Res, New York, NY 10032 USA; Imgenex Corp, San Diego, CA 92121 USA	Columbia University	Wang, HG (corresponding author), H Lee Moffit Canc Ctr & Res Inst, Drug Discovery Program, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Wang, Hong-Gang/A-3018-2015	Wang, Hong-Gang/0000-0003-0551-0571; Wu, Chun-Fang/0000-0002-4973-2021	NATIONAL CANCER INSTITUTE [R01CA072694, R01CA082197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052493] Funding Source: NIH RePORTER; NCI NIH HHS [CA72694, CA82197] Funding Source: Medline; NIGMS NIH HHS [GM52493] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1994, MOL BIOL CELL, V5, P147, DOI 10.1091/mbc.5.2.147; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; Caspari T, 2000, MOL CELL BIOL, V20, P1254, DOI 10.1128/MCB.20.4.1254-1262.2000; Cimprich KA, 1996, P NATL ACAD SCI USA, V93, P2850, DOI 10.1073/pnas.93.7.2850; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; GRIFFITHS DJF, 1995, EMBO J, V14, P5812, DOI 10.1002/j.1460-2075.1995.tb00269.x; Hang HY, 2000, GENOMICS, V65, P24, DOI 10.1006/geno.2000.6142; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Kelman Z, 1998, TRENDS BIOCHEM SCI, V23, P236, DOI 10.1016/S0968-0004(98)01223-7; Komatsu K, 2000, NAT CELL BIOL, V2, P1, DOI 10.1038/71316; Kondo T, 1999, MOL CELL BIOL, V19, P1136; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Kostrub CF, 1997, MOL GEN GENET, V254, P389, DOI 10.1007/PL00008606; Kostrub CF, 1998, EMBO J, V17, P2055, DOI 10.1093/emboj/17.7.2055; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; Lieberman HB, 1996, P NATL ACAD SCI USA, V93, P13890, DOI 10.1073/pnas.93.24.13890; Nojima H, 1997, Hum Cell, V10, P221; Parker AE, 1998, J BIOL CHEM, V273, P18332, DOI 10.1074/jbc.273.29.18332; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; St Onge RP, 1999, MOL BIOL CELL, V10, P1985; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tsurimoto Toshiki, 1999, Frontiers in Bioscience, V4, pd849, DOI 10.2741/Tsurimoto; Udell CM, 1998, NUCLEIC ACIDS RES, V26, P3971, DOI 10.1093/nar/26.17.3971; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Volkmer E, 1999, J BIOL CHEM, V274, P567, DOI 10.1074/jbc.274.2.567; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x	35	23	25	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5291	5297		10.1038/sj.onc.1203901	http://dx.doi.org/10.1038/sj.onc.1203901			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077446				2022-12-25	WOS:000165059700010
J	Xu, DW; Wang, Q; Gruber, A; Bjorkholm, M; Chen, ZG; Zaid, A; Selivanova, G; Peterson, C; Wiman, KG; Pisa, P				Xu, DW; Wang, Q; Gruber, A; Bjorkholm, M; Chen, ZG; Zaid, A; Selivanova, G; Peterson, C; Wiman, KG; Pisa, P			Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells	ONCOGENE			English	Article						hTERT; p53; Sp1; telomerase	CATALYTIC SUBUNIT HTERT; P53-INDUCED APOPTOSIS; GENE-EXPRESSION; GROWTH ARREST; BREAST-CANCER; DNA-BINDING; MUTANT P53; LIFE-SPAN; C-MYC; PROTEIN	The p53 tumor suppressor protein inhibits the formation of tumors through induction of cell cycle arrest and/or apoptosis, In the present study we demonstrated that p53 is also a powerful inhibitor of human telomerase reverse transcriptase (hTERT), a key component for telomerase, Activation of either exogenous temperature-sensitive (ts) p53 in BL41 Burkitt lymphoma cells or endogenous wild type (wt) p53 at a physiological level in MCF-7 breast carcinoma cells triggered a rapid downregulation of hTERT mRNA expression, independently of the induction of the p53 target gene p21, Co-transfection of an hTERT promoter construct with wt p53 but not mutant p53 in HeLa cells inhibited the hTERT promoter activity. Furthermore, the activation of the hTERT promoter in Drosophila Schneider SL2 cells was completely dependent on the ectopic expression of Sp1 and was abrogated by wt p53, Finally, wt p53 inhibited Sp1 binding to the hTERT proximal promoter by forming a p53-Sp1 complex. Since activation of telomerase, widely observed in human tumor cell lines and primary tumors, is a critical step in tumorigenesis, wt p53-triggered inhibition of hTERT/telomerase expression may reflect yet another mechanism of p53-mediated tumor suppression. Our findings provide new insights into both the biological function of p53 and the regulation of hTERT/telomerase expression.	Karolinska Hosp, Hematol Lab, CMM, Radiumhemmet,Dept Med,Div Hematol, SE-17176 Stockholm, Sweden; Karolinska Hosp, Radiumhemmet, Dept Oncol, SE-17176 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, SE-17177 Stockholm, Sweden; Stockholm Univ, Dept Biochem, SE-10405 Stockholm, Sweden; Linkoping Univ, Fac Hlth Sci, SE-58185 Linkoping, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Stockholm University; Linkoping University	Xu, DW (corresponding author), Karolinska Hosp, Hematol Lab, CMM, Radiumhemmet,Dept Med,Div Hematol, L8-03, SE-17176 Stockholm, Sweden.		Wiman, Klas/AAB-8399-2021	Wiman, Klas/0000-0002-7113-524X; Chen, Zhiguo/0000-0003-1508-510X; Zaid, Ahmed/0000-0002-1063-2883; Selivanova, Galina/0000-0002-8698-4332; Xu, Dawei/0000-0003-3141-4524				Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Bargonetti J, 1997, CELL MOL BIOL, V43, P935; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Cong YS, 1999, HUM MOL GENET, V8, P137, DOI 10.1093/hmg/8.1.137; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Gollahon LS, 1998, ONCOGENE, V17, P709, DOI 10.1038/sj.onc.1201987; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Greenberg RA, 1999, ONCOGENE, V18, P1219, DOI 10.1038/sj.onc.1202669; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1994, COLD SPRING HARB SYM, V59, P307, DOI 10.1101/SQB.1994.059.01.035; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Holt SE, 1997, P NATL ACAD SCI USA, V94, P10687, DOI 10.1073/pnas.94.20.10687; Kallassy M, 1998, MOL CARCINOGEN, V21, P26, DOI 10.1002/(SICI)1098-2744(199801)21:1<26::AID-MC5>3.0.CO;2-N; Kanaya T, 2000, CLIN CANCER RES, V6, P1239; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li H, 1999, ONCOGENE, V18, P6785, DOI 10.1038/sj.onc.1203061; Loveday RL, 1999, INT J CANCER, V84, P516, DOI 10.1002/(SICI)1097-0215(19991022)84:5<516::AID-IJC12>3.0.CO;2-Y; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; OKAN I, 1995, ONCOGENE, V11, P1027; PERREM K, 1995, ONCOGENE, V11, P1299; RAMQVIST T, 1993, ONCOGENE, V8, P1495; Roos G, 1998, INT J CANCER, V79, P343, DOI 10.1002/(SICI)1097-0215(19980821)79:4<343::AID-IJC6>3.0.CO;2-V; Sangfelt O, 1996, INT J CANCER, V67, P106, DOI 10.1002/(SICI)1097-0215(19960703)67:1<106::AID-IJC18>3.0.CO;2-C; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; SOUSSI T, 1990, ONCOGENE, V5, P945; Takakura M, 1999, CANCER RES, V59, P551; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769; Wang QJ, 1998, CANCER RES, V58, P5762; Wick M, 1999, GENE, V232, P97, DOI 10.1016/S0378-1119(99)00108-0; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Wu X, 1999, BRIT J CANCER, V80, P453, DOI 10.1038/sj.bjc.6690378; Xu D, 1996, LEUKEMIA, V10, P1354; XU D, 1999, BRIT J CANCER, V80, P453; Xu DW, 1998, BRIT J HAEMATOL, V102, P1367, DOI 10.1046/j.1365-2141.1998.00969.x	47	205	224	0	10	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5123	5133		10.1038/sj.onc.1203890	http://dx.doi.org/10.1038/sj.onc.1203890			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064449				2022-12-25	WOS:000090124100001
J	Perez-Martinez, X; Antaramian, A; Vazquez-Acevedo, M; Funes, S; Tolkunova, E; d'Alayer, J; Claros, MG; Davidson, E; King, MP; Gonzalez-Halphen, D				Perez-Martinez, X; Antaramian, A; Vazquez-Acevedo, M; Funes, S; Tolkunova, E; d'Alayer, J; Claros, MG; Davidson, E; King, MP; Gonzalez-Halphen, D			Subunit II of cytochrome c oxidase in chlamydomonad algae is a heterodimer encoded by two independent nuclear genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL-DNA; SCENEDESMUS-OBLIQUUS; COMPLETE SEQUENCE; GENOME; REINHARDTII; POLYTOMELLA; PRESEQUENCE; EXPRESSION; REDUCTASE; PROTEINS	The mitochondrial genomes of Chlamydomonad algae lack the cox2 gene that encodes the essential subunit COX II of cytochrome c oxidase. COX II is normally a single polypeptide encoded by a single mitochondrial gene. In this work we cloned two nuclear genes encoding COX II from both Chlamydomonas reinhardtii and Polytomella sp. The cox2a gene encodes a protein, COX IIA, corresponding to the N-terminal portion of subunit II of cytochrome c oxidase, and the cox2b gene encodes COX IIB, corresponding to the C-terminal region. The cox2a and cox2b genes are located in the nucleus and are independently transcribed into mRNAs that are translated into separate polypeptides. These two proteins assemble with other cytochrome c oxidase subunits in the inner mitochondrial membrane to form the mature multi-subunit complex. We propose that during the evolution of the Chlorophyte algae, the cox2 gene was divided into two mitochondrial genes that were subsequently transferred to the nucleus. This event was evolutionarily distinct from the transfer of an intact cox2 gene to the nucleus in some members the Leguminosae plant family.	Univ Nacl Autonoma Mexico, Dept Mol Genet, Inst Fisiol Celular, Mexico City 04510, DF, Mexico; Thomas Jefferson Univ, Dept Biochem & Mol Pharmacol, Philadelphia, PA 19107 USA; Inst Pasteur, Lab Microsequencage Proteines, Dept Biotechnol, F-75724 Paris 15, France; Univ Malaga, Fac Ciencias, Dept Biol Mol & Bioquim, E-29071 Malaga, Spain	Universidad Nacional Autonoma de Mexico; Jefferson University; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidad de Malaga	Gonzalez-Halphen, D (corresponding author), Univ Nacl Autonoma Mexico, Dept Mol Genet, Inst Fisiol Celular, Apartado Postal 70-243, Mexico City 04510, DF, Mexico.	dhalphen@ifisiol.unam.mx	Claros, Manuel Gonzalo/K-2274-2014; Gonzalez-Halphen, Diego/C-2664-2013; Funes, Soledad/A-1278-2010; Tolkunova, Elena/U-7174-2017	Claros, Manuel Gonzalo/0000-0002-0112-3550; Gonzalez-Halphen, Diego/0000-0003-0654-655X; Funes, Soledad/0000-0003-1815-1977; Tolkunova, Elena/0000-0003-1254-2619	FIC NIH HHS [TW01176] Funding Source: Medline; NHLBI NIH HHS [HL59646] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059646] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams KL, 1999, P NATL ACAD SCI USA, V96, P13863, DOI 10.1073/pnas.96.24.13863; AMATI BB, 1988, J MOL EVOL, V28, P151, DOI 10.1007/BF02143507; Andersson SGE, 1998, NATURE, V396, P133, DOI 10.1038/24094; Antaramian A, 1996, BBA-BIOENERGETICS, V1273, P198, DOI 10.1016/0005-2728(95)00158-1; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Atteia A, 1997, BBA-BIOENERGETICS, V1320, P275, DOI 10.1016/S0005-2728(97)00031-5; BENNOUN P, 1995, P NATL ACAD SCI USA, V92, P10202, DOI 10.1073/pnas.92.22.10202; BRENNICKE A, 1993, FEBS LETT, V325, P140, DOI 10.1016/0014-5793(93)81430-8; Brumme S, 1998, J BIOL CHEM, V273, P13143, DOI 10.1074/jbc.273.21.13143; CLAROS MG, 1995, COMPUT APPL BIOSCI, V11, P441; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; CLAROS MG, 1995, EUR J BIOCHEM, V228, P762, DOI 10.1111/j.1432-1033.1995.0762m.x; Claros MG, 1997, CURR OPIN STRUC BIOL, V7, P394, DOI 10.1016/S0959-440X(97)80057-7; CONNER TW, 1989, GENE, V84, P345, DOI 10.1016/0378-1119(89)90509-X; COVELLO PS, 1992, EMBO J, V11, P3815, DOI 10.1002/j.1460-2075.1992.tb05473.x; Denovan-Wright  EM, 1998, PLANT MOL BIOL, V36, P285, DOI 10.1023/A:1005995718091; Edqvist J, 2000, J MOL BIOL, V297, P381, DOI 10.1006/jmbi.2000.3530; FEAGIN JE, 1992, MOL BIOCHEM PARASIT, V52, P145, DOI 10.1016/0166-6851(92)90046-M; FRANZEN LG, 1992, PLANT MOL BIOL, V19, P771, DOI 10.1007/BF00027073; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; Gray MW, 1998, NUCLEIC ACIDS RES, V26, P865, DOI 10.1093/nar/26.4.865; GRAY MW, 1988, PHILOS T R SOC B, V319, P135, DOI 10.1098/rstb.1988.0038; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GUTIERREZCIRLOS EB, 1994, J BIOL CHEM, V269, P9147; Handa H, 1996, MOL GEN GENET, V252, P292, DOI 10.1007/BF02173775; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Kroymann J, 1998, J MOL EVOL, V47, P431, DOI 10.1007/PL00006400; Kuck U, 2000, GENE, V253, P13, DOI 10.1016/S0378-1119(00)00228-6; Lefebvre PA, 1999, GENETICS, V151, P9; MICHAELIS G, 1990, MOL GEN GENET, V223, P211, DOI 10.1007/BF00265056; Nedelcu AM, 2000, GENOME RES, V10, P819, DOI 10.1101/gr.10.6.819; NUGENT JM, 1991, CELL, V66, P473, DOI 10.1016/0092-8674(81)90011-8; Perez-Martinez X, 2000, J BIOL CHEM, V275, P30144, DOI 10.1074/jbc.M003940200; POPOT JL, 1990, ANNU REV BIOPHYS BIO, V19, P369; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SCHAGGER H, 1986, METHOD ENZYMOL, V126, P224; Silflow Carolyn D., 1998, Advances in Photosynthesis, V7, P25; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; VANDENBOOGAART P, 1982, NATURE, V298, P187, DOI 10.1038/298187a0; VONHEIJNE G, 1986, FEBS LETT, V198, P1, DOI 10.1016/0014-5793(86)81172-3; Wang XY, 1996, J BIOL CHEM, V271, P6594, DOI 10.1074/jbc.271.12.6594; WOLFF G, 1994, J MOL BIOL, V237, P75, DOI 10.1006/jmbi.1994.1210	47	83	86	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11302	11309		10.1074/jbc.M010244200	http://dx.doi.org/10.1074/jbc.M010244200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11094061	hybrid			2022-12-25	WOS:000167980900098
J	Pandya, K; Donze, D; Townes, TM				Pandya, K; Donze, D; Townes, TM			Novel transactivation domain in erythroid Kruppel-like Factor (EKLF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING PROTEINS; HUMAN GAMMA-GLOBIN; TRANSCRIPTION FACTOR; DEVELOPMENTAL REGULATION; BETA-THALASSEMIA; GENE COMPETITION; MAMMALIAN-CELLS; TRANSGENIC MICE; EXPRESSION; GLUTAMINE	Erythroid Kruppel-like Factor (EKLF) is an erythroid-specific transcription factor that plays a critical role in gamma- to beta -globin gene switching during development. To identify essential domains required for EKLF transactivation function, we cotransfected a human erythroleukemia cell line (K562) with a locus control region gamma /Luc beta /Cat reporter and an EKLF expression vector. In this assay EKLF mediates a 500-fold induction of beta /CAT expression compared with controls. To map essential transactivation domains, progressive NH2-terminal and internal deletion mutants of EKLF were constructed. All EKLF mutants were expressed at wild-type levels, localized to the nucleus, and bound DNA, When mutant EKLF proteins were tested for beta /CAT activation, a novel transactivation domain was identified. This novel domain, encompassing amino acids (aa) 140-358, is sufficient for maximal beta /CAT activation. An 85-amino acid subdomain within this region (aa 140-225) is essential for its activity. Interestingly, this central transactivation subdomain is functionally redundant with the amino-terminal domain (aa 1-139), Thus, EKLF possesses at least two potent transactivation domains that appear to function in a redundant manner.	Univ Alabama, Sch Med, Dept Biochem, Birmingham, AL 35294 USA; Univ Alabama, Sch Med, Dept Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Townes, TM (corresponding author), Univ Alabama, Sch Med, Dept Biochem, Birmingham, AL 35294 USA.							ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Armstrong JA, 1998, CELL, V95, P93, DOI 10.1016/S0092-8674(00)81785-7; BEHRINGER RR, 1990, GENE DEV, V4, P380, DOI 10.1101/gad.4.3.380; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; Chen XY, 1996, EMBO J, V15, P5888, DOI 10.1002/j.1460-2075.1996.tb00975.x; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; ENGEL JD, 1993, TRENDS GENET, V9, P304, DOI 10.1016/0168-9525(93)90248-G; ENVER T, 1990, NATURE, V344, P309, DOI 10.1038/344309a0; FENG WC, 1994, J BIOL CHEM, V269, P1493; GERBER HP, 1994, SCIENCE, V263, P808, DOI 10.1126/science.8303297; Guy LG, 1998, BLOOD, V91, P2259, DOI 10.1182/blood.V91.7.2259.2259_2259_2263; Guy LG, 2000, J BIOL CHEM, V275, P3675, DOI 10.1074/jbc.275.5.3675; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NUEZ B, 1995, NATURE, V375, P316, DOI 10.1038/375316a0; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; Ouyang L, 1998, J BIOL CHEM, V273, P23019, DOI 10.1074/jbc.273.36.23019; Perkins A, 1999, INT J BIOCHEM CELL B, V31, P1175, DOI 10.1016/S1357-2725(99)00083-7; PERKINS AC, 1995, NATURE, V375, P318; Perkins AC, 1996, P NATL ACAD SCI USA, V93, P12267, DOI 10.1073/pnas.93.22.12267; Perkins AC, 2000, BLOOD, V95, P1827, DOI 10.1182/blood.V95.5.1827.004k10_1827_1833; Shields JM, 1997, J BIOL CHEM, V272, P18504, DOI 10.1074/jbc.272.29.18504; SHIIO Y, 1995, METHOD ENZYMOL, V254, P497; Southwood CM, 1996, DEV DYNAM, V206, P248, DOI 10.1002/(SICI)1097-0177(199607)206:3<248::AID-AJA3>3.0.CO;2-I; STAMATOYANNOPOU.G, 1994, MOL BASIS BLOOD DIS; Tewari R, 1998, EMBO J, V17, P2334, DOI 10.1093/emboj/17.8.2334; TOWNES TM, 1990, TRENDS GENET, V6, P219, DOI 10.1016/0168-9525(90)90182-6; Wijgerde M, 1996, GENE DEV, V10, P2894, DOI 10.1101/gad.10.22.2894; Zhang WJ, 1998, P NATL ACAD SCI USA, V95, P9855, DOI 10.1073/pnas.95.17.9855	33	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8239	8243		10.1074/jbc.M008457200	http://dx.doi.org/10.1074/jbc.M008457200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11092887	Green Published, hybrid			2022-12-25	WOS:000167474900079
J	Hegde, SS; Shrader, TE				Hegde, SS; Shrader, TE			FemABX family members are novel nonribosomal peptidyltransferases and important pathogen-specific drug targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; CELL-WALL; SURFACE-PROTEINS; RESISTANCE; CRISIS	Pathogen-specific antibiotics kill the offending species without inviting the patient's flora to help develop a resistance mechanism The current scarcity of pathogen-specific antibiotics reflects the rarity of essential genes that are also not widely represented in and conserved among species. The FemX enzyme that initiates the:synthesis of the interchain peptide of the peptidoglycan in a subset of bacterial species was purified from Lactobacillus viridescens. Subsequently, the encoding femX gene was cloned and sequenced using reverse genetics. The femX gene is a member of the femAB family, a large family of genes previously implicated in interchain peptide synthesis but with unknown specific functions. Mutagenesis of the femX gene identified the members of the extended FemABX family as novel nonribosomal peptidyltransferases. Determinants of FemX complex substrate recognition and a strong stimulator of FemX activity were also identified. The FemABX family members are ideal candidates for pathogen-specific antibiotic development.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Shrader, TE (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.							BERGERBACHI B, 1989, MOL GEN GENET, V219, P263; Casadevall A, 1996, CLIN INFECT DIS, V23, P790, DOI 10.1093/clinids/23.4.790; DEJONGE BLM, 1993, J BACTERIOL, V175, P2779, DOI 10.1128/JB.175.9.2779-2782.1993; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; Ichetovkin IE, 1997, J BIOL CHEM, V272, P33009, DOI 10.1074/jbc.272.52.33009; MATSUHAS.M, 1967, J BIOL CHEM, V242, P3191; MATSUHASHI M, 1965, P NATL ACAD SCI USA, V54, P587, DOI 10.1073/pnas.54.2.587; Mengin-Lecreulx D, 1999, J BACTERIOL, V181, P5909, DOI 10.1128/JB.181.19.5909-5914.1999; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; Perl TM, 1999, AM J MED, V106, p48S; PLAPP R, 1970, J BIOL CHEM, V245, P3675; Rohrer S, 1999, P NATL ACAD SCI USA, V96, P9351, DOI 10.1073/pnas.96.16.9351; STICKGOLD RA, 1967, J BIOL CHEM, V242, P1331; Stranden AM, 1997, J BACTERIOL, V179, P9, DOI 10.1128/jb.179.1.9-16.1997; Ton-That H, 1998, J BIOL CHEM, V273, P29143, DOI 10.1074/jbc.273.44.29143; Tschierske M, 1999, FEMS MICROBIOL LETT, V171, P97, DOI 10.1016/S0378-1097(98)00586-2; Walsh CT, 1996, CHEM BIOL, V3, P21, DOI 10.1016/S1074-5521(96)90079-4	18	75	86	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					6998	7003		10.1074/jbc.M008591200	http://dx.doi.org/10.1074/jbc.M008591200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11083873	hybrid			2022-12-25	WOS:000167442900020
J	Nakajima, H; Honma, Y; Tawara, T; Kato, T; Park, SY; Miyatake, H; Shiro, Y; Aono, S				Nakajima, H; Honma, Y; Tawara, T; Kato, T; Park, SY; Miyatake, H; Shiro, Y; Aono, S			Redox properties and coordination structure of the heme in the CO-sensing transcriptional activator CooA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUBLE GUANYLATE-CYCLASE; LIGAND BOND LENGTHS; OXYGEN SENSOR FIXL; SCATTERING XAFS ANALYSES; RESONANCE RAMAN-SPECTROSCOPY; RHODOSPIRILLUM-RUBRUM; NITRIC-OXIDE; RHIZOBIUM-MELILOTI; CARBON-MONOXIDE; ABSORPTION SPECTROSCOPIES	The CO-sensing transcriptional activator CooA contains a six-coordinate protoheme as a CO sensor. Cys(75) and His(77) are assigned to the fifth ligand of the ferric and ferrous hemes, respectively. In this study, we carried out alanine-scanning mutagenesis and EXAFS analyses to determine the coordination structure of the heme in CooA. Pro(2) is thought to be the sixth ligand of the ferric and ferrous hemes in CooA, which is consistent with the crystal structure of ferrous CooA (Lanzilotta, W, N., Schuller, D. J., Thorsteinsson, M. V., Kerby, R, L,, Roberts, G. P., and Poulos, T. L. (2000) Not. Struct Biol. 7, 876-880). CooA exhibited anomalous redox chemistry, i.e. hysteresis was observed in electrochemical redox titrations in which the observed reduction and oxidation midpoint potentials were -320 mV and -260 mV, respectively. The redox-controlled ligand exchange of the heme between Cys(75) and His(77) is thought to cause the difference between the reduction and oxidation midpoint potentials.	Japan Adv Inst Sci & Technol, Sch Mat Sci, Tatsunokuchi, Ishikawa 9231292, Japan; RIKEN, Harima Inst, Mikazuki, Hyogo 6795148, Japan	Japan Advanced Institute of Science & Technology (JAIST); RIKEN	Aono, S (corresponding author), Japan Adv Inst Sci & Technol, Sch Mat Sci, 1-1 Asahidai, Tatsunokuchi, Ishikawa 9231292, Japan.		Aono, Shigetoshi/ABD-7618-2020; Shiro, Yoshitsugu Y/J-3757-2014	Aono, Shigetoshi/0000-0002-2870-3694; Shiro, Yoshitsugu Y/0000-0003-0695-8327				ADACHI S, 1991, BIOCHEM BIOPH RES CO, V180, P138, DOI 10.1016/S0006-291X(05)81266-5; Aono S, 1997, BIOCHEM BIOPH RES CO, V240, P783, DOI 10.1006/bbrc.1997.7746; Aono S, 1996, BIOCHEM BIOPH RES CO, V228, P752, DOI 10.1006/bbrc.1996.1727; Aono S, 1998, J BIOL CHEM, V273, P25757, DOI 10.1074/jbc.273.40.25757; Aono S, 1999, COORDIN CHEM REV, V190, P267, DOI 10.1016/S0010-8545(99)00070-3; BAYMANN F, 1991, ANAL BIOCHEM, V199, P269, DOI 10.1016/0003-2697(91)90100-8; BINSTED N, 1992, BIOCHEMISTRY-US, V31, P12117, DOI 10.1021/bi00163a021; BONAM D, 1987, J BIOL CHEM, V262, P2980; Cheng MC, 1999, INORG CHEM, V38, P5703, DOI 10.1021/ic990395r; CRAVEN PA, 1979, J BIOL CHEM, V254, P8213; CRAVEN PA, 1978, J BIOL CHEM, V253, P8433; CRUTCHLEY RJ, 1985, J AM CHEM SOC, V107, P5002, DOI 10.1021/ja00303a034; DAWSON JH, 1982, J BIOL CHEM, V257, P3606; Delgado-Nixon VM, 2000, BIOCHEMISTRY-US, V39, P2685, DOI 10.1021/bi991911s; Dhawan IK, 1999, BIOCHEMISTRY-US, V38, P12805, DOI 10.1021/bi991303c; ELLIS PJ, 1995, J SYNCHROTRON RADIAT, V2, P190, DOI 10.1107/S0909049595006789; Feinberg BA, 1998, BIOCHEMISTRY-US, V37, P13091, DOI 10.1021/bi981037n; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; Fox JD, 1996, J BACTERIOL, V178, P6200, DOI 10.1128/jb.178.21.6200-6208.1996; FULOP V, 1995, CELL, V81, P369, DOI 10.1016/0092-8674(95)90390-9; GILLESGONZALEZ MA, 1994, BIOCHEMISTRY-US, V33, P8067, DOI 10.1021/bi00192a011; GILLESGONZALEZ MA, 1995, BIOCHEMISTRY-US, V34, P232, DOI 10.1021/bi00001a027; GILLESGONZALEZ MA, 1991, NATURE, V350, P170, DOI 10.1038/350170a0; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; HAMADA K, 1995, J MOL BIOL, V247, P947, DOI 10.1006/jmbi.1995.0192; He YP, 1996, J BIOL CHEM, V271, P120, DOI 10.1074/jbc.271.1.120; Hou SB, 2000, NATURE, V403, P540, DOI 10.1038/35000570; IGNARRO LJ, 1982, BIOCHIM BIOPHYS ACTA, V718, P49, DOI 10.1016/0304-4165(82)90008-3; IGNARRO LJ, 1986, J BIOL CHEM, V261, P4997; IGNARRO LJ, 1981, ARCH BIOCHEM BIOPHYS, V208, P75, DOI 10.1016/0003-9861(81)90125-9; ITAGAKI E, 1968, BIOCHEM BIOPH RES CO, V32, P1013, DOI 10.1016/0006-291X(68)90130-7; Koppenhofer A, 2000, BIOCHEMISTRY-US, V39, P4243, DOI 10.1021/bi000192a; Lanzilotta WN, 2000, NAT STRUCT BIOL, V7, P876; Lippard S. J., 1994, PRINCIPLES BIOINORGA; LOIS AF, 1993, J BIOL CHEM, V268, P4370; Miyatake H, 1999, J BIOL CHEM, V274, P23176, DOI 10.1074/jbc.274.33.23176; MONSON EK, 1992, P NATL ACAD SCI USA, V89, P4280, DOI 10.1073/pnas.89.10.4280; MONSON EK, 1995, J BIOL CHEM, V270, P5243, DOI 10.1074/jbc.270.10.5243; Obayashi E, 1997, J AM CHEM SOC, V119, P7807, DOI 10.1021/ja9637816; OKURA I, 1985, INORG CHEM, V24, P451, DOI 10.1021/ic00198a001; Reynolds MF, 1998, J AM CHEM SOC, V120, P9080, DOI 10.1021/ja981146p; Rich AM, 1999, BIOCHEMISTRY-US, V38, P16491, DOI 10.1021/bi990730n; Rich AM, 1998, INORG CHEM, V37, P5743, DOI 10.1021/ic9714549; Rich AM, 1998, J AM CHEM SOC, V120, P10827, DOI 10.1021/ja980253g; Rodgers KR, 1996, BIOCHEMISTRY-US, V35, P9539, DOI 10.1021/bi9530853; Rodgers KR, 1999, CURR OPIN CHEM BIOL, V3, P158, DOI 10.1016/S1367-5931(99)80028-3; SHELVER D, 1995, J BACTERIOL, V177, P2157, DOI 10.1128/jb.177.8.2157-2163.1995; Shelver D, 1999, BIOCHEMISTRY-US, V38, P2669, DOI 10.1021/bi982658j; Shelver D, 1997, P NATL ACAD SCI USA, V94, P11216, DOI 10.1073/pnas.94.21.11216; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; Sono M, 1996, CHEM REV, V96, P2841, DOI 10.1021/cr9500500; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; STONE JR, 1995, BIOCHEM BIOPH RES CO, V207, P572, DOI 10.1006/bbrc.1995.1226; STONE JR, 1995, BIOCHEMISTRY-US, V34, P14668, DOI 10.1021/bi00045a007; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; Tamura K, 1996, J AM CHEM SOC, V118, P9434, DOI 10.1021/ja9543457; Thorsteinsson MV, 2000, J BIOL CHEM, V275, P39332, DOI 10.1074/jbc.M007691200; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; Uchida T, 1998, J BIOL CHEM, V273, P19988, DOI 10.1074/jbc.273.32.19988; Uchida T, 2000, BIOCHEMISTRY-US, V39, P12747, DOI 10.1021/bi0011476; Vogel KM, 1999, BIOCHEMISTRY-US, V38, P2679, DOI 10.1021/bi982375r; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; YAMADA H, 1975, ARCH BIOCHEM BIOPHYS, V169, P344, DOI 10.1016/0003-9861(75)90350-1; Yamanaka T., 1992, BIOCH BACTERIAL CYTO; Zahn JA, 1996, EUR J BIOCHEM, V240, P684, DOI 10.1111/j.1432-1033.1996.0684h.x	65	62	63	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7055	7061		10.1074/jbc.M003972200	http://dx.doi.org/10.1074/jbc.M003972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11096066	hybrid			2022-12-25	WOS:000167442900029
J	Rutault, K; Hazzalin, CA; Mahadevan, LC				Rutault, K; Hazzalin, CA; Mahadevan, LC			Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-alpha) mRNA induction - Evidence for selective destabilization of TNF-alpha transcripts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LIPOPOLYSACCHARIDE (LPS)-BINDING PROTEIN; MESSENGER-RNA STABILITY; N-TERMINAL KINASE; AU-RICH ELEMENTS; BACTERIAL LIPOPOLYSACCHARIDE; TRISTETRAPROLIN; BINDING; LPS; CYTOKINE	Tumor necrosis factor-alpha (TNF-alpha) is a potent proinflammatory cytokine whose synthesis and secretion are implicated in diverse pathologies. Hence, inhibition of TNF-alpha transcription or translation and neutralization of its protein product represent major pharmaceutical strategies to control inflammation. We have studied the role of ERK and p38 mitogen activated protein (MAP) kinase in controlling TNF-alpha mRNA levels in differentiated THP-1 cells and in freshly purified human monocytes. We show here that it is possible to produce virtu ally complete inhibition of lipopolysaccharide stimulated TNF-alpha mRNA accumulation by using a combination of ERK and p38 MAP kinase inhibitors. Furthermore, substantial inhibition is achievable using combinations of 1 muM of each inhibitor, whereas inhibitors used individually are incapable of producing complete inhibition even at high concentrations. Finally, addressing mechanisms involved, we show that inhibition of p38 MAP kinase selectively destabilizes TNF-alpha transcripts but does not affect degradation of c-jun transcripts. These results impinge on the controversy in the literature surrounding the mode of action of MAP kinase inhibitors on TNF-alpha mRNA and suggest the use of combinations of MAP kinase inhibitors as an effective anti-inflammatory strategy.	Univ Oxford, Dept Biochem, Nucl Signalling Lab, Oxford OX1 3QU, England	University of Oxford	Mahadevan, LC (corresponding author), Univ Oxford, Dept Biochem, Nucl Signalling Lab, S Parks Rd, Oxford OX1 3QU, England.							Baldassare JJ, 1999, J IMMUNOL, V162, P5367; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHORNCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Foey AD, 1998, J IMMUNOL, V160, P920; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; HOFF T, 1992, J LEUKOCYTE BIOL, V52, P173, DOI 10.1002/jlb.52.2.173; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lewis T, 1998, J BIOL CHEM, V273, P13781, DOI 10.1074/jbc.273.22.13781; Manthey CL, 1998, J LEUKOCYTE BIOL, V64, P409, DOI 10.1002/jlb.64.3.409; Myokai F, 1999, P NATL ACAD SCI USA, V96, P4518, DOI 10.1073/pnas.96.8.4518; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRITCHETT W, 1995, J INFLAMM, V45, P97; Raabe T, 1998, J BIOL CHEM, V273, P974, DOI 10.1074/jbc.273.2.974; Scherle PA, 1998, J IMMUNOL, V161, P5681; SHWENDE H, 1996, J LEUKOCYTE BIOL, V59, P555; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Wang SW, 1999, INFLAMM RES, V48, P533, DOI 10.1007/s000110050499; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; WRIGHT SD, 1995, J IMMUNOL, V155, P6; WURFEL MM, 1994, J EXP MED, V180, P1025, DOI 10.1084/jem.180.3.1025; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; YOUNG P, 1993, AGENTS ACTIONS, V39, pC67, DOI 10.1007/BF01972723	40	157	160	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6666	6674		10.1074/jbc.M005486200	http://dx.doi.org/10.1074/jbc.M005486200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11076936	hybrid			2022-12-25	WOS:000167261000078
J	Luo, D; Broad, LM; Bird, GSJ; Putney, JW				Luo, D; Broad, LM; Bird, GSJ; Putney, JW			Signaling pathways underlying muscarinic receptor-induced [Ca2+](i) oscillations in HEK293 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; LACRIMAL ACINAR-CELLS; SMOOTH-MUSCLE CELLS; ARACHIDONIC-ACID; CA2+ ENTRY; INOSITOL TRISPHOSPHATE; HUMAN-NEUTROPHILS; PLASMA-MEMBRANE; FATTY-ACIDS; ACTIVATION	We have investigated the signaling pathways underlying muscarinic receptor-induced calcium oscillations in human embryonic kidney (HEK293) cells. Activation of muscarinic receptors with a maximal concentration of carbachol (100 muM) induced a biphasic rise in cytoplasmic calcium ([Ca2+](i)) comprised of release of Ca2+ from intracellular stores and influx of Ca2+ from the extracellular space. A lower concentration of carbachol (5 muM) induced repetitive [Ca2+](i) spikes or oscillations, the continuation of which was dependent on extracellular Ca2+. The entry of Ca2+ with 100 muM carbachol and with the sarcoplasmic-endoplasmic reticulum calcium ATPase inhibitor, thapsigargin, was completely blocked by 1 muM Gd3+, as well as 30-100 muM concentrations of the membrane-permeant inositol 1,4,5-trisphosphate receptor inhibitor, 2-aminoethyoxydiphenyl borane (8-APE). Sensitivity to these inhibitors is indicative of capacitative calcium entry. Arachidonic acid, a candidate signal for Ca2+ entry associated with [Ca2+](i) oscillations in HEK293 cells, induced entry that was inhibited only by much higher concentrations of Gd3+ and was unaffected by 100 muM 2-APB. Like arachidonic acid-induced entry, the entry associated with [Ca2+](i) oscillations was insensitive to inhibition by Gd3+ but was completely blocked by 100 muM 8-APE. These findings indicate that the signaling pathway responsible for the Ca2+ entry driving [Ca2+](i) oscillations in HEK293 cells is more complex than originally thought, and may involve neither capacitative calcium entry nor a role for PLA(2) and arachidonic acid.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Putney, JW (corresponding author), NIEHS, Lab Signal Transduct, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Putney, James W/F-7247-2019; Bird, Gary/AAI-8186-2021	Putney, James W/0000-0002-3379-4789; Bird, Gary/0000-0003-1389-8748	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES090087, ZIAES090087] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Akagi K, 1997, JPN J PHARMACOL, V75, P33, DOI 10.1254/jjp.75.33; ALONSO MT, 1990, BIOCHEM J, V272, P435, DOI 10.1042/bj2720435; AlonsoTorre SR, 1997, BBA-BIOMEMBRANES, V1328, P207, DOI 10.1016/S0005-2736(97)00094-1; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1991, CELL CALCIUM, V12, P63, DOI 10.1016/0143-4160(91)90009-4; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Berridge MJ, 2000, SCIENCE, V287, P1604, DOI 10.1126/science.287.5458.1604; BIRD GSJ, 1993, J BIOL CHEM, V268, P8425; Bird GSJ, 1996, J BIOL CHEM, V271, P6766, DOI 10.1074/jbc.271.12.6766; Broad LM, 1999, J PHYSIOL-LONDON, V517, P121, DOI 10.1111/j.1469-7793.1999.0121z.x; CHOW SC, 1990, J BIOL CHEM, V265, P902; Clementi E, 1996, CELL CALCIUM, V19, P269, DOI 10.1016/S0143-4160(96)90068-8; Collins DR, 1998, EUR J PHARMACOL, V342, P213, DOI 10.1016/S0014-2999(97)01590-2; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DEYOUNG GW, 1992, P NATL ACAD SCI USA, V89, P9895, DOI 10.1073/pnas.89.20.9895; FERNANDO KC, 1994, BBA-MOL CELL RES, V1222, P383, DOI 10.1016/0167-4889(94)90044-2; FEWTRELL C, 1993, ANNU REV PHYSIOL, V55, P427, DOI 10.1146/annurev.physiol.55.1.427; FRIEL DD, 1992, NEURON, V8, P1109, DOI 10.1016/0896-6273(92)90132-W; GRABER R, 1994, J LIPID MEDIAT CELL, V9, P91; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; Jorgensen NK, 1999, AM J PHYSIOL-CELL PH, V276, pC26; KHODOROVA AB, 1994, FEBS LETT, V353, P167, DOI 10.1016/0014-5793(94)01029-3; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; KWAN CY, 1990, AM J PHYSIOL, V258, pC1006, DOI 10.1152/ajpcell.1990.258.6.C1006; Lankisch TO, 1999, EUR J CELL BIOL, V78, P632, DOI 10.1016/S0171-9335(99)80048-X; LIU QY, 1995, J PHARMACOL EXP THER, V273, P32; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MEVES H, 1994, PROG NEUROBIOL, V43, P175, DOI 10.1016/0301-0082(94)90012-4; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Munaron L, 1997, CELL CALCIUM, V22, P179, DOI 10.1016/S0143-4160(97)90011-7; Osterhout JL, 2000, J BIOL CHEM, V275, P8248, DOI 10.1074/jbc.275.11.8248; PRINCE WT, 1973, J EXP BIOL, V58, P367; Putney Jr JW, 1997, CAPACITATIVE CALCIUM; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Shuttleworth TJ, 1999, CELL CALCIUM, V25, P237, DOI 10.1054/ceca.1999.0022; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; SHUTTLEWORTH TJ, 1994, CELL CALCIUM, V15, P457, DOI 10.1016/0143-4160(94)90110-4; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TSUNODA Y, 1990, AM J PHYSIOL, V258, pC147, DOI 10.1152/ajpcell.1990.258.1.C147; VANBREEMEN C, 1972, CIRC RES, V30, P44, DOI 10.1161/01.RES.30.1.44; VANDERZEE L, 1995, BIOCHEM J, V305, P859, DOI 10.1042/bj3050859; WAYMAN GA, 1995, J BIOL CHEM, V270, P24108, DOI 10.1074/jbc.270.41.24108	48	116	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5613	5621		10.1074/jbc.M007524200	http://dx.doi.org/10.1074/jbc.M007524200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11096083	hybrid			2022-12-25	WOS:000167115100030
J	Rohdich, F; Wiese, A; Feicht, R; Simon, H; Bacher, A				Rohdich, F; Wiese, A; Feicht, R; Simon, H; Bacher, A			Enoate reductases of Clostridia - Cloning, sequencing, and expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLD YELLOW ENZYME; ESCHERICHIA-COLI; TRIMETHYLAMINE DEHYDROGENASE; GLUTATHIONE-REDUCTASE; HUMAN-ERYTHROCYTES; ACID; GENE; PROTEINS; REDUCTIONS; VIOLOGEN	The enr genes specifying enoate reductases of Clos tridium tyrobutyricum and Clostridium thermoaceticum were cloned and sequenced. Sequence comparison A shows that enoate reductases are similar to a family of flavoproteins comprising 2,4-dienoyl-coenzyme A reductase from Escherichia coli and old yellow enzyme from yeast. The C. thermoaceticum enr gene product was expressed in recombinant Escherichia coli cells growing under anaerobic conditions. The recombinant enzyme was purified and characterized.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Inst Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Rohdich, F (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Inst Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.							BADER J, 1981, H-S Z PHYSIOL CHEM, V362, P809, DOI 10.1515/bchm2.1981.362.1.809; BADER J, 1980, ARCH MICROBIOL, V127, P279, DOI 10.1007/BF00427205; BADER J, 1982, FEBS LETT, V140, P67, DOI 10.1016/0014-5793(82)80522-X; BARBER MJ, 1992, J BIOL CHEM, V267, P6611; BOYD G, 1992, FEBS LETT, V308, P271, DOI 10.1016/0014-5793(92)81291-S; BUHLER M, 1980, FEBS LETT, V109, P244, DOI 10.1016/0014-5793(80)81096-9; BUHLER M, 1982, H-S Z PHYSIOL CHEM, V363, P609, DOI 10.1515/bchm2.1982.363.1.609; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Caldeira J, 1996, J BIOL CHEM, V271, P18743, DOI 10.1074/jbc.271.31.18743; DOMMES V, 1984, J BIOL CHEM, V259, P1781; DURAN E, 1993, J BIOL CHEM, V268, P22391; FINDLAY JBC, 1990, PROTEIN PURIFICATION, P87; FRANKLUND CV, 1993, J BACTERIOL, V175, P3002, DOI 10.1128/JB.175.10.3002-3012.1993; GORGEN G, 1989, HELV CHIM ACTA, V72, P917, DOI 10.1002/hlca.19890720507; GOTTSCHALK G, 1981, PROKARYOTES, V2, P1767; He XY, 1997, EUR J BIOCHEM, V248, P516, DOI 10.1111/j.1432-1033.1997.00516.x; HINZPETER M, 1993, METHODS IMMUNOLOGICA, V1, P529; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; KOIVURANTA KT, 1994, BIOCHEM J, V304, P787, DOI 10.1042/bj3040787; KRAUSE G, 1989, Z NATURFORSCH C, V44, P345; KRAUTHSIEGEL RL, 1982, EUR J BIOCHEM, V121, P259, DOI 10.1111/j.1432-1033.1982.tb05780.x; KUNO S, 1985, BIOL CHEM H-S, V366, P463, DOI 10.1515/bchm3.1985.366.1.463; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU XL, 1993, BIOCHIM BIOPHYS ACTA, V1174, P187, DOI 10.1016/0167-4781(93)90113-R; MALLONEE DH, 1990, J BACTERIOL, V172, P7011, DOI 10.1128/jb.172.12.7011-7019.1990; MEAD DA, 1991, BIO-TECHNOL, V9, P657, DOI 10.1038/nbt0791-657; MEADE HM, 1982, J BACTERIOL, V149, P114, DOI 10.1128/JB.149.1.114-122.1982; Murthy YVSN, 1999, J AM CHEM SOC, V121, P5344, DOI 10.1021/ja990908t; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; SAITO K, 1991, J BIOL CHEM, V266, P20720; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Simon H, 1998, STUD NAT PROD CHEM, V20, P817; SIMON H, 1985, ANGEW CHEM INT EDIT, V24, P539, DOI 10.1002/anie.198505391; SIMON H, 1990, BIOCATALYSIS, P217; SIMON H, 1988, BIOTECHNOLOGY B, V6, P178; SIMON H, 1991, CHEM BIOCH FLAVOENZY, V2, P317; THANOS I, 1988, BIOL CHEM H-S, V369, P451, DOI 10.1515/bchm3.1988.369.1.451; THANOS I, 1986, ANGEW CHEM INT EDIT, V25, P462, DOI 10.1002/anie.198604621; THANOS ICG, 1987, J BIOTECHNOL, V6, P13, DOI 10.1016/0168-1656(87)90042-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UNTUCHTGRAU R, 1981, EUR J BIOCHEM, V120, P407, DOI 10.1111/j.1432-1033.1981.tb05718.x; VAZ ADN, 1995, BIOCHEMISTRY-US, V34, P4246, DOI 10.1021/bi00013a014; WHITE H, 1989, EUR J BIOCHEM, V184, P89, DOI 10.1111/j.1432-1033.1989.tb14993.x; YANG CC, 1995, EUR J BIOCHEM, V232, P264, DOI 10.1111/j.1432-1033.1995.tb20808.x; YOUNG M, 1989, FEMS MICROBIOL LETT, V63, P301, DOI 10.1111/j.1574-6968.1989.tb03402.x; ZAMENHOF PJ, 1972, J BACTERIOL, V110, P171, DOI 10.1128/JB.110.1.171-178.1972	48	44	90	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5779	5787		10.1074/jbc.M008656200	http://dx.doi.org/10.1074/jbc.M008656200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11060310	hybrid			2022-12-25	WOS:000167115100052
J	Cortes-Bratti, X; Karlsson, C; Lagergard, T; Thelestam, M; Frisan, T				Cortes-Bratti, X; Karlsson, C; Lagergard, T; Thelestam, M; Frisan, T			The Haemophilus ducreyi cytolethal distending toxin induces cell cycle arrest and apoptosis via the DNA damage checkpoint pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; G(2) ARREST; T-CELLS; P53; CYTOTOXIN; KINASE; PROTEIN; ATM; PROGRESSION; LINKAGE	The cytolethal distending toxins (CDTs) induce cell cycle arrest by a mechanism still not well characterized. We demonstrate that the effect of the Haemophilus ducreyi CDT (HdCDT) is cell type-specific: B cell lines underwent apoptosis, epithelial cells and keratinocytes arrested exclusively in G(2), whereas normal fibroblasts arrested both in G(1) and G(2). We studied normal keratinocytes and fibroblasts, which are relevant for understanding the pathogenicity of H. ducreyi. The response to HdCDT resembles the checkpoint response activated by ionizing radiation. Both responses were characterized by an early induction of the p53 gene and the cyclin-dependent kinase inhibitor p21 in fibroblasts, and activation of the chk2 kinase in epithelial cells. In the Ataxia Telansectasia-mutated gene (ATM)-deficient lymphoblastoid cell lines, intoxication was significantly delayed compared with ATM wild type cells, and was associated with a slower kinetic of p53 stabilization, suggesting that the early response to HdCDT is ATM-dependent. Activation of ATM-dependent pathways was further confirmed by the ability of caffeine to partially override the HdCDT-mediated cell cycle arrest. Our data shed new light on the mechanism of action of this novel family of bacterial toxins, limiting the target candidates to DNA or molecules directly involved in activation of checkpoint responses.	Karolinska Inst, Microbiol & Tumorbiol Ctr, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden; Gothenburg Univ, Dept Med Microbiol & Immunol, S-41346 Gothenburg, Sweden	Karolinska Institutet; Karolinska Institutet; University of Gothenburg	Frisan, T (corresponding author), Karolinska Inst, Microbiol & Tumorbiol Ctr, Box 280, S-17177 Stockholm, Sweden.		Frisan, Teresa/H-8444-2019	Frisan, Teresa/0000-0002-1209-0942				Aragon V, 1997, INFECT IMMUN, V65, P3774, DOI 10.1128/IAI.65.9.3774-3780.1997; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; Assoian RK, 1997, CURR OPIN CELL BIOL, V9, P93, DOI 10.1016/S0955-0674(97)80157-3; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chehab NH, 2000, GENE DEV, V14, P278; Cortes-Bratti X, 1999, J CLIN INVEST, V103, P107, DOI 10.1172/JCI3831; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Elwell CA, 2000, MOL MICROBIOL, V37, P952, DOI 10.1046/j.1365-2958.2000.02070.x; Escalas N, 2000, EXP CELL RES, V257, P206, DOI 10.1006/excr.2000.4878; Freeman SM, 1996, SEMIN ONCOL, V23, P31; Gelfanova V, 1999, INFECT IMMUN, V67, P6394; Halloran PJ, 1998, CANCER RES, V58, P3855; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGERGARD T, 1993, MICROB PATHOGENESIS, V14, P417, DOI 10.1006/mpat.1993.1041; LAGERGARD T, 1993, INFECT IMMUN, V61, P1589; Lara-Tejero M, 2000, SCIENCE, V290, P354, DOI 10.1126/science.290.5490.354; LENOIR GM, 1985, IARC SCI PUBL, V60, P309; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; MILLER G, 1973, P NATL ACAD SCI USA, V70, P190, DOI 10.1073/pnas.70.1.190; Pickett CL, 1999, TRENDS MICROBIOL, V7, P292, DOI 10.1016/S0966-842X(99)01537-1; Poon RYC, 1997, CANCER RES, V57, P5168; PURVEN M, 1995, FEMS MICROBIOL LETT, V129, P221, DOI 10.1111/j.1574-6968.1995.tb07583.x; Purven M, 1997, INFECT IMMUN, V65, P3496; REID R, 1988, J BIOL CHEM, V263, P3898; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sert V, 1999, ONCOGENE, V18, P6296, DOI 10.1038/sj.onc.1203007; Shenker BJ, 1999, J IMMUNOL, V162, P4773; Shenker BJ, 2000, J IMMUNOL, V165, P2612, DOI 10.4049/jimmunol.165.5.2612; SICILIANO JD, 1997, GENE DEV, V11, P3471; Stevens MK, 1999, INFECT IMMUN, V67, P3900, DOI 10.1128/IAI.67.8.3900-3908.1999; THELESTAM M, 1999, COMPREHENSIVE SOURCE, P147; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342	40	129	137	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5296	5302		10.1074/jbc.M008527200	http://dx.doi.org/10.1074/jbc.M008527200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11076947	hybrid			2022-12-25	WOS:000168484300102
J	Undas, A; Williams, EB; Butenas, S; Orfeo, T; Mann, KG				Undas, A; Williams, EB; Butenas, S; Orfeo, T; Mann, KG			Homocysteine inhibits inactivation of Factor Va by activated protein C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; ENDOTHELIAL-CELLS; VASCULAR-DISEASE; RISK FACTOR; PLASMA HOMOCYSTEINE; MYOCARDIAL-INFARCTION; ATHEROGENIC STIMULUS; THROMBOGENIC AGENT; VENOUS THROMBOSIS; DISULFIDE BRIDGES	We report the effect of homocysteine on the inactivation of factor Va by activated protein C (APC) using clotting assays, immunoblotting, and radiolabeling experiments. Homocysteine, cysteine, or homocysteine thiolactone have no effect on factor V activation by Lu-thrombin. Factor Va derived from homocysteine-treated factor V was inactivated by APC at a reduced rate. The inactivation impairment increased with increasing homocysteine concentration (pseudo first order rate k = 1.2, 0.9, 0.7, 0.4 min(-1) at 0, 0.03, 0.1, 1 mM homocysteine, respectively). Neither cysteine nor homocysteine thiolactone treatment of factor V affected APC inactivation of derived factor Va. Western blot analyses of APC inactivation of homocysteine-modified factor Va are consistent with the results of clotting assays. Factor Va, derived from factor V treated with 1 mM beta -mercaptoethanol was inactivated more rapidly than the untreated protein sample. Factor V incubated with [S-35]homocysteine (10-450 muM) incorporated label within 5 min, which was found only in those fragments that contained free sulfhydryl groups: the light chain (Cys-1960, Cys-2113), the B region (Cys-1085), and the 26/28-kDa (residues 507-709) APC cleavage products of the heavy chain (Cys-539, Cys-585). Treatment with beta -mercaptoethanol removed all radiolabel. Plasma of patients assessed to be hyperhomocysteinemic showed APC resistance in a clot-based assay. Our results indicate that homocysteine rapidly incorporates into factor V and that the prothrombotic tendency in hyperhomocysteinemia may be related to impaired inactivation of factor Va by APC due to homocysteinylation of the cofactor by modification of free cysteine(s).	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA; St Catherines Coll, Dept Chem, St Paul, MN 55105 USA; Jagiellonian Univ, Sch Med, Dept Med, PL-31066 Krakow, Poland	University of Vermont; Jagiellonian University	Mann, KG (corresponding author), Univ Vermont, Coll Med, Dept Biochem, Given Bldg,Hlth Sci Complex, Burlington, VT 05405 USA.				NHLBI NIH HHS [HL-34575] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034575, R01HL034575] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baernstein HD, 1934, J BIOL CHEM, V106, P451; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Cattaneo M, 1999, THROMB HAEMOSTASIS, V81, P165; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAngelo A, 1997, BLOOD, V90, P1; de Visser MCH, 1999, BLOOD, V93, P1271, DOI 10.1182/blood.V93.4.1271.404k22_1271_1276; denHeijer M, 1996, NEW ENGL J MED, V334, P759, DOI 10.1056/NEJM199603213341203; Domagala T B, 1998, J Cardiovasc Risk, V5, P239, DOI 10.1097/00043798-199808000-00006; Egan JO, 1997, PROTEIN SCI, V6, P2016, DOI 10.1002/pro.5560060922; FALCON CR, 1994, ARTERIOSCLER THROMB, V14, P1080, DOI 10.1161/01.ATV.14.7.1080; FERMO I, 1995, ANN INTERN MED, V123, P747, DOI 10.7326/0003-4819-123-10-199511150-00002; FRYER RH, 1993, ARTERIOSCLER THROMB, V13, P1327, DOI 10.1161/01.ATV.13.9.1327; HAJJAR KA, 1993, J CLIN INVEST, V91, P2873, DOI 10.1172/JCI116532; HAYASHI T, 1992, BLOOD, V79, P2930; Hockin MF, 1999, BIOCHEMISTRY-US, V38, P6918, DOI 10.1021/bi981966e; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KALAFATIS M, 1993, J BIOL CHEM, V268, P27246; KALAFATIS M, 1995, J BIOL CHEM, V270, P4053, DOI 10.1074/jbc.270.8.4053; KALAFATIS M, 1994, J BIOL CHEM, V269, P31869; KANG SS, 1992, ANNU REV NUTR, V12, P279, DOI 10.1146/annurev.nu.12.070192.001431; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lane DA, 1996, THROMB HAEMOSTASIS, V76, P651; LENTZ SR, 1991, J CLIN INVEST, V88, P1906, DOI 10.1172/JCI115514; Loscalzo J, 1996, J CLIN INVEST, V98, P5, DOI 10.1172/JCI118776; Malinow MR, 1999, CIRCULATION, V99, P178, DOI 10.1161/01.CIR.99.1.178; MANN KG, 1984, J BIOL CHEM, V259, P2949; Mann KG, 1997, J BIOL CHEM, V272, P20678, DOI 10.1074/jbc.272.33.20678; MANSOOR MA, 1992, CLIN CHEM, V38, P1316; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NISHINAGA M, 1993, J CLIN INVEST, V92, P1381, DOI 10.1172/JCI116712; Nygard O, 1997, NEW ENGL J MED, V337, P230, DOI 10.1056/NEJM199707243370403; PERRY IJ, 1995, LANCET, V346, P1395, DOI 10.1016/S0140-6736(95)92407-8; REES MM, 1993, THROMB RES, V71, P337, DOI 10.1016/0049-3848(93)90160-P; Ridker PM, 1997, CIRCULATION, V95, P1777; RODGERS GM, 1986, J CLIN INVEST, V77, P1909, DOI 10.1172/JCI112519; RODGERS GM, 1990, BLOOD, V75, P895; Schwartz SM, 1997, CIRCULATION, V96, P412; SELHUB J, 1992, AM J CLIN NUTR, V55, P131, DOI 10.1093/ajcn/55.1.131; STAMLER JS, 1993, J CLIN INVEST, V91, P308, DOI 10.1172/JCI116187; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; vandenBerg M, 1996, ARTERIOSCL THROM VAS, V16, P165, DOI 10.1161/01.ATV.16.1.165; Welch GN, 1998, NEW ENGL J MED, V338, P1042, DOI 10.1056/NEJM199804093381507; XUE JC, 1994, BIOCHEMISTRY-US, V33, P13109, DOI 10.1021/bi00248a021; XUE JC, 1993, BIOCHEMISTRY-US, V32, P5917, DOI 10.1021/bi00073a026	51	77	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4389	4397		10.1074/jbc.M004124200	http://dx.doi.org/10.1074/jbc.M004124200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11083858	hybrid			2022-12-25	WOS:000166921200088
J	Krupp, R; Chan, C; Missiakas, D				Krupp, R; Chan, C; Missiakas, D			DsbD-catalyzed transport of electrons across the membrane of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; ACTIVE-SITE CYSTEINES; IN-VIVO; FORMATION INVIVO; PROTEIN DSBD; COPY-NUMBER; THIOREDOXIN; IDENTIFICATION; ISOMERASE; PATHWAY	Dsb proteins catalyze folding and oxidation of polypeptides in the periplasm of Escherichia coli. DsbC reduces wrongly paired disulfides by transferring electrons from its catalytic dithiol motif (98)CGyC. Genetic evidence suggests that recycling of this motif requires at least three proteins, the cytoplasmic thioredoxin reductase (TrxB) and thioredoxin (TrxA) as well as the DsbD membrane protein. We demonstrate here that electrons are transferred directly from thioredoxin to DsbD and from DsbD to DsbC. Three cysteine pairs within DsbD undergo reversible disulfide rearrangements. Our results suggest a novel mechanism for electron transport across membranes whereby electrons are transferred sequentially from cysteine pairs arranged in a thioredoxin-like motif (CXXC) to a cognate reactive disulfide.	Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Missiakas, D (corresponding author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, 609 Charles Young Dr, Los Angeles, CA 90095 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058266] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58266] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; Andersen CL, 1997, MOL MICROBIOL, V26, P121, DOI 10.1046/j.1365-2958.1997.5581925.x; Ansaldi M, 1996, ANAL BIOCHEM, V234, P110, DOI 10.1006/abio.1996.0060; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bessette PH, 1999, J BIOL CHEM, V274, P7784, DOI 10.1074/jbc.274.12.7784; Chung J, 2000, MOL MICROBIOL, V35, P1099, DOI 10.1046/j.1365-2958.2000.01778.x; Creighton T.E., 1993, PROTEINS; Debarbieux L, 1999, CELL, V99, P117, DOI 10.1016/S0092-8674(00)81642-6; ELLIS LBM, 1992, BIOCHEMISTRY-US, V31, P4882, DOI 10.1021/bi00135a020; Fabianek RA, 1998, J BACTERIOL, V180, P1947, DOI 10.1128/JB.180.7.1947-1950.1998; Frand AR, 2000, TRENDS CELL BIOL, V10, P203, DOI 10.1016/S0962-8924(00)01745-1; FREEDMAN RB, 1989, CELL, V57, P1069, DOI 10.1016/0092-8674(89)90043-3; Gordon EHJ, 2000, MOL MICROBIOL, V35, P1360, DOI 10.1046/j.1365-2958.2000.01796.x; GUILHOT C, 1995, P NATL ACAD SCI USA, V92, P9895, DOI 10.1073/pnas.92.21.9895; HOLMGREN A, 1995, STRUCTURE, V3, P239, DOI 10.1016/S0969-2126(01)00153-8; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; Kemmink J, 1997, CURR BIOL, V7, P239, DOI 10.1016/S0960-9822(06)00119-9; KISHIGAMI S, 1995, J BIOL CHEM, V270, P17072, DOI 10.1074/jbc.270.29.17072; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Lennon BW, 2000, SCIENCE, V289, P1190, DOI 10.1126/science.289.5482.1190; MARTIN JL, 1993, NATURE, V365, P464, DOI 10.1038/365464a0; McCarthy AA, 2000, NAT STRUCT BIOL, V7, P196; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; Rietsch A, 1997, J BACTERIOL, V179, P6602, DOI 10.1128/jb.179.21.6602-6608.1997; Rietsch A, 1996, P NATL ACAD SCI USA, V93, P13048, DOI 10.1073/pnas.93.23.13048; RUSSEL M, 1990, J BACTERIOL, V172, P1923, DOI 10.1128/jb.172.4.1923-1929.1990; RUSSEL M, 1995, METHOD ENZYMOL, V252, P264; SMITH DJ, 1975, BIOCHEMISTRY-US, V14, P764; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; Stewart EJ, 1999, EMBO J, V18, P5963, DOI 10.1093/emboj/18.21.5963; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; Wang PF, 1996, BIOCHEMISTRY-US, V35, P4812, DOI 10.1021/bi9526793; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019	41	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3696	3701		10.1074/jbc.M009500200	http://dx.doi.org/10.1074/jbc.M009500200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11085993	hybrid			2022-12-25	WOS:000166784900093
J	Stoka, V; Turk, B; Schendel, SL; Kim, TH; Cirman, T; Snipas, SJ; Ellerby, LM; Bredesen, D; Freeze, H; Abrahamson, M; Bromme, D; Krajewski, S; Reed, JC; Yin, XM; Turk, V; Salvesen, GS				Stoka, V; Turk, B; Schendel, SL; Kim, TH; Cirman, T; Snipas, SJ; Ellerby, LM; Bredesen, D; Freeze, H; Abrahamson, M; Bromme, D; Krajewski, S; Reed, JC; Yin, XM; Turk, V; Salvesen, GS			Lysosomal protease pathways to apoptosis - Cleavage of Bid, not pro-caspases, is the most likely route	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE PROTEINASE-INHIBITOR; PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; CATHEPSIN-B; ESCHERICHIA-COLI; PRECURSOR PROTEIN; OXIDATIVE STRESS; DEFICIENT MICE; CYSTATIN-B; PC12 CELLS	We investigated the mechanism of lysosome-mediated cell death using purified recombinant pro-apoptotic proteins, and cell-free extracts from the human neuronal progenitor cell line NT2, Potential effectors were either isolated lysosomes or purified lysosomal proteases. Purified lysosomal cathepsins B, H, K, L, S, and X or an extract of mouse lysosomes did not directly activate either recombinant caspase zymogens or caspase zymogens present in an NT2 cytosolic extract to any significant extent. In contrast, a cathepsin L-related protease from the protozoan parasite Trypanosana cruzi, cruzipain, showed a measurable caspase activation rate. This demonstrated that members of the papain family can directly activate caspases but that mammalian lysosomal members of this family may have been negatively selected for caspase activation to prevent inappropriate induction of apoptosis, Given the lack of evidence for a direct role in caspase activation by lysosomal proteases, we hypothesized that an indirect mode of caspase activation may involve the Bcl-2 family member Bid. In support of this, Bid was cleaved in the presence of lysosomal extracts, at a site six residues downstream from that seen for pathways involving capase 8, Incubation of mitochondria with Bid that had been cleaved by lysosomal extracts resulted in cytochrome c release. Thus, cleavage of Bid may represent a mechanism by which proteases that have leaked from the lysosomes can precipitate cytochrome c release and subsequent caspase activation. This is supported by the finding that cytosolic extracts from mice ablated in the bid gene are impaired in the ability to release cytochrome c in response to lysosome extracts, Together these data suggest that Bid represents a sensor that allows cells to initiate apoptosis in response to widespread adventitious proteolysis.	Burnham Inst, Program Apoptosis & Cell Death Res, La Jolla, CA 92037 USA; Burnham Inst, Program Glycobiol, La Jolla, CA 92037 USA; Jozef Stefan Inst, Dept Biochem & Mol Biol, Ljubljana 1000, Slovenia; Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; Buck Inst Age Res, Novato, CA 94945 USA; Univ Lund Hosp, Dept Clin Chem, Inst Lab Med, S-22185 Lund, Sweden; CUNY Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	Sanford Burnham Prebys Medical Discovery Institute; Sanford Burnham Prebys Medical Discovery Institute; Slovenian Academy of Sciences & Arts (SASA); Jozef Stefan Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Buck Institute for Research on Aging; Lund University; Skane University Hospital; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Salvesen, GS (corresponding author), Burnham Inst, Program Apoptosis & Cell Death Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gsalvesen@burnham.org	Abrahamson, Magnus/CAG-9507-2022; Stoka, Veronika/AAM-2283-2021	Freeze, Hudson/0000-0001-6316-0501; Turk, Boris/0000-0002-9007-5764; Schendel, Sharon/0000-0002-5062-7261	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060554] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037878, R01NS040251] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60554] Funding Source: Medline; NINDS NIH HHS [NS37878, NS40251] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAHAMSON M, 1988, FEBS LETT, V236, P14, DOI 10.1016/0014-5793(88)80276-X; Barlic-Maganja D, 1998, BIOL CHEM, V379, P1449; BARRETT AJ, 1987, TRENDS BIOCHEM SCI, V12, P193, DOI 10.1016/0968-0004(87)90092-2; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; Bergeron L, 1998, GENE DEV, V12, P1304, DOI 10.1101/gad.12.9.1304; Bi X, 2000, NEUROSCIENCE, V97, P395, DOI 10.1016/S0306-4522(00)00021-X; Bromme D, 1996, PROTEIN SCI, V5, P789; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Clem RJ, 1998, P NATL ACAD SCI USA, V95, P554, DOI 10.1073/pnas.95.2.554; De Duve C, 1966, Proc Inst Med Chic, V26, P73; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; DUNN BM, 1995, ADV EXP MED BIOL, V362, P1; Ellerby HM, 1997, J NEUROSCI, V17, P6165; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FREIJE JP, 1993, J BIOL CHEM, V268, P15737; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; HANNA WL, 1993, PROTEIN EXPRES PURIF, V4, P398, DOI 10.1006/prep.1993.1052; HUBBARD SJ, 1991, J MOL BIOL, V220, P507, DOI 10.1016/0022-2836(91)90027-4; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; Ishisaka R, 1998, FEBS LETT, V435, P233, DOI 10.1016/S0014-5793(98)01080-1; JERALA R, 1994, PROTEIN EXPRES PURIF, V5, P65, DOI 10.1006/prep.1994.1009; JOHNSON DA, 1987, THROMB RES, V48, P187, DOI 10.1016/0049-3848(87)90415-4; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Klemencic I, 2000, EUR J BIOCHEM, V267, P5404, DOI 10.1046/j.1432-1327.2000.01592.x; Koenig H, 1974, Methods Enzymol, V31, P457; Krajewski S, 1997, BLOOD, V89, P3817, DOI 10.1182/blood.V89.10.3817.3817_3817_3825; KUHELJ R, 1995, EUR J BIOCHEM, V229, P533, DOI 10.1111/j.1432-1033.1995.0533k.x; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Linnevers CJ, 1997, PROTEIN SCI, V6, P919; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Mehta DP, 1996, J BIOL CHEM, V271, P10897, DOI 10.1074/jbc.271.18.10897; NAKAMURA Y, 1989, NEUROSCI LETT, V97, P215, DOI 10.1016/0304-3940(89)90166-3; Neuzil J, 1999, FEBS LETT, V445, P295, DOI 10.1016/S0014-5793(99)00141-6; Ni J, 1998, J BIOL CHEM, V273, P24797, DOI 10.1074/jbc.273.38.24797; Ni J, 1997, J BIOL CHEM, V272, P10853; Nilsson E, 1997, HISTOCHEM J, V29, P857, DOI 10.1023/A:1026441907803; Pennacchio LA, 1998, NAT GENET, V20, P251, DOI 10.1038/3059; Pennacchio LA, 1996, SCIENCE, V271, P1731, DOI 10.1126/science.271.5256.1731; POPOVIC T, 1988, BIOL CHEM H-S, V369, P175; Roberg K, 1998, AM J PATHOL, V152, P1151; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Schotte P, 1998, BIOCHEM BIOPH RES CO, V251, P379, DOI 10.1006/bbrc.1998.9425; Shibata M, 1998, BIOCHEM BIOPH RES CO, V251, P199, DOI 10.1006/bbrc.1998.9422; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Stennicke HR, 1999, J BIOL CHEM, V274, P8359, DOI 10.1074/jbc.274.13.8359; Stennicke HR, 2000, BIOCHEM J, V350, P563, DOI 10.1042/0264-6021:3500563; Stennicke HR, 1998, J BIOL CHEM, V273, P27084, DOI 10.1074/jbc.273.42.27084; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; STOKA V, 1995, FEBS LETT, V370, P101, DOI 10.1016/0014-5793(95)00798-E; STORRIE B, 1990, METHOD ENZYMOL, V182, P203; Takai N, 1998, J NEUROSCI RES, V54, P214, DOI 10.1002/(SICI)1097-4547(19981015)54:2<214::AID-JNR9>3.0.CO;2-H; THIELE DL, 1992, J IMMUNOL, V148, P3950; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Troy CM, 2000, J NEUROSCI, V20, P1386; TURK B, 1995, BIOL CHEM H-S, V376, P225, DOI 10.1515/bchm3.1995.376.4.225; TURK V, 1991, FEBS LETT, V285, P213, DOI 10.1016/0014-5793(91)80804-C; Vancompernolle K, 1998, FEBS LETT, V438, P150, DOI 10.1016/S0014-5793(98)01275-7; Wei MC, 2000, GENE DEV, V14, P2060; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692; Yang AJ, 1998, J NEUROSCI RES, V52, P691, DOI 10.1002/(SICI)1097-4547(19980615)52:6<691::AID-JNR8>3.0.CO;2-3; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zhou Q, 1997, BIOCHEM J, V324, P361, DOI 10.1042/bj3240361	73	553	573	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3149	3157		10.1074/jbc.M008944200	http://dx.doi.org/10.1074/jbc.M008944200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11073962	hybrid			2022-12-25	WOS:000166784900024
J	Vallejo, AN; Weyand, CM; Goronzy, JY				Vallejo, AN; Weyand, CM; Goronzy, JY			Functional disruption of the CD28 gene transcriptional initiator in senescent T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; DIRECT BASAL TRANSCRIPTION; CORE PROMOTER STRUCTURE; TATA-LESS PROMOTER; V-BETA PROMOTER; TFII-I; BINDING-PROTEIN; REPLICATIVE SENESCENCE; RHEUMATOID-ARTHRITIS; ELEMENT	We recently reported that aging is accompanied by the emergence of CD4(+)CD28(null) T cells, a functionally aberrant lymphocyte subset rarely seen in individuals younger than 40 years. Here, we directly examined whether the lack of CD28 expression is due to a defect at the level of transcriptional initiation. Molecular studies reveal that CD28 gene transcription is controlled by two sequence motifs, sites alpha and beta. In vitro transcription assays using initiator-dependent DNA templates revealed that reversed polarity or the deletion of either motif inhibited transcription, indicating that alpha/beta sequences constitute a composite initiator. Moreover, nuclear extracts from CD28(null) cells failed to activate transcription of alpha beta -initiator DNA templates. Transcription of such templates was, however, restored with the addition of extracts from CD28(+) cells. Although previously described initiator elements have been defined by a consensus sequence, the alpha beta -initiator has no homology to such sequence. These studies demonstrate that initiators have functions other than positioning elements for the basal transcription complex. Rather, initiators can have a direct role in regulating the expression of specific genes. The gain or loss of initiator activity can be an important determinant of cell phenotypes.	Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Vallejo, AN (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, 200 1st St SW, Rochester, MN 55905 USA.		Weyand, Cornelia/AAH-3343-2021	Goronzy, Jorg/0000-0001-7670-1856	NIAMS NIH HHS [R03 AR045830-03, R03-AR45830] Funding Source: Medline; NIA NIH HHS [R01-AG15043] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR045830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015043] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ASO T, 1994, J BIOL CHEM, V269, P26575; Buchanan KL, 1997, J IMMUNOL, V159, P1247; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; CHEN HJ, 1992, J BIOL CHEM, V267, P25457; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Douek DC, 1998, NATURE, V396, P690, DOI 10.1038/25374; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; EICHBAUM QG, 1994, J EXP MED, V179, P1985, DOI 10.1084/jem.179.6.1985; EMANI KH, 1997, GENE DEV, V11, P3007; Folkers GE, 1998, J BIOL CHEM, V273, P32200, DOI 10.1074/jbc.273.48.32200; Garraway IP, 1996, P NATL ACAD SCI USA, V93, P4336, DOI 10.1073/pnas.93.9.4336; George AJT, 1996, IMMUNOL TODAY, V17, P267, DOI 10.1016/0167-5699(96)80543-3; HANSEN SK, 1995, CELL, V82, P565, DOI 10.1016/0092-8674(95)90029-2; Hodes RJ, 1999, J EXP MED, V190, P153, DOI 10.1084/jem.190.2.153; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; JIANG SW, 1995, J BIOL CHEM, V270, P3683, DOI 10.1074/jbc.270.8.3683; Johnston KA, 1998, MOL CELL BIOL, V18, P5621, DOI 10.1128/MCB.18.10.5621; Jones G, 1998, BIOCHEM J, V335, P79, DOI 10.1042/bj3350079; Kaufmann J, 1996, GENE DEV, V10, P873, DOI 10.1101/gad.10.7.873; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; Kraus RJ, 1996, NUCLEIC ACIDS RES, V24, P1531, DOI 10.1093/nar/24.8.1531; LEE KP, 1990, J IMMUNOL, V145, P344; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LEWIS BA, 1995, J BIOL CHEM, V270, P28139; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Liston DR, 1999, MOL CELL BIOL, V19, P2380; Liuzzo G, 1999, CIRCULATION, V100, P2135, DOI 10.1161/01.CIR.100.21.2135; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; MAI S, 1995, NUCLEIC ACIDS RES, V23, P1, DOI 10.1093/nar/23.1.1; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Martens PB, 1997, ARTHRITIS RHEUM, V40, P1106, DOI 10.1002/art.1780400615; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; Montano MA, 1996, P NATL ACAD SCI USA, V93, P12376, DOI 10.1073/pnas.93.22.12376; Monteiro J, 1996, J IMMUNOL, V156, P3587; Moosig F, 1998, CLIN EXP IMMUNOL, V114, P113; Namekawa T, 1998, ARTHRITIS RHEUM, V41, P2108; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; Park W, 1997, EUR J IMMUNOL, V27, P1082, DOI 10.1002/eji.1830270507; Pelletier MR, 1997, NUCLEIC ACIDS RES, V25, P3995, DOI 10.1093/nar/25.20.3995; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; POSNETT DN, 1994, J EXP MED, V179, P609, DOI 10.1084/jem.179.2.609; Pscherer A, 1996, EMBO J, V15, P6680, DOI 10.1002/j.1460-2075.1996.tb01058.x; Ren B, 1998, EMBO J, V17, P1076, DOI 10.1093/emboj/17.4.1076; ROEDER RG, 1996, TRENDS BIOCHEM SCI, V21, P325; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Rufer N, 1999, J EXP MED, V190, P157, DOI 10.1084/jem.190.2.157; Schirmer M, 1998, J IMMUNOL, V161, P1018; Shelton DN, 1999, CURR BIOL, V9, P939, DOI 10.1016/S0960-9822(99)80420-5; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; USHEVA A, 1994, CELL, V76, P1115, DOI 10.1016/0092-8674(94)90387-5; Vallejo AN, 1996, J BIOL CHEM, V271, P29813, DOI 10.1074/jbc.271.47.29813; Vallejo AN, 2000, J IMMUNOL, V165, P6301, DOI 10.4049/jimmunol.165.11.6301; Vallejo AN, 1998, J BIOL CHEM, V273, P8119, DOI 10.1074/jbc.273.14.8119; Vallejo AN, 1999, J IMMUNOL, V162, P6572; Vallejo AN, 2000, J IMMUNOL, V164, P2947, DOI 10.4049/jimmunol.164.6.2947; VALLEJO AN, 1994, PCR METH APPL, V4, P123; Wang IM, 1996, MOL CELL BIOL, V16, P6313; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; Weyand CM, 1998, MECH AGEING DEV, V102, P131, DOI 10.1016/S0047-6374(97)00161-9; WONG C, 1987, NATURE, V330, P384, DOI 10.1038/330384a0; Wu YX, 1999, J BIOL CHEM, V274, P3207, DOI 10.1074/jbc.274.5.3207; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	67	57	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2565	2570		10.1074/jbc.M005503200	http://dx.doi.org/10.1074/jbc.M005503200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11069899	hybrid			2022-12-25	WOS:000166784800039
J	Lee, J; Ho, WH; Maruoka, M; Corpuz, RT; Baldwin, DT; Foster, JS; Goddard, AD; Yansura, DG; Vandlen, RL; Wood, WI; Gurney, AL				Lee, J; Ho, WH; Maruoka, M; Corpuz, RT; Baldwin, DT; Foster, JS; Goddard, AD; Yansura, DG; Vandlen, RL; Wood, WI; Gurney, AL			IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLOGRAFT-REJECTION; IN-VITRO; T-CELL; INTERLEUKIN-17; CYTOKINE; EXPRESSION; ACTIVATION; PROMOTES; FAMILY; GENE	We report identification of interleukin (IL)-17E, a novel member of the IL-17 family of cytokines, IL-17E is a ligand for the recently identified protein termed EVI27/IL-17BR, which we term IL-17 receptor homolog 1 (IL-17Rh1) in light of the multiple reported ligand-receptor relationships. Murine EVI27 was identified through its location at a common site of retroviral integration in BXH2 murine myeloid leukemias. IL-17Rh1 shows highest level expression in kidney with moderate expression in multiple other organs, whereas IL-17E mRNA was detected at very low levels in several peripheral tissues. IL-17E induces activation of NF-kappaB and stimulates production of the proinflammatory chemokine IL-8.	Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioinformat, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Gurney, AL (corresponding author), 1 DNA Way S, San Francisco, CA 94080 USA.	nico@gene.com						Alimov A, 2000, ONCOGENE, V19, P1392, DOI 10.1038/sj.onc.1203449; Antonysamy MA, 1999, J IMMUNOL, V162, P577; Antonysamy MA, 1999, TRANSPLANT P, V31, P93, DOI 10.1016/S0041-1345(98)01453-5; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Chabaud M, 1999, ARTHRITIS RHEUM-US, V42, P963, DOI 10.1002/1529-0131(199905)42:5<963::AID-ANR15>3.0.CO;2-E; Crow YJ, 2000, AM J HUM GENET, V67, P213, DOI 10.1086/302955; Fossiez F, 1998, Int Rev Immunol, V16, P541, DOI 10.3109/08830189809043008; Fullwood P, 1999, CANCER RES, V59, P4662; Gurney AL, 1999, CURR BIOL, V9, P215, DOI 10.1016/S0960-9822(99)80093-1; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Jovanovic DV, 2000, ARTHRITIS RHEUM-US, V43, P1134, DOI 10.1002/1529-0131(200005)43:5<1134::AID-ANR24>3.0.CO;2-#; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Martinez A, 2000, J CLIN PATHOL-MOL PA, V53, P137, DOI 10.1136/mp.53.3.137; Matusevicius D, 1999, MULT SCLER J, V5, P101, DOI 10.1177/135245859900500206; Orlinick JR, 1998, CELL SIGNAL, V10, P543, DOI 10.1016/S0898-6568(98)00018-7; ROUVIER E, 1993, J IMMUNOL, V150, P5445; Roux-Lombard P, 1998, EUR CYTOKINE NETW, V9, P565; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Shi G, 1996, CYTOGENET CELL GENET, V74, P295, DOI 10.1159/000134439; Shi YG, 2000, J BIOL CHEM, V275, P19167, DOI 10.1074/jbc.M910228199; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V259, P172, DOI 10.1006/bbrc.1999.0746; Subramaniam SV, 1999, BIOCHEM BIOPH RES CO, V262, P14, DOI 10.1006/bbrc.1999.1156; Tartour E, 1999, CANCER RES, V59, P3698; Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x; Tian EM, 2000, ONCOGENE, V19, P2098, DOI 10.1038/sj.onc.1203577; Timmer T, 1999, GENOMICS, V60, P238, DOI 10.1006/geno.1999.5878; Van Bezooijen RL, 1999, J BONE MINER RES, V14, P1513, DOI 10.1359/jbmr.1999.14.9.1513; Van Kooten C, 1998, J AM SOC NEPHROL, V9, P1526; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; YOO ZB, 1995, J IMMUNOL, V155, P5483	34	289	338	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1660	1664		10.1074/jbc.M008289200	http://dx.doi.org/10.1074/jbc.M008289200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11058597	hybrid			2022-12-25	WOS:000166430900106
J	Stucki, M; Jonsson, ZO; Hubscher, U				Stucki, M; Jonsson, ZO; Hubscher, U			In eukaryotic flap endonuclease 1, the C terminus is essential for substrate binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; STRAND DNA-SYNTHESIS; SECONDARY STRUCTURE; REPLICATION; FEN-1; REPAIR; PCNA; INHIBITION; MUTATIONS; MECHANISM	Flap endonuclease 1 (Fen1) is a structure-specific metallonuclease with important functions in DNA replication and DNA repair. It interacts like many other proteins involved in DNA metabolic events with proliferating cell nuclear antigen (PCNA), and its enzymatic activity is stimulated by PCNA in vitro. The PCNA interaction site is located close to the C terminus of Fen1 and is flanked by a conserved basic region of 35-38 amino acids in eukaryotic species but not in archaea. We have constructed two deletion mutants of human Fen1 that lack either the PCNA interaction motif or a part of its adjacent C-terminal region and analyzed them in a variety of assays. Remarkably, deletion of the basic C-terminal region did not affect PCNA interaction but resulted in a protein with significantly reduced enzymatic activity. Electrophoretic mobility shift analysis revealed that this mutant displayed a severe defect in substrate binding. Our results suggest that the C terminus of eukaryotic Fen1 consists of two functionally distinct regions that together might form an important regulatory domain.	Univ Zurich, Univ Vet Biochem, CH-8057 Zurich, Switzerland	University of Zurich	Hubscher, U (corresponding author), Univ Zurich, Univ Vet Biochem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	hubscher@vetbio.unizh.ch	Jónsson, Zophonías Oddur/AAO-1354-2020; Stucki, Manuel/H-4739-2017; Jónsson, Zophonías/E-1960-2015	Jónsson, Zophonías Oddur/0000-0001-5798-9647; 				Bambara RA, 1997, J BIOL CHEM, V272, P4647, DOI 10.1074/jbc.272.8.4647; Chen JJ, 1996, P NATL ACAD SCI USA, V93, P11597, DOI 10.1073/pnas.93.21.11597; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Gary R, 1999, J BIOL CHEM, V274, P4354, DOI 10.1074/jbc.274.7.4354; Gary R, 1999, MOL CELL BIOL, V19, P5373; Gomes XV, 2000, EMBO J, V19, P3811, DOI 10.1093/emboj/19.14.3811; Gordenin DA, 1997, NAT GENET, V16, P116, DOI 10.1038/ng0697-116; HARRINGTON JJ, 1995, J BIOL CHEM, V270, P4503, DOI 10.1074/jbc.270.9.4503; Henricksen LA, 2000, J BIOL CHEM, V275, P16420, DOI 10.1074/jbc.M909635199; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Hosfield DJ, 1998, J BIOL CHEM, V273, P27154, DOI 10.1074/jbc.273.42.27154; Hosfield DJ, 1998, CELL, V95, P135, DOI 10.1016/S0092-8674(00)81789-4; Hubscher U, 1999, PRACT APPROACH SER, V199, P119; Hwang KY, 1998, NAT STRUCT BIOL, V5, P707, DOI 10.1038/1406; Jonsson ZO, 1998, EMBO J, V17, P2412, DOI 10.1093/emboj/17.8.2412; Keller RC, 1999, NUCLEIC ACIDS RES, V27, P3433, DOI 10.1093/nar/27.17.3433; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; Lieber MR, 1997, BIOESSAYS, V19, P233, DOI 10.1002/bies.950190309; Murante RS, 1995, J BIOL CHEM, V270, P30377, DOI 10.1074/jbc.270.51.30377; MURRAY JM, 1994, MOL CELL BIOL, V14, P4878, DOI 10.1128/MCB.14.7.4878; Parenteau J, 1999, MOL CELL BIOL, V19, P4143; Park MS, 1996, P NATL ACAD SCI USA, V93, P8368, DOI 10.1073/pnas.93.16.8368; REAGAN MS, 1995, J BACTERIOL, V177, P364, DOI 10.1128/jb.177.2.364-371.1995; Schurtenberger P, 1998, J MOL BIOL, V275, P123, DOI 10.1006/jmbi.1997.1435; Shen BH, 1998, TRENDS BIOCHEM SCI, V23, P171, DOI 10.1016/S0968-0004(98)01199-2; Shen BH, 1997, NUCLEIC ACIDS RES, V25, P3332, DOI 10.1093/nar/25.16.3332; Shen BH, 1996, J BIOL CHEM, V271, P9173, DOI 10.1074/jbc.271.16.9173; SOMMERS CH, 1995, J BIOL CHEM, V270, P4193, DOI 10.1074/jbc.270.9.4193; Spiro C, 1999, MOL CELL, V4, P1079, DOI 10.1016/S1097-2765(00)80236-1; Stucki M, 2001, PROG NUCLEIC ACID RE, V65, P261; Tom S, 2000, J BIOL CHEM, V275, P10498, DOI 10.1074/jbc.275.14.10498; Wu XT, 1999, P NATL ACAD SCI USA, V96, P1303, DOI 10.1073/pnas.96.4.1303; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036	33	44	51	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7843	7849		10.1074/jbc.M008829200	http://dx.doi.org/10.1074/jbc.M008829200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11083875	Green Accepted, hybrid			2022-12-25	WOS:000167474900025
J	Christian, S; Ahorn, H; Koehler, A; Eisenhaber, F; Rodi, HP; Garin-Chesa, P; Park, JE; Rettig, WJ; Lenter, MC				Christian, S; Ahorn, H; Koehler, A; Eisenhaber, F; Rodi, HP; Garin-Chesa, P; Park, JE; Rettig, WJ; Lenter, MC			Molecular cloning and characterization of endosialin, a C-type lectin-like cell surface receptor of tumor endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; GROWTH-FACTOR; CORE PROTEIN; PREDICTION; THROMBOMODULIN; EXPRESSION; IDENTIFICATION; GLYCOPROTEASE; ACTIVATION; SELECTINS	Endosialin, the antigen identified with monoclonal antibody FB5, is a highly restricted 165-kDa cell surface glycoprotein expressed by tumor blood vessel endothelium in a broad range of human cancers but not detected in blood vessels or other cell types in many normal tissues.:Functional analysis of endosialin has been hampered by a lack of information about its molecular structure. In this study, we describe the purification and partial amino acid sequencing of endosialin, leading to the Cloning of a full-length cDNA with an open reading frame of 2274 base pairs. The endosialin cDNA encodes a type I membrane protein of 757 amino acids with a predicted molecular mass of 80.9 kDa. The sequence matches with an expressed sequence tag of unknown function in public data bases, named TEM1, which was independently linked to tumor endothelium by serial analysis of gene expression profiling. Bioinformatic evaluation classifies endosialin as a C-type lectin-like protein,: composed of a signal leader peptide, five globular extracellular domains (including a C-type lectin domain,: one domain with similarity to the Sushi/ccp/scr pattern, and three EGF repeats), followed by a mucin-like region, a transmembrane segment, and a short cytoplasmic tail. Carbohydrate analysis shows that the endosialin core protein carries abundantly sialylated, O-linked oligosaccharides and is sensitive to O-sialoglycoprotein endopeptidase, placing it in the group of sialomucin-like molecules. The N-terminal 360 amino acids of endosialin show homology to thrombomodulin, a receptor involved in regulating blood coagulation, and to complement receptor C1qRp. This structural kinship may indicate a function for endosialin as a tumor endothelial receptor for as yet unknown ligands, a notion now amenable to molecular investigation.	Boehringer Ingelheim Pharma Inc, Dept Oncol Res, D-88397 Biberach, Germany; Boehringer Ingelheim Pharma Inc, Genom Grp, D-88397 Biberach, Germany; Boehringer Ingelheim Austria GmbH, Dept Drug Discovery, A-1030 Vienna, Austria; Res Inst Mol Pathol, A-1030 Vienna, Austria	Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Lenter, MC (corresponding author), Boehringer Ingelheim Pharma Inc, Dept Oncol Res, D-88397 Biberach, Germany.	martin.lenter@bc.boehringer-ingelheim.com						ABDULLAH KM, 1992, INFECT IMMUN, V60, P56, DOI 10.1128/IAI.60.1.56-62.1992; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BRENDEL V, 1992, P NATL ACAD SCI USA, V89, P2002, DOI 10.1073/pnas.89.6.2002; CARLOS TM, 1994, BLOOD, V84, P2068; Cserzo M, 1997, PROTEIN ENG, V10, P673, DOI 10.1093/protein/10.6.673; Eisenhaber F, 1996, PROTEINS, V25, P157, DOI 10.1002/(SICI)1097-0134(199606)25:2<157::AID-PROT2>3.0.CO;2-F; Frishman D, 1997, PROTEINS, V27, P329, DOI 10.1002/(SICI)1097-0134(199703)27:3<329::AID-PROT1>3.0.CO;2-8; GIRLING A, 1989, INT J CANCER, V43, P1072, DOI 10.1002/ijc.2910430620; Goretzki L, 1999, J BIOL CHEM, V274, P16831, DOI 10.1074/jbc.274.24.16831; HAKOMORI S, 1991, CURR OPIN IMMUNOL, V3, P646, DOI 10.1016/0952-7915(91)90091-E; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Hatzi E, 2000, ADV EXP MED BIOL, V476, P239; Hess KL, 1997, EXP CELL RES, V236, P404, DOI 10.1006/excr.1997.3745; Kokame K, 1998, J BIOL CHEM, V273, P12135, DOI 10.1074/jbc.273.20.12135; LASKY LA, 1992, SCIENCE, V258, P964, DOI 10.1126/science.1439808; LENTER M, 1993, P NATL ACAD SCI USA, V90, P9051, DOI 10.1073/pnas.90.19.9051; Morgan SM, 1999, BLOOD, V93, P165, DOI 10.1182/blood.V93.1.165.401k25_165_175; Nepomuceno RR, 1997, IMMUNITY, V6, P119, DOI 10.1016/S1074-7613(00)80419-7; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Old LJ, 1996, SCI AM, V275, P136, DOI 10.1038/scientificamerican0996-136; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; RETTIG WJ, 1989, ANNU REV IMMUNOL, V7, P481, DOI 10.1146/annurev.iy.07.040189.002405; RETTIG WJ, 1992, P NATL ACAD SCI USA, V89, P10832, DOI 10.1073/pnas.89.22.10832; RETTIG WJ, 1988, P NATL ACAD SCI USA, V85, P3110, DOI 10.1073/pnas.85.9.3110; Saqi M, 1995, PROTEIN ENG, V8, P1069, DOI 10.1093/protein/8.11.1069; Sassetti C, 2000, J BIOL CHEM, V275, P9001, DOI 10.1074/jbc.275.12.9001; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; St Croix B, 2000, SCIENCE, V289, P1197; SUTHERLAND DR, 1992, J IMMUNOL, V148, P1458; SUZUKI K, 1987, EMBO J, V6, P1891, DOI 10.1002/j.1460-2075.1987.tb02448.x; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wang W, 2000, J BIOL CHEM, V275, P22942, DOI 10.1074/jbc.M001760200; WELLER A, 1992, J BIOL CHEM, V267, P15176; Wood MJ, 2000, NAT STRUCT BIOL, V7, P200; WOOTTON JC, 1994, COMPUT CHEM, V18, P269, DOI 10.1016/0097-8485(94)85023-2	38	113	132	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7408	7414		10.1074/jbc.M009604200	http://dx.doi.org/10.1074/jbc.M009604200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11084048	hybrid			2022-12-25	WOS:000167442900076
J	Ogasawara, A; Arakawa, T; Kaneda, T; Takuma, T; Sato, T; Kaneko, H; Kumegawa, M; Hakeda, Y				Ogasawara, A; Arakawa, T; Kaneda, T; Takuma, T; Sato, T; Kaneko, H; Kumegawa, M; Hakeda, Y			Fluid shear stress-induced cyclooxygenase-2 expression is mediated by C/EBP beta, cAMP-response element-binding protein, and AP-1 in osteoblastic MC3T3-E1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-KAPPA-B; VASCULAR ENDOTHELIAL-CELLS; MESSENGER-RNA EXPRESSION; SIGNAL-TRANSDUCTION; NUCLEAR-FACTOR; GENE-EXPRESSION; BONE-FORMATION; TRANSCRIPTION; ACTIVATION; INDUCTION	Mechanical loading is crucial for maintenance of bone integrity-and architecture, and prostaglandins are an important mediator of mechanosensing, Cyclooxygenase-2 (COX-2), an inducible isoform of prostaglandin G/H synthase, is induced by mechanical loading-derived fluid shear stress in bone-forming cells such as osteoblasts and osteocytes. In this study, we investigated transcription factor and transcriptional regulatory elements responsible for the shear stress-induced COX-2 expression in osteoblastic MC3T3-E1 cells. When the cells were transfected with luciferase-reporter plasmids including the 5'-flanking region of the murine cox-2 gene, the fluid shear stress increased the luciferase activities, consistent with the induction of COX-2 mRNA and protein expression. Deletion analysis of the promoter region revealed that the shear stress-induced luciferase responses were regulated by two regions, -172 to -100 base pair (bp) and -79 to -46 bp, of the cox-2 promoter, in which putative cis-elements of C/EBP beta, AP-1, cAMP-response element-binding protein (CREB), and E box are included. Mutation of sites of C/EBP beta, AP-1, and/or cAMP-response element decreased the shear stress-induced luciferase activities, whereas mutation of the E box did not affect the responses. In an electrophoretic mobility shift assay, shear stress enhanced nuclear extract binding to double-stranded oligonucleotide probes containing C/EBP beta and AP-1-binding:motifs, and the bands of the complexes were supershifted by the addition of antibody specific for each regulator. Although the binding activity of CREB toward its probe was unaffected by shear stress, the phosphorylation of CREB was enhanced by the stress. These data suggest that C/EBP beta, AP-1, and CREB play crucial roles in the shear stress-induced cox-e expression in osteoblasts.	Meikai Univ, Sch Dent, Dept Oral Anat, Sakado, Saitama 3500283, Japan; Hlth Sci Univ Hokkaido, Sch Dent, Dept Oral Biochem, Ishikari, Hokkaido 0610293, Japan	Meikai University; Health Sciences University of Hokkaido	Hakeda, Y (corresponding author), Meikai Univ, Sch Dent, Dept Oral Anat, Sakado, Saitama 3500283, Japan.	y-hakeda@dent.meikai.ac.jp						Adams DS, 2000, J CELL BIOCHEM, V77, P221, DOI 10.1002/(SICI)1097-4644(20000501)77:2<221::AID-JCB6>3.0.CO;2-V; Ajubi NE, 1999, AM J PHYSIOL-ENDOC M, V276, pE171, DOI 10.1152/ajpendo.1999.276.1.E171; Akhouayri O, 2000, J CELL BIOCHEM, V76, P217, DOI 10.1002/(SICI)1097-4644(20000201)76:2<217::AID-JCB6>3.3.CO;2-B; BENBROOK DM, 1990, ONCOGENE, V5, P295; Bhullar IS, 1998, J BIOL CHEM, V273, P30544, DOI 10.1074/jbc.273.46.30544; BRUNNER C, 1993, P NATL ACAD SCI USA, V90, P11643, DOI 10.1073/pnas.90.24.11643; Burger EH, 1999, FASEB J, V13, pS101, DOI 10.1096/fasebj.13.9001.s101; Chambers TJ, 1999, OSTEOARTHR CARTILAGE, V7, P422, DOI 10.1053/joca.1998.0231; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Chen NX, 2000, AM J PHYSIOL-CELL PH, V278, pC989, DOI 10.1152/ajpcell.2000.278.5.C989; Chow JWM, 1996, CALCIFIED TISSUE INT, V59, P117, DOI 10.1007/s002239900097; Cowin SC, 1998, BONE, V22, p119S, DOI 10.1016/S8756-3282(98)00011-8; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; Curtis J, 1999, J NEUROSCI RES, V58, P88, DOI 10.1002/(SICI)1097-4547(19991001)58:1<88::AID-JNR9>3.3.CO;2-I; Daly RM, 1999, J BONE MINER RES, V14, P1222, DOI 10.1359/jbmr.1999.14.7.1222; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; DECESARE D, 1995, ONCOGENE, V11, P365; DUNCAN RL, 1995, CALCIFIED TISSUE INT, V57, P344, DOI 10.1007/BF00302070; Forwood MR, 1996, J BONE MINER RES, V11, P1688; Go YM, 1998, AM J PHYSIOL-HEART C, V275, pH1898, DOI 10.1152/ajpheart.1998.275.5.H1898; HAKEDA Y, 1987, ENDOCRINOLOGY, V121, P1966, DOI 10.1210/endo-121-6-1966; HAKEDA Y, 1986, J CELL PHYSIOL, V128, P155, DOI 10.1002/jcp.1041280204; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Ishida T, 1997, ANN NY ACAD SCI, V811, P12, DOI 10.1111/j.1749-6632.1997.tb51984.x; Jadvar H, 2000, AVIAT SPACE ENVIR MD, V71, P640; Jee W.S.S., 1999, Morphologie, V83, P25; Jobin C, 1998, IMMUNOLOGY, V95, P537; Joldersma M, 2000, J BIOMECH, V33, P53, DOI 10.1016/S0021-9290(99)00172-4; Kannus P, 1996, J BONE MINER RES, V11, P1339; KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; KISSANE JM, 1958, J BIOL CHEM, V233, P184; KleinNulend J, 1996, J CELL PHYSIOL, V168, P1, DOI 10.1002/(SICI)1097-4652(199607)168:1<1::AID-JCP1>3.0.CO;2-T; KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45; Miller C, 1998, J CELL BIOCHEM, V69, P392, DOI 10.1002/(SICI)1097-4644(19980615)69:4<392::AID-JCB2>3.3.CO;2-Z; Minden A, 1997, BBA-REV CANCER, V1333, pF85, DOI 10.1016/S0304-419X(97)00018-8; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Newton R, 1997, FEBS LETT, V418, P135, DOI 10.1016/S0014-5793(97)01362-8; NICHOLS M, 1992, EMBO J, V11, P3337, DOI 10.1002/j.1460-2075.1992.tb05412.x; Owan I, 1997, AM J PHYSIOL-CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; PERRONE CE, 1995, J BIOL CHEM, V270, P2099, DOI 10.1074/jbc.270.5.2099; Pitsillides AA, 1995, FASEB J, V9, P1614, DOI 10.1096/fasebj.9.15.8529841; RAABCULLEN DM, 1994, CALCIFIED TISSUE INT, V55, P473, DOI 10.1007/BF00298562; Raisz LG, 1999, OSTEOARTHR CARTILAGE, V7, P419, DOI 10.1053/joca.1998.0230; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Resnick N, 1997, ADV EXP MED BIOL, V430, P155; Rolli M, 1999, J BIOL CHEM, V274, P19559, DOI 10.1074/jbc.274.28.19559; SASSONECORSI P, 1990, ONCOGENE, V5, P427; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Smalt R, 1997, AM J PHYSIOL-ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; SODEK J, 1995, ANN NY ACAD SCI, V760, P223, DOI 10.1111/j.1749-6632.1995.tb44633.x; Suzawa T, 2000, ENDOCRINOLOGY, V141, P1554, DOI 10.1210/en.141.4.1554; Turner C H, 1998, J Orthop Sci, V3, P346, DOI 10.1007/s007760050064; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; Westbroek I, 2000, BIOCHEM BIOPH RES CO, V268, P414, DOI 10.1006/bbrc.2000.2154; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; XIE WL, 1994, MOL CELL BIOL, V14, P6531, DOI 10.1128/MCB.14.10.6531; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315	61	130	135	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7048	7054		10.1074/jbc.M008070200	http://dx.doi.org/10.1074/jbc.M008070200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11092885	hybrid			2022-12-25	WOS:000167442900028
J	Rajan, S; Wischmeyer, E; Karschin, C; Preisig-Muller, R; Grzeschik, KH; Daut, J; Karschin, A; Derst, C				Rajan, S; Wischmeyer, E; Karschin, C; Preisig-Muller, R; Grzeschik, KH; Daut, J; Karschin, A; Derst, C			THIK-1 and THIK-2, a novel subfamily of tandem pore domain K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYUNSATURATED FATTY-ACIDS; TREK-1 POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; CLONING; TASK; LOCALIZATION; MEMBER; FAMILY; TRAAK; PH	Two cDNAs:encoding novel K+ channels, THIK-1 and THIK-2 (tandem pore domain halothane inhibited K+. channel), were isolated from rat brain. The proteins of 405 and 430 amino acids were 58% identical to each other. Homology analysis showed that the novel channels form a separate subfamily among tandem pore domain:K+ channels. The genes of the human orthologs were identified as human genomic data base entries. They possess one intron each and were assigned to chromosomal region 14q24.1-14q24.3 (human (h) THIK-1) and 2p22-2p21 (hTHIK-2), In rat (r), THIK-1 (rTHIK-1) is expressed ubiquitously; rTHIK-2 expression was found in; several tissues including brain and kidney. In situ hybridization:of brain slices showed that rTHIK-2 is strongly expressed in most brain regions, whereas rTHIK-1 expression is more restricted. Heterologous expression of rTHIK-1 in Xenopus oocytes revealed a K+ channel displaying weak inward rectification in symmetrical K+ solution. The current was enhanced by arachidonic acid and inhibited by halothane, rTHIK-2 did not functionally express. Confocal microscopy of oocytes injected with green fluorescent protein-tagged rTHIK-1 or rTHHK-2 showed that both channel subunits are targeted to the outer membrane. However, coinjection of, rTHIK-2 did not affect the currents induced by rTHIK-1, indicating that the two channel subunits do not form heteromers.	Univ Marburg, Inst Humangenet, D-35032 Marburg, Germany; Univ Marburg, Inst Normal & Pathol Physiol, D-35032 Marburg, Germany; Max Planck Inst Biophys Chem, D-37070 Gottingen, Germany	Philipps University Marburg; Philipps University Marburg; Max Planck Society	Karschin, A (corresponding author), Univ Marburg, Inst Humangenet, D-35032 Marburg, Germany.							Arrighi I, 1998, FEBS LETT, V425, P310, DOI 10.1016/S0014-5793(98)00260-9; Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Chavez RA, 1999, J BIOL CHEM, V274, P7887, DOI 10.1074/jbc.274.12.7887; Czirjak G, 2000, MOL ENDOCRINOL, V14, P863, DOI 10.1210/me.14.6.863; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; Gyapay G, 1996, HUM MOL GENET, V5, P339, DOI 10.1093/hmg/5.3.339; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; Kim Y, 1999, AM J PHYSIOL-HEART C, V277, pH1669, DOI 10.1152/ajpheart.1999.277.5.H1669; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 1998, GENOMICS, V51, P478, DOI 10.1006/geno.1998.5397; Lesage F, 2000, J BIOL CHEM, V275, P28398, DOI 10.1074/jbc.M002822200; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 2000, FEBS LETT, V471, P137, DOI 10.1016/S0014-5793(00)01388-0; Lesage F, 1996, EMBO J, V15, P1004, DOI 10.1002/j.1460-2075.1996.tb00437.x; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Maingret F, 1999, J BIOL CHEM, V274, P1381, DOI 10.1074/jbc.274.3.1381; Meadows HJ, 2000, PFLUG ARCH EUR J PHY, V439, P714, DOI 10.1007/s004240050997; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 2000, J BIOL CHEM, V275, P28722, DOI 10.1074/jbc.M003755200; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Salinas M, 1999, J BIOL CHEM, V274, P11751, DOI 10.1074/jbc.274.17.11751; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Wang ZW, 1999, ANN NY ACAD SCI, V868, P286, DOI 10.1111/j.1749-6632.1999.tb11294.x	32	139	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7302	7311		10.1074/jbc.M008985200	http://dx.doi.org/10.1074/jbc.M008985200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11060316	hybrid			2022-12-25	WOS:000167442900062
J	Minopoli, G; de Candia, P; Bonetti, A; Faraonio, R; Zambrano, N; Russo, T				Minopoli, G; de Candia, P; Bonetti, A; Faraonio, R; Zambrano, N; Russo, T			The beta-amyloid precursor protein functions as a cytosolic anchoring site that prevents Fe65 nuclear translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; INTRACELLULAR DOMAIN; TRANSCRIPTION FACTOR; CYTOPLASMIC DOMAIN; ALZHEIMERS-DISEASE; SECRETASE CLEAVAGE; ADAPTER PROTEINS; CELL-ADHESION; INTERACTS; BRAIN	In this study we addressed the question of the intracellular localization of Fe65, an adaptor protein interacting with the beta -amyloid precursor protein (APP) and with the transcription factor CP2/LSF/BP1. By using tagged Fe65 expression vectors, we observed that a significant fraction of Fe65 is localized in the nucleus of transfected COS7 cells. Furthermore, the isolation of nuclei from untransfected PC12 cells allowed us to observe that a part of the endogenous Fe65 is present in the nuclear extract. The analysis of Fe65 mutant constructs demonstrated that the region of the protein required for its nuclear translocation includes the WW domain, and that, on the other hand, a small fragment of 100 residues, including this WW domain, contains enough structural information to target a reporter protein (green fluorescent protein (GFP)-GFP) to the nucleus. To evaluate whether the Fe65-APP interaction could affect Fe65 intracellular trafficking, COS7 cells were cotransfected with APP(695) or APP(751) and with GFP-Fe65 expression vectors. These experiments demonstrated that Fe65 is no longer translocated to the nucleus when the cells overexpress APP, whereas the nuclear targeting of GFP-Fe65 mutants, unable to interact with APP, is unaffected by the coexpression of APP, thus suggesting that the interaction with APP anchors Fe65 in the cytosol.	Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, I-80131 Naples, Italy	University of Naples Federico II	Russo, T (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Via S Pansini 5, I-80131 Naples, Italy.		de Candia, Paola/HGC-8826-2022; Russo, Tommaso/K-1331-2016; faraonio, raffaella/K-3802-2018; de Candia, Paola/Z-1498-2019; Zambrano, Nicola/B-9352-2014	de Candia, Paola/0000-0003-4767-446X; Russo, Tommaso/0000-0003-4426-0106; de Candia, Paola/0000-0003-4767-446X; Zambrano, Nicola/0000-0001-9395-3481; Faraonio, Raffaella/0000-0002-7040-6781	Telethon [E.0522] Funding Source: Medline	Telethon(Fondazione Telethon)		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1999, J NEUROSCI, V19, P1307; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Borg JP, 1998, J BIOL CHEM, V273, P14761, DOI 10.1074/jbc.273.24.14761; Bressler SL, 1996, HUM MOL GENET, V5, P1589, DOI 10.1093/hmg/5.10.1589; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Chow NW, 1996, J BIOL CHEM, V271, P11339, DOI 10.1074/jbc.271.19.11339; De Strooper B, 2000, J CELL SCI, V113, P1857; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Duilio A, 1998, BIOCHEM J, V330, P513, DOI 10.1042/bj3300513; Ermekova KS, 1997, J BIOL CHEM, V272, P32869, DOI 10.1074/jbc.272.52.32869; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Fagotto F, 1996, J CELL BIOL, V132, P1105, DOI 10.1083/jcb.132.6.1105; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; FARAONIO R, 1994, NUCLEIC ACIDS RES, V22, P4876, DOI 10.1093/nar/22.23.4876; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Guenette SY, 1996, P NATL ACAD SCI USA, V93, P10832, DOI 10.1073/pnas.93.20.10832; Guenette SY, 1999, J NEUROCHEM, V73, P985, DOI 10.1046/j.1471-4159.1999.0730985.x; Homayouni R, 1999, J NEUROSCI, V19, P7507, DOI 10.1523/JNEUROSCI.19-17-07507.1999; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kaffman A, 1999, ANNU REV CELL DEV BI, V15, P291, DOI 10.1146/annurev.cellbio.15.1.291; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Kong M, 2000, EMBO J, V19, P1378, DOI 10.1093/emboj/19.6.1378; Koo EH, 1996, J CELL SCI, V109, P991; Lambert JC, 2000, HUM MOL GENET, V9, P2275, DOI 10.1093/oxfordjournals.hmg.a018918; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; MANIER LM, 1999, NEURON, V22, P313; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; McLoughlin DM, 1999, EUR J NEUROSCI, V11, P1988, DOI 10.1046/j.1460-9568.1999.00610.x; McLoughlin DM, 1996, FEBS LETT, V397, P197; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; Perez RG, 1996, J BIOL CHEM, V271, P9100, DOI 10.1074/jbc.271.15.9100; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; Sabo SL, 1999, J BIOL CHEM, V274, P7952, DOI 10.1074/jbc.274.12.7952; SAMBAMURTI K, 1992, J NEUROSCI RES, V33, P319, DOI 10.1002/jnr.490330216; Sastre M, 1998, J BIOL CHEM, V273, P22351, DOI 10.1074/jbc.273.35.22351; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SIMEONE A, 1994, DEV NEUROSCI-BASEL, V16, P53, DOI 10.1159/000112088; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Tanahashi H, 1999, BIOCHEM BIOPH RES CO, V255, P663, DOI 10.1006/bbrc.1999.0265; Tomita S, 1999, J BIOL CHEM, V274, P2243, DOI 10.1074/jbc.274.4.2243; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; YAN R, 1998, NATURE, V398, P525; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zheng PZ, 1998, P NATL ACAD SCI USA, V95, P14745, DOI 10.1073/pnas.95.25.14745	53	117	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6545	6550		10.1074/jbc.M007340200	http://dx.doi.org/10.1074/jbc.M007340200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11085987	hybrid			2022-12-25	WOS:000167261000064
J	Zong, XG; Stieber, J; Ludwig, A; Hofmann, F; Biel, M				Zong, XG; Stieber, J; Ludwig, A; Hofmann, F; Biel, M			A single histidine residue determines the pH sensitivity of the pacemaker channel HCN2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED CATION CURRENT; THALAMIC RELAY NEURONS; MOLECULAR CHARACTERIZATION; UP-REGULATION; S4-S5 LINKER; S4 DOMAIN; MODULATION; HEART; MUTATIONS; IDENTIFICATION	Hyperpolarization activated cyclic nucleotide-gated (HCN) cation channels control the rhythmic activity of heart and neuronal networks. The activation of these channels is regulated in a complex manner by hormones and neurotransmitters. In addition it was suggested that the channels may be controlled by the pH of the cytosol, Here we demonstrate that HCN2, a member of the HCN channel family, is directly modulated by the intracellular pH in the physiological range. Protons inhibit HCN2 channels by shifting the voltage dependence of channel activation to more negative voltages. By using site-directed mutagenesis, we have identified a single histidine residue (His-321) localized at the boundary between the voltage-sensing S4 helix and the cytoplasmic S4-S5 linker of the channel that is a major determinant of pH sensitivity. Replacement of His-321 by either arginine, glutamine, or glutamate results in channels that are no longer sensitive to shifts in intracellular pH. In contrast, cAMP-mediated modulation is completely intact in mutant channels indicating that His-321 is not involved in the molecular mechanism that controls modulation of HCN channel activity by cyclic nucleotides. Because His-321 is conserved in all four HCN channels known so far, regulation by intracellular pH is likely to constitute a general feature of both cardiac and neuronal pacemaker channels.	Univ Munich, Zentrum Pharmaforsch, Dept Pharm, D-81377 Munich, Germany; Tech Univ Munich, Inst Pharmakol & Toxikol, D-80802 Munich, Germany	University of Munich; Technical University of Munich	Biel, M (corresponding author), Univ Munich, Zentrum Pharmaforsch, Dept Pharm, Butenandtstr 7, D-81377 Munich, Germany.	mbiel@cup.uni-muenchen.de	Biel, Martin/G-1175-2014	Biel, Martin/0000-0002-9974-3052				Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Bal T, 1996, NEURON, V17, P297, DOI 10.1016/S0896-6273(00)80161-0; Beaumont V, 2000, NAT NEUROSCI, V3, P133, DOI 10.1038/72072; Biel M, 1999, REV PHYSIOL BIOCH P, V136, P165, DOI 10.1007/BFb0032324; BROWN HF, 1977, J PHYSIOL-LONDON, V271, P783, DOI 10.1113/jphysiol.1977.sp012026; Budde T, 1997, J PHYSIOL-LONDON, V503, P79, DOI 10.1111/j.1469-7793.1997.079bi.x; Carmeliet E, 1999, PHYSIOL REV, V79, P917, DOI 10.1152/physrev.1999.79.3.917; Chen J, 2000, J BIOL CHEM, V275, P36465, DOI 10.1074/jbc.M007034200; de Curtis M, 1998, J NEUROSCI, V18, P7543; DIFRANCESCO D, 1994, J PHYSIOL-LONDON, V474, P473, DOI 10.1113/jphysiol.1994.sp020038; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DIFRANCESCO D, 1981, J PHYSIOL-LONDON, V314, P359, DOI 10.1113/jphysiol.1981.sp013713; DiFrancesco D., 1996, MOL PHYSL PHARM CARD, P31; FAIN GL, 1978, NATURE, V272, P467, DOI 10.1038/272467a0; Franqueza L, 1999, J BIOL CHEM, V274, P21063, DOI 10.1074/jbc.274.30.21063; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; Horn R, 2000, NEURON, V25, P511, DOI 10.1016/S0896-6273(00)81055-7; Ingram SL, 1996, J PHYSIOL-LONDON, V492, P97, DOI 10.1113/jphysiol.1996.sp021292; Ishii TM, 1999, J BIOL CHEM, V274, P12835, DOI 10.1074/jbc.274.18.12835; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 1999, EMBO J, V18, P2323, DOI 10.1093/emboj/18.9.2323; Luthi A, 1998, NEURON, V20, P553, DOI 10.1016/S0896-6273(00)80994-0; Magee JC, 1999, NAT NEUROSCI, V2, P508, DOI 10.1038/9158; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; Moosmang S, 1999, BIOL CHEM, V380, P975, DOI 10.1515/BC.1999.121; MORONI A, 2000, J PHYSIOL-LONDON, V439, P618; Munsch T, 1999, J PHYSIOL-LONDON, V519, P505, DOI 10.1111/j.1469-7793.1999.0505m.x; Munsch T, 1999, J PHYSIOL-LONDON, V519, P493, DOI 10.1111/j.1469-7793.1999.0493m.x; Pape HC, 1996, ANNU REV PHYSIOL, V58, P299, DOI 10.1146/annurev.ph.58.030196.001503; PAPE HC, 1992, NEURON, V9, P441, DOI 10.1016/0896-6273(92)90182-D; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Santoro B, 2000, J NEUROSCI, V20, P5264, DOI 10.1523/JNEUROSCI.20-14-05264.2000; Santoro B, 1997, P NATL ACAD SCI USA, V94, P14815, DOI 10.1073/pnas.94.26.14815; Seifert R, 1999, P NATL ACAD SCI USA, V96, P9391, DOI 10.1073/pnas.96.16.9391; Thoby-Brisson M, 2000, J NEUROSCI, V20, P2994; Vaca L, 2000, FEBS LETT, V479, P35, DOI 10.1016/S0014-5793(00)01837-8; Vaccari T, 1999, BBA-GENE STRUCT EXPR, V1446, P419, DOI 10.1016/S0167-4781(99)00092-5; WOLLMUTH LP, 1992, J GEN PHYSIOL, V100, P749, DOI 10.1085/jgp.100.5.749; YANAGIHARA K, 1980, PFLUG ARCH EUR J PHY, V385, P11, DOI 10.1007/BF00583909; YATANI A, 1990, SCIENCE, V249, P1163, DOI 10.1126/science.1697697	42	46	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6313	6319		10.1074/jbc.M010326200	http://dx.doi.org/10.1074/jbc.M010326200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096117	hybrid			2022-12-25	WOS:000167261000035
J	Malek, RL; Toman, RE; Edsall, LC; Wong, S; Chiu, J; Letterle, CA; Van Brocklyn, JR; Milstien, S; Spiegel, S; Lee, NH				Malek, RL; Toman, RE; Edsall, LC; Wong, S; Chiu, J; Letterle, CA; Van Brocklyn, JR; Milstien, S; Spiegel, S; Lee, NH			Nrg-1 belongs to the endothelial differentiation gene family of G protein-coupled sphingosime-1-phosphate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOSINE 1-PHOSPHATE RECEPTOR; NERVE GROWTH-FACTOR; MULTIPLE SIGNALING PATHWAYS; M1 MUSCARINIC ACETYLCHOLINE; JUN NH2-TERMINAL KINASE; II TYPE-2 RECEPTORS; LYSOPHOSPHATIDIC ACID; MOLECULAR-CLONING; REGULATED KINASE; CELL-MIGRATION	The previously cloned rat nerve growth factor-regulated G protein-coupled receptor NRG-1 (Glickman, M., Malek, R. L., Kwitek-Black, A. E., Jacob, H. J., and Lee N. H. (1999) Mot Cell. Neurosci. 14, 141-52), also known as EDG-8, binds sphingosine-l-phosphate (S1P) with high affinity and specificity, In this paper we examined the signal transduction pathways regulated by the binding of SIP to EDG-8. In Chinese hamster ovary cells heterologously expressing EDG-8, SIP inhibited forskolin-induced cAMP accumulation and activated c-Jun NH2-terminal kinase. Surprisingly, S1P inhibited serum-induced activation of extracellular regulated protein kinase 1 and 2 (ERK1/2). Treatment with pertussis toxin, which ADP-ribosylates and inactivates G(i), blacked S1P-mediated inhibition of cAMP accumulation, but had no effect on c-Jun NH2-terminal kinase activation or inhibition of ERK1/2. The inhibitory effect of SIP on ERK1/2 activity was abolished by treatment with orthovanadate, suggesting the involvement of a tyrosine phosphatase. A subunit selective [S-35] guanosine 5'-3-O-(thio)triphosphate binding assay demonstrates that; EDG-8 activated G(i/o) and G(12) but not G(s) and G(q/11) in response to S1P. In agreement, EDG-8 did not stimulate phosphoinositide turnover or cAMP accumulation. The ability of S1P to induce mitogenesis in cells expressing the EDG-1 subfamily of G protein-coupled receptors is well characterized. In contrast, SIP inhibited proliferation in Chinese hamster ovary cells expressing EDG-8 but not empty vector. The antiproliferative effect, like SIP-mediated ERK1/2 inhibition, was orthovanadate-sensitive and pertussis toxin-insensitive. Our results indicate that EDG-8, a member of the EDG-1 subfamily, couples to unique signaling pathways.	Inst Genome Res, Dept Mol & Cellular Biol, Rockville, MD 20850 USA; Georgetown Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Georgetown Univ, Med Ctr, Interdisciplinary Program Neurosci, Washington, DC 20007 USA; NIMH, Lab Cellular & Mol Regulat, Bethesda, MD 20892 USA	J. Craig Venter Institute; Georgetown University; University System of Ohio; Ohio State University; Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Lee, NH (corresponding author), Inst Genome Res, Dept Mol & Cellular Biol, 9712 Med Ctr Dr, Rockville, MD 20850 USA.	nhlee@tigr.org	Van Brocklyn, Jim/A-9733-2010		NCI NIH HHS [CA61774] Funding Source: Medline; NINDS NIH HHS [NS352321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH001039, Z01MH001039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Alexandrov A, 1999, BIOCHEM BIOPH RES CO, V261, P372, DOI 10.1006/bbrc.1999.1015; An SZ, 1998, J CELL BIOCHEM, P147; An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Ancellin N, 1999, J BIOL CHEM, V274, P18997, DOI 10.1074/jbc.274.27.18997; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bedecs K, 1997, BIOCHEM J, V325, P449, DOI 10.1042/bj3250449; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; Collins LR, 1996, J BIOL CHEM, V271, P17349, DOI 10.1074/jbc.271.29.17349; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fan WT, 1998, CURR BIOL, V8, P935, DOI 10.1016/S0960-9822(07)00376-4; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Fischer TA, 1998, AM J PHYSIOL-HEART C, V275, pH906, DOI 10.1152/ajpheart.1998.275.3.H906; Glickman M, 1999, MOL CELL NEUROSCI, V14, P141, DOI 10.1006/mcne.1999.0776; Gonda K, 1999, BIOCHEM J, V337, P67, DOI 10.1042/0264-6021:3370067; GOODEMOTE KA, 1995, J BIOL CHEM, V270, P10272, DOI 10.1074/jbc.270.17.10272; Graler MH, 1998, GENOMICS, V53, P164, DOI 10.1006/geno.1998.5491; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HLA T, 1990, J BIOL CHEM, V265, P9308; Horiuchi M, 1999, TRENDS ENDOCRIN MET, V10, P391, DOI 10.1016/S1043-2760(99)00191-5; Huang XC, 1996, J BIOL CHEM, V271, P15635, DOI 10.1074/jbc.271.26.15635; Im DS, 2000, J BIOL CHEM, V275, P14281, DOI 10.1074/jbc.275.19.14281; Kimura T, 2000, BIOCHEM J, V348, P71, DOI 10.1042/0264-6021:3480071; Kon J, 1999, J BIOL CHEM, V274, P23940, DOI 10.1074/jbc.274.34.23940; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; LADO DC, 1994, GENE, V149, P331, DOI 10.1016/0378-1119(94)90171-6; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1996, J BIOL CHEM, V271, P11272, DOI 10.1074/jbc.271.19.11272; Lee MJ, 1998, J BIOL CHEM, V273, P22105, DOI 10.1074/jbc.273.34.22105; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee NH, 1998, J BIOL CHEM, V273, P22317, DOI 10.1074/jbc.273.35.22317; LEE NH, 1995, P NATL ACAD SCI USA, V92, P8303, DOI 10.1073/pnas.92.18.8303; LEE NH, 1993, J BIOL CHEM, V268, P7949; Lee NH, 1996, MOL PHARMACOL, V50, P140; MACLENNAN AJ, 1994, MOL CELL NEUROSCI, V5, P201, DOI 10.1006/mcne.1994.1024; Malek RL, 1999, J BIOL CHEM, V274, P35499, DOI 10.1074/jbc.274.50.35499; Masana MI, 1995, RECEPTOR CHANNEL, V3, P255; Meier R, 1996, EUR J BIOCHEM, V236, P796, DOI 10.1111/j.1432-1033.1996.00796.x; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; Okamoto H, 1999, BIOCHEM BIOPH RES CO, V260, P203, DOI 10.1006/bbrc.1999.0886; Okamoto H, 1998, J BIOL CHEM, V273, P27104, DOI 10.1074/jbc.273.42.27104; Olivera A, 1999, J CELL BIOL, V147, P545, DOI 10.1083/jcb.147.3.545; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Sato K, 1999, FEBS LETT, V443, P25, DOI 10.1016/S0014-5793(98)01676-7; Sato K, 1999, MOL PHARMACOL, V55, P126, DOI 10.1124/mol.55.1.126; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Van Brocklyn JR, 1999, J BIOL CHEM, V274, P4626, DOI 10.1074/jbc.274.8.4626; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; VoynoYasenetskaya TA, 1996, J BIOL CHEM, V271, P21081, DOI 10.1074/jbc.271.35.21081; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Yamaguchi F, 1996, BIOCHEM BIOPH RES CO, V227, P608, DOI 10.1006/bbrc.1996.1553; Yamazaki Y, 2000, BIOCHEM BIOPH RES CO, V268, P583, DOI 10.1006/bbrc.2000.2162; Zondag GCM, 1998, BIOCHEM J, V330, P605, DOI 10.1042/bj3300605	62	107	110	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5692	5699		10.1074/jbc.M003964200	http://dx.doi.org/10.1074/jbc.M003964200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11069896	hybrid			2022-12-25	WOS:000167115100040
J	Filipenko, NR; Waisman, DM				Filipenko, NR; Waisman, DM			The C terminus of annexin II mediates binding to F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EZRIN PROTEIN FAMILY; PLASMA-MEMBRANE; ERM PROTEINS; LIGHT-CHAIN; II(2)P11(2) COMPLEX; CELL-ADHESION; CALPACTIN-I; MDCK CELLS; CYTOSKELETON; RHO	Annexin II heterotetramer (AIIt) is a multifunctional Ca2+-binding protein composed of two 11-kDa subunits and two annexin II subunits, The annexin II subunit contains the binding sites for anionic phospholipids, heparin, and F-actin, whereas the pll subunit provides a regulatory function. The F-actin-binding site is presently unknown. In the present study we have utilized site-directed mutagenesis to create annexin II mutants with truncations in the C terminus of the molecule. Interestingly, a mutant annexin II lacking its C-terminal 16, 13, or 9 amino acids was unable to bind to F-actin but still retained its ability to interact with both anionic phospholipids and heparin, Recombinant AIIt, composed of wild-type pll subunits and the mutant annexin II subunits, was also unable to bundle F-actin, This loss of F-actin bundling activity was directly attributable to the inability of mutant AIIt to bind F-actin, These results establish for the first time that the annexin II C-terminal amino acid residues, LLYLCGGDD, participate in F-actin binding.	Univ Calgary, Fac Med, Dept Biochem, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Mol Biol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada; Univ Calgary, Fac Med, Dept Oncol, Canc Biol Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary; University of Calgary; University of Calgary	Waisman, DM (corresponding author), Univ Calgary, Fac Med, Dept Biochem, Canc Biol Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.			Waisman, David/0000-0002-5097-9662	NCI NIH HHS [R01 CA 78639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; Aspenstrom P, 1999, EXP CELL RES, V246, P20, DOI 10.1006/excr.1998.4300; AZIM AC, 1995, J BIOL CHEM, V270, P17407, DOI 10.1074/jbc.270.29.17407; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Burger A, 1996, J MOL BIOL, V257, P839, DOI 10.1006/jmbi.1996.0205; Carlier MF, 1996, J BIOL CHEM, V271, P9231, DOI 10.1074/jbc.271.16.9231; Devineni N, 1999, BRAIN RES, V823, P129, DOI 10.1016/S0006-8993(99)01147-6; Feinberg J, 1996, BIOCHEM BIOPH RES CO, V222, P127, DOI 10.1006/bbrc.1996.0709; FOLLENIUSWUND A, 1993, BIOCHEM MOL BIOL INT, V29, P653; Gallagher PJ, 1997, MOL CELL BIOCHEM, V173, P51, DOI 10.1023/A:1006876318155; GARY R, 1995, MOL BIOL CELL, V6, P1061, DOI 10.1091/mbc.6.8.1061; Gautreau A, 1999, P NATL ACAD SCI USA, V96, P7300, DOI 10.1073/pnas.96.13.7300; Gerke V, 1997, BBA-MOL CELL RES, V1357, P129, DOI 10.1016/S0167-4889(97)00038-4; GLENNEY JR, 1987, J CELL BIOL, V104, P503, DOI 10.1083/jcb.104.3.503; GLENNEY JR, 1985, P NATL ACAD SCI USA, V82, P7884, DOI 10.1073/pnas.82.23.7884; GLENNEY JR, 1986, J BIOL CHEM, V261, P485; GLENNEY JR, 1990, PROG CLIN BIOL RES, V349, P135; HARDER T, 1993, J CELL SCI, V104, P1109; HARDER T, 1994, BBA-MOL CELL RES, V1223, P375, DOI 10.1016/0167-4889(94)90098-1; Hirao M, 1996, J CELL BIOL, V135, P37, DOI 10.1083/jcb.135.1.37; Hiscox S, 1999, J CELL SCI, V112, P3081; HITT AL, 1994, CURR OPIN CELL BIOL, V6, P120, DOI 10.1016/0955-0674(94)90125-2; Hotchin NA, 1996, CANCER SURV, V27, P311; IKEBUCHI NW, 1990, J BIOL CHEM, V265, P3392; JONES PG, 1992, J BIOL CHEM, V267, P13993; Kang HM, 1997, BIOCHEMISTRY-US, V36, P2041, DOI 10.1021/bi962569b; Kassam G, 1998, BIOCHEMISTRY-US, V37, P16958, DOI 10.1021/bi981713l; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; KHANNA NC, 1990, BIOCHEMISTRY-US, V29, P4852, DOI 10.1021/bi00472a015; Kotani H, 1997, ONCOGENE, V14, P1705, DOI 10.1038/sj.onc.1200998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lamb RF, 2000, NAT CELL BIOL, V2, P281, DOI 10.1038/35010550; Lim RWL, 1999, BIOCHEMISTRY-US, V38, P800, DOI 10.1021/bi981392d; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; Nachmias VT, 1993, CURR OPIN CELL BIOL, V5, P56, DOI 10.1016/S0955-0674(05)80008-0; Palmieri SJ, 2000, CELL MOTIL CYTOSKEL, V46, P285, DOI 10.1002/1097-0169(200008)46:4<285::AID-CM6>3.0.CO;2-N; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Pestonjamasp KN, 1997, J CELL BIOL, V139, P1255, DOI 10.1083/jcb.139.5.1255; POLLARD TD, 1994, ANNU REV CELL BIOL, V10, P207, DOI 10.1146/annurev.cellbio.10.1.207; Sagot I, 1997, FEBS LETT, V410, P229, DOI 10.1016/S0014-5793(97)00594-2; Takahashi K, 1997, J BIOL CHEM, V272, P23371, DOI 10.1074/jbc.272.37.23371; THIEL C, 1992, J CELL SCI, V103, P733; TURUNEN O, 1994, J CELL BIOL, V126, P1445, DOI 10.1083/jcb.126.6.1445; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; VanTroys M, 1996, EMBO J, V15, P201, DOI 10.1002/j.1460-2075.1996.tb00350.x; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; Yin HL, 1999, J BIOL CHEM, V274, P32529, DOI 10.1074/jbc.274.46.32529; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497; ZOKAS L, 1987, J CELL BIOL, V105, P2111, DOI 10.1083/jcb.105.5.2111	54	100	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5310	5315		10.1074/jbc.M009710200	http://dx.doi.org/10.1074/jbc.M009710200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11067857	hybrid			2022-12-25	WOS:000168484300104
J	Yang, SC; Sun, Y; Zhang, H				Yang, SC; Sun, Y; Zhang, H			The multimerization of human immunodeficiency virus type I Vif protein - A requirement for Vif function in the viral life cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS REVERSE TRANSCRIPTION; NONPERMISSIVE CELLS; T-LYMPHOCYTES; DNA-SYNTHESIS; HIV-1; MUTANTS; GAG; OLIGOMERIZATION; REPLICATION; EFFICIENCY	The Vif (virion infectivity factor protein of human immunodeficiency virus type I HIV-1) is essential for viral replication in vivo and productive infection of peripheral blood mononuclear cells, macrophages, and H9 T-cells. However, the molecular mechanism(s) of Vif remains unknown and needs to be further determined. In this report, we show that, like many other proteins encoded by HIV-1, Vif proteins possess a strong tendency toward self-association. In relatively native conditions, Vif proteins formed multimers in vitro, including dimers, trimers, or tetramers. Through in vivo binding assays such as coimmunoprecipitation and the mammalian two-hybrid system, we also demonstrated that Vif proteins could interact with each other within a cell, indicating that the multimerization of Vif proteins is not simply due to fortuitous aggregation. Further studies indicated that the domain affecting Vif self-association is located at the C terminus of this protein, especially the proline-enriched 151-164 region. Moreover, we found that a Vif mutant with deletion at amino acid 151-164 was unable to rescue the infectivity of vif-defective viruses generated from H9 T-cells, suggesting that the multimerization of Vif proteins could be important for Vif function in the viral life cycle. Our studies identified a new feature of Vif and should accelerate our understanding of its role in HIV-1 pathogenesis.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Infect Dis,Ctr Human Virol,Dorrance H Hamilto, Philadelphia, PA 19107 USA	Jefferson University	Zhang, H (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Med, Div Infect Dis,Ctr Human Virol,Dorrance H Hamilto, 1020 Locust St,Suite 329, Philadelphia, PA 19107 USA.				NIAID NIH HHS [R01 AI047720, R21 AI047720] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI047720, R01AI047720] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BLANC D, 1993, VIROLOGY, V193, P186, DOI 10.1006/viro.1993.1114; BOGERD H, 1993, J VIROL, V67, P2496, DOI 10.1128/JVI.67.5.2496-2502.1993; Bouyac M, 1997, J VIROL, V71, P9358, DOI 10.1128/JVI.71.12.9358-9365.1997; CIMINALE V, 1990, AIDS RES HUM RETROV, V6, P1281, DOI 10.1089/aid.1990.6.1281; COURCOUL M, 1995, J VIROL, V69, P2068, DOI 10.1128/JVI.69.4.2068-2074.1995; D'Aloja P, 1998, J VIROL, V72, P4308; Dornadula G, 2000, J VIROL, V74, P2594, DOI 10.1128/JVI.74.6.2594-2602.2000; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Frankel AD, 1998, ANNU REV BIOCHEM, V67, P1, DOI 10.1146/annurev.biochem.67.1.1; GABUZDA DH, 1992, J VIROL, V66, P6489, DOI 10.1128/JVI.66.11.6489-6495.1992; GABUZDA DH, 1994, J ACQ IMMUN DEF SYND, V7, P908; GONCALVES J, 1995, J VIROL, V69, P7196, DOI 10.1128/JVI.69.11.7196-7204.1995; Huvent I, 1998, J GEN VIROL, V79, P1069, DOI 10.1099/0022-1317-79-5-1069; Liu LX, 2000, J VIROL, V74, P5310, DOI 10.1128/JVI.74.11.5310-5319.2000; Madani N, 1998, J VIROL, V72, P10251, DOI 10.1128/JVI.72.12.10251-10255.1998; Naldini L, 1996, P NATL ACAD SCI USA, V93, P11382, DOI 10.1073/pnas.93.21.11382; Shimano R, 1998, BIOCHEM BIOPH RES CO, V242, P313, DOI 10.1006/bbrc.1997.7963; Simon JHM, 1999, J VIROL, V73, P2675, DOI 10.1128/JVI.73.4.2675-2681.1999; Simon JHM, 1997, J VIROL, V71, P5259, DOI 10.1128/JVI.71.7.5259-5267.1997; Simon JHM, 1999, J VIROL, V73, P2667, DOI 10.1128/JVI.73.4.2667-2674.1999; Simon JHM, 1998, NAT MED, V4, P1397, DOI 10.1038/3987; SOVA P, 1993, J VIROL, V67, P6322, DOI 10.1128/JVI.67.10.6322-6326.1993; TRONO D, 1995, CELL, V82, P189, DOI 10.1016/0092-8674(95)90306-2; VAISHNAV YN, 1991, ANNU REV BIOCHEM, V60, P577, DOI 10.1146/annurev.bi.60.070191.003045; VONSCHWEDLER U, 1993, J VIROL, V67, P4945, DOI 10.1128/JVI.67.8.4945-4955.1993; Yang XY, 1998, J BIOL CHEM, V273, P29879, DOI 10.1074/jbc.273.45.29879; ZHANG H, 1995, J VIROL, V69, P3929, DOI 10.1128/JVI.69.6.3929-3932.1995; Zhang H, 1996, P NATL ACAD SCI USA, V93, P12519, DOI 10.1073/pnas.93.22.12519; Zhang H, 2000, J VIROL, V74, P8252, DOI 10.1128/JVI.74.18.8252-8261.2000; ZHAO LJ, 1994, J BIOL CHEM, V269, P32131	30	86	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4889	4893		10.1074/jbc.M004895200	http://dx.doi.org/10.1074/jbc.M004895200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11071884	Green Accepted, hybrid			2022-12-25	WOS:000168484300050
J	Storch, S; Braulke, T				Storch, S; Braulke, T			Multiple C-terminal motifs of the 46-kDa mannose 6-phosphate receptor tail contribute to efficient binding of medium chains of AP-2 and AP-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GOLGI NETWORK LOCALIZATION; CASEIN KINASE-II; CYTOPLASMIC DOMAIN; SORTING SIGNALS; DI-LEUCINE; PHOSPHORYLATION SITE; LYSOSOMAL PROTEINS; CLATHRIN ADAPTERS; COMPLEX; CELLS	The interaction of adaptor protein (AP) complexes with signal structures in the cytoplasmic domains of membrane proteins is required for intracellular sorting. Tyrosine- or dileucine-based motifs have been reported to bind to medium chain subunits (mu) of AP-1, AP-2, or AP-3. In the present study, me have examined the interaction of the entire 67-amino acid cytoplasmic domain of the 46-kDa mannose B-phosphate receptor (MPR46-CT) containing tyrosine- as well as dileucine-based motifs with mu2 and mu 3A chains using the yeast two-hybrid system. Both mu2 and mu 3A bind specifically to the MPR46-CT. In contrast, mu 3A fails to bind to the cytoplasmic domain of the 300-kDa mannose 6-phosphate receptor. Mutational analysis of the MPR46-CT revealed that the tyrosine-based motif and distal sequences rich in acidic amino acid residues are sufficient for effective binding to mu2. However, the dileucine motif was found to be one part of a consecutive complex C-terminal structure comprising tyrosine and dileucine motifs as well as clusters of acidic residues necessary for efficient binding of mu 3k Alanine substitution of 2 or 4 acidic amino acid residues of this cluster reduces the binding to mu 3A much more than to mu2. The data suggest that the MPR46 is capable of interacting with different AP complexes using multiple partially overlapping sorting signals, which might depend on posttranslational modifications or subcellular localization of the receptor.	Univ Hamburg, Childrens Hosp, Dept Biochem, D-20246 Hamburg, Germany	University of Hamburg; University Medical Center Hamburg-Eppendorf	Braulke, T (corresponding author), Univ Hamburg, Childrens Hosp, Dept Biochem, Martinistr 52, D-20246 Hamburg, Germany.		Braulke, Thomas/AAV-9121-2020	Braulke, Thomas/0000-0002-2336-8532; Storch, Stephan/0000-0002-8807-5917				Blagoveshchenskaya AD, 1999, MOL BIOL CELL, V10, P3979, DOI 10.1091/mbc.10.11.3979; Bonifacino JS, 1999, J CELL BIOL, V145, P923, DOI 10.1083/jcb.145.5.923; Braulke T, 1996, Subcell Biochem, V27, P15; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; Breuer P, 1998, J BIOL CHEM, V273, P33254, DOI 10.1074/jbc.273.50.33254; Cowles CR, 1997, CELL, V91, P109, DOI 10.1016/S0092-8674(01)80013-1; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; DellAngelica EC, 1997, EMBO J, V16, P917, DOI 10.1093/emboj/16.5.917; Denzer K, 1997, BIOCHEM J, V326, P497, DOI 10.1042/bj3260497; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; KORNER C, 1994, J BIOL CHEM, V269, P16529; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Ohno H, 1996, J BIOL CHEM, V271, P29009, DOI 10.1074/jbc.271.46.29009; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Orsel JG, 2000, P NATL ACAD SCI USA, V97, P9047, DOI 10.1073/pnas.160251397; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; Owen DJ, 1998, SCIENCE, V282, P1327, DOI 10.1126/science.282.5392.1327; POHLMANN R, 1987, P NATL ACAD SCI USA, V84, P5575, DOI 10.1073/pnas.84.16.5575; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Rohrer J, 1996, J CELL BIOL, V132, P565, DOI 10.1083/jcb.132.4.565; SCHAFER W, 1995, EMBO J, V14, P2424, DOI 10.1002/j.1460-2075.1995.tb07240.x; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; Schweizer A, 1997, P NATL ACAD SCI USA, V94, P14471, DOI 10.1073/pnas.94.26.14471; Simmen T, 1999, J CELL SCI, V112, P45; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; VOORHEES P, 1995, EMBO J, V14, P4961, DOI 10.1002/j.1460-2075.1995.tb00179.x	35	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4298	4303		10.1074/jbc.M005548200	http://dx.doi.org/10.1074/jbc.M005548200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11071885	hybrid			2022-12-25	WOS:000166921200076
J	Zhang, XQ; Lee, MS; Zelivianski, S; Lin, MF				Zhang, XQ; Lee, MS; Zelivianski, S; Lin, MF			Characterization of a prostate-specific tyrosine phosphatase by mutagenesis and expression in human prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; RAT ACID-PHOSPHATASE; CARCINOMA-CELLS; PROTEIN PHOSPHATASE; PHOSPHOTYROSYL PHOSPHATASE; INDUCED TRANSFORMATION; SIGNAL-TRANSDUCTION; NEU ONCOGENE; HUMAN-BREAST; ACTIVE-SITE	The cellular form of human prostatic acid phosphatase (PAcP) is a neutral protein-tyrosine phosphatase (PTP) and may play a key role in regulating the growth and androgen responsiveness of prostate cancer cells. The functional role of the enzyme is at least due in part to its dephosphorylation of c-ErbB-2, an in vivo substrate of the enzyme. In this study, we investigated the molecular mechanism of phosphotyrosine dephosphorylation by cellular PAcP. We mutated several amino acid residues including one cysteine residue that was proposed to be involved in the PTP activity of the enzyme by serving as the phosphate acceptor. The cDNA constructs of mutant enzymes were transiently transfected into C-81 LNCaP and PC-3 human prostate cancer cells that lack the endogenous PAcP expression. The phosphotyrosine level of ErbB-2 in these transfected cells was subsequently analyzed. Our results demonstrated that the phosphotyrosine level of ErbB-2 in cells expressing H12A or D258A mutant PAcP is similar to that in control cells without PAcP expression, suggesting that these mutants are incapable of dephosphorylating ErbB-2, In contrast, cells expressing C183A, C281A, or wild-type PAcP had a decreased phosphotyrosine level of ErbB-2, compared with the control cells. Similar results were obtained from in vitro dephosphorylation of immunoprecipitated ErbB-2 by these mutant enzymes. Furthermore, transient expression of C183A, C281A, or the wild-type enzyme, but not H12A or D258A, decreased the growth rate of C-81 LNCaP cells. The data collectively indicate that His-la and Asp-258, but not Cys-183 or Cys-281, are required for the PTP activity of PAcP.	Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Nebraska Med Ctr 984525, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Sect Urol Surg, Dept Surg, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Eppley Canc Inst, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr, Dept Biochem & Mol Biol, Nebraska Med Ctr 984525, 600 S 42nd St, Omaha, NE 68198 USA.	mlin@unmc.edu	Zelivianski, Stanislav/G-3043-2010	LEE, MING-SHYUE/0000-0002-8673-5088; LEE, MING-SHYUE/0000-0002-5884-4535	NATIONAL CANCER INSTITUTE [R01CA072274, R01CA088184] Funding Source: NIH RePORTER; NCI NIH HHS [CA72274, CA88184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BISHOP JM, 1986, J CELL PHYSIOL, P1; BROWNSHIMER S, 1992, CANCER RES, V52, P478; Cao LG, 1998, J BIOL CHEM, V273, P21077, DOI 10.1074/jbc.273.33.21077; Chernoff J, 1999, J CELL PHYSIOL, V180, P173; Chu TM, 1998, J CLIN LIGAND ASSAY, V21, P24; Denu JM, 1998, CURR OPIN CHEM BIOL, V2, P633, DOI 10.1016/S1367-5931(98)80095-1; Dixon JE, 1996, RECENT PROG HORM RES, V51, P405; Falet H, 1996, FEBS LETT, V383, P165, DOI 10.1016/0014-5793(96)00232-3; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GARCIAARENAS R, 1995, MOL CELL ENDOCRINOL, V111, P29, DOI 10.1016/0303-7207(95)03544-H; Garton AJ, 1996, MOL CELL BIOL, V16, P6408; Halleen JM, 1998, ARCH BIOCHEM BIOPHYS, V352, P97, DOI 10.1006/abbi.1998.0600; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Hunter T, 1996, BIOCHEM SOC T, V24, P307, DOI 10.1042/bst0240307; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Jakob CG, 2000, PROSTATE, V42, P211, DOI 10.1002/(SICI)1097-0045(20000215)42:3<211::AID-PROS7>3.0.CO;2-U; Kenner KA, 1996, J BIOL CHEM, V271, P19810, DOI 10.1074/jbc.271.33.19810; LaCount MW, 1998, J BIOL CHEM, V273, P30406, DOI 10.1074/jbc.273.46.30406; LaMontagne KR, 1998, P NATL ACAD SCI USA, V95, P14094, DOI 10.1073/pnas.95.24.14094; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; LI HC, 1984, EUR J BIOCHEM, V138, P45, DOI 10.1111/j.1432-1033.1984.tb07879.x; Li LW, 2000, SEMIN IMMUNOL, V12, P75, DOI 10.1006/smim.2000.0209; Lin MF, 1996, BIOCHEM BIOPH RES CO, V226, P206, DOI 10.1006/bbrc.1996.1334; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; LIN MF, 1986, BIOCHEM J, V235, P351, DOI 10.1042/bj2350351; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; LIN MF, 1993, CELL MOL BIOL RES, V39, P739; LIN MF, 1992, CANCER RES, V52, P4600; LIN MF, 1994, DIFFERENTIATION, V57, P143, DOI 10.1046/j.1432-0436.1994.5720143.x; LIN MF, 1993, BIOCHEM BIOPH RES CO, V192, P413, DOI 10.1006/bbrc.1993.1431; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Liu F, 1998, MOL CELL BIOL, V18, P250, DOI 10.1128/MCB.18.1.250; Meng TC, 2000, ONCOGENE, V19, P2664, DOI 10.1038/sj.onc.1203576; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; MORRIS MF, 1989, CLIN CHIM ACTA, V182, P9, DOI 10.1016/0009-8981(89)90145-9; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; OSTANIN K, 1994, J BIOL CHEM, V269, P8971; Pulido R, 1998, EMBO J, V17, P7337, DOI 10.1093/emboj/17.24.7337; RUGGIERO M, 1993, FEBS LETT, V326, P294, DOI 10.1016/0014-5793(93)81811-D; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Streuli M, 1996, CURR OPIN CELL BIOL, V8, P182, DOI 10.1016/S0955-0674(96)80064-0; SUN H, 1994, TRENDS BIOCHEM SCI, V19, P480, DOI 10.1016/0968-0004(94)90134-1; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; van Huijsduijnen RH, 1998, GENE, V225, P1; VANETTEN RL, 1991, J BIOL CHEM, V266, P2313; VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104; VIHKO P, 1979, INVEST UROL, V16, P349; VIHKO P, 1993, P NATL ACAD SCI USA, V90, P799, DOI 10.1073/pnas.90.3.799; WOODFORDTHOMAS TA, 1992, J CELL BIOL, V117, P401, DOI 10.1083/jcb.117.2.401; YONEMURA Y, 1991, CANCER RES, V51, P1034; ZANDER NF, 1993, ONCOGENE, V8, P1175; Zelivianski S, 1998, BIOCHEM BIOPH RES CO, V245, P108, DOI 10.1006/bbrc.1998.8386; ZHAI YF, 1995, MOL CARCINOGEN, V14, P103, DOI 10.1002/mc.2940140206; Zhang M, 1998, J BIOL CHEM, V273, P21714, DOI 10.1074/jbc.273.34.21714; Zhang XQ, 1999, ARCH BIOCHEM BIOPHYS, V371, P70, DOI 10.1006/abbi.1999.1415; ZHANG ZY, 1994, ADV ENZYMOL RAMB, V68, P1; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	62	37	38	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2544	2550		10.1074/jbc.M006661200	http://dx.doi.org/10.1074/jbc.M006661200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11067847	hybrid			2022-12-25	WOS:000166784800035
J	Blanchard, DJ; Cicek, M; Chen, JL; Esen, A				Blanchard, DJ; Cicek, M; Chen, JL; Esen, A			Identification of beta-glucosidase aggregating factor (BGAF) and mapping of BGAF binding regions on maize beta-glucosidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYSTEMIC ACQUIRED-RESISTANCE; HYDROXAMIC ACIDS; AGLYCONE SPECIFICITY; DISEASE RESISTANCE; ESCHERICHIA-COLI; ZEA-MAYS; DEFENSE; ARABIDOPSIS; JASMONATE; EXPRESSION	In certain maize genotypes (nulls), beta -glucosidase does not enter the gel and therefore cannot be detected on zymograms, Such genotypes were initially thought to be homozygous for a null allele at the glu1 gene. We have shown that a beta -glucosidase aggregating factor (BGAF) is responsible for the null phenotype, and it specifically interacts with maize beta -glucosidases and forms large insoluble aggregates. To understand the mechanism of the beta -glucosidase-BGAF interaction, we constructed chimeric enzymes by domain swapping between the maize beta -glucosidase isozymes Glu1 and Gu2, to which BGAF binds, and the sorghum beta -glucosidase (dhurrinase) isozyme Dhr1, to which BGAF does not bind. The results of binding assays with 12 different chimeric enzymes showed that an N-terminal region (Glu(50)-Val(145)) and extreme C-terminal region (Phe(466)-Ala(512)) together form the BGAF binding site on the enzyme surface. In addition, we purified BGAF, determined its N-terminal sequence, amplified the BGAF cDNA by reverse transcriptase-polymerase chain reaction, expressed it in Escherichia coli, and showed that it encodes a protein whose binding and immunological properties are identical to the native BGAF isolated from maize tissues. A data base search revealed that BGAF is a member of the jasmonite-induced protein family. Interestingly, the deduced BGAF sequence contained an octapeptide sequence (G(P/R)WGGSGG) repeated twice. Each of these repeat units is postulated to be involved in forming a site for binding to maize beta -glucosidases and thus provides a plausible explanation for the divalent function of BGAF predicted from binding assays.	Virginia Polytech Inst & State Univ, Dept Biol, Blacksburg, VA 24061 USA	Virginia Polytechnic Institute & State University	Esen, A (corresponding author), Virginia Polytech Inst & State Univ, Dept Biol, Blacksburg, VA 24061 USA.							BANDARANAYAKE H, 1996, PLANT PHYSIOL, V110, P1048; BRZOBOHATY B, 1993, SCIENCE, V262, P1051, DOI 10.1126/science.8235622; Cicek M, 1999, BIOTECHNOL BIOENG, V63, P392, DOI 10.1002/(SICI)1097-0290(19990520)63:4&lt;392::AID-BIT2&gt;3.0.CO;2-M; Cicek M, 1998, PLANT PHYSIOL, V116, P1469, DOI 10.1104/pp.116.4.1469; Cicek M, 2000, J BIOL CHEM, V275, P20002, DOI 10.1074/jbc.M001609200; Czjzek M, 2000, P NATL ACAD SCI USA, V97, P13555, DOI 10.1073/pnas.97.25.13555; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; ESEN A, 1990, BIOCHEM GENET, V28, P319, DOI 10.1007/BF02401422; Esen A, 2000, PLANT PHYSIOL, V122, P563, DOI 10.1104/pp.122.2.563; FALK A, 1995, PLANT PHYSIOL, V108, P1369, DOI 10.1104/pp.108.4.1369; FIELDES MA, 1994, ELECTROPHORESIS, V15, P654, DOI 10.1002/elps.1150150192; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; Gorlach J, 1996, PLANT CELL, V8, P629, DOI 10.1105/tpc.8.4.629; GUSMAYER S, 1994, PLANT MOL BIOL, V26, P909, DOI 10.1007/BF00028858; HOPKE J, 1994, FEBS LETT, V352, P146, DOI 10.1016/0014-5793(94)00948-1; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Howe GA, 1996, PLANT CELL, V8, P2067, DOI 10.1105/tpc.8.11.2067; KAHLER AL, 1986, THEOR APPL GENET, V72, P15, DOI 10.1007/BF00261448; Knoester M, 1998, P NATL ACAD SCI USA, V95, P1933, DOI 10.1073/pnas.95.4.1933; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; MASSARDO F, 1994, PHYTOCHEMISTRY, V35, P873, DOI 10.1016/S0031-9422(00)90629-0; McConn M, 1997, P NATL ACAD SCI USA, V94, P5473, DOI 10.1073/pnas.94.10.5473; NIEMEYER HM, 1988, PHYTOCHEMISTRY, V27, P3349, DOI 10.1016/0031-9422(88)80731-3; Niemeyer HM, 1991, APHID PLANT INTERACT, P101; NISIUS A, 1988, PLANTA, V173, P474, DOI 10.1007/BF00958960; REESE ET, 1977, RECENT ADV PHYTOCHEM, V11, P311; REID LM, 1991, CROP SCI, V31, P1496, DOI 10.2135/cropsci1991.0011183X003100060020x; SAHI SV, 1990, P NATL ACAD SCI USA, V87, P3879, DOI 10.1073/pnas.87.10.3879; Staswick PE, 1998, PLANT J, V15, P747, DOI 10.1046/j.1365-313X.1998.00265.x; STUBER CW, 1977, BIOCHEM GENET, V15, P383, DOI 10.1007/BF00484468; Thomma BPHJ, 1998, P NATL ACAD SCI USA, V95, P15107, DOI 10.1073/pnas.95.25.15107; van Wees SCM, 2000, P NATL ACAD SCI USA, V97, P8711, DOI 10.1073/pnas.130425197; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Vijayan P, 1998, P NATL ACAD SCI USA, V95, P7209, DOI 10.1073/pnas.95.12.7209; XIE YS, 1991, CAN J BOT, V69, P677, DOI 10.1139/b91-090	36	35	35	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11895	11901		10.1074/jbc.M008872200	http://dx.doi.org/10.1074/jbc.M008872200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11096099	hybrid			2022-12-25	WOS:000168081800063
J	Gueven, N; Keating, KE; Chen, P; Fukao, T; Khanna, KK; Watters, D; Rodemann, PH; Lavin, MF				Gueven, N; Keating, KE; Chen, P; Fukao, T; Khanna, KK; Watters, D; Rodemann, PH; Lavin, MF			Epidermal growth factor sensitizes cells to ionizing radiation by down-regulating protein mutated in ataxia-telangiectasia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-PRODUCT; DNA-DAMAGE; ATM PROTEIN; MOUSE CDC21; IN-VITRO; P53; PHOSPHORYLATION; KINASE; SP1; DEPHOSPHORYLATION	Epidermal growth factor (EGF) has been reported to either sensitize or protect cells against ionizing radiation. We report here that EGF increases radiosensitivity in both human fibroblasts and lymphoblasts and downregulates both ATM (mutated in ataxia-telangiectasia (A-T)) and the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs). No further radiosensitization was observed in A-T cells after pretreatment with EGF. The down-regulation of ATM occurs at the transcriptional level. Concomitant with the down-regulation of ATM, the DNA binding activity of the transcription factor Spl decreased. A causal relationship was established between these:observations by demonstrating that upregulation of Spl DNA binding activity by granulocyte/ macrophage colony-stimulating factor rapidly reversed the EGF-induced decrease in ATM protein and restored radiosensitivity to normal levels. Failure to radiosensitize EGF-treated cells to the same extent as observed for A-T cells ban be explained by induction of ATM protein and kinase activity with time post-irradiation, Although ionizing radiation damage to DNA rapidly activates ATM kinase and cell cycle checkpoints, we have provided evidence for the first time that alteration in the amount of ATM protein occurs in response to both EGF and radiation exposure. Taken together these data support complex control of ATM function that has important repercussions for targeting ATM to improve radiotherapeutic benefit.	Queensland Inst Med Res, Queensland Canc Fund Res Lab, Brisbane, Qld 4029, Australia; Sect Radiobiol & Mol Environm Res, D-72076 Tubingen, Germany; Gifu Univ, Sch Med, Gifu 5008076, Japan; Univ Queensland, Dept Surg, Brisbane, Qld 4029, Australia	QIMR Berghofer Medical Research Institute; Gifu University; University of Queensland	Lavin, MF (corresponding author), Queensland Inst Med Res, Queensland Canc Fund Res Lab, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.		Khanna, Kum Kum/I-1747-2013; Lavin, Martin F/F-5961-2014; Watters, Dianne J/E-6007-2010	Lavin, Martin F/0000-0002-5940-4769; Watters, Dianne J/0000-0002-2555-5825; Khanna, Kum Kum/0000-0001-8650-5381; Guven, Nuri/0000-0003-3782-767X				Balaban N, 1996, BBA-MOL CELL RES, V1314, P147, DOI 10.1016/S0167-4889(96)00068-7; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAMISH H, 1994, INT J RADIAT BIOL, V65, P175, DOI 10.1080/09553009414550211; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BORELLINI F, 1993, J BIOL CHEM, V268, P7923; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Byrd PJ, 1996, HUM MOL GENET, V5, P145, DOI 10.1093/hmg/5.1.145; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; Chehab NH, 2000, GENE DEV, V14, P278; Clarke RA, 1998, J CLIN PATHOL-MOL PA, V51, P224, DOI 10.1136/mp.51.4.224; CORNFORTH MN, 1985, SCIENCE, V227, P1589, DOI 10.1126/science.3975628; Foray N, 1997, INT J RADIAT BIOL, V72, P271, DOI 10.1080/095530097143266; Fukao T, 1999, BLOOD, V94, P1998; GOTOFF SP, 1967, AM J DIS CHILD, V114, P617, DOI 10.1001/archpedi.1967.02090270073006; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; Imai T, 1996, GENOME RES, V6, P439, DOI 10.1101/gr.6.5.439; Imai T, 1997, GENOMICS, V42, P388, DOI 10.1006/geno.1997.4769; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Kavanagh BD, 1995, CLIN CANCER RES, V1, P1557; KHANNA KK, 1993, ONCOGENE, V8, P3307; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; KIMURA H, 1995, NUCLEIC ACIDS RES, V23, P2097, DOI 10.1093/nar/23.12.2097; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; KWOK TT, 1989, J NATL CANCER I, V81, P1020, DOI 10.1093/jnci/81.13.1020; KWOK TT, 1992, INT J RADIAT ONCOL, V22, P525, DOI 10.1016/0360-3016(92)90867-H; Ladenburger EM, 1997, CYTOGENET CELL GENET, V77, P268, DOI 10.1159/000134594; LADEROUTE KR, 1994, CANCER RES, V54, P1407; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin LF, 1999, INT J RADIAT BIOL, V75, P1201; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; Lim DS, 1998, P NATL ACAD SCI USA, V95, P10146, DOI 10.1073/pnas.95.17.10146; Ma TL, 2000, GENE DEV, V14, P2298, DOI 10.1101/gad.829500; Mortensen ER, 1997, J BIOL CHEM, V272, P16540, DOI 10.1074/jbc.272.26.16540; NAGASAWA H, 1983, MUTAT RES, V109, P297, DOI 10.1016/0027-5107(83)90054-4; NELSON J, 1989, EUR J CANCER CLIN ON, V25, P1851, DOI 10.1016/0277-5379(89)90358-1; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Saito T, 1998, MAMM GENOME, V9, P769, DOI 10.1007/s003359900861; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SEDGWICK RP, 1991, HEREDITARY NEUROPATH, P347; SHAIJDAK WM, 1994, RADIAT RES, V138, P47; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Tashita H, 1998, J CLIN INVEST, V101, P677, DOI 10.1172/JCI1672; TAYLOR AMR, 1975, NATURE, V258, P427, DOI 10.1038/258427a0; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; WOLLMAN R, 1994, INT J RADIAT ONCOL, V30, P91, DOI 10.1016/0360-3016(94)90523-1; Xu WM, 2000, NAT CELL BIOL, V2, P339, DOI 10.1038/35014028; Yang CR, 2000, FASEB J, V14, P379, DOI 10.1096/fasebj.14.2.379; Zhang N, 1997, P NATL ACAD SCI USA, V94, P8021, DOI 10.1073/pnas.94.15.8021	50	43	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8884	8891		10.1074/jbc.M006190200	http://dx.doi.org/10.1074/jbc.M006190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11080496	hybrid			2022-12-25	WOS:000167607700038
J	Festy, F; Robert, JC; Brasseur, R; Thomas, A				Festy, F; Robert, JC; Brasseur, R; Thomas, A			Interaction between the N-terminal domain of gastric H,K-ATPase and the spectrin binding domain of ankyrin III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; ALPHA-SUBUNIT; CYTOPLASM; CELLS	We screened a cDNA bank of rabbit gastric fundic mucosa by two-hybrid assays looking for binding partners of the N-terminal domain of the rabbit gastric H,K-ATPase. We extracted five clones sharing more than 90% sequence identity. The longest clone codes for a protein sharing a high identity (96 and 96.8%, respectively) with a fragment of the membrane domain, from Arg-835 to Ser-873, plus the major part of the "spectrin binding domain" going from Glu-874 to Leu-1455 of human and mouse ankyrin III. We conclude that the membrane and spectrin binding domains of the rabbit ankyrin III are candidates for the binding partner of the N terminal domain of the rabbit gastric H,K-ATPase. To validate the ankyrin-ATPase interaction and to test its specificity, we produced both domains in yeast and bacteria, coimmunoprecipitated them with an anti-ATPase antibody, and copurified them by affinity chromatography. The sequence of rabbit ankyrin III was not known, and this is the first report demonstrating that the ankyrin III and the H,K-ATPase interact with no intermediate. The interaction involves the N-terminal domain of the ATPase on one hand and the spectrin binding domain of the ankyrin on the other.	CBMN, Fac Agron Gembloux, B-5030 Gembloux, Belgium; Fac Med Xavier Bichat, INSERM, U410, F-75018 Paris, France	University of Liege; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Thomas, A (corresponding author), CBMN, Fac Agron Gembloux, 2 Passage Deportes, B-5030 Gembloux, Belgium.							BENNETT V, 1992, J BIOL CHEM, V267, P8703; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; DAVIS JQ, 1990, J BIOL CHEM, V265, P17252; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; JORDAN C, 1995, J BIOL CHEM, V270, P29971; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; NELSON WJ, 1987, NATURE, V328, P533, DOI 10.1038/328533a0; PETERS LL, 1995, J CELL BIOL, V130, P313, DOI 10.1083/jcb.130.2.313; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SMITH PR, 1993, AM J PHYSIOL, V264, pC63, DOI 10.1152/ajpcell.1993.264.1.C63	11	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7721	7726		10.1074/jbc.M009980200	http://dx.doi.org/10.1074/jbc.M009980200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11096115	hybrid			2022-12-25	WOS:000167474900009
J	Champeil, P; Henao, F; Lacapere, JJ; McIntosh, DB				Champeil, P; Henao, F; Lacapere, JJ; McIntosh, DB			A remarkably stable phosphorylated form of Ca2+-ATPase prepared from Ca2+-loaded and fluorescein isothiocyanate-labeled sarcoplasmic reticulum vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM ADENOSINE-TRIPHOSPHATASE; CA-ATPASE; HIGH-AFFINITY; CONFORMATIONAL-CHANGES; INORGANIC-PHOSPHATE; BINDING; CA-2+-ATPASE; TRANSPORT; CA-2+; SITE	After the nucleotide binding domain in sarcoplasmic reticulum Ca2+-ATPase has been derivatized with fluorescein isothiocyanate at Lys-515, ATPase phosphorylation in the presence of a calcium gradient, with Ca2+ on the lumenal side but without Ca2+ on the cytosolic side, results in the formation of a species that exhibits exceptionally low probe fluorescence (Pick, U. (1981) FEES Lett. 123, 131-136), We show here that, as long as the free calcium concentration on the cytosolic side is kept in the nanomolar range, this low fluorescence species is remarkably stable, even when the calcium gradient is subsequently dissipated by ionophore, This species is a Ca2+-free phosphorylated species. The kinetics of Ca2+ binding to it indicates that its transport sites are exposed to the cytosolic side of the membrane and retain a high affinity for Ca2+. Thus, in the ATPase catalytic cycle, an intrinsically transient phosphorylated species with transport sites occupied but not yet occluded must also have been stabilized by fluorescein isothiocyanate (FITC), possibly mimicking ADP, The low fluorescence mainly results from a change in FITC absorption. The Ca2+-free low fluorescence FITC-ATPase species remains stable after addition of thapsigargsn in the absence or presence of decavanadate, or after solubilization with dodecylmaltoside. The remarkable stability of this phosphoenzyme species and the changes in FITC spectroscopic properties are discussed in terms of a putative FITC-mediated link between the nucleotide binding domain and the phosphorylation domain in Ca2+-ATPase, and the possible formation of a transition statelike conformation with a compact cytosolic head. These findings might open a path toward structural characterization of a stable phosphorylated form of Ca2+-ATPase for the first time, and thus to further insights into the pump's mechanism.	CEA, CNRS, Unite Rech Associee 2096, F-91191 Gif Sur Yvette, France; Ctr Etud Saclay, Commissariat Energie Atom, Dept Biol Cellulaire & Mol, Sect Biophys Prot & Membranes, F-91191 Gif Sur Yvette, France; Univ Extremadura, Fac Ciencias, Dept Bioquim & Biol Mol, Badajoz 06080, Spain; Fac Xavier Bichat, INSERM, Unite U410, F-75870 Paris 18, France; Univ Cape Town, Sch Med, Dept Chem Pathol, ZA-7925 Cape Town, South Africa	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universidad de Extremadura; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; University of Cape Town	Champeil, P (corresponding author), CEA, CNRS, Unite Rech Associee 2096, F-91191 Gif Sur Yvette, France.		Henao, Fernando/F-6694-2016	Henao, Fernando/0000-0003-1117-8544				Andersen JP, 1995, BIOSCIENCE REP, V15, P243, DOI 10.1007/BF01788358; BEIL FU, 1977, EUR J BIOCHEM, V81, P151, DOI 10.1111/j.1432-1033.1977.tb11936.x; BODLEY AL, 1987, J BIOL CHEM, V262, P13997; CHAMPEIL P, 1985, BIOCHEMISTRY-US, V24, P69, DOI 10.1021/bi00322a012; Champeil P, 1997, BIOCHEMISTRY-US, V36, P12383, DOI 10.1021/bi9709699; CHAMPEIL P, 1988, J BIOL CHEM, V263, P12288; CHAMPEIL P, 1983, J BIOL CHEM, V258, P4453; Champeil P., 1996, BIOMEMBR, V5, P43; CHIESI M, 1983, J BIOL CHEM, V258, P6078; CHIESI M, 1980, BIOCHEMISTRY-US, V19, P2912, DOI 10.1021/bi00554a015; CLARK RJH, 1973, COMPREHENSIVE INORGA, V3, P491; COAN C, 1979, J BIOL CHEM, V254, P2968; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; DUPONT Y, 1984, ANAL BIOCHEM, V142, P504, DOI 10.1016/0003-2697(84)90496-2; DUPONT Y, 1978, BIOCHEM BIOPH RES CO, V82, P893, DOI 10.1016/0006-291X(78)90867-7; DUPONT Y, 1980, EUR J BIOCHEM, V109, P231, DOI 10.1111/j.1432-1033.1980.tb04788.x; DUX L, 1983, J BIOL CHEM, V258, P2599; FEHER JJ, 1980, CELL CALCIUM, V1, P105, DOI 10.1016/0143-4160(80)90024-X; FRIEDMAN Z, 1970, FEBS LETT, V11, P69, DOI 10.1016/0014-5793(70)80494-X; HIGHSMITH S, 1985, BIOCHIM BIOPHYS ACTA, V817, P123, DOI 10.1016/0005-2736(85)90074-4; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1992, ADV ENZYMOL RAMB, V65, P185; JENCKS WP, 1993, BIOCHEMISTRY-US, V32, P7030, DOI 10.1021/bi00078a031; JENCKS WP, 1989, J BIOL CHEM, V264, P18855; Klonis N, 1996, J Fluoresc, V6, P147, DOI 10.1007/BF00732054; Klonis N, 1998, PHOTOCHEM PHOTOBIOL, V67, P500, DOI 10.1562/0031-8655(1998)067<0500:SPOFIS>2.3.CO;2; Lacapere JJ, 1998, BIOPHYS J, V75, P1319, DOI 10.1016/S0006-3495(98)74050-0; LEVY D, 1990, J BIOL CHEM, V265, P19524; MADEIRA VMC, 1984, BIOCHIM BIOPHYS ACTA, V769, P284, DOI 10.1016/0005-2736(84)90308-0; MAKINOSE M, 1973, FEBS LETT, V37, P140, DOI 10.1016/0014-5793(73)80443-0; MCINTOSH DB, 1994, J BIOL CHEM, V269, P21587; MCINTOSH DB, 1991, P NATL ACAD SCI USA, V88, P6437, DOI 10.1073/pnas.88.15.6437; MINTZ E, 1995, J BIOL CHEM, V270, P27160, DOI 10.1074/jbc.270.45.27160; MITCHINSON C, 1982, FEBS LETT, V146, P87, DOI 10.1016/0014-5793(82)80710-2; OBARA M, 1988, J BIOL CHEM, V263, P3690; ORLOWSKI S, 1991, BIOCHEMISTRY-US, V30, P352, DOI 10.1021/bi00216a007; ORLOWSKI S, 1993, FEBS LETT, V328, P296, DOI 10.1016/0014-5793(93)80947-S; PETITHORY JR, 1988, BIOCHEMISTRY-US, V27, P8626, DOI 10.1021/bi00423a018; PETITHORY JR, 1986, BIOCHEMISTRY-US, V25, P4493, DOI 10.1021/bi00364a006; PICK U, 1980, BIOCHIM BIOPHYS ACTA, V626, P255, DOI 10.1016/0005-2795(80)90216-0; PICK U, 1981, FEBS LETT, V123, P131, DOI 10.1016/0014-5793(81)80036-1; PICK U, 1981, FEBS LETT, V123, P127, DOI 10.1016/0014-5793(81)80035-X; PICK U, 1982, J BIOL CHEM, V257, P6120; PUCELL A, 1971, J BIOL CHEM, V246, P3389; RIOLLET S, 1987, ANAL BIOCHEM, V162, P160, DOI 10.1016/0003-2697(87)90022-4; SAGARA Y, 1991, J BIOL CHEM, V266, P13503; SAGARA Y, 1992, J BIOL CHEM, V267, P1286; STAHL N, 1987, BIOCHEMISTRY-US, V26, P7654, DOI 10.1021/bi00398a019; STOKES DL, 1994, J BIOL CHEM, V269, P11606; TAKAKUWA Y, 1984, J BIOCHEM-TOKYO, V95, P543, DOI 10.1093/oxfordjournals.jbchem.a134637; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; TSIEN R, 1989, METHOD ENZYMOL, V172, P230; VERJOVSKIALMEIDA S, 1979, J BIOL CHEM, V254, P18; VILSEN B, 1992, J BIOL CHEM, V267, P3539; VILSEN B, 1986, BIOCHIM BIOPHYS ACTA, V855, P429, DOI 10.1016/0005-2736(86)90089-1; YAMAGUCHI M, 1984, J BIOL CHEM, V259, P9526; Zhang PJ, 1998, NATURE, V392, P835, DOI 10.1038/33959	57	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5795	5803		10.1074/jbc.M006980200	http://dx.doi.org/10.1074/jbc.M006980200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11067849	Green Published, hybrid			2022-12-25	WOS:000167115100054
J	Deinert, K; Fasiolo, F; Hurt, EC; Simos, G				Deinert, K; Fasiolo, F; Hurt, EC; Simos, G			Arc1p organizes the yeast aminoacyl-tRNA synthetase complex and stabilizes its interaction with the cognate tRNAs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; TERMINAL EXTENSION; BINDING; PEPTIDE; DOMAIN; EXPORT; MOTIF; SUBSTRATE; PRECURSOR; COMPONENT	Eukaryotic aminoacyl-tRNA synthetases, in contrast to their prokaryotic counterparts, are often part of high molecular weight complexes. In yeast, two enzymes, the methionyl- and glutamyl-tRNA synthetases associate in vivo with the tRNA-binding protein Arc1p. To study the assembly and function of this complex, we have reconstituted it in vitro from individually purified recombinant proteins. Our results show that Arc1p can readily bind to either or both of the two enzymes, mediating the formation of the respective binary or ternary complexes. Under competition conditions, Arc1p alone exhibits broad specificity and interacts with a defined set of tRNA species. Nevertheless, the in vitro reconstituted Arc1p-containing enzyme complexes can bind only to their cognate tRNAs and tighter than the corresponding monomeric enzymes. These results demonstrate that the organization of aminoacyl-tRNA synthetases with general tRNA-binding proteins into multimeric complexes can stimulate their catalytic efficiency and, therefore, offer a significant advantage to the eukaryotic cell.	Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany; CNRS, Inst Biol Mol & Cellulaire, Biochem Lab, F-67084 Strasbourg, France	Ruprecht Karls University Heidelberg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Simos, G (corresponding author), Heidelberg Univ, Zentrum Biochem, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	cg2@ix.urz.uni-heidelberg.de	Ed Hurt, Dr./AAE-8874-2019; Simos, George/AAH-2596-2021	Ed Hurt, Dr./0000-0002-4535-8255; Simos, George/0000-0001-5453-3185				Agou F, 1997, EUR J BIOCHEM, V243, P259, DOI 10.1111/j.1432-1033.1997.0259a.x; Behrensdorf HA, 2000, FEBS LETT, V466, P143, DOI 10.1016/S0014-5793(99)01777-9; Cahuzac B, 2000, EMBO J, V19, P445, DOI 10.1093/emboj/19.3.445; Cesareni G, 1987, GENETIC ENG PRINCIPL, V9, P135, DOI DOI 10.1007/978-1-4684-5377-5_9; Chihade JW, 1999, P NATL ACAD SCI USA, V96, P12316, DOI 10.1073/pnas.96.22.12316; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; DENTE L, 1983, NUCLEIC ACIDS RES, V11, P1645, DOI 10.1093/nar/11.6.1645; DESPONS L, 1992, J MOL BIOL, V225, P897, DOI 10.1016/0022-2836(92)90409-D; FILONENKO VV, 1994, J BIOL CHEM, V269, P17375; Francklyn C, 1997, RNA, V3, P954; Frugier M, 2000, EMBO J, V19, P2371, DOI 10.1093/emboj/19.10.2371; Grosshans H, 2000, GENE DEV, V14, P830; Hellmuth K, 1998, MOL CELL BIOL, V18, P6374, DOI 10.1128/MCB.18.11.6374; Ibba M, 1997, TRENDS BIOCHEM SCI, V22, P39, DOI 10.1016/S0968-0004(96)20033-7; Kim T, 2000, J BIOL CHEM, V275, P21768, DOI 10.1074/jbc.M002404200; Kim Y, 2000, J BIOL CHEM, V275, P27062; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Martinis SA, 1999, BIOCHIMIE, V81, P683, DOI 10.1016/S0300-9084(99)80126-6; Martinis Susan A., 1999, EMBO (European Molecular Biology Organization) Journal, V18, P4591, DOI 10.1093/emboj/18.17.4591; MIRANDE M, 1991, PROG NUCLEIC ACID RE, V40, P95; Morales AJ, 1999, EMBO J, V18, P3475, DOI 10.1093/emboj/18.12.3475; Nathanson L, 2000, J BIOL CHEM, V275, P31559, DOI 10.1074/jbc.C000385200; NEGRUTSKII BS, 1991, P NATL ACAD SCI USA, V88, P4991, DOI 10.1073/pnas.88.11.4991; Norcum MT, 1998, PROTEIN SCI, V7, P79, DOI 10.1002/pro.5560070108; Norcum MT, 2000, J BIOL CHEM, V275, P17921, DOI 10.1074/jbc.C000266200; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; Quevillon S, 1996, FEBS LETT, V395, P63, DOI 10.1016/0014-5793(96)01005-8; Quevillon S, 1999, J MOL BIOL, V285, P183, DOI 10.1006/jmbi.1998.2316; Quevillon S, 1997, J BIOL CHEM, V272, P32573, DOI 10.1074/jbc.272.51.32573; REED VS, 1994, J BIOL CHEM, V269, P32937; Rho SB, 1996, P NATL ACAD SCI USA, V93, P10128, DOI 10.1073/pnas.93.19.10128; Rho SB, 1999, P NATL ACAD SCI USA, V96, P4488, DOI 10.1073/pnas.96.8.4488; Rho SB, 1998, J BIOL CHEM, V273, P11267, DOI 10.1074/jbc.273.18.11267; Sarkar S, 1999, P NATL ACAD SCI USA, V96, P14366, DOI 10.1073/pnas.96.25.14366; Schimmel P, 1999, TRENDS BIOCHEM SCI, V24, P127, DOI 10.1016/S0968-0004(99)01369-9; Simos G, 1996, EMBO J, V15, P2270, DOI 10.1002/j.1460-2075.1996.tb00580.x; Simos G, 1996, EMBO J, V15, P5437, DOI 10.1002/j.1460-2075.1996.tb00927.x; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Wang CC, 1999, J BIOL CHEM, V274, P16508, DOI 10.1074/jbc.274.23.16508; Weiner AM, 1999, SCIENCE, V284, P63, DOI 10.1126/science.284.5411.63; WeygandDurasevic I, 1996, J BIOL CHEM, V271, P2455, DOI 10.1074/jbc.271.5.2455; Whelihan EF, 1997, EMBO J, V16, P2968, DOI 10.1093/emboj/16.10.2968; Wolin SL, 1999, GENE DEV, V13, P1, DOI 10.1101/gad.13.1.1; Wu H, 1995, BIOCHEMISTRY-US, V34, P16327, DOI 10.1021/bi00050a013	49	50	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					6000	6008		10.1074/jbc.M008682200	http://dx.doi.org/10.1074/jbc.M008682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11069915	hybrid			2022-12-25	WOS:000167115100079
J	Ko, YG; Kim, EK; Kim, T; Park, H; Park, HS; Choi, EJ; Kim, S				Ko, YG; Kim, EK; Kim, T; Park, H; Park, HS; Choi, EJ; Kim, S			Glutamine-dependent antiapoptotic interaction of human glutaminyl-tRNA synthetase with apoptosis signal-regulating kinase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING POLYPEPTIDE II; NF-KAPPA-B; CELL-DEATH; PROTEIN-KINASE; AKT; CYTOKINE; GROWTH; METABOLISM; COMPONENTS; SURVIVAL	Glutamine has been known to be an apoptosis suppressor, since it blocks apoptosis induced by heat shock, irradiation, and c-Myc overexpression, Here, we demonstrated that HeLa cells were susceptible to Fas-mediated apoptosis under the condition of glutamine deprivation. Fas ligation activated apoptosis signal-regulating kinase 1 (ASK1) and c-Jun N-terminal kinase (JNK; also known as stress-activated protein kinase (SAPK)) in Gin-deprived cells but not in normal cells, suggesting that Gin might be involved in the activity control of ASK1 and JNK/SAPK, As one of the possible mechanisms for the suppressive effect of Gln on ASK1, we investigated the molecular interaction between human glutaminyl-tRNA synthetase (QRS) and ASK1 and found the Gin-dependent association of the two molecules. While their association was enhanced by the elevation of Gin concentration, they were dissociated by Fas ligation within 5 min. The association involved the catalytic domains of the two enzymes. The ASK1 activity was inhibited by the interaction with QRS as determined by in vitro kinase and transcription assays. Finally, we have shown that QRS inhibited the cell death induced by ASK1, and this antiapoptotic function of QRS was weakened by the deprivation of Gin, Thus, the antiapoptotic interaction of QRS with ASK1 is controlled positively by the cellular concentration of Gin and negatively by Fas ligation, The results of this work provide one possible explanation for the working mechanism of the antiapoptotic activity of Gin and suggest a novel function of mammalian ARSs.	Sungkyunkwan Univ, Natl Creat Res Initiat Ctr ARS Network, Jangangu, Suwon 440746, Kyunggido, South Korea; Korea Univ, Grad Sch Biotechnol, Natl Creat Res Initiat, Ctr Cell Death, Seoul 136701, South Korea	Sungkyunkwan University (SKKU); Korea University	Kim, S (corresponding author), Sungkyunkwan Univ, Natl Creat Res Initiat Ctr ARS Network, Jangangu, 300 Chunchundong, Suwon 440746, Kyunggido, South Korea.	shkim@yurim.skku.ac.kr	Kim, Sunghoon/AAE-8314-2020					Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bennett MR, 1998, ATHEROSCLEROSIS, V138, P3, DOI 10.1016/S0021-9150(98)00013-6; Berestetskaya YV, 1998, J BIOL CHEM, V273, P27816, DOI 10.1074/jbc.273.43.27816; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunner T, 2000, J BIOL CHEM, V275, P9767, DOI 10.1074/jbc.275.13.9767; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Chow A, 1998, J NUTR, V128, P1296, DOI 10.1093/jn/128.8.1296; DANG CV, 1983, J CELL BIOL, V96, P1138, DOI 10.1083/jcb.96.4.1138; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Holmstrom TH, 1999, MOL CELL BIOL, V19, P5991; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kazama H, 2000, J CELL BIOL, V148, P557, DOI 10.1083/jcb.148.3.557; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kim T, 2000, J BIOL CHEM, V275, P21768, DOI 10.1074/jbc.M002404200; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; KISSELEV LL, 1994, PROG NUCLEIC ACID RE, V48, P83, DOI 10.1016/S0079-6603(08)60854-5; Knies UE, 1998, P NATL ACAD SCI USA, V95, P12322, DOI 10.1073/pnas.95.21.12322; Ko YG, 2000, J CELL BIOL, V149, P567, DOI 10.1083/jcb.149.3.567; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Lee JM, 1999, NATURE, V399, pA7, DOI 10.1038/399a007; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Martinis Susan A., 1999, EMBO (European Molecular Biology Organization) Journal, V18, P4591, DOI 10.1093/emboj/18.17.4591; Neu J, 1996, FASEB J, V10, P829, DOI 10.1096/fasebj.10.8.8666159; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; Ozes ON, 1999, NATURE, V401, P82; PAHUSKI E, 1983, J CELL PHYSIOL, V114, P82, DOI 10.1002/jcp.1041140114; Papaconstantinou HT, 1998, SURGERY, V124, P152, DOI 10.1067/msy.1998.90562; Park SG, 1999, J BIOL CHEM, V274, P16673, DOI 10.1074/jbc.274.24.16673; POPENKO VI, 1994, EUR J CELL BIOL, V65, P60; Rhoads JM, 2000, GASTROENTEROLOGY, V118, P90, DOI 10.1016/S0016-5085(00)70417-3; Rhoads JM, 1997, AM J PHYSIOL-GASTR L, V272, pG943, DOI 10.1152/ajpgi.1997.272.5.G943; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Santoso JT, 1998, GYNECOL ONCOL, V71, P359, DOI 10.1006/gyno.1998.5175; Schimmel P, 1999, TRENDS BIOCHEM SCI, V24, P127, DOI 10.1016/S0968-0004(99)01369-9; Schwarz MA, 1999, J EXP MED, V190, P341, DOI 10.1084/jem.190.3.341; Seshaiah P, 1999, MOL BIOL CELL, V10, P1595, DOI 10.1091/mbc.10.5.1595; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Xu Y, 1997, J CELL PHYSIOL, V170, P192, DOI 10.1002/(SICI)1097-4652(199702)170:2<192::AID-JCP11>3.0.CO;2-K; Yang DCH, 1996, CURR TOP CELL REGUL, V34, P101, DOI 10.1016/S0070-2137(96)80004-5; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511	51	153	169	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					6030	6036		10.1074/jbc.M006189200	http://dx.doi.org/10.1074/jbc.M006189200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11096076	hybrid			2022-12-25	WOS:000167115100083
J	Liu, MY; Gutowski, S; Sternweis, PC				Liu, MY; Gutowski, S; Sternweis, PC			The C terminus of mammalian phospholipase D is required for catalytic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; PROTEIN-KINASE-C; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHATIDIC-ACID; CRYSTAL-STRUCTURE; HL-60 CELLS; RAT-BRAIN; D DEFINES; RHOA; ACTIVATION	The activity of phospholipase D (PLD) is regulated by a variety of hormonal stimuli and provides a mechanistic pathway for response of cells to extracellular stimuli. The two identified mammalian PLD enzymes possess highly homologous C termini, which are required for catalytic activity. Mutational analysis of PLD1 and PLD2 reveals that modification of as little as the C-terminal threonine or the addition of a single alanine attenuates activity of the enzyme. Protein folding appears to be intact because mutant enzymes express to similar levels in Sf9 cells and addition of peptides representing the C-terminal amino acids, including the simple hexamer PMEVWT restores partial activity to several of the mutants. Analysis of several mutants suggests a requirement for the hydrophobic reside at the -2-position but not an absolute requirement for the hydroxyl side chain of threonine at the C terminus. The inability of peptides amidated at their C termini to effect restoration of activity indicates the involvement of the C-terminal alpha -carboxyl group in functional activity of these enzymes. The ability of peptides to restore activity to PLD enzymes mutated at the C terminus suggests a flexible interaction of this portion of the molecule with a catalytic core constructed on conserved HKD motifs. Participation of these C termini residues in either stabilization of the catalytic site or the enzymatic reaction itself remains to be determined. This requirement for the C terminus provides an excellent potential site for interaction with regulatory proteins that may either enhance or down-regulate the activity of these enzymes in vitro.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sternweis, PC (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75235 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031954] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM31954] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Athenstaedt K, 1999, EUR J BIOCHEM, V266, P1, DOI 10.1046/j.1432-1327.1999.00822.x; BALBOA MA, 1995, J BIOL CHEM, V270, P29843; BROWN HA, 1995, J BIOL CHEM, V270, P14935, DOI 10.1074/jbc.270.25.14935; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; BROWN HA, 1995, METHOD ENZYMOL, V257, P313; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; Hodgkin MN, 1998, TRENDS BIOCHEM SCI, V23, P200, DOI 10.1016/S0968-0004(98)01200-6; Houle MG, 1999, BBA-MOL CELL BIOL L, V1439, P135, DOI 10.1016/S1388-1981(99)00090-6; Kodaki T, 1997, J BIOL CHEM, V272, P11408; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LACHMANN PJ, 1986, CIBA F SYMP, V119, P25; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leiros I, 2000, STRUCTURE, V8, P655, DOI 10.1016/S0969-2126(00)00150-7; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; Lopez I, 1998, J BIOL CHEM, V273, P12846, DOI 10.1074/jbc.273.21.12846; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; McPhail LC, 1999, BBA-MOL CELL BIOL L, V1439, P277, DOI 10.1016/S1388-1981(99)00100-6; MUMBY SM, 1986, P NATL ACAD SCI USA, V83, P265, DOI 10.1073/pnas.83.2.265; Ohguchi K, 1996, J BIOL CHEM, V271, P4366; Park SK, 1998, BIOCHEM BIOPH RES CO, V244, P364, DOI 10.1006/bbrc.1998.8275; Ponting CP, 1996, PROTEIN SCI, V5, P914; RANDAZZO PA, 1995, METHOD ENZYMOL, V257, P128; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; Singer WD, 1996, J BIOL CHEM, V271, P4504; Singer WD, 1997, ANNU REV BIOCHEM, V66, P475, DOI 10.1146/annurev.biochem.66.1.475; Stuckey JA, 1999, NAT STRUCT BIOL, V6, P278; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1997, EMBO J, V16, P4519, DOI 10.1093/emboj/16.15.4519; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; Waite M, 1999, BBA-MOL CELL BIOL L, V1439, P187, DOI 10.1016/S1388-1981(99)00094-3; Xie Z, 1998, J BIOL CHEM, V273, P34679, DOI 10.1074/jbc.273.52.34679; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035; Zhang Y, 1999, EMBO J, V18, P6339, DOI 10.1093/emboj/18.22.6339	43	23	24	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5556	5562		10.1074/jbc.M006404200	http://dx.doi.org/10.1074/jbc.M006404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11083860	hybrid			2022-12-25	WOS:000167115100022
J	Slupsky, CM; Desautels, M; Huebert, T; Zhao, RH; Hemmingsen, SM; McIntosh, LP				Slupsky, CM; Desautels, M; Huebert, T; Zhao, RH; Hemmingsen, SM; McIntosh, LP			Structure of Cdc4p, a contractile ring protein essential for cytokinesis in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESSENTIAL LIGHT-CHAIN; MYOSIN HEAVY-CHAIN; NUCLEAR-MAGNETIC-RESONANCE; CALCIUM-SATURATED STATES; FISSION YEAST; REGULATORY DOMAIN; TROPONIN-C; SCALLOP MYOSIN; TARGETED DISRUPTION; BINDING PROTEINS	The Schizosaccharomyces pombe Cdc4 protein is required for the formation and function of the contractile ring, presumably acting as a myosin light chain. By using NMR spectroscopy, we demonstrate that purified Cdc4p is a monomeric protein with two structurally independent domains, each exhibiting a fold reminiscent of the EF-hand class of calcium-binding proteins. Although Cdc4p has one potentially functional calcium-binding site, it does not bind calcium in vitro. Three variants of Cdc4p containing single point mutations responsible for temperature-sensitive arrest of the cell cycle at cytokinesis (Gly-19 to Glu, Gly-82 to Asp, and Gly-107 to Ser) were also characterized by NMR and circular dichroism spectroscopy. In each case, the amino acid substitution only leads to small perturbations in the conformation of the protein. Furthermore, thermal unfolding studies indicate that, like wild-type Cdc4p, the three mutant forms are all extremely stable, remaining completely folded at temperatures significantly above those causing failure of cytokinesis in intact cells. Therefore, the altered phenotype must arise directly from a disruption of the function of Cdc4p rather than indirectly through a disruption of its overall structure. Several mutant alleles of Cdc4p also show interallelic complementation in diploid cells. This phenomenon can be explained if Cdcp4 has more than one essential function or, alternatively, if two mutant proteins assemble to form a functional complex. Based on the structure of Cdc4p, possible models for interallelic complementation including interactions with partner proteins and the formation of a myosin complex with Cdc4p fulfilling the role of both an essential and regulatory light chain are proposed.	Natl Res Council Canada, Inst Plant Biotechnol, Saskatoon, SK S7N 0W9, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Dept Chem, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Univ Saskatchewan, Coll Med, Dept Physiol, Saskatoon, SK S7N 5E5, Canada; Univ Saskatchewan, Coll Med, Dept Microbiol & Immunol, Saskatoon, SK S7N 5E5, Canada	National Research Council Canada; University of British Columbia; University of British Columbia; University of Saskatchewan; University of Saskatchewan	Hemmingsen, SM (corresponding author), Natl Res Council Canada, Inst Plant Biotechnol, 110 Gymnasium Rd, Saskatoon, SK S7N 0W9, Canada.	hemmings@cbrpbi.pbi.nrc.ca; mcintosh@otter.biochem.ubc.ca						BALASUBRAMANIAN MK, 1992, NATURE, V360, P84, DOI 10.1038/360084a0; Balasubramanian MK, 1998, GENETICS, V149, P1265; BAX A, 1994, METHOD ENZYMOL, V239, P79; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; Brunger A. T., 1993, XPLOR SYSTEM XRAY CR; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Chang F, 1996, J CELL SCI, V109, P131; CHEN PX, 1994, J CELL BIOL, V127, P1933, DOI 10.1083/jcb.127.6.1933; CHEN TLL, 1995, J CELL SCI, V108, P3207; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Desautels M, 2001, J BIOL CHEM, V276, P5932, DOI 10.1074/jbc.M008715200; Eng K, 1998, CURR BIOL, V8, P611, DOI 10.1016/S0960-9822(98)70248-9; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Field C, 1999, CURR OPIN CELL BIOL, V11, P68, DOI 10.1016/S0955-0674(99)80009-X; Gagne SM, 1997, BIOCHEMISTRY-US, V36, P4386, DOI 10.1021/bi963076+; GAGNE SM, 1995, NAT STRUCT BIOL, V2, P784, DOI 10.1038/nsb0995-784; GAGNE SM, 1994, PROTEIN SCI, V3, P1961, DOI 10.1002/pro.5560031108; GARRETT DS, 1991, J MAGN RESON, V95, P214, DOI 10.1016/0022-2364(91)90341-P; Gould KL, 1997, GENE DEV, V11, P2939, DOI 10.1101/gad.11.22.2939; Ho GY, 1997, J BIOL CHEM, V272, P4522, DOI 10.1074/jbc.272.7.4522; HO GY, 1995, J BIOL CHEM, V270, P27977, DOI 10.1074/jbc.270.46.27977; HOUDUSSE A, 1995, P NATL ACAD SCI USA, V92, P10644, DOI 10.1073/pnas.92.23.10644; Houdusse A, 1996, STRUCTURE, V4, P21, DOI 10.1016/S0969-2126(96)00006-8; Ishiguro J, 1996, FEBS LETT, V392, P237, DOI 10.1016/0014-5793(96)00819-8; Kitayama C, 1997, J CELL BIOL, V137, P1309, DOI 10.1083/jcb.137.6.1309; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; MARSDEN BJ, 1990, BIOCHEM CELL BIOL, V68, P587, DOI 10.1139/o90-084; May KM, 1998, CELL MOTIL CYTOSKEL, V39, P195, DOI 10.1002/(SICI)1097-0169(1998)39:3<195::AID-CM2>3.0.CO;2-4; McCollum D, 1999, J BIOL CHEM, V274, P17691, DOI 10.1074/jbc.274.25.17691; MCCOLLUM D, 1995, J CELL BIOL, V130, P651, DOI 10.1083/jcb.130.3.651; McCollum D, 1996, EMBO J, V15, P6438, DOI 10.1002/j.1460-2075.1996.tb01035.x; Motegi F, 1997, FEBS LETT, V420, P161, DOI 10.1016/S0014-5793(97)01510-X; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; Naqvi NI, 1999, EMBO J, V18, P854, DOI 10.1093/emboj/18.4.854; NERI D, 1989, BIOCHEMISTRY-US, V28, P7510, DOI 10.1021/bi00445a003; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; PELTON JG, 1993, PROTEIN SCI, V2, P543; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; Slupsky CM, 1995, BIOCHEMISTRY-US, V34, P15953, DOI 10.1021/bi00049a010; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; SLUPSKY CM, 1999, STRUCTURAL BASIS REG, P73; Spyracopoulos L, 1998, BIOCHEMISTRY-US, V37, P18032, DOI 10.1021/bi9816960; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TJANDRA N, 1995, EUR J BIOCHEM, V230, P1014, DOI 10.1111/j.1432-1033.1995.tb20650.x; UYEDA TQP, 1993, SCIENCE, V262, P1867, DOI 10.1126/science.8266074; Waugh DS, 1996, J BIOMOL NMR, V8, P184; XIE X, 1994, NATURE, V368, P306, DOI 10.1038/368306a0; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y	49	19	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5943	5951		10.1074/jbc.M008716200	http://dx.doi.org/10.1074/jbc.M008716200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11087750	hybrid			2022-12-25	WOS:000167115100072
J	Wery, J; Hidayat, B; Kieboom, J; de Bont, JAM				Wery, J; Hidayat, B; Kieboom, J; de Bont, JAM			An insertion sequence prepares Pseudomonas putida S12 for severe solvent stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTIVE MUTATION; ORGANIC-SOLVENTS; RESISTANT BACTERIUM; EFFLUX SYSTEM; ACTIVE EFFLUX; TOLUENE; TOLERANCE; MECHANISMS; AERUGINOSA; EVOLUTION	The novel insertion sequence ISS12 plays a key role in the tolerance of Pseudomonas putida S12, to sudden toluene stress. Under normal culturing conditions the P, putida S12 genome contained seven copies of ISS12. However, a P. putida S12 population,growing to high cell density after sudden addition of a separate phase of toluene carried eight copies. The survival frequency of cells in this variant P. putida S12 population was 1000 times higher than in "normal" P. putida S12 populations. Analysis of the nucleotide sequence flanking the extra ISS12 insertion revealed integration into the sr-pg gene. srpS forms a gene cluster with srpR and both are putative regulators of the solvent resistance pump SrpABC. SrpABC makes a major contribution to solvent tolerance in P. putida S12 and is induced by toluene. The basal level of srp promoter activity in the P. putida S12 variant was seven times higher than in wild-type P, putida S12. Introduction of the intact srpRS gene cluster in the variant resulted in a dramatic decrease of survival frequency after a toluene shock. These findings strongly suggest that interruption of srpS by ISS12 upregulates expression of the solvent pump, enabling the bacterium to tolerate sudden exposure to lethal concentrations of toxic solvents. We propose that P. putida S12 employs ISS12 as a mutator element to generate diverse mutations to swiftly adapt when confronted with severe adverse conditions.	Univ Wageningen & Res Ctr, Div Ind Microbiol, Dept Agrotechnol & Food Sci, NL-6700 EV Wageningen, Netherlands	Wageningen University & Research	Wery, J (corresponding author), Friesland Coberco Dairy Foods, Corp Res, POB 87, NL-7400 AB Deventer, Netherlands.		Hidayat, Budi Juliman/AAF-4805-2020					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ausubel FM., 2006, ENZYMATIC MANIPULATI; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; CAIRNS J, 1988, NATURE, V335, P142, DOI 10.1038/335142a0; CHAO L, 1983, NATURE, V303, P633, DOI 10.1038/303633a0; CRUDEN DL, 1992, APPL ENVIRON MICROB, V58, P2723, DOI 10.1128/AEM.58.9.2723-2729.1992; Dennis J J, 1995, Methods Mol Biol, V47, P125; FOSTER PL, 1993, ANNU REV MICROBIOL, V47, P467; Fukumori F, 1998, EXTREMOPHILES, V2, P395, DOI 10.1007/s007920050084; GALAS DJ, 1989, MOBILE DNA, P109; Haas D, 1996, MOLECULAR BIOLOGY OF PSEUDOMONADS, P238; Hall BG, 1998, GENETICA, V102-3, P109, DOI 10.1023/A:1017015815643; Hall BG, 1999, J BACTERIOL, V181, P1149, DOI 10.1128/JB.181.4.1149-1155.1999; HALL BG, 1990, GENETICS, V126, P5; Harris RS, 1997, GENE DEV, V11, P2426, DOI 10.1101/gad.11.18.2426; HARTMANS S, 1990, APPL ENVIRON MICROB, V56, P1347, DOI 10.1128/AEM.56.5.1347-1351.1990; HEIPIEPER HJ, 1994, TRENDS BIOTECHNOL, V12, P409, DOI 10.1016/0167-7799(94)90029-9; Huertas MJ, 1998, APPL ENVIRON MICROB, V64, P38; Isken S, 1996, J BACTERIOL, V178, P6056, DOI 10.1128/jb.178.20.6056-6058.1996; KATZ RA, 1994, ANNU REV BIOCHEM, V63, P133, DOI 10.1146/annurev.bi.63.070194.001025; Kieboom J, 1998, J BACTERIOL, V180, P6769, DOI 10.1128/JB.180.24.6769-6772.1998; Kieboom J, 1998, J BIOL CHEM, V273, P85, DOI 10.1074/jbc.273.1.85; Kim K, 1998, J BACTERIOL, V180, P3692, DOI 10.1128/JB.180.14.3692-3696.1998; KLECKNER N, 1996, TRANSPOSABLE ELEMENT, P49; Li L, 1995, BIOSCI BIOTECH BIOCH, V59, P2358, DOI 10.1271/bbb.59.2358; Li XZ, 1998, J BACTERIOL, V180, P2987, DOI 10.1128/JB.180.11.2987-2991.1998; Longerich S, 1995, P NATL ACAD SCI USA, V92, P12017, DOI 10.1073/pnas.92.26.12017; Luria SE, 1943, GENETICS, V28, P491; Mahillon J, 1998, MICROBIOL MOL BIOL R, V62, P725, DOI 10.1128/MMBR.62.3.725-774.1998; McKenzie GJ, 2000, P NATL ACAD SCI USA, V97, P6646, DOI 10.1073/pnas.120161797; Miller J.H., 1972, EXPT MOL GENETICS; Mosqueda G, 2000, J BACTERIOL, V182, P937, DOI 10.1128/JB.182.4.937-943.2000; Pinkart HC, 1996, APPL ENVIRON MICROB, V62, P1129, DOI 10.1128/AEM.62.3.1129-1132.1996; Ramos JL, 1998, J BACTERIOL, V180, P3323, DOI 10.1128/JB.180.13.3323-3329.1998; Ramos JL, 1997, J BIOL CHEM, V272, P3887, DOI 10.1074/jbc.272.7.3887; Rosche WA, 1999, P NATL ACAD SCI USA, V96, P6862, DOI 10.1073/pnas.96.12.6862; Rosenberg SM, 1998, GENETICS, V148, P1559; Sambrook J., 2002, MOL CLONING LAB MANU; SIKKEMA J, 1995, MICROBIOL REV, V59, P201, DOI 10.1128/MMBR.59.2.201-222.1995; SOLINAS F, 1995, GENE, V155, P77, DOI 10.1016/0378-1119(94)00922-F; Torkelson J, 1997, EMBO J, V16, P3303, DOI 10.1093/emboj/16.11.3303; Weber FJ, 1996, BBA-REV BIOMEMBRANES, V1286, P225, DOI 10.1016/S0304-4157(96)00010-X; WEBER FJ, 1993, APPL ENVIRON MICROB, V59, P3502, DOI 10.1128/AEM.59.10.3502-3504.1993; WEST SEH, 1994, GENE, V128, P81; Yeo CC, 1998, PLASMID, V39, P187, DOI 10.1006/plas.1997.1331	45	43	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5700	5706		10.1074/jbc.M007687200	http://dx.doi.org/10.1074/jbc.M007687200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11094055	hybrid			2022-12-25	WOS:000167115100041
J	Greene, DJ; Skeggs, JW; Morton, RE				Greene, DJ; Skeggs, JW; Morton, RE			Elevated triglyceride content diminishes the capacity of high density lipoprotein to deliver cholesteryl esters via the scavenger receptor class B type I (SR-BI)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-TRANSFER PROTEIN; TRANSFER INHIBITOR PROTEIN; APOLIPOPROTEIN-A-I; SELECTIVE UPTAKE; HEPATIC LIPASE; STEROIDOGENIC CELLS; TARGETED MUTATION; CELLULAR UPTAKE; ADRENAL-CELLS; HDL RECEPTOR	The selective uptake of high density lipoprotein (HDL) cholesteryl ester (CE) by the scavenger receptor class B type I (SR-BI) is well documented. However, the effect of altered HDL composition, such as occurs in hyperlipidemia, on this important process is not known. This study investigated the impact of variable CE and triglyceride (TG) content on selective uptake. CE selective uptake by YI and HepG2 cells was strongly affected by modification of either the CE or TG content of HDL. Importantly, TG, like CE, was selectively taken up by a dose-dependent, saturable process in these cells. As shown by ACTH up-regulation and receptor overexpression experiments, SR-BI mediated the selective uptake of both CE and TG. With in vitro modified HDLs of varying CE and TG composition, the selective uptake of CE and TG was dependent on the abundance of each lipid within the HDL particle. Furthermore, total selective uptake (CE + TG) remained constant, indicating that these lipids competed for cellular uptake. These data support a novel mechanism whereby SR-BI binds HDL and mediates the incorporation of a nonspecific portion of the HDL lipid core. In this way, TG directly affects the ability of HDL to donate CE to cells. Processes that raise the TG/CE ratio of HDL will impair the delivery of CE to cells via this receptor and may compromise the efficiency of sterol balancing pathways such as reverse cholesterol transport.	Cleveland Clin Fdn, Lerner Inst, Dept Cell Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Morton, RE (corresponding author), Cleveland Clin Fdn, Lerner Inst, Dept Cell Biol, NC10,9500 Euclid Ave, Cleveland, OH 44195 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060934] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60934] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BILHEIMER DW, 1972, BIOCHIM BIOPHYS ACTA, V260, P212, DOI 10.1016/0005-2760(72)90034-3; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BRUNNER J, 1976, BIOCHIM BIOPHYS ACTA, V455, P322, DOI 10.1016/0005-2736(76)90308-4; Collet X, 1999, J LIPID RES, V40, P1185; EISENBERG S, 1984, J LIPID RES, V25, P1017; Fluiter K, 1997, BIOCHEM J, V326, P515, DOI 10.1042/bj3260515; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GLASS C, 1985, J BIOL CHEM, V260, P744; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GORDON T, 1977, AM J MED, V62; GREEN SR, 1991, J LIPID RES, V32, P457; Grundy SM, 1999, J LIPID RES, V40, P229; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HAY R, 1986, BIOCH BIOL PLASMA LI, V11, P11; HILAIRE N, 1994, BIOCHEM J, V297, P467, DOI 10.1042/bj2970467; JOHANSSON J, 1991, ARTERIOSCLER THROMB, V11, P174, DOI 10.1161/01.ATV.11.1.174; JONAS A, 1991, BIOCHIM BIOPHYS ACTA, V1084, P205, DOI 10.1016/0005-2760(91)90062-M; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Lambert G, 1999, J LIPID RES, V40, P1294; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Morton RE, 1999, CURR OPIN LIPIDOL, V10, P321, DOI 10.1097/00041433-199908000-00006; MORTON RE, 1990, J LIPID RES, V31, P1559; MORTON RE, 1990, EXPERIENTIA, V46, P552, DOI 10.1007/BF01939693; MORTON RE, 1983, J BIOL CHEM, V258, P1751; MURAKAMI T, 1995, ARTERIOSCL THROM VAS, V15, P1819, DOI 10.1161/01.ATV.15.11.1819; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; PITTMAN RC, 1983, BIOCHEM J, V212, P791, DOI 10.1042/bj2120791; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rigotti A, 1996, J BIOL CHEM, V271, P33545, DOI 10.1074/jbc.271.52.33545; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; Rigotti A, 1997, CURR OPIN LIPIDOL, V8, P181, DOI 10.1097/00041433-199706000-00009; Rinninger F, 1998, BBA-LIPID LIPID MET, V1393, P277, DOI 10.1016/S0005-2760(98)00082-4; Rinninger F, 1998, J LIPID RES, V39, P1335; Rodrigueza WV, 1999, J BIOL CHEM, V274, P20344, DOI 10.1074/jbc.274.29.20344; Serdyuk AP, 1999, ARTERIOSCL THROM VAS, V19, P718, DOI 10.1161/01.ATV.19.3.718; Tall AR, 1998, EUR HEART J, V19, pA31; Temel RE, 1997, P NATL ACAD SCI USA, V94, P13600, DOI 10.1073/pnas.94.25.13600; THOMPSON JN, 1971, BIOCHEM MED METAB B, V5, P67, DOI 10.1016/0006-2944(71)90076-7; TU AY, 1993, J BIOL CHEM, V268, P23098; Varban ML, 1998, P NATL ACAD SCI USA, V95, P4619, DOI 10.1073/pnas.95.8.4619; Vieira-van Bruggen D, 1998, J BIOL CHEM, V273, P32038; Webb NR, 1998, J BIOL CHEM, V273, P15241, DOI 10.1074/jbc.273.24.15241; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Xu SZ, 1997, J LIPID RES, V38, P1289	50	93	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4804	4811		10.1074/jbc.M008725200	http://dx.doi.org/10.1074/jbc.M008725200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11067853				2022-12-25	WOS:000168484300038
J	Ito, K; Kamei, K; Iwamoto, I; Inaguma, Y; Nohara, D; Kato, K				Ito, K; Kamei, K; Iwamoto, I; Inaguma, Y; Nohara, D; Kato, K			Phosphorylation-induced Change of the Oligomerization state of alpha B-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN-27; KINASE CASCADE; MOLECULAR CHAPERONE; MAPKAP KINASE-2; STRESS; HSP27; THERMORESISTANCE; PURIFICATION; MODULATION; TERMINUS	alphaB-crystallin in cells can be phosphorylated at three serine residues in response to stress or during mitosis (Ito, H., Okamoto, K., Nakayama, H., Isobe, T., and Kato, K. (1997) J. Biol. Chem. 272, 29934-29941 and Kato, K., Ito, H., Kamei, K., Inaguma, Y., Iwamoto, I., and Saga, S. (1998) J. Biol. Chem. 273, 28346-28354). In the present study, we determined effects of phosphorylation of alphaB-crystallin on its oligomerization state, mainly by using site-directed mutagenesis, in which all three phosphorylation sites were substituted with aspartate to mimic the phosphorylation state (3D-alphaB). From results of sucrose density gradient centrifugation, we found that wild type alphaB-crystallin (wt-alphaB) and 3D-alphaB sedimented in fractions corresponding to apparent molecular masses of about 500 and 300 kDa, respectively. Chaperone-like activity of 3D-alphaB was significantly weaker than that of wt-alphaB. When wt-alphaB and 3D-alphaB were expressed in COS-m6 cells, they sedimented at positions corresponding to apparent molecular masses of about 500 and 100 kDa, respectively. In U373 MG human glioma cells, alphaB-crystallin was observed as large oligomers with apparent molecular masses about 500 kDa and the oligomerization size was reduced after phosphorylation induced by phorbol 12-myristate 13-acetate and okadaic acid. Coexpression of luciferase and wt-alphaB or 3D-alphaB in Chinese hamster ovary cells caused protection of the enzyme from heat inactivation although the degree of protection with 3D-alphaB was less than that with wt-alphaB. From these observations, it is suggested that phosphorylation of alphaB-crystallin causes dissociation of large oligomers to smaller sizes molecules and reduction of chaperone-like activity, like in the case of HSP27.	Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Aichi 4800392, Japan; Nagoya City Univ, Fac Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4678603, Japan	Nagoya City University	Ito, K (corresponding author), Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, 713-8 Kamiya, Aichi 4800392, Japan.	itohide@inst-hsc.pref.aichi.jp		Ito, Hidenori/0000-0002-6527-477X				ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARRIGO AP, 1987, J BIOL CHEM, V262, P15359; ARRIGO AP, 1990, MOL CELL BIOL, V10, P1276, DOI 10.1128/MCB.10.3.1276; BENNDORF R, 1994, J BIOL CHEM, V269, P20780; Boelens WC, 1998, J BIOL CHEM, V273, P28085, DOI 10.1074/jbc.273.43.28085; Bova MP, 1999, P NATL ACAD SCI USA, V96, P6137, DOI 10.1073/pnas.96.11.6137; Brophy CM, 1999, J BIOL CHEM, V274, P6324, DOI 10.1074/jbc.274.10.6324; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Clifton AD, 1996, FEBS LETT, V392, P209, DOI 10.1016/0014-5793(96)00816-2; Der Perng M, 1999, J BIOL CHEM, V274, P33235, DOI 10.1074/jbc.274.47.33235; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Ito H, 1999, FEBS LETT, V446, P269, DOI 10.1016/S0014-5793(99)00242-2; Ito H, 1997, J BIOL CHEM, V272, P29934, DOI 10.1074/jbc.272.47.29934; Kato K, 1998, J BIOL CHEM, V273, P28346, DOI 10.1074/jbc.273.43.28346; KATO K, 1994, J BIOL CHEM, V269, P11274; KATO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P201, DOI 10.1016/0304-4165(91)90062-L; KATO K, 1994, J BIOL CHEM, V269, P15302; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambert H, 1999, J BIOL CHEM, V274, P9378, DOI 10.1074/jbc.274.14.9378; LANDRY J, 1992, J BIOL CHEM, V267, P794; LANDRY J, 1991, J CELL PHYSIOL, V147, P93, DOI 10.1002/jcp.1041470113; LAVOIE JN, 1993, J BIOL CHEM, V268, P24210; LAVOIE JN, 1995, MOL CELL BIOL, V15, P505, DOI 10.1128/MCB.15.1.505; Liang P, 1997, J CELL SCI, V110, P1431; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Maizels ET, 1998, BIOCHEM J, V332, P703, DOI 10.1042/bj3320703; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; RAO PV, 1993, BIOCHEM BIOPH RES CO, V190, P786, DOI 10.1006/bbrc.1993.1118; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SPECTOR A, 1985, P NATL ACAD SCI USA, V82, P4712, DOI 10.1073/pnas.82.14.4712; van de Klundert FAJM, 1999, BIOCHEM BIOPH RES CO, V254, P164, DOI 10.1006/bbrc.1998.9917; VOORTER CEM, 1989, FEBS LETT, V259, P50; WANG KY, 1995, EXP EYE RES, V61, P115; Wang KY, 1996, EUR J BIOCHEM, V242, P56, DOI 10.1111/j.1432-1033.1996.0056r.x	39	165	174	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5346	5352		10.1074/jbc.M009004200	http://dx.doi.org/10.1074/jbc.M009004200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11096101	hybrid			2022-12-25	WOS:000168484300109
J	Watts, RN; Richardson, DR				Watts, RN; Richardson, DR			Nitrogen monoxide (NO) and glucose - Unexpected links between energy metabolism and NO-mediated iron mobilization from cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIDOXAL ISONICOTINOYL HYDRAZONE; EFFECTIVE ANTIPROLIFERATIVE AGENTS; ELECTRON-PARAMAGNETIC RESONANCE; CULTURED RAT HEPATOCYTES; NITRIC-OXIDE SYNTHASE; ACTIVATED MACROPHAGES; BUTHIONINE SULFOXIMINE; OXIDATIVE STRESS; PROSTHETIC GROUP; CYTOCHALASIN-B	Nitrogen monoxide (NO) affects cellular iron metabolism due to its high affinity for this metal ion. Indeed, NO has been shown to increase the mRNA binding activity of the iron-regulatory protein 1, which is a major regulator of iron homeostasis, Recently, we have shown that NO generators increase Fe-59 efflux from cells pre-labeled with Fe-59-transferrin (Wardrop, S. L., Watts, R. N., and Richardson, D. R. (2000) Biochemistry 39, 2748-2758), The mechanism involved in this process remains unknown, and in this investigation we demonstrate that it is potentiated upon adding D-glucose (D-Glc) to the reincubation medium. In D-Glc-free or D-Glc-containing media, 5.6 and 16.5% of cellular 59Fe was released, respectively, in the presence of S-nitrosoglutathione. This difference in 59Fe release was observed with a variety of NO generators and cell types and was not due to a change in cell viability. Kinetic studies showed that D-Glc had no effect on the rate of NO production by NO generators. Moreover, only the metabolizable monosaccharides D-Glc and D-mannose could stimulate NO-mediated Fe-59 mobilization, whereas other sugars not easily metabolized by fibroblasts had no effect. Hence, metabolism of the monosaccharides was essential to increase NO-mediated Fe-59 release. Incubation of cells with the citric acid cycle intermediates, citrate and pyruvate, did not enhance NO-mediated Fe-59 release. Significantly, preincubation with the GSH-depleting agents, L-buthionine-[S,R]-sulfoximine or diethyl maleate, prevented NO-mediated Fe-59 mobilization, This effect was reversed by incubating cells with N-acetyl-L-cysteine that reconstitutes GSH. These results indicate that GSH levels are essential for NO-mediated Fe-59 efflux. Hence, D-Glc metabolism via the hexose monophosphate shunt resulting in the generation of GSH may be essential for NO-mediated Fe-59 release. These results have important implications for intracellular signaling by NO and also NO-mediated cytotoxicity of activated macrophages that is due, in part, to iron release from tumor target cells.	Heart Res Inst, Iron Metab & Chelat Grp, Sydney, NSW 2050, Australia	University of Sydney; Heart Research Institute	Richardson, DR (corresponding author), Heart Res Inst, Iron Metab & Chelat Grp, 145 Missenden Rd, Sydney, NSW 2050, Australia.			Richardson, Des/0000-0003-0960-6415; Richardson, Des/0000-0002-5506-3274				Aleryani S, 1998, J BIOL CHEM, V273, P6041, DOI 10.1074/jbc.273.11.6041; AXELROD JD, 1983, BIOCHEMISTRY-US, V22, P2222, DOI 10.1021/bi00278a025; BASTIAN NR, 1994, J BIOL CHEM, V269, P5127; CLANCY RM, 1994, P NATL ACAD SCI USA, V91, P3680, DOI 10.1073/pnas.91.9.3680; Coffey RNT, 2000, CANCER-AM CANCER SOC, V88, P2092, DOI 10.1002/(SICI)1097-0142(20000501)88:9<2092::AID-CNCR15>3.0.CO;2-9; COMMONER B, 1970, CANCER RES, V30, P2091; DELHOTAL B, 1984, IN VITRO CELL DEV B, V20, P699, DOI 10.1007/BF02618875; Donovan A, 2000, NATURE, V403, P776, DOI 10.1038/35001596; DRAPIER JC, 1993, EMBO J, V12, P3643, DOI 10.1002/j.1460-2075.1993.tb06038.x; Drapier JC, 1997, METHODS, V11, P319, DOI 10.1006/meth.1996.0426; DRAPIER JC, 1991, J BIOL CHEM, V266, P10162; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; Esposito F, 1998, CELL DEATH DIFFER, V5, P940, DOI 10.1038/sj.cdd.4400427; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; Graham RM, 1998, J HEPATOL, V29, P603, DOI 10.1016/S0168-8278(98)80156-6; Graham RM, 1998, EUR J BIOCHEM, V253, P139, DOI 10.1046/j.1432-1327.1998.2530139.x; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; GRIFFITH OW, 1979, J BIOL CHEM, V254, P7558; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; Halestrap AP, 1999, BIOCHEM J, V343, P281, DOI 10.1042/0264-6021:3430281; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; HIBBS JB, 1984, BIOCHEM BIOPH RES CO, V123, P716, DOI 10.1016/0006-291X(84)90288-2; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HUANG AR, 1983, BIOCHIM BIOPHYS ACTA, V757, P306, DOI 10.1016/0304-4165(83)90056-9; IGNARRO LJ, 1991, BLOOD VESSELS, V28, P67; KALCKAR HM, 1991, ANNU REV BIOCHEM, V60, P1; Kang KW, 1999, NITRIC OXIDE-BIOL CH, V3, P265, DOI 10.1006/niox.1999.0233; Kennedy MC, 1997, J BIOL CHEM, V272, P20340, DOI 10.1074/jbc.272.33.20340; KHATSENKO OG, 1993, P NATL ACAD SCI USA, V90, P11147, DOI 10.1073/pnas.90.23.11147; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; KLETZIEN RF, 1973, J BIOL CHEM, V248, P711; Koshimura K, 1998, J NEUROSCI RES, V54, P664, DOI 10.1002/(SICI)1097-4547(19981201)54:5<664::AID-JNR11>3.0.CO;2-U; LANCASTER JR, 1990, P NATL ACAD SCI USA, V87, P1223, DOI 10.1073/pnas.87.3.1223; LEE MH, 1994, BIOCHEMISTRY-US, V33, P3679, DOI 10.1021/bi00178a026; LEPOIVRE M, 1991, BIOCHEM BIOPH RES CO, V179, P442, DOI 10.1016/0006-291X(91)91390-X; Lin RY, 1998, J BIOL CHEM, V273, P28959, DOI 10.1074/jbc.273.44.28959; Lomonosova EE, 1998, FREE RADICAL BIO MED, V25, P493, DOI 10.1016/S0891-5849(98)00080-X; MARAGOS CM, 1991, J MED CHEM, V34, P3242, DOI 10.1021/jm00115a013; Mathews CK, 1990, BIOCHEMISTRY-US, P433; MONCADA S, 1991, PHARMACOL REV, V43, P109; Pajor AM, 1999, ANNU REV PHYSIOL, V61, P663, DOI 10.1146/annurev.physiol.61.1.663; Panneerselvam K, 1997, J BIOL CHEM, V272, P23123, DOI 10.1074/jbc.272.37.23123; Pantopoulos K, 1996, MOL CELL BIOL, V16, P3781; PELLAT C, 1990, BIOCHEM BIOPH RES CO, V166, P119, DOI 10.1016/0006-291X(90)91919-J; REIF DW, 1990, ARCH BIOCHEM BIOPHYS, V283, P537, DOI 10.1016/0003-9861(90)90680-W; Richardson DR, 1997, BLOOD, V89, P3025, DOI 10.1182/blood.V89.8.3025; RICHARDSON DR, 1995, BLOOD, V86, P3211; RICHARDSON DR, 1990, BIOCHIM BIOPHYS ACTA, V1053, P1, DOI 10.1016/0167-4889(90)90018-9; RICHARDSON DR, 1995, BLOOD, V86, P4295, DOI 10.1182/blood.V86.11.4295.bloodjournal86114295; Richardson DR, 1997, BBA-BIOENERGETICS, V1320, P45, DOI 10.1016/S0005-2728(97)00008-X; SCHMIDT RF, 1983, HUMAN PHYSL, P2; SCHWARTZ NB, 1995, TXB BIOCH CLIN CORRE, P359; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Theil EC, 1998, MET IONS BIOL SYST, V35, P403; ULLREY DB, 1991, P NATL ACAD SCI USA, V88, P1504, DOI 10.1073/pnas.88.4.1504; Valeri F, 1997, FREE RADICAL BIO MED, V22, P257, DOI 10.1016/S0891-5849(96)00331-0; VANIN A F, 1967, Biofizika, V12, P829; VANIN AF, 1992, BIOCHIM BIOPHYS ACTA, V1135, P275, DOI 10.1016/0167-4889(92)90231-Y; VANIN AF, 1991, FEBS LETT, V289, P1, DOI 10.1016/0014-5793(91)80894-9; Wardrop SL, 2000, BIOCHEMISTRY-US, V39, P2748, DOI 10.1021/bi991099t; WEISS G, 1993, EMBO J, V12, P3651, DOI 10.1002/j.1460-2075.1993.tb06039.x; WOOLUM JC, 1968, BIOCHIM BIOPHYS ACTA, V160, P311, DOI 10.1016/0005-2795(68)90204-3; YOREK MA, 1991, DIABETES, V40, P1016, DOI 10.2337/diabetes.40.8.1016	64	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4724	4732		10.1074/jbc.M006318200	http://dx.doi.org/10.1074/jbc.M006318200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11078730	hybrid			2022-12-25	WOS:000168484300028
J	Yamagishi, S; Yamada, M; Ishikawa, Y; Matsumoto, T; Ikeuchi, T; Hatanaka, H				Yamagishi, S; Yamada, M; Ishikawa, Y; Matsumoto, T; Ikeuchi, T; Hatanaka, H			p38 Mitogen-activated protein kinase regulates low potassium-induced c-Jun phosphorylation and apoptosis in cultured cerebellar granule neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; K+-INDUCED APOPTOSIS; TRANSCRIPTION FACTOR; SYMPATHETIC NEURONS; MAP KINASES; SURVIVAL; GROWTH; IDENTIFICATION; INVOLVEMENT; PREVENTION	Cultured rat cerebellar granule neurons are widely used as a model system for studying neuronal apoptosis, After maturation by culturing in medium containing 26 mM potassium (high K+), changing to medium containing 5 mM potassium (low K+; LK) rapidly induces neuronal apoptosis. Then over 50% of granule cells die within 24 h. However, the molecular mechanisms by which the LK-induced apoptosis occurs in cultured cerebellar granule cells remain unclear. In the present study, we found that p38 MAP kinase (p38) was an important factor for LK-induced apoptosis, Three hours after changing to LK medium, p38 was markedly activated. In addition, SB203580, a specific inhibitor of p38, strongly inhibited the phosphorylation and expression of c-Jun in LK-induced apoptosis of cultured cerebellar granule cells. In vitro kinase assay using glutathione S-transferase-c-Jun as a substrate showed that p38 directly phosphorylated c-Jun. Furthermore, in the presence of SB203580, about 80% of neurons survived. These results indicate that p38 regulates LK-induced apoptosis of cerebellar granule neurons.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Osaka University	Yamada, M (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yamada@protein.osaka-u.ac.jp						Araki T, 1998, BRAIN RES, V794, P239, DOI 10.1016/S0006-8993(98)00231-5; Behrens MM, 1999, NEUROSCIENCE, V94, P917, DOI 10.1016/S0306-4522(99)00212-2; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; D'MELLO SR, 1993, P NATL ACAD SCI USA, V90, P10989, DOI 10.1073/pnas.90.23.10989; Eilers A, 1998, J NEUROSCI, V18, P1713; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAM J, 1995, NEURON, V14, P927, DOI 10.1016/0896-6273(95)90331-3; HANSEN MB, 1989, J IMMUNOL METHODS, V119, P203, DOI 10.1016/0022-1759(89)90397-9; Harada J, 1999, JPN J PHARMACOL, V79, P369, DOI 10.1254/jjp.79.369; HATANAKA H, 1988, DEV BRAIN RES, V39, P85, DOI 10.1016/0165-3806(88)90069-7; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Horstmann S, 1998, J NEUROSCI RES, V52, P483, DOI 10.1002/(SICI)1097-4547(19980515)52:4<483::AID-JNR12>3.3.CO;2-Y; Inamura N, 2000, J NEUROSCI RES, V60, P450, DOI 10.1002/(SICI)1097-4547(20000515)60:4<450::AID-JNR3>3.3.CO;2-G; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kikuchi M, 2000, J NEUROSCI, V20, P5037; KUBO T, 1995, DEV BRAIN RES, V85, P249, DOI 10.1016/0165-3806(94)00220-T; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; LEVI G, 1984, BRAIN RES, V290, P77, DOI 10.1016/0006-8993(84)90737-6; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Miller TM, 1996, J NEUROSCI, V16, P7487; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Shimoke K, 1998, FEBS LETT, V437, P221, DOI 10.1016/S0014-5793(98)01235-6; Shimoke K, 1997, DEV BRAIN RES, V101, P197, DOI 10.1016/S0165-3806(97)00065-5; Shimoke K, 1999, DEV BRAIN RES, V112, P245, DOI 10.1016/S0165-3806(98)00172-2; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Watson A, 1998, J NEUROSCI, V18, P751; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamagishi S, 2000, NEUROSCIENCE, V95, P473; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899	36	64	65	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5129	5133		10.1074/jbc.M007258200	http://dx.doi.org/10.1074/jbc.M007258200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11083864	hybrid			2022-12-25	WOS:000168484300081
J	Dowd, SR; Bier, ME; Patton-Vogt, JL				Dowd, SR; Bier, ME; Patton-Vogt, JL			Turnover of phosphatidylcholine in Saccharomyces cerevisiae - The role of the CDP-choline pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-D ACTIVITY; TRANSFER PROTEIN; RAT-LIVER; IN-VIVO; YEAST; GENE; CELLS; PHOSPHATIDYLETHANOLAMINE; BIOSYNTHESIS; METABOLISM	The regulation of phosphatidylcholine degradation as a function of the route of phosphatidylcholine (PC) synthesis and changing environmental conditions has been investigated in the yeast Saccharomyces cerevisiae. In the wild-type strains studied, deacylation of phosphatidylcholine to glycerophosphocholine is induced when choline is supplied to the culture medium and, also, when the culture temperature is raised from 30 to 37 degreesC. In strains bearing mutations in any of the genes encoding enzymes of the GDP-choline pathway for phosphatidylcholine biosynthesis (CKI1, choline kinase; CPT1, 1, 2-diacylglycerol choline phosphotransferase; PCT1, CTP:phosphocholine cytidylyltransferase), no induction of phosphatidylcholine turnover and glycerophosphocholine production is seen in response to choline availability or elevated temperature. In contrast, the induction of phosphatidylcholine deacylation does occur in a strain bearing mutations in genes encoding enzymes of the methylation pathway for phosphatidylcholine biosynthesis (i.e. CHO2/PEM1 and OPI3/PEM2). Whereas the synthesis of PC via CDP-choline is accelerated when shifted from 30 to 37 degreesC, synthesis of PC via the methylation pathway is largely unaffected by the temperature shift. These results suggest that the deacylation of PC to GroPC requires an active CDP-choline pathway for PC biosynthesis but not an active methylation pathway. Furthermore, the data indicate that the synthesis and turnover of CDP-choline-derived PC, but not methylation pathway-derived PC, are accelerated by the stress of elevated temperature.	Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA	Carnegie Mellon University; Carnegie Mellon University	Patton-Vogt, JL (corresponding author), Carnegie Mellon Univ, Dept Biol Sci, 4400 5th Ave, Pittsburgh, PA 15213 USA.		BIER, MARK E/F-5385-2015	BIER, MARK E/0000-0002-5220-9338	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019629, R01GM059817, R01GM019629] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059817, GM-19629, GM59817] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aboagye EO, 1999, CANCER RES, V59, P80; ANGUS WW, 1972, ARCH BIOCHEM BIOPHYS, V151, P483, DOI 10.1016/0003-9861(72)90525-5; Anthony ML, 1999, J BIOL CHEM, V274, P19686, DOI 10.1074/jbc.274.28.19686; ATKINSON KD, 1984, J BACTERIOL, V160, P80, DOI 10.1128/JB.160.1.80-86.1984; Baburina I, 1999, J BIOL CHEM, V274, P9400, DOI 10.1074/jbc.274.14.9400; Barbour SE, 1999, BBA-MOL CELL BIOL L, V1439, P77, DOI 10.1016/S1388-1981(99)00078-5; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; COOK SJ, 1989, BIOCHEM J, V263, P581, DOI 10.1042/bj2630581; Cui Z, 1996, J BIOL CHEM, V271, P14668, DOI 10.1074/jbc.271.25.14668; Daum G, 1999, YEAST, V15, P601, DOI 10.1002/(SICI)1097-0061(199905)15:7<601::AID-YEA390>3.0.CO;2-N; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; Ella KM, 1996, BIOCHEM J, V314, P15, DOI 10.1042/bj3140015; Fallbrook A, 1999, BRAIN RES, V834, P207, DOI 10.1016/S0006-8993(99)01570-X; GOMEZ F, 1989, EUR J BIOCHEM, V186, P23, DOI 10.1111/j.1432-1033.1989.tb15172.x; Griac P, 1996, J BIOL CHEM, V271, P25692, DOI 10.1074/jbc.271.41.25692; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; Hodges PE, 1999, NUCLEIC ACIDS RES, V27, P69, DOI 10.1093/nar/27.1.69; HONIGBERG SM, 1992, GENETICS, V130, P703; Kent C, 1999, TRENDS BIOCHEM SCI, V24, P146, DOI 10.1016/S0968-0004(99)01365-1; Kim KS, 1999, J BIOL CHEM, V274, P14857, DOI 10.1074/jbc.274.21.14857; LEE KS, 1994, J BIOL CHEM, V269, P19725; MARTIN TW, 1988, BIOCHIM BIOPHYS ACTA, V962, P282, DOI 10.1016/0005-2760(88)90258-5; MASUDA N, 1991, EUR J BIOCHEM, V202, P783, DOI 10.1111/j.1432-1033.1991.tb16433.x; Mayr JA, 1996, FEBS LETT, V393, P236, DOI 10.1016/0014-5793(96)00893-9; McClure R J, 1995, Neuroimaging Clin N Am, V5, P69; Merkel O, 1999, J BIOL CHEM, V274, P28121, DOI 10.1074/jbc.274.40.28121; Morris AJ, 1997, ANAL BIOCHEM, V252, P1, DOI 10.1006/abio.1997.2299; NITSCH RM, 1992, P NATL ACAD SCI USA, V89, P1671, DOI 10.1073/pnas.89.5.1671; PALTAUF F, 1992, MOL CELLULAR BIOL YE, V2, P415; PATTON JL, 1995, J BACTERIOL, V177, P3379, DOI 10.1128/jb.177.12.3379-3385.1995; PattonVogt JL, 1997, J BIOL CHEM, V272, P20873, DOI 10.1074/jbc.272.33.20873; QUINN PJ, 1988, SYM SOC EXP BIOL, V42, P237; Ramanadham S, 2000, BBA-MOL CELL BIOL L, V1484, P251, DOI 10.1016/S1388-1981(00)00022-6; RATNAM S, 1995, ARCH BIOCHEM BIOPHYS, V323, P313, DOI 10.1006/abbi.1995.9959; ROBITAILLE PML, 1991, J MAGN RESON, V92, P73, DOI 10.1016/0022-2364(91)90248-R; Rose K, 1995, P NATL ACAD SCI USA, V92, P12151, DOI 10.1073/pnas.92.26.12151; Sreenivas A, 1998, J BIOL CHEM, V273, P16635, DOI 10.1074/jbc.273.27.16635; Street JC, 1997, MAGNET RESON MED, V38, P769, DOI 10.1002/mrm.1910380513; SUMMERS EF, 1988, GENETICS, V120, P909; THOMPSON W, 1991, BIOCHIM BIOPHYS ACTA, V1083, P207, DOI 10.1016/0005-2760(91)90044-I; TIJBURG LBM, 1991, BIOCHIM BIOPHYS ACTA, V1085, P167, DOI 10.1016/0005-2760(91)90091-U; VELDHUIZEN RAW, 1991, BIOCHIM BIOPHYS ACTA, V1083, P211, DOI 10.1016/0005-2760(91)90045-J; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Waite KA, 2000, J BIOL CHEM, V275, P21197, DOI 10.1074/jbc.M003539200; Waksman M, 1996, J BIOL CHEM, V271, P2361, DOI 10.1074/jbc.271.5.2361; Waksman M, 1997, J BIOL CHEM, V272, P36; WALKEY CJ, 1994, J BIOL CHEM, V269, P5742; WATSON K, 1987, YEASTS, V2, P41; Wells GB, 1998, J BIOL CHEM, V273, P7235, DOI 10.1074/jbc.273.13.7235	50	92	94	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3756	3763		10.1074/jbc.M003694200	http://dx.doi.org/10.1074/jbc.M003694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11078727	hybrid			2022-12-25	WOS:000166921200006
J	Huang, HC; Sherman, MY; Kandror, O; Goldberg, AL				Huang, HC; Sherman, MY; Kandror, O; Goldberg, AL			The molecular chaperone DnaJ is required for the degradation of a soluble abnormal protein in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; DEPENDENT DEGRADATION; BINDING-SPECIFICITY; RAPID DEGRADATION; HSP70 CHAPERONES; QUALITY-CONTROL; CLP PROTEASE; INVOLVEMENT; EXPORT; CYTOPLASM	In addition to promoting protein folding and translocation, molecular chaperones of Hsp70/DnaJ families are essential for the selective breakdown of many unfolded proteins. It has been proposed that chaperones function in degradation to maintain the substrates in a soluble form. In Escherichia coli, a nonsecreted alkaline phosphatase mutant that lacks its signal sequence (PhoA Delta2-22) fails to fold in the cytosol and is rapidly degraded at 37 degreesC. We show that PhoA Delta2-22 is degraded by two ATP-dependent proteases, La (Lon) and ClpAP, and breakdown by both is blocked in a dnaJ259-ts mutant at 37 degreesC. Both proteases could be immunoprecipitated with PhoA, but to a much lesser extent in the dnaJ mutant. Therefore, DnaJ appears to promote formation of protease-substrate complexes. DnaJ could be coimmunoprecipitated with PhoA, and the extent of this association directly correlated with its rate of degradation. Although PhoA was not degraded when DnaJ was inactivated, 50% or more of the PhoA remained soluble. PhoA breakdown and solubility did not require ClpB. PhoA degradation was reduced in a thioredoxin-reductase mutant (trxB), which allowed PhoA Delta2-22 to fold into an active form in the cytosol. Introduction of the dnaJ mutation into trxB cells further stabilized PhoA, increased enzyme activity, and left PhoA completely soluble. Thus, DnaJ, although not necessary for folding (or preventing PhoA aggregation), is required for PhoA degradation and must play an active role in this process beyond maintaining the substrate in a soluble form.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.				NIGMS NIH HHS [GM46147, GM51293] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147, R01GM051293] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; DECROUYCHANEL A, 1995, J BIOL CHEM, V270, P22669, DOI 10.1074/jbc.270.39.22669; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GOFF SA, 1987, J BIOL CHEM, V262, P4508; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; GRAGEROV A, 1992, P NATL ACAD SCI USA, V89, P10341, DOI 10.1073/pnas.89.21.10341; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hayes SA, 1996, J CELL BIOL, V132, P255, DOI 10.1083/jcb.132.3.255; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Jubete Y, 1996, J BIOL CHEM, V271, P30798, DOI 10.1074/jbc.271.48.30798; Kandror O, 1999, J BIOL CHEM, V274, P37743, DOI 10.1074/jbc.274.53.37743; KANDROR O, 1995, EMBO J, V14, P6021, DOI 10.1002/j.1460-2075.1995.tb00290.x; KANDROR O, 1994, J BIOL CHEM, V269, P23575; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; LIU GP, 1989, P NATL ACAD SCI USA, V86, P9213, DOI 10.1073/pnas.86.23.9213; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Prinz WA, 1996, EMBO J, V15, P5209, DOI 10.1002/j.1460-2075.1996.tb00906.x; PripBuus C, 1996, FEBS LETT, V380, P142, DOI 10.1016/0014-5793(96)00049-X; PROUTY WF, 1972, NATURE-NEW BIOL, V240, P147, DOI 10.1038/newbio240147a0; PROUTY WF, 1975, J BIOL CHEM, V250, P1112; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Russell R, 1999, BIOCHEMISTRY-US, V38, P4165, DOI 10.1021/bi9824036; Schneider EL, 1997, NAT BIOTECHNOL, V15, P581, DOI 10.1038/nbt0697-581; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Sherman M Y, 1996, EXS, V77, P57; SHERMAN MY, 1992, EMBO J, V11, P71; STRAUS DB, 1988, GENE DEV, V2, P1851, DOI 10.1101/gad.2.12b.1851; WAGNER I, 1994, EMBO J, V13, P5135, DOI 10.1002/j.1460-2075.1994.tb06843.x; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wild J, 1996, J BACTERIOL, V178, P3608, DOI 10.1128/jb.178.12.3608-3613.1996; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; Yaglom JA, 1996, MOL CELL BIOL, V16, P3679	50	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3920	3928		10.1074/jbc.M002937200	http://dx.doi.org/10.1074/jbc.M002937200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11062236	hybrid			2022-12-25	WOS:000166921200028
J	Pepio, AM; Sossin, WS				Pepio, AM; Sossin, WS			Membrane translocation of novel protein kinase Cs is regulated by phosphorylation of the C2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APLYSIA SENSORY NEURONS; LONG-TERM FACILITATION; PHORBOL ESTER BINDING; APL-II; TYROSINE PHOSPHORYLATION; CRYSTAL-STRUCTURE; ACTIVATION; DELTA; CELLS; ALPHA	Ca2+-independent or novel protein kinase Cs (nPKCs) contain an N-terminal C2 domain of unknown function. Removal of the C2 domain of the Aplysia nPKC Apl II allows activation of the enzyme at lower concentrations of phosphatidylserine, suggesting an inhibitory role far the C2 domain in enzyme activation. However, the mechanism for Ca domain-mediated inhibition is not known. Mapping of the autophosphorylation sites for protein kinase C (PRC) ApI II reveals four phosphopeptides in the regulatory domain of PRC ApI II, two of which are in the C2 domain at serine 2 and serine 36. Unlike most PKC autophosphorylation sites, these serines could be phosphorylated in trans. Interestingly, phosphorylation of serine 36 increased binding of the C2 domain to phosphatidylserine membranes in vitro. In cells, PRC Apl II phosphorylation at serine 36 was increased by PKC activators, and PKC phosphorylated at this position translocated more efficiently to membranes. Moreover, mutation of serine 36 to alanine significantly reduced membrane translocation of PKC Apl II. We suggest that translocation of nPKCs is regulated by phosphorylation of the C2 domain.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada	McGill University	Sossin, WS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Rm 776,3801 Rue Univ, Montreal, PQ H3A 2B4, Canada.	mdws@musica.mcgill.ca						Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brodie C, 1998, J BIOL CHEM, V273, P30713, DOI 10.1074/jbc.273.46.30713; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; Dorn GW, 1999, P NATL ACAD SCI USA, V96, P12798, DOI 10.1073/pnas.96.22.12798; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Dyer JR, 1998, J BIOL CHEM, V273, P29469, DOI 10.1074/jbc.273.45.29469; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; GHIRARDI M, 1992, NEURON, V9, P479, DOI 10.1016/0896-6273(92)90185-G; Gray MO, 1997, J BIOL CHEM, V272, P30945, DOI 10.1074/jbc.272.49.30945; Ibata K, 1998, J BIOL CHEM, V273, P12267, DOI 10.1074/jbc.273.20.12267; Johnson JE, 1997, J BIOL CHEM, V272, P30787, DOI 10.1074/jbc.272.49.30787; Keranen LM, 1997, J BIOL CHEM, V272, P25959, DOI 10.1074/jbc.272.41.25959; KRUGER KE, 1991, J NEUROSCI, V11, P2303; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Manseau F, 1998, J NEUROPHYSIOL, V79, P1210, DOI 10.1152/jn.1998.79.3.1210; Medkova M, 1999, J BIOL CHEM, V274, P19852, DOI 10.1074/jbc.274.28.19852; Medkova M, 1998, J BIOL CHEM, V273, P17544, DOI 10.1074/jbc.273.28.17544; Medkova M, 1998, BIOCHEMISTRY-US, V37, P4892, DOI 10.1021/bi972495j; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOSIOR M, 1995, J BIOL CHEM, V270, P25526, DOI 10.1074/jbc.270.43.25526; Nakhost A, 1999, J BIOL CHEM, V274, P28944, DOI 10.1074/jbc.274.41.28944; Nakhost A, 1998, J NEUROCHEM, V71, P1221; Nalefski EA, 1996, PROTEIN SCI, V5, P2375, DOI 10.1002/pro.5560051201; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; Pappa H, 1998, STRUCT FOLD DES, V6, P885, DOI 10.1016/S0969-2126(98)00090-2; Pepio AM, 1998, J BIOL CHEM, V273, P19040, DOI 10.1074/jbc.273.30.19040; Pepio AM, 1998, BIOCHEMISTRY-US, V37, P1256, DOI 10.1021/bi971841u; Perisic O, 1998, J BIOL CHEM, V273, P1596, DOI 10.1074/jbc.273.3.1596; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Sossin W S, 1994, Learn Mem, V1, P189; SOSSIN WS, 1992, J NEUROSCI, V12, P1160; Sossin WS, 1997, LEARN MEMORY, V3, P389, DOI 10.1101/lm.3.5.389; Sossin WS, 1996, J NEUROCHEM, V67, P220; Sossin WS, 1996, J NEUROSCI, V16, P10; Sugita S, 1997, J NEUROSCI, V17, P7237; SUGITA S, 1992, J NEUROPHYSIOL, V68, P643, DOI 10.1152/jn.1992.68.2.643; Sweatt JD, 1998, J NEUROCHEM, V71, P1075; TANAKA C, 1994, ANNU REV NEUROSCI, V17, P551, DOI 10.1146/annurev.ne.17.030194.003003; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417	45	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3846	3855		10.1074/jbc.M006339200	http://dx.doi.org/10.1074/jbc.M006339200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11073945	hybrid			2022-12-25	WOS:000166921200019
J	Weatherman, RV; Scanlan, TS				Weatherman, RV; Scanlan, TS			Unique protein determinants of the subtype-selective ligand responses of the estrogen receptors (ER alpha and ER beta) at AP-1 sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; PROMOTER-CONTEXT; BINDING DOMAINS; CELL-TYPE; F-DOMAIN; ANTAGONISTS; TAMOXIFEN; REGIONS; ANTIESTROGENS; LOCALIZATION	The two subtypes of human estrogen receptor, alpha (hER alpha and beta (hER beta), regulate transcription at an AP-1 response element differently in response to estradiol and the anti-estrogens tamoxifen and raloxifene. To better understand the protein determinants of these differences, chimeric and deletional mutants of the N-terminal domain and the F region of ER alpha and ER beta were made and tested in transient transfection assays at the classical estrogen response element (ERE) site as well as at an AP-1 site. Although the same regions on each receptor subtype appeared to be primarily responsible for estradiol activation at an ERE and in HeLa cells, major differences between ER alpha and ER beta mutants were seen in the estrogen and anti-estrogen responses at an AP-1 site. This differential ligand response maps to the N-terminal domain and the F region. These results suggest that different estrogenic and anti-estrogenic ligands use different mechanisms of activation and inhibition at the AP-1 site. In contrast to previous studies, this work also shows that many of subtype-specific responses are not transferred to the other subtype by swapping the N-terminal domain of the receptor. This implies that there are other unique surfaces presented by each subtype outside of the N-terminal domain, and these surfaces can play a role in subtype-selective signaling. Together, these data suggest a complex interface between ligand, response element, and receptor that underlies ligand activation in estrogen signaling pathways.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Cellular Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Scanlan, TS (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057574] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 57574] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barkhem T, 1998, MOL PHARMACOL, V54, P105, DOI 10.1124/mol.54.1.105; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Giguere V, 1998, STEROIDS, V63, P335, DOI 10.1016/S0039-128X(98)00024-5; Gustafsson JA, 1998, CURR OPIN CHEM BIOL, V2, P508, DOI 10.1016/S1367-5931(98)80127-0; Jones PS, 1999, J BIOL CHEM, V274, P32008, DOI 10.1074/jbc.274.45.32008; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; KUMAR V, 1986, EMBO J, V5, P2231, DOI 10.1002/j.1460-2075.1986.tb04489.x; KUSHNER PJ, 1990, MOL ENDOCRINOL, V4, P1465, DOI 10.1210/mend-4-10-1465; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Leygue E, 1998, J CLIN ENDOCR METAB, V83, P3754, DOI 10.1210/jc.83.10.3754; MacGregor JI, 1998, PHARMACOL REV, V50, P151; McInerney EM, 1998, ENDOCRINOLOGY, V139, P4513, DOI 10.1210/en.139.11.4513; McInerney EM, 1996, J BIOL CHEM, V271, P24172, DOI 10.1074/jbc.271.39.24172; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; MONTANO MM, 1995, MOL ENDOCRINOL, V9, P814, DOI 10.1210/me.9.7.814; Montano MM, 1998, J BIOL CHEM, V273, P25443, DOI 10.1074/jbc.273.39.25443; Nichols M, 1998, EMBO J, V17, P765, DOI 10.1093/emboj/17.3.765; Norris JD, 1999, SCIENCE, V285, P744, DOI 10.1126/science.285.5428.744; Paech K, 1997, SCIENCE, V277, P1508, DOI 10.1126/science.277.5331.1508; Paige LA, 1999, P NATL ACAD SCI USA, V96, P3999, DOI 10.1073/pnas.96.7.3999; PAKDEL F, 1993, J STEROID BIOCHEM, V46, P663, DOI 10.1016/0960-0760(93)90307-I; PHAM TA, 1992, MOL ENDOCRINOL, V6, P1043, DOI 10.1210/me.6.7.1043; Pike ACW, 1999, EMBO J, V18, P4608, DOI 10.1093/emboj/18.17.4608; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; Saville B, 2000, J BIOL CHEM, V275, P5379, DOI 10.1074/jbc.275.8.5379; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Zou AH, 1999, MOL ENDOCRINOL, V13, P418, DOI 10.1210/me.13.3.418	38	39	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3827	3832		10.1074/jbc.M005414200	http://dx.doi.org/10.1074/jbc.M005414200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11060287	hybrid			2022-12-25	WOS:000166921200016
J	Salvini, R; Bardoni, A; Valli, M; Trinchera, M				Salvini, R; Bardoni, A; Valli, M; Trinchera, M			beta 1,3-galactosyltransferase beta 3Gal-T5 acts on the GlcNA beta 1 -> 3Ga beta 1 -> 4GlcNAc beta 1 -> R sugar chains of carcinoembryonic antigen and other N-linked glycoproteins and is down-regulated in colon adenocarcinomas	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN COLORECTAL-CANCER; CARBOHYDRATE STRUCTURES; UDP-GALACTOSE; CELL-LINES; UDP-GALACTOSE-2-ACETAMIDO-2-DEOXY-D-GLUCOSE 3-BETA-GALACTOSYLTRANSFERASE; ACETYLLACTOSAMINE SYNTHESIS; UP-REGULATION; TYPE-1 CHAIN; EXPRESSION; CLONING	We attempted to determine whether beta1,3-galactosyl-transferase beta 3Gal-T5 is involved in the biosynthesis of a specific subset of type 1 chain carbohydrates and expressed in a cancer-associated manner. We transfected Chinese hamster ovary (CHO) cells expressing Fuc-TIII with beta 3Gal-T cDNAs and studied the relevant glycoconjugates formed. beta 3Gal-T5 directs synthesis of Lewis type 1 antigens in CHO cells more efficiently than beta 3Gal-T1, whereas beta 3Gal-T2, -T3, and -T4 are almost unable to direct synthesis. In the clone expressing Fuc-TIII and beta 3Gal-T5 (CHO-FT-T5), sialyl-Lewis a synthesis is strongly inhibited by swainsonine but not by benzyl-alpha -GalNAc, and sialyl-Lewis x is absent, although it is detected in the clones expressing Fuc-TIII and beta 3Gal-T1 (CHO-FT-T1) or Fuc-TIII and beta 3Gal-T2 (CHO-FT-T2). Endo-beta -galactosidase treatment of N-glycans prepared from clone CHO-FT-TB releases (+/-NeuAc alpha2-->3)Gal beta1-->3[Fuc alpha1-->4]GlcNAc beta1-->3Gal but not GlcNAc beta1-->3Gal or type 2 chain oligosaccharides, which are found in CHO-FT-T1 cells. This result indicates that beta 3Gal-T5 expression prevents poly-N-acetyllactosamine and sialyl-Lewis x synthesis on N-glycans, Kinetic studies confirm that beta 3Gal-T5 prefers accepters having the GlcNAc beta1-->3Gal end, including lactotriosylceramide. Competitive reverse transcriptase mediated-polymerase chain reaction shows that the beta 3Gal-T5 transcript is expressed in normal colon mucosa but not or poorly in adenocarcinomas, Moreover, recombinant carcinoembryonic antigen purified from a CHO clone expressing Fuc-TIII and beta 3Gal-T5 reacts with anti-sialyl-Lewis a and carries type 1 chains on oligosaccharides released by endo-beta -galactosidase. We conclude that beta 3Gal-T5 down-regulation plays a relevant role in determining the cancer-associated glycosylation pattern of N-glycans.	Univ Pavia, Dept Biochem, I-27100 Pavia, Italy	University of Pavia	Trinchera, M (corresponding author), Univ Insubria Med Sch, Pavia, Italy.							Amado M, 1999, BBA-GEN SUBJECTS, V1473, P35, DOI 10.1016/S0304-4165(99)00168-3; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; BAECKSTROM D, 1995, J BIOL CHEM, V270, P13688, DOI 10.1074/jbc.270.23.13688; Bardoni A, 1999, FEBS LETT, V451, P75, DOI 10.1016/S0014-5793(99)00547-5; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIEN JL, 1978, J BIOL CHEM, V253, P4031; CUMMINGS RD, 1993, GLYCOBIOLOGY PRACTIC, P243; DATTI A, 1993, J BIOL CHEM, V268, P5409; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; FUKUSHIMA K, 1995, GLYCOBIOLOGY, V5, P105, DOI 10.1093/glycob/5.1.105; Hakomori S, 1996, CANCER RES, V56, P5309; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V270, P630, DOI 10.1016/0003-9861(89)90546-8; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Ito H, 1997, INT J CANCER, V71, P556, DOI 10.1002/(SICI)1097-0215(19970516)71:4<556::AID-IJC9>3.3.CO;2-J; Kolbinger F, 1998, J BIOL CHEM, V273, P433, DOI 10.1074/jbc.273.1.433; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Kudo T, 1998, LAB INVEST, V78, P797; LEE N, 1990, J BIOL CHEM, V265, P20476; MAGNANI JL, 1983, CANCER RES, V43, P5489; MATSUOKA Y, 1991, TUMOR BIOL, V12, P91, DOI 10.1159/000217693; Murata K, 2000, CLIN CANCER RES, V6, P1772; Narimatsu H, 1998, CANCER RES, V58, P512; Nishihara S, 1999, GLYCOBIOLOGY, V9, P607, DOI 10.1093/glycob/9.6.607; OKAJIMA T, 2000, J BIOL CHEM; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; SASAKI K, 1994, Patent No. 0618759; Seko A, 1996, CANCER RES, V56, P3468; SHEARES BT, 1983, J BIOL CHEM, V258, P9893; Stroop CJM, 2000, ARCH BIOCHEM BIOPHYS, V374, P42, DOI 10.1006/abbi.1999.1660; SUEYOSHI S, 1994, J BIOL CHEM, V269, P32342; Taniguchi N, 1999, BBA-MOL BASIS DIS, V1455, P287, DOI 10.1016/S0925-4439(99)00066-6; Togayachi A, 1999, INT J CANCER, V83, P70, DOI 10.1002/(SICI)1097-0215(19990924)83:1<70::AID-IJC14>3.0.CO;2-K; TRINCHERA M, 1989, J BIOL CHEM, V264, P15766; Trinchera M, 1996, FEBS LETT, V395, P68, DOI 10.1016/0014-5793(96)01003-4; Ujita M, 2000, J BIOL CHEM, V275, P15868, DOI 10.1074/jbc.M001034200; Ujita M, 1999, J BIOL CHEM, V274, P16717, DOI 10.1074/jbc.274.24.16717; Valli M, 1999, GLYCOBIOLOGY, V9, P83, DOI 10.1093/glycob/9.1.83; Valli M, 1998, EUR J BIOCHEM, V256, P494, DOI 10.1046/j.1432-1327.1998.2560494.x; Wojciechowicz DC, 2000, BIOCHEM BIOPH RES CO, V273, P147, DOI 10.1006/bbrc.2000.2906; YAMASHITA K, 1989, J BIOL CHEM, V264, P17873; YAMASHITA K, 1987, CANCER RES, V47, P3451; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x; Zhou DP, 2000, J BIOL CHEM, V275, P22631, DOI 10.1074/jbc.C000263200	45	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3564	3573		10.1074/jbc.M006662200	http://dx.doi.org/10.1074/jbc.M006662200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11058588	hybrid			2022-12-25	WOS:000166784900076
J	Ulivieri, C; Peter, A; Orsini, E; Palmer, E; Baldari, CT				Ulivieri, C; Peter, A; Orsini, E; Palmer, E; Baldari, CT			Defective signaling to Fyn by a T cell antigen receptor lacking the alpha-chain connecting peptide motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; MICE LACKING; PHOSPHOLIPASE C-GAMMA-1; INTERLEUKIN-2 PROMOTER; POSITIVE SELECTION; TCR/CD3 COMPLEX; CALCIUM INFLUX; MUTANT MICE; ACTIVATION; PHOSPHORYLATION	A key role in the communication between the alpha beta TCR and the CD3/xi complex is played by a specific moth within the connecting peptide domain of the TCR alpha chain (alpha -CPM). T cell hybridomas expressing an alpha -CPM-mutated TCR show a dramatic impairment in antigen-driven interleukin-2 production This defect can be complemented by a calcium ionophore, indicating that activation of the calcium pathway is impaired. Several lines of evidence implicate Fyn in the regulation of calcium mobilization, at least in part through the activation of phospholipase C gamma. Here we have investigated the potential involvement of Fyn in the TCR cu-CPM signaling defect, Using T cell hybridomas expressing either a wild-type TCR or an alpha -CPM mutant, we show that Fyn fails to be activated by the mutant receptor following SEE binding and fails to generate tyrosine-phosphorylated Pyk2, a member of the focal adhesion kinase family. This defect correlated with an impairment in phospholipase C gamma phosphorylation. Production of interlukin-2 and activation of the transcription factor NF-AT in response to triggering of the TCR alpha -CPM mutant with SEE were fully restored in the presence of constitutively active Fyn. Hence the signaling defect generated by the TCR alpha -CPM mutation results at least in part from an impaired coupling of the TCR.CD3 complex to Fyn activation.	Univ Siena, Dept Evolut Biol, I-53100 Siena, Italy; Basel Inst Immunol, CH-4005 Basel, Switzerland	University of Siena	Baldari, CT (corresponding author), Univ Siena, Dept Evolut Biol, Via Mattioli 4, I-53100 Siena, Italy.	baldari@unisi.it	Ulivieri, Cristina/AAH-7543-2020	Ulivieri, Cristina/0000-0002-1710-7977; Baldari, Cosima/0000-0002-4414-6744				ALCOVER A, 1988, EMBO J, V7, P1973, DOI 10.1002/j.1460-2075.1988.tb03035.x; AOE T, 1994, INT IMMUNOL, V6, P1671, DOI 10.1093/intimm/6.11.1671; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Ardouin L, 1999, IMMUNITY, V10, P409, DOI 10.1016/S1074-7613(00)80041-2; Backstrom BT, 1998, SCIENCE, V281, P835, DOI 10.1126/science.281.5378.835; Backstrom BT, 1996, IMMUNITY, V5, P437, DOI 10.1016/S1074-7613(00)80500-2; BALDARI CT, 1993, J BIOL CHEM, V268, P8406; BALDARI CT, 1993, FEBS LETT, V323, P233, DOI 10.1016/0014-5793(93)81346-2; BALDARI CT, 1995, EUR J IMMUNOL, V25, P919, DOI 10.1002/eji.1830250409; BALDARI CT, 1992, J BIOL CHEM, V267, P4289; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DASILVA AJ, 1992, MOL IMMUNOL, V29, P1417, DOI 10.1016/0161-5890(92)90215-J; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Dave VP, 1998, INT IMMUNOL, V10, P1481, DOI 10.1093/intimm/10.10.1481; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DAVIDSON D, 1994, MOL CELL BIOL, V14, P4554, DOI 10.1128/MCB.14.7.4554; FUSAKI N, 1994, INT IMMUNOL, V6, P1245, DOI 10.1093/intimm/6.8.1245; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; Genot E, 2000, CURR OPIN IMMUNOL, V12, P289, DOI 10.1016/S0952-7915(00)00089-3; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; HALL CG, 1993, SCIENCE, V261, P915, DOI 10.1126/science.8346442; Jayaraman T, 1996, SCIENCE, V272, P1492, DOI 10.1126/science.272.5267.1492; Katagiri T, 2000, J BIOL CHEM, V275, P19645, DOI 10.1074/jbc.M909828199; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; Law CL, 1996, MOL CELL BIOL, V16, P1305; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; Luton F, 1997, J IMMUNOL, V158, P4162; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Milia E, 1996, ONCOGENE, V13, P767; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; NEL AE, 1995, J BIOL CHEM, V270, P18428, DOI 10.1074/jbc.270.31.18428; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; Qian DP, 1997, CURR OPIN CELL BIOL, V9, P205, DOI 10.1016/S0955-0674(97)80064-6; RIGLEY K, 1995, J IMMUNOL, V154, P1136; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; She J, 1999, INT IMMUNOL, V11, P845, DOI 10.1093/intimm/11.5.845; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STAERZ UD, 1985, J IMMUNOL, V134, P3994; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; Ulivieri C, 1999, EUR J IMMUNOL, V29, P2625; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; VONBOEHMER H, 1994, CELL, V76, P219, DOI 10.1016/0092-8674(94)90330-1; WEISS A, 1991, ANNU REV GENET, V25, P487, DOI 10.1146/annurev.ge.25.120191.002415; Werlen G, 2000, NATURE, V406, P422, DOI 10.1038/35019094; Williams BL, 1999, EMBO J, V18, P1832, DOI 10.1093/emboj/18.7.1832; Yamasaki S, 1997, J BIOL CHEM, V272, P14787, DOI 10.1074/jbc.272.23.14787	56	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3574	3580		10.1074/jbc.M008588200	http://dx.doi.org/10.1074/jbc.M008588200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11058601	Green Published, hybrid			2022-12-25	WOS:000166784900077
J	Yang, J; Song, HB; Walsh, S; Bardes, ESG; Kornbluth, S				Yang, J; Song, HB; Walsh, S; Bardes, ESG; Kornbluth, S			Combinatorial control of cyclin B1 nuclear trafficking through phosphorylation at multiple sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS OOCYTE; PROTEIN-KINASE; CDC25 PROTEIN; DNA-DAMAGE; LOCALIZATION; CELL; P34(CDC2); IMPORT; EXPORT; ACTIVATION	Entry into mitosis is regulated by the Cdc2 kinase complexed to B-type cyclins, We and others recently reported that cyclin B1/Cdc2 complexes, which appear to be constitutively cytoplasmic during interphase, actually shuttle continually into and out of the nucleus, with the rate of nuclear export exceeding the import rate (1-3). At the time of entry into mitosis, the import rate is increased, whereas the export rate is decreased, leading to rapid nuclear accumulation of Cdc2/cyclin Iii, Although it has recently been reported that phosphorylation of 4 serines within cyclin B1 promotes the rapid nuclear translocation of Cdc2/cyclin B1 at G(2)/M, the role that individual phosphorylation sites play in this process has not been examined (3, 4), We report here that phosphorylation of a single serine residue (Ser(113) of Xenopus cyclin B1) abrogates nuclear export of cyclin B1, This serine lies directly within the cyclin B1 nuclear export sequence and, when phosphorylated, prevents binding of the nuclear export factor, CRM1. In contrast, analysis of phosphorylation site mutants suggests that coordinate phosphorylation of all 4 serines (94, 96, 101, and 113) is required for the accelerated nuclear import of cyclin B1/Cdc2 characteristic of G(2)/M. Additionally, binding of cyclin B1 to importin-beta, the factor known to be responsible for the slow interphase nuclear entry of cyclin B1, appears to be unaffected by the phosphorylation state of cyclin B. These data suggest that a distinct import factor must be recruited to enhance nuclear entry of Cdc2/cyclin B1 at the G(2)/M transition.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Kornbluth, S (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Box 3813,C370,C370 LSRC,Res Dr, Durham, NC 27710 USA.				NIGMS NIH HHS [R01GM60500] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060500] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATHERTONFESSLER S, 1994, MOL BIOL CELL, V5, P989, DOI 10.1091/mbc.5.9.989; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Hagting A, 1999, CURR BIOL, V9, P680, DOI 10.1016/S0960-9822(99)80308-X; Hagting A, 1998, EMBO J, V17, P4127, DOI 10.1093/emboj/17.14.4127; IZUMI T, 1991, MOL CELL BIOL, V11, P3860, DOI 10.1128/MCB.11.8.3860; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kong M, 2000, EMBO J, V19, P1378, DOI 10.1093/emboj/19.6.1378; KORNBLUTH S, 1994, MOL BIOL CELL, V5, P273, DOI 10.1091/mbc.5.3.273; KREK W, 1992, J CELL SCI, V102, P43; Kumagai A, 1999, GENE DEV, V13, P1067, DOI 10.1101/gad.13.9.1067; Li J, 1997, P NATL ACAD SCI USA, V94, P502, DOI 10.1073/pnas.94.2.502; LI JK, 1995, MOL BIOL CELL, V6, P1111, DOI 10.1091/mbc.6.9.1111; LUND E, 1990, METHOD ENZYMOL, V181, P36; MCGOWAN CH, 1993, EMBO J, V12, P75, DOI 10.1002/j.1460-2075.1993.tb05633.x; MILLAR JBA, 1992, CELL, V68, P407, DOI 10.1016/0092-8674(92)90177-E; Moore JD, 1999, J CELL BIOL, V144, P213, DOI 10.1083/jcb.144.2.213; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; SOLOMON MJ, 1992, MOL BIOL CELL, V3, P13, DOI 10.1091/mbc.3.1.13; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; SWENSON KI, 1989, CELL, V57, P145, DOI 10.1016/0092-8674(89)90180-3; Takizawa CG, 1999, P NATL ACAD SCI USA, V96, P7938, DOI 10.1073/pnas.96.14.7938; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Yang J, 1999, EMBO J, V18, P2174, DOI 10.1093/emboj/18.8.2174; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	32	62	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3604	3609		10.1074/jbc.M008151200	http://dx.doi.org/10.1074/jbc.M008151200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11060306	hybrid			2022-12-25	WOS:000166784900081
J	Chandler, LJ; Sutton, G; Dorairaj, NR; Norwood, D				Chandler, LJ; Sutton, G; Dorairaj, NR; Norwood, D			N-methyl D-aspartate receptor-mediated bidirectional control of extracellular signal-regulated kinase activity in cortical neuronal cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ELEMENT-BINDING PROTEIN; LONG-TERM-MEMORY; CENTRAL NERVOUS-SYSTEM; MAP KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; SYMPATHETIC NEURONS; CALCIUM INFLUX; CYCLIC-AMP; AREA CA1	N-Methyl D-aspartate (NMDA) receptor activation of extracellular-signal regulated kinase (ERK) was examined in primary cortical cultures. Tetrodotoxin, NMDA receptor antagonists, or reduced extracellular calcium (0.1 mM) greatly decreased basal levels of phospho-ERK2, indicating that activity-dependent activation of NMDA receptors maintained a high level of basal ERK2 activation. This activity-dependent activation of phospho-ERK2 was blocked by pertussis toxin and inhibition of calcium/calmodulin-dependent kinase II and phosphatidylinositol 3-kinase but not by inhibition of protein kinase C or cAMP-dependent protein kinase, Addition of a calcium ionophore or 100 muM NMDA decreased phospho-ERK2 in the presence of 1 mM extracellular calcium but enhanced phospho-ERK2 in 0.1 mM extracellular calcium. The reduction in basal phospho-ERK2 by 100 muM NMDA was also reflected as a decrease in phospho-cAMP response element-binding protein, Inhibition of tyrosine phosphatases and serine/threonine phosphatases protein phosphatase 1 (PP1), PP2A, and PP2B did not prevent the inhibitory effect of NMDA. In the presence of tetrodotoxin, NMDA produced a bell-shaped dose-response curve with stimulation of phospho-ERK2 at 10, 25, and 50 muM NMDA and reduced stimulation at 100 muM NMDA. NMDA (50 muM) stimulation of phospho-ERK2 was completely blocked by pertussis toxin and inhibitors of phosphatidylinositol 3-kinase and was partially blocked by a calcium/calmodulin-dependent kinase II inhibitor. These results suggests that NMDA receptors can bidirectionally control ERK signaling.	Med Univ S Carolina, Dept Physiol Neurosci, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Psychiat, Charleston, SC 29425 USA; Louisiana State Univ, Med Ctr, Dept Pharmacol, Shreveport, LA 71130 USA	Medical University of South Carolina; Medical University of South Carolina; Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	Chandler, LJ (corresponding author), Med Univ S Carolina, Dept Physiol Neurosci, CDAP IOP 4 N,67 President St, Charleston, SC 29425 USA.	chandj@musc.edu	Chandler, Lawrence/N-8569-2017	Chandler, Lawrence/0000-0002-1468-7320				Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brambilla R, 1997, NATURE, V390, P281, DOI 10.1038/36849; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHANDLER LJ, 1993, J NEUROCHEM, V60, P1578, DOI 10.1111/j.1471-4159.1993.tb03326.x; Chandler LJ, 1997, MOL PHARMACOL, V51, P733, DOI 10.1124/mol.51.5.733; Chen HJ, 1998, NEURON, V20, P895, DOI 10.1016/S0896-6273(00)80471-7; CHETKOVICH DM, 1993, J NEUROCHEM, V61, P1933, DOI 10.1111/j.1471-4159.1993.tb09836.x; CHOI DW, 1987, J NEUROSCI, V7, P369; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLLINGRIDGE GL, 1989, PHARMACOL REV, V41, P143; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Dent P, 1998, LEUKEMIA, V12, P1843, DOI 10.1038/sj.leu.2401222; English JD, 1997, J BIOL CHEM, V272, P19103, DOI 10.1074/jbc.272.31.19103; English JD, 1996, J BIOL CHEM, V271, P24329, DOI 10.1074/jbc.271.40.24329; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; FRANKLIN JL, 1992, TRENDS NEUROSCI, V15, P501, DOI 10.1016/0166-2236(92)90103-F; FRANKLIN JL, 1995, J NEUROSCI, V15, P643; Gardner AM, 1996, J BIOL CHEM, V271, P14560, DOI 10.1074/jbc.271.24.14560; Hawes BE, 1996, J BIOL CHEM, V271, P12133, DOI 10.1074/jbc.271.21.12133; Hisatsune C, 1999, GENES CELLS, V4, P657, DOI 10.1046/j.1365-2443.1999.00287.x; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Ikonomidou C, 1999, SCIENCE, V283, P70, DOI 10.1126/science.283.5398.70; IKONOMIDOU C, 1989, J NEUROSCI, V9, P2809; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Joyal JL, 1997, J BIOL CHEM, V272, P28183, DOI 10.1074/jbc.272.45.28183; Kim JH, 1998, NEURON, V20, P683, DOI 10.1016/S0896-6273(00)81008-9; Knall C, 1996, J BIOL CHEM, V271, P2832, DOI 10.1074/jbc.271.5.2832; Kornhauser JM, 1997, NEURON, V18, P839, DOI 10.1016/S0896-6273(00)80322-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Lisman J, 1997, SCIENCE, V276, P2001, DOI 10.1126/science.276.5321.2001; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MCDONALD JW, 1988, BRAIN RES, V459, P200, DOI 10.1016/0006-8993(88)90306-X; MULKEY RM, 1994, NATURE, V369, P486, DOI 10.1038/369486a0; MUROYA K, 1992, ONCOGENE, V7, P277; Orban PC, 1999, TRENDS NEUROSCI, V22, P38, DOI 10.1016/S0166-2236(98)01306-X; Perkinton MS, 1999, J NEUROSCI, V19, P5861, DOI 10.1523/JNEUROSCI.19-14-05861.1999; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Roberson ED, 1999, J NEUROSCI, V19, P4337; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Rosen LB, 1996, P NATL ACAD SCI USA, V93, P1113, DOI 10.1073/pnas.93.3.1113; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Sala C, 2000, J NEUROSCI, V20, P3529, DOI 10.1523/JNEUROSCI.20-10-03529.2000; Sgambato V, 1998, J NEUROSCI, V18, P8814; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Walton M, 1999, J NEUROCHEM, V73, P1836; Walton M, 1996, MOL BRAIN RES, V43, P21, DOI 10.1016/S0169-328X(96)00144-1; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; WHITMARSH AJ, 1996, MOL MED, V74, P589; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Xia ZG, 1996, J NEUROSCI, V16, P5425; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yun HY, 1998, P NATL ACAD SCI USA, V95, P5773, DOI 10.1073/pnas.95.10.5773; Zhang FX, 1998, J BIOL CHEM, V273, P26596, DOI 10.1074/jbc.273.41.26596; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	61	136	137	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2627	2636		10.1074/jbc.M003390200	http://dx.doi.org/10.1074/jbc.M003390200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11062237	hybrid			2022-12-25	WOS:000166784800047
J	Chen, XM; VanValkenburgh, C; Liang, HB; Fang, H; Green, N				Chen, XM; VanValkenburgh, C; Liang, HB; Fang, H; Green, N			Signal peptidase and oligosaccharyltransferase interact in a sequential and dependent manner within the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETORY PATHWAY; YEAST; PROTEIN; DETERMINANT; COMPLEX; GENE	We demonstrate that the signal peptides of prepro-alpha -factor and preinvertase must be cleaved before Asn-X-Ser/Thr acceptor tripeptides located near the signal peptides of these precursors can be efficiently glycosylated within the endoplasmic reticulum of the yeast Saccharomyces cerevisiae. The data support a model whereby the interaction of a signal peptide with the membrane prevents an acceptor tripeptide juxtaposed to the signal peptide from accessing the oligosaccharyltransferase active site until the signal peptide is cleaved.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA	Vanderbilt University	Green, N (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37232 USA.	neil.green@mcmail.vanderbilt.edu			NCI NIH HHS [2 T32 CA09385-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009385] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENNETZEN JL, 1982, J BIOL CHEM, V257, P3018; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; Hasler U, 2000, J BIOL CHEM, V275, P29011, DOI 10.1074/jbc.M002867200; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; Hegde RS, 1998, MOL CELL, V2, P85, DOI 10.1016/S1097-2765(00)80116-1; HICKE L, 1989, EMBO J, V8, P1677, DOI 10.1002/j.1460-2075.1989.tb03559.x; JULIUS D, 1984, CELL, V36, P309, DOI 10.1016/0092-8674(84)90224-1; Mullins C, 1996, J BIOL CHEM, V271, P29094, DOI 10.1074/jbc.271.46.29094; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Paetzel M, 1998, NATURE, V396, P186, DOI 10.1038/24196; TAUSSIG R, 1983, NUCLEIC ACIDS RES, V11, P1943, DOI 10.1093/nar/11.6.1943; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VanValkenburgh C, 1999, J BIOL CHEM, V274, P11519, DOI 10.1074/jbc.274.17.11519; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; YADEAU JT, 1989, J BIOL CHEM, V264, P2928; Yan Q, 1999, BIOCHEM BIOPH RES CO, V266, P684, DOI 10.1006/bbrc.1999.1886	21	38	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2411	2416		10.1074/jbc.M007723200	http://dx.doi.org/10.1074/jbc.M007723200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11058593	hybrid			2022-12-25	WOS:000166784800017
J	Senda, S; Lee, SF; Cote, GP; Titus, MA				Senda, S; Lee, SF; Cote, GP; Titus, MA			Recruitment of a specific amoeboid myosin I isoform to the plasma membrane in chemotactic Dictyostelium cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ISOFORM; ACTIN-BINDING SITE; INTRACELLULAR-LOCALIZATION; UNCONVENTIONAL MYOSIN; SH3 DOMAIN; F-ACTIN; DISCOIDEUM; ACANTHAMOEBA; MUTANTS; MOTILITY	The Dictyostelium class I myosins, MyoA, -B, -C, and -D, participate in plasma membrane-based cellular processes such as pseudopod extension and macropinocytosis. Given the existence of a high affinity membrane-binding site in the C-terminal tail domain of these motor proteins and their localized site of action at the cortical membrane-cytoskeleton, it was of interest to determine whether each myosin I was directly associated with the plasma membrane. The membrane association of a myosin I heavy chain kinase that regulates the activity of one of the class I myosins, MyoD was also examined. Cellular fractionation experiments revealed that the majority of the Dicyostelium MyoA, -B, -C and -D heavy chains and the kinase are cytosolic. However, a small, but significant, fraction (appr, 7. -15%) of each myosin I and the kinase was associated with the plasma membrane. The level of plasma membrane-associated MyoB, but neither that of MyoC nor MyoD, increases up to 2-fold in highly motile, streaming cells. These results indicate that Dictyostelium specifically recruits myoB to the plasma membrane during directed cell migration, consistent with its known role in pseudopod formation.	Univ Minnesota, Dept Genet, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Cell Biol & Dev, Minneapolis, MN 55455 USA; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Duke University; Queens University - Canada	Titus, MA (corresponding author), Univ Minnesota, Dept Genet, 6-160 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	titus@lenti.med.umn.edu						ADAMS RJ, 1989, NATURE, V340, P565, DOI 10.1038/340565a0; Anderson BL, 1998, J CELL BIOL, V141, P1357, DOI 10.1083/jcb.141.6.1357; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BAINES IC, 1992, J CELL BIOL, V119, P1193, DOI 10.1083/jcb.119.5.1193; Balish MF, 1999, ARCH BIOCHEM BIOPHYS, V370, P285, DOI 10.1006/abbi.1999.1409; BORTS RH, 1981, DEV BIOL, V87, P176, DOI 10.1016/0012-1606(81)90070-1; CARDELLI JA, 1987, METHOD CELL BIOL, V28, P139; Coluccio LM, 1997, AM J PHYSIOL-CELL PH, V273, pC347, DOI 10.1152/ajpcell.1997.273.2.C347; DOBERSTEIN SK, 1992, J CELL BIOL, V117, P1241, DOI 10.1083/jcb.117.6.1241; FAIX J, 1992, J CELL SCI, V102, P203; FUKUI Y, 1989, NATURE, V341, P328, DOI 10.1038/341328a0; GADASI H, 1980, NATURE, V286, P452, DOI 10.1038/286452a0; Geli MI, 1996, SCIENCE, V272, P533, DOI 10.1126/science.272.5261.533; GOODLOEHOLLAND CM, 1987, METHOD CELL BIOL, V28, P103; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; Hasegawa Y, 1998, J BIOCHEM, V124, P421, DOI 10.1093/oxfordjournals.jbchem.a022129; HOWARD PK, 1988, NUCLEIC ACIDS RES, V16, P2613, DOI 10.1093/nar/16.6.2613; JUNG G, 1990, J CELL BIOL, V110, P1955, DOI 10.1083/jcb.110.6.1955; JUNG G, 1994, FEBS LETT, V342, P197, DOI 10.1016/0014-5793(94)80500-8; JUNG G, 1993, J BIOL CHEM, V268, P14981; Jung G, 1996, J CELL BIOL, V133, P305, DOI 10.1083/jcb.133.2.305; KUSPA A, 1992, P NATL ACAD SCI USA, V89, P8803, DOI 10.1073/pnas.89.18.8803; Lee SF, 1998, J BIOL CHEM, V273, P27911, DOI 10.1074/jbc.273.43.27911; Lee SF, 1996, J BIOL CHEM, V271, P27044, DOI 10.1074/jbc.271.43.27044; LEE SF, 1995, J BIOL CHEM, V270, P11776, DOI 10.1074/jbc.270.20.11776; LEE SF, 1993, J BIOL CHEM, V268, P20923; Loomis W., 2012, DEV DICTYOSTELIUM DI; LYNCH TJ, 1986, J BIOL CHEM, V261, P7156; MCGOLDRICK CA, 1995, J CELL BIOL, V128, P577, DOI 10.1083/jcb.128.4.577; Mermall V, 1998, SCIENCE, V279, P527, DOI 10.1126/science.279.5350.527; MIYATA H, 1989, J CELL BIOL, V109, P1519, DOI 10.1083/jcb.109.4.1519; Morita YS, 1996, EUR J CELL BIOL, V71, P371; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; Novak KD, 1997, J CELL BIOL, V136, P633, DOI 10.1083/jcb.136.3.633; NOVAK KD, 1995, J CELL BIOL, V131, P1205, DOI 10.1083/jcb.131.5.1205; Novak KD, 1998, MOL BIOL CELL, V9, P75, DOI 10.1091/mbc.9.1.75; Ostap EM, 1996, J CELL BIOL, V132, P1053, DOI 10.1083/jcb.132.6.1053; PADH H, 1989, BIOCHIM BIOPHYS ACTA, V982, P271, DOI 10.1016/0005-2736(89)90064-3; PATTERSON B, 1995, GENETICS, V140, P505; PENNINGTON R, 1961, BIOCHEM J, V80, P649, DOI 10.1042/bj0800649; PETERSON MD, 1995, J CELL SCI, V108, P1093; PODOLSKI JL, 1990, J BIOL CHEM, V265, P1312; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.ph.53.030191.003253; ROSENFELD SS, 1994, BIOCHEMISTRY-US, V33, P2322, DOI 10.1021/bi00174a045; SOLL DR, 1976, J CELL SCI, V20, P513; SPUDICH JA, 1982, METHOD CELL BIOL, V25, P359, DOI 10.1016/S0091-679X(08)61433-8; STOFFLER HE, 1995, J CELL BIOL, V129, P819, DOI 10.1083/jcb.129.3.819; Stoffler HE, 1998, J CELL SCI, V111, P2779; Temesvari LA, 1996, J CELL SCI, V109, P663; TITUS MA, 1989, CELL REGUL, V1, P55, DOI 10.1091/mbc.1.1.55; TITUS MA, 1993, MOL BIOL CELL, V4, P233, DOI 10.1091/mbc.4.2.233; UYEDA TQP, 1997, DICTYOSTELIUM MODEL, P43; VARNUM B, 1986, DEV BIOL, V113, P218, DOI 10.1016/0012-1606(86)90124-7; Wessels D, 1996, CELL MOTIL CYTOSKEL, V33, P64, DOI 10.1002/(SICI)1097-0169(1996)33:1<64::AID-CM7>3.0.CO;2-I; WESSELS D, 1991, CELL MOTIL CYTOSKEL, V20, P301, DOI 10.1002/cm.970200406; YONEMURA S, 1992, J CELL SCI, V102, P629; ZHU QL, 1992, J CELL BIOL, V118, P347, DOI 10.1083/jcb.118.2.347	57	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2898	2904		10.1074/jbc.M008059200	http://dx.doi.org/10.1074/jbc.M008059200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11058595	hybrid			2022-12-25	WOS:000166784800082
J	Abu-Soud, HM; Hazen, SL				Abu-Soud, HM; Hazen, SL			Nitric oxide is a physiological substrate for mammalian peroxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EOSINOPHIL PEROXIDASE; LOW-DENSITY-LIPOPROTEIN; HUMAN NEUTROPHILS EMPLOY; L-TYROSINE OXIDATION; HYDROGEN-PEROXIDE; P-HYDROXYPHENYLACETALDEHYDE; CATALYZED OXIDATION; LIPID-PEROXIDATION; REACTIVE ALDEHYDES; CRYSTAL-STRUCTURE	We now show that NO serves as a substrate for multiple members of the mammalian peroxidase superfamily under physiological conditions. Myeloperoxidase (MPO), eosinophil peroxidase, and lactoperoxidase all catalytically consumed NO in the presence of the co-substrate hydrogen peroxide (H2O2), Near identical rates of NO consumption by the peroxidases were observed in the presence versus absence of plasma levels of Cl-. Although rates of NO consumption in buffer were accelerated in the presence of a superoxide-generating system, subsequent addition of catalytic levels of a model peroxidase, MPO, to NO-containing solutions resulted in the rapid acceleration of NO consumption. The interaction between NO and compounds I and II of MPO were further investigated during steady-state catalysis by stopped-now kinetics. NO dramatically influenced the build-up, duration, and decay of steady-state levels of compound II, the rate-limiting intermediate in the classic peroxidase cycle, in both the presence and absence of Cl-. Collectively, these results suggest that peroxidases may function as a catalytic sink for NO at sites of inflammation, influencing its bioavailability. They also support the potential existence of a complex and interdependent relationship between NO levels and the modulation of steady-state catalysis by peroxidases in vivo.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University	Abu-Soud, HM (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.		Hazen, Stanley L/ABD-5845-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062526, R01HL061878] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62526, HL61878] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; ABUSOUD HM, 1995, J BIOL CHEM, V270, P22997, DOI 10.1074/jbc.270.39.22997; AGNER K, 1963, ACTA CHEM SCAND, V17, pS332; Agner K., 1972, STRUCTURE FUNCTION O, P329; Aratani Y, 1999, INFECT IMMUN, V67, P1828; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; BOLSCHER BGJM, 1984, BIOCHIM BIOPHYS ACTA, V784, P177, DOI 10.1016/0167-4838(84)90125-0; Burner U, 2000, J BIOL CHEM, V275, P20597, DOI 10.1074/jbc.M000181200; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; CASTRO L, 1994, J BIOL CHEM, V269, P29409; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Cyrus T, 1999, J CLIN INVEST, V103, P1597, DOI 10.1172/JCI5897; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Davies MJ, 1999, FREE RADICAL BIO MED, V27, P1151, DOI 10.1016/S0891-5849(99)00206-3; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; EDWARDS SL, 1988, BIOCHEMISTRY-US, V27, P8074, DOI 10.1021/bi00421a016; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; Glover RE, 1999, NITRIC OXIDE-BIOL CH, V3, P439, DOI 10.1006/niox.1999.0256; Goss SPA, 1997, J BIOL CHEM, V272, P21647, DOI 10.1074/jbc.272.34.21647; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HAYASHI K, 1995, FEBS LETT, V370, P37, DOI 10.1016/0014-5793(95)00786-9; Hazen SL, 1999, CIRC RES, V85, P950; Hazen SL, 1997, J BIOL CHEM, V272, P16990, DOI 10.1074/jbc.272.27.16990; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Hazen SL, 1996, J BIOL CHEM, V271, P1861, DOI 10.1074/jbc.271.4.1861; Hobbs AJ, 1996, METHOD ENZYMOL, V269, P134; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; HURST JK, 1991, PEROXIDASES CHEM BIO, P37; Ischiropoulos H, 1996, FREE RADICAL BIO MED, V20, P373, DOI 10.1016/0891-5849(95)02098-5; JESSUP W, 1992, BIOCHIM BIOPHYS ACTA, V1180, P73, DOI 10.1016/0925-4439(92)90029-M; JORG A, 1982, BIOCHIM BIOPHYS ACTA, V701, P185, DOI 10.1016/0167-4838(82)90112-1; Kettle AJ, 1997, REDOX REP, V3, P3, DOI 10.1080/13510002.1997.11747085; KLEBANOFF SJ, 1984, METHOD ENZYMOL, V105, P399; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KOBAYASHI K, 1982, BIOCHEMISTRY-US, V21, P729, DOI 10.1021/bi00533a022; LAMPERT MB, 1983, BLOOD, V62, P645; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; MANTHEY JA, 1986, J BIOL CHEM, V261, P6734; MARQUEZ LA, 1990, J BIOL CHEM, V265, P5666; MARQUEZ LA, 1994, BIOCHEMISTRY-US, V33, P1447, DOI 10.1021/bi00172a022; Moncada S, 1997, FUNCT NEUROL, V12, P134; O'Donnell VB, 1999, J BIOL CHEM, V274, P20083, DOI 10.1074/jbc.274.29.20083; ODonnell VB, 1997, BIOCHEMISTRY-US, V36, P15216, DOI 10.1021/bi971891z; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Patel RP, 1999, BBA-BIOENERGETICS, V1411, P385, DOI 10.1016/S0005-2728(99)00028-6; Petrides PE, 1998, J MOL MED-JMM, V76, P659, DOI 10.1007/s001090050264; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; RAKITA RM, 1990, BIOCHEMISTRY-US, V29, P1075, DOI 10.1021/bi00456a033; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Schmitt D, 1999, BIOCHEMISTRY-US, V38, P16904, DOI 10.1021/bi991623w; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Steinberg D, 1999, J CLIN INVEST, V103, P1487, DOI 10.1172/JCI7298; SUARNA C, 1995, ARTERIOSCL THROM VAS, V15, P1616, DOI 10.1161/01.ATV.15.10.1616; THAYER JR, 1980, ANAL BIOCHEM, V102, P110, DOI 10.1016/0003-2697(80)90325-5; Torres J, 1999, BBA-BIOENERGETICS, V1411, P310, DOI 10.1016/S0005-2728(99)00022-5; TRAYLOR TG, 1992, BIOCHEMISTRY-US, V31, P2847, DOI 10.1021/bi00126a001; vanDalen CJ, 1997, BIOCHEM J, V327, P487; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; WEVER R, 1981, FEBS LETT, V123, P327, DOI 10.1016/0014-5793(81)80320-1; White CR, 1996, P NATL ACAD SCI USA, V93, P8745, DOI 10.1073/pnas.93.16.8745; WINK DA, 1993, ARCH BIOCHEM BIOPHYS, V300, P115, DOI 10.1006/abbi.1993.1016; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; ZENG J, 1992, J MOL BIOL, V226, P185, DOI 10.1016/0022-2836(92)90133-5	68	326	339	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 1	2000	275	48					37524	37532		10.1074/jbc.275.48.37524	http://dx.doi.org/10.1074/jbc.275.48.37524			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	379AL	11090610	hybrid			2022-12-25	WOS:000165618700032
J	Han, GZ; Foster, BA; Mistry, S; Buchanan, G; Harris, JM; Tilley, WD; Greenberg, NM				Han, GZ; Foster, BA; Mistry, S; Buchanan, G; Harris, JM; Tilley, WD; Greenberg, NM			Hormone status selects for spontaneous somatic androgen receptor variants that demonstrate specific ligand and cofactor dependent activities in autochthonous prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; STEROID BINDING CHARACTERISTICS; GENE-MUTATIONS; ADRENAL ANDROGENS; TRANSGENIC MOUSE; PROBASIN GENE; TRAMP MODEL; CELL LINES; COACTIVATOR; CARCINOMA	We have used the autochthonous transgenic adenocarcinoma of mouse prostate (TRAMP) model to investigate the relationship between somatic mutation in the androgen receptor (AR) and the emergence of androgen-independent prostate cancer. Here we report the identification, isolation, and characterization of distinct classes of AR variants from spontaneous prostate tumors in the TRAMP model. Using cDNA cloning, single stranded conformation polymorphism and sequencing strategies, 15 unique somatic mutations in the AR were identified in prostate tumors obtained from eight TRAMP mice between 24 and 29 weeks of age. At least one mutation was isolated from each mouse. All mutations:were single base substitutions, 10 were missense and 5 were silent. Nine mutations in the AR were identified in tumors of four mice that were castrated at 12 weeks of age. Interestingly, the majority of mutations (seven out of nine, 78%) identified in the androgen-independent tumors colocalized in the AR transactivation domain. The remaining mutations colocalized in the AR ligand binding domain. In general, the AR variants demonstrated promoter-, cell-, and cofactor-specific activities in response to various hormones. All AR variants isolated in this study maintained strong sensitivity for androgens, and four AR variants isolated from castrated mice demonstrated increased activities in the absence of ligand. The K638M and F677S variants demonstrated increased activities in response to androgen, and K638M also demonstrated increased response to estradiol, In the presence of AR coactivator ARA70 the E231G variant demonstrated increased activity in response to both androgen and estradiol. However, in the presence of AR coactivator ARA160 the E231G variant was selectively responsive to androgen. Collectively these analyses not only indicate that somatic mutations in the AR gene occur spontaneously in TRAMP tumors but also how changes in the hormonal environment may drive the selection of spontaneous somatic mutations that provide a growth advantage.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA; Flinders Univ S Australia, Flinders Canc Ctr, Adelaide, SA 5042, Australia; Flinders Med Ctr, Adelaide, SA 5042, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	Baylor College of Medicine; Baylor College of Medicine; Flinders University South Australia; Flinders Medical Centre; University of Queensland	Greenberg, NM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza,Suite M626, Houston, TX 77030 USA.			Harris, Jonathan/0000-0003-4209-2380; Tilley, Wayne/0000-0003-1893-2626	NCI NIH HHS [CA73747] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073747] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABAGYAN R, 1992, J MOL BIOL, V225, P519, DOI 10.1016/0022-2836(92)90936-E; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Culig Z, 1996, CANCER DETECT PREV, V20, P68; CULIG Z, 1995, WORLD J UROL, V13, P285; Culig Z, 1997, DRUG AGING, V10, P50, DOI 10.2165/00002512-199710010-00005; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; CULIG Z, 1994, CANCER RES, V54, P5474; ELO JP, 1995, J CLIN ENDOCR METAB, V80, P3494, DOI 10.1210/jc.80.12.3494; Evans BAJ, 1996, PROSTATE, V28, P162, DOI 10.1002/(SICI)1097-0045(199603)28:3<162::AID-PROS3>3.0.CO;2-H; Fenton MA, 1997, CLIN CANCER RES, V3, P1383; Foster BA, 1997, CANCER RES, V57, P3325; Garnick MB, 1997, UROLOGY, V49, P5, DOI 10.1016/S0090-4295(97)00163-5; Gingrich JR, 1996, CANCER RES, V56, P4096; Gingrich JR, 1997, CANCER RES, V57, P4687; GITTES RF, 1991, NEW ENGL J MED, V324, P236, DOI 10.1056/NEJM199101243240406; Gottlieb B, 1999, HUM MUTAT, V14, P103, DOI 10.1002/(SICI)1098-1004(1999)14:2<103::AID-HUMU2>3.0.CO;2-A; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; GUEX N, 1996, EXPERIENTIA, V52, P26; HE WW, 1990, BIOCHEM BIOPH RES CO, V171, P697, DOI 10.1016/0006-291X(90)91202-4; HOBISCH A, 1995, CANCER RES, V55, P3068; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Katzenellenbogen JA, 1996, MOL ENDOCRINOL, V10, P119, DOI 10.1210/me.10.2.119; Koivisto P, 1997, CANCER RES, V57, P314; Koivisto PA, 1999, J PATHOL, V187, P237; Kubinyi H, 1998, J MED CHEM, V41, P2553, DOI 10.1021/jm970732a; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; MOORADIAN AD, 1987, ENDOCR REV, V8, P1, DOI 10.1210/edrv-8-1-1; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; ORLY J, 1994, ENDOCRINOLOGY, V134, P2336, DOI 10.1210/en.134.6.2336; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Snoek R, 1998, PROSTATE, V36, P256; SURLES MC, 1994, PROTEIN SCI, V3, P198; Taplin ME, 1999, CANCER RES, V59, P2511; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Tilley WD, 1996, CLIN CANCER RES, V2, P277; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.biochem.63.1.451; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; VELDSCHOLTE J, 1992, J STEROID BIOCHEM, V41, P665, DOI 10.1016/0960-0760(92)90401-4; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Yeh SY, 1998, P NATL ACAD SCI USA, V95, P5527, DOI 10.1073/pnas.95.10.5527; Zhao XY, 1999, J UROLOGY, V162, P2192, DOI 10.1016/S0022-5347(05)68158-X; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287	50	105	108	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11204	11213		10.1074/jbc.M008207200	http://dx.doi.org/10.1074/jbc.M008207200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11063747	hybrid			2022-12-25	WOS:000167980900084
J	Chan, TF; Bertram, PG; Ai, WD; Zheng, XFS				Chan, TF; Bertram, PG; Ai, WD; Zheng, XFS			Regulation of APG14 expression by the GATA-type transcription factor Gln3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL KINASE HOMOLOG; SACCHAROMYCES-CEREVISIAE; TOR PROTEINS; SIGNALING PATHWAYS; SERINE RESIDUE; YEAST VACUOLE; AUTOPHAGY; RAPAMYCIN; FKBP12-RAPAMYCIN; IDENTIFICATION	Gln3p is a nitrogen catabolite repression-sensitive GATA-type transcription factor. Its nuclear accumulation was recently shown to be under the control of TOR signaling. Gln3p normally resides in the cytoplasm. When cells are starved from nitrogen nutrients or treated with rapamycin, however, Gln3p becomes translocated into the nucleus, thereby activating the expression of genes involved in nitrogen utilization and transport. To identify other genes under the control of Gln3p, we searched for the Gln3p-binding GATAA motifs within 500 base pairs of the promoter sequences upstream of the yeast open reading frames in the Saccharomyces Genome Database. APG14 a gene essential for autophagy, was found to have the most GATAA motifs. We show that nitrogen starvation or rapamycin treatment rap idly causes a more than 20-fold induction of APG14. The expression of APG14 is dependent on Gln3p; deletion of Gln3p severely reduced its induction by rapamycin, whereas depletion of Ure2p caused its constitutive expression. However, overexpression of APG14 led to only a slight increase in autophagy in nitrogen rich medium. Therefore, these results define a signaling cascade leading to the expression of APG14 in response to the availability of nitrogen nutrients and suggest that the regulated expression of APG14 contributes to but is not sufficient for the control of autophagy.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Washington University (WUSTL)	Zheng, XFS (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA.		Chan, TingFung/A-6161-2013	Chan, TingFung/0000-0002-0489-3884	NCI NIH HHS [5R01CA77668] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077668] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851; Alarcon CM, 1999, MOL BIOL CELL, V10, P2531, DOI 10.1091/mbc.10.8.2531; Anglade P, 1997, HISTOL HISTOPATHOL, V12, P25; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 1998, CURR BIOL, V8, P1259, DOI 10.1016/S0960-9822(07)00535-0; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; BURSCH W, 1994, BIOCHEM CELL BIOL, V72, P669, DOI 10.1139/o94-088; CAFFERKEY R, 1994, GENE, V141, P133, DOI 10.1016/0378-1119(94)90141-4; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; Cataldo AM, 1996, J NEUROSCI, V16, P186; CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947; Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DiComo CJ, 1996, GENE DEV, V10, P1904, DOI 10.1101/gad.10.15.1904; Hardwick JS, 1999, P NATL ACAD SCI USA, V96, P14866, DOI 10.1073/pnas.96.26.14866; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Jiang Y, 1999, EMBO J, V18, P2782, DOI 10.1093/emboj/18.10.2782; JONES EW, 1997, MOL CELLULAR BIOL YE, V3, P229; Kametaka S, 1998, J BIOL CHEM, V273, P22284, DOI 10.1074/jbc.273.35.22284; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Kuruvilla FG, 1999, CHEM BIOL, V6, pR129, DOI 10.1016/S1074-5521(99)80070-2; Lang T, 1998, EMBO J, V17, P3597, DOI 10.1093/emboj/17.13.3597; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; MAGASANIK B, 1992, MOL CELLULAR BIOL YE, V2, P283; NODA T, 1995, BIOCHEM BIOPH RES CO, V210, P126, DOI 10.1006/bbrc.1995.1636; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; STAN R, 1994, J BIOL CHEM, V269, P32027; Straub M, 1997, J BACTERIOL, V179, P3875, DOI 10.1128/jb.179.12.3875-3883.1997; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; ZHENG XF, 1995, CELL, V82, P121, DOI 10.1016/0092-8674(95)90058-6	39	52	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6463	6467		10.1074/jbc.M008162200	http://dx.doi.org/10.1074/jbc.M008162200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096087	hybrid			2022-12-25	WOS:000167261000053
J	Bachhawat, K; Thomas, CJ; Amutha, B; Krishnasastry, MV; Khan, MI; Surolia, A				Bachhawat, K; Thomas, CJ; Amutha, B; Krishnasastry, MV; Khan, MI; Surolia, A			On the stringent requirement of mannosyl substitution in mannooligosaccharides for the recognition by garlic (Allium sativum) lectin - A surface plasmon resonance study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; BINDING LECTINS; CONCANAVALIN-A; AGGLUTININ; MECHANISM; GLYCOPROTEIN; SPECIFICITY; PROTEINS; FAMILY	The kinetics of the binding of mannooligo saccharides to the heterodimeric lectin from garlic bulbs was studied using surface plasmon resonance. The interaction of the bound lectin immobilized on the sensor chip with a selected group of high mannose oligosaccharides was monitored in real time with the change in response units. This investigation corroborates our earlier study about the special preference of garlic lectin for terminal alpha -1,2-linked mannose residues. An increase in binding propensity can be directly correlated to the addition of alpha -1,2-linked mannose to the mannooligosaccharide at its nonreducing end. Mannononase glycopeptide (Man(9)GlcNAc(2)Asn), the highest oligomer studied, exhibited the greatest binding affinity (K-alpha = 1.2 x 10(6) M-1 at 25 degreesC). An analysis of these data reveals that the alpha -1,2-linked terminal mannose on the (alpha -1,6 arm is the critical determinant in the recognition of mannooligosaccharides by the lectin, The association (k(1)) and dissociation rate constants (k(-1)) for the binding of Man(9)GlcNAc(2)Asn to Allium sativum agglutinin I are 6.1 x 10(4) M-1 s(-1) and 4.9 x 10(-2) s(-1), respectively, at 25 degreesC. Whereas k(1) increases progressively from Man(3) to Man(7) derivatives, and more dramatically so for Man(8) and Man(9) derivatives, (k-1) decreases relatively much less gradually from Man(3) to Man(9) structures. An unprecedented increase in the association rate constant for interaction with Allium sativum agglutinin I with the structure of the oligosaccharide ligand constitutes a significant finding in protein sugar recognition.	Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India; Natl Chem Lab, Div Biochem Sci, Pune 411008, Maharashtra, India; Natl Ctr Cell Sci, Pune 411007, Maharashtra, India; Indian Inst Sci, Jawaharlal Nehru Ctr Adv Sci Res, Bangalore 560064, Karnataka, India	Indian Institute of Science (IISC) - Bangalore; Council of Scientific & Industrial Research (CSIR) - India; CSIR - National Chemical Laboratory (NCL); Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS); Department of Science & Technology (India); Jawaharlal Nehru Center for Advanced Scientific Research (JNCASR); Indian Institute of Science (IISC) - Bangalore	Surolia, A (corresponding author), Indian Inst Sci, Mol Biophys Unit, Bangalore 560012, Karnataka, India.		SUROLIA, AVADESHA/C-5442-2009					Barre A, 1996, PLANT PHYSIOL, V112, P1531, DOI 10.1104/pp.112.4.1531; Chandra NR, 1999, J MOL BIOL, V285, P1157, DOI 10.1006/jmbi.1998.2353; Chantalat L, 1996, ACTA CRYSTALLOGR D, V52, P1146, DOI 10.1107/S090744499600546X; CLEGG RM, 1977, BIOCHEMISTRY-US, V16, P167, DOI 10.1021/bi00621a002; Dam TK, 1998, J BIOL CHEM, V273, P5528, DOI 10.1074/jbc.273.10.5528; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; GUPTA D, 1992, J BIOL CHEM, V267, P8909; HESTER G, 1995, NAT STRUCT BIOL, V2, P472, DOI 10.1038/nsb0695-472; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Lee RT, 1999, BIOSCIENCE REP, V19, P283, DOI 10.1023/A:1020546307825; LIS H, 1978, J BIOL CHEM, V253, P3468; MANDAL DK, 1992, BIOCHEMISTRY-US, V31, P12602, DOI 10.1021/bi00165a009; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; Patil AR, 2000, J BIOL CHEM, V275, P24348, DOI 10.1074/jbc.M003102200; PURI KD, 1993, J BIOL CHEM, V268, P16378; Rao JH, 1999, J AM CHEM SOC, V121, P2629, DOI 10.1021/ja9838763; SASTRY MVK, 1988, J BIOL CHEM, V263, P14826; Sauerborn MK, 1999, J MOL BIOL, V290, P185, DOI 10.1006/jmbi.1999.2862; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHANKARNARAYANA.R, 1996, NAT STRUCT BIOL, V3, P596; Thomas CJ, 1999, J BIOL CHEM, V274, P29624, DOI 10.1074/jbc.274.42.29624; Van Damme EJM, 2000, EUR J BIOCHEM, V267, P5067, DOI 10.1046/j.1432-1327.2000.01563.x; VANDAMME EJM, 1992, EUR J BIOCHEM, V206, P413, DOI 10.1111/j.1432-1033.1992.tb16941.x; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wood SD, 1999, ACTA CRYSTALLOGR D, V55, P1264, DOI 10.1107/S0907444999005326	25	27	29	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5541	5546		10.1074/jbc.M009533200	http://dx.doi.org/10.1074/jbc.M009533200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11076955	hybrid			2022-12-25	WOS:000167115100020
J	Baek, KJ; Kang, SK; Damron, DS; Im, MJ				Baek, KJ; Kang, SK; Damron, DS; Im, MJ			Phospholipase C delta 1 is a guanine nucleotide exchanging factor for transglutaminase II (G alpha(h)) and promotes alpha(1b)-adrenoreceptor-mediated GTP binding and intracellular calcium release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE TRANSGLUTAMINASE; SIGNAL MEDIATOR; RGS PROTEINS; ALPHA-1-ADRENERGIC RECEPTOR; ACTIVATING PROTEIN; G(H) PROTEIN; C ISOZYMES; G-ALPHA; PURIFICATION; RECONSTITUTION	Effectors involved in G protein-coupled receptor signaling modulate activity of GTPases through GTPase-activating protein or guanine nucleotide exchanging factor (GEF). Phospholipase C delta1 (PLC delta1) is an effector in tissue transglutaminase (TGII)-mediated alpha (1B)-adreno-receptor (alpha (1B)AR) signaling. We investigated whether PLC delta1 modulates TGII: activity. PLC delta1 stimulated GDP release from TGII in a concentration-dependent manner, resulting in an increase in GTP gammaS binding to TGII. PLC delta1 also inhibited GTP hydrolysis by TGII that was independent from the alpha (1B)AR. These results indicate that PLC delta1 is GEF for TGII and stabilizes the GTP TGII complex. When GEF function of PLC delta1 was compared with that of the alpha (1B)AR, the alpha (1B)AR-mediated GTP gammaS binding to TGII was greater than PLC delta1-mediated binding and was accelerated in the presence of PLC delta1. Thus, the LU,,AR is the prime GEF for TGII, and GEF activity of PLC delta1 promotes coupling efficacy of this signaling system. Overexpression of TGII and its mutants with and without PLC delta1 resulted in an increase in alpha (1B)AR-stimulated Ca2+ release from intracellular stores in a TGII-specific manner. We conclude that PLC delta1 assists the alpha (1B)AR function through its GEF action and is primarily activated by the coupling of TGII to the cognate receptors.	Cleveland Clin Fdn, Dept Mol Cardiol NB50, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Anesthesiol, Lerner Res Inst, Cleveland, OH 44195 USA; Chung Ang Univ, Coll Med, Dept Biochem, Seoul 156756, South Korea	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Chung Ang University; Chung Ang University Hospital	Im, MJ (corresponding author), Cleveland Clin Fdn, Dept Mol Cardiol NB50, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	imm@ccf.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045985] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM45985] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; Allen V, 1997, BIOCHEM J, V327, P545, DOI 10.1042/bj3270545; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BAEK KJ, 1993, J BIOL CHEM, V268, P27390; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; Biddlecome GH, 1996, J BIOL CHEM, V271, P7999, DOI 10.1074/jbc.271.14.7999; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Chidiac P, 1999, J BIOL CHEM, V274, P19639, DOI 10.1074/jbc.274.28.19639; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; COTECCHIA S, 1988, P NATL ACAD SCI USA, V85, P7159, DOI 10.1073/pnas.85.19.7159; DAS T, 1993, J BIOL CHEM, V268, P27398; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Feng JF, 1999, BIOCHEMISTRY-US, V38, P2224, DOI 10.1021/bi9823176; Feng JF, 1999, BIOCHEMISTRY-US, V38, P10743, DOI 10.1021/bi9905009; Feng JF, 1996, J BIOL CHEM, V271, P16451, DOI 10.1074/jbc.271.28.16451; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HOMMA Y, 1995, EMBO J, V14, P286, DOI 10.1002/j.1460-2075.1995.tb07002.x; HWANG KC, 1995, J BIOL CHEM, V270, P27058, DOI 10.1074/jbc.270.45.27058; Iismaa SE, 1997, BIOCHEMISTRY-US, V36, P11655, DOI 10.1021/bi970545e; Im MJ, 1997, CELL SIGNAL, V9, P477, DOI 10.1016/S0898-6568(97)00049-1; IM MJ, 1990, J BIOL CHEM, V265, P18952; IM MJ, 1992, J BIOL CHEM, V267, P8887; KANEMATSU T, 1992, J BIOL CHEM, V267, P6518; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1202, P1, DOI 10.1016/0167-4838(93)90055-V; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Monsonego A, 1998, J MOL BIOL, V282, P713, DOI 10.1006/jmbi.1998.2052; Murthy SNP, 1999, P NATL ACAD SCI USA, V96, P11815, DOI 10.1073/pnas.96.21.11815; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Park ES, 1998, BIOCHEM J, V331, P283, DOI 10.1042/bj3310283; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Scholich K, 1999, SCIENCE, V283, P1328, DOI 10.1126/science.283.5406.1328; Small K, 1999, J BIOL CHEM, V274, P21291, DOI 10.1074/jbc.274.30.21291; Vezza R, 1999, J BIOL CHEM, V274, P12774, DOI 10.1074/jbc.274.18.12774; Wu J, 2000, J BIOL CHEM, V275, P22213, DOI 10.1074/jbc.M000091200; Xu Y, 2000, NAT CELL BIOL, V2, P261, DOI 10.1038/35010529; Zhang JW, 1999, BIOCHEM J, V343, P541, DOI 10.1042/0264-6021:3430541	40	55	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5591	5597		10.1074/jbc.M008252200	http://dx.doi.org/10.1074/jbc.M008252200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11087745	hybrid			2022-12-25	WOS:000167115100027
J	Shimizu-Sasaki, K; Yamazaki, M; Furuyama, S; Sugiya, H; Sodek, J; Ogata, Y				Shimizu-Sasaki, K; Yamazaki, M; Furuyama, S; Sugiya, H; Sodek, J; Ogata, Y			Identification of a novel response element in the rat bone sialoprotein (BSP) gene promoter that mediates constitutive and fibroblast growth factor 2-induced expression of BSP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY XENOPUS DEVELOPMENT; HUMAN PROSTATE-CANCER; HUMAN BREAST-CANCER; INVERTED TATA BOX; SIGNAL-TRANSDUCTION; PARATHYROID-HORMONE; MESSENGER-RNA; CYCLIC-AMP; ALKALINE-PHOSPHATASE; MESODERM INDUCTION	Bone sialoprotein (BSP) is a sulfated and phosphorylated glycoprotein, found almost exclusively in mineralized connective tissues, that may function in the nucleation of hydroxyapatite crystals. We have found that expression of BSP in osteoblastic ROS 17/2.8 cells is stimulated by fibroblast growth factor 2 (FGF2), a potent mitogen for mesenchymal cells. Stimulation of BSP mRNA with 10 ng/ml FGF2 was first evident at 3 h (similar to2.6-fold) and reached maximal levels at 6 h (similar to4-fold). From transient transfection assays, a FGF response element (FRE) was identified (nucleotides -92 to -85, "GGT-GAGA") as a target of transcriptional activation by FGF2. Ligation of two copies of the FRE 5' to an SV40 promoter was sufficient to confer FGF-responsive transcription. A sequence-specific protein-DNA complex, formed with a double-stranded oligonucleotide encompassing the FRE and nuclear extracts from ROS 17/2.8 cells, but not from fibroblasts, was increased following FGF2 stimulation. Several point mutations within the critical FRE sequence abrogated the formation of this complex and suppressed both basal and FGF2-mediated promoter activity. These studies, therefore, have identified a novel FRE in the proximal promoter of the BSP gene that mediates both constitutive and FGF2-induced BSP transcription.	Nihon Univ, Sch Dent, Dept Periodontol, Matsudo, Chiba 2718587, Japan; Nihon Univ, Sch Dent, Dept Endodont, Matsudo, Chiba 2718587, Japan; Nihon Univ, Sch Dent, Dept Physiol, Matsudo, Chiba 2718587, Japan; Univ Toronto, Fac Dent, Canadian Inst Hlth Res Grp Periodontal Physiol, Toronto, ON M5S 3E2, Canada; Univ Toronto, Fac Med, Dept Biochem, Toronto, ON M5S 3E2, Canada	Nihon University; Nihon University; Nihon University; University of Toronto; University of Toronto	Ogata, Y (corresponding author), Nihon Univ, Sch Dent, Dept Periodontol, Matsudo, Chiba 2718587, Japan.	ogata@mascat.nihon-u.ac.jp						Aho S, 1997, EUR J BIOCHEM, V247, P503, DOI 10.1111/j.1432-1033.1997.00503.x; Bellahcene A, 1996, INT J CANCER, V69, P350; Bellahcene A, 1997, CALCIFIED TISSUE INT, V61, P183, DOI 10.1007/s002239900320; Bellahcene A, 1998, THYROID, V8, P637, DOI 10.1089/thy.1998.8.637; Benson MD, 2000, J BIOL CHEM, V275, P13907, DOI 10.1074/jbc.275.18.13907; Benson MD, 1999, J BONE MINER RES, V14, P396, DOI 10.1359/jbmr.1999.14.3.396; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; Boudreaux JM, 1996, J BIOL CHEM, V271, P7508, DOI 10.1074/jbc.271.13.7508; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; CHEN JK, 1992, J BONE MINER RES, V7, P987; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; Debiais F, 1998, J BONE MINER RES, V13, P645, DOI 10.1359/jbmr.1998.13.4.645; DEN C, 1996, CELL, V84, P911; Dong ZG, 1996, J BIOL CHEM, V271, P9942, DOI 10.1074/jbc.271.17.9942; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; FISHER LW, 1990, J BIOL CHEM, V265, P2347; Ganss B, 1999, CRIT REV ORAL BIOL M, V10, P79, DOI 10.1177/10454411990100010401; Giri D, 1999, CLIN CANCER RES, V5, P1063; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HUNTER GK, 1993, P NATL ACAD SCI USA, V90, P8562, DOI 10.1073/pnas.90.18.8562; HURLEY MM, 1993, J BIOL CHEM, V268, P5588; Hurley MM, 1996, J BONE MINER RES, V11, P1256; IBRAHIM T, 2001, IN PRESS CLIN EXP ME; JABS EW, 1994, NAT GENET, V8, P275, DOI 10.1038/ng1194-275; KASUGAI S, 1992, J CELL PHYSIOL, V152, P467, DOI 10.1002/jcp.1041520305; KATO Y, 1990, J BIOL CHEM, V265, P5903; KERR JM, 1993, GENOMICS, V17, P408, DOI 10.1006/geno.1993.1340; Kim RH, 1999, CANCER RES, V59, P565; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; KIM RH, 1994, MATRIX BIOL, V14, P31, DOI 10.1016/0945-053X(94)90027-2; Klint P, 1999, ONCOGENE, V18, P3354, DOI 10.1038/sj.onc.1202680; KLINT P, 1999, FRONT BIOSCI, V4, P165; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Kurokouchi K, 1998, J BONE MINER RES, V13, P1290, DOI 10.1359/jbmr.1998.13.8.1290; LI JJ, 1995, BIOCHEM J, V310, P33, DOI 10.1042/bj3100033; LI JJ, 1993, BIOCHEM J, V289, P625, DOI 10.1042/bj2890625; Liang K, 1999, ENDOCRINOLOGY, V140, P5780; Liu Y, 2000, LANCET, V356, P567, DOI 10.1016/S0140-6736(00)02587-3; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MAJESKA RJ, 1982, CALCIFIED TISSUE INT, V34, P59, DOI 10.1007/BF02411210; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MUENKE M, 1994, NAT GENET, V8, P269, DOI 10.1038/ng1194-269; NAKAMURA T, 1995, ENDOCRINOLOGY, V136, P1276, DOI 10.1210/en.136.3.1276; NODA M, 1989, J CELL BIOL, V109, P2529, DOI 10.1083/jcb.109.5.2529; Ogata Y, 2000, MATRIX BIOL, V19, P395, DOI 10.1016/S0945-053X(00)00085-8; OGATA Y, 1995, EUR J BIOCHEM, V230, P183; Ogata Y, 1995, J PERIODONTOL, V66, P1025, DOI 10.1902/jop.1995.66.12.1025; Ogata Y, 1997, J CELL BIOCHEM, V65, P501, DOI 10.1002/(SICI)1097-4644(19970615)65:4<501::AID-JCB6>3.0.CO;2-S; OLDBERG A, 1988, J BIOL CHEM, V263, P19430; PENAULTLLORCA F, 1995, INT J CANCER, V61, P170, DOI 10.1002/ijc.2910610205; REARDON W, 1994, NAT GENET, V8, P98, DOI 10.1038/ng0994-98; RODAN SB, 1989, J BIOL CHEM, V264, P19934; SCHEDLICH LJ, 1994, J BONE MINER RES, V9, P143; Sodek J, 1996, CONNECT TISSUE RES, V35, P23, DOI 10.3109/03008209609029171; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; TAN Y, 1994, MOL CELL BIOL, V14, P7546, DOI 10.1128/MCB.14.11.7546; TAVORMINA PL, 1995, NAT GENET, V9, P321, DOI 10.1038/ng0395-321; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; Waltregny D, 1998, J NATL CANCER I, V90, P1000, DOI 10.1093/jnci/90.13.1000; Waltregny D, 2000, J BONE MINER RES, V15, P834, DOI 10.1359/jbmr.2000.15.5.834; Wang D, 1997, ONCOGENE, V14, P2291, DOI 10.1038/sj.onc.1201069; Yamasaki M, 1996, J BIOL CHEM, V271, P15918, DOI 10.1074/jbc.271.27.15918; Yamauchi M, 1996, MATRIX BIOL, V15, P119, DOI 10.1016/S0945-053X(96)90153-5; ZHANG R, 1990, J BIOL CHEM, V265, P15375	66	54	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5459	5466		10.1074/jbc.M008971200	http://dx.doi.org/10.1074/jbc.M008971200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11087753	hybrid			2022-12-25	WOS:000167115100009
J	Kuhn, J; Gotting, C; Schnolzer, M; Kempf, T; Brinkmann, T; Kleesiek, K				Kuhn, J; Gotting, C; Schnolzer, M; Kempf, T; Brinkmann, T; Kleesiek, K			First isolation of human UDP-D-xylose: Proteoglycan core protein beta-D-xylosyltransferase secreted from cultured JAR choriocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; SWARM RAT CHONDROSARCOMA; HAMSTER OVARY CELLS; LINKAGE REGION; SERUM XYLOSYLTRANSFERASE; ENDOPLASMIC-RETICULUM; SYSTEMIC-SCLEROSIS; PURIFICATION; BIOSYNTHESIS; CARTILAGE	Human UDP-D-xylose:proteoglycan core protein beta -D-xylosyltransferase (EC 2.4.2.26, XT) initiates the biosynthesis of glycosaminoglycan lateral chains in proteoglycans by transfer of xylose from UDP-xylose to specific serine residues of the core protein. In this study, we report the first isolation of the XT and present the first partial amino acid sequence of this enzyme. We purified XT 4,700-fold with 1% yield from serum-free JAR choriocarcinoma cell culture supernatant, The isolation procedure included a combination of ammonium sulfate precipitation, heparin affinity chromatography, ion exchange chromatography, and protamine affinity chromatography, Among other proteins an unknown protein was detected by matrix-assisted laser desorption ionization mass spectrometry-time of flight analysis in the purified sample. The molecular mass of this protein was determined as 120 kDa by SDS-polyacrylamide gel electrophoresis, The isolated protein was enzymatically cleaved by trypsin and endoproteinase Lys-C, Eleven peptide fragments were sequenced by Edman degradation. Searches with the amino acid sequences in protein and EST data bases showed no homology to known sequences. XT was enriched by immunoaffinity chromatography with an immobilized antibody against a synthetic peptide deduced from the sequenced peptide fragments and was specifically eluted with the antigen. In addition, XT was purified alternatively with an aprotinin affinity chromatography and was detected by Western blot analysis in the enzyme-containing fraction.	Ruhr Univ Bochum, Univ Klin, Herz & Diabet Zentrum Nordrhein Westfalen, Inst Lab & Transfus Med, D-32545 Bad Oeynhausen, Germany; Deutsch Krebsforschungszentrum, Zent Prot Anal R0800, D-69120 Heidelberg, Germany	Ruhr University Bochum; Helmholtz Association; German Cancer Research Center (DKFZ)	Kleesiek, K (corresponding author), Ruhr Univ Bochum, Univ Klin, Herz & Diabet Zentrum Nordrhein Westfalen, Inst Lab & Transfus Med, Georgstr 11, D-32545 Bad Oeynhausen, Germany.							Breton C, 1998, J BIOCHEM, V123, P1000; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Brinkmann T, 1997, J BIOL CHEM, V272, P11171; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; FUJITAYAMAGUCHI Y, 1981, J BIOL CHEM, V256, P2701; Gastinel LN, 1999, EMBO J, V18, P3546, DOI 10.1093/emboj/18.13.3546; Gotting C, 1998, J PROTEIN CHEM, V17, P295, DOI 10.1023/A:1022549121672; Gotting C, 1999, J INVEST DERMATOL, V112, P919, DOI 10.1046/j.1523-1747.1999.00590.x; Gotting C, 2000, ACTA DERM-VENEREOL, V80, P60; GREBNER EE, 1966, ARCH BIOCHEM BIOPHYS, V116, P391, DOI 10.1016/0003-9861(66)90045-2; HABUCHI H, 1995, J BIOL CHEM, V270, P4172, DOI 10.1074/jbc.270.8.4172; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; HOFFMANN HP, 1984, CONNECT TISSUE RES, V12, P151, DOI 10.3109/03008208408992780; Jensen ON, 1996, RAPID COMMUN MASS SP, V10, P1371, DOI 10.1002/(SICI)1097-0231(199608)10:11<1371::AID-RCM682>3.0.CO;2-5; JOZIASSE DH, 1992, GLYCOBIOLOGY, V2, P271, DOI 10.1093/glycob/2.4.271; KEARNS AE, 1991, BIOCHEMISTRY-US, V30, P7477, DOI 10.1021/bi00244a016; KIMURA JH, 1984, J CELL BIOCHEM, V26, P261, DOI 10.1002/jcb.240260406; KLEESIEK K, 1987, J CLIN CHEM CLIN BIO, V25, P473; Kobayashi M, 1996, J BIOL CHEM, V271, P7645, DOI 10.1074/jbc.271.13.7645; MARCUM JA, 1986, J BIOL CHEM, V261, P7507; Moses J, 1999, EUR J BIOCHEM, V260, P879, DOI 10.1046/j.1432-1327.1999.00228.x; Moses J, 1997, EUR J BIOCHEM, V248, P521, DOI 10.1111/j.1432-1033.1997.00521.x; NEESE LL, 1994, BLOOD COAGUL FIBRIN, V5, P737, DOI 10.1097/00001721-199410000-00010; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; PAULSON JC, 1987, BIOCHEM SOC T, V15, P618, DOI 10.1042/bst0150618; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SCHWARTZ NB, 1975, ARCH BIOCHEM BIOPHYS, V171, P136, DOI 10.1016/0003-9861(75)90016-8; SCHWARTZ NB, 1974, CARBOHYD RES, V37, P167, DOI 10.1016/S0008-6215(00)87072-X; SCHWARTZ NB, 1977, J BIOL CHEM, V252, P6316; STOOLMILLER AC, 1972, J BIOL CHEM, V247, P3525; SUGAHARA K, 1992, EUR J BIOCHEM, V204, P401, DOI 10.1111/j.1432-1033.1992.tb16649.x; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; Weilke C, 1997, CLIN CHEM, V43, P45; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945	37	65	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4940	4947		10.1074/jbc.M005111200	http://dx.doi.org/10.1074/jbc.M005111200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087729	hybrid			2022-12-25	WOS:000168484300057
J	Ryan, SE; Blanton, MP; Baenziger, JE				Ryan, SE; Blanton, MP; Baenziger, JE			A conformational intermediate between the resting and desensitized states of the nicotinic acetylcholine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFRARED DIFFERENCE SPECTROSCOPY; TORPEDO-MARMORATA; BINDING; SITES; PHOSPHORYLATION; IDENTIFICATION; CALIFORNICA; INHIBITOR; CHANNEL; LIGAND	The structural changes induced in the nicotinic acetylcholine receptor by two noncompetitive channel blockers, proadifen and phencyclidine, have been studied by infrared difference spectroscopy and using the conformationally sensitive photoreactive noncompetitive antagonist 3-(trifluoromethyl)-3-m-([I-125]iodophenyl)diazirine. Simultaneous binding of proadifen to both the ion channel pore and neurotransmitter sites leads to the loss of positive markers near 1663, 1655, 1547, 1430, and 1059 cm(-1) in carbamylcholine difference spectra, suggesting the stabilization of a desensitized conformation. In contrast, only the positive markers near 1663 and 1059 cm(-1) are maximally affected by the binding of either blocker to the ion channel pore suggesting that the conformationally sensitive residues vibrating at these two frequencies are stabilized in a desensitized-like conformation, whereas those vibrating near 1655 and 1430 cm(-1) remain in a resting-like state. The vibrations at 1547 cm(-1) are coupled to those at both 1663 and 1655 cm(-1) and thus exhibit an intermediate pattern of band intensity change. The formation of a structural intermediate between the resting and desensitized states in the presence of phencyclidine is further supported by the pattern of 3-(trifluoromethyl)-3-m-([I-125]iodophenyl)diazirine photoincorporation. In the presence of phencyclidine, the subunit labeling pattern is distinct from that observed in either the resting or desensitized conformations; specifically, there is a concentration-dependent increase in the extent of photoincorporation into the delta -subunit. Our data show that domains of the nicotinic acetylcholine receptor interconvert between the resting and desensitized states independently of each other and suggest a revised model of channel blocker action that involves both low and high affinity agonist binding conformational intermediates.	Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1H 8M5, Canada; Texas Tech Univ, Hlth Sci Ctr, Dept Anesthesiol, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Pharmacol, Lubbock, TX 79430 USA	University of Ottawa; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Baenziger, JE (corresponding author), Univ Ottawa, Dept Biochem Microbiol & Immunol, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.	jebaenz@uottawa.ca		Baenziger, John/0000-0002-2888-5328	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS035786] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35786] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arias HR, 1996, MOL MEMBR BIOL, V13, P1; Baenziger JE, 2000, J BIOL CHEM, V275, P777, DOI 10.1074/jbc.275.2.777; BAENZIGER JE, 1992, BIOPHYS J, V61, P983, DOI 10.1016/S0006-3495(92)81905-7; BAENZIGER JE, 1993, BIOCHEMISTRY-US, V32, P5448, DOI 10.1021/bi00071a022; BLANCHARD SG, 1979, BIOCHEMISTRY-US, V18, P5880, DOI 10.1021/bi00593a019; BOYD ND, 1980, BIOCHEMISTRY-US, V19, P5344, DOI 10.1021/bi00564a031; BOYD ND, 1980, BIOCHEMISTRY-US, V19, P5353, DOI 10.1021/bi00564a032; BOYD ND, 1984, BIOCHEMISTRY-US, V23, P4023, DOI 10.1021/bi00313a003; Chiara DC, 1997, J BIOL CHEM, V272, P32940, DOI 10.1074/jbc.272.52.32940; GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; HEIDMANN T, 1983, BIOCHEMISTRY-US, V22, P3112, DOI 10.1021/bi00282a014; HEIDMANN T, 1978, ANNU REV BIOCHEM, V47, P317, DOI 10.1146/annurev.bi.47.070178.001533; HEIDMANN T, 1979, EUR J BIOCHEM, V94, P255, DOI 10.1111/j.1432-1033.1979.tb12893.x; HUGANIR RL, 1986, NATURE, V321, P774, DOI 10.1038/321774a0; KRODEL EK, 1979, MOL PHARMACOL, V15, P294; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCARTHY MP, 1992, J BIOL CHEM, V267, P7655; MOORE MA, 1994, BBA-BIOMEMBRANES, V1190, P457, DOI 10.1016/0005-2736(94)90108-2; Ryan SE, 1996, J BIOL CHEM, V271, P24590, DOI 10.1074/jbc.271.40.24590; Ryan SE, 1998, TOXICOL LETT, V101, P179, DOI 10.1016/S0378-4274(98)00183-0; Ryan SE, 1999, MOL PHARMACOL, V55, P348, DOI 10.1124/mol.55.2.348; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; WHITE BH, 1991, J BIOL CHEM, V266, P21595; WHITE BH, 1992, J BIOL CHEM, V267, P15770; WU G, 1994, BIOCHEMISTRY-US, V33, P15375, DOI 10.1021/bi00255a018	26	22	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4796	4803		10.1074/jbc.M007063200	http://dx.doi.org/10.1074/jbc.M007063200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11083863	hybrid			2022-12-25	WOS:000168484300037
J	Tarantini, F; Micucci, I; Bellum, S; Landriscina, M; Garfinkel, S; Prudovsky, I; Maciag, T				Tarantini, F; Micucci, I; Bellum, S; Landriscina, M; Garfinkel, S; Prudovsky, I; Maciag, T			The precursor but not the mature form of IL1 alpha blocks the release of FGF1 in response to heat shock	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; FACTOR-I; ENDOTHELIAL-CELLS; INTERLEUKIN-1-ALPHA; SECRETION; DOMAIN; IL-1; RECEPTOR; BINDING; IDENTIFICATION	Interleukin (IL)1 alpha mediates proinflammatory events through its extracellular interaction with the IL1 type I receptor. However, IL1 alpha does not contain a conventional signal peptide sequence that provides access to the endoplasmic reticulum-Golgi apparatus for secretion. Thus, we have studied the release of the precursor (p) and mature (m) forms of IL1 alpha from NIH 3T3 cells. We have demonstrated that mIL1 alpha but not pIL1 alpha was released in response to heat shock with biochemical and pharmacological properties similar to those reported for the stress-mediated release pathway utilized by fibroblast growth factor (FGF)1. However, unlike the FGF1 release pathway, the IL1 alpha release pathway appears to function independently of synaptotagmin (Syt)1 because the expression of a dominant-negative form of Syt1, which represses the release of FGF1, did not inhibit the release of mIL1 alpha in response to temperature stress. Interestingly, whereas the expression of both mIL1 alpha and FGF1 in MH 3T3 cells did not impair the stress-induced release of either polypeptide, the expression of both pIL1 alpha and FGF1 repressed the release of FGF1 in response to temperature stress. These data suggest that the release of mIL1 alpha requires proteolytic processing of its precursor form and that mIL1 alpha and FGF1 may utilize similar but distinct mechanisms for export.	Maine Med Ctr, Res Inst, Ctr Mol Med, Scarborough, ME 04074 USA	Maine Medical Center	Maciag, T (corresponding author), Maine Med Ctr, Res Inst, Ctr Mol Med, 81 Res Dr, Scarborough, ME 04074 USA.	maciat@mail.mmc.org	Prudovsky, Igor/GVU-1521-2022; Tarantini, Francesca/I-6332-2012; Landriscina, Matteo/K-1092-2016	TARANTINI, FRANCESCA/0000-0002-1390-2965; Landriscina, Matteo/0000-0003-0591-9799	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032348] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL32348] Funding Source: Medline; NIA NIH HHS [AG98503] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		CARINCI V, 1992, EUR J BIOCHEM, V205, P295, DOI 10.1111/j.1432-1033.1992.tb16780.x; Carreira CM, 1998, J BIOL CHEM, V273, P22224, DOI 10.1074/jbc.273.35.22224; CARRUTH LM, 1991, J BIOL CHEM, V266, P12162; CERRETTI DP, 1992, SCIENCE, V256, P97, DOI 10.1126/science.1373520; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DINARELLE C, 1991, P NATL ACAD SCI USA, V88, P98485; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; DINARELLO CA, 1991, BLOOD, V77, P1627; GARFINKEL S, 1992, J BIOL CHEM, V267, P24375; GERMINO J, 1983, P NATL ACAD SCI-BIOL, V80, P6848, DOI 10.1073/pnas.80.22.6848; GIRI JG, 1985, J IMMUNOL, V134, P343; GROVES RW, 1995, P NATL ACAD SCI USA, V92, P11874, DOI 10.1073/pnas.92.25.11874; HOGQUIST KA, 1991, J IMMUNOL, V147, P2181; HOGQUIST KA, 1991, P NATL ACAD SCI USA, V88, P8485, DOI 10.1073/pnas.88.19.8485; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; Landriscina M, 2000, J BIOL CHEM, V275, P32753, DOI 10.1074/jbc.M002336200; LaVallee TM, 1998, J BIOL CHEM, V273, P22217, DOI 10.1074/jbc.273.35.22217; Lee RT, 1997, J IMMUNOL, V159, P5084; MACIAG T, 1982, J BIOL CHEM, V257, P5333; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; McMahon GA, 1997, J BIOL CHEM, V272, P28202, DOI 10.1074/jbc.272.45.28202; Minter AJ, 1996, J CELL PHYSIOL, V167, P229; MIZEL SB, 1979, J IMMUNOL, V122, P2173; MOSLEY B, 1987, J BIOL CHEM, V262, P2941; NORIOKA K, 1985, JPN J CANCER RES, V85, P522; PERIN MS, 1991, J BIOL CHEM, V266, P623; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SAWADA H, 1990, IN VITRO CELL DEV B, V26, P213; Shi JP, 1997, J BIOL CHEM, V272, P1142, DOI 10.1074/jbc.272.2.1142; Shin JT, 1996, BBA-MOL CELL RES, V1312, P27, DOI 10.1016/0167-4889(96)00013-4; SIDERS WM, 1993, J BIOL CHEM, V268, P22170; Smith DE, 2000, J BIOL CHEM, V275, P1169, DOI 10.1074/jbc.275.2.1169; Stevenson FT, 1997, P NATL ACAD SCI USA, V94, P508, DOI 10.1073/pnas.94.2.508; SUTTLES J, 1990, J IMMUNOL, V144, P175; Tarantini F, 1998, J BIOL CHEM, V273, P22209, DOI 10.1074/jbc.273.35.22209; TARANTINI F, 1995, J BIOL CHEM, V270, P29039, DOI 10.1074/jbc.270.49.29039; THOMAS KA, 1985, P NATL ACAD SCI USA, V82, P6409, DOI 10.1073/pnas.82.19.6409; WATANABE N, 1994, CYTOKINE, V6, P597, DOI 10.1016/1043-4666(94)90046-9; WESSENDORF JHM, 1993, J BIOL CHEM, V268, P22100; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1	45	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5147	5151		10.1074/jbc.C000714200	http://dx.doi.org/10.1074/jbc.C000714200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087725	hybrid			2022-12-25	WOS:000168484300084
J	Verma, S; Zhao, LJ; Chinnadurai, G				Verma, S; Zhao, LJ; Chinnadurai, G			Phosphorylation of the pro-apoptotic protein BIK - Mapping of phosphorylation sites and effect on apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-DEATH; BCL-2 FAMILY; CYTOCHROME-C; BH3 DOMAIN; SURVIVAL; BAD; ACTIVATION; BINDING; P53; MITOCHONDRIA	BIK is a pro-apoptotic BCL-2 family member and is the founding member of a subfamily of pro-apoptotic proteins known as "BH3-alone" proteins. Ectopic expression of BIK induces apoptosis in variety of mammalian cells. BIK complexes with various anti-apoptotic BCL-2 family proteins such as adenovirus E1B-19K and BCL-2 via the BH3 domain. However, the heterodimerization activity of BIK alone is insufficient for its apoptotic activity. Previous studies have shown that phosphorylation regulates the functional activity of both anti-apoptotic and pro-apoptotic members of the BCL-2 family. Here, we have examined phosphorylation of BIK and its effect on the apoptotic activity of BIK. We show that BIK exists as a phosphoprotein and is phosphorylated at residues 33 (threonine) and 35 (serine). Mutation of the phosphorylation sites, in which the Thr and Ser residues were changed to alanine residues, reduced the apoptotic activity of BIK without significantly affecting its ability to heterodimerize with BCL-2. Our results suggest that phosphorylation of BIK is required for eliciting efficient apoptotic activity. Partial purification of the protein kinase from HeLa cell cytoplasmic extracts suggest that BIK may be phosphorylated by a casein kinase II-related enzyme.	St Louis Univ, Med Ctr, Inst Mol Virol, St Louis, MO 63110 USA	Saint Louis University	Chinnadurai, G (corresponding author), St Louis Univ, Med Ctr, Inst Mol Virol, 3681 Pk Ave, St Louis, MO 63110 USA.	chinnag@slu.edu			NCI NIH HHS [R01 CA033616, CA-73803, CA-33616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073803, R01CA033616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Ausubel FM, 1992, CURRENT PROTOCOLS MO; Blaydes JP, 1998, ONCOGENE, V17, P1045, DOI 10.1038/sj.onc.1202014; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; BOUSSET K, 1994, CELL MOL BIOL RES, V40, P501; BOYD JM, 1995, ONCOGENE, V11, P1921; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chinnaiyan AM, 1997, SCIENCE, V275, P1122, DOI 10.1126/science.275.5303.1122; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; delPeso L, 1997, SCIENCE, V278, P687; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Hall SR, 1996, NUCLEIC ACIDS RES, V24, P1119, DOI 10.1093/nar/24.6.1119; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Jones RG, 2000, J EXP MED, V191, P1721, DOI 10.1084/jem.191.10.1721; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schuster N, 1999, FEBS LETT, V447, P160, DOI 10.1016/S0014-5793(99)00273-2; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; SUBRAMANIAN T, 1998, METHODS MOL MED ADEN, P151; Tan Y, 2000, J BIOL CHEM, V275, P25865, DOI 10.1074/jbc.M004199200; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; Uhlmann EJ, 1996, CANCER RES, V56, P2506; Verma S, 2000, GENE, V254, P157, DOI 10.1016/S0378-1119(00)00276-6; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou XM, 2000, J BIOL CHEM, V275, P25046, DOI 10.1074/jbc.M002526200	37	78	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4671	4676		10.1074/jbc.M008983200	http://dx.doi.org/10.1074/jbc.M008983200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11084041	hybrid			2022-12-25	WOS:000168484300021
J	Mancini, JA; Blood, K; Guay, J; Gordon, R; Claveau, D; Chan, CC; Riendeau, D				Mancini, JA; Blood, K; Guay, J; Gordon, R; Claveau, D; Chan, CC; Riendeau, D			Cloning, expression, and up-regulation of inducible rat prostaglandin E synthase during lipopolysaccharide-induced pyresis and adjuvant-induced arthritis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; LEUKOTRIENE BIOSYNTHESIS INHIBITORS; GLUTATHIONE-S-TRANSFERASE; 5-LIPOXYGENASE-ACTIVATING PROTEIN; G/H SYNTHASE-1; C-4 SYNTHASE; MACULA DENSA; MICE LACKING; IDENTIFICATION; CYCLOOXYGENASE-2	We have cloned and expressed the inducible form of prostaglandin (PG) E synthase from rat and characterized its regulation of expression in several tissues after in vivo lipopoylsaccharide (LPS) challenge. The rat PGE synthase is 80% identical to the human enzyme at the amino acid level and catalyzes the conversion of PGH(2) to PGE(2) when overexpressed in Chinese hamster ovary K1 (CHO-K1) cells. PGE synthase activity was measured using [H-3]PGH(2) as substrate and stannous chloride to terminate the reaction and convert all unreacted unstable PGH(2) to PGF(2 alpha) before high pressure liquid chromatography analysis. We assessed the induction of PGE synthase in tissues from Harlan Sprague-Dawley rats after LPS-induced pyresis in vivo. Rat PGE synthase was up-regulated at the mRNA level in lung, colon, brain, heart, testis, spleen, and seminal vesicles. Cyclooxygenase (COX)-2 and interleukin 1 beta were also up-regulated in these tissues, although to different extents than PGE synthase, PGE synthase and COX-2 were also up-regulated to the greatest extent in a rat model of adjuvant-induced arthritis. The RNA induction of PGE synthase in lung and the adjuvant-treated paw correlated with a 3.8- and 16-fold induction of protein seen in these tissues by immunoblot analysis. Because PGE synthase is a member of the membrane-associated proteins in eicosanoid and glutathione metabolism (MAPEG) family, of which leukotriene (LT) C-4 synthase and 5-lipoxygenase-activating protein are also members, we tested the effect of LTC4 and the 5-lipoxygenase-activating protein inhibitor MK-886 on PGE synthase activity. LTC4 and MK-886 were found to inhibit the activity with IC50 values of 1.2 and 3.2 muM, respectively. The results demonstrate that PGE synthase is up-regulated in vivo after LPS or adjuvant administration and suggest that this is a key enzyme involved in the formation of PGE(2) in COX-2-mediated inflammatory and pyretic responses.	Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, Pointe Claire, PQ H9R 4P8, Canada; Merck Frosst Ctr Therapeut Res, Dept Pharmacol, Pointe Claire, PQ H9R 4P8, Canada	Merck & Company; Merck & Company	Mancini, JA (corresponding author), Merck Frosst Ctr Therapeut Res, Dept Biochem & Mol Biol, POB 1005, Pointe Claire, PQ H9R 4P8, Canada.							ALLISON MC, 1992, NEW ENGL J MED, V327, P749, DOI 10.1056/NEJM199209103271101; Cao CY, 1997, AM J PHYSIOL-REG I, V272, pR1712, DOI 10.1152/ajpregu.1997.272.6.R1712; Chan CC, 1999, J PHARMACOL EXP THER, V290, P551; Fletcher DS, 1998, J PHARMACOL EXP THER, V284, P714; Goldstein JL, 1998, AM J MANAG CARE, V4, P687; Gupta N, 1997, CAN J PHYSIOL PHARM, V75, P1212, DOI 10.1139/cjpp-75-10-11-1212; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Jakobsson PJ, 1997, J BIOL CHEM, V272, P22934, DOI 10.1074/jbc.272.36.22934; Jakobsson PJ, 1999, PROTEIN SCI, V8, P689, DOI 10.1110/ps.8.3.689; Jakobsson PJ, 1996, J BIOL CHEM, V271, P22203, DOI 10.1074/jbc.271.36.22203; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kargman S, 1996, GASTROENTEROLOGY, V111, P445, DOI 10.1053/gast.1996.v111.pm8690211; KARGMAN SL, 1995, CANCER RES, V55, P2556; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; MANCINI JA, 1994, LIFE SCI, V54, pPL137, DOI 10.1016/0024-3205(94)00872-8; MANCINI JA, 1993, FEBS LETT, V318, P277, DOI 10.1016/0014-5793(93)80528-3; Mancini JA, 1998, J BIOL CHEM, V273, P32842, DOI 10.1074/jbc.273.49.32842; MORGENSTERN R, 1982, EUR J BIOCHEM, V128, P243; Mukherjee A, 1996, INFLAMM RES, V45, P531, DOI 10.1007/BF02342223; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Nantel F, 1999, FEBS LETT, V457, P475, DOI 10.1016/S0014-5793(99)01088-1; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PAVORD ID, 1993, AM REV RESPIR DIS, V148, P87, DOI 10.1164/ajrccm/148.1.87; Philippe L, 1997, AM J PHYSIOL-REG I, V273, pR1550, DOI 10.1152/ajpregu.1997.273.4.R1550; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; ROUZER CA, 1990, J BIOL CHEM, V265, P1436; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; Satoh K, 2000, NEUROSCI LETT, V283, P221, DOI 10.1016/S0304-3940(00)00926-5; SMITH WL, 1991, BIOCHIM BIOPHYS ACTA, V1083, P1, DOI 10.1016/0005-2760(91)90119-3; TRAVERSA G, 1995, EPIDEMIOLOGY, V6, P49, DOI 10.1097/00001648-199501000-00010; Ushikubi F, 1998, NATURE, V395, P281, DOI 10.1038/26233; VANE JR, 1995, INFLAMM RES, V44, P1, DOI 10.1007/BF01630479; VICKERS PJ, 1992, MOL PHARMACOL, V42, P94; WELSCH DJ, 1994, P NATL ACAD SCI USA, V91, P9745, DOI 10.1073/pnas.91.21.9745; YAMAGATA K, 1993, NEURON, V11, P371, DOI 10.1016/0896-6273(93)90192-T	39	211	215	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4469	4475		10.1074/jbc.M006865200	http://dx.doi.org/10.1074/jbc.M006865200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11067848	hybrid			2022-12-25	WOS:000166921200098
J	Melo, AMP; Duarte, M; Moller, IM; Prokisch, H; Dolan, PL; Pinto, L; Nelson, MA; Videira, A				Melo, AMP; Duarte, M; Moller, IM; Prokisch, H; Dolan, PL; Pinto, L; Nelson, MA; Videira, A			The external calcium-dependent NADPH dehydrogenase from Neurospora crassa mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXOGENOUS NAD(P)H OXIDATION; IRON-SULFUR SUBUNIT; COMPLEX-I; INNER MEMBRANE; UBIQUINONE OXIDOREDUCTASE; SACCHAROMYCES-CEREVISIAE; RESPIRATORY-CHAIN; PLANT-MITOCHONDRIA; PRECURSOR PROTEINS; MOLECULAR-CLONING	We have inactivated the nuclear gene coding for a putative NAD(P)H dehydrogenase from the inner membrane of Neurospora crassa mitochondria by repeat-induced point mutations. The respiratory rates of mito chondria from the resulting mutant (nde-1) were measured, using NADH or NADPH as substrates under different assay conditions. The results showed that the mutant lacks an external calcium-dependent NADPH dehydrogenase. The observation of NADH and NADPH oxidation by intact mitochondria from the nde-1 mutant suggests the existence of a second external NAD(P)H dehydrogenase, The topology of the NDE1 protein was further studied by protease accessibility, in vitro import experiments, and in silico analysis of the amino acid sequence. Taken together, it appears that most of the NDE1 protein extends into the intermembrane space in a tightly folded conformation and that it remains anchored to the inner mitochondrial membrane by an N-terminal transmembrane domain.	Univ Porto, Inst Biol Mol & Celular, P-4150180 Porto, Portugal; Lund Univ, Dept Plant Physiol, S-22100 Lund, Sweden; Univ Munich, Inst Physiol Chem, D-80336 Munich, Germany; Univ New Mexico, Dept Biol, Albuquerque, NM 87131 USA; Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4099003 Porto, Portugal	Universidade do Porto; Lund University; University of Munich; University of New Mexico; Universidade do Porto	Videira, A (corresponding author), Univ Porto, Inst Biol Mol & Celular, Rua Campo Alegre 823, P-4150180 Porto, Portugal.	asvideir@icbas.up.pt	Melo, Ana/A-5542-2009; Prokisch, Holger/N-8964-2013; Duarte, Margarida/K-1424-2013; Videira, Arnaldo/H-8150-2013	Melo, Ana/0000-0003-0695-3817; Duarte, Margarida/0000-0002-8933-2487; Videira, Arnaldo/0000-0001-7267-4459; Prokisch, Holger/0000-0003-2379-6286				Almeida T, 1999, EUR J BIOCHEM, V265, P86, DOI 10.1046/j.1432-1327.1999.00668.x; ALVES PC, 1994, J BIOL CHEM, V269, P7777; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; daSilva MV, 1996, MOL GEN GENET, V252, P177; Davis R.H., 1970, 789 METHODS ENZYMOLO, VVolume 17, P79, DOI DOI 10.1016/0076-6879(71)17168-6; DEVRIES S, 1987, BIOCHIM BIOPHYS ACTA, V895, P205, DOI 10.1016/S0304-4173(87)80003-4; DUARTE M, 1995, GENETICS, V139, P1211; Duarte M, 1998, MOL GEN GENET, V257, P368; Duarte M, 1996, BBA-BIOENERGETICS, V1275, P151, DOI 10.1016/0005-2728(96)00033-3; EDMAN K, 1985, BIOCHEM J, V232, P471, DOI 10.1042/bj2320471; FECKE W, 1994, EUR J BIOCHEM, V220, P551, DOI 10.1111/j.1432-1033.1994.tb18655.x; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.bi.54.070185.005055; HAWLITSCHEK G, 1988, CELL, V53, P795, DOI 10.1016/0092-8674(88)90096-7; Howitt CA, 1999, J BACTERIOL, V181, P3994, DOI 10.1128/JB.181.13.3994-4003.1999; Kerscher SJ, 1999, J CELL SCI, V112, P2347; Kubrich M, 1998, J BIOL CHEM, V273, P16374, DOI 10.1074/jbc.273.26.16374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee S.B., 1988, FUNGAL GENET REP, V35, P23, DOI [10.4148/1941-4765.1531, DOI 10.4148/1941-4765.1531]; Lesk AM, 1995, CURR OPIN STRUC BIOL, V5, P775, DOI 10.1016/0959-440X(95)80010-7; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; Luttik MAH, 1998, J BIOL CHEM, V273, P24529, DOI 10.1074/jbc.273.38.24529; MARRES CAM, 1991, EUR J BIOCHEM, V195, P857, DOI 10.1111/j.1432-1033.1991.tb15775.x; Melo AMP, 1996, BBA-BIOENERGETICS, V1276, P133, DOI 10.1016/0005-2728(96)00068-0; Melo AMP, 1999, BBA-BIOENERGETICS, V1412, P282, DOI 10.1016/S0005-2728(99)00072-9; MOLLER IM, 1981, BIOCHEM J, V194, P487, DOI 10.1042/bj1940487; MOLLER IM, 1982, PHYSIOL PLANTARUM, V54, P267, DOI 10.1111/j.1399-3054.1982.tb00258.x; MOLLER IM, 1982, EUR J BIOCHEM, V123, P81, DOI 10.1111/j.1432-1033.1982.tb06501.x; Moller IM, 1998, TRENDS PLANT SCI, V3, P21, DOI 10.1016/S1360-1385(97)01156-4; MOLLER IM, 1987, METHOD ENZYMOL, V148, P442; NELSON MA, 1992, GENETICS, V132, P149; NELSON MA, 1989, MOL CELL BIOL, V9, P1271, DOI 10.1128/MCB.9.3.1271; Nelson MA, 1997, FUNGAL GENET BIOL, V21, P348, DOI 10.1006/fgbi.1997.0986; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; Rasmusson AG, 1999, PLANT J, V20, P79, DOI 10.1046/j.1365-313X.1999.00576.x; RASSOW J, 1990, NUCLEIC ACIDS RES, V18, P4922, DOI 10.1093/nar/18.16.4922; ROBERTS TH, 1995, FEBS LETT, V373, P307, DOI 10.1016/0014-5793(95)01059-N; Rojo EE, 1998, J BIOL CHEM, V273, P8040, DOI 10.1074/jbc.273.14.8040; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWITZGUEBEL JP, 1983, J GEN MICROBIOL, V129, P2387; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SELKER EU, 1988, P NATL ACAD SCI USA, V85, P6870, DOI 10.1073/pnas.85.18.6870; SEQUIREAL B, 1993, EMBO J, V12, P2211, DOI 10.1002/j.1460-2075.1993.tb05869.x; Small WC, 1998, J BACTERIOL, V180, P4051, DOI 10.1128/JB.180.16.4051-4055.1998; SOLLNER T, 1989, CELL, V59, P1061, DOI 10.1016/0092-8674(89)90762-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VIDEIRA A, 1993, BIOCHEM J, V291, P729, DOI 10.1042/bj2910729; VIDEIRA A, 1990, J BIOL CHEM, V265, P13060; VIDEIRA A, 1989, EUR J BIOCHEM, V181, P493, DOI 10.1111/j.1432-1033.1989.tb14751.x; VOLLMER SJ, 1986, P NATL ACAD SCI USA, V83, P4869, DOI 10.1073/pnas.83.13.4869; WEISS H, 1970, EUR J BIOCHEM, V14, P75, DOI 10.1111/j.1432-1033.1970.tb00263.x; WERNER S, 1977, EUR J BIOCHEM, V79, P103, DOI 10.1111/j.1432-1033.1977.tb11788.x; Zar J. H., 1996, BIOSTATISTICAL ANAL	54	61	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3947	3951		10.1074/jbc.M008199200	http://dx.doi.org/10.1074/jbc.M008199200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11073955	hybrid			2022-12-25	WOS:000166921200032
J	Sanda, S; Leustek, T; Theisen, MJ; Garavito, RM; Benning, C				Sanda, S; Leustek, T; Theisen, MJ; Garavito, RM; Benning, C			Recombinant Arabidopsis SQD1 converts UDP-glucose and sulfite to the sulfolipid head group precursor UDP-sulfoquinovose in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT SULFUR METABOLISM; RHODOBACTER-SPHAEROIDES; DEFICIENT MUTANT; DIACYLGLYCEROL SULFOQUINOVOSYLTRANSFERASE; CHLOROPLAST ENVELOPES; SPINACH LEAVES; BIOSYNTHESIS; SULFOQUINOVOSYLDIACYLGLYCEROL; ACCUMULATION; TRANSPORT	The sulfolipid sulfoquinovosyldiacylglycerol is a component of plant photosynthetic membranes and represents one of the few naturally occurring sulfonic acids with detergent properties. Sulfolipid biosynthesis involves the transfer of sulfoquinovose, a 6-deoxy-6-sulfoglucose, from UDP-sulfoquinovose to diacylglycerol. The formation of the sulfonic acid precursor, UDP-sulfoquinovose, from UDP-glucose and a sulfur donor is proposed to be catalyzed by the bacterial SQDB proteins or the orthologous plant SQD1 proteins. To investigate the underlying enzymatic mechanism and to elucidate the de novo synthesis of sulfonic acids in biological systems, we developed an in vitro assay for the recombinant SQD1 protein from Arabidopsis thaliana. Among different possible sulfur donors tested, sulfite led to the formation of UDP-sulfoquinovose in the presence of UDP-glucose and SQD1. An SQD1 T145A mutant showed greatly reduced activity, The UDP-sulfoquinovose formed in this assay was identified by co-chromatography with standards and served as substrate for the sulfolipid synthase associated with spinach chloroplast membranes. Approximate K-m values of 150 muM for UDP-glucose and 10 muM for sulfite were established for SQD1, Based on our results, we propose that SQD1 catalyzes the formation of UDP-sulfoquinovose from UDP-glucose and sulfite, derived from the sulfate reduction pathway in the chloroplast.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; Rutgers State Univ, Dept Plant Sci, Ctr Agr Mol Biol, New Brunswick, NJ 08903 USA	Michigan State University; Rutgers State University New Brunswick	Benning, C (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.		Benning, Christoph/Y-2528-2019	Benning, Christoph/0000-0001-8585-3667; Theisen, Michael/0000-0003-4301-5897				BENNING C, 1992, J BACTERIOL, V174, P6479, DOI 10.1128/JB.174.20.6479-6487.1992; BENNING C, 1993, P NATL ACAD SCI USA, V90, P1561, DOI 10.1073/pnas.90.4.1561; Benning C, 1998, ANNU REV PLANT PHYS, V49, P53, DOI 10.1146/annurev.arplant.49.1.53; BENNING C, 1992, J BACTERIOL, V174, P2352, DOI 10.1128/JB.174.7.2352-2360.1992; BENSON AA, 1963, ADV LIPID RES, V1, P387; Bick JA, 1998, CURR OPIN PLANT BIOL, V1, P240, DOI 10.1016/S1369-5266(98)80111-8; Bick JA, 1998, P NATL ACAD SCI USA, V95, P8404, DOI 10.1073/pnas.95.14.8404; BLIGNY R, 1990, J BIOL CHEM, V265, P1319; ERIKSSON B, 1968, ACTA CHEM SCAND, V22, P562, DOI 10.3891/acta.chem.scand.22-0562; ERIKSSON B, 1967, ACTA CHEM SCAND, V21, P1304, DOI 10.3891/acta.chem.scand.21-1304; Essigmann B, 1998, P NATL ACAD SCI USA, V95, P1950, DOI 10.1073/pnas.95.4.1950; Essigmann B, 1999, ARCH BIOCHEM BIOPHYS, V369, P30, DOI 10.1006/abbi.1999.1344; Guler S, 1996, J BIOL CHEM, V271, P7501; HAAS R, 1980, PLANTA, V148, P238, DOI 10.1007/BF00380033; Harwood J. L., 1980, The biochemistry of plants. A comprehensive treatise. Volume 4. Lipids: structure and function., P301; HAYON E, 1972, J AM CHEM SOC, V94, P47, DOI 10.1021/ja00756a009; HEINZ E, 1989, EUR J BIOCHEM, V184, P445, DOI 10.1111/j.1432-1033.1989.tb15037.x; Hell R, 1997, PLANTA, V202, P138, DOI 10.1007/s004250050112; HOPPE W, 1981, Z NATURFORSCH C, V36, P820; ITO W, 1991, GENE, V102, P67, DOI 10.1016/0378-1119(91)90539-N; JOYARD J, 1986, BIOCHIM BIOPHYS ACTA, V879, P78, DOI 10.1016/0005-2760(86)90269-9; KLEPPINGERSPARACE KF, 1985, ARCH BIOCHEM BIOPHYS, V240, P859, DOI 10.1016/0003-9861(85)90096-7; KLEPPINGERSPARACE KF, 1990, PLANT PHYSIOL, V93, P256, DOI 10.1104/pp.93.1.256; Leustek T, 1999, PLANT PHYSIOL, V120, P637, DOI 10.1104/pp.120.3.637; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Liu YJ, 1997, BIOCHEMISTRY-US, V36, P10675, DOI 10.1021/bi970430a; LIZADA MCC, 1981, LIPIDS, V16, P189, DOI 10.1007/BF02535437; Mulichak AM, 1999, P NATL ACAD SCI USA, V96, P13097, DOI 10.1073/pnas.96.23.13097; PUGH CE, 1995, BIOCHEM J, V309, P513, DOI 10.1042/bj3090513; ROSSAK M, 1995, J BIOL CHEM, V270, P25792, DOI 10.1074/jbc.270.43.25792; Rossak M, 1997, ARCH BIOCHEM BIOPHYS, V340, P219, DOI 10.1006/abbi.1997.9931; SEIFERT U, 1992, BOT ACTA, V105, P197, DOI 10.1111/j.1438-8677.1992.tb00287.x; SHIMAZAKI K, 1984, PLANT CELL PHYSIOL, V25, P337; Tietje C, 1998, PLANTA, V206, P72, DOI 10.1007/s004250050375; TUAZON PT, 1977, BIOCHEMISTRY-US, V16, P1183, DOI 10.1021/bi00625a024; Weissenmayer B, 2000, MOL PLANT MICROBE IN, V13, P666, DOI 10.1094/MPMI.2000.13.6.666	36	94	105	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3941	3946		10.1074/jbc.M008200200	http://dx.doi.org/10.1074/jbc.M008200200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11073956	hybrid			2022-12-25	WOS:000166921200031
J	Satoh, S; Ikeuchi, M; Mimuro, M; Tanaka, A				Satoh, S; Ikeuchi, M; Mimuro, M; Tanaka, A			Chlorophyll b expressed in cyanobacteria functions as a light harvesting antenna in photosystem I through flexibility of the proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYGENIC PHOTOSYNTHESIS; GREEN-ALGA; COMPLEXES; EVOLUTION; A/B; CHLOROPLASTS; THYLAKOIDS; EXCITATION	Photosynthetic pigments bind to their specific proteins to form pigment-protein complexes. To investigate the pigment-binding activities of the proteins, chlorophyll b was for introduced the first time to a cyanobacterium that did not synthesize that pigment, and expression of its function in the native pigment-protein complex of cyanobacterium was confirmed by energy transfer. Arabidopsis CAO (chlorophyll a oxygenase) cDNA was introduced into the genome of Synechocystis sp, PCC6803, The transformant cells accumulated chlorophyll b, with the chlorophyll b content being in the range of 1.4 to 10.6% of the total chlorophyll depending on the growth phase. Polyacrylamide gel electrophoresis analysis of the chlorophyll-protein complexes of transformant cells showed that chlorophyll b was incorporated preferentially into the P700-chlorophyll a-protein complex (CP1), Furthermore, chlorophyll b in CP1 transferred light energy to chlorophyll a, indicating a functional transformation, We also found that CP1 of Chlamydomonas reinhardtii, believed to be a chlorophyll a protein, bound chlorophyll b with a chlorophyll b content of similar to4.4%, On the basis of these results, the evolution of pigment systems in an early stage of cyanobacterial development is discussed in this paper.	Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan; Univ Tokyo, Dept Life Sci, Meguro Ku, Tokyo 1538902, Japan; Yamaguchi Univ, Fac Sci, Dept Phys Biol & Informat, Yamaguchi 7538512, Japan	Hokkaido University; University of Tokyo; Yamaguchi University	Tanaka, A (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan.		Tanaka, Ayumi/D-9003-2012	Satoh, Soichirou/0000-0002-7622-1868				ANDERSON JM, 1978, FEBS LETT, V92, P227, DOI 10.1016/0014-5793(78)80760-1; ANDERSON JM, 1986, ANNU REV PLANT PHYS, V37, P93, DOI 10.1146/annurev.arplant.37.1.93; Cogdell RJ, 1996, PHOTOSYNTH RES, V48, P55, DOI 10.1007/BF00040996; Green BR, 1996, ANNU REV PLANT PHYS, V47, P685, DOI 10.1146/annurev.arplant.47.1.685; GREEN BR, 1994, PHOTOSYNTH RES, V39, P149, DOI 10.1007/BF00029382; Grossman AR, 1995, ANNU REV GENET, V29, P231, DOI 10.1146/annurev.ge.29.120195.001311; Hihara Y, 1998, PLANT PHYSIOL, V117, P1205, DOI 10.1104/pp.117.4.1205; Ito H, 1996, J BIOL CHEM, V271, P1475, DOI 10.1074/jbc.271.3.1475; Kamei A, 1998, PHOTOSYNTHESIS: MECHANISMS AND EFFECTS, VOLS I-V, P2901; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LaRoche J, 1996, P NATL ACAD SCI USA, V93, P15244; MURRAY DL, 1991, PLANT MOL BIOL, V16, P71, DOI 10.1007/BF00017918; NAKAYAMA K, 1994, BBA-BIOENERGETICS, V1184, P103, DOI 10.1016/0005-2728(94)90159-7; Oster U, 2000, PLANT J, V21, P305, DOI 10.1046/j.1365-313x.2000.00672.x; PAULSEN H, 1993, EUR J BIOCHEM, V215, P809, DOI 10.1111/j.1432-1033.1993.tb18096.x; Pearlstein RM, 1996, PHOTOSYNTH RES, V48, P75, DOI 10.1007/BF00040998; Polle JEW, 2000, PLANTA, V211, P335, DOI 10.1007/s004250000279; SUKENIK A, 1987, NATURE, V327, P704, DOI 10.1038/327704a0; Tanaka A, 1998, P NATL ACAD SCI USA, V95, P12719, DOI 10.1073/pnas.95.21.12719; TANAKA A, 1987, PLANT CELL PHYSIOL, V28, P1537; TARAO T, 1989, PLANT CELL PHYSL, V30, P571; THORNBER JP, 1974, EUR J BIOCHEM, V41, P109, DOI 10.1111/j.1432-1033.1974.tb03250.x; THORNBER JP, 1993, BIOCHEM SOC T, V21, P15, DOI 10.1042/bst0210015; Tomitani A, 1999, NATURE, V400, P159, DOI 10.1038/22101; UEHARA K, 1988, PHOTOCHEM PHOTOBIOL, V48, P725, DOI 10.1111/j.1751-1097.1988.tb02887.x	25	78	85	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4293	4297		10.1074/jbc.M008238200	http://dx.doi.org/10.1074/jbc.M008238200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11073958	hybrid			2022-12-25	WOS:000166921200075
J	Riquelme, C; Larrain, J; Schonherr, E; Henriquez, JP; Kresse, H; Brandan, E				Riquelme, C; Larrain, J; Schonherr, E; Henriquez, JP; Kresse, H; Brandan, E			Antisense inhibition of decorin expression in myoblasts decreases cell responsiveness to transforming growth factor beta and accelerates skeletal muscle differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCAN; FACTOR SCATTER FACTOR; FIBROBLAST-GROWTH; HEPARAN-SULFATE; TGF-BETA; SYNDECAN-1 EXPRESSION; ENDOCYTOSIS; RECEPTOR; COLLAGEN; MATRIX	Decorin is a member of the family of the small leucine-rich proteoglycans. In addition to its function as an extracellular matrix organizer, it has the ability to activate the epidermal growth factor receptor, and it forms complexes with various isoforms of transforming growth factor beta (TGF-beta), Decorin is expressed during skeletal muscle differentiation and is up-regulated in dystrophic muscle. In this study we investigated the role of decorin in TGF-beta -dependent inhibition of myogenesis, To probe the function of decorin during myogenesis, C2C12 myoblasts were stably transfected with a plasmid expressing antisense decorin mRNA. The re; suiting inhibition of decorin expression led to the expression of myogenin, a master transcription factor for muscle differentiation, under growth conditions and accelerated skeletal muscle differentiation as determined by the expression of creatine kinase, In contrast myogenin expression was inhibited by adenovirally induced decorin expression or by adding exogenous decorin, Reduced synthesis of decorin resulted in a 7-fold decreased sensitivity to TGF-beta -mediated inhibition of myogenin expression. In contrast, adenovirally induced decorin expression in wild type cells resulted in a 5-fold increased sensitivity to TGF-beta -mediated inhibition of myogenin expression. Transfection studies with the TGF-beta -dependent promoter of the plasminogen activator inhibitor-1 coupled with luciferase revealed that the transducing receptors for TGF-beta1 and TGF-beta2 were involved in the different responses of wild type and anti-sense decorin myoblasts, These results demonstrate that a reduction of decorin expression or of decorin availability results in a decreased responsiveness to TGF-beta. These findings strongly suggest a new role for decorin during skeletal muscle terminal differentiation by activating TGF-beta -dependent signaling pathways.	Pontificia Univ Catolica Chile, Fac Biol Sci, Dept Cell & Mol Biol, Ctr Regulac Celular & Patol,MIFAB P, Santiago, Chile; Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany	Pontificia Universidad Catolica de Chile; University of Munster	Brandan, E (corresponding author), Pontificia Univ Catolica Chile, Fac Biol Sci, Dept Cell & Mol Biol, Ctr Regulac Celular & Patol,MIFAB P, POB 114-D, Santiago, Chile.	ebrandan@genes.bio.puc.cl	Brandan, Enrique/A-7063-2017	Brandan, Enrique/0000-0002-6820-5059				Anastasi S, 1997, J CELL BIOL, V137, P1057, DOI 10.1083/jcb.137.5.1057; AVIEZER D, 1994, J BIOL CHEM, V269, P114; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Blaschuk KL, 1997, DEV BIOL, V184, P266, DOI 10.1006/dbio.1997.8527; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDAN E, 1991, EUR J CELL BIOL, V55, P209; BRANDAN E, 1992, J NEUROSCI RES, V32, P51, DOI 10.1002/jnr.490320107; Brandan E, 1998, BASIC APPL MYOL, V8, P107; Brandan E, 1996, EUR J CELL BIOL, V71, P170; BRUNETTI A, 1990, J BIOL CHEM, V265, P5960; Caceres S, 2000, EUR J CELL BIOL, V79, P173, DOI 10.1078/S0171-9335(04)70020-5; Carey DJ, 1997, BIOCHEM J, V327, P1; CORNUET PK, 1994, INVEST OPHTH VIS SCI, V35, P870; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Deakin JA, 1999, J CELL SCI, V112, P1999; DeLuca A, 1996, J BIOL CHEM, V271, P18961, DOI 10.1074/jbc.271.31.18961; EWTON DZ, 1988, J BIOL CHEM, V263, P4029; FLORINI JR, 1986, J BIOL CHEM, V261, P6509; Fuentealba L, 1999, J BIOL CHEM, V274, P37876, DOI 10.1074/jbc.274.53.37876; Grounds MD, 1999, CURR OPIN NEUROL, V12, P535, DOI 10.1097/00019052-199910000-00007; HAUSCHKA SD, 1966, P NATL ACAD SCI USA, V55, P119, DOI 10.1073/pnas.55.1.119; Hausser H, 1998, ARCH BIOCHEM BIOPHYS, V349, P363, DOI 10.1006/abbi.1997.0471; Hausser H, 1996, EUR J CELL BIOL, V71, P325; HAUSSER H, 1992, J BIOL CHEM, V267, P11559; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; Iozzo RV, 1999, J BIOL CHEM, V274, P4489, DOI 10.1074/jbc.274.8.4489; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Isaka Y, 1996, NAT MED, V2, P418, DOI 10.1038/nm0496-418; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; Larrain J, 1997, J BIOL CHEM, V272, P18418, DOI 10.1074/jbc.272.29.18418; Larrain J, 1998, J BIOL CHEM, V273, P32288, DOI 10.1074/jbc.273.48.32288; Larrain J, 1997, EXP CELL RES, V234, P405, DOI 10.1006/excr.1997.3648; LASSAR A, 1994, CURR OPIN CELL BIOL, V6, P432, DOI 10.1016/0955-0674(94)90037-X; LASSAR AB, 1994, CURR OPIN CELL BIOL, V6, P788, DOI 10.1016/0955-0674(94)90046-9; LIM RW, 1984, DEV BIOL, V105, P48, DOI 10.1016/0012-1606(84)90260-4; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; Melo F, 1996, J CELL BIOCHEM, V62, P227, DOI 10.1002/(SICI)1097-4644(199608)62:2<227::AID-JCB11>3.0.CO;2-I; Molkentin JD, 1996, CURR OPIN GENET DEV, V6, P445, DOI 10.1016/S0959-437X(96)80066-9; Moscatello DK, 1998, J CLIN INVEST, V101, P406, DOI 10.1172/JCI846; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RAWLS A, 1995, DEV BIOL, V172, P37, DOI 10.1006/dbio.1995.0004; SAITOH O, 1992, EXP CELL RES, V200, P70, DOI 10.1016/S0014-4827(05)80072-2; Schaefer L, 1998, KIDNEY INT, V54, P1529, DOI 10.1046/j.1523-1755.1998.00149.x; SCHMIDT G, 1990, BIOCHEM J, V266, P591; Schonherr E, 1998, ARCH BIOCHEM BIOPHYS, V355, P241, DOI 10.1006/abbi.1998.0720; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; SCHONHERR E, 1993, BIOCHEM J, V290, P893, DOI 10.1042/bj2900893; Stander M, 1998, GENE THER, V5, P1187, DOI 10.1038/sj.gt.3300709; TAKEUCHI Y, 1994, J BIOL CHEM, V269, P32634; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; Zhao JS, 1999, AM J PHYSIOL-LUNG C, V277, pL412, DOI 10.1152/ajplung.1999.277.2.L412	55	86	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3589	3596		10.1074/jbc.M004602200	http://dx.doi.org/10.1074/jbc.M004602200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11071883	hybrid			2022-12-25	WOS:000166784900079
J	Moriuchi, M; Moriuchi, H				Moriuchi, M; Moriuchi, H			Octamer transcription factors up-regulate the expression of CCR5, a coreceptor for HIV-1 entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CELL-SPECIFIC COACTIVATOR; MACROPHAGE-TROPIC HIV-1; OCT-1 POU DOMAIN; FUNCTIONAL-CHARACTERIZATION; CHEMOKINE RECEPTORS; MOLECULAR-CLONING; PROMOTER ACTIVITY; OCA-B; INFECTION	T cell activation can induce expression of CCR5, a major coreceptor for macrophage-tropic (R5) human immunodeficiency virus type 1 (HIV-1). Here we report that overexpression of the Oct-2 transcription factor and octamer coactivator BOB.1/OBF/OCA-B, both of which are induced in T cells following T cell receptor signaling, synergistically up-regulates CCR5 promoter activity via interaction with an octamer motif on the promoter. We also show that the octamer transcription factors can increase cell surface expression of CCR5 and fusogenicity of the cells with R5 HIV-1 Env. These results suggest that octamer transcription factors may play a critical role in the induction of CCR5 expression on, and thereby susceptibility to, R5 HIV-1 of T cells following antigenic stimulation.	NIAID, Immunoregulat Lab, NIH, Bethesda, MD 20892 USA; Nagasaki Univ, Grad Sch Med Sci, Dept Mol Microbiol & Immunol, Div Med Virol, Nagasaki 8528523, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Nagasaki University	Moriuchi, H (corresponding author), Nagasaki Univ, Sch Med, Dept Pediat, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.							Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Babb R, 1997, MOL CELL BIOL, V17, P7295, DOI 10.1128/MCB.17.12.7295; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Choe H, 1996, CELL, V85, P1135, DOI 10.1016/S0092-8674(00)81313-6; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Deng HK, 1997, NATURE, V388, P296, DOI 10.1038/40894; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1996, CELL, V85, P1149, DOI 10.1016/S0092-8674(00)81314-8; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Fauci AS, 1996, NATURE, V384, P529, DOI 10.1038/384529a0; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; KANG SM, 1992, MOL CELL BIOL, V12, P3149, DOI 10.1128/MCB.12.7.3149; Liu R, 1998, AIDS RES HUM RETROV, V14, P1509, DOI 10.1089/aid.1998.14.1509; LUO Y, 1995, MOL CELL BIOL, V15, P4115; Matthias P, 1998, SEMIN IMMUNOL, V10, P155, DOI 10.1006/smim.1998.0117; Moriuchi H, 1997, J IMMUNOL, V159, P5441; Moriuchi H, 1997, J IMMUNOL, V158, P3483; MORIUCHI H, 1994, VIROLOGY, V205, P238, DOI 10.1006/viro.1994.1639; Moriuchi H, 1996, P NATL ACAD SCI USA, V93, P15341, DOI 10.1073/pnas.93.26.15341; Moriuchi H, 1997, J VIROL, V71, P9664, DOI 10.1128/JVI.71.12.9664-9671.1997; Moriuchi M, 1999, BLOOD, V93, P1433, DOI 10.1182/blood.V93.4.1433.404a36c_1433_1435; Ostrowski MA, 1998, J VIROL, V72, P7772, DOI 10.1128/JVI.72.10.7772-7784.1998; PFISTERER P, 1995, J BIOL CHEM, V270, P29870, DOI 10.1074/jbc.270.50.29870; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Sozzani S, 1998, J EXP MED, V187, P439, DOI 10.1084/jem.187.3.439; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Thivierge M, 1998, BLOOD, V92, P40, DOI 10.1182/blood.V92.1.40.413k43_40_45; Tuttle DL, 1998, J VIROL, V72, P4962, DOI 10.1128/JVI.72.6.4962-4969.1998; VERRIJZER CP, 1992, MOL CELL BIOL, V12, P542, DOI 10.1128/MCB.12.2.542; Wahl SM, 1997, J LEUKOCYTE BIOL, V62, P67, DOI 10.1002/jlb.62.1.67; Wang JH, 1998, J VIROL, V72, P7642, DOI 10.1128/JVI.72.9.7642-7647.1998; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681; Zwilling S, 1997, SCIENCE, V277, P221, DOI 10.1126/science.277.5323.221	39	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					8639	8642		10.1074/jbc.M008391200	http://dx.doi.org/10.1074/jbc.M008391200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11071893	hybrid			2022-12-25	WOS:000167607700005
J	Pleass, RJ; Areschoug, T; Lindahl, G; Woof, JM				Pleass, RJ; Areschoug, T; Lindahl, G; Woof, JM			Streptococcal IgA-binding proteins bind in the C alpha 2-C alpha 3 interdomain region and inhibit binding of IgA to human CD89	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-B STREPTOCOCCI; GROUP-A STREPTOCOCCI; CELL-SURFACE PROTEIN; FC-GAMMA-RI; IMMUNOGLOBULIN-G; MOLECULAR CHARACTERIZATION; CRYSTAL-STRUCTURE; BETA-ANTIGEN; ALPHA-R; RECEPTOR	Certain pathogenic bacteria express surface proteins that bind to the Fc part of human TgA or IgG. These bacterial proteins are important as immunochemical tools and model systems, but their biological function is still unclear. Here, we describe studies of three streptococcal proteins that bind IgA: the Sir22 and Arp4 proteins of Streptococcus pyogenes and the unrelated beta protein of group B streptococcus. Analysis of IgA domain swap and point mutants indicated that two loops at the C alpha2/C alpha3 domain interface are critical for binding of the streptococcal proteins. This region is also used in binding the human IgA receptor CD89, an important mediator of IgA effector function. In agreement with this finding, the three IgA-binding proteins and a 50-residue IgA-binding peptide derived from Sir22 blocked the ability of IgA to bind CD89. Further, the Arp4 protein inhibited the ability of IgA to trigger a neutrophil respiratory burst via CD89. Thus, we have identified residues on IgA-Fc that play a key role in binding of different streptococcal IgA-binding proteins, and we have identified a mechanism by which a bacterial IgA-binding protein may interfere with TgA effector function.	Univ Dundee, Sch Med, Ninewells Hosp, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland; Univ Lund, Dept Lab Med, S-22362 Lund, Sweden	University of Dundee; Lund University	Lindahl, G (corresponding author), Univ Dundee, Sch Med, Ninewells Hosp, Dept Mol & Cellular Pathol, Dundee DD1 9SY, Scotland.		Pleass, Richard/N-7831-2019; Pleass, Richard J/L-4148-2015	Pleass, Richard/0000-0001-7438-8296; Pleass, Richard J/0000-0001-7438-8296				AKERSTROM B, 1991, MOL IMMUNOL, V28, P349, DOI 10.1016/0161-5890(91)90147-C; AKERSTROM B, 1994, MOL IMMUNOL, V31, P393, DOI 10.1016/0161-5890(94)90117-1; AKERSTROM B, 1992, J IMMUNOL, V148, P3238; BESSEN DE, 1994, INFECT IMMUN, V62, P1968, DOI 10.1128/IAI.62.5.1968-1974.1994; BEVANGER L, 1985, ACTA PATH MICRO IM B, V93, P121; Boehm MK, 1999, J MOL BIOL, V286, P1421, DOI 10.1006/jmbi.1998.2556; BOYLE MDP, 1990, BACTERIAL IMMUNOGLOB, V1; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; BURTON DR, 1985, MOL IMMUNOL, V22, P161, DOI 10.1016/0161-5890(85)90151-8; Carayannopoulos L, 1996, J EXP MED, V183, P1579, DOI 10.1084/jem.183.4.1579; Chapman TL, 1999, J BIOL CHEM, V274, P6911, DOI 10.1074/jbc.274.11.6911; CHRISTENSEN P, 1975, ACTA PATH MICRO IM C, V83, P184; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; FRANK I, 1989, J VIROL, V63, P4479, DOI 10.1128/JVI.63.11.4479-4488.1989; FRICK IM, 1992, P NATL ACAD SCI USA, V89, P8532, DOI 10.1073/pnas.89.18.8532; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; HEDEN LO, 1991, EUR J IMMUNOL, V21, P1481, DOI 10.1002/eji.1830210623; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; HUSMANN LK, 1995, INFECT IMMUN, V63, P345, DOI 10.1128/IAI.63.1.345-348.1995; Janoff EN, 1999, J CLIN INVEST, V104, P1139, DOI 10.1172/JCI6310; JERLSTROM PG, 1991, MOL MICROBIOL, V5, P843, DOI 10.1111/j.1365-2958.1991.tb00757.x; Jerlstrom PG, 1996, INFECT IMMUN, V64, P2787; JOHANSSON PJH, 1989, IMMUNOLOGY, V66, P8; JOHNSSON E, 1994, J IMMUNOL, V153, P3557; Johnsson E, 1996, J IMMUNOL, V157, P3021; Johnsson E, 1999, J BIOL CHEM, V274, P14521, DOI 10.1074/jbc.274.21.14521; KEHOE MA, 1994, NEW COMPR BIOCH, V27, P217; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; Kerr MA, 1998, MUCOSAL IMMUNOLOGY, P213; LINDAHL G, 1989, MOL MICROBIOL, V3, P239, DOI 10.1111/j.1365-2958.1989.tb01813.x; LINDAHL G, 1990, EUR J IMMUNOL, V20, P2241, DOI 10.1002/eji.1830201013; LUND J, 1991, J IMMUNOL, V147, P2657; MORTON HC, 1993, J IMMUNOL, V151, P4743; Morton HC, 1996, CRIT REV IMMUNOL, V16, P423; Morton HC, 1999, J EXP MED, V189, P1715; Nagashunmugam T, 1998, J VIROL, V72, P5351, DOI 10.1128/JVI.72.7.5351-5359.1998; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Pleass RJ, 1999, J BIOL CHEM, V274, P23508, DOI 10.1074/jbc.274.33.23508; PUTNAM FW, 1979, J BIOL CHEM, V254, P2865; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; RUSSELLJONES GJ, 1984, J EXP MED, V160, P1467, DOI 10.1084/jem.160.5.1467; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; STALHAMMARCARLEMALM M, 1993, J EXP MED, V177, P1593, DOI 10.1084/jem.177.6.1593; STENBERG L, 1992, MOL MICROBIOL, V6, P1185, DOI 10.1111/j.1365-2958.1992.tb01557.x; STENBERG L, 1994, J BIOL CHEM, V269, P13458; TASHIRO M, 1995, CURR OPIN STRUC BIOL, V5, P471, DOI 10.1016/0959-440X(95)80031-X; Thern A, 1998, J IMMUNOL, V160, P860; van Egmond M, 2000, NAT MED, V6, P680, DOI 10.1038/76261; WALKER MR, 1988, VOX SANG, V55, P222, DOI 10.1111/j.1423-0410.1988.tb04701.x; Wines BD, 1999, J IMMUNOL, V162, P2146; Wines BD, 2000, J IMMUNOL, V164, P5313, DOI 10.4049/jimmunol.164.10.5313	54	94	99	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8197	8204		10.1074/jbc.M009396200	http://dx.doi.org/10.1074/jbc.M009396200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11096107	hybrid			2022-12-25	WOS:000167474900073
J	Goedken, ER; Marqusee, S				Goedken, ER; Marqusee, S			Co-crystal of Escherichia coli RNase HI with Mn2+ ions reveals two divalent metals bound in the active site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-H; DOMAIN; ACTIVATION; MG2+; RESOLUTION; STABILITY; RESIDUES; PROPOSAL; BINDING; HELIX	Ribonuclease H (RNase H) selectively degrades the RNA strand of RNA . DNA hybrids in a divalent cation-dependent manner. Previous structural studies revealed a single Mg2+ ion-binding site in Escherichia coli RNase HI. In: the crystal structure of the related RNase H domain: of human immunodeficiency virus reverse transcriptase, however, two Mn2+ ions were observed suggesting a different mode of metal binding. E, coli RNase HI shows catalytic activity in the presence of Mg2+ or Mn2+ ions, but: these two metals show strikingly different optimal concentrations. Mg2+ ions are required in millimolar concentrations, but Mn2+ ions are only required-in micromolar quantities. Based upon the metal dependence off. coli RNase HI activity, we proposed an activation/attenuation model in which one metal is required for catalysis, and binding of a second metal is inhibitory. We have now solved the co-crystal structure of E, coli RNase HI with Mn2+ ions at 1.9-Angstrom resolution. Two octahedrally coordinated Mn2+ ions are seen to bind to the enzyme-active site. Residues Asp-10, Glu-48, and Asp-70 make direct (inner sphere) coordination contacts to the first (activating) metal, whereas residues Asp-10 and Asp-134 make direct contacts to the second (attenuating) metal. This structure is consistent with biochemical evidence suggesting that two metal ions may bind RNase H but liganding a second ion inhibits RNase H activity.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Marqusee, S (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	marqusee@zebra.berkeley.edu			PHS HHS [50945] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BLACK CB, 1994, INORG CHEM, V33, P5805, DOI 10.1021/ic00103a030; Blain SW, 1996, J BIOL CHEM, V271, P1448, DOI 10.1074/jbc.271.3.1448; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casareno RLB, 1996, CHEM COMMUN, P1813, DOI 10.1039/cc9960001813; Cowan JA, 2000, J BIOL INORG CHEM, V5, P67, DOI 10.1007/s007750050009; CROUCH R J, 1990, New Biologist, V2, P771; DAVIES JF, 1991, SCIENCE, V252, P88, DOI 10.1126/science.1707186; Goedken ER, 2000, PROTEIN SCI, V9, P1914, DOI 10.1110/ps.9.10.1914; Goedken ER, 1997, BIOCHEMISTRY-US, V36, P7256, DOI 10.1021/bi970060q; Goedken ER, 1999, PROTEIN ENG, V12, P975, DOI 10.1093/protein/12.11.975; HARUKI M, 1994, EUR J BIOCHEM, V220, P623, DOI 10.1111/j.1432-1033.1994.tb18664.x; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hostomsky Z., 1993, NUCLEASES, V2nd, P341; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANAYA S, 1989, J BIOL CHEM, V264, P11546; Kanaya S, 1996, J BIOL CHEM, V271, P32729, DOI 10.1074/jbc.271.51.32729; KANAYA S, 1990, J BIOL CHEM, V265, P4615; Kashiwagi T, 1996, PROTEIN ENG, V9, P857, DOI 10.1093/protein/9.10.857; KATAYANAGI K, 1993, PROTEINS, V17, P337, DOI 10.1002/prot.340170402; KATAYANAGI K, 1992, J MOL BIOL, V223, P1029, DOI 10.1016/0022-2836(92)90260-Q; KATAYANAGI K, 1990, NATURE, V347, P306, DOI 10.1038/347306a0; Keck JL, 1996, J BIOL CHEM, V271, P19883, DOI 10.1074/jbc.271.33.19883; Keck JL, 1998, J BIOL CHEM, V273, P34128, DOI 10.1074/jbc.273.51.34128; Keck JL, 1997, TECH PROT CHEM, V8, P409, DOI 10.1016/S1080-8914(97)80041-5; KECK JL, 1995, P NATL ACAD SCI USA, V92, P2740, DOI 10.1073/pnas.92.7.2740; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKAMURA H, 1991, P NATL ACAD SCI USA, V88, P11535, DOI 10.1073/pnas.88.24.11535; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; ODA Y, 1991, Journal of Biomolecular NMR, V1, P247, DOI 10.1007/BF01875518; ODA Y, 1993, J BIOL CHEM, V268, P88; SNAVELY MD, 1990, MET IONS BIOL SYST, V26, P155; STAHL SJ, 1994, PROTEIN ENG, V7, P1103, DOI 10.1093/protein/7.9.1103; TISDALE M, 1991, J GEN VIROL, V72, P59, DOI 10.1099/0022-1317-72-1-59; WILLIAMS RJP, 1993, MAGNESIUM CELL, P15; YANG W, 1990, J BIOL CHEM, V265, P13553; YANG W, 1990, SCIENCE, V249, P1398, DOI 10.1126/science.2169648	38	79	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7266	7271		10.1074/jbc.M009626200	http://dx.doi.org/10.1074/jbc.M009626200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11083878	hybrid			2022-12-25	WOS:000167442900057
J	Kanezaki, R; Toki, T; Yokoyama, M; Yomogida, K; Sugiyama, K; Yamamoto, M; Igarashi, K; Ito, E				Kanezaki, R; Toki, T; Yokoyama, M; Yomogida, K; Sugiyama, K; Yamamoto, M; Igarashi, K; Ito, E			Transcription factor BACH1 is recruited to the nucleus by its novel alternative spliced isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL MAF PROTEINS; LEUCINE ZIPPER PROTEIN; LOCUS-CONTROL REGION; FACTOR NF-E2; DNA-BINDING; FUNCTIONAL-CHARACTERIZATION; CHROMOSOME 21Q22.1; MOLECULAR-CLONING; INTERACTION MOTIF; GENE-EXPRESSION	The transcription factor Bach1 is a member of a novel family of broad complex, tramtrack, bric-a-brac/poxvirus and zinc finger (BTB/POZ) basic region leucine zipper factors. Bach1 forms a heterodimer with MafK, a member of the small Maf protein family (MafF, MafG, and MafK), which recognizes the NF-E2/Maf recognition element, a cis-regulatory motif containing a 12-O-tetra-decanoylphorbol-13-acetate-responsive element. Here we describe the gene structure of human BACH1, including a:newly identified promoter and an alternatively RNA-spliced truncated form of BACH1, designated BACH1t, abundantly transcribed in human testis, The alternate splicing originated from the usage of a novel exon located 5.6 kilobase pairs downstream of the exon encoding, the leucine zipper domain, and produced a protein that contained the conserved BTB/POZ, Cap'n collar, and basic region domains, but lacked the leucine zipper domain essential for NF-E2/Maf recognition element binding, Subcellular localization studies using green fluorescent protein as a reporter showed that full-length BACH1: localized to the cytoplasm, whereas BACH1t accumulated in the nucleus. Interestingly, coexpression of BACH1 and BACH1t demonstrated interaction between the molecules and the induction of nuclear: import of BACH1. These results suggested that BACH1t recruits BACH1 to the nucleus through BTB domain-mediated interaction.	Hirosaki Univ, Sch Med, Dept Pediat, Hirosaki, Aomori 0368563, Japan; Hirosaki Univ, Fac Sci, Dept Biol, Hirosaki, Aomori 0368563, Japan; Osaka Univ, Dept Sci, Lab Anim Experimentat, Microbial Dis Res Inst, Suita, Osaka 5650871, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058575, Japan; Hiroshima Univ, Sch Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan	Hirosaki University; Hirosaki University; Osaka University; University of Tsukuba; University of Tsukuba; Hiroshima University	Ito, E (corresponding author), Hirosaki Univ, Sch Med, Dept Pediat, Hirosaki, Aomori 0368563, Japan.		Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436; Igarashi, Kazuhiko/0000-0002-2470-2475; Ito, Etsuro/0000-0002-0168-2475				ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Bhat KM, 1996, DEVELOPMENT, V122, P1113; Blank V, 1997, BLOOD, V89, P3925, DOI 10.1182/blood.V89.11.3925; Blouin JL, 1998, HUM GENET, V102, P282, DOI 10.1007/s004390050692; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; Chan JY, 1998, EMBO J, V17, P1779, DOI 10.1093/emboj/17.6.1779; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; Gerasimova TI, 1998, CELL, V92, P511, DOI 10.1016/S0092-8674(00)80944-7; Horowitz H, 1996, DEVELOPMENT, V122, P1859; Hoshino H, 2000, J BIOL CHEM, V275, P15370, DOI 10.1074/jbc.275.20.15370; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; INABA T, 1994, MOL CELL BIOL, V14, P3403, DOI 10.1128/MCB.14.5.3403; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; ITOH K, 1995, MOL CELL BIOL, V15, P4184, DOI 10.1128/mcb.15.8.4184; JOHANNISSON R, 1983, HUM GENET, V63, P132, DOI 10.1007/BF00291532; Johnsen O, 1996, NUCLEIC ACIDS RES, V24, P4289, DOI 10.1093/nar/24.21.4289; Johnsen O, 1998, NUCLEIC ACIDS RES, V26, P512, DOI 10.1093/nar/26.2.512; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kobayashi A, 1999, J BIOL CHEM, V274, P6443, DOI 10.1074/jbc.274.10.6443; KORENBERG JR, 1994, P NATL ACAD SCI USA, V91, P4997, DOI 10.1073/pnas.91.11.4997; Lecine P, 1998, J BIOL CHEM, V273, P7572, DOI 10.1074/jbc.273.13.7572; LUNA L, 1994, GENOMICS, V22, P553, DOI 10.1006/geno.1994.1428; Marini MG, 1997, J BIOL CHEM, V272, P16490, DOI 10.1074/jbc.272.26.16490; MOHLER J, 1991, MECH DEVELOP, V34, P3, DOI 10.1016/0925-4773(91)90086-L; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MOSCOVICI C, 1977, CELL, V11, P95, DOI 10.1016/0092-8674(77)90320-8; NEY PA, 1993, MOL CELL BIOL, V13, P5604, DOI 10.1128/MCB.13.9.5604; Ohira M, 1998, GENOMICS, V47, P300, DOI 10.1006/geno.1997.5080; Oyake T, 1996, MOL CELL BIOL, V16, P6083; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Toki T, 1997, ONCOGENE, V14, P1901, DOI 10.1038/sj.onc.1201024; TSUKIYAMA T, 1994, NATURE, V367, P525, DOI 10.1038/367525a0; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yoshida C, 1999, GENES CELLS, V4, P643, DOI 10.1046/j.1365-2443.1999.00291.x	43	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7278	7284		10.1074/jbc.M004227200	http://dx.doi.org/10.1074/jbc.M004227200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11069897	hybrid			2022-12-25	WOS:000167442900059
J	Mukai, M; Mills, CE; Poole, RK; Yeh, SR				Mukai, M; Mills, CE; Poole, RK; Yeh, SR			Flavohemoglobin, a globin with a peroxidase-like catalytic site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C PEROXIDASE; NITRIC-OXIDE DIOXYGENASE; RESONANCE RAMAN-SPECTRA; HEMOGLOBIN-LIKE PROTEIN; ESCHERICHIA-COLI K-12; AMINO-ACID-SEQUENCE; ASCARIS HEMOGLOBIN; HORSERADISH-PEROXIDASE; ALCALIGENES-EUTROPHUS; NITROSATIVE STRESS	Biochemical studies of flavohemoglobin (Hmp) from Escherichia coli suggest that instead of aerobic oxygen delivery, a dioxygenase converts NO to NO3- and anaerobically, an NO reductase converts NO to N2O. To investigate the structural features underlying the chemical reactivity of Hmp, we have measured the resonance Raman spectra of the ligand-free ferric and ferrous protein and the CO derivatives of the ferrous protein. At neutral pH, the ferric protein has a five-coordinate high-spin heme,similar:to peroxidases, In the ferrous protein, a strong iron-histidine stretching mode is present at 244 cm(-1). This frequency is much higher than that of any cm other globin discovered to date, although it is comparable to those of peroxidases, suggesting that the proximal histidine has imidazolate character. In the CO derivative, an open and a closed conformation were detected. The distal environment of the closed conformation is very polar, where the heme-bound CO strongly interacts with the B10 Tyr and/or the E7 Gin. These data demonstrate that the active site structure of Hmp is very similar to that of peroxidases and is tailored to perform oxygen chemistry.	Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England	Yeshiva University; Albert Einstein College of Medicine; University of Sheffield	Yeh, SR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA.			Yeh, Syun-Ru/0000-0002-9858-386X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054806, R01GM054812] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-54806, GM-54812] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; Anni H, 1988, Prog Clin Biol Res, V274, P437; ARGADE PV, 1984, J AM CHEM SOC, V106, P6593, DOI 10.1021/ja00334a024; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; CRAMM R, 1994, J BIOL CHEM, V269, P7349; Crawford MJ, 1998, J BIOL CHEM, V273, P12543, DOI 10.1074/jbc.273.20.12543; Das TK, 2000, BIOCHEMISTRY-US, V39, P837, DOI 10.1021/bi9922087; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; DEBAERE I, 1994, P NATL ACAD SCI USA, V91, P1594, DOI 10.1073/pnas.91.4.1594; Ermler U, 1995, EMBO J, V14, P6067, DOI 10.1002/j.1460-2075.1995.tb00297.x; Feis A, 1998, BIOCHEMISTRY-US, V37, P13575, DOI 10.1021/bi981399v; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; Franzen S, 1998, J AM CHEM SOC, V120, P4658, DOI 10.1021/ja973212d; Gardner AM, 2000, J BIOL CHEM, V275, P12581, DOI 10.1074/jbc.275.17.12581; Gardner PR, 2000, J BIOL CHEM, V275, P31581, DOI 10.1074/jbc.M004141200; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Goodin DB, 1996, J BIOL INORG CHEM, V1, P360, DOI 10.1007/s007750050065; GOODIN DB, 1993, BIOCHEMISTRY-US, V32, P3313, DOI 10.1021/bi00064a014; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; IOANNIDIS N, 1992, BIOCHEM J, V288, P649, DOI 10.1042/bj2880649; IWAASA H, 1992, J MOL BIOL, V227, P948, DOI 10.1016/0022-2836(92)90236-D; KITAGAWA T, 1982, NATURE, V298, P869, DOI 10.1038/298869a0; KLOEK AP, 1994, J BIOL CHEM, V269, P2377; LaCount MW, 2000, J BIOL CHEM, V275, P18712, DOI 10.1074/jbc.M001194200; Lebioda L, 1999, NATURE, V401, P445, DOI 10.1038/46728; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LI XY, 1988, J AM CHEM SOC, V110, P6024, DOI 10.1021/ja00226a017; Liu LM, 2000, P NATL ACAD SCI USA, V97, P4672, DOI 10.1073/pnas.090083597; Membrillo-Hernandez J, 1998, MOL MICROBIOL, V29, P1101, DOI 10.1046/j.1365-2958.1998.01000.x; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; Mills CE, 2001, BIOCHEM J, V353, P207, DOI 10.1042/0264-6021:3530207; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; Ollesch G, 1999, EUR J BIOCHEM, V262, P396, DOI 10.1046/j.1432-1327.1999.00381.x; Pesce A, 2000, EMBO J, V19, P2424, DOI 10.1093/emboj/19.11.2424; Poole RK, 1996, J BACTERIOL, V178, P5487, DOI 10.1128/jb.178.18.5487-5492.1996; Poole RK, 2000, MOL MICROBIOL, V36, P775, DOI 10.1046/j.1365-2958.2000.01889.x; POOLE RK, 1994, P ROY SOC B-BIOL SCI, V255, P251, DOI 10.1098/rspb.1994.0036; POULOS TL, 1980, J BIOL CHEM, V255, P8199; Poulos TL, 1996, J BIOL INORG CHEM, V1, P356, DOI 10.1007/s007750050064; POULOS TL, 1987, ADV INORG BIOCHEM, V7, P1; RAY GB, 1994, J AM CHEM SOC, V116, P162, DOI 10.1021/ja00080a019; ROUSSEAU DG, 1992, J STRUCT BIOL, V109, P13; Smulevich G, 1998, BIOSPECTROSCOPY, V4, pS3, DOI 10.1002/(SICI)1520-6343(1998)4:5+<S3::AID-BSPY2>3.0.CO;2-R; Smulevich G, 1996, BIOSPECTROSCOPY, V2, P365, DOI 10.1002/(SICI)1520-6343(1996)2:6<365::AID-BSPY3>3.0.CO;2-2; SONG SH, 1993, BIOCHEMISTRY-US, V32, P6330, DOI 10.1021/bi00076a005; Tarricone C, 1997, PROTEINS, V27, P154, DOI 10.1002/(SICI)1097-0134(199701)27:1<154::AID-PROT15>3.0.CO;2-M; Tarricone C, 1997, STRUCTURE, V5, P497, DOI 10.1016/S0969-2126(97)00206-2; TERAOKA J, 1981, J BIOL CHEM, V256, P3969; VANSTEELANDTFRENTRUP J, 1981, J AM CHEM SOC, V103, P5981, DOI 10.1021/ja00409a088; VANWART HE, 1985, J BIOL CHEM, V260, P8372; VASUDEVAN SG, 1991, MOL GEN GENET, V226, P49, DOI 10.1007/BF00273586; Vogel KM, 2000, INORG CHIM ACTA, V297, P11, DOI 10.1016/S0020-1693(99)00253-4; WANG J, 1996, RESONANCE RAMAN SCAT, P427; YANG J, 1995, P NATL ACAD SCI USA, V92, P4224, DOI 10.1073/pnas.92.10.4224; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; Yi XW, 1999, P NATL ACAD SCI USA, V96, P12412, DOI 10.1073/pnas.96.22.12412; YONETANI T, 1987, J BIOL CHEM, V262, P9547; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5015, DOI 10.1073/pnas.89.11.5015	61	88	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7272	7277		10.1074/jbc.M009280200	http://dx.doi.org/10.1074/jbc.M009280200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11092893	hybrid			2022-12-25	WOS:000167442900058
J	Panda, M; Ybarra, J; Horowitz, PM				Panda, M; Ybarra, J; Horowitz, PM			High hydrostatic pressure can probe the effects of functionally related ligands on the quaternary structures of the chaperonins GroEL and GroES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; GUANIDINIUM CHLORIDE; PROTEINS; DISSOCIATION; BINDING; CPN60; ATP; OLIGOMERIZATION; INTERMEDIATE	We investigated the effects of high hydrostatic pressure in the range of 1-3 kilobars on tetradecameric GroEL, heptameric GroES, and the GroEL-GroES complex. Unlike GroEL monomers formed by urea dissociation, which can be reassembled back to the tetradecamer, the pressure dissociated monomers do not reassemble readily. This indicates an alteration of their native structures, an example of conformational drift. Pressure versus time profiles and kinetics of the dissociation of both GroEL and GroES at fixed pressures were monitored by light scattering. Unlike GroEL, GroES monomers do reassociate readily. Reaction conditions were varied by adding ATP, Mg2+, ADP, AMP- PNP, and KCl. At any individual pressure, the dissociation process is governed by both thermodynamics and kinetics. This leads to the decrease in the yield of monomers at lower pressures. In the presence of Mg2+ and KCl, GroEL is stable up to 3 kilobars. The presence of either ATP or ADP but not AMP-PNP leads to GroEL dissociation at lower pressures. Interestingly, the GroEL GroES complex is very stable in the range of 1-2.5 kilobars. However, the addition of ADP destabilizes the complex, which dissociates completely at 1.5 kilobars. The results are rationalized in terms of different degrees of cooperativity between individual monomers and heptameric rings in the GroEL tetradecamer. Such allosteric interactions leading to the alteration of quaternary structure of GroEL in the absence of chemical denaturants are important in understanding the mechanism of chaperonin-assisted protein folding by the GroEL-GroES system.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Horowitz, PM (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, Mail Code 7760,7703 Floyd Curl Dr, San Antonio, TX 78229 USA.				NIGMS NIH HHS [GM25177] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM025177] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bochkareva E, 1999, J BIOL CHEM, V274, P20756, DOI 10.1074/jbc.274.30.20756; Boisvert DC, 1996, NAT STRUCT BIOL, V3, P170, DOI 10.1038/nsb0296-170; BONAFE CFS, 1991, J BIOL CHEM, V266, P13210; BONAFE CFS, 1994, BIOCHEMISTRY-US, V33, P2651, DOI 10.1021/bi00175a038; BRAIG K, 1995, NAT STRUCT BIOL, V2, P1083, DOI 10.1038/nsb1295-1083; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; Clark AC, 1996, BIOCHEMISTRY-US, V35, P5893, DOI 10.1021/bi953051v; Drljaca A, 1998, CHEM REV, V98, P2167, DOI 10.1021/cr970461b; Farr GW, 2000, CELL, V100, P561, DOI 10.1016/S0092-8674(00)80692-3; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; GEORGOPOULOS CP, 1973, J MOL BIOL, V76, P45, DOI 10.1016/0022-2836(73)90080-6; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOROVITS B, 1995, J BIOL CHEM, V270, P2061, DOI 10.1074/jbc.270.5.2061; GOROVITS BM, 1995, J BIOL CHEM, V270, P28551, DOI 10.1074/jbc.270.48.28551; Gorovits BM, 1998, BIOCHEMISTRY-US, V37, P6132, DOI 10.1021/bi9730137; GROSS M, 1994, EUR J BIOCHEM, V221, P617, DOI 10.1111/j.1432-1033.1994.tb18774.x; Holzapfel W. B., 1997, HIGH PRESSURE TECHNI; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; Horowitz PM, 1999, P NATL ACAD SCI USA, V96, P2682, DOI 10.1073/pnas.96.6.2682; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Hunt JF, 1996, NATURE, V379, P37, DOI 10.1038/379037a0; Jaenicke R., 1987, CURRENT PERSPECTIVES, P257; Jai EA, 1999, J PROTEIN CHEM, V18, P387, DOI 10.1023/A:1021055932648; LAMINET AA, 1990, EMBO J, V9, P2315, DOI 10.1002/j.1460-2075.1990.tb07403.x; LANDRY SJ, 1993, NATURE, V364, P255, DOI 10.1038/364255a0; Lorimer G, 1997, NATURE, V388, P720, DOI 10.1038/41892; LORIMER G, 1997, NATURE, V388, P723; Markley J. L., 1996, HIGH PRESSURE EFFECT; MARTIN J, 1991, NATURE, V352, P36, DOI 10.1038/352036a0; MENDOZA JA, 1994, J BIOL CHEM, V269, P2447; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; NEUMAN RC, 1973, J PHYS CHEM-US, V77, P2687, DOI 10.1021/j100640a025; PALADINI AA, 1981, BIOCHEMISTRY-US, V20, P2587, DOI 10.1021/bi00512a034; Sasahara K, 1999, J MOL BIOL, V291, P693, DOI 10.1006/jmbi.1999.2982; Sasahara K, 1999, PROTEIN SCI, V8, P1469, DOI 10.1110/ps.8.7.1469; Seale JW, 1996, BIOCHEMISTRY-US, V35, P4079, DOI 10.1021/bi953087n; Seale JW, 1995, J BIOL CHEM, V270, P30268, DOI 10.1074/jbc.270.51.30268; Sherman W. F., 1987, EXPT TECHNIQUES HIGH; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; St John RJ, 1999, P NATL ACAD SCI USA, V96, P13029, DOI 10.1073/pnas.96.23.13029; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; STERNBERG N, 1973, J MOL BIOL, V76, P1, DOI 10.1016/0022-2836(73)90078-8; Sundaram S, 1998, BIOTECHNOL PROGR, V14, P773, DOI 10.1021/bp980066m; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VANELDIK R, 1987, NATO ASI SER C, V197; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; Weber G., 1992, PROTEIN INTERACTIONS; WINTER R, 1993, NATO ASI SER C, V401; Xu ZH, 1997, NATURE, V388, P741, DOI 10.1038/41944; Xu ZH, 1998, J STRUCT BIOL, V124, P129, DOI 10.1006/jsbi.1998.4060; YBARRA J, 1995, J BIOL CHEM, V270, P22113, DOI 10.1074/jbc.270.38.22113; Yifrach O, 2000, P NATL ACAD SCI USA, V97, P1521, DOI 10.1073/pnas.040449997	55	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6253	6259		10.1074/jbc.M009530200	http://dx.doi.org/10.1074/jbc.M009530200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11085994	hybrid			2022-12-25	WOS:000167261000027
J	Redmond, TM; Gentleman, S; Duncan, T; Yu, S; Wiggert, B; Gantt, E; Cunningham, FX				Redmond, TM; Gentleman, S; Duncan, T; Yu, S; Wiggert, B; Gantt, E; Cunningham, FX			Identification, expression, and substrate specificity of a mammalian beta-carotene 15,15 '-dioxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-PAUCIMOBILIS TMY1009; RETINOIC ACID; PIGMENT-EPITHELIUM; FUNCTIONAL-ANALYSIS; MICROSOMAL PROTEIN; ENZYMATIC CLEAVAGE; LYCOPENE CYCLASE; ENZYMES; CLONING; RPE65	We have identified from mouse the first mammalian beta -carotene 15,15'-dioxygenase (beta -CD), a crucial enzyme in development and metabolism that governs the de novo entry of vitamin A from plant-derived precursors. beta -CD is related to the retinal pigment epithelium expressed protein RPE65 and belongs to a diverse family that includes the plant 9-cis-epoxycarotenoid dioxygenase and bacterial lignostilbene dioxygenases. beta -CD expression in Escherichia coli cells engineered to produce beta -carotene led to the accumulation of all-trans-retinal at the expense of beta -carotene, confirming that beta -CD catalyzed the central cleavage of this vitamin A precursor. Purified recombinant beta -CD protein cleaves beta -carotene in vitro with a V-max of 36 pmol of retinal/mg of enzyme/ min and a K-m of 6 muM. Non-provitamin A carotenoids were also cleaved, although with much lower activity. By Northern analysis, a 2.4-kilobase (kb) message was observed in liver, kidney, small intestine, and testis, tissues important in retinoid/carotenoid metabolism. This message encoded a 63-kDa cytosolic protein expressed in these tissues. A shorter transcript of 1.8 kb was found in testis and skin. Developmentally, the 2,4-kb mRNA was abundant at embryonic day 7, with lower expression at embryonic days 11, 13, and 15, suggesting a critical role for this enzyme in gastrulation. Identification of beta -CD in an accessible model organism will create new opportunities to study vitamin A metabolism.	NEI, LRCMB, NIH, Bethesda, MD 20892 USA; Univ Maryland, Dept Mol Genet & Cell Biol, College Pk, MD 20742 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); University System of Maryland; University of Maryland College Park	Redmond, TM (corresponding author), NEI, LRCMB, NIH, Bldg 6,Rm 339,6 Ctr Dr,MSC 2740, Bethesda, MD 20892 USA.			Redmond, T. Michael/0000-0002-1813-5291	NATIONAL EYE INSTITUTE [Z01EY000260, ZIAEY000260] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Ang HL, 1997, DEV DYNAM, V208, P536; CHEN YP, 1994, DEV BIOL, V161, P70, DOI 10.1006/dbio.1994.1008; CHEN YP, 1992, P NATL ACAD SCI USA, V89, P10056, DOI 10.1073/pnas.89.21.10056; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Clinton SK, 1998, NUTR REV, V56, P35, DOI 10.1111/j.1753-4887.1998.tb01691.x; CUNNINGHAM FX, 1994, PLANT CELL, V6, P1107, DOI 10.1105/tpc.6.8.1107; Cunningham FX, 1996, PLANT CELL, V8, P1613, DOI 10.2307/3870254; Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557; Duszka C, 1996, J NUTR, V126, P2550, DOI 10.1093/jn/126.10.2550; Froescheis O, 2000, J CHROMATOGR B, V739, P291, DOI 10.1016/S0378-4347(99)00562-9; HAMEL CP, 1993, J BIOL CHEM, V268, P15751; HAMEL CP, 1993, J NEUROSCI RES, V34, P414, DOI 10.1002/jnr.490340406; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P926, DOI 10.1271/bbb.57.926; KAMODA S, 1993, BIOSCI BIOTECH BIOCH, V57, P931, DOI 10.1271/bbb.57.931; Kerti A, 1999, ACTA VET HUNG, V47, P95, DOI 10.1556/AVet.47.1999.1.9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKSHMAN MR, 1993, METHOD ENZYMOL, V214, P256; LAKSHMANAN MR, 1968, BIOCHEM BIOPH RES CO, V33, P347, DOI 10.1016/0006-291X(68)90791-2; Morriss-Kay GM, 1999, INT REV CYTOL, V188, P73; Nagao A, 1996, ARCH BIOCHEM BIOPHYS, V328, P57, DOI 10.1006/abbi.1996.0142; NAPOLI JL, 1988, J BIOL CHEM, V263, P17372; OLSON JA, 1983, BIOSYNTHESIS ISOPREN, V2, P371; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Saari JC, 2000, INVEST OPHTH VIS SCI, V41, P337; Schwartz SH, 1997, SCIENCE, V276, P1872, DOI 10.1126/science.276.5320.1872; SINGH H, 1974, BIOCHIM BIOPHYS ACTA, V370, P49, DOI 10.1016/0005-2744(74)90030-8; STAHL W, 1992, ARCH BIOCHEM BIOPHYS, V294, P173, DOI 10.1016/0003-9861(92)90153-N; Stahl W, 2000, ARCH BIOCHEM BIOPHYS, V373, P271, DOI 10.1006/abbi.1999.1510; Sun ZR, 1996, J BIOL CHEM, V271, P24349, DOI 10.1074/jbc.271.40.24349; TAM JP, 1988, P NATL ACAD SCI USA, V85, P5409, DOI 10.1073/pnas.85.15.5409; Tan BC, 1997, P NATL ACAD SCI USA, V94, P12235, DOI 10.1073/pnas.94.22.12235; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsilou E, 1997, ARCH BIOCHEM BIOPHYS, V346, P21, DOI 10.1006/abbi.1997.0276; Ulven SM, 2000, DEV BIOL, V220, P379, DOI 10.1006/dbio.2000.9634; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; WOLF G, 1995, NUTR REV, V53, P134, DOI 10.1111/j.1753-4887.1995.tb01537.x; Wyss A, 2000, BIOCHEM BIOPH RES CO, V271, P334, DOI 10.1006/bbrc.2000.2619; YAMANUSHI T, 1995, J NUTR SCI VITAMINOL, V41, P169, DOI 10.3177/jnsv.41.169	39	236	245	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6560	6565		10.1074/jbc.M009030200	http://dx.doi.org/10.1074/jbc.M009030200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11092891	hybrid			2022-12-25	WOS:000167261000066
J	Andersen, RB; Neuhard, J				Andersen, RB; Neuhard, J			Deoxynucleoside kinases encoded by the yaaG and yaaF genes of Bacillus subtilis - Substrate specificity and kinetic analysis of deoxyguanosine kinase with UTP as the preferred phosphate donor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DEOXYCYTIDINE KINASE; LACTOBACILLUS-ACIDOPHILUS R-26; MULTISUBSTRATE DEOXYRIBONUCLEOSIDE KINASE; DROSOPHILA-MELANOGASTER; MOLECULAR-CLONING; GENOME SEQUENCE; EXPRESSION; ENZYME; DNA; TRIPHOSPHATE	The overlapping yaaG and yaaF genes from Bacillus subtilis mere cloned and overexpressed in Escherichia coli. Purification of the gene products showed that yaaG encoded a homodimeric deoxyguanosine kinase (dGK) and that yaaF encoded a homodimeric deoxynucleoside kinase capable of phosphorylating both deoxyadenosine and deoxycytidine. The latter was identical to a previously characterized dAdo/dCyd kinase (Mollgaard, H. (1980) J. Biol. Chem. 255, 8216-8220). The purified recombinant dGK( was highly specific toward 6-oxopurine 2'-deoxyribonucleosides as phosphate acceptors showing only marginal activities with Guo, dAdo, and 2',3'-dideoxyguanosine. UTP was the preferred phosphate donor with a K-m value of 6 muM compared with 36 muM for ATP. In addition, the K-m for dGuo was 0.6 muM with UTP but 6.5 muM with ATP as phosphate donor. The combination of these two effects makes UTP over 50 times more efficient than ATP. Initial velocity and product inhibition studies indicated that the reaction with dGuo and UTP as substrates followed an Ordered Bi Bi reaction mechanism with UTP as the leading substrate and UDP the last product to leave. dGTP was a patent competitive inhibitor with respect to UTP. Above 30 muM of dGuo, substrate inhibition was observed, but only with UTP as phosphate donor.	Univ Copenhagen, Dept Biol Chem, DK-1307 Copenhagen K, Denmark	University of Copenhagen	Neuhard, J (corresponding author), Univ Copenhagen, Dept Biol Chem, Solvgade 83, DK-1307 Copenhagen K, Denmark.		Andersen, Rikke/GRS-3064-2022					ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BOHMAN C, 1988, BIOCHEMISTRY-US, V27, P4258, DOI 10.1021/bi00412a009; BRADSHAW HD, 1983, P NATL ACAD SCI-BIOL, V80, P5588, DOI 10.1073/pnas.80.18.5588; CHOTTINER EG, 1991, P NATL ACAD SCI USA, V88, P1531, DOI 10.1073/pnas.88.4.1531; Cleland W. W, 1970, ENZYMES, V2, P1; DATTA NS, 1989, J BIOL CHEM, V264, P9359; Hughes TL, 1997, BIOCHEMISTRY-US, V36, P7540, DOI 10.1021/bi970059r; IKEDA S, 1986, J BIOL CHEM, V261, P5836; IKEDA S, 1994, BIOCHEMISTRY-US, V33, P5328, DOI 10.1021/bi00183a041; Ives DH, 1998, PROG NUCLEIC ACID RE, V59, P205; JANSSON O, 1990, BIOCHEM J, V269, P201, DOI 10.1042/bj2690201; Johansson M, 1999, J BIOL CHEM, V274, P23814, DOI 10.1074/jbc.274.34.23814; KRAWIEC K, 1995, BIOCHEM BIOPH RES CO, V216, P42, DOI 10.1006/bbrc.1995.2589; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MA GT, 1995, J BIOL CHEM, V270, P6596; Ma N, 1996, P NATL ACAD SCI USA, V93, P14385, DOI 10.1073/pnas.93.25.14385; MCLAUGHLIN JR, 1981, P NATL ACAD SCI-BIOL, V78, P4912, DOI 10.1073/pnas.78.8.4912; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; MOLLGAARD H, 1980, J BIOL CHEM, V255, P8216; Munch-Petersen B, 2000, J BIOL CHEM, V275, P6673, DOI 10.1074/jbc.275.9.6673; Munch-Petersen B, 1998, J BIOL CHEM, V273, P3926, DOI 10.1074/jbc.273.7.3926; MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032; NEUHARD J, 1987, ESCHERICHIA COLI SAL, V1, P446; Nygaard Per, 1993, P359; PARK I, 1988, ARCH BIOCHEM BIOPHYS, V266, P51, DOI 10.1016/0003-9861(88)90235-4; Reichard P, 1997, TRENDS BIOCHEM SCI, V22, P81, DOI 10.1016/S0968-0004(97)01003-7; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGEL IH, 1975, ENZYME KINETICS, P767; SHEWACH DS, 1992, MOL PHARMACOL, V42, P518; Wang JH, 1998, ANTIMICROB AGENTS CH, V42, P2620, DOI 10.1128/AAC.42.10.2620; Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6; WANG LY, 1993, J BIOL CHEM, V268, P22847; Wang LY, 1996, FEBS LETT, V390, P39, DOI 10.1016/0014-5793(96)00623-0; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571	40	26	31	3	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5518	5524		10.1074/jbc.M007918200	http://dx.doi.org/10.1074/jbc.M007918200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11078735	hybrid			2022-12-25	WOS:000167115100017
J	Mukherjee, T; Mandal, D; Bhaduri, A				Mukherjee, T; Mandal, D; Bhaduri, A			Leishmania plasma membrane Mg2+-ATPase is a H+/K+-antiporter involved in glucose symport - Studies with sealed ghosts and vesicles of opposite polarity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; DONOVANI PROMASTIGOTE; SURFACE-MEMBRANE; CALCIUM-TRANSPORT; ACTIVE-TRANSPORT; COUNTERTRANSPORT; PROTEOLIPOSOMES; IDENTIFICATION; CA-2+-ATPASE; CA2+-ATPASE	Experiments from other laboratories conducted with Leishmania donovani promastigote cells had earlier indicated that the plasma membrane Mg2+-ATPase of the parasite is an extrusion pump for H+. Taking advantage of the pellicular microtubular structure of the plasma membrane of the organism, we report procedures for obtaining sealed ghost and sealed everted vesicle of defined polarity. Rapid influx of H+ into everted vesicles was found to be dependent on the simultaneous presence of ATP (1 mM) and Mg2+ (1 mM). Excellent correspondence between rate of H+ entry and the enzyme activity clearly demonstrated the Mg2+-ATPase to be a true H+ pump. HC entry into everted vesicle was strongly inhibited by SCH28080 (IC50 = similar to 40 muM) and by omeprazole (IC50 = similar to 50 muM), both of which are characteristic inhibitors of mammalian gastric H+,K+ -ATPase. H+ influx was completely insensitive to ouabain (250 muM), the typical inhibitor of Na+,K+-ATPase. Mg2(+)-ATPase activity could be partially stimulated with Kt (20 mM) that was inhibitable (>85%) with SCH28080 (50 Cat). ATP-dependent rapid efflux of Rb-86(+) from preloaded vesicles was completely inhibited by preincubation with omeprazole (150 muM) and by 5,5'-dithiobis-(2-nitrobenzoic acid) (1 mM), an inhibitor of the enzyme. Assuming Rb+ to be a true surrogate for Kt, an ATP-dependent, electroneutral stoichiometric exchange of Hf and K+ (1:1) was established. Rapid and 10-fold active accumulation of [U-C-14]2-deoxyglucose in sealed ghosts could be observed when an artificial pH gradient (interior alkaline) was imposed. Rapid efflux of [U-14C]D-glucose from preloaded everted vesicles could also be initiated by activating the enzyme, with ATP. Taken together, the plasma membrane Mg2(+)-ATPase has been identified as an electroneutral H+/K+ antiporter with some properties reminiscent of the gastric H+,K+- ATPase. This enzyme is possibly involved in active accumulation of glucose via a H+-glucose symport system and in KC accumulation.	Indian Inst Chem Biol, Kolkata 700032, W Bengal, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Bhaduri, A (corresponding author), Indian Inst Chem Biol, 4 Raja Sc Mullick Rd, Kolkata 700032, W Bengal, India.	anbhaduri@yahoo.com						ANDERSON SA, 1994, BBA-BIOMEMBRANES, V1195, P81, DOI 10.1016/0005-2736(94)90012-4; ANDERSON SA, 1994, BBA-BIOMEMBRANES, V1195, P71, DOI 10.1016/0005-2736(94)90011-6; APELL HJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P480, DOI 10.1016/0005-2736(87)90055-1; ASHFORD RW, 1992, PARASITOL TODAY, V8, P104, DOI 10.1016/0169-4758(92)90249-2; BAIS R, 1975, ANAL BIOCHEM, V63, P271, DOI 10.1016/0003-2697(75)90215-8; BLATT MR, 1987, J MEMBRANE BIOL, V98, P169, DOI 10.1007/BF01872129; BLUM JJ, 1992, J CELL PHYSIOL, V152, P111, DOI 10.1002/jcp.1041520115; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; CAIRNS BR, 1989, P NATL ACAD SCI USA, V85, P2130; CHAKRABORTY P, 1988, MOL BIOCHEM PARASIT, V28, P55, DOI 10.1016/0166-6851(88)90180-6; Chang K. P., 1985, Leishmaniasis. (Human Parasitic Diseases Vol.1.), P1; DWYER DM, 1983, J CELL BIOCHEM, V23, P35, DOI 10.1002/jcb.240230105; Felibertt P, 1995, MOL BIOCHEM PARASIT, V74, P179, DOI 10.1016/0166-6851(95)02497-2; GHOSH J, 1990, J BIOL CHEM, V265, P11345; GLASER TA, 1992, MOL BIOCHEM PARASIT, V51, P9, DOI 10.1016/0166-6851(92)90195-P; HAO LN, 1994, J BIOL CHEM, V269, P14268; HERSEY SJ, 1995, PHYSIOL REV, V75, P155, DOI 10.1152/physrev.1995.75.1.155; JIANG SP, 1994, J CELL PHYSIOL, V159, P60, DOI 10.1002/jcp.1041590109; KABACK HR, 1986, ANNU REV BIOPHYS BIO, V15, P279; LANGFORD CK, 1994, J BIOL CHEM, V269, P17939; LANGFORD CK, 1994, PARASITOLOGY, V108, P73; LEVY D, 1990, J BIOL CHEM, V265, P19524; LOWRY OH, 1957, METHOD ENZYMOL, V3, P845; Mandal D, 1997, BIOCHEM J, V322, P251, DOI 10.1042/bj3220251; MAZUMDER S, 1992, J BIOL CHEM, V267, P18440; Myler PJ, 1999, P NATL ACAD SCI USA, V96, P2902, DOI 10.1073/pnas.96.6.2902; NEGULESCU PA, 1990, METHOD ENZYMOL, V192, P38; PARSHADSINGH HA, 1980, J BIOL CHEM, V255, P4087; PERLIN DS, 1984, J BIOL CHEM, V259, P7785; RABON EC, 1990, ANNU REV PHYSIOL, V52, P321; ROSS A, 1981, PHYSIOL REV, V61, P296; Rottenberg H, 1979, Methods Enzymol, V55, P547; RUBEN L, 1991, J BIOL CHEM, V266, P24351; SACHS G, 1976, J BIOL CHEM, V251, P7690; SAHA AK, 1986, MOL BIOCHEM PARASIT, V19, P195, DOI 10.1016/0166-6851(86)90001-0; SCHNUR LF, 1995, PARASIT PROTOZ, V10, P1; SCHUMAKER KS, 1986, J BIOL CHEM, V261, P2172; SKRABANJA ATP, 1987, BIOCHIM BIOPHYS ACTA, V903, P434, DOI 10.1016/0005-2736(87)90050-2; SMITH GS, 1982, BIOCHIM BIOPHYS ACTA, V688, P803, DOI 10.1016/0005-2736(82)90295-4; TERKUILE BH, 1993, MOL BIOCHEM PARASIT, V60, P313, DOI 10.1016/0166-6851(93)90142-K; Tetaud E, 1997, BIOCHEM J, V325, P569, DOI 10.1042/bj3250569; TSAO YS, 1985, BIOCHEMISTRY-US, V24, P1092, DOI 10.1021/bi00326a004; Vickerman K, 1976, BIOL KINETOPLASTIDA, P35; VIEIRA L, 1995, J BIOL CHEM, V269, P16254; ZILBERSTEIN D, 1988, BIOCHEM J, V256, P13, DOI 10.1042/bj2560013; ZILBERSTEIN D, 1985, P NATL ACAD SCI USA, V82, P1716, DOI 10.1073/pnas.82.6.1716	46	15	18	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5563	5569		10.1074/jbc.M008469200	http://dx.doi.org/10.1074/jbc.M008469200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11087746	hybrid			2022-12-25	WOS:000167115100023
J	Brassart, B; Fuchs, P; Huet, E; Alix, AJP; Wallach, J; Tamburro, AM; Delacoux, F; Haye, B; Emonard, H; Hornebeck, W; Debelle, L				Brassart, B; Fuchs, P; Huet, E; Alix, AJP; Wallach, J; Tamburro, AM; Delacoux, F; Haye, B; Emonard, H; Hornebeck, W; Debelle, L			Conformational dependence of collagenase (matrix metalloproteinase-1) up-regulation by elastin peptides in cultured fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; MESSENGER-RNA; ENDOTHELIAL-CELLS; HUMAN-LEUKOCYTES; GENE-EXPRESSION; VASCULAR TONE; TROPOELASTIN; RECEPTOR; IDENTIFICATION; PROLIFERATION	We have established that treatment of cultured human skin fibroblasts with tropoelastin or with heterogenic peptides, obtained after organo-alkaline or leukocyte elastase hydrolysis of insoluble elastin, induces a high expression of pro-collagenase-1 (pro-matrix metalloproteinase-1 (pro-MMP-1)). The identical effect was achieved after stimulation with a VGVAPG synthetic peptide, reflecting the elastin-derived domain known to bind to the 67-kDa elastin-binding protein. This clearly indicated involvement of this receptor in the described phenomenon. This notion was further reinforced by the fact that elastin peptides-dependent MMP-1 up-regulation has not been demonstrated in cultures preincubated with 1 mM lactose, which causes shedding of the elastin-binding protein and with pertussis toxin, which blocks the elastin-binding protein-dependent signaling pathway involving G protein, phospholipase C, and protein kinase C. Moreover, we demonstrated that diverse peptides maintaining GXXPG sequences can also induce similar cellular effects as a "principal" VGVAPG ligand of the elastin receptor. Results of our biophysical studies suggest that this peculiar consensus sequence stabilizes a type VIII beta -turn in several similar, but not identical, peptides that maintain a sufficient conformation to be recognized by the elastin receptor. We have also established that GXXPG elastin-derived peptides, in addition to pro-MMP-1, cause up-regulation of pro-matrix metalloproteinase-3 (pro-stromelysin 1). Furthermore, we found that the presence of plasmin in the culture medium activated these MMP proenzymes, leading to a consequent degradation of collagen substrate. Our results may be, therefore, relevant to pathobiology of inflammation, in which elastin-derived peptides bearing the GXXPG conformation (created after leukocyte-dependent proteolysis) bind to the elastin receptor of local fibroblasts and trigger signals leading to expression and activation of MMP-1 and MMP-3, which in turn exacerbate local connective tissue damage.	Univ Reims, Fac Sci, IFR53 Biomol, UPRES A CNRS 6021, F-51687 Reims, France; Univ Reims, Fac Med, F-51687 Reims, France; Univ Reims, Fac Sci, IFR53 Biomol, Lab Biomol Spectroscopies & Struct, F-51687 Reims, France; Univ Lyon 1, Lab Analyt Biochem, F-69622 Villeurbanne, France; Univ Potenza, Dept Chem, Organ Chem Lab, I-85100 Potenza, Italy	Universite de Reims Champagne-Ardenne; Universite de Reims Champagne-Ardenne; Universite de Reims Champagne-Ardenne; UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Basilicata	Debelle, L (corresponding author), Univ Reims, Fac Sci, Biochem Lab, IFR53 Biomol,FRE CNRS 2260, F-51687 Reims, France.	laurent.debelle@univ-reims.fr	HUET, Eric/R-3178-2018; Emonard, Hervé/AAD-5432-2019; Emonard, Herve/R-9718-2019; FUCHS, Patrick/C-8425-2016	HUET, Eric/0000-0002-5541-5954; FUCHS, Patrick/0000-0001-7117-994X				Archilla-Marcos M., 1993, CLIN PHYSIOL BIOCH, V10, P86; Benbow U, 1999, J BIOL CHEM, V274, P25371, DOI 10.1074/jbc.274.36.25371; BISACCIA F, 1994, INT J PEPT PROT RES, V44, P332; BOUDIER C, 1991, AM J RESP CELL MOL, V4, P497, DOI 10.1165/ajrcmb/4.6.497; Brassart B, 1998, CLIN EXP METASTAS, V16, P489, DOI 10.1023/A:1006550503612; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; Debelle L, 1999, BIOCHIMIE, V81, P981, DOI 10.1016/S0300-9084(99)00221-7; Debelle L, 1999, INT J BIOCHEM CELL B, V31, P261, DOI 10.1016/S1357-2725(98)00098-3; Faury G, 1998, P NATL ACAD SCI USA, V95, P2967, DOI 10.1073/pnas.95.6.2967; FAURY G, 1995, J VASC RES, V32, P112, DOI 10.1159/000159084; Faury G, 1998, CIRC RES, V82, P328, DOI 10.1161/01.RES.82.3.328; FULOP T, 1986, BIOCHEM BIOPH RES CO, V141, P92, DOI 10.1016/S0006-291X(86)80339-4; FULOP T, 1990, CLIN PHYSIOL BIOCH, V8, P273; GHUYSENITARD AF, 1992, CR ACAD SCI III-VIE, V315, P473; GROSSO LE, 1993, MATRIX, V13, P157, DOI 10.1016/S0934-8832(11)80074-0; Hauck M, 1995, BIOCHEM MOL BIOL INT, V37, P45; HINEK A, 1993, J CLIN INVEST, V91, P1198, DOI 10.1172/JCI116280; Hinek A, 1996, BIOL CHEM, V377, P471; Hornebeck W, 1999, ANN NY ACAD SCI, V878, P625, DOI 10.1111/j.1749-6632.1999.tb07745.x; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HUTCHINSON EG, 1994, PROTEIN SCI, V3, P2207, DOI 10.1002/pro.5560031206; INDIK Z, 1987, P NATL ACAD SCI USA, V84, P5680, DOI 10.1073/pnas.84.16.5680; Jacob M, 1985, FRONTIERS MATRIX BIO, V10, P92; JACOB MP, 1987, P NATL ACAD SCI USA, V84, P995, DOI 10.1073/pnas.84.4.995; Jung S, 1998, J NEUROPATH EXP NEUR, V57, P439, DOI 10.1097/00005072-199805000-00007; Kamoun A, 1995, CELL ADHES COMMUN, V3, P273, DOI 10.3109/15419069509081013; LABORDA J, 1991, NUCLEIC ACIDS RES, V19, P3998, DOI 10.1093/nar/19.14.3998; Lograno MD, 1998, INT J BIOCHEM CELL B, V30, P497, DOI 10.1016/S1357-2725(98)00008-9; LONG MM, 1988, BIOCHIM BIOPHYS ACTA, V968, P300, DOI 10.1016/0167-4889(88)90021-3; LOWRY OH, 1951, J BIOL CHEM, V257, P5333; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; Morelli MAC, 1997, J PEPT RES, V49, P492; Pins GD, 2000, J INVEST DERMATOL, V114, P647, DOI 10.1046/j.1523-1747.2000.00858.x; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SENIOR RM, 1984, J CELL BIOL, V99, P870, DOI 10.1083/jcb.99.3.870; TREMBLE P, 1995, J CELL BIOL, V129, P1707, DOI 10.1083/jcb.129.6.1707; Uemura Y, 1997, BIOCHEM MOL BIOL INT, V41, P57; VARGA Z, 1989, FEBS LETT, V258, P5, DOI 10.1016/0014-5793(89)81602-3; Vrhovski B, 1998, EUR J BIOCHEM, V258, P1, DOI 10.1046/j.1432-1327.1998.2580001.x; WACHI H, 1995, FEBS LETT, V368, P215, DOI 10.1016/0014-5793(95)00641-L; WILMOT CM, 1988, J MOL BIOL, V203, P221, DOI 10.1016/0022-2836(88)90103-9; WRENN DS, 1986, BIOCHEMISTRY-US, V25, P5172, DOI 10.1021/bi00366a028; YEH H, 1987, COLLAGEN REL RES, V7, P235; YUSA T, 1989, AM REV RESPIR DIS, V140, P1458, DOI 10.1164/ajrccm/140.5.1458	45	138	146	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5222	5227		10.1074/jbc.M003642200	http://dx.doi.org/10.1074/jbc.M003642200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11084020	hybrid			2022-12-25	WOS:000168484300092
J	Wang, CN; Chi, CW; Lin, YL; Chen, CF; Shiao, YJ				Wang, CN; Chi, CW; Lin, YL; Chen, CF; Shiao, YJ			The neuroprotective effects of phytoestrogens on amyloid beta protein-induced toxicity are mediated by abrogating the activation of caspase cascade in rat cortical neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIPPOCAMPAL-NEURONS; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; CELL-DEATH; IN-VITRO; INDUCED NEURODEGENERATION; NEUROBLASTOMA-CELLS; ESTRADIOL PROTECTS; LIPID-PEROXIDATION; APOPTOSIS	Amyloid beta protein (A beta) elicits a toxic effect on neurons in vitro and in vivo. In present study we attempt to elucidate the mechanism by which A beta confers its neurotoxicity. The neuroprotective effects of phytoestrogens on A beta -mediated toxicity were also investigated. Cortical neurons treated with 5 muM A beta-(25-35) for 40 h decreased the cell viability by 45.5 +/- 4.6% concomitant with the appearance of apoptotic morphology. 50 muM kaempferol and apigenin decreased the A beta -induced cell death by 81.5 +/- 9.4% and 49.2 +/- 9.9%, respectively. A beta increased the activity of caspase 3 by 10.6-fold and to a lesser extent for caspase 2, 8, and 9. The A beta -induced activation of caspase 3 and release of cytochrome c showed a biphasic pattern. Apigenin abrogated A beta -induced cytochrome c release, and the activation of caspase cascade. Kaempferol showed a similar effect but to a less extent. Kaempferol was also capable of eliminating A beta -induced accumulation of reactive oxygen species. These two events accounted for the remarkable effect of kaempferol on neuroprotection. Quercetin and probucol did not affect the A beta -mediated neurotoxicity, However, they potentiated the protective effect of apigenin. Therefore, these results demonstrate that A beta elicited activation of caspase cascades and reactive oxygen species accumulation, thereby causing neuronal death. The blockade of caspase activation conferred the major neuroprotective effect of phytoestrogens. The antioxidative activity of phytoestrogens also modulated their neuroprotective effects on A beta -mediated toxicity.	Natl Res Inst Chinese Med, Taipei 112, Taiwan; Natl Yang Ming Univ, Inst Pharmacol, Taipei 112, Taiwan	National Research Institute of Chinese Medicine; National Yang Ming Chiao Tung University	Shiao, YJ (corresponding author), Natl Res Inst Chinese Med, 155-1 Sec 2,LiNung St, Taipei 112, Taiwan.		Shiao, Young-Ji/AAA-9647-2022					BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Behl C, 1997, MOL PHARMACOL, V51, P535, DOI 10.1124/mol.51.4.535; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Birge S J, 1997, Am J Med, V103, p1S, DOI 10.1016/S0002-9343(97)00263-5; Brewer GJ, 1997, J NEUROSCI METH, V71, P143, DOI 10.1016/S0165-0270(96)00136-7; Buxbaum JD, 1996, ANN NY ACAD SCI, V777, P327, DOI 10.1111/j.1749-6632.1996.tb34441.x; Cao GH, 1997, FREE RADICAL BIO MED, V22, P749, DOI 10.1016/S0891-5849(96)00351-6; Chan GCK, 1998, J NEUROSCI, V18, P5322, DOI 10.1523/JNEUROSCI.18-14-05322.1998; Cotelle N, 1996, FREE RADICAL BIO MED, V20, P35, DOI 10.1016/0891-5849(95)02014-4; Ekinci FJ, 1999, J BIOL CHEM, V274, P30322, DOI 10.1074/jbc.274.42.30322; Estus S, 1997, J NEUROSCI, V17, P7736; Ferreira A, 1997, MOL CELL NEUROSCI, V9, P220, DOI 10.1006/mcne.1997.0615; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; Goodman YD, 1996, J NEUROCHEM, V66, P1836; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Green PS, 1997, J NEUROSCI, V17, P511; Green PS, 1996, NEUROSCI LETT, V218, P165, DOI 10.1016/S0304-3940(96)13148-7; Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557; Harada J, 1999, BRAIN RES, V842, P311, DOI 10.1016/S0006-8993(99)01808-9; HENDERSON VW, 1994, ARCH NEUROL-CHICAGO, V51, P896, DOI 10.1001/archneur.1994.00540210068014; IVERSEN LL, 1995, BIOCHEM J, V311, P1; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Keller JN, 1998, J NEUROSCI, V18, P687; Kruman I, 1997, J NEUROSCI, V17, P5089; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; MacManus A, 2000, J BIOL CHEM, V275, P4713, DOI 10.1074/jbc.275.7.4713; MARK RJ, 1995, J NEUROSCI, V15, P6239; Mark RJ, 1997, J NEUROCHEM, V68, P255; Mattson MP, 1998, BRAIN RES, V807, P167, DOI 10.1016/S0006-8993(98)00763-X; Maurice T, 1996, BRAIN RES, V706, P181, DOI 10.1016/0006-8993(95)01032-7; MIKSICEK RJ, 1993, MOL PHARMACOL, V44, P37; Miranda CL, 1999, FOOD CHEM TOXICOL, V37, P271, DOI 10.1016/S0278-6915(99)00019-8; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Pappolla MA, 1997, J NEUROSCI, V17, P1683; Pellegrini N, 1999, METHOD ENZYMOL, V299, P379; Pike CJ, 1997, J NEUROCHEM, V69, P1601; Prehn JHM, 1996, MOL PHARMACOL, V49, P319; Roth A, 1999, J NEUROSCI RES, V57, P399; Saponara R, 1998, J NAT PROD, V61, P1386, DOI 10.1021/np970569m; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SELKOE DJ, 1990, SCIENCE, V248, P1058, DOI 10.1126/science.2111582; Simpkins JW., 1997, AM J MED, V103, p19S, DOI 10.1016/s0002-9343(97)00260-x; Smith MA, 1998, INT REV NEUROBIOL, V42, P1, DOI 10.1016/S0074-7742(08)60607-8; Troy CM, 2000, J NEUROSCI, V20, P1386; Ueda K, 1997, J NEUROCHEM, V68, P265; WOODS AG, 1995, BRAIN RES, V697, P53, DOI 10.1016/0006-8993(95)00775-L; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4	49	167	182	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5287	5295		10.1074/jbc.M006406200	http://dx.doi.org/10.1074/jbc.M006406200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11083861	hybrid			2022-12-25	WOS:000168484300101
J	Yang, EK; Alvira, MR; Levitan, ES; Takimoto, K				Yang, EK; Alvira, MR; Levitan, ES; Takimoto, K			Kv beta subunits increase expression of Kv4.3 channels by interacting with their C termini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; POTASSIUM CHANNEL; RAT-BRAIN; SURFACE EXPRESSION; ALPHA-SUBUNITS; STOICHIOMETRY; TRAFFICKING; FAMILY; DOMAIN; CELLS	Auxiliary Kv beta subunits form complexes with Kv1 family voltage-gated K+ channels by binding to a part of the N terminus of channel polypeptide. This association influences expression and gating of these channels. Here we show that Kv4.3 proteins are associated with Kv beta2 subunits in the brain. Expression of Kv beta1 or Kv beta2 subunits does not affect Kv4.3 channel gating but increases current density and protein expression. The increase in Kv4.3 protein is larger at longer times after transfection, suggesting that Kv beta -associated channel proteins are more stable than those without the auxiliary subunits. This association between Kv4.3 and Kv beta subunits requires the C terminus but not the N terminus of the channel polypeptide. Thus, Kv beta subunits utilize diverse molecular interactions to stimulate the expression of Kv channels from different families.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Takimoto, K (corresponding author), Univ Pittsburgh, Dept Pharmacol, E13555 Biomed Sci Tower, Pittsburgh, PA 15261 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063123, R01HL055312] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63123, HL55312] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bichet D, 2000, NEURON, V25, P177, DOI 10.1016/S0896-6273(00)80881-8; Burke NA, 1999, J GEN PHYSIOL, V113, P71, DOI 10.1085/jgp.113.1.71; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; Fink M, 1996, J BIOL CHEM, V271, P26341, DOI 10.1074/jbc.271.42.26341; FRECH GC, 1989, NATURE, V340, P642, DOI 10.1038/340642a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heinemann SH, 1996, J PHYSIOL-LONDON, V493, P625, DOI 10.1113/jphysiol.1996.sp021409; Li DQ, 2000, J BIOL CHEM, V275, P11597, DOI 10.1074/jbc.275.16.11597; Lombardi SJ, 1998, J BIOL CHEM, V273, P30092, DOI 10.1074/jbc.273.46.30092; MCCORMACK T, 1994, CELL, V79, P1133, DOI 10.1016/0092-8674(94)90004-3; Nakahira K, 1996, J BIOL CHEM, V271, P7084, DOI 10.1074/jbc.271.12.7084; Perez-Garcia MT, 1999, J GEN PHYSIOL, V113, P897, DOI 10.1085/jgp.113.6.897; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; RHODES KJ, 1995, J NEUROSCI, V15, P5360; SCOTT VES, 1994, P NATL ACAD SCI USA, V91, P1637, DOI 10.1073/pnas.91.5.1637; Sewing S, 1996, NEURON, V16, P455, DOI 10.1016/S0896-6273(00)80063-X; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Takimoto K, 1997, CIRC RES, V81, P533, DOI 10.1161/01.RES.81.4.533; TAKIMOTO K, 1996, BIOCHEMISTRY-US, V35, P1419; TAN H, 1996, PLANT CELL, V8, P1545; TRIMMER JS, 1991, P NATL ACAD SCI USA, V88, P10764, DOI 10.1073/pnas.88.23.10764; Wilson GF, 1998, J BIOL CHEM, V273, P6389, DOI 10.1074/jbc.273.11.6389; Xu J, 1998, P NATL ACAD SCI USA, V95, P1846, DOI 10.1073/pnas.95.4.1846; Yao WD, 1999, J NEUROPHYSIOL, V81, P2472, DOI 10.1152/jn.1999.81.5.2472; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	29	80	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4839	4844		10.1074/jbc.M004768200	http://dx.doi.org/10.1074/jbc.M004768200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087728	hybrid			2022-12-25	WOS:000168484300043
J	Pahlman, AK; Granath, K; Ansell, R; Hohmann, S; Adler, L				Pahlman, AK; Granath, K; Ansell, R; Hohmann, S; Adler, L			The yeast glycerol 3-phosphatases gpp1p and gpp2p are required for glycerol biosynthesis and differentially involved in the cellular responses to osmotic, anaerobic, and oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-A; SIGNAL-TRANSDUCTION PATHWAY; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; DEBARYOMYCES-HANSENII; ADENYLATE-CYCLASE; 2 ISOENZYMES; CAMP LEVELS; GROWTH	We have characterized the strongly homologous GPP1/RHR2 and GPP2/HOR2 genes, encoding isoforms of glycerol 3-phosphatase. Mutants lacking both GPP1 and GPP2 are devoid of glycerol S-phosphatase activity and produce only a small amount of glycerol, confirming the essential role for this enzyme in glycerol biosynthesis. Overproduction of Gpp1p and Gpp2p did not significantly enhance glycerol production, indicating that glycerol phosphatase is not rate-limiting for glycerol production. Previous studies have shown that expression of both GPP1 and GPP2 is induced under hyperosmotic stress and that induction partially depends on the HOG thigh osmolarity glycerol) pathway. We here show that expression of GPP1 is strongly decreased in strains having low protein kinase A activity, although it is still responsive to osmotic stress. The gpp1 Delta /gpp2 Delta double mutant is hypersensitive to high osmolarity, whereas the single mutants remain unaffected, indicating GPP1 and GPP2 substitute well for each other. Transfer to anaerobic conditions does not affect expression of GPP2, whereas GPP1 is transiently induced, and mutants lacking GPP1 show poor anaerobic growth. All gpp mutants show increased levels of glycerol 8-phosphate, which is especially pronounced when gpp1 Delta and gpp1 Delta /gpp2 Delta mutants are transferred to anaerobic conditions. The addition of acetaldehyde, a strong oxidizer of NADH, leads to decreased glycerol 3-phosphate levels and restored anaerobic growth of the gpp1/Delta gpp2 Delta mutant, indicating that the anaerobic accumulation of NADH causes glycerol 3-phosphate to reach growth-inhibiting levels. We also found the gpp1 Delta /gpp2 Delta mutant is hypersensitive to the superoxide anion generator, paraquat, Consistent with a role for glycerol 3-phosphatase in protection against oxidative stress, expression of GPP2 is induced in the presence of paraquat,This induction was only marginally affected by the general stress-response transcriptional factors Msn2p/4p or protein kinase A activity. We conclude that glycerol metabolism plays multiple roles in yeast adaptation to altered growth conditions, explaining the complex regulation of glycerol biosynthesis genes.	Gothenburg Univ, Dept Cell & Mol Biol, SE-40530 Gothenburg, Sweden	University of Gothenburg	Adler, L (corresponding author), Gothenburg Univ, Dept Cell & Mol Biol, Box 463, SE-40530 Gothenburg, Sweden.		Hohmann, Stefan/K-9895-2013	Hohmann, Stefan/0000-0002-0809-1985				ALBERTYN J, 1994, MOL CELL BIOL, V14, P4135, DOI 10.1128/MCB.14.6.4135; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; ANDRE L, 1988, J GEN MICROBIOL, V134, P669; ANDREASEN AA, 1954, J CELL COMPAR PHYSL, V43, P271, DOI 10.1002/jcp.1030430303; ANDREASEN AA, 1953, J CELL COMPAR PHYSL, V41, P23, DOI 10.1002/jcp.1030410103; Ansell R, 1997, EMBO J, V16, P2179, DOI 10.1093/emboj/16.9.2179; Athenstaedt K, 1999, J BACTERIOL, V181, P1458, DOI 10.1128/JB.181.5.1458-1463.1999; BERGMEYER HU, 1974, METHODS ENZYMATIC AN, V3; Bjorkqvist S, 1997, APPL ENVIRON MICROB, V63, P128; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Chaturvedi V, 1997, J BACTERIOL, V179, P157, DOI 10.1128/jb.179.1.157-162.1997; Daum G, 1998, YEAST, V14, P1471, DOI 10.1002/(SICI)1097-0061(199812)14:16<1471::AID-YEA353>3.0.CO;2-Y; ERIKSSON P, 1995, MOL MICROBIOL, V17, P95, DOI 10.1111/j.1365-2958.1995.mmi_17010095.x; ESTRUCH F, 1993, MOL CELL BIOL, V13, P3872, DOI 10.1128/MCB.13.7.3872; Fernandes L, 1997, MOL CELL BIOL, V17, P6982, DOI 10.1128/MCB.17.12.6982; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; Gorner W, 1998, GENE DEV, V12, P586, DOI 10.1101/gad.12.4.586; GUSTAFSSON L, 1979, ARCH MICROBIOL, V120, P15, DOI 10.1007/BF00413266; HANAHAN D, 1983, J MOL BIOL, V166, P577; HIRAYAMA T, 1995, MOL GEN GENET, V249, P127, DOI 10.1007/BF00290358; Holst B, 2000, MOL MICROBIOL, V37, P108, DOI 10.1046/j.1365-2958.2000.01968.x; KLEIN C, 1994, MOL CELL BIOL, V14, P1920, DOI 10.1128/MCB.14.3.1920; KREMS B, 1995, CURR GENET, V39, P327; KUGE S, 1994, EMBO J, V13, P655, DOI 10.1002/j.1460-2075.1994.tb06304.x; Larsson C, 1998, YEAST, V14, P347, DOI 10.1002/(SICI)1097-0061(19980315)14:4<347::AID-YEA226>3.0.CO;2-9; LARSSON K, 1993, MOL MICROBIOL, V10, P1101, DOI 10.1111/j.1365-2958.1993.tb00980.x; LUYTEN K, 1995, EMBO J, V14, P1360, DOI 10.1002/j.1460-2075.1995.tb07122.x; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; MAEDA T, 1995, SCIENCE, V269, P554, DOI 10.1126/science.7624781; MARCHLER G, 1993, EMBO J, V12, P1997, DOI 10.1002/j.1460-2075.1993.tb05849.x; Marquez JA, 1996, FEBS LETT, V382, P89, DOI 10.1016/0014-5793(96)00157-3; Miller JH, 1973, EXPT MOL GENETICS; MORBIDONI HR, 1995, J BACTERIOL, V177, P5899, DOI 10.1128/jb.177.20.5899-5905.1995; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; NIKAWA J, 1987, GENE DEV, V1, P931, DOI 10.1101/gad.1.9.931; Norbeck J, 1996, J BIOL CHEM, V271, P13875, DOI 10.1074/jbc.271.23.13875; Norbeck J, 2000, YEAST, V16, P121, DOI 10.1002/(SICI)1097-0061(20000130)16:2<121::AID-YEA511>3.0.CO;2-A; Norbeck J, 1997, J BIOL CHEM, V272, P5544, DOI 10.1074/jbc.272.9.5544; NORBECK J, 1996, THESIS GOTEBORG U; NORDSTROM K, 1966, ACTA CHEM SCAND, V20, P1016, DOI 10.3891/acta.chem.scand.20-1016; PAVLIK P, 1993, CURR GENET, V24, P21, DOI 10.1007/BF00324660; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Rep M, 1999, MICROBIOL-UK, V145, P715, DOI 10.1099/13500872-145-3-715; Rep M, 1999, MOL CELL BIOL, V19, P5474; RONNOW B, 1993, YEAST, V9, P1121, DOI 10.1002/yea.320091013; RUIS H, 1995, BIOESSAYS, V17, P959, DOI 10.1002/bies.950171109; RUSSELL M, 1993, MOL BIOL CELL, V4, P757, DOI 10.1091/mbc.4.7.757; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO N, 1997, YEAST STRESS RESPONS, P172; SCHNELL N, 1992, CURR GENET, V21, P269, DOI 10.1007/BF00351681; SENGSTAG C, 1993, GENE, V124, P141, DOI 10.1016/0378-1119(93)90778-2; SENGSTAG C, 1987, NUCLEIC ACIDS RES, V15, P233, DOI 10.1093/nar/15.1.233; Shen B, 1997, PLANT PHYSIOL, V115, P527, DOI 10.1104/pp.115.2.527; Sherman F., 1983, METHODS YEAST GENETI; SHULLER C, 1994, EMBO J, V13, P4382; SMIRNOFF N, 1989, PHYTOCHEMISTRY, V28, P1057, DOI 10.1016/0031-9422(89)80182-7; SPRAGUE GF, 1977, J BACTERIOL, V129, P1335, DOI 10.1128/JB.129.3.1335-1342.1977; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; VANDIJKEN JP, 1986, FEMS MICROBIOL LETT, V32, P199, DOI 10.1016/0378-1097(86)90291-0; VARELA JCS, 1995, MOL CELL BIOL, V15, P6232; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wach A, 1997, YEAST, V13, P1065, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1065::AID-YEA159>3.3.CO;2-B; [No title captured]	66	196	214	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3555	3563		10.1074/jbc.M007164200	http://dx.doi.org/10.1074/jbc.M007164200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11058591	hybrid			2022-12-25	WOS:000166784900075
J	Palicz, A; Foubert, TR; Jesaitis, AJ; Marodi, L; McPhail, LC				Palicz, A; Foubert, TR; Jesaitis, AJ; Marodi, L; McPhail, LC			Phosphatidic acid and diacylglycerol directly activate NADPH oxidase by interacting with enzyme components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; CELL-FREE SYSTEM; RESPIRATORY BURST ENZYME; FMET-LEU-PHE; PLASMA-MEMBRANE; POLYMORPHONUCLEAR LEUKOCYTES; CONFORMATIONAL-CHANGES; SUPEROXIDE-PRODUCTION; ARACHIDONIC-ACID; PHOSPHOLIPASE-D	The enzyme NADPH oxidase is regulated by phospholipase D in intact neutrophils and is activated by phosphatidic acid (PA) plus diacylglycerol (DG) in cell-free systems. We showed previously that cell-free NADPH oxidase activation by these lipids involves both protein kinase-dependent and -independent pathways. Here we demonstrate that only the protein kinase-independent pathway is operative in a cell-free system of purified and recombinant NADPH oxidase components. Activation by PA + DG was ATP-independent and unaffected by the protein kinase inhibitor staurosporine, indicating the lack of protein kinase involvement. Both PA and DG were required for optimal activation to occur. The drug R59949 reduced activation of NADPH oxidase by either arachidonic acid or PA + DG, with IC50 values of 46 and 25 CCM, respectively. The optimal concentration of arachidonic acid or PA + DG for oxidase activation was shifted to the right with R59949, indicating interference of the drug with the interaction of lipid activators and enzyme components. R59949 inhibited the lipid-induced aggregation/sedimentation of oxidase components p47(phox) and p67(phox), suggesting a disruption of the lipid-mediated assembly process. The direct effects of R59949 on NADPH oxidase activation complicate its use as a "specific" inhibitor of DG kinase, We conclude that the protein kinase-independent pathway of NADPH oxidase activation by PA and DG involves direct interaction with NADPH oxidase components. Thus, NADPH oxidase proteins are functional targets for these lipid messengers in the neutrophil.	Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Univ Debrecen, Dept Infectol & Pediat Immunol, Med & Hlth Sci Ctr, H-4012 Debrecen, Hungary; Montana State Univ, Dept Microbiol, Bozeman, MT 59717 USA	Wake Forest University; Wake Forest Baptist Medical Center; University of Debrecen; Montana State University System; Montana State University Bozeman	McPhail, LC (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.	lmcphail@wfubmc.edu	McPhail, Linda C/D-9505-2013	McPhail, Linda C/0000-0002-8670-306X; Jesaitis, Algirdas/0000-0001-9001-5617	NIAID NIH HHS [R01-AI26711, R01 AI022564, R01-AI-22564] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022564, R01AI026711] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABO A, 1992, J BIOL CHEM, V267, P16767; Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; ARIS JP, 1993, BIOCHIM BIOPHYS ACTA, V1174, P171, DOI 10.1016/0167-4781(93)90111-P; Arnhold J, 1999, LUMINESCENCE, V14, P129, DOI 10.1002/(SICI)1522-7243(199905/06)14:3<129::AID-BIO526>3.0.CO;2-Y; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; Cornell RB, 1998, BIOCHEM SOC T, V26, P539, DOI 10.1042/bst0260539; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; Dana R, 1998, J BIOL CHEM, V273, P441, DOI 10.1074/jbc.273.1.441; DECOURCELLES DD, 1990, ADV SEC MESS PHOSPH, V24, P491; DECOURCELLES DD, 1989, J BIOL CHEM, V264, P3274; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Doussiere J, 1996, BIOCHEMISTRY-US, V35, P13400, DOI 10.1021/bi960916b; Erickson RW, 1999, J BIOL CHEM, V274, P22243, DOI 10.1074/jbc.274.32.22243; Flores I, 1999, J IMMUNOL, V163, P708; GAREWAL HS, 1986, J NATL CANCER I, V77, P1039; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; Gomez-Cambronero J, 1998, CELL SIGNAL, V10, P387, DOI 10.1016/S0898-6568(97)00197-6; GOMEZCAMBRONERO J, 1987, BIOCHEM BIOPH RES CO, V148, P38, DOI 10.1016/0006-291X(87)91073-4; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hantgan RR, 1998, BLOOD, V92, P2064, DOI 10.1182/blood.V92.6.2064.418k07_2064_2074; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; Jiang Y, 2000, BIOCHEM PHARMACOL, V59, P763, DOI 10.1016/S0006-2952(99)00395-0; Jones DR, 1999, J BIOL CHEM, V274, P16846, DOI 10.1074/jbc.274.24.16846; KHAN WA, 1994, J BIOL CHEM, V269, P9729; KOSHKIN V, 1993, FEBS LETT, V327, P57, DOI 10.1016/0014-5793(93)81039-3; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LETO TL, 1991, J BIOL CHEM, V266, P19812; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Lopes LR, 1999, J BIOL CHEM, V274, P15533, DOI 10.1074/jbc.274.22.15533; LUTTER R, 1985, J BIOL CHEM, V260, P2237; MASSEY V, 1959, BIOCHIM BIOPHYS ACTA, V34, P255, DOI 10.1016/0006-3002(59)90259-8; MCPHAIL LC, 1993, EUR J HAEMATOL, V51, P294; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; McPhail LC, 1999, BBA-MOL CELL BIOL L, V1439, P277, DOI 10.1016/S1388-1981(99)00100-6; MCPHAIL LC, 1983, J CLIN INVEST, V72, P192, DOI 10.1172/JCI110957; MCPHAIL LC, 1995, P NATL ACAD SCI USA, V92, P7931, DOI 10.1073/pnas.92.17.7931; METCALF JA, 1986, LABORATORY MANUAL NE, P126; MORRICE NA, 1994, J BIOL CHEM, V269, P20040; NASMITH P, 1989, BIOCHEM BIOPH RES CO, V161, P95, DOI 10.1016/0006-291X(89)91565-9; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Park HS, 1998, BBA-PROTEIN STRUCT M, V1387, P406, DOI 10.1016/S0167-4838(98)00152-6; PARK JW, 1992, J BIOL CHEM, V267, P19901; PARKOS CA, 1987, J CLIN INVEST, V80, P732, DOI 10.1172/JCI113128; QUALLIOTINEMANN D, 1993, J BIOL CHEM, V268, P23843; Regier DS, 2000, J BIOL CHEM, V275, P28406, DOI 10.1074/jbc.M004703200; Regier DS, 1999, J BIOL CHEM, V274, P36601, DOI 10.1074/jbc.274.51.36601; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Sanders KA, 1999, CHEST, V116, p56S, DOI 10.1378/chest.116.suppl_1.56S; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; Sergeant S, 1997, J IMMUNOL, V159, P2877; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Swain SD, 1997, J BIOL CHEM, V272, P29502, DOI 10.1074/jbc.272.47.29502; Topham MK, 1999, J BIOL CHEM, V274, P11447, DOI 10.1074/jbc.274.17.11447; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van Blitterswijk WJ, 1999, CHEM PHYS LIPIDS, V98, P95, DOI 10.1016/S0009-3084(99)00022-5; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569	63	92	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3090	3097		10.1074/jbc.M007759200	http://dx.doi.org/10.1074/jbc.M007759200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11060300	hybrid			2022-12-25	WOS:000166784900017
J	Zeng, XY; Lee, HJ; Zhang, QH; Lui, H				Zeng, XY; Lee, HJ; Zhang, QH; Lui, H			p300 does not require its acetylase activity to stimulate p73 function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; DNA-DAMAGE; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; P53 PROTEIN; SAM DOMAIN; MDM2; CBP; TRANSCRIPTION; DEGRADATION	We previously reported that p73, like p53, utilizes p300 or cAMP-response element-binding protein-binding protein as its coactivator. Here, we extended this work by further examining whether the intrinsic acetylase activity of p300 is necessary for stimulating p73 function. Although p300 acetylated the C-terminal fragment of p73 (amino acids 311-636) in vitro, it was unable to efficiently acetylate the full-length p73. Consistently, p300 did not acetylate p73 in vivo when both the proteins were overexpressed in cells. Also, an acetylase-defective mutant p300 named p300AT2 was able to elevate p73-dependent transcription in cells. p300 associated with p73 when forming DNA-protein complexes and stabilized p73 proteins. These results demonstrate that p300 does not need its acetylase activity to be a coactivator of p73.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University	Lui, H (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							Agami R, 1999, NATURE, V399, P809; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Balint E, 1999, ONCOGENE, V18, P3923, DOI 10.1038/sj.onc.1202781; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; Chi SW, 1999, EMBO J, V18, P4438, DOI 10.1093/emboj/18.16.4438; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gong JG, 1999, NATURE, V399, P806; Goodman RH, 2000, GENE DEV, V14, P1553; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HARLOW E, 1988, ANTIBODIES LAB MANUA, P519; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Kraus WL, 1999, MOL CELL BIOL, V19, P8123; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Liu WG, 2000, INT J ONCOL, V16, P181; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Ng SW, 2000, ONCOGENE, V19, P1885, DOI 10.1038/sj.onc.1203512; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Peng CY, 2000, ANTICANCER RES, V20, P1487; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Shieh SY, 2000, GENE DEV, V14, P289; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; STEIN RW, 1990, J VIROL, V64, P4421, DOI 10.1128/JVI.64.9.4421-4427.1990; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang HW, 2000, INT J MOL MED, V5, P379; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yuan ZM, 1999, J BIOL CHEM, V274, P1883, DOI 10.1074/jbc.274.4.1883; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 2000, MOL CELL BIOL, V20, P1299, DOI 10.1128/MCB.20.4.1299-1310.2000; Zeng XY, 2000, CANCER RES, V60, P6184; Zeng XY, 1999, MOL CELL BIOL, V19, P3257; Zhu JH, 1998, CANCER RES, V58, P5061	51	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					48	52		10.1074/jbc.C000722200	http://dx.doi.org/10.1074/jbc.C000722200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11076933	hybrid			2022-12-25	WOS:000166280700008
J	Thomas, A; Giesler, T; White, E				Thomas, A; Giesler, T; White, E			p53 mediates Bcl-2 phosphorylation and apoptosis via activation of the Cdc42/JNK1 pathway	ONCOGENE			English	Article						Cdc42; p53; Bcl-2; JNK1; PAK1; apoptosis	SIGNAL-TRANSDUCTION PATHWAY; WISKOTT-ALDRICH SYNDROME; PROGRAMMED CELL-DEATH; TUMOR-SUPPRESSOR P53; E1B 19K PROTEIN; P53-DEPENDENT APOPTOSIS; ACTIN CYTOSKELETON; RHO-GTPASES; ION-CHANNEL; BAX GENE	A member of the small G protein family, cdc42, was isolated from a screen undertaken to identify p53-inducible genes during apoptosis in primary baby rat kidney (BRK) cells transformed with E1A and a temperature-sensitive mutant p53 using a PCR-based subtractive hybridization method. Cdc42 is a GTPase that belongs to the Rho/Rac subfamily of Ras-like GTPases, In response to external stimuli, Cdc42 is known to transduce signals to regulate the organization of the actin cytoskeleton, induce DNA synthesis in quiescent fibroblasts, and promote apoptosis in neuronal and immune cells. In this study, we have demonstrated that cdc42 mRNA and protein were up-regulated in the presence of wild-type p53 in BRK cells, followed by cytoplasmic to plasma membrane translocation of Cdc42, Overexpression of Cdc42 in the presence of a dominant-negative mutant p53 induced apoptosis rapidly, indicating that Cdc42 functions downstream of p53, Furthermore, stable expression of a dominant-negative mutant of Cdc42 partially inhibited p53-mediated apoptosis, The Bcl-2 family members Bcl-x(L), and the adenovirus protein E1B 19K, inhibited Cdc42-mediated apoptosis, whereas Bcl-2 did not. We provide evidence that PAK1 and JNK1 may play a role downstream of Cdc42 to transduce its apoptotic signal. Cdc42/PAK1 activates JNK1-induced phosphorylation of Bcl-2, thereby inactivating its function, and that a phosphorylation resistant mutant (Bcl-2S70,87A,T56,74A) gains the ability to inhibit Cdc42- and p53-mediated apoptosis, Thus, one mechanism by which p53 promotes apoptosis is through activation of Cdc42 and inactivation of Bcl-2.	Rutgers State Univ, Howard Hughes Med Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Ctr Adv Biotechnol & Med, Piscataway, NJ 08854 USA; Rutgers State Univ, Canc Inst New Jersey, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick	White, E (corresponding author), HHMI, CABM, 679 Hoes Lane,Room 140, Piscataway, NJ 08854 USA.		White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	NCI NIH HHS [CA60088] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060088] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aspenstrom P, 1996, CURR BIOL, V6, P70, DOI 10.1016/S0960-9822(02)00423-2; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Blagosklonny MV, 1996, CANCER RES, V56, P1851; BOIVIN D, 1995, AM J PHYSIOL-RENAL, V269, pF180, DOI 10.1152/ajprenal.1995.269.2.F180; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; CHIOU SK, 1994, MOL CELL BIOL, V14, P2556, DOI 10.1128/MCB.14.4.2556; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Chuang TH, 1997, MOL BIOL CELL, V8, P1687, DOI 10.1091/mbc.8.9.1687; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Deng XM, 2000, P NATL ACAD SCI USA, V97, P1578, DOI 10.1073/pnas.97.4.1578; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fuchs SY, 1998, ONCOGENE, V17, P1483, DOI 10.1038/sj.onc.1202184; Furukawa Y, 2000, J BIOL CHEM, V275, P21661, DOI 10.1074/jbc.M906893199; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Gulbins E, 1996, J BIOL CHEM, V271, P26389, DOI 10.1074/jbc.271.42.26389; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Han JH, 1996, GENE DEV, V10, P461, DOI 10.1101/gad.10.4.461; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KORSMEYER SJ, 1995, TRENDS GENET, V11, P101, DOI 10.1016/S0168-9525(00)89010-1; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; MAY WS, 1994, J BIOL CHEM, V269, P26865; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; MCGLADE CJ, 1989, VIROLOGY, V168, P119, DOI 10.1016/0042-6822(89)90410-8; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Muraoka M, 1996, ONCOGENE, V12, P1565; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Ruvolo PP, 1998, J BIOL CHEM, V273, P25436, DOI 10.1074/jbc.273.39.25436; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Sabbatini P, 1997, CELL GROWTH DIFFER, V8, P643; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; Tapon N, 1997, CURR OPIN CELL BIOL, V9, P86, DOI 10.1016/S0955-0674(97)80156-1; Thomas A, 1998, GENE DEV, V12, P1975, DOI 10.1101/gad.12.13.1975; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; WHITE E, 1992, MOL CELL BIOL, V12, P2570, DOI 10.1128/MCB.12.6.2570; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; YANG W, 1997, J BIOL CHEM, V222, P24819; Zhao RB, 2000, GENE DEV, V14, P981; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	67	91	94	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 2	2000	19	46					5259	5269		10.1038/sj.onc.1203895	http://dx.doi.org/10.1038/sj.onc.1203895			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077443				2022-12-25	WOS:000165059700007
J	Bourne, Y; Dannenberg, J; Pollmann, V; Marchot, P; Pongs, O				Bourne, Y; Dannenberg, J; Pollmann, V; Marchot, P; Pongs, O			Immunocytochemical localization and crystal structure of human frequenin (neuronal calcium sensor 1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEINS; MEMBRANE; CA2+; RECOVERIN; CHROMAFFIN; SECRETION; HOMOLOG; CLONING; SYSTEM; CELLS	Frequenin, a member of a large family of myristoyl-switch calcium-binding proteins, functions as a calcium-ion sensor to modulate synaptic activity and secretion. We show that human frequenin colocalizes with ARF1 GTPase in COS-7 cells and occurs in similar cellular compartments as the phosphatidylinositol-4-OH kinase PI4K beta, the mammalian homolog of the yeast kinase PIK1. In addition, the crystal structure of unmyristoylated, calcium-bound human frequenin has been determined and refined to 1.9 Angstrom resolution. The overall fold of frequenin resembles those of neurocalcin and the photoreceptor, recoverin, of the same family, with two pairs of calcium-binding EF hands and three bound calcium ions. Despite the similarities, however, frequenin displays significant structural differences. A large conformational shift of the C-terminal region creates a wide hydrophobic crevice at the surface of frequenin. This crevice, which is unique to frequenin and distinct from the myristoyl binding box of recoverin, may accommodate a yet unknown protein ligand.	CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Hamburg, Zentrum Mol Neurobiol, Inst Neurale Signalverarbeitung, D-20249 Hamburg, Germany; Univ Mediterranee, Inst Federat Rech Jean Roche, CNRS, UMR 6560, F-13916 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Hamburg; University Medical Center Hamburg-Eppendorf; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Bourne, Y (corresponding author), CNRS, UMR 6098, F-13402 Marseille 20, France.	yves@afmb.cnrs-mrs.fr	MARCHOT, Pascale/AAC-4752-2022; Bourne, Yves/AAC-4635-2022	MARCHOT, Pascale/0000-0003-0630-0541; Bourne, Yves/0000-0003-3850-0548				Ames JB, 2000, BIOCHEMISTRY-US, V39, P12149, DOI 10.1021/bi0012890; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHEN CK, 1995, J BIOL CHEM, V270, P18060, DOI 10.1074/jbc.270.30.18060; CHRISTOPHER JA, 1998, CTR MACROMOLECULAR D; DIZHOOR AM, 1994, NEURON, V12, P1345, DOI 10.1016/0896-6273(94)90449-9; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; HAUENSCHILD A, 1997, FREQUENIN UNTERSUCHU; Hendricks KB, 1999, NAT CELL BIOL, V1, P234, DOI 10.1038/12058; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LINDEMEIER J, 1995, THESIS FREIE U BERLI; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; McFerran BW, 1999, J BIOL CHEM, V274, P30258, DOI 10.1074/jbc.274.42.30258; McFerran BW, 1998, J BIOL CHEM, V273, P22768, DOI 10.1074/jbc.273.35.22768; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Olafsson P, 1997, MOL BRAIN RES, V44, P73, DOI 10.1016/S0169-328X(96)00188-X; OLAFSSON P, 1995, P NATL ACAD SCI USA, V92, P8001, DOI 10.1073/pnas.92.17.8001; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Polans A, 1996, TRENDS NEUROSCI, V19, P547, DOI 10.1016/S0166-2236(96)10059-X; PONGS O, 1993, NEURON, V11, P15, DOI 10.1016/0896-6273(93)90267-U; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; Roussel A, 1991, SILICON GRAPHICS GEO, P81; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; WONG K, 1994, J BIOL CHEM, V269, P28878; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y	35	154	157	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11949	11955		10.1074/jbc.M009373200	http://dx.doi.org/10.1074/jbc.M009373200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11092894	Green Published, hybrid			2022-12-25	WOS:000168081800069
J	Banci, L; Bertini, I; Ciofi-Baffoni, S; Huffman, DL; O'Halloran, TV				Banci, L; Bertini, I; Ciofi-Baffoni, S; Huffman, DL; O'Halloran, TV			Solution structure of the yeast copper transporter domain Ccc2a in the apo and Cu(I)-loaded states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILSON-DISEASE GENE; MENKES-DISEASE; ATX1 METALLOCHAPERONE; COUPLING-CONSTANTS; CANDIDATE GENE; BIOCHEMICAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; SUPEROXIDE-DISMUTASE; PROTEIN STRUCTURES; PRACTICAL ASPECTS	Ccc2 is an intracellular copper transporter in Saccharomyces cerevisiae and is a physiological target of the copper chaperone Atx1. Here we describe the solution structure of the first N-terminal MTCXXC metal-binding domain, Ccc2a, both in the presence and absence of Cu(I). For Cu(I)-Ccc2a, 1944 meaningful nuclear Overhauser effects were used to obtain a family of 35 structures with root mean square deviation to the average structure of 0.36 +/- 0.06 Angstrom for the backbone and 0.79 +/- 0.05 Angstrom for the heavy atoms. For apo Ccc2a, 1970 meaningful nuclear Overhauser effects have been used with 35 (3)J(HNH alpha) to obtain a family of 35 structures with root mean square deviation to the average structure of 0.38 +/- 0.06 Angstrom for the backbone and 0.82 +/- 0.07 Angstrom for the heavy atoms. The protein exhibits a beta alpha beta beta alpha beta, ferrodoxin-like fold similar to that of its target Atx1 and that of a human counterpart, the fourth metal-binding domain of the Menkes protein. The overall fold remains unchanged upon copper loading, but the copper-binding site itself becomes less disordered. The helical context of the copper-binding site, and the copper-induced conformational changes in Ccc2a differ from those in Atx1, Ccc2a presents a conserved acidic surface which complements the basic surface of Atx1 and a hydrophobic surface. These results open new mechanistic aspects of copper transporter domains with physiological copper donor and acceptor proteins.	Univ Florence, Magnet Resonance Ctr, I-50019 Florence, Italy; Univ Florence, Dept Chem, I-50019 Florence, Italy; Northwestern Univ, Dept Chem, Evanston, IL 60208 USA; Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	University of Florence; University of Florence; Northwestern University; Northwestern University	Bertini, I (corresponding author), Univ Florence, Magnet Resonance Ctr, Via L Sacconi 6,Sesto Fiorentino, I-50019 Florence, Italy.		Ciofi-Baffoni, Simone/AAH-9778-2021; O'Halloran, Thomas/ABE-6125-2021	O'Halloran, Thomas/0000-0001-8732-5059; Ciofi Baffoni, Simone/0000-0002-2376-3321; BANCI, LUCIA/0000-0003-0562-5774	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES007284] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054111] Funding Source: NIH RePORTER; NIEHS NIH HHS [5T32ES07284] Funding Source: Medline; NIGMS NIH HHS [R01 GM054111, GM 54111] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnesano F, 2001, BIOCHEMISTRY-US, V40, P1528, DOI 10.1021/bi0014711; Banci L, 1998, BIOCHEMISTRY-US, V37, P11780, DOI 10.1021/bi9803473; BAX A, 1985, J MAGN RESON, V63, P207, DOI 10.1016/0022-2364(85)90171-4; BORGIAS B, 1989, COMPLETE RELAXATION; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; CHELLY J, 1993, NAT GENET, V3, P14, DOI 10.1038/ng0193-14; ERIKSSON PO, 1993, J BIOMOL NMR, V3, P613; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; FU DD, 1995, YEAST, V11, P283, DOI 10.1002/yea.320110310; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Hung IH, 1997, J BIOL CHEM, V272, P21461, DOI 10.1074/jbc.272.34.21461; KAY LE, 1989, J MAGN RESON, V84, P72, DOI 10.1016/0022-2364(89)90006-1; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lamb AL, 1999, NAT STRUCT BIOL, V6, P724; Larin D, 1999, J BIOL CHEM, V274, P28497, DOI 10.1074/jbc.274.40.28497; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Lin SJ, 1997, J BIOL CHEM, V272, P9215; LUTSENKO S, 1997, J BIOL CHEM, V272, P14030; MACURA S, 1982, J MAGN RESON, V47, P351, DOI 10.1016/0022-2364(82)90128-7; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MERCER JFB, 1993, NAT GENET, V3, P20, DOI 10.1038/ng0193-20; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; PEARLMAN DA, 1997, AMBER VERSION 5 0; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Portnoy ME, 1999, J BIOL CHEM, V274, P15041, DOI 10.1074/jbc.274.21.15041; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Rosenzweig AC, 2000, CURR OPIN CHEM BIOL, V4, P140, DOI 10.1016/S1367-5931(99)00066-6; Rosenzweig AC, 1999, STRUCTURE, V7, P605, DOI 10.1016/S0969-2126(99)80082-3; SCHLEUCHER J, 1994, J BIOMOL NMR, V4, P301; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; Steele RA, 1997, BIOCHEMISTRY-US, V36, P6885, DOI 10.1021/bi9631632; TANZI RE, 1993, NAT GENET, V5, P344, DOI 10.1038/ng1293-344; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; WANG AC, 1995, J AM CHEM SOC, V117, P1810, DOI 10.1021/ja00111a021; WEISEMANN R, 1994, J BIOMOL NMR, V4, P231, DOI 10.1007/BF00175250; Wimmer R, 1999, J BIOL CHEM, V274, P22597, DOI 10.1074/jbc.274.32.22597; Yamaguchi Y, 1996, P NATL ACAD SCI USA, V93, P14030, DOI 10.1073/pnas.93.24.14030; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	46	114	117	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8415	8426		10.1074/jbc.M008389200	http://dx.doi.org/10.1074/jbc.M008389200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11083871	hybrid			2022-12-25	WOS:000167474900101
J	Laitinen, OH; Marttila, AT; Airenne, KJ; Kulik, T; Livnah, O; Bayer, EA; Wilchek, M; Kulomaa, MS				Laitinen, OH; Marttila, AT; Airenne, KJ; Kulik, T; Livnah, O; Bayer, EA; Wilchek, M; Kulomaa, MS			Biotin induces tetramerization of a recombinant monomeric avidin - A model for protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CHICKEN AVIDIN; HIGH-AFFINITY; EGG-WHITE; STREPTAVIDIN; COMPLEX; DIMERIZATION; TRYPTOPHAN; BINDING	Chicken avidin, a homotetramer that binds four molecules of biotin was converted to a monomeric form by successive mutations of interface residues to alanine, The major contribution to monomer formation was the mutation of two aspartic acid residues, which together account for ten hydrogen bonding interactions at the 1-4 interface, Mutation of these residues, together with the three hydrophobic residues at the 1-3 interface, led to stable monomer formation in the absence of biotin. Upon addition of biotin, the monomeric avidin reassociated to the tetramer, which exhibited properties similar to those of native avidin, with respect to biotin binding, thermostability, and protease resistance. To our knowledge, these unexpected results represent the first example of a small monovalent ligand that induces oligomerization of a monomeric protein. This study may suggest a biological role for low molecular weight ligands in inducing oligomerization and in maintaining the stability of multimeric protein assemblies.	Univ Jyvaskyla, Dept Biol & Environm Sci, FIN-40351 Jyvaskyla, Finland; Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Wolfson Ctr Appl Struct Biol, Inst Life Sci, Dept Biol Chem, IL-91904 Jerusalem, Israel	University of Jyvaskyla; Weizmann Institute of Science; Hebrew University of Jerusalem	Kulomaa, MS (corresponding author), Univ Jyvaskyla, Dept Biol & Environm Sci, POB 35 YAB, FIN-40351 Jyvaskyla, Finland.		Kulomaa, Markku S/C-9063-2014; Laitinen, Olli H/A-6618-2016	Laitinen, Olli H/0000-0002-3751-9952				Airenne KJ, 1997, PROTEIN EXPRES PURIF, V9, P100, DOI 10.1006/prep.1996.0660; AIRENNE KJ, 1994, GENE, V144, P75, DOI 10.1016/0378-1119(94)90206-2; Bayer EA, 1996, ELECTROPHORESIS, V17, P1319, DOI 10.1002/elps.1150170808; Beernink PT, 1996, P NATL ACAD SCI USA, V93, P5374, DOI 10.1073/pnas.93.11.5374; CHILKOTI A, 1995, P NATL ACAD SCI USA, V92, P1754, DOI 10.1073/pnas.92.5.1754; ELLISON D, 1995, PROTEIN SCI, V4, P1337, DOI 10.1002/pro.5560040709; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; Ho SN, 1996, NATURE, V382, P822, DOI 10.1038/382822a0; Klemm JD, 1998, ANNU REV IMMUNOL, V16, P569, DOI 10.1146/annurev.immunol.16.1.569; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; Marttila AT, 1998, FEBS LETT, V441, P313, DOI 10.1016/S0014-5793(98)01570-1; Marttila AT, 2000, FEBS LETT, V467, P31, DOI 10.1016/S0014-5793(00)01119-4; Morag E, 1996, BIOCHEM J, V316, P193, DOI 10.1042/bj3160193; O'Reilly D., 1994, BACULOVIRUS EXPRESSI, P130; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; PUGLIESE L, 1994, J MOL BIOL, V235, P42, DOI 10.1016/S0022-2836(05)80010-5; Rollins CT, 2000, P NATL ACAD SCI USA, V97, P7096, DOI 10.1073/pnas.100101997; SARKAR G, 1990, BIOTECHNIQUES, V8, P404	21	49	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8219	8224		10.1074/jbc.M007930200	http://dx.doi.org/10.1074/jbc.M007930200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11076945	hybrid			2022-12-25	WOS:000167474900076
J	Lejeune, F; Cavaloc, Y; Stevenin, J				Lejeune, F; Cavaloc, Y; Stevenin, J			Alternative splicing of intron 3 of the serine/arginine-rich protein 9G8 gene - Identification of flanking exonic splicing enhancers and involvement of 9G8 as a trans-acting factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SR PROTEINS; REGULATORY ELEMENTS; FACTORS ASF/SF2; IN-VIVO; SC35; EXPRESSION; DISTINCT; 5'-SPLICE-SITE; 3'-SPLICE-SITE	9G8 protein belongs to the conserved serine/arginine-rich (SR) protein family, whose members exhibit multiple functions in constitutive and alternative splicing. We have previously shown that 9G8 primary transcripts are subjected to alternative splicing by excision/retention of intron 3 and to a tissue specific modulation. Because both 5'- and 3'-splice sites of intron 3 appear to be suboptimal in vertebrates, we tested the 9G8 intron 3 as a novel model system of alternative splicing. By using an in vitro approach and a mutational analysis, we have identified two purine-rich exonic splicing enhancers (ESE) located in exon 4 and a (GAA)(3) enhancer located in exon 3. These elements act in concert to promote efficient splicing activation both in vitro and in vivo. Titration experiments with an excess of exonic enhancers or SR-specific RNA targets strongly suggest that SR proteins are specifically involved in the activation process. Although ASF/SF2 was expected to interact the most efficiently with ESE according to the enhancer sequences, UV cross-linking coupled or not to immunopurification demonstrates that 9G8 is highly recruited by the three ESE, followed by SC35. In contrast, ASF/SF2 only binds significantly to the (GAA)(3) motif. S100 complementation experiments with individual SR proteins demonstrate that only 9G8 is able to fully restore splicing of intron 3. These results, and the fact that the exon 3 and 4 ESE sequences are conserved in vertebrates, strongly suggest that the alternative splicing of intron 3 represents an important step in the regulation of the expression of 9G8.	Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, CU Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Stevenin, J (corresponding author), Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, 1 Rue Laurent Fries,BP 163, F-67404 Illkirch, CU Strasbourg, France.		Lejeune, Fabrice/P-9843-2019; Lejeune, Fabrice/N-3886-2017	Lejeune, Fabrice/0000-0002-5132-3585; CAVALOC, Yvon/0000-0002-2837-8801				Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; Bourgeois CF, 1999, MOL CELL BIOL, V19, P7347; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Cavaloc Y, 1999, RNA, V5, P468, DOI 10.1017/S1355838299981967; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Cramer P, 1999, MOL CELL, V4, P251, DOI 10.1016/S1097-2765(00)80372-X; CULLEN BR, 1991, TRENDS BIOCHEM SCI, V16, P346, DOI 10.1016/0968-0004(91)90141-H; DelGatto F, 1996, NUCLEIC ACIDS RES, V24, P2017, DOI 10.1093/nar/24.11.2017; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dirksen WP, 2000, J BIOL CHEM, V275, P29170, DOI 10.1074/jbc.M001126200; Dye DT, 1998, RNA, V4, P1523, DOI 10.1017/S1355838298980360; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; FU XD, 1995, RNA, V1, P663; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; Graveley BR, 1998, EMBO J, V17, P6747, DOI 10.1093/emboj/17.22.6747; Heinrichs V, 1998, MOL CELL BIOL, V18, P450, DOI 10.1128/MCB.18.1.450; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Jumaa H, 1997, MOL CELL BIOL, V17, P3116, DOI 10.1128/MCB.17.6.3116; Jumaa H, 1997, EMBO J, V16, P5077, DOI 10.1093/emboj/16.16.5077; Kan JLC, 1999, GENE DEV, V13, P462, DOI 10.1101/gad.13.4.462; Kanopka A, 1996, NATURE, V381, P535, DOI 10.1038/381535a0; Konig H, 1998, EMBO J, V17, P2904, DOI 10.1093/emboj/17.10.2904; Liu HX, 2000, MOL CELL BIOL, V20, P1063, DOI 10.1128/MCB.20.3.1063-1071.2000; Liu HX, 1998, GENE DEV, V12, P1998, DOI 10.1101/gad.12.13.1998; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Lynch KW, 1996, GENE DEV, V10, P2089, DOI 10.1101/gad.10.16.2089; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; McKeown M, 1992, CURR OPIN GENET DEV, V2, P299, DOI 10.1016/S0959-437X(05)80288-6; NEEL H, 1995, CURR BIOL, V5, P413, DOI 10.1016/S0960-9822(95)00082-0; Pagani F, 2000, J BIOL CHEM, V275, P21041, DOI 10.1074/jbc.M910165199; POPIELARZ M, 1995, J BIOL CHEM, V270, P17830, DOI 10.1074/jbc.270.30.17830; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; Schaal TD, 1999, MOL CELL BIOL, V19, P1705; Schaal TD, 1999, MOL CELL BIOL, V19, P261; SCHMITT P, 1987, CELL, V50, P31, DOI 10.1016/0092-8674(87)90659-3; SCREATON GR, 1995, EMBO J, V14, P4336, DOI 10.1002/j.1460-2075.1995.tb00108.x; Selvakumar M, 1999, RNA, V5, P378, DOI 10.1017/S1355838299981050; SIEBEL CW, 1995, GENE DEV, V9, P269, DOI 10.1101/gad.9.3.269; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; TACKE R, 1995, EMBO J, V14, P3540, DOI 10.1002/j.1460-2075.1995.tb07360.x; Tacke R, 1997, P NATL ACAD SCI USA, V94, P1148, DOI 10.1073/pnas.94.4.1148; TANAKA K, 1994, MOL CELL BIOL, V14, P1347, DOI 10.1128/MCB.14.2.1347; Valcarcel J, 1996, TRENDS BIOCHEM SCI, V21, P296, DOI 10.1016/0968-0004(96)10039-6; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; WANG J, 1995, RNA, V1, P335; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; XU RS, 1993, MOL CELL BIOL, V13, P3660, DOI 10.1128/MCB.13.6.3660; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799	53	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					7850	7858		10.1074/jbc.M009510200	http://dx.doi.org/10.1074/jbc.M009510200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11096110	hybrid			2022-12-25	WOS:000167474900026
J	Sekiguchi, T; Hirose, E; Nakashima, N; Ii, M; Nishimoto, T				Sekiguchi, T; Hirose, E; Nakashima, N; Ii, M; Nishimoto, T			Novel G proteins, Rag C and Rag D, interact with GTP-binding proteins, Rag A and Rag B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							XENOPUS EGG EXTRACTS; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; ACTIVATING PROTEIN; MICROTUBULE ASTERS; NUCLEAR-STRUCTURE; BOUND RAN; RCC1; HOMOLOG; CYCLE	Rag A/Gtr1p are G proteins and are known to be involved in the RCC1-Ran pathway. We employed the two-hybrid method using Rag A as the bait to identify proteins binding to Rag A, and we isolated two novel human G proteins, Rag C and Rag D. Rag C demonstrates homology with Rag D (81.1% identity) and with Gtr2p of Saccharomyces cerevisiae (46.1% identity), and it-belongs to the Rag A subfamily of the Ras family. Rag C and Rag D contain conserved GTP-binding motifs (PM-1, -2, and -3) in their N-terminal regions. Recombinant glutathione S-transferase fusion protein of Rag C:efficiently bound to both [H-3]GTP and [3H]GDP. Rag A was associated with both Rag C and Rag D in their C-terminal regions where a potential leucine zipper motif and a coiled-coil structure were found. Rag C and D were associated with both the GDP and GTP forms of Rag A. Both Rag C and Rag D changed their subcellular localization, depending on the nucleotide-bound state of Rag A. In a similar way, the disruption of S. cerevisiae GTR1 resulted in a change in the localization of Gtr2p.	Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan	Kyushu University	Sekiguchi, T (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Nakashima, Nobutaka/G-3777-2016	Nakashima, Nobutaka/0000-0002-5836-9148				AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; Alber T, 1992, CURR OPIN GENET DEV, V2, P205, DOI 10.1016/S0959-437X(05)80275-8; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1994, P NATL ACAD SCI USA, V91, P2587, DOI 10.1073/pnas.91.7.2587; BISCHOFF FR, 1995, P NATL ACAD SCI USA, V92, P1749, DOI 10.1073/pnas.92.5.1749; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; BUN YM, 1992, MOL CELL BIOL, V12, P2958; Carazo-Salas RE, 1999, NATURE, V400, P178, DOI 10.1038/22133; DEBORAH J, 1998, J BIOL CHEM, V273, P20685; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Exton JH, 1998, J BIOL CHEM, V273, P19923, DOI 10.1074/jbc.273.32.19923; FEUERSTEIN J, 1987, EUR J BIOCHEM, V162, P49, DOI 10.1111/j.1432-1033.1987.tb10540.x; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; HAGAN IM, 1988, J CELL SCI, V89, P343; HARPER JW, 1993, CELL, V75, P805; HAYASHI N, 1995, MOL GEN GENET, V247, P661, DOI 10.1007/BF00290397; Hirose E, 1998, J CELL SCI, V111, P11; JOHN J, 1988, J BIOL CHEM, V263, P11792; Kalab P, 1999, CURR BIOL, V9, P481, DOI 10.1016/S0960-9822(99)80213-9; KORNBLUTH S, 1994, J CELL BIOL, V125, P705, DOI 10.1083/jcb.125.4.705; Li YG, 1997, J VIROL, V71, P1576, DOI 10.1128/JVI.71.2.1576-1582.1997; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; Moore MS, 1998, J BIOL CHEM, V273, P22857, DOI 10.1074/jbc.273.36.22857; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Mueller L, 1998, FEBS LETT, V427, P330, DOI 10.1016/S0014-5793(98)00459-1; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nakashima N, 1999, GENETICS, V152, P853; Nakashima N, 1996, J CELL SCI, V109, P2311; NEAL SE, 1988, J BIOL CHEM, V263, P19718; Nishimoto T, 1999, BIOCHEM BIOPH RES CO, V262, P571, DOI 10.1006/bbrc.1999.1252; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; Noguchi E, 1997, MOL CELL BIOL, V17, P2235, DOI 10.1128/MCB.17.4.2235; Ohba T, 1999, SCIENCE, V284, P1356, DOI 10.1126/science.284.5418.1356; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; Oki M, 1998, P NATL ACAD SCI USA, V95, P15388, DOI 10.1073/pnas.95.26.15388; REYNOLDS A, 1991, CURRENT PROTOCOLS MO; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; SCHURMANN A, 1995, J BIOL CHEM, V270, P28982, DOI 10.1074/jbc.270.48.28982; Seki T, 1996, J BIOCHEM, V120, P207; Sekiguchi T, 1999, ONCOGENE, V18, P1797, DOI 10.1038/sj.onc.1202508; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Shiomi T, 1998, J BIOCHEM-TOKYO, V123, P883; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Taura T, 1997, J BIOL CHEM, V272, P31877, DOI 10.1074/jbc.272.50.31877; VALENCIA A, 1991, BIOCHEMISTRY-US, V30, P4637, DOI 10.1021/bi00233a001; VOJTEK AB, 1995, METHOD ENZYMOL, V255, P331; Wilde A, 1999, SCIENCE, V284, P1359, DOI 10.1126/science.284.5418.1359; Wittinghofer A, 1998, BIOL CHEM, V379, P933; WU J, 1995, J BIOL CHEM, V270, P14209, DOI 10.1074/jbc.270.23.14209; YOKOYAMA N, 1995, NATURE, V376, P184, DOI 10.1038/376184a0; Yompakdee C, 1996, GENE, V171, P41, DOI 10.1016/0378-1119(96)00079-0; Zhang CM, 1999, J CELL SCI, V112, P2453	55	172	187	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7246	7257		10.1074/jbc.M004389200	http://dx.doi.org/10.1074/jbc.M004389200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11073942	hybrid			2022-12-25	WOS:000167442900055
J	Kinoshita, Y; Jarell, AD; Flaman, JM; Foltz, G; Schuster, J; Sopher, BL; Irvin, DK; Kanning, K; Kornblum, HI; Nelson, PS; Hieter, P; Morrison, RS				Kinoshita, Y; Jarell, AD; Flaman, JM; Foltz, G; Schuster, J; Sopher, BL; Irvin, DK; Kanning, K; Kornblum, HI; Nelson, PS; Hieter, P; Morrison, RS			Pescadillo, a novel cell cycle regulatory protein abnormally expressed in malignant cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; APOPTOSIS; PROGRESSION; GLIOMAS; PRODUCT; SUMO-1; GENES; GRADE; DEATH; MODEL	Using a culture model of glial tumorigenesis, we identified a novel gene that was up regulated in malignant mouse astrocytes following the loss of p53. The gene represents the murine homologue of pescadillo, an uncharacterized gene that is essential for embryonic development in zebrafish, Pescadillo is a strongly conserved gene containing unique structural motifs such as a BRCA1 C-terminal domain, clusters of acidic amino acids and consensus motifs for post translational modification by SUMO-1. Pescadillo displayed a distinct spatial and temporal pattern of gene expression during brain development, being detected in neural progenitor cells and postmitotic neurons. Although it is not expressed in differentiated astrocytes in, vivo, the pescadillo protein is dramatically elevated in malignant human astrocytomas, Yeast strains harboring temperature-sensitive mutations in the pescadillo gene were arrested in either G(1) or G(2) when grown in nonpermissive conditions, demonstrating that pescadillo is an essential gene in yeast and is required for cell cycle progression. Consistent with the latter finding, DNA synthesis was only observed in mammalian cells expressing the pescadillo protein. These results suggest that pescadillo plays a crucial role in cell proliferation and may be necessary for oncogenic transformation and tumor progression.	Univ Washington, Sch Med, Dept Neurol Surg, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Grad Program Neurobiol & Behav, Seattle, WA 98195 USA; Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada; Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, Dept Mol & Med Pharmacol & Pediat, Los Angeles, CA 90095 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of British Columbia; Fred Hutchinson Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Morrison, RS (corresponding author), Univ Washington, Sch Med, Dept Neurol Surg, Box 356470, Seattle, WA 98195 USA.		Flaman, Jean-Michel/K-8415-2018	Flaman, Jean-Michel/0000-0003-3544-0199	NCI NIH HHS [CA75173] Funding Source: Medline; NINDS NIH HHS [NS35533] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA075173] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035533] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allende ML, 1996, GENE DEV, V10, P3141, DOI 10.1101/gad.10.24.3141; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; BOBOLA MS, 1995, MOL CARCINOGEN, V13, P70, DOI 10.1002/mc.2940130203; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; CHICOINE MR, 1995, CANCER, V75, P2904, DOI 10.1002/1097-0142(19950615)75:12<2904::AID-CNCR2820751218>3.0.CO;2-2; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; Dunham I, 1999, NATURE, V402, P489, DOI 10.1038/990031; Epstein CB, 2000, CURR OPIN BIOTECH, V11, P36, DOI 10.1016/S0958-1669(99)00065-8; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GERRING SL, 1990, EMBO J, V9, P4347, DOI 10.1002/j.1460-2075.1990.tb07884.x; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Hsu YT, 1997, P NATL ACAD SCI USA, V94, P3668, DOI 10.1073/pnas.94.8.3668; Ino Y, 1999, J NEUROPATH EXP NEUR, V58, P881, DOI 10.1097/00005072-199908000-00010; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Johnson MD, 1999, J NEUROSCI, V19, P2996; Johnson PR, 1997, TRENDS CELL BIOL, V7, P408, DOI 10.1016/S0962-8924(97)01132-X; Khan J, 1999, BBA-REV CANCER, V1423, pM17, DOI 10.1016/S0304-419X(99)00004-9; KORNBLUM HI, 1994, MOL BRAIN RES, V21, P107, DOI 10.1016/0169-328X(94)90383-2; LORENZ MC, 1995, GENE, V158, P113, DOI 10.1016/0378-1119(95)00144-U; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Nagane Motoo, 1997, Current Opinion in Oncology, V9, P215, DOI 10.1097/00001622-199709030-00001; Okura T, 1996, J IMMUNOL, V157, P4277; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RSHEED BK, 1999, CURR OPIN ONCOL, V11, P162; Shen ZY, 1996, GENOMICS, V37, P183, DOI 10.1006/geno.1996.0540; SIDRANSKY D, 1992, NATURE, V355, P846, DOI 10.1038/355846a0; WELCH WC, 1995, IN VITRO CELL DEV-AN, V31, P610; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAHANDA AM, 1995, MOL CELL BIOL, V15, P4249; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981	33	73	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6656	6665		10.1074/jbc.M008536200	http://dx.doi.org/10.1074/jbc.M008536200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11071894	hybrid			2022-12-25	WOS:000167261000077
J	Whetstine, JR; Matherly, LH				Whetstine, JR; Matherly, LH			The basal promoters for the human reduced folate carrier gene are regulated by a GC box and a cAMP-response element/AP-1-like element - Basis for tissue-specific gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHOTREXATE SENSITIVITY; STRUCTURAL ORGANIZATION; TRANSPORT-DEFICIENT; MULTIPLE PROMOTERS; FOLIC-ACID; TRANSCRIPTION; ACTIVATION; LEUKEMIA; SP1; MECHANISM	Our laboratory previously identified two functional promoters (designated A and B) for the human reduced folate carrier (hRFC) gene that result in hRFC transcripts with differing 5'-untranslated regions. By transiently transfecting HT1080 and HepG2 cells with a series of 5' and 3' deletions in the hRFC-B and -A promoters, the minimal promoters were localized within 46 and 47 base pairs, respectively. Gel mobility shift assays with the hRFC-B basal promoter region revealed specific DNA-protein complexes involving a highly conserved GC-box and Sp1 or Sp3. In Drosophila SL2 cells, both Sp1 and the long Sp3 isoform potently transactivated the hRFC-B basal promoter; however, the short Sp3 isoforms were transcriptionally inert and resulted in a potent inhibition of Sp1 transactivation. For the hRFC-A basal promoter, a CRE/AP-1-like element was bound by the bZip superfamily of DNA-binding proteins. Cell-specific DNA-protein complexes were identified for hRFC-A (CREB-1 and c-Jun in HT1080 cells; CREB-1 and ATF-1 in HepG2 cells). When the GC-box and CRE/AP-1-like elements were mutated, a 60-90% decrease in promoter activity was observed in both cell lines. These results identify the critical regulatory regions for the hRFC basal promoters and stress the functional importance of the Sp and bZip families of transcription factors in regulating hRFC expression.	Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Wayne State University	Matherly, LH (corresponding author), Wayne State Univ, Sch Med, Barbara Ann Karmanos Canc Inst, Expt & Clin Therapeut Program, 110 E Warren Ave, Detroit, MI 48201 USA.	matherly@kci.wayne.edu			NCI NIH HHS [CA53535] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBANES D, 1994, NUTR CANC, V22, P101; AUSUBLE FM, 1998, CURRENT PROTOCOLS MO, V12; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; Brigle KE, 1997, BBA-GENE STRUCT EXPR, V1353, P191, DOI 10.1016/S0167-4781(97)00082-1; Butterworth CE, 1996, ANNU REV NUTR, V16, P73, DOI [10.1146/annurev.nutr.16.1.73, 10.1146/annurev.nu.16.070196.000445]; Chen SJ, 1998, GENE, V215, P101, DOI 10.1016/S0378-1119(98)00268-6; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIXON KH, 1994, J BIOL CHEM, V269, P17; GOLDMAN ID, 1985, PHARMACOL THERAPEUT, V28, P77, DOI 10.1016/0163-7258(85)90083-X; Gong MK, 1999, GENE, V233, P21, DOI 10.1016/S0378-1119(99)00166-3; Gong MK, 1997, BLOOD, V89, P2494, DOI 10.1182/blood.V89.7.2494; Gorlick R, 1997, BLOOD, V89, P1013, DOI 10.1182/blood.V89.3.1013; Guo W, 1999, CLIN CANCER RES, V5, P621; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Horie N, 1997, J BIOL CHEM, V272, P18375, DOI 10.1074/jbc.272.29.18375; Ihn H, 1997, NUCLEIC ACIDS RES, V25, P3712, DOI 10.1093/nar/25.18.3712; Jansen G, 1998, J BIOL CHEM, V273, P30189, DOI 10.1074/jbc.273.46.30189; Jansen G, 1999, ANTIFOLATE DRUGS CAN, P293; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kim YI, 1999, J NUTR BIOCHEM, V10, P66, DOI 10.1016/S0955-2863(98)00074-6; Kumar CK, 1997, J BIOL CHEM, V272, P6226, DOI 10.1074/jbc.272.10.6226; Li N, 1998, J BIOL CHEM, V273, P16104, DOI 10.1074/jbc.273.26.16104; Mason J B, 1996, Oncology (Williston Park), V10, P1727; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOSCOW JA, 1995, CANCER RES, V55, P3790; Murray RC, 1996, J BIOL CHEM, V271, P19174, DOI 10.1074/jbc.271.32.19174; Nguyen TT, 1997, GASTROENTEROLOGY, V112, P783, DOI 10.1053/gast.1997.v112.pm9041240; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; Sadlish H, 2000, BIOCHEM J, V346, P509, DOI 10.1042/0264-6021:3460509; Said HM, 1997, AM J PHYSIOL-CELL PH, V272, pC729, DOI 10.1152/ajpcell.1997.272.2.C729; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; SIROTNAK FM, 1981, CANCER RES, V41, P4447; Sirotnak FM, 1999, ANNU REV NUTR, V19, P91, DOI 10.1146/annurev.nutr.19.1.91; SIROTNAK FM, 1985, CANCER RES, V45, P3992; Stokstad ELR, 1990, FOLIC ACID METABOLIS, P1; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Tolner B, 1997, GENE, V189, P1, DOI 10.1016/S0378-1119(96)00676-2; Tolner B, 1998, GENE, V211, P331, DOI 10.1016/S0378-1119(98)00123-1; Tolner B, 1999, GENE, V231, P163, DOI 10.1016/S0378-1119(99)00078-5; Williams FMR, 1998, SOMAT CELL MOLEC GEN, V24, P143, DOI 10.1023/B:SCAM.0000007117.50428.63; WILLIAMS FMR, 1994, J BIOL CHEM, V269, P5810; WILLIAMS FMR, 1995, J BIOL CHEM, V270, P2987, DOI 10.1074/jbc.270.7.2987; Wong SC, 1997, BIOCHEM PHARMACOL, V53, P199, DOI 10.1016/S0006-2952(96)00710-1; WONG SC, 1995, J BIOL CHEM, V270, P17468, DOI 10.1074/jbc.270.29.17468; Zhang L, 1998, CLIN CANCER RES, V4, P2169; Zhang L, 1998, BIOCHEM J, V332, P773, DOI 10.1042/bj3320773; Zhang L, 1998, BBA-GENE STRUCT EXPR, V1442, P389, DOI 10.1016/S0167-4781(98)00168-7	52	38	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6350	6358		10.1074/jbc.M008074200	http://dx.doi.org/10.1074/jbc.M008074200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11078737	hybrid			2022-12-25	WOS:000167261000040
J	Fischer, TA; Palmetshofer, A; Gambaryan, S; Butt, E; Jassoy, C; Walter, U; Sopper, S; Lohmann, SM				Fischer, TA; Palmetshofer, A; Gambaryan, S; Butt, E; Jassoy, C; Walter, U; Sopper, S; Lohmann, SM			Activation of cGMP-dependent protein kinase I beta inhibits interleukin 2 release and proliferation of T cell receptor-stimulated human peripheral T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; INTACT HUMAN PLATELETS; NITRIC-OXIDE; CYCLIC-GMP; GENE-EXPRESSION; SIGNAL-TRANSDUCTION; MESANGIAL CELLS; DOWN-REGULATION; RAT; PHOSPHORYLATION	Several major functions of type I cGMP-dependent protein kinase (cGK I) have been established in smooth muscle cells, platelets, endothelial cells, and cardiac myocytes, Here we demonstrate that cGK I beta is endogenously expressed in freshly purified human peripheral blood T lymphocytes and inhibits their proliferation and interleukin 2 release. Incubation of human T cells with the NO donor, sodium nitroprusside, or the mem brane-permeant cGMP analogs PET-cGMP and 8-pCPT-cGMP, activated cGK I and produced (i) a distinct pattern of phosphorylation of vasodilator-stimulated phosphoprotein, (ii) stimulation of the mitogen-activated protein kinases ERK1/2 and p38 kinase, and, upon anti-CD3 stimulation, (iii) inhibition of interleukin 2 release and (iv) inhibition of cell proliferation. cGK I was lost during in vitro culturing of primary T cells and was not detectable in transformed T cell lines. The proliferation of these cGK I-deficient cells was not inhibited by even high cGMP concentrations indicating that cGK I, but not cGMP-regulated phosphodiesterases or channels, cAMP-dependent protein kinase, or other potential cGMP mediators, was responsible for inhibition of T cell proliferation, Consistent with this, overexpression of cGK I beta, but not an inactive cGK I beta mutant, restored cGMP-dependent inhibition of cell proliferation of Jurkat cells, Thus, the NO/cGMP/cGK signaling system is a negative regulator of T cell activation and proliferation and of potential significance for counteracting inflammatory or lymphoproliferative processes.	Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, D-97080 Wurzburg, Germany; Univ Wurzburg, Med Klin, Inst Virol & Immunobiol, D-97080 Wurzburg, Germany; Univ Mainz, Dept Med 2, D-55101 Mainz, Germany	University of Wurzburg; University of Wurzburg; Johannes Gutenberg University of Mainz	Palmetshofer, A (corresponding author), Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, Josef Schneider Str 2, D-97080 Wurzburg, Germany.		Sopper, Sieghart/I-3155-2018; Walter, ulrich/W-2478-2017; Gambaryan, Stepan/I-3940-2016	Sopper, Sieghart/0000-0003-2265-1974; Walter, ulrich/0000-0001-6784-2307; Gambaryan, Stepan/0000-0002-1470-0791				Bachmann C, 1999, J BIOL CHEM, V274, P23549, DOI 10.1074/jbc.274.33.23549; Bauer H, 1997, IMMUNOLOGY, V90, P205, DOI 10.1046/j.1365-2567.1997.00161.x; Berg NN, 1998, J IMMUNOL, V161, P2919; Bingisser RM, 1998, J IMMUNOL, V160, P5729; Boonen GJJC, 1999, EUR J IMMUNOL, V29, P789; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; Burkhardt M, 2000, J BIOL CHEM, V275, P33536, DOI 10.1074/jbc.M005670200; BUTT E, 1994, J BIOL CHEM, V269, P14509; Calderone A, 1998, J CLIN INVEST, V101, P812, DOI 10.1172/JCI119883; Callsen D, 1999, BIOCHEMISTRY-US, V38, P2279, DOI 10.1021/bi982292a; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chau LA, 1998, J EXP MED, V187, P1699, DOI 10.1084/jem.187.10.1699; Chen LH, 1998, CIRC RES, V82, P862; Cicala C, 2000, BRIT J PHARMACOL, V130, P1399, DOI 10.1038/sj.bjp.0703449; Cordelier P, 1997, P NATL ACAD SCI USA, V94, P9343, DOI 10.1073/pnas.94.17.9343; CORNWELL TL, 1994, AM J PHYSIOL, V267, P1; DONG YJ, 1995, EMBO J, V14, P2700, DOI 10.1002/j.1460-2075.1995.tb07270.x; DRAIJER R, 1995, CIRC RES, V77, P897, DOI 10.1161/01.RES.77.5.897; Eder AM, 1998, J BIOL CHEM, V273, P28025, DOI 10.1074/jbc.273.43.28025; EIGENTHALER M, 1993, J BIOL CHEM, V268, P13526; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; Exley M, 1997, MOL IMMUNOL, V34, P221, DOI 10.1016/S0161-5890(97)00027-8; Galle J, 1999, BRIT J PHARMACOL, V127, P195, DOI 10.1038/sj.bjp.0702495; Gambaryan S, 1996, J CLIN INVEST, V98, P662, DOI 10.1172/JCI118837; HEINKELEIN M, 1995, J VIROL, V69, P6925, DOI 10.1128/JVI.69.11.6925-6931.1995; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; JARCHAU T, 1994, P NATL ACAD SCI USA, V91, P9426, DOI 10.1073/pnas.91.20.9426; Kaga S, 1998, J IMMUNOL, V160, P24; Kaga S, 1998, J IMMUNOL, V160, P4182; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Lander HM, 1996, J BIOL CHEM, V271, P19705, DOI 10.1074/jbc.271.33.19705; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; LIEW FY, 1995, CURR OPIN IMMUNOL, V7, P396, DOI 10.1016/0952-7915(95)80116-2; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MAGRINAT G, 1992, BLOOD, V80, P1880; MARKERT T, 1995, J CLIN INVEST, V96, P822, DOI 10.1172/JCI118128; Massberg S, 1999, J EXP MED, V189, P1255, DOI 10.1084/jem.189.8.1255; MEINECKE M, 1994, MOL PHARMACOL, V46, P283; Parry RV, 1997, EUR J IMMUNOL, V27, P2495, DOI 10.1002/eji.1830271006; Pfeifer A, 1999, Rev Physiol Biochem Pharmacol, V135, P105, DOI 10.1007/BFb0033671; POHLER D, 1995, FEBS LETT, V374, P419, DOI 10.1016/0014-5793(95)01168-E; SANDBERG M, 1989, FEBS LETT, V255, P321, DOI 10.1016/0014-5793(89)81114-7; Schafer PH, 1999, J IMMUNOL, V162, P659; SEKHAR KR, 1992, MOL PHARMACOL, V42, P103; Sinnaeve P, 1999, CIRCULATION, V100, P107; Smolenski A, 2000, J BIOL CHEM, V275, P25723, DOI 10.1074/jbc.M909632199; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; Tamir A, 1996, J IMMUNOL, V157, P1514; UHLER MD, 1993, J BIOL CHEM, V268, P13586; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; WERNET W, 1989, FEBS LETT, V251, P191, DOI 10.1016/0014-5793(89)81453-X; Yu SM, 1997, CIRCULATION, V95, P1269; Zhang J, 1999, J IMMUNOL, V162, P3819	55	60	67	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5967	5974		10.1074/jbc.M009781200	http://dx.doi.org/10.1074/jbc.M009781200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11073964	hybrid			2022-12-25	WOS:000167115100075
J	Hashimoto, S; Tsubouchi, A; Mazaki, Y; Sabe, H				Hashimoto, S; Tsubouchi, A; Mazaki, Y; Sabe, H			Interaction of paxillin with p21-activated kinase (PAK) - Association of paxillin alpha with the kinase-inactive and the Cdc42-activated forms of PAK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FOCAL ADHESION; TYROSINE PHOSPHORYLATION; REGULATORY REGION; MOLECULAR-CLONING; ACTIN STRUCTURES; CELL-MIGRATION; SH3 DOMAIN; SERINE; FAMILY	p21-activated kinases (PAKs) are implicated in integrin signalings, and have been proposed to associate with paxillin indirectly. We show here that paxillin can bind directly to PAK3. We examined several representative focal adhesion proteins, and found that paxillin is the sole protein that associates with PAK3. PAK3 associated with the alpha and beta isoforms of paxillin, but not with gamma. We also show that paxillin alpha associated with both the kinase-inactive and the Cdc42-activated forms of PAKS in vivo, without affecting the activation states of the kinase. A number of different functions have been ascribed to PAKs; and PAKs can bind directly to growth factor signaling-adaptor molecule, Nck, and a guanine nucleotide exchanger, beta PIX. Our results revealed that paxillin a can compete with Nck and beta PIX in the binding of PAKS. Moreover, paxillin alpha can be phosphorylated by PAKS at serine. Therefore, paxillin alpha, but not gamma, appears to be capable of linking both the kinase-inactive and activated forms of PAK3 to integrins independent of Nck and beta PIX, as Nck links PAK1 to growth factor receptors. Our results also revealed that paxillin is involved in highly complexed protein-protein interactions in integrin signaling.	Osaka Biosci Inst, Dept Mol Biol, Suita, Osaka 5650874, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Sabe, H (corresponding author), Osaka Biosci Inst, Dept Mol Biol, 6-2-4 Furuedai, Suita, Osaka 5650874, Japan.	sabe@obi.or.jp	Sabe, Hisataka/GPF-4385-2022; Sabe, Hisataka/A-4066-2012	Mazaki, Yuichi/0000-0003-4192-0834				Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bagrodia S, 1998, J BIOL CHEM, V273, P23633, DOI 10.1074/jbc.273.37.23633; Bagrodia S, 1999, J BIOL CHEM, V274, P22393, DOI 10.1074/jbc.274.32.22393; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; Bokoch GM, 1996, J BIOL CHEM, V271, P25746, DOI 10.1074/jbc.271.42.25746; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Brown JL, 1996, CURR BIOL, V6, P598, DOI 10.1016/S0960-9822(02)00546-8; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Dharmawardhane S, 1997, J CELL BIOL, V138, P1265, DOI 10.1083/jcb.138.6.1265; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Frost JA, 1996, MOL CELL BIOL, V16, P3707, DOI 10.1128/mcb.16.7.3707; Galisteo ML, 1996, J BIOL CHEM, V271, P20997, DOI 10.1074/jbc.271.35.20997; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; Harden N, 1996, MOL CELL BIOL, V16, P1896; Hing H, 1999, CELL, V97, P853, DOI 10.1016/S0092-8674(00)80798-9; Ito A, 2000, EMBO J, V19, P562, DOI 10.1093/emboj/19.4.562; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; Jones SL, 1998, J BIOL CHEM, V273, P10556, DOI 10.1074/jbc.273.17.10556; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kondo A, 2000, MOL BIOL CELL, V11, P1315, DOI 10.1091/mbc.11.4.1315; Leberer E, 1997, CURR OPIN GENET DEV, V7, P59, DOI 10.1016/S0959-437X(97)80110-4; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; Manser E, 1999, Prog Mol Subcell Biol, V22, P115; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; MAYER BJ, 1995, CURR BIOL, V5, P296, DOI 10.1016/S0960-9822(95)00060-1; Mazaki Y, 1998, J BIOL CHEM, V273, P22435, DOI 10.1074/jbc.273.35.22435; Mazaki Y, 1997, J BIOL CHEM, V272, P7437, DOI 10.1074/jbc.272.11.7437; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; Price LS, 1998, MOL BIOL CELL, V9, P1863, DOI 10.1091/mbc.9.7.1863; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sanders LC, 1999, SCIENCE, V283, P2083, DOI 10.1126/science.283.5410.2083; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Sells MA, 1999, J CELL BIOL, V145, P837, DOI 10.1083/jcb.145.4.837; Tang Y, 1997, MOL CELL BIOL, V17, P4454, DOI 10.1128/MCB.17.8.4454; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Vitale N, 2000, J BIOL CHEM, V275, P13901, DOI 10.1074/jbc.275.18.13901; Yamaguchi R, 1997, ONCOGENE, V15, P1753, DOI 10.1038/sj.onc.1201345; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934; Zhao ZS, 2000, MOL CELL BIOL, V20, P3906, DOI 10.1128/MCB.20.11.3906-3917.2000; Zhao ZS, 1998, MOL CELL BIOL, V18, P2153, DOI 10.1128/MCB.18.4.2153	56	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					6037	6045		10.1074/jbc.M005854200	http://dx.doi.org/10.1074/jbc.M005854200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11096073	hybrid			2022-12-25	WOS:000167115100084
J	Kunzelmann-Marche, C; Freyssinet, JM; Martinez, MC				Kunzelmann-Marche, C; Freyssinet, JM; Martinez, MC			Regulation of phosphatidylserine transbilayer redistribution by store-operated Ca2+ entry - Role of actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPACITATIVE CALCIUM-ENTRY; PLATELET PLASMA-MEMBRANE; MICROPARTICLE FORMATION; PHOSPHOLIPID ASYMMETRY; SCOTT SYNDROME; AMINOPHOSPHOLIPID EXPOSURE; PROCOAGULANT ACTIVITY; MOLECULAR-CLONING; BLOOD-PLATELETS; LIPID ASYMMETRY	The phosphatidylserine transmembrane redistribution at the cell surface is one of the early characteristics of cells undergoing apoptosis and also occurs in cells fulfilling a more specialized function, such as the phosphatidylserine-dependent procoagulant response of platelets after appropriate activation. Although an increase in cytoplasmic Ca2+ is essential to trigger the remodeling of the plasma membrane, little is known about intracellular signals leading to phosphatidylserine externalization, Here, the role of store-operated Ca2+ entry on phosphatidylserine exposure was investigated in human erythroleukemia HEL cells, a pluripotent lineage with megakaryoblastic properties. Ca2+ entry inhibitors (SKF-96365, LaCl3, and miconazole) inhibited store-operated Ca2+ entry in A23187- or thapsigargin-stimulated cells and reduced the degree of phosphatidylserine externalization concomitantly, providing evidence for a close link between the two processes. In cells pretreated with cytochalasin D, an agent that disrupts the microfilament network of the cytoskeleton, store-operated Ca2+ entry and phosphatidylserine externalization at the cell surface were inhibited, In a context where most of the key actors remain to be identified, these results provide evidence for the implication of both store-operated Ca2+ entry and cytoskeleton architectural organization in the regulation of phosphatidylserine transbilayer migration.	Univ Strasbourg 1, Fac Med, Inst Hematol & Immunol, F-67085 Strasbourg, France; Hop Bicetre, INSERM, U143, F-94275 Le Kremlin Bicetre, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Martinez, MC (corresponding author), Univ Strasbourg 1, Fac Med, Inst Hematol & Immunol, 4 Rue Kirschleger, F-67085 Strasbourg, France.		Freyssinet, Jean-Marie/G-2719-2013					ANDREE HAM, 1990, J BIOL CHEM, V265, P4923; Aussel C, 1996, BIOCHEM J, V313, P909, DOI 10.1042/bj3130909; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BEVERS EM, 1992, BLOOD, V79, P380, DOI 10.1182/blood.V79.2.380.380; Catani L, 1998, HAEMATOLOGICA, V83, P385; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; COMFURIUS P, 1985, BIOCHIM BIOPHYS ACTA, V815, P143, DOI 10.1016/0005-2736(85)90485-7; CONNOR J, 1989, P NATL ACAD SCI USA, V86, P3184, DOI 10.1073/pnas.86.9.3184; DACHARYPRIGENT J, 1995, BIOCHEMISTRY-US, V34, P11625, DOI 10.1021/bi00036a039; DACHARYPRIGENT J, 1993, BLOOD, V81, P2554; DEVAUX PF, 1991, BIOCHEMISTRY-US, V30, P1163, DOI 10.1021/bi00219a001; DRESSLER V, 1984, BIOCHIM BIOPHYS ACTA, V775, P189, DOI 10.1016/0005-2736(84)90170-6; FADOK VA, 1992, J IMMUNOL, V148, P2207; Filipeanu CM, 2000, FEBS LETT, V474, P107, DOI 10.1016/S0014-5793(00)01585-4; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; FUJIMOTO T, 1991, J BIOL CHEM, V266, P16370; GAFFET P, 1995, EUR J CELL BIOL, V67, P336; Gidon-Jeangirard C, 1999, BIOCHEM BIOPH RES CO, V265, P709, DOI 10.1006/bbrc.1999.1752; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILTON KK, 1990, J BIOL CHEM, V265, P3809; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Hampton MB, 1996, FEBS LETT, V399, P277, DOI 10.1016/S0014-5793(96)01341-5; Heijnen HFG, 1999, BLOOD, V94, P3791, DOI 10.1182/blood.V94.11.3791.423a22_3791_3799; HELVOORT A, 1996, CELL, V87, P507; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; Jan CR, 1999, LIFE SCI, V65, P2513, DOI 10.1016/S0024-3205(99)00518-4; Jayadev S, 1999, J BIOL CHEM, V274, P8261, DOI 10.1074/jbc.274.12.8261; Jennings LK, 1996, BLOOD CELL MOL DIS, V22, P23, DOI 10.1006/bcmd.1996.0005; KOCH BD, 1994, BIOCHEM J, V302, P187, DOI 10.1042/bj3020187; Kunzelmann-Marche C, 2000, THROMB HAEMOSTASIS, V83, P282, DOI 10.1055/s-0037-1613800; Mack M, 2000, NAT MED, V6, P769, DOI 10.1038/77498; Martinez MC, 1999, BIOCHEMISTRY-US, V38, P10092, DOI 10.1021/bi990129p; Maximov AV, 1997, FEBS LETT, V412, P94, DOI 10.1016/S0014-5793(97)00754-0; MERRITT JE, 1990, BIOCHEM J, V271, P515, DOI 10.1042/bj2710515; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Pasquet JM, 1996, EUR J BIOCHEM, V239, P647, DOI 10.1111/j.1432-1033.1996.0647u.x; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PETERSHEIM M, 1989, BIOPHYS J, V55, P631, DOI 10.1016/S0006-3495(89)82860-7; Putney J W Jr, 1991, Adv Pharmacol, V22, P251, DOI 10.1016/S1054-3589(08)60037-X; Putney JW, 1999, CELL, V99, P5, DOI 10.1016/S0092-8674(00)80056-2; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Rosado JA, 2000, J PHYSIOL-LONDON, V526, P221, DOI 10.1111/j.1469-7793.2000.t01-2-00221.x; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; SAGE SO, 1990, BIOCHEM J, V265, P675, DOI 10.1042/bj2650675; SARGEANT P, 1994, PHARMACOL THERAPEUT, V64, P395, DOI 10.1016/0163-7258(94)90019-1; SATTA N, 1994, J IMMUNOL, V153, P3245; SCHWIEBERT EM, 1994, J BIOL CHEM, V269, P7081; Sergeeva M, 2000, NEUROSCIENCE, V97, P765, DOI 10.1016/S0306-4522(00)00062-2; Toti F, 1996, BLOOD, V87, P1409, DOI 10.1182/blood.V87.4.1409.bloodjournal8741409; VERHALLEN PFJ, 1987, BIOCHIM BIOPHYS ACTA, V903, P206, DOI 10.1016/0005-2736(87)90170-2; VITTET D, 1992, EXP HEMATOL, V20, P1129; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WEISS HJ, 1994, SEMIN HEMATOL, V31, P312; WILLIAMSON P, 1995, BIOCHEMISTRY-US, V34, P10448, DOI 10.1021/bi00033a017; YANO Y, 1994, BIOCHEM J, V299, P303, DOI 10.1042/bj2990303; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	60	75	77	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5134	5139		10.1074/jbc.M007924200	http://dx.doi.org/10.1074/jbc.M007924200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11076944	hybrid			2022-12-25	WOS:000168484300082
J	Li, L; Omata, W; Kojima, I; Shibata, H				Li, L; Omata, W; Kojima, I; Shibata, H			Direct interaction of Rab4 with syntaxin 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUT4 TRANSLOCATION; BINDING PROTEIN RAB4; 3T3-L1 ADIPOCYTES; RAT ADIPOCYTES; GLUCOSE-TRANSPORTER; INSULIN ACTION; MEMBRANE-FUSION; SUBCELLULAR-LOCALIZATION; NONNEURONAL TISSUES; PLASMA-MEMBRANE	In the present study, we examined the possible interaction between Rab4 and syntaxin 4, both having been implicated in insulin-induced GLUT4 translocation. Rab4 and syntaxin 4 were coimmunoprecipitated from the lysates of electrically permeabilized rat adipocytes. The interaction between the two proteins was reduced by insulin treatment and increased by the addition of guanosine 5'-O-(3-thiotriphosphate) (GTP gammaS). An in vitro binding assay revealed that the bacterially expressed Rabi was bound to a glutathione S-transferase fusion protein containing the cytoplasmic domain of syntaxin 4 (GST-syntaxin 4-(1-273)) but not to syntaxin 1A or vesicle-associated membrane protein-2. The interaction between Rab4 and syntaxin 4 seemed to be regulated by the guanine nucleotide status of Rab4, because 1) GTP gammaS treatment of the cells significantly increased, but guanosine 5'-O-(2-thiodiphosphate) (GDP betaS) treatment decreased the amount of Rab4 pulled down with GST-syntaxin 4-(1-273) from the cell lysates; 2) GTP gammaS loading on Rab4 caused a marked increase in the affinity of Rab4 to syntaxin 4 whereas GDP betaS loading had little effect; and 3) a GTPase-deficient mutant of Rab4 (Rab4(Q67L)), but not a GTP-binding-defective mutant (Rab4(S22N)), was bound to GST-syntaxin 4-(1-273). Although insulin stimulated [gamma-P-32]GTP binding to Rab4 in a time-dependent fashion, its effect on the Rab4 interaction with syntaxin 4 was apparently biphasic; an initial increase in Rab associated with syntaxin 4 was followed by a gradual dissociation of the GTPase from syntaxin 4. Finally, the binding of Rab4(Q67L) to GST-syntaxin 4-(1-273) was inhibited by munc-18c in a dose-dependent manner, indicating that GTP-loaded Rab4 binds to syntaxin 4 in the open conformation. These results suggest that 1) Rab4 interacts with syntaxin 4 in a direct and specific manner, and 2) the interaction is regulated by the guanine nucleotide status of Rab4 as well as by the conformational status of syntaxin 4.	Gunma Univ, Inst Mol & Cellular Regulat, Dept Cell Biol, Maebashi, Gumma 3718512, Japan	Gunma University	Shibata, H (corresponding author), Gunma Univ, Inst Mol & Cellular Regulat, Dept Cell Biol, 3-39-15 Showa Machi, Maebashi, Gumma 3718512, Japan.							Araki S, 1997, BIOCHEM BIOPH RES CO, V234, P257, DOI 10.1006/bbrc.1997.6560; BALDINI G, 1991, J BIOL CHEM, V266, P4037; Bortoluzzi MN, 1996, DIABETOLOGIA, V39, P899, DOI 10.1007/BF00403908; CAIN CC, 1992, J BIOL CHEM, V267, P11681; Charron MJ, 1999, J BIOL CHEM, V274, P3253, DOI 10.1074/jbc.274.6.3253; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; Cheatham B, 1996, P NATL ACAD SCI USA, V93, P15169, DOI 10.1073/pnas.93.26.15169; Cormont M, 1996, MOL CELL BIOL, V16, P6879; CORMONT M, 1993, J BIOL CHEM, V268, P19491; CZECH MP, 1993, J BIOL CHEM, V268, P9187; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Fasshauer D, 1999, J BIOL CHEM, V274, P15440, DOI 10.1074/jbc.274.22.15440; Gerez L, 2000, MOL BIOL CELL, V11, P2201, DOI 10.1091/mbc.11.7.2201; Gonzalez L, 1999, CELL, V96, P755, DOI 10.1016/S0092-8674(00)80585-1; Hashiramoto M, 2000, MOL CELL BIOL, V20, P416, DOI 10.1128/MCB.20.1.416-427.2000; Hay JC, 1997, CURR OPIN CELL BIOL, V9, P505, DOI 10.1016/S0955-0674(97)80026-9; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; JHUN BH, 1992, J BIOL CHEM, V267, P17710; Lupashin VV, 1997, SCIENCE, V276, P1255, DOI 10.1126/science.276.5316.1255; Macaulay SL, 1997, BIOCHEM J, V324, P217, DOI 10.1042/bj3240217; Macaulay SL, 1997, BIOCHEM BIOPH RES CO, V237, P388, DOI 10.1006/bbrc.1997.7143; Millar CA, 1999, MOL BIOL CELL, V10, P3675, DOI 10.1091/mbc.10.11.3675; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Misura KMS, 2000, NATURE, V404, P355, DOI 10.1038/35006120; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; Pelham HRB, 1999, EXP CELL RES, V247, P1, DOI 10.1006/excr.1998.4356; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; PEVSNER J, 1994, P NATL ACAD SCI USA, V91, P1445, DOI 10.1073/pnas.91.4.1445; Ravichandran V, 1996, J BIOL CHEM, V271, P13300, DOI 10.1074/jbc.271.23.13300; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RODBELL M, 1964, J BIOL CHEM, V239, P375; Schimmoller F, 1998, J BIOL CHEM, V273, P22161, DOI 10.1074/jbc.273.35.22161; Sherman LA, 1996, ENDOCRINOLOGY, V137, P266, DOI 10.1210/en.137.1.266; Shibata H, 1997, J BIOL CHEM, V272, P14542, DOI 10.1074/jbc.272.23.14542; SHIBATA H, 1995, J BIOL CHEM, V270, P11489, DOI 10.1074/jbc.270.19.11489; SHIBATA H, 1991, ARCH BIOCHEM BIOPHYS, V285, P97, DOI 10.1016/0003-9861(91)90333-E; Shibata H, 1996, J BIOL CHEM, V271, P9704, DOI 10.1074/jbc.271.16.9704; SHISHEVA A, 1994, J BIOL CHEM, V269, P23865; St-Denis Jean-Francois, 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P153; Tamori Y, 1998, J BIOL CHEM, V273, P19740, DOI 10.1074/jbc.273.31.19740; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; TELLAM JT, 1995, J BIOL CHEM, V270, P5857, DOI 10.1074/jbc.270.11.5857; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Timmers KI, 1996, BIOCHEM J, V320, P429, DOI 10.1042/bj3200429; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; Volchuk A, 1996, MOL BIOL CELL, V7, P1075, DOI 10.1091/mbc.7.7.1075; VOLCHUK A, 1995, J BIOL CHEM, V270, P8233, DOI 10.1074/jbc.270.14.8233; Vollenweider P, 1997, ENDOCRINOLOGY, V138, P4941, DOI 10.1210/en.138.11.4941; Wang GY, 1997, J CELL SCI, V110, P505; Yang B, 1999, J BIOL CHEM, V274, P5649, DOI 10.1074/jbc.274.9.5649; YANG J, 1993, J BIOL CHEM, V268, P4600; YANO Y, 1993, BIOCHIM BIOPHYS ACTA, V1176, P327, DOI 10.1016/0167-4889(93)90062-T	54	38	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5265	5273		10.1074/jbc.M003883200	http://dx.doi.org/10.1074/jbc.M003883200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11063739	hybrid			2022-12-25	WOS:000168484300098
J	Liu, XW; Gong, LJ; Guo, LY; Katagiri, Y; Jiang, H; Wang, ZY; Johnson, AC; Guroff, G				Liu, XW; Gong, LJ; Guo, LY; Katagiri, Y; Jiang, H; Wang, ZY; Johnson, AC; Guroff, G			The Wilms' tumor gene product WT1 mediates the down-regulation of the rat epidermal growth factor receptor by nerve growth factor in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA CELLS; DIFFERENTIATION; MUTANTS; RESPOND	Recently, we characterized the rat epidermal growth factor receptor (EGFR) promoter and demonstrated that TCC repeat sequences are required for the downregulation of EGFR by nerve growth factor (NGF) in PC12 cells. In this study, we report that the Wilms' tumor gene product WT1, a zinc finger transcription factor, is able to enhance the activity of the rat EGFR promoter in cotransfection assays. Gel mobility shift assays demonstrate that WT1 binds to the TCC repeat sequences of the rat EGFR promoter. Overexpression of WT1 resulted in up-regulation of the expression levels of endogenous EGFR in PC12 cells. Interestingly, NGF down-regulated the expression levels of WT1 and EGFR in PC12 cells, but not in the p140(trk)-deficient variant PC12nnr5 cells or in cells expressing either dominant-negative Ras or dominant-negative Src. Most importantly, we evaluated the inhibitory effect of antisense WT1 RNA on EGFR expression, and we found that antisense WT1 RNA could substantially reduce EGFR repression in either histochemical staining study or immunoblot analysis. These results indicate that NGF-induced down-regulation of the EGFR in PC12 cells is mediated through WT1 and that WT1 may play an important role in the differentiation of nerve cells.	NCI, Mol Biol Lab, Div Basic Sci, NIH, Bethesda, MD 20892 USA; NICHHD, Growth Factors Sect, NIH, Bethesda, MD 20892 USA; NICHHD, Dev & Mol Immun Lab, Bethesda, MD 20892 USA; Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Growth Regulat, Boston, MA 02215 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Johnson, AC (corresponding author), NCI, Mol Biol Lab, Div Basic Sci, NIH, Bldg 37,Rm 2D18, Bethesda, MD 20892 USA.							CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; English MA, 1999, J BIOL CHEM, V274, P13258, DOI 10.1074/jbc.274.19.13258; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GREEN SH, 1986, J CELL BIOL, V102, P830, DOI 10.1083/jcb.102.3.830; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Heckman C, 1997, J BIOL CHEM, V272, P19609, DOI 10.1074/jbc.272.31.19609; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; Katagiri Y, 1997, J BIOL CHEM, V272, P31278, DOI 10.1074/jbc.272.50.31278; KIKUCHI H, 1992, AM J PATHOL, V140, P781; Lazarovici P, 1997, J BIOL CHEM, V272, P11026, DOI 10.1074/jbc.272.17.11026; LAZAROVICI P, 1987, J CELL BIOL, V104, P1611, DOI 10.1083/jcb.104.6.1611; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; Liu XW, 2000, J BIOL CHEM, V275, P7280, DOI 10.1074/jbc.275.10.7280; Menke AL, 1998, INT REV CYTOL, V181, P151, DOI 10.1016/S0074-7696(08)60418-0; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; SEKIYA M, 1994, BLOOD, V83, P1876; Shibutani M, 1998, J BIOL CHEM, V273, P6878, DOI 10.1074/jbc.273.12.6878; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; TOGARI A, 1985, J NEUROSCI, V5, P307; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; WANG ZY, 1993, J BIOL CHEM, V268, P9172; Zhang K, 1996, J BIOL CHEM, V271, P3884	25	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5068	5073		10.1074/jbc.M008776200	http://dx.doi.org/10.1074/jbc.M008776200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11071895	hybrid			2022-12-25	WOS:000168484300073
J	Mathieu, MC; Lapierre, I; Brault, K; Raymond, M				Mathieu, MC; Lapierre, I; Brault, K; Raymond, M			Aromatic hydrocarbon receptor (AhR)center dot AhR nuclear translocator- and p53-mediated induction of the murine multidrug resistance mdr1 gene by 3-methylcholanthrene and benzo(a)pyrene in hepatoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLOBAL GENOMIC REPAIR; SMOOTH-MUSCLE CELLS; KINASE C-ABL; P-GLYCOPROTEIN; DNA-DAMAGE; RAT-LIVER; WILD-TYPE; REGULATORY ELEMENTS; APOPTOTIC RESPONSE	The mouse multidrug resistance gene family consists of three genes (mdr1, mdr2, and mdr3) encoding P-glycoprotein, We show that the expression of mdr1 is increased at the transcriptional level upon treatment of the hepatoma cell line Hepa-1c1c7 with the polycyclic aromatic hydrocarbon 3-methylcholanthrene (3-MC). This increase is not observed in the aromatic hydrocarbon receptor (AhR)-defective TAOc1BP(r)c1 and the AhR nuclear translocator (Arnt)-defective BP(r)c1 variants, demonstrating that the induction of mdr1 by 3-MC requires AhR.Arnt. We show that the mdr1 promoter (-1165 to +84) is able to activate the expression of a reporter gene in response to 3-MC in Hepa-1c1c7 but not in BP(r)c1 cells. Deletion analysis indicated that the region from -245 to -141 contains cis-acting sequences mediating the induction, including a potential p53 binding sequence, 3-MC treatment of the cells increased the levels of p53 and induced p53 binding to the mdr1 promoter in an AhR.Arnt-dependent manner. Mutations in the p53 binding site abrogated induction of mdr1 by 3-MC, indicating that p53 binding to the mdr1 promoter is essential for the induction. Benzo(a)pyrene, a polycyclic aromatic hydrocarbon and AhR ligand, which, like 3-MC, is oxidized by metabolizing enzymes regulated by AhR.Arnt, also activated p53 and induced mdr1 transcription. 2,3,7,8-Tetrachlorodibenzo-p-dioxin, an AhR ligand resistant to metabolic breakdown, had no effect. These results indicate that the transcriptional induction of mdr1 by 3-MC and benzo(a)pyrene is directly mediated by p53 but that the metabolic activation of these compounds into reactive species is necessary to trigger p53 activation. The ability of the anticancer drug and potent genotoxic agent daunorubicin to induce mdr1 independently of AhR.Arnt further supports the proposition that mdr1 is transcriptionally up-regulated by p53 in response to DNA damage.	Clin Res Inst Montreal, Montreal, PQ H2W 1R7, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Raymond, M (corresponding author), Clin Res Inst Montreal, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.							Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; BURT RK, 1988, J NATL CANCER I, V80, P1383, DOI 10.1093/jnci/80.17.1383; BUSCHMAN E, 1992, J BIOL CHEM, V267, P18093; CROOP JM, 1989, MOL CELL BIOL, V9, P1346, DOI 10.1128/MCB.9.3.1346; Deng L, 2001, J BIOL CHEM, V276, P413, DOI 10.1074/jbc.M004551200; DEVAULT A, 1990, MOL CELL BIOL, V10, P1652, DOI 10.1128/MCB.10.4.1652; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Fardel O, 1996, BIOCHEM PHARMACOL, V51, P1427, DOI 10.1016/0006-2952(96)00081-0; FernandezSalguero PM, 1996, TOXICOL APPL PHARM, V140, P173, DOI 10.1006/taap.1996.0210; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FISHER JM, 1989, MOL CARCINOGEN, V1, P216, DOI 10.1002/mc.2940010403; Flesher JW, 1998, BIOCHEM BIOPH RES CO, V243, P30, DOI 10.1006/bbrc.1997.8048; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GANT TW, 1991, MOL CARCINOGEN, V4, P499, DOI 10.1002/mc.2940040614; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gong JG, 1999, NATURE, V399, P806; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GROS P, 1986, CELL, V47, P371, DOI 10.1016/0092-8674(86)90594-5; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; ISRAEL DI, 1983, J BIOL CHEM, V258, P390; JONES PBC, 1985, SCIENCE, V227, P1499, DOI 10.1126/science.3856321; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kerzee JK, 2000, MOL PHARMACOL, V58, P152, DOI 10.1124/mol.58.1.152; KIMURA S, 1984, J BIOL CHEM, V259, P705; LAIN ND, 1999, ONCOGENE, V18, P7644; Lloyd DR, 2000, CANCER RES, V60, P517; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; MILLER AG, 1983, J BIOL CHEM, V258, P3523; NEBERT DW, 1993, ANN NY ACAD SCI, V685, P624, DOI 10.1111/j.1749-6632.1993.tb35928.x; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; Pei XH, 1999, J BIOL CHEM, V274, P35240, DOI 10.1074/jbc.274.49.35240; RAYMOND M, 1990, MOL CELL BIOL, V10, P1642, DOI 10.1128/MCB.10.4.1642; RAYMOND M, 1990, MOL CELL BIOL, V10, P6036, DOI 10.1128/MCB.10.11.6036; RUETZ S, 1994, J BIOL CHEM, V269, P12277; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Schmid G, 1999, BIOCHEM BIOPH RES CO, V255, P399, DOI 10.1006/bbrc.1999.0191; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P5419; Schuetz EG, 1998, ARCH BIOCHEM BIOPHYS, V350, P340, DOI 10.1006/abbi.1997.0537; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; STANSBURY KH, 1994, CHEM RES TOXICOL, V7, P254, DOI 10.1021/tx00038a019; TEETER LD, 1991, DNA CELL BIOL, V10, P433, DOI 10.1089/dna.1991.10.433; THIEBAUT F, 1987, P NATL ACAD SCI USA, V84, P7735, DOI 10.1073/pnas.84.21.7735; Vaziri C, 1997, J BIOL CHEM, V272, P2762, DOI 10.1074/jbc.272.5.2762; Venkatachalam S, 1997, ONCOGENE, V14, P801, DOI 10.1038/sj.onc.1200890; Wani MA, 2000, CANCER RES, V60, P2273; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Whitlock JP, 1996, FASEB J, V10, P809, DOI 10.1096/fasebj.10.8.8666157; WOOD AW, 1978, CANCER RES, V38, P3398; Yan ZP, 2000, J BIOL CHEM, V275, P4949, DOI 10.1074/jbc.275.7.4949; YU LJ, 1995, CELL GROWTH DIFFER, V6, P1505; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhou G, 1998, J BIOL CHEM, V273, P15387, DOI 10.1074/jbc.273.25.15387	63	64	64	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4819	4827		10.1074/jbc.M008495200	http://dx.doi.org/10.1074/jbc.M008495200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11096091	hybrid			2022-12-25	WOS:000168484300040
J	Ogura, Y; Inohara, N; Benito, A; Chen, FF; Yamaoka, S; Nunez, G				Ogura, Y; Inohara, N; Benito, A; Chen, FF; Yamaoka, S; Nunez, G			Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; KINASE; PROCASPASE-9; CASPASE-9; COMPLEX; RECRUITMENT; APOPTOSIS; PROTEIN; TOMATO; DOMAIN	Apaf-1 and Nod1 are members of a protein family, each of which contains a caspase recruitment domain (CARD) linked to a nucleotide-binding domain, which regulate apoptosis and/or NF-kappaB activation. Nod2, a third member of the family, was identified. Nod2 is composed of two N-terminal CARDs, a nucleotide-binding domain, and multiple C-terminal leucine-rich repeats. Although Nod1 and Apaf-1 were broadly expressed in tissues, the expression of Nod2 was highly restricted to monocytes, Nod2 induced nuclear factor kappaB (NF-kappaB) activation, which required IKK gamma and was inhibited by dominant negative mutants of I kappaB alpha, IKK alpha, IKK beta, and IKK gamma. Nod2 interacted with the serine-threonine kinase RICK via a hemophilic CARD-CARD interaction. Furthermore, NF-kappaB activity induced by Nod2 correlated with its ability to interact with RICK and was specifically inhibited by a truncated mutant form of RICK containing its CARD. The identification of Nod2 defines a subfamily of Apaf-1-like proteins that function through RICK to activate a NF-kappaB signaling pathway.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Tokyo Med & Dent Univ, Sch Med, Dept Microbiol, Bunkyo Ku, Tokyo 1138519, Japan	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Tokyo Medical & Dental University (TMDU)	Nunez, G (corresponding author), Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA.		Nuñez, Gabriel/A-7160-2014		NATIONAL CANCER INSTITUTE [R01CA064556] Funding Source: NIH RePORTER; NCI NIH HHS [CA-64556] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bertin J, 1999, J BIOL CHEM, V274, P12955, DOI 10.1074/jbc.274.19.12955; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Dixon MS, 2000, P NATL ACAD SCI USA, V97, P8807, DOI 10.1073/pnas.97.16.8807; Hofmann K, 1997, TRENDS BIOCHEM SCI, V22, P155, DOI 10.1016/S0968-0004(97)01043-8; Hu YM, 1998, J BIOL CHEM, V273, P33489, DOI 10.1074/jbc.273.50.33489; Hu YM, 1999, EMBO J, V18, P3586, DOI 10.1093/emboj/18.13.3586; Inohara N, 2000, J BIOL CHEM, V275, P27823; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 1998, J BIOL CHEM, V273, P12296, DOI 10.1074/jbc.273.20.12296; INOHARA N, 2000, IN PRESS J BIOL CHEM, V275; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KOBE B, 1995, CURR OPIN STRUC BIOL, V5, P409, DOI 10.1016/0959-440X(95)80105-7; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MacCorkle RA, 1998, P NATL ACAD SCI USA, V95, P3655, DOI 10.1073/pnas.95.7.3655; McCarthy JV, 1998, J BIOL CHEM, V273, P16968, DOI 10.1074/jbc.273.27.16968; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; Thome M, 1998, CURR BIOL, V8, P885, DOI 10.1016/S0960-9822(07)00352-1; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	20	1104	1167	0	42	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4812	4818		10.1074/jbc.M008072200	http://dx.doi.org/10.1074/jbc.M008072200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087742	hybrid			2022-12-25	WOS:000168484300039
J	Mikkola, I; Bruun, JA; Holm, T; Johansen, T				Mikkola, I; Bruun, JA; Holm, T; Johansen, T			Superactivation of Pax6-mediated transactivation from paired domain-binding sites by DNA-independent recruitment of different homeodomain proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; HOMEOBOX GENE; EYE DEVELOPMENT; TRANSCRIPTIONAL REPRESSOR; CRYSTAL-STRUCTURE; EVOLUTIONARY CONSERVATION; CONFORMATIONAL-CHANGES; FAMILY PROTEINS; CO-REPRESSORS; ECTOPIC EYES		Univ Tromso, Inst Med Biol, Dept Biochem, N-9037 Tromso, Norway	UiT The Arctic University of Tromso	Johansen, T (corresponding author), Univ Tromso, Inst Med Biol, Dept Biochem, POB 977, N-9037 Tromso, Norway.	terjej@fagmed.uit.no	Johansen, Terje/N-2971-2015; Johansen, Terje/AAY-1753-2021	Johansen, Terje/0000-0003-1451-9578; Johansen, Terje/0000-0003-1451-9578; Mikkola, Ingvild/0000-0001-6442-7626; Bruun, Jack-Ansgar/0000-0003-0614-2790				ACAMPORA D, 1989, NUCLEIC ACIDS RES, V17, P10385, DOI 10.1093/nar/17.24.10385; Aidinis V, 1999, MOL CELL BIOL, V19, P6532; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; BILLETER M, 1993, J MOL BIOL, V234, P1084, DOI 10.1006/jmbi.1993.1661; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; CARRIERE C, 1995, CELL GROWTH DIFFER, V6, P1531; CARRIERE C, 1993, MOL CELL BIOL, V13, P7257, DOI 10.1128/MCB.13.12.7257; Casarosa S, 1997, MECH DEVELOP, V61, P187, DOI 10.1016/S0925-4773(96)00640-5; CESKA TA, 1993, EMBO J, V12, P1805, DOI 10.1002/j.1460-2075.1993.tb05828.x; CHALEPAKIS G, 1994, DNA CELL BIOL, V13, P891, DOI 10.1089/dna.1994.13.891; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; Chen CY, 1996, MOL CELL BIOL, V16, P6372; Chow RL, 1999, DEVELOPMENT, V126, P4213; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Cvekl A, 1999, INVEST OPHTH VIS SCI, V40, P1343; Czerny T, 1999, MOL CELL, V3, P297, DOI 10.1016/S1097-2765(00)80457-8; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; Dattani MT, 1998, NAT GENET, V19, P125, DOI 10.1038/477; DiRocco G, 1997, EMBO J, V16, P3644, DOI 10.1093/emboj/16.12.3644; Duncan MK, 1998, MOL CELL BIOL, V18, P5579, DOI 10.1128/MCB.18.9.5579; Eberhard D, 1999, CANCER RES, V59, p1716S; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; EPSTEIN JA, 1994, GENE DEV, V8, P2022, DOI 10.1101/gad.8.17.2022; Fitzsimmons D, 1996, GENE DEV, V10, P2198, DOI 10.1101/gad.10.17.2198; Fortin AS, 1998, NUCLEIC ACIDS RES, V26, P4574, DOI 10.1093/nar/26.20.4574; Fortin AS, 1997, HUM MOL GENET, V6, P1781, DOI 10.1093/hmg/6.11.1781; Furukawa T, 1997, P NATL ACAD SCI USA, V94, P3088, DOI 10.1073/pnas.94.7.3088; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GLASER T, 1994, NAT GENET, V7, P463, DOI 10.1038/ng0894-463; Glenn DJ, 1999, J BIOL CHEM, V274, P36159, DOI 10.1074/jbc.274.51.36159; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HALDER G, 1995, SCIENCE, V267, P1788, DOI 10.1126/science.7892602; HANSON IM, 1994, NAT GENET, V6, P168, DOI 10.1038/ng0294-168; Hollenbach AD, 1999, EMBO J, V18, P3702, DOI 10.1093/emboj/18.13.3702; Jaworski C, 1997, BIOCHEM BIOPH RES CO, V240, P196, DOI 10.1006/bbrc.1997.7623; JOYNER AL, 1987, GENE DEV, V1, P29, DOI 10.1101/gad.1.1.29; Jun S, 1996, DEVELOPMENT, V122, P2639; Kawabe T, 1997, NATURE, V385, P454, DOI 10.1038/385454a0; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; Libermann TA, 1999, J BIOL CHEM, V274, P24671, DOI 10.1074/jbc.274.35.24671; LIU ISC, 1994, NEURON, V13, P377, DOI 10.1016/0896-6273(94)90354-9; MACDONALD R, 1994, NEURON, V13, P1039, DOI 10.1016/0896-6273(94)90044-2; Magnaghi P, 1998, NAT GENET, V20, P74, DOI 10.1038/1739; Maitra S, 2000, MOL CELL BIOL, V20, P1911, DOI 10.1128/MCB.20.6.1911-1922.2000; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Mathers PH, 1997, NATURE, V387, P603, DOI 10.1038/42475; Mikkola I, 1999, J BIOL CHEM, V274, P15115, DOI 10.1074/jbc.274.21.15115; MIKKOLA I, 1992, J NEUROBIOL, V23, P933, DOI 10.1002/neu.480230802; Nead MA, 1998, EMBO J, V17, P2342, DOI 10.1093/emboj/17.8.2342; NOLL M, 1993, CURR OPIN GENET DEV, V3, P595, DOI 10.1016/0959-437X(93)90095-7; Nornes S, 1998, MECH DEVELOP, V77, P185, DOI 10.1016/S0925-4773(98)00156-7; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Oliver G, 1995, DEVELOPMENT, V121, P4045; Plaza S, 1997, CELL GROWTH DIFFER, V8, P1115; Porter FD, 1997, DEVELOPMENT, V124, P2935; Rincon-Limas DE, 1999, P NATL ACAD SCI USA, V96, P2165, DOI 10.1073/pnas.96.5.2165; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Sanchez M, 1997, MOL CELL BIOL, V17, P5369, DOI 10.1128/MCB.17.9.5369; SCHMAHL W, 1993, ACTA NEUROPATHOL, V86, P126, DOI 10.1007/BF00334879; SETH A, 1992, J BIOL CHEM, V267, P24796; Simon KJ, 1997, MOL CELL BIOL, V17, P6653, DOI 10.1128/MCB.17.11.6653; Singh S, 2000, J BIOL CHEM, V275, P17306, DOI 10.1074/jbc.M000359200; STRACHAN T, 1994, CURR OPIN GENET DEV, V4, P427, DOI 10.1016/0959-437X(94)90032-9; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; UM M, 1995, MOL CELL BIOL, V15, P5007; UNDERHILL DA, 1995, P NATL ACAD SCI USA, V92, P3692, DOI 10.1073/pnas.92.9.3692; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; Wallin JJ, 1998, SCIENCE, V279, P1961, DOI 10.1126/science.279.5358.1961; Wang JM, 1999, MOL CELL BIOL, V19, P7106; Wiggan O, 1998, ONCOGENE, V16, P227, DOI 10.1038/sj.onc.1201534; WILSON D, 1993, GENE DEV, V7, P2120, DOI 10.1101/gad.7.11.2120; WILSON DS, 1995, CELL, V82, P709, DOI 10.1016/0092-8674(95)90468-9; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Yang XL, 2000, J BIOL CHEM, V275, P1065, DOI 10.1074/jbc.275.2.1065; Zappavigna V, 1996, EMBO J, V15, P4981, DOI 10.1002/j.1460-2075.1996.tb00878.x; ZHANG YH, 1995, NATURE, V377, P55, DOI 10.1038/377055a0; Zhu AH, 1996, J BIOL CHEM, V271, P20993, DOI 10.1074/jbc.271.35.20993; Zinovieva RD, 1996, GENOMICS, V35, P517, DOI 10.1006/geno.1996.0392	84	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4109	4118		10.1074/jbc.M008882200	http://dx.doi.org/10.1074/jbc.M008882200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11069920	hybrid			2022-12-25	WOS:000166921200052
J	Itoh, A; Howe, GA				Itoh, A; Howe, GA			Molecular cloning of a divinyl ether synthase - Identification as a CYP74 cytochrome P-450	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALLENE OXIDE SYNTHASE; ACID HYDROPEROXIDE LYASE; FATTY-ACIDS; LIPOXYGENASE PATHWAY; 13-HYDROPEROXIDE LYASE; ENZYMATIC CONVERSION; COLNELEIC ACID; LINOLEIC-ACID; TOMATO; BIOSYNTHESIS	Lipoxygenase-derived fatty acid hydroperoxides are metabolized by CYP74 cytochrome P-450s to various oxylipins that play important roles in plant growth and development. Here, we report the characterization of a Lycopersicon esculentum (tomato) cDNA whose predicted amino acid sequence defines a previously unidentified P-450 subfamily (CYP74D). The recombinant protein, expressed in Escherichia coli, displayed spectral properties of a P-450. The enzyme efficiently metabolized 9-hydroperoxy linoleic acid and 9-hydroperoxy linolenic acid but was poorly active against the corresponding 13-hydroperoxides. Incubation of recombinant CYP74D with 9-hydroperoxy linoleic acid and 9-hydroperoxy linolenic acid yielded divinyl ether fatty acids (colneleic acid and colnelenic acid, respectively), which have been implicated as plant anti-fungal toxins. This represents the first identification of a cDNA encoding a divinyl ether synthase and establishment of the enzyme as a CYP74 P-450. Genomic DNA blot analysis revealed the existence of a single divinyl ether synthase gene located on chromosome one of tomato. In tomato seedlings, root tissue was the major site of both divinyl ether synthase mRNA accumulation and enzyme activity. These results indicate that developmental expression of the divinyl ether synthase gene is an important determinant of the tissue specific synthesis of divinyl ether oxylipins.	Michigan State Univ, DOE Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; United States Department of Energy (DOE); Michigan State University	Howe, GA (corresponding author), Michigan State Univ, DOE Plant Res Lab, E Lansing, MI 48824 USA.	howeg@msu.edu	Howe, Gregg A/N-1887-2014	Howe, Gregg A/0000-0002-9218-979X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bate NJ, 1998, PLANT J, V16, P561, DOI 10.1046/j.1365-313x.1998.00324.x; Bergey DR, 1996, P NATL ACAD SCI USA, V93, P12053, DOI 10.1073/pnas.93.22.12053; Blee E, 1998, PROG LIPID RES, V37, P33, DOI 10.1016/S0163-7827(98)00004-6; BRASH AR, 1995, J LIPID MEDIAT CELL, V12, P275, DOI 10.1016/0929-7855(95)00033-M; BRASH AR, 1988, P NATL ACAD SCI USA, V85, P3382, DOI 10.1073/pnas.85.10.3382; Caldelari D, 1998, PHYTOCHEMISTRY, V47, P599, DOI 10.1016/S0031-9422(97)00443-3; Chapple C, 1998, ANNU REV PLANT PHYS, V49, P311, DOI 10.1146/annurev.arplant.49.1.311; Conconi A, 1996, PLANT PHYSIOL, V111, P797, DOI 10.1104/pp.111.3.797; COREY EJ, 1987, TETRAHEDRON LETT, V28, P4917, DOI 10.1016/S0040-4039(00)96658-9; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; CROFT KPC, 1993, PLANT PHYSIOL, V101, P13, DOI 10.1104/pp.101.1.13; CROMBIE L, 1991, J CHEM SOC PERK T 1, P567, DOI 10.1039/p19910000567; Dhondt S, 2000, PLANT J, V23, P431, DOI 10.1046/j.1365-313x.2000.00802.x; ESHED Y, 1994, EUPHYTICA, V79, P175, DOI 10.1007/BF00022516; Farmer EE, 1998, PLANTA, V206, P167, DOI 10.1007/s004250050388; FROEHLICH JE, 2001, IN PRESS PLANT PHYSL; GALLIARD T, 1972, BIOCHEM J, V129, P743, DOI 10.1042/bj1290743; GALLIARD T, 1977, PHYTOCHEMISTRY, V16, P339, DOI 10.1016/0031-9422(77)80060-5; GALLIARD T, 1973, CHEM PHYS LIPIDS, V11, P173, DOI 10.1016/0009-3084(73)90017-0; Gerwick WH, 1996, LIPIDS, V31, P1215, DOI 10.1007/BF02587906; Grechkin A, 1998, PROG LIPID RES, V37, P317, DOI 10.1016/S0163-7827(98)00014-9; Grechkin AN, 1997, EUR J BIOCHEM, V245, P137, DOI 10.1111/j.1432-1033.1997.00137.x; GRECHKIN AN, 1995, FEBS LETT, V371, P159, DOI 10.1016/0014-5793(95)00895-G; Hamberg M, 1999, LIPIDS, V34, P1131, DOI 10.1007/s11745-999-0464-7; Hamberg M, 2000, LIPIDS, V35, P353, DOI 10.1007/s11745-000-532-z; Hamberg M, 1998, LIPIDS, V33, P1061, DOI 10.1007/s11745-998-0306-7; HATANAKA A, 1993, PHYTOCHEMISTRY, V34, P1201, DOI 10.1016/0031-9422(91)80003-J; HECKER M, 1989, J BIOL CHEM, V264, P141; Howe GA, 2000, PLANT PHYSIOL, V123, P711, DOI 10.1104/pp.123.2.711; Jiang ZD, 1997, LIPIDS, V32, P231, DOI 10.1007/s11745-997-0029-9; LAU SMC, 1993, BIOCHEMISTRY-US, V32, P1945, DOI 10.1021/bi00059a010; LIU YG, 1995, PLANT J, V8, P457, DOI 10.1046/j.1365-313X.1995.08030457.x; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; Matsui K, 2000, FEBS LETT, V481, P183, DOI 10.1016/S0014-5793(00)01997-9; Matsui K, 1996, FEBS LETT, V394, P21, DOI 10.1016/0014-5793(96)00924-6; Maucher H, 2000, PLANT J, V21, P199, DOI 10.1046/j.1365-313x.2000.00669.x; Narvaez-Vasquez J, 1999, PLANT CELL, V11, P2249, DOI 10.1105/tpc.11.11.2249; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; Noordermeer MA, 2000, EUR J BIOCHEM, V267, P2473, DOI 10.1046/j.1432-1327.2000.01283.x; PAN ZQ, 1995, J BIOL CHEM, V270, P8487, DOI 10.1074/jbc.270.15.8487; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; PROTEAU PJ, 1993, LIPIDS, V28, P783, DOI 10.1007/BF02536231; Quackenbush J, 2000, NUCLEIC ACIDS RES, V28, P141, DOI 10.1093/nar/28.1.141; Rance I, 1998, P NATL ACAD SCI USA, V95, P6554, DOI 10.1073/pnas.95.11.6554; Rusterucci C, 1999, J BIOL CHEM, V274, P36446, DOI 10.1074/jbc.274.51.36446; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schaller F, 2000, PLANTA, V210, P979, DOI 10.1007/s004250050706; SHIBATA Y, 1995, BIOCHEM BIOPH RES CO, V207, P438, DOI 10.1006/bbrc.1995.1207; SHIBATA Y, 1995, PLANT CELL PHYSIOL, V36, P147; Sivasankar S, 2000, PLANT PHYSIOL, V122, P1335, DOI 10.1104/pp.122.4.1335; Smith JJ, 1997, PHYTOCHEMISTRY, V45, P453, DOI 10.1016/S0031-9422(96)00882-5; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; TANKSLEY SD, 1992, GENETICS, V132, P1141; Tijet N, 2000, LIPIDS, V35, P709, DOI 10.1007/s11745-000-0577-z; Weber H, 1999, PLANT CELL, V11, P485, DOI 10.1105/tpc.11.3.485; Williams PA, 2000, MOL CELL, V5, P121, DOI 10.1016/S1097-2765(00)80408-6; Ziegler J, 2000, J BIOL CHEM, V275, P19132, DOI 10.1074/jbc.M002133200; ZIMMERMAN DC, 1979, PLANT PHYSIOL, V63, P536, DOI 10.1104/pp.63.3.536; ZIMMERMAN DC, 1970, PLANT PHYSIOL, V46, P445, DOI 10.1104/pp.46.3.445	62	89	97	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3620	3627		10.1074/jbc.M008964200	http://dx.doi.org/10.1074/jbc.M008964200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11060314	hybrid			2022-12-25	WOS:000166784900083
J	Tan, KO; Tan, KML; Chan, SL; Yee, KSY; Bevort, M; Ang, KC; Yu, VC				Tan, KO; Tan, KML; Chan, SL; Yee, KSY; Bevort, M; Ang, KC; Yu, VC			MAP-1, a novel proapoptotic protein containing a BH3-like motif that associates with Bax through its Bcl-2 homology domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRO-APOPTOTIC ACTIVITY; CELL-DEATH; BH3 DOMAIN; X-L; FAMILY MEMBERS; HETERODIMERIZATION; BCL-X(L); BINDING; APAF-1; YEAST	A novel Bax-associating protein, named MAP-1 (Modulator of Apoptosis), has been identified in a yeast two-hybrid screen. MAP-1 contains a BH3-like (BH: Bcl-2 homology) motif and mediates caspase-dependent apoptosis in mammalian cells when overexpressed. MAP-1 homodimerizes and associates with the proapoptotic Bax and the prosurvival Bcl-2 and Bcl-X-L of the Bcl-2 family in vitro and in vivo in mammalian cells. Mutagenesis analyses revealed that the BH3-like domain in MAP-1 is not required for its association with Bcl-X-L but is required for association with Bax and for mediating apoptosis, Interestingly, in contrast to other Bax-associating proteins such as Bcl-X-L and Bid, which require the BH3 and BH1 domains of Bax, respectively, for binding, the binding of MAP-1 to Bax appears to require all three BH domains (BH1, BH2, and BH3) of Bax, because point mutation of the critical amino acid in any one of these domains is sufficient to abolish its binding to MAP-1. These data suggest that MAP-1 mediates apoptosis through a mechanism that involves binding to Bax.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Yu, VC (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.		Chan, S.L./X-4154-2018; Yu, Victor/A-7899-2015	Chan, S.L./0000-0002-3270-0525; Yu, Victor/0000-0003-3270-4734; Tan, Karen/0000-0002-7768-037X; Ang, Khay/0000-0002-1846-6963; Tan, Kuan/0000-0002-0947-7337				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Bai C, 1997, METHOD ENZYMOL, V283, P141; Chan SL, 2000, J BIOL CHEM, V275, P17925, DOI 10.1074/jbc.C000146200; Chan SL, 1999, J BIOL CHEM, V274, P32461, DOI 10.1074/jbc.274.45.32461; CHITTENDEN T, 1995, EMBO J, V14, P5589, DOI 10.1002/j.1460-2075.1995.tb00246.x; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Dalmau J, 1999, BRAIN, V122, P27, DOI 10.1093/brain/122.1.27; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Holinger EP, 1999, J BIOL CHEM, V274, P13298, DOI 10.1074/jbc.274.19.13298; Hsu SY, 1997, P NATL ACAD SCI USA, V94, P12401, DOI 10.1073/pnas.94.23.12401; Hsu YT, 1998, J BIOL CHEM, V273, P10777, DOI 10.1074/jbc.273.17.10777; Hu YM, 1998, P NATL ACAD SCI USA, V95, P4386, DOI 10.1073/pnas.95.8.4386; Inohara N, 1997, EMBO J, V16, P1686, DOI 10.1093/emboj/16.7.1686; Kelekar A, 1998, TRENDS CELL BIOL, V8, P324, DOI 10.1016/S0962-8924(98)01321-X; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Moriishi K, 1999, P NATL ACAD SCI USA, V96, P9683, DOI 10.1073/pnas.96.17.9683; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Newmeyer DD, 2000, CELL DEATH DIFFER, V7, P402, DOI 10.1038/sj.cdd.4400665; Pan GH, 1998, J BIOL CHEM, V273, P5841, DOI 10.1074/jbc.273.10.5841; Ray R, 2000, J BIOL CHEM, V275, P1439, DOI 10.1074/jbc.275.2.1439; Ronca F, 1997, J BIOL CHEM, V272, P4252, DOI 10.1074/jbc.272.7.4252; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Voltz R, 1999, NEW ENGL J MED, V340, P1788, DOI 10.1056/NEJM199906103402303; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang K, 1998, MOL CELL BIOL, V18, P6083, DOI 10.1128/MCB.18.10.6083; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yee KSY, 1998, J BIOL CHEM, V273, P5366, DOI 10.1074/jbc.273.9.5366; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Zha HB, 1996, J BIOL CHEM, V271, P7440, DOI 10.1074/jbc.271.13.7440; Zha HB, 1996, MOL CELL BIOL, V16, P6494; Zha JP, 1997, J BIOL CHEM, V272, P24101, DOI 10.1074/jbc.272.39.24101	37	107	115	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2802	2807		10.1074/jbc.M008955200	http://dx.doi.org/10.1074/jbc.M008955200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11060313	hybrid			2022-12-25	WOS:000166784800070
J	Xiao, GT; Sun, SC				Xiao, GT; Sun, SC			Activation of IKK alpha and IKK beta through their fusion with HTLV-I Tax protein	ONCOGENE			English	Article						I kappa B kinase; HTLV-I Tax; NF-kappa B; T-cell activation	NF-KAPPA-B; T-CELL LEUKEMIA; TRANSFORMING PROTEIN; KINASE COMPLEX; VIRUS TYPE-1; GAMMA; IDENTIFICATION; COMPONENT; REPEAT; MEKK1	Human T-cell leukemia virus type I (HTLV-I) Tax protein persistently stimulates the activity of I kappaB kinase (IKK), resulting in constitutive activation of the transcription factor NF-kappaB. Tax activation of IKK requires physical interaction of this viral protein with the IKK regulatory subunit, IKK gamma. The Tax/IKK gamma interaction allows Tax to engage the IKK catalytic subunits, IKK alpha and IKK beta, although it remains unclear whether this linker function of IKK gamma is sufficient for supporting the Tax-specific IKK activation. To address this question, we have examined the sequences of IKK gamma required for modulating the Tax/IKK signaling. We demonstrate that when fused to Tax, a small N-terminal fragment of IKK gamma, containing its minimal IKK alpha/beta -binding domain, is sufficient for bringing Tax to and activating the IKK catalytic subunits, Disruption of the IKK alpha/beta -binding activity of this domain abolishes its function in modulating the Tax/IKK signaling. We further demonstrate that direct fusion of Tax to IKK alpha and IKK beta leads to activation of these kinases. These findings suggest that the IKK gamma -directed Tax/TKK association serves as a molecular trigger for IKK activation.	Penn State Univ, Dept Microbiol & Immunol, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health	Sun, SC (corresponding author), Penn State Univ, Dept Microbiol & Immunol, Coll Med, 500 Univ Dr, Hershey, PA 17033 USA.				NATIONAL CANCER INSTITUTE [R01CA068471] Funding Source: NIH RePORTER; NCI NIH HHS [2R01 CA68471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; FEUER G, 1992, BIOCHIM BIOPHYS ACTA, V1114, P223, DOI 10.1016/0304-419X(92)90017-S; Gerondakis S, 1998, CURR OPIN IMMUNOL, V10, P353, DOI 10.1016/S0952-7915(98)80175-1; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Good L, 1996, BIOCHEM BIOPH RES CO, V223, P123, DOI 10.1006/bbrc.1996.0856; GREEN PL, 1990, FASEB J, V4, P169, DOI 10.1096/fasebj.4.2.2404818; GREENE WC, 1989, IMMUNOL TODAY, V10, P272, DOI 10.1016/0167-5699(89)90141-2; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; HOLBROOK NJ, 1987, VIROLOGY, V157, P211, DOI 10.1016/0042-6822(87)90330-8; Jin DY, 1997, NUCLEIC ACIDS RES, V25, P379, DOI 10.1093/nar/25.2.379; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Siebenlist U., 1997, BIOCHIMICA BIOPHYSIC, V1332, P7; SMITH MR, 1991, J CLIN INVEST, V87, P761, DOI 10.1172/JCI115078; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sun SC, 1999, ONCOGENE, V18, P6948, DOI 10.1038/sj.onc.1203220; Tie F, 1996, J VIROL, V70, P8368, DOI 10.1128/JVI.70.12.8368-8374.1996; Uhlik M, 1998, J BIOL CHEM, V273, P21132, DOI 10.1074/jbc.273.33.21132; XIAO G, 2000, IN PRESS J BIOL CHEM; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zandi E, 1999, MOL CELL BIOL, V19, P4547	30	52	55	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5198	5203		10.1038/sj.onc.1203894	http://dx.doi.org/10.1038/sj.onc.1203894			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064457				2022-12-25	WOS:000090124100009
J	Kramer, W; Sauber, K; Baringhaus, KH; Kurz, M; Stengelin, S; Lange, G; Corsiero, D; Girbig, F; Konig, W; Weyland, C				Kramer, W; Sauber, K; Baringhaus, KH; Kurz, M; Stengelin, S; Lange, G; Corsiero, D; Girbig, F; Konig, W; Weyland, C			Identification of the bile acid-binding site of the ileal lipid-binding protein by photoaffinity labeling, matrix-assisted laser desorption ionization-mass spectrometry, and NMR structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BORDER MEMBRANE-VESICLES; SALT-COTRANSPORT SYSTEM; MAGNETIC-RESONANCE DATA; RAT SMALL-INTESTINE; ESCHERICHIA-COLI; NUCLEAR RECEPTOR; TRANSPORT-SYSTEM; TAUROCHOLATE TRANSPORT; RADIATION-INACTIVATION; FUNCTIONAL EXPRESSION	The ileal lipid-binding protein (ILBP) is the only physiologically relevant bile acid-binding protein in the cytosol of ileocytes, To identify the bile acid-binding site(s) of ILBP, recombinant rabbit ILBP photolabeled with 3-azi- and 7-azi-derivatives of cholyltaurine was analyzed by a combination of enzymatic fragmentation, gel electrophoresis, and matrix-assisted laser desorption ionization (MALDI)-mass spectrometry, The attachment site of the 3-position of cholyltaurine was localized to the amino acid triplet His(100)-Thr(101)-Ser(102) using the photoreactive 3,3-azo-derivative of cholyltaurine, With the corresponding 7,7-azo-derivative, the attachment point of the 7-position could be localized to the C-terminal part (position 112-128) as well as to the N-terminal part suggesting more than one binding site for bile acids. By chemical modification and MMR structure of ILBP, arginine residue 122 was identified as the probable contact point for the negatively charged side chain of cholyltaurine, Consequently, bile acids bind to ILBP with the steroid nucleus deep inside the protein cavity and the negatively charged side chain near the entry portal, The combination of photoaffinity labeling, enzymatic fragmentation, MALDI-mass spectrometry, and NMR structure was successfully used to determine the topology of bile acid binding to ILBP.	Aventis Pharma Deutsch GmbH, DG Metab Dis, D-65926 Frankfurt, Germany	Sanofi-Aventis	Kramer, W (corresponding author), Aventis Pharma Deutsch GmbH, DG Metab Dis, D-65926 Frankfurt, Germany.	Werner.Kramer@aventis.com						ABBERGER H, 1981, BILE ACIDS LIPIDS, P233; ANWER MS, 1986, HOPPESEYLERS Z PHYSL, V375, P1477; Baringhaus KH, 1999, J LIPID RES, V40, P2158; *BRUK AN MESST GMH, 1995, BRUK XWIN NMR SOFTW; BURCKHARDT G, 1983, J BIOL CHEM, V258, P3618; BURCKHARDT G, 1987, BIOCHEM BIOPH RES CO, V143, P1018, DOI 10.1016/0006-291X(87)90353-6; Carey M.C., 1988, LIVER BIOL PATHOBIOL, V2nd, P573; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; ELSNER RH, 1992, J BIOL CHEM, V267, P9788; FUJII H, 1993, BIOCHEM BIOPH RES CO, V190, P175, DOI 10.1006/bbrc.1993.1027; GANTZ I, 1989, J BIOL CHEM, V264, P20248; GLATZ JFC, 1985, BIOCHIM BIOPHYS ACTA, V837, P57, DOI 10.1016/0005-2760(85)90085-2; GONG YZ, 1994, P NATL ACAD SCI USA, V91, P4741, DOI 10.1073/pnas.91.11.4741; GUNTERT P, 1991, J MOL BIOL, V217, P531, DOI 10.1016/0022-2836(91)90755-U; GUNTERT P, 1991, Journal of Biomolecular NMR, V1, P447, DOI 10.1007/BF02192866; GUNTERT P, 1991, J MOL BIOL, V217, P517, DOI 10.1016/0022-2836(91)90754-T; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAUNERLAND N, 1984, H-S Z PHYSIOL CHEM, V365, P365, DOI 10.1515/bchm2.1984.365.1.365; Hofmann A F, 1976, Adv Intern Med, V21, P501; Kanda T, 1996, FEBS LETT, V384, P131, DOI 10.1016/0014-5793(96)00291-8; KAWASHIMA Y, 1984, LIPIDS, V19, P481, DOI 10.1007/BF02534479; Kramer W, 1997, EUR J BIOCHEM, V249, P456, DOI 10.1111/j.1432-1033.1997.00456.x; KRAMER W, 1982, EUR J BIOCHEM, V129, P13, DOI 10.1111/j.1432-1033.1982.tb07015.x; KRAMER W, 1992, BIOCHIM BIOPHYS ACTA, V1111, P93, DOI 10.1016/0005-2736(92)90278-T; Kramer W, 1999, J LIPID RES, V40, P1604; KRAMER W, 1993, J BIOL CHEM, V268, P18035; Kramer W, 1997, FALK SYMP, V93, P161; KRAMER W, 1995, BBA-LIPID LIPID MET, V1257, P230, DOI 10.1016/0005-2760(95)00075-N; Kramer W, 1997, FALK SYMP, V93, P3; KRAMER W, 1989, J LIPID RES, V30, P1281; KRAMER W, 1983, J LIPID RES, V24, P910; KRAMER W, 1995, BIOCHEM J, V306, P241, DOI 10.1042/bj3060241; Kramer W, 1998, BIOCHEM J, V333, P335, DOI 10.1042/bj3330335; KRAMER W, 1983, J BIOL CHEM, V258, P3623; KRAMER W, 1979, EUR J BIOCHEM, V102, P1, DOI 10.1111/j.1432-1033.1979.tb06257.x; KRAMER W, 1981, THESIS U FREIBURG, P1; LACK L, 1979, ENVIRON HEALTH PERSP, V33, P79, DOI 10.2307/3429075; LEHMANN WD, 1996, MASSENSPEKTROMETRIE, P274; LIN MC, 1988, J MEMBRANE BIOL, V106, P1, DOI 10.1007/BF01871762; LIN MC, 1991, BIOCHIM BIOPHYS ACTA, V1078, P329, DOI 10.1016/0167-4838(91)90152-P; LIN MC, 1990, J BIOL CHEM, V265, P14986; Lucke C, 2000, EUR J BIOCHEM, V267, P2929, DOI 10.1046/j.1432-1327.2000.01307.x; Lucke C, 1996, STRUCTURE, V4, P785, DOI 10.1016/S0969-2126(96)00086-X; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; MATARESE V, 1988, J BIOL CHEM, V263, P14544; MEINNEL T, 1993, BIOCHIMIE, V75, P1061, DOI 10.1016/0300-9084(93)90005-D; MULLERFAHRNOW A, 1991, EUR J BIOCHEM, V199, P271, DOI 10.1111/j.1432-1033.1991.tb16120.x; NEIDIG KP, 1995, J BIOMOL NMR, V6, P255, DOI 10.1007/BF00197807; OCKNER RK, 1972, SCIENCE, V177, P56, DOI 10.1126/science.177.4043.56; OCKNER RK, 1974, J CLIN INVEST, V54, P326, DOI 10.1172/JCI107768; OELKERS P, 1995, BBA-LIPID LIPID MET, V1257, P199, DOI 10.1016/0005-2760(95)00098-W; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; SACCHETTINI JC, 1988, J BIOL CHEM, V263, P5815; SACCHETTINI JC, 1989, P NATL ACAD SCI USA, V86, P7736, DOI 10.1073/pnas.86.20.7736; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; SCAPIN G, 1990, MOL CELL BIOCHEM, V98, P95; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWARZ LR, 1975, EUR J BIOCHEM, V55, P617, DOI 10.1111/j.1432-1033.1975.tb02199.x; Stengelin S, 1996, EUR J BIOCHEM, V239, P887, DOI 10.1111/j.1432-1033.1996.0887u.x; VLAHCEVIC ZR, 1990, HEPATOLOGY TXB LIVER, P341; VODENLICH AD, 1991, BIOCHEM BIOPH RES CO, V177, P1147, DOI 10.1016/0006-291X(91)90659-U; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WEINBERG SL, 1986, J CLIN INVEST, V78, P44, DOI 10.1172/JCI112571; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6; WIDER MD, 1984, ENDOCRINOLOGY, V115, P1484, DOI 10.1210/endo-115-4-1484; WILSON FA, 1981, J CLIN INVEST, V67, P1141, DOI 10.1172/JCI110128; WILSON FA, 1991, HDB PHYSL GASTROINTE, V4, P389; WONG MH, 1994, J BIOL CHEM, V269, P1340; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZIEGLER K, 1992, BIOCHIM BIOPHYS ACTA, V1103, P229, DOI 10.1016/0005-2736(92)90091-Y	71	38	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7291	7301		10.1074/jbc.M006877200	http://dx.doi.org/10.1074/jbc.M006877200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11069906	hybrid			2022-12-25	WOS:000167442900061
J	Grossmann, JG; Hasnain, SS; Yousafzai, FK; Eady, RR				Grossmann, JG; Hasnain, SS; Yousafzai, FK; Eady, RR			Evidence for the selective population of FeMo cofactor sites in MoFe protein and its molecular recognition by the Fe protein in transition state complex analogues of nitrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE SCATTERING; X-RAY-SCATTERING; MOLYBDENUM IRON PROTEIN; DIRECT SHAPE DETERMINATION; AZOTOBACTER-VINELANDII; CLOSTRIDIUM-PASTEURIANUM; KLEBSIELLA-PNEUMONIAE; CRYSTALLOGRAPHIC STRUCTURE; ELECTRON-TRANSFER; CRYSTAL-STRUCTURE	We have collected synchrotron x-ray solution scattering data for the MoFe protein of KLebsiella pneumoniae nitrogenase and show that the molecular conformation of the protein that contains only one molybdenum per alpha (2)beta (2) tetramer is different from that of the protein that has full occupancy i.e. two molybdenums per molecule. This structural finding is consistent with the existence of MoFe protein molecules that contain only one FeMo cofactor site occupied and provides a rationale for the 50% loss of the specific activity of such preparations. A stable inactive transition state complex has been shown to form in the presence of MgADP and AlF4-. Gel filtration chromatography data show that the MoFe protein lacking a full complement of the cofactor forms initially a 1:1 complex before forming a low affinity 1:2 complex, A similar behavior is found for the MoFe protein with both cofactors occupied, but the high affinity 1:2 complex is formed at a lower ratio of Fe protein/MoFe protein. The 1:1 complex, MoFe protein-Fe protein . (ADP . AlF4-)(2), formed with MoFe protein that lacks one of the cofactors, is stable. X-ray scattering studies of this complex have enabled us to obtain its low resolution structure at similar to 20-Angstrom resolution, which confirms the gel filtration finding that only one molecule of the Fe protein binds the MoFe protein. By comparison with the low resolution structure of purified MoFe protein that contains only one molybdenum per tetramer, we deduce that the Fe protein interacts with the FeMo cofactor-binding alpha -subunit of the MoFe protein. This observation demonstrates that the conformation of the alpha -subunit or the alpha beta subunit pair that lacks the FeMo cofactor is altered and that the change is recognized by the Fe protein. The structure of the 1:1 complex reveals a similar change in the conformation of the Fe protein as has been observed in the low resolution scattering mask and the high resolution crystallographic study of the 1:2 complex where both cofactors are occupied and with the Fe protein bound to both subunits. This extensive conformational change observed for the Fe protein in the complexes is, however, not observed when MgATP or MgADP binds to the isolated Fe protein. Thus, the large scale conformational change of the Fe protein is associated with the complex formation of the two proteins.	CCLRC, Daresbury Lab, Warrington WA4 4AD, Cheshire, England; John Innes Ctr Plant Sci Res, Dept Biol Chem, Norwich NR4 7UH, Norfolk, England	STFC Daresbury Laboratory; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Grossmann, JG (corresponding author), CCLRC, Daresbury Lab, Warrington WA4 4AD, Cheshire, England.	J.G.Grossmann@dl.ac.uk						BOLIN JT, 1993, ACS SYM SER, V535, P186; BOULIN C, 1986, NUCL INSTRUM METH A, V249, P399, DOI 10.1016/0168-9002(86)90694-7; BRAS W, 1993, NUCL INSTRUM METH A, V326, P587, DOI 10.1016/0168-9002(93)90863-D; Burgess BK, 1996, CHEM REV, V96, P2983, DOI 10.1021/cr950055x; Chan JM, 1999, J BIOL CHEM, V274, P17593, DOI 10.1074/jbc.274.25.17593; CHAN MK, 1993, SCIENCE, V260, P792, DOI 10.1126/science.8484118; CHEN L, 1994, J BIOL CHEM, V269, P3290; Clarke TA, 2000, BIOCHEMISTRY-US, V39, P11434, DOI 10.1021/bi0002939; Clarke TA, 1999, BIOCHEMISTRY-US, V38, P9906, DOI 10.1021/bi9904353; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; Duyvis MG, 1998, BIOCHEMISTRY-US, V37, P17345, DOI 10.1021/bi981509y; Duyvis MG, 1996, FEBS LETT, V380, P233, DOI 10.1016/0014-5793(96)00019-1; Eady RR, 1996, CHEM REV, V96, P3013, DOI 10.1021/cr950057h; EADY RR, 1972, BIOCHEM J, V128, P655, DOI 10.1042/bj1280655; FEIGIN LA, 1987, STRUCTURE ANAL SMALL, P79; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Grossman JG, 1997, J MOL BIOL, V266, P642, DOI 10.1006/jmbi.1996.0846; Grossmann JG, 1999, ACTA CRYSTALLOGR D, V55, P727, DOI 10.1107/S0907444999003856; GROSSMANN JG, 1993, BIOCHEMISTRY-US, V32, P7360, DOI 10.1021/bi00080a005; Grossmann JG, 1997, J APPL CRYSTALLOGR, V30, P770; Grossmann JG, 1998, J MOL BIOL, V279, P461, DOI 10.1006/jmbi.1998.1787; GROSSMANN JG, 1997, DARESBURY ANN REP 19, P246; Howard JB, 1996, CHEM REV, V96, P2965, DOI 10.1021/cr9500545; HOWARD JB, 1994, ANNU REV BIOCHEM, V63, P235, DOI 10.1146/annurev.bi.63.070194.001315; KIM J, 1993, BIOCHEMISTRY-US, V32, P7104, DOI 10.1021/bi00079a006; KIM JS, 1992, NATURE, V360, P553, DOI 10.1038/360553a0; LEWIS R, 1988, NUCL INSTRUM METH A, V273, P773, DOI 10.1016/0168-9002(88)90094-0; Mayer SM, 1999, J MOL BIOL, V292, P871, DOI 10.1006/jmbi.1999.3107; Miller RW, 1998, BIOCHEM J, V334, P601, DOI 10.1042/bj3340601; PETERS JW, 1995, ANNU REV MICROBIOL, V49, P335, DOI 10.1146/annurev.mi.49.100195.002003; POROD G, 1951, KOLLOID Z Z POLYM, V124, P83, DOI 10.1007/BF01512792; Renner KA, 1996, BIOCHEMISTRY-US, V35, P5353, DOI 10.1021/bi960441o; Schindelin N, 1997, NATURE, V387, P370, DOI 10.1038/387370a0; Schlessman JL, 1998, J MOL BIOL, V280, P669, DOI 10.1006/jmbi.1998.1898; SEEFELDT LC, 1998, BIOL NITROGEN FIXATI, P39; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; SONDEK J, 1994, NATURE, V372, P276, DOI 10.1038/372276a0; STUHRMAN.HB, 1970, ACTA CRYSTALL A-CRYS, VA 26, P297, DOI 10.1107/S0567739470000748; STUHRMANN HB, 1970, Z PHYS CHEM NEUE FOL, V72, P177, DOI 10.1524/zpch.1970.72.4_6.177; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; SVERGUN DI, 1991, ACTA CRYSTALLOGR A, V47, P736, DOI 10.1107/S0108767391006414; Svergun DI, 1996, ACTA CRYSTALLOGR A, V52, P419, DOI 10.1107/S0108767396000177; Svergun DI, 1998, P NATL ACAD SCI USA, V95, P2267, DOI 10.1073/pnas.95.5.2267; Yousafzai FK, 1996, BIOCHEM J, V318, P111, DOI 10.1042/bj3180111; Yousafzai FK, 1997, BIOCHEM J, V326, P637, DOI 10.1042/bj3260637	46	8	8	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6582	6590		10.1074/jbc.M005350200	http://dx.doi.org/10.1074/jbc.M005350200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11084023	hybrid			2022-12-25	WOS:000167261000069
J	Kranewitter, WJ; Ylanne, J; Gimona, M				Kranewitter, WJ; Ylanne, J; Gimona, M			UNC-87 is an actin-bundling protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALPONIN; BINDING PROTEINS; F-ACTIN; CH DOMAIN; ACTOMYOSIN; COMPLEX; IDENTIFICATION; REGION	The Caenorhabditis elegans unc-87 gene product is essential for the maintenance of the nematode body wall muscle where it is found colocalized with actin in the I band. The molecular domain structure of the protein reveals similarity to the C-terminal repeat region of the smooth muscle actin-binding protein calponin. In this study we investigated the in vitro function of UNC-87 using both the full-length recombinant molecule and several truncated mutants. According to analytical ultracentrifugation UNC-87 occurs as a monomer in solution. UNC-87 cosedimented with both smooth and skeletal muscle F-actin, but not with monomeric G-actin, and exhibited potent actin filament bundling activity. Actin binding was independent of the presence of tropomyosin and the actin cross-linking proteins filamin and cu-actinin. Consistent with its actin bundling activity in vitro, UNC-87 tagged with green fluorescent protein associated with and promoted the formation of actin stress fiber bundles in living cells. These data identify UNC-87 as an actin-bundling protein and highlight the calponin-like repeats as a novel actin-binding module.	Salzburg Univ, Austrian Acad Sci, Inst Mol Biol, Dept Cell Biol, A-5020 Salzburg, Austria; European Mol Biol Lab, Dept Biol Struct, D-69012 Heidelberg, Germany	Austrian Academy of Sciences; Salzburg University; European Molecular Biology Laboratory (EMBL)	Gimona, M (corresponding author), Salzburg Univ, Austrian Acad Sci, Inst Mol Biol, Dept Cell Biol, Billrothstr 11, A-5020 Salzburg, Austria.			Ylanne, Jari/0000-0003-4627-021X				Ayscough KR, 1998, CURR OPIN CELL BIOL, V10, P102, DOI 10.1016/S0955-0674(98)80092-6; BRETSCHER A, 1981, P NATL ACAD SCI-BIOL, V78, P6849, DOI 10.1073/pnas.78.11.6849; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Danninger C, 2000, J CELL SCI, V113, P3725; ElMezgueldi M, 1996, BIOCHEMISTRY-US, V35, P3654, DOI 10.1021/bi952027e; Ferhat L, 1996, EUR J NEUROSCI, V8, P1501, DOI 10.1111/j.1460-9568.1996.tb01612.x; Fukui Y, 1997, J DERMATOL SCI, V14, P29, DOI 10.1016/S0923-1811(96)00545-2; GIMONA M, 1990, FEBS LETT, V274, P159, DOI 10.1016/0014-5793(90)81353-P; GIMONA M, 1995, P NATL ACAD SCI USA, V92, P9776, DOI 10.1073/pnas.92.21.9776; Gimona M, 1998, J CELL SCI, V111, P1813; GIMONA M, 1987, J MUSCLE RES CELL M, V8, P329, DOI 10.1007/BF01568889; GOETINCK S, 1994, J CELL BIOL, V127, P79, DOI 10.1083/jcb.127.1.79; GOETINCK S, 1994, J CELL BIOL, V127, P71, DOI 10.1083/jcb.127.1.71; HANSEN JC, 1994, BIOCHEMISTRY-US, V33, P13155, DOI 10.1021/bi00249a001; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVINE M, 1994, MOL BIOCHEM PARASIT, V65, P135, DOI 10.1016/0166-6851(94)90122-8; KAKE T, 1995, BIOCHEM J, V312, P587, DOI 10.1042/bj3120587; KOLAKOWSKI J, 1995, BIOCHEM J, V306, P199; Leinweber B, 1999, BIOPHYS J, V77, P3208, DOI 10.1016/S0006-3495(99)77151-1; Martin RM, 1997, INT J PARASITOL, V27, P1561, DOI 10.1016/S0020-7519(97)00146-X; McGough A, 1998, CURR OPIN STRUC BIOL, V8, P166, DOI 10.1016/S0959-440X(98)80034-1; Mino T, 1998, EUR J BIOCHEM, V251, P262, DOI 10.1046/j.1432-1327.1998.2510262.x; POLLARD TD, 1994, ANNU REV CELL BIOL, V10, P207, DOI 10.1146/annurev.cellbio.10.1.207; Puius YA, 1998, CURR OPIN CELL BIOL, V10, P23, DOI 10.1016/S0955-0674(98)80083-5; Sanders MC, 1996, J BIOL CHEM, V271, P2651, DOI 10.1074/jbc.271.5.2651; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Stradal T, 1998, FEBS LETT, V431, P134, DOI 10.1016/S0014-5793(98)00751-0; STRZELECKAGOLASZEWSKA H, 1975, EUR J BIOCHEM, V55, P221, DOI 10.1111/j.1432-1033.1975.tb02154.x; TAKAHASHI K, 1991, J BIOL CHEM, V266, P13284; Tang JX, 1997, EUR J BIOCHEM, V247, P432, DOI 10.1111/j.1432-1033.1997.00432.x; Van Troys M, 1999, BBA-MOL CELL RES, V1448, P323, DOI 10.1016/S0167-4889(98)00152-9; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Volkmann N, 2000, CURR OPIN CELL BIOL, V12, P26, DOI 10.1016/S0955-0674(99)00053-8; WANG YL, 1985, J CELL BIOL, V101, P597, DOI 10.1083/jcb.101.2.597; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x	35	33	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6306	6312		10.1074/jbc.M009561200	http://dx.doi.org/10.1074/jbc.M009561200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096113	hybrid			2022-12-25	WOS:000167261000034
J	Chong, JM; Speicher, DW				Chong, JM; Speicher, DW			Determination of disulfide bond assignments and N-glycosylation sites of the human gastrointestinal carcinoma antigen GA733-2 (CO17-1A, EGP, KS1-4, KSA, and Ep-CAM)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; MONOCLONAL-ANTIBODIES; COLORECTAL-CARCINOMA; SURFACE GLYCOPROTEIN; RANDOMIZED TRIAL; TUMOR; EXPRESSION; BINDING; PROTEINS; THERAPY	The GA733-2 antigen is a cell surface glycoprotein highly expressed on most human gastrointestinal carcinoma and at a lower level on most normal epithelia, It is an unusual cell-cell adhesion protein that does not exhibit any obvious relationship to the four known classes of adhesion molecules. In this study, the disulfide-bonding pattern of the GA733-2 antigen was determined using matrix-assisted laser desorption/ionization mass spectrometry and N-terminal sequencing of purified tryptic peptides treated with 2-[2 '-nitrophenylsulfonyl]-3-methyl-3-bromoindolenine or partially reduced and alkylated, Numbering GA733-2 cysteines sequentially from the N terminus, the first three disulfide linkages are Cys(1)-Cys(4), Cys(2)-Cys(6) and Cys(3)-Cys(5), which is a novel pattern for a cysteine-rich domain instead of the expected epidermal growth factor-like disulfide structure. The next three disulfide linkages are Cys(7)-Cys(8), Cys(9)-Cys(10), and Cys(11)-Cys(12), consistent with the recently determined disulfide pattern of the thyroglobulin type 1A domain of insulin-like growth factor-binding proteins 1 and 6, Analysis of glycosylation sites showed that GA733-2 antigen contained N-linked carbohydrate but that no O-linked carbohydrate groups were detected. Of the three potential N-linked glycosylation sites, Asn(175) was not glycosylated, whereas Asn(88) was completely glycosylated, and Asn(51) was partially glycosylated, These data show that the extracellular domain of the GA733-2 antigen consists of three distinct domains; a novel cysteine-rich N-terminal domain (GA733 type 1 motif), a cysteine-rich thyroglobulin type 1A domain (GA733 type 2 motif), and a unique nonglycosylated domain without cysteines (GA733 type 3 motif).	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Speicher, DW (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	speicher@wistar.upenn.edu			NATIONAL CANCER INSTITUTE [P01CA074294, P30CA010815] Funding Source: NIH RePORTER; NCI NIH HHS [CA74294, CA10815] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; APPELLA E, 1988, FEBS LETT, V231, P1, DOI 10.1016/0014-5793(88)80690-2; Balzar M, 1999, J MOL MED, V77, P699, DOI 10.1007/s001099900038; Cichy J, 2000, J BIOL CHEM, V275, P18061, DOI 10.1074/jbc.M907962199; Cirulli V, 1998, J CELL BIOL, V140, P1519, DOI 10.1083/jcb.140.6.1519; CRIMMINS DL, 2000, CURRENT PROTOCOLS PR; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; GOTTLINGER HG, 1986, INT J CANCER, V38, P47; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; HERLYN D, 1984, J IMMUNOL METHODS, V73, P157, DOI 10.1016/0022-1759(84)90041-3; HERLYN M, 1979, P NATL ACAD SCI USA, V76, P1438, DOI 10.1073/pnas.76.3.1438; Jones MD, 1997, BIOCHEMISTRY-US, V36, P14914, DOI 10.1021/bi971696k; KLEIN CE, 1987, J INVEST DERMATOL, V89, P500, DOI 10.1111/1523-1747.ep12460996; Li WP, 1997, J IMMUNOL, V159, P763; LINNENBACH AJ, 1989, P NATL ACAD SCI USA, V86, P27, DOI 10.1073/pnas.86.1.27; LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437; Litvinov SV, 1996, AM J PATHOL, V148, P865; Molina F, 1996, EUR J BIOCHEM, V240, P125, DOI 10.1111/j.1432-1033.1996.0125h.x; MOMBURG F, 1987, CANCER RES, V47, P2883; Neumann GM, 1999, J BIOL CHEM, V274, P14587, DOI 10.1074/jbc.274.21.14587; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; Rahali V, 1999, J PROTEIN CHEM, V18, P1, DOI 10.1023/A:1020635130077; REIM DF, 1997, CURRENT PROTOCOLS PR; RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1; Riethmuller G, 1998, J CLIN ONCOL, V16, P1788, DOI 10.1200/JCO.1998.16.5.1788; ROSS AH, 1986, BIOCHEM BIOPH RES CO, V135, P297, DOI 10.1016/0006-291X(86)90976-9; SCHON MP, 1993, INT J CANCER, V55, P988, DOI 10.1002/ijc.2910550619; SHETYE J, 1988, CANCER IMMUNOL IMMUN, V27, P154; SHETYE J, 1989, ANTICANCER RES, V9, P395; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIMON B, 1990, P NATL ACAD SCI USA, V87, P2755, DOI 10.1073/pnas.87.7.2755; Stetefeld J, 1996, J MOL BIOL, V257, P644, DOI 10.1006/jmbi.1996.0191; STRASSBURG CP, 1992, CANCER RES, V52, P815; SZALA S, 1990, P NATL ACAD SCI USA, V87, P3542, DOI 10.1073/pnas.87.9.3542; THAMPOE IJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P342, DOI 10.1016/0003-9861(88)90040-9; TSUBURA A, 1992, J CUTAN PATHOL, V19, P73, DOI 10.1111/j.1600-0560.1992.tb01562.x; Zaloudik J, 1997, BRIT J CANCER, V76, P909, DOI 10.1038/bjc.1997.483; ZORAS J, 1995, EUR UROL, V28, P251	38	70	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5804	5813		10.1074/jbc.M008839200	http://dx.doi.org/10.1074/jbc.M008839200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11080501	hybrid			2022-12-25	WOS:000167115100055
J	Hoque, MT; Ishikawa, F				Hoque, MT; Ishikawa, F			Human chromatid cohesin component hRad21 is phosphorylated in M phase and associated with metaphase centromeres	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND-BREAK REPAIR; SCHIZOSACCHAROMYCES-POMBE; SISTER CHROMATIDS; CHROMOSOME ARMS; PROTEIN; GENE; IDENTIFICATION; NUCLEAR; COMPLEXES; RAD21	Sister chromatids duplicated in S phase are connected with each other during G(2) and M phase until the onset of anaphase. This chromatid cohesion is essential for correct segregation of genetic material to daughter cells. Recently, understanding of the molecular mechanisms governing chromatid cohesion in yeast has been greatly advanced, whereas these processes in mammalian cells remain unclear. We report here biochemical and cytological analyses of human Rad21, a homologue of the yeast cohesin subunit, Scc1p/Mcd1p. hRad21 is a nuclear phosphorylated protein. Its abundance does not change during the cell cycle, and it becomes hyperyphosphorylated in M phase. Most hRad21 is not associated with chromatin when the nuclear envelope breakdown takes place in prophase. However, a detailed analysis of the spread chromosomes indicated that hRad21 remains associated with prometaphase-like chromosomes along their entire lengths. The mitotic chromatin-bound hRad21 becomes dissociated in a highly regulated manner because hRad21 remains specifically at the centromeres but disappears from the arm regions on metaphase-like chromosomes. Interestingly, hRad21 at the metaphase centromeres appears to be present at the inner pairing domain where the two sister chromatids are supposed to be in intimate contact. These results suggest that hRad21 has a critical role in chromatid cohesion in human mitotic cells.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan	Tokyo Institute of Technology	Ishikawa, F (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.		Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305				BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Blat Y, 1999, CELL, V98, P249, DOI 10.1016/S0092-8674(00)81019-3; Cutts SM, 1999, HUM MOL GENET, V8, P1145, DOI 10.1093/hmg/8.7.1145; Darwiche N, 1999, GENE, V233, P39, DOI 10.1016/S0378-1119(99)00160-2; EARNSHAW WC, 1991, J CELL SCI, V98, P443; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Harlow E, 1988, ANTIBODIES LABORATOR, P471; Hirano T, 1999, GENE DEV, V13, P11, DOI 10.1101/gad.13.1.11; IKENO M, 1994, HUM MOL GENET, V3, P1245, DOI 10.1093/hmg/3.8.1245; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Losada A, 2000, Curr Biol, V10, pR615, DOI 10.1016/S0960-9822(00)00670-9; McKay MJ, 1996, GENOMICS, V36, P305, DOI 10.1006/geno.1996.0466; Megee PC, 1999, MOL CELL, V4, P445, DOI 10.1016/S1097-2765(00)80347-0; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MIYAZAKI WY, 1994, ANNU REV GENET, V28, P167, DOI 10.1146/annurev.ge.28.120194.001123; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Schmiesing JA, 1998, P NATL ACAD SCI USA, V95, P12906, DOI 10.1073/pnas.95.22.12906; STRUNNIKOV AV, 1993, J CELL BIOL, V123, P1635, DOI 10.1083/jcb.123.6.1635; Tanaka TU, 1999, CELL, V98, P847, DOI 10.1016/S0092-8674(00)81518-4	25	62	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5059	5067		10.1074/jbc.M007809200	http://dx.doi.org/10.1074/jbc.M007809200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11073952	hybrid			2022-12-25	WOS:000168484300072
J	Pucci, M; Fibbi, G; Magnelli, L; Del Rosso, M				Pucci, M; Fibbi, G; Magnelli, L; Del Rosso, M			Regulation of urokinase/urokinase receptor interaction by heparin-like glycosaminoglycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; PLASMINOGEN-ACTIVATOR RECEPTOR; HUMAN UROKINASE RECEPTOR; CELL-SURFACE; EXTRACELLULAR-MATRIX; PERIODATE-OXIDATION; IN-VITRO; SULFATE PROTEOGLYCAN; MOUSE FIBROBLASTS; BINDING DOMAIN	We show here that the interaction between the urokinase-type plasminogen activator and its receptor, which plays a critical role in cell invasion, is regulated by heparan sulfate present on the cell surface and in the extracellular matrix. Heparan sulfate oligomers showing a composition close to the dimeric repeats of heparin (glucosamine-NSO3(6-OSO3)-iduronic acid (2-OSO3)) n = 5 and n > 5, where iduronic acid may alternate with glucuronic acid, exhibit affinity for urokinase plasminogen activator and confer specificity on urokinase/urokinase receptor interaction. Cell surface clearance of heparan sulfate reduces the affinity of such interaction with a parallel decrease of specific urokinase binding in the presence of an unaltered expression of receptor. Transfection of human urokinase plasminogen activator receptor in normal Chinese hamster ovary fibroblasts and in Chinese hamster ovary cells defective for the synthesis of sulfated glycosaminoglycans results in specific urokinase/receptor interaction only in nondefective cells. Heparan sulfate/urokinase and receptor/urokinase interactions exhibit similar K-d values. We concluded that heparan sulfate functions as an adaptor molecule that confers specificity on urokinase/receptor binding.	Univ Florence, Dept Expt Pathol & Oncol, I-50134 Florence, Italy	University of Florence	Pucci, M (corresponding author), Univ Florence, Dept Expt Pathol & Oncol, Viale GB Morgagni 50, I-50134 Florence, Italy.		Magnelli, Lucia/J-7077-2018	Magnelli, Lucia/0000-0003-4585-1450; Fibbi, gabriella/0000-0002-0629-851X; Del Rosso, Mario/0000-0002-2980-2731	Telethon [1074] Funding Source: Medline	Telethon(Fondazione Telethon)		ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; ANICHINI E, 1994, EXP CELL RES, V213, P438, DOI 10.1006/excr.1994.1221; BATTAGLIA C, 1993, EUR J CELL BIOL, V61, P92; Bertolesi GE, 1997, BLOOD COAGUL FIBRIN, V8, P403, DOI 10.1097/00001721-199710000-00005; Besser D, 1996, FIBRINOLYSIS, V10, P215, DOI 10.1016/S0268-9499(96)80018-X; BORK P, 1992, FEBS LETT, V307, P49, DOI 10.1016/0014-5793(92)80900-2; Brunner G, 1998, EXP CELL RES, V239, P301, DOI 10.1006/excr.1997.3877; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Carey DJ, 1997, BIOCHEM J, V327, P1; CARLSTEDT I, 1983, J BIOL CHEM, V258, P1629; Chang AW, 1998, ARTERIOSCL THROM VAS, V18, P1855, DOI 10.1161/01.ATV.18.12.1855; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; Chapman HA, 1997, CURR OPIN CELL BIOL, V9, P714, DOI 10.1016/S0955-0674(97)80126-3; Couchman JR, 1999, J CELL SCI, V112, P3415; COUCHMAN JR, 1990, J INVEST DERMATOL, V94, pS7, DOI 10.1111/1523-1747.ep12874973; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; CUBELLIS MV, 1990, EMBO J, V9, P1079, DOI 10.1002/j.1460-2075.1990.tb08213.x; DAWES J, 1993, HAEMOSTASIS, V23, P212; DELROSSO M, 1981, BIOCHEM J, V199, P699, DOI 10.1042/bj1990699; DELROSSO M, 1992, EXP CELL RES, V203, P427; DELROSSO M, 1985, CANCER RES, V45, P630; DELROSSO M, 1979, BIOCHIM BIOPHYS ACTA, V586, P512, DOI 10.1016/0304-4165(79)90041-2; DIAMOND MS, 1995, J CELL BIOL, V130, P1473, DOI 10.1083/jcb.130.6.1473; DUFFY MJ, 1993, FIBRINOLYSIS, V7, P295, DOI 10.1016/0268-9499(93)90144-K; EDELBERG JM, 1991, BIOCHEM J, V276, P785, DOI 10.1042/bj2760785; FEARS R, 1988, BIOCHEM J, V249, P77, DOI 10.1042/bj2490077; Fibbi G, 1998, LAB INVEST, V78, P1109; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; FRANSSON LA, 1980, CARBOHYD RES, V80, P131, DOI 10.1016/S0008-6215(00)85321-5; FRANSSON LA, 1981, J BIOL CHEM, V256, P3039; FRANSSON LA, 1980, EUR J BIOCHEM, V106, P59; FRANSSON LA, 1978, CARBOHYD RES, V62, P235, DOI 10.1016/S0008-6215(00)80870-8; GUIMOND S, 1993, J BIOL CHEM, V268, P23906; Hershkoviz R, 2000, IMMUNOLOGY, V99, P87, DOI 10.1046/j.1365-2567.2000.00931.x; HOLMBERG L, 1976, BIOCHIM BIOPHYS ACTA, V445, P215, DOI 10.1016/0005-2744(76)90174-1; HoyerHansen G, 1997, EUR J BIOCHEM, V243, P21, DOI 10.1111/j.1432-1033.1997.0021a.x; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Klass CM, 2000, J CELL SCI, V113, P493; Kusano Y, 2000, EXP CELL RES, V256, P434, DOI 10.1006/excr.2000.4802; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Mertens G, 1996, J CELL BIOL, V132, P487, DOI 10.1083/jcb.132.3.487; Miao HQ, 1996, J BIOL CHEM, V271, P4879; Mignatti P, 2000, ADV CANCER RES, V78, P103; MOLLER LB, 1993, J BIOL CHEM, V268, P11152; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; OLWIN BB, 1992, J CELL BIOL, V118, P631, DOI 10.1083/jcb.118.3.631; Parton RG, 1996, CURR OPIN CELL BIOL, V8, P542, DOI 10.1016/S0955-0674(96)80033-0; Plesner T, 1997, STEM CELLS, V15, P398, DOI 10.1002/stem.150398; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; Preissner KT, 1998, THROMB RES, V89, P1, DOI 10.1016/S0049-3848(97)00298-3; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; RIJKEN DC, 1993, THROMB HAEMOSTASIS, V70, P867; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; ROLDAN AL, 1990, EMBO J, V9, P467, DOI 10.1002/j.1460-2075.1990.tb08132.x; SAKSELA O, 1987, J CELL BIOL, V105, P957, DOI 10.1083/jcb.105.2.957; SCHMIDTCHEN A, 1990, BIOCHEM J, V265, P389; STAHL A, 1995, J CELL BIOL, V129, P335, DOI 10.1083/jcb.129.2.335; STAHL A, 1994, CANCER RES, V54, P3066; STEPHENS RW, 1992, BIOCHEMISTRY-US, V31, P7572, DOI 10.1021/bi00148a019; STEPHENS RW, 1991, SEMIN THROMB HEMOST, V17, P201, DOI 10.1055/s-2007-1002610; TIMAR J, 1992, AM J PATHOL, V141, P467; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; Wang GJ, 1998, P NATL ACAD SCI USA, V95, P6296, DOI 10.1073/pnas.95.11.6296; WANG H, 1994, INT J CANCER, V58, P650, DOI 10.1002/ijc.2910580506; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	68	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4756	4765		10.1074/jbc.M005993200	http://dx.doi.org/10.1074/jbc.M005993200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11085980	Green Published, hybrid			2022-12-25	WOS:000168484300032
J	Stahl, SS; Francisco, WA; Merkx, M; Klinman, JP; Lippard, SJ				Stahl, SS; Francisco, WA; Merkx, M; Klinman, JP; Lippard, SJ			Oxygen kinetic isotope effects in soluble methane monooxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYLOCOCCUS-CAPSULATUS BATH; COMPONENT INTERACTIONS; HYDROXYLASE COMPONENT; DIOXYGEN ACTIVATION; CATALYTIC CYCLE; BOND-CLEAVAGE; INTERMEDIATE; O-18; HEMERYTHRIN; MOSSBAUER	Soluble methane monooxygenase (sMMO) contains a nonheme, carboxylate-bridged diiron site that activates dioxygen in the catalytic oxidation of hydrocarbon substrates, Oxygen kinetic isotope effects (KIEs) have been determined under steady-state conditions for the sMMO-catalyzed oxidation of CH3CN, a liquid substrate analog. Kinetic studies of the steady-state sMMO reaction revealed a competition between fully coupled oxygenase activity, which produced glycolonitrile (HOCH2CN) and uncoupled oxidase activity that led to water formation. The oxygen KIE was measured independently for both the oxygenase and oxidase reactions, and values of 1.0152 +/- 0.0007 and 1.0167 +/- 0.0010 were obtained, respectively. The isotope effects and separate dioxygen binding studies do not support irreversible formation of an enzyme-dioxygen Michaelis complex. Additional mechanistic implications are discussed in the context of previous data obtained from single turnover and steady-state kinetic studies.	MIT, Dept Chem, Cambridge, MA 02139 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Massachusetts Institute of Technology (MIT); University of California System; University of California Berkeley; University of California System; University of California Berkeley	Lippard, SJ (corresponding author), MIT, Dept Chem, 77 Massachusetts Ave,Rm 18-590, Cambridge, MA 02139 USA.		Merkx, Maarten/E-7009-2011		NIGMS NIH HHS [GM 25765, GM 32134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032134, R37GM032134, R01GM025765, R37GM025765] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Coufal DE, 2000, EUR J BIOCHEM, V267, P2174, DOI 10.1046/j.1432-1327.2000.01210.x; DEWITT JG, 1991, J AM CHEM SOC, V113, P9219, DOI 10.1021/ja00024a031; Dunietz BD, 2000, J AM CHEM SOC, V122, P2828, DOI 10.1021/ja9920967; FOX BG, 1990, METHOD ENZYMOL, V188, P191; Francisco WA, 1998, J AM CHEM SOC, V120, P4057, DOI 10.1021/ja973543q; GARBETT K, 1969, ARCH BIOCHEM BIOPHYS, V135, P419, DOI 10.1016/0003-9861(69)90559-1; Gassner GT, 1999, BIOCHEMISTRY-US, V38, P12768, DOI 10.1021/bi990841m; Glickman MH, 1997, J AM CHEM SOC, V119, P11357, DOI 10.1021/ja970689g; GREEN J, 1985, J BIOL CHEM, V260, P5795; GREEN J, 1986, BIOCHEM J, V236, P155, DOI 10.1042/bj2360155; KERESZTE.S, 1965, BIOCHEMISTRY-US, V4, P919, DOI 10.1021/bi00881a019; Kim K, 1996, J AM CHEM SOC, V118, P4914, DOI 10.1021/ja9604370; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KLOTZ IM, 1957, ARCH BIOCHEM BIOPHYS, V68, P284, DOI 10.1016/0003-9861(57)90360-0; LEE SK, 1993, J BIOL CHEM, V268, P21569; Lee SY, 1999, BIOCHEMISTRY-US, V38, P4423, DOI 10.1021/bi982712w; LIU KE, 1995, J AM CHEM SOC, V117, P10174, DOI 10.1021/ja00146a002; LIU Y, 1995, J BIOL CHEM, V270, P24662, DOI 10.1074/jbc.270.42.24662; Nesheim JC, 1996, BIOCHEMISTRY-US, V35, P10240, DOI 10.1021/bi960596w; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; Rosenzweig AC, 1997, PROTEINS, V29, P141, DOI 10.1002/(SICI)1097-0134(199710)29:2<141::AID-PROT2>3.3.CO;2-W; Shu LJ, 1997, SCIENCE, V275, P515, DOI 10.1126/science.275.5299.515; STENKAMP RE, 1994, CHEM REV, V94, P715, DOI 10.1021/cr00027a008; Su QJ, 1999, BIOCHEMISTRY-US, V38, P8572, DOI 10.1021/bi990044o; Su QJ, 1998, BIOCHEMISTRY-US, V37, P12513, DOI 10.1021/bi981103l; TIAN GC, 1993, J AM CHEM SOC, V115, P8891, DOI 10.1021/ja00073a001; TIAN GC, 1994, BIOCHEMISTRY-US, V33, P226, DOI 10.1021/bi00167a030; Valentine AM, 1999, J AM CHEM SOC, V121, P3876, DOI 10.1021/ja9839522; Valentine AM, 1997, J CHEM SOC DALTON, P3925, DOI 10.1039/a705116f; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Willems JP, 1998, J AM CHEM SOC, V120, P9410, DOI 10.1021/ja980795y	31	32	32	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4549	4553		10.1074/jbc.M008301200	http://dx.doi.org/10.1074/jbc.M008301200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11073959	hybrid			2022-12-25	WOS:000168484300006
J	Bojovic, BB; Hassell, JA				Bojovic, BB; Hassell, JA			The PEA3 Ets transcription factor comprises multiple domains that regulate transactivation and DNA binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; EWS/FLI-1 FUSION GENE; FAMILY MEMBER ERM; EWINGS-SARCOMA; MURINE ETS-1; MOLECULAR CHARACTERIZATION; CHROMOSOME-TRANSLOCATION; ONCOGENE FAMILY; MAMMALIAN-CELLS; FACTOR ER81	PEAS, a member of the Ets family of transcription factors, is a nuclear phosphoprotein capable of activating transcription, Mouse PEAS comprises 480 amino acids and bears an similar to 85-amino acid ETS domain near its carboxyl terminus. Whereas analyses of bacterially expressed PEAS revealed that the ETS domain is required for sequence-specific DNA binding, Little is known of the functional domains in the protein required for its activity in mammalian cells. To this end, we defined the location of the PEAS functional domains in COS cells. PEAS bears a strong activation domain near its amino terminus, which is flanked by two regions that independently negatively regulate its activity. PEAS expressed in COS cells was incapable of binding to DNA in vitro. However, DNA binding activity could be unmasked by incubation with a PEAS-specific antibody. Analyses of the DNA binding activity of PEAS deletion mutants revealed that two regions flanking the ETS domain independently inhibited DNA binding; deletion of both regions was required to detect DNA binding in the absence of a PEAS-specific antibody. Under these conditions, the ETS domain was sufficient for sequence-specific DNA binding. These findings suggest that the activity of PEAS is exquisitely controlled at multiple functional levels.	McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada	McMaster University	Hassell, JA (corresponding author), McMaster Univ, Inst Mol Biol & Biotechnol, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.							BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; Brown LA, 1998, ONCOGENE, V17, P93, DOI 10.1038/sj.onc.1201911; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; Defossez PA, 1997, NUCLEIC ACIDS RES, V25, P4455, DOI 10.1093/nar/25.22.4455; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; DONALDSON LW, 1994, BIOCHEMISTRY-US, V33, P13509, DOI 10.1021/bi00250a001; Donaldson LW, 1996, EMBO J, V15, P125, DOI 10.1002/j.1460-2075.1996.tb00340.x; Graves BJ, 1998, COLD SPRING HARB SYM, V63, P621, DOI 10.1101/sqb.1998.63.621; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HIGASHINO F, 1993, NUCLEIC ACIDS RES, V21, P547, DOI 10.1093/nar/21.3.547; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Jeon In-Sang, 1998, Journal of Korean Medical Science, V13, P355; JEON IS, 1995, ONCOGENE, V10, P1229; Kaneko Y, 1996, GENE CHROMOSOME CANC, V15, P115, DOI 10.1002/(SICI)1098-2264(199602)15:2<115::AID-GCC6>3.0.CO;2-6; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kodandapani R, 1996, NATURE, V380, P456, DOI 10.1038/380456a0; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Laget MP, 1996, ONCOGENE, V12, P1325; Laudet V, 1999, ONCOGENE, V18, P1351, DOI 10.1038/sj.onc.1202444; LESSNICK SL, 1995, ONCOGENE, V10, P423; LIANG H, 1994, P NATL ACAD SCI USA, V91, P11655, DOI 10.1073/pnas.91.24.11655; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; MONTE D, 1995, ONCOGENE, V11, P771; MONTE D, 1994, ONCOGENE, V9, P1397; Monte D, 1996, GENOMICS, V35, P236, DOI 10.1006/geno.1996.0345; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Skalicky JJ, 1996, PROTEIN SCI, V5, P296; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Urano F, 1996, BIOCHEM BIOPH RES CO, V219, P608, DOI 10.1006/bbrc.1996.0281; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	41	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4509	4521		10.1074/jbc.M005509200	http://dx.doi.org/10.1074/jbc.M005509200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11096072	hybrid			2022-12-25	WOS:000166921200103
J	Schmid, JA; Scholze, P; Kudlacek, O; Freissmuth, M; Singer, EA; Sitte, HH				Schmid, JA; Scholze, P; Kudlacek, O; Freissmuth, M; Singer, EA; Sitte, HH			Oligomerization of the human serotonin transporter and of the rat GABA transporter 1 visualized by fluorescence resonance energy transfer microscopy in living cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTORS; PROTEIN	Recent biochemical studies indicate that the serotonin transporter can form oligomers, We investigated whether the human serotonin transporter (hSERT) can be visualized as an oligomer in the plasma membrane of intact cells. For this purpose, we generated fusion proteins of hSERT and spectral variants of the green fluorescent protein (cyan and yellow fluorescent proteins, CFP and YFP, respectively). When expressed in human embryonic kidney 293 cells, the resulting fusion proteins (CFP-hSERT and PFP-hSERT) were efficiently inserted into the plasma membrane and were functionally indistinguishable from wild-type hSERT. Oligomers were visualized by fluorescence resonance energy transfer microscopy in living cells using two complementary methods, i.e. ratio imaging and donor photobleaching. Interestingly, oligomerization was not confined to hSERT; fluorescence resonance energy transfer was also observed between CFP- and YFP-labeled rat gamma -aminobutyric acid transporter, The bulk of serotonin transporters was recovered as high molecular weight complexes upon gel filtration in detergent solution. In contrast, the monomers of CFP-hSERT and YFP-hSERT were essentially undetectable, This indicates that the homo-oligomeric form is the favored state of hSERT in living cells, which is not significantly affected by coincubation with transporter substrates or blockers. Based on our observations, we conclude that constitutive oligomer formation might be a general property of Na+/Cl--dependent neurotransmitter transporters.	Univ Vienna, Sch Med, Inst Pharmacol, A-1090 Vienna, Austria; Univ Vienna, Sch Med, Dept Vasc Biol & Thrombosis Res, A-1235 Vienna, Austria	University of Vienna; University of Vienna	Sitte, HH (corresponding author), Univ Vienna, Sch Med, Inst Pharmacol, Wahringer Str 13A, A-1090 Vienna, Austria.		Schmid, Johannes A./C-7659-2009; Sitte, Harald/N-2681-2013; Sitte, Harald/O-7025-2019	Schmid, Johannes A./0000-0002-6586-3507; Sitte, Harald/0000-0002-1339-7444; Sitte, Harald/0000-0002-1339-7444; Scholze, Petra/0000-0003-4984-6034; Kudlacek, Oliver/0000-0002-3086-8551; Freissmuth, Michael/0000-0001-9398-1765				BRUNS D, 1993, NEURON, V10, P559, DOI 10.1016/0896-6273(93)90159-O; Chang AS, 1998, BIOCHEM BIOPH RES CO, V249, P416, DOI 10.1006/bbrc.1998.9158; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; Jess U, 1996, FEBS LETT, V394, P44, DOI 10.1016/0014-5793(96)00916-7; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; MAGER S, 1994, NEURON, V12, P845, DOI 10.1016/0896-6273(94)90337-9; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Periasamy A, 1999, METHOD CELL BIOL, V58, P293; PESSINO A, 1991, J BIOL CHEM, V266, P20213; Petersen CI, 1999, NAT NEUROSCI, V2, P605, DOI 10.1038/10158; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; RAMAMOORTHY S, 1993, PLACENTA, V14, P449, DOI 10.1016/S0143-4004(05)80465-5; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; Schloss P, 1998, J PSYCHOPHARMACOL, V12, P115, DOI 10.1177/026988119801200201; Schmid JA, 2000, J BIOL CHEM, V275, P17035, DOI 10.1074/jbc.M000291200; Sitte HH, 1998, J NEUROCHEM, V71, P1289; Sitte HH, 2000, J NEUROCHEM, V74, P1317	23	158	160	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3805	3810		10.1074/jbc.M007357200	http://dx.doi.org/10.1074/jbc.M007357200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11071889	hybrid			2022-12-25	WOS:000166921200013
J	Fass, DM; Craig, JC; Impey, S; Goodman, RH				Fass, DM; Craig, JC; Impey, S; Goodman, RH			Cooperative mechanism of transcriptional activation by a cyclic AMP-response element modulator alpha mutant containing a motif for constitutive binding to CREB-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; GENE-TRANSCRIPTION; CAMP; PROMOTER; C/EBP; FOS; EXPRESSION; COMPONENT; LIVER; P300	Cyclic AMP-response element modulator cu (CREM alpha) is a transcription factor that is highly related to cAMP-response element-binding protein (CREB) but represses cAMP-induced gene expression from simple artificial promoters containing a cAMP-response element (CRE), CREM alpha lacks two glutamine-rich Q regions that, in CREB, are thought to be necessary for transcriptional activation. Nevertheless, protein kinase A stimulation induces CREM alpha to activate the complex native promoter in the phosphoenolpyruvate carboxykinase (PEPCK) gene. To study this phenomenon in the absence of protein kinase A stimulation, we introduced a mutation into CREM alpha to allow constitutive binding to the coactivator CREB-binding protein. This mutant, CREM alpha (DIEDML) constitutively activated the PEPCK promoter. By engineering the leucine zipper regions of CREM alpha (DIEDML) and CREB alpha (DIEDML) to direct their patterns of dimerization, we found that only CREM alpha (DIEDML) homodimers fully activated the PEPCK promoter. By using a series of deletion and block mutants of the PEPCK promoter, we found that activation by CREM alpha (DIEDML) depended on the CRE and two CCAAT/enhancer-binding protein (C/EBP) sites. A dominant negative inhibitor of C/EBP, A-C/EBP, suppressed activation by CREM alpha (DIEDML) Furthermore, a GAL4-C/EBP alpha fusion protein and CREM alpha (DIEDML) cooperatively activated a promoter containing three GAL4 sites and the PEPCK CRE, Thus, we propose that the C/EBP sites in the PEPCK promoter allow CREMa to activate transcription despite its lack of Q regions.	Oregon Hlth Sci Univ, Vollum Inst, Portland, OR 97201 USA	Oregon Health & Science University	Goodman, RH (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.							BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Crosson SM, 2000, J BIOL CHEM, V275, P5804, DOI 10.1074/jbc.275.8.5804; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; FOULKES NS, 1991, P NATL ACAD SCI USA, V88, P5448, DOI 10.1073/pnas.88.12.5448; GORAYA TY, 1995, J BIOL CHEM, V270, P19078, DOI 10.1074/jbc.270.32.19078; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Inada A, 1999, J BIOL CHEM, V274, P21095, DOI 10.1074/jbc.274.30.21095; KRYLOV D, 1995, EMBO J, V14, P5329, DOI 10.1002/j.1460-2075.1995.tb00217.x; LAOIDE BM, 1993, EMBO J, V12, P1179, DOI 10.1002/j.1460-2075.1993.tb05759.x; Laurance ME, 1997, J BIOL CHEM, V272, P2646, DOI 10.1074/jbc.272.5.2646; LIU JS, 1991, J BIOL CHEM, V266, P19095; LORIAUX MM, 1994, J BIOL CHEM, V269, P28839; Lundblad JR, 1996, MOL ENDOCRINOL, V10, P607, DOI 10.1210/me.10.6.607; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; METZ R, 1991, ONCOGENE, V6, P2165; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PARK EA, 1993, J BIOL CHEM, V268, P613; Roesler WJ, 1996, J BIOL CHEM, V271, P8068, DOI 10.1074/jbc.271.14.8068; ROESLER WJ, 1994, J BIOL CHEM, V269, P14276; SassoneCorsi P, 1995, ANNU REV CELL DEV BI, V11, P355, DOI 10.1146/annurev.cellbio.11.1.355; Schumacher MA, 2000, J BIOL CHEM, V275, P35242, DOI 10.1074/jbc.M007293200; Zhang QH, 2000, MOL CELL BIOL, V20, P4970, DOI 10.1128/MCB.20.14.4970-4978.2000	28	9	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					2992	2997		10.1074/jbc.M008274200	http://dx.doi.org/10.1074/jbc.M008274200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11092886	hybrid			2022-12-25	WOS:000166784900004
J	Cantwell, AM; Di Cera, E				Cantwell, AM; Di Cera, E			Rational design of a potent anticoagulant thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; PROTEIN-C; THROMBOMODULIN; SITE; COAGULATION; FIBRINOGEN; ADDITIVITY	Thrombin acts as a procoagulant when it cleaves fibrinogen and promotes the formation of a fibrin clot and functions as an anticoagulant when it activates protein C with the assistance of the cofactor thrombomodulin. The dual function of thrombin in the blood poses the challenge to turn the enzyme into a potent anticoagulant by selectively abrogating fibrinogen cleavage. Using functional and structural data, we have rationally designed a thrombin mutant, W215A/E217A, that cleaves fibrinogen with a value of k(cat)/K-m about 20,000-fold slower than wild-type but activates protein C in the presence of thrombomodulin with a specificity comparable with wild-type. This mutant demonstrates for the first time that the relative specificity of thrombin toward fibrinogen and protein C can be completely reversed.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, Box 8231, St Louis, MO 63110 USA.	enrico@caesar.wustl.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL058141, R01HL049413] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58141, HL49413] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arosio D, 2000, BIOCHEMISTRY-US, V39, P8095, DOI 10.1021/bi0006215; BODE W, 1992, PROTEIN SCI, V1, P426; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Di Cera E, 1998, TRENDS CARDIOVAS MED, V8, P340, DOI 10.1016/S1050-1738(98)00030-9; Di Cera E, 1998, ADV PROTEIN CHEM, V51, P59; DiCera E, 1997, CELL MOL LIFE SCI, V53, P701, DOI 10.1007/s000180050091; Dill KA, 1997, J BIOL CHEM, V272, P701, DOI 10.1074/jbc.272.2.701; ESMON CT, 1989, J BIOL CHEM, V264, P4743; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; GIBBS CS, 1995, NATURE, V378, P413, DOI 10.1038/378413a0; GRIFFIN JH, 1995, NATURE, V378, P337, DOI 10.1038/378337a0; Guinto ER, 1999, P NATL ACAD SCI USA, V96, P1852, DOI 10.1073/pnas.96.5.1852; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; MATHEWS II, 1994, BIOCHEMISTRY-US, V33, P3266, DOI 10.1021/bi00177a018; Monnaie D, 2000, BIOCHEMISTRY-US, V39, P5349, DOI 10.1021/bi9926781; OLSON ST, 1991, J BIOL CHEM, V266, P6342; Renatus M, 1998, J MED CHEM, V41, P5445, DOI 10.1021/jm981068g; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; Vindigni A, 1997, BIOCHEMISTRY-US, V36, P6674, DOI 10.1021/bi962766a; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001	24	67	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 22	2000	275	51					39827	39830		10.1074/jbc.C000751200	http://dx.doi.org/10.1074/jbc.C000751200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	386BD	11060281	hybrid			2022-12-25	WOS:000166039500007
J	Krosl, J; Sauvageau, G				Krosl, J; Sauvageau, G			AP-1 complex is effector of Hox-induced cellular proliferation and transformation	ONCOGENE			English	Article						Hox; Pbx; AP-1; proliferation; transformation	HEMATOPOIETIC-CELLS CAUSES; BONE-MARROW CELLS; MYELOID-LEUKEMIA; HOMEOBOX GENES; MAMMARY-GLAND; CLUSTER GENES; GROWTH-FACTOR; FRA-1 GENE; EXPRESSION; PROTEIN	Hox gene products, initially characterized as master regulators of embryonic patterning, are also required for proper functioning of adult tissues. There is also a growing body of evidence that links Hox proteins to regulation of cellular proliferation/transformation. However, the underlying molecular mechanisms of Hox-associated transformation and tissue growth have yet to be elucidated. Using a well established model system for studying changes in cellular proliferation induced by Hoxb4, we show that AP-I activity is markedly increased in Hoxb4-transduced cells due to significant upregulation of Jun-B and Fra-1 protein levels, Furthermore, we also show that the specific changes in AP-1 protein expression are necessary for the proliferation effects induced by Hoxb4, and that these changes converge to increase levels of cyclin D1, a known integrator of proliferation signals. Our observations thus link Hox gene products with key elements of the cell cycle machinery.	Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, Montreal, PQ H2W 1R7, Canada; Univ Montreal, Dept Med, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Hop Maison Neuve Rosemont, Div Hematol, Montreal, PQ H1T 2M4, Canada	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal; Universite de Montreal; Universite de Montreal	Sauvageau, G (corresponding author), Clin Res Inst Montreal, Lab Mol Genet Hemopoiet Stem Cells, 110 Pine Ave W, Montreal, PQ H2W 1R7, Canada.			Sauvageau, Guy/0000-0002-4333-7266				ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Amato SF, 1996, J IMMUNOL, V157, P146; Asahara H, 1999, MOL CELL BIOL, V19, P8219; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Borrow J, 1996, NAT GENET, V12, P159, DOI 10.1038/ng0296-159; CARE A, 1994, MOL CELL BIOL, V14, P4872, DOI 10.1128/MCB.14.7.4872; Care A, 1996, MOL CELL BIOL, V16, P4842; Chariot A, 1999, ONCOGENE, V18, P4007, DOI 10.1038/sj.onc.1202776; Chen F, 1999, P NATL ACAD SCI USA, V96, P541, DOI 10.1073/pnas.96.2.541; CILLO C, 1994, INVAS METAST, V14, P38; COFFER P, 1994, ONCOGENE, V9, P911; DEVITA G, 1993, EUR J CANCER, V29A, P887, DOI 10.1016/S0959-8049(05)80432-0; FRIEDMANN Y, 1994, CANCER RES, V54, P5981; HERBER, 1994, ONCOGENE, V9, P2105; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Krosl J, 1998, ONCOGENE, V16, P3403, DOI 10.1038/sj.onc.1201883; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Lallemand D, 1997, ONCOGENE, V14, P819, DOI 10.1038/sj.onc.1200901; Lawrence HJ, 1997, BLOOD, V89, P1922, DOI 10.1182/blood.V89.6.1922; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Mamo A, 1999, BLOOD, V94, p250A; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; McCarthy SA, 1997, MOL CELL BIOL, V17, P2401, DOI 10.1128/MCB.17.5.2401; Mechta F, 1997, ONCOGENE, V14, P837, DOI 10.1038/sj.onc.1200900; Nakamura T, 1996, NAT GENET, V12, P154, DOI 10.1038/ng0296-154; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Quaranta MT, 1996, J IMMUNOL, V157, P2462; SALSER SJ, 1994, TRENDS GENET, V10, P159, DOI 10.1016/0168-9525(94)90092-2; SAUVAGEAU G, 1994, P NATL ACAD SCI USA, V91, P12223, DOI 10.1073/pnas.91.25.12223; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Snowden AW, 1998, BIOCHEM PHARMACOL, V55, P1947, DOI 10.1016/S0006-2952(98)00020-3; Stelnicki EJ, 1998, J INVEST DERMATOL, V110, P110, DOI 10.1046/j.1523-1747.1998.00092.x; Vallone D, 1997, EMBO J, V16, P5310, DOI 10.1093/emboj/16.17.5310; Yueh YG, 1998, P NATL ACAD SCI USA, V95, P9956, DOI 10.1073/pnas.95.17.9956; Zakany J, 1996, NATURE, V384, P69, DOI 10.1038/384069a0; ZAPPAVIGNA V, 1994, GENE DEV, V8, P732, DOI 10.1101/gad.8.6.732	39	48	50	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5134	5141		10.1038/sj.onc.1203897	http://dx.doi.org/10.1038/sj.onc.1203897			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064450				2022-12-25	WOS:000090124100002
J	Khanna, SJ; Brown, R; Whetton, AD; Ball, KL; Dive, C				Khanna, SJ; Brown, R; Whetton, AD; Ball, KL; Dive, C			v-Abl protein-tyrosine kinase up-regulates p21WAF-1 in cell cycle arrested and proliferating myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT KINASES; DNA-REPLICATION; S-PHASE; P21; APOPTOSIS; P21(CIP1); SUPPRESSION; EXPRESSION; INHIBITOR; PCNA	v-Abl protein-tyrosine kinase (PTK) promotes cell survival without cell proliferation in interleukin (IL)3-deprived IC,DP premast cells (1), We now show that in these conditions v-Abl PTK transcriptionally up-regulated the cyclin-dependent kinase inhibitor (CDKI) p21(WAF-1) and inhibited CDK2 and CDK4, When readdition of IL-3 stimulated cell proliferation, p21(WAF-1) was inactivated as a CDKI despite maintenance of elevated protein level. p21(WAF-1) was also up-regulated yet was nonfunctional as a CDKI when v-Abl PTK was activated in cells maintained in IL-3, but this occurred without increased p21(WAF-1) transcription. Using a C-terminal epitope-specific p21(WAF-1) antibody, v-Abl PTK-mediated increase in p21(WAF-1) could be detected in intact cells only in the presence of IL-3, This indicated different binding partners of p21(WAF-1) and/or protein conformation in nondividing or proliferating cells, respectively. The binding of CDK2, CDK4, or proliferating cell nuclear antigen to p21(WAF-1) and its subcellular localization were unchanged in the presence or absence of IL-3, However, two-dimensional analysis revealed different forms of up regulated p21(WAF-1) in IL-3-deprived, nondividing cells compared with IL-3-stimulated proliferating cells. These data demonstrate that elevation of the CDKI p21(WAF-1) is not always sufficient for cell cycle arrest and indicate an IL-3-sensitive pathway for the inactivation of p21(WAF-1) function as a CDKI.	Univ Manchester, Sch Biol Sci, Canc Res Campaign, Mol Pharmacol Grp, Manchester M13 9PT, Lancs, England; Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Stevenage SG1 2NY, Herts, England; Univ Manchester, Inst Sci & Technol, Leukaemia Res Fund, Cellular Dev Unit,Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Dundee, Ninewells Med Sch, Biomed Res Ctr, Canc Res Campaign Lab, Dundee DD1 9SY, Scotland	University of Manchester; GlaxoSmithKline; University of Manchester; University of Dundee	Dive, C (corresponding author), Univ Manchester, Sch Biol Sci, Canc Res Campaign, Mol Pharmacol Grp, G38 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			WHETTON, ANTHONY D/0000-0002-1098-3878; Dive, Caroline/0000-0002-1726-8850				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chen Q, 1997, ONCOGENE, V15, P2249, DOI 10.1038/sj.onc.1201371; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; COLOMBEL M, 1992, CANCER RES, V52, P4313; DANIAL NN, 1995, SCIENCE, V269, P1875, DOI 10.1126/science.7569929; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Duttaroy A, 1997, J CELL BIOCHEM, V64, P434; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Estanyol JM, 1999, J BIOL CHEM, V274, P33161, DOI 10.1074/jbc.274.46.33161; EVANS CA, 1993, CANCER RES, V53, P1735; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Harlow E., 1988, ANTIBODIES LAB MANUA, P481; HARPER JW, 1993, CELL, V75, P805; Joseph B, 1998, J BIOL CHEM, V273, P20511, DOI 10.1074/jbc.273.32.20511; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KEARSEY JM, 1995, ONCOGENE, V11, P1675; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Medema RH, 1998, ONCOGENE, V16, P431, DOI 10.1038/sj.onc.1201558; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Scott MT, 2000, J BIOL CHEM, V275, P11529, DOI 10.1074/jbc.275.15.11529; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Tian H, 2000, CANCER RES, V60, P679; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	33	3	3	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 6	2001	276	14					11143	11150		10.1074/jbc.M007073200	http://dx.doi.org/10.1074/jbc.M007073200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420AC	11098052	hybrid			2022-12-25	WOS:000167980900076
J	Vido, K; Spector, D; Lagniel, G; Lopez, S; Toledano, MB; Labarre, J				Vido, K; Spector, D; Lagniel, G; Lopez, S; Toledano, MB; Labarre, J			A proteome analysis of the cadmium response in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS-RESPONSE; FATTY-ACID UNSATURATION; METAL RESISTANCE; GSH1 GENE; YEAST; GLUTATHIONE; INDUCTION; REQUIRES; PROTEINS; ANTIOXIDANT	Cadmium is very toxic at low concentrations, but the basis for its toxicity is not clearly understood. We analyzed the proteomic response of yeast cells to acute cadmium stress and identified 54 induced and 43 repressed proteins. A striking result is the strong induction of 9 enzymes of the sulfur amino acid biosynthetic pathway. Accordingly, we observed that glutathione synthesis is strongly increased in response to cadmium treatment. Several proteins with antioxidant properties were also induced. The induction of nine proteins is dependent upon the transactivator Yap1p, consistent with the cadmium hypersensitive phenotype of the YAP1-disrupted strain. Most of these proteins are also overexpressed in a strain overexpressing Yap1p, a result that correlates with the cadmium hyper-resistant phenotype of this strain. Two of these Yap1p-dependent proteins, thioredoxin and thioredoxin reductase, play an important role in cadmium tolerance because strains lacking the corresponding genes are hypersensitive to this metal. Altogether, our data indicate that the two cellular thiol redox systems, glutathione and thioredoxin, are essential for cellular defense against cadmium.	CEA Saclay, Serv Biochim & Genet Mol, F-91191 Gif Sur Yvette, France	CEA; UDICE-French Research Universities; Universite Paris Saclay	Labarre, J (corresponding author), CEA Saclay, Serv Biochim & Genet Mol, Bat 142, F-91191 Gif Sur Yvette, France.							BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Boucherie H, 1996, ELECTROPHORESIS, V17, P1683, DOI 10.1002/elps.1150171106; Boy-Marcotte E, 1999, MOL MICROBIOL, V33, P274, DOI 10.1046/j.1365-2958.1999.01467.x; Brennan RJ, 1996, MUTAT RES-FUND MOL M, V356, P171, DOI 10.1016/0027-5107(96)00051-6; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; Dormer UH, 2000, J BIOL CHEM, V275, P32611, DOI 10.1074/jbc.M004167200; Godon C, 1998, J BIOL CHEM, V273, P22480, DOI 10.1074/jbc.273.35.22480; GUPTA S, 1991, IND HEALTH, V29, P1, DOI 10.2486/indhealth.29.1; GUTHRIE C, 1991, METHOD ENZYMOL, V194, P273; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; Howlett NG, 1997, APPL ENVIRON MICROB, V63, P2971, DOI 10.1128/AEM.63.8.2971-2976.1997; Howlett NG, 1997, APPL MICROBIOL BIOT, V48, P539, DOI 10.1007/s002530051093; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; KUMARI K, 1994, ANAL BIOCHEM, V220, P374, DOI 10.1006/abio.1994.1352; Lee J, 1999, J BIOL CHEM, V274, P4537, DOI 10.1074/jbc.274.8.4537; Lee J, 1999, J BIOL CHEM, V274, P16040, DOI 10.1074/jbc.274.23.16040; Li ZS, 1997, P NATL ACAD SCI USA, V94, P42, DOI 10.1073/pnas.94.1.42; Maillet I, 1996, J BIOL CHEM, V271, P10263, DOI 10.1074/jbc.271.17.10263; Morgan BA, 1997, EMBO J, V16, P1035, DOI 10.1093/emboj/16.5.1035; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Norbeck J, 1997, J BIOL CHEM, V272, P5544, DOI 10.1074/jbc.272.9.5544; ORTIZ DF, 1995, J BIOL CHEM, V270, P4721, DOI 10.1074/jbc.270.9.4721; RAMOS F, 1970, EUR J BIOCHEM, V12, P40, DOI 10.1111/j.1432-1033.1970.tb00818.x; Sambrook J., 2002, MOL CLONING LAB MANU; Sarkar S, 1998, BIOMETALS, V11, P153, DOI 10.1023/A:1009286130324; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIKORSKI RS, 1989, GENETICS, V122, P19; Silver S, 1996, ANNU REV MICROBIOL, V50, P753, DOI 10.1146/annurev.micro.50.1.753; Stephen DWS, 1997, MOL MICROBIOL, V23, P203, DOI 10.1046/j.1365-2958.1997.2081572.x; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Toone WM, 1999, CURR OPIN GENET DEV, V9, P55, DOI 10.1016/S0959-437X(99)80008-2; WEMMIE JA, 1994, J BIOL CHEM, V269, P32592; WU AL, 1993, J BIOL CHEM, V268, P18850; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832	36	316	332	0	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8469	8474		10.1074/jbc.M008708200	http://dx.doi.org/10.1074/jbc.M008708200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11078740	hybrid			2022-12-25	WOS:000167474900107
J	Ding, YM; Stec, DE; Sigmund, CD				Ding, YM; Stec, DE; Sigmund, CD			Genetic evidence that lethality in angiotensinogen-deficient mice is due to loss of systemic but not renal angiotensinogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT PROXIMAL TUBULE; TRANSGENIC MICE; CONVERTING ENZYME; BLOOD-PRESSURE; HUMAN RENIN; RECEPTOR GENES; EXPRESSION; CELLS; HYBRIDIZATION; HYPERTROPHY	Angiotensinogen (AGT)-deficient mice die shortly after birth presumably due to renal dysfunction caused by the presence of severe vascular and tubular lesions in the kidney. Because AGT is expressed in renal proximal tubule cells, we hypothesized that its loss may be the primary mediator of the lethal phenotype, We generated two models to test this hypothesis by breeding transgenic mice expressing human renin with mice expressing human AGT (hAGT) either systemically or kidney-specifically. We then bred double transgenic mice with AGT+/- mice, intercrossed the compound heterozygotes, and examined the offspring. We previously reported that the presence of the human renin and systemically expressed hAGT transgene complemented the lethality observed in AGT-/- mice. On the contrary, we show herein that the presence of the human renin and kidney-specific hAGT transgene cannot rescue lethality in AGT-/- mice. An analysis of newborns indicated that AGT-/- mice were born in normal numbers, and collection of dead 10-day old pups revealed an enrichment in AGT-/-. Importantly, we demonstrated that angiotensinogen protein and functional angiotensin II was generated in the kidney, and the kidney specific transgene was temporally expressed during renal development similar to the endogenous AGT gene. These data strongly support the notion that the loss of systemic AGT, but not intrarenal AGT, is responsible for death in the AGT-/- mouse model, Taken together with our previous studies, we conclude that the intrarenal renin-angiotensin system located in the proximal tubule plays an important role in blood pressure regulation and may cause hypertension if overexpressed, but may not be required for continued development of the kidney after birth.	Univ Iowa, Coll Med, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Genet Interdisciplinary Grad Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa	Sigmund, CD (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, 2191 Med Lab, Iowa City, IA 52242 USA.	curt-sigmund@uiowa.edu	Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NHLBI NIH HHS [HL48058, HL55006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL048058, P50HL055006, R01HL048058] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON PW, 1993, HYPERTENSION, V21, P29, DOI 10.1161/01.HYP.21.1.29; BARR M, 1994, TERATOLOGY, V50, P399, DOI 10.1002/tera.1420500606; DARBY IA, 1995, CELL TISSUE RES, V281, P197, DOI 10.1007/s004410050416; Davids L., 1999, TIS ENGN INTELL UNIT, P3; Davisson RL, 1997, J CLIN INVEST, V99, P1258, DOI 10.1172/JCI119283; Ding YM, 1997, J BIOL CHEM, V272, P28142, DOI 10.1074/jbc.272.44.28142; DUBEY RK, 1992, CIRC RES, V71, P1143, DOI 10.1161/01.RES.71.5.1143; FRIBERG P, 1994, KIDNEY INT, V45, P485, DOI 10.1038/ki.1994.63; GOMEZ RA, 1995, AM J KIDNEY DIS, V26, P409, DOI 10.1016/0272-6386(95)90487-5; Gomez RA, 1998, KIDNEY INT, V54, pS12, DOI 10.1046/j.1523-1755.1998.06703.x; GOMEZ RA, 1990, PEDIATR NEPHROL, V4, P421, DOI 10.1007/BF00862529; HATAE T, 1994, MOL CELL BIOCHEM, V131, P43, DOI 10.1007/BF01075723; INGELFINGER JR, 1990, J CLIN INVEST, V85, P417, DOI 10.1172/JCI114454; JUNG FF, 1993, PEDIATR NEPHROL, V7, P834, DOI 10.1007/BF01213370; KAKUCHI J, 1995, KIDNEY INT, V47, P140, DOI 10.1038/ki.1995.16; Kang NL, 1999, HYPERTENSION, V34, P344; KIM HS, 1995, P NATL ACAD SCI USA, V92, P2735, DOI 10.1073/pnas.92.7.2735; KREGE JH, 1995, NATURE, V375, P146, DOI 10.1038/375146a0; Le Thu H., 1999, Journal of the American Society of Nephrology, V10, p396A; Merrill DC, 1996, J CLIN INVEST, V97, P1047, DOI 10.1172/JCI118497; Navar LG, 1997, SEMIN NEPHROL, V17, P412; Oliverio MI, 1998, P NATL ACAD SCI USA, V95, P15496, DOI 10.1073/pnas.95.26.15496; PLOTH DW, 1979, J CLIN INVEST, V64, P1325, DOI 10.1172/JCI109589; Quan A, 1996, J CLIN INVEST, V97, P2878, DOI 10.1172/JCI118745; Rohrwasser A, 1999, HYPERTENSION, V34, P1265, DOI 10.1161/01.HYP.34.6.1265; SACCOMANI G, 1990, AM J PHYSIOL, V258, pF1188, DOI 10.1152/ajprenal.1990.258.5.F1188; SIGMUND CD, 1992, CIRC RES, V70, P1070, DOI 10.1161/01.RES.70.5.1070; Tsuchida S, 1998, J CLIN INVEST, V101, P755, DOI 10.1172/JCI1899; TUFROMCREDDIE A, 1993, J CLIN INVEST, V91, P530, DOI 10.1172/JCI116232; WOLF G, 1995, ADV EXP MED BIOL, V377, P225; WOLF G, 1990, AM J PHYSIOL, V259, pF768, DOI 10.1152/ajprenal.1990.259.5.F768; YANG GY, 1994, J BIOL CHEM, V269, P32497; Yang GY, 1998, AM J PHYSIOL-RENAL, V274, pF932, DOI 10.1152/ajprenal.1998.274.5.F932	33	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7431	7436		10.1074/jbc.M003892200	http://dx.doi.org/10.1074/jbc.M003892200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11096065	hybrid			2022-12-25	WOS:000167442900079
J	Bounou, S; Dumais, N; Tremblay, MJ				Bounou, S; Dumais, N; Tremblay, MJ			Attachment of human immunodeficiency virus-1 (HIV-1) particles bearing host-encoded B7-2 proteins leads to nuclear factor-kappa B- and nuclear factor of activated T cells-dependent activation of HIV-1 long terminal repeat transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE-TROPIC HIV; CLASS-I MOLECULES; ENVELOPE GLYCOPROTEIN; GENE-EXPRESSION; ADHESION RECEPTORS; COSTIMULATORY SIGNALS; CHEMOKINE RECEPTORS; CYTOPLASMIC DOMAIN; CELLULAR RECEPTOR; VIRAL INFECTIVITY	Previous studies have shown that human immunodeficiency virus type-1 (HIV-1) can incorporate several surface proteins of host origin. Recent findings indicate that host encoded cell surface constituents retain their functionality when found embedded into the viral envelope. The primary objective of the current study was to define whether interaction between some specific virion-bound host proteins with their natural cognate ligands present on target cells could mediate intracellular signaling cascade(s). For this purpose, we have generated a whole series of isogenic virus stocks (NL4-3 backbone) bearing or not bearing on their surface foreign CD28, CD54 (ICAM-1), CD80 (B7-1) or CD86 (B7-2) proteins, Our results indicate that incubation of human T lymphoid cells with virions bearing host-derived B7-2 proteins and anti-CD3 antibody can potently activate HIV-1 long terminal repeat driven gene expression. This up-regulating effect necessitates the involvement of nuclear factor-kappaB (NF-kappaB) and nuclear factor of activated T cells (NFAT) as revealed by the use of vectors coding for dominant negative versions of both transcription factors (i.e. I kappaB alpha S32A/36A and dnNFAT) and band shift assays. The increase of NF-kappaB activity was abolished when infection with B7-2-bearing HIV-1 particles was performed in the presence of the fusion protein CTLA-4 Ig suggesting that the interaction between virally embedded B7-2 and CD28 on the target cell is responsible for the observed NF-kappaB induction. The findings presented here provide the first demonstration that host-encoded proteins acquired by HIV-1 can mediate signal transduction events.	CHU Quebec, Ctr Rech Infectiol, Lab ImmunoRetrovirol Humaine, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Fac Med, Dept Med Biol, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Tremblay, MJ (corresponding author), CHU Quebec, Ctr Rech Infectiol, Lab ImmunoRetrovirol Humaine, RC709,Pavillon CHUL,2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.							ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; AGUILARCORDOVA E, 1994, AIDS RES HUM RETROV, V10, P295, DOI 10.1089/aid.1994.10.295; ARTHUR LO, 1992, SCIENCE, V258, P1935, DOI 10.1126/science.1470916; AZOCAR J, 1979, CANCER RES, V39, P3388; AZUMA M, 1992, J EXP MED, V175, P353, DOI 10.1084/jem.175.2.353; BENKIRANE M, 1994, EMBO J, V13, P5559, DOI 10.1002/j.1460-2075.1994.tb06893.x; BENKIRANE M, 1994, J VIROL, V68, P6332, DOI 10.1128/JVI.68.10.6332-6339.1994; Berube P, 1996, J VIROL, V70, P4009; BRADDOCK M, 1994, J VIROL, V68, P25, DOI 10.1128/JVI.68.1.25-33.1994; Briand G, 1997, VIROLOGY, V228, P171, DOI 10.1006/viro.1996.8399; Briant L, 1996, J IMMUNOL, V156, P3994; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BUBBERS JE, 1977, NATURE, V266, P458, DOI 10.1038/266458a0; Cantin R, 1997, J VIROL, V71, P1922, DOI 10.1128/JVI.71.3.1922-1930.1997; Cantin R, 1997, BLOOD, V90, P1091, DOI 10.1182/blood.V90.3.1091.1091_1091_1100; Cantin R, 1996, VIROLOGY, V218, P372, DOI 10.1006/viro.1996.0206; CHIRMULE N, 1995, J BIOL CHEM, V270, P19364, DOI 10.1074/jbc.270.33.19364; Chirmule N, 1996, MICROBIOL REV, V60, P386, DOI 10.1128/MMBR.60.2.386-406.1996; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Cicala C, 1999, J IMMUNOL, V163, P420; Cosma A, 1999, AIDS, V13, P2033, DOI 10.1097/00002030-199910220-00005; CRABTREE GR, 1989, SCIENCE, V243, P355, DOI 10.1126/science.2783497; CRUIKSHANK WW, 1990, BIOMED PHARMACOTHER, V44, P5, DOI 10.1016/0753-3322(90)90062-E; Davis CB, 1997, J EXP MED, V186, P1793, DOI 10.1084/jem.186.10.1793; DETHE G, 1964, JNCI-J NATL CANCER I, V32, P201; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; Dumais N, 1998, J BIOL CHEM, V273, P27306, DOI 10.1074/jbc.273.42.27306; Eck SC, 1997, TRANSPLANTATION, V64, P1497, DOI 10.1097/00007890-199711270-00025; Ehret A, 1996, J VIROL, V70, P6502, DOI 10.1128/JVI.70.9.6502-6507.1996; ENGEL P, 1994, BLOOD, V84, P1402, DOI 10.1182/blood.V84.5.1402.bloodjournal8451402; FENOUILLET E, 1989, J EXP MED, V169, P807, DOI 10.1084/jem.169.3.807; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; Fortin JF, 1997, J VIROL, V71, P3588, DOI 10.1128/JVI.71.5.3588-3596.1997; Fortin JF, 1998, J VIROL, V72, P2105, DOI 10.1128/JVI.72.3.2105-2112.1998; FREEMAN GJ, 1995, IMMUNITY, V2, P523, DOI 10.1016/1074-7613(95)90032-2; Fujiwara M, 1999, J VIROL, V73, P3603, DOI 10.1128/JVI.73.5.3603-3607.1999; Gajewski TF, 1996, J IMMUNOL, V156, P465; GAYNOR R, 1992, AIDS, V6, P347, DOI 10.1097/00002030-199204000-00001; GELDERBLOM HR, 1985, LANCET, V2, P1016; GLUSHAKOVA S, 1995, NAT MED, V1, P1320, DOI 10.1038/nm1295-1320; GUO MML, 1995, AIDS RES HUM RETROV, V11, P1007, DOI 10.1089/aid.1995.11.1007; HENDERSON AJ, 1995, J VIROL, V69, P5337, DOI 10.1128/JVI.69.9.5337-5344.1995; HIVROZ C, 1993, EUR J IMMUNOL, V23, P600, DOI 10.1002/eji.1830230303; Horuk R, 1999, IMMUNOL TODAY, V20, P89, DOI 10.1016/S0167-5699(98)01396-6; HSU MC, 1993, P NATL ACAD SCI USA, V90, P6395, DOI 10.1073/pnas.90.14.6395; Jason J, 1999, AIDS RES HUM RETROV, V15, P173, DOI 10.1089/088922299311592; JUNE CH, 1987, MOL CELL BIOL, V7, P4472, DOI 10.1128/MCB.7.12.4472; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; KOONG AC, 1994, CANCER RES, V54, P1425; Korin YD, 1998, J VIROL, V72, P3161, DOI 10.1128/JVI.72.4.3161-3168.1998; KORNFELD H, 1988, NATURE, V335, P445, DOI 10.1038/335445a0; LANDO Z, 1983, NATURE, V305, P733, DOI 10.1038/305733a0; LANIER LL, 1995, J IMMUNOL, V154, P97; LEE TH, 1982, CANCER RES, V42, P3995; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LINSLEY PS, 1994, IMMUNITY, V1, P793, DOI 10.1016/S1074-7613(94)80021-9; LINSLEY PS, 1991, J EXP MED, V174, P561, DOI 10.1084/jem.174.3.561; Low P, 1997, J ACQ IMMUN DEF SYND, V15, P264; MARTIN PJ, 1986, J IMMUNOL, V136, P3282; MCKEATING JA, 1991, J VIROL, V65, P852, DOI 10.1128/JVI.65.2.852-860.1991; Misse D, 1999, BLOOD, V93, P2454, DOI 10.1182/blood.V93.8.2454.408k35_2454_2462; Ni HT, 1999, J IMMUNOL, V162, P5183; ORENTAS RJ, 1993, AIDS RES HUM RETROV, V9, P1157, DOI 10.1089/aid.1993.9.1157; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; Paquette JS, 1998, J VIROL, V72, P9329, DOI 10.1128/JVI.72.11.9329-9336.1998; Popik W, 1996, MOL CELL BIOL, V16, P6532; Popik W, 1998, J VIROL, V72, P6406, DOI 10.1128/JVI.72.8.6406-6413.1998; Popik W, 1998, VIROLOGY, V252, P210, DOI 10.1006/viro.1998.9466; Rizzuto CD, 1997, J VIROL, V71, P4847, DOI 10.1128/JVI.71.6.4847-4851.1997; Roberts BD, 1999, AIDS, V13, P425, DOI 10.1097/00002030-199902250-00020; Rossio JL, 1995, AIDS RES HUM RETROV, V11, P1433, DOI 10.1089/aid.1995.11.1433; SAIFUDDIN M, 1994, AIDS RES HUM RETROV, V10, P829, DOI 10.1089/aid.1994.10.829; SAIFUDDIN M, 1995, J EXP MED, V182, P501, DOI 10.1084/jem.182.2.501; SchmidAntomarchi H, 1996, EUR J IMMUNOL, V26, P717, DOI 10.1002/eji.1830260331; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; Siefken R, 1998, J IMMUNOL, V161, P1645; SIEKEVITZ M, 1987, SCIENCE, V238, P1575, DOI 10.1126/science.2825351; SMITHGALL MD, 1995, AIDS RES HUM RETROV, V11, P885, DOI 10.1089/aid.1995.11.885; SPINA CA, 1995, J VIROL, V69, P2977, DOI 10.1128/JVI.69.5.2977-2988.1995; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; STAUNTON DE, 1989, CELL, V56, P849, DOI 10.1016/0092-8674(89)90689-2; STEVENSON M, 1990, EMBO J, V9, P1551, DOI 10.1002/j.1460-2075.1990.tb08274.x; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Sun SC, 1996, MOL CELL BIOL, V16, P1058; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TONGSTARKSEN SE, 1989, J IMMUNOL, V142, P702; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; TREMBLAY M, 1994, EMBO J, V13, P774, DOI 10.1002/j.1460-2075.1994.tb06320.x; Tremblay MJ, 1998, IMMUNOL TODAY, V19, P346, DOI 10.1016/S0167-5699(98)01286-9; Truneh A, 1996, MOL IMMUNOL, V33, P321, DOI 10.1016/0161-5890(95)00077-1; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; Ward SG, 1996, BIOCHEM J, V318, P361, DOI 10.1042/bj3180361; WEISS A, 1986, J IMMUNOL, V137, P819; Weissman D, 1997, NATURE, V389, P981, DOI 10.1038/40173; Wolthers KC, 1996, EUR J IMMUNOL, V26, P1700, DOI 10.1002/eji.1830260806; ZACK JA, 1992, J VIROL, V66, P1717, DOI 10.1128/JVI.66.3.1717-1725.1992	98	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6359	6369		10.1074/jbc.M002198200	http://dx.doi.org/10.1074/jbc.M002198200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096063	hybrid			2022-12-25	WOS:000167261000041
J	Henderson, AM; Wang, SJ; Taylor, AC; Aitkenhead, M; Hughes, CCW				Henderson, AM; Wang, SJ; Taylor, AC; Aitkenhead, M; Hughes, CCW			The basic helix-loop-helix transcription factor HESR1 regulates endothelial cell tube formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; TYROSINE KINASE; NERVOUS-SYSTEM; FACTOR-BETA; ANGIOGENESIS; RECEPTOR; MECHANISMS; HAIRY; EXPRESSION; PROTEINS	Human endothelial cells can be induced to form capillary-like tubular networks in collagen gels. We have used this in vitro model and representational difference analysis to identify genes involved in the formation of new blood vessels. HESR1 (HEY-1/HRT-1/CHF-2/gridlock), a basic helix-loop-helix protein related to the hairy/enhancer of split/HES family, is absent in migrating and proliferating cultures of endothelial cells but is rapidly induced during capillary-like network formation. HESR1 is detectable in all adult tissues and at high levels in well vascularized organs such as heart and brain. Its expression is also enriched in aorta and purified capillaries. Overexpression of HESR1 in endothelial cells down-regulates vascular endothelial cell growth factor receptor-2 (VEGFR2) mRNA levels and blocks proliferation, migration, and network formation. Interestingly, reduction of expression of HESR1 by antisense oligonucleotides also blocks endothelial cell network formation in vitro. Finally, HESR1 expression is altered in several breast, lung, and kidney tumors. These data are consistent with a temporal model for HESR1 action where down-regulation at the initiation of new vessel budding is required to allow VEGFR2-mediated migration and proliferation, but re-expression of HESR1 is necessary for induction of tubular network formation and continued maintenance of the mature, quiescent vessel.	Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Hughes, CCW (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92697 USA.		Hughes, Christopher/F-7510-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060067] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60067] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aronson BD, 1997, MOL CELL BIOL, V17, P5581, DOI 10.1128/MCB.17.9.5581; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chin MT, 2000, J BIOL CHEM, V275, P6381, DOI 10.1074/jbc.275.9.6381; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DUFFY JB, 1994, ADV GENET, V31, P1, DOI 10.1016/S0065-2660(08)60394-6; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Grbavec D, 1996, BIOCHEM BIOPH RES CO, V223, P701, DOI 10.1006/bbrc.1996.0959; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Kageyama R, 1997, CURR OPIN GENET DEV, V7, P659, DOI 10.1016/S0959-437X(97)80014-7; Kokubo H, 1999, BIOCHEM BIOPH RES CO, V260, P459, DOI 10.1006/bbrc.1999.0880; Krebs LT, 2000, GENE DEV, V14, P1343; Lee JE, 1997, CURR OPIN NEUROBIOL, V7, P13, DOI 10.1016/S0959-4388(97)80115-8; Leimeister C, 1999, MECH DEVELOP, V85, P173, DOI 10.1016/S0925-4773(99)00080-5; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; Murphy LLS, 1999, CELL IMMUNOL, V194, P150; Nakagawa O, 1999, DEV BIOL, V216, P72, DOI 10.1006/dbio.1999.9454; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; PEPPER MS, 1992, BIOCHEM BIOPH RES CO, V189, P824, DOI 10.1016/0006-291X(92)92277-5; Philpott NJ, 1996, BLOOD, V87, P2244, DOI 10.1182/blood.V87.6.2244.bloodjournal8762244; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SPRINGHORN JP, 1995, IN VITRO CELL DEV-AN, V31, P473; Steingrimsson E, 1998, DEVELOPMENT, V125, P4607; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; VILLASCHI S, 1994, LAB INVEST, V71, P291; Zhong TP, 2000, SCIENCE, V287, P1820, DOI 10.1126/science.287.5459.1820; Zimrin AB, 1996, J BIOL CHEM, V271, P32499, DOI 10.1074/jbc.271.51.32499	46	123	134	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6169	6176		10.1074/jbc.M008506200	http://dx.doi.org/10.1074/jbc.M008506200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11069914	hybrid			2022-12-25	WOS:000167261000017
J	Lefebvre-Legendre, L; Vaillier, J; Benabdelhak, H; Velours, J; Slonimski, PP; di Rago, JP				Lefebvre-Legendre, L; Vaillier, J; Benabdelhak, H; Velours, J; Slonimski, PP; di Rago, JP			Identification of a nuclear gene (FMC1) required for the assembly/stability of yeast mitochondrial F-1-ATPase in heat stress conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE-TRIPHOSPHATASE COMPLEX; ATP SYNTHASE; SACCHAROMYCES-CEREVISIAE; STRUCTURAL GENE; DELTA-SUBUNIT; ALPHA-SUBUNIT; BETA-SUBUNIT; F1-ATPASE; DISRUPTION; PROTEINS	We have identified a yeast nuclear gene (FMC1) that is required at elevated temperatures (37 degreesC) for the formation/stability of the F-1 sector of the mitochondrial ATP synthase, Western blot analysis showed that Fmc1p is a soluble protein located in the mitochondrial matrix. At elevated temperatures in yeast cells lacking Fmc1p, the alpha -F-1 and beta -F-1 proteins are synthesized, transported, and processed to their mature size. However, instead of being incorporated into a functional F-1 oligomer, they form large aggregates in the mitochondrial matrix. Identical perturbations were reported previously for yeast cells lacking either Atp12p or Atp11p, two specific assembly factors of the F-1 sector (Ackerman, S, H,, and Tzagoloff, A. (1990) Proc. Natl, Acad, Sci. U.S.A. 87, 4986-4990), and we show that the absence of Fmc1p can be efficiently compensated for by increasing the expression of Atp12p, However, unlike Atp12p and Atp11p, Fmc1p is not required in normal growth conditions (28-30 degreesC). We propose that Fmc1p is required for the proper folding/stability or functioning of Atp12p in heat stress conditions.	Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, F-33077 Bordeaux, France; Univ Paris 06, CNRS, Ctr Mol Genet, Lab Propre Associe, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay	di Rago, JP (corresponding author), Univ Bordeaux 2, CNRS, Inst Biochim & Genet Cellulaires, 1 Rue Camille St Saens, F-33077 Bordeaux, France.	jp.dirago@ibgc.u-bordeaux2.fr						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ACKERMAN SH, 1992, J BIOL CHEM, V267, P7386; ACKERMAN SH, 1990, P NATL ACAD SCI USA, V87, P4986, DOI 10.1073/pnas.87.13.4986; ANSORGE W, 1983, ELECTROPHORESIS, V82, P235; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; BIANCHET M, 1994, BBA-BIOENERGETICS, V1187, P163, DOI 10.1016/0005-2728(94)90103-1; BOWMAN S, 1991, J BIOL CHEM, V266, P7517; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; Chen XJ, 2000, INT REV CYTOL, V194, P197; CLAISSE ML, 1980, MOL GEN GENET, V177, P375, DOI 10.1007/BF00271476; DAUM G, 1982, J BIOL CHEM, V257, P3028; DIRAGO JP, 1990, J BIOL CHEM, V265, P3323; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Giraud MF, 1997, EUR J BIOCHEM, V245, P813, DOI 10.1111/j.1432-1033.1997.00813.x; GIRAUD MF, 1994, EUR J BIOCHEM, V222, P851, DOI 10.1111/j.1432-1033.1994.tb18932.x; GUELIN E, 1993, J BIOL CHEM, V268, P161; Guerin B, 1979, Methods Enzymol, V55, P149; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; JACQUIER A, 1983, MOL GEN GENET, V192, P487, DOI 10.1007/BF00392195; LABOUESSE M, 1983, EMBO J, V2, P269, DOI 10.1002/j.1460-2075.1983.tb01416.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MICHON T, 1988, EUR J BIOCHEM, V172, P621, DOI 10.1111/j.1432-1033.1988.tb13934.x; MUKHOPADHYAY A, 1994, FEBS LETT, V343, P160, DOI 10.1016/0014-5793(94)80310-2; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; PAUL MF, 1994, J BIOL CHEM, V269, P26158; PAUL MF, 1992, THESIS U BORDEAUX 2; Pedersen PL, 1996, J BIOENERG BIOMEMBR, V28, P389, DOI 10.1007/BF02113979; RIGOULET M, 1979, FEBS LETT, V102, P18, DOI 10.1016/0014-5793(79)80919-9; Rose MD., 1990, METHODS YEAST GENETI; Rouillard JM, 1996, MOL GEN GENET, V252, P700, DOI 10.1007/s004380050279; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIKORSKI RS, 1989, GENETICS, V122, P19; SOMLO M, 1968, EUR J BIOCHEM, V5, P276, DOI 10.1111/j.1432-1033.1968.tb00368.x; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Szczepanek T, 1996, EMBO J, V15, P3758, DOI 10.1002/j.1460-2075.1996.tb00746.x; TAKEDA M, 1985, J BIOL CHEM, V260, P5458; TAKEDA M, 1986, J BIOL CHEM, V261, P5126; TODD RD, 1980, J BIOL CHEM, V255, P5461; Tokatlidis K, 1999, J BIOL CHEM, V274, P35285, DOI 10.1074/jbc.274.50.35285; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; Vaillier J, 1999, J BIOL CHEM, V274, P543, DOI 10.1074/jbc.274.1.543; Wach A, 1996, YEAST, V12, P259, DOI 10.1002/(SICI)1097-0061(19960315)12:3<259::AID-YEA901>3.0.CO;2-C; Wang ZG, 1998, J BIOL CHEM, V273, P2993, DOI 10.1074/jbc.273.5.2993; Wang ZG, 2000, EMBO J, V19, P1486, DOI 10.1093/emboj/19.7.1486; Wang ZG, 2000, J BIOL CHEM, V275, P5767, DOI 10.1074/jbc.275.8.5767; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; YANG MJ, 1994, J BIOL CHEM, V269, P1270; [No title captured]	52	100	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6789	6796		10.1074/jbc.M009557200	http://dx.doi.org/10.1074/jbc.M009557200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096112	hybrid			2022-12-25	WOS:000167261000092
J	Marianovsky, I; Aizenman, E; Engelberg-Kulka, H; Glaser, G				Marianovsky, I; Aizenman, E; Engelberg-Kulka, H; Glaser, G			The regulation of the Escherichia coli mazEF promoter involves an unusual alternating palindrome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; BACTERIOPHAGE-LAMBDA; ADDICTION OPERON; FIS PROTEIN; HOST FACTOR; CCD OPERON; F-PLASMID; GENES; SYSTEM; AUTOREGULATION	The Escherichia coli mazEF system is a chromosomal "addiction module" that, under starvation conditions in which guanosine-3',5'-bispyrophosphate (ppGpp) is produced, is responsible for programmed cell death. This module specifies for the toxic stable protein MazF and the labile antitoxic protein MazE, Upstream from the mazEF module are two promoters, P-2 and P-3 that are strongly negatively autoregulated by MazE and MazF, We show that the expression of this module is positively regulated by the factor for inversion stimulation. What seems to be responsible for the negative autoregulation of mazEF is an unusual DNA structure, which we have called an "alternating palindrome." The middle part, "a," of this structure may complement either the downstream fragment,"b," or the upstream fragment, "c", When the MazE MazF complex binds either of these arms of the alternating palindrome, strong negative autoregulation results. We suggest that the combined presence of the two promoters, the alternating palindrome structure and the factor for inversion stimulation-binding site, all permit the expression of the mazEF module to be sensitively regulated under various growth conditions.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Cellular Biochem, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Glaser, G (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Cellular Biochem, IL-91120 Jerusalem, Israel.							Aizenman E, 1996, P NATL ACAD SCI USA, V93, P6059, DOI 10.1073/pnas.93.12.6059; Aviv M, 1996, FEMS MICROBIOL LETT, V140, P71; BALL CA, 1992, J BACTERIOL, V174, P8043, DOI 10.1128/JB.174.24.8043-8056.1992; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CASADABAN MJ, 1979, P NATL ACAD SCI USA, V76, P4530, DOI 10.1073/pnas.76.9.4530; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; Couturier M, 1998, TRENDS MICROBIOL, V6, P269, DOI 10.1016/S0966-842X(98)01311-0; DEFEYTER R, 1989, MOL GEN GENET, V218, P481, DOI 10.1007/BF00332413; DIEDERICH L, 1994, BIOTECHNIQUES, V16, P916; Engelberg-Kulka H, 1998, P NATL ACAD SCI USA, V95, P15481, DOI 10.1073/pnas.95.26.15481; Engelberg-Kulka H, 1999, ANNU REV MICROBIOL, V53, P43, DOI 10.1146/annurev.micro.53.1.43; FINKEL SE, 1992, MOL MICROBIOL, V6, P3257, DOI 10.1111/j.1365-2958.1992.tb02193.x; GAFNY R, 1988, NUCLEIC ACIDS RES, V16, P61, DOI 10.1093/nar/16.1.61; GILADI H, 1992, J MOL BIOL, V224, P937, DOI 10.1016/0022-2836(92)90461-R; Gotfredsen M, 1998, MOL MICROBIOL, V29, P1065, DOI 10.1046/j.1365-2958.1998.00993.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JENSEN RB, 1995, MOL MICROBIOL, V17, P205, DOI 10.1111/j.1365-2958.1995.mmi_17020205.x; KOCH C, 1986, J BIOL CHEM, V261, P5673; Magnuson P, 1996, J BIOL CHEM, V271, P18705, DOI 10.1074/jbc.271.31.18705; Magnuson R, 1998, J BACTERIOL, V180, P6342; Maniatis T., 1982, MOL CLONING LAB MANU; MASUDA Y, 1994, J BACTERIOL, V176, P5861, DOI 10.1128/JB.176.18.5861-5863.1994; MASUDA YJ, 1993, J BACTERIOL, V175, P6850, DOI 10.1128/jb.175.21.6850-6856.1993; METZGER S, 1988, J BIOL CHEM, V263, P15699; Miller J.H., 1972, EXPT MOL GENETICS; Pan CQ, 1996, J MOL BIOL, V264, P675, DOI 10.1006/jmbi.1996.0669; ROBERTS RC, 1993, J BIOL CHEM, V268, P27109; RUIZECHEVARRIA MJ, 1991, MOL MICROBIOL, V5, P2685, DOI 10.1111/j.1365-2958.1991.tb01977.x; SANGER F, 1977, P NATL ACAD SCI USA, V80, P7010; TAM JE, 1989, J BACTERIOL, V171, P2353, DOI 10.1128/jb.171.5.2353-2360.1989; TAM JE, 1989, MOL GEN GENET, V219, P26, DOI 10.1007/BF00261153; TSUCHIMOTO S, 1993, MOL GEN GENET, V237, P81, DOI 10.1007/BF00282787; Xu JM, 1997, J MOL BIOL, V270, P346, DOI 10.1006/jmbi.1997.1133; YARMOLINSKY MB, 1995, SCIENCE, V267, P836, DOI 10.1126/science.7846528	34	111	118	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5975	5984		10.1074/jbc.M008832200	http://dx.doi.org/10.1074/jbc.M008832200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11071896	hybrid			2022-12-25	WOS:000167115100076
J	Peck, RF; Echavarri-Erasun, C; Johnson, EA; Ng, WV; Kennedy, SP; Hood, L; DasSarma, S; Krebs, MP				Peck, RF; Echavarri-Erasun, C; Johnson, EA; Ng, WV; Kennedy, SP; Hood, L; DasSarma, S; Krebs, MP			Brp and blh are required for synthesis of the retinal cofactor of bacteriorhodopsin in Halobacterium salinarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPSIN GENE-EXPRESSION; HALOPHILIC ARCHAEBACTERIUM; MEMBRANE INSERTION; BACTERIOOPSIN GENE; PURPLE MEMBRANE; BETA-CAROTENE; BOP GENE; IN-VIVO; HALOBIUM; PROTEIN	Bacteriorhodopsin, the light-driven proton pump of Halobacterium salinarum, consists of the membrane apoprotein bacterioopsin and a covalently bound retinal cofactor. The mechanism by which retinal is synthesized and bound to bacterioopsin in vivo is unknown. As a step toward identifying cellular factors involved in this process, we constructed an in-frame deletion of brp, a gene implicated in bacteriorhodopsin biogenesis. In the Delta brp strain, bacteriorhodopsin levels are decreased similar to4.0-fold compared with wild type, whereas bacterioopsin levels are normal. The probable precursor of retinal, beta -carotene, is increased similar to3.8-fold, whereas retinal is decreased by similar to3.7-fold. These results suggest that brp is involved in retinal synthesis. Additional cellular factors may substitute for brp function in the Delta brp strain because retinal production is not abolished. The in-frame deletion of blh, a brp paralog identified by analysis of the Halobacterium sp, NRC-1 genome, reduced bacteriorhodopsin accumulation on solid medium but not in liquid. However, deletion of both brp and blh abolished bacteriorhodopsin and retinal production in liquid medium, again without affecting bacterioopsin accumulation. The level of beta -carotene increased similar to5.3-fold. The simplest interpretation of these results is that brp and blh encode similar proteins that catalyze or regulate the conversion of beta -carotene to retinal.	Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA; Univ Wisconsin, Dept Food Microbiol & Toxicol, Madison, WI 53706 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Massachusetts, Dept Microbiol, Amherst, MA 01003 USA; Inst Syst Biol, Seattle, WA 98105 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Massachusetts System; University of Massachusetts Amherst; Institute for Systems Biology (ISB)	Krebs, MP (corresponding author), Univ Wisconsin, Sch Med, Dept Biomol Chem, Madison, WI 53706 USA.			DasSarma, Shiladitya/0000-0003-4162-2810; Krebs, Mark/0000-0001-9017-6066; Peck, Ronald/0000-0002-6498-5035; Echavarri-Erasun, Carlos/0000-0001-8363-5199; Kennedy, Sean/0000-0002-3932-8922				Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; BETLACH M, 1984, NUCLEIC ACIDS RES, V12, P7949, DOI 10.1093/nar/12.20.7949; Bieszke JA, 1999, P NATL ACAD SCI USA, V96, P8034, DOI 10.1073/pnas.96.14.8034; Dale H, 2000, P NATL ACAD SCI USA, V97, P7847, DOI 10.1073/pnas.140216497; Dale H, 1999, J BIOL CHEM, V274, P22693, DOI 10.1074/jbc.274.32.22693; DASSARMA S, 1984, P NATL ACAD SCI-BIOL, V81, P125, DOI 10.1073/pnas.81.1.125; DESHPANDE A, 1909, J BIOL CHEM, V274, P23535; GARTNER W, 1995, PHOTOCHEM PHOTOBIOL, V62, P1, DOI 10.1111/j.1751-1097.1995.tb05231.x; GROPP F, 1994, SYST APPL MICROBIOL, V16, P716; GROPP F, 1994, P NATL ACAD SCI USA, V91, P5475, DOI 10.1073/pnas.91.12.5475; Hoff WD, 1997, ANNU REV BIOPH BIOM, V26, P223, DOI 10.1146/annurev.biophys.26.1.223; HUANG KS, 1981, J BIOL CHEM, V256, P3802; Isenbarger TA, 1999, BIOCHEMISTRY-US, V38, P9023, DOI 10.1021/bi9905563; Kamekura M., 1988, HALOPHILIC BACTERIA, P25; Krebs MP, 2000, BBA-BIOENERGETICS, V1460, P15, DOI 10.1016/S0005-2728(00)00126-2; KREBS MP, 1991, P NATL ACAD SCI USA, V88, P859, DOI 10.1073/pnas.88.3.859; KREBS MP, 1993, P NATL ACAD SCI USA, V90, P1987, DOI 10.1073/pnas.90.5.1987; KUSHWAHA SC, 1980, CAN J MICROBIOL, V26, P1011, DOI 10.1139/m80-171; KUSHWAHA SC, 1976, CAN J BIOCHEM CELL B, V54, P816, DOI 10.1139/o76-117; LEONG D, 1988, J BACTERIOL, V170, P4910, DOI 10.1128/jb.170.10.4910-4915.1988; LEONG D, 1988, J BACTERIOL, V170, P4903, DOI 10.1128/jb.170.10.4903-4909.1988; Ng WV, 2000, P NATL ACAD SCI USA, V97, P12176, DOI 10.1073/pnas.190337797; Oesterhelt D, 1998, CURR OPIN STRUC BIOL, V8, P489, DOI 10.1016/S0959-440X(98)80128-0; OESTERHELT D, 1974, FEBS LETT, V44, P262, DOI 10.1016/0014-5793(74)81153-1; Oesterhelt D, 1974, Methods Enzymol, V31, P667; Peck RF, 2000, MOL MICROBIOL, V35, P667, DOI 10.1046/j.1365-2958.2000.01739.x; PFEIFER FA, 1985, J BACTERIOL, V164, P414, DOI 10.1128/JB.164.1.414-420.1985; SHAND RF, 1991, J BACTERIOL, V173, P4692, DOI 10.1128/jb.173.15.4692-4699.1991; STAHL W, 1994, METHOD ENZYMOL, V234, P388; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; Yang CF, 1996, J BACTERIOL, V178, P840, DOI 10.1128/jb.178.3.840-845.1996; YANG CF, 1990, J BACTERIOL, V172, P4118, DOI 10.1128/jb.172.7.4118-4121.1990; Yokoyama S, 1997, ANNU REV GENET, V31, P315, DOI 10.1146/annurev.genet.31.1.315; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	34	72	76	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5739	5744		10.1074/jbc.M009492200	http://dx.doi.org/10.1074/jbc.M009492200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11092896	hybrid			2022-12-25	WOS:000167115100047
J	Park, SJ; Itoh, T; Takenawa, T				Park, SJ; Itoh, T; Takenawa, T			Phosphatidylinositol 4-phosphate 5-kinase type I is regulated through phosphorylation response by extracellular stimuli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PROTEIN-TYROSINE PHOSPHORYLATION; ADP-RIBOSYLATION FACTOR-1; PHOSPHOINOSITIDE KINASES; LYSOPHOSPHATIDIC ACID; SIGNAL TRANSDUCTION; RAT-1 FIBROBLASTS; FACTOR RECEPTOR; A431 CELLS; 4,5-BISPHOSPHATE	Phosphatidylinositol 4-phosphate 5-kinase (PIPK) catalyzes a final step in the synthesis of phosphatidylinositol 4,5-bisphosphate (PIP2), a lipid signaling molecule. Strict regulation of PIPK activity is thought to be essential in intact cells. Here we show that type I enzymes of PIPK (PIPKI) are phosphorylated by cyclic AMP-dependent protein kinase (PKA), and phosphorylation of PIPKI suppresses its activity. Serine 214 was found to be a major phosphorylation site of PIPK type I alpha (PIPKI alpha) that is catalyzed by PKA. In contrast, lysophosphatidic acid-induced protein kinase C activation increased PIPKI alpha activity. Activation of PIPKI alpha was induced by dephosphorylation, which was catalyzed by an okadaic acid-sensitive phosphatase, protein phosphatase 1 (PP1). In vitro dephosphorylation of PIPKI alpha with PP1 increased PIPK activity, indicating that PP1 plays a role in lysophosphatidic acid-induced dephosphorylation of PIPKI alpha. These results strongly suggest that activity of PIPKI alpha in NIH 3T3 cells is regulated by the reversible balance between PKA-dependent phosphorylation and PP1-dependent dephosphorylation.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 108, Japan; Japan Sci & Technol Corp, CREST, Tokyo 108, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 108, Japan.							ANGER KR, 1989, CELL, V57, P167; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BOON AM, 1985, BIOCHEM BIOPH RES CO, V129, P431, DOI 10.1016/0006-291X(85)90169-X; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Carvajal JJ, 1996, NAT GENET, V14, P157, DOI 10.1038/ng1096-157; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COCHET C, 1991, J BIOL CHEM, V266, P637; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; HALENDA SP, 1984, BIOCHEM BIOPH RES CO, V124, P507, DOI 10.1016/0006-291X(84)91583-3; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hokin L E, 1968, Int Rev Cytol, V23, P187, DOI 10.1016/S0074-7696(08)60272-7; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; ITO T, 1998, J BIOL CHEM, V273, P20292; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; Jones DH, 2000, J BIOL CHEM, V275, P13962, DOI 10.1074/jbc.C901019199; KAULENHD, 1976, THROMB HAEMOSTASIS, V35, P364; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; LUO K, 1990, ONCOGENE, V5, P921; Martin ME, 2000, J BIOL CHEM, V275, P19050, DOI 10.1074/jbc.275.25.19050; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; MICHELL RH, 1975, BIOCHIM BIOPHYS ACTA, V415, P81, DOI 10.1016/0304-4157(75)90017-9; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; PAYRASTRE B, 1990, BIOCHEM J, V272, P665, DOI 10.1042/bj2720665; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Rumenapp U, 1998, BIOCHEM J, V334, P625; SCHACHT J, 1978, J LIPID RES, V19, P1063; SMITH CD, 1989, J BIOL CHEM, V264, P3206; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; URUMOW T, 1990, FEBS LETT, V264, P15; VANCORVEN EJ, 1993, P NATL ACAD SCI USA, V90, P1257, DOI 10.1073/pnas.90.4.1257; Vancurova I, 1999, J BIOL CHEM, V274, P1147, DOI 10.1074/jbc.274.2.1147; vonWillebrand M, 1996, EUR J BIOCHEM, V235, P828; WALKER DH, 1987, P NATL ACAD SCI USA, V84, P7513, DOI 10.1073/pnas.84.21.7513; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105	46	71	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4781	4787		10.1074/jbc.M010177200	http://dx.doi.org/10.1074/jbc.M010177200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087761	hybrid			2022-12-25	WOS:000168484300035
J	Sun, WY; Kesavan, K; Schaefer, BC; Garrington, TP; Ware, M; Johnson, NL; Gelfand, EW; Johnson, GL				Sun, WY; Kesavan, K; Schaefer, BC; Garrington, TP; Ware, M; Johnson, NL; Gelfand, EW; Johnson, GL			MEKK2 associates with the adapter protein Lad/RIBP and regulates the MEK5-BMK1/ERK5 pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; MAP KINASE CASCADE; C-JUN PROMOTER; TRANSCRIPTION FACTOR MEF2C; SIGNAL-TRANSDUCTION; CYCLE PROGRESSION; COUPLED RECEPTORS; ACTIVATION; BINDING; KSR	MEKK2 and MEKK3 are two closely related mitogen-activated protein kinase (MAPK) kinase kinases, The kinase domains of MEKK2 and MEKK3 are nearly identical, although their N-terminal regulatory domains are significantly divergent. By yeast two-hybrid library screening, we have identified MEK5, the MAPK kinase in the big mitogen-activated protein kinase 1 (BMK1)/ ERK5 pathway, as a binding partner for MEKK2. MEKK2 expression stimulates BMK1/ERK5 activity, the downstream substrate for MEK5. Compared with MEKK3, MEKK2 activated BMK1/ERK5 to a greater extent, which might correlate with a higher affinity MEKK2-MEK5 interaction. A dominant negative form of MEK5 blocked the activation of BMK1/ERK5 by MEKK2, whereas activation of c-Jun N-terminal kinase (JNK) was unaffected, showing that MEK5 is a specific downstream effector of MEKK2 in the BMK1/ERK5 pathway. Activation of BMK1/ERK5 by epidermal growth factor and H2O2 in Cos7 and HEK293 cells was completely blocked by a kinase-inactive MEKK3 (MEKK3kin(-)), whereas MEKK2kin(-) had no effect. However, in D10 T cells, expression of MEKK2kin(-) but not MEKK3kin(-) inhibited BMK1/ERK5 activity. Two-hybrid screening also identified Lck-associated adapter/Rlk- and Itk-binding protein (Lad/RIBP), a T cell adapter protein, as a binding partner for MEKK2. MEKK2 and Lad/RIBP colocalize at the T cell contact site with antigen-loaded presenting cells, demonstrating cotranslocation of MEKK2 and Lad/RIBP during T cell activation. MEKK3 neither binds Lad/RIBP nor is recruited to the T cell contact with antigen presenting cell. MEKK2 and MEKK3 are differentially associated with signaling from specific upstream receptor systems, whereas both activate the MEK5-BMK1/ERK5 pathway.	Univ Colorado, Hlth Sci Ctr, Dept Pharmacol C236, Denver, CO 80262 USA; Univ Colorado, Ctr Canc, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Denver; National Jewish Health; National Jewish Health	Johnson, GL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pharmacol C236, 4200 E 9th Ave, Denver, CO 80262 USA.			Schaefer, Brian C/0000-0001-8877-3507	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042246, R01AI042246] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42246] Funding Source: Medline; NIDDK NIH HHS [DK37871] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe J, 1997, J BIOL CHEM, V272, P20389, DOI 10.1074/jbc.272.33.20389; ABI JI, 1996, J BIOL CHEM, V271, P16586; ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; Bartel P. L., 1993, CELLULAR INTERACTION, P153; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Bunnell SC, 2000, J BIOL CHEM, V275, P2219, DOI 10.1074/jbc.275.3.2219; Cacace AM, 1999, MOL CELL BIOL, V19, P229; CARTER R, 1991, ONCOGENE, V6, P229; CHAO TH, 1999, J BIOL CHEM, V274, P36305; Cheng JK, 2000, MOL CELL BIOL, V20, P2334, DOI 10.1128/MCB.20.7.2334-2342.2000; Ching KA, 1999, J IMMUNOL, V163, P6006; Ching KA, 2000, J IMMUNOL, V165, P256, DOI 10.4049/jimmunol.165.1.256; CHOI KY, 1994, CELL, V78, P499; Choi YB, 1999, J IMMUNOL, V163, P5242; Coso OA, 1997, J BIOL CHEM, V272, P20691, DOI 10.1074/jbc.272.33.20691; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Fanger GR, 1997, EMBO J, V16, P4961, DOI 10.1093/emboj/16.16.4961; Faruki S, 2000, J CELL SCI, V113, P2557; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Liao XC, 1995, IMMUNITY, V3, P757, DOI 10.1016/1074-7613(95)90065-9; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; PRINTEN JA, 1994, GENETICS, V138, P609; Rajagopal K, 1999, J EXP MED, V190, P1657, DOI 10.1084/jem.190.11.1657; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; RUDDEN DM, 1991, NATURE, V350, P250; RUDDEN DM, 1992, CHROMOSOMA, V101, P342; Schaefer BC, 1999, IMMUNITY, V11, P411, DOI 10.1016/S1074-7613(00)80116-8; Schaeffer EM, 1999, SCIENCE, V284, P638, DOI 10.1126/science.284.5414.638; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Schneider H, 2000, J BIOL CHEM, V275, P3835, DOI 10.1074/jbc.275.6.3835; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Sun WY, 2000, J BIOL CHEM, V275, P24421, DOI 10.1074/jbc.M003148200; Therrien M, 1996, GENE DEV, V10, P2684, DOI 10.1101/gad.10.21.2684; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Xia Y, 1998, GENE DEV, V12, P3369, DOI 10.1101/gad.12.21.3369; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; Yang CC, 1998, NUCLEIC ACIDS RES, V26, P4771, DOI 10.1093/nar/26.20.4771; Yang JH, 2000, NAT GENET, V24, P309, DOI 10.1038/73550; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; Zhao M, 1999, MOL CELL BIOL, V19, P21; ZHENG CF, 1994, EMBO J, V13, P1123, DOI 10.1002/j.1460-2075.1994.tb06361.x; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	65	120	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5093	5100		10.1074/jbc.M003719200	http://dx.doi.org/10.1074/jbc.M003719200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11073940	hybrid			2022-12-25	WOS:000168484300076
J	Wolins, NE; Rubin, D; Brasaemle, DL				Wolins, NE; Rubin, D; Brasaemle, DL			TIP47 associates with lipid droplets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-RELATED PROTEIN; PERILIPIN-A; STORAGE; ACCUMULATION; EXPRESSION; SEQUENCE; CLONING; CELLS; CDNAS; ADRP	Most mammalian cells package neutral lipids into droplets that are surrounded by a monolayer of phospholipids and a specific set of proteins including the adipose differentiation-related protein (ADRP; also called adipophilin), which is found in a wide array of cell types, and the perilipins, which are restricted to adipocytes and steroidogenic cells, TIP47 was initially identified in a yeast two-hybrid screen for proteins that interact with the cytoplasmic tail of the mannose B-phosphate receptor, yet its sequence is highly similar to the lipid droplet protein, ADRP, and more distantly related to perilipins. Hence, we hypothesized that TIP47 might be associated with lipid droplets. In HeLa cells grown in standard low lipid-containing culture media, immunofluorescence microscopy revealed that the cells had few lipid droplets; however, TIP47 and ADRP were found on the surfaces of the small lipid droplets present. When the cells were grown in media supplemented with physiological levels of fatty acids, the amount of neutral lipid stored in lipid droplets increased dramatically, as did the staining of TIP47 and ADRP surrounding these droplets. TIP47 was found primarily in the cytosolic fractions of HeLa cells and murine MA10 Leydig cells grown in low lipid-containing culture medium, while ADRP was undetectable in these fractionated cell homogenates, When HeLa and MA10 Leydig cells were lipid-loaded, significant levels of ADRP were found in the floating lipid droplet fractions and TIP47 levels remained constant, but the distribution of a significant portion of TIP47 shifted from the cytosolic fractions to the lipid droplet fractions. Thus, we conclude that TIP47 associates with nascent lipid droplets and can be classified as a lipid droplet-associated protein.	Rutgers State Univ, Dept Nutr Sci, New Brunswick, NJ 08901 USA	Rutgers State University New Brunswick	Brasaemle, DL (corresponding author), Rutgers State Univ, Dept Nutr Sci, 96 Lipman Dr, New Brunswick, NJ 08901 USA.	Brasaemle@AESOP.Rutgers.edu		Brasaemle, Dawn/0000-0002-8553-8285				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; [Anonymous], 1987, FUNCTIONAL HISTOLOGY; BLANCHETTEMACKIE EJ, 1995, J LIPID RES, V36, P1211; BOHN H, 1983, ONCODEV BIOL MED, V4, P343; Bonifacino J. S., 1998, CURRENT PROTOCOLS CE; Brasaemle DL, 1997, J LIPID RES, V38, P2249; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; Brasaemle DL, 1997, J BIOL CHEM, V272, P9378; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; COLEMAN R, 1976, J BIOL CHEM, V251, P4537; DELALLERA M, 1979, BIOCHIM BIOPHYS ACTA, V574, P414, DOI 10.1016/0005-2760(79)90237-6; Diaz E, 1998, CELL, V93, P433, DOI 10.1016/S0092-8674(00)81171-X; FREEMAN DA, 1982, J BIOL CHEM, V257, P4231; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gao J, 1999, J BIOL CHEM, V274, P16825, DOI 10.1074/jbc.274.24.16825; Gao J, 2000, J CELL PHYSIOL, V182, P297; GOCZE PM, 1994, CYTOMETRY, V17, P151, DOI 10.1002/cyto.990170207; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; GREENBERG AS, 1993, P NATL ACAD SCI USA, V90, P12035, DOI 10.1073/pnas.90.24.12035; Hammersen F., 1985, HISTOLOGY COLOR ATLA; Heid HW, 1996, BIOCHEM J, V320, P1025, DOI 10.1042/bj3201025; Heid HW, 1998, CELL TISSUE RES, V294, P309, DOI 10.1007/s004410051181; JIANG HP, 1992, P NATL ACAD SCI USA, V89, P7856, DOI 10.1073/pnas.89.17.7856; Lin S, 1999, J BIOL CHEM, V274, P23276, DOI 10.1074/jbc.274.33.23276; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; MARCO R, 1974, MOL CELL BIOCHEM, V3, P53, DOI 10.1007/BF01660077; Scherer PE, 1998, NAT BIOTECHNOL, V16, P581, DOI 10.1038/nbt0698-581; SERVETNICK DA, 1995, J BIOL CHEM, V270, P16970, DOI 10.1074/jbc.270.28.16970; Spector A A, 1980, Prog Lipid Res, V19, P155; Than NG, 1998, EUR J BIOCHEM, V258, P752, DOI 10.1046/j.1432-1327.1998.2580752.x; Weiss L., 1983, HISTOLOGY CELL TISSU	32	240	248	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5101	5108		10.1074/jbc.M006775200	http://dx.doi.org/10.1074/jbc.M006775200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11084026	hybrid			2022-12-25	WOS:000168484300077
J	Khoo, HH; Tang, JB; Chatterjee, D				Khoo, HH; Tang, JB; Chatterjee, D			Variation in mannose-capped terminal arabinan motifs of lipoarabinomannans from clinical isolates of Mycobacterium tuberculosis and Mycobacterium avium complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONREDUCING TERMINI; ATTENUATED STRAINS; MASS-SPECTROMETRY; HUMAN MACROPHAGES; PHAGOCYTOSIS; ETHAMBUTOL; VIRULENT; BIOSYNTHESIS; SMEGMATIS; BINDING	The unique terminal arabinan motifs of mycobacterial lipoarabinomannan (LAM), which are mannose-capped to different extents, probably constitute the single most important structural entity engaged in receptor binding and subsequent immunopathogenesis. We have developed a concerted approach of endoarabinanase digestion coupled with chromatography and mass spectrometry analysis to rapidly identify and quantitatively map the complement of such terminal units among the clinical isolates of different virulence and drug resistance profiles. In comparison with LAM from laboratory strains of Mycobacterium tuberculosis, an ethambutol (Emb) resistant clinical isolate was shown to have a significantly higher proportion of nonmannose capped arabinan termini, More drastically, the mannose capping was completely inhibited when an Emb-susceptible strain was grown in the presence of subminimal inhibitory concentration of Emb. Both cases resulted in an increase of arabinose to mannose ratio in the overall glycosyl composition of LAM. Emb, therefore, not only could affect the complete elaboration of the arabinan as found previously for LAM from Mycobacterium smegmatis resistant mutant but also could inhibit the extent of mannose capping and hence its associated biological functions in M. tuberculosis. Unexpectedly, an intrinsically Emb-resistant Mycobacterium avium isolate of smooth transparent colony morphology was found to have most of its arabinan termini capped with a single mannose residue instead of the more common dimannoside as established for LAM from M, tuberculosis. This is the first report on the LAM structure from M. avium complex, an increasingly important opportunistic infectious agent afflicting AIDS patients.	Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA; Acad Sinica, Inst Biol Chem, Taipei 115, Taiwan	Colorado State University; Academia Sinica - Taiwan	Chatterjee, D (corresponding author), Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA.		Khoo, Kay-Hooi/E-1989-2019	Khoo, Kay-Hooi/0000-0003-2906-406X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037139, R21AI037139] Funding Source: NIH RePORTER; FIC NIH HHS [TW 00943] Funding Source: Medline; NIAID NIH HHS [AI-37139] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELISLE JT, 1994, RES MICROBIOL, V145, P237, DOI 10.1016/0923-2508(94)90024-8; BIGGE JC, 1995, ANAL BIOCHEM, V230, P229, DOI 10.1006/abio.1995.1468; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6234; CHATTERJEE D, 1993, GLYCOBIOLOGY, V3, P497, DOI 10.1093/glycob/3.5.497; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; DELL A, 1994, METHOD ENZYMOL, V230, P108; DENG SJ, 1995, P NATL ACAD SCI USA, V92, P4992, DOI 10.1073/pnas.92.11.4992; Ferguson JS, 1999, J IMMUNOL, V163, P312; Gilleron M, 1997, J BIOL CHEM, V272, P117; Kang BK, 1998, INFECT IMMUN, V66, P2769, DOI 10.1128/IAI.66.6.2769-2777.1998; KHOO KH, 1995, J BIOL CHEM, V270, P12380, DOI 10.1074/jbc.270.21.12380; Khoo KH, 1996, J BIOL CHEM, V271, P28682, DOI 10.1074/jbc.271.45.28682; MCNEIL MR, 1994, GLYCOBIOLOGY, V4, P165, DOI 10.1093/glycob/4.2.165; MIKUSOVA K, 1995, ANTIMICROB AGENTS CH, V39, P2484, DOI 10.1128/AAC.39.11.2484; PRINZIS S, 1993, J GEN MICROBIOL, V139, P2649, DOI 10.1099/00221287-139-11-2649; Schlesinger LS, 1996, J IMMUNOL, V157, P4568; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; SCHLESINGER LS, 1993, J IMMUNOL, V150, P2920; Sidobre S, 2000, J BIOL CHEM, V275, P2415, DOI 10.1074/jbc.275.4.2415; TAKAYAMA K, 1989, ANTIMICROB AGENTS CH, V226, P139; WOLUCKA BA, 1994, J BIOL CHEM, V269, P23328	23	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3863	3871		10.1074/jbc.M004010200	http://dx.doi.org/10.1074/jbc.M004010200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11073941	hybrid			2022-12-25	WOS:000166921200021
J	McCormac, DJ; Litz, H; Wang, JX; Gollnick, PD; Berry, JO				McCormac, DJ; Litz, H; Wang, JX; Gollnick, PD; Berry, JO			Light-associated and processing-dependent protein binding to 5 ' regions of rbcL mRNA in the chloroplasts of a C-4 plant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSBA MESSENGER-RNA; PHOTOSYNTHETIC GENE-EXPRESSION; CHLAMYDOMONAS-REINHARDTII; UNTRANSLATED REGION; TRANSLATIONAL INITIATION; 5'-UNTRANSLATED REGION; TOBACCO PLASTIDS; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; AMARANTHUS-HYPOCHONDRIACUS; TRANSCRIPT LEVELS	In amaranth, a C-4 dicotyledonous plant, the plastid rbcL gene (encoding the large subunit of ribulose-1,5-bisphosphate carboxylase) is regulated post-transcriptionally during many developmental processes, including light-mediated development. To identify posttranscriptional regulators of rbcL expression, three types of analyses (polysome heel printing, gel retardation, and UV cross-linking) were utilized. These approaches revealed that multiple proteins interact with 5' regions of rbcL mRNA in light-grown, but not etiolated, amaranth plants. Light-associated binding of a 47-kDa protein (p47), observed by UV cross-linking, was highly specific for the rbcL 5' RNA. Binding of p47 occurred only with RNAs corresponding to mature processed rbcL transcripts (5'-untranslated region (UTR) terminating at -66); transcripts with longer 5'-UTRs did not associate with p47 in vitro, Variations in the length of the rbcL 5'-UTR were found to occur in vivo and these different 5' termini may prevent or enhance light-associated p47 binding, possibly affecting rbcL expression as well. p47 binding correlates with light-dependent rbcL polysome association of the fully processed transcripts in photosynthetic leaves and cotyledons but not with cell-specific rbcL mRNA accumulation in bundle sheath and mesophyll chloroplasts.	SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Berry, JO (corresponding author), SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA.							Alexander C, 1998, NUCLEIC ACIDS RES, V26, P2265, DOI 10.1093/nar/26.10.2265; BARKAN A, 1994, EMBO J, V13, P3170, DOI 10.1002/j.1460-2075.1994.tb06616.x; BARKAN A, 1993, PLANT CELL, V5, P389, DOI 10.1105/tpc.5.4.389; Berry JO, 1997, AUST J PLANT PHYSIOL, V24, P423, DOI 10.1071/PP97001; BERRY JO, 1988, P NATL ACAD SCI USA, V85, P4190, DOI 10.1073/pnas.85.12.4190; BERRY JO, 1986, MOL CELL BIOL, V6, P2347, DOI 10.1128/MCB.6.7.2347; BERRY JO, 1990, PLANT CELL, V2, P795, DOI 10.1105/tpc.2.8.795; BETHANY D, 1997, PLANT CELL, V9, P283; BOINSKI JJ, 1993, PLANT MOL BIOL, V22, P397, DOI 10.1007/BF00015971; Bruick RK, 1998, J CELL BIOL, V143, P1145, DOI 10.1083/jcb.143.5.1145; CHEN HC, 1991, MOL CELL BIOL, V11, P4380, DOI 10.1128/MCB.11.9.4380; CHEN QY, 1995, MOL CELL BIOL, V15, P2010; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; DANON A, 1994, SCIENCE, V266, P1717, DOI 10.1126/science.7992056; Edhofer I, 1998, EUR J BIOCHEM, V257, P78, DOI 10.1046/j.1432-1327.1998.2570078.x; Eibl C, 1999, PLANT J, V19, P333, DOI 10.1046/j.1365-313X.1999.00543.x; FRANZETTI B, 1992, J BIOL CHEM, V267, P19075; FURBANK RT, 1995, PLANT CELL, V7, P797, DOI 10.2307/3870037; GALLIE DR, 1993, ANNU REV PLANT PHYS, V44, P77, DOI 10.1146/annurev.pp.44.060193.000453; GILLHAM NW, 1994, ANNU REV GENET, V28, P71, DOI 10.1146/annurev.ge.28.120194.000443; GREENBERG JR, 1980, NUCLEIC ACIDS RES, V8, P5685, DOI 10.1093/nar/8.23.5685; GRUISSEM W, 1989, CELL, V56, P161, DOI 10.1016/0092-8674(89)90889-1; GRUISSEM W, 1986, METHOD ENZYMOL, V118, P253; Hauser CR, 1996, J BIOL CHEM, V271, P1486, DOI 10.1074/jbc.271.3.1486; Hayes R, 1996, EMBO J, V15, P1132, DOI 10.1002/j.1460-2075.1996.tb00451.x; Hirose T, 1996, EMBO J, V15, P1687, DOI 10.1002/j.1460-2075.1996.tb00514.x; KIM J, 1994, PLANT MOL BIOL, V25, P437, DOI 10.1007/BF00043872; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; Klaff P, 1995, PHOTOSYNTH RES, V46, P235, DOI 10.1007/BF00020436; KOO JS, 1994, J BIOL CHEM, V269, P7501; KOO JS, 1994, J BIOL CHEM, V269, P7494; MANEN JF, 1994, J MOL EVOL, V38, P577; MAYFIELD SP, 1994, J CELL BIOL, V127, P1537, DOI 10.1083/jcb.127.6.1537; MAYFIELD SP, 1995, ANNU REV PLANT PHYS, V46, P147, DOI 10.1146/annurev.pp.46.060195.001051; McCormac D, 1997, PLANT PHYSIOL, V114, P801, DOI 10.1104/pp.114.3.801; McCormac DJ, 1999, PLANT CELL, V11, P1709, DOI 10.1105/tpc.11.9.1709; MICHALOWSKI CB, 1990, NUCLEIC ACIDS RES, V18, P2187, DOI 10.1093/nar/18.8.2187; MULLET JE, 1987, EMBO J, V6, P1571, DOI 10.1002/j.1460-2075.1987.tb02402.x; Nagai K., 1992, CURR OPIN STRUC BIOL, V2, P131; NICKELSEN J, 1994, EMBO J, V13, P3182, DOI 10.1002/j.1460-2075.1994.tb06617.x; Ramsperger VC, 1996, PLANT PHYSIOL, V111, P999, DOI 10.1104/pp.111.4.999; REINBOTHE S, 1993, EMBO J, V12, P1505, DOI 10.1002/j.1460-2075.1993.tb05794.x; ROCHAIX JD, 1989, EMBO J, V8, P1013, DOI 10.1002/j.1460-2075.1989.tb03468.x; ROUAULT TA, 1996, TRANSLATIONAL CONTRO, P335; SAKAMOTO W, 1994, PLANT J, V6, P503, DOI 10.1046/j.1365-313X.1994.6040503.x; SALVADOR ML, 1993, P NATL ACAD SCI USA, V90, P1556, DOI 10.1073/pnas.90.4.1556; Shiina T, 1998, PLANT CELL, V10, P1713, DOI 10.1105/tpc.10.10.1713; STAUB JM, 1994, PLANT J, V6, P547, DOI 10.1046/j.1365-313X.1994.6040547.x; STAUB JM, 1993, EMBO J, V12, P601, DOI 10.1002/j.1460-2075.1993.tb05692.x; Stern DB, 1997, TRENDS PLANT SCI, V2, P308, DOI 10.1016/S1360-1385(97)89953-0; STOLLAR NE, 1994, PLANT PHYSIOL, V105, P1167, DOI 10.1104/pp.105.4.1167; Trebitsh T, 2000, MOL CELL BIOL, V20, P1116, DOI 10.1128/MCB.20.4.1116-1123.2000; WANG JL, 1993, PLANT PHYSIOL, V102, P1085, DOI 10.1104/pp.102.4.1085; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; YAO WS, 1995, J VIROL, V69, P1917, DOI 10.1128/JVI.69.3.1917-1919.1995; Yohn CB, 1998, J CELL BIOL, V142, P435, DOI 10.1083/jcb.142.2.435; Zerges W, 1997, MOL CELL BIOL, V17, P3440, DOI 10.1128/MCB.17.6.3440	58	17	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3476	3483		10.1074/jbc.M009236200	http://dx.doi.org/10.1074/jbc.M009236200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11076953	hybrid			2022-12-25	WOS:000166784900064
J	Su, LF; Knoblauch, R; Garabedian, MJ				Su, LF; Knoblauch, R; Garabedian, MJ			Rho GTPases as modulators of the estrogen receptor transcriptional response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GDP-DISSOCIATION INHIBITOR; GTP-BINDING PROTEINS; BOTULINUM ADP-RIBOSYLTRANSFERASE; STEROID-HORMONE RECEPTORS; FACTOR-KAPPA-B; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; HUMAN HOMOLOGS	The estrogen receptor cu (ER) is a ligand-dependent transcription factor that plays a critical role in the development and progression of breast cancer, in part, by regulating target genes involved in cellular proliferation. To identify novel components that affect the ER transcriptional response, we performed a genetic screen in yeast and identified RDI1, a Rho guanine nucleotide dissociation inhibitor (Rho GDI), as a positive regulator of ER transactivation. Overexpression of the human homologue of RDI1, Rho GDI alpha, increases ER alpha, ER beta, androgen receptor, and glucocorticoid receptor transcriptional activation in mammalian cells but not activation by the unrelated transcription factors serum response factor and Spl, In contrast, expression of constitutively active forms of RhoA, Rad, and Cdc42 decrease ER transcriptional activity, suggesting that Rho GDI increases ER transactivation by antagonizing Rho function. Inhibition of RhoA by expression of either the Clostridium botulinum C3 transferase or a dominant negative RhoA resulted in enhanced ER transcriptional activation, thus phenocopying the effect of Rho GDI expression on ER transactivation. Together, these findings establish the Rho GTPases as important modulators of EHL transcriptional activation. Since Rho GTPases regulate actin polymerization, our findings suggest a link between the major regulators of cellular architecture and steroid receptor transcriptional response.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Comprehens Canc Ctr, New York, NY 10016 USA	New York University; New York University	Garabedian, MJ (corresponding author), NYU, Sch Med, Dept Microbiol, 550 1st Ave, New York, NY 10016 USA.	garabm01@med.nyu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007308] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM07308] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; BIANCHI MW, 1993, GENE, V134, P51, DOI 10.1016/0378-1119(93)90173-Z; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bland R, 2000, CLIN SCI, V98, P217, DOI 10.1042/CS19990252; Botstein D, 1997, SCIENCE, V277, P1259, DOI 10.1126/science.277.5330.1259; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cairns BR, 1998, MOL CELL, V2, P639, DOI 10.1016/S1097-2765(00)80162-8; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Endoh H, 1999, MOL CELL BIOL, V19, P5363; ENGEBRECHT J, 1990, CELL, V62, P927, DOI 10.1016/0092-8674(90)90267-I; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HANCOCK JF, 1993, EMBO J, V12, P1915, DOI 10.1002/j.1460-2075.1993.tb05840.x; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Hittelman AB, 1999, EMBO J, V18, P5380, DOI 10.1093/emboj/18.19.5380; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; Ichinose H, 1997, GENE, V188, P95, DOI 10.1016/S0378-1119(96)00785-8; Jordan VC, 1999, J LAB CLIN MED, V133, P408, DOI 10.1016/S0022-2143(99)90017-3; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Kato S, 1998, ONCOLOGY-BASEL, V55, P5, DOI 10.1159/000055253; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Knoblauch R, 1999, MOL CELL BIOL, V19, P3748; Koch G, 1997, ONCOGENE, V15, P417, DOI 10.1038/sj.onc.1201194; Kuiper GGJM, 1997, ENDOCRINOLOGY, V138, P863, DOI 10.1210/en.138.3.863; Lawler S, 1999, CURR BIOL, V9, pR800, DOI 10.1016/S0960-9822(99)80493-X; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LEONARD D, 1992, J BIOL CHEM, V267, P22860; MASUDA T, 1994, J BIOL CHEM, V269, P19713; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; MULLER L, 1994, NUCLEIC ACIDS RES, V22, P3151, DOI 10.1093/nar/22.15.3151; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; Narumiya S, 1996, J BIOCHEM-TOKYO, V120, P215; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Parker MG, 1998, BIOCHEM SOC SYMP, P45; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Peterson CL, 1998, J BIOL CHEM, V273, P23641, DOI 10.1074/jbc.273.37.23641; PICARD D, 1990, NATURE, V348, P166, DOI 10.1038/348166a0; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; Rubino D, 1998, ONCOGENE, V16, P2513, DOI 10.1038/sj.onc.1201783; Schapira M, 2000, P NATL ACAD SCI USA, V97, P1008, DOI 10.1073/pnas.97.3.1008; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SEKINE A, 1989, J BIOL CHEM, V264, P8602; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; SU SSY, 1993, GENETICS, V133, P67; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Uht RM, 1997, ENDOCRINOLOGY, V138, P2900, DOI 10.1210/en.138.7.2900; Warner M, 1999, CURR OPIN OBSTET GYN, V11, P249, DOI 10.1097/00001703-199906000-00003; Weigel NL, 1996, BIOCHEM J, V319, P657, DOI 10.1042/bj3190657; WU AL, 1993, J BIOL CHEM, V268, P18850; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	68	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3231	3237		10.1074/jbc.M005547200	http://dx.doi.org/10.1074/jbc.M005547200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11060289	hybrid			2022-12-25	WOS:000166784900034
J	Sekino, Y; Bruner, SD; Verdine, GL				Sekino, Y; Bruner, SD; Verdine, GL			Selective inhibition of herpes simplex virus type-1 uracil-DNA glycosylase by designed substrate analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOSIDE PHOSPHORYLASE; TRANSITION-STATE ANALYSIS; CRYSTAL-STRUCTURE; CATALYTIC MECHANISM; VIRAL REPLICATION; ESCHERICHIA-COLI; EXCISION-REPAIR; BASE EXCISION; DAMAGED DNA; COMPLEX	Cytosine deamination and the misincorporation of 2'-dUrd into DNA during replication result in the presence of uracil in DNA. Uracil-DNA glycosylases (UDGs) initiate the excision repair of this aberrant base by catalyzing the hydrolysis of the N-glycosidic bond. UDGs are expressed by nearly all known organisms, including some viruses, in which the functional role of the UDG protein remains unresolved. This issue could in principle be addressed by the availability of designed synthetic inhibitors that target the viral UDG without affecting the endogenous human UDG. Here, we report that double-stranded and single-stranded oligonucleotides incorporating either of two dUrd analogs tightly bind and inhibit the activity of herpes simplex virus type-1 (HSV-1) UDG. Both inhibitors are exquisitely specific for the Hm-l UDG over the human UDG. These inhibitors should prove useful in structural studies aimed at understanding substrate recognition and catalysis by UDGs, as well as in elucidating the biologic role of UDGs in the life cycle of herpesviruses.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA	Harvard University	Verdine, GL (corresponding author), Harvard Univ, Dept Chem & Biol Chem, 12 Oxford St, Cambridge, MA 02138 USA.							ARGNANI R, 1995, VIROLOGY, V211, P307, DOI 10.1006/viro.1995.1406; Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; BLAISDELL P, 1983, J BIOL CHEM, V258, P1603; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; EFTEDAL I, 1993, NUCLEIC ACIDS RES, V21, P2095, DOI 10.1093/nar/21.9.2095; Erion MD, 1997, BIOCHEMISTRY-US, V36, P11735, DOI 10.1021/bi961970v; FOCHER F, 1990, MUTAT RES, V237, P65, DOI 10.1016/0921-8734(90)90012-G; FOCHER F, 1993, BIOCHEM J, V292, P883, DOI 10.1042/bj2920883; Haug T, 1996, GENOMICS, V36, P408, DOI 10.1006/geno.1996.0485; HORENSTEIN BA, 1991, BIOCHEMISTRY-US, V30, P10788, DOI 10.1021/bi00108a026; Hossain N, 1996, TETRAHEDRON, V52, P5563, DOI 10.1016/0040-4020(96)00192-5; HOWELL HG, 1988, J ORG CHEM, V53, P85, DOI 10.1021/jo00236a017; KLINE PC, 1995, BIOCHEMISTRY-US, V34, P1153, DOI 10.1021/bi00004a008; Labahn J, 1996, CELL, V86, P321, DOI 10.1016/S0092-8674(00)80103-8; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; MOL CD, 1995, CELL, V80, P869, DOI 10.1016/0092-8674(95)90290-2; MOL CD, 1995, CELL, V82, P701, DOI 10.1016/0092-8674(95)90467-0; MOSBAUGH DW, 1994, PROG NUCLEIC ACID RE, V48, P315, DOI 10.1016/S0079-6603(08)60859-4; MULLANEY J, 1989, J GEN VIROL, V70, P449, DOI 10.1099/0022-1317-70-2-449; Nash HM, 1997, CHEM BIOL, V4, P693, DOI 10.1016/S1074-5521(97)90225-8; Prichard MN, 1996, J VIROL, V70, P3018, DOI 10.1128/JVI.70.5.3018-3025.1996; PYLES RB, 1994, J VIROL, V68, P4963, DOI 10.1128/JVI.68.8.4963-4972.1994; Reddy SM, 1998, VIROLOGY, V251, P393, DOI 10.1006/viro.1998.9428; SAVVA R, 1995, NAT STRUCT BIOL, V2, P752, DOI 10.1038/nsb0995-752; Sawa R., 1995, NATURE, V373, P487; Scharer OD, 1997, CURR OPIN CHEM BIOL, V1, P526, DOI 10.1016/S1367-5931(97)80048-8; Scharer OD, 1997, P NATL ACAD SCI USA, V94, P4878, DOI 10.1073/pnas.94.10.4878; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Sun HM, 1999, J MED CHEM, V42, P2344, DOI 10.1021/jm980718d; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; Willetts KE, 1999, J VIROL, V73, P1682, DOI 10.1128/JVI.73.2.1682-1688.1999; Xiao GY, 1999, PROTEINS, V35, P13	35	23	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 24	2000	275	47					36506	36508		10.1074/jbc.C000585200	http://dx.doi.org/10.1074/jbc.C000585200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	378GY	11084051	hybrid, Green Published			2022-12-25	WOS:000165577700008
J	Gartel, AL; Goufman, E; Najmabadi, F; Tyner, AL				Gartel, AL; Goufman, E; Najmabadi, F; Tyner, AL			Sp1 and Sp3 activate p21 (WAF1/CIP1) gene transcription in the Caco-2 colon adenocarcinoma cell line	ONCOGENE			English	Article						p21; Caco-2; promoter; Sp1; Sp3	MEDIATED NEURONAL DIFFERENTIATION; HISTONE DEACETYLASE INHIBITOR; REPRESS TRANSCRIPTION; BINDING-SITES; DNA-BINDING; CHLORAMPHENICOL ACETYLTRANSFERASE; PROMOTER ACTIVITY; CYCLE REGULATION; FAMILY MEMBERS; PC12 CELLS	The CDK inhibitor p21(WAF1/CIP1) is a negative regulator of the cell cycle, and its expression is induced during terminal differentiation in vitro and in vivo. Expression of p21 is controlled at the transcriptional level by both p53-dependent and -independent mechanisms. Our previous studies established that p21 is expressed in the Caco-2 adenocarcinoma cell line, and its expression is induced by a p53-independent mechanism during differentiation of these cells, Here we have found that transcription of p21 in Caco-2 cells is controlled primarily by the transcription factors Sp1 and Sp3 through two Spl binding sites, Sp1-1 and Sp1-2 located between -119 and -114 bp and between -109 and -104 bp of the p21 promoter, respectively, Spl and Sp3 binding to the p21 promoter increased during Caco-2 cell differentiation, while the absolute level of Spl did not change and the absolute level of Sp3 increased approximately twofold. Transfection experiments in the SL2 Drosophila cell line that lacks endogenous Sp3 activity demonstrated that Spl transactivates the p21 promoter primarily through the Sp1-2 site, while Sp3 acts through the Spl-l site, In these cells Sp3 is a stronger transactivator of the p21 promoter than Spl, Our data suggest that induction of p21 transcription during Caco-2 differentiation is modulated by Sp1/Sp3 interactions with the p21 promoter.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Gartel, AL (corresponding author), Univ Illinois, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.		Goufman, Eugene/AAG-6882-2019	Tyner, Angela/0000-0001-7448-8625	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048836, R01DK056283] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK056283, R01 DK056283-05, DK48836] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham C, 1998, GASTROENTEROLOGY, V114, P503, DOI 10.1016/S0016-5085(98)70533-5; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; Billon N, 1999, ONCOGENE, V18, P2872, DOI 10.1038/sj.onc.1202712; Billon N, 1996, ONCOGENE, V13, P2047; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DESJARDINS E, 1993, MOL CELL BIOL, V13, P5710, DOI 10.1128/MCB.13.9.5710; Djelloul S, 1997, FEBS LETT, V406, P234, DOI 10.1016/S0014-5793(97)00208-1; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; ELDEIRY WS, 1995, CANCER RES, V55, P2910; Evers BM, 1996, AM J PHYSIOL-GASTR L, V271, pG722, DOI 10.1152/ajpgi.1996.271.4.G722; Gartel A L, 1998, Prog Mol Subcell Biol, V20, P43; Gartel AL, 1996, P SOC EXP BIOL MED, V213, P138; Gartel AL, 1998, ONCOGENE, V17, P3463, DOI 10.1038/sj.onc.1202240; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 1996, EXP CELL RES, V227, P171, DOI 10.1006/excr.1996.0264; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HARPER JW, 1993, CELL, V75, P805; Hata Y, 1998, J BIOL CHEM, V273, P19294, DOI 10.1074/jbc.273.30.19294; JIANG HP, 1994, ONCOGENE, V9, P3397; Karantzoulis-Fegaras F, 1999, J BIOL CHEM, V274, P3076, DOI 10.1074/jbc.274.5.3076; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Lee SJ, 1998, J BIOL CHEM, V273, P10618, DOI 10.1074/jbc.273.17.10618; Li JM, 1998, NUCLEIC ACIDS RES, V26, P2449, DOI 10.1093/nar/26.10.2449; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MAJELLO B, 1995, ONCOGENE, V10, P1841; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; Moustakas A, 1998, P NATL ACAD SCI USA, V95, P6733, DOI 10.1073/pnas.95.12.6733; MURRAY IA, 1991, NUCLEIC ACIDS RES, V19, P6648; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Nielsen SJ, 1998, BIOCHEM J, V333, P511, DOI 10.1042/bj3330511; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Owen GI, 1998, J BIOL CHEM, V273, P10696, DOI 10.1074/jbc.273.17.10696; Pagliuca A, 1998, J BIOL CHEM, V273, P7668, DOI 10.1074/jbc.273.13.7668; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PINTO M, 1983, BIOL CELL, V47, P323; Prowse DM, 1997, J BIOL CHEM, V272, P1308, DOI 10.1074/jbc.272.2.1308; Rajakumar RA, 1998, J BIOL CHEM, V273, P27474, DOI 10.1074/jbc.273.42.27474; Ray A, 1999, J BIOL CHEM, V274, P4300, DOI 10.1074/jbc.274.7.4300; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Scaglione-Sewell B, 1998, CANCER RES, V58, P1074; Schafer D, 1997, FEBS LETT, V417, P325, DOI 10.1016/S0014-5793(97)01314-8; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; STEINMAN RA, 1994, ONCOGENE, V9, P3389; Wildhage I, 1999, ENDOCRINOLOGY, V140, P624, DOI 10.1210/en.140.2.624; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yan GZ, 1997, J NEUROSCI, V17, P6122; Zhang YG, 1999, J BIOL CHEM, V274, P12367, DOI 10.1074/jbc.274.18.12367; Zhao LY, 1997, J BIOL CHEM, V272, P4869, DOI 10.1074/jbc.272.8.4869	62	70	70	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 26	2000	19	45					5182	5188		10.1038/sj.onc.1203900	http://dx.doi.org/10.1038/sj.onc.1203900			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064455				2022-12-25	WOS:000090124100007
J	Noguchi, K; Ishikawa, K; Yokoyama, K; Ohtsuka, T; Nio, N; Suzuki, E				Noguchi, K; Ishikawa, K; Yokoyama, K; Ohtsuka, T; Nio, N; Suzuki, E			Crystal structure of red sea bream transglutaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-TYPE TRANSGLUTAMINASE; COAGULATION FACTOR-XIII; CROSS-LINKING ENZYMES; MOLECULAR-CLONING; PAGRUS-MAJOR; PURIFICATION; EXPRESSION; SEQUENCE; CDNA; ACTIVATION	The crystal structure of the tissue-type transglutaminase from red sea bream liver (fish-derived transglutaminase, FTG) has been determined at 2.5-Angstrom resolution using the molecular replacement method, based on the crystal structure of human blood coagulation factor XIIII, which is a transglutaminase zymogen. The model contains 666 residues of a total of 695 residues, 382 water molecules, and 1 sulfate ion. FTG consists of four domains, and its overall and active site structures are similar to those of human factor XIII, However, significant structural differences are observed in both the acyl do nor and acyl acceptor binding sites, which account for the difference in substrate preferences. The active site of the enzyme is inaccessible to the solvent, because the catalytic Cys-272 hydrogen-bonds to Tyr-515, which is thought to be displaced upon acyl donor binding to FTG. It is postulated that the binding of an inappropriate substrate to FTG would lead to inactivation of the enzyme because of the formation of a new disulfide bridge between Cys-272 and the adjacent Cys-333 immediately after the displacement of Tyr-515. Considering the mutational studies previously reported on the tissue-type transglutaminases, we propose that Cys-333 and Tyr-515 are important in strictly controlling the enzymatic activity of FTG.	Ajinomoto Co Inc, Cent Res Labs, Kawasaki Ku, Kawasaki, Kanagawa 2108681, Japan; Ajinomoto Co Inc, Food Res & Dev Labs, Kawasaki Ku, Kawasaki, Kanagawa 2108681, Japan	Ajinomoto Co Inc; Ajinomoto Co Inc	Suzuki, E (corresponding author), Ajinomoto Co Inc, Cent Res Labs, Kawasaki Ku, 1-1 Suzuki Cho, Kawasaki, Kanagawa 2108681, Japan.							AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; ANDO H, 1989, AGR BIOL CHEM TOKYO, V53, P2613, DOI 10.1080/00021369.1989.10869735; BISHOP PD, 1990, BIOCHEMISTRY-US, V29, P1861, DOI 10.1021/bi00459a028; BRUNERLORAND J, 1966, NATURE, V210, P1273; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHUNG SI, 1972, P NATL ACAD SCI USA, V69, P303, DOI 10.1073/pnas.69.2.303; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FOLK JE, 1980, ANNU REV BIOCHEM, V49, P517, DOI 10.1146/annurev.bi.49.070180.002505; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; GLADNER JA, 1983, THROMB RES, V30, P273, DOI 10.1016/0049-3848(83)90081-6; GRANT FJ, 1994, BIOCHEM BIOPH RES CO, V203, P1117, DOI 10.1006/bbrc.1994.2298; GREENBERG CS, 1988, BIOCHEM J, V256, P1013, DOI 10.1042/bj2561013; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HO KC, 1992, J BIOL CHEM, V267, P12660; HORNYAK TJ, 1989, BIOCHEMISTRY-US, V28, P7326, DOI 10.1021/bi00444a027; HORNYAK TJ, 1991, BIOCHEMISTRY-US, V30, P6175, DOI 10.1021/bi00239a014; KANAJI T, 1993, J BIOL CHEM, V268, P11565; KIM IG, 1993, J BIOL CHEM, V268, P12682; KLEIN JD, 1992, J BACTERIOL, V174, P2599, DOI 10.1128/jb.174.8.2599-2605.1992; KRAULIS PJ, 1993, J APPL CRYSTALLOGR, V26, P283; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MARGOSIAK SA, 1990, PLANT PHYSIOL, V92, P88, DOI 10.1104/pp.92.1.88; Myhrman R., 1970, METHOD ENZYMOL, V19, P765, DOI 10.1016/0076-6879(70)19064-1; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OTWINOWSKI Z, 1993, DATA COLLECTION PROC, P55; SHEN L, 1983, J CLIN INVEST, V71, P1336, DOI 10.1172/JCI110885; SINGH RN, 1994, EUR J BIOCHEM, V225, P625, DOI 10.1111/j.1432-1033.1994.00625.x; TOKUNAGA F, 1993, J BIOL CHEM, V268, P262; Weiss MS, 1998, FEBS LETT, V423, P291, DOI 10.1016/S0014-5793(98)00098-2; WERAARCHAKULBOONMARK N, 1992, P NATL ACAD SCI USA, V89, P9804, DOI 10.1073/pnas.89.20.9804; WONG WSD, 1990, INT J BIOCHEM, V22, P53, DOI 10.1016/0020-711X(90)90077-G; YASUEDA H, 1995, EUR J BIOCHEM, V232, P411, DOI 10.1111/j.1432-1033.1995.tb20826.x; YASUEDA H, 1994, BIOSCI BIOTECH BIOCH, V58, P2041, DOI 10.1271/bbb.58.2041; YEE VC, 1995, THROMB RES, V78, P389, DOI 10.1016/0049-3848(95)00072-Y; YEE VC, 1994, P NATL ACAD SCI USA, V91, P7296, DOI 10.1073/pnas.91.15.7296	37	71	76	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					12055	12059		10.1074/jbc.M009862200	http://dx.doi.org/10.1074/jbc.M009862200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11080504	hybrid			2022-12-25	WOS:000168081800084
J	McRae, JL; Cowan, PJ; Power, DA; Mitchelhill, KI; Kemp, BE; Morgan, BP; Murphy, BF				McRae, JL; Cowan, PJ; Power, DA; Mitchelhill, KI; Kemp, BE; Morgan, BP; Murphy, BF			Human factor H-related protein 5 (FHR-5) - A new complement-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES; REGULATORY DOMAINS; IMMUNE DEPOSITS; HUMAN PLASMA; IDENTIFICATION; BINDING; FAMILY; C3B; GLYCOPROTEIN; LIPOPROTEINS	A novel human plasma protein has been identified as a universal component of complement deposits, when complement is detected immunohistochemically in vivo. The protein is homologous to complement factor H and related proteins and has been designated factor H-related protein 5 (FHR-5). FHR-5 was identified by a monoclonal antibody raised using pathologic human glomerular preparations as the immunogen. FHR-5 was purified by affinity chromatography from complement-lysed erythrocytes, and the peptide sequence was obtained. The cDNA was cloned from a human liver library, and FHR-5 was deduced to be a protein containing 551 amino acids organized into nine short consensus repeat motifs. The short consensus repeats of FHR-5 show homology to Factor H and to other Factor H-related proteins, with some unique features demonstrated. Recombinant FHR-5, expressed in insect cells, was shown to bind C3b in vitro. The strong association of FHR-5 with tissue complement deposits in vivo suggests that this additional member of the Factor H family of proteins has a function in complement regulation.	St Vincents Hosp, Dept Nephrol, Fitzroy, Vic 3065, Australia; St Vincents Hosp, Immunol Res Ctr, Fitzroy, Vic 3065, Australia; St Vincents Hosp, St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia; Cardiff Univ, Dept Biochem Med, Cardiff CF4 4XN, S Glam, Wales	St Vincent's Hospital Melbourne; St Vincent's Hospital Melbourne; St Vincent's Hospital Melbourne; St. Vincent's Institute of Medical Research; Cardiff University	McRae, JL (corresponding author), St Vincents Hosp, Dept Nephrol, Fitzroy, Vic 3065, Australia.	mcraej@svhm.org.au	Cowan, Peter J/B-8730-2013; Cowan, Peter/AAH-7218-2020; Kemp, Bruce/G-9602-2019; Kemp, Bruce E/L-2633-2014; Power, David/AAM-6012-2021	Cowan, Peter J/0000-0001-9016-4954; Kemp, Bruce/0000-0001-6735-5082; Kemp, Bruce E/0000-0001-6735-5082; Power, David/0000-0003-3983-0581; Morgan, Paul/0000-0003-4075-7676				ALSENZ J, 1984, BIOCHEM J, V224, P389, DOI 10.1042/bj2240389; ALSENZ J, 1985, BIOCHEM J, V232, P841, DOI 10.1042/bj2320841; BHAKDI S, 1983, BIOCHIM BIOPHYS ACTA, V737, P343, DOI 10.1016/0304-4157(83)90006-0; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DODDS AW, 1993, METHOD ENZYMOL, V223, P46; ESTALLER C, 1991, J IMMUNOL, V146, P3190; FUNAKOSHI M, 1988, BIOCHIM BIOPHYS ACTA, V963, P98, DOI 10.1016/0005-2760(88)90342-6; GORDON DL, 1995, J IMMUNOL, V155, P348; Hellwage J, 1999, FEBS LETT, V462, P345, DOI 10.1016/S0014-5793(99)01554-9; Hellwage J, 1997, IMMUNOPHARMACOLOGY, V38, P149, DOI 10.1016/S0162-3109(97)00075-1; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; JENNE DE, 1991, J BIOL CHEM, V266, P11030; JENNE DE, 1992, TRENDS BIOCHEM SCI, V17, P154, DOI 10.1016/0968-0004(92)90325-4; Jokiranta TS, 1996, FEBS LETT, V393, P297; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUHN S, 1995, GENE, V162, P225, DOI 10.1016/0378-1119(95)00360-I; Kuhn S, 1996, EUR J IMMUNOL, V26, P2383, DOI 10.1002/eji.1830261017; KUHN S, 1995, J IMMUNOL, V155, P5663; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mitchelhill KI, 1997, J BIOL CHEM, V272, P24475, DOI 10.1074/jbc.272.39.24475; Morgan B P, 2000, Methods Mol Biol, V150, P61; Murphy B F, 1989, Int Immunol, V1, P551, DOI 10.1093/intimm/1.5.551; MURPHY BF, 1988, PATHOLOGY, V20, P130, DOI 10.3109/00313028809066623; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; Prodinger WM, 1998, BIOCHEM J, V331, P41, DOI 10.1042/bj3310041; RIPOCHE J, 1987, BIOCHEM SOC T, V15, P651, DOI 10.1042/bst0150651; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHWAEBLE W, 1987, EUR J IMMUNOL, V17, P1485, DOI 10.1002/eji.1830171015; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; SKERKA C, 1991, J BIOL CHEM, V266, P12015; SKERKA C, 1992, J IMMUNOL, V148, P3313; SKERKA C, 1993, J BIOL CHEM, V268, P2904; Skerka C, 1997, J BIOL CHEM, V272, P5627, DOI 10.1074/jbc.272.9.5627; SOAMES CJ, 1995, BIOCHEM SOC T, V23, pS53, DOI 10.1042/bst023053s; VAKEVA A, 1994, IMMUNOLOGY, V82, P28; WHALEY K, 1976, J EXP MED, V144, P1147, DOI 10.1084/jem.144.5.1147; ZIPFEL PF, 1994, IMMUNOL TODAY, V15, P121, DOI 10.1016/0167-5699(94)90155-4	37	60	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6747	6754		10.1074/jbc.M007495200	http://dx.doi.org/10.1074/jbc.M007495200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11058592	hybrid			2022-12-25	WOS:000167261000087
J	Shields, RL; Namenuk, AK; Hong, K; Meng, YG; Rae, J; Briggs, J; Xie, D; Lai, J; Stadlen, A; Li, B; Fox, JA; Presta, LG				Shields, RL; Namenuk, AK; Hong, K; Meng, YG; Rae, J; Briggs, J; Xie, D; Lai, J; Stadlen, A; Li, B; Fox, JA; Presta, LG			High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-RESIDUES; CRYSTAL-STRUCTURE; MONOCLONAL-ANTIBODY; MODULATE RECOGNITION; HUMAN-IMMUNOGLOBULIN; CH2 DOMAIN; CELL-LINES; RECEPTOR-I; PROTEIN; POLYMORPHISM	Immunoglobulin G (IgG) Fc receptors play a critical role in linking IgG antibody-mediated immune responses with cellular effector functions. A high resolution map of the binding site on human IgG1 for human Fc gamma RI, Fc gamma RIIA, Fc gamma RIIB, Fc gamma RIIIA, and FcRn receptors has been determined. A common set of IgG1 residues is involved in binding to all Fc gammaR; Fc gamma RII and Fc gamma RIII also utilize residues outside this common set. In addition to residues which, when altered, abrogated binding to one or more of the receptors, several residues were found that improved binding only to specific receptors or simultaneously improved binding to one type of receptor and reduced binding to another type. Select IgG1 variants with improved binding to Fc gamma RIILA exhibited up to 100% enhancement in antibody-dependent cell cytotoxicity using human effector cells; these variants included changes at residues not found at the binding interface in the IgG/Fc gamma RIIIA co-crystal structure (Sondermann, P., Huber, R., Oosthuizen, V., and Jacob, U. (2000) Nature 406, 267-273). These engineered antibodies may have important implications for improving antibody therapeutic efficacy.	Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioanalyt Technol, San Francisco, CA 94080 USA; Genentech Inc, Dept Analyt Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Pharmacokinet & Metab, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Presta, LG (corresponding author), Genentech Inc, Dept Immunol, MS 34,1 DNA Way, San Francisco, CA 94080 USA.	presta@gene.com		Briggs, John/0000-0001-6165-097X				Anderson DR, 1997, BIOCHEM SOC T, V25, P705, DOI 10.1042/bst0250705; Armour KL, 1999, EUR J IMMUNOL, V29, P2613, DOI 10.1002/(SICI)1521-4141(199908)29:08<2613::AID-IMMU2613>3.0.CO;2-J; BURMEISTER WP, 1994, NATURE, V372, P379, DOI 10.1038/372379a0; BURTON DR, 1988, MOL IMMUNOL, V25, P1175, DOI 10.1016/0161-5890(88)90153-8; CANFIELD SM, 1991, J EXP MED, V173, P1483, DOI 10.1084/jem.173.6.1483; CAPON DJ, 1989, NATURE, V337, P525, DOI 10.1038/337525a0; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; CHAPPEL MS, 1991, P NATL ACAD SCI USA, V88, P9036, DOI 10.1073/pnas.88.20.9036; CHAPPEL MS, 1993, J BIOL CHEM, V268, P25124; CLARK MR, 1989, J IMMUNOL, V143, P1731; Clynes R, 1998, P NATL ACAD SCI USA, V95, P652, DOI 10.1073/pnas.95.2.652; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DUNCAN AR, 1988, NATURE, V332, P563, DOI 10.1038/332563a0; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; Gavin A, 1998, IMMUNOL MED, V26, P11; GERGELY J, 1984, BIOCHEM SOC T, V12, P739, DOI 10.1042/bst0120739; Gessner JE, 1998, ANN HEMATOL, V76, P231, DOI 10.1007/s002770050396; Ghetie V, 1997, NAT BIOTECHNOL, V15, P637, DOI 10.1038/nbt0797-637; Ghetie V, 1997, IMMUNOL TODAY, V18, P592, DOI 10.1016/S0167-5699(97)01172-9; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GUDDAT LW, 1993, P NATL ACAD SCI USA, V90, P4271, DOI 10.1073/pnas.90.9.4271; HAAGEN IA, 1995, J IMMUNOL, V154, P1852; Harris LJ, 1998, J MOL BIOL, V275, P861, DOI 10.1006/jmbi.1997.1508; Harris LJ, 1997, BIOCHEMISTRY-US, V36, P1581, DOI 10.1021/bi962514+; Hogarth P M, 1994, Immunomethods, V4, P17, DOI 10.1006/immu.1994.1003; Holliger P, 1998, NAT BIOTECHNOL, V16, P1015, DOI 10.1038/3460; HUDZIAK RM, 1989, MOL CELL BIOL, V9, P1165, DOI 10.1128/MCB.9.3.1165; HUIZINGA TWJ, 1989, J IMMUNOL, V142, P2359; HULETT MD, 1991, J IMMUNOL, V147, P1863; Idusogie EE, 2000, J IMMUNOL, V164, P4178, DOI 10.4049/jimmunol.164.8.4178; JEFFERIS R, 1990, MOL IMMUNOL, V27, P1237, DOI 10.1016/0161-5890(90)90027-W; Kabat EA, 1991, SEQUENCES PROTEINS I; KIM JK, 1994, SCAND J IMMUNOL, V40, P457, DOI 10.1111/j.1365-3083.1994.tb03488.x; KIM JK, 1994, EUR J IMMUNOL, V24, P2429, DOI 10.1002/eji.1830241025; KIM JK, 1994, EUR J IMMUNOL, V24, P542, DOI 10.1002/eji.1830240308; King D J, 1999, Curr Opin Drug Discov Devel, V2, P110; Koene HR, 1997, BLOOD, V90, P1109, DOI 10.1182/blood.V90.3.1109.1109_1109_1114; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lehrnbecher T, 1999, BLOOD, V94, P4220, DOI 10.1182/blood.V94.12.4220.424k08_4220_4232; Lehrnbecher T, 2000, BLOOD, V95, P2386; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Lifely MR, 1995, GLYCOBIOLOGY, V5, P813, DOI 10.1093/glycob/5.8.813; LIU J, 1995, BIOCHEMISTRY-US, V34, P10474, DOI 10.1021/bi00033a020; Lucas BK, 1996, NUCLEIC ACIDS RES, V24, P1774, DOI 10.1093/nar/24.9.1774; Lund J, 1996, J IMMUNOL, V157, P4963; LUND J, 1995, FASEB J, V9, P115, DOI 10.1096/fasebj.9.1.7821750; LUND J, 1992, MOL IMMUNOL, V29, P53, DOI 10.1016/0161-5890(92)90156-R; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; Medesan C, 1997, J IMMUNOL, V158, P2211; Meng YG, 2000, GENE, V242, P201, DOI 10.1016/S0378-1119(99)00524-7; Miller KL, 1996, J EXP MED, V183, P2227, DOI 10.1084/jem.183.5.2227; Nieto A, 2000, ARTHRITIS RHEUM, V43, P735, DOI 10.1002/1529-0131(200004)43:4<735::AID-ANR3>3.0.CO;2-Q; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477; Papac DI, 1998, GLYCOBIOLOGY, V8, P445, DOI 10.1093/glycob/8.5.445; Papac DI, 1996, ANAL CHEM, V68, P3215, DOI 10.1021/ac960324z; Peng LS, 1999, J IMMUNOL, V163, P250; PORGES AJ, 1992, J CLIN INVEST, V90, P2102, DOI 10.1172/JCI116094; Presta LG, 1997, CANCER RES, V57, P4593; PRESTA LG, 1993, J IMMUNOL, V151, P2623; RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005; Raghavan M, 1996, ANNU REV CELL DEV BI, V12, P181, DOI 10.1146/annurev.cellbio.12.1.181; SARMAY G, 1984, MOL IMMUNOL, V21, P43, DOI 10.1016/0161-5890(84)90088-9; SARMAY G, 1992, MOL IMMUNOL, V29, P633, DOI 10.1016/0161-5890(92)90200-H; SAUTES C, 1997, CELL MEDIATED EFFECT, P29; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; Tamm A, 1996, J BIOL CHEM, V271, P3659; TAX WJM, 1984, J IMMUNOL, V133, P1185; TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208; UMAA P, 1999, NAT BIOTECHNOL, V17, P176; VANDENHERIKOUDIJK IE, 1994, J IMMUNOL, V152, P574; Vaswani SK, 1998, ANN ALLERG ASTHMA IM, V81, P105, DOI 10.1016/S1081-1206(10)62794-9; Ward E S, 1995, Ther Immunol, V2, P77; Weiner LM, 1997, CANCER IMMUNOL IMMUN, V45, P190, DOI 10.1007/s002620050430; Wines BD, 2000, J IMMUNOL, V164, P5313, DOI 10.4049/jimmunol.164.10.5313; WOOF JM, 1986, MOL IMMUNOL, V23, P319, DOI 10.1016/0161-5890(86)90059-3; Wu JM, 1997, J CLIN INVEST, V100, P1059, DOI 10.1172/JCI119616	79	867	2018	3	45	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6591	6604		10.1074/jbc.M009483200	http://dx.doi.org/10.1074/jbc.M009483200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096108	hybrid			2022-12-25	WOS:000167261000070
J	Cohen, I; Guillerault, F; Girard, J; Prip-Buus, C				Cohen, I; Guillerault, F; Girard, J; Prip-Buus, C			The N-terminal domain of rat liver carnitine palmitoyltransferase 1 contains an internal mitochondrial import signal and residues essential for folding of its C-terminal catalytic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN STRUCTURE; MALONYL-COA SENSITIVITY; OUTER-MEMBRANE; ANCHOR SEQUENCE; YEAST PORIN; TOM COMPLEX; INSERTION; PEROXISOMES; BIOGENESIS; EXPRESSION	We have previously shown that the first 147 N-terminal residues of the rat liver carnitine palmitoyltransferase 1 (CPT1), encompassing its two transmembrane (TM) segments, specify both mitochondrial targeting and anchorage at the outer mitochondrial membrane (OMM), In the present study, we have identified the precise import sequence in this polytopic OMM protein. In vitro import studies with fusion and deletion CPT1 proteins demonstrated that none of its TRI segments behave as a signal anchor sequence, Analysis of the regions flanking the TM segments revealed that residues 123-147, located immediately downstream of TM2, function as a noncleavable, matrix-targeting signal, They specify mitochondrial targeting, whereas the hydrophobic TM segment(s) acts as a stop-transfer sequence that stops and anchors the translocating CPT1 into the OMM, Heterologous expression in Saccharomyces cerevisiae of several deleted CPT1 proteins not only confirms the validity of the "stop-transfer" import model but also indicates that residues 1-82 of CPT1 contain a putative microsomal targeting signal whose cellular significance awaits further investigation. Finally, we identified a highly folded core within the C-terminal domain of CPT1 that is hidden in the entire protein by its cytosolic N-terminal residues. Functional analysis of the deleted CPT1 proteins indicates that this folded C-terminal core, which may belong to the catalytic domain of CPT1, requires TM2 for its correct folding achievement and is in close proximity to residues 1-47.	CNRS, UPR 1524, F-92190 Meudon, France	Centre National de la Recherche Scientifique (CNRS)	Prip-Buus, C (corresponding author), CNRS, UPR 1524, 9 Rue J Hetzel, F-92190 Meudon, France.	pripbuus@infobiogen.fr	PRIP-BUUS, Carina/P-9084-2017	Prip-Buus, Carina/0000-0002-2153-7857				Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; BROADWAY NM, 1995, BIOCHEM J, V310, P989, DOI 10.1042/bj3100989; BROWN NF, 1994, J BIOL CHEM, V269, P26438; CAO W, 1995, J BIOL CHEM, V270, P5674, DOI 10.1074/jbc.270.10.5674; Cohen I, 1998, J BIOL CHEM, V273, P29896, DOI 10.1074/jbc.273.45.29896; Cohen I, 1999, ADV EXP MED BIOL, V466, P1; Court DA, 1996, FEBS LETT, V390, P73, DOI 10.1016/0014-5793(96)00629-1; DERRICK JP, 1989, BIOCHEM J, V262, P801, DOI 10.1042/bj2620801; deVries Y, 1997, BIOCHEMISTRY-US, V36, P5285, DOI 10.1021/bi962875p; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; ESSER V, 1993, J BIOL CHEM, V268, P5817; Fraser F, 1999, FEBS LETT, V446, P69, DOI 10.1016/S0014-5793(99)00179-9; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Gafvelin G, 1997, J BIOL CHEM, V272, P6119, DOI 10.1074/jbc.272.10.6119; HAMAJIMA S, 1988, J BIOCHEM-TOKYO, V104, P362, DOI 10.1093/oxfordjournals.jbchem.a122474; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; KLEBE RJ, 1983, GENE, V25, P333, DOI 10.1016/0378-1119(83)90238-X; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; Lemmon MA., 1992, CURR OPIN STRUC BIOL, V2, P511; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCBRIDE HM, 1992, J CELL BIOL, V119, P1451, DOI 10.1083/jcb.119.6.1451; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; POPOT JL, 1993, CURR OPIN STRUC BIOL, V3, P532, DOI 10.1016/0959-440X(93)90079-Z; Prip-Buus C, 1998, FEBS LETT, V429, P173, DOI 10.1016/S0014-5793(98)00584-5; Rapaport D, 1999, J CELL BIOL, V146, P321, DOI 10.1083/jcb.146.2.321; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P11527, DOI 10.1074/jbc.273.19.11527; ROISE D, 1986, EMBO J, V5, P1327, DOI 10.1002/j.1460-2075.1986.tb04363.x; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; SHORE GC, 1995, EUR J BIOCHEM, V227, P9, DOI 10.1111/j.1432-1033.1995.tb20354.x; SMITH MD, 1995, J BIOL CHEM, V270, P28331; Steenaart NAE, 1997, J BIOL CHEM, V272, P12057, DOI 10.1074/jbc.272.18.12057; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C	36	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5403	5411		10.1074/jbc.M009555200	http://dx.doi.org/10.1074/jbc.M009555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087756	hybrid			2022-12-25	WOS:000168484300116
J	Saitoh, O; Masuho, I; Terakawa, I; Nomoto, S; Asano, T; Kubo, Y				Saitoh, O; Masuho, I; Terakawa, I; Nomoto, S; Asano, T; Kubo, Y			Regulator of G protein signaling 8 (RGS8) requires its NH2 terminus for subcellular localization and acute desensitization of G protein-gated K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; SACCHAROMYCES-CEREVISIAE; MEDIATED MODULATION; PLASMA-MEMBRANE; ALPHA-SUBUNITS; EXPRESSION; DOMAIN; CURRENTS; KINASE; FAMILY	Functional roles of the NH2-terminal region of RGS (regulators of G protein signaling) 8 in G protein signaling were studied. The deletion of the NH2-terminal region of RGS8 (Delta NRGS8) resulted in a partial loss of the inhibitory function in pheromone response of yeasts, although G alpha binding was not affected. To examine roles in subcellular distribution, we coexpressed two fusion proteins of RGS8-RFP and Delta NRGS8-GFP in DDT1MF2 cells. RGS8-RFP was highly concentrated in nuclei of unstimulated cells. Coexpression of constitutively active G alpha (o), resulted in translocation of RGS8 protein to the plasma membrane. In contrast, Delta NRGS8-GFP was distributed diffusely through the cytoplasm in the presence or absence of active G alpha (o). When coexpressed with G protein-gated inwardly rectifying K+ channels, Delta NRGS8 accelerated both turning on and off similar to RGS8. Acute desensitization of G protein-gated inwardly rectifying K+ current observed in the presence of RGS8, however, was not induced by Delta NRGS8. Thus, we, for the first time, showed that the NH2 terminus of RGS8 contributes to the subcellular localization and to the desensitization of the G protein-coupled response.	Tokyo Metropolitan Inst Neurosci, Dept Mol & Cellular Neurobiol, Fuchu, Tokyo 1838526, Japan; Hamamatsu Univ Sch Med, Hamamatsu, Aichi 4313192, Japan; Jichi Med Sch, Dept Hlth Sci, Minami Kawachi, Tochigi 3290498, Japan; CREST, Minami Kawachi, Tochigi 3290498, Japan; Aichi Human Serv Ctr, Inst Dev Res, Dept Biochem, Kasugai, Aichi 48003, Japan; Tokyo Metropolitan Inst Neurosci, Dept Neurophysiol, Fuchu, Tokyo 1838526, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Physiol, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Fac Med, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Hamamatsu University School of Medicine; Jichi Medical University; Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute for Neuroscience; Tokyo Metropolitan Institute of Medical Science; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Saitoh, O (corresponding author), Tokyo Metropolitan Inst Neurosci, Dept Mol & Cellular Neurobiol, 2-6 Mushahidai, Fuchu, Tokyo 1838526, Japan.	osaito@tmin.ac.jp	Masuho, Ikuo/J-6115-2014	Kubo, Yoshihiro/0000-0001-6707-0837				Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CH, 1998, FEBS LETT, V422, P359, DOI 10.1016/S0014-5793(98)00042-8; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chuang HH, 1998, P NATL ACAD SCI USA, V95, P11727, DOI 10.1073/pnas.95.20.11727; Dohlman HG, 1997, J BIOL CHEM, V272, P3871, DOI 10.1074/jbc.272.7.3871; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1998, J BIOL CHEM, V273, P18405, DOI 10.1074/jbc.273.29.18405; Dulin NO, 2000, J BIOL CHEM, V275, P21317, DOI 10.1074/jbc.M910079199; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Hunt TW, 1996, NATURE, V383, P175, DOI 10.1038/383175a0; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Kovoor A, 2000, J BIOL CHEM, V275, P3397, DOI 10.1074/jbc.275.5.3397; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; LESAGE F, 1995, J BIOL CHEM, V270, P28660, DOI 10.1074/jbc.270.48.28660; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nomoto S, 1997, BIOCHEM BIOPH RES CO, V241, P281, DOI 10.1006/bbrc.1997.7802; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Saitoh O, 1999, J BIOL CHEM, V274, P9899, DOI 10.1074/jbc.274.14.9899; Saitoh O, 2000, BIOCHEM BIOPH RES CO, V270, P34, DOI 10.1006/bbrc.2000.2379; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; Velimirovic BM, 1996, FEBS LETT, V379, P31, DOI 10.1016/0014-5793(95)01465-9; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924	28	58	61	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5052	5058		10.1074/jbc.M006917200	http://dx.doi.org/10.1074/jbc.M006917200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087736	hybrid			2022-12-25	WOS:000168484300071
J	Stipp, CS; Orlicky, D; Hemler, ME				Stipp, CS; Orlicky, D; Hemler, ME			FPRP, a major, highly stoichiometric, highly specific CD81 and CD9-associated protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR REGULATORY PROTEIN; LEUKEMIA-VIRUS TYPE-1; MHC CLASS-II; TRANSMEMBRANE-4 SUPERFAMILY; CELL-SURFACE; MONOCLONAL-ANTIBODY; PLASMA-MEMBRANE; B-LYMPHOCYTES; T-CELLS; ANTIPROLIFERATIVE ANTIBODY-1	CD81 and CD9, members of the transmembrane-4 superfamily (TM4SF; tetraspanins), form extensive complexes with other TM4SF proteins, integrins, and other proteins, especially in mild detergents. In moderately stringent Brij 96 lysis conditions, CD81 and CD9 complexes are virtually identical to each other, but clearly distinct from other TM4SF complexes. One of the most prominent proteins within CD81 and CD9 complexes is identified here as FPRP, the 133-kDa prostaglandin F-2 alpha receptor regulatory protein. FPRP, a cell-surface Ig superfamily protein, associates specifically with CD81 or with CD81 and CD9, but not with integrins or other TM4SF proteins. In contrast to other CD81- and CD9-associating proteins, FPRP associates at very high stoichiometry, with essentially 100% of cell-surface FPRP on 293 cells being CD81- and CD9-associated. Also, CD81.CD9.FPRP complexes have a discrete size (<4 x 10(6) Da) as measured by gel permeation chromatography and remain intact after disruption of cholesterol-rich membrane microdomains by methyl-<beta>-cyclodextrin. Although CD81 associated with both alpha (3) integrin and FPRP in 293 cells, the alpha (3)beta (1).CD81 and CD81.CD9.FPRP complexes were distinct, as determined by immunoprecipitation and immunodepletion experiments. In conclusion, our data affirm the existence of distinct TM4SF complexes with unique compositions and specifically characterize FPRP as the most robust, highly stoichiometric CD81- and/or CDS-associated protein yet described.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Colorado, Hlth Sci Ctr, Ctr Canc, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Hemler, ME (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Rm D-1430,44 Binney St, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038903] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38903] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANGELISOVA P, 1994, IMMUNOGENETICS, V39, P249; BEHR S, 1995, J EXP MED, V182, P1191, DOI 10.1084/jem.182.5.1191; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Berditchevski F, 1996, MOL BIOL CELL, V7, P193, DOI 10.1091/mbc.7.2.193; BERDITCHEVSKI F, 1995, J BIOL CHEM, V270, P17784, DOI 10.1074/jbc.270.30.17784; BERGELSON JM, 1994, CELL ADHES COMMUN, V2, P455, DOI 10.3109/15419069409004455; Boismenu R, 1996, SCIENCE, V271, P198, DOI 10.1126/science.271.5246.198; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chen MS, 1999, P NATL ACAD SCI USA, V96, P11830, DOI 10.1073/pnas.96.21.11830; Chittum HS, 1998, BIOCHEMISTRY-US, V37, P10866, DOI 10.1021/bi981042r; CLAAS C, 2001, IN PRESS J BIOL CHEM, V276; DIPERSIO CM, 1995, J CELL SCI, V108, P2321; Domanico SZ, 1997, MOL BIOL CELL, V8, P2253, DOI 10.1091/mbc.8.11.2253; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; FEARON DT, 1995, ANNU REV IMMUNOL, V13, P127, DOI 10.1146/annurev.immunol.13.1.127; Fitter S, 1999, BIOCHEM J, V338, P61, DOI 10.1042/0264-6021:3380061; FUKUDOME K, 1992, J VIROL, V66, P1394, DOI 10.1128/JVI.66.3.1394-1401.1992; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hemler ME, 1996, BBA-REV CANCER, V1287, P67, DOI 10.1016/0304-419X(96)00007-8; HIGASHIYAMA S, 1995, J CELL BIOL, V128, P929, DOI 10.1083/jcb.128.5.929; Horvath G, 1998, J BIOL CHEM, V273, P30537, DOI 10.1074/jbc.273.46.30537; IMAI T, 1993, J IMMUNOL, V151, P6470; IMAI T, 1995, J IMMUNOL, V155, P1229; Indig FE, 1997, BIOCHEM J, V327, P291, DOI 10.1042/bj3270291; KERSEY JH, 1981, J EXP MED, V153, P726, DOI 10.1084/jem.153.3.726; Krauss K, 1999, J BIOL CHEM, V274, P36921, DOI 10.1074/jbc.274.52.36921; Le Naour F, 2000, SCIENCE, V287, P319, DOI 10.1126/science.287.5451.319; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Maecker HT, 1997, J EXP MED, V185, P1505, DOI 10.1084/jem.185.8.1505; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Mannion BA, 1996, J IMMUNOL, V157, P2039; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; Miyado K, 2000, SCIENCE, V287, P321, DOI 10.1126/science.287.5451.321; MIYAKE M, 1995, CANCER RES, V55, P4127; MIYAKE M, 1991, J EXP MED, V174, P1347, DOI 10.1084/jem.174.6.1347; Miyazaki T, 1997, EMBO J, V16, P4217, DOI 10.1093/emboj/16.14.4217; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Orlicky DJ, 1996, PROSTAG LEUKOTR ESS, V54, P247, DOI 10.1016/S0952-3278(96)90055-1; ORLICKY DJ, 1990, PROSTAG LEUKOTR ESS, V41, P51, DOI 10.1016/0952-3278(90)90131-4; Orlicky DJ, 1996, PROSTAG LEUKOTR ESS, V55, P261, DOI 10.1016/S0952-3278(96)90007-1; Orlicky DJ, 1998, J LIPID RES, V39, P1152; PESANDO JM, 1986, J IMMUNOL, V136, P2709; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; Radford KJ, 1996, BIOCHEM BIOPH RES CO, V222, P13, DOI 10.1006/bbrc.1996.0690; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHICK MR, 1993, J IMMUNOL, V151, P4090; Schmidt C, 1996, J NEUROSCI RES, V43, P12, DOI 10.1002/jnr.490430103; SEEHAFER JG, 1988, BIOCHIM BIOPHYS ACTA, V957, P399, DOI 10.1016/0167-4838(88)90231-2; SEEHAFER JG, 1990, BIOCHIM BIOPHYS ACTA, V1039, P218, DOI 10.1016/0167-4838(90)90189-M; Serru V, 1999, BIOCHEM J, V340, P103, DOI 10.1042/0264-6021:3400103; Shevchenko A, 1997, ELECTROPHORESIS, V18, P2591, DOI 10.1002/elps.1150181415; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Sincock PM, 1999, J CELL SCI, V112, P833; Skubitz KM, 2000, FEBS LETT, V469, P52, DOI 10.1016/S0014-5793(00)01240-0; Stipp CS, 2000, J CELL SCI, V113, P1871; Szollosi J, 1996, J IMMUNOL, V157, P2939; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; TAKAHASHI S, 1990, J IMMUNOL, V145, P2207; Thorne RF, 2000, J BIOL CHEM, V275, P35264, DOI 10.1074/jbc.M003969200; Tsitsikov EN, 1997, P NATL ACAD SCI USA, V94, P10844, DOI 10.1073/pnas.94.20.10844; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; Witherden DA, 2000, J IMMUNOL, V165, P1902, DOI 10.4049/jimmunol.165.4.1902; WRIGHT MD, 1994, IMMUNOL TODAY, V15, P588, DOI 10.1016/0167-5699(94)90222-4; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; Yashiro-Ohtani Y, 2000, J IMMUNOL, V164, P1251, DOI 10.4049/jimmunol.164.3.1251; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751	71	111	116	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4853	4862		10.1074/jbc.M009859200	http://dx.doi.org/10.1074/jbc.M009859200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087758	hybrid			2022-12-25	WOS:000168484300045
J	Yamada, T; Katagiri, H; Asano, T; Inukai, K; Tsuru, M; Kodama, T; Kikuchi, M; Oka, Y				Yamada, T; Katagiri, H; Asano, T; Inukai, K; Tsuru, M; Kodama, T; Kikuchi, M; Oka, Y			3-Phosphoinositide-dependent protein kinase 1, an Akt1 kinase, is involved in dephosphorylation of Thr-308 of Akt1 in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3; PHOSPHATASE-2A ACTIVITIES; 3T3-L1 ADIPOCYTES; MAMMALIAN-CELLS; MUSCLE-CELLS; RAT-BRAIN; B-ALPHA; C-ZETA; ACTIVATION; PHOSPHORYLATION	To investigate the role of 3-phosphoinositide-dependent protein kinase 1 (PDK1) in the Akt1 phosphorylation state, wild-type (wt) PDK1 and its kinase dead (kd) mutant were expressed using an adenovirus gene transduction system in Chinese hamster ovary cells stably expressing insulin receptor. Immunoblotting using anti-phosphorylated Akt1 antibody revealed Thr-308 already to be maximally phosphorylated at 1 min but completely dephosphorylated at 5 min, with insulin stimulation, whereas insulin-induced Akt1 activation was maintained even after dephosphorylation of Thr-308. Overexpression of wt-PDK1 further increased insulin-stimulated phosphorylation of Thr-308, also followed by rapid dephosphorylation. The insulin-stimulated Akt1 activity was also enhanced by wt-PDK1 expression but was maintained even at 15 min. Thus, phosphorylation of Thr-308 is not essential for maintaining the Akt1 activity once it has been achieved. Interestingly, the insulin-stimulated phosphorylation state of Thr-308 was maintained even at 15 min in cells expressing kd-PDK1, suggesting that kd-PDK1 has a dominant negative effect on dephosphorylation of Thr-808 of Akt1. Calyculin A, an inhibitor of PP1 and PP2A, also prolonged the insulin-stimulated phosphorylation state of Thr-308. In addition, in vitro experiments revealed PP2A, but not PP1, to dephosphorylate completely Thr-308 of Akt1. These findings suggest that a novel pathway involving dephosphorylation of Akt1 at Thr-308 by a phosphatase, possibly PP2A, originally, identified as is regulated downstream from PDK1, an Akt1 kinase.	Yamaguchi Univ, Sch Med, Dept Internal Med 3, Yamaguchi 7558505, Japan; Univ Tokyo, Fac Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138566, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Dept Mol Biol & Med, Meguro Ku, Tokyo 1538904, Japan; Asahi Life Fdn, Inst Adult Dis, Shinjuku Ku, Tokyo 160, Japan	Yamaguchi University; University of Tokyo; University of Tokyo; Asahi Life Foundation	Oka, Y (corresponding author), Yamaguchi Univ, Sch Med, Dept Internal Med 3, Yamaguchi 7558505, Japan.							Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; BARNES GN, 1995, J NEUROCHEM, V64, P340; BEGUM N, 1995, J BIOL CHEM, V270, P709, DOI 10.1074/jbc.270.2.709; BEGUM N, 1993, ENDOCRINOLOGY, V133, P2085, DOI 10.1210/en.133.5.2085; Belham C, 1999, CURR BIOL, V9, pR93, DOI 10.1016/S0960-9822(99)80058-X; BELLACOSA A, 1993, ONCOGENE, V8, P745; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Coffer PJ, 1998, BIOCHEM J, V335, P1; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; DEREMER MF, 1992, J BIOL CHEM, V267, P13466; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Hajduch E, 1998, DIABETES, V47, P1006, DOI 10.2337/diabetes.47.7.1006; Hawkins PT, 1997, BIOCHEM SOC T, V25, P1147, DOI 10.1042/bst0251147; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; KATAGIRI H, 1995, J BIOL CHEM, V270, P4963, DOI 10.1074/jbc.270.10.4963; Katagiri H, 1996, J BIOL CHEM, V271, P16987, DOI 10.1074/jbc.271.29.16987; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; LEE TH, 1991, CELL, V64, P415, DOI 10.1016/0092-8674(91)90649-J; MACKINTOSH C, 1994, TRENDS BIOCHEM SCI, V19, P444, DOI 10.1016/0968-0004(94)90127-9; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; SRINIVASAN M, 1994, J BIOL CHEM, V269, P12514; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Yan Y, 1999, J BIOL CHEM, V274, P31917, DOI 10.1074/jbc.274.45.31917; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	46	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5339	5345		10.1074/jbc.M005685200	http://dx.doi.org/10.1074/jbc.M005685200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087733	hybrid			2022-12-25	WOS:000168484300108
J	Condrescu, M; Reeves, JP				Condrescu, M; Reeves, JP			Inhibition of sodium-calcium exchange by ceramide and sphingosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; SARCOLEMMAL NA+-CA2+ EXCHANGER; DYNAMIC PROPERTIES; NA+/CA2+ EXCHANGE; STEADY-STATE; CA2+; ATP; SPHINGOMYELINASE; ACCUMULATION; STIMULATION	Na+/Ca2+ exchange activity in Chinese hamster ovary cells expressing the bovine cardiac Na+/Ca2+ exchanger was inhibited by the short chain ceramide analogs N-acetylsphingosine and N-hexanoylsphingosine (5-15 muM). The sphingolipids reduced exchange-mediated Ba2+ influx by 50-70% and also inhibited the Ca2+ efflux mode of exchange activity. The biologically inactive ceramide analog N-acetylsphinganine had only modest effects on exchange activity. Cells expressing the Delta (241-680) and Delta (680-685) deletion mutants of the Na+/Ca2+ exchanger were not inhibited by ceramide; these mutants show defects in both Naf-dependent and Ca2+-dependent regulatory behavior Another mutant, which was defective only in Na+-dependent regulation, was as sensitive to ceramide inhibition as the wild-type exchanger. Inhibition of exchange activity by ceramide was time-dependent and was accelerated by depletion of internal Ca2+ stores. Sphingosine (2.5 muM) also inhibited the Ca2+ influx and efflux modes of exchange activity in cells expressing the wild-type exchanger; sphingosine did not affect Ba2+ influx in the Delta (241-680) mutant. The effects of the exogenous sphingolipids were reproduced by blocking cellular ceramide utilization pathways, suggesting that exchange activity is inhibited by increased levels of endogenous ceramide and/or sphingosine. We propose that sphingolipids impair Ca2+-dependent activation of the exchanger and that in cardiac myocytes, this process serves as a feedback mechanism that links exchange activity to the diastolic concentration of cytosolic Ca2+.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol & Physiol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Reeves, JP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pharmacol & Physiol, 185 S Orange Ave, Newark, NJ 07103 USA.							ABE A, 1992, J BIOCHEM-TOKYO, V111, P191, DOI 10.1093/oxfordjournals.jbchem.a123736; ACETO JF, 1992, ARCH BIOCHEM BIOPHYS, V298, P553, DOI 10.1016/0003-9861(92)90449-7; Bielawska AE, 1997, AM J PATHOL, V151, P1257; Blaustein MP, 1999, PHYSIOL REV, V79, P763, DOI 10.1152/physrev.1999.79.3.763; CHIN TK, 1993, CIRC RES, V72, P497, DOI 10.1161/01.RES.72.3.497; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; Condrescu M, 1997, J GEN PHYSIOL, V109, P41, DOI 10.1085/jgp.109.1.41; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; CONDRESCU M, 1999, BIOPHYS J, V76, P253; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; deChaves EIP, 1997, J BIOL CHEM, V272, P3028, DOI 10.1074/jbc.272.5.3028; Fang Y, 1998, AM J PHYSIOL-CELL PH, V275, pC50, DOI 10.1152/ajpcell.1998.275.1.C50; Fang Y, 1999, CELL CALCIUM, V26, P15, DOI 10.1054/ceca.1999.0046; Fujioka Y, 2000, J PHYSIOL-LONDON, V523, P339, DOI 10.1111/j.1469-7793.2000.t01-2-00339.x; Ghidoni R, 1999, BBA-MOL CELL BIOL L, V1439, P17, DOI 10.1016/S1388-1981(99)00074-8; He ZP, 2000, AM J PHYSIOL-CELL PH, V278, pC661, DOI 10.1152/ajpcell.2000.278.4.C661; Hernandez OM, 2000, CIRC RES, V86, P198, DOI 10.1161/01.RES.86.2.198; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; Iwamoto T, 1999, FEBS LETT, V446, P264, DOI 10.1016/S0014-5793(99)00218-5; Jaffrezou JP, 1998, FASEB J, V12, P999, DOI 10.1096/fasebj.12.11.999; Ji L, 1998, ARCH BIOCHEM BIOPHYS, V359, P107, DOI 10.1006/abbi.1998.0883; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Lepple-Wienhues A, 1999, P NATL ACAD SCI USA, V96, P13795, DOI 10.1073/pnas.96.24.13795; Liu LH, 1999, NUMER HEAT TR A-APPL, V36, P511, DOI 10.1080/104077899274651; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Maceyka M, 1997, J CELL BIOL, V139, P1411, DOI 10.1083/jcb.139.6.1411; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; Matsuoka S, 1997, J GEN PHYSIOL, V109, P273, DOI 10.1085/jgp.109.2.273; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; Maxwell K, 1999, AM J PHYSIOL-HEART C, V277, pH2212, DOI 10.1152/ajpheart.1999.277.6.H2212; Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577, DOI 10.1152/ajpregu.1998.274.3.R577; MIURA Y, 1989, J GEN PHYSIOL, V93, P1129, DOI 10.1085/jgp.93.6.1129; Negishi T, 1999, ENDOCRINOLOGY, V140, P5691, DOI 10.1210/en.140.12.5691; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; NODA M, 1988, BIOPHYS J, V53, P342; Pan Y, 2000, AM J PHYSIOL-CELL PH, V279, pC393, DOI 10.1152/ajpcell.2000.279.2.C393; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; RADIN NS, 1993, ADV LIPID RES, V26, P183; Reeves JP, 1998, J BIOENERG BIOMEMBR, V30, P151, DOI 10.1023/A:1020569224915; REEVES JP, 1984, J BIOL CHEM, V259, P7733; REEVES JP, 1998, INT ASS BIOM SCI 98; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005	45	10	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4046	4054		10.1074/jbc.M006862200	http://dx.doi.org/10.1074/jbc.M006862200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11058589	hybrid			2022-12-25	WOS:000166921200044
J	Piotrowicz, RS; Ding, L; Maher, P; Levin, EG				Piotrowicz, RS; Ding, L; Maher, P; Levin, EG			Inhibition of cell migration by 24-kDa fibroblast growth factor-2 is dependent upon the estrogen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVATION; SIGNALING PATHWAYS; FACTOR-I; EXTRACELLULAR-MATRIX; ENDOTHELIAL-CELLS; GENE-EXPRESSION; CROSS-TALK; PHOSPHORYLATION; PEPTIDE	The single-copy gene for fibroblast growth factor-2 (FGF-2) encodes for multiple forms of the protein with molecular masses of 24, 22.5, 22, and 18 kDa, We reported previously that the 24-22-kDa FGF-2 forms inhibit the migration of endothelial and MCF-7 cells by 50% and 70%, respectively. Here we show that this inhibition of migration is mediated by the estrogen receptor (ER). We have found that depletion of the receptor in either cell line abrogates the inhibitory activity of 24-kDa FGF-2 while re-introduction of the ER into deficient cells once again promotes the inhibitory response. To determine whether exposure to 24-kDa FGF-2 resulted in the activation of the estrogen receptor, 3T3 cells were cotransfected with estrogen receptor cDNA and an estrogen regulatory element-luciferase gene reporter construct and treated with 24- and 18-kDa FGF-2. The high molecular weight form stimulated luciferase activity 5-fold while 18-kDa FGF-2 at the same concentration had no effect, Treatment of ER-positive MCF-7 cells transfected with the reporter construct only showed the same results. Inclusion of the pure estrogen antagonist ICI 182,780 blocked the increase in luciferase activity by 24-kDa FGF-8, further indicating that the response was estrogen receptor dependent. Expression of dominant negative FGF receptor 1 inhibited ER activation, indicating that this was the cell surface receptor mediating the effect. Although growth factor-dependent activation of the ER was reported to require mitogen-activated protein kinase-induced phosphorylation at Ser(118) in COS and HeLa cells, this mechanism is not involved with the activation by 24-kDa FGF-8, These results suggest that the addition of 55 amino acids to the amino-terminal end of 18-kDa FGF-2 by alternative translation alters FGF-8 function and allows for the activation of a second signaling pathway involving the estrogen receptor.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute	Levin, EG (corresponding author), La Jolla Inst Mol Med, 4570 Execut Dr, San Diego, CA 92121 USA.				NCI NIH HHS [R01 CA81209] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081209] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; AMALRIC F, 1991, ANN NY ACAD SCI, V638, P127, DOI 10.1111/j.1749-6632.1991.tb49023.x; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BOMFELDT KE, 1994, J CLIN INVEST, V93, P1266; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; CALLIGARIS R, 1995, P NATL ACAD SCI USA, V92, P11598, DOI 10.1073/pnas.92.25.11598; CHEN P, 1994, J CELL BIOL, V124, P547, DOI 10.1083/jcb.124.4.547; CHO HS, 1994, ENDOCRINOLOGY, V134, P658, DOI 10.1210/en.134.2.658; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; DELMAS V, 1992, P NATL ACAD SCI USA, V89, P4226, DOI 10.1073/pnas.89.10.4226; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; GROTHE C, 1900, BRAIN RES MOL BRAIN, V57, P97; Hafner F, 1996, J STEROID BIOCHEM, V58, P385, DOI 10.1016/0960-0760(96)00054-4; IgnarTrowbridge DM, 1996, ENDOCRINOLOGY, V137, P1735, DOI 10.1210/en.137.5.1735; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Karas RH, 1998, J CLIN INVEST, V101, P2851, DOI 10.1172/JCI1416; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LALLEMAIN G, 1990, BIOCHEM BIOPH RES CO, V172, P306; LANDGREN E, 1995, ONCOGENE, V10, P2027; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; McClelland RA, 1996, EUR J CANCER, V32A, P413, DOI 10.1016/0959-8049(95)00517-X; METZGER D, 1995, J BIOL CHEM, V270, P9535, DOI 10.1074/jbc.270.16.9535; Miao HQ, 1996, J BIOL CHEM, V271, P4879; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOSCATELLI D, 1991, ANN NY ACAD SCI, V638, P177, DOI 10.1111/j.1749-6632.1991.tb49028.x; MOSCATELLI D, 1988, BIOCHIMIE, V70, P83, DOI 10.1016/0300-9084(88)90162-9; NEWTON CJ, 1994, J STEROID BIOCHEM, V48, P481, DOI 10.1016/0960-0760(94)90197-X; O'Donovan KJ, 1999, MOL CELL BIOL, V19, P4711; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; Piotrowicz RS, 1999, J CELL PHYSIOL, V178, P144, DOI 10.1002/(SICI)1097-4652(199902)178:2<144::AID-JCP3>3.0.CO;2-Z; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; QUARTO N, 1991, CELL REGUL, V2, P669; RENKO M, 1990, J CELL PHYSIOL, V144, P108, DOI 10.1002/jcp.1041440114; RIFKIN DB, 1994, MOL REPROD DEV, V39, P102, DOI 10.1002/mrd.1080390115; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; SPIVAKKROIZMAN T, 1994, J BIOL CHEM, V269, P14419; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; ZHAN X, 1993, J BIOL CHEM, V268, P24427	50	16	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3963	3970		10.1074/jbc.M004868200	http://dx.doi.org/10.1074/jbc.M004868200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11083859	hybrid			2022-12-25	WOS:000166921200034
J	Wells, GB; Lin, L; Jeanclos, EM; Anand, R				Wells, GB; Lin, L; Jeanclos, EM; Anand, R			Assembly and ligand binding properties of the water-soluble extracellular domains of the glutamate receptor 1 subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; CRYSTAL-STRUCTURE; 3-DIMENSIONAL STRUCTURE; TETRAMERIC STRUCTURE; KAINATE RECEPTORS; GROWTH-HORMONE; AMPA RECEPTOR; AMINO-ACIDS; COMPLEX; CHANNEL	High resolution structural studies of models of glutamate receptors (GluRs) have been limited to monomeric models of the ligand-binding site, To obtain oligomeric models of glutamate receptors that can reveal more complete structural information, we examined the assembly and ligand binding properties of two truncated versions of the GluR1 subunit, The first version, GluR1-WS, consisted of only the N-terminal extracellullar segment (Ala(1)-Glu(520)) bridged by a synthetic linker to the second extracellular domain (Asn(615)-Gly(790)). The second version, GluR1-M1, consisted of the first N-terminal extracellular domain (Ala(1)-Glu(520)) bridged by a synthetic linker to a second segment containing the second extracellular domain, the third transmembrane domain, and the intracellular C-terminal domain (Asn(615)-Leu(889)). When expressed in Xenopus oocytes, GluR-WS was secreted and water-soluble; GluR1-M1 was displayed on the surface of oocytes, GluR1-WS exhibited a velocity sedimentation profile that was consistent with assembly of homooligomers and bound the glutamate receptor agonist alpha -amino-3-hydroxy-5-methyl-4-isoxazole propionic acid with high affinity, These findings show that the extracellular domains of GluR1 that are sufficient for ligand binding apparently are sufficient for subunit assembly and might be a suitable target for structural studies of a water-soluble GluR1 oligomer.	Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Neurol, New Orleans, LA 70112 USA; Texas A&M Univ, Syst Hlth Sci Ctr, Dept Pathol & Lab Med, College Stn, TX 77843 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Anand, R (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Neurosci Ctr Excellence, 2020 Gravier St,Suite D, New Orleans, LA 70112 USA.		Wells, Gregg/AAU-7798-2021		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS033625] Funding Source: NIH RePORTER; NINDS NIH HHS [NS01903, NS33625] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANAND R, 1993, BIOCHEMISTRY-US, V32, P9975, DOI 10.1021/bi00089a013; Anand R, 2000, BIOCHEM BIOPH RES CO, V276, P157, DOI 10.1006/bbrc.2000.3457; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Arvola M, 1996, J BIOL CHEM, V271, P15527, DOI 10.1074/jbc.271.26.15527; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BENTLEY GA, 1995, RES IMMUNOL, V146, P277, DOI 10.1016/0923-2494(96)80262-8; BROSE N, 1994, J BIOL CHEM, V269, P16780; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DAS MK, 1991, BIOCHEMISTRY-US, V30, P2470, DOI 10.1021/bi00223a025; FerrerMontiel AV, 1996, P NATL ACAD SCI USA, V93, P2741, DOI 10.1073/pnas.93.7.2741; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; Fletcher EJ, 1996, PHARMACOL THERAPEUT, V70, P65, DOI 10.1016/0163-7258(96)00014-9; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; HEADLEY PM, 1990, TRENDS PHARMACOL SCI, V11, P205, DOI 10.1016/0165-6147(90)90116-P; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; Kuusinen A, 1999, J BIOL CHEM, V274, P28937, DOI 10.1074/jbc.274.41.28937; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Laube B, 1998, J NEUROSCI, V18, P2954; Leuschner WD, 1999, J BIOL CHEM, V274, P16907, DOI 10.1074/jbc.274.24.16907; Mano I, 1998, NEUROREPORT, V9, P327, DOI 10.1097/00001756-199801260-00027; Muller YA, 1998, PROTEIN SCI, V7, P1106, DOI 10.1002/pro.5560070504; OLNEY JW, 1990, ANNU REV PHARMACOL, V30, P47; Premkumar LS, 1997, J GEN PHYSIOL, V110, P485, DOI 10.1085/jgp.110.5.485; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; ULTSCH MH, 1994, J MOL BIOL, V236, P286, DOI 10.1006/jmbi.1994.1135; WALTER MR, 1995, NATURE, V376, P230, DOI 10.1038/376230a0; Wang F, 1996, J BIOL CHEM, V271, P17656, DOI 10.1074/jbc.271.30.17656; Wells GB, 1998, J BIOL CHEM, V273, P964, DOI 10.1074/jbc.273.2.964; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; WO ZGL, 1995, J BIOL CHEM, V270, P2000, DOI 10.1074/jbc.270.5.2000	38	13	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3031	3036		10.1074/jbc.M006668200	http://dx.doi.org/10.1074/jbc.M006668200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11076939	hybrid			2022-12-25	WOS:000166784900010
J	Su, LH; Garber, EA; Hsu, YM				Su, LH; Garber, EA; Hsu, YM			CD154 variant lacking tumor necrosis factor homologous domain inhibits cell surface expression of wild-type protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYPER-IGM SYNDROME; X-LINKED IMMUNODEFICIENCY; CD40 LIGAND GENE; DEFECTIVE EXPRESSION; MUTATIONS; GP39	X-linked hyper-IgM (XHIM) syndrome is an immunological disorder resulting from mutations in the CD154 gene. Some mutations occur in splicing sites and result in transcripts encoding wild-type and mutant proteins. These mutants lack the tumor necrosis factor homologous (TNFH) domain and consequently fail to trimerize. Given that the TNFH domain is responsible for trimerization, one may predict that the TNFH mutant can not participate in the assembly of wild-type CD154. Thus, it was puzzling why these patients exhibit XHIM phenotype, presumably resulting from a lack of functional CD154. One possibility is that the TNFH mutant exhibits a dominant negative effect over the wild-type protein. To investigate this, we coexpressed the wild-type protein and a TNFH mutant and examined the biochemical and functional properties of the resulting CD154 products. We demonstrate that despite the lack of the TNFH domain, the TNFH mutant can associate with the wild-type protein. Furthermore, such an association compromises the ability of the wild-type protein to mature onto the cell surface. These results provide a mechanism for the defect of CD154 in XHIM patients producing both wild-type and TNFH variants and suggest that besides the TNFH domain, the stalk region participates in the assembly of CD154 trimers.	Biogen Inc, Dept Prot Engn, Cambridge, MA 02142 USA; Biogen Inc, Dept Mol Genet, Cambridge, MA 02142 USA	Biogen; Biogen	Hsu, YM (corresponding author), Biogen Inc, Dept Prot Engn, 12 Cambridge Ctr, Cambridge, MA 02142 USA.							ALLEN RC, 1993, SCIENCE, V259, P990, DOI 10.1126/science.7679801; Ameratunga R, 1996, CLIN DIAGN LAB IMMUN, V3, P722, DOI 10.1128/CDLI.3.6.722-726.1996; ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; Foy TM, 1996, ANNU REV IMMUNOL, V14, P591, DOI 10.1146/annurev.immunol.14.1.591; FULEIHAN R, 1993, P NATL ACAD SCI USA, V90, P2170, DOI 10.1073/pnas.90.6.2170; Garber E, 1999, J BIOL CHEM, V274, P33545, DOI 10.1074/jbc.274.47.33545; Hsu YM, 1997, J BIOL CHEM, V272, P911, DOI 10.1074/jbc.272.2.911; KARPUSAS M, 1995, STRUCTURE, V3, P1031, DOI 10.1016/S0969-2126(01)00239-8; KORTHAUER U, 1993, NATURE, V361, P539, DOI 10.1038/361539a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Notarangelo LD, 1996, IMMUNOL TODAY, V17, P511, DOI 10.1016/0167-5699(96)30059-5; Seyama K, 1998, BLOOD, V92, P2421, DOI 10.1182/blood.V92.7.2421.2421_2421_2434; Seyama K, 1999, J BIOL CHEM, V274, P11310, DOI 10.1074/jbc.274.16.11310; van Kooten C, 2000, J LEUKOCYTE BIOL, V67, P2, DOI 10.1002/jlb.67.1.2; VILLA A, 1994, P NATL ACAD SCI USA, V91, P2110, DOI 10.1073/pnas.91.6.2110	17	4	6	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					1673	1676		10.1074/jbc.C000674200	http://dx.doi.org/10.1074/jbc.C000674200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11073939	hybrid			2022-12-25	WOS:000166528000003
J	Yan, CH; Wang, H; Boyd, DD				Yan, CH; Wang, H; Boyd, DD			KiSS-1 represses 92-kDa type IV collagenase expression by down-regulating NF-kappa B binding to the promoter as a consequence of I kappa B alpha-induced block of p65/p50 nuclear translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METASTASIS-SUPPRESSOR GENE; ACTIVATED PROTEIN-KINASES; MATRIX METALLOPROTEINASE-9 GENE; SQUAMOUS-CELL CARCINOMA; COLON-CANCER-CELLS; RAT EMBRYO CELLS; C-JUN KINASE; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL ACTIVATION; EXTRACELLULAR-MATRIX	The 92-kDa type IV collagenase (MMP-9) plays a critical role in tissue remodeling. We undertook a study to determine whether the KiSS-1 gene, previously shown to suppress cancer spread (metastases), negatively regulates MMP-9 expression. Six cell lines positive for MMP-9 mRNA were deficient in KiSS-1 mRNA One of these cell lines, HT-1080, stably transfected with a KiSS-1 expression construct, demonstrated substantially lower MMP-9 enzyme activity/protein and in vitro invasiveness, The lower MMP-9 enzyme activity reflected reduced steady-state mRNA levels which, in turn, was due to attenuated transcription. Activation of ERKs and JNKs by phorbol 12-myristate 13-acetate and tumor necrosis factor LY, respectively, leading to increased MMP-9 amounts was not antagonized by KiSS-1 expression, suggesting that MAPK pathways modulating MMP-9 synthesis are not the target of KiSS-1. Although MMP-9 expression is regulated by AP-1, Spl, and Ets transcription factors, KiSS-1 did not alter the binding of these factors to the MMP-9 promoter. However, NF-KB binding to the MMP-9 promoter required for expression of this collagenase was reduced by KiSS-1 expression. Diminished NF-KB binding reflected less pe()! p65 in the nucleus secondary to increased I kappaB alpha levels in the cytosols of the KiSS-1 transfectants. Thus, KiSS-I diminishes MMP-9 expression by effecting reduced NF-KB binding to the promoter.	MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Boyd, DD (corresponding author), MD Anderson Canc Ctr, Dept Canc Biol, Box 179,1515 Holcombe Blvd, Houston, TX 77030 USA.	dboyd@mdanderson.org		Yan, Chunhong/0000-0002-3974-7991	NATIONAL CANCER INSTITUTE [R01CA058311] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE010845, P50DE011906] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA58311] Funding Source: Medline; NIDCR NIH HHS [R01 DE10845, P50 DE11906-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Allgayer H, 1999, J BIOL CHEM, V274, P18428, DOI 10.1074/jbc.274.26.18428; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BOYD D, 1989, CANCER RES, V49, P816; Christensen CRL, 1998, CANCER RES, V58, P1238; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; Davidson B, 1999, GYNECOL ONCOL, V73, P372, DOI 10.1006/gyno.1999.5381; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; FINI ME, 1994, J BIOL CHEM, V269, P28620; FRIDMAN R, 1995, CANCER RES, V55, P2548; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gum R, 1997, ONCOGENE, V14, P1481, DOI 10.1038/sj.onc.1200973; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Himelstein BP, 1998, CLIN EXP METASTAS, V16, P169; Hua J, 1996, CANCER RES, V56, P5279; HUHTALA P, 1990, J BIOL CHEM, V265, P11077; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; JONES LG, 1994, J BIOL CHEM, V269, P23790; JUAREZ C, 1993, INT J CANCER, V54, P73; Kumar A, 1999, FEBS LETT, V462, P140, DOI 10.1016/S0014-5793(99)01487-8; Lee JH, 1997, CANCER RES, V57, P2384; Lee JH, 1996, JNCI-J NATL CANCER I, V88, P1731, DOI 10.1093/jnci/88.23.1731; Legrand C, 1999, J CELL BIOL, V146, P517, DOI 10.1083/jcb.146.2.517; Lentsch AB, 1997, J CLIN INVEST, V100, P2443, DOI 10.1172/JCI119786; Linn R, 1996, CYTOGENET CELL GENET, V72, P159, DOI 10.1159/000134175; Lombardi DP, 1999, CANCER RES, V59, P5724; Martin AG, 2000, J BIOL CHEM, V275, P24383, DOI 10.1074/jbc.M909396199; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MIYAJIMA Y, 1995, ANN OTO RHINOL LARYN, V104, P678, DOI 10.1177/000348949510400902; Mohan R, 1998, J BIOL CHEM, V273, P25903, DOI 10.1074/jbc.273.40.25903; Moses MA, 1998, CANCER RES, V58, P1395; Munaut C, 1999, J BIOL CHEM, V274, P5588, DOI 10.1074/jbc.274.9.5588; NEAD MA, 1995, J INVEST DERMATOL, V105, P668, DOI 10.1111/1523-1747.ep12324367; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; PULVERER BJ, 1993, ONCOGENE, V8, P407; PUTNINS EE, 1995, J INVEST DERMATOL, V104, P989, DOI 10.1111/1523-1747.ep12606233; PYKE C, 1992, CANCER RES, V52, P1336; Reeder JA, 1998, CANCER RES, V58, P3719; Sanz L, 2000, EMBO J, V19, P1576, DOI 10.1093/emboj/19.7.1576; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; SCHLECHTE W, 1990, CANCER COMMUN, V2, P173; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; SHIMA I, 1993, BRIT J CANCER, V67, P721, DOI 10.1038/bjc.1993.132; Shimizu S, 1996, CANCER RES, V56, P3366; SINGH S, 1995, J BIOL CHEM, V270, P10631, DOI 10.1074/jbc.270.18.10631; Sorsa T, 1997, J BIOL CHEM, V272, P21067, DOI 10.1074/jbc.272.34.21067; Takaoka A, 1998, ONCOGENE, V16, P1443, DOI 10.1038/sj.onc.1201648; TANAKA K, 1995, CANCER RES, V55, P2927; Trecca D, 1997, ONCOGENE, V14, P791, DOI 10.1038/sj.onc.1200895; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WELCH DR, 1997, JNCI-J NATL CANCER I, V89, P1549; West A, 1998, GENOMICS, V54, P145, DOI 10.1006/geno.1998.5566; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; Yu Q, 2000, GENE DEV, V14, P163	64	181	220	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 12	2001	276	2					1164	1172		10.1074/jbc.M008681200	http://dx.doi.org/10.1074/jbc.M008681200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	392UL	11060311	hybrid			2022-12-25	WOS:000166430900044
J	Tauchi, H; Kobayashi, J; Morishima, K; Matsuura, S; Nakamura, A; Shiraishi, T; Ito, E; Masnada, D; Delia, D; Komatsu, K				Tauchi, H; Kobayashi, J; Morishima, K; Matsuura, S; Nakamura, A; Shiraishi, T; Ito, E; Masnada, D; Delia, D; Komatsu, K			The forkhead-associated domain of NBS1 is essential for nuclear foci formation after irradiation but not essential for hRAD50 center dot hMRE11 center dot NBS1 complex DNA repair activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; FHA DOMAIN; PROTEIN; RECOMBINATION; RECOGNITION	NBS1 (p95), the protein responsible for Nijmegen breakage syndrome, shows a weak homology to the yeast Xrs2 protein at the N terminus region, known as the forkhead-associated (FHA) domain and the BRCA1 C terminus domain. The protein interacts with hMRE11 to form a complex with a nuclease activity for initiation of both nonhomologous end joining and homologous recombination. Here, we show in vivo direct evidence that NBS1 recruits the hMRE11 nuclease complex into the cell nucleus and leads to the formation of foci by utilizing different functions from several domains. The amino acid sequence at 665-693 on the C terminus of NBS1, where a novel identical sequence with yeast Xrs2 protein was found, is essential for hMRE11 binding. The hMRE11-binding region is necessary for both nuclear localization of the complex and for cellular radiation resistance. On the other hand, the FHA domain regulates nuclear foci formation of the multiprotein complex in response to DNA damage but is not essential for nuclear transportation of the complex and radiation resistance. Because the FHA/BRCA1 C terminus domain is widely conserved in eukaryotic nuclear proteins related to the cell cycle, gene regulation, and DNA repair, the foci formation could be associated with many phenotypes of Nijmegen breakage syndrome other than radiation sensitivity.	Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Radiat Biol, Minami Ku, Hiroshima 7348553, Japan; Ist Nazl Tumori, Dept Expt Oncol, I-20133 Milan, Italy	Hiroshima University; Fondazione IRCCS Istituto Nazionale Tumori Milan	Komatsu, K (corresponding author), Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Radiat Biol, Minami Ku, Kasumi 1-2-3, Hiroshima 7348553, Japan.	komatsu@hiroshima-u.ac.jp	Kobayashi, Junya/AAX-6390-2021; Matsuura, Shinya/U-4182-2017	Kobayashi, Junya/0000-0003-4645-7500; Matsuura, Shinya/0000-0001-5294-081X				Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Durocher D, 1999, MOL CELL, V4, P387, DOI 10.1016/S1097-2765(00)80340-8; HARBER JE, 1998, CELL, V95, P583; HOFMANN K, 1995, TRENDS BIOCHEM SCI, V20, P347, DOI 10.1016/S0968-0004(00)89072-6; Ito A, 1999, BIOCHEM BIOPH RES CO, V265, P716, DOI 10.1006/bbrc.1999.1737; KOMATSU K, 1995, CANCER RES, V55, P1774; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang Y, 2000, GENE DEV, V14, P927; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083	16	109	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	2001	276	1					12	15		10.1074/jbc.C000578200	http://dx.doi.org/10.1074/jbc.C000578200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	390DP	11062235	hybrid			2022-12-25	WOS:000166280700002
J	Bourguignon, LYW; Zhu, HB; Shao, LJ; Chen, YW				Bourguignon, LYW; Zhu, HB; Shao, LJ; Chen, YW			CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPHOMA TRANSMEMBRANE GLYCOPROTEIN; ANKYRIN-BINDING DOMAIN; BREAST-CANCER CELLS; TYROSINE PHOSPHORYLATION; FAMILY KINASES; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; CATALYTIC ACTIVITY; ENDOTHELIAL-CELLS; ONCOGENE PRODUCT	In this study we have demonstrated that both CD44 (the hyaluronan (HA) receptor) and c-Src kinase are expressed in human ovarian tumor cells (SK-OV-3.ipl cell line), and that these two proteins are physically associated as a complex in vivo. Using a recombinant cytoplasmic domain of CD44 and an in vitro binding assay, we have detected a specific interaction between CD44 and c-Src kinase, Furthermore, the binding of HA to SK-OV-3.ipl cells promotes c-Src kinase recruitment to CD44 and stimulates c-Src kinase activity, which, in turn, increases tyrosine phosphorylation of the cytoskeletal protein, cortactin, Subsequently, tyrosine phosphorylation of cortactin attenuates its ability to cross-link filamentous actin in vitro. In addition, transfection of SK-OV-3.ipl cells with a dominant active form of c-Src (Y527F)cDNA promotes CD44 and c-Src association with cortactin in membrane projections, and stimulates HA-dependent/CD44-specific ovarian tumor cell migration. Finally, overexpression of a dominant-negative mutant of c-Src kinase (K295R) in SK-OV-3.ipl cells impairs the tumor cell-specific phenotype, Taken together, these findings strongly suggest that CD44 interaction with c-Src kinase plays a pivotal role in initiating cortactin-regulated cytoskeleton function and HA-dependent tumor cell migration, which may be required for human ovarian cancer progression.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	University of Miami	Bourguignon, LYW (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat, 1600 NW 10th Ave, Miami, FL 33101 USA.	lbourgui@med.miami.edu			NCI NIH HHS [CA78633, CA66163] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA066163, R01CA078633] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATFI A, 1994, J BIOL CHEM, V269, P30688; BAGRODIA S, 1991, NATURE, V349, P172, DOI 10.1038/349172a0; BARONE MV, 1995, NATURE, V378, P509, DOI 10.1038/378509a0; BOLEN JB, 1993, ONCOGENE, V8, P2025; Bourguignon Lilly Y. W., 1998, Frontiers in Bioscience, V3, pD637; Bourguignon LYW, 2000, J CELL BIOL, V150, P177, DOI 10.1083/jcb.150.1.177; BOURGUIGNON LYW, 1991, J BIOL CHEM, V266, P11761; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Bourguignon LYW, 1996, CURR TOP MEMBR, V43, P293; BOURGUIGNON LYW, 1992, MOL CELL BIOL, V12, P4464, DOI 10.1128/MCB.12.10.4464; Bourguignon LYW, 2000, J BIOL CHEM, V275, P1829, DOI 10.1074/jbc.275.3.1829; BOURGUIGNON LYW, 1993, J IMMUNOL, V151, P6634; Bourguignon LYW, 1998, J CELL PHYSIOL, V176, P206, DOI 10.1002/(SICI)1097-4652(199807)176:1<206::AID-JCP22>3.0.CO;2-3; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Broome MA, 1996, J BIOL CHEM, V271, P16798, DOI 10.1074/jbc.271.28.16798; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CANNISTRA SA, 1995, CLIN CANCER RES, V1, P333; CANNISTRA SA, 1993, CANCER RES, V53, P3830; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; Cooper J.A, 1990, PEPT PROT PHOSPH, P85; DEHIO C, 1995, EMBO J, V14, P2471, DOI 10.1002/j.1460-2075.1995.tb07244.x; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; GREEN SJ, 1988, EXP CELL RES, V178, P224, DOI 10.1016/0014-4827(88)90393-X; Hall CL, 1996, ONCOGENE, V13, P2213; Hansen K, 1996, EMBO J, V15, P5299, DOI 10.1002/j.1460-2075.1996.tb00915.x; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang C, 1997, J BIOL CHEM, V272, P13911, DOI 10.1074/jbc.272.21.13911; Ilangumaran S, 1998, BLOOD, V91, P3901; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KALOMIRIS EL, 1989, J BIOL CHEM, V264, P8113; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; LESLEY J, 1993, ADV IMMUNOL, V54, P271, DOI 10.1016/S0065-2776(08)60537-4; Liu MY, 1996, J BIOL CHEM, V271, P7066, DOI 10.1074/jbc.271.12.7066; LOKESHWAR VB, 1992, J BIOL CHEM, V267, P22073; LOKESHWAR VB, 1994, J CELL BIOL, V126, P1099, DOI 10.1083/jcb.126.4.1099; Lokeshwar VB, 2000, J BIOL CHEM, V275, P27641; MAA MC, 1992, ONCOGENE, V7, P2429; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; OKADA M, 1991, J BIOL CHEM, V266, P24249; OSUSKY M, 1995, J BIOL CHEM, V270, P25729, DOI 10.1074/jbc.270.43.25729; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Rahimi N, 1998, J BIOL CHEM, V273, P33714, DOI 10.1074/jbc.273.50.33714; RODIER JM, 1995, J CELL BIOL, V131, P761, DOI 10.1083/jcb.131.3.761; ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511; ROSEN N, 1986, J BIOL CHEM, V261, P3754; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Schuuring E, 1998, CELL ADHES COMMUN, V6, P185, DOI 10.3109/15419069809004475; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Taher TEI, 1996, J BIOL CHEM, V271, P2863, DOI 10.1074/jbc.271.5.2863; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; TURLEY EA, 1991, J CELL BIOL, V112, P1041, DOI 10.1083/jcb.112.5.1041; Wang K, 1996, J BIOL CHEM, V271, P4304; WEST DC, 1989, EXP CELL RES, V183, P179, DOI 10.1016/0014-4827(89)90428-X; WONG S, 1992, ONCOGENE, V7, P2407; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Yeo TK, 1996, AM J PATHOL, V148, P1733; YU DH, 1993, CANCER RES, V53, P891; ZHAN X, 1993, J BIOL CHEM, V268, P24427; Zhu D, 2000, J CELL PHYSIOL, V183, P182, DOI 10.1002/(SICI)1097-4652(200005)183:2<182::AID-JCP5>3.0.CO;2-O; Zhu D, 1998, CELL MOTIL CYTOSKEL, V39, P209, DOI 10.1002/(SICI)1097-0169(1998)39:3<209::AID-CM4>3.0.CO;2-#	72	200	206	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7327	7336		10.1074/jbc.M006498200	http://dx.doi.org/10.1074/jbc.M006498200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11084024	hybrid			2022-12-25	WOS:000167442900065
J	Elnitski, L; Li, J; Noguchi, CT; Miller, W; Hardison, R				Elnitski, L; Li, J; Noguchi, CT; Miller, W; Hardison, R			A negative cis-element regulates the level of enhancement by hypersensitive site 2 of the beta-globin locus control region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; BZIP TRANSCRIPTION FACTOR; PROTEIN DNA INTERACTIONS; OPEN CHROMATIN STRUCTURE; TRANSGENIC MICE; GENE-EXPRESSION; ERYTHROID-CELLS; DEVELOPMENTAL REGULATION; ERYTHROLEUKEMIA-CELLS; ACTIVATION REGION	The core of DNase hypersensitive site (HS) 2 from the beta -globin locus control region is a potent enhancer of globin gene expression. Although it has been considered to contain only positive cis-regulatory sequences, our study of the enhancement conferred by segments of HS2 in erythroid cells reveals a novel negative element. Individual cis-regulatory elements from HS2 such as E boxes or Maf-response elements produced as great or greater enhancement than the intact core in mouse erythroleukemia (MEL) cells, indicating the presence of negative elements within HS2. A deletion series through HS2 revealed negative elements at the 5' and 3' ends of the core. Analysis of constructs with and without the 5' negative element showed that the effect is exerted on the promoters of globin genes expressed at embryonic, fetal, or adult stages. The negative effect was observed in bipotential human cells (K562 and human erythroleukemia (HEL) cells), proerythroblastic mouse (MEL) cells, and normal adult human erythroid cells. The novel negative element also functions after stable integration into MEL chromosomes. Smaller deletions at the 5' end of the HS2 core map the negative element within a 20-base pair region containing two conserved sequences.	Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 206, University Pk, PA 16802 USA; Penn State Univ, Dept Comp Sci & Engn, University Pk, PA 16802 USA; Penn State Univ, Ctr Gene Regulat, University Pk, PA 16802 USA; NIDDK, Biol Chem Lab, NIH, Bethesda, MD 20892 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hardison, R (corresponding author), Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 206, University Pk, PA 16802 USA.		Elnitski, Laura/AAD-3595-2021; Hardison, Ross C/G-1142-2010	Hardison, Ross C/0000-0003-4084-7516; Elnitski, Laura/0000-0003-1065-019X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK025021, R01DK027635, ZIADK025021] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R01LM005110, R01LM005773] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01DK27635] Funding Source: Medline; NLM NIH HHS [R01LM05773, R01LM05110] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANTONIOU M, 1988, EMBO J, V7, P377, DOI 10.1002/j.1460-2075.1988.tb02824.x; Bouhassira EE, 1997, BLOOD, V90, P3332, DOI 10.1182/blood.V90.9.3332; Bresnick EH, 1997, P NATL ACAD SCI USA, V94, P4566, DOI 10.1073/pnas.94.9.4566; Bulger M, 1999, GENE DEV, V13, P2465, DOI 10.1101/gad.13.19.2465; Bungert J, 1995, GENE DEV, V9, P3083, DOI 10.1101/gad.9.24.3083; CAO SX, 1989, P NATL ACAD SCI USA, V86, P5306, DOI 10.1073/pnas.86.14.5306; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P1006, DOI 10.1093/nar/22.6.1006; CATERINA JJ, 1994, NUCLEIC ACIDS RES, V22, P2383, DOI 10.1093/nar/22.12.2383; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; Cavallesco R, 1997, BLOOD CELL MOL DIS, V23, P8, DOI 10.1006/bcmd.1997.0115; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11366, DOI 10.1073/pnas.90.23.11366; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; CROSSLEY M, 1993, CURR OPIN GENET DEV, V3, P232, DOI 10.1016/0959-437X(93)90028-N; DEAN A, 1983, P NATL ACAD SCI-BIOL, V80, P5515, DOI 10.1073/pnas.80.18.5515; DHAR V, 1990, MOL CELL BIOL, V10, P4324, DOI 10.1128/MCB.10.8.4324; ELLIS J, 1993, EMBO J, V12, P127, DOI 10.1002/j.1460-2075.1993.tb05638.x; Elnitski L, 1997, J BIOL CHEM, V272, P369; Elnitski L, 1999, BLOOD CELL MOL DIS, V25, P299, DOI 10.1006/bcmd.1999.0257; ELNITSKI L, 1998, THESIS PENNSYLVANIA; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; FIBACH E, 1989, BLOOD, V73, P100; FORRESTER WC, 1989, P NATL ACAD SCI USA, V86, P5439, DOI 10.1073/pnas.86.14.5439; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GONG QH, 1993, MOL CELL BIOL, V13, P911, DOI 10.1128/MCB.13.2.911; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GROSVELD F, 1993, PHILOS T ROY SOC B, V339, P183, DOI 10.1098/rstb.1993.0015; HARDISON R, 1993, NUCLEIC ACIDS RES, V21, P1265, DOI 10.1093/nar/21.5.1265; Hardison R, 1997, GENE, V205, P73, DOI 10.1016/S0378-1119(97)00474-5; HARDISON R, 1993, DNA SEQUENCE, V4, P163, DOI 10.3109/10425179309015629; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; JACKSON J, 1995, MOL BIOL HEMOGLOBIN, P87; Jackson JD, 1996, J BIOL CHEM, V271, P11871, DOI 10.1074/jbc.271.20.11871; Jackson JD, 1996, NUCLEIC ACIDS RES, V24, P4327, DOI 10.1093/nar/24.21.4327; KOUSSIS D, 1983, NATURE, V38, P662; Lam LT, 1996, J BIOL CHEM, V271, P32421, DOI 10.1074/jbc.271.50.32421; Li J, 1998, J BIOL CHEM, V273, P10202, DOI 10.1074/jbc.273.17.10202; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; LUNA L, 1994, GENOMICS, V22, P553, DOI 10.1006/geno.1994.1428; MACLEOD K, 1991, MOL CELL BIOL, V11, P4324, DOI 10.1128/MCB.11.9.4324; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; Milot E, 1996, CELL, V87, P105, DOI 10.1016/S0092-8674(00)81327-6; MOI P, 1990, P NATL ACAD SCI USA, V87, P9000, DOI 10.1073/pnas.87.22.9000; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MOON AM, 1991, BLOOD, V77, P2272; MORLEY BJ, 1992, MOL CELL BIOL, V12, P2057, DOI 10.1128/MCB.12.5.2057; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; Peterson KR, 1996, P NATL ACAD SCI USA, V93, P6605, DOI 10.1073/pnas.93.13.6605; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; REEVES R, 1985, NUCLEIC ACIDS RES, V13, P3599, DOI 10.1093/nar/13.10.3599; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; RUTHERFORD TR, 1979, NATURE, V280, P164, DOI 10.1038/280164a0; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; SADELAIN M, 1995, P NATL ACAD SCI USA, V92, P6728, DOI 10.1073/pnas.92.15.6728; Slightom JL, 1997, GENOMICS, V39, P90, DOI 10.1006/geno.1996.4458; SORRENTINO B, 1990, NUCLEIC ACIDS RES, V18, P2721, DOI 10.1093/nar/18.9.2721; Stamatoyannopolous G., 1994, MOL BASIS BLOOD DIS, P107; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; TALBOT D, 1989, NATURE, V338, P352, DOI 10.1038/338352a0; TAXMAN DJ, 1995, J BIOL CHEM, V270, P6619, DOI 10.1074/jbc.270.12.6619; TREPICCHIO WL, 1993, MOL CELL BIOL, V13, P7457, DOI 10.1128/MCB.13.12.7457; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; Tuan D, 1987, DEV CONTROL GLOBIN G, P211; TUAN DYH, 1989, P NATL ACAD SCI USA, V86, P2554, DOI 10.1073/pnas.86.8.2554; WIJGERDE M, 1995, NATURE, V377, P209, DOI 10.1038/377209a0	74	13	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6289	6298		10.1074/jbc.M009624200	http://dx.doi.org/10.1074/jbc.M009624200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11092897	hybrid			2022-12-25	WOS:000167261000032
J	Nijtmans, LGJ; Henderson, NS; Attardi, G; Holt, LJ				Nijtmans, LGJ; Henderson, NS; Attardi, G; Holt, LJ			Impaired ATP synthase assembly associated with a mutation in the human ATP synthase subunit 6 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE-NATIVE-ELECTROPHORESIS; MITOCHONDRIAL OXIDATIVE-PHOSPHORYLATION; MEMBRANE-PROTEIN COMPLEXES; CULTURED HUMAN-CELLS; ATPASE-6 GENE; LESS CELLS; DNA; MTDNA; INHIBITOR; COMPLEMENTATION	Mutations in human mitochondrial DNA are a well recognized cause of disease. A mutation at nucleotide position 8993 of human mitochondrial DNA, located within the gene for ATP synthase subunit 6, is associated with the neurological muscle weakness, ataxia, and retinitis pigmentosa (NARP) syndrome. To enable analysis of this mutation in control nuclear backgrounds, two different cell lines were transformed with mitochondria carrying NARP mutant mitochondrial DNA. Transformant cell lines had decreased ATP synthesis capacity, and many also had abnormally high levels of two ATP synthase sub-complexes, one of which was F-1-ATPase. A combination of metabolic labeling and immunoblotting experiments indicated that assembly of ATP synthase was slowed and that the assembled holoenzyme was unstable in cells carrying NARP mutant mitochondrial DNA compared with control cells. These findings indicate that altered assembly and stability of ATP synthase are underlying molecular defects associated with the NARP mutation in subunit 6 of ATP synthase, yet intrinsic enzyme activity is also compromised.	Wellcome Trust, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Dundee, Ninewells Hosp & Med Sch, Dept Mol Pathol, Dundee DD1 9SY, Scotland; CALTECH, Div Biol, Pasadena, CA 91125 USA	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Wellcome Trust Sanger Institute; University of Dundee; California Institute of Technology	Holt, LJ (corresponding author), Wellcome Trust, Dunn Human Nutr Unit, MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.			holt, ian/0000-0001-5468-0193	Medical Research Council [MC_U105663140] Funding Source: Medline; MRC [MC_U105663140] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Baracca A, 2000, J BIOL CHEM, V275, P4177, DOI 10.1074/jbc.275.6.4177; BODNAR AG, 1993, AM J HUM GENET, V53, P663; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Cabezon E, 2000, J BIOL CHEM, V275, P25460, DOI 10.1074/jbc.M003859200; CHOMYN A, 1994, AM J HUM GENET, V54, P966; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221; DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319; DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562; Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Garcia JJ, 2000, J BIOL CHEM, V275, P11075, DOI 10.1074/jbc.275.15.11075; GAY NJ, 1985, EMBO J, V4, P3519, DOI 10.1002/j.1460-2075.1985.tb04111.x; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; Holt IJ, 1997, HUM MOL GENET, V6, P1251, DOI 10.1093/hmg/6.8.1251; HOLT IJ, 1990, AM J HUM GENET, V46, P428; HOUSTEK J, 1995, BBA-MOL BASIS DIS, V1271, P349, DOI 10.1016/0925-4439(95)00063-A; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480; KLEIN G, 1980, BIOCHEMISTRY-US, V19, P2919, DOI 10.1021/bi00554a016; KLEMENT P, 1995, ANAL BIOCHEM, V231, P218, DOI 10.1006/abio.1995.1523; LOPEZMEDIAVILLA C, 1993, EUR J BIOCHEM, V215, P487, DOI 10.1111/j.1432-1033.1993.tb18058.x; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x; NIJTMANS LGJ, 1995, BBA-MOL BASIS DIS, V1270, P193, DOI 10.1016/0925-4439(95)00044-5; Nijtmans LGJ, 1995, BBA-MOL BASIS DIS, V1272, P190, DOI 10.1016/0925-4439(95)00087-9; PENIN F, 1988, BIOCHEMISTRY-US, V27, P8969, DOI 10.1021/bi00425a014; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; Sangawa H, 1997, J BIOL CHEM, V272, P6034, DOI 10.1074/jbc.272.9.6034; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; TATUCH Y, 1993, BIOCHEM BIOPH RES CO, V192, P124, DOI 10.1006/bbrc.1993.1390; TATUCH Y, 1992, AM J HUM GENET, V50, P852; TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334; WANDERS RJA, 1993, BIOCHIM BIOPHYS ACTA, V1181, P219, DOI 10.1016/0925-4439(93)90024-U; Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131	39	87	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6755	6762		10.1074/jbc.M008114200	http://dx.doi.org/10.1074/jbc.M008114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11076946	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000167261000088
J	Xiao, J; Liu, CC; Chen, PL; Lee, WH				Xiao, J; Liu, CC; Chen, PL; Lee, WH			RINT-1, a novel Rad50-interacting protein, participates in radiation-induced G(2)/M checkpoint control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NIJMEGEN BREAKAGE SYNDROME; DNA-DAMAGE RESPONSE; RETINOBLASTOMA GENE-PRODUCT; BREAST-CANCER; CELL-CYCLE; WILD-TYPE; COMPLEX; REPAIR; MRE11; RAD50	Rad50, an structural maintenance of chromosomes (SMC) protein family member, participates in a variety of cellular processes, including DNA double-strand break repair, cell cycle checkpoint activation, telomere maintenance, and meiosis. Disruption of Rad50 in mice leads to lethality during early embryogenesis, indicating its essential function in normal proliferating cells. In addition to its ability to form a complex with the DNA double-strand break repair proteins Mre11 and NBS1, Rad50 may interact with other cellular proteins to execute its full range of biological activities. A novel 87-kDa protein named RINT-1 was identified using the C-terminal region of human Rad50 as the bait in a yeast two-hybrid screen. Human RINT-1 shares sequence homology with a novel protein identified in Drosophila melanogaster, including a coiled-coil domain within its N-terminal 150 amino acids, a conserved central domain of about 350 amino acids, and a C terminal region of 90 amino acids exhibiting 35-38% identity. The conserved central and C-terminal regions of RINT-1 are required for its interaction with Rad50. While Rad50 and RINT-1 are both expressed throughout the cell cycle, RINT-1 specifically binds to Rad50 only during late S and G(2)/M phases, suggesting that RINT-1 may be involved in cell cycle regulation. Consistent with this possibility, MCF-7 cells expressing an N-terminally truncated RINT-1 protein displayed a defective radiation-induced G(2)/M checkpoint. These results suggest that RINT-1 may play a role in the regulation of cell cycle control after DNA damage.	Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA; Univ Texas, Hlth Sci Ctr, Inst Biotechnol, San Antonio, TX 78245 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Lee, WH (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Mol Med, San Antonio, TX 78245 USA.	Leew@uthscsa.edu			NCI NIH HHS [CA81020, CA58183] Funding Source: Medline; NEI NIH HHS [EY05758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA058183, P01CA081020] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; ALANI E, 1989, GENETICS, V122, P47; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BOECK R, 1994, EMBO J, V13, P3608, DOI 10.1002/j.1460-2075.1994.tb06668.x; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Chen CF, 1999, J BIOL CHEM, V274, P32931, DOI 10.1074/jbc.274.46.32931; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Dolganov GM, 1996, MOL CELL BIOL, V16, P4832; DURFEE T, 1994, J CELL BIOL, V127, P609, DOI 10.1083/jcb.127.3.609; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Furuse M, 1998, EMBO J, V17, P6412, DOI 10.1093/emboj/17.21.6412; GAME JC, 1974, MUTAT RES, V24, P281, DOI 10.1016/0027-5107(74)90176-6; HALL JM, 1990, SCIENCE, V250, P1684, DOI 10.1126/science.2270482; JOHZUKA K, 1995, GENETICS, V139, P1521; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Melby TE, 1998, J CELL BIOL, V142, P1595, DOI 10.1083/jcb.142.6.1595; MITELMAN F, 1991, CATALOG CHROMOSOME A, P475; Moreau S, 1999, MOL CELL BIOL, V19, P556; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; Petrini JHJ, 1999, AM J HUM GENET, V64, P1264, DOI 10.1086/302391; SAITOH N, 1995, BIOESSAYS, V17, P759, DOI 10.1002/bies.950170905; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Trujillo KM, 1998, J BIOL CHEM, V273, P21447, DOI 10.1074/jbc.273.34.21447; Usui T, 1998, CELL, V95, P705, DOI 10.1016/S0092-8674(00)81640-2; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Wang Y, 2000, GENE DEV, V14, P927; Wim JM, 1997, MOL CELL BIOL, V17, P5016, DOI 10.1128/MCB.17.9.5016; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	39	53	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6105	6111		10.1074/jbc.M008893200	http://dx.doi.org/10.1074/jbc.M008893200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096100	hybrid			2022-12-25	WOS:000167261000009
J	Spielewoy, N; Schulz, H; Grienenberger, JM; Thony-Meyer, L; Bonnard, G				Spielewoy, N; Schulz, H; Grienenberger, JM; Thony-Meyer, L; Bonnard, G			CCME, a nuclear-encoded heme-binding protein involved in cytochrome c maturation in plant mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; ESCHERICHIA-COLI; BRADYRHIZOBIUM-JAPONICUM; GENE-CLUSTER; SACCHAROMYCES-CEREVISIAE; SEQUENCE-ANALYSIS; TRANSFER-RNA; COMPLEX-I; GENOME; BIOGENESIS	The maturation of c-type cytochromes requires the covalent attachment of the heme cofactor to the apoprotein. For this process, plant mitochondria follow a pathway distinct from that of animal or yeast mitochondria, closer to that found in alpha- and gamma -proteobacteria. We report the first characterization of a nuclear-encoded component, namely AtCCME, the Arabidopsis thaliana orthologue of CcmE, a periplasmic heme chaperone in bacteria. AtCCME is targeted to mitochondria, and its N-terminal signal peptide is cleaved upon import. AtCCME is a peripheral protein of the mitochondrial inner membrane, and its major hydrophilic domain is oriented toward the intermembrane space. Although a AtCCME (Met(79)-Ser(256)) is not fully able to complement an Escherichia coli CcmE mutant strain for bacterial holocytochrome c production, it is able to bind heme covalently through a conserved histidine, a feature previously shown for E. coli CcmE. Our results suggest that AtCCME is important for cytochrome c maturation in A. thaliana mitochondria and that its heme-binding function has been conserved evolutionary between land plant mitochondria and cu-proteobacteria.	Univ Strasbourg, CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France; Swiss Fed Inst Technol, Inst Mikrobiol, CH-8092 Zurich, Switzerland	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Swiss Federal Institutes of Technology Domain; ETH Zurich	Bonnard, G (corresponding author), Univ Strasbourg, CNRS, Inst Biol Mol Plantes, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.	geraldine.bonnard@ibmp-ulp.u-strasbg.fr						Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; BONNARD G, 1995, MOL GEN GENET, V246, P91, DOI 10.1007/BF00290137; BOWLER C, 1989, EMBO J, V8, P31, DOI 10.1002/j.1460-2075.1989.tb03345.x; BREYTON C, 1994, J BIOL CHEM, V269, P7597; Chow KS, 1997, J BIOL CHEM, V272, P27565, DOI 10.1074/jbc.272.44.27565; Comella P, 1999, PLANT MOL BIOL, V41, P687, DOI 10.1023/A:1006395324818; CREISSEN G, 1995, PLANT J, V8, P167, DOI 10.1046/j.1365-313X.1995.08020167.x; DAY DA, 1985, AUST J PLANT PHYSIOL, V12, P219, DOI 10.1071/PP9850219; Dellaporta SL, 1983, PLANT MOL BIOL REP, V1, P19, DOI DOI 10.1007/BF02712670; Deshmukh M, 2000, MOL MICROBIOL, V35, P123, DOI 10.1046/j.1365-2958.2000.01683.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUMONT ME, 1987, EMBO J, V6, P235, DOI 10.1002/j.1460-2075.1987.tb04744.x; Fey J, 1999, FEBS LETT, V458, P124, DOI 10.1016/S0014-5793(99)01140-0; FUJIKI Y, 1982, J CELL BIOL, V93, P103, DOI 10.1083/jcb.93.1.103; GAVEL Y, 1988, FEBS LETT, V235, P173, DOI 10.1016/0014-5793(88)81257-2; Goldman BS, 1998, P NATL ACAD SCI USA, V95, P5003, DOI 10.1073/pnas.95.9.5003; GONZALEZ DH, 1993, CURR GENET, V24, P248, DOI 10.1007/BF00351799; Grimm B, 1998, CURR OPIN PLANT BIOL, V1, P245, DOI 10.1016/S1369-5266(98)80112-X; HARBIN BM, 1985, BIOCHEMISTRY-US, V24, P366, DOI 10.1021/bi00323a019; HEINS L, 1994, J BIOL CHEM, V269, P26402; IOBBINIVOL C, 1994, FEMS MICROBIOL LETT, V119, P89, DOI 10.1016/0378-1097(94)90397-2; JAHN D, 1992, TRENDS BIOCHEM SCI, V17, P215, DOI 10.1016/0968-0004(92)90380-R; Jordan PM, 1990, BIOSYNTHESIS HEME CH, P55; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; LAMATTINA L, 1993, EUR J BIOCHEM, V217, P831, DOI 10.1111/j.1432-1033.1993.tb18311.x; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; Mackenzie S, 1999, PLANT CELL, V11, P571, DOI 10.1105/tpc.11.4.571; MEISSNER PS, 1987, P NATL ACAD SCI USA, V84, P4171, DOI 10.1073/pnas.84.12.4171; Menand B, 1998, P NATL ACAD SCI USA, V95, P11014, DOI 10.1073/pnas.95.18.11014; ODA K, 1992, J MOL BIOL, V223, P1, DOI 10.1016/0022-2836(92)90708-R; Ohta N, 1998, NUCLEIC ACIDS RES, V26, P5190, DOI 10.1093/nar/26.22.5190; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PASCAL N, 1993, PLANT PHYSIOL, V103, P1329, DOI 10.1104/pp.103.4.1329; Reid E, 1998, FEMS MICROBIOL LETT, V166, P369, DOI 10.1016/S0378-1097(98)00357-7; RITZ D, 1995, MOL GEN GENET, V247, P27, DOI 10.1007/BF00425818; Sadowski J, 1996, MOL GEN GENET, V251, P298, DOI 10.1007/s004380050170; Sakamoto W, 2000, PLANT CELL PHYSIOL, V41, P1157, DOI 10.1093/pcp/pcd045; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schulz H, 1998, SCIENCE, V281, P1197, DOI 10.1126/science.281.5380.1197; Schulz H, 1999, P NATL ACAD SCI USA, V96, P6462, DOI 10.1073/pnas.96.11.6462; Schulz H, 2000, MOL MICROBIOL, V37, P1379, DOI 10.1046/j.1365-2958.2000.02083.x; SCHUSTER W, 1994, ANNU REV PLANT PHYS, V45, P61, DOI 10.1146/annurev.pp.45.060194.000425; Sjoling S, 1998, TRENDS PLANT SCI, V3, P136, DOI 10.1016/S1360-1385(98)01212-6; Small I, 1998, PLANT MOL BIOL, V38, P265, DOI 10.1023/A:1006081903354; SPARACE SA, 1979, PLANT PHYSIOL, V63, P963, DOI 10.1104/pp.63.5.963; Steiner H, 1996, J BIOL CHEM, V271, P32605, DOI 10.1074/jbc.271.51.32605; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Thony-Meyer L, 2000, BBA-BIOENERGETICS, V1459, P316, DOI 10.1016/S0005-2728(00)00167-5; THONYMEYER L, 1989, CELL, V57, P683, DOI 10.1016/0092-8674(89)90137-2; THONYMEYER L, 1995, J BACTERIOL, V177, P4321; ThonyMeyer L, 1997, MICROBIOL MOL BIOL R, V61, P337; Unseld M, 1997, NAT GENET, V15, P57, DOI 10.1038/ng0197-57; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; Whelan J, 1997, PLANT MOL BIOL, V33, P771, DOI 10.1023/A:1005755505738; WISCHMANN C, 1995, FEBS LETT, V374, P152, DOI 10.1016/0014-5793(95)01100-S; ZHANG L, 1995, EMBO J, V14, P313, DOI 10.1002/j.1460-2075.1995.tb07005.x; ZHUO DG, 1993, MOL GEN GENET, V236, P395, DOI 10.1007/BF00277139; ZOLLNER A, 1992, EUR J BIOCHEM, V207, P1093, DOI 10.1111/j.1432-1033.1992.tb17146.x	58	51	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5491	5497		10.1074/jbc.M008853200	http://dx.doi.org/10.1074/jbc.M008853200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11069919	hybrid			2022-12-25	WOS:000167115100013
J	Nissen, LJ; Gelly, JC; Hipskind, RA				Nissen, LJ; Gelly, JC; Hipskind, RA			Induction-independent recruitment of CREB-binding protein to the c-fos serum response element through interactions between the bromodomain and Elk-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-REGULATED KINASE; TERNARY COMPLEX; MAP KINASE; TRANSCRIPTIONAL ACTIVATION; DNA-BINDING; TFII-I; PROMOTER; CBP; PHOSPHORYLATION; BETA	Proliferative signals lead to the rapid and transient induction of the c-fos proto-oncogene by targeting the ternary complex assembled on the serum response element (SRE). Transactivation by both components of this complex, serum response factor (SRF) and the ternary complex factor Elk-1, can be potentiated by the coactivator CREB-binding protein (CBP). We report a novel interaction between the bromodomain of CBP, amino acids 1100-1286, and Elk-1. DNA binding and glutathione S-transferase pull-down assays demonstrate that binding requires Elk-1(1-212) but not the C-terminal transactivation domain. Competition and antibody controls show that the bromocomplex involves both SRF and Elk-1 on the c-fos SRE and uniquely Elk-1 on the E74 Ets binding site. Interestingly, methylation interference and DNA footprinting analyses show almost indistinguishable patterns between ternary and bromocomplexes, suggesting that CBP-(1100-1286) interacts via Elk-1 and does not require specific DNA contacts. Functionally, the bromocomplex blocks activation, because cotransfection of CBP-(1100-1286) reduces RasV12-driven activation of SRE and E74 luciferase reporters. Repression is relieved moderately or strongly by linking the bromodomain to the N- or C-terminal transactivation domains of CBP, respectively. These results are consistent with a model in which CBP is constitutively bound to the SRE in a higher order complex that would facilitate the rapid transcriptional activation of c-fos by signaling-driven phosphorylation.	CNRS, IFR24, Inst Genet Mol Montpellier, F-34293 Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Hipskind, RA (corresponding author), CNRS, IFR24, Inst Genet Mol Montpellier, 1919 Rte Mende, F-34293 Montpellier, France.		Gelly, Jean-Christophe/A-9321-2010	Gelly, Jean-Christophe/0000-0001-5138-361X				CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GRAHAM R, 1991, SCIENCE, V251, P189, DOI 10.1126/science.1898992; Hanlon M, 1999, J BIOL CHEM, V274, P14224, DOI 10.1074/jbc.274.20.14224; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; Herrera RE, 1997, CHROMOSOMA, V106, P284, DOI 10.1007/s004120050249; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Hipskind Robert A., 1998, Frontiers in Bioscience, V3, pD804; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Janknecht R, 1996, ONCOGENE, V12, P1961; JANKNECHT R, 1992, NUCLEIC ACIDS RES, V20, P3317, DOI 10.1093/nar/20.13.3317; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Kim DW, 2000, MOL CELL BIOL, V20, P1140, DOI 10.1128/MCB.20.4.1140-1148.2000; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; Lee SK, 2000, MOL ENDOCRINOL, V14, P915, DOI 10.1210/me.14.6.915; Maxam A M, 1980, Methods Enzymol, V65, P499; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; NATESAN S, 1995, MOL CELL BIOL, V15, P5975; Philips A, 1999, ONCOGENE, V18, P6222, DOI 10.1038/sj.onc.1203017; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; Sealy L, 1997, MOL CELL BIOL, V17, P1744, DOI 10.1128/MCB.17.3.1744; SHAW PE, 1992, EMBO J, V11, P3011, DOI 10.1002/j.1460-2075.1992.tb05371.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1995, EMBO J, V14, P4905, DOI 10.1002/j.1460-2075.1995.tb00173.x; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; VANHOUTTE P, 2000, IN PRESS J BIOL CHEM; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Yates PR, 1999, EMBO J, V18, P968, DOI 10.1093/emboj/18.4.968; Zhang JJ, 1996, P NATL ACAD SCI USA, V93, P15092, DOI 10.1073/pnas.93.26.15092; Zhu C, 1997, MOL CELL BIOL, V17, P4957, DOI 10.1128/MCB.17.9.4957; ZINCK R, 1993, EMBO J, V12, P2377, DOI 10.1002/j.1460-2075.1993.tb05892.x	40	48	50	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5213	5221		10.1074/jbc.M007824200	http://dx.doi.org/10.1074/jbc.M007824200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11083868	Green Published, hybrid			2022-12-25	WOS:000168484300091
J	Abdouh, M; Storring, JM; Riad, M; Paquette, Y; Albert, PR; Drobetsky, E; Kouassi, E				Abdouh, M; Storring, JM; Riad, M; Paquette, Y; Albert, PR; Drobetsky, E; Kouassi, E			Transcriptional mechanisms for induction of 5-HT1A receptor mRNA and protein in activated B and T lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; HIV-SEROPOSITIVE SUBJECTS; IMMUNE-SYSTEM; CALCIUM IONOPHORES; SYNTHETIC PEPTIDE; MESSENGER-RNA; CYCLIC-AMP; RAT-BRAIN; IN-VITRO; SEROTONIN	Serotonin (5-HT) up-regulates B and T lymphocyte proliferation by activating mitogen-induced cell surface 5-HT1A receptors. The mechanism of 5-HT1A receptor induction by B and T cell mitogens at the mRNA and protein levels in mouse splenocytes was addressed. Quantitation by RNase protection assay showed maximal increases of 3.4-, 3.0-, 3.8-, and 4.9-fold in relative 5-HT1A mRNA levels after 48 h of stimulation of splenocytes with Lipopolysaccharide, phytohemagglutinin, concanavalin A, or phorbol la-myristate 13-acetate plus ionomycin, respectively as compared with unstimulated cells. Mitogens did not alter 5-HT1A mRNA stability (t(1/2) = 26 h), but induction of 5-HT1A mRNA was blocked by the transcriptional inhibitor actinomycin D (10 mug/ml) and by inhibition of nuclear factor-kappaB signaling. Additionally, mitogenic stimulation of transcription was paralleled by increased cell surface 5-HT1A receptor immunoreactivity in splenocytes. Thus, mitogen-induced 5-HT, receptor expression appears to involve transcriptional regulation by the nuclear factor-kappaB signaling cascade. Increased expression of the 5-HT1A receptor in activated B and T lymphocytes may enhance the immune response and provide therapeutic target for tissue inflammation and immune stimulation.	Inst Armand Frappier, INRS, Human Hlth Res Ctr, Pointe Claire, PQ H9R 1G6, Canada; Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada; Hop Maison Neuve Rosemont, Guy Bernier Res Ctr, Ottawa, ON K1H 8M5, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Univ Montreal, Dept Pathol & Cellular Biol, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada	University of Quebec; Institut national de la recherche scientifique (INRS); University of Ottawa; Universite de Montreal; McGill University; Universite de Montreal; Universite de Montreal	Kouassi, E (corresponding author), Inst Armand Frappier, INRS, Human Hlth Res Ctr, Pointe Claire, PQ H9R 1G6, Canada.	edouard.kouassi@inrs-iaf.uquebec.ca	Albert, Paul/E-4804-2010	Albert, Paul/0000-0002-1809-3554; Abdouh, Mohamed/0000-0003-0702-9335; Kouassi, Edouard/0000-0002-3626-4863				Afzelius P, 1997, SCAND J INFECT DIS, V29, P117, DOI 10.3109/00365549709035870; ALBERT PR, 1990, J BIOL CHEM, V265, P5825; AUNE TM, 1993, J IMMUNOL, V151, P1175; AUNE TM, 1994, J IMMUNOL, V153, P489; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; CHAREST A, 1993, J NEUROSCI, V13, P5164, DOI 10.1523/JNEUROSCI.13-12-05164.1993; Cowen DS, 1997, MOL PHARMACOL, V52, P221, DOI 10.1124/mol.52.2.221; CRIVELLATO E, 1991, ACTA ANAT, V141, P127; ELMESTIKAWY S, 1990, NEUROSCI LETT, V118, P189, DOI 10.1016/0304-3940(90)90623-H; Essmann W. B., 1978, SEROTONIN HLTH DISEA, P15; EugenOlsen J, 1997, CLIN IMMUNOL IMMUNOP, V84, P115, DOI 10.1006/clin.1997.4384; FARGIN A, 1989, J BIOL CHEM, V264, P14848; FELTEN DL, 1985, J IMMUNOL, V135, pS755; FUCHS BA, 1988, CELL IMMUNOL, V117, P339, DOI 10.1016/0008-8749(88)90123-2; GOZLAN H, 1995, EUR J PHARM-MOLEC PH, V288, P173, DOI 10.1016/0922-4106(95)90192-2; Grumont RJ, 1998, J EXP MED, V187, P663, DOI 10.1084/jem.187.5.663; Hofmann B, 1996, AIDS, V10, P1339, DOI 10.1097/00002030-199610000-00005; HOYER D, 1994, PHARMACOL REV, V46, P157; IKEN K, 1995, CELL IMMUNOL, V163, P1, DOI 10.1006/cimm.1995.1092; KLAUS GGB, 1986, EUR J IMMUNOL, V16, P92, DOI 10.1002/eji.1830160118; KOBILKA BK, 1987, NATURE, V329, P75, DOI 10.1038/329075a0; LI YS, 1989, EUR J IMMUNOL, V19, P1721, DOI 10.1002/eji.1830190929; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; MARAZZITI D, 1995, LIFE SCI, V57, P2197, DOI 10.1016/0024-3205(95)02128-6; Mossner R, 1998, BRAIN BEHAV IMMUN, V12, P249, DOI 10.1006/brbi.1998.0532; Ou XM, 2000, J BIOL CHEM, V275, P8161, DOI 10.1074/jbc.275.11.8161; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; PAIVA MQ, 1984, N-S ARCH PHARMACOL, V325, P62, DOI 10.1007/BF00507055; Riad N, 2000, J COMP NEUROL, V417, P181, DOI 10.1002/(SICI)1096-9861(20000207)417:2<181::AID-CNE4>3.0.CO;2-A; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; Sha WC, 1998, J EXP MED, V187, P143, DOI 10.1084/jem.187.2.143; Storring JM, 1999, J NEUROCHEM, V72, P2238, DOI 10.1046/j.1471-4159.1999.0722238.x; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; UNLAP T, 1995, NEUROSCI LETT, V198, P41, DOI 10.1016/0304-3940(95)11963-W; Wissink S, 2000, J BIOL CHEM, V275, P1321, DOI 10.1074/jbc.275.2.1321	37	54	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4382	4388		10.1074/jbc.M004559200	http://dx.doi.org/10.1074/jbc.M004559200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11080494	hybrid			2022-12-25	WOS:000166921200087
J	Canaff, L; Petit, JL; Kisiel, M; Watson, PH; Gascon-Barre, M; Hendy, GN				Canaff, L; Petit, JL; Kisiel, M; Watson, PH; Gascon-Barre, M; Hendy, GN			Extracellular calcium-sensing receptor is expressed in rat hepatocytes - Coupling to intracellular calcium mobilization and stimulation of bile flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL HYPOCALCIURIC HYPERCALCEMIA; CA2+-SENSING RECEPTOR; PARATHYROID-HORMONE; CA2+; MUTATIONS; PROTEIN; GENE; IDENTIFICATION; LOCALIZATION; HYPOCALCEMIA	Liver cells respond to changes in Ca-o(2+). The hepatic functions affected include bile secretion, metabolic activity, liver regeneration, and the response to xenobiotics. In the present study, we demonstrate the presence, in the liver, of the extracellular calcium-sensing receptor (CASR), described previously in the parathyroid and thyroid glands and kidney. CASR mRNA was specifically expressed in hepatocytes and was absent in nonparenchymal liver cells (stellate, endothelial, and Kupffer cells). Western blot analysis using a specific CASR antibody showed staining in both whole liver and hepatocyte extracts. Immunohistochemistry and in situ hybridization of rat liver sections showed expression of CASR protein and mRNA by a subset of hepatocytes. The known agonists of the CASR, gadolinium (Gd3+; 0.5-3.0 mM) and spermine (1.25-20 mM), in the absence of Ca-o(2+), elicited dose-related increases in Ca-i(2+) in isolated rat hepatocytes loaded with Fura-2/acetoxymethyl ester. There was a greatly attenuated response to a second challenge with either agonist. The response was also abrogated when inositol 1,4,5-trisphosphate (IP3)-sensitive calcium pools had been depleted by pretreatment with either thapsigargin or phenylephrine, an alpha (1)-adrenergic receptor agonist known to mobilize Ca-i(2+) from IP,-sensitive pools. Addition of the deschloro-phenylalkylamine compound, NPS R-467, but not the S enantiomer, NPS S-467, increased the sensitivity of the Ca-i(2+) mobilization response to 1.25 mar spermine. Bile flow ceased after Ca-o(2+), withdrawal, and its recovery was enhanced by spermine in isolated perfused liver preparations. The CASR agonists Ca2+ and Gd3+ increased bile flow, and the response to a submaximal Ca2+ concentration was enhanced by NPS R-467 but not the S compound. Thus, the data indicate that rat hepatocytes harbor a CASR capable of mobilizing Ca-i(2+) from IP3-sensitive stores and that activation of the CASR stimulates bile flow.	Royal Victoria Hosp, Calcium Res Lab, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Physiol & Human Genet, Montreal, PQ H3A 1A1, Canada; Ctr Hosp Univ Montreal, Ctr Rech, Montreal, PQ H2X 1P1, Canada; Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H2X 1P1, Canada; Univ Western Ontario, Dept Med, London, ON N6A 4V2, Canada; Lawson Res Inst, London, ON N6A 4V2, Canada	McGill University; Royal Victoria Hospital; McGill University; McGill University; Universite de Montreal; Universite de Montreal; Western University (University of Western Ontario); Western University (University of Western Ontario)	Hendy, GN (corresponding author), Royal Victoria Hosp, Calcium Res Lab, Rm H4-67,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	gnhendy@med.mcgill.ca	Centeno, Patricia Pacios/O-8368-2016					ANWER MS, 1985, AM J PHYSIOL, V249, pG711, DOI 10.1152/ajpgi.1985.249.6.G711; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bapty BW, 1998, KIDNEY INT, V53, P583, DOI 10.1046/j.1523-1755.1998.00790.x; BENBRAHIM N, 1988, BIOCHEM J, V255, P91, DOI 10.1042/bj2550091; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 1999, VITAM HORM, V55, P1; Brown EM, 1999, AM J MED, V106, P238, DOI 10.1016/S0002-9343(98)00418-5; BROWN EM, 1990, ENDOCRINOLOGY, V127, P1064, DOI 10.1210/endo-127-3-1064; Bruce JIE, 1999, J BIOL CHEM, V274, P20561, DOI 10.1074/jbc.274.29.20561; Chattopadhyay N, 1998, AM J PHYSIOL-GASTR L, V274, pG122, DOI 10.1152/ajpgi.1998.274.1.G122; CHEN CJ, 1989, ENDOCRINOLOGY, V124, P233, DOI 10.1210/endo-124-1-233; Cheng I, 1999, GASTROENTEROLOGY, V116, P118, DOI 10.1016/S0016-5085(99)70235-0; Cole DEC, 1999, LANCET, V353, P112, DOI 10.1016/S0140-6736(98)06434-4; DAMOUR P, 1979, J CLIN INVEST, V63, P89, DOI 10.1172/JCI109283; DAmour P, 1996, J BONE MINER RES, V11, P1075; DAVIES M, 1981, BRIT MED J, V282, P1023, DOI 10.1136/bmj.282.6269.1023; DOUMITH R, 1980, NOUV PRESSE MED, V9, P1157; Fan GF, 1997, ENDOCRINOLOGY, V138, P1916, DOI 10.1210/en.138.5.1916; Gama L, 1997, AM J PHYSIOL-CELL PH, V273, pC1168, DOI 10.1152/ajpcell.1997.273.4.C1168; Gascon-Barre M., 1997, Vitamin D., P41; Gascon-Barre M, 1997, CELL CALCIUM, V22, P343, DOI 10.1016/S0143-4160(97)90019-1; GASCONBARRE M, 1991, ENDOCRINOLOGY, V129, P2335, DOI 10.1210/endo-129-5-2335; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEATH H, 1993, J ENDOCRINOL METAB, V81, P1312; Hendy GN, 2000, HUM MUTAT, V16, P281, DOI 10.1002/1098-1004(200010)16:4<281::AID-HUMU1>3.0.CO;2-A; JANICIC N, 1995, AM J HUM GENET, V56, P880; JANICIC N, 1995, MAMM GENOME, V6, P798, DOI 10.1007/BF00539007; KNOOK DL, 1976, EXP CELL RES, V99, P444, DOI 10.1016/0014-4827(76)90605-4; LAW WM, 1985, ANN INTERN MED, V102, P511, DOI 10.7326/0003-4819-102-4-511; LIMLOMWONGSE L, 1988, DIGEST DIS SCI, V33, P685, DOI 10.1007/BF01540431; Lin KI, 1998, BIOCHEM BIOPH RES CO, V249, P325, DOI 10.1006/bbrc.1998.9124; MARX SJ, 1981, MEDICINE, V60, P397, DOI 10.1097/00005792-198111000-00002; MITHAL A, 1995, ENDOCRINOLOGY, V136, P3087, DOI 10.1210/en.136.7.3087; NEMETH EF, 1987, J BIOL CHEM, V262, P5188; Nemeth EF, 1999, TRENDS ENDOCRIN MET, V10, P66, DOI 10.1016/S1043-2760(98)00119-2; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Ott SM, 1998, J CLIN ENDOCR METAB, V83, P1080, DOI 10.1210/jc.83.4.1080; OWEN CA, 1977, P SOC EXP BIOL MED, V155, P314; PARADIS K, 1995, GASTROENTEROLOGY, V109, P1308, DOI 10.1016/0016-5085(95)90593-6; Patel Tushar, 1999, Hepatology, V30, P811, DOI 10.1002/hep.510300334; Pearce SHS, 1996, NEW ENGL J MED, V335, P1115, DOI 10.1056/NEJM199610103351505; PLOURDE V, 1988, J BONE MINER RES, V3, P461; POLLAK MR, 1994, NAT GENET, V8, P303, DOI 10.1038/ng1194-303; POLLAK MR, 1993, CELL, V75, P1297, DOI 10.1016/0092-8674(93)90617-Y; Quinn SJ, 1998, J BIOL CHEM, V273, P19579, DOI 10.1074/jbc.273.31.19579; Quinn SJ, 1997, AM J PHYSIOL-CELL PH, V273, pC1315, DOI 10.1152/ajpcell.1997.273.4.C1315; Ray JM, 1997, J CLIN INVEST, V99, P2328, DOI 10.1172/JCI119413; REICHEN J, 1985, AM J PHYSIOL, V249, pG48, DOI 10.1152/ajpgi.1985.249.1.G48; Riccardi D, 1998, AM J PHYSIOL-RENAL, V274, pF611, DOI 10.1152/ajprenal.1998.274.3.F611; RICCARDI D, 1995, P NATL ACAD SCI USA, V92, P131, DOI 10.1073/pnas.92.1.131; ROULEAU MF, 1986, ENDOCRINOLOGY, V118, P919, DOI 10.1210/endo-118-3-919; RUAT M, 1995, P NATL ACAD SCI USA, V92, P3161, DOI 10.1073/pnas.92.8.3161; SEGRE GV, 1981, J CLIN INVEST, V67, P449, DOI 10.1172/JCI110053; Silverberg SJ, 1997, NEW ENGL J MED, V337, P1506, DOI 10.1056/NEJM199711203372104; VARRAULT A, 1995, ENDOCRINOLOGY, V136, P4390, DOI 10.1210/en.136.10.4390; Wang WH, 1996, AM J PHYSIOL-CELL PH, V271, pC103, DOI 10.1152/ajpcell.1996.271.1.C103; WINER BJ, 1971, STATISTICAL PRINCIPL, P309; ZAKIM D, 1996, HEPATOLOGY, P362; [No title captured]	59	78	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4070	4079		10.1074/jbc.M009317200	http://dx.doi.org/10.1074/jbc.M009317200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11071898	hybrid			2022-12-25	WOS:000166921200047
J	Shi, Q; Gross, KW; Sigmund, CD				Shi, Q; Gross, KW; Sigmund, CD			Retinoic acid-mediated activation of the mouse renin enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPONSIVE ELEMENT; GENE-TRANSCRIPTION; DNA-BINDING; RECEPTOR; PROMOTER; EXPRESSION; MICE; IDENTIFICATION; HYPERTENSION; COACTIVATORS	Previous studies demonstrate that the mouse renin gene is regulated by a complex enhancer of transcription located 2.6 kilobases upstream of the transcription start site which is under both positive and negative influence. We demonstrate herein that a positive regulatory element (Eb) is repeated 10 bp upstream (Ec), and both are required for baseline activity of the enhancer. The Eb and Ec core sequences are identical to the consensus sequence for the nuclear hormone receptor superfamily of transcription factors, and transcriptional activity of constructs containing the enhancer is increased after treatment with retinoic acid. Maximal induction requires both Eb and Ec. Expression of endogenous renin and a renin-promoter controlled transgene in As4.1 cells, and kidney renin mRNA in C57BL/6J mice was induced after retinoid treatment. Gel mobility supershift analysis revealed the binding of RAR alpha and RXR alpha to oligonucleotides containing both Eb and Ec, Reverse transcriptase-polymerase chain reaction analysis revealed that As4.1 cells express both receptor isoforms, along with RAR gamma, but do not express RAR beta, RXR beta, or RXR gamma, Co-transfection of an expression vector encoding wild-type RAR alpha increased enhancer activity, whereas a dominant negative mutant of RAR alpha significantly attenuated retinoic acid-induced activity of the enhancer. These results demonstrate the importance of the Eb and Ec motifs in controlling baseline activity of the renin enhancer, and suggest the potential importance of retinoids in regulating renin expression.	Univ Iowa, Coll Med, Dept Internal Med,Transgen & Gene Targeting Facil, Mol Biol Interdisciplinary Program, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Roswell Pk Canc Inst, Dept Mol & Cellular Biol, Buffalo, NY 14263 USA	University of Iowa; University of Iowa; Roswell Park Cancer Institute	Sigmund, CD (corresponding author), Univ Iowa, Coll Med, Dept Internal Med,Transgen & Gene Targeting Facil, Mol Biol Interdisciplinary Program, 2191 Med Lab, Iowa City, IA 52242 USA.		Sigmund, Curt D./W-1611-2019	Sigmund, Curt D./0000-0002-1453-0921	NHLBI NIH HHS [HL48058, HL55006, HL61446, HL48459] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL048058, R01HL048058, R01HL061446, R01HL048459, P50HL055006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARTER ME, 1994, MOL CELL BIOL, V14, P4360, DOI 10.1128/MCB.14.7.4360; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; Davisson RL, 1998, CIRC RES, V83, P1047, DOI 10.1161/01.RES.83.10.1047; De Cesare D, 1999, TRENDS BIOCHEM SCI, V24, P281, DOI 10.1016/S0968-0004(99)01414-0; DURAND B, 1994, EMBO J, V13, P5370, DOI 10.1002/j.1460-2075.1994.tb06872.x; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GOMEZ RA, 1989, AM J PHYSIOL, V257, pF850, DOI 10.1152/ajprenal.1989.257.5.F850; Gopal-Srivastava R, 1998, J BIOL CHEM, V273, P17954, DOI 10.1074/jbc.273.28.17954; JONES CA, 1990, MOL ENDOCRINOL, V4, P375, DOI 10.1210/mend-4-3-375; KUROKAWA R, 1994, NATURE, V371, P528, DOI 10.1038/371528a0; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; Petrovic N, 1996, J BIOL CHEM, V271, P22499, DOI 10.1074/jbc.271.37.22499; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; RICHARD S, 1991, J BIOL CHEM, V266, P21428; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; Scott DK, 1996, J BIOL CHEM, V271, P6260, DOI 10.1074/jbc.271.11.6260; Shi Q, 1999, CIRC RES, V85, P479, DOI 10.1161/01.RES.85.6.479; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; Sinn PL, 1999, J BIOL CHEM, V274, P35785, DOI 10.1074/jbc.274.50.35785; Stec DE, 1998, TRENDS CARDIOVAS MED, V8, P256, DOI 10.1016/S1050-1738(98)00016-4; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; VASIOS G, 1991, EMBO J, V10, P1149, DOI 10.1002/j.1460-2075.1991.tb08055.x; Westin S, 1998, NATURE, V395, P199, DOI 10.1038/26040; WILSON JG, 1948, AM J ANAT, V83, P357, DOI 10.1002/aja.1000830303; WILSON TE, 1992, SCIENCE, V256, P107, DOI 10.1126/science.1314418; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yan Y, 1997, CIRC RES, V81, P558, DOI 10.1161/01.RES.81.4.558; Ying LH, 1997, J BIOL CHEM, V272, P2412	29	53	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3597	3603		10.1074/jbc.M008361200	http://dx.doi.org/10.1074/jbc.M008361200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11058598	hybrid			2022-12-25	WOS:000166784900080
J	Piotrowski, M; Schonfelder, S; Weiler, EW				Piotrowski, M; Schonfelder, S; Weiler, EW			The Arabidopsis thaliana isogene NIT4 and its orthologs in tobacco encode beta-cyano-L-alanine hydratase/nitrilase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLANT HORMONE; CYANOALANINE SYNTHASE; CYSTEINE SYNTHASE; CHINESE-CABBAGE; NITRILASE; BIOSYNTHESIS; ENZYME; ROOTS; ASPARAGINE; METABOLISM	Nitrilases (nitrile aminohydrolases, EC 3.5.5.1) are enzymes that catalyze the hydrolysis of nitriles to the corresponding carbon acids. Among the four known nitrilases of Arabidopsis thaliana, the isoform NIT4 is the most divergent one, and homologs of NITI are also known from species not belonging to the Brassicaceae like Nicotiana tabacum and Oryza sativa. We expressed A. thaliana NIT4 as hexahistidine tag fusion protein in Escherichia coli. The purified enzyme showed a strong substrate specificity for P-cyano-L-alanine (Ala(CN)), an intermediate product of cyanide detoxification in higher plants. Interestingly, not only aspartic acid but also asparagine were identified as products of NIT4-catalyzed Ala(CN) hydrolysis, Asn itself was no substrate for NIT4, indicating that it is not an intermediate but one of two reaction products. NIT4 therefore has both nitrilase and nitrile hydratase activity. Several lines of evidence indicate that the catalytic center for both reactions is the same. The NIT4 homologs of N. tabacum were found to catalyze the same reactions and protein extracts of A. thaliana, N, tabacum and Lupinus angustifolius also converted Ala(CN) to Asp and Asn in vitro. NIT4 may play a role in cyanide detoxification during ethylene biosynthesis because extracts from senescent leaves of A. thaliana showed higher Ala(CN) hydratase/nitrilase activities than extracts from nonsenescent tissue.	Ruhr Univ Bochum, Dept Plant Physiol, D-44801 Bochum, Germany	Ruhr University Bochum	Piotrowski, M (corresponding author), Ruhr Univ Bochum, Dept Plant Physiol, Univ Str 150, D-44801 Bochum, Germany.	Markus.Piotrowski@ruhr-uni-bochum.de	Piotrowski, Markus/F-5419-2010	Piotrowski, Markus/0000-0002-6347-3337				ADAMS DO, 1981, TRENDS BIOCHEM SCI, V6, P161, DOI 10.1016/0968-0004(81)90059-1; BARTEL B, 1994, P NATL ACAD SCI USA, V91, P6649, DOI 10.1073/pnas.91.14.6649; BARTLING D, 1992, EUR J BIOCHEM, V205, P417, DOI 10.1111/j.1432-1033.1992.tb16795.x; BARTLING D, 1994, P NATL ACAD SCI USA, V91, P6021, DOI 10.1073/pnas.91.13.6021; Bischoff M, 1995, J PLANT PHYSIOL, V147, P341, DOI 10.1016/S0176-1617(11)82164-4; BLUMENTHAL S G, 1968, Journal of Biological Chemistry, V243, P5302; Bunch AW, 1998, ANTON LEEUW INT J G, V74, P89, DOI 10.1023/A:1001760129546; CASTRIC PA, 1972, ARCH BIOCHEM BIOPHYS, V152, P62, DOI 10.1016/0003-9861(72)90193-2; Chaimbault P, 1999, J CHROMATOGR A, V855, P191, DOI 10.1016/S0021-9673(99)00685-8; Dohmoto M, 1999, DNA Res, V6, P313, DOI 10.1093/dnares/6.5.313; Dufour E, 1995, BIOCHEMISTRY-US, V34, P16382, DOI 10.1021/bi00050a019; GALOYAN S M, 1982, Biokhimiya, V47, P1949; Grsic S, 1999, PHYSIOL PLANTARUM, V105, P521, DOI 10.1034/j.1399-3054.1999.105318.x; Hatzfeld Y, 2000, PLANT PHYSIOL, V123, P1163, DOI 10.1104/pp.123.3.1163; MAHADEVAN S, 1964, ARCH BIOCHEM BIOPHYS, V107, P62, DOI 10.1016/0003-9861(64)90269-3; Muller A, 2000, BIOL CHEM, V381, P679, DOI 10.1515/BC.2000.088; Muller A, 1998, PLANTA, V206, P362, DOI 10.1007/s004250050411; Quirino BF, 1999, PLANT MOL BIOL, V40, P267, DOI 10.1023/A:1006199932265; Sambrook J., 2002, MOL CLONING LAB MANU; Schmidt RC, 1996, PLANT J, V9, P683, DOI 10.1046/j.1365-313X.1996.9050683.x; Smith J.A., 2000, CURRENT PROTOCOLS MO; THIMANN KV, 1958, NATURE, V181, P1466, DOI 10.1038/1811466a0; TING IP, 1970, PLANT PHYSIOL, V45, P429, DOI 10.1104/pp.45.4.429; Tsunoda H., 1995, PLANT PHYSIOL, V109, P339; VORWERK S, 2000, IN PRESS PLANTA; Yamaguchi Y, 2000, PLANT CELL PHYSIOL, V41, P465, DOI 10.1093/pcp/41.4.465; YANASE H, 1983, AGR BIOL CHEM TOKYO, V47, P473, DOI 10.1080/00021369.1983.10865685	27	151	162	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2616	2621		10.1074/jbc.M007890200	http://dx.doi.org/10.1074/jbc.M007890200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11060302	hybrid			2022-12-25	WOS:000166784800045
J	Kurokouchi, K; Jacobs, CR; Donahue, HJ				Kurokouchi, K; Jacobs, CR; Donahue, HJ			Oscillating fluid flow inhibits TNF-alpha-induced NF-kappa B activation via an I kappa B kinase pathway in osteoblast-like UMR106 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; SHEAR-STRESS ACTIVATION; ENDOTHELIAL-CELLS; PROTEIN-KINASE; IKK-BETA; OSTEOCLAST DEVELOPMENT; ROS17/2.8 CELLS; GENE-EXPRESSION; BONE-CELLS; ROS 17/2.8	Fluid flow plays an important role in load-induced bone remodeling. However, the molecular mechanism of flow-induced signal transduction in osteoblasts remains unclear. In endothelial cells, fluid flow alters activation of NF-kappaB resulting in changes in expression of cell adhesion molecules. To test the hypothesis that fluid flow alters NF-kappaB activation and expression of cell adhesion molecules in osteoblastic cells, we examined the effect of oscillating fluid flow (OFF) on tumor necrosis factor (TNF)-alpha -induced NF-kappaB activation in rat osteoblast-like UMR106 cells, We found that OFF inhibits NF-kappaB-DNA binding activities, especially TNF-alpha -induced p50-p65 heterodimer NF-kappaB activation and TNF-alpha -induced intercellular adhesion molecule-1 mRNA expression. The inhibitory effects of OFF on both TNF-alpha -induced NF-kappaB activation and intercellular adhesion molecule-1 mRNA expression were shear stress-dependent and also increased with OFF exposure duration, indicating that OFF has potent effects on mechanotransduction pathways. OFF also inhibited TNF-alpha -induced I kappaB alpha degradation and TNF-alpha -induced I kappaB kinase (IKK) activity in a shear stress dependent manner. These results demonstrate that IKK is an initial target molecule for OFF effects on osteoblastic cells. Thus, OFF inhibits TNF-alpha -induced IKK activation, leading to a decrease in phosphorylation and degradation of inhibitory I kappaB alpha, which in turn results in the decrease of TNF-alpha -induced NF-kappaB activation and potentially the transcription of target genes.	Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Musculoskeletal Res Lab,Dept Orthopaed & Rehabil, Hershey, PA 17033 USA; Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Musculoskeletal Res Lab,Dept Cellular & Mol Physi, Hershey, PA 17033 USA; Nagoya Univ, Sch Med, Dept Orthopaed, Nagoya, Aichi 4668550, Japan	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; Nagoya University	Donahue, HJ (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Musculoskeletal Res Lab,Dept Orthopaed & Rehabil, POB 850, Hershey, PA 17033 USA.	hdonahue@psu.edu			NATIONAL INSTITUTE ON AGING [R01AG013087] Funding Source: NIH RePORTER; NIA NIH HHS [AG13087] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ammann P, 1997, J CLIN INVEST, V99, P1699, DOI 10.1172/JCI119333; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; Gilbert L, 2000, ENDOCRINOLOGY, V141, P3956, DOI 10.1210/en.141.11.3956; GORBSKY GJ, 1993, J CELL BIOL, V122, P1311, DOI 10.1083/jcb.122.6.1311; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; ISHIMI Y, 1990, J IMMUNOL, V145, P3297; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; ISRAEL N, 1992, J IMMUNOL, V149, P3386; Jacobs CR, 1998, J BIOMECH, V31, P969, DOI 10.1016/S0021-9290(98)00114-6; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; Jo H, 1997, J BIOL CHEM, V272, P1395, DOI 10.1074/jbc.272.2.1395; Johnson DL, 1996, AM J PHYSIOL-ENDOC M, V271, pE205, DOI 10.1152/ajpendo.1996.271.1.E205; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; KHACHIGIAN LM, 1995, J CLIN INVEST, V96, P1169, DOI 10.1172/JCI118106; KleinNulend J, 1997, J BONE MINER RES, V12, P45, DOI 10.1359/jbmr.1997.12.1.45; Kurokouchi K, 1998, J BONE MINER RES, V13, P1290, DOI 10.1359/jbmr.1998.13.8.1290; Kurokouchi K, 2000, J BONE MINER RES, V15, P1707, DOI 10.1359/jbmr.2000.15.9.1707; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Li YS, 1996, MOL CELL BIOL, V16, P5947; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mohan S, 1997, AM J PHYSIOL-CELL PH, V273, pC572, DOI 10.1152/ajpcell.1997.273.2.C572; Mohan S, 1999, AM J PHYSIOL-CELL PH, V276, pC1100, DOI 10.1152/ajpcell.1999.276.5.C1100; NANES MS, 1989, ENDOCRINOLOGY, V124, P339, DOI 10.1210/endo-124-1-339; NANES MS, 1991, ENDOCRINOLOGY, V128, P2577, DOI 10.1210/endo-128-5-2577; Nasuhara Y, 1999, J BIOL CHEM, V274, P19965, DOI 10.1074/jbc.274.28.19965; Owan I, 1997, AM J PHYSIOL-CELL PH, V273, pC810, DOI 10.1152/ajpcell.1997.273.3.C810; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PASSERI G, 1994, BONE MINER, V24, P109, DOI 10.1016/S0169-6009(08)80149-3; Pavalko FM, 1998, AM J PHYSIOL-CELL PH, V275, pC1591; PLAKSIN D, 1993, J EXP MED, V177, P1651, DOI 10.1084/jem.177.6.1651; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REICH KM, 1990, J CELL PHYSIOL, V143, P100, DOI 10.1002/jcp.1041430113; REICH KM, 1991, AM J PHYSIOL, V261, pC428, DOI 10.1152/ajpcell.1991.261.3.C428; Schwachtgen JL, 1998, J CLIN INVEST, V101, P2540, DOI 10.1172/JCI1404; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Smalt R, 1997, AM J PHYSIOL-ENDOC M, V273, pE751, DOI 10.1152/ajpendo.1997.273.4.E751; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; VASSALLI P, 1992, ANNU REV IMMUNOL, V10, P411, DOI 10.1146/annurev.iy.10.040192.002211; WEINBAUM S, 1994, J BIOMECH, V27, P339, DOI 10.1016/0021-9290(94)90010-8; Yao GQ, 2000, ENDOCRINOLOGY, V141, P2914, DOI 10.1210/en.141.8.2914; Yaron A, 1997, EMBO J, V16, P6486, DOI 10.1093/emboj/16.21.6486; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360	49	30	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 20	2001	276	16					13499	13504		10.1074/jbc.M003795200	http://dx.doi.org/10.1074/jbc.M003795200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	423VN	11096064	hybrid			2022-12-25	WOS:000168198600140
J	Orlicky, SM; Tran, PT; Sayre, MH; Edwards, AM				Orlicky, SM; Tran, PT; Sayre, MH; Edwards, AM			Dissociable Rpb4-Rpb7 subassembly of RNA polymerase II binds to single-strand nucleic acid and mediates a post-recruitment step in transcription initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL REPEAT DOMAIN; SACCHAROMYCES-CEREVISIAE; PREINITIATION COMPLEX; HIGH-TEMPERATURE; STRESS SURVIVAL; YEAST; SUBUNIT; ACTIVATION; RPB4; DNA	The Rpb4 and Rpb7 subunits of yeast RNA polymerase II form a heterodimeric complex essential for promoter-directed transcription initiation in a reconstituted system. Results of template competition experiments indicate that the Rpb4-Rpb7 complex is not required for stable recruitment of polymerase to active preinitiation complexes, suggesting that Rpb4-Rpb7 mediates an essential step subsequent to promoter binding. Sequence and structure-based alignments revealed a possible OB-fold single-strand nucleic acid-binding motif in Rpb7, Purified Rpb4-Rpb7 complex exhibited both single-strand DNA- and RNA-binding activities, and a small deletion in the putative OB-fold nucleic acid-binding surface of Rpb7 abolished binding activity without affecting the stability of the Rpb4-Rpb7 complex or its ability to associate with polymerase, The same mutation destroyed the transcription activity of the Rpb4-Rpb7 complex. A separate deletion elsewhere in the OB-fold motif of Rpb7 also blocked transcription but did not affect nucleic acid binding, suggesting that the OB-fold of Rpb7 mediates both DNA-protein and protein-protein interactions required for productive initiation.	Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Charles H Best Inst, Dept Med Genet & Microbiol, Toronto, ON M5G 1L6, Canada; Johns Hopkins Univ, Dept Biochem, Baltimore, MD 21205 USA	University of Toronto; University of Toronto; Johns Hopkins University	Edwards, AM (corresponding author), Univ Toronto, Charles H Best Inst, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.			Edwards, Aled/0000-0002-4782-6016; Orlicky, Stephen/0000-0002-8172-2042	NATIONAL CANCER INSTITUTE [F31CA073466] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050724] Funding Source: NIH RePORTER; NCI NIH HHS [CA73466] Funding Source: Medline; NIGMS NIH HHS [GM50724] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARCHAMBAULT J, 1993, MICROBIOL REV, V57, P703, DOI 10.1128/MMBR.57.3.703-724.1993; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; CHODER M, 1993, MOL CELL BIOL, V13, P6984, DOI 10.1128/MCB.13.11.6984; Conaway RC, 1997, PROG NUCLEIC ACID RE, V56, P327, DOI 10.1016/S0079-6603(08)61009-0; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; Cramer P, 2000, SCIENCE, V288, P640, DOI 10.1126/science.288.5466.640; Davison B L, 1983, Cold Spring Harb Symp Quant Biol, V47 Pt 2, P965; Dvir A, 1996, J BIOL CHEM, V271, P23352, DOI 10.1074/jbc.271.38.23352; Dvir A, 1996, J BIOL CHEM, V271, P7245, DOI 10.1074/jbc.271.13.7245; EDWARDS AM, 1991, J BIOL CHEM, V266, P71; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; Gebara MM, 1997, J CELL BIOCHEM, V64, P390; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; HENRY NL, 1992, J BIOL CHEM, V267, P23388; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; Jensen GJ, 1998, EMBO J, V17, P2353, DOI 10.1017/S1431927600024983; KHAZAK V, 1995, MOL BIOL CELL, V6, P759, DOI 10.1091/mbc.6.7.759; KIM YJ, 1994, CELL, V77, P599, DOI 10.1016/0092-8674(94)90221-6; KOLESKE AJ, 1994, NATURE, V368, P466, DOI 10.1038/368466a0; Kugel JF, 2000, J BIOL CHEM, V275, P40483, DOI 10.1074/jbc.M006401200; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; LANGER D, 1994, NUCLEIC ACIDS RES, V22, P694, DOI 10.1093/nar/22.4.694; Maillet I, 1999, J BIOL CHEM, V274, P22586, DOI 10.1074/jbc.274.32.22586; MCKUNE K, 1993, YEAST, V9, P295, DOI 10.1002/yea.320090309; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; Myers LC, 1998, GENE DEV, V12, P45, DOI 10.1101/gad.12.1.45; Reinberg D, 1998, COLD SPRING HARB SYM, V63, P83, DOI 10.1101/sqb.1998.63.83; Rosenheck S, 1998, J BACTERIOL, V180, P6187; SADHALE PP, 1994, MOL CELL BIOL, V14, P6164, DOI 10.1128/MCB.14.9.6164; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; Sheffer A, 1999, MOL CELL BIOL, V19, P2672; SVEJSTRUP JQ, 1994, J BIOL CHEM, V269, P28044; Tijerina P, 1998, J BIOL CHEM, V273, P1107, DOI 10.1074/jbc.273.2.1107; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; WOYCHIK NA, 1989, MOL CELL BIOL, V9, P2854, DOI 10.1128/MCB.9.7.2854	40	75	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 30	2001	276	13					10097	10102		10.1074/jbc.M003165200	http://dx.doi.org/10.1074/jbc.M003165200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	420GC	11087726	hybrid			2022-12-25	WOS:000167996400069
J	Gaspar, LP; Terezan, AF; Pinheiro, AS; Foguel, D; Rebello, MA; Silva, JL				Gaspar, LP; Terezan, AF; Pinheiro, AS; Foguel, D; Rebello, MA; Silva, JL			The metastable state of nucleocapsids of enveloped viruses as probed by high hydrostatic pressure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; SINDBIS-VIRUS; CORE PROTEIN; MOSAIC-VIRUS; ICOSAHEDRAL VIRUSES; SERINE PROTEINASE; COLD DENATURATION; CAPSID PROTEIN; COAT PROTEIN; HEMAGGLUTININ	Enveloped viruses fuse their membranes with cellular membranes to transfer their genomes into cells at the beginning of infection. What is not clear, however, is the role of the envelope (lipid bilayer and glycoproteins) in the stability of the viral particle. To address this question, we compared the stability between enveloped and nucleocapsid particles of the alphavirus Mayaro using hydrostatic pressure and urea. The effects were monitored by intrinsic fluorescence, light scattering, and binding of fluorescent dyes, including bis(8-anilinonaphthalene-1-sulfonate) and ethidium bromide. Pressure caused a drastic dissociation of the nucleocapsids as determined by tryptophan fluorescence, light scattering, and gel filtration chromatography, Pressure-induced dissociation of the nucleocapsids was poorly reversible, In contrast, when the envelope was present, pressure effects were much less marked and were highly reversible. Binding of ethidium bromide occurred when nucleocapsids were dissociated under pressure, indicating exposure of the nucleic acid, whereas enveloped particles underwent no changes, Overall, our results demonstrate that removal of the envelope with the glycoproteins leads the particle to a metastable state and, during infection, may serve as the trigger for disassembly and delivery of the genome. The envelope acts as a "Trojan horse," gaining entry into the host cell to allow release of a metastable nucleocapsid prone to disassembly.	Univ Fed Rio de Janeiro, Ctr Nacl Ressonan Magnet Nucl Macromol, Inst Ciencias Biomed, Dept Bioquim Med,Programa Biol Estrutural, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Virol, Inst Microbiol Professor Paulo Goes, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Silva, JL (corresponding author), Univ Fed Rio de Janeiro, Ctr Nacl Ressonan Magnet Nucl Macromol, Inst Ciencias Biomed, Dept Bioquim Med,Programa Biol Estrutural, BR-21941590 Rio De Janeiro, Brazil.		SILVA, JERSON Lima/GRF-1442-2022; Silva, Jerson/J-8984-2014; Pinheiro, Anderson S/B-6350-2014; Pinheiro, Anderson/AAL-5299-2021	SILVA, JERSON Lima/0000-0001-9523-9441; Silva, Jerson/0000-0001-9523-9441; Foguel, Debora/0000-0001-7312-7115; Pinheiro, Anderson/0000-0001-5118-6931				Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Bonafe CFS, 2000, BIOCHEM BIOPH RES CO, V275, P955, DOI 10.1006/bbrc.2000.3402; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; Chen J, 1998, CELL, V95, P409, DOI 10.1016/S0092-8674(00)81771-7; CHENG RH, 1995, CELL, V80, P621; CHOI HK, 1991, NATURE, V354, P37, DOI 10.1038/354037a0; Choi HK, 1996, J MOL BIOL, V262, P151, DOI 10.1006/jmbi.1996.0505; COOMBS K, 1984, VIRUS RES, V4, P297; DAPOIAN AT, 1995, BIOCHEMISTRY-US, V34, P2672, DOI 10.1021/bi00008a034; de Sousa PC, 1999, J MOL BIOL, V287, P527; Desai G, 1999, J MOL BIOL, V288, P461, DOI 10.1006/jmbi.1999.2692; ERIJMAN L, 1993, BIOCHEMISTRY-US, V32, P5187, DOI 10.1021/bi00070a030; Ferrao-Gonzales AD, 2000, P NATL ACAD SCI USA, V97, P6445, DOI 10.1073/pnas.97.12.6445; FOGUEL D, 1994, P NATL ACAD SCI USA, V91, P8244, DOI 10.1073/pnas.91.17.8244; FOGUEL D, 1995, BIOCHEMISTRY-US, V34, P1120, DOI 10.1021/bi00004a003; Frye KJ, 1998, PROTEIN SCI, V7, P2217, DOI 10.1002/pro.5560071020; Gaspar LP, 1997, J MOL BIOL, V273, P456, DOI 10.1006/jmbi.1997.1299; GEIGENMULLERGNIRKE U, 1993, J VIROL, V67, P1620; GOROVITS B, 1995, J BIOL CHEM, V270, P2061, DOI 10.1074/jbc.270.5.2061; HARRISON SC, 1992, J MOL BIOL, V226, P277, DOI 10.1016/0022-2836(92)90141-6; Harrison Stephen C., 1996, P59; HELENIUS A, 1980, EUR J BIOCHEM, V106, P613, DOI 10.1111/j.1432-1033.1980.tb04609.x; Heremans K, 1998, BBA-PROTEIN STRUCT M, V1386, P353, DOI 10.1016/S0167-4838(98)00102-2; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Hummer G, 1998, P NATL ACAD SCI USA, V95, P1552, DOI 10.1073/pnas.95.4.1552; Johnson JE, 1996, P NATL ACAD SCI USA, V93, P27, DOI 10.1073/pnas.93.1.27; JONAS J, 1994, ANNU REV BIOPH BIOM, V23, P287, DOI 10.1146/annurev.bb.23.060194.001443; JURKIEWICZ E, 1995, P NATL ACAD SCI USA, V92, P6935, DOI 10.1073/pnas.92.15.6935; Korte T, 1999, J VIROL, V73, P4567, DOI 10.1128/JVI.73.6.4567-4574.1999; KORTE T, 1994, EUR BIOPHYS J BIOPHY, V23, P105; Lee C, 2000, P NATL ACAD SCI USA, V97, P7727, DOI 10.1073/pnas.97.14.7727; Leimkuhler M, 2000, J MOL BIOL, V296, P1295, DOI 10.1006/jmbi.2000.3538; Mohana-Borges R, 2000, J BIOL CHEM, V275, P4708, DOI 10.1074/jbc.275.7.4708; Mozhaev VV, 1996, PROTEINS, V24, P81, DOI 10.1002/(SICI)1097-0134(199601)24:1<81::AID-PROT6>3.0.CO;2-R; Nash DP, 1997, BIOCHEMISTRY-US, V36, P14375, DOI 10.1021/bi970881v; NEUMAN RC, 1973, J PHYS CHEM-US, V77, P2687, DOI 10.1021/j100640a025; Northrop DB, 2000, BIOPHYS J, V79, P1621, DOI 10.1016/S0006-3495(00)76412-5; Oliveira AC, 1999, BIOPHYS J, V76, P1270, DOI 10.1016/S0006-3495(99)77290-5; Oliveira AC, 2000, J BIOL CHEM, V275, P16037, DOI 10.1074/jbc.M910145199; Orosz A, 1996, MOL CELL BIOL, V16, P7018; Owen KE, 1996, J VIROL, V70, P2757, DOI 10.1128/JVI.70.5.2757-2763.1996; PALADINI AA, 1981, REV SCI INSTRUM, V52, P419, DOI 10.1063/1.1136596; PAREDES AM, 1992, VIROLOGY, V187, P329, DOI 10.1016/0042-6822(92)90322-G; PREVELIGE PE, 1994, BIOPHYS J, V66, P1631, DOI 10.1016/S0006-3495(94)80955-5; REBELLO MCS, 1993, ACTA VIROL, V37, P223; Reddy VS, 1998, BIOPHYS J, V74, P546, DOI 10.1016/S0006-3495(98)77813-0; ROBINSON CR, 1995, P NATL ACAD SCI USA, V92, P3444, DOI 10.1073/pnas.92.8.3444; ROSEN CG, 1969, BIOCHEMISTRY-US, V8, P3915, DOI 10.1021/bi00838a006; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; Ruan KC, 1997, BIOCHEM BIOPH RES CO, V239, P150, DOI 10.1006/bbrc.1997.7313; SILVA JL, 1992, J VIROL, V66, P2111, DOI 10.1128/JVI.66.4.2111-2117.1992; SILVA JL, 1988, J MOL BIOL, V199, P149, DOI 10.1016/0022-2836(88)90385-3; Silva JL, 1996, CURR OPIN STRUC BIOL, V6, P166, DOI 10.1016/S0959-440X(96)80071-6; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; SINGH I, 1992, J VIROL, V66, P7049, DOI 10.1128/JVI.66.12.7049-7058.1992; SPEIR JA, 1995, STRUCTURE, V3, P63, DOI 10.1016/S0969-2126(01)00135-6; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; Tellinghuisen TL, 2000, J VIROL, V74, P4302, DOI 10.1128/JVI.74.9.4302-4309.2000; Tellinghuisen TL, 1999, J VIROL, V73, P5309, DOI 10.1128/JVI.73.7.5309-5319.1999; Tian SM, 2000, EUR J BIOCHEM, V267, P4486, DOI 10.1046/j.1432-1327.2000.01496.x; TONG L, 1993, J MOL BIOL, V230, P228, DOI 10.1006/jmbi.1993.1139; VOLKMER N, 1981, IRCS MED SCI-BIOCHEM, V9, P157; WENGLER G, 1992, VIROLOGY, V191, P880, DOI 10.1016/0042-6822(92)90263-O; ZLOTNICK A, 1994, J BIOL CHEM, V269, P13680	65	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7415	7421		10.1074/jbc.M010037200	http://dx.doi.org/10.1074/jbc.M010037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11092899	hybrid			2022-12-25	WOS:000167442900077
J	Hans, A; Syan, S; Crosio, C; Sassone-Corsi, P; Brahic, M; Gonzalez-Dunia, D				Hans, A; Syan, S; Crosio, C; Sassone-Corsi, P; Brahic, M; Gonzalez-Dunia, D			Borna disease virus persistent infection activates mitogen-activated protein kinase and blocks neuronal differentiation of PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; PSYCHIATRIC-PATIENTS; BDV INFECTION; P-PROTEIN; IN-VIVO; BRAIN; RATS; RNA; RESPONSES; ERK	Persistence of Borna disease virus (BDV) in the central nervous system causes damage to specific neuronal populations. BDV is noncytopathic, and the mechanisms underlying neuronal pathology are not well understood. One hypothesis is that infection affects the response of neurons to factors that are crucial for their proliferation, differentiation, or survival. To test this hypothesis, we analyzed the response of PC12 cells persistently infected with BDV to the neurotrophin nerve growth factor (NGF). PC12 is a neural crest-derived cell line that exhibits features of neuronal differentiation in response to NGF. We report that persistence of BDV led to a progressive change of phenotype of PC12 cells and blocked neurite outgrowth in response to NGF. Infection downregulated the expression of synaptophysin and growth-associated protein-43, two molecules involved in neuronal plasticity, as well as the expression of the chromaffin-specific gene tyrosine hydroxylase. We showed that the block in response to NGF was due in part to the down-regulation of NGF receptors. Moreover, although BDV caused constitutive activation of the ERK1/2 pathway, activated ERKs were not translocated to the nucleus efficiently. These observations may account for the absence of neuronal differentiation of persistently infected PC12 cells treated with NGF.	Inst Pasteur, Unite virus Lents, CNRS, URA 1930, F-75724 Paris 15, France; CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gonzalez-Dunia, D (corresponding author), Inst Pasteur, Unite virus Lents, CNRS, URA 1930, 28 Rue Dr Roux, F-75724 Paris 15, France.		Sassone-Corsi, Paolo/H-6182-2011; Dunia, Daniel/K-1090-2014	Dunia, Daniel/0000-0002-2837-7120				Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; BARKER PA, 1994, NEURON, V13, P203, DOI 10.1016/0896-6273(94)90470-7; BAUTISTA JR, 1994, BRAIN RES BULL, V34, P31, DOI 10.1016/0361-9230(94)90183-X; Bautista JR, 1995, DEV BRAIN RES, V90, P45, DOI 10.1016/0165-3806(96)83485-7; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BODE L, 1995, NAT MED, V1, P232, DOI 10.1038/nm0395-232; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BOULUKOS KE, 1993, ONCOGENE, V8, P237; CARBONE KM, 1991, J VIROL, V65, P6154, DOI 10.1128/JVI.65.11.6154-6164.1991; CHAO MV, 1995, TRENDS NEUROSCI, V18, P321, DOI 10.1016/0166-2236(95)93922-K; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; Colucci-D'Amato GL, 2000, J BIOL CHEM, V275, P19306, DOI 10.1074/jbc.275.25.19306; DelaTorre JC, 1996, VIROLOGY, V223, P272, DOI 10.1006/viro.1996.0479; DELATORRE JC, 1994, J VIROL, V68, P7669, DOI 10.1128/JVI.68.12.7669-7675.1994; delaTorre JC, 1996, VIROLOGY, V220, P508, DOI 10.1006/viro.1996.0340; DITTRICH W, 1989, BIOL PSYCHIAT, V26, P818, DOI 10.1016/0006-3223(89)90122-4; Eisenman LM, 1999, J NEUROVIROL, V5, P181, DOI 10.3109/13550289909022000; FINKBEINER S, 2000, NEURON, V11, P25; Gies U, 1998, BRAIN PATHOL, V8, P39; GINTY DD, 1994, CELL, V77, P713, DOI 10.1016/0092-8674(94)90055-8; GISPEN WH, 1991, MOL NEUROBIOL, V5, P61, DOI 10.1007/BF02935540; Gonzalez-Dunia D, 2000, J VIROL, V74, P3441, DOI 10.1128/JVI.74.8.3441-3448.2000; GonzalezDunia D, 1997, J VIROL, V71, P3208, DOI 10.1128/JVI.71.4.3208-3218.1997; GOSZTONYI G, 1995, BORNA DIS, P39; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GRIMA B, 1985, P NATL ACAD SCI USA, V82, P617, DOI 10.1073/pnas.82.2.617; Hornig M, 1999, P NATL ACAD SCI USA, V96, P12102, DOI 10.1073/pnas.96.21.12102; KISHI M, 1995, FEBS LETT, V364, P293, DOI 10.1016/0014-5793(95)00406-Y; LEONARD DGB, 1987, MOL CELL BIOL, V7, P3156, DOI 10.1128/MCB.7.9.3156; LeviMontalcini R, 1996, TRENDS NEUROSCI, V19, P514, DOI 10.1016/S0166-2236(96)10058-8; Lipkin W. Ian, 1995, Trends in Microbiology, V3, P64, DOI 10.1016/S0966-842X(00)88877-0; Malik TH, 1999, VIROLOGY, V258, P65, DOI 10.1006/viro.1999.9715; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MARUYAMA K, 1987, ONCOGENE, V1, P361; MorishimaKawashima M, 1996, MOL BIOL CELL, V7, P893, DOI 10.1091/mbc.7.6.893; Nakamura Y, 2000, J VIROL, V74, P4601, DOI 10.1128/JVI.74.10.4601-4611.2000; NARAYAN O, 1983, SCIENCE, V220, P1401, DOI 10.1126/science.6602380; Planz O, 1999, J VIROL, V73, P6251, DOI 10.1128/JVI.73.8.6251-6256.1999; Pletnikov MV, 2000, DEV BRAIN RES, V119, P179, DOI 10.1016/S0165-3806(99)00168-6; Pletnikov MV, 1999, PHYSIOL BEHAV, V66, P823, DOI 10.1016/S0031-9384(99)00021-9; Rubin SA, 1999, DEV BRAIN RES, V112, P237, DOI 10.1016/S0165-3806(98)00180-1; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; Sauder C, 1999, J NEUROIMMUNOL, V96, P29, DOI 10.1016/S0165-5728(98)00272-0; SCHNEEMANN A, 1995, VIROLOGY, V210, P1, DOI 10.1006/viro.1995.1311; Schwemmle M, 1998, J BIOL CHEM, V273, P9007, DOI 10.1074/jbc.273.15.9007; Schwemmle M, 1997, J BIOL CHEM, V272, P21818, DOI 10.1074/jbc.272.35.21818; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sgambato V, 1998, J NEUROSCI, V18, P214; Sgambato V, 1998, J NEUROSCI, V18, P8814; STITZ L, 1995, BORNA DIS, P75; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Weissenbock H, 2000, BRAIN PATHOL, V10, P260, DOI 10.1111/j.1750-3639.2000.tb00259.x; Wolff T, 2000, J GEN VIROL, V81, P939, DOI 10.1099/0022-1317-81-4-939; WU YY, 1995, J CELL PHYSIOL, V164, P522, DOI 10.1002/jcp.1041640310; Yaka R, 1998, J CELL BIOCHEM, V70, P425, DOI 10.1002/(SICI)1097-4644(19980901)70:3<425::AID-JCB15>3.0.CO;2-J	56	40	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7258	7265		10.1074/jbc.M005107200	http://dx.doi.org/10.1074/jbc.M005107200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11073944	hybrid			2022-12-25	WOS:000167442900056
J	Gazziola, C; Ferraro, P; Moras, M; Reichard, P; Bianchi, V				Gazziola, C; Ferraro, P; Moras, M; Reichard, P; Bianchi, V			Cytosolic high K-m 5 '-nucleotidase and 5 '(3 ')-deoxyribonucleotidase in substrate cycles involved in nucleotide metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEOSIDE TRIPHOSPHATES; THYMIDINE KINASE; ENZYME; 5-NUCLEOTIDASE; CLONING	5'-Nucleotidases are the catabolic members of the substrate cycles postulated to be involved in the regulation of intracellular deoxyribonucleoside triphosphate pools. Here, we attempt to identify the nature of the nucleotidases. Earlier, we constructed various mammalian cell lines that can be induced to overproduce the high K-m 5'-nucleotidase (hkm-NT) or the 5'(3')-deoxynucleotidase (dNT-1). Now we labeled control and induced human 293 cells and hamster V79 cells with radioactive hypoxanthine or uridine and during a chase measured quantitatively the metabolism of ribo- and deoxyribonucleotides, DNA replication, and excretion of nucleosides into the medium. Overproduction of hkm-NT greatly increased excretion of inosine and guanosine but did not affect adenosine or deoxyribonucleosides. dNT-1 overproduction increased excretion of deoxycytidine, thymidine, and in particular deoxyuridine but also uridine and cytidine. We conclude that the hkm-NT is not involved in the regulation of deoxyribonucleotide pools but affects IMP and GTP pools. dNT-1, instead, appears to be the catabolic arm of substrate cycles regulating pyrimidine nucleotide pools.	Univ Padua, Dept Biol, I-35131 Padua, Italy; Karolinska Inst, Dept Biochem, S-17177 Stockholm, Sweden	University of Padua; Karolinska Institutet	Bianchi, V (corresponding author), Univ Padua, Dept Biol, I-35131 Padua, Italy.	vbianchi@civ.bio.unipd.it						BIANCHI V, 1986, P NATL ACAD SCI USA, V83, P986, DOI 10.1073/pnas.83.4.986; BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218; Bianchi V, 1998, ADV EXP MED BIOL, V431, P501; BIANCHI V, 1994, J BIOL CHEM, V269, P16677; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARSON DA, 1981, J IMMUNOL, V126, P348; FRITZSON P, 1971, BIOCHIM BIOPHYS ACTA, V235, P128, DOI 10.1016/0005-2744(71)90040-4; Gazziola C, 1999, EXP CELL RES, V253, P474, DOI 10.1006/excr.1999.4681; HOGLUND L, 1991, EUR J BIOCHEM, V196, P239, DOI 10.1111/j.1432-1033.1991.tb15810.x; HOGLUND L, 1988, CANCER RES, V48, P3681; ITOH R, 1993, COMP BIOCHEM PHYS B, V105, P13, DOI 10.1016/0305-0491(93)90163-Y; Ives D H, 1978, Methods Enzymol, V51, P337; KOSHLAND DE, 1984, TRENDS BIOCHEM SCI, V9, P155, DOI 10.1016/0968-0004(84)90125-7; KUNZ BA, 1994, MUTAT RES-REV GENET, V318, P1, DOI 10.1016/0165-1110(94)90006-X; MARTIN DW, 1981, ANNU REV BIOCHEM, V50, P845, DOI 10.1146/annurev.bi.50.070181.004213; Miles RW, 1998, BIOCHEMISTRY-US, V37, P8615, DOI 10.1021/bi980658d; NEWBY AC, 1988, BIOCHEM J, V253, P123, DOI 10.1042/bj2530123; NEWSHOLME EA, 1984, TRENDS BIOCHEM SCI, V9, P277, DOI 10.1016/0968-0004(84)90165-8; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Rampazzo C, 2000, J BIOL CHEM, V275, P5409, DOI 10.1074/jbc.275.8.5409; Rampazzo C, 2000, P NATL ACAD SCI USA, V97, P8239, DOI 10.1073/pnas.97.15.8239; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; Sala-Newby GB, 1999, J BIOL CHEM, V274, P17789, DOI 10.1074/jbc.274.25.17789; Sala-Newby GB, 2000, J BIOL CHEM, V275, P11666, DOI 10.1074/jbc.275.16.11666; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	28	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6185	6190		10.1074/jbc.M007623200	http://dx.doi.org/10.1074/jbc.M007623200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11083867	hybrid			2022-12-25	WOS:000167261000019
J	Moore, SD; Prevelige, PE				Moore, SD; Prevelige, PE			Structural transformations accompanying the assembly of bacteriophage P22 portal protein rings in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA PHAGE-P22; DNA ENCAPSULATION; PACKAGED DNA; MECHANISM; IDENTIFICATION; PURIFICATION; MATURATION; BINDING; PROBE; VIRUS	The Salmonella typhimurium bacteriophage P22 assembles an icosahedral capsid precursor called a procapsid, The oligomeric portal protein ring, located at one vertex, comprises the conduit for DNA entry and exit, In conjunction with the DNA packaging enzymes, the portal ring is an integral component of a nanoscale machine that pumps DNA into the phage head, Although the portal vertex is assembled with high fidelity, the mechanism by which a single portal complex is incorporated during procapsid assembly remains unknown. The assembly of bacteriophage P22 portal rings has been characterized in vitro using a recombinant, His-tagged protein. Although the portal protein remained primarily unassembled within the cell, once purified, the highly soluble monomer assembled into rings at room temperature at high concentrations with a half time of approximately 1 h, Circular dichroic analysis of the monomers and rings indicated that the protein gained alpha -helicity upon polymerization, Thermal denaturation studies suggested that the rings contained an ordered domain that was not present in the unassembled monomer, A combination of 4,4'-dianilino-1,1'-binapthyl-5,5'-disulfonic acid (bis-ANS) binding fluorescence studies and limited proteolysis revealed that the N-terminal portion of the unassembled subunit is metastable and is susceptible to structural perturbation by bis-ANS. In conjunction with previously obtained data on the behavior of the P22 portal protein, we propose an assembly model for P22 portal rings that involves a meta-stable monomeric subunit.	Univ Alabama, Dept Microbiol, Birmingham, AL 35205 USA	University of Alabama System; University of Alabama Birmingham	Prevelige, PE (corresponding author), Univ Alabama, Dept Microbiol, BBRB Rm 416,845 S 19th St, Birmingham, AL 35205 USA.				NIGMS NIH HHS [GM47980] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047980, R55GM047980] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASAKURA S, 1966, J MOL BIOL, V16, P302, DOI 10.1016/S0022-2836(66)80174-2; ASAKURA S, 1968, J MOL BIOL, V35, P237, DOI 10.1016/S0022-2836(68)80051-8; BAZINET C, 1988, BIOCHEMISTRY-US, V27, P1849, DOI 10.1021/bi00406a009; BAZINET C, 1990, J MOL BIOL, V216, P701, DOI 10.1016/0022-2836(90)90393-Z; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; BOTSTEIN D, 1973, J MOL BIOL, V80, P669, DOI 10.1016/0022-2836(73)90204-0; BOTSTEIN D, 1968, J MOL BIOL, V34, P643, DOI 10.1016/0022-2836(68)90186-1; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P1216; CARRASCOSA JL, 1982, J MOL BIOL, V154, P311, DOI 10.1016/0022-2836(82)90066-3; CASJENS S, 1974, Journal of Supramolecular Structure, V2, P202, DOI 10.1002/jss.400020215; CASJENS S, 1991, GENETICS, V127, P637; CASJENS S, 1982, J MOL BIOL, V157, P287, DOI 10.1016/0022-2836(82)90235-2; CASJENS S, 1992, J MOL BIOL, V224, P1055, DOI 10.1016/0022-2836(92)90469-Z; Caspar D L, 1990, Adv Biophys, V26, P157, DOI 10.1016/0065-227X(90)90011-H; CASPAR DLD, 1980, BIOPHYS J, V32, P103, DOI 10.1016/S0006-3495(80)84929-0; Driedonks R A, 1981, Prog Clin Biol Res, V64, P315; Droge A, 2000, J MOL BIOL, V296, P117, DOI 10.1006/jmbi.1999.3450; Eftink MR, 1997, METHOD ENZYMOL, V278, P221; EPPLER K, 1991, VIROLOGY, V183, P519, DOI 10.1016/0042-6822(91)90981-G; FARRIS FJ, 1978, J AM CHEM SOC, V100, P4469, DOI 10.1021/ja00482a026; Gaspar LP, 1997, J MOL BIOL, V273, P456, DOI 10.1006/jmbi.1997.1299; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Greene B, 1996, VIROLOGY, V225, P82, DOI 10.1006/viro.1996.0577; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; GUO PX, 1991, VIROLOGY, V183, P366, DOI 10.1016/0042-6822(91)90149-6; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0; HOROWITZ P, 1984, J BIOL CHEM, V259, P4647; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; ISRAEL V, 1977, J VIROL, V23, P91, DOI 10.1128/JVI.23.1.91-97.1977; JACKSON EN, 1982, J MOL BIOL, V154, P551, DOI 10.1016/S0022-2836(82)80014-4; Jaenicke R, 2000, ADV PROTEIN CHEM, V53, P329; JARVIK J, 1975, P NATL ACAD SCI USA, V72, P2738, DOI 10.1073/pnas.72.7.2738; Jekow P, 1999, EUR J BIOCHEM, V264, P724, DOI 10.1046/j.1432-1327.1999.00601.x; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KING J, 1971, J MOL BIOL, V58, P693, DOI 10.1016/0022-2836(71)90034-9; KING J, 1973, J MOL BIOL, V80, P697, DOI 10.1016/0022-2836(73)90205-2; KOCHAN J, 1984, J MOL BIOL, V174, P433, DOI 10.1016/0022-2836(84)90330-9; Kocsis E, 1995, ULTRAMICROSCOPY, V60, P219, DOI 10.1016/0304-3991(95)00070-2; KOREN R, 1976, BIOCHEMISTRY-US, V15, P1165, DOI 10.1021/bi00650a032; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P52; Lanman J, 1999, BIOCHEMISTRY-US, V38, P14614, DOI 10.1021/bi9915420; Lee C, 2000, P NATL ACAD SCI USA, V97, P7727, DOI 10.1073/pnas.97.14.7727; LENK E, 1975, VIROLOGY, V68, P182, DOI 10.1016/0042-6822(75)90160-9; LEVINE M, 1971, J MOL BIOL, V62, P53, DOI 10.1016/0022-2836(71)90130-6; MICHAUD G, 1989, J MOL BIOL, V209, P667, DOI 10.1016/0022-2836(89)90599-8; Moody MF, 1999, J MOL BIOL, V293, P401, DOI 10.1006/jmbi.1999.3011; MOONEN M, 1995, SVD SIGNAL PROCESSIN, V3; MUSCI G, 1985, BIOCHEMISTRY-US, V24, P2034, DOI 10.1021/bi00329a035; NAKASU S, 1985, VIROLOGY, V143, P422, DOI 10.1016/0042-6822(85)90382-4; NEAL BL, 1993, J BACTERIOL, V175, P7115, DOI 10.1128/jb.175.21.7115-7118.1993; NORTHRUP SH, 1992, P NATL ACAD SCI USA, V89, P3338, DOI 10.1073/pnas.89.8.3338; Orlova EV, 1999, NAT STRUCT BIOL, V6, P842; POTEETE AR, 1979, VIROLOGY, V95, P550, DOI 10.1016/0042-6822(79)90508-7; PREVELIGE PE, 1988, J MOL BIOL, V202, P743, DOI 10.1016/0022-2836(88)90555-4; Schwartz R, 1998, BIOPHYS J, V75, P2626, DOI 10.1016/S0006-3495(98)77708-2; SERWER P, 1987, J THEOR BIOL, V127, P155, DOI 10.1016/S0022-5193(87)80126-1; SHI L, 1994, BIOCHEMISTRY-US, V33, P7536, DOI 10.1021/bi00190a006; Smulders RHPH, 1997, FEBS LETT, V409, P101, DOI 10.1016/S0014-5793(97)00498-5; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; STRAUSS H, 1984, J MOL BIOL, V172, P523, DOI 10.1016/S0022-2836(84)80021-2; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; TAVARES P, 1992, J MOL BIOL, V225, P81, DOI 10.1016/0022-2836(92)91027-M; Tsurimoto Toshiki, 1999, Frontiers in Bioscience, V4, pd849, DOI 10.2741/Tsurimoto; Tuma R, 1998, P NATL ACAD SCI USA, V95, P9885, DOI 10.1073/pnas.95.17.9885; VALPUESTA JM, 1994, Q REV BIOPHYS, V27, P107, DOI 10.1017/S0033583500004510; Vanderheeren G, 1998, BIOPHYS J, V75, P2195, DOI 10.1016/S0006-3495(98)77663-5; vanHeel M, 1996, EMBO J, V15, P4785, DOI 10.1002/j.1460-2075.1996.tb00858.x; VANHOLDE KE, 1998, PRINCIPLES PHYSICAL, P438; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110	73	27	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6779	6788		10.1074/jbc.M007702200	http://dx.doi.org/10.1074/jbc.M007702200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11092883	hybrid			2022-12-25	WOS:000167261000091
J	Yang, S; Madyastha, P; Bingel, S; Ries, W; Key, L				Yang, S; Madyastha, P; Bingel, S; Ries, W; Key, L			A new superoxide-generating oxidase in murine osteoclasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH-OXIDASE; BONE-RESORPTION; FREE-RADICALS; NEUTROPHILS; CYTOCHROME-B558; COMPONENT; IODONIUM	Superoxide production contributes to osteoclastic bone resorption. Evidence strongly indicates that NADPH oxidase is an enzyme system responsible for superoxide generation in osteoclasts. A membrane-bound subunit, p91, is the catalytic domain of NADPH oxidase. However, osteoclasts from p91 knockout mice still produce superoxide at a rate similar to that observed in wild type mice. This unexpected phenomenon prompted us to examine the osteoclasts for an alternative to the p91-containing oxidase. In this study, the cloning of a NADPH oxidase subunit (Nox 4) with 578 amino acids is reported. Nor 4 has 58% similarity in amino acids with the known p91 subunit of NADPH oxidase. Nor 4 is present and active in osteoclasts. antisense oligonucleotides of Nor 4 reduced osteoclastic superoxide generation as well as resorption pit formation by osteoclasts. This new oxidase complex was present and functional in osteoclasts from p91 knockout mice, explaining the normal resorptive activity seen in the osteoclasts where no p91 is present.	Med Univ S Carolina, Dept Pediat, Div Endocrinol, Charleston, SC 29425 USA	Medical University of South Carolina	Yang, S (corresponding author), Med Univ S Carolina, Dept Pediat, Div Endocrinol, 316 CSB,171 Ashley Ave, Charleston, SC 29425 USA.	yangs@musc.edu			NIAMS NIH HHS [R01-AR41463] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041463] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEARD CJ, 1986, J LAB CLIN MED, V108, P498; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; Darden AG, 1996, J BONE MINER RES, V11, P671; DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x; FALLON M, 1987, J BONE MINER RES S, V1, P1; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; GARRETT IR, 1990, J CLIN INVEST, V85, P632, DOI 10.1172/JCI114485; HALL TJ, 1995, BIOCHEM BIOPH RES CO, V207, P280, DOI 10.1006/bbrc.1995.1184; JONES OTG, 1994, BIOESSAYS, V16, P919, DOI 10.1002/bies.950161211; KEY LL, 1994, BONE, V15, P431, DOI 10.1016/8756-3282(94)90821-4; KEY LL, 1995, NEW ENGL J MED, V332, P1594, DOI 10.1056/NEJM199506153322402; KEY LL, 1990, BONE, V11, P115, DOI 10.1016/8756-3282(90)90058-7; Kubo H, 1996, J CLIN INVEST, V97, P2680, DOI 10.1172/JCI118718; Madyastha PR, 2000, J INTERF CYTOK RES, V20, P645, DOI 10.1089/107999000414826; MEIER B, 1993, BIOCHEM J, V289, P481, DOI 10.1042/bj2890481; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; REYNOLDS J J, 1970, Calcified Tissue Research, V4, P339; RIES WL, 1992, J BONE MINER RES, V7, P931; RODRIGUIZ RM, 1993, PEDIATR RES, V33, P384; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; STEINBECK MJ, 1994, J CELL BIOL, V126, P765, DOI 10.1083/jcb.126.3.765; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; SUMIMOTO H, 1992, BIOCHEM BIOPH RES CO, V186, P1368, DOI 10.1016/S0006-291X(05)81557-8; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; TAKAHASHI N, 1991, J BONE MINER RES, V6, P977; Yang S, 1998, CALCIFIED TISSUE INT, V63, P346, DOI 10.1007/s002239900538; Yang S, 1999, MOL CELL BIOCHEM, V199, P15, DOI 10.1023/A:1006990730115; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993	31	179	194	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5452	5458		10.1074/jbc.M001004200	http://dx.doi.org/10.1074/jbc.M001004200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11098048	hybrid			2022-12-25	WOS:000167115100008
J	Blaise, R; Guillaudeux, T; Tavernier, G; Daegelen, D; Evrard, B; Mairal, A; Holm, C; Jegou, B; Langin, D				Blaise, R; Guillaudeux, T; Tavernier, G; Daegelen, D; Evrard, B; Mairal, A; Holm, C; Jegou, B; Langin, D			Testis hormone-sensitive lipase expression in spermatids is governed by a short promoter in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; SERTOLI CELLS; RAT TESTIS; IN-VIVO; GENE; TRANSCRIPTION; PROTEIN; MOUSE; SRY; SPERMATOGENESIS	A testicular form of hormone-sensitive lipase (HSLtes), a triacylglycerol lipase, and cholesterol esterase, is expressed in male germ cells. Northern blot analysis showed HSLtes mRNA expression in early spermatids. Immunolocalization of the protein in human and rodent seminiferous tubules indicated that the highest level of expression occurred in elongated spermatids. We have previously shown that 0.5 kilobase pairs of the human HSLtes promoter directs testis-specific expression of a chloramphenicol acetyltransferase reporter gene in transgenic mice and determined regions binding nuclear proteins expressed in testis but not in liver (Blaise, R,, Grober, J,, Rouet, P., Tavernier, G., Daegelen, D., and Langin, D. (1999) J. Biol. Chem. 274, 9327-9334). Mutation of a SRY/Sox-binding site in one of the regions did not impair in vivo testis-specific expression of the reporter gene. Further transgenic analyses established that 95 base pairs upstream of the transcription start site were sufficient for correct testis expression. In gel retardation assays using early spermatid nuclear extracts, a germ cell-specific DNA-protein interaction was mapped between -46 and -29 base pairs. The DNA binding nuclear protein showed properties of zinc finger transcription factors. Mutation of the region abolished reporter gene activity in transgenic mice, showing that it is necessary for testis expression of HSLtes.	Univ Toulouse 3, Hop Rangueil, Inst Louis Bugnard, INSERM,U317, F-31403 Toulouse 4, France; Univ Rennes 1, GERM, INSERM, U435, F-35042 Rennes, Bretagne, France; Fac Med, Inst Cochin Genet Mol, INSERM, U129, F-75014 Paris, France; Lund Univ, Dept Cell & Mol Biol, Sect Mol Signaling, S-22100 Lund, Sweden	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Lund University	Langin, D (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U317, Batiment L3, F-31403 Toulouse 4, France.	langin@rangueil.inserm.fr	Jégou, Bernard/I-4742-2015	Blaise, Regis/0000-0001-7759-3244; Tavernier, Genevieve/0000-0002-0214-0344; Langin, Dominique/0000-0002-2669-7825; JEGOU, Bernard/0000-0003-0623-3609				Ausubel F., 1999, CURRENT PROTOCOLS MO; Blaise R, 1999, J BIOL CHEM, V274, P9327, DOI 10.1074/jbc.274.14.9327; BREUCKER H, 1985, CELL TISSUE RES, V240, P303; Charron M, 1999, MOL CELL BIOL, V19, P5823; CLERMONT Y, 1963, AM J ANAT, V112, P35, DOI 10.1002/aja.1001120103; CONNER F, 1994, NUCLEIC ACIDS RES, V22, P3339, DOI 10.1093/nar/22.16.3339; CONNOR F, 1995, NUCLEIC ACIDS RES, V23, P3365, DOI 10.1093/nar/23.17.3365; DEJUCQ N, 1995, ENDOCRINOLOGY, V136, P4925, DOI 10.1210/en.136.11.4925; DELMAS V, 1993, MOL ENDOCRINOL, V7, P1502, DOI 10.1210/me.7.11.1502; DENNY P, 1992, EMBO J, V11, P3705, DOI 10.1002/j.1460-2075.1992.tb05455.x; DYM M, 1970, AM J ANAT, V128, P265, DOI 10.1002/aja.1001280302; Grober J, 1997, BIOCHEM J, V328, P453, DOI 10.1042/bj3280453; HOLM C, 1987, BIOCHEM BIOPH RES CO, V148, P99, DOI 10.1016/0006-291X(87)91081-3; HOLM C, 1988, SCIENCE, V241, P1503, DOI 10.1126/science.3420405; HOLST LS, 1994, FEBS LETT, V355, P125, DOI 10.1016/0014-5793(94)01185-0; Holst LS, 1996, GENOMICS, V35, P441, DOI 10.1006/geno.1996.0383; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; Kleene KC, 1996, MOL REPROD DEV, V43, P268, DOI 10.1002/(SICI)1098-2795(199602)43:2&lt;268::AID-MRD17&gt;3.0.CO;2-#; Kumari M, 1996, J BIOL CHEM, V271, P14390, DOI 10.1074/jbc.271.24.14390; LANGIN D, 1993, P NATL ACAD SCI USA, V90, P4897, DOI 10.1073/pnas.90.11.4897; Langin D, 1996, P NUTR SOC, V55, P93, DOI 10.1079/PNS19960013; Laurell H, 1997, BIOCHEM J, V328, P137, DOI 10.1042/bj3280137; LEBLOND CP, 1952, ANN NY ACAD SCI, V55, P548, DOI 10.1111/j.1749-6632.1952.tb26576.x; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Li SM, 1998, J BIOL CHEM, V273, P31191, DOI 10.1074/jbc.273.47.31191; Liu F, 1997, J BIOL CHEM, V272, P5056, DOI 10.1074/jbc.272.8.5056; OAKBERG EF, 1956, AM J ANAT, V99, P391, DOI 10.1002/aja.1000990303; Osuga J, 2000, P NATL ACAD SCI USA, V97, P787, DOI 10.1073/pnas.97.2.787; Pevny LH, 1997, CURR OPIN GENET DEV, V7, P338, DOI 10.1016/S0959-437X(97)80147-5; PINEAU C, 1993, J ANDROL, V14, P87; Riley JY, 1998, J EXP ZOOL, V282, P179; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Sharpe Richard M., 1994, P1363; TAKAMATSU N, 1995, MOL CELL BIOL, V15, P3759; WEGNER M, 1990, BIOCHEM BIOPH RES CO, V166, P1110, DOI 10.1016/0006-291X(90)90981-R; WESTIN G, 1988, NUCLEIC ACIDS RES, V16, P5771, DOI 10.1093/nar/16.13.5771; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071; Zhou G, 1998, J BIOL CHEM, V273, P14989, DOI 10.1074/jbc.273.24.14989; Zhou YD, 1996, P NATL ACAD SCI USA, V93, P12262, DOI 10.1073/pnas.93.22.12262	39	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5109	5115		10.1074/jbc.M009103200	http://dx.doi.org/10.1074/jbc.M009103200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11076952	hybrid			2022-12-25	WOS:000168484300078
J	Trebitsh, T; Meiri, E; Ostersetzer, O; Adam, Z; Danon, A				Trebitsh, T; Meiri, E; Ostersetzer, O; Adam, Z; Danon, A			The protein disulfide isomerase-like RB60 is partitioned between stroma and thylakoids in Chlamydomonas reinhardtii chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSBA MESSENGER-RNA; 5' UNTRANSLATED REGION; ENDOPLASMIC-RETICULUM; GENE-EXPRESSION; TRANSLATIONAL REGULATION; BINDING-PROTEINS; PHOTOSYSTEM-II; MEMBRANE; LIGHT; COMPLEX	Translation of psbA mRNA in Chlamydomonas reinhardtii chloroplasts is regulated by a redox signal(s), RB60 is a member of a protein complex that binds with high affinity to the 5'-untranslated region of psbA mRNA. RB60 has been suggested to act as a redox-sensor subunit of the protein complex regulating translation of chloroplast psbA mRNA, Surprisingly, cloning of RB60 identified high homology to the endoplasmic reticulum-localized protein disulfide isomerase, including an endoplasmic reticulum-retention signal at its carboxyl terminus. Here we show, by in vitro import studies, that the recombinant RB60 is imported into isolated chloroplasts of C, reinhardtii and pea in a transit peptide-dependent manner. Subfractionation of C, reinhardtii chloroplasts revealed that the native RB60 is partitioned between the stroma and the thylakoids, The nature of association of native RB60, and imported recombinant RB60, with thylakoids is similar and suggests that RB60 is tightly bound to thylakoids, The targeting characteristics of RB60 and the potential implications of the association of RB60 with thylakoids are discussed.	Weizmann Inst Sci, Dept Plant Sci, IL-76100 Rehovot, Israel; Hebrew Univ Jerusalem, Dept Agr Bot, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Hebrew University of Jerusalem	Danon, A (corresponding author), Weizmann Inst Sci, Dept Plant Sci, POB 12, IL-76100 Rehovot, Israel.		/AAM-4620-2021					ADAM Z, 1993, PLANT PHYSIOL, V102, P35, DOI 10.1104/pp.102.1.35; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; AVITAL S, 1991, J BIOL CHEM, V266, P7067; Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; BELKNAP WR, 1983, PLANT PHYSIOL, V72, P1130, DOI 10.1104/pp.72.4.1130; Bennett TA, 2000, J IMMUNOL, V164, P4120, DOI 10.4049/jimmunol.164.8.4120; BETTS SD, 1994, PLANT MOL BIOL, V26, P117, DOI 10.1007/BF00039525; Bhagwat SV, 1999, J BIOL CHEM, V274, P24014, DOI 10.1074/jbc.274.34.24014; BROWN NG, 1994, MOL CELL BIOL, V14, P1045, DOI 10.1128/MCB.14.2.1045; CLINE K, 1986, J BIOL CHEM, V261, P4804; Danon A, 1997, PLANT PHYSIOL, V115, P1293, DOI 10.1104/pp.115.4.1293; DANON A, 1994, EMBO J, V13, P2227, DOI 10.1002/j.1460-2075.1994.tb06500.x; DANON A, 1991, EMBO J, V10, P3993, DOI 10.1002/j.1460-2075.1991.tb04974.x; Fisk DG, 1999, EMBO J, V18, P2621, DOI 10.1093/emboj/18.9.2621; Fox TD, 1996, EXPERIENTIA, V52, P1130, DOI 10.1007/BF01952112; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GILLHAM NW, 1994, ANNU REV GENET, V28, P71, DOI 10.1146/annurev.ge.28.120194.000443; GIRARDBASCOU J, 1992, CURR GENET, V22, P47, DOI 10.1007/BF00351741; GOLDSCHMIDTCLERMONT M, 1989, PLANT PHYSIOL, V89, P15, DOI 10.1104/pp.89.1.15; GORMAN DS, 1965, P NATL ACAD SCI USA, V54, P1665, DOI 10.1073/pnas.54.6.1665; HARRIS EH, 1994, MICROBIOL REV, V58, P700, DOI 10.1128/MMBR.58.4.700-754.1994; Itzhaki H, 1998, J BIOL CHEM, V273, P7094, DOI 10.1074/jbc.273.12.7094; JENSEN KH, 1986, J CELL BIOL, V103, P1315, DOI 10.1083/jcb.103.4.1315; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; Kim JM, 1997, SCIENCE, V278, P1954, DOI 10.1126/science.278.5345.1954; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; Koussevitzky S, 1998, J BIOL CHEM, V273, P27064, DOI 10.1074/jbc.273.42.27064; KUCHKA MR, 1988, EMBO J, V7, P319, DOI 10.1002/j.1460-2075.1988.tb02815.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Markus M, 1999, J BIOL CHEM, V274, P1040, DOI 10.1074/jbc.274.2.1040; MAYFIELD SP, 1994, J CELL BIOL, V127, P1537, DOI 10.1083/jcb.127.6.1537; MAYFIELD SP, 1995, ANNU REV PLANT PHYS, V46, P147, DOI 10.1146/annurev.pp.46.060195.001051; McCormac DJ, 1999, PLANT CELL, V11, P1709, DOI 10.1105/tpc.11.9.1709; MINAMI EI, 1984, ARCH BIOCHEM BIOPHYS, V235, P562, DOI 10.1016/0003-9861(84)90230-3; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ostersetzer O, 1996, PLANT MOL BIOL, V31, P673, DOI 10.1007/BF00042238; Ostersetzer O, 1996, EUR J BIOCHEM, V236, P932, DOI 10.1111/j.1432-1033.1996.00932.x; PEDRAZZINI E, 1994, PLANT J, V5, P103, DOI 10.1046/j.1365-313X.1994.5010103.x; PELHAM HRB, 1990, TRENDS BIOCHEM SCI, V15, P483, DOI 10.1016/0968-0004(90)90303-S; Pollard MG, 1998, MOL CELL, V1, P171, DOI 10.1016/S1097-2765(00)80018-0; Rochaix JD, 1996, PLANT MOL BIOL, V32, P327, DOI 10.1007/BF00039389; SAKAMOTO W, 1994, PLANT J, V6, P503, DOI 10.1046/j.1365-313X.1994.6040503.x; Snyders S, 1999, J BIOL CHEM, V274, P9137, DOI 10.1074/jbc.274.14.9137; Soltys BJ, 1999, TRENDS BIOCHEM SCI, V24, P174, DOI 10.1016/S0968-0004(99)01390-0; Stampacchia O, 1997, PLANT CELL, V9, P773; Stern DB, 1997, TRENDS PLANT SCI, V2, P308, DOI 10.1016/S1360-1385(97)89953-0; Sugiura M, 1998, ANNU REV GENET, V32, P437, DOI 10.1146/annurev.genet.32.1.437; Trebitsh T, 2000, MOL CELL BIOL, V20, P1116, DOI 10.1128/MCB.20.4.1116-1123.2000; Yohn CB, 1996, MOL CELL BIOL, V16, P3560; Yohn CB, 1998, P NATL ACAD SCI USA, V95, P2238, DOI 10.1073/pnas.95.5.2238; Zerges W, 1998, J CELL BIOL, V140, P101, DOI 10.1083/jcb.140.1.101; Zerges W, 1997, MOL CELL BIOL, V17, P3440, DOI 10.1128/MCB.17.6.3440; ZERGES W, 1994, MOL CELL BIOL, V14, P5268, DOI 10.1128/MCB.14.8.5268	54	46	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4564	4569		10.1074/jbc.M005950200	http://dx.doi.org/10.1074/jbc.M005950200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087734	hybrid			2022-12-25	WOS:000168484300008
J	Kamdar, G; Penado, KMY; Rudnick, G; Stephan, MM				Kamdar, G; Penado, KMY; Rudnick, G; Stephan, MM			Functional role of critical stripe residues in transmembrane span 7 of the serotonin transporter - Effects of Na+, Li+, and methanethiosulfonate reagents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DOPAMINE TRANSPORTER; EXPRESSION SYSTEM; COCAINE BINDING; AMINO-ACID; DOMAIN; MUTATIONS; SUBSTRATE; SITE; NOREPINEPHRINE; ACCESSIBILITY	Mutations at critical residue positions in transmembrane span 7 (TM7) of the serotonin transporter affect the Na+ dependence of transport. It was possible that these residues, which form a stripe along one side of the predicted alpha -helix. formed part of a water-filled pore for Na+. We tested whether cysteine substitutions in TM7 mere accessible to hydrophilic, membrane-impermeant methanethiosulfonate (MTS) reagents. Although all five cysteine-containing mutants tested were sensitive to these reagents, noncysteine control mutants at the same positions were in most cases equally sensitive. In all cases, MTS sensitivity could be traced to changes in accessibility of a native cysteine residue in extracellular loop 1, Cys-109. Moreover, none of the TM7 cysteines reacted with the biotinylating reagent MTSEA-biotin when tested in the C109A background. It is thus unlikely that the critical stripe forms part of a water-filled pore. Instead, studies of the ion dependence of the reaction between Cys-109 and MTS reagents lead to the conclusion that TM7 is involved in propagating conformational changes caused by ion binding, perhaps as part of the translocation mechanism. The critical stripe residues on TM7 probably represent a close contact region between TM7 and one or more other TMs in the transporter's three-dimensional structure.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA	Yale University	Stephan, MM (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06510 USA.							Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1996, MOL PHARMACOL, V50, P957; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; BLAKELY RD, 1994, J EXP BIOL, V196, P263; BLAKELY RD, 1991, ANAL BIOCHEM, V194, P302, DOI 10.1016/0003-2697(91)90233-J; Burgess KSD, 1999, J NEUROCHEM, V73, P656, DOI 10.1046/j.1471-4159.1999.0730656.x; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; Itokawa M, 2000, MOL PHARMACOL, V57, P1093; KANNER BI, 1994, J EXP BIOL, V196, P237; Karlin A, 1998, METHOD ENZYMOL, V293, P123; KITAYAMA S, 1993, SYNAPSE, V15, P58, DOI 10.1002/syn.890150107; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SH, 1998, BIOCHEM BIOPH RES CO, V246, P347, DOI 10.1006/bbrc.1998.8618; Lin F, 1996, BIOPHYS J, V71, P3126, DOI 10.1016/S0006-3495(96)79506-1; Lin ZC, 2000, FASEB J, V14, P715, DOI 10.1096/fasebj.14.5.715; Lin ZC, 1999, MOL PHARMACOL, V56, P434, DOI 10.1124/mol.56.2.434; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Penado KMY, 1998, J BIOL CHEM, V273, P28098, DOI 10.1074/jbc.273.43.28098; RUDNICK G, 1993, BIOCHIM BIOPHYS ACTA, V1144, P249, DOI 10.1016/0005-2728(93)90109-S; Smicun Y, 1999, J BIOL CHEM, V274, P36058, DOI 10.1074/jbc.274.51.36058; Stephan MM, 1997, BIOCHEMISTRY-US, V36, P1322, DOI 10.1021/bi962150l; STRADER CD, 1989, AM J RESP CELL MOL, V1, P81, DOI 10.1165/ajrcmb/1.2.81; TATE CG, 1994, J BIOL CHEM, V269, P26303; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	33	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4038	4045		10.1074/jbc.M008483200	http://dx.doi.org/10.1074/jbc.M008483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11058600	hybrid			2022-12-25	WOS:000166921200043
J	Legrand, P; Bibert, S; Jaquinod, L; Ebel, C; Hewat, E; Vincent, F; Vanbelle, C; Concord, E; Vernet, T; Gulino, D				Legrand, P; Bibert, S; Jaquinod, L; Ebel, C; Hewat, E; Vincent, F; Vanbelle, C; Concord, E; Vernet, T; Gulino, D			Self-assembly of the vascular endothelial cadherin ectodomain in a Ca2+-dependent hexamerie structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; EXTRACELLULAR DOMAIN; CALCIUM-BINDING; EPITHELIAL CADHERIN; HOMOASSOCIATION; DIMERIZATION; PERMEABILITY; RECOGNITION; JUNCTIONS; CATENINS	Vascular endothelial cadherin (VE-cadherin) is a transmembrane protein essential for endothelial cell monolayer integrity (Gulino, D., Delachanal, E., Con cord, E., Genoux, Y., Morand, B., Valiron, M. O., Sulpice, E., Scaife, R., Alemany, M., and Vernet, T. (1998) J. Biol. Chem. 273, 29786-29793). This molecule belongs to the cadherin family of cell-cell adhesion receptors, for which molecular details of homotypic interactions are still lacking. In this study, a recombinant fragment encompassing the four N-terminal modules of VE-cadherin (VE-EC1-4) was shown to associate, in solution, as a stable Ca2+-dependent oligomeric structure. Cross-linking experiments combined with mass spectrometry demonstrated that this oligomer is a hexamer. Gel filtration chromatography experiments and analytical ultracentrifugation analyses revealed the existence of an equilibrium between the hexameric and monomeric species of VE-EC1-4 The concentration at which 50% of VE-EC1-4 is in its hexameric form was estimated as 1 muM. The dimensions of the hexamer, measured by cryoelectron microscopy to be 233 +/- 10 x 77 +/- 7 Angstrom, are comparable to the thickness of adherens endothelial cell-cell junctions. Altogether, the results allow us to propose a novel homotypic interaction model for the class II VE-cadherin, in which six molecules of cadherin form a hexamer.	State Atom Energy Commiss, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Ingn Macromol, F-38027 Grenoble, France; State Atom Energy Commiss, CNRS, Inst Biol Struct Jean Pierre Ebel, Cristallog & Cristallogenese Prot Lab, F-38027 Grenoble, France; State Atom Energy Commiss, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Mol Biophys, F-38027 Grenoble, France; State Atom Energy Commiss, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Microscopie Electron Struct, F-38027 Grenoble, France; State Atom Energy Commiss, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Resonance Magnet Nucl, F-38027 Grenoble, France; State Atom Energy Commiss, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Spectrometrie Masse Prot, F-38027 Grenoble, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS)	Gulino, D (corresponding author), State Atom Energy Commiss, CNRS, Inst Biol Struct Jean Pierre Ebel, Lab Ingn Macromol, 41 Rue Jules Horowitz, F-38027 Grenoble, France.		Vernet, Thierry/G-1118-2012; LEGRAND, Pierre/G-7709-2011	LEGRAND, Pierre/0000-0003-2431-2255; Bibert, Stephanie/0000-0001-5170-7506; Ebel, Christine/0000-0002-6912-500X				Alattia JR, 1997, FEBS LETT, V417, P405, DOI 10.1016/S0014-5793(97)01333-1; Allport JR, 1997, J EXP MED, V186, P517, DOI 10.1084/jem.186.4.517; Baumgartner W, 2000, P NATL ACAD SCI USA, V97, P4005, DOI 10.1073/pnas.070052697; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BREVIARIO F, 1995, ARTERIOSCL THROM VAS, V15, P1229, DOI 10.1161/01.ATV.15.8.1229; Brieher WM, 1996, J CELL BIOL, V135, P487, DOI 10.1083/jcb.135.2.487; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Chitaev NA, 1998, J CELL BIOL, V142, P837, DOI 10.1083/jcb.142.3.837; DelMaschio A, 1996, J CELL BIOL, V135, P497, DOI 10.1083/jcb.135.2.497; Gory-Faure S, 1999, DEVELOPMENT, V126, P2093; Gotsch U, 1997, J CELL SCI, V110, P583; Gulino D, 1998, J BIOL CHEM, V273, P29786, DOI 10.1074/jbc.273.45.29786; Hordijk PL, 1999, J CELL SCI, V112, P1915; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; Koch AW, 1997, BIOCHEMISTRY-US, V36, P7697, DOI 10.1021/bi9705624; Koch C, 1999, NAT NEUROSCI, V2, P9, DOI 10.1038/4511; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; Leach L, 1997, MICROSC RES TECHNIQ, V38, P137; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Navarro P, 1995, J BIOL CHEM, V270, P30965, DOI 10.1074/jbc.270.52.30965; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; Overduin M, 1996, J BIOMOL NMR, V7, P173; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; OZAWA M, 1990, CELL, V63, P1033, DOI 10.1016/0092-8674(90)90506-A; PATEL DJ, 1995, NATURE, V374, P306, DOI 10.1038/374306a0; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; Philo JS, 1997, BIOPHYS J, V72, P435, DOI 10.1016/S0006-3495(97)78684-3; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; Shan WS, 2000, J CELL BIOL, V148, P579, DOI 10.1083/jcb.148.3.579; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; STAFFORD WF, 1992, ANAL BIOCHEM, V203, P295, DOI 10.1016/0003-2697(92)90316-Y; Stafford WF, 1997, CURR OPIN BIOTECH, V8, P14, DOI 10.1016/S0958-1669(97)80152-8; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; TANIHARA H, 1994, CELL ADHES COMMUN, V2, P15, DOI 10.3109/15419069409014199; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x	38	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3581	3588		10.1074/jbc.M002667200	http://dx.doi.org/10.1074/jbc.M002667200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11069895	hybrid			2022-12-25	WOS:000166784900078
J	Sano, Y; Ishii, S				Sano, Y; Ishii, S			Increased affinity of c-Myb for CREB-binding protein (CBP) after CBP-induced acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-B-MYB; T-CELL DEVELOPMENT; DNA-BINDING; V-MYB; TRANSCRIPTIONAL ACTIVATION; HISTONE ACETYLTRANSFERASE; FUNCTIONAL DOMAINS; TERMINAL DOMAIN; COACTIVATOR CBP; GENE-PRODUCT	The c-myb proto-oncogene product (c-Myb) is a sequence-specific DNA-binding protein that functions as a transcriptional activator. The transcriptional coactivator CREB-binding protein (CBP) binds via its KM domain to the activation domain of c-Myb and mediates c-Myb-dependent transcriptional activation, CBP possesses intrinsic histone acetyltransferase activity, and can acetylate not only histones but also certain transcriptional factors such as GATA1 and p53. Here we demonstrate that the C/H2 domain of CBP, which is critical for the acetyltransferase activity, also directly interacts with the negative regulatory domain (NRD) of c-Myb. Consistent with this observation, CBP acetylated c-Myb in vitro at Lys(438) and Lys(441) within the NRD. In addition, CBP acetylated c-Myb in vivo not only at the sites found in this study but also at the p300-induced acetylation sites reported recently. Replacement of lysine by arginine at all of these sites dramatically decreased the trans-activating capacity of c-Myb. The results of transcriptional activation assays with c-Myb acetylation site mutants suggested that acetylation of c-Myb at each of these five sites synergistically enhances c-Myb activity. Mutations of these acetylation sites reduced the strength of the interaction between c-Myb and CBP. Thus, acetylation of c-Myb by CBP increases the trans-activating capacity of c-Myb by enhancing its association with CBP. These results demonstrate a novel molecular mechanism of regulation of c-Myb activity.	RIKEN, Tsukuba Inst, Genet Mol Lab, Tsukuba, Ibaraki 3050074, Japan; Japan Sci & Technol Corp, JST, Res Project, CREST, Tsukuba, Ibaraki 3050074, Japan	RIKEN; Japan Science & Technology Agency (JST)	Ishii, S (corresponding author), RIKEN, Tsukuba Inst, Genet Mol Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				Allen RD, 1999, GENE DEV, V13, P1073, DOI 10.1101/gad.13.9.1073; ARANY Z, 1995, NATURE, V374, P81, DOI 10.1038/374081a0; BADIANI P, 1994, GENE DEV, V8, P770, DOI 10.1101/gad.8.7.770; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HIGUCHI R, 1990, PCR TECHNOLOGY PRINC, P61; HU LY, 1991, ONCOGENE, V6, P1549; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KowenzLeutz E, 1997, CELL, V91, P185, DOI 10.1016/S0092-8674(00)80401-8; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lane S, 1997, ONCOGENE, V14, P2445, DOI 10.1038/sj.onc.1201086; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; MIZUGUCHI G, 1990, J BIOL CHEM, V265, P9280; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; Munshi N, 1998, MOL CELL, V2, P457, DOI 10.1016/S1097-2765(00)80145-8; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; OGATA K, 1995, NAT STRUCT BIOL, V2, P309, DOI 10.1038/nsb0495-309; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oh IH, 1998, MOL CELL BIOL, V18, P499, DOI 10.1128/MCB.18.1.499; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sala A, 1997, P NATL ACAD SCI USA, V94, P532, DOI 10.1073/pnas.94.2.532; Sano Y, 1998, J BIOL CHEM, V273, P29098, DOI 10.1074/jbc.273.44.29098; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; TASHIRO S, 1995, ONCOGENE, V10, P1699; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Tomita A, 2000, ONCOGENE, V19, P444, DOI 10.1038/sj.onc.1203329; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Ziebold U, 1997, CURR BIOL, V7, P253, DOI 10.1016/S0960-9822(06)00121-7	56	69	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3674	3682		10.1074/jbc.M006896200	http://dx.doi.org/10.1074/jbc.M006896200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11073948	hybrid			2022-12-25	WOS:000166784900090
J	Sato, N; Mizumoto, K; Nakamura, M; Ueno, H; Minamishima, YA; Farber, JL; Tanaka, M				Sato, N; Mizumoto, K; Nakamura, M; Ueno, H; Minamishima, YA; Farber, JL; Tanaka, M			A possible role for centrosome overduplication in radiation-induced cell death	ONCOGENE			English	Article						centrosome; ionizing radiation; multinucleated cells; mitotic cell death; apoptosis; p21(Waf1/Cip1)	TERMINAL PROLIFERATION ARREST; PANCREATIC-CANCER CELLS; HAMSTER OVARY CELLS; TUMOR-CELLS; GENOMIC INSTABILITY; DNA-SYNTHESIS; CYCLE ARREST; P53; APOPTOSIS; DAMAGE	Radiotherapy plays a key role in the treatment of many tumors; however, the precise mechanisms responsible for radiation-induced cell death remain uncertain. We have reported previously that ionizing radiation induces centrosome overduplication in human tumor cells. The present study was designed to elucidate a possible link between centrosome dysregulation and radiation-induced cell death. Exposure to 10 Gy gamma -radiation resulted in a substantial increase in cells containing an abnormally high number of centrosomes in a variety of cell lines derived from different types of human solid tumors. These aberrant centrosomes contribute to the assembly of multipolar spindles, thereby causing an unbalanced division of chromosomes and mitotic cell death characterized by the appearance of multi- or micronucleated cells. An extensive analysis of a panel of 10 tumor cell lines revealed a positive correlation between the fraction of cells with multiple centrosomes and the fraction with these nuclear abnormalities after irradiation. When the centrosome overduplication was blocked by enforced expression of p21(Waf1/Cip1), the radiation-induced lethality was drastically rescued. Taken together, these results indicate that centrosome overduplication may be a critical event leading to mitotic failure and subsequent cell death following exposure to ionizing radiation.	Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Fukuoka 8128582, Japan; Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19017 USA	Kyushu University; Kyushu University; Jefferson University	Mizumoto, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Surg & Oncol, Fukuoka 8128582, Japan.		Minamishima, Yoji Andrew/E-5380-2010	Minamishima, Yoji Andrew/0000-0001-7995-9318				BAE IS, 1995, CANCER RES, V55, P2387; BALCZON R, 1995, J CELL BIOL, V130, P105, DOI 10.1083/jcb.130.1.105; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; BRINKLEY BR, 1985, ANNU REV CELL BIOL, V1, P145, DOI 10.1146/annurev.cellbio.1.1.145; Brinkley BR, 1998, CELL MOTIL CYTOSKEL, V41, P281, DOI 10.1002/(SICI)1097-0169(1998)41:4<281::AID-CM1>3.0.CO;2-C; Carroll PE, 1999, ONCOGENE, V18, P1935, DOI 10.1038/sj.onc.1202515; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chang BD, 1999, CANCER RES, V59, P3761; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; CHANG WP, 1991, INT J RADIAT BIOL, V60, P483, DOI 10.1080/09553009114552331; Cohen-Jonathan E, 1999, CURR OPIN CHEM BIOL, V3, P77, DOI 10.1016/S1367-5931(99)80014-3; DEWEY WC, 1995, INT J RADIAT ONCOL, V33, P781, DOI 10.1016/0360-3016(95)00214-8; Doxsey S, 1998, NAT GENET, V20, P104, DOI 10.1038/2392; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLOGG DR, 1994, ANNU REV BIOCHEM, V63, P639, DOI 10.1146/annurev.bi.63.070194.003231; Kuo KK, 2000, HEPATOLOGY, V31, P59, DOI 10.1002/hep.510310112; Kusumoto M, 1999, CLIN CANCER RES, V5, P2140; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; Lingle WL, 1998, P NATL ACAD SCI USA, V95, P2950, DOI 10.1073/pnas.95.6.2950; Lock RB, 1996, CANCER RES, V56, P4006; Mantel C, 1999, BLOOD, V93, P1390, DOI 10.1182/blood.V93.4.1390.404k25_1390_1398; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; McDonald E, 1996, CANCER RES, V56, P2250; Muller WU, 1996, MUTAT RES-REV GENET, V366, P163, DOI 10.1016/S0165-1110(96)90037-8; Pihan GA, 1998, CANCER RES, V58, P3974; RAFF JW, 1988, J CELL BIOL, V107, P2009, DOI 10.1083/jcb.107.6.2009; Sablina AA, 1998, J CELL SCI, V111, P977; Sato N, 2000, EXP CELL RES, V255, P321, DOI 10.1006/excr.1999.4797; Sato N, 1999, CLIN CANCER RES, V5, P963; Schwartz D, 1997, ONCOGENE, V15, P2597, DOI 10.1038/sj.onc.1201436; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Ueno H, 1997, ANN NY ACAD SCI, V811, P401, DOI 10.1111/j.1749-6632.1997.tb52020.x; UENO H, 1995, ARTERIOSCL THROM VAS, V15, P2246, DOI 10.1161/01.ATV.15.12.2246; Urbani L, 1999, CURR BIOL, V9, pR315, DOI 10.1016/S0960-9822(99)80201-2; Wang YC, 1999, ONCOGENE, V18, P2643, DOI 10.1038/sj.onc.1202632; Weber RG, 1998, CYTOGENET CELL GENET, V83, P266, DOI 10.1159/000015168; Winey M, 1996, CURR BIOL, V6, P962, DOI 10.1016/S0960-9822(02)00639-5; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Zhang L, 1999, CANCER LETT, V142, P129, DOI 10.1016/S0304-3835(99)00107-X	47	82	89	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5281	5290		10.1038/sj.onc.1203902	http://dx.doi.org/10.1038/sj.onc.1203902			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077445				2022-12-25	WOS:000165059700009
J	Ikari, Y; Mulvihill, E; Schwartz, SM				Ikari, Y; Mulvihill, E; Schwartz, SM			alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and alpha 2-macroglolbulin are the antiapoptotic factors of vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE INHIBITOR; EXTRACELLULAR-MATRIX; IN-VITRO; MELANOMA-CELLS; B-CELLS; APOPTOSIS; INVASION; DEATH; SUPPRESSION; TIMP-3	Serum depletion induces cell death. Whereas serum contains growth factors and adhesion molecules that are important for survival, serum is also likely to have antiapoptotic factor(s). We show here that the plasma proteinase inhibitors alpha1-proteinase inhibitor, alpha1-anti-chymotrypsin, and alpha2-macroglobulin function as critical antiapoptotic factors for human vascular smooth muscle cells. Cell survival was assured when serum-free medium was supplemented with any one or all of the above serine proteinase inhibitors. In contrast, the cells were sensitive to apoptosis when cultured in medium containing serum from which the proteinase inhibitors were removed. The antiapoptotic effect conferred by the proteinase inhibitors was proportional to proteinase inhibitory activity. Without proteinase inhibitors, the extracellular matrix was degraded, and cells could not attach to the matrix. cell survival was dependent on the intact extracellular matrix. In the presence of the caspase inhibitor z-VAD, the cells detached but did not die. The activity of caspases was elevated without proteinase inhibitors; in contrast, caspases were not activated when medium was supplemented with one of the proteinase inhibitors. In conclusion, the plasma proteinase inhibitors prevent degradation of extracellular matrix by proteinases derived from cells. Presumably an intact cell-matrix interaction inhibits caspase activation and supports cell survival.	Mitsui Mem Hosp, Div Cardiol, Chiyoda Ku, Tokyo 1018643, Japan; Univ Washington, Dept Pathol, Seattle, WA 98195 USA	Mitsui Memorial Hospital; University of Washington; University of Washington Seattle	Ikari, Y (corresponding author), Mitsui Mem Hosp, Div Cardiol, Chiyoda Ku, 1 Kanda Izumi Cho, Tokyo 1018643, Japan.				NHLBI NIH HHS [HL-03174, R01 HL-61860] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061860] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahonen M, 1998, CANCER RES, V58, P2310; Alexander CM, 1996, J CELL BIOL, V135, P1669, DOI 10.1083/jcb.135.6.1669; Baker AH, 1999, BRIT J CANCER, V79, P1347, DOI 10.1038/sj.bjc.6690217; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Blavier L, 1999, ANN NY ACAD SCI, V878, P108, DOI 10.1111/j.1749-6632.1999.tb07677.x; BOND M, 2000, J BIOL CHEM; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; FALCONE DJ, 1993, J CELL PHYSIOL, V155, P595, DOI 10.1002/jcp.1041550317; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; HOWLETT AR, 1993, EPITHELIAL CELL BIOL, V2, P79; Huang STJ, 1999, FASEB J, V13, P467, DOI 10.1096/fasebj.13.3.467; Ikari Y, 2000, J BIOL CHEM, V275, P12799, DOI 10.1074/jbc.275.17.12799; Ingber DE, 1995, J BIOMECH, V28, P1471, DOI 10.1016/0021-9290(95)00095-X; JOHNSON D, 1979, J BIOL CHEM, V254, P4022; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; McGill G, 1997, J CELL BIOL, V138, P901, DOI 10.1083/jcb.138.4.901; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; PEREZREYES N, 1992, P NATL ACAD SCI USA, V89, P1224, DOI 10.1073/pnas.89.4.1224; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Smith MR, 1997, CYTOKINE, V9, P770, DOI 10.1006/cyto.1997.0233; STARKEY PM, 1983, ANN NY ACAD SCI, V421, P112, DOI 10.1111/j.1749-6632.1983.tb18097.x; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; UMANS L, 1995, J BIOL CHEM, V270, P19778, DOI 10.1074/jbc.270.34.19778; Valente P, 1998, INT J CANCER, V75, P246, DOI 10.1002/(SICI)1097-0215(19980119)75:2<246::AID-IJC13>3.0.CO;2-B	33	61	73	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 13	2001	276	15					11798	11803		10.1074/jbc.M008503200	http://dx.doi.org/10.1074/jbc.M008503200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	421UK	11096092	hybrid			2022-12-25	WOS:000168081800051
J	Fiermonte, G; Dolce, V; Palmieri, L; Ventura, M; Runswick, MJ; Palmieri, F; Walker, JE				Fiermonte, G; Dolce, V; Palmieri, L; Ventura, M; Runswick, MJ; Palmieri, F; Walker, JE			Identification of the human mitochondrial oxodicarboxylate carrier - Bacterial expression, reconstitution functional characterization, tissue distribution, and chromosomal location	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMINOADIPATE AMINOTRANSFERASE; KYNURENINE AMINOTRANSFERASE; OXOGLUTARATE CARRIER; BOVINE MITOCHONDRIA; PURIFICATION; TRANSPORT; PROTEINS; YEAST; GENE; ACIDURIA	In Saccharomyces cerevisiae, the genes ODC1 and ODC2 encode isoforms of the oxodicarboxylate carrier. They both transport C5-C7 oxodicarboxylates across the inner membranes of mitochondria and are members of the family of mitochondrial carrier proteins. Orthologs are encoded in the genomes of Caenorhabditis elegans and Drosophila melanogaster, and a human expressed sequence tag (EST) encodes part of a closely related protein. Information from the EST has been used to complete the human cDNA sequence. This sequence has been used to map the gene to chromosome 14q11.2 and to show that the gene is expressed in all tissues that were examined. The human protein was produced by overexpression in Escherichia coli, purified, and reconstituted into phospholipid vesicles. It has similar transport characteristics to the yeast oxodicarboxylate carrier proteins (ODCs), Both the human and yeast ODCs catalyzed the transport of the oxodicarboxylates 2-oxoadipate and 2-oxoglutarate by a counter-exchange mechanism. Adipate, glutarate, and to a lesser extent, pimelate, 2-oxopimelate, 2-aminoadipate, oxaloacetate, and citrate were also transported by the human ODC. The main differences between the human and yeast ODCs are that 2-aminoadipate is transported by the former but not by the latter, whereas malate is transported by the yeast ODCs but not by the human ortholog, In mammals, 2-oxoadipate is a common intermediate in the catabolism of lysine, tryptophan, and hydroxylysine. It is transported from the cytoplasm into mitochondria where it is converted into acetyl-CoA. Defects in human ODC are likely to be a cause of 2-oxoadipate acidemia, an inborn error of metabolism of lysine, tryptophan, and hydroxylysine.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; Univ Calabria, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-87030 Cosenza, Italy; Univ Bari, Inst Genet, I-70125 Bari, Italy	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; Universita degli Studi di Bari Aldo Moro; University of Calabria; Universita degli Studi di Bari Aldo Moro	Walker, JE (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.		Fiermonte, Giuseppe/F-3159-2010; Ventura, Mario/E-6420-2011; Fiermonte, Giuseppe/D-3680-2018	Ventura, Mario/0000-0001-7762-8777; Fiermonte, Giuseppe/0000-0002-6764-9395; Dolce, Vincenza/0000-0003-2966-4866; Walker, John/0000-0001-7929-2162				BISACCIA F, 1994, BIOCHEMISTRY-US, V33, P3705, DOI 10.1021/bi00178a030; BISACCIA F, 1985, BIOCHIM BIOPHYS ACTA, V810, P362, DOI 10.1016/0005-2728(85)90222-1; DOLCE V, 2001, IN PRESS P NATL ACAD, V98; DON RH, 1991, NUCLEIC ACIDS RES, V19, P4008, DOI 10.1093/nar/19.14.4008; DURAN M, 1984, J INHERIT METAB DIS, V7, P61, DOI 10.1007/BF01805803; Fiermonte G, 1998, J BIOL CHEM, V273, P22782, DOI 10.1074/jbc.273.35.22782; Fiermonte G, 1998, J BIOL CHEM, V273, P24754, DOI 10.1074/jbc.273.38.24754; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; FISCHER MH, 1980, AM J MED GENET, V5, P35, DOI 10.1002/ajmg.1320050106; Indiveri C, 1997, BIOCHEM J, V321, P713, DOI 10.1042/bj3210713; Krumer R., 1992, MOL MECHANISMS BIOEN, P359, DOI DOI 10.1016/50167-7306(08)60184-2; Nishizuka Y., 1970, METHODS ENZYMOL A, P463; Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3; PALMIERI F, 1972, EUR J BIOCHEM, V29, P408, DOI 10.1111/j.1432-1033.1972.tb02003.x; PALMIERI F, 1994, FEBS LETT, V346, P48, DOI 10.1016/0014-5793(94)00329-7; Palmieri Ferdinando, 1999, P489; Palmieri L, 1996, FEBS LETT, V399, P299, DOI 10.1016/S0014-5793(96)01350-6; Palmieri L, 1997, FEBS LETT, V410, P447, DOI 10.1016/S0014-5793(97)00630-3; Palmieri L, 2001, J BIOL CHEM, V276, P1916, DOI 10.1074/jbc.M004332200; Pannone E, 1998, CYTOGENET CELL GENET, V83, P238, DOI 10.1159/000015190; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; PRZYREMBEL H, 1975, CLIN CHIM ACTA, V58, P257, DOI 10.1016/0009-8981(75)90445-3; TAKEUCHI F, 1983, BIOCHIM BIOPHYS ACTA, V743, P323, DOI 10.1016/0167-4838(83)90389-8; TOBES MC, 1977, J BIOL CHEM, V252, P4591; VIANEYLIAUD C, 1985, J INHERIT METAB DIS, V8, P133, DOI 10.1007/BF01811495; Walker J.E., 1992, CURR OPIN STRUC BIOL, V2, P519, DOI DOI 10.1016/0959-440X(92)90081-H; WENDEL U, 1975, CLIN CHIM ACTA, V58, P271, DOI 10.1016/0009-8981(75)90446-5; WILSON RW, 1975, PEDIATR RES, V9, P522, DOI 10.1203/00006450-197506000-00002; WILSON RW, 1976, CLIN CHIM ACTA, V69, P323, DOI 10.1016/0009-8981(76)90512-X	29	85	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8225	8230		10.1074/jbc.M009607200	http://dx.doi.org/10.1074/jbc.M009607200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11083877	hybrid			2022-12-25	WOS:000167474900077
J	Stefansson, S; Petitclerc, E; Wong, MKK; McMahon, GA; Brooks, PC; Lawrence, DA				Stefansson, S; Petitclerc, E; Wong, MKK; McMahon, GA; Brooks, PC; Lawrence, DA			Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; GROWTH-FACTOR; INTEGRIN ALPHA(V)BETA(3); UROKINASE RECEPTOR; PERICELLULAR PROTEOLYSIS; EXTRACELLULAR-MATRIX; TUBULAR STRUCTURES; CANCER INVASION; UP-REGULATION; MOUSE MODEL	The process of angiogenesis is important in both normal and pathologic physiology. However, the mechanisms whereby factors such as basic fibroblast growth factor promote the formation of new blood vessels are not known. In the present study, we demonstrate that exogenously added plasminogen activator inhibitor-1 (PAI-1) at therapeutic concentrations is a potent inhibitor of basic fibroblast growth factor-induced angiogenesis in the chicken chorioallantoic membrane. By using specific PAI-1 mutants with either their vitronectin binding or proteinase inhibitor activities ablated, we show that the inhibition of angiogenesis appears to occur via two distinct but apparently overlapping pathways. The first is dependent on PAI-1 inhibition of proteinase activity, most likely chicken plasmin, while the second is independent of PAI-1's anti-proteinase activity and instead appears to act through PAI-1 binding to vitronectin. Together, these data suggest that PAI-1 may be an important factor regulating angiogenesis in vivo.	Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; Univ So Calif, Norris Canc Ctr, Dept Mol Biol, Los Angeles, CA 90033 USA	American Red Cross; University of Southern California	Lawrence, DA (corresponding author), Amer Red Cross, Jerome H Holland Lab, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.			Lawrence, Daniel/0000-0003-3126-1935	NATIONAL CANCER INSTITUTE [R29CA074132, R01CA083090] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055374, R01HL055747] Funding Source: NIH RePORTER; NCI NIH HHS [CA83090, CA74132] Funding Source: Medline; NHLBI NIH HHS [HL55747, HL55374] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARGRAVES KM, 1995, J BIOL CHEM, V270, P26550, DOI 10.1074/jbc.270.44.26550; Bacharach E, 1998, BLOOD, V92, P939, DOI 10.1182/blood.V92.3.939.415k28_939_945; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BERKENPAS MB, 1995, EMBO J, V14, P2969, DOI 10.1002/j.1460-2075.1995.tb07299.x; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Brooks PC, 1998, CELL, V92, P391, DOI 10.1016/S0092-8674(00)80931-9; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Bugge TH, 1996, CELL, V87, P709, DOI 10.1016/S0092-8674(00)81390-2; CARMELIET P, 1994, NATURE, V368, P419, DOI 10.1038/368419a0; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CLYMAN RI, 1992, EXP CELL RES, V200, P272, DOI 10.1016/0014-4827(92)90173-6; Debrock S, 1997, BBA-PROTEIN STRUCT M, V1337, P257, DOI 10.1016/S0167-4838(96)00173-2; Deng G, 1996, J BIOL CHEM, V271, P12716, DOI 10.1074/jbc.271.22.12716; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1987, LAB INVEST, V57, P673; Eitzman DT, 1996, BLOOD, V87, P4718; FAY WP, 1992, NEW ENGL J MED, V327, P1729, DOI 10.1056/NEJM199212103272406; *FOOD DRUG ADM, 1985, INSP TECHN GUID; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gibson A, 1997, J BIOL CHEM, V272, P5112, DOI 10.1074/jbc.272.8.5112; Giuliani R, 1999, J CELL SCI, V112, P2597; GRODAHLHANSEN J, 1988, J INVEST DERMATOL, V90, P790; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; HEKMAN CM, 1988, BIOCHEMISTRY-US, V27, P2911, DOI 10.1021/bi00408a037; Johnsen M, 1998, CURR OPIN CELL BIOL, V10, P667, DOI 10.1016/S0955-0674(98)80044-6; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177; KU PT, 1995, J CELL BIOCHEM, V58, P328, DOI 10.1002/jcb.240580307; KVASSMAN JO, 1995, FIBRINOLYSIS, V9, P215, DOI 10.1016/S0268-9499(08)80062-8; Lansink M, 1998, BLOOD, V92, P927; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; LAWRENCE DA, 1990, J BIOL CHEM, V265, P20293; LAWRENCE DA, 1995, J BIOL CHEM, V270, P25309, DOI 10.1074/jbc.270.43.25309; LAWRENCE DA, 1994, J BIOL CHEM, V269, P15223; Lawrence DA, 1997, J BIOL CHEM, V272, P7676, DOI 10.1074/jbc.272.12.7676; LAWRENCE DA, 1994, J BIOL CHEM, V269, P27657; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; Lijnen HR, 2000, J BIOL CHEM, V275, P37645, DOI 10.1074/jbc.M006475200; Loskutoff DJ, 1998, ARTERIOSCL THROM VAS, V18, P1, DOI 10.1161/01.ATV.18.1.1; Mazzieri R, 1997, EMBO J, V16, P2319, DOI 10.1093/emboj/16.9.2319; MORE RS, 1995, CARDIOVASC RES, V29, P22, DOI 10.1016/0008-6363(96)88541-5; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; PEPPER MS, 1990, CELL DIFFER DEV, V32, P319, DOI 10.1016/0922-3371(90)90046-Y; PEPPER MS, 1990, J CELL BIOL, V111, P743, DOI 10.1083/jcb.111.2.743; Podor TJ, 2000, J BIOL CHEM, V275, P19788, DOI 10.1074/jbc.M908079199; Podor TJ, 2000, J BIOL CHEM, V275, P25402, DOI 10.1074/jbc.M000362200; Robbie LA, 1996, ARTERIOSCL THROM VAS, V16, P539, DOI 10.1161/01.ATV.16.4.539; Romer J, 1996, NAT MED, V2, P287, DOI 10.1038/nm0396-287; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; Seiffert D, 1997, J BIOL CHEM, V272, P13705, DOI 10.1074/jbc.272.21.13705; Sipley JD, 1997, P NATL ACAD SCI USA, V94, P2933, DOI 10.1073/pnas.94.7.2933; Soff GA, 1995, J CLIN INVEST, V96, P2593, DOI 10.1172/JCI118323; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; Stefansson S, 1996, J BIOL CHEM, V271, P8215, DOI 10.1074/jbc.271.14.8215; Stefansson S, 1998, TRENDS CARDIOVAS MED, V8, P175, DOI 10.1016/S1050-1738(98)00003-6; Stefansson S, 1998, J BIOL CHEM, V273, P6358, DOI 10.1074/jbc.273.11.6358; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; Ukraincik K, 1981, Methods Enzymol, V74 Pt C, P497; vanAken BE, 1997, HISTOCHEM CELL BIOL, V107, P313, DOI 10.1007/s004180050116; Verhamme I, 1999, J BIOL CHEM, V274, P17511, DOI 10.1074/jbc.274.25.17511; WEI Y, 1994, J BIOL CHEM, V269, P32380; WU K, 1995, BLOOD, V86, P1056, DOI 10.1182/blood.V86.3.1056.bloodjournal8631056; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281	65	157	164	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8135	8141		10.1074/jbc.M007609200	http://dx.doi.org/10.1074/jbc.M007609200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11083866	hybrid			2022-12-25	WOS:000167474900065
J	Gobel, C; Feussner, I; Schmidt, A; Scheel, D; Sanchez-Serrano, J; Hamberg, M; Rosahl, S				Gobel, C; Feussner, I; Schmidt, A; Scheel, D; Sanchez-Serrano, J; Hamberg, M; Rosahl, S			Oxylipin profiling reveals the preferential stimulation of the 9-lipoxygenase pathway in elicitor-treated potato cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-BODY LIPOXYGENASE; SYRINGAE PV-PHASEOLICOLA; SOLANUM-TUBEROSUM L; GENE-EXPRESSION; DIFFERENTIAL INDUCTION; TRANSGENIC TOBACCO; METHYL JASMONATE; FUNGAL ELICITOR; BARLEY LEAVES; HIGHER-PLANTS	Lipoxygenases are key enzymes in the synthesis of oxylipins and play an important role in the response of plants to wounding and pathogen attack. In cultured potato cells treated with elicitor from Phytophthora infestans, the causal agent of late blight disease, transcripts encoding a Linoleate 9-lipoxygenase and a Linoleate 13-lipoxygenase accumulate. However, lipoxygenase activity assays and oxylipin profiling revealed only increased 9-lipoxygenase activity and formation of products derived therefrom, such as 9-hydroxy octadecadienoic acid and colneleic acid. Furthermore, the 9-lipoxygenase products 9(S),10(S),11(R)-trihydroxy-12(Z)-octadecenoic and 9(S),10(S),11(R)-trihydroxy-12(Z),15(Z)-octadecadienoic acid were identified as novel, elicitor-inducible oxylipins in potato, suggesting a role of these compounds in the defense response against pathogen attack. Neither 13-lipoxygenase activity nor 13-lipoxygenase products were detected in higher amounts in potato cells after elicitation. Thus, formation of products by the 9-lipoxygenase pathway, including the enzymes hydroperoxide reductase, divinyl ether synthase, and epoxy alcohol synthase, is preferentially stimulated in cultured potato cells in response to treatment with P. infestans elicitor. Moreover, elicitor-induced accumulation of desaturase transcripts and increased phospholipase A(2) activity after elicitor treatment suggest that substrates for the lipoxygenase pathway might be provided by de novo synthesis and subsequent release hom lipids of the endomembrane system.	Inst Plant Biochem, Dept Stress & Dev Biol, D-06120 Halle, Germany; Inst Plant Biochem, Dept Secondary Metab, D-06120 Halle, Germany; Inst Plant Genet & Crop Plant Res, Dept Mol Cell Biol, D-06466 Gatersleben, Germany; Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, E-28049 Madrid, Spain; Karolinska Inst, Dept Med Biochem & Biophys, Div Physiol Chem 2, S-17177 Stockholm, Sweden	Leibniz Institut fur Pflanzenbiochemie; Leibniz Institut fur Pflanzenbiochemie; Leibniz Institut fur Pflanzengenetik und Kulturpflanzenforschung; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Karolinska Institutet	Rosahl, S (corresponding author), Inst Plant Biochem, Dept Stress & Dev Biol, Weinberg 3, D-06120 Halle, Germany.	srosahl@ipb-halle.de	Feussner, Ivo/H-9320-2013; Serrano, Jose J Sanchez/H-6955-2015	Feussner, Ivo/0000-0002-9888-7003; Serrano, Jose J Sanchez/0000-0002-4489-4785; Hamberg, Mats/0000-0002-8910-7810				BECKERANDRE M, 1991, J BIOL CHEM, V266, P8551; BELL E, 1995, P NATL ACAD SCI USA, V92, P8675, DOI 10.1073/pnas.92.19.8675; Blee E, 1998, PROG LIPID RES, V37, P33, DOI 10.1016/S0163-7827(98)00004-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bohland C, 1997, PLANT PHYSIOL, V114, P679, DOI 10.1104/pp.114.2.679; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Buchter R, 1997, PLANT MOL BIOL, V35, P749, DOI 10.1023/A:1005830706507; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; CROFT KPC, 1990, PHYSIOL MOL PLANT P, V36, P49, DOI 10.1016/0885-5765(90)90091-B; CROFT KPC, 1993, PLANT PHYSIOL, V101, P13, DOI 10.1104/pp.101.1.13; DENG WL, 1992, PLANTA, V187, P203, DOI 10.1007/BF00201939; FEUSSNER I, 1995, FEBS LETT, V367, P12, DOI 10.1016/0014-5793(95)00531-D; Feussner I, 1997, J BIOL CHEM, V272, P21635, DOI 10.1074/jbc.272.34.21635; FEUSSNER I, 2000, ENZYMES LIPID MODIFI, P309; Fidantsef AL, 1998, PHYSIOL PLANTARUM, V102, P257, DOI 10.1034/j.1399-3054.1998.1020214.x; FOURNIER J, 1993, PLANT J, V3, P63, DOI 10.1111/j.1365-313X.1993.tb00011.x; Fritsche K, 1999, FEBS LETT, V462, P249, DOI 10.1016/S0014-5793(99)01541-0; GEERTS A, 1994, PLANT PHYSIOL, V105, P269, DOI 10.1104/pp.105.1.269; Hamberg M, 1999, LIPIDS, V34, P1131, DOI 10.1007/s11745-999-0464-7; Hamberg M, 1999, J BIOL CHEM, V274, P24503, DOI 10.1074/jbc.274.35.24503; Hause B, 2000, PLANTA, V210, P708, DOI 10.1007/s004250050671; HEINZ E, 1993, BIOSYNTHESIS POLYUNS, P33; JOOS HJ, 1992, EUR J BIOCHEM, V204, P621, DOI 10.1111/j.1432-1033.1992.tb16675.x; KATO T, 1985, TETRAHEDRON LETT, V26, P2357, DOI 10.1016/S0040-4039(00)95098-6; Kirsch C, 1997, PLANT PHYSIOL, V115, P283, DOI 10.1104/pp.115.1.283; Koch T, 1999, PLANT PHYSIOL, V121, P153, DOI 10.1104/pp.121.1.153; Kohlmann M, 1999, EUR J BIOCHEM, V260, P885, DOI 10.1046/j.1432-1327.1999.00231.x; McConn M, 1997, P NATL ACAD SCI USA, V94, P5473, DOI 10.1073/pnas.94.10.5473; MUELLER MJ, 1994, ANAL BIOCHEM, V218, P425, DOI 10.1006/abio.1994.1202; OCAMPO CA, 1986, Z NATURFORSCH C, V41, P559; Parchmann S, 1997, PLANT PHYSIOL, V115, P1057, DOI 10.1104/pp.115.3.1057; PENG YL, 1994, J BIOL CHEM, V269, P3755; Rance I, 1998, P NATL ACAD SCI USA, V95, P6554, DOI 10.1073/pnas.95.11.6554; Reymond P, 1998, CURR OPIN PLANT BIOL, V1, P404, DOI 10.1016/S1369-5266(98)80264-1; Rickauer M, 1997, PLANTA, V202, P155, DOI 10.1007/s004250050114; ROHWER F, 1987, PLANTA, V170, P556, DOI 10.1007/BF00402991; Rosahl S, 1996, Z NATURFORSCH C, V51, P123; Royo J, 1999, P NATL ACAD SCI USA, V96, P1146, DOI 10.1073/pnas.96.3.1146; Royo J, 1996, J BIOL CHEM, V271, P21012, DOI 10.1074/jbc.271.35.21012; Rusterucci C, 1999, J BIOL CHEM, V274, P36446, DOI 10.1074/jbc.274.51.36446; Schmidt A, 1999, J BIOL CHEM, V274, P4273, DOI 10.1074/jbc.274.7.4273; Schmidt A, 1998, PLANTA, V205, P51, DOI 10.1007/s004250050295; SIEDOW JN, 1991, ANNU REV PLANT PHYS, V42, P145, DOI 10.1146/annurev.pp.42.060191.001045; Slusarenko Alan J., 1996, P176, DOI 10.1201/9781439831977.ch10; Staswick PE, 1998, PLANT J, V15, P747, DOI 10.1046/j.1365-313X.1998.00265.x; Thomma BPHJ, 1998, P NATL ACAD SCI USA, V95, P15107, DOI 10.1073/pnas.95.25.15107; Veronesi C, 1996, PLANT PHYSIOL, V112, P997, DOI 10.1104/pp.112.3.997; Vijayan P, 1998, P NATL ACAD SCI USA, V95, P7209, DOI 10.1073/pnas.95.12.7209; Wasternack C, 1997, TRENDS PLANT SCI, V2, P302, DOI 10.1016/S1360-1385(97)89952-9; Weber H, 1999, PLANT CELL, V11, P485, DOI 10.1105/tpc.11.3.485; Weichert H, 1999, FEBS LETT, V464, P133, DOI 10.1016/S0014-5793(99)01697-X	51	137	143	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6267	6273		10.1074/jbc.M008606200	http://dx.doi.org/10.1074/jbc.M008606200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11085991	hybrid			2022-12-25	WOS:000167261000029
J	Osdoit, S; Rosa, JP				Osdoit, S; Rosa, JP			Fibrin clot retraction by human platelets correlates with alpha(IIb)beta(3) integrin-dependent protein tyrosine dephosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; MURINE MONOCLONAL-ANTIBODY; CYTOSKELETAL REORGANIZATION; PHOSPHATASE-ACTIVITY; SIGNAL-TRANSDUCTION; GPIIB-IIIA; PHOSPHORYLATION; ACTIVATION; THROMBIN; IIB/IIIA	We have analyzed tyrosine phosphorylation associated with retraction of the fibrin clot by washed platelets in purified fibrinogen. Retraction was dependent on integrin alpha (IIb)beta (3), based on absence of retraction of alpha (IIb)beta (3)-deficient thrombasthenic platelets. However, only a subset of alpha (IIb)beta (3)-blocking antibodies or peptides were able to inhibit retraction, suggesting a differential engagement of alpha (IIb)beta (3) in fibrin clot retraction versus aggregation. Immunoblotting demonstrated a phosphorylated protein pattern comparable with aggregation at early time points. However, as opposed to aggregation tyrosine phosphorylation decreased rapidly in parallel to retraction (up to 60 min). Dephosphorylation was alpha (IIb)beta (3)-dependent, since it was blocked by alpha (IIb)beta (3)-specific inhibitors and was absent in thrombasthenic platelets, Inhibition of platelet clot retraction by phenyl-arsine oxide and peroxovanadate, suggested a role for tyrosine phosphatases. Cytochalasin D and E (5 muM) blocked fibrin clot retraction and tyrosine dephosphorylation, suggesting regulation by actin cytoskeleton assembly. Tyrosine phosphatase activities were found associated with clot retraction using the "in-gel" tyrosine phosphatase assay; however, none were alpha (IIb)beta (3)-dependent. An 85-kDa protein and to a lesser degree "Src" showed the closest dose dependent correlation between inhibition of tyrosine dephosphorylation and inhibition of retraction. We thus postulate that alpha (IIb)beta (3) engagement in fibrin clot retraction drives, in an actin cytoskeleton-dependent manner, the interaction of tyrosine phosphatases and of the tyrosine-phosphorylated substrates 85-kDa protein and Src, the dephosphorylation of which regulates the force generation and/or transmission required for full contraction of the fibrin matrix.	Hop Lariboisiere, INSERM, U348, F-75475 Paris 10, France; Hop Lariboisiere, Circulat Lab IFR6, F-75475 Paris 10, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP	Rosa, JP (corresponding author), Hop Lariboisiere, INSERM, U348, 41 Blvd Chapelle, F-75475 Paris 10, France.	jean-philippe.rosa@inserm.lrb.ap-hop-paris.fr	ROSA, JEAN-PHILIPPE/B-6245-2018	ROSA, JEAN-PHILIPPE/0000-0001-7342-0389				BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; CARR ME, 1995, THROMB HAEMOSTASIS, V73, P499; CARTEAUX JP, 1993, THROMB HAEMOSTASIS, V70, P817; Cheresh DA, 1999, J CELL BIOL, V146, P1107, DOI 10.1083/jcb.146.5.1107; Choquet D, 1997, CELL, V88, P39, DOI 10.1016/S0092-8674(00)81856-5; COHEN I, 1989, BLOOD, V73, P1880; COHEN I, 1982, J CELL BIOL, V93, P775, DOI 10.1083/jcb.93.3.775; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; DJAFFAR I, 1993, HUM MOL GENET, V2, P2183, DOI 10.1093/hmg/2.12.2183; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1990, J CELL BIOL, V111, P483, DOI 10.1083/jcb.111.2.483; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; Grinnell F, 1999, CURR TOPICS PATHOL, V93, P61; Hantgan RR, 1998, THROMB RES, V89, P271, DOI 10.1016/S0049-3848(98)00021-8; Jackson SP, 1996, THROMB HAEMOSTASIS, V76, P640; Jennings LK, 1995, THROMB HAEMOSTASIS, V74, P1551; KOUNS WC, 1992, BLOOD, V80, P2539; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Leng LJ, 1998, BLOOD, V91, P4206, DOI 10.1182/blood.V91.11.4206.411k30_4206_4215; LevyToledano S, 1997, THROMB HAEMOSTASIS, V78, P226; Li RY, 1997, THROMB HAEMOSTASIS, V77, P150; LI RY, 1994, FEBS LETT, V343, P89, DOI 10.1016/0014-5793(94)80613-6; MCEVER RP, 1980, J CLIN INVEST, V66, P1311, DOI 10.1172/JCI109983; NEWMAN PJ, 1985, BLOOD, V65, P227; Nurden AT, 1999, THROMB HAEMOSTASIS, V82, P468; Pasquet JM, 1998, BIOCHEM J, V333, P591, DOI 10.1042/bj3330591; PHILLIPS DR, 1988, BLOOD, V71, P831; PIDARD D, 1983, J BIOL CHEM, V258, P2582; PUMIGLIA KM, 1992, BIOCHEM J, V286, P441, DOI 10.1042/bj2860441; Rooney MM, 1996, J BIOL CHEM, V271, P8553, DOI 10.1074/jbc.271.15.8553; Rosa JP, 1997, BLOOD, V89, P4385, DOI 10.1182/blood.V89.12.4385; SCARBOROUGH RM, 1993, J BIOL CHEM, V268, P1066; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P24876, DOI 10.1074/jbc.272.40.24876; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; TAKAYAMA H, 1993, BIOCHEM BIOPH RES CO, V194, P472, DOI 10.1006/bbrc.1993.1843; YANO Y, 1994, BIOCHEM J, V299, P303, DOI 10.1042/bj2990303; Yu DH, 1998, J BIOL CHEM, V273, P21125, DOI 10.1074/jbc.273.33.21125	41	59	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6703	6710		10.1074/jbc.M008945200	http://dx.doi.org/10.1074/jbc.M008945200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11084040	hybrid			2022-12-25	WOS:000167261000082
J	Hofmann, G; Bernabei, PA; Crociani, O; Cherubini, A; Guasti, L; Pillozzi, S; Lastraioli, E; Polvani, S; Bartolozzi, B; Solazzo, V; Gragnani, L; Defilippi, P; Rosati, B; Wanke, E; Olivotto, R; Arcangeli, A				Hofmann, G; Bernabei, PA; Crociani, O; Cherubini, A; Guasti, L; Pillozzi, S; Lastraioli, E; Polvani, S; Bartolozzi, B; Solazzo, V; Gragnani, L; Defilippi, P; Rosati, B; Wanke, E; Olivotto, R; Arcangeli, A			HERG K+ channels activation during beta(1) integrin-mediated adhesion to fibronectin induces an up-regulation of alpha(v)beta(3) integrin in the preosteoclastic leukemia cell line FLG 29.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEUROBLASTOMA-CELLS; CARDIAC-ARRHYTHMIA; MESSENGER-RNA; PROTEIN CD47; IN-VITRO; EXPRESSION; DIFFERENTIATION; CYTOSKELETON; MODULATION; MIGRATION	Integrin receptors have been demonstrated to mediate either "inside-to-out" and "outside-to-in" signals, and by this way are capable of regulating many cellular functions, such as cell growth and differentiation, cell migration, and activation. Among the various integrin-centered signaling pathways discovered so far, we demonstrated that the modulation of the electrical potential of the plasma membrane (V-REST) is an early integrin-mediated signal, which is related to neurite emission in neuroblastoma cells. This modulation is sustained by the activation of HERG K+ channels, encoded by the ether-a-go-go-related gene (herg). The involvement of integrin-mediated signaling is being discovered in the hemopoietic system: in particular, osteoclasts are generated as well as induced to differentiate by interaction of osteoclast progenitors with the stromal cells, through the involvement of integrin receptors. We studied the effects of cell interaction with the extracellular matrix protein fibronectin (FN) in a human leukemic preosteoclastic cell line (FLG 29.1 cells), which has been demonstrated to express HERG currents. We report here that FLG 29.1 cells indeed adhere to purified FN through integrin receptors, and that this adhesion induces an osteoclast phenotype in these cells, as evidenced by the appearance of tartrate-resistant acid phosphatase, as well as by the increased expression of CD51/alpha (v)beta (3) integrin and calcitonin receptor. An early activation of HERG current (I-HERG), without any increase in herg RNA or modifications of HERG protein was also observed in FN-adhering cells. This activation is apparently sustained by the beta (1), integrin subunit activation, through the involvement of a pertussis-toxin sensitive G(i) protein, and appears to be a determinant signal for the up-regulation of alpha (v)beta (3) integrin, as well as for the increased expression of calcitonin receptor.	Univ Florence, Dept Expt Pathol & Oncol, I-50134 Florence, Italy; Policlin Careggi, UO Hematol, I-50134 Florence, Italy; Univ Milano Bicocca, Dept Biotechnol & Biosci, I-20126 Milan, Italy; Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy	University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Milano-Bicocca; University of Turin	Arcangeli, A (corresponding author), Univ Florence, Dept Expt Pathol & Oncol, Viale GB Morgagni 50, I-50134 Florence, Italy.	annarosa.arcangeli@unifi.it	pillozzi, serena/K-5876-2016; GRAGNANI, LAURA/K-7751-2013; Lastraioli, Elena/AAD-1967-2022; Gragnani, Laura/H-7755-2019; DEFILIPPI, Paola/L-2232-2014	pillozzi, serena/0000-0001-8861-8718; GRAGNANI, LAURA/0000-0001-6800-9149; Gragnani, Laura/0000-0001-6800-9149; Polvani, Simone/0000-0002-3707-1043; Defilippi, Paola/0000-0001-6427-4906; Crociani, Olivia/0000-0003-3485-2132; GUASTI, LUIGINA/0000-0002-4524-4864; Guasti, Leonardo/0000-0002-4616-6044	Telethon [1046] Funding Source: Medline	Telethon(Fondazione Telethon)		Arcangeli A, 1996, CELL ADHES COMMUN, V4, P369, DOI 10.3109/15419069609010779; Arcangeli A, 1999, J NEUROBIOL, V40, P214; Arcangeli A, 1998, BIOCHEM BIOPH RES CO, V244, P706, DOI 10.1006/bbrc.1998.8319; Arcangeli A, 1997, EUR J NEUROSCI, V9, P2596, DOI 10.1111/j.1460-9568.1997.tb01689.x; Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; ARCANGELI A, 1993, J CELL BIOL, V122, P1131, DOI 10.1083/jcb.122.5.1131; BARTOLAZZI A, 1993, ANTICANCER RES, V13, P1; Beaudreuil J, 2000, BONE, V27, P161, DOI 10.1016/S8756-3282(00)00305-7; BECCHETTI A, 1992, P ROY SOC B-BIOL SCI, V248, P235, DOI 10.1098/rspb.1992.0067; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; Bianchi L, 1998, CANCER RES, V58, P815; BIANCHI L, 1995, BIOCHEM BIOPH RES CO, V210, P823, DOI 10.1006/bbrc.1995.1732; CHAMBERS TJ, 1993, P NATL ACAD SCI USA, V90, P5578, DOI 10.1073/pnas.90.12.5578; CLAPHAM DE, 1993, NATURE, V365, P403, DOI 10.1038/365403a0; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; DEFILIPPI P, 1991, J BIOL CHEM, V266, P7638; Faravelli L, 1996, J PHYSIOL-LONDON, V496, P13, DOI 10.1113/jphysiol.1996.sp021661; FORMIGLI L, 1995, J CELL PHYSIOL, V162, P199, DOI 10.1002/jcp.1041620206; Frazier WA, 1999, J BIOL CHEM, V274, P8554, DOI 10.1074/jbc.274.13.8554; Gao AG, 1996, J CELL BIOL, V135, P533, DOI 10.1083/jcb.135.2.533; GATTEI V, 1992, J CELL BIOL, V116, P437, DOI 10.1083/jcb.116.2.437; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hirsch E, 1996, NATURE, V380, P171, DOI 10.1038/380171a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Ivanina T, 2000, FEBS LETT, V466, P327, DOI 10.1016/S0014-5793(99)01738-X; Levesque JP, 1999, EXP HEMATOL, V27, P579, DOI 10.1016/S0301-472X(98)00069-1; Levite M, 2000, J EXP MED, V191, P1167, DOI 10.1084/jem.191.7.1167; London B, 1997, CIRC RES, V81, P870; MARTINPADURA I, 1994, J BIOL CHEM, V269, P6124; McPhee JC, 1998, J BIOL CHEM, V273, P34696, DOI 10.1074/jbc.273.52.34696; Olivotto M, 1996, BIOESSAYS, V18, P495, DOI 10.1002/bies.950180612; Papayannopoulou T, 1998, BLOOD, V91, P2231, DOI 10.1182/blood.V91.7.2231.2231_2231_2239; Rodan SB, 1997, J ENDOCRINOL, V154, pS47; Roodman GD, 1999, EXP HEMATOL, V27, P1229, DOI 10.1016/S0301-472X(99)00061-2; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd, ed.; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Schonherr R, 1999, EUR J NEUROSCI, V11, P753, DOI 10.1046/j.1460-9568.1999.00493.x; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Simmons PJ, 1997, BAILLIERE CLIN HAEM, V10, P485, DOI 10.1016/S0950-3536(97)80022-4; SUDA T, 1995, ENDOCRINE REV MONOGR, P266; Wang XQ, 1999, J CELL BIOL, V147, P389, DOI 10.1083/jcb.147.2.389; WIJNGAERT FB, 1986, J HISTOL CYTOL, V34, P1317; Wymore RS, 1997, CIRC RES, V80, P261, DOI 10.1161/01.RES.80.2.261; Yokota T, 1998, BLOOD, V91, P3263, DOI 10.1182/blood.V91.9.3263.3263_3263_3272; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3	47	73	76	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4923	4931		10.1074/jbc.M005682200	http://dx.doi.org/10.1074/jbc.M005682200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11080495	hybrid			2022-12-25	WOS:000168484300055
J	Sergeant, S; Waite, KA; Heravi, J; McPhail, LC				Sergeant, S; Waite, KA; Heravi, J; McPhail, LC			Phosphatidic acid regulates tyrosine phosphorylating activity in human neutrophils - Enhancement of Fgr activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SRC-FAMILY KINASES; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; NADPH OXIDASE COMPONENT; PHOSPHOLIPASE-D; SELECTIVE INHIBITOR; RESPIRATORY BURST; CELL ACTIVATION; MAP KINASE; IN-VITRO	In human neutrophils, the activation of phospholipase D and the Tyr phosphorylation of proteins are early signaling events upon cell stimulation. We found that the pretreatment of neutrophils with ethanol (0.8%) or 1-butanol (0.3%), which results in the accumulation of phosphatidylalcohol at the expense of phosphatidic acid (PA), decreased the phorbol myristate acetate-stimulated Tyr phosphorylation of endogenous proteins (42, 115 kDa), When neutrophil cytosol was incubated in the presence or absence of PA, these and other endogenous proteins became Tyr-phosphorylated in a PA-dependent manner. In contrast, phosphatidylalcohols exhibited only 25% (phosphatidylethanol) or 5% (phosphatidylbutanol) of the ability of PA to stimulate Tyr phosphorylation in the cell-free assay. Similarly, other phospholipids (phosphatidylcholine, phosphatidylethanolamine, phosphatidylglycerol, phosphatidylserine, phosphatidylinositol, polyphosphoinositides, and sphingosine 1-phosphate) showed little ability to stimulate Tyr phosphorylation, These data suggest that PA can function as an intracellular regulator of Tyr phosphorylating activity. Gel filtration chromatography of leukocyte cytosol revealed a peak of PA-dependent Tyr phosphorylating activity distinct from a previously described PA-dependent phosphorylating activity (Waite, K. A., Wallin, R., Qualliotine-Mann, D., and McPhail, L. C. (1997) J. Biol. Chem. 272, 15569-15578). Among the protein Tyr kinases expressed in neutrophils, only Fgr eluted exclusively in the peak of PA-dependent Tyr phosphorylating activity, Importantly, Fgr isolated from unstimulated neutrophil. lysates showed increased activity in the presence of PA but not phosphatidylbutanol. Moreover, the pretreatment of neutrophils with 1-butanol decreased Fgr activity in cells stimulated with formyl-methionyl-leucyl phenylalanine plus dihydrocytochalasin B. Together, these results suggest a new second messenger role for PA in the regulation of Tyr phosphorylation.	Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Med, Div Infect Dis, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Sergeant, S (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Med Ctr Blvd, Winston Salem, NC 27157 USA.	ssergean@wfubmc.edu	McPhail, Linda C/D-9505-2013	McPhail, Linda C/0000-0002-8670-306X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022564] Funding Source: NIH RePORTER; NIAID NIH HHS [2R01 AI22564, R01 AI022564] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BERKOW RL, 1990, BLOOD, V75, P2445; Berton G, 1999, Curr Opin Hematol, V6, P51, DOI 10.1097/00062752-199901000-00009; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; Bokoch GM, 1998, J BIOL CHEM, V273, P8137, DOI 10.1074/jbc.273.14.8137; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P28766, DOI 10.1074/jbc.273.44.28766; BRAYTON RG, 1970, NEW ENGL J MED, V282, P123, DOI 10.1056/NEJM197001152820303; Brumelll JH, 1996, J BIOL CHEM, V271, P1455, DOI 10.1074/jbc.271.3.1455; Brunati AM, 1999, J BIOL CHEM, V274, P7557, DOI 10.1074/jbc.274.11.7557; CALDWELL SE, 1988, J CLIN INVEST, V81, P1485, DOI 10.1172/JCI113480; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; DUSI S, 1994, BIOCHEM J, V304, P243, DOI 10.1042/bj3040243; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; English D, 1996, CELL SIGNAL, V8, P341, DOI 10.1016/0898-6568(95)00076-3; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FIALKOW L, 1993, J BIOL CHEM, V268, P17131; Frohman MA, 1999, BBA-MOL CELL BIOL L, V1439, P175, DOI 10.1016/S1388-1981(99)00093-1; Geng D, 1998, J BIOL CHEM, V273, P12195, DOI 10.1074/jbc.273.20.12195; GERARD C, 1986, J CLIN INVEST, V77, P61, DOI 10.1172/JCI112302; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; Groundwater P W, 1996, Prog Med Chem, V33, P233, DOI 10.1016/S0079-6468(08)70307-2; GUTKIND JS, 1989, P NATL ACAD SCI USA, V86, P8783, DOI 10.1073/pnas.86.22.8783; HAMADA F, 1993, P NATL ACAD SCI USA, V90, P6305, DOI 10.1073/pnas.90.13.6305; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; HARDIE G, 1995, PROTEIN KINASE FACTS, P41; HARTSON SD, 1994, BIOCHEMISTRY-US, V33, P8912, DOI 10.1021/bi00196a008; Houle MG, 1999, BBA-MOL CELL BIOL L, V1439, P135, DOI 10.1016/S1388-1981(99)00090-6; JONES GA, 1993, J BIOL CHEM, V268, P20845; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; KHAN WA, 1994, J BIOL CHEM, V269, P9729; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Kusner DJ, 1999, J IMMUNOL, V162, P2266; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lennartz MR, 1999, INT J BIOCHEM CELL B, V31, P415, DOI 10.1016/S1357-2725(98)00108-3; LETO TL, 1991, J BIOL CHEM, V266, P19812; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; Lowell CA, 1996, J CELL BIOL, V133, P895, DOI 10.1083/jcb.133.4.895; MACGREGOR RR, 1974, NEW ENGL J MED, V291, P642, DOI 10.1056/NEJM197409262911302; MARCOZ P, 1993, BIOCHIM BIOPHYS ACTA, V1176, P129, DOI 10.1016/0167-4889(93)90187-T; MCPHAIL LC, 1983, J CLIN INVEST, V72, P192, DOI 10.1172/JCI110957; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; Mocsai A, 1999, J IMMUNOL, V162, P1120; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; NOTARIO V, 1989, J CELL BIOL, V109, P3129, DOI 10.1083/jcb.109.6.3129; Ohguchi K, 1997, BBA-LIPID LIPID MET, V1346, P301, DOI 10.1016/S0005-2760(97)00043-X; OLIVER JM, 1994, J BIOL CHEM, V269, P29697; PAI JK, 1987, CARCINOGENESIS, V8, P173, DOI 10.1093/carcin/8.1.173; Patel M, 1996, ALCOHOL CLIN EXP RES, V20, P275, DOI 10.1111/j.1530-0277.1996.tb01640.x; Prieschl EE, 2000, J IMMUNOL, V164, P5389, DOI 10.4049/jimmunol.164.10.5389; Regier DS, 2000, J BIOL CHEM, V275, P28406, DOI 10.1074/jbc.M004703200; Regier DS, 1999, J BIOL CHEM, V274, P36601, DOI 10.1074/jbc.274.51.36601; ROLLET E, 1994, J IMMUNOL, V153, P353; ROTROSEN D, 1990, J BIOL CHEM, V265, P19910; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Sato K, 1997, FEBS LETT, V410, P136, DOI 10.1016/S0014-5793(97)00539-5; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Sergeant S, 1997, J IMMUNOL, V159, P2877; Siddiqui RA, 1997, BBA-LIPID LIPID MET, V1349, P81, DOI 10.1016/S0005-2760(97)00085-4; SIDDIQUI RA, 1995, CELL SIGNAL, V7, P247, DOI 10.1016/0898-6568(94)00083-N; Tamura DY, 1998, J TRAUMA, V44, P320, DOI 10.1097/00005373-199802000-00015; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; TORRES M, 1993, J IMMUNOL, V150, P1563; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSAI MH, 1989, MOL CELL BIOL, V9, P5260, DOI 10.1128/MCB.9.11.5260; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; UEHARA Y, 1991, METHOD ENZYMOL, V201, P370; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; Welch H, 1997, ONCOGENE, V15, P2021, DOI 10.1038/sj.onc.1201356; Welch Heidi, 1996, Methods (Orlando), V9, P607, DOI 10.1006/meth.1996.0067; Yan SR, 1996, FEBS LETT, V380, P198; ZHAO ZH, 1993, P NATL ACAD SCI USA, V90, P4251, DOI 10.1073/pnas.90.9.4251; ZIEMIECKI A, 1986, BIOCHEM BIOPH RES CO, V138, P1298, DOI 10.1016/S0006-291X(86)80424-7	82	39	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4737	4746		10.1074/jbc.M006571200	http://dx.doi.org/10.1074/jbc.M006571200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11078731	hybrid			2022-12-25	WOS:000168484300030
J	Burgess, BR; Richardson, JP				Burgess, BR; Richardson, JP			RNA passes through the hole of the protein hexamer in the complex with the Escherichia coli Rho factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINATION FACTOR-RHO; RNP1-LIKE SEQUENCE MOTIF; SINGLE-STRANDED-DNA; TRANSCRIPTION TERMINATION; CRYSTAL-STRUCTURE; BINDING DOMAIN; HELICASE-PRIMASE; ATP; FORM	Escherichia coli transcription termination factor Rho is a ring-shaped hexameric protein that uses the energy derived from ATP hydrolysis to dissociate RNA transcripts from the ternary elongation complex. To test a current model for the interaction of Rho with RNA, three derivatives of Rho were made containing single cysteine residues and modified with a photo-activable cross-linker. The positions for the cysteines were: 1) in part of the primary RNA-binding site in the N terminus (Cys-82 Rho); 2) in a connecting polypeptide proposed to be on the outside of the hexamer (Cys-153 Rho); and 3) near the proposed secondary RNA-binding site in the ATP-binding domain (Cys-325 Rho). Results from the cross-linking of the modified Rho proteins to a series of lambda cro RNA derivatives showed that Cys-82 Rho formed cross-links with all transcripts containing the Rho utilization (rut site, that Cys-325 Rho formed cross-links to transcripts that had the rut site and 10 or more residues 3' of the rut site, and that Cys-153 did not form cross-links with any of the transcripts. From a model of the quaternary structure of Rho, which is largely based on homology to the F-1-ATPase, amino acid 82 is located near the top of the hexamer, and amino acid 325 is located on a solvent-accessible loop in the center of the hexamer. These data are consistent with binding of the rut region of RNA around the crown, with its 3'-segment passing through the center of the Rho hexamer.	Indiana Univ, Dept Chem, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Richardson, JP (corresponding author), Indiana Univ, Dept Chem, 800 E Kirkwood Ave, Bloomington, IN 47405 USA.	richardj@indiana.edu			NIGMS NIH HHS [GM 56095] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Allison TJ, 1998, NAT STRUCT BIOL, V5, P352, DOI 10.1038/nsb0598-352; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BEAR DG, 1985, P NATL ACAD SCI USA, V82, P1911, DOI 10.1073/pnas.82.7.1911; Bird LE, 1998, CURR OPIN STRUC BIOL, V8, P14, DOI 10.1016/S0959-440X(98)80004-3; Bogden CE, 1999, MOL CELL, V3, P487, DOI 10.1016/S1097-2765(00)80476-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; DOLAN JW, 1990, J BIOL CHEM, V265, P5747; DOMBROSKI AJ, 1988, P NATL ACAD SCI USA, V85, P2538, DOI 10.1073/pnas.85.8.2538; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FINGER LR, 1982, J MOL BIOL, V156, P203, DOI 10.1016/0022-2836(82)90467-3; GALLUPPI GR, 1980, J MOL BIOL, V138, P513, DOI 10.1016/S0022-2836(80)80016-7; Gan E, 1999, BIOCHEMISTRY-US, V38, P16882, DOI 10.1021/bi991559i; GEISELMANN J, 1992, BIOCHEMISTRY-US, V31, P111, DOI 10.1021/bi00116a017; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; Jezewska MJ, 1998, J BIOL CHEM, V273, P10515, DOI 10.1074/jbc.273.17.10515; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Martinez A, 1996, J MOL BIOL, V257, P895, DOI 10.1006/jmbi.1996.0210; Martinez A, 1996, J MOL BIOL, V257, P909, DOI 10.1006/jmbi.1996.0211; MIWA Y, 1995, J MOL BIOL, V254, P815, DOI 10.1006/jmbi.1995.0658; Nowatzke W, 1996, METHOD ENZYMOL, V274, P353; Nowatzke WL, 1996, J BIOL CHEM, V271, P742, DOI 10.1074/jbc.271.2.742; ODA T, 1972, J MOL BIOL, V71, P799; OPPERMAN T, 1994, J BACTERIOL, V176, P5033, DOI 10.1128/jb.176.16.5033-5043.1994; PEREIRA S, 1995, J MOL BIOL, V251, P30, DOI 10.1006/jmbi.1995.0413; Riba I, 1998, J BIOL CHEM, V273, P34033, DOI 10.1074/jbc.273.51.34033; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; RICHARDSON JP, 1986, J MOL BIOL, V189, P413, DOI 10.1016/0022-2836(86)90313-X; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5760; Richardson JP, 1996, J BIOL CHEM, V271, P1251, DOI 10.1074/jbc.271.3.1251; RICHARDSON JP, 1982, J BIOL CHEM, V257, P5767; RICHARDSON LV, 1992, GENE, V118, P103, DOI 10.1016/0378-1119(92)90255-N; Richardson LV, 1996, J BIOL CHEM, V271, P21597, DOI 10.1074/jbc.271.35.21597; ROBERTS JW, 1969, NATURE, V224, P1168, DOI 10.1038/2241168a0; Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7; STITT BL, 1988, J BIOL CHEM, V263, P11130; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; Walstrom KM, 1997, BIOCHEMISTRY-US, V36, P7993, DOI 10.1021/bi963180r; West SC, 1996, CELL, V86, P177, DOI 10.1016/S0092-8674(00)80088-4; WOOD TC, 1999, THESIS U VIRGINIA; Yu X, 2000, J MOL BIOL, V299, P1279, DOI 10.1006/jmbi.2000.3810; Yu X, 1997, NAT STRUCT BIOL, V4, P101, DOI 10.1038/nsb0297-101	45	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4182	4189		10.1074/jbc.M007066200	http://dx.doi.org/10.1074/jbc.M007066200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11071888	hybrid			2022-12-25	WOS:000166921200061
J	Creemers, JWM; Dominguez, DI; Plets, E; Serneels, L; Taylor, NA; Multhaup, G; Craessaerts, K; Annaert, W; De Strooper, D				Creemers, JWM; Dominguez, DI; Plets, E; Serneels, L; Taylor, NA; Multhaup, G; Craessaerts, K; Annaert, W; De Strooper, D			Processing of beta-secretase by furin and other members of the proprotein convertase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; CLEAVAGE; SITE; PURIFICATION; INHIBITORS; PORTLAND; GENE	The amyloid plaques in brain of Alzheimer's disease patients. This peptide is generated from the amyloid precursor protein by two consecutive cleavages. Cleavage at the N terminus is performed by the recently discovered beta -secretase (Bace). This aspartyl protease contains a propeptide that has to be removed to obtain mature Bace. Furin and other members of the furin family of prohormone convertases are involved in this process. Surprisingly, beta -secretase activity, neither at the classical Asp(1) position nor at the Glu(11) position of amyloid precursor protein, seems to be controlled by this maturation step. Furthermore, we show that Glu(11) cleavage is a function of the expression level of Bace, that it depends on the membrane anchorage of Bace, and that Asp(1) cleavage can be followed by Glu(11) cleavage. Our data suggest that pro-Bace could be active as a beta -secretase in the early biosynthetic compartments of the cell and could be involved in the generation of the intracellular pool of the amyloid peptide. We conclude that modulation of the conversion of pro-Bace to mature Bace is not a relevant drug target to treat Alzheimer's disease.	Katholieke Univ Leuven, Neuronal Cell Biol Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, Mol Oncol Lab, Ctr Human Genet, B-3000 Louvain, Belgium; Flemish Interuniv Inst Biotechnol, B-3000 Louvain, Belgium; Heidelberg Univ, ZMBH, D-6900 Heidelberg, Germany	KU Leuven; KU Leuven; Ruprecht Karls University Heidelberg	De Strooper, D (corresponding author), Katholieke Univ Leuven, Neuronal Cell Biol Lab, B-3000 Louvain, Belgium.	Bart.Destrooper@med.kuleuven.ac.be	De Strooper, Bart/F-6507-2012; de+Strooper, Bart/Z-1638-2019	De Strooper, Bart/0000-0001-5455-5819; Serneels, Lutgarde/0000-0002-5463-4231; Plets, Evelyn/0000-0001-7312-8804				Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; Bennett BD, 2000, J BIOL CHEM, V275, P37712, DOI 10.1074/jbc.M005339200; BUXBAUM JD, 1993, P NATL ACAD SCI USA, V90, P9195, DOI 10.1073/pnas.90.19.9195; Capell A, 2000, J BIOL CHEM, V275, P30849, DOI 10.1074/jbc.M003202200; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DeStrooper B, 1995, J BIOL CHEM, V270, P30310, DOI 10.1074/jbc.270.51.30310; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Haniu M, 2000, J BIOL CHEM, V275, P21099, DOI 10.1074/jbc.M002095200; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; PLOEGH HL, 1995, CURRENT PROTOCOLS PR; Savage MJ, 1998, J NEUROSCI, V18, P1743; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Simons M, 1996, J NEUROSCI, V16, P899; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Thinakaran G, 1996, J BIOL CHEM, V271, P9390, DOI 10.1074/jbc.271.16.9390; Tienari PJ, 1997, P NATL ACAD SCI USA, V94, P4125, DOI 10.1073/pnas.94.8.4125; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; Vidal R, 1999, NATURE, V399, P776; WildBode C, 1997, J BIOL CHEM, V272, P16085, DOI 10.1074/jbc.272.26.16085; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107	37	162	174	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4211	4217		10.1074/jbc.M006947200	http://dx.doi.org/10.1074/jbc.M006947200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11071887	hybrid			2022-12-25	WOS:000166921200065
J	Gao, XD; Nishikawa, A; Dean, N				Gao, XD; Nishikawa, A; Dean, N			Identification of a conserved motif in the yeast Golgi GDP-mannose transporter required for binding to nucleotide sugar	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-GALACTOSE TRANSPORTER; SIALIC ACID TRANSPORTER; BETA-GLUCAN SYNTHESIS; SACCHAROMYCES-CEREVISIAE; POLYSACCHARIDE BIOSYNTHESIS; MOLECULAR CHARACTERIZATION; ENDOPLASMIC-RETICULUM; VRG4 GENE; IN-VIVO; APPARATUS	Glycoproteins and lipids in the Golgi complex are modified by the addition of sugars. In the yeast Saccharomyces cerevisiae, these terminal Golgi carbohydrate modifications primarily involve mannose additions that utilize GDP-mannose as the substrate. The transport of GDP-mannose from its site of synthesis in the cytosol into the lumen of the Golgi is mediated by the VRG4 gene product, a nucleotide sugar transporter that is a member of a large family of related membrane proteins. Loss of VRG4 function leads to lethality, but several viable vrg4 mutants were isolated whose GDP-mannose transport activity was reduced but not obliterated. Mutations in these alleles mapped to a region of the Vrg4 protein that is highly conserved among other GDP-mannose transporters but not other types of nucleotide sugar transporters. Here, we present evidence that suggest an involvement of this region of the protein in binding GDP-mannose. Most of the mutations that mere introduced within this conserved domain, spanning amino acids 280-291 of Vrg4p, lead to lethality, and none interfere with Vrg4 protein stability, localization, or dimer formation. The null phenotype of these mutant vrg4 alleles can be complemented by their overexpression. Vesicles prepared from vrg4 mutant strains were reduced in luminal GDP-mannose transport activity, but this effect could be suppressed by increasing the concentration of GDP-mannose in vitro. Thus, either an increased substrate concentration, in vitro, or an increased Vrg4 protein concentration In vivo, can suppress these vrg4 mutant phenotypes. Vrg4 proteins with alterations in this region were reduced in binding to guanosine 5'[-gamma-P-32]triphosphate gamma -azidoanilide, a photoaffinity substrate analogue whose binding to Vrg4-HAp was specifically inhibited by GDP-mannose. Taken together, these data are consistent with the model that amino acids in this region of the yeast GDP-mannose transporter mediate the recognition of or binding to nucleotide sugar prior to its transport into the Golgi.	SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Dean, N (corresponding author), SUNY Stony Brook, Inst Cell & Dev Biol, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	Neta.Dean@sunysb.edu			NIGMS NIH HHS [GM48467] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048467] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe M, 1999, FEBS LETT, V458, P309, DOI 10.1016/S0014-5793(99)01177-1; Abeijon C, 1996, J BIOL CHEM, V271, P8851, DOI 10.1074/jbc.271.15.8851; Abeijon C, 1998, MOL BIOL CELL, V9, P2729, DOI 10.1091/mbc.9.10.2729; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aoki K, 1999, J BIOCHEM, V126, P940, DOI 10.1093/oxfordjournals.jbchem.a022538; CAPASSO JM, 1984, BIOCHIM BIOPHYS ACTA, V777, P133, DOI 10.1016/0005-2736(84)90505-4; Castro O, 1999, MOL BIOL CELL, V10, P1019, DOI 10.1091/mbc.10.4.1019; Chi JH, 1996, J BIOL CHEM, V271, P3132, DOI 10.1074/jbc.271.6.3132; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; Dean N, 1997, J BIOL CHEM, V272, P31908, DOI 10.1074/jbc.272.50.31908; DEAN N, 1995, P NATL ACAD SCI USA, V92, P1287, DOI 10.1073/pnas.92.5.1287; DESCOTEAUX A, 1995, SCIENCE, V269, P1869, DOI 10.1126/science.7569927; Eckhardt M, 1998, J BIOL CHEM, V273, P20189, DOI 10.1074/jbc.273.32.20189; Edwards ME, 1999, PLANT J, V19, P691, DOI 10.1046/j.1365-313x.1999.00566.x; Gao XD, 1999, J BIOL CHEM, V274, P21450, DOI 10.1074/jbc.274.30.21450; Gao XD, 2000, J BIOL CHEM, V275, P17718, DOI 10.1074/jbc.M909946199; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Hirschberg CB, 1998, ANNU REV BIOCHEM, V67, P49, DOI 10.1146/annurev.biochem.67.1.49; Hong KJ, 2000, BIOCHEMISTRY-US, V39, P2013, DOI 10.1021/bi992363l; KANIKENNULAT C, 1995, GENETICS, V140, P933; Kawakita M, 1998, J BIOCHEM, V123, P777; Ma DQ, 1997, J BIOL CHEM, V272, P3799, DOI 10.1074/jbc.272.6.3799; Machida M, 1996, CURR GENET, V30, P423, DOI 10.1007/s002940050152; Miera N, 1996, J BIOCHEM-TOKYO, V120, P236; Munoz P, 1996, PLANT PHYSIOL, V112, P1585, DOI 10.1104/pp.112.4.1585; Neckelmann G, 1998, PLANT PHYSIOL, V117, P1007, DOI 10.1104/pp.117.3.1007; Poster JB, 1996, J BIOL CHEM, V271, P3837; Puglielli L, 1999, J BIOL CHEM, V274, P35596, DOI 10.1074/jbc.274.50.35596; ROEMER T, 1994, J CELL BIOL, V127, P567, DOI 10.1083/jcb.127.2.567; ROEMER T, 1993, MOL CELL BIOL, V13, P4039, DOI 10.1128/MCB.13.7.4039; ROEMER T, 1991, P NATL ACAD SCI USA, V88, P11295, DOI 10.1073/pnas.88.24.11295; Roy SK, 1998, J BIOL CHEM, V273, P2583, DOI 10.1074/jbc.273.5.2583; Roy SK, 2000, J BIOL CHEM, V275, P13580, DOI 10.1074/jbc.275.18.13580; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SIKORSKI RS, 1989, GENETICS, V122, P19; WHITE AR, 1993, BIOCHEM J, V294, P231, DOI 10.1042/bj2940231; Wulff C, 2000, PLANT PHYSIOL, V122, P867, DOI 10.1104/pp.122.3.867; ZHANG GF, 1992, PLANT PHYSIOL, V99, P1070, DOI 10.1104/pp.99.3.1070	38	37	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4424	4432		10.1074/jbc.M009114200	http://dx.doi.org/10.1074/jbc.M009114200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11067855	hybrid			2022-12-25	WOS:000166921200092
J	Li, XH; Fang, XQ; Gaynor, RB				Li, XH; Fang, XQ; Gaynor, RB			Role of IKK gamma/NEMO in assembly of the I kappa B kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-VIRUS TYPE-1; SITE-SPECIFIC PHOSPHORYLATION; TUMOR-NECROSIS-FACTOR; TAX PROTEIN; ALPHA PROTEOLYSIS; UBIQUITIN LIGASE; ACTIVATION; BETA; SIGNAL; IDENTIFICATION	IKK gamma /NEMO is a protein that is critical for the assembly of the high molecular weight I kappaB kinase (IKK) complex. To investigate the role of IKK gamma /NEMO in the assembly of the IKK complex, we conducted a series of experiments in which the chromatographic distribution of extracts prepared from cells transiently expressing epitope-tagged IKK gamma /NEMO and the IKKs were examined. When expressed alone following transfection, IKK alpha and IKK beta were present in low molecular weight complexes migrating between 200 and 400 kDa. However, when coexpressed with IKK gamma /NEMO, both IKK alpha and IKK beta migrated at similar to 600 kDa which was similar to the previously described IKK complex that is activated by cytokines such as tumor necrosis factor-alpha. When either IKK alpha or IKK beta was expressed alone with IKK gamma /NEMO, IKK beta but not IKK alpha: migrated in the higher molecular weight IKK complex. Constitutively active or inactive forms of IKK beta were both incorporated into the high molecular weight IKK complex in the presence of IKK gamma /NEMO. The amino-terminal region of IKK gamma /NEMO, which interacts directly with IKK beta, was required for formation of the high molecular weight IKK complex and for stimulation of IKK beta kinase activity. These results suggest that recruitment of the IKKs into a high molecular complex by IKK gamma /NEMO is a crucial step involved in IKK function.	Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Gaynor, RB (corresponding author), Univ Texas, SW Med Ctr, Dept Med, Div Hematol Oncol,Harold Simmons Canc Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.				NATIONAL CANCER INSTITUTE [R01CA074128] Funding Source: NIH RePORTER; NCI NIH HHS [CA74128] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, INT J BIOCHEM CELL B, V29, P867, DOI 10.1016/S1357-2725(96)00159-8; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Courtois G, 1997, MOL CELL BIOL, V17, P1441, DOI 10.1128/MCB.17.3.1441; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Inohara N, 2000, J BIOL CHEM, V275, P27823; Jin DY, 1999, J BIOL CHEM, V274, P17402, DOI 10.1074/jbc.274.25.17402; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 1999, GENE EXPRESSION, V7, P233; Li XH, 1999, J BIOL CHEM, V274, P34417, DOI 10.1074/jbc.274.48.34417; Li XH, 2000, AIDS RES HUM RETROV, V16, P1583, DOI 10.1089/08892220050192994; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakano H, 1998, P NATL ACAD SCI USA, V95, P3537, DOI 10.1073/pnas.95.7.3537; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Smahi A, 2000, NATURE, V405, P466; Spencer E, 1999, GENE DEV, V13, P284, DOI 10.1101/gad.13.3.284; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; WHITESIDE ST, 1995, MOL CELL BIOL, V15, P5339; Winston JT, 1999, GENE DEV, V13, P270, DOI 10.1101/gad.13.3.270; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yin MJ, 1998, CELL, V93, P875, DOI 10.1016/S0092-8674(00)81447-6; YIN MJ, 1995, J VIROL, V69, P6209, DOI 10.1128/JVI.69.10.6209-6218.1995; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	58	63	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4494	4500		10.1074/jbc.M008353200	http://dx.doi.org/10.1074/jbc.M008353200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11080499	hybrid			2022-12-25	WOS:000166921200101
J	Nourbakhsh, M; Kalble, S; Dorrie, A; Hauser, H; Resch, K; Kracht, M				Nourbakhsh, M; Kalble, S; Dorrie, A; Hauser, H; Resch, K; Kracht, M			The NF-kappa B repressing factor is involved in basal repression and interleukin (IL)-1-induced activation of IL-8 transcription by binding to a conserved NF-kappa B-flanking sequence element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PROTEIN-KINASE PATHWAYS; GENE-EXPRESSION; CELL-LINE; DEPENDENT TRANSCRIPTION; EPITHELIAL-CELLS; MAMMALIAN-CELLS; P65; PHOSPHORYLATION; CYTOKINE	Interleukin (IL)-8, a prototypic chemokine, is rapidly induced by the pro-inflammatory cytokine IL-1 but is barely detectable in noninduced cells. Although there is clear evidence that the transcription factor NF-kappaB plays a central role in inducible IL-8 transcription, very little is known about the cis-elements and trans-acting factors involved in silencing of the IL-8 promoter. By sequence comparison with the interferon-beta promoter, we found a negative regulatory element (NRE) in the IL-g promoter overlapping partially with the NF-kappaB response element. Here we show that an NF-kappaB-repressing factor (NRF) binds to the IL-8 promoter NF-kappaB-NRE. Reduction of cellular NRF by expressing NRF antisense RNA results in spontaneous IL-8 gene expression. In contrast, IL-1-induced IL-8 secretion is strongly impaired by expressing NRF antisense RNA. Mutation of the NRE site results in loss of NRF binding and increased basal IL-8 transcription. On the other hand IL-I-induced IL-8 transcription is decreased by mutating the NRE, These data provide evidence for a dual role of the NRF in IL-8 transcription. Although in the absence of stimulation it is involved in transcriptional silencing, in IL-l-induced cells it is required for full induction of the IL-8 promoter.	Hannover Med Sch, Inst Pharmacol, D-30625 Hannover, Germany; GBF Natl Res Inst Biotechnol, Dept Gene Regulat & Differentiat, D-38124 Braunschweig, Germany	Hannover Medical School; Helmholtz Association; Helmholtz-Center for Infection Research	Kracht, M (corresponding author), Hannover Med Sch, Inst Pharmacol, Carl Neuberg Str 1, D-30625 Hannover, Germany.		Nourbakhsh, Mahtab/U-8818-2019	Nourbakhsh, Mahtab/0000-0003-4102-0748; Kracht, Michael/0000-0002-8501-043X; Nourbakhsh, Mahtab/0000-0003-0918-1736				Aihara M, 1997, INFECT IMMUN, V65, P3218, DOI 10.1128/IAI.65.8.3218-3224.1997; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; Casola A, 2000, J IMMUNOL, V164, P5944, DOI 10.4049/jimmunol.164.11.5944; CAVIGELLI M, 1995, EMBO J, V14, P5957, DOI 10.1002/j.1460-2075.1995.tb00284.x; Chen YQ, 1998, NAT STRUCT BIOL, V5, P67, DOI 10.1038/nsb0198-67; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; DeBosscher K, 1997, P NATL ACAD SCI USA, V94, P13504, DOI 10.1073/pnas.94.25.13504; DEFORGE LE, 1993, J BIOL CHEM, V268, P25568; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Finch A, 1997, FEBS LETT, V418, P144, DOI 10.1016/S0014-5793(97)01364-1; Gerritsen ME, 1997, P NATL ACAD SCI USA, V94, P2927, DOI 10.1073/pnas.94.7.2927; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Guan ZH, 1998, J BIOL CHEM, V273, P12901, DOI 10.1074/jbc.273.21.12901; Heyninck K, 1999, J CELL BIOL, V145, P1471, DOI 10.1083/jcb.145.7.1471; Hobbie S, 1997, J IMMUNOL, V159, P5550; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Kannabiran C, 1997, MOL CELL BIOL, V17, P1, DOI 10.1128/MCB.17.1.1; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; KASAHARA T, 1991, IMMUNOLOGY, V74, P60; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lee LF, 1997, MOL CELL BIOL, V17, P5097, DOI 10.1128/MCB.17.9.5097; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Mastronarde JG, 1998, J INFECT DIS, V177, P1275, DOI 10.1086/515279; Merika M, 1998, MOL CELL, V1, P277, DOI 10.1016/S1097-2765(00)80028-3; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554, DOI 10.1002/jlb.56.5.554; Murayama T, 1997, J VIROL, V71, P5692, DOI 10.1128/JVI.71.7.5692-5695.1997; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Nemoto S, 1998, MOL CELL BIOL, V18, P7336, DOI 10.1128/MCB.18.12.7336; NINOMIYATSUJI J, 1999, NATURE, V398; NOURBAKHSH M, 1993, EMBO J, V12, P451, DOI 10.1002/j.1460-2075.1993.tb05677.x; Nourbakhsh M, 1997, IMMUNOBIOLOGY, V198, P65, DOI 10.1016/S0171-2985(97)80027-7; Nourbakhsh M, 1999, EMBO J, V18, P6415, DOI 10.1093/emboj/18.22.6415; OLIVEIRA IC, 1994, MOL CELL BIOL, V14, P5300, DOI 10.1128/MCB.14.8.5300; Oswald F, 1998, MOL CELL BIOL, V18, P2077, DOI 10.1128/MCB.18.4.2077; Plaisance S, 1997, MOL CELL BIOL, V17, P3733, DOI 10.1128/MCB.17.7.3733; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; SCHMITZ ML, 1995, J BIOL CHEM, V270, P7219, DOI 10.1074/jbc.270.13.7219; SCHMITZ ML, 1995, J BIOL CHEM, V270, P15576, DOI 10.1074/jbc.270.26.15576; Shapiro L, 1995, P NATL ACAD SCI USA, V92, P12230, DOI 10.1073/pnas.92.26.12230; Sonoda Y, 1997, J BIOL CHEM, V272, P15366, DOI 10.1074/jbc.272.24.15366; STEIN B, 1993, MOL CELL BIOL, V13, P7191, DOI 10.1128/MCB.13.11.7191; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1995, MOL CELL BIOL, V15, P4971; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wu GD, 1997, J BIOL CHEM, V272, P2396; YAN MH, 1994, NATURE, V372, P798; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	65	105	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4501	4508		10.1074/jbc.M007532200	http://dx.doi.org/10.1074/jbc.M007532200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11071890	hybrid			2022-12-25	WOS:000166921200102
J	Pradhan, D; Lombardo, CR; Roe, S; Rimm, DL; Morrow, JS				Pradhan, D; Lombardo, CR; Roe, S; Rimm, DL; Morrow, JS			alpha-Catenin binds directly to spectrin and facilitates spectrin-membrane assembly in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; BETA-CATENIN; GOLGI-COMPLEX; E-CADHERIN; ANKYRIN BINDS; REAL-TIME; PROTEIN; CYTOSKELETON; SITE; LOCALIZATION	The anchorage of spectrin to biological membranes is mediated by protein and phosphoinositol phospholipid interactions. In epithelial cells, a nascent spectrin skeleton assembles in regions of cadherin-mediated cell-cell contact, and conversely, cytoskeletal assembly is required to complete the cell-adhesion process. The molecular interactions guiding these processes remain incompletely understood. We have examined the interaction of spectrin with alpha -catenin, a component of the adhesion complex. Spectrin (alpha II beta II) and alpha -catenin co-precipitate from extracts of confluent Madin-Darby canine kidney, HT29, and Clone A cells and from solutions of purified spectrin and alpha -catenin in vitro, By surface plasmon resonance and in vitro binding assays, we find that alpha -catenin binds alpha II beta II spectrin with an apparent K-d of approximate to 20-100 nM. By gel-overlay assay, alpha -catenin binds recombinant beta II-spectrin peptides that include the first 313 residues of spectrin but not to peptides that lack this region. Similarly, the binding activity of alpha -catenin is fully accounted for in recombinant peptides encompassing the NH2-terminal 228 amino acid region of alpha -catenin. An in vivo role for the interaction of spectrin with alpha -catenin is suggested by the impaired membrane assembly of spectrin and its enhanced detergent solubility in Clone A cells that harbor a defective alpha -catenin. Transfection of these cells with wild-type alpha -catenin reestablishes alpha -catenin at the plasma membrane and coincidentally recruits spectrin to the membrane. We propose that ankyrin-independent interactions of modest affinity between alpha -catenin and the amino-terminal domain of beta -spectrin augment the interaction between alpha -catenin and actin, and together they provide a polyvalent linkage directing the topographic assembly of a nascent spectrin-actin skeleton to membrane regions enriched in E-cadherin.	Yale Univ, Dept Pathol, New Haven, CT 06510 USA	Yale University	Morrow, JS (corresponding author), Yale Univ, Dept Pathol, 310 Cedar St, New Haven, CT 06510 USA.	jon.morrow@yale.edu	Pradhan, Debabrata/W-5476-2019	Pradhan, Debabrata/0000-0003-4995-6882; Rimm, David/0000-0001-5820-4397				BENNETT V, 1986, METHOD ENZYMOL, V134, P55; Bouley M, 2000, J NEUROSCI, V20, P4515, DOI 10.1523/JNEUROSCI.20-12-04515.2000; BREEN E, 1993, CELL ADHES COMMUN, V1, P239, DOI 10.3109/15419069309097257; Canziani G, 1999, METHODS, V19, P253, DOI 10.1006/meth.1999.0855; DAVIS JQ, 1994, J BIOL CHEM, V269, P27163; DAVIS LH, 1994, J BIOL CHEM, V269, P4409; DAVIS LH, 1991, J BIOL CHEM, V266, P11163; De Matteis MA, 2000, J CELL SCI, V113, P2331; Devarajan P, 1997, P NATL ACAD SCI USA, V94, P10711, DOI 10.1073/pnas.94.20.10711; Devarajan P, 1996, J CELL BIOL, V133, P819, DOI 10.1083/jcb.133.4.819; DEVARAJAN P, 1994, P NATL ACAD SCI USA, V91, P2965, DOI 10.1073/pnas.91.8.2965; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Dubreuil RR, 1998, BIOESSAYS, V20, P875, DOI 10.1002/(SICI)1521-1878(199811)20:11&lt;875::AID-BIES1&gt;3.0.CO;2-P; Dubreuil RR, 1999, BIOCHEM BIOPH RES CO, V265, P372, DOI 10.1006/bbrc.1999.1689; Dubreuil RR, 1996, J CELL BIOL, V133, P647, DOI 10.1083/jcb.133.3.647; FURUKAWA Y, 1994, CYTOGENET CELL GENET, V65, P74, DOI 10.1159/000133603; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; Godi A, 1998, P NATL ACAD SCI USA, V95, P8607, DOI 10.1073/pnas.95.15.8607; GUMBINER BM, 1993, J CELL SCI, P155; HULSKEN J, 1994, J CELL BIOL, V127, P2061, DOI 10.1083/jcb.127.6.2061; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KENNEDY SP, 1991, J CELL BIOL, V115, P267, DOI 10.1083/jcb.115.1.267; Koslov ER, 1997, J BIOL CHEM, V272, P27301, DOI 10.1074/jbc.272.43.27301; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LI ZP, 1993, J BIOL CHEM, V268, P11489; LOMBARDO CR, 1994, J BIOL CHEM, V269, P29212; LOMBARDO CR, 1992, J BIOL CHEM, V267, P9540; LUNA EJ, 1992, SCIENCE, V258, P955, DOI 10.1126/science.1439807; MCNEILL H, 1993, J CELL BIOL, V120, P1217, DOI 10.1083/jcb.120.5.1217; MORROW JS, 1997, HDB PHYSIOL 14, P485; Nieset JE, 1997, J CELL SCI, V110, P1013; Panayotou G, 1998, METH MOL B, V88, P1; Parra M, 2000, J BIOL CHEM, V275, P3247, DOI 10.1074/jbc.275.5.3247; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; Piepenhagen PA, 1998, MOL BIOL CELL, V9, P3161, DOI 10.1091/mbc.9.11.3161; Provost E, 1999, CURR OPIN CELL BIOL, V11, P567, DOI 10.1016/S0955-0674(99)00015-0; RIMM DL, 1994, BIOCHEM BIOPH RES CO, V203, P1691, DOI 10.1006/bbrc.1994.2381; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Roe S, 1998, CELL ADHES COMMUN, V5, P283, DOI 10.3109/15419069809040298; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SRINIVASAN Y, 1992, J BIOL CHEM, V267, P7483; STEINER JP, 1989, J BIOL CHEM, V264, P2783; WILLARDSON BM, 1989, J BIOL CHEM, V264, P15893; Zhang ZS, 1998, J BIOL CHEM, V273, P18681, DOI 10.1074/jbc.273.30.18681; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020	47	53	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4175	4181		10.1074/jbc.M009259200	http://dx.doi.org/10.1074/jbc.M009259200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11069925	hybrid			2022-12-25	WOS:000166921200060
J	Stafford, JM; Waltner-Law, M; Granner, DK				Stafford, JM; Waltner-Law, M; Granner, DK			Role of accessory factors and steroid receptor coactivator 1 in the regulation of phosphoenolpyruvate carboxykinase gene transcription by glucocorticoids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-KINASE GENE; ELEMENT-BINDING PROTEIN; ACID RESPONSE ELEMENT; RETINOIC ACID; NUCLEAR RECEPTOR; MOLECULAR PHYSIOLOGY; ESTROGEN-RECEPTOR; DNA-BINDING; YOUNG MODY1; CYCLIC-AMP	In the liver, glucocorticoids induce a 10-15-fold increase in the rate of transcription of the phosphoenol-pyruvate carboxykinase (PEPCK) gene, which encodes a key gluconeogenic enzyme. This induction requires a multicomponent glucocorticoid response unit (GRU) comprised of four glucocorticoid accessory factor (AF) elements and two glucocorticoid receptor binding sites. We show that the AFs that bind the gAF1, gAF2, and gAF3 elements (hepatocyte nuclear factor [HNF]4/chicken ovalbumin upstream promoter transcription factor 1 and HNF3 beta) all interact with steroid receptor coactivator 1 (SRC1). This suggests that the AFs function in part by recruiting coactivators to the GRU. The binding of a GAL4-SRC1 chimeric protein completely restores the glucocorticoid induction that is lost when any one of these elements is replaced with a GAL4 binding site. Thus, when SRC1 is recruited directly to gAF1, gAF2, or gAF3, the requirement for the corresponding AF is bypassed. Surprisingly, glucocorticoid receptor is still required when SRC1 is recruited directly to the GAL4 site, suggesting a role for the receptor in activating SRC1 in the context of the GRU, Structural variants of GAT4-SRC1 were used to identify requirements for the basic-helix-loop-helix and histone acetyltransferase domains of SRC1, and these are specific to the region of the promoter to which the coactivator is recruited.	Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; Nashville Vet Adm Hosp, Nashville, TN 37232 USA	Vanderbilt University	Granner, DK (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, 707 Light Hall, Nashville, TN 37232 USA.		Stafford, John/K-7763-2017	Stafford, John/0000-0001-6527-959X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, R37DK035107, R01DK035107] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20593, DK35107] Funding Source: Medline; NIGMS NIH HHS [GM07347] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERGOT MO, 1992, NUCLEIC ACIDS RES, V20, P1871, DOI 10.1093/nar/20.8.1871; CHANDLER VL, 1983, CELL, V33, P489, DOI 10.1016/0092-8674(83)90430-0; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; FABER S, 1993, J BIOL CHEM, V268, P24976; FRANCKHAUSER S, 1994, CELL MOL BIOL, V40, P723; FranckhauserVogel S, 1997, J CELL BIOCHEM, V66, P386, DOI 10.1002/(SICI)1097-4644(19970901)66:3<386::AID-JCB10>3.0.CO;2-D; FRIEDMAN JE, 1993, J BIOL CHEM, V268, P12952; Fu MF, 2000, J BIOL CHEM, V275, P20853, DOI 10.1074/jbc.M000660200; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; Gourdon L, 1999, FEBS LETT, V459, P9, DOI 10.1016/S0014-5793(99)01203-X; GRANNER D, 1990, J BIOL CHEM, V265, P10173; GRANNER DK, 1992, DIABETES CARE, V15, P369, DOI 10.2337/diacare.15.3.369; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUERRA MJMD, 1993, MOL CELL BIOL, V13, P7725, DOI 10.1128/MCB.13.12.7725; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Ikuta T, 1998, J BIOL CHEM, V273, P2895, DOI 10.1074/jbc.273.5.2895; IMAI E, 1993, J BIOL CHEM, V268, P5353; IMAI E, 1990, MOL CELL BIOL, V10, P4712, DOI 10.1128/MCB.10.9.4712; IP YT, 1989, MOL CELL BIOL, V9, P1289, DOI 10.1128/MCB.9.3.1289; Jenster G, 1997, P NATL ACAD SCI USA, V94, P7879, DOI 10.1073/pnas.94.15.7879; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; Long CNH, 1936, J EXP MED, V63, P465, DOI 10.1084/jem.63.4.465; LUCAS PC, 1992, ANNU REV BIOCHEM, V61, P1131; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McInerney EM, 1996, P NATL ACAD SCI USA, V93, P10069, DOI 10.1073/pnas.93.19.10069; MITCHELL J, 1994, MOL ENDOCRINOL, V8, P585, DOI 10.1210/me.8.5.585; Moriizumi S, 1998, GENE EXPRESSION, V7, P103; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; OSBORNE TF, 1988, J BIOL CHEM, V263, P3380; PETERSEN DD, 1988, MOL CELL BIOL, V8, P96, DOI 10.1128/MCB.8.1.96; PILKIS SJ, 1992, ANNU REV PHYSIOL, V54, P885, DOI 10.1146/annurev.ph.54.030192.004321; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; ROUX J, 1995, DNA CELL BIOL, V14, P385, DOI 10.1089/dna.1995.14.385; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Scott DK, 1998, MOL ENDOCRINOL, V12, P482, DOI 10.1210/me.12.4.482; Scott DK, 1996, J BIOL CHEM, V271, P6260, DOI 10.1074/jbc.271.11.6260; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Soutoglou E, 2000, J BIOL CHEM, V275, P12515, DOI 10.1074/jbc.275.17.12515; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Stoffel M, 1997, P NATL ACAD SCI USA, V94, P13209, DOI 10.1073/pnas.94.24.13209; Sugiyama T, 1998, MOL ENDOCRINOL, V12, P1487, DOI 10.1210/me.12.10.1487; Sugiyama T, 2000, J BIOL CHEM, V275, P3446, DOI 10.1074/jbc.275.5.3446; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Vallett SM, 1996, J BIOL CHEM, V271, P12247, DOI 10.1074/jbc.271.21.12247; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; Wang JC, 1999, MOL ENDOCRINOL, V13, P604, DOI 10.1210/me.13.4.604; Wang JC, 1998, J BIOL CHEM, V273, P30847, DOI 10.1074/jbc.273.47.30847; Wang JC, 1996, MOL ENDOCRINOL, V10, P794, DOI 10.1210/me.10.7.794; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yamada K, 1999, J BIOL CHEM, V274, P5880, DOI 10.1074/jbc.274.9.5880; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; YIEH L, 1995, P NATL ACAD SCI USA, V92, P6102, DOI 10.1073/pnas.92.13.6102; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871; Zimmermann PL, 1997, DNA CELL BIOL, V16, P713, DOI 10.1089/dna.1997.16.713	69	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3811	3819		10.1074/jbc.M009389200	http://dx.doi.org/10.1074/jbc.M009389200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11069927	hybrid			2022-12-25	WOS:000166921200014
J	Gunjan, A; Sittman, DB; Brown, DT				Gunjan, A; Sittman, DB; Brown, DT			Core histone acetylation is regulated by linker histone stoichiometry in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-BINDING; RIBOSOMAL-RNA GENE; IN-VIVO; CHROMATIN STRUCTURE; MMTV PROMOTER; ACETYLTRANSFERASE ACTIVITY; NUCLEOSOME MOBILITY; H1; REPRESSION; ACTIVATION	We investigated the relationship between linker histone stoichiometry and the acetylation of core histones in vivo. Exponentially growing cell lines induced to overproduce either of two H1 variants, H1(0) or H1c, displayed significantly reduced rates of incorporation of [H-3]acetate into all four core histones. Pulse-chase experiments indicated that the rates of histone deacetylation were similar in all cell lines. These effects were also observed in nuclei isolated from these cells upon labeling with [H-3]acetyl-CoA. Nuclear extracts prepared from control and H1-overexpressing cell lines displayed similar levels of histone acetylation activity on chromatin templates prepared from control cells, In contrast, extracts prepared from control cells were significantly less active on chromatin templates prepared from H1-overexpressing cells than on templates prepared from control cells. Reduced levels of acetylation in H1-overproducing cell lines do not appear to depend on higher order chromatin structure, because it persists even after digestion of the chromatin with micrococcal nuclease, The results suggest that alterations in chromatin structure, resulting from changes in linker histone stoichiometry may modulate the levels or rates of core histone acetylation in vivo.	Univ Mississippi, Med Ctr, Dept Biochem, Jackson, MS 39216 USA	University of Mississippi; University of Mississippi Medical Center	Brown, DT (corresponding author), Univ Mississippi, Med Ctr, Dept Biochem, 2500 N State St, Jackson, MS 39216 USA.							ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; BATES DL, 1981, NUCLEIC ACIDS RES, V9, P5883, DOI 10.1093/nar/9.22.5883; BELIKOFF E, 1980, J BIOL CHEM, V255, P1448; Berger SL, 1999, CURR OPIN CELL BIOL, V11, P336, DOI 10.1016/S0955-0674(99)80046-5; BOUVET P, 1994, GENE DEV, V8, P1147, DOI 10.1101/gad.8.10.1147; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; Brown DT, 1996, NUCLEIC ACIDS RES, V24, P486, DOI 10.1093/nar/24.3.486; Brown DT, 1997, NUCLEIC ACIDS RES, V25, P5003, DOI 10.1093/nar/25.24.5003; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Carruthers LM, 1998, BIOCHEMISTRY-US, V37, P14776, DOI 10.1021/bi981684e; COVAULT J, 1980, J BIOL CHEM, V255, P9110; Davie JR, 1998, CURR OPIN GENET DEV, V8, P173, DOI 10.1016/S0959-437X(98)80138-X; Dimitrov S, 1996, EMBO J, V15, P5897, DOI 10.1002/j.1460-2075.1996.tb00976.x; Ding HF, 1997, MOL CELL BIOL, V17, P5843, DOI 10.1128/MCB.17.10.5843; GARCEA RL, 1980, J BIOL CHEM, V255, P1454; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gunjan A, 1999, NUCLEIC ACIDS RES, V27, P3355, DOI 10.1093/nar/27.16.3355; Gunjan A, 1999, J BIOL CHEM, V274, P37950, DOI 10.1074/jbc.274.53.37950; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Herrera JE, 2000, MOL CELL BIOL, V20, P523, DOI 10.1128/MCB.20.2.523-529.2000; Juan LJ, 1997, J BIOL CHEM, V272, P3635, DOI 10.1074/jbc.272.6.3635; JUAN LJ, 1994, EMBO J, V13, P6031, DOI 10.1002/j.1460-2075.1994.tb06949.x; KAMAKAKA RT, 1990, EMBO J, V9, P3997, DOI 10.1002/j.1460-2075.1990.tb07621.x; Karetsou Z, 1998, NUCLEIC ACIDS RES, V26, P3111, DOI 10.1093/nar/26.13.3111; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Lee HL, 1998, EMBO J, V17, P1454, DOI 10.1093/emboj/17.5.1454; LEE KY, 1998, BIOCHEMISTRY-US, V37, P8633; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; Nagpal S, 1999, J BIOL CHEM, V274, P22563, DOI 10.1074/jbc.274.32.22563; NELSON PP, 1979, J BIOL CHEM, V254, P1751; Nightingale KP, 1996, J BIOL CHEM, V271, P7090, DOI 10.1074/jbc.271.12.7090; Panetta G, 1998, J MOL BIOL, V282, P683, DOI 10.1006/jmbi.1998.2087; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; PARSEGHIAN MH, 1994, PROTEIN SCI, V3, P575; PENNINGS S, 1994, P NATL ACAD SCI USA, V91, P10275, DOI 10.1073/pnas.91.22.10275; PERRY CA, 1991, EXP CELL RES, V196, P337, DOI 10.1016/0014-4827(91)90269-Z; Pham AD, 2000, SCIENCE, V289, P2357, DOI 10.1126/science.289.5488.2357; POLACH KJ, 1995, J MOL BIOL, V254, P130, DOI 10.1006/jmbi.1995.0606; Ramakrishnan V, 1997, CRIT REV EUKAR GENE, V7, P215, DOI 10.1615/CritRevEukarGeneExpr.v7.i3.20; RICHARDFOY H, 1987, EMBO J, V6, P2321, DOI 10.1002/j.1460-2075.1987.tb02507.x; RIDSDALE JA, 1990, J BIOL CHEM, V265, P5150; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Thomas JO, 1999, CURR OPIN CELL BIOL, V11, P312, DOI 10.1016/S0955-0674(99)80042-8; URA K, 1995, EMBO J, V14, P3752, DOI 10.1002/j.1460-2075.1995.tb00045.x; Ura K, 1997, EMBO J, V16, P2096, DOI 10.1093/emboj/16.8.2096; Usachenko SI, 1996, J BIOL CHEM, V271, P3831; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; van Holde KE., 1989, SPRINGER SERIES MOL; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; WEINTRAUB H, 1984, CELL, V38, P17, DOI 10.1016/0092-8674(84)90522-1; Widom J, 1998, CURR BIOL, V8, pR788, DOI 10.1016/S0960-9822(07)00500-3; Wolffe A., 1995, CHROMATIN STRUCTURE; Wolffe AP, 1999, NUCLEIC ACIDS RES, V27, P711, DOI 10.1093/nar/27.3.711; WOLFFE AP, 1997, BIOESSAYS, V19, P1; ZLATANOVA J, 1992, J CELL SCI, V103, P889; Zweidler A, 1984, HISTONE GENES STRUCT, P339	61	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3635	3640		10.1074/jbc.M007590200	http://dx.doi.org/10.1074/jbc.M007590200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11062242	hybrid			2022-12-25	WOS:000166784900085
J	Wells, WW; Xu, DP; Washburn, MP; Cirrito, HK; Olson, LK				Wells, WW; Xu, DP; Washburn, MP; Cirrito, HK; Olson, LK			Polyhydroxybenzoates inhibit ascorbic acid activation of mitochondrial glycerol-3-phosphate dehydrogenase - Implications for glucose metabolism and insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCEROL-PHOSPHATE DEHYDROGENASE; FAD-GLYCEROPHOSPHATE DEHYDROGENASE; PANCREATIC-ISLETS; SN-GLYCEROL-3-PHOSPHATE OXIDASE; LACTATE-DEHYDROGENASE; TRYPANOSOMA-BRUCEI; PLANT-MITOCHONDRIA; BETA-CELLS; RAT-LIVER; B-CELL	Glycerol-3-phosphate dehydrogenase from pig brain mitochondria was stimulated 2.2-fold by the addition of 50 muM L-ascorbic acid. Enzyme activity, dependent upon the presence of L-ascorbic acid, was inhibited by lauryl gallate, propyl gallate, protocatechuic acid ethyl ester, and salicylhydroxamic acid. Homogeneous pig brain mitochondrial glycerol-3-phosphate dehydrogenase was activated by either 150 muM L-ascorbic acid (56%) or 300 muM iron (Fe2+ or Fe3+ (62%)) and 2.6-fold by the addition of both L-ascorbic acid and iron. The addition of L-ascorbic acid and iron resulted in a significant increase of k(cat) from 21.1 to 64.1 s(-1), without significantly increasing the gm of L-glycerol-3-phosphate (10.0-14.5 mM), The activation of pure glycerol-3-phosphate dehydrogenase by either L-ascorbic acid or iron or its combination could be totally inhibited by 200 muM propyl gallate, The metabolism of [5-H-3]glucose and the glucose-stimulated insulin secretion from rat insulinoma cells, INS-I, were effectively inhibited by 500 muM or 1 mM propyl gallate and to a lesser extent by 5 mM aminooxyacetate, a potent malate-aspartate shuttle inhibitor, The combined data support the conclusion that L-ascorbic acid is a physiological activator of mitochondrial glycerol-3-phosphate dehydrogenase, that the enzyme is potently inhibited by agents that specifically inhibit certain classes of di-iron metalloenzymes, and that the enzyme is chiefly responsible for the proximal signal events in INS-1 cell glucose-stimulated insulin release.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Michigan State University; Michigan State University	Olson, LK (corresponding author), Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA.			Washburn, Michael/0000-0001-7568-2585				AMOLE BO, 1981, EXP PARASITOL, V51, P133, DOI 10.1016/0014-4894(81)90050-3; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; BEINERT H, 1973, IRON SURLFUR PROTEIN, P1; BELEZNAI Z, 1987, EUR J BIOCHEM, V170, P631; BROWN LJ, 1994, J BIOL CHEM, V269, P14363; CLARKSON AB, 1981, MOL BIOCHEM PARASIT, V3, P271, DOI 10.1016/0166-6851(81)90002-5; COLE ES, 1978, J BIOL CHEM, V253, P7952; COTTINGHAM IR, 1980, BIOCHEM J, V192, P9, DOI 10.1042/bj1920009; Dawson A P, 1975, Methods Enzymol, V41, P254; Dou CZ, 1997, BIOCHEM BIOPH RES CO, V231, P820, DOI 10.1006/bbrc.1997.6106; DUKES ID, 1994, J BIOL CHEM, V269, P10979; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; FAIRLAMB AH, 1977, INT J BIOCHEM, V8, P669, DOI 10.1016/0020-711X(77)90105-7; FERNANDEZALVAREZ J, 1994, DIABETOLOGIA, V37, P177, DOI 10.1007/s001250050090; Fox B. G., 1997, COMPREHENSIVE BIOL C, P261; GARRIB A, 1984, ANAL BIOCHEM, V139, P319, DOI 10.1016/0003-2697(84)90011-3; GARRIB A, 1986, J BIOL CHEM, V261, P8042; GIROIX MH, 1991, DIABETES, V40, P227, DOI 10.2337/diabetes.40.2.227; GRADY RW, 1986, MOL BIOCHEM PARASIT, V21, P55, DOI 10.1016/0166-6851(86)90079-4; GRADY RW, 1986, MOL BIOCHEM PARASIT, V19, P231, DOI 10.1016/0166-6851(86)90005-8; GRANT PT, 1960, BIOCHEM J, V76, P229, DOI 10.1042/bj0760229; GREEN DE, 1963, METHOD ENZYMOL, V6, P416, DOI 10.1016/0076-6879(63)06198-X; Greenawalt J W, 1974, Methods Enzymol, V31, P310; Hagopian K, 1999, ANAL BIOCHEM, V273, P240, DOI 10.1006/abio.1999.4219; HATEFI Y, 1976, ENZYMES            C, V13, P175; Ishihara H, 1999, J CLIN INVEST, V104, P1621, DOI 10.1172/JCI7515; Jung CH, 1997, BIOCHEM BIOPH RES CO, V239, P457, DOI 10.1006/bbrc.1997.7438; KEKOW J, 1988, DIABETES, V37, P321, DOI 10.2337/diabetes.37.3.321; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai J C, 1979, Methods Enzymol, V55, P51; LEHN DA, 1994, GENE, V150, P417, DOI 10.1016/0378-1119(94)90469-3; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MACDONALD MJ, 1982, ARCH BIOCHEM BIOPHYS, V213, P643, DOI 10.1016/0003-9861(82)90594-X; MACDONALD MJ, 1983, J CLIN ENDOCR METAB, V57, P662, DOI 10.1210/jcem-57-3-662; MALAISSE WJ, 1992, INT J BIOCHEM, V24, P693, DOI 10.1016/0020-711X(92)90002-I; MALAISSE WJ, 1982, ENDOCRINOLOGY, V111, P392, DOI 10.1210/endo-111-2-392; MALAISSE WJ, 1995, DIABETIC MED, V12, P479, DOI 10.1111/j.1464-5491.1995.tb00527.x; RASSCHAERT J, 1991, BIOCHEM J, V278, P335, DOI 10.1042/bj2780335; RASSCHAERT J, 1993, MOL CELL BIOCHEM, V120, P135, DOI 10.1007/BF00926086; RINGLER RL, 1962, METHOD ENZYMOL, V5, P432, DOI 10.1016/S0076-6879(62)05255-6; RINGLER RL, 1959, J BIOL CHEM, V234, P2211; ROSS JL, 1994, GENE, V139, P219, DOI 10.1016/0378-1119(94)90759-5; Rouault TA, 1996, TRENDS BIOCHEM SCI, V21, P174, DOI 10.1016/0968-0004(96)10024-4; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; SCHONBAUM GR, 1971, PLANT PHYSIOL, V47, P124, DOI 10.1104/pp.47.1.124; SEKINE N, 1994, J BIOL CHEM, V269, P4895; SIEDOW JN, 1995, FEBS LETT, V362, P10, DOI 10.1016/0014-5793(95)00196-G; Sigal A, 1936, J BIOL CHEM, V116, P489; Singer T P, 1974, Methods Biochem Anal, V22, P123, DOI 10.1002/9780470110423.ch3; WELLS WW, 1995, P NATL ACAD SCI USA, V92, P11869, DOI 10.1073/pnas.92.25.11869; ZAWALICH WS, 1977, ENDOCRINOLOGY, V100, P1276, DOI 10.1210/endo-100-5-1276; ZAWALICH WS, 1977, ENDOCRINOLOGY, V100, P1	53	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2404	2410		10.1074/jbc.M007268200	http://dx.doi.org/10.1074/jbc.M007268200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11060297	hybrid			2022-12-25	WOS:000166784800016
J	Glaunsinger, BA; Lee, SS; Thomas, M; Banks, L; Javier, R				Glaunsinger, BA; Lee, SS; Thomas, M; Banks, L; Javier, R			Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins	ONCOGENE			English	Article						adenovirus E4-ORF1; MAGI-1; papillomavirus; E6; PDZ	LARGE TUMOR-SUPPRESSOR; READING FRAME-1 ENCODES; MOLECULAR CHARACTERIZATION; TIGHT JUNCTION; SEPTATE JUNCTIONS; GUANYLATE KINASE; MAMMARY-TUMORS; HUMAN HOMOLOG; CREF CELLS; TYPE-9	The oncoproteins of small DNA tumor viruses promote tumorigenesis by complexing with cellular factors intimately involved in the control of cell proliferation. The major oncogenic determinants for human adenovirus type 9 (Ad9) and high-risk human papillomaviruses (HPV) are the E4-ORF1 and E6 proteins, respectively. These seemingly unrelated viral oncoproteins are similar in that their transforming activities in cells depend, in part, on a carboxyl-terminal PDZ domain-binding motif which mediates interactions with the cellular PDZ-protein DLG. Here we demonstrated that both Ad9 E4-ORF1 and high-risk HPV E6 proteins also bind to the DLG-related PDZ-protein MAGI-1. These interactions resulted in MAGI-1 being aberrantly sequestered in the cytoplasm by the Ad9 E4-ORF1 protein or being targeted for degradation by high-risk HPV E6 proteins. Transformation-defective mutant viral proteins, however, were deficient for these activities. Our findings indicate that MAGI-1 is a member of a select group of cellular PDZ proteins targeted by both adenovirus E4-ORF1 and high-risk HPV E6 proteins and, in addition, suggest that the tumorigenic potentials of these viral oncoproteins depend, in part, on an ability to inhibit the function of MAGI-1 in cells.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	Baylor College of Medicine; International Center for Genetic Engineering & Biotechnology (ICGEB)	Javier, R (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [R01CA058541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007471] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058541, R01CA58541, R01 CA058541-06] Funding Source: Medline; NIAID NIH HHS [T32 AI007471, T32AI07471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOSCH FX, 1995, JNCI-J NATL CANCER I, V87, P796, DOI 10.1093/jnci/87.11.796; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Fanning AS, 1999, J CLIN INVEST, V103, P767, DOI 10.1172/JCI6509; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; Gardiol D, 1999, ONCOGENE, V18, P5487, DOI 10.1038/sj.onc.1202920; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Gottardi CJ, 1996, P NATL ACAD SCI USA, V93, P10779, DOI 10.1073/pnas.93.20.10779; Harlow E, 1988, ANTIBODIES LABORATOR, P359; Haskins J, 1998, J CELL BIOL, V141, P199, DOI 10.1083/jcb.141.1.199; Howley M. P., 1996, FIELDS VIROLOGY, P2045; JAVIER R, 1991, J VIROL, V65, P3192, DOI 10.1128/JVI.65.6.3192-3202.1991; JAVIER RT, 1994, J VIROL, V68, P3917, DOI 10.1128/JVI.68.6.3917-3924.1994; JESAITIS LA, 1994, J CELL BIOL, V124, P949, DOI 10.1083/jcb.124.6.949; Kiyono T, 1997, P NATL ACAD SCI USA, V94, P11612, DOI 10.1073/pnas.94.21.11612; Le SS, 1997, P NATL ACAD SCI USA, V94, P6670, DOI 10.1073/pnas.94.13.6670; LUE RA, 1994, P NATL ACAD SCI USA, V91, P9818, DOI 10.1073/pnas.91.21.9818; MCALLISTER RM, 1971, NATURE-NEW BIOL, V230, P279, DOI 10.1038/newbio230279a0; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; NEVINS JR, 1996, FIELDS VIROLOGY, V1, P301; Philipp S, 1997, FEBS LETT, V413, P243, DOI 10.1016/S0014-5793(97)00877-6; PRASAD R, 1993, CANCER RES, V53, P5624; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SHENK T, 1996, FIELDS VIROLOGY, V2, P2111; SMITH DB, 1994, CURRENT PROTOCOLS MO, V2; Thomas DL, 1999, J VIROL, V73, P3071, DOI 10.1128/JVI.73.4.3071-3079.1999; Thomas U, 1997, MECH DEVELOP, V62, P161, DOI 10.1016/S0925-4773(97)00658-8; Weiss RS, 1997, J VIROL, V71, P4385, DOI 10.1128/JVI.71.6.4385-4394.1997; Weiss RS, 1996, J VIROL, V70, P862, DOI 10.1128/JVI.70.2.862-872.1996; Weiss RS, 1997, J VIROL, V71, P7873, DOI 10.1128/JVI.71.10.7873-7880.1997; Weiss RS, 1997, J VIROL, V71, P1857, DOI 10.1128/JVI.71.3.1857-1870.1997; WILLOTT E, 1993, P NATL ACAD SCI USA, V90, P7834, DOI 10.1073/pnas.90.16.7834; WOODS DF, 1991, CELL, V66, P451, DOI 10.1016/0092-8674(81)90009-X; Wu HJ, 1998, J CELL SCI, V111, P2365; Yang N, 1998, EXP CELL RES, V241, P242, DOI 10.1006/excr.1998.4053	37	234	247	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5270	5280		10.1038/sj.onc.1203906	http://dx.doi.org/10.1038/sj.onc.1203906			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077444	Green Accepted			2022-12-25	WOS:000165059700008
J	Lee, CH; Chang, SC; Wu, CHH; Chang, MF				Lee, CH; Chang, SC; Wu, CHH; Chang, MF			A novel chromosome region maintenance 1-independent nuclear export signal of the large form of hepatitis delta antigen that is required for the viral assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS LARGE ANTIGEN; LEPTOMYCIN-B; RNA-BINDING; REPLICATION INHIBITION; LEUCINE ZIPPER; PROTEIN; CRM1; REV; TRANSPORT; SEQUENCE	Hepatitis delta virus (HDV) is a satellite virus of hepatitis B virus, as it requires hepatitis B virus for virion production and transmission. We have previously demonstrated that sequences within the C-terminal 19-amino acid domain flanking the isoprenylation motif of the large hepatitis delta antigen (HDAg-L) are important for virion assembly, In this study, site-directed mutagenesis and immunofluorescence staining demonstrated that in the absence of hepatitis B virus surface antigen (HBsAg), the wild-type HDAg-L was localized in the nuclei of transfected COS7 cells. Nevertheless, in the presence of HBsAg, the HDAg-L became both nuclei- and cytoplasm-distributed in about half of the cells, An HDAg-L mutant with a substitution of Pro-205 to alanine could neither form HDV-like particles nor shift the subcellular localization in the presence of HBsAg, In addition, nuclear trafficking of HDAg-L in heterokaryons indicated that HDAg-L is a nucleocytoplasmic shuttling protein. A proline-rich HDAg peptide spanning amino acid residues 198 to 210, designated NES (HDAg-L), can function as a nuclear export signal (NES) in Xenopus oocytes, Pro-205 is critical for the NES function. Furthermore, assembly of HDV is insensitive to leptomycin B, indicating that the NES(HDAg-L) directs nuclear export of HDAg-L to the cytoplasm via a chromosome region maintenance 1-independent pathway.	Natl Taiwan Univ, Coll Med, Inst Biochem, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Microbiol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Inst Mol Med, Taipei, Taiwan	National Taiwan University; National Taiwan University; National Taiwan University	Chang, MF (corresponding author), Natl Taiwan Univ, Coll Med, Inst Biochem, No 1 Jen Ai Rd,1st Sect, Taipei, Taiwan.		Lee, Chia-Huei/B-1063-2010	CHANG, MING-FU/0000-0001-7062-3578; Lee, Chia-Huei/0000-0002-8847-3288				CHANG FL, 1991, P NATL ACAD SCI USA, V88, P8490, DOI 10.1073/pnas.88.19.8490; CHANG MF, 1988, J VIROL, V62, P2403, DOI 10.1128/JVI.62.7.2403-2410.1988; CHANG MF, 1994, J VIROL, V68, P646, DOI 10.1128/JVI.68.2.646-653.1994; CHANG MF, 1995, J VIROL, V69, P2508, DOI 10.1128/JVI.69.4.2508-2514.1995; CHANG MF, 1993, J VIROL, V67, P2529, DOI 10.1128/JVI.67.5.2529-2536.1993; CHANG MF, 1992, J VIROL, V66, P6019, DOI 10.1128/JVI.66.10.6019-6027.1992; CHAO M, 1990, J VIROL, V64, P5066, DOI 10.1128/JVI.64.10.5066-5069.1990; CHEN PJ, 1992, J VIROL, V66, P2853, DOI 10.1128/JVI.66.5.2853-2859.1992; DERBYSHIRE KM, 1986, GENE, V46, P145, DOI 10.1016/0378-1119(86)90398-7; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GLENN JS, 1992, SCIENCE, V256, P1331, DOI 10.1126/science.1598578; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; HILL DE, 1987, METHOD ENZYMOL, V155, P558; Hope TJ, 1997, CHEM BIOL, V4, P335, DOI 10.1016/S1074-5521(97)90124-1; HWANG SB, 1993, J VIROL, V67, P7659, DOI 10.1128/JVI.67.12.7659-7662.1993; KOS A, 1986, NATURE, V323, P558, DOI 10.1038/323558a0; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; KUO MYP, 1989, J VIROL, V63, P1945, DOI 10.1128/JVI.63.5.1945-1950.1989; Lee CH, 1998, J BIOL CHEM, V273, P7650, DOI 10.1074/jbc.273.13.7650; LEE CZ, 1995, J VIROL, V69, P5332, DOI 10.1128/JVI.69.9.5332-5336.1995; LEE CZ, 1994, VIROLOGY, V199, P169, DOI 10.1006/viro.1994.1109; LIN JH, 1990, J VIROL, V64, P4051, DOI 10.1128/JVI.64.9.4051-4058.1990; Love DC, 1998, P NATL ACAD SCI USA, V95, P10608, DOI 10.1073/pnas.95.18.10608; MAKINO S, 1987, NATURE, V329, P343, DOI 10.1038/329343a0; Murphy R, 1996, NATURE, V383, P357, DOI 10.1038/383357a0; RYU WS, 1992, J VIROL, V66, P2310, DOI 10.1128/JVI.66.4.2310-2315.1992; Sachdev S, 1998, MOL CELL BIOL, V18, P5445, DOI 10.1128/MCB.18.9.5445; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; STAUBER R, 1995, VIROLOGY, V213, P439, DOI 10.1006/viro.1995.0016; WANG HW, 1994, J VIROL, V68, P6363, DOI 10.1128/JVI.68.10.6363-6371.1994; WANG KS, 1986, NATURE, V323, P508, DOI 10.1038/323508a0; WEN W, 1994, J BIOL CHEM, V269, P32214; Whittaker G, 1996, J VIROL, V70, P2743, DOI 10.1128/JVI.70.5.2743-2756.1996; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; WU JC, 1991, J VIROL, V65, P1099, DOI 10.1128/JVI.65.3.1099-1104.1991; XIA YP, 1990, VIROLOGY, V178, P331, DOI 10.1016/0042-6822(90)90415-N; XIA YP, 1992, J VIROL, V66, P914, DOI 10.1128/JVI.66.2.914-921.1992	41	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8142	8148		10.1074/jbc.M004477200	http://dx.doi.org/10.1074/jbc.M004477200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11076934	hybrid			2022-12-25	WOS:000167474900066
J	Mohammad-Panah, R; Gyomorey, K; Rommens, J; Choudhury, M; Li, CH; Wang, YC; Bear, CE				Mohammad-Panah, R; Gyomorey, K; Rommens, J; Choudhury, M; Li, CH; Wang, YC; Bear, CE			ClC-2 contributes to native chloride secretion by a human intestinal cell line, Caco-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY VOLUME DECREASE; EPITHELIAL-CELLS; APICAL MEMBRANE; TIGHT JUNCTIONS; CHANNEL CLC-2; FETAL LUNG; CONDUCTANCE; DIFFERENTIATION; ACTIVATION; MODULATION	It has been previously determined that ClC-2, a member of the ClC chloride channel superfamily, is expressed in certain epithelial tissues. These findings fueled speculation that ClC-2 can compensate for impaired chloride transport in epithelial tissues affected by cystic fibrosis and lacking the cystic fibrosis transmembrane conductance regulator. However, direct evidence linking ClC-2 channel expression to epithelial chloride secretion was lacking. In the present studies, we show that ClC-2 transcripts and protein are present endogenously in the Caco-2 cell line, a cell line that models the human small intestine. Using an antisense strategy we show that ClC-2 contributes to native chloride currents in Caco-2 cells measured by patch clamp electrophysiology, Antisense ClC-2-transfected monolayers of Caco-2 cells exhibited less chloride secretion (monitored as iodide efflux) than did mock transfected monolayers, providing the first direct molecular evidence that ClC-2 can contribute to chloride secretion by the human intestinal epithelium. Further, examination of ClC-2 localization by confocal microscopy revealed that ClC-2 contributes to secretion from a unique location in this epithelium, from the apical aspect of the tight junction complex. Hence, these studies provide the necessary rationale for considering ClC-2 as a possible therapeutic target for diseases affecting intestinal chloride secretion such as cystic fibrosis.	Hosp Sick Children, Res Inst, Cell Biol & Genet Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol Genet, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto	Bear, CE (corresponding author), Hosp Sick Children, Res Inst, Cell Biol & Genet Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	bear@sickkids.on.ca						Anderson JM, 1999, CURR BIOL, V9, pR922, DOI 10.1016/S0960-9822(00)80105-0; Bajnath RB, 1997, PFLUG ARCH EUR J PHY, V433, P276; Blaisdell CJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1248, DOI 10.1152/ajplung.2000.278.6.L1248; Bond T, 1999, J GEN PHYSIOL, V113, P441, DOI 10.1085/jgp.113.3.441; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; Diener M, 1996, PFLUG ARCH EUR J PHY, V432, P293, DOI 10.1007/s004240050136; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; Fritsch J, 1997, AM J PHYSIOL-CELL PH, V272, pC778, DOI 10.1152/ajpcell.1997.272.3.C778; Fritsch J, 1996, J PHYSIOL-LONDON, V490, P115, DOI 10.1113/jphysiol.1996.sp021130; GIRALDEZ F, 1988, J PHYSIOL-LONDON, V395, P597, DOI 10.1113/jphysiol.1988.sp016937; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Gyomorey K, 2000, AM J PHYSIOL-CELL PH, V279, pC1787, DOI 10.1152/ajpcell.2000.279.6.C1787; Hagos Y, 1999, PFLUG ARCH EUR J PHY, V437, P724, DOI 10.1007/s004240050838; HAMILL OP, 1981, PFLUEGERS ARCH EUR J, V191, P85; Haws CM, 1996, AM J PHYSIOL-CELL PH, V270, pC1544, DOI 10.1152/ajpcell.1996.270.5.C1544; Jentsch TJ, 1999, PFLUG ARCH EUR J PHY, V437, P783, DOI 10.1007/s004240050847; Joo NS, 1999, BBA-GENE STRUCT EXPR, V1446, P431, DOI 10.1016/S0167-4781(99)00110-4; Jordt SE, 1997, EMBO J, V16, P1582, DOI 10.1093/emboj/16.7.1582; Kajita H, 2000, J PHYSIOL-LONDON, V523, P313, DOI 10.1111/j.1469-7793.2000.t01-1-00313.x; MACLEOD RJ, 1991, AM J PHYSIOL, V260, pG26, DOI 10.1152/ajpgi.1991.260.1.G26; MCCANN JD, 1989, J GEN PHYSIOL, V94, P1015, DOI 10.1085/jgp.94.6.1015; MCEWAN GTA, 1993, PFLUG ARCH EUR J PHY, V423, P213, DOI 10.1007/BF00374397; MCEWAN GTA, 1992, BIOCHIM BIOPHYS ACTA, V1135, P180, DOI 10.1016/0167-4889(92)90135-X; Mohammad-Panah R, 1998, AM J PHYSIOL-CELL PH, V274, pC310, DOI 10.1152/ajpcell.1998.274.2.C310; MURRAY CB, 1995, AM J RESP CELL MOL, V12, P597, DOI 10.1165/ajrcmb.12.6.7766424; ROUSSET M, 1985, J CELL PHYSIOL, V123, P377, DOI 10.1002/jcp.1041230313; Schwartz R, 1998, OPHTHALMOLOGE, V95, P3; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; SHIMADA K, 2000, AM J PHYSIOL, V279, pG269; SHUBEITA HE, 1992, CIRCULATION, V85, P2236, DOI 10.1161/01.CIR.85.6.2236; SOOD R, 1992, EMBO J, V11, P2487, DOI 10.1002/j.1460-2075.1992.tb05313.x; Staley K, 1996, NEURON, V17, P543, DOI 10.1016/S0896-6273(00)80186-5; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Tsukita S, 1999, CURR OPIN CELL BIOL, V11, P628, DOI 10.1016/S0955-0674(99)00016-2; WALTERS RJ, 1991, PFLUG ARCH EUR J PHY, V419, P537, DOI 10.1007/BF00370802; Wang LW, 2000, J PHYSIOL-LONDON, V524, P63, DOI 10.1111/j.1469-7793.2000.t01-1-00063.x; Xiong H, 1999, J MEMBRANE BIOL, V167, P215, DOI 10.1007/s002329900485; YADA T, 1984, J MEMBRANE BIOL, V77, P33, DOI 10.1007/BF01871098	38	61	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8306	8313		10.1074/jbc.M006764200	http://dx.doi.org/10.1074/jbc.M006764200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11096079	hybrid			2022-12-25	WOS:000167474900087
J	Hofsteenge, J; Huwiler, KG; Macek, B; Hess, D; Lawler, J; Mosher, DF; Peter-Katalinic, J				Hofsteenge, J; Huwiler, KG; Macek, B; Hess, D; Lawler, J; Mosher, DF; Peter-Katalinic, J			C-mannosylation and O-fucosylation of the thrombospondin type 1 module	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; FUCOSE GLYCOSYLATION PATHWAY; GROWTH-FACTOR DOMAIN; HUMAN FACTOR-IX; HEPARIN-BINDING; LINKED FUCOSE; MASS-SPECTROMETRY; PROTEIN LINKAGE; INSECT CELLS; PROPERDIN	Thrombospondin-1 (TSP-1) is a multidomain protein that has been implicated in cell adhesion, motility, and growth. Some of these functions have been localized to the three thrombospondin type 1 repeats (TSRs), modules of similar to 60 amino acids in length with conserved Cys and Trp residues. The Trp residues occur in WXXW patterns, which are the recognition motifs for protein C-mannosylation. This modification involves the attachment of an cu-mannosyl residue to the C-2 atom of the first tryptophan. Analysis of human platelet TSP-1 revealed that Trp-368, -420, -423, and -480 are C-mannosylated. Mannosylation also occurred in recombinant, baculovirally expressed TSR modules from Sf9 and "High Five" cells, contradictory to earlier reports that such cells do not carry out this reaction. In the course of these studies it was appreciated that the TSRs in TSP-1 undergo a second form of unusual glycosylation. By using a novel mass spectrometric approach, it was found that Ser-377, Thr-432, and Thr-489 in the motif CSX(S/T)CG carry the O-Linked disaccharide Glc-Fuc-O-Ser-Thr. This is the first protein in which such a disaccharide has been identified, although protein O-fucosylation is well described in epidermal growth factor-like modules. Both C- and O-glycosylations take place on residues that have been implicated in the interaction of TSP-1 with glycosaminoglycans or other cellular receptors.	Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA; Univ Munster, Inst Med Phys & Biophys, D-48149 Munster, Germany; Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA	Friedrich Miescher Institute for Biomedical Research; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Munster; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Hofsteenge, J (corresponding author), Friedrich Miescher Inst, POB 2543, CH-4002 Basel, Switzerland.		Macek, Boris/N-1442-2015; Lawler, Jack/AAJ-1379-2020	Macek, Boris/0000-0002-1206-2458; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054462, R01HL028749] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54462, HL28749] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS J, 1993, CURR BIOL, V3, P188, DOI 10.1016/0960-9822(93)90270-X; ADAMS JC, 1994, MOL BIOL CELL, V5, P423, DOI 10.1091/mbc.5.4.423; Adams JC, 2000, DEV DYNAM, V218, P280; Aho S, 1998, MATRIX BIOL, V17, P401, DOI 10.1016/S0945-053X(98)90100-7; Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951; Alving K, 1999, J MASS SPECTROM, V34, P395, DOI 10.1002/(SICI)1096-9888(199904)34:4<395::AID-JMS771>3.3.CO;2-T; ASCH AS, 1992, BIOCHEM BIOPH RES CO, V182, P1208, DOI 10.1016/0006-291X(92)91860-S; BALE MD, 1987, SEMIN THROMB HEMOST, V13, P326, DOI 10.1055/s-2007-1003508; BALE MD, 1986, J BIOL CHEM, V261, P862; BARANSKI TJ, 1991, J BIOL CHEM, V266, P23365; BJOERN S, 1991, J BIOL CHEM, V266, P11051; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DIXIT VM, 1984, J BIOL CHEM, V259, P100; Doucey MA, 1999, GLYCOBIOLOGY, V9, P435, DOI 10.1093/glycob/9.5.435; Doucey MA, 1998, MOL BIOL CELL, V9, P291, DOI 10.1091/mbc.9.2.291; DOUCEY MA, 1998, THESIS U L PASTEUR S; Frazier WA, 1991, CURR OPIN CELL BIOL, V3, P792, DOI 10.1016/0955-0674(91)90052-Z; GADE G, 1992, BIOCHEM BIOPH RES CO, V189, P1303, DOI 10.1016/0006-291X(92)90215-7; Greis KD, 1996, ANAL BIOCHEM, V234, P38, DOI 10.1006/abio.1996.0047; GUO NH, 1992, J BIOL CHEM, V267, P19349; GUO NH, 1992, P NATL ACAD SCI USA, V89, P3040, DOI 10.1073/pnas.89.7.3040; HALLGREN P, 1975, J BIOL CHEM, V250, P5312; HARRIS RJ, 1993, GLYCOBIOLOGY, V3, P219, DOI 10.1093/glycob/3.3.219; HARRIS RJ, 1993, BIOCHEMISTRY-US, V32, P6539, DOI 10.1021/bi00077a007; HARRIS RJ, 1992, J BIOL CHEM, V267, P5102; HARRIS RJ, 1991, BIOCHEMISTRY-US, V30, P2311, DOI 10.1021/bi00223a004; Hartmann S, 2000, J BIOL CHEM, V275, P28569, DOI 10.1074/jbc.M001732200; Hofsteenge J, 1999, J BIOL CHEM, V274, P32786, DOI 10.1074/jbc.274.46.32786; HOFSTEENGE J, 1994, BIOCHEMISTRY-US, V33, P13524, DOI 10.1021/bi00250a003; Iwasaki W, 1997, EMBO J, V16, P6936, DOI 10.1093/emboj/16.23.6936; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; KENTZER EJ, 1990, BIOCHEM BIOPH RES CO, V171, P401, DOI 10.1016/0006-291X(90)91407-J; Kilpelainen I, 2000, J BIOL CHEM, V275, P13564, DOI 10.1074/jbc.275.18.13564; KLINGER MM, 1981, J BIOL CHEM, V256, P7932; Krieg J, 1998, MOL BIOL CELL, V9, P301, DOI 10.1091/mbc.9.2.301; Krieg J, 1997, J BIOL CHEM, V272, P26687, DOI 10.1074/jbc.272.42.26687; LAWLER J, 1986, J CELL BIOL, V74, P2022; LAWLER JW, 1978, J BIOL CHEM, V253, P8609; LEGRAND C, 1992, BLOOD, V79, P1995; Lopez M, 1999, BBA-GEN SUBJECTS, V1427, P49, DOI 10.1016/S0304-4165(98)00176-7; Misenheimer TM, 2000, J BIOL CHEM, V275, P40938, DOI 10.1074/jbc.M007022200; Moloney DJ, 1999, GLYCOBIOLOGY, V9, P679, DOI 10.1093/glycob/9.7.679; Moloney DJ, 1997, J BIOL CHEM, V272, P19046, DOI 10.1074/jbc.272.30.19046; Moloney DJ, 2000, J BIOL CHEM, V275, P9604, DOI 10.1074/jbc.275.13.9604; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; MOSHER DF, 1990, ANNU REV MED, V41, P85; NAKAKURA N, 1992, EUR J BIOCHEM, V204, P147, DOI 10.1111/j.1432-1033.1992.tb16617.x; NISHIMURA H, 1992, J BIOCHEM-TOKYO, V111, P460, DOI 10.1093/oxfordjournals.jbchem.a123780; NISHIMURA H, 1992, J BIOL CHEM, V267, P17520; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; Panetti TS, 1999, J BIOL CHEM, V274, P430, DOI 10.1074/jbc.274.1.430; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; RICH KA, 1990, SCIENCE, V249, P1574, DOI 10.1126/science.2120774; Roberts DD, 1996, FASEB J, V10, P1183, DOI 10.1096/fasebj.10.10.8751720; Rudd PM, 2000, BIOCHEMISTRY-US, V39, P1596, DOI 10.1021/bi9918285; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; SILVERSTEIN RL, 1987, SEMIN THROMB HEMOST, V13, P335, DOI 10.1055/s-2007-1003509; SIPES JM, 1993, J CELL BIOL, V121, P469, DOI 10.1083/jcb.121.2.469; TUSZYNSKI GP, 1992, J CELL BIOL, V116, P209, DOI 10.1083/jcb.116.1.209; Wang Y, 1998, J BIOL CHEM, V273, P8112, DOI 10.1074/jbc.273.14.8112	61	196	205	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6485	6498		10.1074/jbc.M008073200	http://dx.doi.org/10.1074/jbc.M008073200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11067851	hybrid			2022-12-25	WOS:000167261000057
J	Jost, M; Huggett, TM; Kari, C; Boise, LH; Rodeck, U				Jost, M; Huggett, TM; Kari, C; Boise, LH; Rodeck, U			Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-x(L) expression through a MEK-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; BCL-X-L; PHOSPHOLIPASE-C; PHOSPHATIDYLINOSITOL 3-KINASE; MONOCLONAL-ANTIBODY; INDUCED APOPTOSIS; CELL-SURVIVAL; TYROSINE PHOSPHORYLATION; SIGNALING PATHWAY; CARCINOMA-CELLS	Previous work has shown that the epidermal growth factor receptor (EGFR) tyrosine kinase moiety provides protection to normal human keratinocytes against apoptosis. This protection is, at least in part, due to EGFR-dependent expression of the antiapoptotic Bcl-2 family member, Bcl-x(L). Here we focused on intracellular signaling pathways relevant to keratinocyte survival and/or Bcl-x(L) expression. By using pharmacological inhibitors and dominant negative expression constructs, we observed that phosphatidylinositol 3-kinase/AKT and phospholipase C gamma /protein kinase C alpha activation were required for keratinocyte survival independently of EGFR activation or Bcl-x(L) expression. By contrast, MEK activity required EGFR activation and, as shown by use of the MEK inhibitor PD98059 and a dominant negative MEK construct, was necessary for Bcl-x(L) expression and survival. Consistent with an earlier study, blocking SRC kinase activities similarly led to down-regulation of Bcl-x(L) protein expression and impaired keratinocyte survival. In conclusion, our results demonstrate that EGFR-dependent MEK activity contributes to both Bcl-x(L) expression and survival of normal keratinocytes. Other signaling pathways (i.e. phosphatidylinositol 3-kinase/AKT and phospholipase C gamma /protein kinase C alpha) are obligatory to keratinocyte survival but not to Bcl-x(L) expression, and control of these pathways by EGFR activation is not rate-limiting to normal keratinocyte survival.	Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33101 USA	Jefferson University; Jefferson University; University of Miami; University of Miami	Rodeck, U (corresponding author), Thomas Jefferson Univ, Dept Dermatol, 319 BLSB,233 S 10th St, Philadelphia, PA 19107 USA.		Boise, Lawrence/AAD-2314-2019	Boise, Lawrence/0000-0001-9436-8815	NATIONAL CANCER INSTITUTE [R01CA081008, R29CA077837] Funding Source: NIH RePORTER; NCI NIH HHS [CA77837, CA81008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; CHEN P, 1994, J CELL BIOL, V127, P847, DOI 10.1083/jcb.127.3.847; Cheng AL, 1998, BIOCHEM PHARMACOL, V55, P523, DOI 10.1016/S0006-2952(97)00594-7; Cifone MG, 1999, BLOOD, V93, P2282, DOI 10.1182/blood.V93.7.2282.407a23_2282_2296; COOK PW, 1991, MOL CELL BIOL, V11, P2547, DOI 10.1128/MCB.11.5.2547; COOK PW, 1991, J CELL PHYSIOL, V146, P277, DOI 10.1002/jcp.1041460213; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; Hauser PJ, 1998, CELL GROWTH DIFFER, V9, P847; Jost M, 1999, J INVEST DERMATOL, V112, P443, DOI 10.1046/j.1523-1747.1999.00543.x; Jost M, 1997, NUCLEIC ACIDS RES, V25, P3131, DOI 10.1093/nar/25.15.3131; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Keenan C, 1999, CELL IMMUNOL, V196, P104, DOI 10.1006/cimm.1999.1549; KIDO Y, 1995, BIOCHEM BIOPH RES CO, V209, P131, DOI 10.1006/bbrc.1995.1480; Kuhn C, 1999, INT J CANCER, V80, P431, DOI 10.1002/(SICI)1097-0215(19990129)80:3<431::AID-IJC16>3.3.CO;2-X; Leirdal M, 1999, BRIT J CANCER, V80, P1558, DOI 10.1038/sj.bjc.6690560; Li LW, 1999, MOL CELL BIOL, V19, P8547; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MAA MC, 1995, P NATL ACAD SCI USA, V92, P6981, DOI 10.1073/pnas.92.15.6981; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MCNEILL H, 1990, CELL REGUL, V1, P843, DOI 10.1091/mbc.1.11.843; Miao JY, 1997, J BIOCHEM-TOKYO, V121, P612; Minshall C, 1996, J IMMUNOL, V156, P939; Mufson RA, 1998, EXP CELL RES, V240, P228, DOI 10.1006/excr.1998.3932; MURTHY U, 1987, ARCH BIOCHEM BIOPHYS, V252, P549, DOI 10.1016/0003-9861(87)90062-2; MURTHY U, 1990, BIOCHEM BIOPH RES CO, V172, P471, DOI 10.1016/0006-291X(90)90696-K; Mutoh T, 1999, FEBS LETT, V446, P91, DOI 10.1016/S0014-5793(99)00188-X; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; PITTELKOW MR, 1993, CELL GROWTH DIFFER, V4, P513; RODECK U, 1987, CANCER RES, V47, P3692; RODECK U, 1990, J CELL BIOCHEM, V44, P69, DOI 10.1002/jcb.240440202; Rodeck U, 1997, P NATL ACAD SCI USA, V94, P5067, DOI 10.1073/pnas.94.10.5067; Rodeck U, 1997, J CELL SCI, V110, P113; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; Stoll SW, 1998, ONCOGENE, V16, P1493, DOI 10.1038/sj.onc.1201657; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; VARDY DA, 1995, J CELL PHYSIOL, V163, P257, DOI 10.1002/jcp.1041630206; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; Yao R, 1996, ONCOGENE, V13, P343; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	55	133	141	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6320	6326		10.1074/jbc.M008210200	http://dx.doi.org/10.1074/jbc.M008210200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11098053	hybrid, Green Published			2022-12-25	WOS:000167261000036
J	Majka, J; Zakrzewska-Czerwinska, J; Messer, W				Majka, J; Zakrzewska-Czerwinska, J; Messer, W			Sequence recognition, cooperative interaction, and dimerization of the initiator protein DnaA of Streptomyces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; REPLICATION ORIGIN; BINDING; REGION; TRANSCRIPTION; CHROMOSOME; DOMAIN; TARGET; SITE; GENE	Using a combined PCR-gel retardation assay, the preferred recognition sequence of the Streptomyces initiator protein DnaA was determined. The protein showed a preference toward DNA containing two Escherichia coli-like DnaA boxes in a head-to-head arrangement (consensus sequence TTATCCACA, whereas the consensus sequence of the DnaA boxes found in the Streptomyces oriC region is TTGTCCACA). In quantitative band shift experiments, the kinetics of the Streptomyces DnaA-DnaA box interaction was characterized. The DnaA protein can form dimers while binding to a single DnaA box; dimer formation is mediated by the domain III of the protein, and the dissociation constant of this process was between 35 and 115 nM. Streptomyces initiator protein DnaA interacts in a cooperative manner with DNA containing multiple binding sites. For the cooperativity effect, which seems to be independent of the distance separating the DnaA boxes, domain I (or I and II) is responsible. The cooperativity constant is moderate and is in the range of 20-110.	Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Ludwik Hirszfeld Inst Immunol & Expt Therapy, PL-53114 Wroclaw, Poland	Max Planck Society; Polish Academy of Sciences; Hirszfeld Institute of Immunology & Experimental Therapy of the Polish Academy of Sciences	Messer, W (corresponding author), Max Planck Inst Mol Genet, Ihnestr 73, D-14195 Berlin, Germany.							Bell CE, 2000, CELL, V101, P801, DOI 10.1016/S0092-8674(00)80891-0; Jakimowicz D, 2000, J MOL BIOL, V298, P351, DOI 10.1006/jmbi.2000.3686; Jakimowicz D, 1998, MICROBIOL-SGM, V144, P1281, DOI 10.1099/00221287-144-5-1281; Jakimowicz D, 2000, MOL GEN GENET, V262, P1093, DOI 10.1007/PL00008652; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Kaguni JM, 1997, MOL CELLS, V7, P145; Kornberg A., 1992, DNA REPLICATION; KUTZNER HJ, 1981, PROKARYOTES, V2, P2028; LIN YS, 1993, MOL MICROBIOL, V10, P923, DOI 10.1111/j.1365-2958.1993.tb00964.x; Majka J, 1997, J BACTERIOL, V179, P2426, DOI 10.1128/jb.179.7.2426-2432.1997; Majka J, 1999, EUR J BIOCHEM, V260, P325, DOI 10.1046/j.1432-1327.1999.00168.x; MAJKA J, 1997, THESIS L HIRSZFELD I; Messer W, 1999, BIOCHIMIE, V81, P819, DOI 10.1016/S0300-9084(00)87165-5; Messer W, 1997, MOL MICROBIOL, V24, P1, DOI 10.1046/j.1365-2958.1997.3171678.x; MESSER W, 1996, ESCHERICHIA COLI SAL, P1779; MUSIALOWSKI MS, 1994, J BACTERIOL, V176, P5123, DOI 10.1128/jb.176.16.5123-5125.1994; POLLOCK R, 1990, NUCLEIC ACIDS RES, V18, P6197, DOI 10.1093/nar/18.21.6197; ROTH A, 1995, EMBO J, V14, P2106, DOI 10.1002/j.1460-2075.1995.tb07202.x; SCHAPER S, 1995, J BIOL CHEM, V270, P17622, DOI 10.1074/jbc.270.29.17622; SENEAR DF, 1991, J BIOL CHEM, V266, P13661; SKARSTAD K, 1994, BBA-GENE STRUCT EXPR, V1217, P111, DOI 10.1016/0167-4781(94)90025-6; Speck C, 1999, EMBO J, V18, P6169, DOI 10.1093/emboj/18.21.6169; Speck C, 1997, NUCLEIC ACIDS RES, V25, P3242, DOI 10.1093/nar/25.16.3242; Weigel C, 1999, MOL MICROBIOL, V34, P53, DOI 10.1046/j.1365-2958.1999.01568.x; ZAKRZEWSKACZERWINSKA J, 1994, MOL GEN GENET, V242, P440, DOI 10.1007/BF00281794; ZAKRZEWSKACZERWINSKA J, 1992, J BACTERIOL, V174, P2688, DOI 10.1128/jb.174.8.2688-2693.1992	26	22	24	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6243	6252		10.1074/jbc.M007876200	http://dx.doi.org/10.1074/jbc.M007876200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11073953	hybrid			2022-12-25	WOS:000167261000026
J	Waas, WF; Lo, HH; Dalby, KN				Waas, WF; Lo, HH; Dalby, KN			The kinetic mechanism of the dual phosphorylation of the ATF2 transcription factor by p38 mitogen-activated protein (MAP) kinase alpha - Implications for signal/response profiles of map kinase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE 2A; SIGNAL-TRANSDUCTION; MOLECULAR-CLONING; DOCKING SITE; FAMILY; IDENTIFICATION; CASCADE; SWITCH; INDUCTION; APOPTOSIS	The mitogen-activated protein kinases (MAPKs) are a family of enzymes conserved among eukaryotes that regulate cellular activities in response to numerous external signals. They are the terminal component of a three-kinase cascade that is evolutionarily conserved and whose arrangement appears to offer considerable flexibility in encompassing the diverse biological situations for which they are employed. Although multistep protein phosphorylation within mitogen-activated protein kinase (MAPK) cascades can dramatically influence the sensitivity of signal propagation, an investigation of the mechanism of multisite phosphorylation by a MAPK has not been reported. Here we report a kinetic examination of the phosphorylation of Thr-69 and Thr-71 of the glutathione S-transferase fusion protein of the trans-activation domain of activating transcription factor-a (GST-ATFB-(1-115)) by p38 MAPK alpha (p38 alpha) as a model system for the phosphorylation of ATF2 by p38 alpha. Our experiments demonstrated that GST-ATF2-(1-115) is phosphorylated in a two-step distributive mechanism, where p38 alpha dissociates from GST-ATFB-(1-115) after the initial phosphorylation of either Thr-69 or Thr-71, Whereas p38 alpha showed similar specificity for Thr-71 and Thr-69 in the unphosphorylated protein, it displayed a marked difference in specificity toward the mono-phosphoisomers. Phosphorylation of Thr-71 had no significant effect on the rate of Thr-69 phosphorylation, but Thr-69 phosphorylation reduced the specificity, k(cat)/K-M, of p38 alpha for Thr-71 by approximately 40-fold. Computer simulation of the mechanism suggests that the activation of ATF2 by p38 alpha in vivo is essentially Michaelian and provides insight into how the kinetics of a two-step distributive mechanism can be adapted to modulate effectively the sensitivity of a signal transduction pathway. This work also suggests that whereas MAPKs utilize docking interactions to bind substrates, they can be weak and transient in nature, providing just enough binding energy to promote the phosphorylation of a specific substrate.	Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA; Univ Texas, Coll Pharm, Div Toxicol, Austin, TX 78712 USA; Univ Texas, Grad Program Biochem, Austin, TX 78712 USA; Univ Texas, Grad Program Mol Biol, Austin, TX 78712 USA; Univ Texas, Ctr Mol & Cellular Toxicol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Dalby, KN (corresponding author), Univ Texas, Coll Pharm, Div Med Chem, Austin, TX 78712 USA.	Dalby@mail.utexas.edu	Dalby, Kevin N/A-1905-2013	Dalby, Kevin N/0000-0001-9272-5129	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30 ES07784] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aggen JB, 2000, CHEM BIOL, V7, pR13, DOI 10.1016/S1074-5521(00)00069-7; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Burack WR, 1997, BIOCHEMISTRY-US, V36, P5929, DOI 10.1021/bi970535d; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chen GJ, 2000, BIOCHEMISTRY-US, V39, P2079, DOI 10.1021/bi9919495; Cobb MH, 1999, PROG BIOPHYS MOL BIO, V71, P479, DOI 10.1016/S0079-6107(98)00056-X; Cornish-Bowden A., 1995, FUNDAMENTALS ENZYME, P297; Cuenda A, 1997, EMBO J, V16, P295, DOI 10.1093/emboj/16.2.295; Ferrell JE, 1998, TRENDS BIOCHEM SCI, V23, P461, DOI 10.1016/S0968-0004(98)01316-4; Ferrell JE, 1997, J BIOL CHEM, V272, P19008, DOI 10.1074/jbc.272.30.19008; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Goldberg Y, 1999, BIOCHEM PHARMACOL, V57, P321, DOI 10.1016/S0006-2952(98)00245-7; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; Gum RJ, 1999, BIOCHEM BIOPH RES CO, V266, P284, DOI 10.1006/bbrc.1999.1787; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HIROSE T, 1994, MOL ENDOCRINOL, V8, P1667, DOI 10.1210/me.8.12.1667; Huang CYF, 1996, P NATL ACAD SCI USA, V93, P10078, DOI 10.1073/pnas.93.19.10078; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1038, DOI 10.1073/pnas.73.4.1038; Keyse SM, 2000, CURR OPIN CELL BIOL, V12, P186, DOI 10.1016/S0955-0674(99)00075-7; Keyse SM, 1999, FREE RADICAL RES, V31, P341, DOI 10.1080/10715769900300911; Khokhlatchev A, 1997, J BIOL CHEM, V272, P11057; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Levchenko A, 2000, P NATL ACAD SCI USA, V97, P5818, DOI 10.1073/pnas.97.11.5818; LoGrasso PV, 1997, BIOCHEMISTRY-US, V36, P10422, DOI 10.1021/bi9706778; Millward TA, 1999, TRENDS BIOCHEM SCI, V24, P186, DOI 10.1016/S0968-0004(99)01375-4; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Porter AC, 1999, ONCOGENE, V18, P7794, DOI 10.1038/sj.onc.1203214; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; Smith JA, 1999, J BIOL CHEM, V274, P2893, DOI 10.1074/jbc.274.5.2893; Takekawa M, 1998, CELL, V95, P521, DOI 10.1016/S0092-8674(00)81619-0; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tobiume K, 1997, BIOCHEM BIOPH RES CO, V239, P905, DOI 10.1006/bbrc.1997.7580; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; Zhao M, 1999, MOL CELL BIOL, V19, P21; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9	52	68	68	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5676	5684		10.1074/jbc.M008787200	http://dx.doi.org/10.1074/jbc.M008787200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11069918	hybrid			2022-12-25	WOS:000167115100038
J	Budd, DC; Willars, GB; McDonald, JE; Tobin, AB				Budd, DC; Willars, GB; McDonald, JE; Tobin, AB			Phosphorylation of the G(q/11)-coupled M-3-muscarinic receptor is involved in receptor activation of the ERK-1/2 mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; FOCAL TYROSINE KINASE; BETA-GAMMA-SUBUNITS; SMOOTH-MUSCLE CELLS; COUPLED RECEPTORS; MAP KINASE; MUSCARINIC RECEPTOR; SIGNALING PATHWAY; RAS; SRC	We investigated the role played by agonist-mediated phosphorylation of the G(q/11)-coupled M-3-muscarinic receptor in the mechanism of activation of the mitogen-activated protein kinase pathway, ERK-1/2, in transfected Chinese hamster ovary cells. A mutant of the M-3-muscarinic receptor, where residues Lys(370)-Ser(425) Of the third intracellular loop had been deleted, showed a reduced ability to activate the ERK-1/2 pathway. This reduction was evident despite the fact that the receptor was able to couple efficiently to the phospholipase C second messenger pathway. Importantly, the ERK-1/2 responses to both the wild-type M-3-muscarinic receptor and Delta Lys(370)-Ser(425) receptor mutant were dependent on the activity of protein kinase C. Our results, therefore, indicate the existence of two mechanistic components to the ERK-1/2 response, which appear to act in concert. First, the activation of protein kinase C through the diacylglycerol arm of the phospholipase C signaling pathway and a second component, absent in the Delta Lys(370)-Ser(425) receptor mutant, that is independent of the phospholipase C signaling pathway. The reduced ability of the Delta Lys(370)-Ser(425) receptor mutant to activate the ERK-1/2 pathway correlated with an similar to 80% decrease in the ability of the receptor to undergo agonist-mediated phosphorylation. Furthermore, we have previously shown that M-3-muscarinic receptor phosphorylation can be inhibited by a dominant negative mutant of casein kinase 1 alpha and by expression of a peptide corresponding to the third intracellular loop of the M-3-muscarinic receptor. Expression of these inhibitors of receptor phosphorylation reduced the wild-type M-3-muscarinic receptor ERK-1/2 response. We conclude that phosphorylation of the M-3-muscarinic receptor on sites in the third intracellular loop by casein kinase 1 alpha contributes to the mechanism of receptor activation of ERK-1/2 by working. in concert with the diacylglycerol/ PKC arm of the phospholipase C signaling pathway.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Tobin, AB (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, POB 138,Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.							Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; CHALLISS RAJ, 1988, BIOCHEM BIOPH RES CO, V157, P684, DOI 10.1016/S0006-291X(88)80304-8; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; FAURE M, 1994, J BIOL CHEM, V269, P7851; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Kim JY, 1999, BIOCHEM J, V337, P275, DOI 10.1042/0264-6021:3370275; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Launay JM, 1996, J BIOL CHEM, V271, P3141, DOI 10.1074/jbc.271.6.3141; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LopezIlasaca M, 1997, SCIENCE, V275, P394, DOI 10.1126/science.275.5298.394; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MALARKEY K, 1995, BIOCHEM J, V309, P361, DOI 10.1042/bj3090361; Palomero T, 1998, MOL PHARMACOL, V53, P613, DOI 10.1124/mol.53.4.613; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Slack BE, 2000, BIOCHEM J, V348, P381, DOI 10.1042/0264-6021:3480381; Soltoff SP, 1998, J BIOL CHEM, V273, P2653, DOI 10.1074/jbc.273.5.2653; Soltoff SP, 1998, J BIOL CHEM, V273, P23110, DOI 10.1074/jbc.273.36.23110; Tapia JA, 1999, J BIOL CHEM, V274, P31261, DOI 10.1074/jbc.274.44.31261; Tobin AB, 1997, J BIOL CHEM, V272, P20844, DOI 10.1074/jbc.272.33.20844; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; Tobin AB, 1996, J BIOL CHEM, V271, P3907; TOBIN AB, 1992, MOL PHARMACOL, V42, P1042; Velarde V, 1999, AM J PHYSIOL-CELL PH, V277, pC253, DOI 10.1152/ajpcell.1999.277.2.C253; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; WATANABE T, 1995, J BIOL CHEM, V270, P8984, DOI 10.1074/jbc.270.15.8984; Waugh MG, 1999, BIOCHEM J, V338, P175, DOI 10.1042/0264-6021:3380175; WINITZ S, 1993, J BIOL CHEM, V268, P19196; Wylie PG, 1999, BIOCHEM J, V338, P619, DOI 10.1042/0264-6021:3380619; XIONG L, 1998, EMBO J, V17, P2574; Zou YZ, 1996, J BIOL CHEM, V271, P33592, DOI 10.1074/jbc.271.52.33592; Zwick E, 1997, J BIOL CHEM, V272, P24767, DOI 10.1074/jbc.272.40.24767	42	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4581	4587		10.1074/jbc.M008827200	http://dx.doi.org/10.1074/jbc.M008827200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11083874	hybrid			2022-12-25	WOS:000168484300010
J	Carpenter, L; Cordery, D; Biden, TJ				Carpenter, L; Cordery, D; Biden, TJ			Protein kinase C delta activation by interleukin-1 beta stabilizes inducible nitric-oxide synthase mRNA in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; GENE-EXPRESSION; MESSENGER-RNA; PERITONEAL-MACROPHAGES; PKC-DELTA; ALPHA; INVOLVEMENT; INHIBITION; INDUCTION; ISOFORMS	Exposure of pancreatic islets to cytokines such as interleukin (IL)-1 beta induces a variety of proinflammatory genes including type II nitric-oxide synthase (MOS) which produces nitric oxide (NO). NO is thought to be a major cause of islet beta -cell dysfunction and apoptotic beta -cell death, which results in type I diabetes. Since protein kinase C (PKC) mediates some of the actions of cytokines in other cell types, our aim was to assess the role of PKC in IL-1 beta -induced iNOS expression in pancreatic beta -cells. PKC delta, but not PKC alpha, was specifically activated in the rat INS-1 beta -cell line by IL-1 beta as assessed by membrane translocation. Moreover, MOS expression and NO production were significantly attenuated by the PKC delta specific inhibitor rottlerin and overexpression of a PKC delta kinase-dead mutant protein. Conversely, overexpression of PKC delta wild type protein significantly potentiated this response. These results were confirmed at the mRNA level by reverse transcriptase-polymerase chain reaction. However, a role at the level of transcriptional regulation appeared unlikely, since PKC delta was not required for the activation of NF-kappaB, activating protein 1, and activating transcription factor 2 signaling pathways in response to IL-1 beta. There was, however, a significant increase in MOS mRNA stability mediated by PKC delta wild type, while PKC delta kinase-dead acted reciprocally, reducing MOS mRNA stability. The results indicate that, in addition to transcriptional activation, mRNA stabilization is a key component of the mechanism by which IL-1 beta stimulates MOS expression in beta -cells and that PKC delta plays an essential role in this process. PKC delta activation may therefore have significant consequences with regard to cellular function and viability when beta -cells are exposed to IL-1 beta and potentially other cytokines.	St Vincents Hosp, Garvan Inst Med Res, Sydney, NSW 2010, Australia	Garvan Institute of Medical Research; St Vincents Hospital Sydney	Biden, TJ (corresponding author), Garvan Inst Med Res, Cell Signalling Grp, 384 Victoria St, Sydney, NSW 2010, Australia.		Biden, Trevor/AAW-2829-2021	Biden, Trevor/0000-0001-5211-0234				Ammendrup A, 2000, DIABETES, V49, P1468, DOI 10.2337/diabetes.49.9.1468; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; BaierBitterlich G, 1996, MOL CELL BIOL, V16, P1842; Bonizzi G, 1999, BIOCHEM PHARMACOL, V57, P713, DOI 10.1016/S0006-2952(98)00353-0; Brachat A, 2000, ONCOGENE, V19, P5073, DOI 10.1038/sj.onc.1203882; BROOKS G, 1992, MOL CARCINOGEN, V5, P328, DOI 10.1002/mc.2940050414; Chen CC, 1998, J BIOL CHEM, V273, P19424, DOI 10.1074/jbc.273.31.19424; Chen CC, 1998, J IMMUNOL, V161, P6206; Chen NY, 1999, J BIOL CHEM, V274, P15389, DOI 10.1074/jbc.274.22.15389; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Darville MI, 1998, DIABETOLOGIA, V41, P1101, DOI 10.1007/s001250051036; Das KC, 1998, J BIOL CHEM, V273, P34639, DOI 10.1074/jbc.273.51.34639; DiazGuerra MJM, 1996, J BIOL CHEM, V271, P32028, DOI 10.1074/jbc.271.50.32028; DIAZMECO MT, 1994, EMBO J, V13, P2842, DOI 10.1002/j.1460-2075.1994.tb06578.x; DIAZMECO MT, 1993, MOL CELL BIOL, V13, P4770, DOI 10.1128/MCB.13.8.4770; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; EIZIRIK DL, 1995, MOL CELL ENDOCRINOL, V111, P159, DOI 10.1016/0303-7207(95)03561-K; Eizirik DL, 1996, DIABETOLOGIA, V39, P875; Graham F L, 1991, Methods Mol Biol, V7, P109, DOI 10.1385/0-89603-178-0:109; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Guan ZH, 1996, AM J PHYSIOL-RENAL, V270, pF634, DOI 10.1152/ajprenal.1996.270.4.F634; HEVEL JM, 1994, METHOD ENZYMOL, V233, P250; HIRAI S, 1994, EMBO J, V13, P2331, DOI 10.1002/j.1460-2075.1994.tb06517.x; HIRANO M, 1995, BIOCHEM BIOPH RES CO, V206, P429, DOI 10.1006/bbrc.1995.1059; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HOLTMANN H, 2000, J BIOL CHEM, V19, P6742; HORTELANO S, 1993, FEBS LETT, V320, P135, DOI 10.1016/0014-5793(93)80078-9; JUN CD, 1994, J IMMUNOL, V153, P3684; Kawasaki H, 1998, GENE DEV, V12, P233, DOI 10.1101/gad.12.2.233; Keinanen R, 1999, GENE, V234, P297, DOI 10.1016/S0378-1119(99)00196-1; KNUTSON KL, 1994, ENDOCRINOLOGY, V135, P881, DOI 10.1210/en.135.3.881; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Larsen CM, 1998, J BIOL CHEM, V273, P15294, DOI 10.1074/jbc.273.24.15294; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; MandrupPoulsen T, 1996, DIABETOLOGIA, V39, P1005, DOI 10.1007/BF00400649; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; McDaniel ML, 1997, ADV EXP MED BIOL, V426, P313; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MESSMER UK, 1994, CELL SIGNAL, V6, P17; Nunokawa Y, 1997, BIOCHEM BIOPH RES CO, V233, P523, DOI 10.1006/bbrc.1997.6471; OHNO S, 1990, J BIOL CHEM, V265, P6296; Rabinovitch A, 1998, BIOCHEM PHARMACOL, V55, P1139, DOI 10.1016/S0006-2952(97)00492-9; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Sambrook J., 2002, MOL CLONING LAB MANU; SchmitzPeiffer C, 1997, DIABETES, V46, P169, DOI 10.2337/diabetes.46.2.169; Schultz H, 1997, J CELL PHYSIOL, V173, P310, DOI 10.1002/(SICI)1097-4652(199712)173:3<310::AID-JCP2>3.0.CO;2-Q; Shimabukuro M, 1997, J CLIN INVEST, V100, P290, DOI 10.1172/JCI119534; Short S, 2000, J BIOL CHEM, V275, P12963, DOI 10.1074/jbc.275.17.12963; SPESSOT R, 1989, VIROLOGY, V168, P378, DOI 10.1016/0042-6822(89)90279-1; St-Denis A, 1998, J BIOL CHEM, V273, P32787, DOI 10.1074/jbc.273.49.32787; Tian YM, 1996, MOL CELL ENDOCRINOL, V119, P185, DOI 10.1016/0303-7207(96)03811-7; Toyoda M, 1998, BIOCHEM BIOPH RES CO, V250, P430, DOI 10.1006/bbrc.1998.9332; Welsh N, 1996, J BIOL CHEM, V271, P8307, DOI 10.1074/jbc.271.14.8307; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969	56	93	96	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5368	5374		10.1074/jbc.M010036200	http://dx.doi.org/10.1074/jbc.M010036200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087760	hybrid			2022-12-25	WOS:000168484300112
J	Fang, D; Wang, HY; Fang, N; Altman, Y; Elly, C; Liu, YC				Fang, D; Wang, HY; Fang, N; Altman, Y; Elly, C; Liu, YC			Cbl-b, a RING-type E3 ubiquitin ligase, targets phosphatidylinositol 3-kinase for ubiquitination in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; C-CBL; TRANSCRIPTION FACTOR; NEGATIVE REGULATOR; PROTEIN; ACTIVATION; SIGNAL; PROTOONCOPROTEIN; ASSOCIATION; PROTEOLYSIS	Cbl-b is implicated in setting the threshold of T lymphocyte activation. In Cbl-b-deficient T cells, the activation of Vav, a guanine nucleotide exchange factor, is significantly enhanced. The molecular mechanism underlying Cbl-b-regulated Vav activation was unclear, Here it is shown that Cbl-b interacts with and induces ubiquitin conjugation to the p85 regulatory subunit of phosphatidylinositol 3-kinase, an upstream regulator of Vav. A functional RING finger of Cbl-b was essential for p85 ubiquitination. However, a loss of function mutation at the well-conserved amino-terminal variant src homology (SH) 2 domain of Cbl-b did not affect its ligase activity. A distal carboxyl-terminal proline-rich region in Cbl-b was mapped to contain the primary binding sequences for the SH3 domain of p85. Deletion of either the distal proline-rich region in Cbl-b or the SH3 domain of p85 severely reduced ubiquitin conjugation to p85. The data suggest a molecular link for Cbl-b-mediated negative regulation of Vav, with phosphatidylinositol 3-kinase as a direct target for Cbl-b E3 ubiquitin ligase.	La Jolla Inst Allergy & Immunol, Div Cell Biol, San Diego, CA 92121 USA	La Jolla Institute for Immunology	Liu, YC (corresponding author), La Jolla Inst Allergy & Immunol, Div Cell Biol, 10355 Sci Ctr Dr, San Diego, CA 92121 USA.	yuncail@liai.org	Fang, Deyu/I-7245-2013	Fang, Deyu/0000-0002-4211-2751; LIU, YUN-CAI/0000-0002-0996-7109	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056558] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK56558] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bustelo XR, 1997, ONCOGENE, V15, P2511, DOI 10.1038/sj.onc.1201430; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Donovan JA, 1996, J BIOL CHEM, V271, P26369, DOI 10.1074/jbc.271.42.26369; Elly C, 1999, ONCOGENE, V18, P1147, DOI 10.1038/sj.onc.1202411; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Harpur AG, 1999, J BIOL CHEM, V274, P12323, DOI 10.1074/jbc.274.18.12323; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoppe T, 2000, CELL, V102, P577, DOI 10.1016/S0092-8674(00)00080-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; KEANE MM, 1995, ONCOGENE, V10, P2367; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; LANGDON WY, 1989, P NATL ACAD SCI USA, V86, P1168, DOI 10.1073/pnas.86.4.1168; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Li EG, 2000, J BIOL CHEM, V275, P14729, DOI 10.1074/jbc.275.19.14729; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Qiu L, 2000, J BIOL CHEM, V275, P35734, DOI 10.1074/jbc.M007300200; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; RICKLES RJ, 1994, EMBO J, V13, P5598, DOI 10.1002/j.1460-2075.1994.tb06897.x; van Leeuwen JEM, 1999, CURR OPIN IMMUNOL, V11, P242, DOI 10.1016/S0952-7915(99)80040-5; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297; Zhang ZH, 1999, CURR BIOL, V9, P203, DOI 10.1016/S0960-9822(99)80090-6; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	33	153	160	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4872	4878		10.1074/jbc.M008901200	http://dx.doi.org/10.1074/jbc.M008901200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087752	hybrid			2022-12-25	WOS:000168484300047
J	Li, LT; Kaplan, J				Li, LT; Kaplan, J			The yeast gene MSC2, a member of the cation diffusion facilitator family, affects the cellular distribution of zinc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TRANSPORTERS; IDENTIFICATION; MITOCHONDRIAL; RESISTANCE; CLONING; PROTEIN; ZAP1P	The sequence of the yeast gene YDR205W places it within the family of cation diffusion facilitators: membrane proteins that transport transition metals. Deletion of YDR205W was reported to result in an increase in unequal sister chromatid recombination and was named meiotic sister chromatid recombination 2 (MSC2; Thompson, D. A., and Stahl, F, W. (1999) Genetics 153, 621-641), We report here that a msc2 strain shows a phenotype of decreased viability in glycerol-ethanol media at 37 degreesC, Associated with decreased growth is an abnormal morphology typified by an increase in size of both cells and vacuoles. Addition of extracellular Zn2+ completely suppresses the morphological changes and partially suppresses the growth defect. Regardless of the concentration of Zn2+ in the media, the msc2 strain had a higher Zn2+ content than wild type cells. Zinquin staining also revealed that msc2 had a marked increase in fluorescence compared with the wild type, again reflecting an increase in intracellular Zn2+, The deletion strain accumulated excess Zn2+ in nuclei-enriched membrane fractions, and when grown at 37 degreesC in glycerol-ethanol media, it showed a decreased expression of Zn2+-regulated genes. The expression of genes regulated by either Fe2+ or Cu2+ was not affected. An epitope-tagged Msc2p was localized to the endoplasmic reticulum/nucleus, These results suggest that Msc2p affects the cellular distribution of zinc and, in particular, the zinc content of nuclei.	Univ Utah, Sch Med, Dept Pathol, Div Immunol & Cell Biol, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Kaplan, J (corresponding author), Univ Utah, Sch Med, Dept Pathol, Div Immunol & Cell Biol, Salt Lake City, UT 84132 USA.				NIDDK NIH HHS [DK52380, DK30534] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK030534, R01DK030534, R01DK052380] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBERG DC, 1995, YEAST, V11, P1275, DOI 10.1002/yea.320111307; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Bird AJ, 2000, EMBO J, V19, P3704, DOI 10.1093/emboj/19.14.3704; CAO CX, 1992, J INFECT DIS, V165, P322, DOI 10.1093/infdis/165.2.322; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; Glick BS, 1995, METHOD ENZYMOL, V260, P213, DOI 10.1016/0076-6879(95)60139-2; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; Huang LP, 1997, NAT GENET, V17, P292, DOI 10.1038/ng1197-292; Iyer V, 1996, P NATL ACAD SCI USA, V93, P5208, DOI 10.1073/pnas.93.11.5208; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Li LT, 1997, J BIOL CHEM, V272, P28485, DOI 10.1074/jbc.272.45.28485; Lyons TJ, 2000, P NATL ACAD SCI USA, V97, P7957, DOI 10.1073/pnas.97.14.7957; Moore DD, 1995, GLOB MOB SURV; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Perou CM, 1996, NAT GENET, V13, P303, DOI 10.1038/ng0796-303; Radisky DC, 1999, J BIOL CHEM, V274, P4497, DOI 10.1074/jbc.274.8.4497; Romano JD, 1998, MOL BIOL CELL, V9, P2231, DOI 10.1091/mbc.9.8.2231; Thompson DA, 1999, GENETICS, V153, P621; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044	22	70	72	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5036	5043		10.1074/jbc.M008969200	http://dx.doi.org/10.1074/jbc.M008969200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11058603	hybrid			2022-12-25	WOS:000168484300069
J	Zhang, ZX; Sun, S; Quinn, SJ; Brown, EM; Bai, M				Zhang, ZX; Sun, S; Quinn, SJ; Brown, EM; Bai, M			The extracellular calcium-sensing receptor dimerizes through multiple types of intermolecular interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CA2+ RECEPTOR; CELL-SURFACE; DOMAIN; MUTATIONS; EXPRESSION	Recent studies have shown that the G protein-coupled, extracellular calcium ([Ca2+](o))-sensing receptor (CaR) forms disulfide-linked dimers through cysteine residues within its extracellular domain and that dimerization of the CaR has functional implications. In this study, we have investigated which of these disulfide linkages are essential for dimerization of the CaR and whether they are required for these functional interactions, Our results confirm the key roles of Cys(129) and Cys(131) in CaR dimerization, However, utilizing crosslinking of the CaR or immunoprecipitation of a non-FLAG-tagged CaR with a FLAG-tagged CaR using anti-FLAG antibody, we demonstrate that CaRs with or without these two cysteines form dimers on the cell surface to a similar extent. In addition, reconstitution of CaR-mediated signaling by cotransfection of two individually inactive mutant CaRs is nearly identical in the presence or absence of both Cys(129) and Cys(131), showing that covalent linkage of CaR dimers is not needed for functional interactions between CaR monomers, These findings suggest that the CaR has at least two distinct types of motifs mediating dimerization and functional interactions, i.e. covalent interactions involving intermolecular disulfide bonds and noncovalent, possibly hydrophobic, interactions.	Brigham & Womens Hosp, Div Endocrine Hypertens, Boston, MA 02115 USA; Brigham & Womens Hosp, Membrane Biol Program, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Bai, M (corresponding author), Brigham & Womens Hosp, Div Endocrine Hypertens, 221 Longwood Ave, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041415, R01DK048330, R01DK052005, R01DK054934] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41415, DK54934, DK52005, DK48330] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bai M, 1999, P NATL ACAD SCI USA, V96, P2834, DOI 10.1073/pnas.96.6.2834; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; DUNCAN DB, 1955, BIOMETRICS, V2, P1; FAJTOVA VT, 1991, AM J PHYSIOL, V261, pE151, DOI 10.1152/ajpendo.1991.261.1.E151; Fan GF, 1998, FEBS LETT, V436, P353, DOI 10.1016/S0014-5793(98)01165-X; HAWLEY-NELSON P, 1993, FOCUS MADISON, V15, P73; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612	19	112	119	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5316	5322		10.1074/jbc.M005958200	http://dx.doi.org/10.1074/jbc.M005958200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11069904	hybrid			2022-12-25	WOS:000168484300105
J	Gao, DX; McHenry, CS				Gao, DX; McHenry, CS			tau binds and organizes Escherichia coli replication proteins through distinct domains - Domain III, shared by gamma and tau binds delta delta ' and x psi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; ONE HOLOENZYME PARTICLE; SLIDING CLAMPS; LAGGING-STRAND; ALPHA-SUBUNIT; GENE-PRODUCT; COMPLEX; MACHINE; LOADER; IDENTIFICATION	The DnaX complex of the DNA polymerase holoenzyme assembles the beta (2) processivity factor onto the primed template enabling highly processive replication. The key ATPases within this complex are tau and gamma, alternative frameshift products of the dnaX gene. Of the five domains of tau, I-III are shared with gamma In vivo, gamma binds the auxiliary subunits delta delta' and chi psi (Glover, B. P., and McHenry, C. S. (2000) J. Biol. Chem. 275, 3017-3020), To localize delta delta' and chi psi binding domains within gamma domains I-III, we measured the binding of purified biotin-tagged DnaX proteins lacking specific domains to delta delta' and chi psi by surface plasmon resonance. Fusion proteins containing either DnaX domains I-III or domains III-V bound delta delta' and chi psi subunits, A DnaX protein only containing domains I and II did not bind delta delta' or chi psi The binding affinity of chi psi for DnaX domains I-III and domains III-V was the same as that of chi psi for full-length tau, indicating that domain III contained all structural elements required for chi psi binding. Domain III of tau also contained delta delta' binding sites, although the interaction between delta delta' and domains III-V of tau was 10-fold weaker than the interaction between SS' and full length tau. The presence of both S and chi psi strengthened the delta'-C(0)tau interaction by at least 15-fold. Domain III was the only domain common to all of tau fusion proteins whose interaction with delta' was enhanced in the presence of S and chi psi. Thus, domain III of the DnaX proteins not only contains the delta delta' and chi psi binding sites but also contains the elements required for the positive cooperative assembly of the DnaX complex.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gao, DX (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.				NIGMS NIH HHS [GM35695] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CARTER JR, 1993, J BACTERIOL, V175, P3812, DOI 10.1128/JB.175.12.3812-3822.1993; Cull MG, 1995, METHOD ENZYMOL, V262, P22; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; DALLMANN HG, 1995, J BIOL CHEM, V270, P29563, DOI 10.1074/jbc.270.49.29563; Gao DX, 2001, J BIOL CHEM, V276, P4433, DOI 10.1074/jbc.M009828200; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KODAIRA M, 1983, MOL GEN GENET, V192, P80, DOI 10.1007/BF00327650; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MOK M, 1987, J BIOL CHEM, V262, P16644; MULLIN DA, 1983, MOL GEN GENET, V192, P73, DOI 10.1007/BF00327649; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; OLSON MW, 1995, J BIOL CHEM, V270, P29570, DOI 10.1074/jbc.270.49.29570; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; ONRUST R, 1995, J BIOL CHEM, V270, P13348, DOI 10.1074/jbc.270.22.13348; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Pritchard AE, 1996, J BIOL CHEM, V271, P10291, DOI 10.1074/jbc.271.17.10291; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; WU YH, 1984, J BIOL CHEM, V259, P2117; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	27	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4447	4453		10.1074/jbc.M009827200	http://dx.doi.org/10.1074/jbc.M009827200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11078742	hybrid			2022-12-25	WOS:000166921200095
J	Mestre, JR; Mackrell, PJ; Rivadeneira, DE; Stapleton, PP; Tanabe, T; Daly, JM				Mestre, JR; Mackrell, PJ; Rivadeneira, DE; Stapleton, PP; Tanabe, T; Daly, JM			Redundancy in the signaling pathways and promoter elements regulating cyclooxygenase-8 gene expression in endotoxin-treated macrophage/monocytic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN-ENDOPEROXIDE SYNTHASE-2; ARACHIDONIC-ACID OXYGENATION; NF-KAPPA-B; EPITHELIAL-CELLS; PHORBOL ESTER; ANTIINFLAMMATORY DRUGS; RESPONSE ELEMENT; NUCLEAR FACTOR; LIPOPOLYSACCHARIDE; TRANSCRIPTION	Macrophage expression of cyclooxygenase-2 (COX-2), the inducible isoform of COX, is up-regulated by proinflammatory stimuli both in vivo and in vitro. Here we investigated the mechanisms regulating COX-2 gene expression in macrophage/monocytic cells. Lipopolysaccharide (LPS) is known to induce de novo COX-2 mRNA expression in these cells. Transient cotransfections with a COX-2 promoter-luciferase construct and different expression vectors showed that LPS up-regulates COX-2 transcription through both mitogen-activated protein kinase (MAPK) and protein kinase C (PKC) pathways. Cotransfections with expression vectors for dominant negative mutants of MAPK and PKC isoforms did not suppress the effects of LPS on COX-2. Electrophoretic mobility shift assays and transient transfection experiments with deleted and mutated variants of a COX-2 promoter-luciferase construct showed that NFKB, NF-IL6, and CRE promoter sites mediate gene transcription independently in response to LPS treatment. In these experiments, isolated NFKB, NF-IL6, and CRE promoter sites were less effective than the intact promoter in mediating COX-2 transcription. Cotransfections with mutated COX-2 promoter-luciferase constructs and expression vectors showed that each one of these promoter elements can be activated by LPS through both MAPK and PKC pathways to induce gene expression. In summary, there is redundancy in the signaling pathways and promoter elements regulating COX-2 transcription in endotoxin-treated cells of macrophage/monocytic lineage.	New York Presbyterian Hosp, Dept Surg, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Surg, New York, NY 10021 USA; Strang Canc Prevent Ctr, New York, NY 10021 USA; Natl Cardiovasc Ctr, Res Inst, Dept Pharmacol, Suita, Osaka 565, Japan	NewYork-Presbyterian Hospital; Cornell University; National Cerebral & Cardiovascular Center - Japan	Daly, JM (corresponding author), New York Presbyterian Hosp, Dept Surg, Rm F-739,York Ave,Cornell Campus, New York, NY 10021 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050201] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK50201] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; DAVIES P, 1984, ANNU REV IMMUNOL, V2, P335, DOI 10.1146/annurev.immunol.2.1.335; DINCHUK JE, 1995, NATURE, V378, P406, DOI 10.1038/378406a0; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Inoue H, 1998, BIOCHEM BIOPH RES CO, V244, P143, DOI 10.1006/bbrc.1998.8222; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Kelley DJ, 1997, CARCINOGENESIS, V18, P795, DOI 10.1093/carcin/18.4.795; KOSAKA T, 1994, EUR J BIOCHEM, V221, P889, DOI 10.1111/j.1432-1033.1994.tb18804.x; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Mestre JR, 1997, CANCER RES, V57, P1081; NANAYAMA T, 1995, PROSTAGLANDINS, V49, P371, DOI 10.1016/0090-6980(95)00068-L; RIESE J, 1994, J LEUKOCYTE BIOL, V55, P476, DOI 10.1002/jlb.55.4.476; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Simmons DL, 1999, P NATL ACAD SCI USA, V96, P3275, DOI 10.1073/pnas.96.6.3275; SMITH WL, 1992, AM J PHYSIOL, V263, P181; Subbaramaiah K, 1996, CANCER RES, V56, P4424; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; Zhang F, 1999, CARCINOGENESIS, V20, P445, DOI 10.1093/carcin/20.3.445	27	129	135	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3977	3982		10.1074/jbc.M005077200	http://dx.doi.org/10.1074/jbc.M005077200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11092878	hybrid			2022-12-25	WOS:000166921200036
J	McMahon, HEM; Mange, A; Nishida, N; Creminon, C; Casanova, D; Lehmann, S				McMahon, HEM; Mange, A; Nishida, N; Creminon, C; Casanova, D; Lehmann, S			Cleavage of the amino terminus of the prion protein by reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREUTZFELDT-JAKOB-DISEASE; OXIDATIVE STRESS; COPPER-BINDING; IN-VITRO; SUPEROXIDE-DISMUTASE; HYDROGEN-PEROXIDE; CULTURED-CELLS; SCRAPIE AGENT; MICE; PRP	Relatively limited information is available on the processing and function of the normal cellular prion protein, PrPC. Here it is reported for the first time that PrPC undergoes a site-specific cleavage of the octapeptide repeat region of the amino terminus on exposure to reactive oxygen species. This cleavage was both copperand pH-dependent and was retarded by the presence of other divalent metal ions. The oxidative state of the cell also decreased detection of full-length PrPC and increased detection of amino-terminally fragmented PrPC within cells. Such a post-translational modification has vast implications for PrPC, in its processing, because such cleavage could alter further proteolysis, and in the formation of the scrapie isoform of the prion protein, PrPSc, because abnormal cleavage of PrPSc occurs into the octapeptide repeat region.	CNRS, IGH, F-34396 Montpellier 5, France; CEA Saclay, Serv Pharmacol & Immunol, F-91191 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; CEA; UDICE-French Research Universities; Universite Paris Saclay	Lehmann, S (corresponding author), CNRS, IGH, 141 Rue de la Cardonille, F-34396 Montpellier 5, France.		Lehmann, Sylvain/P-1301-2017; Mange, Alain/U-1157-2017	Lehmann, Sylvain/0000-0001-6117-562X; Mange, Alain/0000-0002-1566-9407; McMahon, Hilary/0000-0003-0016-522X				AMSTAD P, 1994, J BIOL CHEM, V269, P1606; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; Brown DR, 1998, BIOCHEM J, V334, P423, DOI 10.1042/bj3340423; BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Chao CC, 1997, P NATL ACAD SCI USA, V94, P2969, DOI 10.1073/pnas.94.7.2969; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; Choi SI, 1998, ACTA NEUROPATHOL, V96, P279, DOI 10.1007/s004010050895; Collinge J, 1999, LANCET, V354, P317, DOI 10.1016/S0140-6736(99)05128-4; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Guentchev M, 2000, NEUROBIOL DIS, V7, P270, DOI 10.1006/nbdi.2000.0290; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; Herms J, 1999, J NEUROSCI, V19, P8866, DOI 10.1523/JNEUROSCI.19-20-08866.1999; Hill AF, 1999, J GEN VIROL, V80, P11, DOI 10.1099/0022-1317-80-1-11; HOPE J, 1988, EUR J BIOCHEM, V172, P271, DOI 10.1111/j.1432-1033.1988.tb13883.x; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; HYSLOP PA, 1995, BRAIN RES, V671, P181, DOI 10.1016/0006-8993(94)01291-O; Jimenez-Huete A, 1998, AM J PATHOL, V153, P1561, DOI 10.1016/S0002-9440(10)65744-6; KIM K, 1985, J BIOL CHEM, V260, P5394; Krasemann S, 1996, MOL MED, V2, P725, DOI 10.1007/BF03401656; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Lee DW, 1999, FREE RADICAL RES, V30, P499, DOI 10.1080/10715769900300541; Lehmann S, 1996, P NATL ACAD SCI USA, V93, P5610, DOI 10.1073/pnas.93.11.5610; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; Miura T, 1996, FEBS LETT, V396, P248, DOI 10.1016/0014-5793(96)01104-0; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Multhaup G, 1998, BIOCHEMISTRY-US, V37, P7224, DOI 10.1021/bi980022m; MURAMOTO T, 1992, AM J PATHOL, V140, P1411; NAKAMURA K, 1985, ARCH BIOCHEM BIOPHYS, V240, P319, DOI 10.1016/0003-9861(85)90037-2; OWEN F, 1989, LANCET, V1, P51; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PARCHI P, 1995, CURR OPIN NEUROL, V8, P286, DOI 10.1097/00019052-199508000-00007; Pauly PC, 1998, J BIOL CHEM, V273, P33107, DOI 10.1074/jbc.273.50.33107; POCCHIARI M, 1994, MOL ASPECTS MED, V15, P195, DOI 10.1016/0098-2997(94)90042-6; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Ruiz FH, 2000, BIOCHEM BIOPH RES CO, V269, P491, DOI 10.1006/bbrc.2000.2270; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Simonian NA, 1996, ANNU REV PHARMACOL, V36, P83, DOI 10.1146/annurev.pa.36.040196.000503; Viles JH, 1999, P NATL ACAD SCI USA, V96, P2042, DOI 10.1073/pnas.96.5.2042; Waggoner DJ, 2000, J BIOL CHEM, V275, P7455, DOI 10.1074/jbc.275.11.7455; Weissmann C, 1999, SCIENCE, V286, P914, DOI 10.1126/science.286.5441.914; White AR, 1999, AM J PATHOL, V155, P1723, DOI 10.1016/S0002-9440(10)65487-9; Whittal RM, 2000, PROTEIN SCI, V9, P332; Wille H, 1996, J MOL BIOL, V259, P608, DOI 10.1006/jmbi.1996.0343	51	129	137	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2286	2291		10.1074/jbc.M007243200	http://dx.doi.org/10.1074/jbc.M007243200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11060296	hybrid			2022-12-25	WOS:000166528000085
J	Perrotti, N; He, RA; Phillips, SA; Haft, CR; Taylor, SI				Perrotti, N; He, RA; Phillips, SA; Haft, CR; Taylor, SI			Activation of serum- and glucocorticoid-induced protein kinase (Sgk) by cyclic AMP and insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNALING PATHWAY; INDUCIBLE KINASE; SODIUM-TRANSPORT; GRANULOSA-CELLS; RAT; VASOPRESSIN; PHOSPHORYLATION; PHOSPHATASES; SPECIFICITY; EXPRESSION	Sgk (serum- and glucocorticoid-induced protein kinase) is a serine/threonine-specific protein kinase that is transcriptionally regulated by serum, glucorticoids, and mineralocorticoids, Sgk regulates the amiloride-sensitive sodium channel in kidney principal cells. Insulin and insulin-like growth factor-1 stimulate activity of Sgk by a mechanism mediated by phosphoinositide-dependent kinases (PDK)-1 and -2. In this study, we demonstrate that incubation of transfected cells with 8-(4-chlorophenylthio)-cAMP (8CPT-cAMP; 0.2 mM) led to a 2-fold activation of recombinant Sgk expressed in COS7 cells. Furthermore, the combination of insulin plus 8CPT-cAMP elicited a larger response than either agent alone. The effect of insulin was inhibited by wortmannin (100 nM), but not by the eyelid AMP-dependent protein kinase (PKA) inhibitor, H89 (10 muM). As expected, the effect of 8CPT-cAMP was completely blocked by H89, Surprisingly, the effect of 8CPT-cAMP was also inhibited by wortmannin, suggesting that phosphorylation of Sgk by PDK-1 and/or -2 is required for activation by 8CPT-cAMP. Mutational analysis led to similar conclusions. The Thr(369) --> Ala mutant, lacking the PKA phosphorylation site, was activated by insulin but not 8CPT-cAMP, In contrast, the Ser(422) --> Ala mutant, lacking a PDK-2 phosphorylation site, was inactive and resistant to activation by either insulin or 8CPT-cAMP. In summary, Sgk is subject to complex regulatory mechanisms. In addition to regulation at the level of gene expression, the enzymatic activity of Sgk is regulated by multiple protein kinases, including PKA, PDK-1, and PDK-2. Cross-talk among these signaling pathways may play an important role in the pathogenesis of the hypertension associated with hyperinsulinemia, obesity, and insulin resistance.	NIDDK, Diabet Branch, Div Intramural Res, Bethesda, MD 20892 USA; Univ Catanzaro, Dipartimento Med Sperimentale & Clin Gaetano Salv, I-88100 Catanzaro, Italy	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Magna Graecia University of Catanzaro	Taylor, SI (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Mail Drop 424,355 E Merrill St, Indianapolis, IN 46285 USA.							Alliston TN, 1997, MOL ENDOCRINOL, V11, P1934, DOI 10.1210/me.11.13.1934; BECK NP, 1971, J CLIN INVEST, V50, P2461, DOI 10.1172/JCI106746; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Edinger RS, 1999, AM J PHYSIOL-RENAL, V277, pF575, DOI 10.1152/ajprenal.1999.277.4.F575; Gonzalez-Robayna IJ, 1999, MOL ENDOCRINOL, V13, P1318, DOI 10.1210/me.13.8.1318; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; PERROTTI N, 1987, P NATL ACAD SCI USA, V84, P3137, DOI 10.1073/pnas.84.10.3137; REIF MC, 1986, J CLIN INVEST, V77, P1291, DOI 10.1172/JCI112433; TASKEN KA, 1995, BBA-GENE STRUCT EXPR, V1260, P269, DOI 10.1016/0167-4781(94)00203-F; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Yenush L, 1998, MOL CELL BIOL, V18, P6784, DOI 10.1128/MCB.18.11.6784	17	111	116	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9406	9412		10.1074/jbc.M007052200	http://dx.doi.org/10.1074/jbc.M007052200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11096081	hybrid			2022-12-25	WOS:000167607700105
J	Sadir, R; Baleux, F; Grosdidier, A; Imberty, A; Lortat-Jacob, H				Sadir, R; Baleux, F; Grosdidier, A; Imberty, A; Lortat-Jacob, H			Characterization of the stromal cell-derived factor-l alpha-heparin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSAMINOGLYCAN-BINDING-SITE; CHEMOKINE RECEPTOR CXCR4; FIBROBLAST-GROWTH-FACTOR; N-TERMINAL PEPTIDES; PLATELET FACTOR-IV; SULFATE OLIGOSACCHARIDES; MOLECULAR-ORGANIZATION; CRYSTAL-STRUCTURE; NMR; ENDOTHELIUM	The binding of chemokines to glycosaminoglycans is thought to play a crucial role in chemokine functions. It has recently been shown that stromal cell-derived factor-1 alpha (SDF-1 alpha), a CXC chemokine with potent anti-human immunodeficiency virus activity, binds to heparan sulfate through a typical consensus sequence for heparin recognition (BBXB, where B is a basic residue KHLK, amino acids 24-27). Calculation of the accessible surface, together with the electrostatic potential of the SDF-1 alpha dimer, revealed that other amino acids (Arg-41 and Lys-43) are found in the same surface area and contribute to the creation of a positively charged crevice, located at the dimer interface. GRID calculations confirmed that this binding site will be the most energetically favored area for the interaction with sulfate groups, Site-directed mutagenesis and surface plasmon resonance-based binding assays were used to investigate the structural basis for SDF-1 alpha binding to heparin. Among the residues clustered in this basic surface area, Lys-24 and Lys-27 have dominant roles and are essential for interaction with heparin. Amino acids Arg-41 and Lys-43 participate in the binding but are not strictly required for the interaction to take place. Direct binding assays and competition analysis with monoclonal antibodies also permitted us to show that the N-terminal residue (Lys-1), an amino acid critical for receptor activation, is involved in complex formation. Binding studies with selectively desulfated heparin, heparin oligo saccharides, and heparitinase-resistant heparan sulfate fragments showed that a minimum size of 12-14 monosaccharide units is required for efficient binding and that 2-O- and N-sulfate groups have a dominant role in the interaction. Finally, the heparin-binding site was identified on the crystal structure of SDF-1 alpha, and a docking study was undertaken. During the energy minimization process, heparin lost its perfect ribbon shape and fitted the protein surface perfectly. In the model, Lys-1, Lys-24, Lys-27, and Arg-41 were found to have the major role in binding a polysaccharide fragment consisting of 13 monosaccharide units.	Univ Grenoble 1, Inst Biol Struct, CNRS, CEA,Lab Biophys Mol, F-38027 Grenoble 01, France; Inst Pasteur, Unite Chim Organ, F-75015 Paris, France; Univ Grenoble 1, CNRS, Ctr Rech Macromol Vegetales, F-38041 Grenoble 09, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Lortat-Jacob, H (corresponding author), Univ Grenoble 1, Inst Biol Struct, CNRS, CEA,Lab Biophys Mol, 41 Rue Horowitz, F-38027 Grenoble 01, France.	Hugues.Lortat-Jacob@ibs.fr	Imberty, Anne/P-6451-2018	Imberty, Anne/0000-0001-6825-9527; Grosdidier, Aurelien/0000-0001-9873-3461				Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CLARK M, 1989, J COMPUT CHEM, V10, P982, DOI 10.1002/jcc.540100804; Coulomb-L'Hermine A, 1999, P NATL ACAD SCI USA, V96, P8585, DOI 10.1073/pnas.96.15.8585; Cros S, 1997, BIOORGAN MED CHEM, V5, P1301, DOI 10.1016/S0968-0896(97)00087-4; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; David G, 1998, MATRIX BIOL, V17, P461, DOI 10.1016/S0945-053X(98)90092-0; Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941; Elisseeva EL, 2000, J BIOL CHEM, V275, P26799; Gale LM, 1999, BIOESSAYS, V21, P17, DOI 10.1002/(SICI)1521-1878(199901)21:1<17::AID-BIES3>3.0.CO;2-4; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; IMBERTY A, 1999, PERSPECTIVES STRUCTU, P392; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; *IUPAC IUB, 1971, ARCH BIOCHEM BIOPHYS, V145, P405; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Koopmann W, 1997, J BIOL CHEM, V272, P10103; Koopmann W, 1999, J IMMUNOL, V163, P2120; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MACCARANA M, 1993, GLYCOBIOLOGY, V3, P271, DOI 10.1093/glycob/3.3.271; MAYO KH, 1995, BIOCHEM J, V312, P357, DOI 10.1042/bj3120357; McFadden G, 1997, BIOCHEM PHARMACOL, V54, P1271, DOI 10.1016/S0006-2952(97)00182-2; Melchers F, 1999, CELL, V99, P351, DOI 10.1016/S0092-8674(00)81521-4; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MULLOY B, 1993, BIOCHEM J, V293, P849, DOI 10.1042/bj2930849; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Ohnishi Y, 2000, J INTERF CYTOK RES, V20, P691, DOI 10.1089/10799900050116390; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; PEREZ S, 1995, JERUS SYM Q, V27, P425; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Petitou M, 1999, NATURE, V398, P417, DOI 10.1038/18877; Pye DA, 1998, J BIOL CHEM, V273, P22936, DOI 10.1074/jbc.273.36.22936; Pye DA, 1999, J BIOL CHEM, V274, P13456, DOI 10.1074/jbc.274.19.13456; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Spillmann D, 1998, J BIOL CHEM, V273, P15487, DOI 10.1074/jbc.273.25.15487; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tanaka Y, 1996, J EXP MED, V184, P1987, DOI 10.1084/jem.184.5.1987; Tanaka Y, 1998, ARTHRITIS RHEUM-US, V41, P1365, DOI 10.1002/1529-0131(199808)41:8<1365::AID-ART5>3.0.CO;2-W; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; TURNBULL JE, 1990, BIOCHEM J, V265, P715, DOI 10.1042/bj2650715; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Waldherr-Teschner M., 1992, Advances in Scientific Visualization, P58; Weber KSC, 1999, EUR J IMMUNOL, V29, P700, DOI 10.1002/(SICI)1521-4141(199902)29:02<700::AID-IMMU700>3.0.CO;2-1; Wells TNC, 1998, TRENDS PHARMACOL SCI, V19, P376, DOI 10.1016/S0165-6147(98)01247-4; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; Zimmermann P, 1999, FASEB J, V13, pS91	57	187	191	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8288	8296		10.1074/jbc.M008110200	http://dx.doi.org/10.1074/jbc.M008110200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11087743	hybrid			2022-12-25	WOS:000167474900085
J	Lefebvre, S; Berrih-Aknin, S; Adrian, F; Moreau, P; Poea, S; Gourand, L; Dausset, J; Carosella, ED; Paul, P				Lefebvre, S; Berrih-Aknin, S; Adrian, F; Moreau, P; Poea, S; Gourand, L; Dausset, J; Carosella, ED; Paul, P			A specific interferon (IFN)-stimulated response element of the distal HLA-G promoter binds IFN-regulatory factor 1 and mediates enhancement of this nonclassical class I gene by IFN-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE ANTIGEN-G; HUMAN TROPHOBLAST CELLS; HUMAN CYTOMEGALOVIRUS; G EXPRESSION; PROTEIN EXPRESSION; EPITHELIAL-CELLS; NK CELLS; GAMMA; MOLECULES; TRANSCRIPTION	Type I interferons display a broad range of immunomodulatory functions. Interferon beta increases gene expression at the transcriptional level through binding of factors to the interferon-stimulated response element (ISRE) within the promoters of interferon-inducible genes, such as HLA class I. Despite mutation of the class I ISRE sequence within the nonclassical HLA-G class I gene promoter, we show that interferon beta enhances both transcription and cell surface expression of HLA-G in trophoblasts and amniotic and thymic epithelial cells that selectively express it in vivo. Deletion and mutagenesis analysis of a putative interferon-regulatory factor (IRF)-1 binding site within the HLA-G promoter show that HLA-G transactivation is mediated through an ISRE sequence 746 base pairs upstream from ATG, which is distinct from the interferon-responsive element described within proximal classical class I gene promoters. Electrophoretic mobility shift analysis and supershift analysis further demonstrate that interferon-responsive transcription factors, including IRF-1, specifically bind to the HLA-G ISRE. Our results provide evidence that IRF-1 binding to a functional ISRE within the HLA-G promoter mediates interferon beta -induced expression of the HLA-G gene. These observations are of general interest considering the implication of HLA-G in mechanisms of immune escape involved in fetal-maternal tolerance and other immune privilege situations.	CEA, Hop St Louis, Inst Hematol,DSV DRM, Serv Rech Hematoimmunol, F-75475 Paris 10, France; Hop Marie Lannelongue, CNRS, Lab Immunol Cellulaire & Mol, F-92350 Le Plessis Robinson, France; Hop Bluets, F-75011 Paris, France; Ctr Etud Polymorphisme Humain, Fdn Jean Dausset, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; CEA; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Hopital Marie Lannelongue; Foundation Jean Dausset-CEPH	Paul, P (corresponding author), CEA, Hop St Louis, Inst Hematol,DSV DRM, Serv Rech Hematoimmunol, Ctr Hayem 1,Ave Claude Vellefaux, F-75475 Paris 10, France.		PAUL, Pascale/R-1484-2016; PAUL, Pascale/AAI-1772-2020; Berrih‐Aknin, Sonia/F-8025-2013	PAUL, Pascale/0000-0002-6734-4479; PAUL, Pascale/0000-0002-6734-4479; Berrih‐Aknin, Sonia/0000-0001-9199-4175; Moreau, Philippe/0000-0002-2868-7401				ADRIANCABESTRE F, 1999, SEMIN CANCER BIOL, V9, P27; Alcami A, 2000, IMMUNOL TODAY, V21, P447, DOI 10.1016/S0167-5699(00)01699-6; BERRIH S, 1985, J IMMUNOL, V135, P1165; Carvalho AF, 1998, PLACENTA, V19, P307, DOI 10.1016/S0143-4004(98)90063-7; Chu WJ, 1999, HUM IMMUNOL, V60, P1113, DOI 10.1016/S0198-8859(99)00091-9; Chu WJ, 1999, J REPROD IMMUNOL, V42, P1, DOI 10.1016/S0165-0378(98)00077-1; Cousens LP, 1999, J EXP MED, V189, P1315, DOI 10.1084/jem.189.8.1315; Cross JC, 1999, BIOL REPROD, V60, P312, DOI 10.1095/biolreprod60.2.312; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Dorling A, 2000, EUR J IMMUNOL, V30, P586, DOI 10.1002/1521-4141(200002)30:2<586::AID-IMMU586>3.0.CO;2-Y; Duncan GS, 1996, J EXP MED, V184, P2043, DOI 10.1084/jem.184.5.2043; Durbin JE, 2000, J IMMUNOL, V164, P4220, DOI 10.4049/jimmunol.164.8.4220; ELLIS SA, 1986, IMMUNOLOGY, V59, P595; Fournel S, 2000, J IMMUNOL, V164, P6100, DOI 10.4049/jimmunol.164.12.6100; Fukushima Y, 1998, INT J MOL MED, V2, P349; Galon J, 1999, J IMMUNOL, V162, P7256; Gao GF, 2000, J BIOL CHEM, V275, P15232, DOI 10.1074/jbc.275.20.15232; Gobin SJP, 1998, J IMMUNOL, V161, P2276; Gobin SJP, 1997, IMMUNITY, V6, P601, DOI 10.1016/S1074-7613(00)80348-9; Gobin SJP, 1999, J IMMUNOL, V163, P1428; Goldman-Wohl DS, 2000, MOL HUM REPROD, V6, P88, DOI 10.1093/molehr/6.1.88; Gustafson KS, 1996, J BIOL CHEM, V271, P20035, DOI 10.1074/jbc.271.33.20035; Halwachs-Baumann G, 1998, J VIROL, V72, P7598, DOI 10.1128/JVI.72.9.7598-7602.1998; Hamai Y, 1999, AM J REPROD IMMUNOL, V41, P153; Hammer A, 1997, AM J REPROD IMMUNOL, V37, P161; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; Hobart M, 1997, J IMMUNOL, V158, P4260; Horuzsko A, 1997, INT IMMUNOL, V9, P645, DOI 10.1093/intimm/9.5.645; Hunter CA, 1997, IMMUNOL LETT, V59, P1, DOI 10.1016/S0165-2478(97)00091-6; Ibrahim EC, 2000, CELL STRESS CHAPERON, V5, P207, DOI 10.1379/1466-1268(2000)005<0207:HSAAIE>2.0.CO;2; Jun Y, 2000, J IMMUNOL, V164, P805, DOI 10.4049/jimmunol.164.2.805; KOVATS S, 1990, SCIENCE, V248, P220, DOI 10.1126/science.2326636; Le Bouteiller P, 1999, IMMUNOL REV, V167, P233; LEE N, 1995, IMMUNITY, V3, P591, DOI 10.1016/1074-7613(95)90130-2; Lefebvre S, 1999, PLACENTA, V20, P293, DOI 10.1053/plac.1998.0380; Lefebvre S, 2000, HUM IMMUNOL, V61, P1095, DOI 10.1016/S0198-8859(00)00192-0; Lefebvre S, 1999, J REPROD IMMUNOL, V43, P213, DOI 10.1016/S0165-0378(99)00035-2; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LEW DJ, 1991, MOL CELL BIOL, V11, P182, DOI 10.1128/MCB.11.1.182; Lila N, 2000, LANCET, V355, P2138, DOI 10.1016/S0140-6736(00)02386-2; Llano M, 1998, EUR J IMMUNOL, V28, P2854, DOI 10.1002/(SICI)1521-4141(199809)28:09<2854::AID-IMMU2854>3.0.CO;2-W; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Lopez-Botet M, 2000, HUM IMMUNOL, V61, P7, DOI 10.1016/S0198-8859(99)00161-5; Maejima M, 1997, AM J REPROD IMMUNOL, V38, P79; Marie JC, 1999, J IMMUNOL, V162, P2103; Moreau P, 1999, INT IMMUNOL, V11, P803, DOI 10.1093/intimm/11.5.803; MULLER U, 1994, SCIENCE, V264, P1918, DOI 10.1126/science.8009221; Onno M, 2000, J IMMUNOL, V164, P6426, DOI 10.4049/jimmunol.164.12.6426; Pangault C, 1999, TISSUE ANTIGENS, V53, P335, DOI 10.1034/j.1399-0039.1999.530403.x; Paradowska E, 1996, J INTERF CYTOK RES, V16, P941, DOI 10.1089/jir.1996.16.941; Paul P, 1999, CANCER RES, V59, P1954; Paul P, 1998, P NATL ACAD SCI USA, V95, P4510, DOI 10.1073/pnas.95.8.4510; Rouas-Freiss N, 1999, SEMIN CANCER BIOL, V9, P3, DOI 10.1006/scbi.1998.0103; SANDERS SK, 1991, J EXP MED, V174, P737, DOI 10.1084/jem.174.3.737; Schust DJ, 1996, J IMMUNOL, V157, P3375; Schust DJ, 1998, J EXP MED, V188, P497, DOI 10.1084/jem.188.3.497; Tomasec P, 2000, SCIENCE, V287, P1031, DOI 10.1126/science.287.5455.1031; Wagner SN, 2000, LANCET, V356, P220, DOI 10.1016/S0140-6736(00)02486-7; WARING JF, 1995, J BIOL CHEM, V270, P12276, DOI 10.1074/jbc.270.20.12276; Yang YP, 1996, J IMMUNOL, V156, P4224; Yang YP, 1995, J REPROD IMMUNOL, V29, P179, DOI 10.1016/0165-0378(95)00942-E	61	90	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6133	6139		10.1074/jbc.M008496200	http://dx.doi.org/10.1074/jbc.M008496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11087747	hybrid			2022-12-25	WOS:000167261000013
J	Takita, Y; Engstrom, L; Ungermann, C; Cunningham, KW				Takita, Y; Engstrom, L; Ungermann, C; Cunningham, KW			Inhibition of the Ca2+-ATPase Pmc1p by the v-SNARE protein Nyv1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; SECRETORY PATHWAY; TRANSCRIPTION FACTOR; ISOLATED VACUOLES; H+/CA2+ EXCHANGE; HOMOTYPIC FUSION; GENE-EXPRESSION; CA2+ CHANNELS; LACKING PMR1	Pmc1p, the Ca2+-ATPase of budding yeast related to plasma membrane Ca2+-ATPases of animals, is transcriptionally up-regulated in response to signaling by the calmodulin calcineurin-Tcn1p/Crz1p signaling pathway. Little is known about post-translational regulation of Pmc1p. In a genetic screen for potential negative regulators of Pmc1p, a vacuolar v-SNARE protein, Nyv1p, was recovered. Cells overproducing Nyv1p show decreased Ca2+ tolerance and decreased accumulation of Ca2+ in the vacuole, similar to pmc1 null mutants. Overexpression of Nyv1p had no such effects on pmc1 mutants, suggesting that Nyv1p may inhibit Pmc1p function. Overexpression of Nyv1p did not decrease Pmc1p levels but decreased the specific ATP-dependent Ca2+ transport activity of Pmc1p in purified vacuoles by at least 2-fold. The effect of Nyv1p on Pmc1p function is likely to be direct because native immunoprecipitation experiments showed that Pmc1p coprecipitated with Nyv1p. Complexes between Nyv1p and its t-SNARE partner Vam3p were also isolated, but these complexes lacked Pmc1p. We conclude that Nyv1p can interact physically with Pmc1p and inhibit its Ca2+ transport activity in the vacuole membrane. This is the first example of a Ca2+-ATPase regulation by a v-SNARE protein involved in membrane fusion reactions.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Univ Heidelberg, Zentrum Biochem, D-69120 Heidelberg, Germany	Johns Hopkins University; Ruprecht Karls University Heidelberg	Cunningham, KW (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.		Yashiroda, Yoko/C-8769-2014					ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; CUNNINGHAM KW, 1994, J EXP BIOL, V196, P157; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; DUNN T, 1994, J BIOL CHEM, V269, P7273; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; EILAM Y, 1985, J GEN MICROBIOL, V131, P623; Geisler M, 2000, BBA-BIOMEMBRANES, V1465, P52, DOI 10.1016/S0005-2736(00)00131-0; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Haas Albert, 1995, Methods in Cell Science, V17, P283, DOI 10.1007/BF00986234; Halachmi D, 1996, FEBS LETT, V392, P194, DOI 10.1016/0014-5793(96)00799-5; Juhaszova M, 2000, EUR J NEUROSCI, V12, P839, DOI 10.1046/j.1460-9568.2000.00974.x; Locke EG, 2000, MOL CELL BIOL, V20, P6686, DOI 10.1128/MCB.20.18.6686-6694.2000; Marchi V, 1999, FEBS LETT, V454, P181, DOI 10.1016/S0014-5793(99)00803-0; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Pozos TC, 1996, MOL CELL BIOL, V16, P3730; Putney JW, 1999, BIOESSAYS, V21, P38; QADOTA H, 1992, YEAST, V8, P735, DOI 10.1002/yea.320080906; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Sherman F., 1986, METHODS YEAST GENETI; Sorin A, 1997, J BIOL CHEM, V272, P9895; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Strayle J, 1999, EMBO J, V18, P4733, DOI 10.1093/emboj/18.17.4733; Taubenblatt P, 1999, J CELL SCI, V112, P3559; Ungermann C, 1999, P NATL ACAD SCI USA, V96, P11194, DOI 10.1073/pnas.96.20.11194; Ungermann C, 1999, J CELL BIOL, V145, P1435, DOI 10.1083/jcb.145.7.1435; Ungermann C, 1998, J CELL BIOL, V140, P61, DOI 10.1083/jcb.140.1.61; VanRheenen SM, 1998, J CELL BIOL, V141, P1107, DOI 10.1083/jcb.141.5.1107; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; von Mollard GF, 1999, MOL BIOL CELL, V10, P1719, DOI 10.1091/mbc.10.6.1719; Wada Y, 1997, J CELL SCI, V110, P1299; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6	37	18	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6200	6206		10.1074/jbc.M009191200	http://dx.doi.org/10.1074/jbc.M009191200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11080502	hybrid			2022-12-25	WOS:000167261000021
J	Fernandes, H; Cohen, S; Bishayee, S				Fernandes, H; Cohen, S; Bishayee, S			Glycosylation-induced conformational modification positively regulates receptor-receptor association - A study with an aberrant epidermal growth factor receptor (EGFRvIII/Delta EGFR) expressed in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ACTIVATION; ANTIPEPTIDE ANTIBODY; TYROSINE KINASE; PHOSPHORYLATION; RECOGNIZES; LOCATION; COMMON; GENE	The epidermal growth factor receptor (EGFR) is a multisited and multifunctional transmembrane glycoprotein with intrinsic tyrosine kinase activity. Upon ligand binding, the monomeric receptor undergoes dimerization resulting in kinase activation. The consequences of kinase stimulation are the phosphorylation of its own tyrosine residues (autophosphorylation) followed by association with and activation of signal transducers, Deregulation of signaling resulting from aberrant expression of the EGFR has been implicated in a number of neoplasms including breast, brain, and skin tumors, A mutant epidermal growth factor (EGF) receptor missing 267 amino acids from the exoplasmic domain is common in human glioblastomas. The truncated receptor (EGFRvIII/Delta EGFR) lacks EGF binding activity; however, the kinase is constitutively active, and cells expressing the receptor are tumorigenic. Our studies revealed that the high kinase activity of the Delta EGFR is due to self-dimerization, and contrary to earlier reports, the kinase activity per molecule of the dimeric Delta EGFR is comparable to that of the EGF-stimulated wild-type receptor. Furthermore, the phosphorylation patterns of both receptors are similar as determined by interaction with a conformation-specific antibody and by phosphopeptide analysis. This eliminates the possibility that the defective down-regulation of the Delta EGFR is due to its altered phosphorylation pattern as has been suggested previously. Interestingly, the receptor-receptor self-association is highly dependent on a conformation induced by N-linked glycosylation, We have identified four potential sites that might participate in self-dimerization; these sites are located in a domain that plays an important role in EGFR functioning.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Bishayee, S (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Pathol & Lab Med, Med Sci Bldg,Rm C-567,185 S Orange Ave, Newark, NJ 07103 USA.	bishayee@umdnj.edu						Abe Y, 1998, J BIOL CHEM, V273, P11150, DOI 10.1074/jbc.273.18.11150; Antonyak MA, 1998, J BIOL CHEM, V273, P2817, DOI 10.1074/jbc.273.5.2817; Bishayee A, 1999, BIOSCIENCE REP, V19, P397, DOI 10.1023/A:1020260105524; Bishayee A, 1999, MOL BIOL CELL, V10, P525, DOI 10.1091/mbc.10.3.525; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; Bishayee S, 1999, PRACT APPROACH SER, V215, P95; BISHAYEE S, 1986, P NATL ACAD SCI USA, V83, P6756, DOI 10.1073/pnas.83.18.6756; BISHAYEE S, 1988, MOL CELL BIOL, V8, P3696, DOI 10.1128/MCB.8.9.3696; Cadena Deborah L., 1996, P265, DOI 10.1002/9783527615032.ch9; EKSTRAND AJ, 1995, ONCOGENE, V10, P1455; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; HUMPHREY PA, 1991, BIOCHEM BIOPH RES CO, V178, P1413, DOI 10.1016/0006-291X(91)91051-D; KANAKARAJ P, 1991, BIOCHEMISTRY-US, V30, P1761, DOI 10.1021/bi00221a005; KLINGBEIL CK, 1995, ARCH BIOCHEM BIOPHYS, V316, P745, DOI 10.1006/abbi.1995.1099; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; MURTHY U, 1987, ARCH BIOCHEM BIOPHYS, V252, P549, DOI 10.1016/0003-9861(87)90062-2; MURTHY U, 1986, J CELL BIOL, V103, P333, DOI 10.1083/jcb.103.2.333; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; PANNEERSELVAM K, 1995, EUR J BIOCHEM, V230, P951, DOI 10.1111/j.1432-1033.1995.tb20641.x; PANNEERSELVAM K, 1995, J BIOL CHEM, V270, P7975, DOI 10.1074/jbc.270.14.7975; Prigent SA, 1996, J BIOL CHEM, V271, P25639, DOI 10.1074/jbc.271.41.25639; RAJ S, 1992, BIOCHEMISTRY-US, V31, P1774, DOI 10.1021/bi00121a027; SLIEKER LJ, 1986, J BIOL CHEM, V261, P5233; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965	30	116	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5375	5383		10.1074/jbc.M005599200	http://dx.doi.org/10.1074/jbc.M005599200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087732	hybrid			2022-12-25	WOS:000168484300113
J	Bellamy, TC; Garthwaite, J				Bellamy, TC; Garthwaite, J			Sub-second kinetics of the nitric oxide receptor, soluble guanylyl cyclase, in intact cerebellar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE LUNG; HIPPOCAMPAL SYNAPSES; CARBON-MONOXIDE; ACTIVATION; RELEASE; DESENSITIZATION; OXYHEMOGLOBIN; PURIFICATION; CALCIUM; KAINATE	Soluble guanylyl cyclase (sGC) catalyzes cGMP synthesis and serves as a physiological receptor for nitric oxide (NO)). Recent evidence indicates that key properties of sGC within cells differ from those of purified sGC. We have devised a technique for resolving NO-stimulated sGC activity in cells on a sub-second time scale, enabling the first quantitative description of the kinetics of the enzyme within its natural environment. Upon release of NO from a caged derivative, sGC became activated without any lag observable at a 20-ms sampling time. Deactivation of sGC on removal of NO occurred with a rate constant of 3.7 s(-1), which is 25-fold faster than the fastest estimate for purified sGC. Desensitization of sGC occurred with a time constant of 6.9 s at an estimated 70 nM NO and became faster at a higher concentration, indicating that NO accelerates desensitization. The concentration-response curve for NO consequently became increasingly bell-shaped with time, a phenomenon that causes the apparent potency of NO to increase with time. The results indicate that sGC within cells behaves in a highly dynamic fashion, allowing the NO-cGMP pathway to operate within a kinetic framework more resembling that of neurotransmission than the properties of purified sGC suggest.	UCL, Wolfson Inst Biomed Res, London WC1E 6BT, England	University of London; University College London	Garthwaite, J (corresponding author), UCL, Wolfson Inst Biomed Res, Cruciform Bldg,Gower St, London WC1E 6BT, England.	john.garthwaite@ucl.ac.uk		Bellamy, Tomas/0000-0003-0204-7366				BARMAN T. E., 1964, P339; Bellamy TC, 2000, P NATL ACAD SCI USA, V97, P2928, DOI 10.1073/pnas.97.6.2928; Bellamy TC, 2001, MOL PHARMACOL, V59, P54, DOI 10.1124/mol.59.1.54; Brandish PE, 1998, BIOCHEMISTRY-US, V37, P16898, DOI 10.1021/bi9814989; BREER H, 1990, NATURE, V345, P65, DOI 10.1038/345065a0; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Eich RF, 1996, BIOCHEMISTRY-US, V35, P6976, DOI 10.1021/bi960442g; GARTHWAITE J, 1995, ANNU REV PHYSIOL, V57, P683, DOI 10.1146/annurev.ph.57.030195.003343; GERZER R, 1981, EUR J BIOCHEM, V116, P479, DOI 10.1111/j.1432-1033.1981.tb05361.x; Hobbs AJ, 1997, TRENDS PHARMACOL SCI, V18, P484, DOI 10.1016/S0165-6147(97)01137-1; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; Juilfs D M, 1999, Rev Physiol Biochem Pharmacol, V135, P67, DOI 10.1007/BFb0033670; KAUPP UB, 1995, CURR OPIN NEUROBIOL, V5, P434, DOI 10.1016/0959-4388(95)80002-6; Kharitonov VG, 1997, BIOCHEM BIOPH RES CO, V239, P284, DOI 10.1006/bbrc.1997.7470; Lincoln TM, 1996, METHOD ENZYMOL, V269, P149; Makino R, 1999, J BIOL CHEM, V274, P7714, DOI 10.1074/jbc.274.12.7714; Margulis A, 2000, BIOCHEMISTRY-US, V39, P1034, DOI 10.1021/bi992040p; MONEADA S, 1991, PHARMACOL REV, V43, P109; MURPHY KPSJ, 1994, NEUROPHARMACOLOGY, V33, P1375, DOI 10.1016/0028-3908(94)90039-6; Murthy VN, 2000, P NATL ACAD SCI USA, V97, P901, DOI 10.1073/pnas.97.2.901; Paternain AV, 1998, NEUROPHARMACOLOGY, V37, P1249, DOI 10.1016/S0028-3908(98)00098-7; RAMAN IM, 1992, NEURON, V9, P173, DOI 10.1016/0896-6273(92)90232-3; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; SALVEMINI D, 1990, BRIT J PHARMACOL, V101, P991, DOI 10.1111/j.1476-5381.1990.tb14194.x; Schmidt K, 1997, N-S ARCH PHARMACOL, V355, P457, DOI 10.1007/PL00004969; Schrammel A, 1996, MOL PHARMACOL, V50, P1; Sharma VS, 1999, METHODS, V19, P494, DOI 10.1006/meth.1999.0892; STONE JR, 1994, BIOCHEMISTRY-US, V33, P5636, DOI 10.1021/bi00184a036; Stone JR, 1996, BIOCHEMISTRY-US, V35, P1093, DOI 10.1021/bi9519718; WOOD J, 1994, NEUROPHARMACOLOGY, V33, P1235, DOI 10.1016/0028-3908(94)90022-1; Zhao Y, 1999, P NATL ACAD SCI USA, V96, P14753, DOI 10.1073/pnas.96.26.14753	31	94	97	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4287	4292		10.1074/jbc.M006677200	http://dx.doi.org/10.1074/jbc.M006677200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11073946	hybrid			2022-12-25	WOS:000166921200074
J	Carragher, NO; Fincham, VJ; Riley, D; Frame, MC				Carragher, NO; Fincham, VJ; Riley, D; Frame, MC			Cleavage of focal adhesion kinase by different proteases during Src-reguIated transformation and apoptosis - Distinct roles for calpain and caspases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED NEUTRAL PROTEASE; V-SRC; ALPHA-ACTININ; INHIBITION; CALPASTATIN; DEGRADATION; PP125(FAK); PROTEINASE; PAXILLIN; PROTEOLYSIS	Integrin-associated focal adhesion complexes provide the main adhesive links between the cellular actin cytoskeleton and the surrounding extracellular matrix. In vitro, cells utilize a complex temporal and spatially regulated mechanism of focal adhesion assembly and disassembly required for cell migration. Recent studies indicate that members of both calpain and caspase protease families can promote Limited proteolytic cleavage of several components of focal adhesions leading to disassembly of these complexes, Such mechanisms that influence cell adhesion may be deregulated under pathological conditions characterized by increased cell motility, such as tumor invasion. v-Src-induced oncogenic transformation is associated with loss of focal adhesion structures and transition to a less adherent, more motile phenotype, while inactivating temperature-sensitive v-Src in serum-deprived transformed cells leads to detachment and apoptosis. In this report, we demonstrate that;v-Src-induced disassembly of focal adhesions is accompanied by calpain-dependent proteolysis of focal adhesion kinase, Furthermore, inhibitors of calpain repress v-Src-induced focal adhesion disruption, loss of substrate adhesion, and cell migration. In contrast, focal adhesion loss during detachment and apoptosis induced after switching off temperature-sensitive v-Src in serum-deprived transformed cells is accompanied by caspase-mediated proteolysis of focal adhesion kinase. Thus, calpain and caspase differentially regulate focal adhesion turnover during Src-regulated cell transformation, motility, and apoptosis.	Beatson Inst Canc Res, Canc Res Campaign Beatson Labs, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute	Carragher, NO (corresponding author), Beatson Inst Canc Res, Canc Res Campaign Beatson Labs, Garscube Estate, Glasgow G61 1BD, Lanark, Scotland.	n.carragher@beatson.gla.ac.uk		Carragher, Neil/0000-0001-5541-9747				BECKERLE MC, 1987, CELL, V51, P569, DOI 10.1016/0092-8674(87)90126-7; Bi RF, 2000, J BIOL CHEM, V275, P26477, DOI 10.1074/jbc.M003763200; Braun C, 1999, INT J CANCER, V84, P6, DOI 10.1002/(SICI)1097-0215(19990219)84:1<6::AID-IJC2>3.3.CO;2-K; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carragher NO, 1999, J CELL BIOL, V147, P619, DOI 10.1083/jcb.147.3.619; Cooray P, 1996, BIOCHEM J, V318, P41, DOI 10.1042/bj3180041; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; ETO A, 1995, J BIOL CHEM, V270, P25115, DOI 10.1074/jbc.270.42.25115; Fang F, 1996, SCIENCE, V271, P499, DOI 10.1126/science.271.5248.499; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Gilmore AP, 1996, MOL BIOL CELL, V7, P1209, DOI 10.1091/mbc.7.8.1209; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hayashi M, 1999, ARCH BIOCHEM BIOPHYS, V371, P133, DOI 10.1006/abbi.1999.1427; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Huang C, 1997, J BIOL CHEM, V272, P19248, DOI 10.1074/jbc.272.31.19248; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; HUTTENLOCHER A, 1995, CURR OPIN CELL BIOL, V7, P697, DOI 10.1016/0955-0674(95)80112-X; ILLC D, 1995, NATURE, V377, P539; Johnson D, 2000, CELL DEATH DIFFER, V7, P685, DOI 10.1038/sj.cdd.4400700; Johnson D, 1998, ONCOGENE, V16, P2017, DOI 10.1038/sj.onc.1201727; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; Kato M, 2000, J BIOCHEM, V127, P297, DOI 10.1093/oxfordjournals.jbchem.a022607; KELLIE S, 1988, BIOESSAYS, V8, P25, DOI 10.1002/bies.950080107; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; MAKI M, 1989, J BIOL CHEM, V264, P18866; MELLGREN RL, 1980, FEBS LETT, V109, P129, DOI 10.1016/0014-5793(80)81326-3; Milligan SA, 1996, ARCH BIOCHEM BIOPHYS, V335, P388, DOI 10.1006/abbi.1996.9998; MOHAN PS, 1995, J NEUROCHEM, V64, P859; Molinari M, 1997, J MEMBRANE BIOL, V156, P1, DOI 10.1007/s002329900181; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; ODA A, 1993, J BIOL CHEM, V268, P12603; Potter DA, 1998, J CELL BIOL, V141, P647, DOI 10.1083/jcb.141.3.647; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; Sasaki T, 1990, J Enzyme Inhib, V3, P195, DOI 10.3109/14756369009035837; SEGLEN PO, 1979, EUR J BIOCHEM, V95, P215, DOI 10.1111/j.1432-1033.1979.tb12956.x; Selliah N, 1996, J IMMUNOL, V156, P3215; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Squier MKT, 1999, J CELL PHYSIOL, V178, P311, DOI 10.1002/(SICI)1097-4652(199903)178:3<311::AID-JCP5>3.3.CO;2-K; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Wen LP, 1997, J BIOL CHEM, V272, P26056, DOI 10.1074/jbc.272.41.26056; WYKE AW, 1995, CELL GROWTH DIFFER, V6, P1225; YAMAGUCHI R, 1994, FEBS LETT, V356, P114, DOI 10.1016/0014-5793(94)01246-6; YOSHIDA H, 1984, FEBS LETT, V170, P259, DOI 10.1016/0014-5793(84)81324-1; Yuan YP, 1997, J BIOL CHEM, V272, P21847, DOI 10.1074/jbc.272.35.21847; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	51	118	119	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4270	4275		10.1074/jbc.M008972200	http://dx.doi.org/10.1074/jbc.M008972200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11069922	hybrid			2022-12-25	WOS:000166921200072
J	Karp, DR; Shimooku, K; Lipsky, PE				Karp, DR; Shimooku, K; Lipsky, PE			Expression of gamma-glutamyl transpeptidase protects Ramos B cells from oxidation-induced cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED REDOX REGULATION; EXTRACELLULAR GLUTATHIONE; TRANSFERASE TRANSPEPTIDASE; REACTIVE OXYGEN; T-LYMPHOCYTES; AMINO-ACIDS; IN-VITRO; APOPTOSIS; TRANSPORT; GAMMA-GLUTAMYLCYST(E)INE	The ectoenzyme, gamma -glutamyl transpeptidase (GGT, EC 2.3.2.2) cleaves glutathione (GSH) to facilitate the recapture of cysteine for synthesis of intracellular GSH. The impact of GGT expression on cell survival during oxidative stress was investigated using the human B cell lymphoblastoid cell line, Ramos. Ramos cells did not ex press surface GGT and exhibited no GGT enzyme activity. In contrast, Ramos cells stably transfected with the human GGT cDNA expressed high levels of surface GGT and enzymatic activity. GGT-transfected Ramos cells were protected from apoptosis when cultured in cyst(e)ine-deficient medium. The GGT-expressing cells also had lower levels of intracellular reactive oxygen species (ROS). Homocysteic acid and alanine, inhibitors of cystine and cysteine uptake, respectively, caused increased ROS content and diminished viability of GGT expressing cells. Exogenous GSH increased the viability of the GGT-transfected cells more effectively than that of control cells, whereas the products of GSH metabolism prevented death of both the control and GGT-transfected cells comparably. These data indicate that GGT cleavage of GSH and the subsequent recapture of cysteine and cystine allow cells to maintain low levels of cellular ROS and thereby avoid apoptosis induced by oxidative stress.	Univ Texas, SW Med Ctr, Harold C Simmons Arthrit Res Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Karp, DR (corresponding author), Univ Texas, SW Med Ctr, Harold C Simmons Arthrit Res Ctr, Dept Internal Med, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	David.Karp@UTSouthwestern.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042772] Funding Source: NIH RePORTER; NIAID NIH HHS [AI42772] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON ME, 1983, P NATL ACAD SCI-BIOL, V80, P707, DOI 10.1073/pnas.80.3.707; BANNAI S, 1984, BIOCHIM BIOPHYS ACTA, V779, P289, DOI 10.1016/0304-4157(84)90014-5; BREZINSCHEK RI, 1995, J IMMUNOL, V154, P3062; Chaudiere J, 1999, METHOD ENZYMOL, V299, P276; CURTHOYS NP, 1979, ENZYME, V24, P383, DOI 10.1159/000458694; Del Bello B, 1999, FASEB J, V13, P69; DENEKE SM, 1995, AM J RESP CELL MOL, V12, P662, DOI 10.1165/ajrcmb.12.6.7766429; Dobmeyer TS, 1997, FREE RADICAL BIO MED, V22, P775, DOI 10.1016/S0891-5849(96)00403-0; GRABER R, 1995, INT J CANCER, V62, P443, DOI 10.1002/ijc.2910620414; Grammer AC, 1998, J IMMUNOL, V161, P1183; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P6319, DOI 10.1073/pnas.76.12.6319; GRIFFITH OW, 1981, P NATL ACAD SCI-BIOL, V78, P2777, DOI 10.1073/pnas.78.5.2777; GRIFFITH OW, 1978, P NATL ACAD SCI USA, V75, P5405, DOI 10.1073/pnas.75.11.5405; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Hanigan MH, 1999, CARCINOGENESIS, V20, P553, DOI 10.1093/carcin/20.4.553; HANIGAN MH, 1993, BIOCHEMISTRY-US, V32, P6302, DOI 10.1021/bi00075a026; HANIGAN MH, 1995, CARCINOGENESIS, V16, P181, DOI 10.1093/carcin/16.2.181; HEDLEY DW, 1994, CYTOMETRY, V15, P349, DOI 10.1002/cyto.990150411; HEISTERKAMP N, 1991, P NATL ACAD SCI USA, V88, P6303, DOI 10.1073/pnas.88.14.6303; Henson SE, 1999, J IMMUNOL, V163, P1845; Hildeman DA, 1999, IMMUNITY, V10, P735, DOI 10.1016/S1074-7613(00)80072-2; Iwata S, 1997, J IMMUNOL, V158, P3108; JAYARAM HN, 1975, CANCER CHEMOTH REP 1, V59, P481; Karp DR, 1999, INT IMMUNOL, V11, P1791, DOI 10.1093/intimm/11.11.1791; Lens SMA, 1998, J IMMUNOL, V160, P6083; Lens SMA, 1996, J IMMUNOL, V156, P507; LIEBERMAN MW, 1995, AM J PATHOL, V147, P1175; Lu SC, 1998, SEMIN LIVER DIS, V18, P331, DOI 10.1055/s-2007-1007168; MEISTER A, 1995, METHOD ENZYMOL, V251, P3, DOI 10.1016/0076-6879(95)51106-7; MEYTS ERD, 1992, TOXICOL APPL PHARM, V114, P56, DOI 10.1016/0041-008X(92)90096-B; Miyashita T, 1997, J IMMUNOL, V158, P4620; Nichols TC, 1998, EUR J IMMUNOL, V28, P4123, DOI 10.1002/(SICI)1521-4141(199812)28:12<4123::AID-IMMU4123>3.0.CO;2-G; NOVOGRODSKY A, 1976, P NATL ACAD SCI USA, V73, P2414, DOI 10.1073/pnas.73.7.2414; SATO N, 1995, J IMMUNOL, V154, P3194; Sen CK, 1999, METHOD ENZYMOL, V299, P247; SHI M, 1993, FREE RADICAL BIO MED, V15, P57, DOI 10.1016/0891-5849(93)90125-E; THIOUDELLET C, 1994, EUR J BIOCHEM, V222, P1009, DOI 10.1111/j.1432-1033.1994.tb18952.x; vanKlaveren RJ, 1997, EUR RESPIR J, V10, P1392, DOI 10.1183/09031936.97.10061392; Zettl UK, 1997, CELL IMMUNOL, V178, P1, DOI 10.1006/cimm.1997.1113	40	156	159	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3798	3804		10.1074/jbc.M008484200	http://dx.doi.org/10.1074/jbc.M008484200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11080500	hybrid			2022-12-25	WOS:000166921200012
J	Plotnikov, AN; Eliseenkova, AV; Ibrahimi, OA; Shriver, Z; Sasisekharan, R; Lemmon, MA; Mohammadi, M				Plotnikov, AN; Eliseenkova, AV; Ibrahimi, OA; Shriver, Z; Sasisekharan, R; Lemmon, MA; Mohammadi, M			Crystal structure of fibroblast growth factor 9 reveals regions implicated in dimerization and autoinhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; LASER-DESORPTION-IONIZATION; 3-DIMENSIONAL STRUCTURE; HEPARIN; BINDING; FGF; IDENTIFICATION; LIGAND; OLIGOMERIZATION; COMPLEXES	Fibroblast growth factors (FGFs) constitute a large family of heparin-binding growth factors with diverse biological activities. FGF9 was originally described as glia-activating factor and is expressed in the nervous system as a potent mitogen for glia cells. Unlike most FGFs, FGF9 forms dimers in solution with a K-d of 680 nr. To elucidate the molecular mechanism of FGF9 dimerization, the crystal structure of FGF9 was determined at 2.2 Angstrom resolution. FGFS adopts a beta -trefoil fold similar to other FGFs. However, unlike other FGFs, the N- and C-terminal regions outside the beta -trefoil core in FGFS are ordered and involved in the formation of a 2-fold crystallographic dimer. A significant surface area (>2000 Angstrom (2)) is buried in the dimer interface that occludes a major receptor binding site of FGFS, Thus, we propose an autoinhibitory mechanism for FGFS that is dependent on sequences outside of the beta -trefoil core. Moreover, a model is presented providing a molecular basis for the preferential affinity of FGFS toward FGF9.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Johnson Fdn, Philadelphia, PA 19104 USA; Harvard Mit Div Hlth Sci & Technol, Div Bioengn & Environm Hlth, Cambridge, MA 02139 USA	New York University; University of Pennsylvania; University of Pennsylvania; Harvard University	Mohammadi, M (corresponding author), NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA.		Mohammadi, Moosa/ABA-6745-2020; kasaei, fahime/T-7197-2018	Mohammadi, Moosa/0000-0003-2434-9437; Lemmon, Mark/0000-0002-3379-5319	NCI NIH HHS [CA79992] Funding Source: Medline; NIDCR NIH HHS [DE13686] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013686] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Chellaiah A, 1999, J BIOL CHEM, V274, P34785, DOI 10.1074/jbc.274.49.34785; DiGabriele AD, 1998, NATURE, V393, P812, DOI 10.1038/31741; ERIKSSON AE, 1991, P NATL ACAD SCI USA, V88, P3441, DOI 10.1073/pnas.88.8.3441; Faham S, 1998, CURR OPIN STRUC BIOL, V8, P578, DOI 10.1016/S0959-440X(98)80147-4; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; HECHT D, 1995, GROWTH FACTORS, V12, P223, DOI 10.3109/08977199509036882; Jespersen S, 1998, J MASS SPECTROM, V33, P1088; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; MatsumotoYoshitomi S, 1996, HYBRIDOMA, V15, P299, DOI 10.1089/hyb.1996.15.299; MatsumotoYoshitomi S, 1997, INT J CANCER, V71, P442; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Moniatte M, 1997, INT J MASS SPECTROM, V169, P179, DOI 10.1016/S0168-1176(97)00213-9; NARUO K, 1993, J BIOL CHEM, V268, P2857; Naski M C, 1998, Front Biosci, V3, pd781; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nishimura T, 2000, BBA-GENE STRUCT EXPR, V1492, P203, DOI 10.1016/S0167-4781(00)00067-1; Osslund TD, 1998, PROTEIN SCI, V7, P1681, DOI 10.1002/pro.5560070803; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Plotnikov AN, 2000, CELL, V101, P413, DOI 10.1016/S0092-8674(00)80851-X; Revest JM, 2000, J BIOL CHEM, V275, P8083, DOI 10.1074/jbc.275.11.8083; SantosOcampo S, 1996, J BIOL CHEM, V271, P1726, DOI 10.1074/jbc.271.3.1726; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Song JW, 1996, DEV DYNAM, V206, P427, DOI 10.1002/(SICI)1097-0177(199608)206:4<427::AID-AJA8>3.0.CO;2-K; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THOMPSON LD, 1994, BIOCHEMISTRY-US, V33, P3831, DOI 10.1021/bi00179a006; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P3658, DOI 10.1073/pnas.96.7.3658; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P1892, DOI 10.1073/pnas.96.5.1892; XIANG F, 1994, RAPID COMMUN MASS SP, V8, P199, DOI 10.1002/rcm.1290080215; ZHANG JD, 1991, P NATL ACAD SCI USA, V88, P3446, DOI 10.1073/pnas.88.8.3446; ZHU X, 1991, SCIENCE, V251, P90, DOI 10.1126/science.1702556; ZHU XT, 1993, STRUCTURE, V1, P27, DOI 10.1016/0969-2126(93)90006-3	42	56	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4322	4329		10.1074/jbc.M006502200	http://dx.doi.org/10.1074/jbc.M006502200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11060292	hybrid			2022-12-25	WOS:000166921200079
J	Yamazaki, T; Chang, TY; Haass, C; Ihara, Y				Yamazaki, T; Chang, TY; Haass, C; Ihara, Y			Accumulation and aggregation of amyloid beta-protein in late endosomes of Niemann-Pick type C cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; INSOLUBLE MEMBRANE COMPARTMENT; PRECURSOR PROTEIN; CHOLESTEROL HOMEOSTASIS; ALZHEIMERS-DISEASE; SECRETASE CLEAVAGE; ENDOCYTIC PATHWAY; TRANSPORT; 3-BETA-<2-(DIETHYLAMINO)ETHOXY>ANDROST-5-EN-17-ONE; A-BETA-42(43)	There is growing evidence suggesting that cholesterol metabolism is linked to susceptibility to Alzheimer's disease by influencing amyloid beta -protein (A beta) metabolism. However, the precise cellular linkage sites between cholesterol and A beta have not yet been clarified. To address this issue, we investigated Niemann-Pick type C (NPC) model cells and NPC mutant cells, which showed aberrant cholesterol trafficking. me observed a remarkable A beta accumulation in late endosomes of both NPC model cells and mutant cells where cholesterol accumulates and a significant accumulation in the NPC mouse brain. This A beta accumulation was independent of its constitutive secretion and production through an endocytic pathway. In addition, it is characterized by a marked predominance of A beta 42 and insolubility in SDS, suggesting the presence of aggregated A beta in late endosomes. Most importantly, A beta accumulation is coupled with the cholesterol levels in late endosomes. Thus, late endosomes of NPC cells are a novel pool of aggregated A beta 42 as web as cholesterol, suggesting a direct interaction between aggregated A beta and cholesterol.	Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, Tokyo 1130033, Japan; Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA; Univ Munich, Adolf Butenandt Inst, Dept Biochem, Lab Alzheimers Dis Res, D-80336 Munich, Germany; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi 3320012, Japan	University of Tokyo; Dartmouth College; University of Munich; Japan Science & Technology Agency (JST)	Ihara, Y (corresponding author), Univ Tokyo, Fac Med, Dept Neuropathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.			Chang, Ta-Yuan/0000-0002-3249-0468				Avdulov NA, 1997, J NEUROCHEM, V69, P1746; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; Chyung ASC, 1997, J CELL BIOL, V138, P671, DOI 10.1083/jcb.138.3.671; Cruz JC, 2000, J BIOL CHEM, V275, P4013, DOI 10.1074/jbc.275.6.4013; Enya M, 1999, AM J PATHOL, V154, P271, DOI 10.1016/S0002-9440(10)65273-X; FURUCHI T, 1993, J BIOL CHEM, V268, P27345; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HARMALA AS, 1994, BBA-LIPID LIPID MET, V1211, P317, DOI 10.1016/0005-2760(94)90156-2; Howland DS, 1998, J BIOL CHEM, V273, P16576, DOI 10.1074/jbc.273.26.16576; IWATSUBO T, 1994, NEURON, V13, P45, DOI 10.1016/0896-6273(94)90458-8; IWATSUBO T, 1995, ANN NEUROL, V37, P294, DOI 10.1002/ana.410370305; JARRETT JT, 1993, CELL, V73, P1055, DOI 10.1016/0092-8674(93)90635-4; Kobayashi T, 1999, NAT CELL BIOL, V1, P113, DOI 10.1038/10084; Kobayashi T, 1998, NATURE, V392, P193, DOI 10.1038/32440; KOO EH, 1994, J BIOL CHEM, V269, P17386; Kuo YM, 1998, BIOCHEM BIOPH RES CO, V252, P711, DOI 10.1006/bbrc.1998.9652; Lange Y, 2000, J BIOL CHEM, V275, P17468, DOI 10.1074/jbc.M000875200; Lange Y, 1997, J BIOL CHEM, V272, P17018, DOI 10.1074/jbc.272.27.17018; LANGE Y, 1994, J BIOL CHEM, V269, P29371; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Liscum L, 1998, CURR OPIN LIPIDOL, V9, P131, DOI 10.1097/00041433-199804000-00009; LISCUM L, 1989, J BIOL CHEM, V264, P11796; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Meresse S, 1997, ELECTROPHORESIS, V18, P2682, DOI 10.1002/elps.1150181425; Morishima-Kawashima M, 1998, BIOCHEMISTRY-US, V37, P15247, DOI 10.1021/bi981843u; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Pentchev P. G., 1995, METABOLIC MOL BASES, P2625; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Puri V, 1999, NAT CELL BIOL, V1, P386, DOI 10.1038/14084; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; Sawamura N, 2000, J BIOL CHEM, V275, P27901; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; SHINKAI Y, 1995, ANN NEUROL, V38, P421, DOI 10.1002/ana.410380312; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; SOKOL J, 1988, J BIOL CHEM, V263, P3411; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; UMEDA M, 1989, J IMMUNOL, V143, P2273; van der Goot FG, 1997, ELECTROPHORESIS, V18, P2689, DOI 10.1002/elps.1150181426; Vanier MT, 1998, BRAIN PATHOL, V8, P163; Walsh DM, 2000, BIOCHEMISTRY-US, V39, P10831, DOI 10.1021/bi001048s; Xu HX, 1997, P NATL ACAD SCI USA, V94, P3748, DOI 10.1073/pnas.94.8.3748; YANAGISAWA K, 1995, NAT MED, V1, P1062, DOI 10.1038/nm1095-1062	44	127	130	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4454	4460		10.1074/jbc.M009598200	http://dx.doi.org/10.1074/jbc.M009598200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11085995	hybrid			2022-12-25	WOS:000166921200096
J	Zywietz, A; Gohla, A; Schmelz, M; Schultz, G; Offermanns, S				Zywietz, A; Gohla, A; Schmelz, M; Schultz, G; Offermanns, S			Pleiotropic effects of Pasteurella multocida toxin are mediated by G(q)-dependent and -independent mechanisms - Involvement of G(q) but not G(11)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; STRESS FIBER FORMATION; SWISS 3T3 CELLS; PHOSPHOLIPASE-C; ALPHA-SUBUNITS; POTENT MITOGEN; RHO-KINASE; ALPHA(1)-ADRENERGIC RECEPTOR; DEPENDENT ACTIVATION; NEURITE RETRACTION	Pasteurella multocida toxin (PRTT) is a highly potent mitogen for a variety of cell types. PMT has been shown to induce various cellular signaling processes, and it has been suggested to function through the heterotrimeric G-proteins G(q)/G(11). To analyze the role of G(q)/G(11) in the action of PMT, we have studied the effect of the toxin in G alpha (q)/G alpha (11) double-deficient fibroblasts as web as in fibroblasts lacking only G alpha (q) or G alpha (11). Interestingly, formation of inositol phosphates in response to PIT was exclusively dependent on Go, but not on the closely related G alpha (11). Although G alpha (q)/G alpha (11) double-deficient and G alpha (q)-deficient cells did not respond with any production of inositol phosphates to PMT, PMT was still able to induce various other cellular effects in these cells, including the activation of Rho, the Rho-dependent formation of actin stress fibers and focal adhesions, as well as the stimulation of c-Jun N-terminal kinase and extracellular signal-regulated kinase. These data show that PMT leads to a variety of cellular effects that are mediated only in part by the heterotrimeric G-protein G(q).	Univ Heidelberg, Inst Pharmakol, D-69120 Heidelberg, Germany; Free Univ Berlin, Inst Pharmakol, D-14195 Berlin, Germany	Ruprecht Karls University Heidelberg; Free University of Berlin	Offermanns, S (corresponding author), Univ Heidelberg, Inst Pharmakol, Neuenheimer Feld 336, D-69120 Heidelberg, Germany.		Offermanns, Stefan/L-3313-2017	Offermanns, Stefan/0000-0001-8676-6805; Gohla, Antje/0000-0002-7442-1487				ACKERMANN MR, 1994, J VET DIAGN INVEST, V6, P375, DOI 10.1177/104063879400600318; AKTORIES K, 1992, CURR TOP MICROBIOL, V175, P115; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; BISGAARD M, 1993, ZBL BAKT-INT J MED M, V279, P7, DOI 10.1016/S0934-8840(11)80487-1; BLANK JL, 1991, J BIOL CHEM, V266, P18206; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; Boquet P, 1999, ANN NY ACAD SCI, V886, P83, DOI 10.1111/j.1749-6632.1999.tb09403.x; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; BUYS WE, 1990, NUCLEIC ACIDS RES, V11, P2815; Chihara K, 1997, J BIOL CHEM, V272, P25121, DOI 10.1074/jbc.272.40.25121; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; Dudet LI, 1996, J CELL PHYSIOL, V168, P173; Essler M, 1998, J IMMUNOL, V161, P5640; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Garcia V F, 1997, Pediatr Rev, V18, P127, DOI 10.1542/pir.18-4-127; Gohla A, 1998, J BIOL CHEM, V273, P4653, DOI 10.1074/jbc.273.8.4653; Gohla A, 1999, J BIOL CHEM, V274, P17901, DOI 10.1074/jbc.274.25.17901; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Heasley LE, 1996, MOL CELL BIOL, V16, P648; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HIGGINS TE, 1992, P NATL ACAD SCI USA, V89, P4240, DOI 10.1073/pnas.89.10.4240; Hirshman CA, 1999, AM J PHYSIOL-LUNG C, V277, pL653, DOI 10.1152/ajplung.1999.277.3.L653; Ishizaki T, 2000, MOL PHARMACOL, V57, P976; Katoh H, 1998, J BIOL CHEM, V273, P28700, DOI 10.1074/jbc.273.44.28700; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Lacerda HM, 1996, J BIOL CHEM, V271, P439, DOI 10.1074/jbc.271.1.439; LAX AJ, 1990, J GEN MICROBIOL, V136, P81, DOI 10.1099/00221287-136-1-81; Leung T, 1996, MOL CELL BIOL, V16, P5313; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MORRIS MJT, 1992, SOUTH MED J, V85, P442; Mullan PB, 1998, CALCIFIED TISSUE INT, V63, P340, DOI 10.1007/s002239900537; MURPHY AC, 1992, J BIOL CHEM, V267, P25296; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; OFFERMANNS S, 1994, FEBS LETT, V349, P201, DOI 10.1016/0014-5793(94)00667-9; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; OFFERMANNS S, 1995, J BIOL CHEM, V270, P15175, DOI 10.1074/jbc.270.25.15175; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; PETERSEN SK, 1990, MOL MICROBIOL, V4, P821, DOI 10.1111/j.1365-2958.1990.tb00652.x; PETTIT RK, 1993, LAB INVEST, V69, P94; PRASAD MVVSV, 1995, J BIOL CHEM, V270, P18655, DOI 10.1074/jbc.270.31.18655; Ramirez MT, 1997, J BIOL CHEM, V272, P14057, DOI 10.1074/jbc.272.22.14057; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; ROZENGURT E, 1990, P NATL ACAD SCI USA, V87, P123, DOI 10.1073/pnas.87.1.123; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Schmidt G, 1998, J BIOL CHEM, V273, P13669, DOI 10.1074/jbc.273.22.13669; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Seo B, 2000, J BIOL CHEM, V275, P2239, DOI 10.1074/jbc.275.3.2239; STADDON JM, 1991, J BIOL CHEM, V266, P4840; STADDON JM, 1990, J BIOL CHEM, V265, P11841; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; WANGE RL, 1991, J BIOL CHEM, V266, P11409; Wilson BA, 1997, J BIOL CHEM, V272, P1268, DOI 10.1074/jbc.272.20.12961; WU DQ, 1992, J BIOL CHEM, V267, P25798; ZOHN IE, 1995, MOL CELL BIOL, V15, P6160	60	85	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3840	3845		10.1074/jbc.M007819200	http://dx.doi.org/10.1074/jbc.M007819200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11062245	hybrid			2022-12-25	WOS:000166921200018
J	Chang, NS; Pratt, N; Heath, J; Schultz, L; Sleve, D; Carey, GB; Zevotek, N				Chang, NS; Pratt, N; Heath, J; Schultz, L; Sleve, D; Carey, GB; Zevotek, N			Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-DEATH; TNF RECEPTOR-1; CYTOCHROME-C; EXTRACELLULAR-MATRIX; PROTEIN; ACTIVATION; APOPTOSIS; REQUIREMENT; INHIBITION	To determine how hyaluronidase increases certain cancer cell sensitivity to tumor necrosis factor (TNF) cytotoxicity, we report here the isolation and characterization of a hyaluronidase-induced murine WW domain-containing oxidoreductase (WOX1), WOX1 is composed of two N-terminal WW domains, a nuclear localization sequence, and a C-terminal alcohol dehydrogenase (ADH) domain. WOX1 is mainly located in the mitochondria, and the mitochondrial targeting sequence was mapped within the ADH domain. Induction of mitochondrial permeability transition by TNF, staurosporine, and atractyloside resulted in WOX1 release from mitochondria and subsequent nuclear translocation, TNF-mediated WOX1 nuclear translocation occurred shortly after that of nuclear factor-kappaB nuclear translocation, whereas both were independent events. WOX1 enhanced TNF cytotoxicity in L929 cells via its WW and ADH domains as determined using stable cell transfectants, In parallel with this observation, WOX1 also enhanced TRADD (TNF receptor-associated death domain protein)-mediated cell death in transient expression experiments. Antisense expression of WOX1 raised TNF resistance in L929 cells. Enhancement of TNF cytotoxicity by WOX1 is due, in part, to its significant downregulation of the apoptosis inhibitors Bcl-2 and Bcl-x(L) (>85%), but up-regulation of pro-apoptotic p53 (similar to 200%) by the ADH domain. When overexpressed, the ADH domain mediated apoptosis, probably due to modulation of expression of these proteins. The WW domains failed to modulate the expression of these proteins, but sensitized COS-7 cells to TNF killing and mediated apoptosis in various cancer cells independently of caspases, Transient cotransfection of cells with both p53 and WOX1 induced apoptosis in a synergistic manner. WOX1 colocalizes with p53 in the cytosol and binds to the proline-rich region of p53 via its WW domains. Blocking of WOX1 expression by antisense mRNA abolished p53 apoptosis, Thus, WOX1 is a mitochondrial apoptogenic protein and an essential partner of p53 in cell death.	Guthrie Res Inst, Lab Mol Immunol, Sayre, PA 18840 USA		Chang, NS (corresponding author), Guthrie Res Inst, Lab Mol Immunol, 1 Guthrie Sq, Sayre, PA 18840 USA.	nschang@inet.guthrie.org			NATIONAL CANCER INSTITUTE [R55CA064423, R01CA061879] Funding Source: NIH RePORTER; NCI NIH HHS [R55CA64423, R01CA61879] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Baumgartner G, 1998, CANCER LETT, V131, P85, DOI 10.1016/S0304-3835(98)00204-3; Bedford MT, 1998, P NATL ACAD SCI USA, V95, P10602, DOI 10.1073/pnas.95.18.10602; Bednarek AK, 2000, CANCER RES, V60, P2140; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bertrand P, 1997, INT J CANCER, V73, P327, DOI 10.1002/(SICI)1097-0215(19971104)73:3<327::AID-IJC4>3.0.CO;2-1; BORK P, 1994, TRENDS BIOCHEM SCI, V19, P531, DOI 10.1016/0968-0004(94)90053-1; Bossy-Wetzel E, 1999, J BIOL CHEM, V274, P17484, DOI 10.1074/jbc.274.25.17484; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Carey GB, 1998, BIOCHEM BIOPH RES CO, V249, P283, DOI 10.1006/bbrc.1998.9132; Chang NS, 1997, AM J PHYSIOL-CELL PH, V273, pC1987, DOI 10.1152/ajpcell.1997.273.6.C1987; Chang NS, 1998, INT J MOL MED, V2, P653; Chang NS, 1998, CANCER LETT, V131, P45, DOI 10.1016/S0304-3835(98)00200-6; CHANG NS, 1995, J BIOL CHEM, V270, P7765, DOI 10.1074/jbc.270.13.7765; Chang NS, 1998, BIOCHEM BIOPH RES CO, V253, P743, DOI 10.1006/bbrc.1998.9846; DEMAEYER E, 1992, INT J CANCER, V51, P657, DOI 10.1002/ijc.2910510425; Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Kelly LM, 2000, EMBO J, V19, P1987, DOI 10.1093/emboj/19.9.1987; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Komuro A, 1999, NUCLEIC ACIDS RES, V27, P1957, DOI 10.1093/nar/27.9.1957; Liu DC, 1996, P NATL ACAD SCI USA, V93, P7832, DOI 10.1073/pnas.93.15.7832; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lokeshwar VB, 1998, CANCER LETT, V131, P21, DOI 10.1016/S0304-3835(98)00197-9; Lokeshwar VB, 1996, CANCER RES, V56, P651; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Meldrum DR, 1998, AM J PHYSIOL-REG I, V274, pR577, DOI 10.1152/ajpregu.1998.274.3.R577; Natoli G, 1997, J BIOL CHEM, V272, P26079, DOI 10.1074/jbc.272.42.26079; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Paige AJW, 2000, CANCER RES, V60, P1690; Podyma KA, 1997, BIOCHEM BIOPH RES CO, V241, P446, DOI 10.1006/bbrc.1997.7829; Reid K, 2000, HUM MOL GENET, V9, P1651; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Smith KJ, 1997, J AM ACAD DERMATOL, V36, P239, DOI 10.1016/S0190-9622(97)70288-3; StCroix B, 1996, JNCI-J NATL CANCER I, V88, P1285, DOI 10.1093/jnci/88.18.1285; Susin SA, 1999, NATURE, V397, P441, DOI 10.1038/17135; Tamakoshi K, 1997, BRIT J CANCER, V75, P1807, DOI 10.1038/bjc.1997.308; TorreAmione G, 1996, CIRCULATION, V93, P704, DOI 10.1161/01.CIR.93.4.704; VAN AD, 1996, SCIENCE, V274, P787; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wei MC, 2000, GENE DEV, V14, P2060; Whitman S, 2000, MOL CELL BIOL, V20, P583, DOI 10.1128/MCB.20.2.583-593.2000; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200	49	182	197	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3361	3370		10.1074/jbc.M007140200	http://dx.doi.org/10.1074/jbc.M007140200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11058590	hybrid			2022-12-25	WOS:000166784900051
J	Fritz, G; Kaina, B				Fritz, G; Kaina, B			Ras-related GTPase RhoB represses NF-kappa B signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; BINDING PROTEIN; FARNESYLTRANSFERASE INHIBITORS; GROWTH-FACTOR; C-JUN; ACTIVATION; APOPTOSIS; INDUCTION; KINASE; CDC42	rhoB encoding a Ras-related GTPase is immediate-early inducible by genotoxic treatments, indicating that it is part of the cellular stress response. Here, we investigated the influence of RhoB on signal pathways that are rapidly evoked by genotoxic compounds. The data obtained show that wild-type RhoB neither affects activation of mitogen-activated protein kinases nor AP-1-dependent gene expression. However, RhoB inhibited both basal and genotoxic agent-stimulated activity of the transcription factor nuclear factor KB (NF-kappaB), Thus, RhoB attenuated alkylation-induced increase in the DNA binding activity of NF-kappaB and abrogated NF-kappaB-driven gene expression. Furthermore, RhoB inhibited decrease in the cellular amount of I kappaB alpha after genotoxic stress as well as after tumor necrosis factor a and 12-O-tetradecanoylphorbol acetate treatment. This indicates that RhoB represses NF-kappaB activation by inhibiting dissociation and subsequent degradation of I kappaB alpha. On the basis of the data, we suggest that RhoB is a novel negative regulator of NF-kappaB signaling.	Johannes Gutenberg Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Fritz, G (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Div Appl Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	fritz@mail.uni-mainz.de						ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ADAMSON P, 1992, J BIOL CHEM, V267, P20033; Aktories K, 1997, J CLIN INVEST, V99, P827, DOI 10.1172/JCI119245; AKTORIES K, 1988, EUR J BIOCHEM, V172, P445, DOI 10.1111/j.1432-1033.1988.tb13908.x; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baumann B, 1998, J BIOL CHEM, V273, P11448, DOI 10.1074/jbc.273.19.11448; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Bender K, 1998, EMBO J, V17, P5170, DOI 10.1093/emboj/17.17.5170; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Canman CE, 1996, NATURE, V384, P213, DOI 10.1038/384213a0; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; Engel ME, 1998, J BIOL CHEM, V273, P9921, DOI 10.1074/jbc.273.16.9921; Esteve P, 1998, ONCOGENE, V17, P1855, DOI 10.1038/sj.onc.1202082; Esteve P, 1995, ONCOGENE, V11, P2657; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; Fritz G, 2000, BIOCHEM BIOPH RES CO, V268, P784, DOI 10.1006/bbrc.2000.2211; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; Fritz G, 1999, MOL CELL BIOL, V19, P1768; Gibbs JB, 1996, BREAST CANCER RES TR, V38, P75, DOI 10.1007/BF01803786; GIBBS JB, 1994, CELL, V77, P175, DOI 10.1016/0092-8674(94)90308-5; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JIMENEZ B, 1995, ONCOGENE, V10, P811; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lebowitz PF, 1998, ONCOGENE, V17, P1439, DOI 10.1038/sj.onc.1202175; Lebowitz PF, 1998, CELL ADHES COMMUN, V6, P277, DOI 10.3109/15419069809010787; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Mellor H, 1998, J BIOL CHEM, V273, P4811, DOI 10.1074/jbc.273.9.4811; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Molnar A, 1997, J BIOL CHEM, V272, P13229, DOI 10.1074/jbc.272.20.13229; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; ZALCMAN G, 1995, ONCOGENE, V10, P1935; Zalcman G, 1996, J BIOL CHEM, V271, P30366, DOI 10.1074/jbc.271.48.30366; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	49	57	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3115	3122		10.1074/jbc.M005058200	http://dx.doi.org/10.1074/jbc.M005058200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11062238	hybrid			2022-12-25	WOS:000166784900020
J	Ravichandran, LV; Esposito, DL; Chen, J; Quon, MJ				Ravichandran, LV; Esposito, DL; Chen, J; Quon, MJ			Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADIPOSE-CELLS; TYROSINE PHOSPHORYLATION; GLUCOSE-TRANSPORT; SH2 DOMAINS; STIMULATED TRANSLOCATION; SERINE PHOSPHORYLATION; POTENTIAL ROLE; TNF-ALPHA; IN-VIVO; IRS-1	Protein kinase C-zeta (PKC-zeta is a serine/threonine kinase downstream from phosphatidylinositol 3-kinase in insulin signaling pathways. However, specific substrates for PKC-zeta that participate in the biological actions of insulin have not been reported. In the present study, we identified insulin receptor substrate-1 (IRS-1) as a novel substrate for PKC-zeta Under in vitro conditions, wild-type PKC-C (but not kinase-deficient mutant :PKC-zeta significantly phosphorylated IRS-1, This phosphorylation was reversed by treatment with the serine-specific phosphatase, protein phosphatase 2A, In addition, the overexpression of PKC-zeta in NIH-3T3(IR) cells caused significant phosphorylation of cotransfected IRS-1 as demonstrated by [P-32]orthophosphate labeling experiments. In rat adipose cells, endogenous IRS-1 coimmunoprecipitated with endogenous PKC-5, and this association was increased S-fold upon insulin stimulation. Furthermore, the overexpression of PKC-zeta in NIH-3T3(IR) cells significantly impaired insulin-stimulated tyrosine phosphorylation of cotransfected IRS-1. Importantly, this was accompanied by impaired IRS-l-associated phosphatidylinositol 3-kinase activity. Taken together, our results raise the possibility that IRS-1 is a novel physiological substrate for PKC-5. Because PKC-5 is located downstream from IRS-1 and phosphatidylinositol 3-kinase in established insulin signaling pathways, PKC-C may participate in negative feedback pathways to IRS-1 similar to those described previously for Akt and GSK-3.	NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA; Univ G DAnnunzio, Dept Oncol & Neurosci, I-66013 Chieti, Italy	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); G d'Annunzio University of Chieti-Pescara	Quon, MJ (corresponding author), NHLBI, Cardiol Branch, NIH, Bldg 10,Rm 8C-218,10 Ctr Dr,MSC 1755, Bethesda, MD 20892 USA.	quonm@nih.gov	Quon, Michael/B-1970-2008	Quon, Michael/0000-0002-9601-9915; QUON, MICHAEL/0000-0002-5289-3707	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [Z01AT000002, ZIAAT000002] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL003608] Funding Source: NIH RePORTER; Telethon [E.0606] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Telethon(Fondazione Telethon)		Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, MOL ENDOCRINOL, V13, P1766, DOI 10.1210/me.13.10.1766; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Cengel KA, 1999, J BIOL CHEM, V274, P27969, DOI 10.1074/jbc.274.39.27969; Chen H, 1997, J BIOL CHEM, V272, P8026, DOI 10.1074/jbc.272.12.8026; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; DiazMeco MT, 1996, MOL CELL BIOL, V16, P105; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Esposito D, 2000, DIABETES, V49, pA237; Etgen GJ, 1999, J BIOL CHEM, V274, P22139, DOI 10.1074/jbc.274.32.22139; Folli F, 1997, J CLIN INVEST, V100, P2158, DOI 10.1172/JCI119752; HERBST JJ, 1994, BIOCHEMISTRY-US, V33, P9376, DOI 10.1021/bi00198a002; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; Hu MCT, 1998, GENE, V222, P31, DOI 10.1016/S0378-1119(98)00462-4; Huntley CC, 1997, J BIOL CHEM, V272, P16578, DOI 10.1074/jbc.272.26.16578; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; Kellerer M, 1998, DIABETOLOGIA, V41, P833, DOI 10.1007/s001250050995; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Mendez R, 1997, MOL CELL BIOL, V17, P5184, DOI 10.1128/MCB.17.9.5184; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MUNICIO MM, 1995, J BIOL CHEM, V270, P15884, DOI 10.1074/jbc.270.26.15884; Myers MG, 1996, ANNU REV PHARMACOL, V36, P615, DOI 10.1146/annurev.pa.36.040196.003151; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Nystrom FH, 1999, CELL SIGNAL, V11, P563, DOI 10.1016/S0898-6568(99)00025-X; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Pal S, 1998, J BIOL CHEM, V273, P26277, DOI 10.1074/jbc.273.41.26277; Paz K, 1997, J BIOL CHEM, V272, P29911, DOI 10.1074/jbc.272.47.29911; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; QUON MJ, 1994, J BIOL CHEM, V269, P27920; QUON MJ, 1993, BIOCHEM BIOPH RES CO, V194, P338, DOI 10.1006/bbrc.1993.1825; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; RORDORFNIKOLIC T, 1995, J BIOL CHEM, V270, P3662, DOI 10.1074/jbc.270.8.3662; Sajan MP, 1999, J BIOL CHEM, V274, P30495, DOI 10.1074/jbc.274.43.30495; Sauvage M, 2000, EUR J BIOCHEM, V267, P955, DOI 10.1046/j.1432-1327.2000.01084.x; Standaert ML, 1997, J BIOL CHEM, V272, P30075, DOI 10.1074/jbc.272.48.30075; Staubs PA, 1998, J BIOL CHEM, V273, P25139, DOI 10.1074/jbc.273.39.25139; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Yenush L, 1997, BIOESSAYS, V19, P491, DOI 10.1002/bies.950190608; Zhou GS, 1997, J BIOL CHEM, V272, P31130, DOI 10.1074/jbc.272.49.31130	47	178	184	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3543	3549		10.1074/jbc.M007231200	http://dx.doi.org/10.1074/jbc.M007231200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11063744	hybrid			2022-12-25	WOS:000166784900073
J	Glickman, MS; Cahill, SM; Jacobs, WR				Glickman, MS; Cahill, SM; Jacobs, WR			The Mycobacterium tuberculosis cmaA2 gene encodes a mycolic acid trans-cyclopropane synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; IDENTIFICATION; ENVELOPE; SEQUENCE	Infection with Mycobacterium tuberculosis remains a major global health emergency. Although detailed understanding of the molecular events of M. tuberculosis pathogenesis is still limited, recent genetic analyses have implicated specific lipids of the cell envelope as important effecters in M. tuberculosis pathogenesis. We have shown that pcaA, a novel member of a family of M. tuberculosis S-adenosyl methionine (SAM)-dependent methyl transferases, is required for alpha -mycolic acid cyclopropanation and lethal chronic persistent M. tuberculosis infection. To examine the apparent redundancy between pcaA and cmaA2, another cyclopropane synthetase of M. tuberculosis thought to be involved in alpha -mycolate synthesis, we have disrupted the cmaA2 gene in virulent M. tuberculosis by specialized transduction. Inactivation of cmaA2 causes accumulation of unsaturated derivatives of both the methoxy- and ketomycolates. Analysis by proton NMR indicates that the mycolic acids of the cmaA2 mutant lack, trans-cyclopropane rings but are otherwise intact with respect to cyclopropane and methyl branch content. Thus, cmaA2 is required for the synthesis of the trans cyclopropane rings of both the methoxymycolates and ketomycolates. These results define cmaA2 as a trans-cyclopropane synthetase and expand our knowledge of the substrate specificity of a large family of highly homologous mycolic acid methyl transferases recently shown to be critical to M. tuberculosis pathogenesis.	Yeshiva Univ Albert Einstein Coll Med, Div Infect Dis, Montefiore Med Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Struct NMR Resource, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Bronx, NY 10461 USA	Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine	Glickman, MS (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Div Infect Dis, Montefiore Med Ctr, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Glickman, Michael S/0000-0001-7918-5164; Jacobs, William/0000-0003-3321-3080	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K08AI001534] Funding Source: NIH RePORTER; NIAID NIH HHS [AI01534] Funding Source: Medline; NIAMS NIH HHS [AR27160] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Barry CE, 1998, PROG LIPID RES, V37, P143, DOI 10.1016/S0163-7827(98)00008-3; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Carriere C, 1997, J CLIN MICROBIOL, V35, P3232; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cox JS, 1999, NATURE, V402, P79, DOI 10.1038/47042; Daffe M, 1998, ADV MICROB PHYSIOL, V39, P131; Dubnau E, 1998, MOL MICROBIOL, V29, P1526; Dubnau E, 1997, MOL MICROBIOL, V23, P313, DOI 10.1046/j.1365-2958.1997.2301589.x; Dubnau E, 2000, MOL MICROBIOL, V36, P630, DOI 10.1046/j.1365-2958.2000.01882.x; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; GEORGE KM, 1995, J BIOL CHEM, V270, P27292, DOI 10.1074/jbc.270.45.27292; Glickman MS, 2000, MOL CELL, V5, P717, DOI 10.1016/S1097-2765(00)80250-6; Grogan DW, 1997, MICROBIOL MOL BIOL R, V61, P429, DOI 10.1128/.61.4.429-441.1997; LEE MH, 1991, P NATL ACAD SCI USA, V88, P3111, DOI 10.1073/pnas.88.8.3111; Yuan Y, 1998, MOL MICROBIOL, V29, P1449, DOI 10.1046/j.1365-2958.1998.01026.x; YUAN Y, 1995, P NATL ACAD SCI USA, V92, P6630, DOI 10.1073/pnas.92.14.6630; Yuan Y, 1996, P NATL ACAD SCI USA, V93, P12828, DOI 10.1073/pnas.93.23.12828; Yuan Y, 1997, J BIOL CHEM, V272, P10041	19	103	113	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2228	2233		10.1074/jbc.C000652200	http://dx.doi.org/10.1074/jbc.C000652200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11092877	hybrid			2022-12-25	WOS:000166528000077
J	Hirst, SK; Grandori, C				Hirst, SK; Grandori, C			Differential activity of conditional MYC and its variant MYC-S in human mortal fibroblasts	ONCOGENE			English	Article						Myc-ER; Myc-S; WI38; human fibroblasts; cell-cycle; apoptosis; Myc target genes	C-MYC; TRANSCRIPTIONAL REPRESSION; TUMOR-SUPPRESSOR; TARGET GENES; CELL-GROWTH; IN-VIVO; MAX; APOPTOSIS; PROTEINS; TRANSFORMATION	We have explored the effects of the conditional MYC-estrogen receptor fusion protein, MYC-ERT(TM), in human mortal fibroblasts, WI38, on cell-cycle entry, apoptosis and gene expression, The results indicate that activation of MYC-ER(TM) in WI38 cells is sufficient to cause S phase entry of quiescent cells, which is preceded by phosphorylation of Rb and activation of the Cdk2-associated kinase, We also analysed the MYC protein variant, MYC-S, which lacks part of the transcriptional activation domain but includes the conserved MYC box II and 26 amino acids N-terminal to it, MYC-S was previously shown to promote proliferation and apoptosis of immortalized rodent cell lines, The results indicate that MYC-S has undetectable activity as an inducer of S phase or apoptosis of quiescent WI38 cells. However, Myc-S stimulates proliferation of WI38 cells in the presence of 10% fetal calf serum, Surprisingly, we found that MYC-S, previously considered solely a repressor of specific reporter genes, is instead a weak transactivator of endogenous target genes both in mortal and immortalized cells. In addition, MYC-S exhibit a weak repressor activity upon an endogenous target gene only in immortalized cells, MYC-S transcriptional properties suggest that MYC box II and the adjacent N-terminal amino acids, while not sufficient for full repression function, participate in transactivation of endogenous target genes.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Grandori, C (corresponding author), Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N, Seattle, WA 98109 USA.				NCI NIH HHS [CA75125, CA20525] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA020525, R01CA020525, R29CA075125] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASKEW DS, 1991, ONCOGENE, V6, P1915; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; Dang CV, 1999, MOL CELL BIOL, V19, P1; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; Eilers M, 1999, MOL CELLS, V9, P1; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; Ge K, 1999, P NATL ACAD SCI USA, V96, P9689, DOI 10.1073/pnas.96.17.9689; Grandori C, 1996, EMBO J, V15, P4344, DOI 10.1002/j.1460-2075.1996.tb00808.x; Grandori C, 1997, TRENDS BIOCHEM SCI, V22, P177, DOI 10.1016/S0968-0004(97)01025-6; Hurlin PJ, 1996, EMBO J, V15, P2030, DOI 10.1002/j.1460-2075.1996.tb00555.x; Hurlin PJ, 1997, GENE DEV, V11, P44, DOI 10.1101/gad.11.1.44; Iritani BM, 1999, P NATL ACAD SCI USA, V96, P13180, DOI 10.1073/pnas.96.23.13180; Johnston LA, 1999, CELL, V98, P779, DOI 10.1016/S0092-8674(00)81512-3; KAHANA C, 1984, P NATL ACAD SCI-BIOL, V81, P3645, DOI 10.1073/pnas.81.12.3645; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; MILTENBERGER RJ, 1995, MOL CELL BIOL, V15, P2527; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; QUELLE DE, 1995, ONCOGENE, V11, P635; RABINOVITCH PS, 1994, METHOD CELL BIOL, V41, P263; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Schuhmacher M, 1999, CURR BIOL, V9, P1255, DOI 10.1016/S0960-9822(99)80507-7; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; WechslerReya R, 1997, J BIOL CHEM, V272, P31453, DOI 10.1074/jbc.272.50.31453; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	42	19	19	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 26	2000	19	45					5189	5197		10.1038/sj.onc.1203904	http://dx.doi.org/10.1038/sj.onc.1203904			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	368NP	11064456				2022-12-25	WOS:000090124100008
J	Ding, M; Shi, XL; Lu, YJ; Huang, CS; Leonard, S; Roberts, J; Antonini, J; Castranova, V; Vallyathan, V				Ding, M; Shi, XL; Lu, YJ; Huang, CS; Leonard, S; Roberts, J; Antonini, J; Castranova, V; Vallyathan, V			Induction of activator protein-1 through reactive oxygen species by crystalline silica in JB6 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE-RADICALS; AP-1; TRANSACTIVATION; TRANSFORMATION; CARCINOGENESIS; CYTOTOXICITY; MECHANISMS; GENERATION; PROMOTION; REDUCTION	We reported previously that freshly fractured silica (FFSi) induces activator protein-1 (AP-1) activation through extracellular signal-regulated protein kinases (ERKs) and p38 kinase pathways. In the present study, the biologic activities of FFSi and aged silica (ASi) were compared by measuring their effects on the AP-1 activation and phosphorylation of ERKs and p38 kinase. The roles of reactive oxygen species (ROS) in this silica-induced AP-1 activation mere also investigated. We found that FFSi-induced AP-1 activation was four times higher than that of ASi in JB6 cells. FFSi also caused greater phosphorylation of ERKs and p38 kinase than ASi, FFSi generated more ROS than ASi when incubated with the cells as measured by electron spin resonance (ESR). Studies using ROS-sensitive dyes and oxygen consumption support the conclusion that ROS are generated by silica-treated cells. N-Acetylcysteine (an antioxidant) and polyvinyl pyridine-N-oxide (an agent that binds to Si-OH groups on silica surfaces) decreased AP-1 activation and phosphorylation of ERKs and p38 kinase. Catalase inhibited phosphorylation of ERKs and p38 kinase, as well as AP-1 activation induced by FFSi, suggesting the involvement of H2O2 in the mechanism of silica-induced AP-1 activation. Sodium formate (an (OH)-O-. scavenger) had no influence on silica-induced MAPKs or AP-1 activation. Superoxide dismutase enhanced both AP-1 and MAPKs activation, indicating that H2O2, but not O-2(radical anion), may play a critical role in silica-induced AP-I activation. These studies indicate that freshly ground silica is more biologically active than aged silica and that ROS, in particular H2O2, play a significant role in silica-induced AP-I activation.	NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Vallyathan, V (corresponding author), NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, 1095 Willowdale Rd, Morgantown, WV 26505 USA.		Shi, Xianglin/B-8588-2012	Huang, Chuanshu/0000-0003-4133-5096				ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; [Anonymous], 1997, IARC Monogr Eval Carcinog Risks Hum, V68, P1; Barthelman M, 1998, CANCER RES, V58, P711; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BRITIGAN BE, 1986, J BIOL CHEM, V261, P7026; CASTRANOVA V, 1996, SILICA SILICA INDUCE, P293; Chen F, 1998, ANN CLIN LAB SCI, V28, P1; CRAIGHEAD JE, 1988, ARCH PATHOL LAB MED, V112, P673; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; DALAL NS, 1990, J TOXICOL ENV HEALTH, V29, P307, DOI 10.1080/15287399009531393; DALAL NS, 1990, FREE RADICAL RES COM, V9, P259, DOI 10.3109/10715769009145684; Daniel LN, 1995, SCAND J WORK ENV HEA, V21, P22; Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611; DONG ZG, 1995, CARCINOGENESIS, V16, P749, DOI 10.1093/carcin/16.4.749; Huang CS, 1996, J BIOL CHEM, V271, P31262, DOI 10.1074/jbc.271.49.31262; *INT AG RES CANC, 1987, IARC MON EV CARC RIS, V42, P1; KEISUKE M, 1992, CAN J CHEM, V70, P2818; MCDONALD JC, 1996, SILICA SILICA INDUCE, P383; REISER KM, 1979, TOXICOLOGY, V13, P51, DOI 10.1016/S0300-483X(79)80010-4; Rosen G.M., 1985, ADV FREE RADIC BIOL, V1, P345, DOI [10.1016/8755-9668(85)90012-2, DOI 10.1016/8755-9668(85)90012-2]; SAFFIOTTI U, 1992, PROG CLIN BIOL RES, V374, P51; SAFFIOTTI U, 1996, SILICA SILICA INDUCE, P345; SHI XG, 1988, J TOXICOL ENV HEALTH, V25, P237, DOI 10.1080/15287398809531205; SHI XL, 1994, ENVIRON HEALTH PERSP, V102, P149, DOI 10.2307/3432231; Shi XL, 1998, J TOXICOL ENV HEAL B, V1, P181, DOI 10.1080/10937409809524551; SIMONATO L, 1990, IARC SCI PUBL, V97, P1; VALLYATHAN V, 1988, AM REV RESPIR DIS, V138, P1213, DOI 10.1164/ajrccm/138.5.1213; VALLYATHAN V, 1992, AM J RESP CELL MOL, V6, P404, DOI 10.1165/ajrcmb/6.4.404; WAGNER MMF, 1972, J NATL CANCER I, V49, P81; Young MR, 1999, P NATL ACAD SCI USA, V96, P9827, DOI 10.1073/pnas.96.17.9827; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661	32	57	68	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 23	2001	276	12					9108	9114		10.1074/jbc.M007666200	http://dx.doi.org/10.1074/jbc.M007666200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	413HV	11096084	hybrid			2022-12-25	WOS:000167607700067
J	Caunt, CJ; Kiss-Toth, E; Carlotti, F; Chapman, R; Qwarnstrom, EE				Caunt, CJ; Kiss-Toth, E; Carlotti, F; Chapman, R; Qwarnstrom, EE			Ras controls tumor necrosis factor receptor-associated factor (TRAF)6-dependent induction of nuclear factor-kappa B - Selective regulation through receptor signaling components	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FIBRONECTIN ATTACHMENT; IL-1 RECEPTOR; TRANSCRIPTIONAL ACTIVITY; INFLAMMATORY CYTOKINES; CELL-SURFACE; MAP KINASE; INTERLEUKIN-1; PATHWAY; BINDING	In the present study, we show that Ras activity differentially controls interleukin (IL)-1 induced transcription factor activation by selective regulation of responses mediated by receptor complex components. Initial experiments revealed that stimulation with IL-1 caused a rapid, matrix-dependent activation of Ras. The effect was transient, peaking at 5 min and returning to base levels after 30 min. Activation correlated with pronounced changes in cell shape in EGFPH-Ras transfected cells. Transfection with the dominant negative mutant, Ras(Asn-17), inhibited IL-1 induced activation of the IL-8 promoter as well as of NF-kappaB and AP-1 synthetic promoters in transient transfection assays. Furthermore, overexpression of the IL-1 signaling proteins TRAF6 or MyD88 gave characteristic activation of IL-8, which was accentuated in the presence of IL-1. Co-transfection with Ras(Asn-17) gave a dose-dependent inhibition of TRAF6-induced responses in the presence and absence of IL-1, but had no effect on MyD88 mediated activity. Similarly, induction of NF-kappaB was abolished by Ras(Asn-17) only in TRAF6-transfected cells. In contrast, inhibiting Ras activity limited AP-1-mediated responses through both receptor complex proteins. Constitutively active Ras(VaI-12) increased the TRAF6 induced activity of the NF-kappaB pathway similar to the effect induced by IL-1, while the Ras(VaI-12) induced activity was not inhibited by co-transfection with a dominant negative TRAF6. Our data show that activation of the Ras GTPase is an early, matrix-dependent response in IL-1 signaling which participates in structural regulation of IL-1-induced genes. In addition, they show that the Ras induced effect selectively regulates TRAF6-mediated activation of the NF-kappaB pathway, suggesting that Ras GTPase represents a convergence point in structural and cytokine responses, with distinct effects on a subset of downstream signaling events.	Univ Sheffield, Royal Hallamshire Hosp, Div Mol & Genet Med, Sheffield S10 2JF, S Yorkshire, England; Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA	University of Sheffield; University of Washington; University of Washington Seattle	Qwarnstrom, EE (corresponding author), Univ Sheffield, Royal Hallamshire Hosp, Div Mol & Genet Med, Glossop Rd, Sheffield S10 2JF, S Yorkshire, England.		Kiss-Toth, Endre/A-8596-2014; Kiss-Toth, Endre/AAC-4252-2020	Kiss-Toth, Endre/0000-0003-4406-4017; Kiss-Toth, Endre/0000-0003-4406-4017; Qwarnstrom, Eva/0000-0003-4417-8663				BROWN PJ, 1985, SCIENCE, V228, P1448, DOI 10.1126/science.4012302; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Carlotti F, 1999, J BIOL CHEM, V274, P37941, DOI 10.1074/jbc.274.53.37941; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DEVARY Y, 1993, SCIENCE, V261, P1442, DOI 10.1126/science.8367725; DUCKETT CS, 1993, MOL CELL BIOL, V15, P2413; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Jefferies CA, 2000, J BIOL CHEM, V275, P3114, DOI 10.1074/jbc.275.5.3114; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kiss-Toth E, 2000, J IMMUNOL METHODS, V239, P125, DOI 10.1016/S0022-1759(00)00151-4; Kopp E, 1999, GENE DEV, V13, P2059, DOI 10.1101/gad.13.16.2059; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; Lim L, 1996, EUR J BIOCHEM, V242, P171, DOI 10.1111/j.1432-1033.1996.0171r.x; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Lukashev ME, 1998, TRENDS CELL BIOL, V8, P437, DOI 10.1016/S0962-8924(98)01362-2; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; Niv H, 1999, J BIOL CHEM, V274, P1606, DOI 10.1074/jbc.274.3.1606; NOBES CD, 1999, J CELL BIOL; OSTBERG CO, 1995, FEBS LETT, V367, P93, DOI 10.1016/0014-5793(95)00509-8; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Puls A, 1999, J CELL SCI, V112, P2983; QWARNSTROM EE, 1988, J BIOL CHEM, V263, P8261; QWARNSTROM EE, 1991, P NATL ACAD SCI USA, V88, P1232, DOI 10.1073/pnas.88.4.1232; QWARNSTROM EE, 1994, J BIOL CHEM, V269, P30765; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; SIMS JE, 1995, CYTOKINE, P324; Singh R, 1999, J CLIN INVEST, V103, P1561, DOI 10.1172/JCI5754; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; Valles S, 1999, J BIOL CHEM, V274, P20103, DOI 10.1074/jbc.274.29.20103; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1999, J BIOL CHEM, V274, P19403, DOI 10.1074/jbc.274.27.19403; WINITZ S, 1993, J BIOL CHEM, V268, P19196; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhu P, 1998, BIOCHEM J, V330, P975, DOI 10.1042/bj3300975	51	27	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6280	6288		10.1074/jbc.M006772200	http://dx.doi.org/10.1074/jbc.M006772200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11080497	hybrid			2022-12-25	WOS:000167261000031
J	McRee, DE; Williams, PA; Sridhar, V; Pastuszyn, A; Bren, KL; Patel, KM; Chen, Y; Todaro, TR; Sanders, D; Luna, E; Fee, JA				McRee, DE; Williams, PA; Sridhar, V; Pastuszyn, A; Bren, KL; Patel, KM; Chen, Y; Todaro, TR; Sanders, D; Luna, E; Fee, JA			Recombinant cytochrome rC(557) obtained from Escherichia coli cells expressing a truncated Thermus thermophilus cycA gene - Heme inversion in an improperly matured protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ELECTRONIC-STRUCTURE; IRON COORDINATION; EUGLENA-GRACILIS; C BIOGENESIS; H-1-NMR; C(552); MITOCHONDRIAL; BINDING; ASSIGNMENTS	Cytochrome rC(557) is an improperly matured, dimeric cytochrome c obtained from expression of the "signal peptide-lacking" Thermus thermophilus cycA gene in the cytoplasm of Escherichia coli. It is characterized by its Q(00) (or alpha-) optical absorption band at 557 nm in the reduced form (Keightley, J. A., Sanders, D., Todaro, T. R., Pastuszyn, A., and Fee, J. A. (1998) J. Biol. Chem. 273, 12006-12016). We report results of a broad ranging, biochemical and spectral characterization of this protein that reveals the presence of a free vinyl group on the porphyrin and a disulfide bond between the protomers and supports His-Met ligation in both valence states of the iron. A 3-Angstrom resolution x-ray structure shows that, in comparison with the native protein, the heme moiety is rotated 180 degrees about its alpha,gamma -axis; cysteine 14 has formed a thioether bond with the 2-vinyl of pyrrole ring I instead of the 4-vinyl of pyrrole ring II, as occurs in the native protein; and a cysteine 11 from each protomer has formed an intermolecular disulfide bond. Numerous, minor perturbations exist within the structure of rC(557) in comparison with that of native protein, which result from heme inversion and protein-protein interactions across the dimer interface. The unusual spectral properties of rC(557) are rationalized in terms of this structure.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Univ New Mexico, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA; Univ Rochester, Dept Chem, Rochester, NY 14627 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	University of California System; University of California San Diego; Scripps Research Institute; University of New Mexico; University of Rochester; University of California System; University of California San Diego	Fee, JA (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.	jfee@ucsd.edu		Bren, Kara/0000-0002-8082-3634; Williams, Pamela/0000-0002-1257-2351	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM048495] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35342, GM48495] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aitken Alastair, 1996, P339, DOI 10.1007/978-1-60327-259-9_51; ARNESANO F, 1990, EUR J BIOCHEM, V260, P347; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banci L, 2000, EUR J BIOCHEM, V267, P755, DOI 10.1046/j.1432-1327.2000.01054.x; BARKER PD, 1995, BIOCHEMISTRY-US, V34, P15191, DOI 10.1021/bi00046a027; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; COHEN SA, 1988, ANAL BIOCHEM, V174, P1, DOI 10.1016/0003-2697(88)90512-X; COWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148, DOI 10.1107/S0907444992007698; Fee JA, 2000, PROTEIN SCI, V9, P2074, DOI 10.1110/ps.9.11.2074; Fischer H, 1941, LIEBIGS ANN CHEM, V548, P183; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; Keightley JA, 1998, J BIOL CHEM, V273, P12006, DOI 10.1074/jbc.273.20.12006; KEIGHTLEY JA, 1995, J BIOL CHEM, V270, P20345, DOI 10.1074/jbc.270.35.20345; KELLER RM, 1980, BIOCHIM BIOPHYS ACTA, V621, P204, DOI 10.1016/0005-2795(80)90172-5; Kohler M, 1996, BIOPHYS J, V71, P77, DOI 10.1016/S0006-3495(96)79237-8; Kranz R, 1998, MOL MICROBIOL, V29, P383, DOI 10.1046/j.1365-2958.1998.00869.x; La Mar G.N., 1993, BIOL MAGN RESON, P1; LAMAR GN, 1978, P NATL ACAD SCI USA, V75, P5755, DOI 10.1073/pnas.75.12.5755; LEE KB, 1990, BIOCHEMISTRY-US, V29, P9623, DOI 10.1021/bi00493a017; LEE KB, 1993, BIOCHIM BIOPHYS ACTA, V1202, P189, DOI 10.1016/0167-4838(93)90004-B; LESLIE AGW, 1992, MOSFLM S; MCDONALD CC, 1969, BIOCHEM BIOPH RES CO, V36, P442, DOI 10.1016/0006-291X(69)90584-1; MCLACHLAN SJ, 1986, BIOCHIM BIOPHYS ACTA, V874, P274, DOI 10.1016/0167-4838(86)90026-9; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MUKAI K, 1989, EUR J BIOCHEM, V178, P649, DOI 10.1111/j.1432-1033.1989.tb14494.x; Page MD, 1998, TRENDS BIOCHEM SCI, V23, P103, DOI 10.1016/S0968-0004(98)01173-6; PETTIGREW GW, 1975, BIOCHEM J, V147, P291, DOI 10.1042/bj1470291; Pollock WBR, 1998, BIOCHEMISTRY-US, V37, P6124, DOI 10.1021/bi972188d; Reddy KS, 1996, BIOCHEMISTRY-US, V35, P12820, DOI 10.1021/bi960895l; RIBBING W, 1978, FEBS LETT, V92, P105, DOI 10.1016/0014-5793(78)80732-7; SAMBONGI Y, 1994, FEBS LETT, V340, P65, DOI 10.1016/0014-5793(94)80174-6; Sambongi Y, 1996, MOL MICROBIOL, V19, P1193, DOI 10.1111/j.1365-2958.1996.tb02465.x; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SENN H, 1980, BIOCHEM BIOPH RES CO, V92, P1362, DOI 10.1016/0006-291X(80)90436-2; SENN H, 1985, Q REV BIOPHYS, V18, P111, DOI 10.1017/S0033583500005151; Shokhirev NV, 1998, J BIOL INORG CHEM, V3, P581, DOI 10.1007/s007750050271; Sinha N, 1998, FEMS MICROBIOL LETT, V161, P1; SIUZDAK G, 1994, P NATL ACAD SCI USA, V91, P11290, DOI 10.1073/pnas.91.24.11290; Soulimane T, 1997, BIOCHEM BIOPH RES CO, V237, P572, DOI 10.1006/bbrc.1997.7041; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TANAKA Y, 1990, J BIOCHEM-TOKYO, V108, P7, DOI 10.1093/oxfordjournals.jbchem.a123165; Than ME, 1997, J MOL BIOL, V271, P629, DOI 10.1006/jmbi.1997.1181; THONYMEYER L, 1994, MOL MICROBIOL, V12, P1, DOI 10.1111/j.1365-2958.1994.tb00988.x; ThonyMeyer L, 1997, EUR J BIOCHEM, V246, P794, DOI 10.1111/j.1432-1033.1997.t01-1-00794.x; TURNER DL, 1995, EUR J BIOCHEM, V227, P829, DOI 10.1111/j.1432-1033.1995.tb20208.x; WU JZ, 1991, BIOCHEMISTRY-US, V30, P2156, DOI 10.1021/bi00222a020; ZIMMERMANN BH, 1988, STUDIES RESP PROTEIN	49	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6537	6544		10.1074/jbc.M008421200	http://dx.doi.org/10.1074/jbc.M008421200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11069913	hybrid			2022-12-25	WOS:000167261000063
J	Nelson, SW; Kurbanov, FT; Honzatko, RB; Fromm, HJ				Nelson, SW; Kurbanov, FT; Honzatko, RB; Fromm, HJ			The N-terminal segment of recombinant porcine fructose-1,6-bisphosphatase participates in the allosteric regulation of catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG-KIDNEY FRUCTOSE-1,6-BISPHOSPHATASE; FRUCTOSE 1,6-BISPHOSPHATASE; CHLOROPLAST FRUCTOSE-1,6-BISPHOSPHATASE; AMP COOPERATIVITY; CRYSTAL-STRUCTURE; DYNAMIC LOOP; T-STATE; INHIBITION; MECHANISM; INTERFACE	Residues 1-10 of porcine fructose-1,6-bisphosphatase (FBPase) are poorly ordered or are in different conformations, sensitive to the state of ligation of the enzyme. Deletion of the first 10 residues of FBPase reduces k(cat) by 30-fold and Mg2+ affinity by 20-fold and eliminates cooperativity in Mg2+ activation. Although a fluorescent analogue of AMP binds with high affinity to the truncated enzyme, AMP itself potently inhibits only 50% of the enzyme activity. Additional inhibition occurs only when the concentration of AMP exceeds 10 mM. Deletion of the first seven residues reduces k(cat) and Mg2+ affinity significantly but has no effect on AMP inhibition. The mutation of Asp(9) to alanine reproduces the weakened affinity for Mg2+ observed in the deletion mutants, and the mutation of Ile(10) to aspartate reproduces the AMP inhibition of the 10-residue deletion mutant. Changes in the relative stability of the known conformational states for loop 52-72, in response to changes in the quaternary structure of FBPase, can account for the phenomena above. Some aspects of the proposed model may be relevant to all forms of FBPase, including the thioredoxin-regulated FBPase from the chloroplast.	Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Fromm, HJ (corresponding author), Iowa State Univ, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA.				NINDS NIH HHS [NS 10546] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010546, R56NS010546] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENKOVIC SJ, 1982, ADV ENZYMOL RAMB, V53, P45; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carcamo JG, 2000, EUR J BIOCHEM, V267, P2242, DOI 10.1046/j.1432-1327.2000.01227.x; CHATTERJEE T, 1985, J BIOL CHEM, V260, P3553; Chiadmi M, 1999, EMBO J, V18, P6809, DOI 10.1093/emboj/18.23.6809; Choe JY, 2000, BIOCHEMISTRY-US, V39, P8565, DOI 10.1021/bi000574g; Choe JY, 1998, BIOCHEMISTRY-US, V37, P11441, DOI 10.1021/bi981112u; HORECKER BL, 1975, ADV ENZYMOL RAMB, V42, P193; Jacquot JP, 1997, FEBS LETT, V401, P143, DOI 10.1016/S0014-5793(96)01459-7; KE HM, 1990, P NATL ACAD SCI USA, V87, P5243, DOI 10.1073/pnas.87.14.5243; KE HM, 1989, P NATL ACAD SCI USA, V86, P1475, DOI 10.1073/pnas.86.5.1475; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kurbanov FT, 1998, J BIOL CHEM, V273, P17511, DOI 10.1074/jbc.273.28.17511; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P52; LEATHERBARROW RJ, 1987, ENZFITTER, P13; LIU F, 1988, J BIOL CHEM, V263, P9122; Lu GQ, 1996, PROTEIN SCI, V5, P2333, DOI 10.1002/pro.5560051120; Lu GQ, 1997, J BIOL CHEM, V272, P5076, DOI 10.1074/jbc.272.8.5076; LUI F, 1990, J BIOL CHEM, V265, P7401; NEL W, 1992, INT J BIOCHEM, V24, P1267, DOI 10.1016/0020-711X(92)90201-B; Nelson SW, 2000, BIOCHEMISTRY-US, V39, P11100, DOI 10.1021/bi000609c; Nelson SW, 2000, J BIOL CHEM, V275, P29986, DOI 10.1074/jbc.M000473200; NIMMO HG, 1975, EUR J BIOCHEM, V58, P567, DOI 10.1111/j.1432-1033.1975.tb02407.x; PILKIS SJ, 1988, ANNU REV BIOCHEM, V57, P755, DOI 10.1146/annurev.bi.57.070188.003543; SCHEFFLER JE, 1986, BIOCHEMISTRY-US, V25, P6659, DOI 10.1021/bi00369a050; Shyur LF, 1996, J BIOL CHEM, V271, P33301, DOI 10.1074/jbc.271.52.33301; TEJWANI GA, 1983, ADV ENZYMOL RAMB, V54, P121; Van Schaftingen E., 1987, ADV ENZYMOL RELAT AR, V59, P45; VILLERET V, 1995, BIOCHEMISTRY-US, V34, P4299, DOI 10.1021/bi00013a019; VILLERET V, 1995, BIOCHEMISTRY-US, V34, P4307, DOI 10.1021/bi00013a020; XUE YF, 1994, P NATL ACAD SCI USA, V91, P12482, DOI 10.1073/pnas.91.26.12482; ZHANG YP, 1994, J MOL BIOL, V244, P609, DOI 10.1006/jmbi.1994.1755	33	16	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6119	6124		10.1074/jbc.M009485200	http://dx.doi.org/10.1074/jbc.M009485200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096109	hybrid			2022-12-25	WOS:000167261000011
J	Celver, JP; Lowe, J; Kovoor, A; Gurevich, VV; Chavkin, C				Celver, JP; Lowe, J; Kovoor, A; Gurevich, VV; Chavkin, C			Threonine 180 is required for G-protein-coupled receptor kinase 3- and beta-arrestin 2-mediated desensitization of the mu-opioid receptor in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-INDUCED DESENSITIZATION; MUSCARINIC ACETYLCHOLINE-RECEPTOR; DOWN-REGULATION; AMINO-ACIDS; PHOSPHORYLATION; INTERNALIZATION; MECHANISMS; EFFICACY	To determine the sites in the mu -opioid receptor (MOR) critical for agonist-dependent desensitization, we constructed and coexpressed MORs lacking potential phosphorylation sites along with G-protein activated inwardly rectifying potassium channels composed of K(ir)3.1 and K(ir)3.4 subunits in Xenopus oocytes, Activation of MOR by the stable enkephalin analogue, [D-Ala(2),MePhe(4),Glyol(5)]enkephalin, led to homologous MOR desensitization in oocytes coexpressing both G-protein-coupled receptor kinase 3 (GRK3) and beta -arrestin 2 (arr3), Coexpression with either GRK3 or arr3 individually did not significantly enhance desensitization of responses evoked by wild type MOR activation. Mutation of serine or threonine residues to alanines in the putative third cytoplasmic loop and truncation of the C-terminal tail did not block GRK/arr3-mediated desensitization of MOR. Instead, alanine substitution of a single threonine in the second cytoplasmic loop to produce MOR(T180A) was sufficient to block homologous desensitization. The insensitivity of MOR(T180A) might have resulted either from a block of arrestin activation or arrestin binding to MOR. To distinguish between these alternatives, we expressed a dominant positive arrestin, arr2(R169E), that desensitizes G protein-coupled receptors in an agonist-dependent but phosphorylation-independent manner. arr2(R169E) produced robust desensitization of MOR and MOR(T180A) in the absence of GRK3 coexpression. These results demonstrate that the T180A mutation probably blocks GRK3- and arr3-mediated desensitization of MOR by preventing a critical agonist-dependent receptor phosphorylation and suggest a novel GRK3 site of regulation not yet described for other G-protein-coupled receptors.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Sun Hlth Res Inst, Ralph & Muriel Roberts Lab Vis Sci, Sun City, AZ 85351 USA	University of Washington; University of Washington Seattle; Banner Research; Banner Health; Banner Sun Health Research Institute	Chavkin, C (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.		Chavkin, Charles/G-2797-2010; Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NIDA NIH HHS [DA11672] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011672, R37DA011672] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Appleyard SM, 1999, J BIOL CHEM, V274, P23802, DOI 10.1074/jbc.274.34.23802; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; CHAVKIN C, 1982, LIFE SCI, V31, P1687, DOI 10.1016/0024-3205(82)90186-2; CHAVKIN C, 1984, P NATL ACAD SCI-BIOL, V81, P7253, DOI 10.1073/pnas.81.22.7253; CHRISTIE MJ, 1987, MOL PHARMACOL, V32, P633; Deng HB, 2000, BIOCHEMISTRY-US, V39, P5492, DOI 10.1021/bi991938b; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Haga K, 1996, J BIOL CHEM, V271, P2776, DOI 10.1074/jbc.271.5.2776; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Jin WZ, 1999, J NEUROSCI, V19, P3773; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Kovoor A, 1998, MOL PHARMACOL, V54, P704; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; KRAMER TH, 1989, J PHARMACOL EXP THER, V249, P544; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Pak Y, 1996, MOL PHARMACOL, V50, P1214; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; PORRECA F, 1983, J PHARMACOL EXP THER, V227, P22; Sim LJ, 1996, J NEUROSCI, V16, P2684; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; TAO PL, 1993, EUR J PHARM-MOLEC PH, V246, P233, DOI 10.1016/0922-4106(93)90036-9; Tsuga H, 1998, J BIOL CHEM, V273, P5323, DOI 10.1074/jbc.273.9.5323; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; Wang HL, 2000, NEUROPHARMACOLOGY, V39, P353, DOI 10.1016/S0028-3908(99)00174-4; WERLING LL, 1989, P NATL ACAD SCI USA, V86, P6393, DOI 10.1073/pnas.86.16.6393; Wolf R, 1999, MOL PHARMACOL, V55, P263, DOI 10.1124/mol.55.2.263; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869	32	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4894	4900		10.1074/jbc.M007437200	http://dx.doi.org/10.1074/jbc.M007437200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11060299	Green Accepted, hybrid			2022-12-25	WOS:000168484300051
J	Das, KC				Das, KC			c-Jun NH2-terminal kinase-mediated redox-dependent degradation of I kappa B - Role of thioredoxin in NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; ENDOTHELIAL-CELLS; BINDING-ACTIVITY; GENE-EXPRESSION; TRANSCRIPTION; MECHANISM; REDUCTION; ALPHA; MODULATION; COMPLEX	NF-kappaB is a redox-sensitive transcription factor known to be activated by oxidative stress as well as chemical and biological reductants, Its DNA binding activity requires reduced cysteines present in the p65 subunit of the dimer, Thioredoxin (Trx) is an endogenous disulfide oxidoreductase known to modulate several redox-dependent functions in the cell. NF-kappaB was activated by addition of Escherichia coli thioredoxin in a redox-dependent manner in A549 cells. Such activation was accompanied by degradation of I kappaB in the cytosol. In addition, only the reduced form of thioredoxin activated NF-kappaB, whereas the oxidized form was without any effect. Overexpression of human thioredoxin also caused activation of NF-kappaB and degradation of I kappaB. On the contrary, dominant-negative redox-inactive mutant thioredoxin expression did not activate NF-kappaB, further confirming the redox-dependent activation of NF-kappaB. We also investigated the mechanism of activation of NF-kappaB by thioredoxin, We demonstrate that thioredoxin activates c-Jun NH2-terminal kinase (JNK)-signaling cascade, and dominant-negative expression of mitogen-activated protein kinase kinase kinase 1 (MEKK1), JNK kinase, or JNK inhibits NF-kappaB activation by thioredoxin. In contrast, wild-type MEKK1 or JNK kinase induced NF-kappaB activation alone or in combination with thioredoxin expression plasmid. These findings were also confirmed by NF-kappaB-dependent luciferase reporter gene transcription.	Univ Texas Hlth Ctr, Dept Mol Biol, Tyler, TX 75708 USA		Das, KC (corresponding author), Univ Texas Hlth Ctr, Dept Mol Biol, 11937 US Hwy 271, Tyler, TX 75708 USA.		Das, Kumuda/A-7662-2012					Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BIGUET C, 1994, J BIOL CHEM, V269, P28865; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Das KC, 1997, AM J RESP CELL MOL, V17, P713, DOI 10.1165/ajrcmb.17.6.2809; Das KC, 1997, J BIOL CHEM, V272, P14914, DOI 10.1074/jbc.272.23.14914; DAS KC, 1995, MOL CELL BIOCHEM, V148, P45, DOI 10.1007/BF00929502; DAS KC, 1995, AM J PHYSIOL-LUNG C, V269, pL588, DOI 10.1152/ajplung.1995.269.5.L588; DAVIS RJ, 1998, BIOCH SOC S, V64, P1; FERNANDO MR, 1992, EUR J BIOCHEM, V209, P917, DOI 10.1111/j.1432-1033.1992.tb17363.x; Freemerman AJ, 1999, CANCER RES, V59, P4090; Gasdaska JR, 1996, BIOCHEM PHARMACOL, V52, P1741, DOI 10.1016/S0006-2952(96)00595-3; GILMORE TD, 1990, CELL, V62, P841, DOI 10.1016/0092-8674(90)90257-F; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; Hirano M, 1996, J BIOL CHEM, V271, P13234, DOI 10.1074/jbc.271.22.13234; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P9113; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; KAROLY K, 1991, J BIOL CHEM, V266, P16135; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; MATTHEWS JR, 1992, NUCLEIC ACIDS RES, V20, P3821, DOI 10.1093/nar/20.15.3821; Meyer CF, 1996, J BIOL CHEM, V271, P8971, DOI 10.1074/jbc.271.15.8971; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; MOISSAC D, 1998, J BIOL CHEM, V273, P23946; Patel JM, 1996, AM J RESP CELL MOL, V15, P410, DOI 10.1165/ajrcmb.15.3.8810647; QIN J, 1995, STRUCTURE, V3, P289, DOI 10.1016/S0969-2126(01)00159-9; SPECTOR A, 1988, J BIOL CHEM, V263, P4984; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOLEDANO MB, 1991, P NATL ACAD SCI USA, V88, P4328, DOI 10.1073/pnas.88.10.4328; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Wang TH, 1998, J BIOL CHEM, V273, P4928, DOI 10.1074/jbc.273.9.4928	35	76	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					4662	4670		10.1074/jbc.M006206200	http://dx.doi.org/10.1074/jbc.M006206200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11063742	hybrid			2022-12-25	WOS:000168484300020
J	Pereira, JS; Pavlov, D; Nili, M; Greaser, M; Homsher, E; Moss, RL				Pereira, JS; Pavlov, D; Nili, M; Greaser, M; Homsher, E; Moss, RL			Kinetic differences in cardiac myosins with identical loop 1 sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE VENTRICULAR MYOCYTES; SMOOTH-MUSCLE; SKELETAL-MUSCLE; CHIMERIC SUBSTITUTIONS; SHORTENING VELOCITY; STRIATED-MUSCLE; SURFACE LOOPS; LIGHT-CHAINS; ACTIN; SUBFRAGMENT-1	The kinetics of nucleotide turnover vary considerably among isoforms of vertebrate type II myosin, possibly due to differences in the rate of ADP release from the nucleotide binding pocket. Current ideas about likely mechanisms by which ADP release is regulated have focused on the hyperflexible surface loops of myosin, i.e, loop 1 (ATPase loop) and loop 2 (actin binding loop). In the present study, we investigated the kinetic properties of rat and pig beta -myosin heavy chains (beta -MHC) in which we have found the sequences of loop 1 (residues 204-216) to be virtually identical, i.e, DQSKKDSQTPKG, with a single conservative substitution (rat E210D pig), Pig myocardium normally expresses 100% beta -MHC, whereas rat myocardium was induced to express 100% beta -MHC by surgical thyroidectomy and subsequent treatment with propylthiouracil. Slack test measurements at 15 degreesC yielded unloaded shortening velocities of 1.1 +/- 0.8 muscle lengths/s in rat skinned ventricular myocytes and 0.35 +/- 0.05 muscle lengths/s in pig skinned myocytes. Similarly, solution measurements at the same temperature showed that actin-activated ATPase activity was 2.9-fold greater for rat beta -myosin than for pig beta -myosin, Stopped-flow methods were then used to assess the rates of acto-myosin dissociation by MgATP both in the presence and absence of MgADP. Although the rates of MgATP-induced dissociation of acto-heavy meromyosin (acto-HMM) were virtually identical for the two myosins, the rate of ADP dissociation was similar to3.8-fold faster for rat beta -myosin (135 s(-1)) than for pig beta -myosin (35 s(-1)). ATP cleavage rates were nearly 30% faster for rat beta myosin, Thus, whereas loop 1 appears from other studies to be involved in nucleotide turnover in the pocket, our results show that loop 1 does not account for large differences in turnover kinetics in these two myosin isoforms, Instead, the differences appear to be due to sequence differences in other parts of the MHC backbone.	Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA; Univ Calif Los Angeles, Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; Univ Wisconsin, Dept Anim Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Wisconsin System; University of Wisconsin Madison	Pereira, JS (corresponding author), Univ Wisconsin, Sch Med, Dept Physiol, Madison, WI 53706 USA.		Greaser, Marion L/C-6147-2012	Greaser, Marion L/0000-0002-6583-9566	NHLBI NIH HHS [HL61635, HL30988] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061635] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bobkov AA, 1996, P NATL ACAD SCI USA, V93, P2285, DOI 10.1073/pnas.93.6.2285; BOTTINELLI R, 1994, J PHYSIOL-LONDON, V478, P241; CARTER SG, 1982, J BIOCHEM BIOPH METH, V7, P7, DOI 10.1016/0165-022X(82)90031-8; Chromczynski P, 1987, ANAL BIOCHEM, V162, P156; Goodson HV, 1999, J MOL BIOL, V287, P173, DOI 10.1006/jmbi.1999.2565; Gulick J, 1997, CIRC RES, V80, P655, DOI 10.1161/01.RES.80.5.655; Haddad F, 1997, J MOL CELL CARDIOL, V29, P559, DOI 10.1006/jmcc.1996.0299; Hill A. V., 1950, Science Progress London, V38, P209; HOUK TW, 1974, ANAL BIOCHEM, V62, P66, DOI 10.1016/0003-2697(74)90367-4; HUXLEY AF, 1957, PROG BIOPHYS MOL BIO, V7, P255, DOI 10.1016/S0096-4174(18)30128-8; JOHNSON KA, 1978, BIOCHEMISTRY-US, V17, P3432, DOI 10.1021/bi00610a002; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MARGOSSIAN SS, 1982, METHOD ENZYMOL, V85, P55; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; MOCZ G, 1984, EUR J BIOCHEM, V145, P221, DOI 10.1111/j.1432-1033.1984.tb08542.x; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; MOSS RL, 1995, REV PHYSIOL BIOCH P, V126, P1, DOI 10.1007/BFb0049775; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; Pereira JAAS, 1997, PFLUG ARCH EUR J PHY, V435, P151, DOI 10.1007/s004240050495; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROME LC, 1988, NATURE, V335, P824, DOI 10.1038/335824a0; Rovner AS, 1995, J BIOL CHEM, V270, P30260, DOI 10.1074/jbc.270.51.30260; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; Sant'ana Pereira J A, 1995, J Muscle Res Cell Motil, V16, P21; SATA M, 1993, CIRC RES, V73, P696, DOI 10.1161/01.RES.73.4.696; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; SIEMANKOPWSKI LM, 1985, P NATL ACAD SCI USA, V82, P685; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SPUDICH JA, 1994, NATURE, V372, P515, DOI 10.1038/372515a0; STRANG KT, 1995, CIRC RES, V77, P114, DOI 10.1161/01.RES.77.1.114; STRANG KT, 1994, CIRC RES, V74, P542, DOI 10.1161/01.RES.74.3.542; Sweeney HL, 1998, J BIOL CHEM, V273, P6262, DOI 10.1074/jbc.273.11.6262; SWEENEY L, 1995, BIOPHYS J, V68, pS112; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; UYEDA TQP, 1994, NATURE, V368, P567, DOI 10.1038/368567a0	36	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4409	4415		10.1074/jbc.M006441200	http://dx.doi.org/10.1074/jbc.M006441200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11076938	hybrid			2022-12-25	WOS:000166921200090
J	Williams, DD; Pavitt, GD; Proud, CG				Williams, DD; Pavitt, GD; Proud, CG			Characterization of the initiation factor eIF2B and its regulation in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-SYNTHESIS; TRANSLATIONAL REGULATORS; RABBIT RETICULOCYTES; MAMMALIAN HOMOLOG; SIGNALING PATHWAY; ALPHA-SUBUNIT; FACTOR-II; PHOSPHORYLATION	Eukaryotic initiation factor (eIF) 2B catalyzes a key regulatory step in the initiation of mRNA translation. eIF2B is well characterized in mammals and in yeast, although little is known about it in other eukaryotes. eIF2B is a hetropentamer which mediates the exchange of GDP for GTP on eIF2. In mammals and yeast, its activity is regulated by phosphorylation of eIF2 alpha. Here we have cloned Drosophila melanogaster cDNAs encoding polypeptides showing substantial similarity to eIF2B subunits from yeast and mammals, They also exhibit the other conserved features of these proteins. D. melanogaster eIF2B alpha confers regulation of eIF2B function in yeast, while eIF2B epsilon shows guanine nucleotide exchange activity, In common with mammalian eIF2B epsilon, D. melanogaster eIF2B epsilon is phosphorylated by glycogen synthase kinase-3 and casein kinase II, Phosphorylation of partially purified D. melanogaster eIF2B by glycogen synthase kinase-3 inhibits its activity. Extracts of D. melanogaster S2 Schneider cells display eIF2B activity, which is inhibited by phosphorylation of eIF2 alpha; showing the insect factor is regulated similarly to eIF2B from other species. In S2 cells, serum starvation increases eIF2 alpha phosphorylation, which correlates with inhibition of eIF2B, and both effects are reversed by serum treatment. This shows that eIF2 alpha phosphorylation and eIF2B activity are under dynamic regulation by serum. eIF2 alpha phosphorylation is also increased by endoplasmic reticulum stress in S2 cells. These are the first data concerning the structure, function or control of eIF2B from D. melanogaster.	Univ Dundee, Sch Life Sci, Inst Med Sci, Wellcome Trust Bioctr Complex, Dundee DD1 5EH, Scotland; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	University of Dundee; University of Manchester	Proud, CG (corresponding author), Univ Dundee, Sch Life Sci, Inst Med Sci, Wellcome Trust Bioctr Complex, Dundee DD1 5EH, Scotland.	c.g.proud@dundee.ac.uk	Pavitt, Graham D/A-1363-2010	Pavitt, Graham D/0000-0002-8593-2418; Proud, Christopher/0000-0003-0704-6442				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BUSHMAN JL, 1993, MOL CELL BIOL, V13, P1920, DOI 10.1128/MCB.13.3.1920; CHEFALO PJ, 1994, J BIOL CHEM, V269, P25788; CHEN JJ, 1995, TRENDS BIOCHEM SCI, V20, P105, DOI 10.1016/S0968-0004(00)88975-6; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; Cook D, 1996, EMBO J, V15, P4526, DOI 10.1002/j.1460-2075.1996.tb00830.x; DEALDANA CRV, 1994, MOL CELL BIOL, V14, P3208, DOI 10.1128/MCB.14.5.3208; DEVER TE, 1992, CELL, V68, P585, DOI 10.1016/0092-8674(92)90193-G; DHOLAKIA JN, 1988, P NATL ACAD SCI USA, V85, P51, DOI 10.1073/pnas.85.1.51; Fabian JR, 1997, J BIOL CHEM, V272, P12359, DOI 10.1074/jbc.272.19.12359; FELDHOFF RC, 1993, PREP BIOCHEM, V23, P363, DOI 10.1080/10826069308544562; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FLOWERS KM, 1995, P NATL ACAD SCI USA, V92, P4274, DOI 10.1073/pnas.92.10.4274; Gomez E, 2000, MOL CELL BIOL, V20, P3965, DOI 10.1128/MCB.20.11.3965-3976.2000; HANNIG EM, 1988, MOL CELL BIOL, V8, P4808, DOI 10.1128/MCB.8.11.4808; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HOFFMANN F, 1992, J MOL BIOL, V223, P17, DOI 10.1016/0022-2836(92)90710-2; KIMBALL SR, 1987, J BIOL CHEM, V262, P2220; Kleijn M, 1998, J BIOL CHEM, V273, P5536, DOI 10.1074/jbc.273.10.5536; KOONIN EV, 1995, PROTEIN SCI, V4, P1608, DOI 10.1002/pro.5560040819; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATEU MG, 1987, EUR J BIOCHEM, V162, P221, DOI 10.1111/j.1432-1033.1987.tb10564.x; MATEU MG, 1987, EUR J BIOCHEM, V165, P507, DOI 10.1111/j.1432-1033.1987.tb11468.x; MATEU MG, 1989, BIOCHIM BIOPHYS ACTA, V1007, P55, DOI 10.1016/0167-4781(89)90129-2; MEHTA HB, 1983, J BIOL CHEM, V258, P3438; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; OLDFIELD S, 1992, EUR J BIOCHEM, V208, P73, DOI 10.1111/j.1432-1033.1992.tb17160.x; Olsen DS, 1998, GENETICS, V149, P1495; PADDON CJ, 1989, GENETICS, V122, P551; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Pavitt GD, 1997, MOL CELL BIOL, V17, P1298, DOI 10.1128/MCB.17.3.1298; Pavitt GD, 1998, GENE DEV, V12, P514, DOI 10.1101/gad.12.4.514; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Price NT, 1996, BIOCHEM J, V318, P637, DOI 10.1042/bj3180637; PROUD CG, 1982, FEBS LETT, V143, P55, DOI 10.1016/0014-5793(82)80273-1; QU SM, 1994, GENE, V140, P239, DOI 10.1016/0378-1119(94)90550-9; RAMAKRISHNA S, 1990, BIOCHEMISTRY-US, V29, P7617, DOI 10.1021/bi00485a011; RAMIREZ M, 1992, MOL CELL BIOL, V12, P5801, DOI 10.1128/MCB.12.12.5801; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Sood R, 2000, GENETICS, V154, P787; WANG QM, 1994, BIOCHEMISTRY-US, V33, P143, DOI 10.1021/bi00167a018; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Webb BLJ, 1997, INT J BIOCHEM CELL B, V29, P1127, DOI 10.1016/S1357-2725(97)00039-3; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Welsh GI, 1997, FEBS LETT, V410, P418, DOI 10.1016/S0014-5793(97)00579-6; Welsh GI, 1998, FEBS LETT, V421, P125, DOI 10.1016/S0014-5793(97)01548-2; Williams DD, 1999, FEBS LETT, V448, P86, DOI 10.1016/S0014-5793(99)00342-7	54	35	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3733	3742		10.1074/jbc.M008041200	http://dx.doi.org/10.1074/jbc.M008041200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11060303	hybrid			2022-12-25	WOS:000166921200004
J	El Meskini, R; Galano, GJ; Marx, R; Mains, RE; Eipper, BA				El Meskini, R; Galano, GJ; Marx, R; Mains, RE; Eipper, BA			Targeting of membrane proteins to the regulated secretory pathway in anterior pituitary endocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-AMIDATING MONOOXYGENASE; TRANS-GOLGI NETWORK; PEPTIDE PROCESSING ENZYME; ATT-20 CELLS; P-SELECTIN; ROUTING DETERMINANTS; GRANULE BIOGENESIS; CYTOPLASMIC DOMAIN; CYTOSOLIC DOMAIN; CHROMAFFIN CELLS	Unlike the neuroendocrine cell lines widely used to study trafficking of soluble and membrane proteins to secretory granules, the endocrine cells of the anterior pituitary are highly specialized for the production of mature secretory granules. Therefore, we investigated the trafficking of three membrane proteins in primary anterior pituitary endocrine cells. Peptidylglycine alpha -amidating monooxygenase (PAM), an integral membrane protein essential to the production of many bioactive peptides, is cleaved and enters the regulated secretory pathway even when expressed at levels 40-fold higher than endogenous levels. Myc-TMD/CD, a membrane protein lacking the lumenal, catalytic domains of PAM, is still stored in granules. Secretory granules are not the default pathway for all membrane proteins, because Tac accumulates on the surface of pituitary endocrine cells. Overexpression of PAM is accompanied by a diminution in its endoproteolytic cleavage and in its BaCl2-stimulated release from mature granules. Because internalized PAM/PAM-antibody complexes are returned to secretory granules, the endocytic machinery of the pituitary endocrine cells is not saturated. As in corticotrope tumor cells, expression of PAM or Myc-TMD/CD alters the organization of the actin cytoskeleton. PAM-mediated alterations in the cytoskeleton may limit maturation of PAM and storage in mature granules.	Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA	University of Connecticut	Eipper, BA (corresponding author), Univ Connecticut, Ctr Hlth, Dept Neurosci, 263 Farmington Ave, Farmington, CT 06030 USA.	eipper@uchc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032949, R37DK032949, R01DK032949] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32949] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arvan P, 1998, BIOCHEM J, V332, P593, DOI 10.1042/bj3320593; Benmerah A, 1995, J CELL BIOL, V131, P1831, DOI 10.1083/jcb.131.6.1831; Billiard J, 1997, P NATL ACAD SCI USA, V94, P12192, DOI 10.1073/pnas.94.22.12192; Blagoveshchenskaya AD, 1999, J CELL BIOL, V145, P1419, DOI 10.1083/jcb.145.7.1419; BRAAS KM, 1989, MOL ENDOCRINOL, V3, P1387, DOI 10.1210/mend-3-9-1387; Bruzzaniti A, 1999, J BIOL CHEM, V274, P24703, DOI 10.1074/jbc.274.35.24703; Caldwell BD, 1999, J BIOL CHEM, V274, P34646, DOI 10.1074/jbc.274.49.34646; Carbajal ME, 1997, ENDOCRINOLOGY, V138, P5374, DOI 10.1210/en.138.12.5374; Castle AM, 1997, J CELL BIOL, V138, P45, DOI 10.1083/jcb.138.1.45; Ciccotosto GD, 1999, J CELL BIOL, V144, P459, DOI 10.1083/jcb.144.3.459; Dannies PS, 1999, ENDOCR REV, V20, P3, DOI 10.1210/er.20.1.3; de Wit H, 1999, MOL BIOL CELL, V10, P4163, DOI 10.1091/mbc.10.12.4163; DISDIER M, 1992, MOL BIOL CELL, V3, P309, DOI 10.1091/mbc.3.3.309; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Elkind NB, 2000, J CELL BIOL, V149, P95, DOI 10.1083/jcb.149.1.95; Fleming JC, 1998, EUR J CELL BIOL, V75, P331, DOI 10.1016/S0171-9335(98)80066-6; Hirst J, 1998, BBA-MOL CELL RES, V1404, P173, DOI 10.1016/S0167-4889(98)00056-1; HU HM, 1993, FEBS LETT, V324, P331, DOI 10.1016/0014-5793(93)80145-K; HUSTEN EJ, 1991, J BIOL CHEM, V266, P17004; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; Ling WLW, 1998, METHODS, V16, P141, DOI 10.1006/meth.1998.0661; Mains RE, 1999, J BIOL CHEM, V274, P2929, DOI 10.1074/jbc.274.5.2929; Majo G, 1998, LIFE SCI, V62, P607, DOI 10.1016/S0024-3205(97)01156-9; MALTESE JY, 1993, ENDOCRINOLOGY, V133, P2579, DOI 10.1210/en.133.6.2579; Marx R, 1999, J NEUROSCI, V19, P8300; Meskini RE, 2000, ENDOCRINOLOGY, V141, P3020; Milgram SL, 1996, J BIOL CHEM, V271, P17526, DOI 10.1074/jbc.271.29.17526; MILGRAM SL, 1994, J CELL BIOL, V124, P33, DOI 10.1083/jcb.124.1.33; MILGRAM SL, 1992, J CELL BIOL, V117, P717, DOI 10.1083/jcb.117.4.717; Milgram SL, 1997, J CELL SCI, V110, P695; MILGRAM SL, 1993, J CELL BIOL, V121, P23, DOI 10.1083/jcb.121.1.23; Modderman PW, 1998, BIOCHEM J, V336, P153, DOI 10.1042/bj3360153; Orzech E, 1999, J BIOL CHEM, V274, P2201, DOI 10.1074/jbc.274.4.2201; OYARCE AM, 1993, J NEUROCHEM, V60, P1105, DOI 10.1111/j.1471-4159.1993.tb03261.x; OYARCE AM, 1995, J CELL SCI, V108, P287; Reeves R, 2000, MOL CELL BIOL, V20, P4666, DOI 10.1128/MCB.20.13.4666-4679.2000; SCHNABEL E, 1989, MOL ENDOCRINOL, V3, P1223, DOI 10.1210/mend-3-8-1223; Siddhanta A, 1998, J BIOL CHEM, V273, P17995, DOI 10.1074/jbc.273.29.17995; Sloan DC, 1997, BIOCHEM J, V328, P13; Steveson TC, 1999, J BIOL CHEM, V274, P21128, DOI 10.1074/jbc.274.30.21128; TOOZE J, 1989, EUR J CELL BIOL, V49, P259; TRAUB LM, 1995, J BIOL CHEM, V270, P4933, DOI 10.1074/jbc.270.9.4933; Traub LM, 1997, CURR OPIN CELL BIOL, V9, P527, DOI 10.1016/S0955-0674(97)80029-4; Valentijn K, 1999, BIOCHEM BIOPH RES CO, V266, P652, DOI 10.1006/bbrc.1999.1883; VONRUDEN L, 1993, SCIENCE, V262, P1061, DOI 10.1126/science.8235626; VONRUDEN L, 1993, FEBS LETT, V336, P48, DOI 10.1016/0014-5793(93)81606-Z; Watanabe T, 1998, ENDOCRINOLOGY, V139, P2765, DOI 10.1210/en.139.6.2765	48	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3384	3393		10.1074/jbc.M008062200	http://dx.doi.org/10.1074/jbc.M008062200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11060304	hybrid			2022-12-25	WOS:000166784900053
J	Hansen, JB; Zhang, HB; Rasmussen, TH; Petersen, RK; Flindt, EN; Kristiansen, K				Hansen, JB; Zhang, HB; Rasmussen, TH; Petersen, RK; Flindt, EN; Kristiansen, K			Peroxisome proliferator-activated receptor delta (PPhR delta)-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; PROTEIN-KINASE-A; PPAR-GAMMA; ADIPOCYTE DIFFERENTIATION; FATTY-ACIDS; TRANSCRIPTIONAL ACTIVITY; MEDIATED PHOSPHORYLATION; LIGAND-BINDING; C/EBP-ALPHA; INSULIN	The peroxisome proliferator-activated receiptor gamma (PPAR gamma) is a key regulator of terminal adipocyte differentiation. PPAR delta is expressed in preadipocytes, but the importance of this PPAR subtype in adipogenesis has been a matter of debate. Here we present a critical evaluation of the role of PPAR delta in adipocyte differentiation. We demonstrate that treatment of NIH-3T3 fibroblasts overexpressing PPAR delta with standard adipogenic inducers led to induction of PPAR gamma2 expression and terminal adipocyte differentiation in a manner that was strictly dependent on simultaneous administration of a PPAR delta ligand and methylisobutylxanthine (MM) or other cAMP elevating agents. We further show that ligands and MM synergistically stimulated PPAR delta -mediated transactivation. In 3T3-L1 preadipocytes, simultaneous administration of a PPAR delta -selective ligand and MM significantly enhanced the early expression of PPAR gamma and ALBP/aP2, but only modestly promoted terminal differentiation as determined by lipid accumulation. Finally, we provide evidence that synergistic activation of PPAR delta promotes mitotic clonal expansion in 3T3-L1 cells with or without forced expression of PPAR delta. In conclusion, our results suggest that PPAR delta may play a role in the proliferation of adipocyte precursor cells, whereas activation of endogenous PPAR delta in 3T3-L1 cells appears to have only minor impact on the processes leading to terminal adipocyte differentiation.	Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense M, Denmark	University of Southern Denmark	Kristiansen, K (corresponding author), Odense Univ, Dept Biochem & Mol Biol, Campusvej 55, DK-5230 Odense M, Denmark.		Kristiansen, Karsten/J-5148-2014; Hansen, Jacob B/F-3775-2010	Kristiansen, Karsten/0000-0002-6024-0917; Hansen, Jacob B/0000-0001-5249-2586; Flindt, Esben/0000-0002-2245-2556				Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Bastie C, 1999, J BIOL CHEM, V274, P21920, DOI 10.1074/jbc.274.31.21920; Basu-Modak S, 1999, J BIOL CHEM, V274, P35881, DOI 10.1074/jbc.274.50.35881; Berger J, 1999, J BIOL CHEM, V274, P6718, DOI 10.1074/jbc.274.10.6718; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; Brown PJ, 1997, CHEM BIOL, V4, P909, DOI 10.1016/S1074-5521(97)90299-4; Brun RP, 1996, GENE DEV, V10, P974, DOI 10.1101/gad.10.8.974; Camp HS, 1999, ENDOCRINOLOGY, V140, P392, DOI 10.1210/en.140.1.392; Camp HS, 1997, J BIOL CHEM, V272, P10811; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CHAWLA A, 1994, P NATL ACAD SCI USA, V91, P1786, DOI 10.1073/pnas.91.5.1786; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Elbrecht A, 1999, J BIOL CHEM, V274, P7913, DOI 10.1074/jbc.274.12.7913; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Granneman J, 1998, J NEUROSCI RES, V51, P563, DOI 10.1002/(SICI)1097-4547(19980301)51:5<563::AID-JNR3>3.0.CO;2-D; Hansen JB, 1999, J BIOL CHEM, V274, P2386, DOI 10.1074/jbc.274.4.2386; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jehl-Pietri C, 2000, BIOCHEM J, V350, P93, DOI 10.1042/0264-6021:3500093; Juge-Aubry CE, 1999, J BIOL CHEM, V274, P10505, DOI 10.1074/jbc.274.15.10505; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Krey G, 1997, MOL ENDOCRINOL, V11, P779, DOI 10.1210/me.11.6.779; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Lane MD, 1999, BIOCHEM BIOPH RES CO, V266, P677, DOI 10.1006/bbrc.1999.1885; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Leibowitz MD, 2000, FEBS LETT, V473, P333, DOI 10.1016/S0014-5793(00)01554-4; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Matsuura H, 1999, MOL CELL ENDOCRINOL, V147, P85, DOI 10.1016/S0303-7207(98)00214-7; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; ROCHETTEEGLY C, 1995, MOL ENDOCRINOL, V9, P860, DOI 10.1210/me.9.7.860; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Sadar MD, 1999, J BIOL CHEM, V274, P7777, DOI 10.1074/jbc.274.12.7777; Schulman IG, 1998, MOL CELL BIOL, V18, P3483, DOI 10.1128/MCB.18.6.3483; Shalev A, 1996, ENDOCRINOLOGY, V137, P4499, DOI 10.1210/en.137.10.4499; Shao DL, 1998, NATURE, V396, P377, DOI 10.1038/24634; SUGAWARA A, 1994, J BIOL CHEM, V269, P433; Taneja R, 1997, EMBO J, V16, P6452, DOI 10.1093/emboj/16.21.6452; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Wagner BL, 1998, MOL CELL BIOL, V18, P1369, DOI 10.1128/MCB.18.3.1369; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; Yan ZH, 1998, J BIOL CHEM, V273, P10948, DOI 10.1074/jbc.273.18.10948; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771; ZHU YJ, 1995, P NATL ACAD SCI USA, V92, P7921, DOI 10.1073/pnas.92.17.7921	62	148	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3175	3182		10.1074/jbc.M005567200	http://dx.doi.org/10.1074/jbc.M005567200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11069900	hybrid			2022-12-25	WOS:000166784900027
J	Mansharamani, M; Hewetson, A; Chilton, BS				Mansharamani, M; Hewetson, A; Chilton, BS			Cloning and characterization of an atypical type IVP-type ATPase that binds to the RING motif of RUSH transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE H+-ATPASE; P-TYPE ATPASE; GENE-EXPRESSION; MOLECULAR-CLONING; FINGER DOMAIN; RNA ISOLATION; RT-PCR; PROTEIN; QUANTIFICATION; PROGESTERONE	RUSH proteins are SWI/SNF-related transcription factors with RING finger signatures near their COOH termini. Long suspected of mediating protein-protein interactions, the RING motif was used to clone a binding partner. The RING finger binding protein (RFBP) is a Type IV P-type ATPase, a putative phospholipid pump, with conserved sequences for two loop segments, an ATP-binding site, a phosphorylation domain, and transmembrane passes potentially involved in substrate binding and translocation, However, RFBP differs from all other Type IV P-type ATPases in three ways. It has only three of four highly conserved NH2-terminal transmembrane passes, it is located in the inner nuclear membrane, and it binds the RING domain. Topographically the orientation of the adjacent hydrophilic domains and the determinants of transport specificity are altered. ks a result, the small, hydrophilic loop extends into the perinuclear space that is contiguous with the lumen of the endoplasmic reticulum, The large, conformationally flexible loop extends into the nucleoplasm to contact euchromatin. Competitive reverse transcriptase-polymerase chain reaction and high performance liquid chromatography analysis revealed that endometrial RFBP mRNA expression is hormonally regulated,The physical association of a hormone-dependent RING finger-binding protein with transcriptionally active chromatin supports the speculation that RFBP plays a role in the subnuclear trafficking of transcription factors with RING motifs.	Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Chilton, BS (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Biochem & Cell Biol, 3601 4th St, Lubbock, TX 79430 USA.	beverly.chilton@ttmc.ttuhsc.edu		Chilton, Beverly/0000-0002-8066-8697	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029457] Funding Source: NIH RePORTER; NICHD NIH HHS [HD29457] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ackland ML, 1997, BIOCHEM J, V328, P237, DOI 10.1042/bj3280237; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; Aravind L, 1998, TRENDS BIOCHEM SCI, V23, P127, DOI 10.1016/S0968-0004(98)01189-X; ARGOS P, 1982, EUR J BIOCHEM, V128, P565; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; AULAND ME, 1994, P NATL ACAD SCI USA, V91, P10938, DOI 10.1073/pnas.91.23.10938; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; Cao TY, 1997, J CELL SCI, V110, P1563; Chilton BS, 1998, BIOL REPROD, V58, P285, DOI 10.1095/biolreprod58.2.285; CHILTON BS, 1988, MOL ENDOCRINOL, V2, P1169, DOI 10.1210/mend-2-12-1169; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Copps K, 1998, EMBO J, V17, P5409, DOI 10.1093/emboj/17.18.5409; Devine JH, 1999, MOL CELL ENDOCRINOL, V151, P49, DOI 10.1016/S0303-7207(99)00013-1; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; FAN CM, 1990, GENE DEV, V4, P29, DOI 10.1101/gad.4.1.29; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Geering K, 2000, J MEMBRANE BIOL, V174, P181, DOI 10.1007/s002320001042; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HaywardLester A, 1996, BIOTECHNIQUES, V20, P250; HaywardLester A, 1996, MOL ENDOCRINOL, V10, P1335, DOI 10.1210/me.10.11.1335; HaywardLester A, 1995, GENOME RES, V5, P494, DOI 10.1101/gr.5.5.494; KELLER AD, 1991, NUCLEIC ACIDS RES, V19, P4675, DOI 10.1093/nar/19.17.4675; Kentsis A, 2000, CURR PROTEIN PEPT SC, V1, P49, DOI 10.2174/1389203003381478; KLEISSANFRANCISCO S, 1993, MOL ENDOCRINOL, V7, P214, DOI 10.1210/me.7.2.214; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Kuhlbrandt W, 1998, CURR OPIN STRUC BIOL, V8, P510, DOI 10.1016/S0959-440X(98)80130-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LANINI L, 1992, J BIOL CHEM, V267, P11548; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; LI WI, 1989, ENDOCRINOLOGY, V125, P2862, DOI 10.1210/endo-125-6-2862; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACGREGOR PF, 1990, ONCOGENE, V5, P451; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Robinson CA, 1997, GENE, V198, P1, DOI 10.1016/S0378-1119(97)00305-3; ROSE HG, 1965, BIOCHIM BIOPHYS ACTA, V106, P577, DOI 10.1016/0005-2760(65)90073-1; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Scarborough GA, 1999, CURR OPIN CELL BIOL, V11, P517, DOI 10.1016/S0955-0674(99)80075-1; SHARP PA, 1994, CELL, V77, P805, DOI 10.1016/0092-8674(94)90130-9; SINGH H, 1989, BIOTECHNIQUES, V7, P252; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Stein GS, 2000, J CELL SCI, V113, P2527; Stein GS, 1999, CRIT REV EUKAR GENE, V9, P183, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.30; Stokes DL, 1999, CURR BIOL, V9, P672, DOI 10.1016/S0960-9822(99)80307-8; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; Woo AL, 2000, J BIOL CHEM, V275, P20693, DOI 10.1074/jbc.M002323200; Zylinska L, 1999, BBA-MOL CELL BIOL L, V1437, P257, DOI 10.1016/S1388-1981(99)00015-3	60	34	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3641	3649		10.1074/jbc.M004231200	http://dx.doi.org/10.1074/jbc.M004231200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11058586	hybrid			2022-12-25	WOS:000166784900086
J	Sturany, S; Van Lint, J; Muller, F; Wilda, R; Hameister, H; Hocker, M; Brey, A; Gern, U; Vandenheede, J; Gress, T; Adler, G; Seufferlein, T				Sturany, S; Van Lint, J; Muller, F; Wilda, R; Hameister, H; Hocker, M; Brey, A; Gern, U; Vandenheede, J; Gress, T; Adler, G; Seufferlein, T			Molecular cloning and characterization of the human protein kinase D2 - A novel member of the protein kinase D family of serine threonine kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER; C FAMILY; SIGNAL-TRANSDUCTION; ACTIVATION; DOMAIN; ETA; MU; RECEPTOR; BINDING; CELLS	We have isolated the full-length cDNA of a novel human serine threonine protein kinase gene. The deduced protein sequence contains two cysteine-rich motifs at the N terminus, a pleckstrin homology domain, and a catalytic domain containing all the characteristic sequence motifs of serine protein kinases. It exhibits the strongest homology to the serine threonine protein kinases PKD/PKC mu, and PKC nu, particularly in the duplex zinc finger-like cysteine-rich motif, in the pleckstrin homology domain and in the protein kinase domain, In contrast, it shows only a low degree of sequence similarity to other members of the PKC family, Therefore, the new protein has been termed protein kinase D2 (PKD2). The mRNA of PKD2 is widely expressed in human and murine tissues. It encodes a protein with a molecular mass of 105 kDa in SDS-polyacrylamide gel electrophoresis, which is expressed in various human cell lines, including HL60 cells, which do not express PKC mu. lit vivo phorbol ester binding studies demonstrated a concentration-dependent binding of [H-3]phorbol 12,13-dibutyrate to PKD2. The addition of phorbol 12,13-dibutyrate in the presence of dioleoylphosphatidylserine stimulated the autophosphorylation of PKD2 in a synergistic fashion. Phorbol esters also stimulated autophosphorylation of PKD2 in intact cells. PKD2 activated by phorbol esters efficiently phosphorylated the exogenous substrate histone H1. In addition, we could identify the C-terminal Ser(876) residue as an in vivo phosphorylation site within PKD2. Phosphorylation of Ser(876) of PKD2 correlated with the activation status of the kinase. Finally, gastrin was found to be a physiological activator of PKD2 in human AGS-B cells stably transfected with the CCKB/gastrin receptor. Thus, PKD2 is a novel phorbol ester- and growth factor-stimulated protein kinase.	Univ Ulm, Med Klin, Innere Med Abt 1, D-89081 Ulm, Germany; Univ Ulm, Fak Med, Inst Human Genet, D-89081 Ulm, Germany; Katholieke Univ Leuven, Afdeling Biochem, Louvain, Belgium; Humboldt Univ, Klinikum Charite, Med Klin, Schwerpunkt Gastroenterol & Hepatol, Berlin, Germany	Ulm University; Ulm University; KU Leuven; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Seufferlein, T (corresponding author), Univ Ulm, Med Klin, Innere Med Abt 1, Robert Koch Str 8, D-89081 Ulm, Germany.		Van Lint, Johan/P-9073-2019; Seufferlein, Thomas TW/P-7147-2018	Gress, Thomas/0000-0002-9333-5461				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BLOCK C, 1992, J BIOL CHEM, V267, P19824; DEKKER LV, 1993, FEBS LETT, V329, P129, DOI 10.1016/0014-5793(93)80208-C; DEKKER LV, 1993, J BIOL CHEM, V268, P19498; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Exton JH, 1997, EUR J BIOCHEM, V243, P10, DOI 10.1111/j.1432-1033.1997.t01-1-00010.x; Gschwendt M, 1997, J BIOL CHEM, V272, P20742, DOI 10.1074/jbc.272.33.20742; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Hocker M, 1997, J BIOL CHEM, V272, P27015, DOI 10.1074/jbc.272.43.27015; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; JOHANNES FJ, 1994, J BIOL CHEM, V269, P6140; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; LEE YM, 1993, J BIOL CHEM, V268, P8164; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; OSADA S, 1990, J BIOL CHEM, V265, P22434; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; VANLINT J, 1995, J BIOL CHEM, V270, P1455, DOI 10.1074/jbc.270.3.1455; Vertommen D, 2000, J BIOL CHEM, V275, P19567, DOI 10.1074/jbc.M001357200; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; WEINSTEIN IB, 1991, ENVIRON HEALTH PERSP, V93, P175, DOI 10.2307/3431186; Yassin RR, 1999, PEPTIDES, V20, P885, DOI 10.1016/S0196-9781(99)00077-7; Yonemoto W, 1997, PROTEIN ENG, V10, P915, DOI 10.1093/protein/10.8.915; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	31	153	160	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3310	3318		10.1074/jbc.M008719200	http://dx.doi.org/10.1074/jbc.M008719200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11062248	hybrid			2022-12-25	WOS:000166784900044
J	Tsubamoto, Y; Eto, K; Noda, M; Daniel, S; Suga, S; Yamashita, S; Kasai, H; Wakui, M; Sharp, GWG; Kimura, S; Kadowaki, T				Tsubamoto, Y; Eto, K; Noda, M; Daniel, S; Suga, S; Yamashita, S; Kasai, H; Wakui, M; Sharp, GWG; Kimura, S; Kadowaki, T			Hexamminecobalt(III) chloride inhibits glucose-induced insulin secretion at the exocytotic process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; ELECTRICAL-ACTIVITY; MOUSE ISLETS; CA2+; MITOCHONDRIAL; CALCIUM; ACTIVATION; CHANNELS; RELEASE; FUSION	Hexamminecobalt(III) (HAC) chloride was found to have a potent inhibitory effect on glucose-induced insulin secretion from pancreatic islets, HAC at 2 mM inhibited the secretion in response to 22.2 mM glucose by 90% in mouse islets, Perifusion experiments revealed that the first phase of insulin secretion was severely suppressed and that the second phase of secretion was completely abrogated. Removal of HAC from the perifusate immediately restored insulin secretion with a transient overshooting above the normal level. However, BAC failed to affect glucose-induced changes in D-[6-C-14]glucose oxidation, levels of reduced forms of NAD and NADP, mitochondrial membrane potential, ATP content, cytosolic calcium concentration, or calcium influx into mitochondria, Furthermore, HAC inhibited 50 mM potassium-stimulated insulin secretion by 77% and 10 muM mastoparan-stimulated insulin secretion in the absence of extracellular Ca2+ by 80%. The results of a co-immunoprecipitation study of lysates from insulin-secreting beta HC9 cells using anti-syntaxin and anti-vesicle-associated membrane protein antibodies for immunoprecipitation or Western blotting suggested that HAC inhibited disruption of the SNARE complex, which is normally observed upon glucose challenge. These results suggest that the inhibitory effect of HAC on glucose-induced insulin secretion is exerted at a site(s) distal to the elevation of cytosolic [Ca2+], possibly in the exocytotic machinery per se; and thus, HAC may serve as a useful tool for dissecting the molecular mechanism of insulin exocytotic processes.	Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, Tokyo 1138655, Japan; Univ Tokyo, Grad Sch Med, Dept Physiol, Bunkyo Ku, Tokyo 1138655, Japan; Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Hirosaki Univ, Sch Med, Dept Physiol, Hirosaki, Aomori 0368562, Japan	University of Tokyo; University of Tokyo; Cornell University; Hirosaki University	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Metab Dis, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Noda, Mitsuhiko/W-3905-2019	Noda, Mitsuhiko/0000-0003-0413-4631; Kasai, Haruo/0000-0003-2327-9027				ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; BOKVIST K, 1995, EMBO J, V14, P50, DOI 10.1002/j.1460-2075.1995.tb06974.x; BOYD RS, 1995, J BIOL CHEM, V270, P18216, DOI 10.1074/jbc.270.31.18216; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; DEVIS G, 1975, DIABETES, V24, P547, DOI 10.2337/diab.24.6.547; Ding WG, 1997, DIABETES, V46, P615, DOI 10.2337/diabetes.46.4.615; DORMER RL, 1974, BIOCHEM J, V140, P135, DOI 10.1042/bj1400135; DUCHEN MR, 1993, BIOCHEM J, V294, P35, DOI 10.1042/bj2940035; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; EDDLESTONE GT, 1985, AM J PHYSIOL, V248, pC145, DOI 10.1152/ajpcell.1985.248.1.C145; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; FERRER R, 1984, AM J PHYSIOL, V246, pC520, DOI 10.1152/ajpcell.1984.246.5.C520; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GHAFGHAZI T, 1981, DIABETES, V30, P341, DOI 10.2337/diabetes.30.4.341; GUNTER TE, 1990, AM J PHYSIOL, V258, pC755, DOI 10.1152/ajpcell.1990.258.5.C755; HENQUIN JC, 1975, AM J PHYSIOL, V228, P1669, DOI 10.1152/ajplegacy.1975.228.6.1669; HERMANSEN K, 1978, DIABETOLOGIA, V15, P475, DOI 10.1007/BF02342873; Kanno T, 1999, DIABETES, V48, P1741, DOI 10.2337/diabetes.48.9.1741; Kennedy ED, 1996, J CLIN INVEST, V98, P2524, DOI 10.1172/JCI119071; KOMATSU M, 1993, J BIOL CHEM, V268, P23297; KONRAD RJ, 1995, J BIOL CHEM, V270, P12869, DOI 10.1074/jbc.270.21.12869; Lacy P E, 1973, Recent Prog Horm Res, V29, P199; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI C, 1995, NATURE, V375, P594, DOI 10.1038/375594a0; Litsky ML, 1997, BIOCHEMISTRY-US, V36, P7071, DOI 10.1021/bi970180y; LUTHRA R, 1976, BIOCHIM BIOPHYS ACTA, V440, P744, DOI 10.1016/0005-2728(76)90056-6; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Maechler P, 1997, EMBO J, V16, P3833, DOI 10.1093/emboj/16.13.3833; MALAISSE WJ, 1977, HORM RES, V8, P203; MALAISSE WJ, 1976, DIABETES METAB, V2, P1; MALAISSE WJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P190, DOI 10.1016/0167-4889(87)90134-0; MARTIN F, 1995, DIABETOLOGIA, V38, P860, DOI 10.1007/s001250050364; Mertz RJ, 1996, J BIOL CHEM, V271, P4838, DOI 10.1074/jbc.271.9.4838; Nichols BJ, 1997, NATURE, V387, P199, DOI 10.1038/387199a0; NILSSON T, 1986, BIOCHIM BIOPHYS ACTA, V888, P270, DOI 10.1016/0167-4889(86)90225-9; Noda M, 1996, DIABETES, V45, P1766, DOI 10.2337/diabetes.45.12.1766; Regazzi R, 1996, EMBO J, V15, P6951, DOI 10.1002/j.1460-2075.1996.tb01087.x; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; RICHMOND RC, 1975, RADIAT RES, V63, P140, DOI 10.2307/3574313; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; Schuit F, 1997, J BIOL CHEM, V272, P18572, DOI 10.1074/jbc.272.30.18572; SEHLIN J, 1981, AM J PHYSIOL, V240, pC35, DOI 10.1152/ajpcell.1981.240.1.C35; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; Stanley EF, 1997, NATURE, V385, P340, DOI 10.1038/385340a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; TASHMUKH.BA, 1972, FEBS LETT, V28, P239, DOI 10.1016/0014-5793(72)80721-X; VASINGTON FD, 1972, BIOCHIM BIOPHYS ACTA, V256, P43, DOI 10.1016/0005-2728(72)90161-2; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; WHEELERJONES CPD, 1992, BIOCHEM J, V281, P465, DOI 10.1042/bj2810465; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Yajima H, 1999, DIABETES, V48, P1006, DOI 10.2337/diabetes.48.5.1006	52	7	7	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					2979	2985		10.1074/jbc.M005816200	http://dx.doi.org/10.1074/jbc.M005816200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11069902	hybrid			2022-12-25	WOS:000166784900002
J	Shiraishi, A; Yamada, Y; Tsuura, Y; Fijimoto, S; Tsukiyama, K; Mukai, E; Toyoda, Y; Miwa, I; Seino, Y				Shiraishi, A; Yamada, Y; Tsuura, Y; Fijimoto, S; Tsukiyama, K; Mukai, E; Toyoda, Y; Miwa, I; Seino, Y			A novel glucokinase regulator in pancreatic beta cells - Precursor of propionyl-CoA carboxylase beta subunit interacts with glucokinase and augments its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; GLUCOSE; INHIBITION; ISLETS; HYPERSENSITIVITY; DEHYDROGENASE; HEXOKINASE; SEQUENCE; PROTEIN; GENE	A glucokinase regulatory protein has been reported to exist in the liver, which suppresses enzyme activity in a complex with fructose 6-phosphate, whereas no corresponding protein has been found in pancreatic beta cells. To search for such a protein in pancreatic beta cells, we screened for a cDNA library of the HIT-T15 cell line with the cDNA of glucokinase from rat islet by the yeast two hybrid system. We detected a cDNA encoding the precursor of propionyl-CoA carboxylase beta subunit (p beta PCCase), and glutathione S-transferase pull-down assay illustrated that p beta PCCase interacted with recombinant rat islet glucokinase and with glucokinase in rat liver and islet extracts. Functional analysis indicated that p beta PCCase decreased the K-m value of recombinant islet glucokinase for glucose by 18% and increased V-max value by 23%, We concluded that p beta PCCase might be a novel activator of glucokinase in pancreatic beta cells.	Kyoto Univ, Grad Sch Med, Dept Metab & Clin Nutr, Sakyo Ku, Kyoto 6068507, Japan; Meijo Univ, Fac Pharm, Dept Pathobiochem, Tempaku Ku, Nagoya, Aichi 4688503, Japan	Kyoto University; Meijo University	Shiraishi, A (corresponding author), Kyoto Univ, Grad Sch Med, Dept Metab & Clin Nutr, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	siraisi@metab.kuhp.kyoto-u.ac.jp						ASHCROFT SJH, 1986, DIABETOLOGIA, V29, P727, DOI 10.1007/BF00870283; Becker TC, 1996, J BIOL CHEM, V271, P390, DOI 10.1074/jbc.271.1.390; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BROWNER MF, 1989, J BIOL CHEM, V264, P12680; HOGEBOOM GH, 1955, METHOD ENZYMOL, V1, P16, DOI 10.1016/0076-6879(55)01007-0; Hosokawa H, 1997, DIABETOLOGIA, V40, P392, DOI 10.1007/s001250050692; Inada A, 1999, J BIOL CHEM, V274, P21095, DOI 10.1074/jbc.274.30.21095; Kajikawa M, 1999, ENDOCRINOLOGY, V140, P4706, DOI 10.1210/en.140.10.4706; Kotake K, 1997, J BIOL CHEM, V272, P29407, DOI 10.1074/jbc.272.47.29407; KRAUS JP, 1983, J BIOL CHEM, V258, P7245; KRAUS JP, 1986, P NATL ACAD SCI USA, V83, P8049, DOI 10.1073/pnas.83.21.8049; Liu YQ, 1998, J CLIN INVEST, V101, P1870, DOI 10.1172/JCI1211; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MAGNUSON MA, 1989, J BIOL CHEM, V264, P15936; MALAISSE WJ, 1990, EUR J BIOCHEM, V190, P539, DOI 10.1111/j.1432-1033.1990.tb15607.x; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; Matschinsky FM, 1997, CHEM BIOL, V4, P249, DOI 10.1016/S1074-5521(97)90068-5; MATSCHINSKY FM, 1990, DIABETES, V39, P647, DOI 10.2337/diabetes.39.6.647; MIWA I, 1994, ENZYME PROTEIN, V48, P135, DOI 10.1159/000474980; MOSS J, 1971, ADV ENZYMOL RAMB, V35, P321; PRINTZ RL, 1993, ANNU REV NUTR, V13, P463, DOI 10.1146/annurev.nu.13.070193.002335; SCHOLTE HR, 1969, BIOCHIM BIOPHYS ACTA, V178, P137, DOI 10.1016/0005-2744(69)90140-5; Schuit F, 1999, J BIOL CHEM, V274, P32803, DOI 10.1074/jbc.274.46.32803; SEKINE N, 1994, J BIOL CHEM, V269, P4895; SENER A, 1978, DIABETES METAB, V4, P127; Shiota C, 1999, J BIOL CHEM, V274, P37125, DOI 10.1074/jbc.274.52.37125; Tiedge M, 1999, DIABETES, V48, P514, DOI 10.2337/diabetes.48.3.514; TIPPETT PS, 1982, J BIOL CHEM, V257, P2839; TIPPETT PS, 1982, J BIOL CHEM, V257, P2846; TOYODA Y, 1995, FEBS LETT, V359, P81, DOI 10.1016/0014-5793(94)01452-7; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; VANDERCAMMEN A, 1990, EUR J BIOCHEM, V191, P483, DOI 10.1111/j.1432-1033.1990.tb19147.x; VANSCHAFTINGEN E, 1994, FASEB J, V8, P414, DOI 10.1096/fasebj.8.6.8168691; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; WARNOTTE C, 1994, DIABETES, V43, P703, DOI 10.2337/diabetes.43.5.703; XU LZ, 1995, J BIOL CHEM, V270, P9939, DOI 10.1074/jbc.270.17.9939	37	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2325	2328		10.1074/jbc.C000530200	http://dx.doi.org/10.1074/jbc.C000530200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11085976	hybrid			2022-12-25	WOS:000166784800005
J	Yao, XD; Elias, P				Yao, XD; Elias, P			Recombination during early herpes simplex virus type 1 infection is mediated by cellular proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; HOMOLOGOUS RECOMBINATION; DNA-REPLICATION; MAMMALIAN-CELLS; HAMSTER-CELLS; NUCLEAR FOCI; P53; INHIBITION; SEQUENCE; GENOME	Homologous recombination was examined in cells infected with herpes simplex virus type I. Circular and linear DNA with directly repeated sequences was introduced as recombination substrates into cells. Recombination was measured either by origin-dependent amplification of recombination products or by recombination-dependent expression of luciferase from a disrupted gene. Homologous recombination in baby hamster kidney cells converted linear DNA to circular templates for DNA replication and luciferase expression in the complete absence of virus. The products of homologous recombination were efficiently amplified by the viral replication apparatus. The efficiency of recombination was dependent on the structure of the substrate as well as the cell type. Linear DNA with the direct repeats at internal positions failed to recombine in Balb/c 3T3 cells and induced p53-dependent apoptosis. In contrast, linear DNA with directly repeated sequences precisely at the ends recombined and replicated in 3T3 cells. Homologous recombination in baby hamster kidney cells did not depend on the position of the repeated sequences. We conclude that homologous recombination is independent of viral gene functions and that it is likely to be carried out by cellular proteins. We suggest that homologous recombination between directly repeated sequences in the linear herpes simplex virus type I chromosome may help to avoid p58-dependent apoptosis and to promote viral DNA replication.	Univ Gothenburg, Dept Med Biochem, SE-40530 Gothenburg, Sweden; Univ Guelph, Coll Biol Sci, Dept Mol Biol & Genet, Guelph, ON N1G 2W1, Canada	University of Gothenburg; University of Guelph	Elias, P (corresponding author), Univ Gothenburg, Dept Med Biochem, Box 440, SE-40530 Gothenburg, Sweden.	per.elias@medkem.gu.se						Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Chu G, 1997, J BIOL CHEM, V272, P24097, DOI 10.1074/jbc.272.39.24097; DUTCH RE, 1992, J VIROL, V66, P277, DOI 10.1128/JVI.66.1.277-285.1992; DUTCH RE, 1995, J VIROL, V69, P3084, DOI 10.1128/JVI.69.5.3084-3089.1995; GIULOTTO E, 1987, CELL, V48, P837, DOI 10.1016/0092-8674(87)90080-8; HAAF T, 1995, P NATL ACAD SCI USA, V92, P2298, DOI 10.1073/pnas.92.6.2298; HALLIBURTON IW, 1980, J GEN VIROL, V48, P1, DOI 10.1099/0022-1317-48-1-1; Hammarsten O, 1996, J VIROL, V70, P4523, DOI 10.1128/JVI.70.7.4523-4529.1996; Huang LC, 1996, P NATL ACAD SCI USA, V93, P4827, DOI 10.1073/pnas.93.10.4827; IVANOV EL, 1995, MOL CELL BIOL, V15, P2245; Jimenez GS, 1999, NATURE, V400, P81, DOI 10.1038/21913; KANG SS, 1992, VIROLOGY, V191, P754, DOI 10.1016/0042-6822(92)90251-J; KEITH CT, 1995, SCIENCE, V270, P50, DOI 10.1126/science.270.5233.50; Kogoma T, 1997, MICROBIOL MOL BIOL R, V61, P212, DOI 10.1128/.61.2.212-238.1997; KOPS AD, 1994, J VIROL, V68, P3512; LEGROS Y, 1992, GENE, V112, P247, DOI 10.1016/0378-1119(92)90384-2; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; Lim DS, 1996, MOL CELL BIOL, V16, P7133; Martin DW, 1996, J VIROL, V70, P8801, DOI 10.1128/JVI.70.12.8801-8812.1996; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Maul GG, 1998, BIOESSAYS, V20, P660, DOI 10.1002/(SICI)1521-1878(199808)20:8<660::AID-BIES9>3.0.CO;2-M; McVoy MA, 1997, J VIROL, V71, P4209, DOI 10.1128/JVI.71.6.4209-4217.1997; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Melton DW, 1998, J CELL SCI, V111, P395; MESSER LI, 1979, J GEN VIROL, V45, P431, DOI 10.1099/0022-1317-45-2-431; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; Roizman B, 1996, FIELDS VIROLOGY, P2231; ROTH DB, 1985, P NATL ACAD SCI USA, V82, P3355, DOI 10.1073/pnas.82.10.3355; RUBNITZ J, 1984, MOL CELL BIOL, V4, P2253, DOI 10.1128/MCB.4.11.2253; Sargent RG, 1997, P NATL ACAD SCI USA, V94, P13122, DOI 10.1073/pnas.94.24.13122; SARISKY RT, 1994, J VIROL, V68, P34, DOI 10.1128/JVI.68.1.34-47.1994; SHULMAN MJ, 1995, EMBO J, V14, P4102, DOI 10.1002/j.1460-2075.1995.tb00082.x; STOW ND, 1993, VIROLOGY, V196, P413, DOI 10.1006/viro.1993.1496; Sturzbecher HW, 1996, EMBO J, V15, P1992, DOI 10.1002/j.1460-2075.1996.tb00550.x; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tashiro S, 1996, ONCOGENE, V12, P2165; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tsuzuki T, 1996, P NATL ACAD SCI USA, V93, P6236, DOI 10.1073/pnas.93.13.6236; UMENE K, 1985, J GEN VIROL, V66, P2659, DOI 10.1099/0022-1317-66-12-2659; Vispe S, 1998, NUCLEIC ACIDS RES, V26, P2859, DOI 10.1093/nar/26.12.2859; WEBER PC, 1988, CELL, V54, P369, DOI 10.1016/0092-8674(88)90200-0; WHITE E, 1989, P NATL ACAD SCI USA, V86, P9886, DOI 10.1073/pnas.86.24.9886; Wiesmuller L, 1996, J VIROL, V70, P737; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; Yao XD, 1997, J VIROL, V71, P6842, DOI 10.1128/JVI.71.9.6842-6849.1997; ZAKIAN VA, 1995, CELL, V82, P685, DOI 10.1016/0092-8674(95)90463-8; ZERRAHN J, 1992, ONCOGENE, V7, P1371	49	19	21	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2905	2913		10.1074/jbc.M005627200	http://dx.doi.org/10.1074/jbc.M005627200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11069901	hybrid			2022-12-25	WOS:000166784800083
J	Teter, SA; Eggerton, KP; Scott, SV; Kim, J; Fischer, AM; Klionsky, DJ				Teter, SA; Eggerton, KP; Scott, SV; Kim, J; Fischer, AM; Klionsky, DJ			Degradation of lipid vesicles in the yeast vacuole requires function of Cvt17, a putative lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TARGETING PATHWAY; SACCHAROMYCES-CEREVISIAE; AMINOPEPTIDASE-I; CYTOPLASM; AUTOPHAGY; MUTANTS	The vacuole/lysosome serves an essential role in allowing cellular components to be degraded and recycled under starvation conditions. Vacuolar hydrolases are key proteins in this process. In Saccharyomces cerevisiae, some resident vacuolar hydrolases are delivered by the cytoplasm to vacuole targeting (Cvt) pathway, which shares mechanistic features with autophagy, Autophagy is a degradative pathway that is used to degrade and recycle cellular components under starvation conditions. Both the Cvt pathway and autophagy employ double-membrane cytosolic vesicles to deliver cargo to the vacuole, As a result, these pathways share a common terminal step, the degradation of subvacuolar vesicles. We have identified a protein, Cvt17, which is essential for this membrane lytic event. Cvt17 is a membrane glycoprotein that contains a motif conserved in esterases and lipases. The active-site serine of this motif is required for subvacuolar vesicle lysis, This is the first characterization of a putative lipase implicated in vacuolar function in yeast.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA; Univ Calif Davis, Microbiol Sect, Davis, CA 95616 USA	University of Michigan System; University of Michigan; University of California System; University of California Davis	Klionsky, DJ (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM053396, R01 GM053396-11, GM53396, R01 GM053396-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; BLOW D, 1990, NATURE, V343, P694, DOI 10.1038/343694a0; Coleman M, 1997, MOL PLANT MICROBE IN, V10, P1106, DOI 10.1094/MPMI.1997.10.9.1106; Cousin X, 1998, NUCLEIC ACIDS RES, V26, P226, DOI 10.1093/nar/26.1.226; DEREWENDA ZS, 1993, TRENDS BIOCHEM SCI, V18, P20, DOI 10.1016/0968-0004(93)90082-X; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; Gerhardt B, 1998, J BIOL CHEM, V273, P15818, DOI 10.1074/jbc.273.25.15818; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Labbe S, 1999, METHOD ENZYMOL, V306, P145; Matsuura A, 1997, GENE, V192, P245, DOI 10.1016/S0378-1119(97)00084-X; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1996, P NATL ACAD SCI USA, V93, P12304, DOI 10.1073/pnas.93.22.12304; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Tomashek JJ, 1996, J BIOL CHEM, V271, P10397, DOI 10.1074/jbc.271.17.10397; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Wang YX, 1998, J CELL BIOL, V140, P1063, DOI 10.1083/jcb.140.5.1063; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930	26	143	146	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 19	2001	276	3					2083	2087		10.1074/jbc.C000739200	http://dx.doi.org/10.1074/jbc.C000739200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	394MN	11085977	Green Accepted, hybrid			2022-12-25	WOS:000166528000060
J	Shimaoka, T; Kume, N; Minami, M; Hayashida, K; Kataoka, H; Kita, T; Yonehara, S				Shimaoka, T; Kume, N; Minami, M; Hayashida, K; Kataoka, H; Kita, T; Yonehara, S			Molecular cloning of a novel scavenger receptor for oxidized low density lipoprotein, SR-PSOX, on macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ATHEROSCLEROTIC LESIONS; ENDOTHELIAL RECEPTOR; CELLS; EXPRESSION; PROTEIN; CD36	Receptor-mediated endocytosis of oxidized low density lipoprotein (OxLDL) by macrophages has been implicated in foam cell transformation in the process of atherogenesis. Although several scavenger receptor molecules, including class A scavenger receptors and CD36, have been identified as OxLDL receptors on macrophages, additional molecules on macrophages may also be involved in the recognition of OxLDL. From a cDNA library of phorbol Ig-myristate Is-acetate-stimulated THP-1 cells, we isolated a cDNA encoding a novel protein designated SR-PSOX (scavenger receptor that binds Ehosphatidylserine and oxidized lipoprotein), which acts as a receptor for OxLDL, SR-PSOX was a type I membrane protein consisting of 254 amino acids, expression of which was shown on human and murine macrophages with a molecular mass of 30 kDa, SR-PSOX could specifically bind with high affinity, internalize, and degrade OxLDL. The recognition of OxLDL was blocked by polyinosinic acid and dextran sulfate but not by acetylated low density lipoprotein. Taken together, SR-PSOX is a novel class of molecule belonging to the scavenger receptor family, which may play important roles in pathophysiology including atherogenesis.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University; Kyoto University	Yonehara, S (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Shogoin Kawahara Cho 53, Kyoto 6068507, Japan.		Kataoka, Hiroharu/GPT-3596-2022	Kataoka, Hiroharu/0000-0001-8507-7557				CALOS MP, 1983, P NATL ACAD SCI-BIOL, V80, P3015, DOI 10.1073/pnas.80.10.3015; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; Kataoka H, 1999, CIRCULATION, V99, P3110, DOI 10.1161/01.CIR.99.24.3110; Kataoka H, 2000, J BIOL CHEM, V275, P6573, DOI 10.1074/jbc.275.9.6573; KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0; KUME N, 1991, BIOCHIM BIOPHYS ACTA, V1091, P63, DOI 10.1016/0167-4889(91)90223-K; Moriwaki H, 1998, ARTERIOSCL THROM VAS, V18, P1541, DOI 10.1161/01.ATV.18.10.1541; Nakata A, 1999, ARTERIOSCL THROM VAS, V19, P1333, DOI 10.1161/01.ATV.19.5.1333; RAMPRASAD MP, 1995, P NATL ACAD SCI USA, V92, P9580, DOI 10.1073/pnas.92.21.9580; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; Steinbrecher UP, 1999, BBA-MOL CELL BIOL L, V1436, P279, DOI 10.1016/S0005-2760(98)00127-1; STEPHAN ZF, 1993, J LIPID RES, V34, P325; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; YLAHERTTUALA S, 1991, J CLIN INVEST, V87, P1146, DOI 10.1172/JCI115111	21	260	281	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 29	2000	275	52					40663	40666		10.1074/jbc.C000761200	http://dx.doi.org/10.1074/jbc.C000761200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	387GJ	11060282	hybrid			2022-12-25	WOS:000166114600002
J	Meplan, C; Richard, MJ; Hainaut, P				Meplan, C; Richard, MJ; Hainaut, P			Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells	ONCOGENE			English	Article						p53; zinc; chelator; metallothionein; metals	WILD-TYPE P53; DNA-BINDING ACTIVITY; IN-VITRO; NNN'N'-TETRAKIS-(2-PYRIDYLMETHYL)ETHYLENE DIAMINE; TRANSITION-METALS; KAPPA-B; METALLOTHIONEIN; CONFORMATION; ACTIVATION; EXPRESSION	The tumor suppressor p53 is a transcription factor which binds DNA through a structurally complex domain stabilized by a zinc atom. Zinc chelation disrupts the architecture of this domain, inducing the protein to adopt an immunological phenotype identical to that of many mutant forms of p53, In this report, we used Zn-65 to show that incorporation of zinc within the protein was required for folding in the 'wild-type' conformation capable of specific DNA-binding, Using a cellular assay, we show that addition of extracellular zinc at concentrations within the physiological range (5 muM) was required for renaturation and reactivation of wild-type p53, Among other divalent metals tested (Cd2+, Cu2+, Co2+, Fe2+ and Ni2+), only Co2+ at 125 muM had a similar effect. Recombinant metallothionein (MT), a metal chelator protein, was found to modulate p53 conformation in vitro. In cultured cells, overexpression of MT by transfection could modulate p53 transcriptional activity. Taken together, these results suggest that zinc binding plays a regulatory role in the control of p53 folding and DNA-binding activity.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon 08, France; Ctr Hosp & Univ Albert Michalon, Biochim Lab C, F-38043 Grenoble 9, France	World Health Organization; International Agency for Research on Cancer (IARC)	Hainaut, P (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biochem Res Ctr, Dundee DD1 9SY, Scotland.		Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				Abdel-Mageed AB, 1998, CANCER RES, V58, P2335; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; Bittel D, 1998, J BIOL CHEM, V273, P7127, DOI 10.1074/jbc.273.12.7127; CanoGauci DF, 1996, FEBS LETT, V386, P1, DOI 10.1016/0014-5793(96)00356-0; Canzoniero LMT, 1997, NEUROBIOL DIS, V4, P275, DOI 10.1006/nbdi.1997.0160; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fojta M, 1999, J BIOL CHEM, V274, P25749, DOI 10.1074/jbc.274.36.25749; FREBOURG T, 1992, CANCER RES, V52, P6976; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; HAINAUT P, 1995, BRIT J CANCER, V71, P227, DOI 10.1038/bjc.1995.48; HAINAUT P, 1993, CANCER RES, V53, P1739; Hainaut P, 2000, ADV CANCER RES, V77, P81; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Jacob C, 1998, P NATL ACAD SCI USA, V95, P3489, DOI 10.1073/pnas.95.7.3489; Janus F, 1999, CELL MOL LIFE SCI, V55, P12, DOI 10.1007/s000180050266; Jiang LJ, 1998, P NATL ACAD SCI USA, V95, P3483, DOI 10.1073/pnas.95.7.3483; Kaelin WG, 1998, SCIENCE, V281, P57, DOI 10.1126/science.281.5373.57; KARIN M, 1983, P NATL ACAD SCI-BIOL, V80, P4040, DOI 10.1073/pnas.80.13.4040; KILLE P, 1991, FEBS LETT, V295, P171, DOI 10.1016/0014-5793(91)81411-Z; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Linke SP, 1997, CANCER RES, V57, P1171; Maret W, 1999, P NATL ACAD SCI USA, V96, P1936, DOI 10.1073/pnas.96.5.1936; Meplan C, 1999, J BIOL CHEM, V274, P31663, DOI 10.1074/jbc.274.44.31663; Meplan C, 2000, BIOCHEM PHARMACOL, V59, P25, DOI 10.1016/S0006-2952(99)00297-X; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NAGEL WW, 1995, P NATL ACAD SCI USA, V92, P579, DOI 10.1073/pnas.92.2.579; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Parat MO, 1999, BIOL TRACE ELEM RES, V70, P51, DOI 10.1007/BF02783849; Parat MO, 1998, BIOL TRACE ELEM RES, V65, P261, DOI 10.1007/BF02789101; PATTISON SE, 1986, FASEB J, V45, P2805; PATTISON SE, 1986, AM J PHYSIOL, V250, pE677, DOI 10.1152/ajpendo.1986.250.6.E677; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Roesijadi G, 1998, J BIOL CHEM, V273, P17425, DOI 10.1074/jbc.273.28.17425; Sakurai A, 1999, FEBS LETT, V455, P55, DOI 10.1016/S0014-5793(99)00839-X; Schmidt C, 1999, ARCH BIOCHEM BIOPHYS, V364, P91, DOI 10.1006/abbi.1999.1107; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; THIESEN HJ, 1991, BIOCHEM BIOPH RES CO, V176, P551, DOI 10.1016/S0006-291X(05)80219-0; TSUJIKAWA K, 1994, EUR J CELL BIOL, V63, P240; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; VALLEE BL, 1991, METHOD ENZYMOL, V205, P3; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Verhaegh GW, 1998, MOL CARCINOGEN, V21, P205, DOI 10.1002/(SICI)1098-2744(199803)21:3<205::AID-MC8>3.0.CO;2-K; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WLOSTOWSKI T, 1993, BIOMETALS, V6, P71, DOI 10.1007/BF00140106; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141; Zalewski P D, 1994, Chem Biol, V1, P153, DOI 10.1016/1074-5521(94)90005-1; Zalewski PD, 1996, REPROD FERT DEVELOP, V8, P1097, DOI 10.1071/RD9961097; ZENG J, 1991, FEBS LETT, V279, P310, DOI 10.1016/0014-5793(91)80175-3; ZENG J, 1991, P NATL ACAD SCI USA, V88, P9984, DOI 10.1073/pnas.88.22.9984	63	195	199	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 2	2000	19	46					5227	5236		10.1038/sj.onc.1203907	http://dx.doi.org/10.1038/sj.onc.1203907			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	369HK	11077439				2022-12-25	WOS:000165059700003
J	Paris, F; Grassme, H; Cremesti, A; Zager, J; Fong, YM; Haimovitz-Friedman, A; Fuks, Z; Gulbin, E; Kolesnick, R				Paris, F; Grassme, H; Cremesti, A; Zager, J; Fong, YM; Haimovitz-Friedman, A; Fuks, Z; Gulbin, E; Kolesnick, R			Natural ceramide reverses Fas resistance of acid sphingomyelinase(-/-) hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RADIATION-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; EPSTEIN-BARR-VIRUS; DAUNORUBICIN-INDUCED APOPTOSIS; PROGRAMMED CELL-DEATH; IONIZING-RADIATION; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; MEDIATED APOPTOSIS; KINASE ACTIVATION	The role of the second messenger ceramide in Fas-mediated death requires clarification. To address this issue, we generated hepatocytes from paired acid sphingomyelinase (ASMase; asmase)(+/+) and asmase(-/-) mice. asmase(-/-) hepatocytes, derived from 8-week old mice, manifested normal sphingomyelin content and normal morphological, biochemical, and biologic features. Nonetheless, ASMase-deficient hepatocytes did not display rapid ceramide elevation or apoptosis in response to Jo2 anti-Fas antibody. asmase(-/-) hepatocytes were not inherently resistant to apoptosis because staurosporine, which did not induce early ceramide elevation, stimulated a normal apoptotic response. The addition of low nanomolar quantities of natural C-16-ceramide, which by itself did not induce apoptosis, completely restored the apoptotic response to anti-Fas in asmase(-/-) hepatocytes. Other sphingolipids did not replace natural ceramide and restore Fas sensitivity. Overcoming resistance to Fas in asmase(-/-) hepatocytes by natural ceramide is evidence that it is the lack of ceramide and not ASMase which determines the apoptotic phenotype. The ability of natural ceramide to rescue the phenotype without reversing the genotype provides evidence that ceramide is obligate for Fas induction of apoptosis in hepatocytes.	Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Radiat Oncol, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; St Jude Children's Research Hospital	Kolesnick, R (corresponding author), Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, 1275 York Ave, New York, NY 10021 USA.	r-kolesnick@ski.mskcc.org	Gulbins, Erich/L-6989-2014; Paris, francois E/L-4915-2015	Gulbins, Erich/0000-0002-3117-1342; Paris, francois E/0000-0002-0176-7348	NCI NIH HHS [CA52462, CA61524, CA72632, CA42385] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA072632, R01CA052462, R01CA061524] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Allouche M, 2000, BLOOD, V96, P1187, DOI 10.1182/blood.V96.3.1187.015k01_1187_1190; Allouche M, 1997, ONCOGENE, V14, P1837, DOI 10.1038/sj.onc.1201023; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Bettaieb A, 1999, MOL PHARMACOL, V55, P118, DOI 10.1124/mol.55.1.118; Boesen-de Cock JGR, 1998, J BIOL CHEM, V273, P7560, DOI 10.1074/jbc.273.13.7560; Bose R, 1998, J BIOL CHEM, V273, P28852, DOI 10.1074/jbc.273.44.28852; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Brady RO, 1998, ARCH NEUROL-CHICAGO, V55, P1055, DOI 10.1001/archneur.55.8.1055; Brenner B, 1998, CELL DEATH DIFFER, V5, P29, DOI 10.1038/sj.cdd.4400307; Bruno AP, 1998, CELL DEATH DIFFER, V5, P172, DOI 10.1038/sj.cdd.4400330; Burow ME, 2000, J BIOL CHEM, V275, P9628, DOI 10.1074/jbc.275.13.9628; Cai ZZ, 1997, J BIOL CHEM, V272, P6918, DOI 10.1074/jbc.272.11.6918; CasacciaBonnefil P, 1996, NATURE, V383, P716, DOI 10.1038/383716a0; Chiu SM, 2000, INT J ONCOL, V16, P423; Chmura SJ, 2000, MOL PHARMACOL, V57, P792, DOI 10.1124/mol.57.4.792; Chmura SJ, 1997, CANCER RES, V57, P4340; Chmura SJ, 1997, CANCER RES, V57, P1270; Cifone MG, 1999, BLOOD, V93, P2282, DOI 10.1182/blood.V93.7.2282.407a23_2282_2296; CIFONE MG, 1994, J EXP MED, V180, P1547, DOI 10.1084/jem.180.4.1547; Coligan JKA, 1991, CURRENT PROTOCOLS IM; Come MG, 1999, INT J CANCER, V81, P580, DOI 10.1002/(SICI)1097-0215(19990517)81:4<580::AID-IJC13>3.0.CO;2-T; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; De la Coste A, 1999, AM J PHYSIOL-GASTR L, V277, pG702, DOI 10.1152/ajpgi.1999.277.3.G702; De Maria R, 1998, J EXP MED, V187, P897, DOI 10.1084/jem.187.6.897; De Nadai C, 2000, P NATL ACAD SCI USA, V97, P5480, DOI 10.1073/pnas.070062397; DeMaria R, 1996, J CLIN INVEST, V97, P316, DOI 10.1172/JCI118418; Furuke K, 1998, INT IMMUNOL, V10, P1261, DOI 10.1093/intimm/10.9.1261; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Genestier L, 1998, J BIOL CHEM, V273, P5060, DOI 10.1074/jbc.273.9.5060; Golstein P, 2000, SCIENCE, V288, P2328, DOI 10.1126/science.288.5475.2328; Grullich C, 2000, J BIOL CHEM, V275, P8650, DOI 10.1074/jbc.275.12.8650; Gulbins E, 1996, IMMUNOLOGY, V89, P205, DOI 10.1046/j.1365-2567.1996.d01-743.x; HaimovitzFriedman A, 1997, J EXP MED, V186, P1831, DOI 10.1084/jem.186.11.1831; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hauck CR, 2000, FEBS LETT, V478, P260, DOI 10.1016/S0014-5793(00)01851-2; HORINOUCHI K, 1995, NAT GENET, V10, P288, DOI 10.1038/ng0795-288; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; Ishizuka N, 1999, METABOLISM, V48, P1485, DOI 10.1016/S0026-0495(99)90234-2; Jaffrezou JP, 1996, EMBO J, V15, P2417, DOI 10.1002/j.1460-2075.1996.tb00599.x; Jones RA, 1998, HEPATOLOGY, V27, P1632, DOI 10.1002/hep.510270624; Kelly ML, 1998, BLOOD, V92, P416, DOI 10.1182/blood.V92.2.416.414k01_416_424; Khanna KK, 1997, J BIOL CHEM, V272, P9489; Kirschnek S, 2000, J BIOL CHEM, V275, P27316; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Kondo T, 2000, J BIOL CHEM, V275, P8872, DOI 10.1074/jbc.275.12.8872; Liao WC, 1999, J BIOL CHEM, V274, P17908, DOI 10.1074/jbc.274.25.17908; Lin T, 2000, J BIOL CHEM, V275, P8657, DOI 10.1074/jbc.275.12.8657; Lin XH, 1998, J BIOL CHEM, V273, P14374, DOI 10.1074/jbc.273.23.14374; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; Lozano J, 2001, J BIOL CHEM, V276, P442, DOI 10.1074/jbc.M006353200; Lozano J, 2001, CELL DEATH DIFFER, V8, P100, DOI 10.1038/sj.cdd.4400775; Mansat V, 1997, FASEB J, V11, P695, DOI 10.1096/fasebj.11.8.9240970; Mansat V, 1997, CANCER RES, V57, P5300; Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; MILLER CL, 1995, IMMUNITY, V2, P155, DOI 10.1016/S1074-7613(95)80040-9; MILLER CL, 1994, P NATL ACAD SCI USA, V91, P772, DOI 10.1073/pnas.91.2.772; Morita Y, 2000, NAT MED, V6, P1109, DOI 10.1038/80442; Morita Y, 2000, ANN NY ACAD SCI, V905, P209; OHTA H, 1994, FEBS LETT, V355, P267, DOI 10.1016/0014-5793(94)01218-0; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Pahan K, 2000, J NEUROCHEM, V75, P576, DOI 10.1046/j.1471-4159.2000.0750576.x; Pena LA, 2000, CANCER RES, V60, P321; Picardo A, 1996, J SURG RES, V63, P452, DOI 10.1006/jsre.1996.0291; Redondo C, 1996, J CLIN INVEST, V98, P1245, DOI 10.1172/JCI118908; Rodriguez I, 1996, J EXP MED, V183, P1031, DOI 10.1084/jem.183.3.1031; Santana P, 1996, CELL, V86, P189, DOI 10.1016/S0092-8674(00)80091-4; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SCHUCHMAN EH, 1994, METABOLIC MOL BASES, P2601; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Segui B, 1999, J BIOL CHEM, V274, P37251, DOI 10.1074/jbc.274.52.37251; Separovic D, 1997, CANCER RES, V57, P1717; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Takehara T, 1999, GASTROENTEROLOGY, V117, P661, DOI 10.1016/S0016-5085(99)70460-9; Tepper AD, 1997, J BIOL CHEM, V272, P24308, DOI 10.1074/jbc.272.39.24308; Tonnetti L, 1999, J EXP MED, V189, P1581, DOI 10.1084/jem.189.10.1581; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Woo M, 1999, J IMMUNOL, V163, P4909; Yamamoto M, 2000, GASTROENTEROLOGY, V118, P380, DOI 10.1016/S0016-5085(00)70220-4; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zundel W, 1998, GENE DEV, V12, P1941, DOI 10.1101/gad.12.13.1941	86	96	99	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 16	2001	276	11					8297	8305		10.1074/jbc.M008732200	http://dx.doi.org/10.1074/jbc.M008732200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	411AA	11096096	hybrid			2022-12-25	WOS:000167474900086
J	Gutierrez-Cruz, G; Van Heerden, AH; Wang, K				Gutierrez-Cruz, G; Van Heerden, AH; Wang, K			Modular motif, structural folds and affinity profiles of the PEVK segment of human fetal skeletal muscle titin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN NEBULIN FRAGMENTS; VERTEBRATE SKELETAL; GLOBULAR-PROTEINS; ELASTICITY; FILAMENTS; STABILITY; EXTENSION; DOMAINS; EXTENSIBILITY; STIFFNESS	The extension of the PEVK segment of the giant elastic protein titin is a key event in the elastic response of striated muscle to passive stretch. PEVK behaves mechanically as an entropic spring and is thought to be a random coil. cDNA sequencing of human fetal skeletal PEVK reveals a modular motif with tandem repeats of modules averaging 28 residues and with superrepeats of seven;modules. Conformational studies of bacterially expressed 53-kDa fragment (TP1) by circular dichroism suggest; that this soluble protein contains substantial polyproline II (PPII) type left-handed helices. Urea and thermal titrations cause gradual and reversible decrease in PPII content. The absence of sharp melting in urea and thermal titrations suggests that there is no long range cooperativity among the PPII helices. Studies with solid phase and surface plasmon resonance assays indicate that TP1 interacts with actin and some but not all cloned nebulin fragments with high affinity. Interestingly, Ca2+/calmodulin and Ca2+/S100 abolish nebulin/PEVK interaction. We suggest that in aqueous solution) PEVK is an open and flexible chain of relatively stable structural folds of the polyproline II type. PEVK region of titin may be involved in interfilament association with thin filaments in a calcium/calmodulin-sensitive manner. This adhesion may modulate titin extensibility and elasticity.	NIAMSD, Lab Phys Biol, NIH, Bethesda, MD 20892 USA; Univ Texas, Dept Chem & Biochem, Austin, TX 78712 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Texas System; University of Texas Austin	Wang, K (corresponding author), NIAMSD, Lab Phys Biol, NIH, Bldg 6,Rm 401, Bethesda, MD 20892 USA.				NIAMS NIH HHS [AR 45315] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADZHUBEI AA, 1993, J MOL BIOL, V229, P472, DOI 10.1006/jmbi.1993.1047; Bhatnagar RS, 1996, CIRCULAR DICHROISM C, P183; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; Freiburg A, 2000, CIRC RES, V86, P1114; GRANZIER HLM, 1993, BIOPHYS J, V65, P2141, DOI 10.1016/S0006-3495(93)81262-1; Greaser ML, 2000, BIOPHYS J, V78, p18A; JIN JP, 1991, J BIOL CHEM, V266, P21215; KAWAHARA K, 1966, J BIOL CHEM, V241, P3228; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; KRUGER M, 1991, J CELL BIOL, V115, P97, DOI 10.1083/jcb.115.1.97; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LABEIT S, 1995, J MOL BIOL, V248, P308, DOI 10.1016/S0022-2836(95)80052-2; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; LAURENT TC, 1964, J CHROMATOGR, V14, P317, DOI 10.1016/S0021-9673(00)86637-6; Linke WA, 2000, BIOPHYS J, V78, p229A; Linke WA, 1998, BIOPHYS J, V75, P2613, DOI 10.1016/S0006-3495(98)77706-9; Linke WA, 1998, P NATL ACAD SCI USA, V95, P8052, DOI 10.1073/pnas.95.14.8052; Linke WA, 1996, J MOL BIOL, V261, P62, DOI 10.1006/jmbi.1996.0441; Machado C, 1998, J CELL BIOL, V141, P321, DOI 10.1083/jcb.141.2.321; MARTIN JH, 1993, P NATL ACAD SCI USA, V90, P1531, DOI 10.1073/pnas.90.4.1531; MuhleGoll C, 1997, J BIOMOL NMR, V9, P2, DOI 10.1023/A:1018611316059; Pastore A, 1996, J MUSCLE RES CELL M, V17, P114; POLITOU AS, 1994, BIOCHEMISTRY-US, V33, P4730, DOI 10.1021/bi00181a604; ROOT DD, 1994, BIOCHEMISTRY-US, V33, P12581, DOI 10.1021/bi00208a008; SREERAMA N, 1994, BIOCHEMISTRY-US, V33, P10022, DOI 10.1021/bi00199a028; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; TIFFANY ML, 1973, BIOPOLYMERS, V12, P575, DOI 10.1002/bip.1973.360120310; Trombitas K, 1998, J STRUCT BIOL, V122, P188, DOI 10.1006/jsbi.1998.3984; Trombitas K, 1998, J CELL BIOL, V140, P853, DOI 10.1083/jcb.140.4.853; Trombitas K, 1999, BIOPHYS J, V76, pA31; Wang K, 1996, J BIOL CHEM, V271, P4304; WANG K, 1993, BIOPHYS J, V64, P1161, DOI 10.1016/S0006-3495(93)81482-6; WANG K, 1991, P NATL ACAD SCI USA, V88, P7101, DOI 10.1073/pnas.88.16.7101; WRIGHT J, 1993, J MUSCLE RES CELL M, V14, P476, DOI 10.1007/BF00297210	34	74	75	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7442	7449		10.1074/jbc.M008851200	http://dx.doi.org/10.1074/jbc.M008851200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11084039	hybrid			2022-12-25	WOS:000167442900081
J	Schumacher, S; Jung, M; Norenberg, U; Dorner, A; Chiquet-Ehrismann, R; Stuermer, CAO; Rathjen, FG				Schumacher, S; Jung, M; Norenberg, U; Dorner, A; Chiquet-Ehrismann, R; Stuermer, CAO; Rathjen, FG			CALEB binds via its acidic stretch to the fibrinogen-like domain of tenascin-C or tenascin-R and its expression is dynamically regulated after optic nerve lesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL GANGLION-CELLS; TYROSINE PHOSPHATASE-ZETA/BETA; CHONDROITIN SULFATE PROTEOGLYCAN; EXTRACELLULAR-MATRIX PROTEINS; ADULT-RATS; NEURITE OUTGROWTH; NEUROGLYCAN-C; AXON GROWTH; EGF FAMILY; RECEPTOR	Recently, we described a novel chick neural transmembrane glycoprotein, which interacts with the extracellular matrix proteins tenascin-C and tenascin-R This protein, termed CALEB, contains an epidermal growth factor-like domain and appears to be a novel member of the epidermal growth factor family of growth and differentiation factors. Here we analyze the interaction between CALEB and tenascin-C as well as tenascin-ft in more detail, and we demonstrate that the central acidic peptide segment of CALEB is necessary to mediate this binding. The fibrinogen-like globe within tenascin-C or -R enables both proteins to bind to CALEB, We show that two isoforms of CALEB in chick and rodents exist that differed in their cytoplasmic segments. To begin to understand the in vivo function of CALEB and since in vitro antibody perturbation experiments indicated that CALEB might be important for neurite formation, we analyzed the expression pattern of the rat homolog of CALEB during development of retinal ganglion cells, after optic nerve lesion and during graft-assisted retinal ganglion cell axon regeneration by in situ hybridization. These investigations demonstrate that CALEB mRNA is dynamically regulated after optic nerve lesion and that this mRNA is expressed in most developing and in one-third of the few regenerating (GAP-43 expressing) retinal ganglion cells.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Univ Konstanz, D-78457 Constance, Germany; Friedrich Miescher Inst, CH-4002 Basel, Switzerland	Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Konstanz; Friedrich Miescher Institute for Biomedical Research	Rathjen, FG (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.							AIGNER L, 1995, CELL, V83, P269, DOI 10.1016/0092-8674(95)90168-X; Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Aono S, 2000, J BIOL CHEM, V275, P337, DOI 10.1074/jbc.275.1.337; Aspberg A, 1997, P NATL ACAD SCI USA, V94, P10116, DOI 10.1073/pnas.94.19.10116; BAHR M, 1992, EXP NEUROL, V116, P13, DOI 10.1016/0014-4886(92)90172-M; BAHR M, 1994, TRENDS NEUROSCI, V17, P473, DOI 10.1016/0166-2236(94)90136-8; BELL GI, 1986, NUCLEIC ACIDS RES, V14, P8427, DOI 10.1093/nar/14.21.8427; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; Bovolenta P, 2000, PROG NEUROBIOL, V61, P113, DOI 10.1016/S0301-0082(99)00044-1; Brummendorf T, 1996, Methods Mol Biol, V66, P319; BRUMMENDORF T, 1993, NEURON, V10, P711; Buchstaller A, 1996, J CELL BIOL, V135, P1593, DOI 10.1083/jcb.135.6.1593; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; CHIQUETEHRISMANN R, 1995, EXPERIENTIA, V51, P853, DOI 10.1007/BF01921736; CHUNG CY, 1995, J BIOL CHEM, V270, P29012, DOI 10.1074/jbc.270.48.29012; CHUNG CY, 1994, J CELL BIOL, V126, P539, DOI 10.1083/jcb.126.2.539; Clark RA, 1997, J CELL BIOL, V137, P755, DOI 10.1083/jcb.137.3.755; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DOOLITTLE RF, 1984, ANNU REV BIOCHEM, V53, P195, DOI 10.1146/annurev.bi.53.070184.001211; DOSTER SK, 1991, NEURON, V6, P635, DOI 10.1016/0896-6273(91)90066-9; ERICKSON HP, 1994, PERSPECT DEV NEUROBI, V2, P9; Faissner A, 1997, CELL TISSUE RES, V290, P331, DOI 10.1007/s004410050938; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; FISCHER D, 1995, J BIOL CHEM, V270, P3378, DOI 10.1074/jbc.270.7.3378; Fischer D, 1997, J CELL SCI, V110, P1513; Fitch MT, 1997, CELL TISSUE RES, V290, P379, DOI 10.1007/s004410050944; Gassmann M, 1997, CURR OPIN NEUROBIOL, V7, P87, DOI 10.1016/S0959-4388(97)80125-0; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; JONES FS, 2000, DEV DYNAM, V318, P325; Jung M, 1997, MOL CELL NEUROSCI, V9, P116, DOI 10.1006/mcne.1997.0611; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kermer P, 1998, J NEUROSCI, V18, P4656; Kikuchi M, 2000, J NEUROSCI, V20, P5037; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LOEB JA, 1995, J CELL BIOL, V130, P127, DOI 10.1083/jcb.130.1.127; Milev P, 1997, J BIOL CHEM, V272, P15501, DOI 10.1074/jbc.272.24.15501; Milev P, 1998, J BIOL CHEM, V273, P6998, DOI 10.1074/jbc.273.12.6998; Milev P, 1996, J BIOL CHEM, V271, P15716, DOI 10.1074/jbc.271.26.15716; NORENBERG U, 1992, NEURON, V8, P849, DOI 10.1016/0896-6273(92)90199-N; NORENBERG U, 1995, J CELL BIOL, V130, P473, DOI 10.1083/jcb.130.2.473; Petrausch B, 2000, MOL CELL NEUROSCI, V16, P350, DOI 10.1006/mcne.2000.0877; Plagge A, 1997, GENE, V192, P215, DOI 10.1016/S0378-1119(97)00066-8; PLOWMAN GD, 1990, P NATL ACAD SCI USA, V87, P4905, DOI 10.1073/pnas.87.13.4905; PRIETO AL, 1993, P NATL ACAD SCI USA, V90, P10154, DOI 10.1073/pnas.90.21.10154; RATHJEN FG, 1991, DEVELOPMENT, V113, P151; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; SCHADEN H, 1994, J NEUROBIOL, V25, P1570, DOI 10.1002/neu.480251209; Schumacher S, 1997, J CELL BIOL, V136, P895, DOI 10.1083/jcb.136.4.895; SRIRAMARAO P, 1993, J CELL SCI, V105, P1001; VARNUMFINNEY B, 1995, NEURON, V14, P1213, DOI 10.1016/0896-6273(95)90268-6; VILLEGASPEREZ MP, 1993, J NEUROBIOL, V24, P23, DOI 10.1002/neu.480240103; VILLEGASPEREZ MP, 1988, J NEUROSCI, V8, P265; Volkmer H, 1998, J CELL BIOL, V142, P1083, DOI 10.1083/jcb.142.4.1083; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; Xiao ZC, 1999, J BIOL CHEM, V274, P26511, DOI 10.1074/jbc.274.37.26511; Yasuda Y, 1998, NEUROSCI RES, V32, P313, DOI 10.1016/S0168-0102(98)00098-4; Yokoyama K, 2000, J BIOL CHEM, V275, P16891, DOI 10.1074/jbc.M000610200; Zacharias U, 1999, J BIOL CHEM, V274, P24357, DOI 10.1074/jbc.274.34.24357	62	32	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7337	7345		10.1074/jbc.M007234200	http://dx.doi.org/10.1074/jbc.M007234200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11069908	hybrid, Green Published			2022-12-25	WOS:000167442900066
J	Sztajer, H; Gamain, B; Aumann, KD; Slomianny, C; Becker, K; Brigelius-Flohe, R; Flohe, L				Sztajer, H; Gamain, B; Aumann, KD; Slomianny, C; Becker, K; Brigelius-Flohe, R; Flohe, L			The putative glutathione peroxidase gene of Plasmodium falciparum codes for a thioredoxin peroxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B ACTIVATION; MOLECULAR CHARACTERIZATION; HYDROPEROXIDE METABOLISM; SCHISTOSOMA-MANSONI; MALARIA PARASITE; CDNA SEQUENCE; HUMAN PLASMA; SELENIUM; SELENOENZYME; PROTEIN	A putative glutathione peroxidase gene (Swiss-Prot accession number Z 68200) of Plasmodium falciparum, the causative agent of tropical malaria, was expressed in Escherichia coli and purified to electrophoretic homogeneity, Like phospholipid hydroperoxide glutathione peroxidase of mammals, it proved to be monomeric, It was active with H2O2 and organic hydroperoxides but, unlike phospholipid hydroperoxide glutathione peroxidase, not with phosphatidylcholine hydroperoxide, With glutathione peroxidases it shares the ping pong mechanism with infinite V-max and K-m when analyzed with GSH as substrate, As a homologue with selenocysteine replaced by cysteine, its reactions with hydroperoxides and GSH are 3 orders of magnitude slower than those of the selenoperoxidases, Unexpectedly, the plasmodial enzyme proved to react faster with thioredoxins than with GSH and most efficiently with thioredoxin of P. falciparum (Swiss-Prot accession number 202664), It is therefore reclassified as thioredoxin peroxidase. With plasmodial thioredoxin, the enzyme also displays ping-pong kinetics, yet with a limiting K-m of 10 muM and a k(1)' of 0.55 s(-1). The apparent k(1)' for oxidation with cumene, t-butyl, and hydrogen peroxides are 2.0 x 10(4) M-1 s(-1) 3.3 x 10(3) M-1 s(-1), and 2.5 x 10(3) M-1 s(-1) respectively. k(2)' for reduction by autologous thioredoxin is 5.4 x 10(4) M-1 s(-1) (21.2 M-1 s(-1) for GSH), The newly discovered enzymatic function of the plasmodial gene product suggests a reconsideration of its presumed role in parasitic antioxidant defense.	Tech Univ Braunschweig, Dept Biochem, D-38124 Braunschweig, Germany; NIAID, NIH, Bethesda, MD 20892 USA; Natl Biotechnol Ctr, D-38124 Braunschweig, Germany; Univ Sci & Tech Lille Flandres Artois, INSERM, EPI 9938, F-59655 Villeneuve Dascq, France; Univ Wurzburg, Res Ctr Infect Dis, D-97070 Wurzburg, Germany; German Inst Human Nutr, D-14558 Bergholz Rehbrucke, Germany	Braunschweig University of Technology; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; University of Wurzburg; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)	Flohe, L (corresponding author), Tech Univ Braunschweig, Dept Biochem, Mascheroder Weg 1, D-38124 Braunschweig, Germany.		Gamain, Benoit/N-9985-2017; Slomianny, Christian/L-8285-2018	Gamain, Benoit/0000-0002-8255-2145; 				Andreesen JR, 1999, BIOFACTORS, V10, P263, DOI 10.1002/biof.5520100226; Arai M, 1996, BIOCHEM BIOPH RES CO, V227, P433, DOI 10.1006/bbrc.1996.1525; ATAMNA H, 1993, MOL BIOCHEM PARASIT, V61, P231, DOI 10.1016/0166-6851(93)90069-A; Aumann KD, 1997, BIOMED ENVIRON SCI, V10, P136; Ayi K, 1998, FEBS LETT, V424, P257, DOI 10.1016/S0014-5793(98)00185-9; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brigelius-Flohe R, 1997, BIOCHEM J, V328, P199, DOI 10.1042/bj3280199; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; BUFFINTON GD, 1988, BIOCHEM J, V249, P63, DOI 10.1042/bj2490063; BUTCHER LA, 1985, ANAL BIOCHEM, V148, P348; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P1706, DOI 10.3891/acta.chem.scand.11-1706; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; ESWORTHY RS, 1993, ARCH BIOCHEM BIOPHYS, V307, P29, DOI 10.1006/abbi.1993.1555; FAIRFIELD AS, 1988, MOL BIOCHEM PARASIT, V30, P77, DOI 10.1016/0166-6851(88)90134-X; Farber PM, 1996, EUR J BIOCHEM, V239, P655, DOI 10.1111/j.1432-1033.1996.0655u.x; FLOHE L, 1972, H-S Z PHYSIOL CHEM, V353, P987, DOI 10.1515/bchm2.1972.353.1.987; Flohe L, 2000, IUBMB LIFE, V49, P411; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; FLOHE L, 1973, FEBS LETT, V32, P132, DOI 10.1016/0014-5793(73)80755-0; FLOHE L, 1971, H-S Z PHYSIOL CHEM, V352, P159, DOI 10.1515/bchm2.1971.352.1.159; FLOHE L, 1988, CRC HDB FREE RADICAL, V3, P281; FLOHE L, 1993, ACTIVE OXYGENS LIPID, P291; FLOHE L, 1979, CIBA F S, V65, P95; FORSTROM JW, 1979, ARCH BIOCHEM BIOPHYS, V193, P51, DOI 10.1016/0003-9861(79)90007-9; FRIEDRICH MJ, 1986, J BACTERIOL, V167, P928, DOI 10.1128/jb.167.3.928-934.1986; Gamain B, 1996, MOL BIOCHEM PARASIT, V78, P237, DOI 10.1016/S0166-6851(96)02632-1; Gamain B, 1996, FREE RADICAL BIO MED, V21, P559, DOI 10.1016/0891-5849(96)00120-7; GHYSELINCK NB, 1990, NUCLEIC ACIDS RES, V18, P7144, DOI 10.1093/nar/18.23.7144; Godeas C, 1996, BIOCHEM MOL MED, V59, P118, DOI 10.1006/bmme.1996.0076; GUNZLER WA, 1972, H-S Z PHYSIOL CHEM, V353, P1001; HOLLAND D, 1993, PLANT MOL BIOL, V21, P923, DOI 10.1007/BF00027124; JENSEN JB, 1988, J IMMUNOL METHODS, V112, P201; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Luersen K, 1999, MOL BIOCHEM PARASIT, V98, P131, DOI 10.1016/S0166-6851(98)00161-3; Maiorino M, 1996, EUR J BIOCHEM, V238, P838, DOI 10.1111/j.1432-1033.1996.0838w.x; Maiorino M, 1998, FASEB J, V12, P1359, DOI 10.1096/fasebj.12.13.1359; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MAIORINO M, 1995, BIOL CHEM H-S, V376, P651, DOI 10.1515/bchm3.1995.376.11.651; MALHOTRA K, 1988, INFECT IMMUN, V56, P3305, DOI 10.1128/IAI.56.12.3305-3309.1988; Muller S, 1996, MOL BIOCHEM PARASIT, V80, P215, DOI 10.1016/0166-6851(96)02694-1; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; PUSHPAREKHA TR, 1995, J BIOL CHEM, V270, P26993, DOI 10.1074/jbc.270.45.26993; Ren B, 1997, J MOL BIOL, V268, P869, DOI 10.1006/jmbi.1997.1005; ROCHER C, 1992, EUR J BIOCHEM, V205, P955, DOI 10.1111/j.1432-1033.1992.tb16862.x; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; Schwarzer E, 1996, FEBS LETT, V388, P119, DOI 10.1016/0014-5793(96)00523-6; Ursini F, 1999, SCIENCE, V285, P1393, DOI 10.1126/science.285.5432.1393; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; URSINI F, 1995, METHOD ENZYMOL, V252, P38; WILLIAMS DL, 1992, MOL BIOCHEM PARASIT, V52, P127, DOI 10.1016/0166-6851(92)90042-I	54	126	132	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 9	2001	276	10					7397	7403		10.1074/jbc.M008631200	http://dx.doi.org/10.1074/jbc.M008631200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	410MC	11087748	hybrid			2022-12-25	WOS:000167442900074
J	Kouba, DJ; Nakano, H; Nishiyama, T; Kang, J; Uitto, J; Mauviel, A				Kouba, DJ; Nakano, H; Nishiyama, T; Kang, J; Uitto, J; Mauviel, A			Tumor necrosis factor-alpha induces distinctive NF-kappa B signaling within human dermal fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; TNF-RECEPTOR; NEUTRAL SPHINGOMYELINASE; TRANSDUCTION PATHWAYS; MAMMALIAN-CELLS; IKK-ALPHA; C-REL; ACTIVATION; KINASE; PROTEIN	The TNF-alpha receptor-associated factor 2 (TRAF2) and its downstream mediator, the NF-kappaB-inducing kinase (NIK), have been shown to induce NF-kappaB activation in 293 cells. Investigating the role these mediators play in human skin, we found that both NIK and TRAF2 failed to evoke transcription from NF-kappaB dependent promoters linked to the CAT reporter in human dermal fibroblast cultures, while epidermal keratinocyte cultures demonstrated NIK-dependent signaling. Further, NF-kappaB activation by TNF-alpha was unaffected by overexpression of a dominant negative mutant NIK in fibroblasts, despite detection of endogenous TRAF2 and NIK by Western analysis. To explore alternative signaling mechanisms in dermal fibroblasts, we found that the intracellular calcium chelator, 3,4,5-trimethoxybenzoic acid, and the calpain inhibitor, N-acetyl-Leu-Leu-norleucinal, both blocked NF-kappaB activation; however, the specific proteosome inhibitor, lactacystin, failed to do so. Furthermore, TNF-alpha receptor mutants lacking a functional death domain failed to stimulate NF-kappaB, while phosphatidylcholine-phospholipase C inhibition and alkalization of endolysosomal compartments blocked its activation by TNF-alpha. These data indicate that, while epidermal keratinocytes utilize previously defined, NIK-dependent NF-kappaB pathways, dermal fibroblasts demonstrate unique NIK/TRAF2 independent signal transduction, where both acidic sphingomyelinase and calpain activity act as surrogate mediators for NF-kappaB activation.	Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Inst Mol Med, Dept Dermatol & Cutaneous Surg, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Inst Mol Med, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Stanford Univ, Med Ctr, Div Pulm & Crit Care Med, Stanford, CA 94305 USA; Hop St Louis, INSERM, U532, Skin Res Inst, F-75010 Paris, France	Jefferson University; Jefferson University; Jefferson University; Stanford University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Uitto, J (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Jefferson Inst Mol Med, Dept Dermatol & Cutaneous Surg, Philadelphia, PA 19107 USA.		MAUVIEL, Alain/F-6251-2013	Mauviel, Alain/0000-0002-0438-2793	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041439, R29AR043751] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01-AR41439, R29-AR43751] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adam D, 1996, J BIOL CHEM, V271, P14617, DOI 10.1074/jbc.271.24.14617; Adam-Klages S, 1998, J LEUKOCYTE BIOL, V63, P678, DOI 10.1002/jlb.63.6.678; AdamKlages S, 1996, CELL, V86, P937, DOI 10.1016/S0092-8674(00)80169-5; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baker SJ, 1996, ONCOGENE, V12, P1; Cuervo AM, 1998, MOL BIOL CELL, V9, P1995, DOI 10.1091/mbc.9.8.1995; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Han YQ, 1997, J BIOL CHEM, V272, P9825; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HSU H, 1995, CELL, V81, P491; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Jamaluddin M, 1998, J VIROL, V72, P4849, DOI 10.1128/JVI.72.6.4849-4857.1998; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kretz-Remy C, 1998, J BIOL CHEM, V273, P3180, DOI 10.1074/jbc.273.6.3180; LANOIX J, 1994, ONCOGENE, V9, P841; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; Ling L, 1998, P NATL ACAD SCI USA, V95, P3792, DOI 10.1073/pnas.95.7.3792; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; Pahl HL, 1996, FEBS LETT, V392, P129, DOI 10.1016/0014-5793(96)00800-9; Pahl HL, 1996, J CELL BIOL, V132, P511, DOI 10.1083/jcb.132.4.511; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; SAMBROOK J, 1989, MOL CLONING LAB MANU, P1166; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; Schwandner R, 1998, J BIOL CHEM, V273, P5916, DOI 10.1074/jbc.273.10.5916; Song HY, 1997, P NATL ACAD SCI USA, V94, P9792, DOI 10.1073/pnas.94.18.9792; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; TAN TH, 1992, MOL CELL BIOL, V12, P4067, DOI 10.1128/MCB.12.9.4067; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; Xiao GT, 2000, J BIOL CHEM, V275, P21081, DOI 10.1074/jbc.M002552200; Xie HQ, 1997, J NEUROCHEM, V69, P1020; Yamada T, 2000, J IMMUNOL, V165, P804, DOI 10.4049/jimmunol.165.2.804; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	46	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6214	6224		10.1074/jbc.M004511200	http://dx.doi.org/10.1074/jbc.M004511200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11087727	hybrid			2022-12-25	WOS:000167261000023
J	Walmsley, AR; Zhou, TQ; Borges-Walmsley, MI; Rosen, BP				Walmsley, AR; Zhou, TQ; Borges-Walmsley, MI; Rosen, BP			A kinetic model for the action of a resistance efflux pump	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN P-GLYCOPROTEIN; STIMULATED ATPASE ACTIVITY; NUCLEOTIDE-BINDING SITE; CATALYTIC SUBUNIT; DRUG-RESISTANCE; ARSA ATPASE; MECHANISM; TRANSPORTER; MUTAGENESIS; DOMAINS	ArsA is the catalytic subunit of the arsenical pump, coupling ATP hydrolysis to the efflux of arsenicals through the ArsB membrane protein. It is a paradigm for understanding the structure-function of the nucleotide binding domains (NBD) of medically important efflux pumps, such as P-glycoprotein, because it has two sequence-related, interacting NBD, for which the structure is known. On the basis of a rigorous analysis of the pre-steady-state kinetics of nucleotide binding and hydrolysis, we propose a model in which ArsA alternates between two mutually exclusive conformations as follows: the ArsA(1) conformation in which the A1 site is closed but the A2 site open; and the ArsA(2) conformation, in which the A1 and A2 sites are open and closed, respectively. Antimonite elicits its effects by sequestering ArsA in the ArsA(1) conformation, which catalyzes rapid ATP hydrolysis at the A2 site to drive ArsA between conformations that have high (nucleotide-bound ArsA) and low affinity (nucleotide-free ArsA) for Sb(III). ArsA potentially utilizes this process to sequester Sb(III) from the medium and eject it into the channel of ArsB.	Univ Glasgow, Div Infect & Immun, Glasgow G11 6NU, Lanark, Scotland; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G11 6NU, Lanark, Scotland; Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	University of Glasgow; University of Glasgow; Wayne State University	Walmsley, AR (corresponding author), Univ Glasgow, Div Infect & Immun, Robertson Bldg, Glasgow G11 6NU, Lanark, Scotland.	A.Walmsley@bio.gla.ac.uk	Zhou, Tongqing/A-6880-2010	Zhou, Tongqing/0000-0002-3935-4637; Rosen, Barry P./0000-0002-5230-4271	NIGMS NIH HHS [GM55425] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM055425, R01GM055425] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; BHATTACHARJEE H, 1995, J BIOL CHEM, V270, P11245, DOI 10.1074/jbc.270.19.11245; BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; Conseil G, 1998, P NATL ACAD SCI USA, V95, P9831, DOI 10.1073/pnas.95.17.9831; DEY S, 1995, DRUG TRANSPORT ANTIM, P103; FERSHT A, 1985, ENZYME STRUCTURE MEC, P139; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gatti D, 2000, J BIOL CHEM, V275, P34009, DOI 10.1074/jbc.R000012200; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; JACKSON AP, 1988, BIOCHEM J, V251, P527, DOI 10.1042/bj2510527; KARKARIA CE, 1990, J BIOL CHEM, V265, P7832; KAUR P, 1992, J BIOL CHEM, V267, P19272; Kaur P, 1999, J BIOL CHEM, V274, P25849, DOI 10.1074/jbc.274.36.25849; Kaur P, 1997, J BACTERIOL, V179, P569, DOI 10.1128/jb.179.3.569-575.1997; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; Li JX, 1996, J BIOL CHEM, V271, P25247, DOI 10.1074/jbc.271.41.25247; Li JX, 1998, J BIOL CHEM, V273, P6796, DOI 10.1074/jbc.273.12.6796; Loo TW, 2000, J BIOL CHEM, V275, P19435, DOI 10.1074/jbc.C000222200; LOO TW, 1994, J BIOL CHEM, V269, P7750; LOO TW, 1995, J BIOL CHEM, V270, P22957, DOI 10.1074/jbc.270.39.22957; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Nikaido K, 1999, J BIOL CHEM, V274, P26727, DOI 10.1074/jbc.274.38.26727; Rosen BP, 1999, BBA-BIOMEMBRANES, V1461, P207, DOI 10.1016/S0005-2736(99)00159-5; Senior AE, 1998, ACTA PHYSIOL SCAND, V163, P213; Sharom FJ, 1999, BBA-BIOMEMBRANES, V1461, P327, DOI 10.1016/S0005-2736(99)00166-2; van Veen HW, 1998, BBA-BIOENERGETICS, V1365, P31, DOI 10.1016/S0005-2728(98)00039-5; Vanden Bossche H, 1998, MED MYCOL, V36, P119; Walmsley AR, 1999, J BIOL CHEM, V274, P16153, DOI 10.1074/jbc.274.23.16153; WALMSLEY AR, 1989, ANAL BIOCHEM, V176, P313, DOI 10.1016/0003-2697(89)90315-1; Walmsley AR, 2000, PRACT APPROACH SER, P167; WALMSLEY AR, 2001, IN PRESS BIOCHEMISTR; Zhou TQ, 2000, EMBO J, V19, P4838, DOI 10.1093/emboj/19.17.4838; Zhou TQ, 1997, J BIOL CHEM, V272, P19731, DOI 10.1074/jbc.272.32.19731	34	14	15	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6378	6391		10.1074/jbc.M008105200	http://dx.doi.org/10.1074/jbc.M008105200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096086	hybrid, Green Accepted			2022-12-25	WOS:000167261000043
J	Wolner, BS; Gralla, JD				Wolner, BS; Gralla, JD			TATA-flanking sequences influence the rate and stability of TATA-binding protein and TFIIB binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION REINITIATION RATE; CRYSTAL-STRUCTURE; DNA-BINDING; IN-VITRO; SITE SELECTION; BOX COMPLEX; PROMOTER; TBP; INITIATION	The kinetics of TATA-binding protein (TBP) and TFIIB binding were measured on a series of promoter constructs that had varying sequences within and flanking the TATA box. The flanking sequences were found to influence TBP stability even though they do not contact the protein. This occurs by altering the decay rate rather than the association rate. TFIIB association is accompanied by protein-protein cooperativity as indicated by the simultaneous release of both proteins in challenge experiments. The sequence of the TATA box and the sequences that flank it can influence the kinetics of the TFIIB TBP DNA complex. TFIIB can contribute to tighter TATA binding in two ways. It always slows the decay rate of TBP, but it can also increase the rate of association at promoters with certain combinations of TATA and flanking sequences. The results imply that the interplay between the TATA box and flanking elements leads to variations in the kinetics of preinitiation complex formation that may account for the observed effects of all of these diverse sequences on transcription.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gralla, JD (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA.		Wolner, Branden/A-9615-2015	Wolner, Branden/0000-0003-0021-2073	NIGMS NIH HHS [GM49048, GM07185] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bryant GO, 1996, GENE DEV, V10, P2491, DOI 10.1101/gad.10.19.2491; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; Cho EJ, 1999, J BIOL CHEM, V274, P25807, DOI 10.1074/jbc.274.36.25807; Coleman RA, 1997, P NATL ACAD SCI USA, V94, P7221, DOI 10.1073/pnas.94.14.7221; COULOMBE B, 1994, J BIOL CHEM, V269, P19962; Forget D, 1997, P NATL ACAD SCI USA, V94, P7150, DOI 10.1073/pnas.94.14.7150; Gao YG, 1999, EUR J BIOCHEM, V261, P413, DOI 10.1046/j.1432-1327.1999.00270.x; Grove A, 1998, J MOL BIOL, V282, P731, DOI 10.1006/jmbi.1998.2058; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; Hawkes NA, 1999, J BIOL CHEM, V274, P14337, DOI 10.1074/jbc.274.20.14337; HOOPES BC, 1992, J BIOL CHEM, V267, P11539; Hoopes BC, 1998, J MOL BIOL, V277, P1015, DOI 10.1006/jmbi.1998.1651; HORI R, 1995, P NATL ACAD SCI USA, V92, P6047, DOI 10.1073/pnas.92.13.6047; Huh JR, 1999, BIOCHEM BIOPH RES CO, V256, P45, DOI 10.1006/bbrc.1999.0280; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; Kim TK, 1997, P NATL ACAD SCI USA, V94, P12268, DOI 10.1073/pnas.94.23.12268; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; Lagrange T, 1998, GENE DEV, V12, P34, DOI 10.1101/gad.12.1.34; Lagrange T, 1996, P NATL ACAD SCI USA, V93, P10620, DOI 10.1073/pnas.93.20.10620; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MCCALL M, 1985, J MOL BIOL, V183, P385, DOI 10.1016/0022-2836(85)90009-9; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; Nikolov DB, 1996, P NATL ACAD SCI USA, V93, P4862, DOI 10.1073/pnas.93.10.4862; Oelgeschlager T, 1996, NATURE, V382, P735, DOI 10.1038/382735a0; Parkhurst KM, 1999, J MOL BIOL, V289, P1327, DOI 10.1006/jmbi.1999.2835; Robert F, 1996, J BIOL CHEM, V271, P8517, DOI 10.1074/jbc.271.15.8517; Robert F, 1998, MOL CELL, V2, P341, DOI 10.1016/S1097-2765(00)80278-6; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STARR DB, 1995, J MOL BIOL, V250, P434; Weideman CA, 1997, J MOL BIOL, V271, P61, DOI 10.1006/jmbi.1997.1152; Wolner BS, 1997, J BIOL CHEM, V272, P32301, DOI 10.1074/jbc.272.51.32301; Wolner BS, 2000, MOL CELL BIOL, V20, P3608, DOI 10.1128/MCB.20.10.3608-3615.2000; Yean D, 1997, MOL CELL BIOL, V17, P3809, DOI 10.1128/MCB.17.7.3809; Yean D, 1999, NUCLEIC ACIDS RES, V27, P831, DOI 10.1093/nar/27.3.831	36	26	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 2	2001	276	9					6260	6266		10.1074/jbc.M008273200	http://dx.doi.org/10.1074/jbc.M008273200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	407FF	11096089	hybrid			2022-12-25	WOS:000167261000028
J	Grunewald, K; Hirschberg, J; Hagen, C				Grunewald, K; Hirschberg, J; Hagen, C			Ketocarotenoid biosynthesis outside of plastids in the unicellular green alga Haematococcus pluvialis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	11th International Congress on Photosynthesis	AUG 17-22, 1998	BUDAPEST, HUNGARY				GIROD ROSTAFINSKI VOLVOCALES; SECONDARY CAROTENOIDS; BETA-CAROTENE; ASTAXANTHIN SYNTHESIS; DUNALIELLA-BARDAWIL; FUNCTIONAL-ASPECTS; ESCHERICHIA-COLI; ACCUMULATION; LACUSTRIS; PLANTS	The carotenoid biosynthetic pathway in algae and plants takes place within plastids. In these organelles, carotenoids occur either in a free form or bound to proteins. Under stress, the unicellular green alga Haematococcus pluvialis accumulates secondary carotenoids, mainly astaxanthin esters, in cytoplasmic lipid vesicles up to 4% of its dry mass. It is therefore one of the favored organisms for the biotechnological production of these antioxidative compounds. We have studied the cellular localization and regulation of the enzyme beta -carotene oxygenase in H. pluvialis that catalyzes the introduction of keto functions at position C-4 of the beta -ionone ring of beta -carotene and zeaxanthin, Using immunogold labeling of ultrathin sections and Western blot analysis of cell fractions, we discovered that under inductive conditions, beta -carotene oxygenase was localized both in the chloroplast and in the cytoplasmic lipid vesicles, which are (according to their lipid composition) derived from cytoplasmic membranes. However, p-carotene oxygenase activity was confined to the lipid vesicle compartment, Because an early carotenogenic enzyme in the pathway, phytoene desaturase, was found only in the chloroplast (Grunewald, K,, Eckert, M., Hirschberg, J,, and Hagen, C, (2000) Plant Physiol. 122, 1261-1268), a transport of intermediates from the site of early biosynthetic steps in the chloroplast to the site of oxygenation and accumulation in cytoplasmic lipid vesicles is proposed.	Univ Jena, Inst Gen Bot, D-07743 Jena, Germany; Hebrew Univ Jerusalem, Dept Genet, IL-91904 Jerusalem, Israel	Friedrich Schiller University of Jena; Hebrew University of Jerusalem	Grunewald, K (corresponding author), Univ Jena, Inst Gen Bot, Planetarium 1, D-07743 Jena, Germany.	kay.gruenewald@uni-jena.de	Hagen, Christoph/B-5025-2010; Grünewald, Kay/AAW-3652-2020	Hagen, Christoph/0000-0003-0327-3744; Grünewald, Kay/0000-0002-4788-2691				Boussiba S, 2000, PHYSIOL PLANTARUM, V108, P111, DOI 10.1034/j.1399-3054.2000.108002111x./; Camara B, 1995, INT REV CYTOL, V163, P175, DOI 10.1016/S0074-7696(08)62211-1; Chumpolkulwong N, 1997, BIOTECHNOL LETT, V19, P443, DOI 10.1023/A:1018392010218; Cunningham FX, 1998, ANNU REV PLANT PHYS, V49, P557, DOI 10.1146/annurev.arplant.49.1.557; Eckert M, 1996, CELL TISSUE RES, V284, P401, DOI 10.1007/s004410050601; EICHENBERGER W, 1993, PLANT PHYSIOL BIOCH, V31, P213; Fan L, 1995, PLANT CELL PHYSIOL, V36, P1519; FOLCH J, 1957, J BIOL CHEM, V226, P497; Frank HA, 1996, PHOTOCHEM PHOTOBIOL, V63, P257, DOI 10.1111/j.1751-1097.1996.tb03022.x; Fraser PD, 1998, EUR J BIOCHEM, V252, P229, DOI 10.1046/j.1432-1327.1998.2520229.x; Fraser PD, 1997, J BIOL CHEM, V272, P6128, DOI 10.1074/jbc.272.10.6128; GODIN P, 1954, NATURE, V174, P134, DOI 10.1038/174134a0; Grunewald K, 1997, EUR J PHYCOL, V32, P387, DOI 10.1080/09670269710001737329; Grunewald K, 2000, J APPL BOT-ANGEW BOT, V74, P141; Grunewald K, 2000, PLANT PHYSIOL, V122, P1261, DOI 10.1104/pp.122.4.1261; HAGEN C, 1993, J PHOTOCH PHOTOBIO B, V20, P153, DOI 10.1016/1011-1344(93)80145-Y; HAGEN C, 1994, J PHYCOL, V30, P241, DOI 10.1111/j.0022-3646.1994.00241.x; Hagen C, 2000, J APPL BOT-ANGEW BOT, V74, P137; Hagen C, 2000, EUR J PHYCOL, V35, P75, DOI 10.1017/S0967026299002528; HARKER M, 1995, EUR J PHYCOL, V30, P179, DOI 10.1080/09670269500650961; Hartel H, 2000, P NATL ACAD SCI USA, V97, P10649, DOI 10.1073/pnas.180320497; Hirschberg J., 1998, CAROTENOIDS, V3, P149; HUANG AHC, 1992, ANNU REV PLANT PHYS, V43, P177, DOI 10.1146/annurev.pp.43.060192.001141; KAJIWARA S, 1995, PLANT MOL BIOL, V29, P343, DOI 10.1007/BF00043657; KATZ A, 1995, PLANT PHYSIOL, V108, P1657, DOI 10.1104/pp.108.4.1657; Krishna KB, 1998, J SCI IND RES INDIA, V57, P51; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LICHTENTHALER HK, 1987, METHOD ENZYMOL, V148, P350; Lichtenthaler HK, 1999, ANNU REV PLANT PHYS, V50, P47, DOI 10.1146/annurev.arplant.50.1.47; Linden H, 1999, BBA-GENE STRUCT EXPR, V1446, P203, DOI 10.1016/S0167-4781(99)00088-3; Lorenz RT, 2000, TRENDS BIOTECHNOL, V18, P160, DOI 10.1016/S0167-7799(00)01433-5; LOTAN T, 1995, FEBS LETT, V364, P125, DOI 10.1016/0014-5793(95)00368-J; MAROTTA L, 1984, J IMMUNOL METHODS, V71, P69, DOI 10.1016/0022-1759(84)90207-2; Nishiuchi T, 1998, J PLANT RES, V111, P481, DOI 10.1007/BF02507782; Rabbani S, 1998, PLANT PHYSIOL, V116, P1239, DOI 10.1104/pp.116.4.1239; SANTOS MF, 1984, CYTOLOGIA, V49, P215; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; Sun Z, 1998, P NATL ACAD SCI USA, V95, P11482, DOI 10.1073/pnas.95.19.11482	38	115	139	2	40	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					6023	6029		10.1074/jbc.M006400200	http://dx.doi.org/10.1074/jbc.M006400200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	404RU	11085982	hybrid			2022-12-25	WOS:000167115100082
J	Korotchkina, LG; Patel, MS				Korotchkina, LG; Patel, MS			Probing the mechanism of inactivation of human pyruvate dehydrogenase by phosphorylation of three sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-KETOACID DEHYDROGENASE; ACTIVE-SITE; PIG-HEART; MULTIENZYME COMPLEXES; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; BOVINE KIDNEY; KINASE; COMPONENT; BINDING	Activity of the mammalian pyruvate dehydrogenase complex (PDC) is regulated by phosphorylation-dephosphorylation of three serine residues (designated site 1, Ser-264; site 2, Ser-271; site 3, Ser-203) in the alpha subunit of the pyruvate dehydrogenase (E1) component. Substitutions of the phosphorylation sites were generated by site-directed mutagenesis. Glutamate (S1E) and aspartate (S1D) substitutions at site 1 resulted in the complete loss of PDC activity; however, these mutants were variably active in the decarboxylation and 2,6-dichlorophenolindophenol assays. S1Q had only 3% of wild-type PDC activity. The apparent K-m values for pyruvate increased for the mutants of site 1 when determined in the 2,6-dichlorophenolindophenol assay. The substitutions at sites 2 and 3 caused only moderate reductions in activity in the three assays. S3E had a 27-fold increase in the apparent K-m for thiamine pyrophosphate and 8-fold in crease in the K-i for pyrophosphate. Site 3 was almost completely protected from phosphorylation by thiamine pyrophosphate. The results show that the size rather than negative charge of the substituted amino acid residue affects the active site of E1 and that modification of each of the three serine residues affect the active site in a site-specific manner for its ability to bind the cofactor and substrates.	SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Patel, MS (corresponding author), SUNY Buffalo, Dept Biochem, Sch Med & Biomed Sci, 140 Farber Hall,3435 Main St, Buffalo, NY 14214 USA.	mspatel@buffalo.edu			NIDDK NIH HHS [DK20478] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK020478] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AEvarsson A, 2000, STRUCTURE, V8, P277, DOI 10.1016/S0969-2126(00)00105-2; AEvarsson A, 1999, NAT STRUCT BIOL, V6, P785; ALI MS, 1993, J BIOL CHEM, V268, P22353; ALI MS, 1995, J BIOL CHEM, V270, P4570, DOI 10.1074/jbc.270.9.4570; Baker JC, 2000, J BIOL CHEM, V275, P15773, DOI 10.1074/jbc.M909488199; BERG A, 1996, BIOCH PHYSL THIAMIN, P278; BISSWANGER H, 1981, J BIOL CHEM, V256, P815; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTLER JR, 1977, BIOCHEM BIOPH RES CO, V74, P1667, DOI 10.1016/0006-291X(77)90636-2; CATE RL, 1980, J BIOL CHEM, V255, P7556; COOPER RH, 1974, BIOCHEM J, V143, P625, DOI 10.1042/bj1430625; DAHL HHM, 1987, J BIOL CHEM, V262, P7398; DEAN AM, 1990, SCIENCE, V249, P1044, DOI 10.1126/science.2204110; ESWARAN D, 1995, BBA-PROTEIN STRUCT M, V1252, P203, DOI 10.1016/0167-4838(95)00119-F; Gong XM, 2000, J BIOL CHEM, V275, P13645, DOI 10.1074/jbc.275.18.13645; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Huang BL, 1998, J BIOL CHEM, V273, P17680, DOI 10.1074/jbc.273.28.17680; Huang YJ, 1998, ARCH BIOCHEM BIOPHYS, V352, P263, DOI 10.1006/abbi.1998.0596; KERBEY AL, 1985, BIOCHEM J, V231, P523, DOI 10.1042/bj2310523; KERR DS, 1987, PEDIATR RES, V22, P312, DOI 10.1203/00006450-198709000-00015; Khailova L S, 1977, Biokhimiia, V42, P113; KHAILOVA LS, 1989, ANN NY ACAD SCI, V573, P36, DOI 10.1111/j.1749-6632.1989.tb14985.x; KHAILOVA LS, 1982, BIOCHEM INT, V5, P525; Korotchkina LG, 1999, ARCH BIOCHEM BIOPHYS, V369, P277, DOI 10.1006/abbi.1999.1364; KOROTCHKINA LG, 1995, J BIOL CHEM, V270, P14297, DOI 10.1074/jbc.270.24.14297; KOROTCHKINA LG, 1995, PROTEIN EXPRES PURIF, V6, P79, DOI 10.1006/prep.1995.1011; KOROTCHKINA LG, 1995, FEBS LETT, V364, P185, DOI 10.1016/0014-5793(95)00382-J; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LIU TC, 1995, J BIOL CHEM, V270, P15545, DOI 10.1074/jbc.270.26.15545; Nemerya NS, 1996, FEBS LETT, V394, P96, DOI 10.1016/0014-5793(96)00871-X; OMKUMAR RV, 1994, J BIOL CHEM, V269, P16862; PATEL MS, 1990, FASEB J, V4, P3224, DOI 10.1096/fasebj.4.14.2227213; Popov KM, 1997, ADV SEC MESS PHOSPH, V31, P105; PRATT ML, 1979, BIOCHEM BIOPH RES CO, V91, P289, DOI 10.1016/0006-291X(79)90616-8; PRATT ML, 1979, J BIOL CHEM, V254, P7191; REED LJ, 1974, ACCOUNTS CHEM RES, V7, P40, DOI 10.1021/ar50074a002; ROBINSON BH, 1993, FEBS LETT, V328, P99, DOI 10.1016/0014-5793(93)80973-X; ROCHE TE, 1972, BIOCHEM BIOPH RES CO, V48, P840, DOI 10.1016/0006-291X(72)90684-5; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; SALE GJ, 1982, BIOCHEM J, V206, P221, DOI 10.1042/bj2060221; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEU KFR, 1981, J CLIN INVEST, V67, P1463, DOI 10.1172/JCI110176; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; SUGDEN PH, 1978, BIOCHEM J, V173, P659, DOI 10.1042/bj1730659; SUMEGI B, 1983, EUR J BIOCHEM, V136, P347, DOI 10.1111/j.1432-1033.1983.tb07748.x; Tripatara A, 1999, ARCH BIOCHEM BIOPHYS, V367, P39, DOI 10.1006/abbi.1999.1231; WALSH DA, 1976, BIOCHEM J, V157, P41, DOI 10.1042/bj1570041; WU TL, 1984, BIOCHEMISTRY-US, V23, P221, DOI 10.1021/bi00297a008; Yang DQ, 1997, J BIOL CHEM, V272, P6361, DOI 10.1074/jbc.272.10.6361; YEAMAN SJ, 1978, BIOCHEMISTRY-US, V17, P2364, DOI 10.1021/bi00605a017; ZHAO Y, 1994, J BIOL CHEM, V269, P18583	52	71	76	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5731	5738		10.1074/jbc.M007558200	http://dx.doi.org/10.1074/jbc.M007558200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11092882	hybrid			2022-12-25	WOS:000167115100046
J	Ujvari, A; Aron, R; Eisenhaure, T; Cheng, E; Parag, HA; Smicun, Y; Halaban, R; Hebert, DN				Ujvari, A; Aron, R; Eisenhaure, T; Cheng, E; Parag, HA; Smicun, Y; Halaban, R; Hebert, DN			Translation rate of human tyrosinase determines its N-linked glycosylation level	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; INFLUENZA HEMAGGLUTININ; QUALITY-CONTROL; MEMBRANE-PROTEINS; MAMMALIAN-CELLS; MELANOMA-CELLS; CALNEXIN; ASSOCIATION; GLYCOPROTEINS; CALRETICULIN	Tyrosinase is a type I membrane glycoprotein essential for melanin synthesis. Mutations in tyrosinase lead to albinism due, at least in part, to aberrant retention of the protein in the endoplasmic reticulum and subsequent degradation by the cytosolic ubiquitin-proteasomal pathway. A similar premature degradative fate for wild type tyrosinase also occurs in amelanotic melanoma cells, To understand critical cotranslational events, the glycosylation and rate of translation of tyrosinase was studied in normal melanocytes, melanoma cells, an in vitro cell-free system, and semi-permeabilized cells, Site-directed mutagenesis revealed that all seven N-linked consensus sites are utilized in human tyrosinase, However, glycosylation at Asn-290 (Asn-Gly-Thr-Pro) was suppressed, particularly when translation proceeded rapidly, producing a protein doublet with six or seven N-linked core glycans, The inefficient glycosylation of Asn-290, due to the presence of a proximal Pro, was enhanced in melanoma cells possessing 2-3-foId faster (7.7-10.0 amino acids/s) protein translation rates compared with normal melanocytes (3.5 amino acids/s), Slowing the translation rate with the protein synthesis inhibitor cycloheximide increased the glycosylation efficiency in live cells and in the cell-free system, Therefore, the rate of protein translation can regulate the level of tyrosinase N-linked glycosylation, as well as other potential cotranslational maturation events.	Univ Massachusetts, Dept Biochem & Mol Biol, Program Mol & Cellular Biol, Amherst, MA 01003 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA	University of Massachusetts System; University of Massachusetts Amherst; Yale University	Hebert, DN (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Program Mol & Cellular Biol, Amherst, MA 01003 USA.				NCI NIH HHS [CA78964] Funding Source: Medline; NIAMS NIH HHS [AR41942, AR39848] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041942, R01AR039848] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; Berson JF, 2000, J BIOL CHEM, V275, P12281, DOI 10.1074/jbc.275.16.12281; BIJLMAKERS MJE, 1993, EUR J IMMUNOL, V23, P1305, DOI 10.1002/eji.1830230618; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; BOUCHARD B, 1989, J EXP MED, V169, P2029, DOI 10.1084/jem.169.6.2029; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; Branza-Nichita N, 2000, J BIOL CHEM, V275, P8169, DOI 10.1074/jbc.275.11.8169; Cannon KS, 1996, J BIOL CHEM, V271, P14280, DOI 10.1074/jbc.271.24.14280; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; Dell'Angelica EC, 1999, MOL CELL, V3, P11, DOI 10.1016/S1097-2765(00)80170-7; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; Feldman DE, 2000, CURR OPIN STRUC BIOL, V10, P26, DOI 10.1016/S0959-440X(99)00044-5; Feng LJ, 1999, HUM MOL GENET, V8, P323, DOI 10.1093/hmg/8.2.323; Frydman J, 1999, NAT STRUCT BIOL, V6, P697, DOI 10.1038/10754; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Halaban R, 2000, P NATL ACAD SCI USA, V97, P5889, DOI 10.1073/pnas.97.11.5889; HALABAN R, 1984, ARCH BIOCHEM BIOPHYS, V230, P383, DOI 10.1016/0003-9861(84)90121-8; Halaban R, 1997, P NATL ACAD SCI USA, V94, P6210, DOI 10.1073/pnas.94.12.6210; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; Hebert DN, 1996, EMBO J, V15, P2961, DOI 10.1002/j.1460-2075.1996.tb00659.x; Hebert DN, 1997, J CELL BIOL, V139, P613, DOI 10.1083/jcb.139.3.613; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; HORWITZ MS, 1969, VIROLOGY, V39, P682, DOI 10.1016/0042-6822(69)90006-3; Hovland R, 1999, FEBS LETT, V444, P97, DOI 10.1016/S0014-5793(99)00039-3; Huppa JB, 1997, J EXP MED, V186, P393, DOI 10.1084/jem.186.3.393; Kantheti P, 1998, NEURON, V21, P111, DOI 10.1016/S0896-6273(00)80519-X; KIM JM, 1991, J BIOL CHEM, V266, P14931; King R., 1998, PIGMENTARY SYSTEM PH; KOMFELD R, 1985, ANNU REV BIOCHEM, V54, P631; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LERNER AB, 1949, J BIOL CHEM, V178, P185; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; Molinari M, 2000, SCIENCE, V288, P331, DOI 10.1126/science.288.5464.331; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Netzer WJ, 1997, NATURE, V388, P343, DOI 10.1038/41024; NILSSON I, 1993, J BIOL CHEM, V268, P5798; Oetting WS, 1999, HUM MUTAT, V13, P99, DOI 10.1002/(SICI)1098-1004(1999)13:2<99::AID-HUMU2>3.3.CO;2-3; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; Pan M, 2000, J BIOL CHEM, V275, P27399; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; Petrescu SM, 2000, BIOCHEMISTRY-US, V39, P5229, DOI 10.1021/bi000107z; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; RUPPERT S, 1988, EMBO J, V7, P2715, DOI 10.1002/j.1460-2075.1988.tb03125.x; Spritz RA, 1999, TRENDS GENET, V15, P337, DOI 10.1016/S0168-9525(99)01785-0; TRIPATHI RK, 1992, J BIOL CHEM, V267, P23707; TURCO SJ, 1977, P NATL ACAD SCI USA, V74, P4411, DOI 10.1073/pnas.74.10.4411; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; WILSON R, 1995, BIOCHEM J, V307, P679, DOI 10.1042/bj3070679; WOLIN SL, 1988, EMBO J, V7, P3559, DOI 10.1002/j.1460-2075.1988.tb03233.x; YAMAMOTO H, 1989, JPN J GENET, V64, P121, DOI 10.1266/jjg.64.121	60	64	67	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 23	2001	276	8					5924	5931		10.1074/jbc.M009203200	http://dx.doi.org/10.1074/jbc.M009203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	404RU	11069924	hybrid			2022-12-25	WOS:000167115100070
J	Dietze, EC; Caldwell, LE; Grupin, SL; Mancini, M; Seewaldt, VL				Dietze, EC; Caldwell, LE; Grupin, SL; Mancini, M; Seewaldt, VL			Tamoxifen but not 4-hydroxytamoxifen initiates apoptosis in p53(-) normal human mammary epithelial cells by inducing mitochondrial depolarization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; HUMAN PAPILLOMAVIRUS TYPE-16; PROTEIN-KINASE; INTRACELLULAR CALCIUM; CATALYTIC ACTIVITY; ESTROGEN ACTION; GROWTH ARREST; DEATH; PROLIFERATION; DISEASE	Despite the widespread clinical use of tamoxifen as a breast cancer prevention agent, the molecular mechanism of tamoxifen chemoprevention is poorly understood. Abnormal expression of p53 is felt to be an early event in mammary carcinogenesis. We developed an in vitro model of early breast cancer prevention to investigate how tamoxifen and 4-hydroxytamoxifen may act in normal human mammary epithelial cells (HMECs) that have acutely lost p53 function. p53 function was suppressed by retrovirally mediated expression of the human papillomavirus type 16 E6 protein. Tamoxifen, but not 4-hydroxytamoxifen, rapidly induced apoptosis in p53(-) HMEC-E6 cells as evidenced by characteristic morphologic changes, annexin V binding, and DNA fragmentation. We observed that a decrease in mitochondrial membrane potential, mitochondrial condensation, and caspase activation preceded the morphologic appearance of apoptosis in tamoxifen-treated early passage p53(-) HMEC-E6 cells, p53(-) HMEC-E6 cells rapidly developed resistance to tamoxifen-mediated apoptosis within 10 passages in vitro. Resistance to tamoxifen in late passage p53(-) HMEC-E6 cells correlated with an increase in mitochondrial mass and a lack of mitochondrial depolarization and caspase activation following tamoxifen treatment. We hypothesize that an early event in the induction of apoptosis by tamoxifen involves mitochondrial depolarization and caspase activation, and this may be important for effective chemoprevention.	Duke Univ, Med Ctr, Program Chem Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Med Oncol, Durham, NC 27710 USA; Fred Hutchinson Canc Res Ctr, Program Electron Microscopy, Seattle, WA 98109 USA; Univ Padua, Inst Urol, I-35128 Padua, Italy	Duke University; Duke University; Fred Hutchinson Cancer Center; University of Padua	Seewaldt, VL (corresponding author), Duke Univ, Med Ctr, Program Chem Biol, Box 2628, Durham, NC 27710 USA.	seewa001@mc.duke.edu	Mancini, Mariangela/AAR-2090-2020	Mancini, Mariangela/0000-0001-6766-8767	NATIONAL CANCER INSTITUTE [P30CA016058, R01CA088799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK035816] Funding Source: NIH RePORTER; NCI NIH HHS [5-P30 CA16058, R01 CA88799] Funding Source: Medline; NIDDK NIH HHS [2P30 DK35816-11] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alnemri ES, 1996, CELL, V87, P171, DOI 10.1016/S0092-8674(00)81334-3; Anderson E, 1998, J MAMMARY GLAND BIOL, V3, P23, DOI 10.1023/A:1018718117113; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; BARBARESCHI M, 1992, AM J CLIN PATHOL, V98, P408, DOI 10.1093/ajcp/98.4.408; BOSERMA AWM, 1996, CYTOMETRY, V24, P123; BRUNNER N, 1989, CANCER RES, V49, P1515; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; ETIENNE MC, 1989, BRIT J CANCER, V60, P30, DOI 10.1038/bjc.1989.214; Fabian CJ, 1996, J CELL BIOCHEM, P112; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Friedman ZY, 1998, CANCER INVEST, V16, P391, DOI 10.3109/07357909809115779; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hansen R, 1997, CURR OPIN GENET DEV, V7, P46, DOI 10.1016/S0959-437X(97)80108-6; Harbeck N, 1998, ANTICANCER RES, V18, P2187; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Hawkins DS, 1996, CANCER RES, V56, P892; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HOTZ MA, 1994, CYTOMETRY, V15, P237, DOI 10.1002/cyto.990150309; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Jordan V C, 1982, Breast Cancer Res Treat, V2, P123, DOI 10.1007/BF01806449; KARNOVSKY MJ, 1965, J CELL BIOL, V27, pA137; Kawai T, 1999, ONCOGENE, V18, P3471, DOI 10.1038/sj.onc.1202701; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KYPRIANOU N, 1991, CANCER RES, V51, P162; LANGANFAHEY SM, 1990, EUR J CANCER, V26, P883, DOI 10.1016/0277-5379(90)90191-U; Lanni JS, 1997, P NATL ACAD SCI USA, V94, P9679, DOI 10.1073/pnas.94.18.9679; Levesque MA, 1998, J CLIN ONCOL, V16, P2641, DOI 10.1200/JCO.1998.16.8.2641; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; MACCALLUM J, 1999, BRIT J CANCER, V82, P1629; MAFTAH A, 1989, BIOCHEM BIOPH RES CO, V164, P185, DOI 10.1016/0006-291X(89)91700-2; Mancini M, 1997, J CELL BIOL, V138, P449, DOI 10.1083/jcb.138.2.449; Micoli KJ, 2000, J BIOL CHEM, V275, P1233, DOI 10.1074/jbc.275.2.1233; MORLEY P, 1992, ENDOCRINOLOGY, V131, P1305, DOI 10.1210/en.131.3.1305; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; PERRY RR, 1995, ANN SURG ONCOL, V2, P238, DOI 10.1007/BF02307030; ROBERTSON DW, 1982, J STEROID BIOCHEM, V16, P1, DOI 10.1016/0022-4731(82)90137-6; Rohan TE, 1998, JNCI-J NATL CANCER I, V90, P1262, DOI 10.1093/jnci/90.17.1262; RUSSELL WC, 1975, NATURE, V253, P461, DOI 10.1038/253461a0; Saikumar P, 1999, AM J MED, V107, P489, DOI 10.1016/S0002-9343(99)00259-4; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SEEWALDT VL, 1995, CELL GROWTH DIFFER, V6, P1077; Seewaldt VL, 1997, CELL GROWTH DIFFER, V8, P631; Seewaldt VL, 1997, EXP CELL RES, V236, P16, DOI 10.1006/excr.1997.3694; SMILEY ST, 1991, P NATL ACAD SCI USA, V88, P3671, DOI 10.1073/pnas.88.9.3671; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Wahl AF, 1996, NAT MED, V2, P72, DOI 10.1038/nm0196-72; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; Wolf BB, 1999, J BIOL CHEM, V274, P20049, DOI 10.1074/jbc.274.29.20049; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; [No title captured]	55	61	67	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5384	5394		10.1074/jbc.M007915200	http://dx.doi.org/10.1074/jbc.M007915200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11094056	hybrid			2022-12-25	WOS:000168484300114
J	Shen, BQ; Lee, DY; Cortopassi, KM; Damico, LA; Zioncheck, TF				Shen, BQ; Lee, DY; Cortopassi, KM; Damico, LA; Zioncheck, TF			Vascular endothelial growth factor KDR receptor signaling potentiates tumor necrosis factor-induced tissue factor expression in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PERMEABILITY FACTOR; KDR/FLK-1 RECEPTOR; FACTOR-ALPHA; TNF-ALPHA; FLK-1/KDR ACTIVATION; MITOGENIC ACTIVITY; GENE-EXPRESSION; TYROSINE KINASE; UP-REGULATION	Vascular endothelial growth factor (VEGF) and tumor necrosis factor-alpha (TNF-alpha) have been shown to synergistically increase tissue factor (TF) expression in endothelial cells; however, the role of the VEGF receptors (KDR, Flt-1, and neuropilin) in this process is unclear. Here we report that VEGF binding to the KDR receptor is necessary and sufficient for the potentiation of TNF-induced TF expression in human umbilical vein endothelial cells. TF expression was evaluated by Western blot analysis and fluorescence-activated cell sorting. In the absence of TNF-alpha, wild-type VEGF- or KDR receptor-selective variants induced an approximate 7-fold increase in total TF expression. Treatment with TNF alone produced an approximate 110-fold increase in total TF expression, whereas coincubation of TNF-alpha with wild-type VEGF- or KDR-selective variants resulted in an approximate 250-fold increase in TF expression. VEGF lacking the heparin binding domain was also able to potentiate TF expression, indicating that heparin-sulfate proteoglycan or neuropilin binding is not required for TF up-regulation. Neither placental growth factor nor an Flt-1-selective variant was capable of inducing TF expression in the presence or absence of TNF, Inhibition of protein-tyrosine kinase or protein kinase C activity significantly blocked the TNF/VEGF potentiation of TF up-regulation, whereas phorbol 12-myristate 13-acetate, a protein kinase C activator, increased TF expression. These data demonstrate that KDR receptor signaling governs both VEGF-induced TF expression and the potentiation of TNF-induced up-regulation of TF.	Genentech Inc, Dept Metab & Pharmacokinet, S San Francisco, CA 94080 USA	Roche Holding; Genentech	Zioncheck, TF (corresponding author), Genentech Inc, Dept Metab & Pharmacokinet, MS 70,1 DNA Way, S San Francisco, CA 94080 USA.							Abdulkadir SA, 2000, HUM PATHOL, V31, P443, DOI 10.1053/hp.2000.6547; Abe K, 1999, P NATL ACAD SCI USA, V96, P8663, DOI 10.1073/pnas.96.15.8663; Al-Saady NM, 1999, HEART, V81, P134, DOI 10.1136/hrt.81.2.134; BREIER G, 1992, DEVELOPMENT, V114, P521; Camera M, 1999, ARTERIOSCL THROM VAS, V19, P531, DOI 10.1161/01.ATV.19.3.531; Camerer E, 2000, J BIOL CHEM, V275, P6580, DOI 10.1074/jbc.275.9.6580; Carmeliet P, 1997, ANN NY ACAD SCI, V811, P191, DOI 10.1111/j.1749-6632.1997.tb52002.x; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Clauss M, 1996, FEBS LETT, V390, P334, DOI 10.1016/0014-5793(96)00690-4; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; CONNOLLY DT, 1989, J CLIN INVEST, V84, P1470, DOI 10.1172/JCI114322; CONNOLLY DT, 1991, J CELL BIOCHEM, V47, P219, DOI 10.1002/jcb.240470306; Decoster E, 1998, J CELL BIOL, V143, P2057, DOI 10.1083/jcb.143.7.2057; FERRARA N, 1992, ENDOCR REV, V13, P18, DOI 10.1210/er.13.1.18; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Fuh G, 2000, J BIOL CHEM, V275, P26690; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Gluzman-Poltorak Z, 2000, J BIOL CHEM, V275, P18040, DOI 10.1074/jbc.M909259199; GOSPODAROWICZ D, 1989, P NATL ACAD SCI USA, V86, P7311, DOI 10.1073/pnas.86.19.7311; Guo DQ, 2000, J BIOL CHEM, V275, P11216, DOI 10.1074/jbc.275.15.11216; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; JAKEMAN LB, 1993, ENDOCRINOLOGY, V133, P848, DOI 10.1210/en.133.2.848; Kanno S, 2000, ONCOGENE, V19, P2138, DOI 10.1038/sj.onc.1203533; KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Koolwijk P, 1996, J CELL BIOL, V132, P1177, DOI 10.1083/jcb.132.6.1177; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; Li DY, 1999, CARDIOVASC RES, V42, P805, DOI 10.1016/S0008-6363(98)00342-3; LUPIA E, 1996, EUR J IMMUNOL, V26, P12690; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; MILES DW, 1994, INT J CANCER, V56, P777, DOI 10.1002/ijc.2910560603; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Patterson C, 1996, J CLIN INVEST, V98, P490, DOI 10.1172/JCI118816; Pendurthi UR, 1997, P NATL ACAD SCI USA, V94, P12598, DOI 10.1073/pnas.94.23.12598; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Sato Y, 1996, THROMB HAEMOSTASIS, V75, P389; Sawano A, 1996, CELL GROWTH DIFFER, V7, P213; SCHWEIKI D, 1993, J CLIN INVEST, V91, P2235; SENGER DR, 1986, CANCER RES, V46, P5629; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Shen BQ, 1999, J BIOL CHEM, V274, P33057, DOI 10.1074/jbc.274.46.33057; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wellner M, 1999, ARTERIOSCL THROM VAS, V19, P178, DOI 10.1161/01.ATV.19.1.178; Xia P, 1996, J CLIN INVEST, V98, P2018, DOI 10.1172/JCI119006; ZHANG YM, 1994, J CLIN INVEST, V94, P1320, DOI 10.1172/JCI117451; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871; Zucker S, 1998, INT J CANCER, V75, P780, DOI 10.1002/(SICI)1097-0215(19980302)75:5<780::AID-IJC19>3.3.CO;2-N	54	38	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5281	5286		10.1074/jbc.M007969200	http://dx.doi.org/10.1074/jbc.M007969200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11058594	hybrid			2022-12-25	WOS:000168484300100
J	Snyder, SR; Wang, J; Waring, JF; Ginder, GD				Snyder, SR; Wang, J; Waring, JF; Ginder, GD			Identification of CCAAT displacement protein (CDP/cut) as a locus-specific repressor of major histocompatibility complex gene expression in human tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I GENE; MHC CLASS-I; CUT HOMEODOMAIN PROTEIN; NEGATIVE REGULATORY ELEMENT; DOWN-REGULATION; HLA-E; BINDING-FACTOR; TRANSCRIPTIONAL REPRESSOR; LYMPHOCYTE RECOGNITION; MESSENGER-RNA	Human major histocompatibility (MHC) class I antigen expression is important in controlling the metastatic growth of malignant tumors. Locus-specific downregulation of MHC class I gene expression is frequently observed in human tumors, leading to decreased susceptibility to cytotoxic T-cell-mediated lysis. The mechanism of this down-regulation is incompletely understood. Here, we describe the identification of human CCAAT displacement protein (CDP/cut) as a locus-specific repressor of HLA-B and C gene expression. Transient and stable transfections in HeLa and K562 cells demonstrated the presence of a repressor element 650 base pairs upstream of the first exon of HLA-B7. A specific binding complex with the HLA-B7 and Cw2 repressor elements was demonstrated by EMSA. Formation of the ERISA complex was inhibited specifically with polyclonal antiserum to human CDP/cut, demonstrating that CDP/cut binds the HLA-B7 repressor element. The corresponding region of the HLA-A2 promoter neither repressed HLA-A2 gene expression nor bound CDP/cut. Overexpression of CDP/cut in cell lines deficient in CDP/ cub resulted in a nearly 4-fold repression of reporter constructs containing the HLA-B7 repressor element but not the corresponding region of the HLA-A2 promoter. Repression of HLA-B and C gene expression by CDP/cut does not involve displacement of NF-Y, nor is CDP/cut associated with the histone deacetylase HDAC1 when bound to the HLA-B7 repressor element. To our knowledge, these results identify CDP/cut as the first example of a locus-specific repressor of MHC class I gene transcription in human tumor cells.	Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Internal Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Med Coll Virginia, Dept Human Genet, Richmond, VA 23298 USA; Univ Minnesota, Inst Human Genet, Minneapolis, MN 55455 USA	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University; University of Minnesota System; University of Minnesota Twin Cities	Snyder, SR (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Massey Canc Ctr, Richmond, VA 23298 USA.	ssnyder@hsc.vsc.edu			NATIONAL CANCER INSTITUTE [R01CA045634] Funding Source: NIH RePORTER; NCI NIH HHS [R01-CA45634] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ai WD, 1999, J VIROL, V73, P4220, DOI 10.1128/JVI.73.5.4220-4229.1999; Anichini A, 1999, J EXP MED, V190, P651, DOI 10.1084/jem.190.5.651; Antes TJ, 2000, J BIOL CHEM, V275, P26649, DOI 10.1074/jbc.M002852200; AUFIERO B, 1994, P NATL ACAD SCI USA, V91, P7757, DOI 10.1073/pnas.91.16.7757; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BLOCHLINGER K, 1988, NATURE, V333, P629, DOI 10.1038/333629a0; Braud VM, 1998, NATURE, V391, P795, DOI 10.1038/35869; Brooks AG, 1999, J IMMUNOL, V162, P305; BROWN RB, 1993, INFECT DIS CLIN PRAC, V2, P163, DOI 10.1097/00019048-199305000-00001; Coqueret O, 1998, EMBO J, V17, P4680, DOI 10.1093/emboj/17.16.4680; Cormier JN, 1999, INT J CANCER, V80, P781, DOI 10.1002/(SICI)1097-0215(19990301)80:5<781::AID-IJC24>3.0.CO;2-A; COWAN EP, 1985, P NATL ACAD SCI USA, V82, P4490, DOI 10.1073/pnas.82.13.4490; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DOYLE A, 1985, J EXP MED, V161, P1135, DOI 10.1084/jem.161.5.1135; DRIGGERS PH, 1992, NUCLEIC ACIDS RES, V20, P2533, DOI 10.1093/nar/20.10.2533; DUFORT D, 1994, MOL CELL BIOL, V14, P4251, DOI 10.1128/MCB.14.6.4251; FLANAGAN JR, 1991, P NATL ACAD SCI USA, V88, P3145, DOI 10.1073/pnas.88.8.3145; Fromm SV, 1998, J BIOL CHEM, V273, P15209, DOI 10.1074/jbc.273.24.15209; Gobin SJP, 1997, IMMUNITY, V6, P601, DOI 10.1016/S1074-7613(00)80348-9; Gustafson KS, 1996, J BIOL CHEM, V271, P20035, DOI 10.1074/jbc.271.33.20035; HARADA R, 1995, MOL CELL BIOL, V15, P129, DOI 10.1128/MCB.15.1.129; HENSELING U, 1990, MOL CELL BIOL, V10, P4100, DOI 10.1128/MCB.10.8.4100; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jackson RJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P290, DOI 10.1006/abbi.1999.1459; Johnsen A, 1998, CANCER RES, V58, P3660; KATOH S, 1990, EMBO J, V9, P127, DOI 10.1002/j.1460-2075.1990.tb08088.x; KhannaGupta A, 1997, BLOOD, V90, P2784, DOI 10.1182/blood.V90.7.2784.2784_2784_2795; Kim EC, 1997, CELL GROWTH DIFFER, V8, P1329; Last TJ, 1998, GENE, V221, P267, DOI 10.1016/S0378-1119(98)00415-6; LEBOUTEILLER P, 1994, CRIT REV IMMUNOL, V14, P89, DOI 10.1615/CritRevImmunol.v14.i2.10; Lee N, 1998, P NATL ACAD SCI USA, V95, P5199, DOI 10.1073/pnas.95.9.5199; Leibson PJ, 1998, IMMUNITY, V9, P289, DOI 10.1016/S1074-7613(00)80611-1; Li S, 1999, J BIOL CHEM, V274, P7803, DOI 10.1074/jbc.274.12.7803; LIEVENS PMJ, 1995, J BIOL CHEM, V270, P12745, DOI 10.1074/jbc.270.21.12745; LIU XH, 1994, ONCOGENE, V9, P2183; MAGUIRE JE, 1992, MOL CELL BIOL, V12, P3078, DOI 10.1128/MCB.12.7.3078; Mailly F, 1996, MOL CELL BIOL, V16, P5346; MANSKY P, 1994, J IMMUNOL, V153, P5082; Mantovani R, 1999, GENE, V239, P15, DOI 10.1016/S0378-1119(99)00368-6; MARINCOLA FM, 1994, J IMMUNOL, V153, P1225; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; Mavria G, 1998, BIOCHEM J, V330, P155, DOI 10.1042/bj3300155; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MOLLER P, 1987, INT J CANCER, V40, P32, DOI 10.1002/ijc.2910400107; Moon NS, 2000, J BIOL CHEM, V275, P31325, DOI 10.1074/jbc.M002912200; NEUFELD EJ, 1992, NAT GENET, V1, P50, DOI 10.1038/ng0492-50; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; O'Connor MJ, 2000, J VIROL, V74, P401, DOI 10.1128/JVI.74.1.401-410.2000; PLOEGH HL, 1981, CELL, V24, P287, DOI 10.1016/0092-8674(81)90318-4; PROFFITT JL, 1994, NUCLEIC ACIDS RES, V22, P4779, DOI 10.1093/nar/22.22.4779; RESTIFO NP, 1993, J IMMUNOTHER, V14, P182, DOI 10.1097/00002371-199310000-00004; RIVOLTINI L, 1995, CANCER RES, V55, P3149; Saji M, 1997, J BIOL CHEM, V272, P20096, DOI 10.1074/jbc.272.32.20096; SCHOUTEN GJ, 1995, EMBO J, V14, P1498, DOI 10.1002/j.1460-2075.1995.tb07136.x; Singal R, 1997, P NATL ACAD SCI USA, V94, P13724, DOI 10.1073/pnas.94.25.13724; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SKALNIK DG, 1991, J BIOL CHEM, V266, P16736; SOONG TW, 1992, J IMMUNOL, V149, P2008; SOONG TW, 1991, INT J CANCER, P131; Speiser DE, 1999, J EXP MED, V190, P775, DOI 10.1084/jem.190.6.775; SRIVASTAVA R, 1985, IMMUNOL REV, V84, P93, DOI 10.1111/j.1600-065X.1985.tb01127.x; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; TANAKA K, 1985, SCIENCE, V228, P26, DOI 10.1126/science.3975631; Teerawatanasuk N, 1999, J NEUROCHEM, V72, P29, DOI 10.1046/j.1471-4159.1999.0720029.x; Travers P J, 1982, Natl Cancer Inst Monogr, V60, P175; van den Elsen PJ, 1998, IMMUNOGENETICS, V48, P208, DOI 10.1007/s002510050425; VANTVEER LJ, 1993, EMBO J, V12, P195, DOI 10.1002/j.1460-2075.1993.tb05645.x; Wang ZY, 1999, MOL CELL BIOL, V19, P284; WARING JF, 1995, J BIOL CHEM, V270, P12276, DOI 10.1074/jbc.270.20.12276; WEISSMAN JD, 1991, MOL CELL BIOL, V11, P4217, DOI 10.1128/MCB.11.8.4217; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Zhu Q, 2000, J VIROL, V74, P6348, DOI 10.1128/JVI.74.14.6348-6357.2000	74	13	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5323	5330		10.1074/jbc.M009454200	http://dx.doi.org/10.1074/jbc.M009454200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11084046	hybrid			2022-12-25	WOS:000168484300106
J	Ye, JP; Zeidler, P; Young, SH; Martinez, A; Robinson, VA; Jones, W; Baron, P; Shi, XL; Castranova, V				Ye, JP; Zeidler, P; Young, SH; Martinez, A; Robinson, VA; Jones, W; Baron, P; Shi, XL; Castranova, V			Activation of mitogen-activated protein kinase p38 and extracellular signal-regulated kinase is involved in glass fiber-induced tumor necrosis factor-alpha production in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ALVEOLAR MACROPHAGES; GENE-EXPRESSION; NUCLEAR FACTOR; T-CELLS; LENGTH; PROMOTER; TRANSCRIPTION; CYTOKINES; BINDING	In a previous study, we demonstrated that the length of glass fibers was a critical determinant of fiber potency in induction of tumor necrosis factor (TNF)-alpha and that activation of NF-kappaB was an important factor in this response. In the present study, we analyzed the role of mitogen-activated protein (MAP) kinases in the induction of TNF-alpha by glass fibers. Glass fibers induced phosphorylation of MAP kinases, p38, and ERK in primary rat alveolar macrophages, and this phosphorylation was associated with TNF-alpha gene expression. Long fibers were more potent than short fibers in activation of MAP kinases. Results from mechanistic analysis support that MAP kinases activate transcription factor c-Jun. The activated c-Jun acts on the TNF-alpha gene promoter through two binding sites, the cyclic AMP response element and the activator protein 1-binding site. These results suggest that in addition to the NF-kappaB pathway for TNF-alpha production, glass fibers are able to activate c-Jun through MAP kinase pathways that lead to induction of TNF-gamma expression.	NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA; NIOSH, Div Resp Dis Studies, Morgantown, WV 26505 USA; Div Appl Res & Technol, Cincinnati, OH 45226 USA	Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH); Centers for Disease Control & Prevention - USA; National Institute for Occupational Safety & Health (NIOSH)	Castranova, V (corresponding author), NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA.	vic1@cdc.gov	Ye, Jianping/N-1998-2017; Shi, Xianglin/B-8588-2012	Ye, Jianping/0000-0003-3875-365X; 				ARANY Z, 1994, CELL, V77, P799, DOI 10.1016/0092-8674(94)90127-9; ARIAS J, 1994, NATURE, V370, P226, DOI 10.1038/370226a0; BARON PA, 1994, AEROSOL SCI TECH, V21, P179, DOI 10.1080/02786829408959707; Blake T, 1998, J TOXICOL ENV HEAL A, V54, P243; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; Castranova V, 1996, J TOXICOL ENV HEALTH, V49, P357; CASTRANOVA V, 1991, TOXICOL APPL PHARM, V108, P242, DOI 10.1016/0041-008X(91)90115-U; CASTRANOVA V, 1992, P 16 COTT DUST RES C, P251; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Davis RJ, 1999, BIOCHEM SOC SYMP, P1; Deye GJ, 1999, AEROSOL SCI TECH, V30, P420, DOI 10.1080/027868299304471; Ding M, 1999, CANCER RES, V59, P1884; Ding M, 1999, J BIOL CHEM, V274, P30611, DOI 10.1074/jbc.274.43.30611; DRISCOLL KE, 1990, AM J RESP CELL MOL, V2, P381, DOI 10.1165/ajrcmb/2.4.381; Falvo JV, 2000, P NATL ACAD SCI USA, V97, P3925, DOI 10.1073/pnas.97.8.3925; Falvo JV, 2000, MOL CELL BIOL, V20, P2239, DOI 10.1128/MCB.20.6.2239-2247.2000; GAULDIE J, 1993, THORAX, V48, P931, DOI 10.1136/thx.48.9.931; Hazzalin CA, 1997, ONCOGENE, V15, P2321, DOI 10.1038/sj.onc.1201403; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; LEITMAN DC, 1991, J BIOL CHEM, V266, P9343; LEVINE SJ, 1995, J INVEST MED, V43, P241; Luoto K, 1995, ENVIRON RES, V70, P51, DOI 10.1006/enrs.1995.1046; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Martinet Y, 1996, ARCH TOX S, V18, P127; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; RHOADES KL, 1992, J BIOL CHEM, V267, P22102; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tsai EY, 1996, MOL CELL BIOL, V16, P5232; Tsai EY, 1996, MOL CELL BIOL, V16, P459; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Ye JP, 1999, AM J PHYSIOL-LUNG C, V276, pL426, DOI 10.1152/ajplung.1999.276.3.L426	35	22	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 16	2001	276	7					5360	5367		10.1074/jbc.M008814200	http://dx.doi.org/10.1074/jbc.M008814200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	428WH	11087751	hybrid			2022-12-25	WOS:000168484300111
J	Gao, DX; McHenry, CS				Gao, DX; McHenry, CS			tau binds and organizes Escherichia coli replication proteins through distinct domains - Domain IV, located within the unique C terminus of tau, binds the replication fork helicase, Dnab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III HOLOENZYME; GAMMA-SUBUNIT; PURIFICATION; ALPHA; MODEL	Interaction between the tau subunit of the DNA polymerase III holoenzyme and the DnaB helicase is critical for coupling the replicase and the primosomal apparatus at the replication fork (Kim, S., Dallmann, H. G., McHenry, C. S., and Marians, K. J. (1996) Cell 84, 643-650). In the preceding manuscript, we reported the identification of five putative structural domains within the tau subunit (Gao, D., and McHenry, C, (2000) J. Biol, Chem, 275, 4433-4440). As part of our systematic effort to assign functions to each of these domains, we expressed a series of truncated, biotin-tagged tau fusion proteins and determined their ability to bind DnaB by surface plasmon resonance on streptavidin-coated surfaces. Only tau fusion proteins containing domain IV bound DnaB, The DnaB-binding region was further limited to a highly basic 66-amino acid residue stretch within domain TV. Unlike the binding of immobilized tau (4) to the DnaB hexamer, the binding of monomeric domain IV to DnaB(6) was dependent upon the density of immobilized domain IV, indicating that DnaB(6) is bound by more than one (tau) protomer, This observation implies that both the leading and lagging strand polymerases are tethered to the DnaB helicase via dimeric tau, These double tethers of the leading and lagging strand polymerases proceeding through the tau-tau link and an additional tau -DnaB link are likely important for the dynamic activities of the replication fork.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Program Mol Biol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gao, DX (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.				NIGMS NIH HHS [GM36255] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036255] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; Cull MG, 1995, METHOD ENZYMOL, V262, P22; Dallmann HG, 2000, J BIOL CHEM, V275, P15512, DOI 10.1074/jbc.M909257199; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gao DX, 2001, J BIOL CHEM, V276, P4433, DOI 10.1074/jbc.M009828200; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim DR, 1996, J BIOL CHEM, V271, P20690, DOI 10.1074/jbc.271.34.20690; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; MCHENRY CS, 1991, J BIOL CHEM, V266, P19127; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1989, MOL MECH DNA REPLICA, P115; Muller KM, 1998, ANAL BIOCHEM, V261, P149, DOI 10.1006/abio.1998.2725; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; SANMARTIN MC, 1995, J STRUCT BIOL, V114, P167, DOI 10.1006/jsbi.1995.1016; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; Yu X, 1996, J MOL BIOL, V259, P7, DOI 10.1006/jmbi.1996.0297; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	21	76	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					4441	4446		10.1074/jbc.M009830200	http://dx.doi.org/10.1074/jbc.M009830200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11078744	Green Submitted, hybrid			2022-12-25	WOS:000166921200094
J	Wu, YF; Xu, B; Koenig, RJ				Wu, YF; Xu, B; Koenig, RJ			Thyroid hormone response element sequence and the recruitment of retinoid X receptors for thyroid hormone responsiveness	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION FUNCTION AF-2; LIGAND-BINDING DOMAIN; NUCLEAR RECEPTORS; TRANSACTIVATION DOMAIN; DEPENDENT ACTIVATION; TRANSCRIPTIONAL ENHANCEMENT; SACCHAROMYCES-CEREVISIAE; GLUCOCORTICOID RECEPTOR; CO-REPRESSOR; GENE	Thyroid hormone receptors (TRs) are transcription factors that bind to thyroid hormone response elements (TREs) in the regulatory regions of target genes. TRs are thought to activate transcription primarily as heterodimers with retinoid X receptors (RXRs), with RXR binding upstream to the two directly repeated half-sites in a typical TRE. However, given that TRs and RXRs prefer to bind to different DNA sequences (T(A/G)AGGTCA and GGGGTCA), we postulate that only certain TREs require RXR-TR heterodimerization, depending on the TRE sequence. We have tested this hypothesis by comparing in Saccharomyces cerevisiae the functional activity of TR +/- RXR on 10 naturally occurring mammalian TREs. S. cerevisiae was used as a model system because yeast lack endogenous nuclear receptors and thus can be manipulated to express TRs and/or RXRs. We first studied ligand-independent reporter gene activation, which reflects the activity of the activator function 1 (AF-1) domain. The 10 TREs formed a continuous spectrum from being fully dependent on RXR for TR AF-1 activity to being essentially independent of RXR, Relative independence of RXR generally was seen when the TRE upstream half-site has a TA or TG 5' to the core hexamer, Gel mobility shift assays revealed that functional independence of RXR correlates with the strong binding of TR alone, whereas more RXR dependence correlates with higher binding of RXR-TR heterodimers. Restoration of ligand-dependent (AF-2 domain) reporter gene activation was achieved by expression of the coactivator TIF2. This ligand-induced stimulation was stronger in the presence of TR alone than with RXR plus TR, suggesting a preference for TIF2 activation of TR homodimers. Overall the data support the notion that the TRE sequence plays an important role in determining the nuclear hormone receptor and coactivator requirements for TR action.	Univ Michigan, Med Ctr, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Koenig, RJ (corresponding author), Univ Michigan, Med Ctr, Div Endocrinol & Metab, 5560 MSRB-2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044155] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44155] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BANIAHMAD C, 1995, MOL ENDOCRINOL, V9, P34, DOI 10.1210/me.9.1.34; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BRAELL WA, 1995, DYNA QUANT APPL 2; BRENT GA, 1992, MOL ENDOCRINOL, V6, P502, DOI 10.1210/me.6.4.502; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CARR FE, 1983, J CLIN INVEST, V72, P154, DOI 10.1172/JCI110953; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; DESVERGNE B, 1991, J BIOL CHEM, V266, P1008; Feng X, 2000, MOL ENDOCRINOL, V14, P947, DOI 10.1210/me.14.7.947; Gaudon C, 1999, EMBO J, V18, P2229, DOI 10.1093/emboj/18.8.2229; Glass CK, 2000, GENE DEV, V14, P121; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HARTONG R, 1994, J BIOL CHEM, V269, P13021; Henriksson A, 1997, MOL CELL BIOL, V17, P3065, DOI 10.1128/MCB.17.6.3065; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HSU JH, 1995, ENDOCRINOLOGY, V136, P421, DOI 10.1210/en.136.2.421; KATZ RW, 1993, J BIOL CHEM, V268, P19392; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KOENIG RJ, 1987, P NATL ACAD SCI USA, V84, P5670, DOI 10.1073/pnas.84.16.5670; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; OHASHI H, 1991, BIOCHEM BIOPH RES CO, V178, P1167, DOI 10.1016/0006-291X(91)91015-5; OLeary KA, 1997, MOL PHARMACOL, V52, P46, DOI 10.1124/mol.52.1.46; Olson DP, 1997, J BIOL CHEM, V272, P9907; ONATE SA, 1995, SCIENCE, V270, P1354; QI JS, 1995, MOL CELL BIOL, V15, P1817; RABELO R, 1995, ENDOCRINOLOGY, V136, P1003, DOI 10.1210/en.136.3.1003; RASTINEJAD F, 1995, NATURE, V375, P203, DOI 10.1038/375203a0; Reynolds A., 1997, CURRENT PROTOCOLS MO; SPANJAARD RA, 1991, P NATL ACAD SCI USA, V88, P8587, DOI 10.1073/pnas.88.19.8587; SUBAUSTE JS, 1994, J BIOL CHEM, V269, P30232; Thurmond DC, 1998, J BIOL CHEM, V273, P15373, DOI 10.1074/jbc.273.25.15373; TONE Y, 1994, J BIOL CHEM, V269, P31157; TOYODA N, 1995, MOL CELL BIOL, V15, P5100; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; VOZ ML, 1991, J BIOL CHEM, V266, P13397; Walfish PG, 1997, P NATL ACAD SCI USA, V94, P3697, DOI 10.1073/pnas.94.8.3697; Wilkinson JR, 1997, J BIOL CHEM, V272, P23824, DOI 10.1074/jbc.272.38.23824; WILLIAMS GR, 1994, ENDOCRINOLOGY, V134, P1888, DOI 10.1210/en.134.4.1888; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; YANG YZ, 1995, ENDOCRINOLOGY, V136, P2896, DOI 10.1210/en.136.7.2896; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	50	42	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 9	2001	276	6					3929	3936		10.1074/jbc.M006743200	http://dx.doi.org/10.1074/jbc.M006743200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	401HB	11084025	hybrid			2022-12-25	WOS:000166921200029
J	Rodda, S; Sharma, S; Scherer, M; Chapman, G; Rathjen, P				Rodda, S; Sharma, S; Scherer, M; Chapman, G; Rathjen, P			CRTR-1, a developmentally regulated transcriptional repressor related to the CP2 family of transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MOLECULAR-CLONING; DNA-BINDING; EXPRESSION; GENE; PROTEIN; PROMOTER; INVITRO; KIDNEY; DOMAIN	CP2-related proteins comprise a family of DNA-binding transcription factors that are generally activators of transcription and expressed ubiquitously. We reported a differential display polymerase chain reaction fragment, Psc2, which was expressed in a regulated fashion in mouse pluripotent cells in vitro and in vivo. Here, we report further characterization of the Psc2 cDNA and function. The Psc2 cDNA contained an open reading frame homologous to CP2 family proteins. Regions implicated in DNA binding and oligomeric complex formation, but not transcription activation, were conserved. Psc2 expression in vivo during embryogenesis and in the adult mouse demonstrated tight spatial and temporal regulation, with the highest levels of expression in the epithelial lining of distal convoluted tubules in embryonic and adult kidneys. Functional analysis demonstrated that PSC2 repressed transcription 2.5-15-fold when bound to a heterologous promoter in ES, 293T, and COS-l cells. The N-terminal 52 amino acids of PSC2 were shown to be necessary and sufficient for this activity and did not share obvious homology with reported repressor motifs. These results represent the first report of a CP2 family member that is expressed in a developmentally regulated fashion in vivo and that acts as a direct repressor of transcription. Accordingly, the protein has been named CP2-Related Transcriptional Repressor-1 (CRTR-1).	Univ Adelaide, ARC Special Res Ctr Mol Genet Dev, Adelaide, SA 5005, Australia; Univ Adelaide, Dept Mol Biosci, Adelaide, SA 5005, Australia	University of Adelaide; University of Adelaide	Rathjen, P (corresponding author), Univ Adelaide, ARC Special Res Ctr Mol Genet Dev, Adelaide, SA 5005, Australia.		Chapman, Gavin/A-9534-2012	Chapman, Gavin/0000-0002-3513-723X; Sharma, Shiwani/0000-0002-0828-025X; Scherer, Michaela/0000-0001-7867-6498				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bing ZY, 1999, J BIOL CHEM, V274, P24649, DOI 10.1074/jbc.274.35.24649; BRAY SJ, 1989, GENE DEV, V3, P1130, DOI 10.1101/gad.3.8.1130; BURKITT HG, 1993, WHEATERS FUNCTIONAL, P236; Castella P, 2000, MOL CELL BIOL, V20, P6170, DOI 10.1128/MCB.20.16.6170-6183.2000; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Chen SL, 2000, GENE DEV, V14, P1209; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Davies JA, 1998, CURR TOP DEV BIOL, V39, P245, DOI 10.1016/S0070-2153(08)60458-5; Dowhan DH, 1996, NUCLEIC ACIDS RES, V24, P264, DOI 10.1093/nar/24.2.264; EDWARDS DR, 1985, MOL CELL BIOL, V5, P3280, DOI 10.1128/MCB.5.11.3280; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Fawcett D.W., 1997, BLOOM FAWCETT CONCIS; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; Haines BP, 2000, MOL BIOL CELL, V11, P1369, DOI 10.1091/mbc.11.4.1369; Horster M, 1997, PFLUG ARCH EUR J PHY, V434, P647, DOI 10.1007/s004240050448; Huang NW, 2000, J BIOL CHEM, V275, P2852, DOI 10.1074/jbc.275.4.2852; JANE SM, 1995, EMBO J, V14, P97, DOI 10.1002/j.1460-2075.1995.tb06979.x; JOHNSON AD, 1995, CELL, V81, P655, DOI 10.1016/0092-8674(95)90524-3; JUNQUERIA LC, 1995, BASIC HISTOLOGY, P359; KANG T, 1993, J BIOL CHEM, V268, P9629; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KIM CG, 1990, MOL CELL BIOL, V10, P5958, DOI 10.1128/MCB.10.11.5958; KIM CH, 1987, P NATL ACAD SCI USA, V84, P6025, DOI 10.1073/pnas.84.17.6025; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; Lando D, 2000, J BIOL CHEM, V275, P4618, DOI 10.1074/jbc.275.7.4618; Lau KF, 1999, GENOMICS, V60, P121, DOI 10.1006/geno.1999.5875; Lau P, 1999, NUCLEIC ACIDS RES, V27, P411, DOI 10.1093/nar/27.2.411; LIM LC, 1993, J BIOL CHEM, V268, P18008; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; LOMBES M, 1990, P NATL ACAD SCI USA, V87, P1086, DOI 10.1073/pnas.87.3.1086; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Murata T, 1998, GENES CELLS, V3, P443, DOI 10.1046/j.1365-2443.1998.00204.x; NY HH, 2000, TRENDS BIOCHEM SCI, V25, P121; OBERLEITHNER H, 1987, P NATL ACAD SCI USA, V84, P1464, DOI 10.1073/pnas.84.5.1464; Potter EL, 1972, NORMAL ABNORMAL DEV; POWELL BC, 1990, EMBO J, V9, P1485, DOI 10.1002/j.1460-2075.1990.tb08266.x; Rathjen J, 1999, J CELL SCI, V112, P601; RATHJEN PD, 1990, GENE DEV, V4, P2308, DOI 10.1101/gad.4.12b.2308; ROLAND BL, 1995, MOL CELL ENDOCRINOL, V111, pR1, DOI 10.1016/0303-7207(95)03559-P; Romerio F, 1997, J VIROL, V71, P9375, DOI 10.1128/JVI.71.12.9375-9382.1997; ROSEN B, 1993, TRENDS GENET, V9, P162, DOI 10.1016/0168-9525(93)90162-B; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Saxen L., 1987, ORGANOGENESIS KIDNEY; Schaeper U, 1998, J BIOL CHEM, V273, P8549, DOI 10.1074/jbc.273.15.8549; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; SHIRRA MK, 1994, MOL CELL BIOL, V14, P5076, DOI 10.1128/MCB.14.8.5076; Shirra MK, 1998, J BIOL CHEM, V273, P19260, DOI 10.1074/jbc.273.30.19260; STANTON BA, 1986, J CLIN INVEST, V78, P1612, DOI 10.1172/JCI112754; SUEYOSHI T, 1995, MOL CELL BIOL, V15, P4158; SWENDEMAN SL, 1994, J BIOL CHEM, V269, P11663; THOMAS PQ, 1995, J BIOL CHEM, V270, P3869, DOI 10.1074/jbc.270.8.3869; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; UV AE, 1994, MOL CELL BIOL, V14, P4020, DOI 10.1128/MCB.14.6.4020; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; Yu F, 2000, NUCLEIC ACIDS RES, V28, P2201, DOI 10.1093/nar/28.10.2201; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128; ZHONG FM, 1994, J BIOL CHEM, V269, P21269	62	37	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 2	2001	276	5					3324	3332		10.1074/jbc.M008167200	http://dx.doi.org/10.1074/jbc.M008167200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YW	11073954	hybrid			2022-12-25	WOS:000166784900046
J	Horney, MJ; Evangelista, CA; Rosenzweig, SA				Horney, MJ; Evangelista, CA; Rosenzweig, SA			Synthesis and characterization of insulin-like growth factor (IGF)-1 photoprobes selective for the IGF-binding proteins (IGFBPs) - Photoaffinity labeling of the IGF-binding domain on IGFBP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; MOLECULAR-CLONING; SERUM; IDENTIFICATION; LOCALIZATION; DELETION; DYNAMICS; PEPTIDE; SUBUNIT; ANALOGS	Elevated insulin-like growth factor (IGF)-1 levels are prognostic for the development of prostate and breast cancers and exacerbate the complications of diabetes. In each case, perturbation of the balance between IGF-1/2, the IGF-1 receptor, and the IGF-binding proteins (IGFBPs) leads to elevated IGF-1 sensitivity. Blockade of IGF action in these diseases would be clinically significant. Unfortunately, effective IGF antagonists are currently unavailable. The IGFBPs exhibit high affinity and specificity for the IGFs and serve as natural IGF antagonists, limiting their mitogenic/anti-apoptotic effects. As an initial step in designing IGFBP-based agents that antagonize IGF action, we have begun to analyze the structure of the IGF-binding site on IGFBP-2. To this end, two IGF-1 photoprobes, N-alpha Gly1-(4-azidobenzoyl)-IGF-1 (abG(1)IGF-1) and N-alpha Gly1-([2-6-(biotinamido)-2(p-azidobenzamido) hexanoamido] ethyl-1,3'-dithiopropionoyl)IGF-1 (bedG(1)IGF-1), selective for the IGFBPs were synthesized by derivatization of the alpha -amino group of Gly(1), known to be part of the IGFBP-binding domain. Mass spectrometric analysis of the reduced, alkylated, and trypsin-digested abG(1)IGF-1 recombinant human IGFBP-2 (rhIGFBP-2) complex indicated photoincorporation near the carboxyl terminus of rhIGFBP-2, between residues 266 and 287, Mass spectrometric analysis of avidin-purified tryptic peptides of the bedG(1)IGF-1.rhIGFBP-2 complex revealed photoincorporation within residues 212-227. Taken together, these data indicate that the IGFBP-binding domain on IGF-1 contacts the distal third of IGFBP-2, providing evidence that the IGF-1-binding domain is located within the C terminus of IGFBP-2.	Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, Charleston, SC 29425 USA	Medical University of South Carolina	Rosenzweig, SA (corresponding author), Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut, 171 Ashley Ave, Charleston, SC 29425 USA.	rosenzsa@musc.edu	Rosenzweig, Steven A/O-5062-2018	Rosenzweig, Steven/0000-0002-7022-6086	NCI NIH HHS [CA-78887] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA078887, R01CA078887] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASERGA R, 1995, CANCER RES, V55, P249; Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; BAYLEY H, 1984, AZIDES NITRENES REAC, P434; BINKERT C, 1989, EMBO J, V8, P2497, DOI 10.1002/j.1460-2075.1989.tb08386.x; BLUNDELL TL, 1978, P NATL ACAD SCI USA, V75, P180, DOI 10.1073/pnas.75.1.180; BOURNER MJ, 1992, J CELL BIOCHEM, V48, P215; BRINKMAN A, 1991, MOL ENDOCRINOL, V5, P987, DOI 10.1210/mend-5-7-987; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; CASCIERI MA, 1989, J BIOL CHEM, V264, P2199; Chan JM, 1998, SCIENCE, V279, P563, DOI 10.1126/science.279.5350.563; CLEMMONS DR, 1992, ENDOCRINOLOGY, V131, P890, DOI 10.1210/en.131.2.890; CLEMMONS DR, 1993, ANN NY ACAD SCI, V692, P10; COOKE RM, 1991, BIOCHEMISTRY-US, V30, P5484, DOI 10.1021/bi00236a022; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; Forbes BE, 1998, J BIOL CHEM, V273, P4647, DOI 10.1074/jbc.273.8.4647; FORSBERG G, 1990, BIOCHEM J, V271, P357, DOI 10.1042/bj2710357; GALARDY RE, 1974, J BIOL CHEM, V249, P3510; HAN JC, 1994, ANAL BIOCHEM, V220, P5, DOI 10.1006/abio.1994.1290; Hankinson SE, 1998, LANCET, V351, P1393, DOI 10.1016/S0140-6736(97)10384-1; Ho PJ, 1997, ENDOCRINOLOGY, V138, P3811, DOI 10.1210/en.138.9.3811; Hobba GD, 1996, J BIOL CHEM, V271, P30529, DOI 10.1074/jbc.271.48.30529; Holly J. M. P., 1993, P47; HONEGGER A, 1986, J BIOL CHEM, V261, P569; Horney MJ, 1998, AM J PHYSIOL-RENAL, V274, pF1045, DOI 10.1152/ajprenal.1998.274.6.F1045; HUHTALA ML, 1986, BIOCHEM BIOPH RES CO, V141, P263, DOI 10.1016/S0006-291X(86)80363-1; HUMBEL RE, 1990, EUR J BIOCHEM, V190, P445, DOI 10.1111/j.1432-1033.1990.tb15595.x; Hwa V, 1999, ENDOCR REV, V20, P761, DOI 10.1210/er.20.6.761; Imai Y, 2000, J BIOL CHEM, V275, P18188, DOI 10.1074/jbc.M000070200; Jansson M, 1997, J BIOL CHEM, V272, P8189, DOI 10.1074/jbc.272.13.8189; Jansson M, 1998, J BIOL CHEM, V273, P24701, DOI 10.1074/jbc.273.38.24701; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kalus W, 1998, EMBO J, V17, P6558, DOI 10.1093/emboj/17.22.6558; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KIEFER MC, 1991, J BIOL CHEM, V266, P9043; KIEFER MC, 1991, BIOCHEM BIOPH RES CO, V176, P219, DOI 10.1016/0006-291X(91)90912-Q; KUROSE T, 1994, J BIOL CHEM, V269, P29190; Laajoki LG, 2000, J BIOL CHEM, V275, P10009, DOI 10.1074/jbc.275.14.10009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liu CL, 1997, J MASS SPECTROM, V32, P33, DOI 10.1002/(SICI)1096-9888(199701)32:1<33::AID-JMS446>3.0.CO;2-X; LONG L, 1995, CANCER RES, V55, P1006; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; SCHULLER AGP, 1993, GROWTH REGULAT, V3, P32; Spencer E. Martin, 1995, Progress in Growth Factor Research, V6, P209; Standker L, 1998, FEBS LETT, V441, P281, DOI 10.1016/S0014-5793(98)01497-5; SZABO L, 1988, BIOCHEM BIOPH RES CO, V151, P207, DOI 10.1016/0006-291X(88)90580-3; URLAUB G, 1983, CELL, V33, P405, DOI 10.1016/0092-8674(83)90422-1; WANG JF, 1988, BIOCHEM BIOPH RES CO, V157, P718, DOI 10.1016/S0006-291X(88)80309-7; Yamanaka Y, 1997, J BIOL CHEM, V272, P30729, DOI 10.1074/jbc.272.49.30729; YIP CC, 1993, PEPTIDES, V14, P325, DOI 10.1016/0196-9781(93)90048-L; YIP CC, 1980, BIOCHEMISTRY-US, V19, P70, DOI 10.1021/bi00542a011	52	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2880	2889		10.1074/jbc.M007526200	http://dx.doi.org/10.1074/jbc.M007526200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11063745	hybrid			2022-12-25	WOS:000166784800080
J	Lee, JJ; Moon, YA; Ha, JH; Yoon, DJ; Ahn, YH; Kim, KS				Lee, JJ; Moon, YA; Ha, JH; Yoon, DJ; Ahn, YH; Kim, KS			Cloning of human acetyl-CoA carboxylase beta promoter and its regulation by muscle regulatory factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; LIGHT-CHAIN GENE; SKELETAL-MUSCLE; MOLECULAR-CLONING; TRANSGENIC MICE; BINDING-SITES; MYOGENIN GENE; DNA-SEQUENCE; MALONYL-COA; 2 ISOFORMS	The 280-kDa beta -isoform of acetyl-CoA carboxylase (ACC beta) is predominantly expressed in heart and skeletal muscle, whereas the 265-kDa alpha -isoform (ACC alpha) is the major ACC in lipogenic tissues. The ACC beta promoter showed myoblast-specific promoter activity and was strongly induced by MyoD in NIH3T3 cells. Serial deletions of the promoter revealed that MyoD acts on the E-boxes located at positions -498 to -403 and on the proximal region including the 5'-untranslated region. Destruction of the E-boxes at positions -498 to -403 by site-directed mutagenesis resulted in a significant decrease of MyoD responsiveness. The "TGAAA" at -32 to -28 and the region around the transcription start site play important roles in basal transcription, probably as a TATA box and an Inr element, respectively. Mutations of another E-box at -14 to -9 and a "GCCTGTCA" sequence at +17 to +24 drastically decreased the MyoD responsiveness. The novel cis-element GCCTGTCA was preferentially bound by MyoD homodimer in EMSA and conferred MyoD responsiveness to a luciferase reporter, which was repressed by the overexpression of E12, This finding is unique since activation via E-boxes is mediated by heterodimers of MyoD and E-proteins. We screened a human skeletal muscle cDNA library to isolate clones expressing proteins that bind to the region around the GCCTGTCA (+8 to +27) sequence, and isolated Myf4 and Myf6 cDNAs. Electrophoretic mobility shift assay showed that recombinant Myf4 and Myf6 bind to this novel cis-element. Moreover, transient expression of MyfG induced significant activation on the ACC beta promoter or an artificial promoter harboring this novel vis-element, These findings suggest that muscle regulatory factors, such as MyoD, Myf4, and MyfG, contribute to the muscle-specific expression of ACC beta via E-boxes and the novel cis-element GCCTGTCA.	Yonsei Univ, Coll Med, Inst Genet Sci, Dept Biochem & Mol Biol,Seodaemun Gu, Seoul 120752, South Korea; Kyung Hee Univ, Coll Med, Dept Mol Biol, Seoul 130050, South Korea; Kwandong Univ, Coll Med, Dept Biochem, Kangnung 210701, South Korea	Yonsei University; Yonsei University Health System; Kyung Hee University; Catholic Kwandong University	Kim, KS (corresponding author), Yonsei Univ, Coll Med, Inst Genet Sci, Dept Biochem & Mol Biol,Seodaemun Gu, 134 Shinchon Dong, Seoul 120752, South Korea.		AHN, Yong Ho/H-6712-2017	AHN, Yong Ho/0000-0002-4133-0757				ABUELHEIGA L, 1995, P NATL ACAD SCI USA, V92, P4011, DOI 10.1073/pnas.92.9.4011; AbuElheiga L, 1997, J BIOL CHEM, V272, P10669; Alam N, 1998, BIOCHEM J, V334, P233, DOI 10.1042/bj3340233; AMACHER SL, 1993, MOL CELL BIOL, V13, P2753, DOI 10.1128/MCB.13.5.2753; APONE S, 1995, J BIOL CHEM, V270, P21420, DOI 10.1074/jbc.270.36.21420; Atchley WR, 1997, P NATL ACAD SCI USA, V94, P5172, DOI 10.1073/pnas.94.10.5172; AWAN MM, 1993, BIOCHEM J, V295, P61, DOI 10.1042/bj2950061; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Ceccarelli E, 1999, DEV BIOL, V213, P217, DOI 10.1006/dbio.1999.9345; Fandos C, 1999, J MOL BIOL, V294, P103, DOI 10.1006/jmbi.1999.3216; FRENCH BA, 1991, MOL CELL BIOL, V11, P2439, DOI 10.1128/MCB.11.5.2439; GILMOUR BP, 1991, J BIOL CHEM, V266, P19871; Ha J, 1996, P NATL ACAD SCI USA, V93, P11466, DOI 10.1073/pnas.93.21.11466; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HINTERBERGER TJ, 1991, DEV BIOL, V147, P144, DOI 10.1016/S0012-1606(05)80014-4; HINTERBERGER TJ, 1992, GENE, V117, P201, DOI 10.1016/0378-1119(92)90730-D; Huang J, 1996, MOL CELL BIOL, V16, P3893; IVERSON AJ, 1990, BIOCHEM J, V269, P365, DOI 10.1042/bj2690365; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LOPASCHUK GD, 1994, CAN J PHYSIOL PHARM, V72, P1101, DOI 10.1139/y94-156; MCGARRY JD, 1995, BIOCHEM SOC T, V23, P321, DOI 10.1042/bst0230321; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON E, 1992, SYM SOC EXP BIOL, V46, P331; Rao MV, 1996, MOL CELL BIOL, V16, P3909; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; WENTWORTH BM, 1991, P NATL ACAD SCI USA, V88, P1242, DOI 10.1073/pnas.88.4.1242; WINDER WW, 1995, J APPL PHYSIOL, V78, P578, DOI 10.1152/jappl.1995.78.2.578; YUN K, 1996, CURR OPIN CELL BIOL, V6, P877	37	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 26	2001	276	4					2576	2585		10.1074/jbc.M007002200	http://dx.doi.org/10.1074/jbc.M007002200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	398YV	11076940	hybrid			2022-12-25	WOS:000166784800041
